PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Le, TN; Du, GY; Fonseca, M; Zhou, QP; Wigle, JT; Eisenstat, DD				Le, Trung N.; Du, Guoyan; Fonseca, Mario; Zhou, Qing-Ping; Wigle, Jeffrey T.; Eisenstat, David D.			Dlx homeobox genes promote cortical interneuron migration from the basal forebrain by direct repression of the semaphorin receptor Neuropilin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; GANGLIONIC EMINENCE; TRANSCRIPTIONAL REGULATION; NEOCORTICAL PROJECTION; TANGENTIAL MIGRATION; GABAERGIC NEURONS; RETINAL GANGLION; AXON GUIDANCE; HOMEODOMAIN; PROTEIN	Dlx homeobox genes play an important role in vertebrate forebrain development. Dlx1/Dlx2 null mice die at birth with an abnormal cortical phenotype, including impaired differentiation and migration of GABAergic interneurons to the neocortex. However, the molecular basis for these defects downstream of loss of Dlx1/Dlx2 function is unknown. Neuropilin-2 (NRP-2) is a receptor for Class III semaphorins, which inhibit neuronal migration. Herein, we show that Neuropilin-2 is a specific DLX1 and DLX2 transcriptional target by applying chromatin immunoprecipitation to embryonic forebrain tissues. Both homeobox proteins repress Nrp-2 expression in vitro, confirming the functional significance of DLX binding. Furthermore, the homeodomain of DLX1 and DLX2 is necessary for DNA binding and this binding is essential for Dlx repression of Nrp-2 expression. Of importance, there is up-regulated and aberrant expression of NRP-2 in the forebrains of Dlx1/Dlx2 null mice. This is the first report that DLX1 or DLX2 can function as transcriptional repressors. Our data show that DLX proteins specifically mediate the repression of Neuropilin-2 in the developing forebrain. As well, our results support the hypothesis that down-regulation of Neuropilin-2 expression may facilitate tangential interneuron migration from the basal forebrain.	Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Eisenstat, DD (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	eisensta@cc.umanitoba.ca	Eisenstat, David/AAA-4653-2020; Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684				Anderson S, 1999, CEREB CORTEX, V9, P646, DOI 10.1093/cercor/9.6.646; Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; Anderson SA, 2002, CEREB CORTEX, V12, P702, DOI 10.1093/cercor/12.7.702; Anderson SA, 2001, DEVELOPMENT, V128, P353; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Chase MB, 2002, MOL CELL BIOL, V22, P2505, DOI 10.1128/MCB.22.8.2505-2514.2002; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Chiba S, 2003, P NATL ACAD SCI USA, V100, P15577, DOI 10.1073/pnas.2536757100; Cloutier JF, 2002, NEURON, V33, P877, DOI 10.1016/S0896-6273(02)00635-9; Cobos I, 2005, NAT NEUROSCI, V8, P1059, DOI 10.1038/nn1499; de Melo J, 2005, DEVELOPMENT, V132, P311, DOI 10.1242/dev.01560; de Melo J, 2003, J COMP NEUROL, V461, P187, DOI 10.1002/cne.10674; Eisenstat DD, 1999, J COMP NEUROL, V414, P217, DOI 10.1002/(SICI)1096-9861(19991115)414:2<217::AID-CNE6>3.0.CO;2-I; Falk J, 2005, NEURON, V48, P63, DOI 10.1016/j.neuron.2005.08.033; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106; Flames N, 2004, NEURON, V44, P251, DOI 10.1016/j.neuron.2004.09.028; Garrity PA, 2005, NAT NEUROSCI, V8, P1635, DOI 10.1038/nn1205-1635; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7; Givens ML, 2005, J BIOL CHEM, V280, P19156, DOI 10.1074/jbc.M502004200; Guan KL, 2003, NAT REV NEUROSCI, V4, P941, DOI 10.1038/nrn1254; Hanashima C, 2006, CELL, V125, P24, DOI 10.1016/j.cell.2006.03.021; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; ILER N, 1995, MECH DEVELOP, V53, P87, DOI 10.1016/0925-4773(95)00427-0; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Lee H, 2006, GENE DEV, V20, P784, DOI 10.1101/gad.1392006; Letinic K, 2002, NATURE, V417, P645, DOI 10.1038/nature00779; Liu JK, 1997, DEV DYNAM, V210, P498, DOI 10.1002/(SICI)1097-0177(199712)210:4<498::AID-AJA12>3.0.CO;2-3; Long JE, 2003, J NEUROSCI, V23, P568, DOI 10.1523/JNEUROSCI.23-02-00568.2003; Lopez-Bendito G, 2006, CELL, V125, P127, DOI 10.1016/j.cell.2006.01.042; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Marin O, 2003, DEVELOPMENT, V130, P1889, DOI 10.1242/dev.00417; Marin O, 2000, J NEUROSCI, V20, P6063; Marin O, 2001, SCIENCE, V293, P872, DOI 10.1126/science.1061891; Marin O, 2001, NAT REV NEUROSCI, V2, P780, DOI 10.1038/35097509; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Park GT, 2001, FEBS LETT, V496, P60, DOI 10.1016/S0014-5793(01)02398-5; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Pleasure SJ, 2000, NEURON, V28, P727, DOI 10.1016/S0896-6273(00)00149-5; PORTELLA G, 1994, INVAS METAST, V14, P7; Pozas E, 2005, NEURON, V45, P701, DOI 10.1016/j.neuron.2005.01.043; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; Shinozaki K, 2002, DEVELOPMENT, V129, P3479; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; Stenman J, 2003, DEVELOPMENT, V130, P1113, DOI 10.1242/dev.00328; Stoykova A, 2000, J NEUROSCI, V20, P8042; Stuhmer T, 2002, CEREB CORTEX, V12, P75, DOI 10.1093/cercor/12.1.75; Tamamaki N, 2003, J COMP NEUROL, V455, P238, DOI 10.1002/cne.10476; Wichterle H, 2003, P NATL ACAD SCI USA, V100, P727, DOI 10.1073/pnas.242721899; Wichterle H, 2001, DEVELOPMENT, V128, P3759; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131; Wonders C, 2005, NAT NEUROSCI, V8, P979, DOI 10.1038/nn0805-979; Yu GY, 2001, DEV BRAIN RES, V130, P217, DOI 10.1016/S0165-3806(01)00239-5; Yun K, 2001, DEVELOPMENT, V128, P193; Zerucha T, 2000, J NEUROSCI, V20, P709, DOI 10.1523/JNEUROSCI.20-02-00709.2000; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhou QP, 2004, NUCLEIC ACIDS RES, V32, P884, DOI 10.1093/nar/gkh233	65	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19071	19081		10.1074/jbc.M607486200	http://dx.doi.org/10.1074/jbc.M607486200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17259176	hybrid			2022-12-27	WOS:000247475300049
J	Chiang, YR; Ismail, W; Muller, M; Fuchs, G				Chiang, Yin-Ru; Ismail, Wael; Mueller, Michael; Fuchs, Georg			Initial steps in the anoxic metabolism of cholesterol by the denitrifying Sterolibacterium denitrificans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLBENZENE DEHYDROGENASE; STREPTOMYCES-HYGROSCOPICUS; SP-NOV; OXIDASE; DEGRADATION; BIOHYDROGENATION; REDUCTION; MECHANISM; MEMBER; GENE	The anoxic metabolism of the ubiquitous triterpene cholesterol is challenging because of its complex chemical structure, low solubility in water, low number of active functional groups, and the presence of four alicyclic rings and two quaternary carbon atoms. Consequently, the aerobic metabolism depends on oxygenase catalyzed reactions requiring molecular oxygen as co-substrate. Sterolibacterium denitrificans is shown to metabolize cholesterol anoxically via the oxidation of ring A, followed by an oxygen-independent hydroxylation of the terminal C-25 of the side chain. The anaerobic hydroxylation of a tertiary carbon using water as oxygen donor is unprecedented and may be catalyzed by a novel molybdenum containing enzyme.	Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Pharmazeut Wissensch, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Fuchs, G (corresponding author), Univ Freiburg, Fak Biol, Schanzlestr 1, D-79104 Freiburg, Germany.	georg.fuchs@biologie.uni-freiburg.de	Chiang, Yin-Ru/L-7727-2019; Ismail, Wael/X-5336-2019	Ahmed Ismail El Moslimany, Wael/0000-0002-3027-928X; Chiang, Yin-Ru/0000-0001-6899-3166				BJORKHEM I, 1971, EUR J BIOCHEM, V21, P428, DOI 10.1111/j.1432-1033.1971.tb01488.x; BRINKLEY AW, 1982, APPL ENVIRON MICROB, V43, P86, DOI 10.1128/AEM.43.1.86-89.1982; CHEETHAM PSJ, 1982, BIOCHEM J, V201, P515, DOI 10.1042/bj2010515; EYSSEN HJ, 1973, EUR J BIOCHEM, V36, P411, DOI 10.1111/j.1432-1033.1973.tb02926.x; Foss S, 1998, SYST APPL MICROBIOL, V21, P365, DOI 10.1016/S0723-2020(98)80046-5; FREIER TA, 1994, INT J SYST BACTERIOL, V44, P137, DOI 10.1099/00207713-44-1-137; Gadda G, 1997, EUR J BIOCHEM, V250, P369, DOI 10.1111/j.1432-1033.1997.0369a.x; Harder J, 1997, ARCH MICROBIOL, V167, P269, DOI 10.1007/s002030050442; Hayakawa S, 1973, Adv Lipid Res, V11, P143; Heyen U, 2000, APPL ENVIRON MICROB, V66, P3004, DOI 10.1128/AEM.66.7.3004-3009.2000; Hille R, 2005, ARCH BIOCHEM BIOPHYS, V433, P107, DOI 10.1016/j.abb.2004.08.012; Horinouchi M, 2003, APPL ENVIRON MICROB, V69, P4421, DOI 10.1128/AEM.69.8.4421-4430.2003; HORINOUCHI S, 1991, APPL ENVIRON MICROB, V57, P1386, DOI 10.1128/AEM.57.5.1386-1393.1991; Hylemon PB, 1998, FEMS MICROBIOL REV, V22, P475, DOI 10.1111/j.1574-6976.1998.tb00382.x; Jin CJ, 1997, ARCH BIOCHEM BIOPHYS, V341, P207, DOI 10.1006/abbi.1997.9949; Johnson HA, 2001, J BACTERIOL, V183, P4536, DOI 10.1128/JB.183.15.4536-4542.2001; KIESLICH K, 1985, J BASIC MICROB, V25, P461, DOI 10.1002/jobm.3620250713; Kniemeyer O, 2001, J BIOL CHEM, V276, P21381, DOI 10.1074/jbc.M101679200; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; LI L, 1995, APPL MICROBIOL BIOT, V43, P887, DOI 10.1007/s002530050501; MACKENZIE AS, 1982, SCIENCE, V217, P491, DOI 10.1126/science.217.4559.491; MacLachlan J, 2000, J STEROID BIOCHEM, V72, P169, DOI 10.1016/S0960-0760(00)00044-3; MATHEWS CK, 1996, BIOCHEMISTRY-US, P678; OWEN RW, 1983, J LIPID RES, V24, P1500; PARMENTIER G, 1974, BIOCHIM BIOPHYS ACTA, V348, P279, DOI 10.1016/0005-2760(74)90239-2; PFENNIG N, 1978, INT J SYST BACTERIOL, V28, P283, DOI 10.1099/00207713-28-2-283; Pollegioni L, 1999, EUR J BIOCHEM, V264, P140, DOI 10.1046/j.1432-1327.1999.00586.x; RABUS R, 1995, ARCH MICROBIOL, V163, P96, DOI 10.1007/BF00381782; Ramon DJ, 2004, CURR ORG CHEM, V8, P149, DOI 10.2174/1385272043486025; RUDEL LL, 1973, J LIPID RES, V14, P364; SADZIKOWSKI MR, 1977, APPL ENVIRON MICROB, V34, P355, DOI 10.1128/AEM.34.4.355-362.1977; Tarlera S, 2003, INT J SYST EVOL MICR, V53, P1085, DOI 10.1099/ijs.0.02039-0; WAKEHAM SG, 1989, NATURE, V342, P787, DOI 10.1038/342787a0	34	47	47	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13240	13249		10.1074/jbc.M610963200	http://dx.doi.org/10.1074/jbc.M610963200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17307741	hybrid			2022-12-27	WOS:000246060300012
J	Grinstein, E; Du, YH; Santourlidis, S; Christ, J; Uhrberg, M; Wernet, P				Grinstein, Edgar; Du, Yihua; Santourlidis, Simeon; Christ, Julia; Uhrberg, Markus; Wernet, Peter			Nucleolin regulates gene expression in CD34-positive hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; BCL-2 MESSENGER-RNA; HUMAN CD34 GENE; ACUTE MYELOGENOUS LEUKEMIA; AU-RICH ELEMENT; STEM-CELLS; C-MYB; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN	CD34 glycoprotein in human hematopoiesis is expressed on a subset of progenitor cells capable of self-renewal, multilineage differentiation, and hematopoietic reconstitution. Nucleolin is an abundant multifunctional phosphoprotein of growing eukaryotic cells, involved in regulation of gene transcription, chromatin remodeling, and RNA metabolism, whose transcripts are enriched in murine hematopoietic stem cells, as opposed to differentiated tissue. Here we show that, in human CD34-positive hematopoietic cells, nucleolin activates endogenous CD34 and Bcl-2 gene expression, and cell surface CD34 protein expression is thereby enhanced by nucleolin. Nucleolin-mediated activation of CD34 gene transcription results from direct sequence-specific interactions with the CD34 promoter region. Nucleolin expression prevails in CD34-positive cells mobilized into peripheral blood ( PB), as opposed to CD34-negative peripheral blood mononuclear cells ( PBMCs). Therefore, in intact CD34-positive mobilized PB cells, a recruitment of nucleolin to the CD34 promoter region takes place, accompanied by nucleosomal determinants of gene activity, which are absent from the CD34 promoter region in CD34-negative PBMCs. Our data show that nucleolin acts as a component of the gene regulation program of CD34-positive hematopoietic cells and provide further insights into processes by which human CD34-positive hematopoietic stem/progenitor cells are maintained.	Univ Dusseldorf, Med Ctr, Inst Transplantat Diagnost & Cellular Therapeut, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Grinstein, E (corresponding author), Univ Dusseldorf, Med Ctr, Inst Transplantat Diagnost & Cellular Therapeut, Moorenstr 5,Bldg 14-80, D-40225 Dusseldorf, Germany.	Edgar.Grinstein@web.de		Santourlidis, Simeon/0000-0002-0743-5336				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; BURN TC, 1992, BLOOD, V80, P3051; CAMPOS L, 1993, BLOOD, V81, P3091; CIVIN CI, 1984, J IMMUNOL, V133, P157; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; DERENZINI M, 1995, LAB INVEST, V73, P497; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Drew E, 2005, IMMUNITY, V22, P43, DOI 10.1016/j.immuni.2004.11.014; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; Graffmann N, 2006, ANAL BIOCHEM, V354, P308, DOI 10.1016/j.ab.2006.03.039; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Grinstein E, 2006, J BIOL CHEM, V281, P22223, DOI 10.1074/jbc.M513335200; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; HE XY, 1992, BLOOD, V79, P2296; HE XY, 1994, BLOOD, V83, P1822, DOI 10.1182/blood.V83.7.1822.bloodjournal8371822; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; Huddleson JP, 2006, J BIOL CHEM, V281, P15121, DOI 10.1074/jbc.M513406200; KASTAN MB, 1991, CANCER RES, V51, P4279; KOEFFLER HP, 1980, BLOOD, V56, P265; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Krause DS, 1996, BLOOD, V87, P1; KRAUSE DS, 1994, BLOOD, V84, P691; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Lee SJ, 2004, BLOOD, V104, P2194, DOI 10.1182/blood-2003-07-2430; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Masumi A, 2006, ONCOGENE, V25, P5113, DOI 10.1038/sj.onc.1209522; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MORRIS JF, 1995, BLOOD, V86, P3640; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Orelio C, 2004, BLOOD, V103, P4084, DOI 10.1182/blood-2003-06-1827; Otake Y, 2005, MOL PHARMACOL, V67, P319, DOI 10.1124/mol.104.006080; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; Perrotti D, 1996, BLOOD, V88, P3336, DOI 10.1182/blood.V88.9.3336.bloodjournal8893336; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Radomska HS, 1999, BLOOD, V94, P3772, DOI 10.1182/blood.V94.11.3772.423k19_3772_3780; Radomska HS, 1998, GENE, V222, P305, DOI 10.1016/S0378-1119(98)00491-0; Roger B, 2002, J BIOL CHEM, V277, P10209, DOI 10.1074/jbc.M106412200; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Trompeter HI, 2005, J IMMUNOL, V174, P4135, DOI 10.4049/jimmunol.174.7.4135; Unwin RD, 2006, BLOOD, V107, P4687, DOI 10.1182/blood-2005-12-4995; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006	64	38	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12439	12449		10.1074/jbc.M608068200	http://dx.doi.org/10.1074/jbc.M608068200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17255095	hybrid			2022-12-27	WOS:000245942800012
J	Malmquist, NA; Baldwin, J; Phillips, MA				Malmquist, Nicholas A.; Baldwin, Jeffrey; Phillips, Margaret A.			Detergent-dependent kinetics of truncated Plasmodium falciparum dihydroorotate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDATE PHOSPHATASE-ACTIVITY; YEAST SACCHAROMYCES-CEREVISIAE; CRITICAL MICELLE CONCENTRATION; MALARIA PARASITE; TRITON X-100; PHOSPHATIDYLINOSITOL 4-KINASE; TITRATION CALORIMETRY; ESCHERICHIA-COLI; MIXED MICELLES; MEMBRANE	The survival of the malaria parasite Plasmodium falciparum is dependent upon the de novo biosynthesis of pyrimidines. P. falciparum dihydroorotate dehydrogenase ( PfDHODH) catalyzes the fourth step in this pathway in an FMN-dependent reaction. The full-length enzyme is associated with the inner mitochondrial membrane, where ubiquinone ( CoQ) serves as the terminal electron acceptor. The lipophilic nature of the co-substrate suggests that electron transfer to CoQ occurs at the two-dimensional lipid-solution interface. Here we show that PfDHODH associates with liposomes even in the absence of the N-terminal transmembrane-spanning domain. The association of a series of ubiquinone substrates with detergent micelles was studied by isothermal titration calorimetry, and the data reveal that CoQ analogs with long decyl ( CoQ(D)) or geranyl ( CoQ(2)) tails partition into detergent micelles, whereas that with a short prenyl tail ( CoQ(1)) remains in solution. PfDHODH-catalyzed reduction of CoQD and CoQ2, but not CoQ(1), is stimulated as detergent concentrations ( Tween 80 or Triton X-100) are increased up to their critical micelle concentrations, beyond which activity declines. Steady-state kinetic data acquired for the reaction with CoQ(D) and CoQ(2) in substrate-detergent mixed micelles fit well to a surface dilution kinetic model. In contrast, the data for CoQ(1) as a substrate were well described by solution steady-state kinetics. Our results suggest that the partitioning of lipophilic ubiquinone analogues into detergent micelles needs to be an important consideration in the kinetic analysis of enzymes that utilize these substrates.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	margaret.phillips@utsouthwestern.edu		Malmquist, Nicholas/0000-0003-2822-8245	NIAID NIH HHS [R01 AI053680, R01-AI053680] Funding Source: Medline; NIGMS NIH HHS [T32-GM008203] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin J, 2005, J BIOL CHEM, V280, P21847, DOI 10.1074/jbc.M501100200; Baldwin J, 2002, J BIOL CHEM, V277, P41827, DOI 10.1074/jbc.M206854200; Boa AN, 2005, BIOORGAN MED CHEM, V13, P1945, DOI 10.1016/j.bmc.2005.01.017; Breman JG, 2001, AM J TROP MED HYG, V64, P1; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; COPELAND RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P79, DOI 10.1006/abbi.1995.0012; Davis JP, 1996, BIOCHEMISTRY-US, V35, P1270, DOI 10.1021/bi952168g; de Macedo CS, 2002, FEMS MICROBIOL LETT, V207, P13, DOI 10.1111/j.1574-6968.2002.tb11021.x; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Deems RA, 2000, ANAL BIOCHEM, V287, P1, DOI 10.1006/abio.2000.4766; ENGEL WD, 1980, BIOCHIM BIOPHYS ACTA, V592, P211, DOI 10.1016/0005-2728(80)90182-6; Gelb MH, 2000, BBA-MOL CELL BIOL L, V1488, P20, DOI 10.1016/S1388-1981(00)00106-2; Hansen M, 2004, PROTEIN SCI, V13, P1031, DOI 10.1110/ps.03533004; Heerklotz H, 1996, J PHYS CHEM-US, V100, P6764, DOI 10.1021/jp9523534; Heerklotz H, 2000, BIOPHYS J, V78, P2435, DOI 10.1016/S0006-3495(00)76787-7; Heerklotz H, 2000, BBA-BIOMEMBRANES, V1508, P69, DOI 10.1016/S0304-4157(00)00009-5; Heikkila T, 2006, BIOORG MED CHEM LETT, V16, P88, DOI 10.1016/j.bmcl.2005.09.045; Hurt DE, 2006, BIOORG MED CHEM LETT, V16, P1610, DOI 10.1016/j.bmcl.2005.12.029; Hurt DE, 2006, ACTA CRYSTALLOGR D, V62, P312, DOI 10.1107/S0907444905042642; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Karibian D, 1978, Methods Enzymol, V51, P58; KRUNGKRAI J, 1991, BIOCHEMISTRY-US, V30, P1934, DOI 10.1021/bi00221a029; KRUNGKRAI J, 1995, BBA-GEN SUBJECTS, V1243, P351, DOI 10.1016/0304-4165(94)00158-T; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Nara T, 2000, GENE, V257, P209, DOI 10.1016/S0378-1119(00)00411-X; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; Norager S, 2002, STRUCTURE, V10, P1211, DOI 10.1016/S0969-2126(02)00831-6; Qin CB, 2002, J BIOL CHEM, V277, P49685, DOI 10.1074/jbc.M209598200; Rawls J, 2000, EUR J BIOCHEM, V267, P2079, DOI 10.1046/j.1432-1327.2000.01213.x; Rowland P, 1997, STRUCTURE, V5, P239, DOI 10.1016/S0969-2126(97)00182-2; Rowland P, 2000, STRUCTURE, V8, P1227, DOI 10.1016/S0969-2126(00)00530-X; SEELIG J, 1991, BIOCHEMISTRY-US, V30, P9354, DOI 10.1021/bi00102a031; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; Ullrich A, 2001, EUR J BIOCHEM, V268, P1861, DOI 10.1046/j.1432-1033.2001.02061.x; Vial HJ, 2003, MOL BIOCHEM PARASIT, V126, P143, DOI 10.1016/S0166-6851(02)00281-5; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	48	18	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12678	12686		10.1074/jbc.M609893200	http://dx.doi.org/10.1074/jbc.M609893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329250	hybrid			2022-12-27	WOS:000245942800037
J	Pratt, JT; Tamayo, R; Tischler, AD; Camilli, A				Pratt, Jason T.; Tamayo, Rita; Tischler, Anna D.; Camilli, Andrew			PilZ domain proteins bind cyclic diguanylate and regulate diverse processes in Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DI-GMP; CELLULOSE SYNTHESIS; BIOFILM FORMATION; ACETOBACTER-XYLINUM; EAL DOMAIN; ALLOSTERIC CONTROL; ESCHERICHIA-COLI; GENE FUSIONS; EXPRESSION; PHOSPHODIESTERASE	Cyclic diguanylate (c-di-GMP) is an allosteric activator and second messenger implicated in the regulation of a variety of biological processes in diverse bacteria. In Vibrio cholerae, c-diGMP has been shown to inversely regulate biofilm-specific and virulence gene expression, suggesting that c-di-GMP signaling is important for the transition of V. cholerae from the environment to the host. However, the mechanism behind this regulation remains unknown. Recently, it was proposed that the PilZ protein domain represents a c-di-GMP-binding domain. Here we show that V. cholerae PilZ proteins bind c-di-GMP specifically and are involved in the regulation of biofilm formation, motility, and virulence. These findings confirm a role for PilZ proteins as c-di-GMP-sensing proteins within the c-di-GMP signaling network.	Tufts Univ, Howard Hughes Med Inst, Sch Med, Boston, MA 02111 USA; Tufts Univ, Dept Mol Biol & Microbiol, Sch Med, Boston, MA 02111 USA	Howard Hughes Medical Institute; Tufts University; Tufts University	Camilli, A (corresponding author), Tufts Univ, Howard Hughes Med Inst, Sch Med, 136 Harrison Ave, Boston, MA 02111 USA.	andrew.camilli@tufts.edu		Tischler, Anna/0000-0001-8404-0250	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI045746, R01 AI045746-06A1, AI45746] Funding Source: Medline; NIDDK NIH HHS [P30 DK34928, P30 DK034928] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aldridge P, 2003, MOL MICROBIOL, V47, P1695, DOI 10.1046/j.1365-2958.2003.03401.x; Amikam D, 2006, BIOINFORMATICS, V22, P3, DOI 10.1093/bioinformatics/bti739; AMIKAM D, 1989, J BACTERIOL, V171, P6649, DOI 10.1128/jb.171.12.6649-6655.1989; Ausmees N, 2001, FEMS MICROBIOL LETT, V204, P163, DOI 10.1111/j.1574-6968.2001.tb10880.x; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Beyhan S, 2006, J BACTERIOL, V188, P3600, DOI 10.1128/JB.188.10.3600-3613.2006; Bobrov AG, 2005, FEMS MICROBIOL LETT, V247, P123, DOI 10.1016/j.femsle.2005.04.036; CALLAHAN LT, 1971, INFECT IMMUN, V4, P611, DOI 10.1128/IAI.4.5.611-618.1971; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; Correa NE, 2005, J BACTERIOL, V187, P6324, DOI 10.1128/JB.187.18.6324-6332.2005; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hickman JW, 2005, P NATL ACAD SCI USA, V102, P14422, DOI 10.1073/pnas.0507170102; Hisert KB, 2005, MOL MICROBIOL, V56, P1234, DOI 10.1111/j.1365-2958.2005.04632.x; HOLMGREN J, 1973, INFECT IMMUN, V7, P759, DOI 10.1128/IAI.7.5.759-763.1973; Huang BX, 2003, J BACTERIOL, V185, P7068, DOI 10.1128/JB.185.24.7068-7076.2003; HUQ A, 1983, APPL ENVIRON MICROB, V45, P275, DOI 10.1128/AEM.45.1.275-283.1983; Kaper James B., 1994, P145; Kaysner Charles A., 1994, P27; Kirillina O, 2004, MOL MICROBIOL, V54, P75, DOI 10.1111/j.1365-2958.2004.04253.x; Klose KE, 1998, MOL MICROBIOL, V28, P501, DOI 10.1046/j.1365-2958.1998.00809.x; Klose KE, 1998, J BACTERIOL, V180, P303, DOI 10.1128/JB.180.2.303-316.1998; Ko M, 2000, J MOL BIOL, V303, P371, DOI 10.1006/jmbi.2000.4147; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; Lee SH, 1998, J BACTERIOL, V180, P2298, DOI 10.1128/JB.180.9.2298-2305.1998; Lee SH, 1999, CELL, V99, P625, DOI 10.1016/S0092-8674(00)81551-2; Lee SH, 2001, P NATL ACAD SCI USA, V98, P6889, DOI 10.1073/pnas.111581598; MAYER R, 1991, P NATL ACAD SCI USA, V88, P5472, DOI 10.1073/pnas.88.12.5472; MILLER VL, 1985, J BACTERIOL, V163, P580, DOI 10.1128/JB.163.2.580-585.1985; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Prouty MG, 2001, MOL MICROBIOL, V39, P1595, DOI 10.1046/j.1365-2958.2001.02348.x; Ramelot TA, 2007, PROTEINS, V66, P266, DOI 10.1002/prot.21199; ROSS P, 1986, CARBOHYD RES, V149, P101, DOI 10.1016/S0008-6215(00)90372-0; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; Ryan RP, 2006, P NATL ACAD SCI USA, V103, P6712, DOI 10.1073/pnas.0600345103; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Ryjenkov DA, 2006, J BIOL CHEM, V281, P30310, DOI 10.1074/jbc.C600179200; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; Schoolnik GK, 2001, METHOD ENZYMOL, V336, P3, DOI 10.1016/S0076-6879(01)36573-4; SENANAYAKE SD, 1995, MOL BIOTECHNOL, V4, P13, DOI 10.1007/BF02907467; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200; TAMPLIN ML, 1990, APPL ENVIRON MICROB, V56, P1977, DOI 10.1128/AEM.56.6.1977-1980.1990; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Tischler AD, 2004, MOL MICROBIOL, V53, P857, DOI 10.1111/j.1365-2958.2004.04155.x; Tischler AD, 2005, INFECT IMMUN, V73, P5873, DOI 10.1128/IAI.73.9.5873-5882.2005; Watnick PI, 1999, MOL MICROBIOL, V34, P586, DOI 10.1046/j.1365-2958.1999.01624.x; Weinhouse H, 1997, FEBS LETT, V416, P207, DOI 10.1016/S0014-5793(97)01202-7; Yildiz FH, 2001, J BACTERIOL, V183, P1716, DOI 10.1128/JB.183.5.1716-1726.2001	58	141	150	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12860	12870		10.1074/jbc.M611593200	http://dx.doi.org/10.1074/jbc.M611593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17307739	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000245942800058
J	Bright, DP; Adham, SD; Lemaire, LCJM; Benavides, R; Gruss, M; Taylor, GW; Smith, EH; Franks, NP				Bright, Damian P.; Adham, Sara D.; Lemaire, Lucienne C. J. M.; Benavides, Rodrigo; Gruss, Marco; Taylor, Graham W.; Smith, Edward H.; Franks, Nicholas P.			Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GENERAL-ANESTHETICS; HALOTHANE BINDING; STRUCTURAL BASIS; AMINO-ACID; RAT; DIAZIRINES; RESOLUTION; ISOMERS; KINASE	We have synthesized a novel analog of the general anesthetic etomidate in which the ethoxy group has been replaced by an azide group, and which can be used as a photolabel to identify etomidate binding sites. This acyl azide analog is a potent general anesthetic in both rats and tadpoles and, as with etomidate, is stereoselective in its actions, with the R( +) enantiomer being significantly more potent than the S( -) enantiomer. Its effects on alpha 1 beta 2 gamma 2s GABA(A) receptors expressed in HEK-293 cells are virtually indistinguishable from the parent compound etomidate, showing stereoselective potentiation of GABA-induced currents, as well as direct mimetic effects at higher concentrations. In addition, a point mutation ( beta 2 N265M), which is known to attenuate the potentiating actions of etomidate, also blocks the effects of the acyl azide analog. We have investigated the utility of the analog to identify etomidate binding sites by using it to photolabel human serum albumin, a protein that binds similar to 75% of etomidate in human plasma and which is thought to play a major role in its pharmacokinetics. Using HPLC/mass spectrometry we have identified two anesthetic binding sites on HSA. One site is the well-characterized drug binding site I, located in HSA subdomain IIA, and the second site is also an established drug binding site located in subdomain IIIB, which also binds propofol. The acyl azide etomidate may prove to be a useful new photolabel to identify anesthetic binding sites on the GABAA receptor or other putative targets.	Univ London Imperial Coll Sci Technol & Med, Biophys Sect, Blackett Lab, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England	Imperial College London; Imperial College London	Franks, NP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Biophys Sect, Blackett Lab, London SW7 2AZ, England.	n.franks@imperial.ac.uk	Taylor, Graham Walter/R-4811-2019	Taylor, Graham Walter/0000-0002-9672-8463; Franks, Nicholas/0000-0003-4874-4212; Bright, Damian/0000-0001-9130-2677				Addona GH, 2002, J BIOL CHEM, V277, P25685, DOI 10.1074/jbc.M201303200; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Blencowe A, 2005, SOFT MATTER, V1, P178, DOI 10.1039/b501989c; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Curry S, 1999, BBA-MOL CELL BIOL L, V1441, P131, DOI 10.1016/S1388-1981(99)00148-1; Darbandi-Tonkabon R, 2003, J BIOL CHEM, V278, P13196, DOI 10.1074/jbc.M213168200; Das J, 2004, J BIOL CHEM, V279, P37964, DOI 10.1074/jbc.M405137200; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 2002, J MED CHEM, V45, P1879, DOI 10.1021/jm0104926; FLEMING SA, 1995, TETRAHEDRON, V51, P12479; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Ghuman J, 2005, J MOL BIOL, V353, P38, DOI 10.1016/j.jmb.2005.07.075; GODEFROI EF, 1965, J MED CHEM, V8, P220, DOI 10.1021/jm00326a017; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; Husain SS, 2003, J MED CHEM, V46, P1257, DOI 10.1021/jm020465v; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Li GD, 2006, J NEUROSCI, V26, P11599, DOI 10.1523/JNEUROSCI.3467-06.2006; McGurk KA, 1998, BRIT J PHARMACOL, V124, P13, DOI 10.1038/sj.bjp.0701787; MEULDERMANS WEG, 1976, ARCH INT PHARMACOD T, V221, P150; Petitpas I, 2003, P NATL ACAD SCI USA, V100, P6440, DOI 10.1073/pnas.1137188100; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Tomlin SL, 1998, ANESTHESIOLOGY, V88, P708, DOI 10.1097/00000542-199803000-00022; WAUD DR, 1972, J PHARMACOL EXP THER, V183, P577; Ziebell MR, 2004, J BIOL CHEM, V279, P17640, DOI 10.1074/jbc.M313886200	28	8	8	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12038	12047		10.1074/jbc.M700479200	http://dx.doi.org/10.1074/jbc.M700479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17311911	hybrid			2022-12-27	WOS:000245941900046
J	Ishida, H; Li, K; Yi, M; Lemon, SM				Ishida, Hisashi; Li, Kui; Yi, MinKyung; Lemon, Stanley M.			p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis c virus in human hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBGENOMIC RNA REPLICATION; RIBOSOME ENTRY SITE; IFN-BETA PROMOTER; PROTEIN-KINASE; ADAPTER PROTEIN; B ACTIVITY; IDENTIFICATION; TRANSLATION; CULTURE; PHOSPHORYLATION	Cellular mechanisms that regulate the replication of hepatitis C virus ( HCV) RNA are poorly understood. p21-activated kinase 1 ( PAK1) is a serine/threonine kinase that has been suggested to participate in antiviral signaling. We studied its role in the cellular control of HCV replication. Transfection of PAK1-specific small interfering RNA enhanced viral RNA and protein abundance in established replicon cell lines as well as cells infected with chimeric genotype 1a/2a HCV, despite reducing cellular proliferation, suggesting specific regulation of HCV replication. PAK1 knockdown did not reduce interferon regulatory factor 3-dependent gene expression, indicating that this regulation is independent of the retinoic acid-inducible gene I/interferon regulatory factor 3 pathway. On the other hand, LY294002 and rapamycin abolished PAK1 phosphorylation and enhanced HCV abundance, suggesting that the mammalian target of rapamycin ( mTOR) is involved in PAK1 regulation of HCV. Small interfering RNA knockdown of the mTOR substrate p70 S6 kinase abrogated PAK1 phosphorylation and enhanced HCV RNA abundance, whereas overexpression of a constitutively active alternate substrate, eukaryotic translation initiation factor 4E-binding protein 1, increased cap-independent viral translation and viral RNA abundance without influencing PAK1 phosphorylation. Similar data indicated that mTOR is regulated by both phosphatidylinositol 3-kinase/Akt and ERK. Taken together, the data indicate that p70 S6 kinase activates PAK1 and contributes to phosphatidylinositol 3-kinase- and ERK-mediated regulation of HCV RNA replication.	Univ Texas, Med Branch, Ctr Hepatitis Res, Inst Human Infect & Immun, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Lemon, SM (corresponding author), Univ Texas, Med Branch, Ctr Hepatitis Res, Inst Human Infect & Immun, 4-104 Blocker Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	smlemon@utmb.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040035, R21AI063451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA018054] Funding Source: NIH RePORTER; NIAID NIH HHS [R21-AI063451, U19-AI40035] Funding Source: Medline; NIDA NIH HHS [R21-DA018054] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bost AG, 2003, J VIROL, V77, P4401, DOI 10.1128/JVI.77.7.4401-4408.2003; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Coito C, 2004, J VIROL, V78, P3502, DOI 10.1128/JVI.78.7.3502-3513.2004; Conzelmann KK, 2005, J VIROL, V79, P5241, DOI 10.1128/JVI.79.9.5241-5248.2005; Dhanak D, 2002, J BIOL CHEM, V277, P38322, DOI 10.1074/jbc.M205566200; Ehrhardt C, 2004, FEBS LETT, V567, P230, DOI 10.1016/j.febslet.2004.04.069; Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fredericksen B, 2002, VIRAL IMMUNOL, V15, P29, DOI 10.1089/088282402317340215; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; Frese M, 2001, J GEN VIROL, V82, P723, DOI 10.1099/0022-1317-82-4-723; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ishii N, 2006, J VIROL, V80, P4510, DOI 10.1128/JVI.80.9.4510-4520.2006; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Mannova P, 2005, J VIROL, V79, P8742, DOI 10.1128/JVI.79.14.8742-8749.2005; Menard RE, 2003, CELL SIGNAL, V15, P1099, DOI 10.1016/S0898-6568(03)00087-1; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Murata T, 2005, VIROLOGY, V340, P105, DOI 10.1016/j.virol.2005.06.015; Murata T, 2005, VIROLOGY, V331, P407, DOI 10.1016/j.virol.2004.10.036; Neddermann P, 2004, J VIROL, V78, P13306, DOI 10.1128/JVI.78.23.13306-13314.2004; Noyce RS, 2006, J VIROL, V80, P226, DOI 10.1128/JVI.80.1.226-235.2006; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Pause A, 2003, J BIOL CHEM, V278, P20374, DOI 10.1074/jbc.M210785200; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Quintavalle M, 2006, J VIROL, V80, P11305, DOI 10.1128/JVI.01465-06; Randall G, 2003, P NATL ACAD SCI USA, V100, P235, DOI 10.1073/pnas.0235524100; Scholle F, 2004, J VIROL, V78, P1513, DOI 10.1128/JVI.78.3.1513-1524.2004; Seeff LB, 1997, HEPATOLOGY, V26, pS21, DOI 10.1002/hep.510260704; Sharrard RM, 2007, CELL SIGNAL, V19, P129, DOI 10.1016/j.cellsig.2006.05.029; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang TH, 2000, J VIROL, V74, P11347, DOI 10.1128/JVI.74.23.11347-11358.2000; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yi M, 2006, P NATL ACAD SCI USA, V103, P2310, DOI 10.1073/pnas.0510727103; Yi MK, 2007, J VIROL, V81, P629, DOI 10.1128/JVI.01890-06; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zhu HZ, 2003, J VIROL, V77, P5493, DOI 10.1128/JVI.77.9.5493-5498.2003	60	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11836	11848		10.1074/jbc.M610106200	http://dx.doi.org/10.1074/jbc.M610106200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17255101	hybrid			2022-12-27	WOS:000245941900026
J	Antignani, A; Youle, RJ				Antignani, Antonella; Youle, Richard J.			The cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), can deliver Bcl-XL as an extracellular fusion protein to protect cells from apoptosis and retain differentiation induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL APOPTOSIS; STEM-CELLS; IN-VITRO; RECEPTOR; INHIBITION; LEUKEMIA; FAMILY; DEATH; TRANSDUCTION; ACTIVATION	Bcl-XL, a member of the Bcl-2 protein family, is able to suppress cell death induced by diverse stimuli in many cell types, including hematopoietic cells. Human granulocyte-macrophage colony-stimulating factor ( GM-CSF) is a cytokine that promotes the proliferation and maturation of neutrophils, eosinophils, and macrophages from bone marrow progenitors. We fused GM-CSF to Bcl-XL and examined the capacity of this chimera to bind human cells through the GM-CSF receptor and prevent apoptosis. We found that the chimeric protein increased the proliferation of human monocytes in culture from 24 h until at least 72 h. In the presence of different apoptotic agents, GM-CSF-Bcl-XL protected cells from induced cell death and promoted proliferation, whereas GM-CSF alone was completely inhibited. In the presence of cytarabine, GM-CSF-Bcl-XL was able also to promote the differentiation of the CD34(+) myeloid precursor whereas Lfn-Bcl-XL, lacking the GM-CSF domain-stimulated cell proliferation and not differentiation. We conclude that recombinant GM-CSF-Bcl-XL binds the GM-CSF receptor on human monocyte/macrophage cells and bone marrow progenitors inducing differentiation and allowing Bcl-XL entry into cells where it blocks cell death and allows amplified cell proliferation. This fully human fusion protein has potential to prevent monocytopenia and represents a new strategy for engineering anti-apoptotic therapeutics.	NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Youle, RJ (corresponding author), NINDS, Biochem Sect, Surg Neurol Branch, NIH, 35 Convent Dr MSC 3704, Bethesda, MD 20892 USA.	youler@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002674, Z01NS002674] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Antignani A, 2005, BIOCHEMISTRY-US, V44, P4074, DOI 10.1021/bi0477687; Basak SK, 2002, BLOOD, V99, P2869, DOI 10.1182/blood.V99.8.2869; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bruserud O, 2000, STEM CELLS, V18, P343; BURGESS AW, 1980, BLOOD, V56, P947; Cao GD, 2002, J NEUROSCI, V22, P5423; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dietz GPH, 2002, MOL CELL NEUROSCI, V21, P29, DOI 10.1006/mcne.2002.1165; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Eager R, 2005, MOL THER, V12, P18, DOI 10.1016/j.ymthe.2005.02.012; GRABSTEIN KH, 1986, SCIENCE, V232, P506, DOI 10.1126/science.3083507; Guchelaar HJ, 1998, CANCER CHEMOTH PHARM, V42, P77, DOI 10.1007/s002800050788; Guthridge MA, 1998, STEM CELLS, V16, P301, DOI 10.1002/stem.160301; Haman A, 1999, J BIOL CHEM, V274, P34155, DOI 10.1074/jbc.274.48.34155; Hillion JA, 2005, J CEREBR BLOOD F MET, V25, P154, DOI 10.1038/sj.jcbfm.9600003; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hubel K, 2002, J INFECT DIS, V185, P1490, DOI 10.1086/340221; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Kreitman RJ, 1997, BLOOD, V90, P252; Liu XH, 1999, P NATL ACAD SCI USA, V96, P9563, DOI 10.1073/pnas.96.17.9563; Liu XH, 2001, J BIOL CHEM, V276, P46326, DOI 10.1074/jbc.M108930200; Masquelier M, 2004, BIOCHEM PHARMACOL, V67, P1047, DOI 10.1016/j.bcp.2003.10.025; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAWADA M, 1993, NEUROSCI LETT, V160, P131, DOI 10.1016/0304-3940(93)90396-3; Slukvin II, 2006, J IMMUNOL, V176, P2924, DOI 10.4049/jimmunol.176.5.2924; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Theilgaard-Monch K, 2003, BONE MARROW TRANSPL, V32, P1125, DOI 10.1038/sj.bmt.1704297; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	37	7	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11246	11254		10.1074/jbc.M609824200	http://dx.doi.org/10.1074/jbc.M609824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311927	hybrid			2022-12-27	WOS:000245941500047
J	Sjoberg, AP; Trouw, LA; Clark, SJ; Sjolander, J; Heinegard, D; Sim, RB; Day, AJ; Blom, AM				Sjoberg, Andreas P.; Trouw, Leendert A.; Clark, Simon J.; Sjolander, Jonatan; Heinegard, Dick; Sim, Robert B.; Day, Anthony J.; Blom, Anna M.			The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT ACTIVATION; ALTERNATIVE PATHWAY; C4B-BINDING PROTEIN; INHIBITORY-ACTIVITY; SITE; PROTEOGLYCANS; INFLAMMATION; PATHOGENESIS; POLYMORPHISM; HEPARIN	Recently, a polymorphism in the complement regulator factor H (FH) gene has been associated with age-related macular degeneration. When histidine instead of tyrosine is present at position 384 in the seventh complement control protein (CCP) domain of FH, the risk for age-related macular degeneration is increased. It was recently shown that these allotypic variants of FH, in the context of a recombinant construct corresponding to CCPs 6 - 8, recognize polyanionic structures differently, which may lead to altered regulation of the alternative pathway of complement. We show now that His-384, corresponding to the risk allele, binds C-reactive protein (CRP) poorly compared with the Tyr-384 form. We also found that C1q and phosphorylcholine do not compete with FH for binding to C-reactive protein. The interaction with extracellular matrix protein fibromodulin, which we now show to be mediated, at least in part, by CCP6 - 8 of FH, occurs via the polypeptide of fibromodulin and not through its glycosaminoglycan modifications. The Tyr-384 variant of FH bound fibromodulin better than the His-384 form. Furthermore, we find that CCP6 - 8 is able to interact with DNA and necrotic cells, but in contrast the His-384 allotype binds these ligands more strongly than the Tyr-384 variant. The variations in binding affinity of the two alleles indicate that complement activation and local inflammation in response to different targets will differ between His/His and Tyr/Tyr homozygotes.	Lund Univ, Dept Lab Med, Sect Med Prot Chem, Malmo Univ Hosp, S-20502 Malmo, Sweden; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Lund Univ, Dept Expt Med Sci, S-22184 Lund, Sweden; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	Lund University; Skane University Hospital; University of Oxford; Lund University; University of Manchester	Blom, AM (corresponding author), Lund Univ, Dept Lab Med, Sect Med Prot Chem, Malmo Univ Hosp, S-20502 Malmo, Sweden.	anna.blom@med.lu.se	Day, Anthony/O-1658-2015; Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009; Sim, Bob/A-1354-2008; Trouw, Leendert/AGK-5202-2022	Day, Anthony/0000-0002-1415-3134; Blom, Anna/0000-0002-1348-1734; Sim, Bob/0000-0002-2855-7455; Trouw, Leendert/0000-0001-5186-2290; Clark, Simon/0000-0001-8394-8355	Medical Research Council [MC_U138274352] Funding Source: Medline; NIAMS NIH HHS [5U01 AR050926] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U01AR050926] Funding Source: NIH RePORTER; MRC [MC_U138274352] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; ARONOV RA, 1992, PRIRODA, V3, P87; Bang R, 2005, J BIOL CHEM, V280, P25095, DOI 10.1074/jbc.M504782200; BIRO A, 2007, IMMUNOLOGY      0117; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102; BUCKWALTER JA, 1994, MICROSC RES TECHNIQ, V28, P398, DOI 10.1002/jemt.1070280506; Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588; Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200; Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4; GARDNER WD, 1980, BIOCHEM BIOPH RES CO, V94, P61, DOI 10.1016/S0006-291X(80)80187-2; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; Jarva H, 1999, J IMMUNOL, V163, P3957; JIANG HX, 1992, J BIOL CHEM, V267, P25597; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6; Lutz HU, 2006, MOL IMMUNOL, V43, P2, DOI 10.1016/j.molimm.2005.06.020; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; Muller M, 2001, SCHMERZ, V15, P3, DOI 10.1007/s004820170042; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Padilla ND, 2004, J IMMUNOL METHODS, V293, P1, DOI 10.1016/j.jim.2004.06.011; Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268; Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806; Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704; Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200; Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612; STANESCU V, 1990, SEMIN ARTHRITIS RHEU, V20, P51, DOI 10.1016/0049-0172(90)90047-J; Sztrolovics R, 1999, SPINE, V24, P1765, DOI 10.1097/00007632-199909010-00003; Taylor KE, 2005, ARTERIOSCL THROM VAS, V25, P1225, DOI 10.1161/01.ATV.0000164623.41250.28; TENNER AJ, 1981, J IMMUNOL, V127, P648; Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189	45	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10894	10900		10.1074/jbc.M610256200	http://dx.doi.org/10.1074/jbc.M610256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17293598	hybrid			2022-12-27	WOS:000245941500008
J	Zhang, X; Zhou, K; Wang, RS; Cui, JK; Lipton, SA; Liao, FF; Xu, HX; Zhang, YW				Zhang, Xian; Zhou, Kun; Wang, Ruishan; Cui, Jiankun; Lipton, Stuart A.; Liao, Francesca-Fang; Xu, Huaxi; Zhang, Yun-wu			Hypoxia-inducible factor 1 alpha (HIF-1 alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA SH-SY5Y; ALPHA-SECRETASE CLEAVAGE; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; TRANSCRIPTIONAL REGULATION; CEREBRAL-ISCHEMIA; INDUCIBLE FACTOR-1-ALPHA; GENE-EXPRESSION; MESSENGER-RNA; APP	The incidence of Alzheimer disease (AD) and vascular dementia is greatly increased following cerebral ischemia and stroke in which hypoxic conditions occur in affected brain areas. beta-Amyloid peptide (A beta), which is derived from the beta-amyloid precursor protein (APP) by sequential proteolytic cleavages from beta-secretase (BACE1) and presenilin-1 (PS1)/gamma-secretase, is widely believed to trigger a cascade of pathological events culminating in AD and vascular dementia. However, a direct molecular link between hypoxic insults and APP processing has yet to be established. Here, we demonstrate that acute hypoxia increases the expression and the enzymatic activity of BACE1 by up-regulating the level of BACE1 mRNA, resulting in increases in the APP C-terminal fragment-beta (beta CTF) and A beta. Hypoxia has no effect on the level of PS1, APP, and tumor necrosis factor-alpha-converting enzyme (TACE, an enzyme known to cleave APP at the alpha-secretase cleavage site). Sequence analysis, mutagenesis, and gel shift studies revealed binding of HIF-1 to the BACE1 promoter. Overexpression of HIF-1 alpha increases BACE1 mRNA and protein level, whereas down-regulation of HIF-1 alpha reduced the level of BACE1. Hypoxic treatment fails to further potentiate the stimulatory effect of HIF-1 alpha overexpression on BACE1 expression, suggesting that hypoxic induction of BACE1 expression is primarily mediated by HIF-1 alpha. Finally, we observed significant reduction in BACE1 protein levels in the hippocampus and the cortex of HIF-1 alpha conditional knock-out mice. Our results demonstrate an important role for hypoxia/ HIF-1 alpha in modulating the amyloidogenic processing of APP and provide a molecular mechanism for increased incidence of AD following cerebral ischemic and stroke injuries.	Burnham Inst Med Res, La Jolla, CA 92037 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; Xiamen Univ, Inst Biomed Res, Xiamen 361005, Peoples R China; Xiamen Univ, Sch Life Sci, Xiamen 361005, Peoples R China	Sanford Burnham Prebys Medical Discovery Institute; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Xiamen University; Xiamen University	Zhang, X (corresponding author), Burnham Inst Med Res, La Jolla, CA 92037 USA.	xuh@burnham.org; yunzhang@burnham.org	Zhang, Xian/AAV-7491-2021; Zhang, YW/G-3999-2010; Xu, Huaxi/AAV-7177-2021	Zhang, Yun-wu/0000-0002-7152-7630; Lipton, Stuart/0000-0002-3490-1259	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054880, R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG030197, R01AG021173] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG030197, R01 AG021173] Funding Source: Medline; NINDS NIH HHS [R01 NS046673, R01 NS054880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Chun YS, 2001, J CELL SCI, V114, P4051; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Greenfield JP, 2000, FRONT BIOSCI, V5, pD72, DOI 10.2741/Greenfield; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Johnston JA, 2005, BIOCHEM SOC T, V33, P1096, DOI 10.1042/BST0331096; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Koistinaho M, 2005, BRAIN RES REV, V48, P240, DOI 10.1016/j.brainresrev.2004.12.014; Kokmen E, 1996, NEUROLOGY, V46, P154, DOI 10.1212/WNL.46.1.154; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee EB, 2005, J CELL BIOL, V168, P291, DOI 10.1083/jcb.200407070; Lee PH, 2006, NEUROCHEM RES, V31, P821, DOI 10.1007/s11064-006-9086-y; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Marshall AJ, 2006, BRAIN RES, V1099, P18, DOI 10.1016/j.brainres.2006.05.008; Maxwell P, 2004, CANCER BIOL THER, V3, P29, DOI 10.4161/cbt.3.1.547; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Nowak K, 2006, J NEUROCHEM, V96, P1696, DOI 10.1111/j.1471-4159.2006.03692.x; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Ono Y, 2006, J CELL BIOCHEM, V98, P642, DOI 10.1002/jcb.20804; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; Shi J, 2000, BRAIN RES, V853, P1, DOI 10.1016/S0006-8993(99)02113-7; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Sun XL, 2006, FASEB J, V20, P1361, DOI 10.1096/fj.05-5628com; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-4; Wang RS, 2006, MOL CELL BIOL, V26, P1347, DOI 10.1128/MCB.26.4.1347-1354.2006; Wang RS, 2006, FASEB J, V20, P1275, DOI 10.1096/fj.06-5839fje; Webster NJ, 2004, MOL BRAIN RES, V130, P161, DOI 10.1016/j.molbrainres.2004.06.042; Webster NJ, 2002, J NEUROCHEM, V83, P1262, DOI 10.1046/j.1471-4159.2002.01236.x; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zheng H, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-5	47	306	319	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10873	10880		10.1074/jbc.M608856200	http://dx.doi.org/10.1074/jbc.M608856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303576	hybrid			2022-12-27	WOS:000245941500006
J	Hashikawa, N; Yamamoto, N; Sakurai, H				Hashikawa, Naoya; Yamamoto, Noritaka; Sakurai, Hiroshi			Different mechanisms are involved in the transcriptional activation by yeast heat shock transcription factor through two different types of heat shock elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; METALLOTHIONEIN GENE-EXPRESSION; GENOME-WIDE ANALYSIS; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; FACTOR CONTAINS; COILED-COIL; FACTOR HSF1; TRIMERIZATION DOMAIN; NUCLEAR-LOCALIZATION	The hydrophobic repeat is a conserved structural motif of eukaryotic heat shock transcription factor ( HSF) that enables HSF to form a homotrimer. Homotrimeric HSF binds to heat shock elements ( HSEs) consisting of three inverted repeats of the sequence nGAAn. Sequences consisting of four or more nGAAn units are bound cooperatively by two HSF trimers. We show that in Saccharomyces cerevisiae cells oligomerization-defective Hsf1 is not able to bind HSEs with three units and is not extensively phosphorylated in response to stress; it is therefore unable to activate genes containing this type of HSE. Several lines of evidence indicate that oligomerization is a prerequisite for stress-induced hyperphosphorylation of Hsf1. In contrast, oligomerization and hyperphosphorylation are not necessary for gene activation via HSEs with four units. Intragenic suppressor screening of oligomerization- defective hsf1 showed that an interface between adjacent DNA- binding domains is important for the binding of Hsf1 to the HSE. We suggest that Saccharomyces cerevisiae HSEs with different structures are regulated differently; HSEs with three units require Hsf1 to be both oligomerized and hyperphosphorylated, whereas HSEs with four or more units do not require either.	Kanazawa Univ, Div Hlth Sci, Grad Sch Med Sci, Kanazawa, Ishikawa 9200942, Japan	Kanazawa University	Sakurai, H (corresponding author), Kanazawa Univ, Div Hlth Sci, Grad Sch Med Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 9200942, Japan.	sakurai@kenroku.kanazawa-u.ac.jp	SAKURAI, Hiroshi/L-3693-2015	Hashikawa, Naoya/0000-0001-8192-6881; Sakurai, Hiroshi/0000-0002-0336-2301				Ahn SG, 2001, GENE DEV, V15, P2134, DOI 10.1101/gad.894801; Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Drees BL, 1997, J MOL BIOL, V273, P61, DOI 10.1006/jmbi.1997.1283; Eastmond DL, 2006, J BIOL CHEM, V281, P32909, DOI 10.1074/jbc.M602454200; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FLICK KE, 1994, J BIOL CHEM, V269, P12475; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hashikawa N, 2006, J BIOL CHEM, V281, P3936, DOI 10.1074/jbc.M510827200; Hashikawa N, 2004, MOL CELL BIOL, V24, P3648, DOI 10.1128/MCB.24.9.3648-3659.2004; Imazu H, 2005, EUKARYOT CELL, V4, P1050, DOI 10.1128/EC.4.6.1050-1056.2005; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marchler G, 2001, EMBO J, V20, P499, DOI 10.1093/emboj/20.3.499; Morano KA, 1999, MOL CELL BIOL, V19, P402; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Orosz A, 1996, MOL CELL BIOL, V16, P7018; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Peteranderl R, 1999, BIOCHEMISTRY-US, V38, P3559, DOI 10.1021/bi981774j; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Sakurai H, 2003, GENES CELLS, V8, P951, DOI 10.1046/j.1356-9597.2003.00689.x; Sakurai H, 2001, BIOCHEM BIOPH RES CO, V285, P696, DOI 10.1006/bbrc.2001.5234; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Takemori Y, 2006, MOL GENET GENOMICS, V275, P89, DOI 10.1007/s00438-005-0065-9; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Trott A, 2003, TOP CURR GENET, V1, P71; Vinson C, 2006, BBA-GENE STRUCT EXPR, V1759, P4, DOI 10.1016/j.bbaexp.2005.12.005; Voellmy R, 2004, CELL STRESS CHAPERON, V9, P122, DOI 10.1379/CSC-14R.1; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Yamamoto A, 2006, BIOCHEM BIOPH RES CO, V346, P1324, DOI 10.1016/j.bbrc.2006.06.057; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Zarzov P, 1997, J CELL SCI, V110, P1879; Zhao J, 2005, MOL CELL BIOL, V25, P8985, DOI 10.1128/MCB.25.20.8985-8999.2005; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zou JY, 1998, CELL STRESS CHAPERON, V3, P130, DOI 10.1379/1466-1268(1998)003<0130:CBGOAT>2.3.CO;2; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	60	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10333	10340		10.1074/jbc.M609708200	http://dx.doi.org/10.1074/jbc.M609708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289668	hybrid			2022-12-27	WOS:000245941000023
J	Wilhelm, D; Hiramatsu, R; Mizusaki, H; Widjaja, L; Combes, AN; Kanai, Y; Koopman, P				Wilhelm, Dagmar; Hiramatsu, Ryuji; Mizusaki, Hirofumi; Widjaja, Laura; Combes, Alexander N.; Kanai, Yoshiakira; Koopman, Peter			SOX9 regulates prostaglandin D synthase gene transcription in vivo to ensure testis development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRY-RELATED GENE; SEX DETERMINATION REVEALS; CAMPOMELIC DYSPLASIA; ENHANCER ELEMENTS; GONAD DEVELOPMENT; COLLAGEN GENE; GENITAL RIDGE; MOUSE; EXPRESSION; DIFFERENTIATION	In mammals, male sex is determined by the Y-chromosomal gene Sry ( sex-determining region of Y chromosome). The expression of Sry and subsequently Sox9 ( SRY box containing gene 9) in precursors of the supporting cell lineage results in the differentiation of these cells into Sertoli cells. Sertoli cells in turn orchestrate the development of all other male-specific cell types. To ensure that Sertoli cells differentiate in sufficient numbers to induce normal testis development, the early testis produces prostaglandin D-2 ( PGD(2)), which recruits cells of the supporting cell lineage to a Sertoli cell fate. Here we show that the gene encoding prostaglandin D synthase ( Pgds), the enzyme that produces PGD2, is expressed in Sertoli cells immediately after the onset of Sox9 expression. Promoter analysis in silico and in vitro identified a paired SOX/SRY binding site. Interestingly, only SOX9, and not SRY, was able to bind as a dimer to this site and transactivate the Pgds promoter. In line with this, a transgenic mouse model showed that Pgds expression is not affected by ectopic Sry expression. Finally, chromatin immuno-precipitation proved that SOX9 but not SRY binds to the Pgds promoter in vivo.	Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Tokyo, Dept Vet Anat, Bunkyo Ku, Tokyo 1138657, Japan; Univ Queensland, ARC Ctr Excellence Biotechnol & Dev, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland; University of Tokyo; University of Queensland	Koopman, P (corresponding author), Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	p.koopman@imb.uq.edu.Au	Wilhelm, Dagmar/B-6915-2009; Combes, Alexander N/B-7228-2011; Koopman, Peter A/C-9416-2009	Wilhelm, Dagmar/0000-0002-7757-4075; Combes, Alexander N/0000-0001-6008-8786; Koopman, Peter A/0000-0001-6939-0914; Kanai, Yoshiakira/0000-0003-2116-7806				Adams IR, 2002, DEVELOPMENT, V129, P1155; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bernard P, 2003, HUM MOL GENET, V12, P1755, DOI 10.1093/hmg/ddg182; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Beverdam A, 2003, CYTOGENET GENOME RES, V101, P242, DOI 10.1159/000074344; Beverdam A, 2006, HUM MOL GENET, V15, P417, DOI 10.1093/hmg/ddi463; Bishop CE, 2000, NAT GENET, V26, P490, DOI 10.1038/82652; Bridgewater LC, 2003, NUCLEIC ACIDS RES, V31, P1541, DOI 10.1093/nar/gkg230; Bullejos M, 2001, DEV DYNAM, V221, P201, DOI 10.1002/dvdy.1134; BURGOYNE PS, 1988, DEVELOPMENT, V104, P683; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Fujimori K, 2005, J BIOL CHEM, V280, P18452, DOI 10.1074/jbc.M411755200; Fujimori K, 2003, J BIOL CHEM, V278, P6018, DOI 10.1074/jbc.M208288200; Gao F, 2006, P NATL ACAD SCI USA, V103, P11987, DOI 10.1073/pnas.0600994103; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HACKER A, 1995, DEVELOPMENT, V121, P1603; Hiramatsu R, 2003, DEV DYNAM, V228, P247, DOI 10.1002/dvdy.10379; Huang B, 1999, AM J MED GENET, V87, P349, DOI 10.1002/(SICI)1096-8628(19991203)87:4<349::AID-AJMG13>3.0.CO;2-N; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; Jenkins E, 2005, MATRIX BIOL, V24, P177, DOI 10.1016/j.matbio.2005.02.004; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Kent J, 1996, DEVELOPMENT, V122, P2813; Kidokoro T, 2005, DEV BIOL, V278, P511, DOI 10.1016/j.ydbio.2004.11.006; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Malki S, 2005, EMBO J, V24, P1798, DOI 10.1038/sj.emboj.7600660; McDowall S, 1999, J BIOL CHEM, V274, P24023, DOI 10.1074/jbc.274.34.24023; Nef S, 2005, DEV BIOL, V287, P361, DOI 10.1016/j.ydbio.2005.09.008; PALMER SJ, 1991, DEVELOPMENT, V112, P265; PATEK CE, 1991, DEVELOPMENT, V113, P311; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; Rentsendorj O, 2005, BIOCHEM J, V389, P705, DOI 10.1042/BJ20050214; Schepers G, 2003, J BIOL CHEM, V278, P28101, DOI 10.1074/jbc.M304067200; Small CL, 2005, BIOL REPROD, V72, P492, DOI 10.1095/biolreprod.104.033696; Sock E, 2003, HUM MOL GENET, V12, P1439, DOI 10.1093/hmg/ddg158; Urade Y, 2000, BBA-PROTEIN STRUCT M, V1482, P259, DOI 10.1016/S0167-4838(00)00161-8; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; White DM, 1997, J BIOL CHEM, V272, P14387, DOI 10.1074/jbc.272.22.14387; Wilhelm D, 2005, DEV BIOL, V287, P111, DOI 10.1016/j.ydbio.2005.08.039; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Wilhelm D, 2006, NAT REV GENET, V7, P620, DOI 10.1038/nrg1903; Wilhelm D, 2006, GENESIS, V44, P168, DOI 10.1002/dvg.20200; Wilson MJ, 2005, J BIOL CHEM, V280, P5917, DOI 10.1074/jbc.M412806200; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	49	172	175	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10553	10560		10.1074/jbc.M609578200	http://dx.doi.org/10.1074/jbc.M609578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17277314	hybrid			2022-12-27	WOS:000245941000048
J	Basu, S; Jala, VR; Mathis, S; Rajagopal, ST; Del Prete, A; Maturu, P; Trent, JO; Haribabu, B				Basu, Sudeep; Jala, Venkatakrishna R.; Mathis, Steven; Rajagopal, Soujanya T.; Del Prete, Annalisa; Maturu, Paramahamsa; Trent, John O.; Haribabu, Bodduluri			Critical role for polar residues in coupling leukotriene B-4 binding to signal transiduction in BLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; LIGAND-BINDING; RECEPTOR ACTIVATION; MOLECULAR-MECHANISMS; PARTIAL AGONISTS; GPCR FUNCTION; AMINO-ACIDS; RHODOPSIN; SITE; MUTAGENESIS	Leukotriene B-4 (LTB4) mediates a variety of inflammatory diseases such as asthma, arthritis, atherosclerosis, and cancer through activation of the G-protein-coupled receptor, BLT1. Using in silica molecular dynamics simulations combined with site-directed mutagenesis we characterized the ligand binding site and activation mechanism for BLT1. Mutation of residues predicted as potential ligand contact points in transmembrane domains (TMs) III (H94A and Y102A), V (E185A), and VI (N241A) resulted in reduced binding affinity. Analysis of arginines in extracellular loop 2 revealed that mutating arginine 156 but not arginine 171 or 178 to alanine resulted in complete loss of LTB4 binding to BLT1. Structural models for the ligand-free and ligand-bound states of BLT1 revealed an activation core formed around Asp-64, displaying multiple dynamic interactions with Asn-36, Ser-100, and Asn-281 and a triad of serines, Ser-276, Ser-277, and Ser-278. Mutagenesis of many of these residues in BLT1 resulted in loss of signaling capacity while retaining normal LTB4 binding function. Thus, polar residues within TMs III, V, and VI and extracellular loop 2 are critical for ligand binding, whereas polar residues in TMs II, III, and VII play a central role in transducing the ligand-induced conformational change to activation. The delineation of a validated binding site and activation mechanism should facilitate structurebased design of inhibitors targeting BLT1.	Univ Louisville, James Graham Brown Canc Ctr, Tumor Immunobiol Program, Louisville, KY 40202 USA; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville	Haribabu, B (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Tumor Immunobiol Program, 529 S Jackson St, Louisville, KY 40202 USA.	H0bodd01@gwise.louisville.edu	Bodduluri, Haribabu/A-2584-2010; Jala, Venkatakrishna R/K-7255-2018; Del Prete, Annalisa/Z-1368-2019	Bodduluri, Haribabu/0000-0002-8261-3294; Jala, Venkatakrishna R/0000-0002-4206-7305; Del Prete, Annalisa/0000-0002-3738-412X; Mathis, Steven/0000-0001-7704-1220; trent, John/0000-0002-7346-4231	NIAID NIH HHS [AI52381] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052381] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Baneres JL, 2003, J MOL BIOL, V329, P801, DOI 10.1016/S0022-2836(03)00438-8; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Colvin RA, 2006, MOL CELL BIOL, V26, P5838, DOI 10.1128/MCB.00556-06; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; Eddy S R, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P114; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Fanelli F, 2005, CHEM REV, V105, P3297, DOI 10.1021/cr000095n; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gao ZG, 2002, J BIOL CHEM, V277, P19056, DOI 10.1074/jbc.M110960200; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Hata AN, 2005, J BIOL CHEM, V280, P32442, DOI 10.1074/jbc.M502563200; Helgadottir A, 2006, NAT GENET, V38, P68, DOI 10.1038/ng1692; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; Jala VR, 2004, TRENDS IMMUNOL, V25, P315, DOI 10.1016/j.it.2004.04.003; Jongejan A, 2005, NAT CHEM BIOL, V1, P98, DOI 10.1038/nchembio714; Kim ND, 2006, J EXP MED, V203, P829, DOI 10.1084/jem.20052349; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liu W, 2004, J MOL BIOL, V337, P713, DOI 10.1016/j.jmb.2004.02.001; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miyahara N, 2005, AM J RESP CRIT CARE, V172, P161, DOI 10.1164/rccm.200502-205OC; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Ogilvie P, 2004, J IMMUNOL, V172, P6715, DOI 10.4049/jimmunol.172.11.6715; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; Rader AJ, 2004, P NATL ACAD SCI USA, V101, P7246, DOI 10.1073/pnas.0401429101; Rao JVK, 2000, EUR J BIOCHEM, V267, P5967, DOI 10.1046/j.1432-1327.2000.01667.x; Sabirsh A, 2006, BIOCHEMISTRY-US, V45, P5733, DOI 10.1021/bi060076t; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Shao WH, 2006, J IMMUNOL, V176, P6254, DOI 10.4049/jimmunol.176.10.6254; Shin N, 2002, MOL PHARMACOL, V62, P38, DOI 10.1124/mol.62.1.38; Spijker P, 2006, P NATL ACAD SCI USA, V103, P4882, DOI 10.1073/pnas.0511329103; Steeber DA, 1997, J IMMUNOL, V159, P952; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Trent JO, 2003, J BIOL CHEM, V278, P47136, DOI 10.1074/jbc.M307850200; Tunaru S, 2005, MOL PHARMACOL, V68, P1271, DOI 10.1124/mol.105.015750; Urizar E, 2005, J BIOL CHEM, V280, P17135, DOI 10.1074/jbc.M414678200; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; ZHOU W, 1994, MOL PHARMACOL, V45, P165	58	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10005	10017		10.1074/jbc.M609552200	http://dx.doi.org/10.1074/jbc.M609552200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17237498	Green Published, hybrid			2022-12-27	WOS:000245421700075
J	Chen, KH; Liu, S; Bankston, LA; Liddington, RC; Leppla, SH				Chen, Kuang-Hua; Liu, Shihui; Bankston, Laurie A.; Liddington, Robert C.; Leppla, Stephen H.			Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY MORPHOGENESIS PROTEIN-2; CRYSTAL-STRUCTURE; BACILLUS-ANTHRACIS; LETHAL FACTOR; DOMAIN; UROKINASE; BINDING; IDENTIFICATION; ENDOTHELIUM; SPECIFICITY	Anthrax toxin, a three-component protein toxin secreted by Bacillus anthracis, assembles into toxic complexes at the surface of receptor-bearing eukaryotic cells. The protective antigen (PA) protein binds to receptors, either tumor endothelial cell marker 8 (TEM8) or CMG2 (capillary morphogenesis protein 2), and orchestrates the delivery of the lethal and edema factors into the cytosol. TEM8 is reported to be overexpressed during tumor angiogenesis, whereas CMG2 is more widely expressed in normal tissues. To extend prior work on targeting of tumor with modified anthrax toxins, we used phage display to select PA variants that preferentially bind to TEM8 as compared with CMG2. Substitutions were randomly introduced into residues 605-729 of PA, within the C-terminal domain 4 of PA, which is the principal region that contacts receptor. Candidates were characterized in cellular cytotoxicity assays with Chinese hamster ovary (CHO) cells expressing either TEM8 or CMG2. A PA mutant having the substitutions R659S and M662R had enhanced specificity toward TEM8-overexpressing CHO cells. This PA variant also displayed broad and potent tumoricidal activity to various human tumor cells, especially to HeLa and A549/ATCC cells. By contrast, the substitution N657Q significantly reduced toxicity to TEM8 but not CMG2-overexpressing CHO cells. Our results indicate that certain amino acid substitutions within PA domain 4 create anthrax toxins that selectively kill human tumor cells. The PA R659S/M662R protein may be useful as a therapeutic agent for cancer treatment.	NIAID, NIH, Lab Bacterial Dis, Bethesda, MD 20892 USA; Burnham Inst Med Res, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Sanford Burnham Prebys Medical Discovery Institute	Leppla, SH (corresponding author), NIAID, NIH, Lab Bacterial Dis, Bldg 33,Rm 1W20B, Bethesda, MD 20892 USA.	sleppla@niaid.nih.gov		Liu, Shihui/0000-0003-3444-1069	Intramural NIH HHS [Z01 AI000929-05] Funding Source: Medline; NIAID NIH HHS [AI055789, P01 AI055789, P01 AI055789-040001] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055789, Z01AI001031, Z01AI000929] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrami L, 2005, TRENDS MICROBIOL, V13, P72, DOI 10.1016/j.tim.2004.12.004; ARORA N, 1993, J BIOL CHEM, V268, P3334; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Brossier F, 1999, INFECT IMMUN, V67, P964, DOI 10.1128/IAI.67.2.964-967.1999; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Ke SH, 1997, J BIOL CHEM, V272, P20456, DOI 10.1074/jbc.272.33.20456; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LEPPLA SH, 2006, COMPREHENSIVE SOURCE, P323; LIU S, 2006, CELL MICROB; Liu SH, 2000, CANCER RES, V60, P6061; Liu SH, 2005, NAT BIOTECHNOL, V23, P725, DOI 10.1038/nbt1091; Liu SH, 2003, EXPERT OPIN BIOL TH, V3, P843, DOI 10.1517/14712598.3.5.843; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Liu SH, 2003, P NATL ACAD SCI USA, V100, P657, DOI 10.1073/pnas.0236849100; Liu SH, 2001, J BIOL CHEM, V276, P17976, DOI 10.1074/jbc.M011085200; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Ramirez DM, 2002, J IND MICROBIOL BIOT, V28, P232, DOI 10.1038/sj/jim/700239; Rosovitz MJ, 2003, J BIOL CHEM, V278, P30936, DOI 10.1074/jbc.M301154200; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2006, PLOS PATHOG, V2, P949, DOI 10.1371/journal.ppat.0020111; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; SINGH Y, 1989, J BIOL CHEM, V264, P19103; St Croix B, 2000, SCIENCE, V289, P1197; Varughese M, 1999, INFECT IMMUN, V67, P1860; Zaccolo M, 1996, J MOL BIOL, V255, P589, DOI 10.1006/jmbi.1996.0049	33	30	35	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9834	9845		10.1074/jbc.M611142200	http://dx.doi.org/10.1074/jbc.M611142200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251181	hybrid, Green Accepted			2022-12-27	WOS:000245421700058
J	Murphy, JW; Cho, Y; Sachpatzidis, A; Fan, CP; Hodsdon, ME; Lolis, E				Murphy, James W.; Cho, Yoonsang; Sachpatzidis, Aristidis; Fan, Chengpeng; Hodsdon, Michael E.; Lolis, Elias			Structural and functional basis of CXCL12 (strornal cell-derived factor-1 alpha) binding to heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSAMINOGLYCAN BINDING; CHEMOKINE-RECEPTOR; BREAST-CANCER; FACTOR-I; LYMPHOCYTE CHEMOATTRACTANT; CRYSTAL-STRUCTURE; STEM-CELLS; CXCR4; LIGAND; IDENTIFICATION	CXCL12 (SDF-1 alpha) and CXCR4 are critical for embryonic development and cellular migration in adults. These proteins are involved in HIV-1 infection, cancer metastasis, and WHIM disease. Sequestration and presentation of CXCL12 to CXCR4 by glycosaminoglycans (GAGs) is proposed to be important for receptor activation. Mutagenesis has identified CXCL12 residues that bind to heparin. However, the molecular details of this interaction have not yet been determined. Here we demonstrate that soluble heparin and heparan sulfate negatively affect CXCL12-mediated in vitro chernotaxis. We also show that a cluster of basic residues in the dimer interface is required for chemotaxis and is a target for inhibition by heparin. We present structural evidence for binding of an unsaturated heparin disaccharide to CXCL12 attained through solution NMR spectroscopy and x-ray crystallography. Increasing concentrations of the disaccharide altered the two-dimensional H-1-N-15-HSQC spectra of CXCL12, which identified two clusters of residues. One cluster corresponds to beta-strands in the dimer interface. The second includes the amino-terminal loop and the a-helix. In the x-ray structure two unsaturated disaccharides are present. One is in the dimer interface with direct contacts between residues His(25) Lys(27), and Arg(41) of CXCL12 and the heparin disaccharide. The second disaccharide contacts Ala(20), Arg(21), Asn(30), and Lys(64). This is the first x-ray structure of a CXC class chemokine in complex with glycosaminoglycans. Based on the observation of two heparin binding sites, we propose a mechanism in which GAGs bind around CXCL12 dimers as they sequester and present CXCL12 to CXCR4.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA	Yale University; Yale University	Lolis, E (corresponding author), 333 Cedar St, New Haven, CT 06510 USA.	elias.lolis@yale.edu		Lolis, Elias/0000-0002-7902-7868; Sachpatzidis, Aristidis/0000-0002-5237-0842	NIAID NIH HHS [R01 AI065029, R01 AI082295] Funding Source: Medline; NINDS NIH HHS [T32 NS007136] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065029, R01AI082295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bajetto A, 2001, FRONT NEUROENDOCRIN, V22, P147, DOI 10.1006/frne.2001.0214; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai SH, 2004, ACTA PHARMACOL SIN, V25, P152; Campanella GSV, 2003, J BIOL CHEM, V278, P17066, DOI 10.1074/jbc.M212077200; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Diaz GA, 2005, CURR ALLERGY ASTHM R, V5, P350, DOI 10.1007/s11882-005-0005-0; Epstein RJ, 2004, NAT REV CANCER, V4, P901, DOI 10.1038/nrc1473; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Gozansky EK, 2005, J MOL BIOL, V345, P651, DOI 10.1016/j.jmb.2004.11.003; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Holmes WD, 2001, PROTEIN EXPRES PURIF, V21, P367, DOI 10.1006/prep.2001.1402; Johnson Z, 2005, CYTOKINE GROWTH F R, V16, P625, DOI 10.1016/j.cytogfr.2005.04.006; Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776; Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384; Kucia M, 2004, J MOL HISTOL, V35, P233; Kucia M, 2005, BIOL CELL, V97, P133, DOI 10.1042/BC20040069; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lau EK, 2004, ADV PROTEIN CHEM, V68, P351; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Mbemba E, 1999, VIROLOGY, V265, P354, DOI 10.1006/viro.1999.0033; Mbemba E, 2000, GLYCOBIOLOGY, V10, P21, DOI 10.1093/glycob/10.1.21; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mikhailov D, 1999, J BIOL CHEM, V274, P25317, DOI 10.1074/jbc.274.36.25317; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1998, SEMIN IMMUNOL, V10, P179, DOI 10.1006/smim.1998.0128; Ohnishi Y, 2000, J INTERF CYTOK RES, V20, P691, DOI 10.1089/10799900050116390; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Sachpatzidis A, 2003, J BIOL CHEM, V278, P896, DOI 10.1074/jbc.M204667200; Sadir R, 2004, J BIOL CHEM, V279, P43854, DOI 10.1074/jbc.M405392200; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Shaw JP, 2004, STRUCTURE, V12, P2081, DOI 10.1016/j.str.2004.08.014; Stringer SE, 2003, BLOOD, V101, P2243, DOI 10.1182/blood-2002-08-2588; TYRRELL DJ, 1995, TRENDS PHARMACOL SCI, V16, P198, DOI 10.1016/S0165-6147(00)89022-7; Veldkamp CT, 2005, PROTEIN SCI, V14, P1071, DOI 10.1110/ps.041219505; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; White FA, 2005, NAT REV DRUG DISCOV, V4, P834, DOI 10.1038/nrd1852; Xanthou G, 2003, EUR J IMMUNOL, V33, P2927, DOI 10.1002/eji.200324235; Zemla A, 2003, NUCLEIC ACIDS RES, V31, P3370, DOI 10.1093/nar/gkg571; Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200	54	142	146	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10018	10027		10.1074/jbc.M608796200	http://dx.doi.org/10.1074/jbc.M608796200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17264079	Green Accepted, hybrid			2022-12-27	WOS:000245421700076
J	Murray, IVJ; Liu, L; Komatsu, H; Uryu, K; Xiao, G; Lawson, JA; Axelsen, PH				Murray, Ian V. J.; Liu, Liu; Komatsu, Hiroaki; Uryu, Kunihiro; Xiao, Gang; Lawson, John A.; Axelsen, Paul H.			Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; PRECURSOR PROTEIN; CEREBROSPINAL-FLUID; MASS-SPECTROMETRY; FIBRIL FORMATION; GENE-EXPRESSION; PEROXIDATION; STRESS; PEPTIDES	Evidence of oxidative stress and the accumulation of fibrillar amyloid beta proteins (A beta) in senile plaques throughout the cerebral cortex are consistent features in the pathology of Alzheimer disease. To define a mechanistic link between these two processes, various aspects of the relationship between oxidative lipid membrane damage and amyloidogenesis were characterized by chemical and physical techniques. Earlier studies of this relationship demonstrated that oxidatively damaged synthetic lipid membranes promoted amyloidogenesis. The studies reported herein specify that 4-hydroxy-2-nonenal (HNE) is produced in both synthetic lipids and human brain lipid extracts by oxidative lipid damage and that it can account for accelerated amyloidogenesis. A beta promotes the copper-mediated generation of HNE from polyunsaturated lipids, and in turn, HNE covalently modifies the histidine side chains of A beta. HNE-modified A beta have an increased affinity for lipid membranes and an increased tendency to aggregate into amyloid fibrils. Thus, the prooxidant activity of A beta leads to its own covalent modification and to accelerated amyloidogenesis. These results illustrate how lipid membranes may be involved in templating the pathological misfolding of A beta, and they suggest a possible chemical mechanism linking oxidative stress with amyloid formation.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Proteom Core Facil, Penn Genom Inst, Philadelphia, PA 19104 USA; Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Axelsen, PH (corresponding author), Univ Penn, Dept Pharmacol, 105 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.	axe@pharm.med.upenn.edu	Murray, Ian/O-5983-2015	Murray, Ian/0000-0003-1196-1360	NIA NIH HHS [R03 AG027893-02, R03 AG027893-01, P30 AG010124, R03 AG027893-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010124, R03AG027893] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alderton AL, 2003, BIOCHEMISTRY-US, V42, P4398, DOI 10.1021/bi0271695; Ando Y, 1998, J NEUROL SCI, V156, P172, DOI 10.1016/S0022-510X(98)00042-2; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Bassett CN, 1999, LIPIDS, V34, P1273, DOI 10.1007/s11745-999-0478-1; Bayer TA, 2006, CLIN NEUROPATHOL, V25, P163; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bieschke J, 2005, BIOCHEMISTRY-US, V44, P4977, DOI 10.1021/bi0501030; Bolgar MS, 1996, J BIOL CHEM, V271, P27999, DOI 10.1074/jbc.271.45.27999; Bolgar MS, 1996, ANAL CHEM, V68, P2325, DOI 10.1021/ac9601021; Boutaud O, 2002, J NEUROCHEM, V82, P1003, DOI 10.1046/j.1471-4159.2002.01064.x; Boutaud O, 2001, ADV EXP MED BIOL, V500, P133; Boyd-Kimball D, 2005, BRAIN RES, V1044, P206, DOI 10.1016/j.brainres.2005.02.086; Bradbury Lisa E, 2004, Methods Mol Biol, V264, P245; BRUENNER BA, 1995, CHEM RES TOXICOL, V8, P552, DOI 10.1021/tx00046a009; Butterfield DA, 2004, BRAIN PATHOL, V14, P426; Butterfield DA, 2004, BRAIN RES, V1000, P1, DOI 10.1016/j.brainres.2003.12.012; Carini M, 2004, MASS SPECTROM REV, V23, P281, DOI 10.1002/mas.10076; CHRISTIE WW, 2003, LIPID ANAL, P96; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Fenaille F, 2003, J AM SOC MASS SPECTR, V14, P215, DOI 10.1016/S1044-0305(02)00911-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; Galbusera C, 2004, CURR ALZHEIMER RES, V1, P103, DOI 10.2174/1567205043332171; HALLIWELL B, 1999, FREE RADIC BIOL MED; Hayashi H, 2004, J NEUROSCI, V24, P4894, DOI 10.1523/JNEUROSCI.0861-04.2004; Koppaka V, 2000, BIOCHEMISTRY-US, V39, P10011, DOI 10.1021/bi000619d; Koppaka V, 2003, J BIOL CHEM, V278, P36277, DOI 10.1074/jbc.M301334200; Koppaka V, 2001, LANGMUIR, V17, P6309, DOI 10.1021/la010731s; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lewczuk P, 2004, BIOL PSYCHIAT, V55, P524, DOI 10.1016/j.biopsych.2003.10.014; Lewis HD, 2004, NEUROBIOL AGING, V25, P1175, DOI 10.1016/j.neurobiolaging.2003.12.009; Li F, 2004, J NEUROCHEM, V89, P1308, DOI 10.1111/j.1471-4159.2004.02455.x; Liu ZF, 2003, CHEM RES TOXICOL, V16, P901, DOI 10.1021/tx0300030; Loeffler DA, 1996, BRAIN RES, V738, P265, DOI 10.1016/S0006-8993(96)00782-2; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Magni F, 2002, RAPID COMMUN MASS SP, V16, P1485, DOI 10.1002/rcm.743; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Markesbery WR, 1998, NEUROBIOL AGING, V19, P33, DOI 10.1016/S0197-4580(98)00009-8; McGowan E, 1999, NEUROBIOL DIS, V6, P231, DOI 10.1006/nbdi.1999.0243; McGrath LT, 2001, QJM-MON J ASSOC PHYS, V94, P485, DOI 10.1093/qjmed/94.9.485; Meagher EA, 2001, JAMA-J AM MED ASSOC, V285, P1178, DOI 10.1001/jama.285.9.1178; Misonou H, 2000, BIOCHEMISTRY-US, V39, P6951, DOI 10.1021/bi000169p; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Murray IVJ, 2005, BIOCHEMISTRY-US, V44, P12606, DOI 10.1021/bi050926p; NADKARNI DV, 1995, CHEM RES TOXICOL, V8, P284, DOI 10.1021/tx00044a014; Nelson TJ, 2005, J BIOL CHEM, V280, P7377, DOI 10.1074/jbc.M409071200; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Puglielli L, 2005, J CLIN INVEST, V115, P2556, DOI 10.1172/JCI23610; Pype S, 2003, J NEUROCHEM, V84, P602, DOI 10.1046/j.1471-4159.2003.01556.x; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Rofina JE, 2004, AMYLOID, V11, P90, DOI 10.1080/13506120412331285779; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SCHAUR RJ, 2006, MOL ASPECTS MED, V24, P149; Schippling S, 2000, FREE RADICAL BIO MED, V28, P351, DOI 10.1016/S0891-5849(99)00247-6; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Schuessel K, 2005, NEUROBIOL DIS, V18, P89, DOI 10.1016/j.nbd.2004.09.003; Shringarpure R, 2000, CELL MOL LIFE SCI, V57, P1802, DOI 10.1007/PL00000660; Silvestro L, 1999, BIOCHEMISTRY-US, V38, P113, DOI 10.1021/bi981289o; Smith MA, 2002, FREE RADICAL BIO MED, V33, P1194, DOI 10.1016/S0891-5849(02)01021-3; Standridge John B., 2006, Current Alzheimer Research, V3, P95, DOI 10.2174/156720506776383068; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; Tamagno E, 2005, J NEUROCHEM, V92, P628, DOI 10.1111/j.1471-4159.2004.02895.x; Tamagno E, 2006, FREE RADICAL BIO MED, V41, P202, DOI 10.1016/j.freeradbiomed.2006.01.021; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; TOYOKUNI S, 1995, FEBS LETT, V359, P189, DOI 10.1016/0014-5793(95)00033-6; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; WHITE DA, 1973, PHOSPHOLIPID COMPOSI, P441; Wu Yanjue, 2005, Current Alzheimer Research, V2, P37, DOI 10.2174/1567205052772768; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yao Y, 2003, NEUROLOGY, V61, P475, DOI 10.1212/01.WNL.0000070185.02546.5D; Yoshimoto N, 2005, J BIOSCI BIOENG, V100, P455, DOI 10.1263/jbb.100.455; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101	82	94	96	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9335	9345		10.1074/jbc.M608589200	http://dx.doi.org/10.1074/jbc.M608589200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17255094	Green Accepted, hybrid			2022-12-27	WOS:000245421700005
J	Park, JE; Park, JY; Kim, YS; Staswick, PE; Jeon, J; Yun, J; Kim, SY; Kim, J; Lee, YH; Park, CM				Park, Jung-Eun; Park, Ju-Young; Kim, Youn-Sung; Staswick, Paul E.; Jeon, Jin; Yun, Ju; Kim, Sun-Young; Kim, Jungmook; Lee, Yong-Hwan; Park, Chung-Mo			GH3-mediated auxin homeostasis links growth regulation with stress adaptation response in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFENSE GENE-EXPRESSION; SIGNALING PATHWAYS; TRANSCRIPTION FACTOR; DISEASE RESISTANCE; FITNESS COSTS; CROSS-TALK; ACID; HYPOCOTYL; THALIANA; PLANTS	Plants constantly monitor environmental fluctuations to optimize their growth and metabolism. One example is adaptive growth occurring in response to biotic and abiotic stresses. Here, we demonstrate that GH3-mediated auxin homeostasis is an essential constituent of the complex network of auxin actions that regulates stress adaptation responses in Arabidopsis. Endogenous auxin pool is regulated, at least in part, through negative feedback by a group of auxin-inducible GH3 genes encoding auxin-conjugating enzymes. An Arabidopsis mutant, wes1-D, in which a GH3 gene WES1 is activated by nearby insertion of the S-35 enhancer, exhibited auxin-deficient traits, including reduced growth and altered leaf shape. Interestingly, WES1 is also induced by various stress conditions as well as by salicylic acid and abscisic acid. Accordingly, wes1-D was resistant to both biotic and abiotic stresses, and stress-responsive genes, such as pathogenesis-related genes and CBF genes, were upregulated in this mutant. In contrast, a T-DNA insertional mutant showed reduced stress resistance. We therefore propose that GH3-mediated growth suppression directs reallocation of metabolic resources to resistance establishment and represents the fitness costs of induced resistance.	Seoul Natl Univ, Dept Chem, Mol Signalling Lab, Seoul 151742, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Seoul 151742, South Korea; Univ Nebraska, Dept Agron & Hort, Lincoln, NE 68583 USA; Chonnam Natl Univ, Dept Plant Biotechnol, Agr Plant Stress Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Biotechnol Res Inst, Kwangju 500757, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); University of Nebraska System; University of Nebraska Lincoln; Chonnam National University; Chonnam National University	Park, CM (corresponding author), Seoul Natl Univ, Dept Chem, Mol Signalling Lab, Seoul 151742, South Korea.	cmpark@snu.ac.kr	Kim, Youn/AAT-3380-2021; Kim, Sun/GSN-4867-2022; Park, Chung-Mo/B-6175-2012	Kim, Jungmook/0000-0003-1735-5564				Berleth T, 2004, CURR OPIN PLANT BIOL, V7, P553, DOI 10.1016/j.pbi.2004.07.016; BOHNERT HJ, 1995, PLANT CELL, V7, P1099, DOI 10.1105/tpc.7.7.1099; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Burdon JJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-227; COHEN JD, 1981, J LABELLED COMPD RAD, V18, P1393, DOI 10.1002/jlcr.2580180916; COHEN JD, 1986, PLANT PHYSIOL, V80, P14, DOI 10.1104/pp.80.1.14; Desveaux D, 2004, DEV CELL, V6, P229, DOI 10.1016/S1534-5807(04)00028-0; Dong XN, 2004, CURR OPIN PLANT BIOL, V7, P547, DOI 10.1016/j.pbi.2004.07.005; EPSTEIN E, 1981, J CHROMATOGR, V209, P413, DOI 10.1016/S0021-9673(00)80609-3; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; Gazzarrini S, 2003, ANN BOT-LONDON, V91, P605, DOI 10.1093/aob/mcg064; GEE MA, 1991, PLANT CELL, V3, P419, DOI 10.1105/tpc.3.4.419; Genoud T, 1998, PLANT CELL, V10, P889, DOI 10.1105/tpc.10.6.889; Genoud T, 2002, PLANT J, V31, P87, DOI 10.1046/j.1365-313X.2002.01338.x; Glickmann E, 1998, MOL PLANT MICROBE IN, V11, P156, DOI 10.1094/MPMI.1998.11.2.156; Hagen G, 2002, PLANT MOL BIOL, V49, P373, DOI 10.1023/A:1015207114117; Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1; Heil M, 2002, TRENDS PLANT SCI, V7, P61, DOI 10.1016/S1360-1385(01)02186-0; Jackson MW, 2004, MOL ECOL, V13, P3609, DOI 10.1111/j.1365-294X.2004.02343.x; Kachroo P, 2001, P NATL ACAD SCI USA, V98, P9448, DOI 10.1073/pnas.151258398; Katagiri F, 2004, CURR OPIN PLANT BIOL, V7, P506, DOI 10.1016/j.pbi.2004.07.013; Kim HJ, 2002, PLANT J, V29, P693, DOI 10.1046/j.1365-313X.2002.01249.x; KOCH E, 1990, PLANT CELL, V2, P437, DOI 10.1105/tpc.2.5.437; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; Mengiste T, 2003, PLANT CELL, V15, P2551, DOI 10.1105/tpc.014167; Nakazawa M, 2001, PLANT J, V25, P213, DOI 10.1046/j.1365-313x.2001.00957.x; Navarro L, 2006, SCIENCE, V312, P436, DOI 10.1126/science.1126088; O'Donnell PJ, 2003, PLANT J, V33, P245, DOI 10.1046/j.1365-313X.2003.01619.x; Oetiker JH, 1997, PLANT PHYSIOL, V114, P1385, DOI 10.1104/pp.114.4.1385; Pieterse CM, 2004, CURR OPIN PLANT BIOL, V7, P456, DOI 10.1016/j.pbi.2004.05.006; Rampey RA, 2004, PLANT PHYSIOL, V135, P978, DOI 10.1104/pp.104.039677; Reymond P, 1998, CURR OPIN PLANT BIOL, V1, P404, DOI 10.1016/S1369-5266(98)80264-1; RISTIC Z, 1993, PROTOPLASMA, V172, P111, DOI 10.1007/BF01379368; Sakamoto H, 2004, PLANT PHYSIOL, V136, P2734, DOI 10.1104/pp.104.046599; Staswick PE, 2005, PLANT CELL, V17, P616, DOI 10.1105/tpc.104.026690; Staswick PE, 2004, PLANT CELL, V16, P2117, DOI 10.1105/tpc.104.023549; Staswick PE, 2002, PLANT CELL, V14, P1405, DOI 10.1105/tpc.000885; Steindler C, 1999, DEVELOPMENT, V126, P4235; Takase T, 2004, PLANT J, V37, P471, DOI 10.1046/j.1365-313X.2003.01973.x; Takase T, 2003, PLANT CELL PHYSIOL, V44, P1071, DOI 10.1093/pcp/pcg130; TANAKA S, 2002, PLANT PHYSIOL, V130, P887; Uppalapati SR, 2005, PLANT J, V42, P201, DOI 10.1111/j.1365-313X.2005.02366.x; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; WOODWARD AW, 2005, PLANT CELL S, pS165; Yang TB, 2000, J BIOL CHEM, V275, P3137, DOI 10.1074/jbc.275.5.3137	47	333	367	6	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10036	10046		10.1074/jbc.M610524200	http://dx.doi.org/10.1074/jbc.M610524200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276977	hybrid			2022-12-27	WOS:000245421700078
J	Ridge, KD; Palczewski, K				Ridge, Kevin D.; Palczewski, Krzysztof			Visual rhodopsin sees the light: Structure and mechanism of G protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HETEROTRIMERIC G-PROTEIN; BETA-IONONE RING; COUPLED-RECEPTOR; ALPHA-SUBUNIT; CONFORMATIONAL-CHANGES; ACTIVATION MECHANISM; CRYSTAL-STRUCTURE; GROUND-STATE; PHOTOACTIVATION; INTERMEDIATE	The availability of crystal structures for the dark, inactive, and several light-activated photointermediate states of vertebrate visual rhodopsin has provided important mechanistic and energetic insights into the transformations underlying agonist-dependent activation of this and other G protein-coupled receptors (GPCRs). The high natural abundance of rhodopsin in the vertebrate retina, together with its specific localization to the disk membranes of the rod cell, has also enabled direct imaging of rhodopsin in its native environment. These advances have provided compelling evidence that rhodopsin, like many other GPCRs, forms highly organized oligomeric structures that, in all likelihood, are important for receptor biosynthesis, optimal activation, and signaling.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Univ Texas, Hlth Sci Ctr, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Case Western Reserve University; University of Texas System; University of Texas Health Science Center Houston	Ridge, KD (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA.	Kevin.D.Ridge@uth.tmc.edu; kxp65@case.edu			NATIONAL EYE INSTITUTE [R01EY016493, R01EY009339] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 2006, BIOCHEMISTRY-US, V45, P12986, DOI 10.1021/bi061088h; Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Alves ID, 2005, BIOPHYS J, V88, P198, DOI 10.1529/biophj.104.046722; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Carrillo JJ, 2003, J BIOL CHEM, V278, P42578, DOI 10.1074/jbc.M306165200; Chabre M, 2005, BIOCHEMISTRY-US, V44, P9395, DOI 10.1021/bi050720o; Crocker E, 2006, J MOL BIOL, V357, P163, DOI 10.1016/j.jmb.2005.12.046; Damian M, 2006, EMBO J, V25, P5693, DOI 10.1038/sj.emboj.7601449; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Fotiadis D, 2006, CURR OPIN STRUC BIOL, V16, P252, DOI 10.1016/j.sbi.2006.03.013; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; Lefkowitz RJ, 2004, TRENDS PHARMACOL SCI, V25, P413, DOI 10.1016/j.tips.2004.06.006; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Morizumi T, 2005, BIOCHEMISTRY-US, V44, P9936, DOI 10.1021/bi0504512; Nakamichi H, 2006, P NATL ACAD SCI USA, V103, P12729, DOI 10.1073/pnas.0601765103; Nakamichi H, 2006, ANGEW CHEM INT EDIT, V45, P4270, DOI 10.1002/anie.200600595; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Oldham WM, 2006, NAT STRUCT MOL BIOL, V13, P772, DOI 10.1038/nsmb1129; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ridge KD, 2006, J BIOL CHEM, V281, P7635, DOI 10.1074/jbc.M509851200; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; Shichida Y, 1998, CELL MOL LIFE SCI, V54, P1299, DOI 10.1007/s000180050256; Sommer ME, 2005, J BIOL CHEM, V280, P6861, DOI 10.1074/jbc.M411341200; Spooner PJR, 2004, J MOL BIOL, V343, P719, DOI 10.1016/j.jmb.2004.08.049; Spooner PJR, 2003, BIOCHEMISTRY-US, V42, P13371, DOI 10.1021/bi0354029; Struthers M, 2000, BIOCHEMISTRY-US, V39, P7938, DOI 10.1021/bi000771f; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Van Eps N, 2006, P NATL ACAD SCI USA, V103, P16194, DOI 10.1073/pnas.0607972103; Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100; Yao XJ, 2006, NAT CHEM BIOL, V2, P417, DOI 10.1038/nchembio801	53	83	88	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9297	9301		10.1074/jbc.R600032200	http://dx.doi.org/10.1074/jbc.R600032200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17289671	hybrid			2022-12-27	WOS:000245421700001
J	Roukos, V; Iliou, MS; Nishitani, H; Gentzel, M; Wilm, M; Taraviras, S; Lygerou, Z				Roukos, Vassilis; Iliou, Maria S.; Nishitani, Hideo; Gentzel, Marc; Wilm, Matthias; Taraviras, Stavros; Lygerou, Zoi			Geminin cleavage during apoptosis by caspase-3 alters its binding ability to the SWI/SNF subunit brahma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN CDC6; CASEIN KINASE-II; DNA-REPLICATION; CELL-CYCLE; LICENSING FACTOR; PHOSPHORYLATION; INHIBITION; DEATH; CDT1; DIFFERENTIATION	Geminin has been proposed to coordinate cell cycle and differentiation events through balanced interactions with the cell cycle regulator Cdt1 and with homeobox transcription factors and chromatin remodeling activities implicated in cell fate decisions. Here we show that Geminin is cleaved in primary cells and cancer cell lines induced to undergo apoptosis by a variety of stimuli. Geminin targeting is mediated by caspase-3 both in vivo and in vitro. Two sites at the carboxyl terminus of Geminin (named C1 and C2) are cleaved by the caspase, producing truncated forms of Geminin. We provide evidence that Geminin cleavage is regulated by phosphorylation. Casein kinase II alters Geminin cleavage at site C1 in vitro, whereas mutating phosphorylation competent Ser/Thr residues proximal to site C1 affects Geminin cleavage in vivo. We show that truncated Geminin produced by cleavage at Cl can promote apoptosis. In contrast, Geminin cleaved at site C2 has lost the ability to interact with Brahma (Brm), a catalytic subunit of the SWI/SNF chromatin remodeling complex, while binding efficiently to Cdt1, indicating that targeting of Geminin during apoptosis differentially affects interactions with its binding partners.	Univ Patras, Lab Gen Biol, Sch Med, Patras 26500, Greece; Kyushu Univ, Grad Sch Med Sci, Dept Biol Mol, Fukuoka 8128582, Japan; European Mol Biol Lab, Gene Express Unit, D-69117 Heidelberg, Germany; Univ Patras, Pharmacol Lab, Sch Med, Patras 26500, Greece	University of Patras; Kyushu University; European Molecular Biology Laboratory (EMBL); University of Patras	Lygerou, Z (corresponding author), Univ Patras, Lab Gen Biol, Sch Med, Patras 26500, Greece.	lygerou@med.upatras.gr	Roukos, Vassilis/K-6248-2012; Roukos, Vassilis/AAC-4827-2020; Taraviras, Stavros/AAJ-4690-2020	Taraviras, Stavros/0000-0002-7455-647X; Roukos, Vassilis/0000-0002-5065-3937; Wilm, Matthias/0000-0002-5461-6834; Nishitani, Hideo/0000-0001-5907-9380; Gentzel, Marc/0000-0002-4482-6010				BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Blanchard F, 2002, MOL BIOL CELL, V13, P1536, DOI 10.1091/mbc.02-02-0010; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Chan SL, 2000, J BIOL CHEM, V275, P17925, DOI 10.1074/jbc.C000146200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JARVIS WD, 1994, CANCER RES, V54, P1707; Kroll KL, 1998, DEVELOPMENT, V125, P3247; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Kulartz M, 2004, BIOCHEM BIOPH RES CO, V315, P1011, DOI 10.1016/j.bbrc.2004.01.164; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Li A, 2004, NAT CELL BIOL, V6, P260, DOI 10.1038/ncb1100; Luo LF, 2004, CELL CYCLE, V3, P711; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; MIYASHITA T, 1993, BLOOD, V81, P151; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Okorokov AL, 2004, NAT STRUCT MOL BIOL, V11, P1021, DOI 10.1038/nsmb835; Pelizon C, 2002, EMBO REP, V3, P780, DOI 10.1093/embo-reports/kvf161; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105; Seo S, 2006, CELL CYCLE, V5, P374, DOI 10.4161/cc.5.4.2438; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Xouri G, 2004, EUR J BIOCHEM, V271, P3368, DOI 10.1111/j.1432-1033.2004.04271.x; Yim H, 2003, MOL BIOL CELL, V14, P4250, DOI 10.1091/mbc.E03-01-0029; Yin XY, 2001, J BIOL CHEM, V276, P34567, DOI 10.1074/jbc.M106073200; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	46	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9346	9357		10.1074/jbc.M611643200	http://dx.doi.org/10.1074/jbc.M611643200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17261582	hybrid			2022-12-27	WOS:000245421700006
J	Barfod, ET; Moore, AL; Roe, MW; Lidofsky, SD				Barfod, Elisabeth T.; Moore, Ann L.; Roe, Michael W.; Lidofsky, Steven D.			Ca2+-activated IK1 channels associate with lipid rafts upon cell swelling and mediate volume recovery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-CONDUCTANCE; K+ CHANNEL; PHOSPHATIDYLINOSITOL 3-KINASE; FUNCTIONAL EXPRESSION; INDUCED TRANSLOCATION; DEPENDENT REGULATION; ACTIN CYTOSKELETON; CA2+ CHANNELS; CALCIUM; MEMBRANE	Restoration of cell volume in the continued presence of osmotic stimuli is essential, particularly in hepatocytes, which swell upon nutrient uptake. Responses to swelling involve the Ca2+-dependent activation of K+ channels, which promote fluid efflux to drive volume recovery; however, the channels involved in hepatocellular volume regulation have not been identified. We found that hypotonic exposure of HTC hepatoma cells evoked the opening of 50 pS K+-permeable channels, consistent with intermediate conductance (IK) channels. We isolated from rat liver and HTC cells a cDNA with sequence identity to the coding region of IK1. Swelling-activated currents were inhibited by transfection with a dominant interfering IK1 mutant. The IK channel blockers clotrimazole and TRAM-34 inhibited whole cell swelling-activated K+ currents and volume recovery. To determine whether IK1 underwent volume-sensitive localization, we expressed a green fluorescent protein fusion of IK1 in HTC cells. The localization of IK1 was suggestive of distribution in lipid rafts. Consistent with this, there was a time-dependent increase in colocalization between IK1 and the lipid raft ganglioside GM1 on the plasma membrane, which subsequently decreased with volume recovery. Pharmacological disruption of lipid rafts altered the plasma membrane distribution of IK1 and inhibited volume recovery after hypotonic exposure. Collectively, these findings support the hypothesis that IK1 regulates compensatory responses to hepatocellular swelling and suggest that regulation of cell volume involves coordination of signaling from lipid rafts with IK1 function.	Univ Vermont, Dept Med, Burlington, VT 05405 USA; Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Lidofsky, SD (corresponding author), Univ Vermont, Dept Med, Given C-327, Burlington, VT 05405 USA.	steven.lidofsky@uvm.edu			NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056644, R56DK056644] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA22435] Funding Source: Medline; NCRR NIH HHS [P20 RR16435] Funding Source: Medline; NIDDK NIH HHS [DK56644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barfod ET, 2005, J BIOL CHEM, V280, P25548, DOI 10.1074/jbc.M411717200; Barfod ET, 2001, AM J PHYSIOL-CELL PH, V280, pC836, DOI 10.1152/ajpcell.2001.280.4.C836; BEAR CE, 1987, PFLUG ARCH EUR J PHY, V410, P342, DOI 10.1007/BF00580288; Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bodily K, 1997, HEPATOLOGY, V25, P403; Caprini M, 2003, EMBO J, V22, P3004, DOI 10.1093/emboj/cdg294; Carini R, 2000, BBA-MOL BASIS DIS, V1500, P297, DOI 10.1016/S0925-4439(99)00114-3; Carton I, 2003, AM J PHYSIOL-CELL PH, V285, pC935, DOI 10.1152/ajpcell.00069.2003; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Feranchak AP, 2000, J HEPATOL, V33, P174, DOI 10.1016/S0168-8278(00)80357-8; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; Golub T, 2005, J CELL BIOL, V169, P151, DOI 10.1083/jcb.200407058; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; Haussinger D, 1996, Prog Liver Dis, V14, P29; Hayashi M, 2004, AM J PHYSIOL-CELL PH, V286, pC635, DOI 10.1152/ajpcell.00283.2003; Herrera GM, 2002, J PHYSIOL-LONDON, V541, P483, DOI 10.1113/jphysiol.2002.017707; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Junankar PR, 2004, CELL PHYSIOL BIOCHEM, V14, P143, DOI 10.1159/000078106; Junankar PR, 2002, J BIOL CHEM, V277, P40324, DOI 10.1074/jbc.M204712200; KHALBUSS WE, 1991, HEPATOLOGY, V13, P962, DOI 10.1016/0270-9139(91)90271-V; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kindzelskii AL, 2004, J IMMUNOL, V172, P4681, DOI 10.4049/jimmunol.172.8.4681; Kuzhikandathil EV, 2000, J GEN PHYSIOL, V115, P697, DOI 10.1085/jgp.115.6.697; Lan WZ, 2006, AM J PHYSIOL-CELL PH, V291, pC93, DOI 10.1152/ajpcell.00602.2005; Leitinger B, 2002, J CELL SCI, V115, P963; Li X, 2004, GASTROENTEROLOGY, V126, P122, DOI 10.1053/j.gastro.2003.10.061; LIDOFSKY SD, 1995, P NATL ACAD SCI USA, V92, P7115, DOI 10.1073/pnas.92.15.7115; Lidofsky SD, 1997, AM J PHYSIOL-GASTR L, V273, pG849, DOI 10.1152/ajpgi.1997.273.4.G849; Magee AI, 2005, J CELL SCI, V118, P3141, DOI 10.1242/jcs.02442; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Mazzone A, 2006, HEPATOLOGY, V43, P287, DOI 10.1002/hep.21039; Meder D, 2006, P NATL ACAD SCI USA, V103, P329, DOI 10.1073/pnas.0509885103; Moore AL, 2002, J BIOL CHEM, V277, P34030, DOI 10.1074/jbc.M205945200; Morita T, 1997, AM J PHYSIOL-RENAL, V273, pF615, DOI 10.1152/ajprenal.1997.273.4.F615; Musch MW, 2004, J BIOL CHEM, V279, P39447, DOI 10.1074/jbc.M405363200; Neylon CB, 1999, CIRC RES, V85, pE33, DOI 10.1161/01.RES.85.9.e33; NICOLAOU SA, 2007, IN PRESS AM J PHYSL; Nyasae LK, 2003, MOL BIOL CELL, V14, P2689, DOI 10.1091/mbc.E02-12-0816; Pon DC, 1997, J CELL PHYSIOL, V171, P87; Roe MW, 2001, J BIOL CHEM, V276, P30871, DOI 10.1074/jbc.M102362200; Roman R, 2002, AM J PHYSIOL-GASTR L, V282, pG116, DOI 10.1152/ajpgi.2002.282.1.G116; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; Sand P, 2004, ACTA PHYSIOL SCAND, V182, P361, DOI 10.1111/j.1365-201X.2004.01366.x; Sharma DK, 2005, CANCER RES, V65, P8233, DOI 10.1158/0008-5472.CAN-05-0803; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Srivastava S, 2005, MOL CELL BIOL, V25, P3630, DOI 10.1128/MCB.25.9.3630-3638.2005; Thompson-Vest N, 2006, J ANAT, V208, P219, DOI 10.1111/j.1469-7580.2006.00515.x; Vazquez E, 2001, P NATL ACAD SCI USA, V98, P5329, DOI 10.1073/pnas.091096498; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; vom Dahl S, 1998, GASTROENTEROLOGY, V114, P1046, DOI 10.1016/S0016-5085(98)70325-7; Wang J, 2003, AM J PHYSIOL-CELL PH, V284, pC77, DOI 10.1152/ajpcell.00132.2002; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wang YJ, 2002, BIOCHEM J, V363, P117, DOI 10.1042/0264-6021:3630117; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151	61	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8984	8993		10.1074/jbc.M607730200	http://dx.doi.org/10.1074/jbc.M607730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264085	hybrid			2022-12-27	WOS:000245780300045
J	Yang, W; Zheng, CY; Song, QL; Yang, XJ; Qiu, S; Liu, CQ; Chen, Z; Duan, SM; Luo, JH				Yang, Wei; Zheng, Chanying; Song, Qilin; Yang, Xiujuan; Qiu, Shuang; Liu, Chunqing; Chen, Zhong; Duan, Shumin; Luo, Jianhong			A three amino acid tail following the TM4 region of the N-methyl-D-aspartate receptor (NR) 2 subunits is sufficient to overcome endoplasmic reticulum retention of NR1-1a subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; CELL-SURFACE EXPRESSION; NMDA RECEPTOR; ER RETENTION; CHANNEL; TRAFFICKING; GLUTAMATE; SIGNAL; PREASSOCIATION; STOICHIOMETRY	The cytoplasmic C-terminal domains of NR2 subunits have been proposed to modulate the assembly and trafficking of NMDA receptors. However, questions remain concerning which domains in the C terminus of NR2 subunits control the assembly of receptor complexes and how the assembled complexes are selectively trafficked through the various cellular compartments such as endoplasmic reticulum (ER) to the cell surface. In the present study, we found that the three amino acid tail after the TM4 region of NR2 subunits is necessary for surface expression of functional NMDA receptors, while truncations with only two amino acids following the TM4 region (NR2 Delta 2) completely eliminated surface expression of the NMDA receptor on co-expression with NR1-1a in HEK293 cells. FRET (fluorescence resonance energy transfer) analysis showed that these NR2 Delta 2 truncations are able to form homomers and heteromers on co-expression with NR1-1a. Furthermore, when NR2 Delta 2 subunits were cotransfected with either the NR1-4a or NR1-1a(AAA) mutant, lacking the ER retention motif (RRR), functional NMDA receptors were detected in the transfected HEK293 cells. Unexpectedly, we found that the replacement of five residues after TM4 with alanines gave results indistinguishable from those of NR2B Delta 5 (EHLFY), demonstrating the short tail following the TM4 of NR2 subunits is not sequence-specific-dependent. Taken together, our results show that the C terminus of the NR2 subunits is not necessary for the assembly of NMDA receptor complexes, whereas a three amino acid long cytoplasmic tail following the TM4 of NR2 subunits is sufficient to overcome the ER retention existing in the C terminus of NR1, allowing the assembled NMDA receptors to reach the cell surface.	Zhejiang Univ, Sch Med, Inst Neurosci, Dept Neurobiol, Hangzhou 3100058, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China	Zhejiang University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Luo, JH (corresponding author), Zhejiang Univ, Sch Med, Inst Neurosci, Dept Neurobiol, Hangzhou 3100058, Peoples R China.	luojianhong@zju.edu.cn	Luo, jian/HGE-7331-2022					CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; de Armentia ML, 2003, J NEUROSCI, V23, P6876; Dingledine R, 1999, PHARMACOL REV, V51, P7; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fitzsimonds RM, 1997, NATURE, V388, P439, DOI 10.1038/41267; Fukaya M, 2003, P NATL ACAD SCI USA, V100, P4855, DOI 10.1073/PNAS.0830996100; Hawkins LM, 2004, J BIOL CHEM, V279, P28903, DOI 10.1074/jbc.M402599200; Holmes KD, 2002, J BIOL CHEM, V277, P1457, DOI 10.1074/jbc.M107809200; Khalil H, 2005, J CELL SCI, V118, P4679, DOI 10.1242/jcs.02592; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Litovchick L, 1998, J BIOL CHEM, V273, P29043, DOI 10.1074/jbc.273.44.29043; Luo JH, 2002, NEUROPHARMACOLOGY, V42, P306, DOI 10.1016/S0028-3908(01)00188-5; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; McIlhinney RAJ, 1996, NEUROSCIENCE, V70, P989, DOI 10.1016/0306-4522(95)00419-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; Mohrmann R, 2002, J NEUROSCI RES, V68, P265, DOI 10.1002/jnr.10219; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Okabe S, 1999, J NEUROSCI, V19, P7781; Papadakis M, 2004, J BIOL CHEM, V279, P14703, DOI 10.1074/jbc.M313446200; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Qiu S, 2005, J BIOL CHEM, V280, P24923, DOI 10.1074/jbc.M413915200; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Rossi P, 2002, J NEUROSCI, V22, P9687; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Steigerwald F, 2000, J NEUROSCI, V20, P4573, DOI 10.1523/JNEUROSCI.20-12-04573.2000; Thompson SM, 2000, CURR BIOL, V10, pR218, DOI 10.1016/S0960-9822(00)00370-5; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	37	34	37	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9269	9278		10.1074/jbc.M700050200	http://dx.doi.org/10.1074/jbc.M700050200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255096	hybrid			2022-12-27	WOS:000245780300074
J	Ashworth, R; Devogelaere, B; Fabes, J; Tunwell, RE; Koh, KR; De Smedt, H; Patel, S				Ashworth, Rachel; Devogelaere, Benoit; Fabes, Jez; Tunwell, Richard E.; Koh, Kevin R.; De Smedt, Humbert; Patel, Sandip			Molecular and functional characterization of inositol trisphosphate receptors during early zebrafish development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; 1,4,5-TRISPHOSPHATE RECEPTOR; IP3 RECEPTOR; CALCIUM-RELEASE; ENDOPLASMIC-RETICULUM; CA2+ RELEASE; 2-AMINOETHOXYDIPHENYL BORATE; TYROSINE PHOSPHORYLATION; INTRACELLULAR CALCIUM; EMBRYONIC-DEVELOPMENT	Fluctuations in cytosolic Ca2+ are crucial for a variety of cellular processes including many aspects of development. Mobilization of intracellular Ca2+ stores via the production of inositol trisphosphate (IP3) and the consequent activation of IP3-sensitive Ca2+ channels is a ubiquitous means by which diverse stimuli mediate their cellular effects. Although IP3 receptors have been well studied at fertilization, information regarding their possible involvement during subsequent development is scant. In the present study we examined the role of IP3 receptors in early development of the zebrafish. We report the first molecular analysis of zebrafish IP3 receptors which indicates that, like mammals, the zebrafish genome contains three distinct IP3 receptor genes. mRNA for all isoforms was detectable at differing levels by the 64 cell stage, and IP3-induced Ca2+ transients could be readily generated (by flash photolysis) in a controlled fashion throughout the cleavage period in vivo. Furthermore, we show that early blastula formation was disrupted by pharmacological blockade of IP3 receptors or phospholipase C, by molecular inhibition of the former by injection of IRBIT (IP3 receptor-binding protein released with IP3) and by depletion of thapsigargin-sensitive Ca2+ stores after completion of the second cell cycle. Inhibition of Ca2+ entry or ryanodine receptors, however, had little effect. Our work defines the importance of IP3 receptors during early development of a genetically and optically tractable model vertebrate organism.	Queen Mary Univ London, Sch Biol & Chem Sci, London E1 4NS, England; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; UCL, Dept Physiol, London WC1E 6BT, England	University of London; Queen Mary University London; KU Leuven; University of London; University College London	Ashworth, R (corresponding author), Queen Mary Univ London, Sch Biol & Chem Sci, Mile End Rd, London E1 4NS, England.	r.ashworth@qmul.ac.uk	Zebrafish, UCL/A-3125-2009; Patel, Sandip/O-9591-2015	Patel, Sandip/0000-0001-7247-2013	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Ando H, 2006, MOL CELL, V22, P795, DOI 10.1016/j.molcel.2006.05.017; Ashworth R, 2004, CELL CALCIUM, V35, P393, DOI 10.1016/j.ceca.2004.01.002; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Boulware MJ, 2005, CURR BIOL, V15, P765, DOI 10.1016/j.cub.2005.02.065; CHANG DC, 1995, J CELL BIOL, V131, P1539, DOI 10.1083/jcb.131.6.1539; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Cooper BJ, 2006, J BIOL CHEM, V281, P22471, DOI 10.1074/jbc.M602520200; Creton R, 1998, J CELL SCI, V111, P1613; Cui J, 2004, J BIOL CHEM, V279, P16311, DOI 10.1074/jbc.M400206200; Devogelaere B, 2006, BIOCHEM BIOPH RES CO, V343, P49, DOI 10.1016/j.bbrc.2006.02.119; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Field SJ, 2005, CURR BIOL, V15, P1407, DOI 10.1016/j.cub.2005.06.059; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FitzHarris G, 2003, MOL BIOL CELL, V14, P288, DOI 10.1091/mbc.E02-07-0431; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; He CL, 1999, BIOL REPROD, V61, P935, DOI 10.1095/biolreprod61.4.935; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kume S, 1997, MECH DEVELOP, V66, P157, DOI 10.1016/S0925-4773(97)00101-9; Kume S, 1997, SCIENCE, V278, P1940, DOI 10.1126/science.278.5345.1940; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Lee B, 2006, DEVELOPMENT, V133, P4355, DOI 10.1242/dev.02624; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; Lee KW, 2006, ZYGOTE, V14, P143, DOI 10.1017/S0967199406003637; Lee KW, 2003, INT J DEV BIOL, V47, P411; Li XG, 2005, J IMMUNOL, V175, P6205, DOI 10.4049/jimmunol.175.9.6205; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MEHLMANN LM, 1994, BIOL REPROD, V51, P1088, DOI 10.1095/biolreprod51.6.1088; Mehlmann LM, 1996, DEV BIOL, V180, P489, DOI 10.1006/dbio.1996.0322; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; Muto A, 1996, J CELL BIOL, V135, P181, DOI 10.1083/jcb.135.1.181; Nojima H, 2004, MECH DEVELOP, V121, P371, DOI 10.1016/j.mod.2004.02.003; Parrington J, 1998, DEV BIOL, V203, P451, DOI 10.1006/dbio.1998.9071; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; REINHARD E, 1995, DEV BIOL, V170, P50, DOI 10.1006/dbio.1995.1194; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Szlufcik K, 2006, CELL CALCIUM, V39, P325, DOI 10.1016/j.ceca.2005.11.007; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Webb SE, 2000, BIOESSAYS, V22, P113, DOI 10.1002/(SICI)1521-1878(200002)22:2<113::AID-BIES3>3.0.CO;2-L; Webb SE, 1997, DEV BIOL, V192, P78, DOI 10.1006/dbio.1997.8724; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Westfall TA, 2003, DEV BIOL, V259, P380, DOI 10.1016/S0012-1606(03)00209-4; Whitaker M, 2006, PHYSIOL REV, V86, P25, DOI 10.1152/physrev.00023.2005; Wong R, 2005, CURR BIOL, V15, P1401, DOI 10.1016/j.cub.2005.06.060; Xu Z, 2003, DEV BIOL, V254, P163, DOI 10.1016/S0012-1606(02)00049-0; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Zimprich F, 1998, PFLUG ARCH EUR J PHY, V436, P489, DOI 10.1007/s004240050662	74	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13984	13993		10.1074/jbc.M700940200	http://dx.doi.org/10.1074/jbc.M700940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17331947	hybrid			2022-12-27	WOS:000246245800008
J	Cosen-Binker, LI; Lam, PPL; Binker, MG; Reeve, J; Pandol, S; Gaisano, HY				Cosen-Binker, Laura I.; Lam, Patrick P. L.; Binker, Marcelo G.; Reeve, Joseph; Pandol, Stephen; Gaisano, Herbert Y.			Alcohol/cholecystokinin-evoked pancreatic acinar basolateral exocytosis is mediated by protein kinase C alpha phosphorylation of Munc18c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; ALCOHOLIC PANCREATITIS; REGULATED EXOCYTOSIS; MEMBRANE-FUSION; PLASMA-MEMBRANE; PKC-DELTA; CELLS; CHOLECYSTOKININ; MECHANISMS; MACHINERY	The pancreatic acinus is the functional unit of the exocrine pancreas whose role is to secrete zymogens into the gut lumen for food digestion via apical exocytosis. We previously reported that supramaximal CCK induced apical blockade and redirected exocytosis to ectopic sites on the basolateral plasma membrane (BPM) of this polarized cell, leading to pancreatitis. Basolateral exocytosis was mediated by protein kinase C phosphorylation of BPM Munc18c, causing its displacement into the cytosol and activation of BPM-bound Syntaxin-4 to form aSNARE complex. To mimic the conditions of alcoholic pancreatitis, we now examined whether 20 mM alcohol followed by submaximal CCK might mimic supramaximal CCK in inducing these pathologic exocytotic events. We show that a non-secretory but clinically relevant alcohol concentration (20 mM) inhibited submaximal CCK (50 pM)-stimulated amylase secretion by blocking apical exocytosis and redirecting exocytosis to less efficient BPM, indeed mimicking supramaximal CCK (10 nM) stimulation. We further demonstrate that basolateral exocytosis caused by both stimulation protocols is mediated by PKC alpha-induced phosphorylation of Munc18c: 1) PKC alpha is activated, which binds and induces phosphorylation of PM-Munc18c at a Thr site, and these events can be inhibited by PKC alpha blockade; 2) PKC alpha inhibition blocks Munc18c displacement from the BPM; 3) PKC alpha inhibition prevents basolateral exocytosis but does not rescue apical exocytosis. We conclude that 20 mM alcohol/submaximal CCK as well supramaximal CCK stimulation can trigger pathologic basolateral exocytosis in pancreatic acinar cells via PKC alpha-mediated activation of Munc18c, which enables Syntaxin-4 to become receptive in forming a SNARE complex in the BPM; and we further postulate this to be an underlying mechanism contributing to alcoholic pancreatitis.	Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Univ Hlth Network, Dept Physiol, Toronto, ON M5S 1A8, Canada; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Gaisano, HY (corresponding author), Univ Toronto, Univ Hlth Network, Dept Med, Rm 7226,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	herbert.gaisano@utoronto.ca			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA015579] Funding Source: NIH RePORTER; NIAAA NIH HHS [R21 AA015579-01A1] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Bedford D, 2006, Ir Med J, V99, P80; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fujita H, 1998, BIOCHEM J, V329, P527, DOI 10.1042/bj3290527; Gaisano HY, 2000, PANCREAS, V20, P217, DOI 10.1097/00006676-200004000-00001; Gaisano HY, 2004, PANCREAS, V28, P395, DOI 10.1097/00006676-200405000-00008; GAISANO HY, 1992, BIOCHEM BIOPH RES CO, V187, P498, DOI 10.1016/S0006-291X(05)81522-0; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; Gaisano HY, 2001, J CLIN INVEST, V108, P1597; Gorelick FS, 2003, PANCREAS, V27, P305, DOI 10.1097/00006676-200311000-00006; Gukovskaya AS, 2004, AM J PHYSIOL-GASTR L, V286, pG204, DOI 10.1152/ajpgi.00088.2003; Hanck C, 2004, GASTROENTEROL CLIN N, V33, P751, DOI 10.1016/j.gtc.2004.07.002; James DE, 2005, J CLIN INVEST, V115, P219, DOI 10.1172/JCI200524158; JUNGERMANN J, 1995, AM J PHYSIOL-GASTR L, V268, pG328, DOI 10.1152/ajpgi.1995.268.2.G328; Latham CF, 2006, TRAFFIC, V7, P1408, DOI 10.1111/j.1600-0854.2006.00474.x; LI C, 2000, AM J PHYSIOL-GASTR L, V287, pG764; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MURPHY JA, 2006, PANCREAS, V33, P485; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Oh E, 2005, DIABETES, V54, P638, DOI 10.2337/diabetes.54.3.638; Pandol SJ, 2003, PANCREAS, V27, P297, DOI 10.1097/00006676-200311000-00004; Pickett JA, 2005, J BIOL CHEM, V280, P1506, DOI 10.1074/jbc.M411967200; Purohit V, 2003, PANCREAS, V27, P281, DOI 10.1097/00006676-200311000-00001; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Saluja AK, 2003, PANCREAS, V27, P327, DOI 10.1097/00006676-200311000-00010; Satoh A, 2004, AM J PHYSIOL-GASTR L, V287, pG582, DOI 10.1152/ajpgi.00087.2004; STEER M, 1998, NEW ENGL J MED, V316, P144; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Xu KP, 2001, AM J PHYSIOL-CELL PH, V281, pC603, DOI 10.1152/ajpcell.2001.281.2.C603; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	35	53	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13047	13058		10.1074/jbc.M611132200	http://dx.doi.org/10.1074/jbc.M611132200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324928	hybrid			2022-12-27	WOS:000245942800074
J	Porras-Yakushi, TR; Whitelegge, JP; Clarke, S				Porras-Yakushi, Tanya R.; Whitelegge, Julian P.; Clarke, Steven			Yeast ribosomal/cytochrome c SET domain methyltransferase subfamily - Identification of Rpl23ab methylation sites and recognition motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HISTONE H3; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; 80S RIBOSOME; PROTEIN; LYSINE-4; TRIMETHYLATION; SUBSTRATE; FINGER	Ribosomal protein L23ab is specifically dimethylated at two distinct sites by the SET domain-containing enzyme Rkm1 in the yeast Saccharomyces cerevisiae. Using liquid column chromatography with electrospray-ionization mass spectrometry, we determined that Rpl23ab purified from the Delta rkm1 deletion strain demonstrated a loss in mass of similar to 56 Da when compared with Rpl23ab purified from the wild type strain. When Rpl23ab was proteolyzed, using proteinase ArgC or CNBr, and the peptides derived were analyzed by tandem mass spectrometry, no sites of methylation were found in Rpl23ab purified from the Delta rkm1 deletion strain, whereas two sites of dimethylation were observed in the wild type strain at lysine residues 105 and 109. We show that both Rpl23a and Rpl23b are expressed and methylated in vivo in yeast. Using polysomal fractionation, we demonstrate that the deletion of RKM1 has no effect on ribosomal complex formation. Comparison of SET domain methyltransferase substrates in yeast reveal sequence similarities around the lysine methylation sites and suggest that an (Asn/Pro)-Pro-Lys consensus sequence may be a target for methylation by subfamily 2 SET domain methyltransferases. Finally, we show the presence of Rkm1 homologs in fungi, plants, and mammals including humans.	Univ Calif Los Angeles, Dept Chem & Biochem, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), 611 Charles E Young Dr E,Paul Boyer Hall 639, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu			NIGMS NIH HHS [GM026020, GM07185, GM075381] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020, F31GM075381] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachand F, 2006, MOL CELL BIOL, V26, P1731, DOI 10.1128/MCB.26.5.1731-1742.2006; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Boa S, 2003, YEAST, V20, P827, DOI 10.1002/yea.995; Cheng XD, 2005, ANNU REV BIOPH BIOM, V34, P267, DOI 10.1146/annurev.biophys.34.040204.144452; Chern MK, 2002, J BIOL CHEM, V277, P15345, DOI 10.1074/jbc.M111379200; Davies C, 1996, STRUCTURE, V4, P55, DOI 10.1016/S0969-2126(96)00009-3; Dirk LMA, 2006, ENZYMES, V24, P179, DOI 10.1016/S1874-6047(06)80009-0; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; Houtz RL, 2003, ARCH BIOCHEM BIOPHYS, V414, P150, DOI 10.1016/S0003-9861(03)00122-X; Jacobs SA, 2002, NAT STRUCT BIOL, V9, P833, DOI 10.1038/nsb861; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; Min JR, 2002, NAT STRUCT BIOL, V9, P828, DOI 10.1038/nsb860; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Odintsova TI, 2003, J PROTEIN CHEM, V22, P249, DOI 10.1023/A:1025068419698; Polevoda B, 2000, J BIOL CHEM, V275, P20508, DOI 10.1074/jbc.M001891200; Porras-Yakushi TR, 2006, J BIOL CHEM, V281, P35835, DOI 10.1074/jbc.M606578200; Porras-Yakushi TR, 2005, J BIOL CHEM, V280, P34590, DOI 10.1074/jbc.M507672200; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; Whitelegge Julian P, 2004, Methods Mol Biol, V251, P323; Williamson NA, 1997, EUR J BIOCHEM, V246, P786, DOI 10.1111/j.1432-1033.1997.00786.x; Wilson JR, 2002, CELL, V111, P105, DOI 10.1016/S0092-8674(02)00964-9; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yeates TO, 2002, CELL, V111, P5, DOI 10.1016/S0092-8674(02)01010-3; Zanchin NIT, 1997, MOL CELL BIOL, V17, P5001, DOI 10.1128/MCB.17.9.5001; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6	41	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12368	12376		10.1074/jbc.M611896200	http://dx.doi.org/10.1074/jbc.M611896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327221	hybrid			2022-12-27	WOS:000245942800005
J	Rodamilans, B; Munoz, IG; Bragado-Nilsson, E; Sarrias, MR; Padilla, O; Blanco, FJ; Lozano, F; Montoya, G				Rodamilans, Bernardo; Munoz, Ines G.; Bragado-Nilsson, Elisabeth; Sarrias, Maria Rosa; Padilla, Olga; Blanco, Francisco J.; Lozano, Francisco; Montoya, Guillermo			Crystal structure of the third extracellular domain of CD5 reveals the fold of a group B scavenger cysteine-rich receptor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL SURFACE-IMMUNOGLOBULIN; POTENTIAL SELECTING LIGAND; SRCR DOMAIN; IDENTIFICATION; MEMBRANE; GLYCOPROTEIN; SUPERFAMILY; ANCIENT; DESIGN; MODULE	Scavenger receptor cysteine-rich ( SRCR) domains are ancient protein modules widely found among cell surface and secreted proteins of the innate and adaptive immune system, where they mediate ligand binding. We have solved the crystal structure at 2.2 angstrom of resolution of the SRCR CD5 domain III, a human lymphocyte receptor involved in the modulation of antigen specific receptor-mediated T cell activation and differentiation signals. The first structure of a member of a group B SRCR domain reveals the fold of this ancient protein module into a central core formed by two antiparallel beta-sheets and one alpha-helix, illustrating the conserved core at the protein level of genes coding for group A and B members of the SRCR superfamily. The novel SRCR group B structure permits the interpretation of site-directed mutagenesis data on the binding of activated leukocyte cell adhesion molecule ( ALCAM/CD166) binding to CD6, a closely related lymphocyte receptor homologue to CD5.	Macromol Crystallog Ctr, Madrid 28029, Spain; NMR Grp, Madrid 28029, Spain; Spanish Natl Canc Ctr, CNIO, Struct Biol & Biocomp Program, Madrid 28029, Spain; Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Immunol, E-08036 Barcelona, Spain; Univ Barcelona, Fac Med, Dept Cell Biol & Pathol, E-08036 Barcelona, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona	Montoya, G (corresponding author), Macromol Crystallog Ctr, Madrid 28029, Spain.	gmontoya@cnio.es	sarrias, maria rosa/D-6205-2014; Blanco, Francisco J/D-4401-2009; LOZANO, FRANCISCO/AAB-7888-2019; Rodamilans, Bernardo/ABA-9093-2021; Munoz, Ines G/M-3285-2014; Abrams, William R/A-5782-2008; Lozano-Soto, Francisco/AAB-7930-2019	sarrias, maria rosa/0000-0001-6929-8069; Blanco, Francisco J/0000-0003-2545-4319; LOZANO, FRANCISCO/0000-0003-1119-4368; Rodamilans, Bernardo/0000-0002-6541-2589; Munoz, Ines G/0000-0001-6732-4059; Lozano-Soto, Francisco/0000-0003-3714-2304				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; Biancone L, 1996, J EXP MED, V184, P811, DOI 10.1084/jem.184.3.811; Bikah G, 1998, INT IMMUNOL, V10, P1185, DOI 10.1093/intimm/10.8.1185; Bodian DL, 1997, BIOCHEMISTRY-US, V36, P2637, DOI 10.1021/bi962560+; Bowen MA, 1996, J BIOL CHEM, V271, P17390, DOI 10.1074/jbc.271.29.17390; Bowen MA, 2000, PROTEINS, V40, P420; Calvo J, 1999, TISSUE ANTIGENS, V54, P128, DOI 10.1034/j.1399-0039.1999.540203.x; Calvo J, 1999, EUR J IMMUNOL, V29, P2119, DOI 10.1002/(SICI)1521-4141(199907)29:07<2119::AID-IMMU2119>3.3.CO;2-6; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dustin ML, 2002, ARTHRITIS RES THER, V4, pS119, DOI 10.1186/ar559; Gimferrer I, 2003, J BIOL CHEM, V278, P8564, DOI 10.1074/jbc.M209591200; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HARDY RR, 1994, IMMUNOL REV, V137, P91, DOI 10.1111/j.1600-065X.1994.tb00660.x; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; LUO W, 1992, J IMMUNOL, V148, P1630; McAlister MSB, 1998, PROTEIN ENG, V11, P847, DOI 10.1093/protein/11.10.847; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pospisil R, 2000, LEUKEMIA LYMPHOMA, V36, P353, DOI 10.3109/10428190009148857; Pospisil R, 1996, J EXP MED, V184, P1279, DOI 10.1084/jem.184.4.1279; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Rodamilans B, 2007, J STRUCT BIOL, V159, P144, DOI 10.1016/j.jsb.2007.01.003; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Skonier JE, 1997, PROTEIN ENG, V10, P943, DOI 10.1093/protein/10.8.943; Somoza JR, 2003, STRUCTURE, V11, P1123, DOI 10.1016/S0969-2126(03)00148-5; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Van de Velde H, 1996, CELL IMMUNOL, V172, P84, DOI 10.1006/cimm.1996.0218; VAN DE VELDE H, 1991, NATURE, V351, P662; vanderMerwe PA, 1996, CURR OPIN IMMUNOL, V8, P257, DOI 10.1016/S0952-7915(96)80065-3; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	41	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12669	12677		10.1074/jbc.M611699200	http://dx.doi.org/10.1074/jbc.M611699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322294	Green Published, hybrid			2022-12-27	WOS:000245942800036
J	Straszewski-Chavez, SL; Visintin, IP; Karassina, N; Los, G; Liston, P; Halaban, R; Fadiel, A; Mor, G				Straszewski-Chavez, Shawn L.; Visintin, Irene P.; Karassina, Natasha; Los, Georgyi; Liston, Peter; Halaban, Ruth; Fadiel, Ahmed; Mor, Gil			XAF1 mediates tumor necrosis factor-alpha-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAUTERINE GROWTH RESTRICTION; XIAP-ASSOCIATED FACTOR-1; PLACENTAL APOPTOSIS; PROTEASE OMI/HTRA2; CASPASE ACTIVITY; FACTOR RECEPTORS; SERINE-PROTEASE; TNF SUPERFAMILY; MESSENGER-RNA; LIGAND SYSTEM	Tumor necrosis factor-alpha (TNF-alpha) and Fas ligand induce apoptosis by interacting with their corresponding membrane bound death receptors and activating caspases. Since both systems share several components of the intracellular apoptotic cascade and are expressed by first trimester trophoblasts, it is unknown how these cells remain resistant to Fas ligand while sensitive to TNF-alpha. XAF1 (X-linked inhibitor of apoptosis (XIAP)-associated factor 1) is a proapoptotic protein that antagonizes the caspase-inhibitory activity of XIAP. Here, we demonstrated that XAF1 functions as an alternative pathway for TNF alpha-induced apoptosis by translocating to the mitochondria and promoting XIAP inactivation. In addition, we showed that the overexpression of XAF1 sensitized first trimester trophoblast cells to Fas-mediated apoptosis. Furthermore, we also determined that the differential expression of XAF1 in first and third trimester trophoblast cells was due to changes in XAF1 gene methylation. Our results establish a novel regulatory pathway controlling trophoblast cell survival and provide a molecular mechanism to explain trophoblast sensitivity to TNF-alpha and the increased number of apoptotic trophoblast cells observed near term. Aberrant XAF1 expression and/or localization may have consequences for normal pregnancy outcome.	Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Promega Corp, Madison, WI 53711 USA; Univ Ottawa, Dept Pediat, Ottawa, ON K1H 8M5, Canada	Yale University; Yale University; Yale University; Promega Corporation; University of Ottawa	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, 333 Cedar St,FMB 301, New Haven, CT 06520 USA.	Gil.Mor@yale.edu	Chavez, Shawn L./ABF-6125-2021	Chavez, Shawn L./0000-0002-8285-0222; Fadiel Metwaly, Ahmed/0000-0002-5759-6891				Allaire AD, 2000, OBSTET GYNECOL, V96, P271, DOI 10.1016/S0029-7844(00)00895-4; Arima T, 2006, DEV BIOL, V297, P361, DOI 10.1016/j.ydbio.2006.05.003; Aschkenazi S, 2002, BIOL REPROD, V66, P1853, DOI 10.1095/biolreprod66.6.1853; Byun DS, 2003, CANCER RES, V63, P7068; CHEN HL, 1991, AM J PATHOL, V139, P327; Cilenti L, 2003, J BIOL CHEM, V278, P11489, DOI 10.1074/jbc.M212819200; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Crocker IP, 2003, AM J PATHOL, V162, P637, DOI 10.1016/S0002-9440(10)63857-6; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DiFederico E, 1999, AM J PATHOL, V155, P293, DOI 10.1016/S0002-9440(10)65123-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Genbacev O, 1999, HUM REPROD, V14, P59, DOI 10.1093/humrep/14.suppl_2.59; Gruslin A, 2001, BIOL REPROD, V64, P1264, DOI 10.1095/biolreprod64.4.1264; Ishihara N, 2002, AM J OBSTET GYNECOL, V186, P158, DOI 10.1067/mob.2002.119176; Johnson DE, 2000, CANCER RES, V60, P1818; Ka H, 2003, AM J PATHOL, V163, P413, DOI 10.1016/S0002-9440(10)63671-1; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Knofler M, 2000, PLACENTA, V21, P525, DOI 10.1053/plac.1999.0501; Lareef MH, 2004, MOL CARCINOGEN, V39, P234, DOI 10.1002/mc.20014; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Lehner R, 2001, OBSTET GYNECOL, V97, P965, DOI 10.1016/S0029-7844(01)01131-0; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Ma Tian Le, 2005, Chin J Dig Dis, V6, P10, DOI 10.1111/j.1443-9573.2005.00180.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mor G, 1998, AM J REPROD IMMUNOL, V40, P89; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Payne SG, 1999, BIOL REPROD, V60, P1144, DOI 10.1095/biolreprod60.5.1144; Phillips TA, 2001, PLACENTA, V22, P663, DOI 10.1053/plac.2001.0703; Pijnenborg R, 1998, PLACENTA, V19, P231, DOI 10.1016/S0143-4004(98)90054-6; Rasmussen CA, 1999, PLACENTA, V20, P213, DOI 10.1053/plac.1998.0356; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Seong YM, 2004, J BIOL CHEM, V279, P37588, DOI 10.1074/jbc.M401408200; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shiozaki A, 2003, PLACENTA, V24, P65, DOI 10.1053/plac.2002.0860; Smith SC, 2000, AM J OBSTET GYNECOL, V183, P697, DOI 10.1067/mob.2000.106555; Smith SC, 1997, AM J OBSTET GYNECOL, V177, P1395, DOI 10.1016/S0002-9378(97)70081-4; Smith SC, 1997, AM J OBSTET GYNECOL, V177, P57, DOI 10.1016/S0002-9378(97)70438-1; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Straszewski-Chavez SL, 2005, ENDOCR REV, V26, P877, DOI 10.1210/er.2005-0003; Straszewski-Chavez SL, 2004, MOL HUM REPROD, V10, P33, DOI 10.1093/molehr/gah001; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang JD, 2006, J BIOL CHEM, V281, P2451, DOI 10.1074/jbc.M505890200; Xia Y, 2006, MOL CELL BIOCHEM, V286, P67, DOI 10.1007/s11010-005-9094-2; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; YELAVARTHI KK, 1993, AM J PATHOL, V143, P1131; Yin WH, 2006, BIOCHEM BIOPH RES CO, V339, P1148, DOI 10.1016/j.bbrc.2005.11.128; Yui J, 1996, BIOL REPROD, V55, P400, DOI 10.1095/biolreprod55.2.400; YUI J, 1994, PLACENTA, V15, P819, DOI 10.1016/S0143-4004(05)80184-5	57	61	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13059	13072		10.1074/jbc.M609038200	http://dx.doi.org/10.1074/jbc.M609038200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329253	hybrid			2022-12-27	WOS:000245942800075
J	Wang, ZB; Cotney, J; Shadel, GS				Wang, Zhibo; Cotney, Justin; Shadel, Gerald S.			Human mitochondrial ribosomal protein MRPL12 interacts directly with mitochondrial RNA polymerase to modulate mitochondrial gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; MESSENGER-RNA; METHYLTRANSFERASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; ETHIDIUM-BROMIDE; INNER MEMBRANE; B1; TRANSLATION	The core human mitochondrial transcription machinery comprises a single subunit bacteriophage-related RNA polymerase, POLRMT, the high mobility group box DNA-binding protein h-mtTFA/TFAM, and two transcriptional co-activator proteins, h-mtTFB1 and h-mtTFB2 that also have rRNA methyltransferase activity. Recapitulation of specific initiation of transcription in vitro can be achieved by a complex of POLRMT, h-mtTFA, and either h-mtTFB1 or h-mtTFB2. However, the nature of mitochondrial transcription complexes in vivo and the potential involvement of additional proteins in the transcription process in human mitochondria have not been extensively investigated. In Saccharomyces cerevisiae, transcription and translation are physically coupled via the formation of a multiprotein complex nucleated by the binding of Nam1p to the amino-terminal domain of mtRNA polymerase ( Rpo41p). This model system paradigm led us to search for proteins that interact with POLRMT to regulate mitochondrial gene expression in humans. Using an affinity capture strategy to identify POLRMT-binding proteins, we identified mitochondrial ribosomal protein L7/L12 ( MRPL12) as a protein in HeLa mitochondrial extracts that interacts specifically with POLRMT in vitro. Purified recombinant MRPL12 binds to POLRMT and stimulates mitochondrial transcription activity in vitro, demonstrating that this interaction is both direct and functional. Finally, from HeLa cells that overexpress FLAG epitope-tagged MRPL12, increased steady-state levels of mtDNA-encoded transcripts are observed and MRPL12-POLRMT complexes can be co-immunoprecipitated, providing strong evidence that this interaction enhances mitochondrial transcription or RNA stability in vivo. We speculate that the MRPL12 interaction with POLRMT is likely part of a novel regulatory mechanism that coordinates mitochondrial transcription with translation and/or ribosome biogenesis during human mitochondrial gene expression.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Yale University; Emory University	Shadel, GS (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.	gerald.shadel@yale.edu	Wang, Zhibo/B-3945-2010; Cotney, Justin/C-9631-2012; Cotney, Justin L/ABE-8500-2021	Cotney, Justin/0000-0001-8230-2157; Cotney, Justin L/0000-0001-8230-2157	NHLBI NIH HHS [R01 HL059655, HO-059655, R01 HL059655-09] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024; Bryan AC, 2002, GENETICS, V160, P75; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; Cotney J, 2006, J MOL EVOL, V63, P707, DOI 10.1007/s00239-006-0075-1; Dey D, 1995, BIOCHIMIE, V77, P925, DOI 10.1016/0300-9084(95)80003-4; DUHL DM, 1992, J NEUROSCI METH, V42, P211, DOI 10.1016/0165-0270(92)90100-R; Eykholt RL, 2000, BIOTECHNIQUES, V28, P864, DOI 10.2144/00285bm07; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Frei C, 2005, EMBO J, V24, P623, DOI 10.1038/sj.emboj.7600523; JOHNSEN M, 1982, EMBO J, V1, P999, DOI 10.1002/j.1460-2075.1982.tb01284.x; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Marty L, 1997, GENOMICS, V41, P453, DOI 10.1006/geno.1997.4691; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Matsushima Y, 2005, J BIOL CHEM, V280, P16815, DOI 10.1074/jbc.M500569200; McCulloch V, 2003, MOL CELL BIOL, V23, P5816, DOI 10.1128/MCB.23.16.5816-5824.2003; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; Nam SC, 2001, PROTEIN EXPRES PURIF, V21, P485, DOI 10.1006/prep.2000.1383; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; O'Brien T, 2003, IUBMB LIFE, V55, P505, DOI 10.1080/15216540310001626610; O'Brien TW, 2002, GENE, V286, P73, DOI 10.1016/S0378-1119(01)00808-3; RAMAGOPAL S, 1976, EUR J BIOCHEM, V69, P289, DOI 10.1111/j.1432-1033.1976.tb10885.x; Rodeheffer MS, 2003, J BIOL CHEM, V278, P18695, DOI 10.1074/jbc.M301399200; Rodeheffer MS, 2001, J BIOL CHEM, V276, P8616, DOI 10.1074/jbc.M009901200; Savelsbergh A, 2000, J BIOL CHEM, V275, P890, DOI 10.1074/jbc.275.2.890; Seidel-Rogol BL, 2003, NAT GENET, V33, P23, DOI 10.1038/ng1064; Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Shadel GS, 2004, TRENDS GENET, V20, P513, DOI 10.1016/j.tig.2004.08.005; Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; Wang YH, 1999, P NATL ACAD SCI USA, V96, P8046, DOI 10.1073/pnas.96.14.8046	35	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12610	12618		10.1074/jbc.M700461200	http://dx.doi.org/10.1074/jbc.M700461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337445	Green Accepted, hybrid			2022-12-27	WOS:000245942800030
J	Baron, S; Escande, A; Alberola, G; Bystricky, K; Balaguer, P; Richard-Foy, H				Baron, Sylvain; Escande, Aurelie; Alberola, Geraldine; Bystricky, Kerstin; Balaguer, Patrick; Richard-Foy, Helene			Estrogen receptor alpha and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; C-JUN; CATHEPSIN-D; PS2 GENE; RESPONSIVE ELEMENT; LEUCINE ZIPPER; MCF7 CELLS; CROSS-TALK; HA-RAS; PHOSPHORYLATION	Insulin like growth factor I ( IGF-I) displays estrogenic activity in breast cancer cells. This activity is strictly dependent on the presence of estrogen receptor alpha ( ER alpha). However the precise molecular mechanisms involved in this process are still unclear. IGF-I treatment induces phosphorylation of the AF1 domain of ER alpha and activation of estrogen regulated genes. These genes are characterized by important differences in promoter architecture and response element composition. We show that promoter structure is crucial for IGF-I-induced transcription activation. We demonstrate that on a complex promoter such as the pS2/TFF1 promoter, which contains binding sites for ER alpha and for the activating protein-1 ( AP1) complex, transcriptional activation by IGF-I requires both ER alpha and the AP1 complex. IGF-I is unable to stimulate transcription of an estrogen-regulated gene under the control of a minimal promoter containing only a binding site for ER alpha. We propose a molecular mechanism with stepwise assembly of the AP1 complex and ER alpha during transcription activation of pS2/TFF1 by IGF-I. IGF-I stimulation induces rapid phosphorylation and an increase in protein levels of the AP1 complex. Binding of the phosphorylated AP1 complex to the pS2/TFF1 promoter allows recruitment of the chromatin remodeling factor Brg1 followed by binding of ER alpha via its interaction with c-Jun.	Univ Toulouse 3, UMR 5099, CNRS, Lab Biol Mol Eucaryote,IFR109, F-31062 Toulouse, France; INSERM U540, F-34090 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm)	Richard-Foy, H (corresponding author), Univ Toulouse 3, UMR 5099, CNRS, Lab Biol Mol Eucaryote,IFR109, 118 Route Narbonne, F-31062 Toulouse, France.	hrfoy@ibcg.biotoul.fr	Bystricky, Kerstin/AAA-3003-2020; BYSTRICKY, Kerstin/B-8670-2009; Balaguer, Patrick/I-2973-2016	Bystricky, Kerstin/0000-0001-6717-3721; BYSTRICKY, Kerstin/0000-0001-6717-3721; 				ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; Balaguer P, 2001, LUMINESCENCE, V16, P153, DOI 10.1002/bio.630; Barkhem T, 2002, MOL PHARMACOL, V61, P1273, DOI 10.1124/mol.61.6.1273; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317; Giamarchi C, 2002, BBA-GENE STRUCT EXPR, V1578, P12, DOI 10.1016/S0167-4781(02)00480-3; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LE GP, 1994, J BIOL CHEM, V269, P4458; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Pillon A, 2005, ENVIRON HEALTH PERSP, V113, P278, DOI 10.1289/ehp.7522; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Takahashi T, 2005, ENDOCRINOLOGY, V146, P4082, DOI 10.1210/en.2005-0302; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; Varma H, 2002, CANCER RES, V62, P3985; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; WILLIAM F, 1990, J BIOL CHEM, V265, P18166	47	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11732	11741		10.1074/jbc.M610079200	http://dx.doi.org/10.1074/jbc.M610079200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317669	hybrid			2022-12-27	WOS:000245941900015
J	Binet, V; Duthey, B; Lecaillon, J; Vol, C; Quoyer, J; Labesse, G; Pin, JP; Prezeau, L				Binet, Virginie; Duthey, Beatrice; Lecaillon, Jennifer; Vol, Claire; Quoyer, Julie; Labesse, Gilles; Pin, Jean-Philippe; Prezeau, Laurent			Common structural requirements for heptahelical domain function in class A and class C G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; POSITIVE ALLOSTERIC MODULATOR; HIGHLY-CONSERVED ARGININE; 3RD INTRACELLULAR LOOPS; GABA(B) RECEPTOR; MUTATIONAL ANALYSIS; ALPHA(1B)-ADRENERGIC RECEPTOR; DRY MOTIF; CONSTITUTIVE ACTIVATION; CRYSTAL-STRUCTURE	Gprotein-coupled receptors (GPCRs) are key players in cell communication. Several classes of such receptors have been identified. Although all GPCRs possess a heptahelical domain directly activating G proteins, important structural and sequence differences within receptors from different classes suggested distinct activation mechanisms. Here we show that highly conserved charged residues likely involved in an interaction network between transmembrane domains (TM) 3 and 6 at the cytoplasmic side of class C GPCRs are critical for activation of the gamma-aminobutyric acid type B receptor. Indeed, the loss of function resulting from the mutation of the conserved lysine residue into aspartate or glutamate in the TM3 of gamma-aminobutyric acid type B-2 can be partly rescued by mutating the conserved acidic residue of TM6 into either lysine or arginine. In addition, mutation of the conserved lysine into an acidic residue leads to a nonfunctional receptor that displays a high agonist affinity. This is reminiscent of a similar ionic network that constitutes a lock stabilizing the inactive state of many class A rhodopsin-like GPCRs. These data reveal that despite their original structure, class C GPCRs share with class A receptors at least some common structural feature controlling G protein activation.	Univ Montpellier I, Dept Mol Pharmacol, Inst Genom Fonctionnelle, CNRS,UMR 5203,INSERM U661, F-34094 Montpellier 5, France; Univ Montpellier 2, Dept Mol Pharmacol, Inst Genom Fonctionnelle, CNRS,UMR 5203,INSERM U661, F-34094 Montpellier 5, France; Ctr Hosp Univ Montpellier, F-34000 Montpellier, France; Univ Montpellier I, INSERM, U554, CNRS,UMR 5048,Ctr Biochim Struct, F-34000 Montpellier, France; Univ Montpellier 2, INSERM, U554, CNRS,UMR 5048,Ctr Biochim Struct, F-34000 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Prezeau, L (corresponding author), Univ Montpellier I, Dept Mol Pharmacol, Inst Genom Fonctionnelle, CNRS,UMR 5203,INSERM U661, 141 Rue Cardonille, F-34094 Montpellier 5, France.	laurent.prezeau@igf.cnrs.fr	Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Labesse, Gilles/0000-0002-6861-3300				Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200; Bockaert J, 2002, INT REV CYTOL, V212, P63; Brock C, 2005, MOL BIOL CELL, V16, P5572, DOI 10.1091/mbc.E05-05-0400; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Capra V, 2004, MOL PHARMACOL, V66, P880, DOI 10.1124/mol.104.001487; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Chang WH, 2000, J BIOL CHEM, V275, P19955, DOI 10.1074/jbc.M909613199; Chen A, 2001, BIOCHEM BIOPH RES CO, V284, P596, DOI 10.1006/bbrc.2001.5027; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Fanelli F, 1999, PROTEINS, V37, P145, DOI 10.1002/(SICI)1097-0134(19991101)37:2<145::AID-PROT1>3.0.CO;2-R; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Flanagan CA, 2005, MOL PHARMACOL, V68, P1, DOI 10.1124/mol.105.014183; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Gaillard I, 2004, HUM MOL GENET, V13, P771, DOI 10.1093/hmg/ddh086; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Goudet C., 2004, DRUG DISCOV TODAY TH, V1, P125, DOI DOI 10.1016/J.DDSTR.2004.08.017; Greasley PJ, 2002, MOL PHARMACOL, V61, P1025, DOI 10.1124/mol.61.5.1025; Gruijthuijsen YK, 2004, J GEN VIROL, V85, P897, DOI 10.1099/vir.0.19709-0; Havlickova M, 2003, J BIOL CHEM, V278, P35063, DOI 10.1074/jbc.M306555200; HIGGINS D, 1994, NUCLEIC ACIDS RES, P4673; Jiang PH, 2005, J BIOL CHEM, V280, P15238, DOI 10.1074/jbc.M414287200; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; Malherbe P, 2003, MOL PHARMACOL, V64, P823, DOI 10.1124/mol.64.4.823; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Mezler M, 2001, EUR J NEUROSCI, V13, P477, DOI 10.1046/j.1460-9568.2001.01410.x; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Pagano A, 2001, J NEUROSCI, V21, P1189; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742-4658.2005.04728.x; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; Pin JP, 2004, BIOL CELL, V96, P335, DOI 10.1016/j.biolcel.2004.03.005; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Ray K, 2005, J BIOL CHEM, V280, P37013, DOI 10.1074/jbc.M506681200; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Rosenkilde MM, 2005, MOL PHARMACOL, V68, P11, DOI 10.1124/mol.105.011239; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Scheer A, 2000, MOL PHARMACOL, V57, P219; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Seibold A, 1998, RECEPTOR CHANNEL, V5, P375; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wilbanks AM, 2002, BIOCHEMISTRY-US, V41, P11981, DOI 10.1021/bi020275m; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162	78	58	60	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12154	12163		10.1074/jbc.M611071200	http://dx.doi.org/10.1074/jbc.M611071200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17310064	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000245941900058
J	Ong, HL; Liu, XB; Tsaneva-Atanasova, K; Singh, BB; Bandyopadhyay, BC; Swaim, WD; Russell, JT; Hegde, RS; Sherman, A; Ambudkar, IS				Ong, Hwei Ling; Liu, Xibao; Tsaneva-Atanasova, Krasimira; Singh, Brij B.; Bandyopadhyay, Bidhan C.; Swaim, William D.; Russell, James T.; Hegde, Ramanujan S.; Sherman, Arthur; Ambudkar, Indu S.			Relocalization of STIM1 for activation of store-operated Ca2+ entry is determined by the depletion of subplasma membrane endoplasmic reticulum Ca2+ store	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CHANNEL FUNCTION; CRAC CHANNELS; CALCIUM-ENTRY; GLAND CELLS; INFLUX; SENSOR; DYNAMICS; RELEASE; ORAI1	STIM1 (stromal interacting molecule 1), an endoplasmic reticulum (ER) protein that controls store-operated Ca2+ entry (SOCE), redistributes into punctae at the cell periphery after store depletion. This redistribution is suggested to have a causal role in activation of SOCE. However, whether peripheral STIM1 punctae that are involved in regulation of SOCE are determined by depletion of peripheral or more internal ER has not yet been demonstrated. Here we show that Ca2+ depletion in subplasma membrane ER is sufficient for peripheral redistribution of STIM1 and activation of SOCE. 1 mu M thapsigargin (Tg) induced substantial depletion of intracellular Ca2+ stores and rapidly activated SOCE. In comparison, 1 nM Tg induced slower, about 60 - 70% less Ca2+ depletion but similar SOCE. SOCE was confirmed by measuring I-SOC in addition to Ca2+, Mn2+, and Ba2+ entry. Importantly, 1 nM Tg caused redistribution of STIM1 only in the ER-plasma membrane junction, whereas 1 mu M Tg caused a relatively global relocalization of STIM1 in the cell. During the time taken for STIM1 relocalization and SOCE activation, 1 nM Bodipy-fluorescein Tg primarily labeled the subplasma membrane region, whereas 1 mu M Tg labeled the entire cell. The localization of Tg in the subplasma membrane region was associated with depletion of ER in this region and activation of SOCE. Together, these data suggest that peripheral STIM1 relocalization that is causal in regulation of SOCE is determined by the status of [Ca2+] in the ER in close proximity to the plasma membrane. Thus, the mechanism involved in regulation of SOCE is contained within the ER-plasma membrane junctional region.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biol Modeling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Dakota Grand Forks; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113,10 Ctr Dr, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov	Tsaneva-Atanasova, Krasimira T/AAG-6766-2019; Bandyopadhyay, Bidhan/AAC-6828-2022	Tsaneva-Atanasova, Krasimira T/0000-0002-6294-7051; Bandyopadhyay, Bidhan/0000-0003-2364-8945; Hegde, Ramanujan/0000-0001-8338-852X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008752, Z01HD001206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK013028] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR017699, P20 RR017699-077011] Funding Source: Medline; NIDCR NIH HHS [R01 DE017102, R01 DE017102-03, R01 DE017102-01A1, R01 DE017102-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMBUDKAR IS, 2004, SCI STKE, pPE32; Bandyopadhyay BC, 2005, J BIOL CHEM, V280, P12908, DOI 10.1074/jbc.M410013200; Berridge Michael, 2004, Sci STKE, V2004, ppe33; Bollimuntha S, 2005, J BIOL CHEM, V280, P2132, DOI 10.1074/jbc.M407384200; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Burdakov D, 2005, CELL CALCIUM, V38, P303, DOI 10.1016/j.ceca.2005.06.010; Glitsch MD, 2000, J PHYSIOL-LONDON, V523, P283, DOI 10.1111/j.1469-7793.2000.t01-2-00283.x; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lee MY, 2006, P NATL ACAD SCI USA, V103, P13232, DOI 10.1073/pnas.0605757103; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu X, 2004, J MEMBRANE BIOL, V200, P93, DOI 10.1007/s00232-004-0698-3; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Liu XB, 1999, J BIOL CHEM, V274, P25121, DOI 10.1074/jbc.274.35.25121; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; Ong HL, 2007, PFLUG ARCH EUR J PHY, V453, P797, DOI 10.1007/s00424-006-0163-5; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; Putney J W Jr, 2001, Mol Interv, V1, P84; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Smyth JT, 2006, BBA-MOL CELL RES, V1763, P1147, DOI 10.1016/j.bbamcr.2006.08.050; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Won JH, 2006, AM J PHYSIOL-GASTR L, V291, pG146, DOI 10.1152/ajpgi.00003.2006; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Yao J, 2004, J BIOL CHEM, V279, P21511, DOI 10.1074/jbc.M314028200; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	42	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12176	12185		10.1074/jbc.M609435200	http://dx.doi.org/10.1074/jbc.M609435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17298947	Green Accepted, hybrid			2022-12-27	WOS:000245941900060
J	Zhao, TJ; Yan, YB; Liu, Y; Zhou, HM				Zhao, Tong-Jin; Yan, Yong-Bin; Liu, Yang; Zhou, Hai-Meng			The generation of the oxidized form of creatine kinase is a negative regulation on muscle creatine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; M-LINE; MYOFIBRILLAR PROTEINS; M-BAND; COMPARTMENTATION; UBIQUITINATION; INACTIVATION; FLUORESCENCE; DEGRADATION; EXPRESSION	Muscle creatine kinase ( CK) is a crucial enzyme in energy metabolism, and it exists in two forms, the reduced form ( R-CK) and the oxidized form ( O-CK). In contrast with R-CK, O-CK contained an intrachain disulfide bond in each subunit. Here we explored the properties of O-CK and its regulatory role on muscle CK. The intrachain disulfide bond in O-CK was demonstrated to be formed between Cys(74) and Cys(146) by site-directed mutagenesis. Biophysical analysis indicated that O-CK showed decreased catalytic activity and that it might be structurally unstable. Further assays through guanidine hydrochloride denaturation and proteolysis by trypsin and protease K revealed that the tertiary structure of O-CK was more easily disturbed than that of R-CK. Surprisingly, O-CK, unlike R-CK, cannot interact with the M-line protein myomesin through biosensor assay, indicating that O-CK might have no role in muscle contraction. Through in vitro ubiquitination assay, CK was demonstrated to be a specific substrate of muscle ring finger protein 1 ( MURF-1). O-CK can be rapidly ubiquitinated by MURF-1, while R-CK can hardly be ubiquitinated, implying that CK might be degraded by the ATP-ubiquitin-proteasome pathway through the generation of O-CK. The results above were further confirmed by molecular modeling of the structure of O-CK. Therefore, it can be concluded that the generation of O-CK was a negative regulation of R-CK and that O-CK might play essential roles in the molecular turnover of MM-CK.	Tsinghua Univ, Dept Biol Sci & Technol, Beijing 100084, Peoples R China; Tsinghua Univ, Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, Sch Life Sci & Engn, Prot Sci Lab, Minist Educ, Beijing 100084, Peoples R China; Tsing Hua Univ, Yangtze Delta Reg Inst, Jiaxing 314050, Zhejiang, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University; Tsinghua University	Zhou, HM (corresponding author), Tsinghua Univ, Dept Biol Sci & Technol, Beijing 100084, Peoples R China.	zhm-dbs@mail.tsinghua.edu.cn	Yan, Yong-Bin/A-4282-2008; Zhao, Tong-Jin/AFH-2915-2022	Yan, Yong-Bin/0000-0002-8565-3558; 				Borders CL, 2003, PROTEIN SCI, V12, P532, DOI 10.1110/ps.0230403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; Burtis C.A., 1999, TIETZ TXB CLIN CHEM, P1654; Cox JM, 2003, BIOCHEMISTRY-US, V42, P1863, DOI 10.1021/bi027083b; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; GROSS M, 1995, BIOCHEMISTRY-US, V34, P10350, DOI 10.1021/bi00033a005; Guo SY, 2003, BIOCHIMIE, V85, P999, DOI 10.1016/j.biochi.2003.08.002; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hornemann T, 2000, J CELL BIOL, V149, P1225, DOI 10.1083/jcb.149.6.1225; Hornemann T, 2003, J MOL BIOL, V332, P877, DOI 10.1016/S0022-2836(03)00921-5; Hurne AM, 2000, J BIOL CHEM, V275, P25202, DOI 10.1074/jbc.M002278200; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Kraft T, 2000, J MUSCLE RES CELL M, V21, P691, DOI 10.1023/A:1005623002979; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P13861, DOI 10.1021/bi026655p; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Liu Y, 2005, PROTEIN EXPRES PURIF, V44, P155, DOI 10.1016/j.pep.2005.03.030; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; MILLWARD DJ, 1981, ACTA BIOL MED GER, V40, P1309; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rao JK, 1998, FEBS LETT, V439, P133; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; VENTURACLAPIER R, 1994, MOL CELL BIOCHEM, V133, P125, DOI 10.1007/BF01267952; VINKEMEIER U, 1993, J CELL SCI, V106, P319; WALLIMANN T, 1978, P NATL ACAD SCI USA, V75, P4296, DOI 10.1073/pnas.75.9.4296; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WANG XC, 1994, SCI CHINA SER B, V37, P964; Webb TI, 2001, PROTEINS, V42, P269, DOI 10.1002/1097-0134(20010201)42:2<269::AID-PROT140>3.0.CO;2-Y; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; WYSS M, 1993, BIOCHEMISTRY-US, V32, P10727, DOI 10.1021/bi00091a025; YAO QZ, 1982, SCI SIN B-CHEM B A M, V25, P1296; Zhao TJ, 2006, FEBS LETT, V580, P3835, DOI 10.1016/j.febslet.2006.05.076; Zhao TJ, 2006, INT J BIOCHEM CELL B, V38, P1614, DOI 10.1016/j.biocel.2006.04.002	38	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12022	12029		10.1074/jbc.M610363200	http://dx.doi.org/10.1074/jbc.M610363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17303563	hybrid			2022-12-27	WOS:000245941900044
J	Lo, KWH; Kogoy, JM; Pfister, KK				Lo, Kevin W. -H.; Kogoy, John M.; Pfister, K. Kevin			The DYNLT3 light chain directly links cytoplasmic dynein to a spindle checkpoint protein, Bub3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; DROSOPHILA EMBRYOS; INTERMEDIATE CHAIN; KINETOCHORE FIBERS; BETA-TUBULIN; LIVING CELLS; IN-VIVO; MITOSIS; TRANSPORT; TCTEX-1	Cytoplasmic dynein is the motor protein responsible for the intracellular transport of various organelles and other cargoes toward microtubule minus ends. However, it remains to be determined how dynein is regulated to accomplish its varied roles. The dynein complex contains six subunits, including three classes of light chains. The two isoforms of the DYNLT ( Tctex1) family of light chains, DYNLT1 and DYNLT3, have been proposed to link dynein to specific cargoes. However, no specific binding partner had been found for the DYNLT3 light chain. We find that DYNLT3 binds to Bub3, a spindle checkpoint protein. Bub3 binds exclusively to DYNLT3 and not to the other dynein light chains. Glutathione S-transferase pull-down and co-immunoprecipitation assays demonstrate that Bub3 interacts with the cytoplasmic dynein complex. DYNLT3 is present on kinetochores at prometaphase, but not later mitotic stages, demonstrating that this dynein light chain, like Bub3 and other checkpoint proteins, is depleted from the kinetochore during chromosome alignment. Knockdown of DYNLT3 with small interference RNA increases the mitotic index, in particular, the number of cells in prophase/prometaphase. These results demonstrate that dynein binds directly to a component of the spindle checkpoint complex through the DYNLT3 light chain. Thus, DYNLT3 contributes to dynein cargo binding specificity. These data also suggest that the subpopulation of dynein, containing the DYNLT3 light chain, may be important for chromosome congression, in addition to having a role in the transport of checkpoint proteins from the kinetochore to the spindle pole.	Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Pfister, KK (corresponding author), Univ Virginia, Sch Med, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.	kkp9w@virginia.edu						Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; Basto R, 2004, CURR BIOL, V14, P56, DOI 10.1016/j.cub.2003.12.025; Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431; Chuang JZ, 2001, J NEUROSCI, V21, P5501, DOI 10.1523/JNEUROSCI.21-15-05501.2001; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Douglas MW, 2004, J BIOL CHEM, V279, P28522, DOI 10.1074/jbc.M311671200; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; Gee M, 1998, EUR BIOPHYS J BIOPHY, V27, P466, DOI 10.1007/s002490050157; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Koonce MP, 2004, TRENDS CELL BIOL, V14, P612, DOI 10.1016/j.tcb.2004.09.013; Lai MZ, 2005, NAT NEUROSCI, V8, P435, DOI 10.1038/nn1418; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; LEE MK, 1990, P NATL ACAD SCI USA, V87, P7195, DOI 10.1073/pnas.87.18.7195; Lo Kevin W-H, 2007, Methods Mol Biol, V392, P85, DOI 10.1007/978-1-59745-490-2_6; Lo KWH, 2006, J BIOL CHEM, V281, P9552, DOI 10.1074/jbc.M511721200; Lopes CS, 2005, J CELL SCI, V118, P187, DOI 10.1242/jcs.01602; Maiato H, 2004, J CELL BIOL, V167, P831, DOI 10.1083/jcb.200407090; Mallik R, 2004, CURR BIOL, V14, pR971, DOI 10.1016/j.cub.2004.10.046; Meraldi P, 2005, EMBO J, V24, P1621, DOI 10.1038/sj.emboj.7600641; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; MYERS KR, 2007, J NEUROSCI RES; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; NAKAGAWA J, 1989, J CELL SCI, V94, P449; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; Ohka S, 2004, J VIROL, V78, P7186, DOI 10.1128/JVI.78.13.7186-7198.2004; Oiwa K, 2005, CURR OPIN CELL BIOL, V17, P98, DOI 10.1016/j.ceb.2004.12.006; Pfister KK, 2006, PLOS GENET, V2, P11, DOI 10.1371/journal.pgen.0020001; Pfister KK, 2005, J CELL BIOL, V171, P411, DOI 10.1083/jcb.200508078; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Schmidt DJ, 2005, MOL BIOL CELL, V16, P1200, DOI 10.1091/mbc.E04-06-0523; Schwarzer C, 2002, INT J BIOCHEM CELL B, V34, P1059, DOI 10.1016/S1357-2725(02)00026-2; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; Tang ZY, 2004, P NATL ACAD SCI USA, V101, P18012, DOI 10.1073/pnas.0408600102; Topper LM, 2001, J CELL BIOL, V154, P707, DOI 10.1083/jcb.200104130; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Wilson DK, 2005, J BIOL CHEM, V280, P13944, DOI 10.1074/jbc.M412919200; Wilson MJ, 2001, CELL MOTIL CYTOSKEL, V49, P229, DOI 10.1002/cm.1036; Wojcik E, 2001, NAT CELL BIOL, V3, P1001, DOI 10.1038/ncb1101-1001; Wu HW, 2005, STRUCTURE, V13, P213, DOI 10.1016/j.str.2004.11.013	58	39	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11205	11212		10.1074/jbc.M611279200	http://dx.doi.org/10.1074/jbc.M611279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17289665	hybrid			2022-12-27	WOS:000245941500042
J	Rigoni, M; Pizzo, P; Schiavo, G; Weston, AE; Zatti, G; Caccin, P; Rossetto, O; Pozzan, T; Montecucco, C				Rigoni, Michela; Pizzo, Paola; Schiavo, Giampietro; Weston, Anne E.; Zatti, Giancarlo; Caccin, Paola; Rossetto, Ornella; Pozzan, Tullio; Montecucco, Cesare			Calcium influx and mitochondrial alterations at synapses exposed to snake neurotoxins or their phospholipid hydrolysis products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-BUNGAROTOXIN; NEUROMUSCULAR-JUNCTION; NERVE-TERMINALS; MEMBRANE-FUSION; SMOOTH-MUSCLE; CELLS; LYSOPHOSPHATIDYLCHOLINE; HEMIFUSION; EXOCYTOSIS; VESICLES	Snake presynaptic phospholipase A2 neurotoxins ( SPANs) bind to the presynaptic membrane and hydrolyze phosphatidylcholine with generation of lysophosphatidylcholine ( LysoPC) and fatty acid ( FA). The LysoPC + FA mixture promotes membrane fusion, inducing the exocytosis of the ready-to-release synaptic vesicles. However, also the reserve pool of synaptic vesicles disappears from nerve terminals intoxicated with SPAN or LysoPC + FA. Here, we show that LysoPC + FA and SPANs cause a large influx of extracellular calcium into swollen nerve terminals, which accounts for the extensive synaptic vesicle release. This is paralleled by the change of morphology and the collapse of membrane potential of mitochondria within nerve bulges. These results complete the picture of events occurring at nerve terminals intoxicated by SPANs and define the LysoPC + FA lipid mixture as a novel and effective agonist of synaptic vesicle release.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Lincolns Inn Field Labs, Canc Res UK London Res Inst, London WC2A 3PX, England; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Cancer Research UK; Veneto Institute Molecular Medicine	Montecucco, C (corresponding author), Univ Padua, Dept Biomed Sci, Viale G Colombo 3, I-35121 Padua, Italy.	cesare.montecucco@unipd.it	Pizzo, Paola/T-4874-2018; rossetto, ornella/AAC-3866-2022	Pizzo, Paola/0000-0001-6077-3265; rossetto, ornella/0000-0002-6113-3857; Schiavo, Giampietro/0000-0002-4319-8745; Weston, Anne/0000-0001-6701-224X; Zatti, Giancarlo/0000-0002-1434-8783				Arce V, 1999, J NEUROSCI RES, V55, P119, DOI 10.1002/(SICI)1097-4547(19990101)55:1<119::AID-JNR13>3.0.CO;2-6; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bohnert S, 2005, J BIOL CHEM, V280, P42336, DOI 10.1074/jbc.M506750200; Bonanomi D, 2005, MOL PHARMACOL, V67, P1901, DOI 10.1124/mol.104.005678; Campanella M, 2004, BIOL RES, V37, P653; CECCARELLI B, 1972, J CELL BIOL, V54, P30, DOI 10.1083/jcb.54.1.30; CHEN I, 1970, VIRCHOWS ARCH B, V6, P318; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; Corda D, 2006, TRENDS CELL BIOL, V16, P167, DOI 10.1016/j.tcb.2006.01.007; CULLCANDY SG, 1976, NEUROSCIENCE, V1, P175, DOI 10.1016/0306-4522(76)90074-9; Dixon RW, 1999, AM J PATHOL, V154, P447, DOI 10.1016/S0002-9440(10)65291-1; FASOLATO C, 1989, J BIOL CHEM, V264, P19630; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; Giacomello M, 2005, NEUROBIOL DIS, V18, P638, DOI 10.1016/j.nbd.2004.10.016; Giraudo CG, 2005, J CELL BIOL, V170, P249, DOI 10.1083/jcb.200501093; GOPALAKRISHNAKONE P, 1984, TOXICON, V22, P791, DOI 10.1016/0041-0101(84)90162-4; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kini R.M., 1997, VENOM PHOSPHOLIPASE; Leung YM, 1998, LIFE SCI, V63, P965, DOI 10.1016/S0024-3205(98)00354-3; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; Montecucco C, 2000, TRENDS BIOCHEM SCI, V25, P266, DOI 10.1016/S0968-0004(00)01556-5; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; NG RH, 1978, BIOCHEMISTRY-US, V17, P4978, DOI 10.1021/bi00616a019; NICHOLLS D, 1985, BIOCHEM J, V229, P653, DOI 10.1042/bj2290653; Reese C, 2005, J CELL BIOL, V171, P981, DOI 10.1083/jcb.200510018; Rigoni M, 2005, SCIENCE, V310, P1678, DOI 10.1126/science.1120640; Rigoni M, 2004, J CELL SCI, V117, P3561, DOI 10.1242/jcs.01218; Rizzoli SO, 2005, NAT REV NEUROSCI, V6, P57, DOI 10.1038/nrn1583; Rossetto O, 2006, J NEUROCHEM, V97, P1534, DOI 10.1111/j.1471-4159.2006.03965.x; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; RUGOLO M, 1986, BIOCHEM J, V233, P519, DOI 10.1042/bj2330519; Ryan TA, 2006, CURR OPIN CELL BIOL, V18, P416, DOI 10.1016/j.ceb.2006.06.013; So I, 2005, INT J IMPOT RES, V17, P475, DOI 10.1038/sj.ijir.3901356; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Ushkaryov YA, 2004, TOXICON, V43, P527, DOI 10.1016/j.toxicon.2004.02.008; Wilson-Ashworth HA, 2004, J MEMBRANE BIOL, V200, P25, DOI 10.1007/s00232-004-0691-x; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; WOODLEY SL, 1991, J MOL CELL CARDIOL, V23, P671, DOI 10.1016/0022-2828(91)90977-T; Wright CE, 1996, BRIT J PHARMACOL, V119, P49, DOI 10.1111/j.1476-5381.1996.tb15676.x; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Zheng MQ, 2006, PHARMACOLOGY, V76, P192, DOI 10.1159/000092041; Zimmerberg J, 2005, SCIENCE, V310, P1626, DOI 10.1126/science.1122439	44	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11238	11245		10.1074/jbc.M610176200	http://dx.doi.org/10.1074/jbc.M610176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311918	hybrid			2022-12-27	WOS:000245941500046
J	Valencia, JC; Rouzaud, F; Julien, S; Chen, KG; Passeron, T; Yamaguchi, Y; Abu-Asab, M; Tsokos, M; Costin, GE; Yamaguchi, H; Jenkins, LMM; Nagashima, K; Appella, E; Hearing, VJ				Valencia, Julio C.; Rouzaud, Francois; Julien, Sylvain; Chen, Kevin G.; Passeron, Thierry; Yamaguchi, Yuji; Abu-Asab, Mones; Tsokos, Maria; Costin, Gertrude E.; Yamaguchi, Hiroshi; Jenkins, Lisa M. Miller; Nagashima, Kunio; Appella, Ettore; Hearing, Vincent J.			Sialylated core 1 O-glycans influence the sorting of Pmel17/gp100 and determine its capacity to form fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN PMEL17/GP100; SURFACE SIALIC-ACID; LINKED GLYCOSYLATION; MELANOMA-CELLS; MESSENGER-RNA; GENOMIC ORGANIZATION; MUTANT DEFICIENT; PLASMA-MEMBRANE; UDP-GALACTOSE; DNA-DAMAGE	Pmel17 is a melanocyte/melanoma-specific protein that is essential for the maturation of melanosomes to form mature, fibrillar, and pigmented organelles. Recently, we reported that the less glycosylated form of Pmel17 ( termed iPmel17) is sorted via the plasma membrane in a manner distinct from mature Pmel17 ( termed mPmel17), which is sorted directly to melanosomes. To clarify the mechanism( s) underlying the distinct processing and sorting of Pmel17, we generated a highly specific antibody ( termed alpha PEP25h) against an epitope within the repeat domain of Pmel17 that is sensitive to changes in O-glycosylation. alpha PEP25h recognizes only iPmel17 and allows analysis of the processing and sorting of iPmel17 when compared with alpha PEP13h, an antibody that recognizes both iPmel17 and mPmel17. Our novel findings using alpha PEP25h demonstrate that iPmel17 differs from mPmel17 not only in its sensitivity to endoglycosidase H, but also in the content of core 1 O-glycans modified with sialic acid. This evidence reveals that iPmel17 is glycosylated differently in the Golgi and that it is sorted through the secretory pathway. Analysis of Pmel17 processing in glycosylation-deficient mutant cells reveals that Pmel17 lacking the correct addition of sialic acid and galactose loses the ability to form fibrils. Furthermore, we show that addition of sialic acid affects the stability and sorting of Pmel17 and reduces pigmentation. Alterations in sialyltransferase activity and substrates differ between normal and transformed melanocytes and may represent a critical change during malignant transformation.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Guys Hosp, Canc Res UK, Breast Canc Biol Grp, London SE1 9RT, England; NCI, Image Anal Lab, NIH, Ft Detrick, MD 21702 USA; NCI, Lab Pathol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Valencia, JC (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 2132, Bethesda, MD 20892 USA.	valencij@mail.nih.gov; hearingv@nih.gov	Chen, Kevin/GYU-8963-2022; Chen, Kevin G/D-6769-2011; Yamaguchi, Yuji/X-6681-2019; Jenkins, Lisa/AAI-2490-2021; Yamaguchi, Yuji/B-9312-2008	Chen, Kevin G/0000-0003-2983-6330; Abu-Asab, Mones/0000-0002-4047-1232; Passeron, Thierry/0000-0002-0797-6570; Yamaguchi, Yuji/0000-0003-4338-2662	Intramural NIH HHS [Z99 NS999999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010786, Z01SC009394] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEMA GJ, 1993, AM J PATHOL, V143, P1579; ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Azuma Y, 2000, GLYCOCONJUGATE J, V17, P301, DOI 10.1023/A:1007165403771; Bailin T, 1996, J INVEST DERMATOL, V106, P24, DOI 10.1111/1523-1747.ep12326976; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; BOSMANN HB, 1973, NATURE, V246, P487, DOI 10.1038/246487a0; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3356; Chen KG, 2005, PIGM CELL RES, V18, P102, DOI 10.1111/j.1600-0749.2005.00214.x; Chiamenti AM, 1996, MELANOMA RES, V6, P291, DOI 10.1097/00008390-199608000-00003; Costin GE, 2005, BIOCHEM J, V391, P249, DOI 10.1042/BJ20042070; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Dell'Angelica EC, 2003, TRENDS CELL BIOL, V13, P503, DOI 10.1016/j.tcb.2003.08.001; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOBROSSY L, 1981, CANCER RES, V41, P2262; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; Gasbarri A, 2003, MELANOMA RES, V13, P325, DOI 10.1097/00008390-200308000-00001; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GOTTESMAN MM, 1980, SOMAT CELL GENET, V6, P45, DOI 10.1007/BF01538695; GOWN AM, 1986, AM J PATHOL, V123, P195; Hayes GR, 1997, BIOCHEMISTRY-US, V36, P5276, DOI 10.1021/bi962884y; Hoashi T, 2005, J BIOL CHEM, V280, P14006, DOI 10.1074/jbc.M413692200; Hoashi T, 2006, J BIOL CHEM, V281, P21198, DOI 10.1074/jbc.M601643200; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Kim KK, 1996, PIGM CELL RES, V9, P42, DOI 10.1111/j.1600-0749.1996.tb00085.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Land EJ, 2003, PIGM CELL RES, V16, P397, DOI 10.1034/j.1600-0749.2003.00063.x; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; Mendoza L, 1998, J CELL PHYSIOL, V174, P322; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; Nakagawa K, 2006, J NEUROCHEM, V96, P924, DOI 10.1111/j.1471-4159.2005.03595.x; Negroiu G, 2003, J BIOL CHEM, V278, P27035, DOI 10.1074/jbc.M303167200; Nichols SE, 2003, J INVEST DERMATOL, V121, P821, DOI 10.1046/j.1523-1747.2003.12474.x; Ochwat D, 2004, MELANOMA RES, V14, P479, DOI 10.1097/00008390-200412000-00007; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Otto VI, 2004, J BIOL CHEM, V279, P35201, DOI 10.1074/jbc.M404947200; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Rossi P, 2002, BIOCHEM CELL BIOL, V80, P41, DOI 10.1139/o01-209; Rottger S, 1998, J CELL SCI, V111, P45; Rouzaud F, 2003, FASEB J, V17, P2154, DOI 10.1096/fj.03-0206fje; Sewell R, 2006, J BIOL CHEM, V281, P3586, DOI 10.1074/jbc.M511826200; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Sugrue RJ, 2001, J GEN VIROL, V82, P1375, DOI 10.1099/0022-1317-82-6-1375; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Theos AC, 2006, DEV CELL, V10, P343, DOI 10.1016/j.devcel.2006.01.012; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Valencia JC, 2006, J CELL SCI, V119, P1080, DOI 10.1242/jcs.02804; Valencia JC, 2001, J INVEST MED, V49, P421, DOI 10.2310/6650.2001.33787; Valencia JC, 2006, PIGM CELL RES, V19, P250, DOI 10.1111/j.1600-0749.2006.00308.x; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; Varki A., 1999, ESSENTIALS GLYCOBIOL; Virador VM, 1999, ANAL BIOCHEM, V270, P207, DOI 10.1006/abio.1999.4090; Wang X, 2001, J BIOL CHEM, V276, P35953, DOI 10.1074/jbc.M103680200; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; Yamaguchi Y, 2006, FASEB J, V20, P1486, DOI 10.1096/fj.06-5725fje; Yasumoto K, 2004, J BIOL CHEM, V279, P28330, DOI 10.1074/jbc.M401269200; YOGEESWARAN G, 1980, BIOCHEM BIOPH RES CO, V95, P1452, DOI 10.1016/S0006-291X(80)80060-X	68	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11266	11280		10.1074/jbc.M608449200	http://dx.doi.org/10.1074/jbc.M608449200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303571	hybrid			2022-12-27	WOS:000245941500049
J	Yang, L; Sun, M; Sun, XM; Cheng, GZ; Nicosia, SV; Cheng, JQ				Yang, Lin; Sun, Mei; Sun, Xia-meng; Cheng, George Z.; Nicosia, Santo V.; Cheng, Jin Q.			Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine 212	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-DEATH; KINASE-B; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; CANCER-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS PROTEINS; C-AKT; OMI/HTRA2; INHIBITOR	The serine protease HtrA2/Omi is released from the mitochondria into the cytosol following apoptosis stimuli, leading to the programmed cell death in caspase-dependent and -independent manners. The function of HtrA2/Omi closely relates to its protease activity, which is required for cleavage of its substrate such as the members of the X-linked inhibitor of apoptotic protein family. However, the regulation of HtrA2/Omi by signaling molecule has not been documented. Here we report that serine/threonine kinases Akt1 and Akt2 phosphorylate mitochondria-released HtrA2/Omi on serine 212 in vivo and in vitro, which results in attenuation of its serine protease activity and pro-apoptotic function. Abolishing HtrA2/Omi phosphorylation by Akt through mutation of serine 212 to alanine ( HtrA2/ Omi-S212A) retains its serine protease activity and induces more apoptosis as compared with wild-type HtrA2/Omi. Conversely, HtrA2/ Omi-S212D, a mutant mimicking phosphorylation, lost the protease activity and failed to induce the programmed cell death. Furthermore, the phosphorylated HtrA2/ Omi fails to cleave X-linked inhibitor of apoptotic protein without interfering with their complex formation. In addition, Akt inhibits the release of HtrA2/ Omi from the mitochondria into the cytoplasm in response to cisplatin treatment. These data reveal for the first time that HtrA2/ Omi is directly regulated by Akt and provide a mechanism by which Akt induces cell survival at post-mitochondrial level.	Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pathol & Cell Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cheng, JQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jin.cheng@moffitt.org		Sun, Ellen/0000-0001-7399-4075				AHMED NN, 1993, ONCOGENE, V8, P1957; Althaus J, 2007, NEUROCHEM INT, V50, P172, DOI 10.1016/j.neuint.2006.07.018; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Blink E, 2004, CELL DEATH DIFFER, V11, P937, DOI 10.1038/sj.cdd.4401409; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cilenti L, 2005, AM J PHYSIOL-RENAL, V288, pF371, DOI 10.1152/ajprenal.00154.2004; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Ekert PG, 2005, CURR OPIN CELL BIOL, V17, P626, DOI 10.1016/j.ceb.2005.09.001; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Gamero AM, 2006, CELL SIGNAL, V18, P1299, DOI 10.1016/j.cellsig.2005.10.008; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kuninaka S, 2005, ONCOGENE, V24, P5287, DOI 10.1038/sj.onc.1208682; Liu AX, 1998, CANCER RES, V58, P2973; Liu HR, 2005, CIRCULATION, V111, P90, DOI 10.1161/01.CIR.0000151613.90994.17; Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nam MK, 2006, EXP MOL MED, V38, P36, DOI 10.1038/emm.2006.5; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Seong YM, 2004, J BIOL CHEM, V279, P37588, DOI 10.1074/jbc.M401408200; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	49	35	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10981	10987		10.1074/jbc.M700445200	http://dx.doi.org/10.1074/jbc.M700445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311912	hybrid			2022-12-27	WOS:000245941500018
J	Roberts, SA; Ramsden, DA				Roberts, Steven A.; Ramsden, Dale A.			Loading of the nonhomologous end joining factor, Ku, on protein-occluded DNA ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV-DEPENDENT LIGATION; STRAND BREAK REPAIR; V(D)J RECOMBINATION; LIGASE-IV; EQUILIBRIUM ACCESSIBILITY; COMPLEX; BINDING; SINGLE; MECHANISM; AFFINITY	The nonhomologous end joining pathway for DNA double strand break repair requires Ku to bind DNA ends and subsequently recruit other nonhomologous end joining factors, including the DNA-dependent protein kinase catalytic subunit and the XRCC4-Ligase IV complex, to the break site. Ku loads at a break by threading the DNA ends through a circular channel in its structure. This binding mechanism explains both the high specificity of Ku for ends and its ability to translocate along DNA once loaded. However, DNA in cells is typically coated with other proteins ( e. g. histones), which might be expected to block the ability of Ku to load in this manner. Here we address how the nature of a protein obstruction dictates how Ku interacts with a DNA end. Ku is unable to access the ends within an important intermediate in V(D)J recombination ( a complex of RAG proteins bound to cleaved recombination targeting signals), but Ku readily displaces the linker histone, H1, from DNA. Ku also retains physiological affinity for nucleosome-associated ends. Loading onto nucleosome-associated ends still occurs by threading the end through its channel, but rather than displacing the nucleosome, Ku peels as much as 50 bp of DNA away from the histone octamer surface. We suggest a model where Ku utilizes an unusual characteristic of its three-dimensional structure to recognize certain protein-occluded ends without the extensive remodeling of chromatin structure required by other DNA repair pathways.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ramsden, DA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB-7295, Chapel Hill, NC 27599 USA.	dale_ramsden@med.unc.edu		Ramsden, Dale/0000-0003-1575-4748	NATIONAL CANCER INSTITUTE [R01CA084442] Funding Source: NIH RePORTER; NCI NIH HHS [CA-84442, R01 CA084442] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Anderson JD, 2000, J MOL BIOL, V296, P979, DOI 10.1006/jmbi.2000.3531; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; CHRISTOPHER JA, 2004, SPOCK STRUCTURAL PRO; Clejan I, 2006, GENETICS, V173, P1301, DOI 10.1534/genetics.106.058628; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; FALZON M, 1993, J BIOL CHEM, V268, P10546; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; Jones JM, 2003, P NATL ACAD SCI USA, V100, P15446, DOI 10.1073/pnas.2637012100; Jones JM, 2001, P NATL ACAD SCI USA, V98, P12926, DOI 10.1073/pnas.221471198; Kysela B, 2005, P NATL ACAD SCI USA, V102, P1877, DOI 10.1073/pnas.0401179102; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Lee J, 1999, IMMUNITY, V11, P771, DOI 10.1016/S1074-7613(00)80151-X; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Ma YM, 2001, BIOCHEMISTRY-US, V40, P9638, DOI 10.1021/bi010932v; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; MIMORI T, 1986, J BIOL CHEM, V261, P375; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Park EJ, 2003, NUCLEIC ACIDS RES, V31, P6819, DOI 10.1093/nar/gkg921; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Reddy YVR, 2006, GENE DEV, V20, P1575, DOI 10.1101/gad.1432706; SCHNITZLER G, 2000, CURRENT PROTOCOLS MO, P21; Schwanbeck R, 2004, J BIOL CHEM, V279, P39933, DOI 10.1074/jbc.M406060200; Shim EY, 2007, MOL CELL BIOL, V27, P1602, DOI 10.1128/MCB.01956-06; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; WAGNER JP, 1995, J BIOL CHEM, V270, P7394, DOI 10.1074/jbc.270.13.7394; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WeisGarcia F, 1997, MOL CELL BIOL, V17, P6379, DOI 10.1128/MCB.17.11.6379; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034; Yurchenko V, 2003, GENE DEV, V17, P581, DOI 10.1101/gad.1058103; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	49	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10605	10613		10.1074/jbc.M611125200	http://dx.doi.org/10.1074/jbc.M611125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289670	Green Published, hybrid			2022-12-27	WOS:000245941000054
J	vanVickle-Chavez, SJ; van Gelder, RN				vanVickle-Chavez, Sarah J.; van Gelder, Russell N.			Action spectrum of Drosophila cryptochrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-LIGHT PHOTORECEPTORS; CIRCADIAN PHOTORECEPTION; FISH CYPRINIDAE; S-POTENTIALS; ARABIDOPSIS; CLOCK; MELANOGASTER; PROTEIN; RETINA; UNITS	Cryptochromes are a highly conserved class of UV-A/blue light photoreceptors. In Drosophila, cryptochrome is required for the normal entrainment of circadian rhythms to light dark cycles. The photocycle and molecular mechanism of animal cryptochrome photoreception are presently unknown. Drosophila cryptochrome undergoes light-dependent degradation when heterologously expressed in Schneider-2 cells. We have generated Drosophila luciferase-cryptochrome fusion proteins to more precisely monitor light-dependent cryptochrome degradation. We found that the luciferase-cryptochrome fusion protein undergoes light-dependent degradation with luciferase activity declining similar to 50% within 5 min of light exposure and similar to 85% within 1 h of light exposure. Degradation is inhibited by MG-132, consistent with a proteasomal degradation mechanism. Irradiance-response curves yield an action spectrum similar to absorption spectra for prokaryotic and eukaryotic cryptochromes with highest sensitivity in the UV-A. A luciferase-cryptochrome fusion protein lacking the terminal 15 amino acids is stably expressed in the dark but demonstrates increased sensitivity to light-induced degradation. The conferral of light-dependent degradation on a heterologous protein by fusion to cryptochrome may be a useful tool for probing protein function in cell expression systems.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	van Gelder, RN (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave, St Louis, MO 63110 USA.	vangelder@vision.wustl.edu	Van Gelder, Russell/ABB-4225-2021	Van Gelder, Russell/0000-0001-5368-3659				Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Bogyo M, 1997, BIOPOLYMERS, V43, P269, DOI 10.1002/(SICI)1097-0282(1997)43:4<269::AID-BIP2>3.0.CO;2-T; Bouly JP, 2007, J BIOL CHEM, V282, P9383, DOI 10.1074/jbc.M609842200; Busza A, 2004, SCIENCE, V304, P1503, DOI 10.1126/science.1096973; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Cermakian N, 2002, CURR BIOL, V12, P844, DOI 10.1016/S0960-9822(02)00835-7; Dissel S, 2004, NAT NEUROSCI, V7, P834, DOI 10.1038/nn1285; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Helfrich-Forster C, 2002, J NEUROSCI, V22, P9255; Hendil KB, 2002, J MOL BIOL, V315, P627, DOI 10.1006/jmbi.2001.5285; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Kleine T, 2003, PLANT J, V35, P93, DOI 10.1046/j.1365-313X.2003.01787.x; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; NAKA KI, 1966, J PHYSIOL-LONDON, V185, P587, DOI 10.1113/jphysiol.1966.sp008003; NAKA KI, 1966, J PHYSIOL-LONDON, V185, P536, DOI 10.1113/jphysiol.1966.sp008001; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Tu DC, 2004, SCIENCE, V306, P129, DOI 10.1126/science.1101484; Worthington EN, 2003, J BIOL CHEM, V278, P39143, DOI 10.1074/jbc.M305792200; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; ZETTLER F, 1969, Z VERGL PHYSIOL, V64, P432, DOI 10.1007/BF00340437	26	51	52	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10561	10566		10.1074/jbc.M609314200	http://dx.doi.org/10.1074/jbc.M609314200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284451	hybrid			2022-12-27	WOS:000245941000049
J	Heffernan, TP; Unsal-Kacmaz, K; Heinloth, AN; Simpson, DA; Paules, RS; Sancar, A; Cordeiro-Stone, M; Kaufmann, WK				Heffernan, Timothy P.; Unsal-Kacmaz, Keziban; Heinloth, Alexandra N.; Simpson, Dennis A.; Paules, Richard S.; Sancar, Aziz; Cordeiro-Stone, Marila; Kaufmann, William K.			Cdc7-dbf4 and the human S checkpoint response to UVC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; DIPLOID HUMAN FIBROBLASTS; CELL-CYCLE REGULATION; PHASE CHECKPOINT; PROTEIN-KINASE; DOWNSTREAM EFFECTOR; IONIZING-RADIATION; CDC7P-DBF4P KINASE; ULTRAVIOLET-LIGHT; POLYMERASE ALPHA	The S checkpoint response to ultraviolet radiation (UVC) that inhibits replicon initiation is dependent on the ATR and Chk1 kinases. Downstream effectors of this response, however, are not well characterized. Data reported here eliminated Cdc25A degradation and inhibition of Cdk2-cyclin E as intrinsic components of the UVC-induced pathway of inhibition of replicon initiation in human cells. A sublethal dose of UVC (1 j/m(2)), which selectively inhibits replicon initiation by 50%, failed to reduce the amount of Cdc25A protein or decrease Cdk2-cyclin E kinase activity. Cdc25A degradation was observed after irradiation with cytotoxic fluences of UVC, suggesting that severe inhibition of DNA chain elongation and activation of the replication checkpoint might be responsible for the UVC-induced degradation of Cdc25A. Another proposed effector of the S checkpoint is the Cdc7-Dbf4 complex. Dbf4 interacted weakly with Chk1 in vivo but was recognized as a substrate for Chk1-dependent phosphorylation in vitro. FLAG-Dbf4 formed complexes with endogenous Cdc7, and this interaction was stable in UVC-irradiated HeLa cells. Overexpression of FLAG- or Myc-tagged Dbf4 abrogated the S checkpoint response to UVC but not ionizing radiation. These findings implicate a Dbf4-dependent kinase as a possible target of the ATR- and Chk1-dependent S checkpoint response to UVC.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Hlth & Susceptibil, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; NIEHS, Growth Control & Canc Grp, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kaufmann, WK (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.	wkarlk@med.unc.edu		Paules, Richard S/0000-0001-9106-7486	NATIONAL CANCER INSTITUTE [P30CA016086, R55CA055065, R01CA055065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011012, P30ES010126, Z01ES021157, ZIAES021157] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA055065, CA055065, P30-CA 16086, P30 CA016086] Funding Source: Medline; NIEHS NIH HHS [P30 ES010126, ES07017, T32 ES007017, R01 ES011012, ES11012, P30-ES10126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Agner J, 2005, EXP CELL RES, V302, P162, DOI 10.1016/j.yexcr.2004.08.035; Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chou DM, 2006, P NATL ACAD SCI USA, V103, P18143, DOI 10.1073/pnas.0609251103; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cistulli CA, 1998, CANCER RES, V58, P1993; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; Cordeiro-Stone M, 2002, CARCINOGENESIS, V23, P959, DOI 10.1093/carcin/23.6.959; CORDEIROSTONE M, 1986, CARCINOGENESIS, V7, P1775, DOI 10.1093/carcin/7.10.1775; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; D Bomgarden R, 2006, EMBO J, V25, P2605, DOI 10.1038/sj.emboj.7601123; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Ishimi Y, 2003, J BIOL CHEM, V278, P24644, DOI 10.1074/jbc.M213252200; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAUFMANN WK, 1981, J MOL BIOL, V149, P171, DOI 10.1016/0022-2836(81)90297-7; KAUFMANN WK, 1990, MUTAT RES, V236, P107, DOI 10.1016/0921-8777(90)90038-7; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu PJ, 2006, J BIOL CHEM, V281, P30631, DOI 10.1074/jbc.M602982200; Lopes M, 2006, MOL CELL, V21, P15, DOI 10.1016/j.molcel.2005.11.015; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H, 2006, J BIOL CHEM, V281, P39249, DOI 10.1074/jbc.M608935200; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MENEGHINI R, 1981, BIOPHYS J, V33, P81, DOI 10.1016/S0006-3495(81)84873-4; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tenca P, 2007, J BIOL CHEM, V282, P208, DOI 10.1074/jbc.M604457200; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Unsal-Kacmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	81	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9458	9468		10.1074/jbc.M611292200	http://dx.doi.org/10.1074/jbc.M611292200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276990	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000245421700018
J	Miller, SLH; Scappini, EL; O'Bryan, J				Miller, Stephanie L. H.; Scappini, Erica L.; O'Bryan, John			Ubiquitin-interacting motifs inhibit aggregation of PolyQ-expanded huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DISEASE; IDENTIFICATION; UBIQUITYLATION; PATHOGENESIS; AGGRESOMES; COMPONENTS; ATAXIN-3; EPS15; EPSIN	Expansion of polyglutamine (polyQ) tracts within proteins underlies a number of neurodegenerative diseases, such as Huntington disease, Kennedy disease, and spinocerebellar ataxias. The resulting mutant proteins are unstable, forming insoluble aggregates that are associated with components of the ubiquitin system, including ubiquitin, ubiquitin-like proteins, and proteins that bind to ubiquitin. Given the presence of these ubiquitin-binding proteins in the insoluble aggregates, we examined whether heterologous expression of short motifs that bind ubiquitin, termed ubiquitin-interacting motifs (UIMs), altered the aggregation of polyQ-expanded huntingtin (Htt), the protein product of the Huntington disease gene. We found that a subset of UIMs associated with mutant Htt. The ability to interact with ubiquitin was necessary, but not sufficient, for interaction with mutant Htt. Furthermore, we found that expression of single, isolated UIMs inhibited aggregation of mutant Htt. These data suggest that isolated UIMs might serve as potential inhibitors of polyQ-aggregation in vivo.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	O'Bryan, J (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott,Rm E403,M-C 868, Chicago, IL 60612 USA.	obryanj@uic.edu	Scappini, Erica/C-7684-2019	Scappini, Erica/0000-0002-9100-0027; O'Bryan, John/0000-0001-5386-1080	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Davidson JD, 2000, HUM MOL GENET, V9, P2305, DOI 10.1093/oxfordjournals.hmg.a018922; Doi H, 2004, FEBS LETT, V571, P171, DOI 10.1016/j.febslet.2004.06.077; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Hecker CM, 2006, J BIOL CHEM, V281, P16117, DOI 10.1074/jbc.M512757200; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Lim KL, 2006, NEUROBIOL AGING, V27, P524, DOI 10.1016/j.neurobiolaging.2005.07.023; Matsumoto G, 2006, J BIOL CHEM, V281, P4477, DOI 10.1074/jbc.M509201200; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Oved S, 2006, J BIOL CHEM, V281, P21640, DOI 10.1074/jbc.M513034200; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qin ZH, 2004, ACTA PHARMACOL SIN, V25, P1243; Regan-Klapisz E, 2005, J CELL SCI, V118, P4437, DOI 10.1242/jcs.02571; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Timsit YE, 2005, BIOCHEM BIOPH RES CO, V328, P550, DOI 10.1016/j.bbrc.2005.01.022; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030	29	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10096	10103		10.1074/jbc.M611151200	http://dx.doi.org/10.1074/jbc.M611151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276991	hybrid			2022-12-27	WOS:000245421700083
J	Stempelj, M; Kedinger, M; Augenlicht, L; Klampfer, L				Stempelj, Mateja; Kedinger, Michele; Augenlicht, Leonard; Klampfer, Lidija			Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL ULCERATIVE-COLITIS; ABERRANT CRYPT FOCI; FACTOR-KAPPA-B; IFN-GAMMA; TUMOR ANGIOGENESIS; COLORECTAL-CANCER; GENE-EXPRESSION; ACTIVATION; CYCLOOXYGENASE-2; PROTEIN	Nitric oxide (NO) is a highly reactive free radical that modulates tumorigenesis through its ability to regulate cell proliferation, cell death, migration and angiogenesis. Although the role of NO has been well studied in inflammatory cells, much less is known about the regulation of NO production in epithelial cells. We demonstrated that in intestinal epithelial cells the expression of inducible NO synthase (iNOS), the critical enzyme in the synthesis of NO, is synergistically stimulated by bacterial lipopolysaccharide (LPS) and interferon gamma (IFN gamma) or by the combination of tumor necrosis factor (TNF) and IFN gamma at the transcriptional level. Expression of iNOS and the production of NO in response to LPS/IFN gamma were significantly increased upon induction of oncogenic K-Ras, underlying frequently elevated expression of iNOS in colon cancer. Silencing of STAT1, a major transcription factor involved in signaling by IFN gamma, or pharmacological inhibition of JAKs, kinases that phosphorylate STATs, prevented the induction of iNOS and the production of NO in response to stimulation of cells with LPS/IFN gamma or TNF/IFN gamma, underscoring the importance of the intact JAK/STAT signaling in the regulation of iNOS expression in intestinal epithelial cells. Butyrate, a histone deacetylase (HDAC) inhibitor and a dietary chemopreventive agent, decreased NO production in macrophages and in intestinal myofibroblasts, consistent with its anti-inflammatory activity. In contrast, in intestinal epithelial cells, butyrate significantly enhanced the expression of iNOS and the production of NO in response to treatment with LPS/IFN gamma. Despite the fact that, like butyrate, three structurally unrelated inhibitors of HDAC activity, trichostatin A, suberoylanilide hydroxamic acid, and apicidin, induced acetylation of H3 and H4 in epithelial cells, they failed to increase the production of NO, demonstrating that butyrate regulates NO production in epithelial cells in an HDAC-independent manner. The ability of butyrate to regulate the production of NO in a variety of cell types is likely to underlie its potent chemopreventive and anti-inflammatory activity.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Univ Strasbourg 1, INSERM, U682, F-67200 Strasbourg, France	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NCI NIH HHS [U54 CA100926, R01 CA111361] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA100926, R01CA111361] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn B, 2001, CANCER RES, V61, P8357; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Ambs S, 1998, CANCER RES, V58, P334; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192; Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X; COBBS CS, 1995, CANCER RES, V55, P727; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Edwards P, 1996, J SURG RES, V63, P49, DOI 10.1006/jsre.1996.0221; Ellerhorst JA, 2006, ONCOGENE, V25, P3956, DOI 10.1038/sj.onc.1209419; Gauthier N, 2004, CARCINOGENESIS, V25, P1559, DOI 10.1093/carcin/bgh158; Gibson PR, 1999, CARCINOGENESIS, V20, P539, DOI 10.1093/carcin/20.4.539; Hao XP, 2001, CANCER RES, V61, P419; Heigold S, 2002, CARCINOGENESIS, V23, P929, DOI 10.1093/carcin/23.6.929; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; Kitano H, 1999, THYROID, V9, P113, DOI 10.1089/thy.1999.9.113; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Lanas A, 2000, NEW ENGL J MED, V343, P834, DOI 10.1056/NEJM200009213431202; Loibl S, 2005, EUR J CANCER, V41, P265, DOI 10.1016/j.ejca.2004.07.010; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; Nam KT, 2004, GUT, V53, P1250, DOI 10.1136/gut.2003.030684; Plateroti M, 1998, AM J PHYSIOL-GASTR L, V274, pG945, DOI 10.1152/ajpgi.1998.274.5.G945; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Rao CV, 1999, CARCINOGENESIS, V20, P641, DOI 10.1093/carcin/20.4.641; Rao CV, 2002, CANCER RES, V62, P165; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Sasahara Y, 2002, CANCER LETT, V177, P155, DOI 10.1016/S0304-3835(01)00778-9; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; SCHEPPACH W, 1997, SCAND J GASTROENTE S, V222, P53; Scott DJ, 2001, GASTROENTEROLOGY, V121, P889, DOI 10.1053/gast.2001.27994; Sheng HM, 2001, CANCER RES, V61, P2670; Sparmann A, 2005, CELL CYCLE, V4, P735, DOI 10.4161/cc.4.6.1714; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Suuronen T, 2003, J NEUROCHEM, V87, P407, DOI 10.1046/j.1471-4159.2003.02004.x; Takahashi M, 2003, ONCOGENE, V22, P7667, DOI 10.1038/sj.onc.1207051; Vecchini F, 1997, CELL GROWTH DIFFER, V8, P261; Vernia P, 2003, EUR J CLIN INVEST, V33, P244, DOI 10.1046/j.1365-2362.2003.01130.x; Yamaguchi S, 2002, BRIT J NEUROSURG, V16, P567	47	98	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9797	9804		10.1074/jbc.M609426200	http://dx.doi.org/10.1074/jbc.M609426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251186	hybrid			2022-12-27	WOS:000245421700054
J	Phimister, AJ; Lango, J; Lee, EH; Ernst-Russell, MA; Takeshima, H; Ma, JJ; Allen, PD; Pessah, IN				Phimister, Andrew J.; Lango, Jozsef; Lee, Eun Hui; Ernst-Russell, Michael A.; Takeshima, Hiroshi; Ma, Jianjie; Allen, Paul D.; Pessah, Isaac N.			Conformation-dependent stability of junctophilin 1 (JP1) and ryanodine receptor type 1 (RyRl) channel complex is mediated by their hyper-reactive thiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; DISULFIDE-BOND; SKELETAL-TYPE; REDOX SENSOR; HYPERREACTIVE CYSTEINES; S-GLUTATHIONYLATION; TRIADIN; BINDING; DOMAIN	Junctophilin 1 (JP1), a 72-kDa protein localized at the skeletal muscle triad, is essential for stabilizing the close apposition of T-tubule and sarcoplasmic reticulum membranes to form junctions. In this study we report that rapid and selective labeling of hyper-reactive thiols found in both JP1 and ryanodine receptor type 1 (RyR1) with 7-diethylamino-3-(4'-mateimidylphenyl)-4-methylcoumarin, a fluorescent thiol-reactive probe, proceeded 12-fold faster under conditions that minimize RyR1 gating (e,g. 10 mm Mg2+) compared with conditions that promote high channel activity (e.g. 100 mu m Ca2+, 10 mm caffeine, 5 mm ATP). The reactivity of these thiol groups was very sensitive to oxidation by naphthoquinone, H2O2, NO, or O-2, all known modulators of the RyR1 channel complex. Using preparative SDS-PAGE, in-get tryptic digestion, high pressure liquid chromatography, and mass spectrometry-based peptide sequencing, we identified 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin-thioether adducts on three cysteine residues of JP1 (101, 402, and 627); the remaining five cysteines of JP1 were unlabeled. Co-immunoprecipitation experiments demonstrated a physical interaction between JP1 and RyR1 that, like thiol reactivity, was sensitive to RyR1 conformation and chemical status of the hyper-reactive cysteines of JP1 and RyR1. These findings support a model in which JP1 interacts with the RyR1 channel complex in a conformationally sensitive manner and may contribute integral redox-sensing properties through reactive sulfhydryl chemistry.	Univ Calif Davis, Dept Vet Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA; Brigham & Womens Hosp, Dept Anesthesia Res, Boston, MA 02115 USA; Catholic Univ Korea, Dept Physiol, Coll Med, Seoul 137701, South Korea; Tohoku Univ, Dept Biochem, Sendai, Miyagi 9808575, Japan; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	University of California System; University of California Davis; University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital; Catholic University of Korea; Tohoku University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Pessah, IN (corresponding author), Univ Calif Davis, Dept Vet Mol Biosci, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X; Lee, Eun Hui/0000-0003-4555-1730; Takeshima, Hiroshi/0000-0003-4525-3725	NCRR NIH HHS [P20 RR16464] Funding Source: Medline; NIAMS NIH HHS [2R01-AR43140, 2P01-AR17605] Funding Source: Medline; NIEHS NIH HHS [P42-ES04699, 1P01-ES11269] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269, P42ES004699] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABDELLATIF Y, 2007, IN PRESS CELL CALCIU; Aracena P, 2005, ANTIOXID REDOX SIGN, V7, P870, DOI 10.1089/ars.2005.7.870; Aracena P, 2003, J BIOL CHEM, V278, P42927, DOI 10.1074/jbc.M306969200; Baker ML, 2002, P NATL ACAD SCI USA, V99, P12155, DOI 10.1073/pnas.182058899; Chelu MG, 2004, TRENDS CARDIOVAS MED, V14, P227, DOI 10.1016/j.tcm.2004.06.003; Cherednichenko G, 2004, CIRC RES, V94, P478, DOI 10.1161/01.RES.0000115554.65513.7C; Di Biase V, 2005, J CELL BIOL, V171, P695, DOI 10.1083/jcb.200503077; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Feng W, 1999, MOL PHARMACOL, V55, P821; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Feng W, 2002, METHOD ENZYMOL, V353, P240; Finehout EJ, 2003, ELECTROPHORESIS, V24, P3508, DOI 10.1002/elps.200305615; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; Fomenko DE, 2003, ANTIOXID REDOX SIGN, V5, P397, DOI 10.1089/152308603768295131; Franzini-Armstrong C, 2005, ANN NY ACAD SCI, V1047, P76, DOI 10.1196/annals.1341.007; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; Gao J, 2005, TOXICOL SCI, V87, P419, DOI 10.1093/toxsci/kfi265; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Hirata Y, 2006, BIOPHYS J, V90, P4418, DOI 10.1529/biophysj.105.076570; Hurne AM, 2005, J BIOL CHEM, V280, P36994, DOI 10.1074/jbc.M506441200; Ito K, 2001, J CELL BIOL, V154, P1059, DOI 10.1083/jcb.200105040; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Komazaki S, 2002, FEBS LETT, V524, P225, DOI 10.1016/S0014-5793(02)03042-9; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; Ma H, 2006, CELL RES, V16, P466, DOI 10.1038/sj.cr.7310058; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Moriguchi S, 2006, P NATL ACAD SCI USA, V103, P10811, DOI 10.1073/pnas.0509863103; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; Nishi M, 2000, BIOCHEM BIOPH RES CO, V273, P920, DOI 10.1006/bbrc.2000.3011; Nishi M, 2003, MOL BRAIN RES, V118, P102, DOI 10.1016/S0169-328X(03)00341-3; Perez CF, 2003, J BIOL CHEM, V278, P39644, DOI 10.1074/jbc.M305160200; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; Pessah IN, 2001, MOL PHARMACOL, V59, P506, DOI 10.1124/mol.59.3.506; Pessah IN, 2002, FRONT BIOSCI-LANDMRK, V7, pA72, DOI 10.2741/pessah; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Voss AA, 2004, J BIOL CHEM, V279, P34514, DOI 10.1074/jbc.M404290200; Wallin M, 2004, EMBO J, V23, P54, DOI 10.1038/sj.emboj.7600012; Wolf M, 2003, J MOL BIOL, V332, P171, DOI 10.1016/S0022-2836(03)00899-4; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200	50	48	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8667	8677		10.1074/jbc.M609936200	http://dx.doi.org/10.1074/jbc.M609936200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17237236	hybrid			2022-12-27	WOS:000245780300013
J	Elson-Schwab, L; Garner, OB; Schuksz, M; Crawford, BE; Esko, JD; Tor, Y				Elson-Schwab, Lev; Garner, Omai B.; Schuksz, Manuela; Crawford, Brett E.; Esko, Jeffrey D.; Tor, Yitzhak			Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan sulfate-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CELLULAR-UPTAKE; FIBROBLAST-GROWTH; RICH PEPTIDES; TAT PEPTIDE; TRANSLOCATION; MOLECULES; PROTEIN; MEMBRANES; ARGININE	Facilitating the uptake of molecules into living cells is of substantial interest for basic research and drug delivery applications. Arginine-rich peptides have been shown to facilitate uptake of high molecular mass cargos into cells, but the mechanism of uptake is complex and may involve multiple receptors. In this report, we show that a derivative of the aminoglycoside antibiotic neomycin, in which all of the ammonium groups have been converted into guanidinium groups, can carry large (> 300 kDa) bioactive molecules across cell membranes. Delivery occurs at nanomolar transporter concentrations and under these conditions depends entirely on cell surface heparan sulfate proteoglycans. Conjugation of guanidinoneomycin to the plant toxin saporin, a ribosome-inactivating agent, results in proteoglycan-dependent cell toxicity. In contrast, an arginine-rich peptide shows both heparan sulfate-dependent and -independent cellular uptake. The high selectivity of guanidi-noneomycin for heparan sulfate suggests the possibility of exploiting differences in proteoglycan compositions to target delivery to different cell types.	Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Zacharon Pharmaceut Inc, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; BioMarin Pharmaceutical Inc.; Zacharon Pharmaceuticals Inc.	Esko, JD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.	jesko@ucsd.edu; ytor@ucsd.edu			NCI NIH HHS [CA11227, CA67754] Funding Source: Medline; NIAID NIH HHS [5F31AI05891602, AI47673] Funding Source: Medline; NIGMS NIH HHS [GM77471, GM33063] Funding Source: Medline; NINDS NIH HHS [NS047101] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM077471, R01GM033063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Caesar CEB, 2006, BIOCHEMISTRY-US, V45, P7682, DOI 10.1021/bi052095t; Chung HH, 2004, BIOPOLYMERS, V76, P83, DOI 10.1002/bip.10597; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fernandex-Carneado J, 2005, J AM CHEM SOC, V127, P869, DOI 10.1021/ja044006q; Fillon YA, 2005, J AM CHEM SOC, V127, P11798, DOI 10.1021/ja052377g; Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Futaki S, 2006, BIOPOLYMERS, V84, P241, DOI 10.1002/bip.20421; Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hardman J, 2006, AMINOGLYCOSIDES GOOD, V11; Hitz T, 2006, BIOCHEMISTRY-US, V45, P5817, DOI 10.1021/bi060285d; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Luedtke NW, 2003, J AM CHEM SOC, V125, P12374, DOI 10.1021/ja0360135; Luedtke NW, 2000, J AM CHEM SOC, V122, P12035, DOI 10.1021/ja002421m; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003; Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536; RYSER HJP, 1968, SCIENCE, V159, P390, DOI 10.1126/science.159.3813.390; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Umezawa N, 2002, J AM CHEM SOC, V124, P368, DOI 10.1021/ja017283v; Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	61	71	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13585	13591		10.1074/jbc.M700463200	http://dx.doi.org/10.1074/jbc.M700463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17311923	hybrid			2022-12-27	WOS:000246060300047
J	Madan, P; Rose, K; Watson, AJ				Madan, Pavneesh; Rose, Keeley; Watson, Andrew J.			Na/K-ATPase beta 1 subunit expression is required for blastocyst formation and normal assembly of trophectoderm tight junction-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PREIMPLANTATION DEVELOPMENT; NA,K-ATPASE ALPHA-SUBUNIT; EMBRYO DEVELOPMENT; NA+/K+-ATPASE; IN-VITRO; DIFFERENTIATION; BETA(1)-SUBUNIT; SUPPRESSION; BIOGENESIS; CAVITATION	Na/K-ATPase plays an important role in mediating blastocyst formation. Despite the expression of multiple Na/K-ATPase alpha and beta isoforms during mouse preimplantation development, only the alpha 1 and beta 1 isoforms have been localized to the basolateral membrane regions of the trophectoderm. The aim of the present study was to selectively down-regulate the Na/KATPase beta 1 subunit employing microinjection of mouse 1 cell zygotes with small interfering RNA (siRNA) oligos. Experiments comprised of non- injected controls and two groups microinjected with either Stealth (TM) Na/K- ATPase beta 1 subunit oligos or nonspecific Stealth (TM) siRNA as control. Development to the 2-, 4-, 8-, and 16-cell and morula stages did not vary between the three groups. However, only 2.3% of the embryos microinjected with Na/K-ATPase beta 1 subunit siRNA oligos developed to the blastocyst stage as compared with 73% for control-injected and 91% for non-injected controls. Na/K-ATPase beta 1 subunit down-regulation was validated by employing reverse transcription-PCR and whole-mount immunofluorescence methods to demonstrate that Na/K-ATPase beta 1 subunit mRNAs and protein were not detectable in beta 1 subunit siRNA-microinjected embryos. Aggregation chimera experiments between beta 1 subunit siRNA-microinjected embryos and controls demonstrated that blockade of blastocyst formation was reversible. The distribution of Na/K-ATPase beta 1 and tight junction-associated proteins occludin and ZO-1 were compared among the three treatment groups. No differences in protein distribution were observed between control groups; however, all three polypeptides displayed an aberrant distribution in Na/K-ATPase beta 1 subunit siRNA-microinjected embryos. Our results demonstrate that the beta 1 subunit of the Na/K-ATPase is required for blastocyst formation and that this subunit is also required to maintain a normal Na/K-ATPase distribution and localization of tight junction-associated polypeptides during preimplantation development.	Univ Western Ontario, VRL, CHRI, Dept Obstet & Gynaecol, London, ON N6A 4G5, Canada; Univ Western Ontario, VRL, CHRI, Dept Physiol, London, ON N6A 4G5, Canada; Univ Western Ontario, VRL, CHRI, Dept Pharmacol, London, ON N6A 4G5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Watson, AJ (corresponding author), Univ Western Ontario, VRL, CHRI, Dept Obstet & Gynaecol, 5th Floor,800 Commissioners Rd E, London, ON N6A 4G5, Canada.	awatson@uwo.ca	Watson, Andrew J/A-5636-2015	Watson, Andrew J/0000-0002-2344-3061				Barcroft LC, 1998, J REPROD FERTIL, V114, P327, DOI 10.1530/jrf.0.1140327; Barcroft LC, 2004, MECH DEVELOP, V121, P417, DOI 10.1016/j.mod.2004.04.005; Barwe SP, 2005, MOL BIOL CELL, V16, P1082, DOI 10.1091/mbc.E04-05-0427; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; BENOS DJ, 1981, DEV BIOL, V83, P69, DOI 10.1016/S0012-1606(81)80009-7; Betts DH, 1998, DEV BIOL, V197, P77, DOI 10.1006/dbio.1998.8874; Betts DH, 1997, MOL REPROD DEV, V46, P114, DOI 10.1002/(SICI)1098-2795(199702)46:2&lt;114::AID-MRD2&gt;3.0.CO;2-T; BIGGERS JD, 1978, J PHYSIOL-LONDON, V280, P319, DOI 10.1113/jphysiol.1978.sp012386; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIZIO SM, 1977, DEV BIOL, V59, P198, DOI 10.1016/0012-1606(77)90254-8; DUMOULIN JCM, 1993, MOL REPROD DEV, V36, P320, DOI 10.1002/mrd.1080360306; Espineda CE, 2004, MOL BIOL CELL, V15, P1364, DOI 10.1091/mbc.E03-09-0646; FLEMING TP, 1989, J CELL BIOL, V108, P1407, DOI 10.1083/jcb.108.4.1407; FLEMING TP, 1993, J CELL SCI, P119; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; GARDINER CS, 1990, BIOL REPROD, V43, P788, DOI 10.1095/biolreprod43.5.788; Gardner RL, 2000, METH MOL B, V135, P397; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; Houghton FD, 2003, DEV BIOL, V263, P360, DOI 10.1016/j.ydbio.2003.07.014; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; KAPLAN JH, 2005, SCI STKE, pPE31; MacPhee DJ, 2000, DEV BIOL, V222, P486, DOI 10.1006/dbio.2000.9708; Madan P, 2005, REPRODUCTION, V130, P41, DOI 10.1530/rep.1.00554; Natale DR, 2004, DEV BIOL, V268, P76, DOI 10.1016/j.ydbio.2003.12.011; OVERSTROM EW, 1989, J REPROD FERTIL, V85, P283, DOI 10.1530/jrf.0.0850283; Rajasekaran AK, 2003, ANN NY ACAD SCI, V986, P649, DOI 10.1111/j.1749-6632.2003.tb07276.x; Rajasekaran AK, 2003, AM J PHYSIOL-RENAL, V285, pF388, DOI 10.1152/ajprenal.00439.2002; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P279, DOI 10.1091/mbc.12.2.279; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P3717, DOI 10.1091/mbc.12.12.3717; Rajasekaran SA, 2004, MOL BIOL CELL, V15, P3224, DOI 10.1091/mbc.e04-03-0222; Sheth B, 2000, MECH DEVELOP, V97, P93, DOI 10.1016/S0925-4773(00)00416-0; Sheth B, 2000, DEVELOPMENT, V127, P831; SPINDLE A, 1980, IN VITRO CELL DEV B, V16, P669, DOI 10.1007/BF02619196; SUMMERS MC, 1995, BIOL REPROD, V53, P431, DOI 10.1095/biolreprod53.2.431; Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x; VANWINKLE LJ, 1991, DEV BIOL, V146, P158, DOI 10.1016/0012-1606(91)90456-D; Violette MI, 2006, DEV BIOL, V289, P406, DOI 10.1016/j.ydbio.2005.11.004; Waelchli RO, 1997, BIOL REPROD, V57, P630, DOI 10.1095/biolreprod57.3.630; WATSON AJ, 1990, DEV GENET, V11, P41, DOI 10.1002/dvg.1020110106; WATSON AJ, 1988, DEV BIOL, V126, P80, DOI 10.1016/0012-1606(88)90241-2; WILEY LM, 1984, DEV BIOL, V105, P330, DOI 10.1016/0012-1606(84)90290-2	46	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12127	12134		10.1074/jbc.M700696200	http://dx.doi.org/10.1074/jbc.M700696200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317668	hybrid			2022-12-27	WOS:000245941900055
J	Sharma, A; Awasthi, S; Harrod, CK; Matlock, EF; Khan, S; Xu, L; Chan, S; Yang, H; Thammavaram, CK; Rasor, RA; Burns, DK; Skiest, DJ; Van Lint, C; Girard, AM; McGee, M; Monnat, RJ; Harrod, R				Sharma, Anima; Awasthi, Soumya; Harrod, Carolyn K.; Matlock, Elizabeth F.; Khan, Saiqa; Xu, Louisa; Chan, Stephanie; Yang, Helen; Thammavaram, Charu K.; Rasor, Randall A.; Burns, Dennis K.; Skiest, Daniel J.; Van Lint, Carine; Girard, Anne-Marie; McGee, Monnie; Monnat, Raymond J., Jr.; Harrod, Robert			The Werner syndrome helicase is a cofactor for HIV-1 long terminal repeat transactivation and retroviral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CREB-BINDING-PROTEIN; P-TEFB KINASE; NF-KAPPA-B; IN-VITRO; TRANSCRIPTIONAL REGULATION; HISTONE ACETYLTRANSFERASE; PCAF BROMODOMAIN; MESSENGER-RNA; T-LYMPHOCYTES	The Werner syndrome helicase ( WRN) participates in DNA replication, double strand break repair, telomere maintenance, and p53 activation. Mutations of wrn cause Werner syndrome ( WS), an autosomal recessive premature aging disorder associated with cancer predisposition, atherosclerosis, and other aging related symptoms. Here, we report that WRN is a novel cofactor for HIV-1 replication. Immortalized human WRN-/- WS fibroblasts, lacking a functional wrn gene, are impaired for basal and Tat-activated HIV-1 transcription. Overexpression of wild-type WRN transactivates the HIV-1 long terminal repeat ( LTR) in the absence of Tat, and WRN cooperates with Tat to promote high-level LTR transactivation. Ectopic WRN induces HIV-1 p24(Gag) production and retroviral replication in HIV-1-infected H9(HIV-1IIIB) lymphocytes. A dominant-negative helicase-minus mutant, WRNK577M, inhibits LTR transactivation and HIV-1 replication. Inhibition of endogenous WRN, through co-expression of WRNK577M, diminishes recruitment of p300/CREB-binding protein-associated factor ( PCAF) and positive transcription elongation factor b ( P-TEFb) to Tat/transactivation response-RNA complexes, and immortalized WRN-/- WS fibroblasts exhibit comparable defects in recruitment of PCAF and P-TEFb to the HIV-1 LTR. Our results demonstrate that WRN is a novel cellular cofactor for HIV-1 replication and suggest that the WRN helicase participates in the recruitment of PCAF/P-TEFb-containing transcription complexes. WRN may be a plausible target for antiretroviral therapy.	So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA; Univ Texas, SW Med Ctr, Dept Pathol, Div Neuropathol, Dallas, TX 75235 USA; Baystate Med Ctr, Div Infect Dis, HIV Sect, Springfield, MA 01109 USA; Univ Libre Bruxelles, Inst Biol & Med Mol, Mol Virol Lab, Serv Chim Biol, B-6041 Brussels, Belgium; Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA; So Methodist Univ, Dept Stat Sci, Dallas, TX 75275 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Southern Methodist University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baystate Medical Center; Universite Libre de Bruxelles; Oregon State University; Southern Methodist University; University of Washington; University of Washington Seattle	Harrod, R (corresponding author), 6501 Airline Dr,334-DLS, Dallas, TX 75275 USA.	rharrod@mail.smu.edu	xu, louisa/HGT-8566-2022	Girard, Anne-Marie/0000-0002-5346-981X				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bai YL, 2003, HUM GENET, V113, P337, DOI 10.1007/s00439-003-0972-y; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; Bordi L, 2004, CLIN EXP IMMUNOL, V138, P251, DOI 10.1111/j.1365-2249.2004.02622.x; Bres V, 2005, GENE DEV, V19, P1211, DOI 10.1101/gad.1291705; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Bres V, 2002, J BIOL CHEM, V277, P22215, DOI 10.1074/jbc.M201895200; CHANG SYP, 1993, NATURE, V363, P466, DOI 10.1038/363466a0; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; Deng LW, 2001, VIROLOGY, V289, P312, DOI 10.1006/viro.2001.1129; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819; Kaehlcke K, 2003, MOL CELL, V12, P167, DOI 10.1016/S1097-2765(03)00245-4; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Laine JP, 2003, CANCER RES, V63, P7136; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Pagans S, 2005, PLOS BIOL, V3, P210, DOI 10.1371/journal.pbio.0030041; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; Shiratori M, 2002, ONCOGENE, V21, P2447, DOI 10.1038/sj.onc.1205334; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; TONGSTARKSEN SE, 1990, J IMMUNOL, V145, P4348; Treand C, 2006, EMBO J, V25, P1690, DOI 10.1038/sj.emboj.7601074; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wong KS, 2005, J BIOL CHEM, V280, P9390, DOI 10.1074/jbc.M408643200; Zhou MS, 2004, J VIROL, V78, P13522, DOI 10.1128/JVI.78.24.13522-13533.2004; Zhou MS, 2003, P NATL ACAD SCI USA, V100, P12666, DOI 10.1073/pnas.1835726100; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	50	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12048	12057		10.1074/jbc.M608104200	http://dx.doi.org/10.1074/jbc.M608104200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317667	hybrid			2022-12-27	WOS:000245941900047
J	Carrigan, A; Walther, RF; Salem, HA; Wu, DM; Atlas, E; Lefebvre, YA; Hache, RJG				Carrigan, Amanda; Walther, Rhian F.; Salem, Houssein Abdou; Wu, Dongmei; Atlas, Ella; Lefebvre, Yvonne A.; Hache, Robert J. G.			An active nuclear retention signal in the glucocorticoid receptor functions as a strong inducer of transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; NUCLEOCYTOPLASMIC TRANSPORT; SUBNUCLEAR TRAFFICKING; EXPORT; LOCALIZATION; PATHWAY; CHAPERONES; EXPRESSION; DOMAINS	The glucocorticoid receptor (GR) cycles between a naive chaperone-complexed form in the cytoplasm and a transcriptionally active steroid-bound nuclear form. Nuclear import of GR occurs rapidly and is mediated through the importin alpha/beta karyopherin import pathway. By contrast, nuclear export of GR occurs only slowly under most conditions, despite a dependence on active signaling. In this study we have defined a nuclear retention signal (NRS) in the hinge region of GR that actively opposes the nuclear export of GR as well as the nuclear export mediated through an ectopic CRM1-dependent nuclear export signal (NES). The GR NRS overlaps closely with the basic NL1 nuclear localization signal (NLS) but can be distinguished from NL1 by targeted mutagenesis. Substitution of the classical NLS from SV40 T antigen for the GR NL1 results in a receptor in which nuclear export is accelerated. Remarkably, although the SV40-modified GR remains predominantly nuclear in the presence of steroid and is recruited to transcriptional regulatory regions indistinguishably from wild-type GR, the substitution dramatically weakens the ability of GR to activate transcription of a mouse mammary tumor virus reporter gene. These results suggest that active nuclear retention of GR plays an integral role in glucocorticoid signaling.	Ottawa Hlth Res Inst, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Med & Biochem, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Microbiol, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Immunol, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Grad Program Biochem, Ottawa, ON K1Y 4K9, Canada; Univ British Columbia, Providence Hlth Care, Vancouver, BC V6Z 1Y6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of British Columbia	Hache, RJG (corresponding author), Ottawa Hosp, Ottawa Hlth Res Inst, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	rhache@ohri.ca						ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Charmandari E, 2004, ANN NY ACAD SCI, V1024, P1, DOI 10.1196/annals.1321.001; Chrousos GP, 2004, J CLIN ENDOCR METAB, V89, P563, DOI 10.1210/jc.2003-032026; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GUSTAFSSON JA, 1986, J STEROID BIOCHEM, V24, P63, DOI 10.1016/0022-4731(86)90033-6; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; JEWELL CM, 1995, J STEROID BIOCHEM, V55, P135, DOI 10.1016/0960-0760(95)00174-X; Kino T, 2003, J BIOL CHEM, V278, P25651, DOI 10.1074/jbc.M302818200; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Nagaich AK, 2004, ANN NY ACAD SCI, V1024, P213, DOI 10.1196/annals.1321.002; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; Tago K, 2004, MOL CELL ENDOCRINOL, V213, P131, DOI 10.1016/j.mce.2003.10.057; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Walther RF, 2003, J BIOL CHEM, V278, P37858, DOI 10.1074/jbc.M306356200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523	37	43	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10963	10971		10.1074/jbc.M602931200	http://dx.doi.org/10.1074/jbc.M602931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17314103	hybrid			2022-12-27	WOS:000245941500016
J	Hardwick, SW; Pane-Farre, J; Delumeau, O; Marles-Wright, J; Murray, JW; Hecker, M; Lewis, RJ				Hardwick, Steven W.; Pane-Farre, Jan; Delumeau, Olivier; Marles-Wright, Jon; Murray, James W.; Hecker, Michael; Lewis, Richard J.			Structural and functional characterization of partner switching regulating the environmental stress response in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA(B) TRANSCRIPTION FACTOR; SIGNALING PATHWAY; FACTOR SPOIIAB; ENERGY STRESS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN; ACTIVATION; PHOSPHATASE; COMPLEX	The general stress response of Bacillus subtilis and close relatives provides the cell with protection from a variety of stresses. The upstream component of the environmental stress signal transduction cascade is activated by the RsbT kinase that switches binding partners from a 25 S macromolecular complex, the stressosome, to the RsbU phosphatase. Once the RsbU phosphatase is activated by interacting with RsbT, the alternative sigma factor, sigma(B), directs transcription of the general stress regulon. Previously, we demonstrated that the N-terminal domain of RsbU mediates the binding of RsbT. We now describe residues in N-RsbU that are crucial to this interaction by experimentation both in vitro and in vivo. Furthermore, crystal structures of the N-RsbU mutants provide a molecular explanation for the loss of interaction. Finally, we also characterize mutants in RsbT that affect binding to both RsbU and a simplified, binary model of the stressosome and thus identify overlapping binding surfaces on the RsbT "switch.".	Newcastle Univ, Fac Med Sci, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Ernst Moritz Arndt Univ Greifswald, Inst Microbiol, D-17487 Greifswald, Germany	Newcastle University - UK; Ernst Moritz Arndt Universitat Greifswald	Lewis, RJ (corresponding author), Newcastle Univ, Fac Med Sci, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	R.Lewis@ncl.ac.uk		Murray, James/0000-0002-8897-0161; Hardwick, Steven/0000-0001-9246-1864; Marles-Wright, Jon/0000-0002-9156-3284; lewis, richard/0000-0003-2641-8643	Biotechnology and Biological Sciences Research Council [BB/D000521/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BENSON AK, 1993, J BACTERIOL, V175, P2347, DOI 10.1128/JB.175.8.2347-2356.1993; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BOYLAN SA, 1992, J BACTERIOL, V174, P3695, DOI 10.1128/JB.174.11.3695-3706.1992; BOYLAN SA, 1993, J BACTERIOL, V175, P7931, DOI 10.1128/JB.175.24.7931-7937.1993; Brigulla M, 2003, J BACTERIOL, V185, P4305, DOI 10.1128/JB.185.15.4305-4314.2003; Brody MS, 2001, J BACTERIOL, V183, P6422, DOI 10.1128/JB.183.21.6422-6428.2001; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Campbell EA, 2002, CELL, V108, P795, DOI 10.1016/S0092-8674(02)00662-1; Chen CC, 2003, MOL MICROBIOL, V49, P1657, DOI 10.1046/j.1365-2958.2003.03663.x; Delumeau O, 2004, J BIOL CHEM, V279, P40927, DOI 10.1074/jbc.M405464200; Delumeau O, 2002, J BACTERIOL, V184, P5583, DOI 10.1128/JB.184.20.5583-5589.2002; Delumeau O, 2006, J BACTERIOL, V188, P7885, DOI 10.1128/JB.00892-06; Dufour A, 1996, J BACTERIOL, V178, P3701, DOI 10.1128/jb.178.13.3701-9sigma.1996; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Dutta S, 2003, ACTA CRYSTALLOGR D, V59, P191, DOI 10.1107/SO907444902020723; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; Hecker M, 2001, ADV MICROB PHYSIOL, V44, P35, DOI 10.1016/S0065-2911(01)44011-2; Ho MS, 2003, J BIOL CHEM, V278, P20898, DOI 10.1074/jbc.M302305200; Iber D, 2006, NATURE, V441, P371, DOI 10.1038/nature04666; Kang CM, 1996, J BACTERIOL, V178, P3846, DOI 10.1128/jb.178.13.3846-3853.1996; Kang CM, 1998, MOL MICROBIOL, V30, P189, DOI 10.1046/j.1365-2958.1998.01052.x; Kim TJ, 2004, J BACTERIOL, V186, P6124, DOI 10.1128/jb.186.18.6124-6132.2004; Kim TJ, 2004, J MOL BIOL, V341, P135, DOI 10.1016/j.jmb.2004.05.043; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kuo S, 2004, MICROBIOL-SGM, V150, P4125, DOI 10.1099/mic.0.27421-0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Magnin T, 1997, J BACTERIOL, V179, P3922, DOI 10.1128/jb.179.12.3922-3927.1997; Masuda S, 2004, J MOL BIOL, V340, P941, DOI 10.1016/j.jmb.2004.05.040; Murray JW, 2005, P NATL ACAD SCI USA, V102, P17320, DOI 10.1073/pnas.0506599102; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167; Pane-Farre J, 2005, J MOL MICROB BIOTECH, V9, P65, DOI 10.1159/000088837; Pane-Farre J, 2006, INT J MED MICROBIOL, V296, P237, DOI 10.1016/j.ijmm.2005.11.011; Petersohn A, 2001, J BACTERIOL, V183, P5617, DOI 10.1128/JB.183.19.5617-5631.2001; Price CW, 2001, MOL MICROBIOL, V41, P757, DOI 10.1046/j.1365-2958.2001.02534.x; Rollenhagen C, 2003, J BACTERIOL, V185, P35, DOI 10.1128/JB.185.1.35-40.2003; Sonenshein AL., 2002, BACILLUS SUBTILIS IT, P369; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STULKE J, 1993, J GEN MICROBIOL, V139, P2041, DOI 10.1099/00221287-139-9-2041; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vijay K, 2000, MOL MICROBIOL, V35, P180, DOI 10.1046/j.1365-2958.2000.01697.x; VOELKER U, 1995, J BACTERIOL, V177, P114, DOI 10.1128/jb.177.1.114-122.1995; Woodbury RL, 2004, J BACTERIOL, V186, P2789, DOI 10.1128/JB.186.9.2789-2797.2004; Yang XF, 1996, GENE DEV, V10, P2265, DOI 10.1101/gad.10.18.2265	50	23	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11562	11572		10.1074/jbc.M609733200	http://dx.doi.org/10.1074/jbc.M609733200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303566	hybrid			2022-12-27	WOS:000245941500077
J	Kalie, E; Jaitin, DA; Abramovich, R; Schreiber, G				Kalie, Eyal; Jaitin, Diego A.; Abramovich, Renne; Schreiber, Gideon			An interferon alpha 2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING; I INTERFERONS; MUTATIONAL ANALYSIS; SIGNALING PATHWAYS; INDUCED APOPTOSIS; ALPHA-INTERFERON; CELLS; BETA; IFN-ALPHA-2; ANGIOGENESIS	All alpha-interferons ( IFN alpha) bind the IFNAR1 receptor subunit with low affinity. Increasing the binding affinity was shown to specifically increase the antiproliferative potency of IFN alpha 2. Here, we constructed a phage display library by randomizing three positions on IFN alpha 2 previously shown to confer weak binding to IFNAR1. The tightest binding variant selected, comprised of mutations H57Y, E58N, and Q61S ( YNS), was shown to bind IFNAR1 60-fold tighter compared with wild-type IFN alpha 2, and 3-fold tighter compared with IFN beta. Binding of YNS to IFNAR2 was comparable with wild-type IFN alpha 2. The YNS mutant conferred a 150-fold higher antiproliferative potency in WISH cells compared with wild-type IFN alpha 2, whereas its antiviral activity was increased by only 3.5-fold. The high antiproliferative activity was related to an induction of apoptosis, as demonstrated by annexin V binding assays, and to specific gene induction, particularly TRAIL. To determine the potency of the YNS mutant in a xenograft cancer model, we injected it twice a week to nude mice carrying transplanted MDA231 human breast cancer cells. After 5 weeks, no tumors remained in mice treated with YNS, whereas most mice treated with wild-type IFN alpha 2 showed visible tumors. Histological analysis of these tumors showed a significant anti-angiogenic effect of YNS, compared with wild-type IFN alpha 2. This work demonstrates the application of detailed biophysical understanding in the process of protein engineering, yielding an interferon variant with highly increased biological potency.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Schreiber, G (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	gideon.schreiber@weizmann.ac.il	Schreiber, Gideon/C-7332-2008					Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; Caraglia M, 2004, CURR PROTEIN PEPT SC, V5, P475, DOI 10.2174/1389203043379378; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chen JB, 2004, J INTERF CYTOK RES, V24, P687, DOI 10.1089/jir.2004.24.687; COHEN B, 1995, MOL CELL BIOL, V15, P4208; Cooksley WGE, 2003, J VIRAL HEPATITIS, V10, P298, DOI 10.1046/j.1365-2893.2003.00450.x; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DVORAK HF, 1989, J NATL CANCER I, V81, P497, DOI 10.1093/jnci/81.7.497; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; Fidler I J, 2001, J Natl Cancer Inst Monogr, P10; Goldman LA, 1999, J INTERF CYTOK RES, V19, P15, DOI 10.1089/107999099314379; Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; Grumbach IM, 1999, J INTERF CYTOK RES, V19, P797, DOI 10.1089/107999099313659; Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024; JACOBS S, 1979, P NATL ACAD SCI USA, V76, P4918, DOI 10.1073/pnas.76.10.4918; Jaitin DA, 2006, MOL CELL BIOL, V26, P1888, DOI 10.1128/MCB.26.5.1888-1897.2006; Jaks E, 2007, J MOL BIOL, V366, P525, DOI 10.1016/j.jmb.2006.11.053; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; Lamken P, 2004, J MOL BIOL, V341, P303, DOI 10.1016/j.jmb.2004.05.059; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 2001, ANAL BIOCHEM, V289, P173, DOI 10.1006/abio.2000.4920; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Pokrovskaja K, 2005, J INTERF CYTOK RES, V25, P799, DOI 10.1089/jir.2005.25.799; Rani MRS, 1999, J BIOL CHEM, V274, P32507, DOI 10.1074/jbc.274.45.32507; Riss TL, 2004, ASSAY DRUG DEV TECHN, V2, P51, DOI 10.1089/154065804322966315; Roisman LC, 2005, J MOL BIOL, V353, P271, DOI 10.1016/j.jmb.2005.08.042; ROSENBLUM MG, 1990, J INTERFERON RES, V10, P141, DOI 10.1089/jir.1990.10.141; Rubinstein M, 1981, Methods Enzymol, V78, P464; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SIDKY YA, 1987, CANCER RES, V47, P5155; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Slaton JW, 2001, CLIN CANCER RES, V7, P2840; Slutzki M, 2006, J MOL BIOL, V360, P1019, DOI 10.1016/j.jmb.2006.05.069; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Streck CJ, 2005, CANCER LETT, V228, P163, DOI 10.1016/j.canlet.2004.11.063; Subramaniam PS, 1998, ONCOGENE, V16, P1885, DOI 10.1038/sj.onc.1201712; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Thyrell L, 2004, J BIOL CHEM, V279, P24152, DOI 10.1074/jbc.M312219200; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; Vannucchi S, 2005, ONCOGENE, V24, P2536, DOI 10.1038/sj.onc.1208403; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wagner TC, 2004, INT J CANCER, V111, P32, DOI 10.1002/ijc.20236	45	78	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11602	11611		10.1074/jbc.M610115200	http://dx.doi.org/10.1074/jbc.M610115200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17310065	hybrid			2022-12-27	WOS:000245941500081
J	Park, PSH; Sapra, KT; Kolinski, M; Filipek, S; Palczewski, K; Muller, DJ				Park, Paul S. -H.; Sapra, K. Tanuj; Kolinski, Michal; Filipek, Slawomir; Palczewski, Krzysztof; Muller, Daniel J.			Stabilizing effect of Zn2+ in native bovine rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; DETECTING MOLECULAR-INTERACTIONS; ATOMIC-FORCE MICROSCOPY; PARTICLE MESH EWALD; SINGLE-MOLECULE; ZINC-BINDING; UNFOLDING PATHWAYS; DOPAMINE-RECEPTORS; MEMBRANE-PROTEINS; DISULFIDE BOND	Single-molecule force spectroscopy ( SMFS) is a powerful tool to dissect molecular interactions that govern the stability and function of proteins. We applied SMFS to understand the effect of Zn2+ on the molecular interactions underlying the structure of rhodopsin. Force-distance curves obtained from SMFS assays revealed the strength and location of molecular interactions that stabilize structural segments within this receptor. The inclusion of ZnCl2 inSMFSassay buffer increased the stability of most structural segments. This effect was not mimicked by CaCl2, CdCl2, or CoCl2. Thus, Zn2+ stabilizes the structure of rhodopsin in a specific manner.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Technol, Ctr Biotechnol, D-01307 Dresden, Germany; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	Case Western Reserve University; Technische Universitat Dresden; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Muller, DJ (corresponding author), Tatzberg 47, D-01307 Dresden, Germany.	mueller@biotec.tu-dresden.de	Kolinski, Michal/AAO-2946-2020; Müller, Daniel J./A-5967-2010; Filipek, Slawomir/A-2985-2008	Kolinski, Michal/0000-0003-1047-2186; Müller, Daniel J./0000-0003-3075-0665; Sapra, Tanuj/0000-0001-6945-0876; Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [K99EY018085, R00EY018085, R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NEI NIH HHS [K99 EY018085-01, R01 EY008061, R01 EY008061-21, R00 EY018085-03, K99 EY018085-02, R00 EY018085, R00 EY018085-04, EY08061, K99 EY018085, R00 EY018085-05] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3; BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957-4484/6/1/001; Cisneros DA, 2005, STRUCTURE, V13, P235, DOI 10.1016/j.str.2004.12.005; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; del Valle LJ, 2003, J BIOL CHEM, V278, P4719, DOI 10.1074/jbc.M210760200; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fowler CB, 2004, BIOCHEMISTRY-US, V43, P8700, DOI 10.1021/bi036067r; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022; HIRAYAMA Y, 1990, ACTA HISTOCHEM, V89, P107, DOI 10.1016/S0065-1281(11)80328-4; Holst B, 2002, J BIOL CHEM, V277, P47662, DOI 10.1074/jbc.M202103200; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Janovjak H, 2006, NEUROBIOL AGING, V27, P546, DOI 10.1016/j.neurobiolaging.2005.03.031; Janovjak H, 2003, EMBO J, V22, P5220, DOI 10.1093/emboj/cdg509; KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3; Kedrov A, 2005, EMBO REP, V6, P668, DOI 10.1038/sj.embor.7400455; Kedrov A, 2006, J MOL BIOL, V362, P925, DOI 10.1016/j.jmb.2006.07.049; Klein-Seetharaman J, 2005, TRENDS PHARMACOL SCI, V26, P183, DOI 10.1016/j.tips.2005.02.009; Kono M, 1998, BIOCHEMISTRY-US, V37, P1302, DOI 10.1021/bi9721445; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liu Y, 2006, BIOCHEM BIOPH RES CO, V339, P873, DOI 10.1016/j.bbrc.2005.11.110; Moller C, 2003, J STRUCT BIOL, V142, P369, DOI 10.1016/S1047-8477(03)00066-2; Muller DJ, 2006, CURR OPIN STRUC BIOL, V16, P489, DOI 10.1016/j.sbi.2006.06.001; Muller DJ, 2002, BIOPHYS J, V83, P3578, DOI 10.1016/S0006-3495(02)75358-7; Oesterhelt F, 2000, SCIENCE, V288, P143, DOI 10.1126/science.288.5463.143; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Park PSH, 2004, BIOCHEMISTRY-US, V43, P15643, DOI 10.1021/bi047907k; Rader AJ, 2004, P NATL ACAD SCI USA, V101, P7246, DOI 10.1073/pnas.0401429101; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rosenkilde MM, 1998, FEBS LETT, V439, P35, DOI 10.1016/S0014-5793(98)01331-3; Sapra KT, 2006, J MOL BIOL, V358, P255, DOI 10.1016/j.jmb.2006.02.008; Sapra KT, 2006, J MOL BIOL, V355, P640, DOI 10.1016/j.jmb.2005.10.080; Schetz JA, 1999, J PHARMACOL EXP THER, V289, P956; Schetz JA, 1997, J NEUROCHEM, V68, P1990; Shuster TA, 1996, CURR EYE RES, V15, P1019, DOI 10.3109/02713689609017650; SHUSTER TA, 1992, BIOCHEM J, V282, P123, DOI 10.1042/bj2820123; Stojanovic A, 2004, J BIOL CHEM, V279, P35932, DOI 10.1074/jbc.M403821200; Swaminath G, 2003, J BIOL CHEM, V278, P352, DOI 10.1074/jbc.M206424200; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5; Ugarte M, 1999, EXP EYE RES, V69, P459, DOI 10.1006/exer.1999.0727; Ugarte M, 1998, GEN PHARMACOL-VASC S, V30, P297, DOI 10.1016/S0306-3623(97)00358-3; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; van der Spoel D, 1998, J CHEM PHYS, V108, P10220, DOI 10.1063/1.476482; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8	57	52	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11377	11385		10.1074/jbc.M610341200	http://dx.doi.org/10.1074/jbc.M610341200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303564	hybrid, Green Accepted			2022-12-27	WOS:000245941500060
J	Ban, N; Matsumura, Y; Sakai, H; Takanezawa, Y; Sasaki, M; Arai, H; Inagaki, N				Ban, Nobuhiro; Matsumura, Yoshihiro; Sakai, Hiromichi; Takanezawa, Yasukazu; Sasaki, Mayumi; Arai, Hiroyuki; Inagaki, Nobuya			ABCA3 as a lipid transporter in pulmonary surfactant biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; INTERSTITIAL LUNG-DISEASE; CELLULAR CHOLESTEROL; PROTEIN-B; RAT LUNG; II CELLS; GENE; DEFICIENCY; MUTATIONS; PHOSPHOLIPIDS	ABCA3 protein is expressed predominantly at the limiting membrane of the lamellar bodies in alveolar type 11 cells, and mutations in the ABCA3 gene cause lethal respiratory distress in newborn infants. To investigate the function of ABCA3 protein, we generated Abca3-deficient mice by targeting Abca3. Fullterm Abca3(-/-) newborn pups died within an hour after birth because of acute respiratory failure. Ultrastructural analysis revealed abnormally dense lamellar body-like organelles and no normal lamellar bodies in Abca3(-/-) alveolar type II cells. TLC and electrospray ionization mass spectrometry analyses of lipids in the pulmonary interstitium showed that phosphatidylcholine and phosphatidylglycerol, which contain palmitic acid and are abundant in normal surfactant lipids, were dramatically decreased in Abca3(-/-) lung. These findings indicate that ABCA3 plays an essential role in pulmonary surfactant lipid metabolism and lamellar body biogenesis, probably by transporting these lipids as substrates.	Kyoto Univ, Dept Diabet & Clin Nutr, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; JST, CREST, Kyoto 6068507, Japan; JST, CREST, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan; Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Kyoto University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Akita University; University of Tokyo	Inagaki, N (corresponding author), Kyoto Univ, Dept Diabet & Clin Nutr, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	inagaki@metab.kuhp.kyoto-u.ac.jp	Sakai, Hiromichi/K-8457-2019	Matsumura, Yoshihiro/0000-0002-3108-0440; Takanezawa, Yasukazu/0000-0002-9220-5825; Inagaki, Nobuya/0000-0001-8261-2593				Abe-Dohmae S, 2004, J BIOL CHEM, V279, P604, DOI 10.1074/jbc.M309888200; Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100; BATENBURG JJ, 1989, BIOCHIM BIOPHYS ACTA, V1006, P329, DOI 10.1016/0005-2760(89)90020-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURBON JR, 1982, BIOCHIM BIOPHYS ACTA, V712, P382, DOI 10.1016/0005-2760(82)90356-3; Bullard JE, 2005, AM J RESP CRIT CARE, V172, P1026, DOI 10.1164/rccm.200503-504OC; BURRI PH, 1984, ANNU REV PHYSIOL, V46, P617, DOI 10.1146/annurev.ph.46.030184.003153; CHANDER A, 1990, AM J PHYSIOL, V258, P241; Cheong N, 2006, J BIOL CHEM, V281, P9791, DOI 10.1074/jbc.M507515200; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DOBBS LG, 1989, ANNU REV MED, V40, P431; FARRELL PM, 1975, AM REV RESPIR DIS, V111, P657; FITZGERALD ML, 2007, IN PRESS J LIPID RES; Garmany TH, 2006, PEDIATR RES, V59, P801, DOI 10.1203/01.pdr.0000219311.14291.df; HALLMAN M, 1975, BIOCHIM BIOPHYS ACTA, V409, P172, DOI 10.1016/0005-2760(75)90152-6; Hiramatsu T, 2003, J BIOL CHEM, V278, P49438, DOI 10.1074/jbc.M213018200; HOLM BA, 1989, ANESTH ANALG, V69, P805; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Johansson J, 1997, EUR J BIOCHEM, V244, P675, DOI 10.1111/j.1432-1033.1997.00675.x; LANG MJ, 1990, J PEDIATR-US, V116, P295, DOI 10.1016/S0022-3476(05)82897-5; MAGOON MW, 1983, BIOCHIM BIOPHYS ACTA, V750, P18, DOI 10.1016/0005-2760(83)90200-X; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Ridsdale R, 2004, AM J PHYSIOL-LUNG C, V287, pL743, DOI 10.1152/ajplung.00146.2004; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Taguchi R, 2000, J MASS SPECTROM, V35, P953, DOI 10.1002/1096-9888(200008)35:8<953::AID-JMS23>3.0.CO;2-4; VORBROKER DK, 1995, AM J PHYSIOL, V268, P647; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3; Yoshida I, 2004, BIOCHEM BIOPH RES CO, V323, P547, DOI 10.1016/j.bbrc.2004.08.133	36	161	166	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9628	9634		10.1074/jbc.M611767200	http://dx.doi.org/10.1074/jbc.M611767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267394	hybrid			2022-12-27	WOS:000245421700036
J	Su, HW; Yeh, HH; Wang, SW; Shen, MR; Chen, TL; Kiela, PR; Ghishan, FK; Tang, MJ				Su, Hsiao-Wen; Yeh, Hsuan-Heng; Wang, Shainn-Wei; Shen, Meng-Ru; Chen, Tsu-Ling; Kiela, Pawel R.; Ghishan, Fayez K.; Tang, Ming-Jer			Cell confluence-induced activation of signal transducer and activator of transcription-3 (Stat3) triggers epithelial dome formation via augmentation of sodium hydrogen exchanger-3 (NHE3) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; IN-VITRO; NA+/H+ EXCHANGER; CYCLIC-AMP; MDCK CELLS; DIFFERENTIATION; MEMBRANE; GENE; TRANSPORT; CHANNEL	Cell confluence induces the activation of signal transducer and activator of transcription-3 (Stat3) in various cancer and epithelial cells, yet the biological implications and the associated regulatory mechanisms remain unclear. Because confluent polarized epithelia demonstrate dome formation and sodium influx that mimic the onset of differentiation, we sought to elucidate the role of Stat3 in association with the regulation of selective epithelial transporters in this biological phenomenon. This study established the correlation between Stat3 activation and cell confluence-induced dome formation in Madin-Darby canine kidney cells (MDCK) by following Stat3 activation events in dome-forming cells. Epifluorescent and confocal microscopy provided evidence showing specific localization of phosphorylated Stat3 Tyr(705) in the nuclei of dome-forming cells at initial stages. The relationship was further elucidated by the establishment of tetracycline-inducible expression of constitutive Stat3 mutant (Stat3-C) in MDCK cells or expression of dominant negative Stat3 (Stat3-D) stable cell lines (MDCK and NMuMG). Dome formation was promoted by the expression of Stat3-C but inhibited by Stat3-D. Two trans-epithelial transporters, NHE3 and ENaC alpha-subunit, were found to be increased during cell confluence. Interestingly, NHE3 expression could be specifically up-regulated by Stat3-C but inhibited by Stat3-13 through promoter regulation, whereas NHE1 and ENaC alpha-subunit were not affected by Stat3 expression. Application of NHE3 shRNA, NHE3 inhibitors (EIPA and S3226) suppressed confluence-induced dome formation in MDCK or NMuMG cells. These results demonstrate a cell confluence-induced Stat3 signaling pathway in epithelial cells in triggering dome formation through NHE3 augmentation.	Natl Cheng Kung Univ, Dept Physiol, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Inst Mol Med, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Coll Med, Tainan 701, Taiwan; Univ Arizona, Hlth Sci Ctr, Dept Pediat, Steele Childrens Res Ctr, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Dept Physiol, Steele Childrens Res Ctr, Tucson, AZ 85724 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Tang, MJ (corresponding author), Natl Cheng Kung Univ, Dept Physiol, Coll Med, 1 Da Hsueh Rd, Tainan 701, Taiwan.	mjtang1@mail.ncku.edu.tw	Wang, Shainn-Wei/B-9644-2009; Kiela, Pawel/AAF-5320-2020	Tang, Ming-Jer/0000-0002-0883-4363; Kiela, Pawel/0000-0002-0014-3517	NIDDK NIH HHS [5R01-DK41274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1983, AM J PHYSIOL, V245, P647; BECK JC, 1991, J CLIN INVEST, V87, P2067, DOI 10.1172/JCI115237; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brouard M, 1999, J CELL SCI, V112, P3343; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DREHER D, 1992, AM J PHYSIOL, V262, pC358, DOI 10.1152/ajpcell.1992.262.2.C358; Galey F R, 1980, Am J Otol, V1, P218; GAUSH CR, 1966, P SOC EXP BIOL MED, V122, P931; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Horster M, 2000, AM J PHYSIOL-RENAL, V279, pF982, DOI 10.1152/ajprenal.2000.279.6.F982; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Kandasamy RA, 1996, J BIOL CHEM, V271, P10551, DOI 10.1074/jbc.271.18.10551; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KENNEDY BG, 1984, J CELL PHYSIOL, V121, P51, DOI 10.1002/jcp.1041210108; Kiela PR, 2001, AM J PHYSIOL-GASTR L, V281, pG947, DOI 10.1152/ajpgi.2001.281.4.G947; LEVER JE, 1979, J SUPRAMOL STR CELL, V12, P259, DOI 10.1002/jss.400120210; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; MCROBERTS JA, 1982, J BIOL CHEM, V257, P2260; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OBERLEITHNER H, 1990, PFLUG ARCH EUR J PHY, V416, P526, DOI 10.1007/BF00382685; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; RABITO CA, 1980, IN VITRO CELL DEV B, V16, P461, DOI 10.1007/BF02626458; RINDLER MJ, 1981, J BIOL CHEM, V256, P820; SAHAI A, 1992, KIDNEY INT, V42, P1145, DOI 10.1038/ki.1992.398; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SEIFTER JL, 1986, J CLIN INVEST, V78, P859, DOI 10.1172/JCI112671; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Shlyonsky V, 2005, J BIOL CHEM, V280, P24181, DOI 10.1074/jbc.M413823200; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Tattersall AL, 2003, CELL PHYSIOL BIOCHEM, V13, P215, DOI 10.1159/000072424; VALENTICH JD, 1979, J CELL PHYSIOL, V100, P291, DOI 10.1002/jcp.1041000210; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Wang YN, 2006, MOL PHARMACOL, V69, P85, DOI 10.1124/mol.105.016220; Warth R, 2003, PFLUG ARCH EUR J PHY, V446, P505, DOI 10.1007/s00424-003-1075-2; WEINMAN SA, 1984, J GEN PHYSIOL, V83, P57, DOI 10.1085/jgp.83.1.57; Xu H, 2005, AM J PHYSIOL-GASTR L, V289, pG36, DOI 10.1152/ajpgi.00552.2004; Yanagisawa M, 1999, NEUROSCI LETT, V269, P169, DOI 10.1016/S0304-3940(99)00447-4; Zegers MMP, 2003, TRENDS CELL BIOL, V13, P169, DOI 10.1016/S0962-8924(03)00036-9; Zucchi I, 1999, P NATL ACAD SCI USA, V96, P13766, DOI 10.1073/pnas.96.24.13766	49	37	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9883	9894		10.1074/jbc.M606754200	http://dx.doi.org/10.1074/jbc.M606754200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276988	hybrid			2022-12-27	WOS:000245421700063
J	Bae, JS; Yang, LK; Manithody, C; Rezaie, AR				Bae, Jong-Sup; Yang, Likui; Manithody, Chandrashekhara; Rezaie, Alireza R.			Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; KAPPA-B ACTIVATION; ENDOTHELIAL-CELLS; FACTOR-VA; CRYSTAL-STRUCTURE; RECEPTOR; APOPTOSIS; EXPRESSION; EXOSITE; CA2+	In addition to an anticoagulant activity, activated protein C (APC) also exhibits anti-inflammatory and cytoprotective properties. These properties may contribute to the beneficial effect of APC in treating severe sepsis patients. A higher incidence of bleeding because of its anticoagulant function has been found to be a major drawback of APC as an effective anti-inflammatory drug. In this study, we have prepared a protein C variant in which an engineered disulfide bond between two beta-sheets stabilized the functionally critical Ca2+ -binding 70 - 80 loop of the molecule. The 70 - 80 loop of this mutant no longer bound Ca2+- and the activation of the mutant by thrombin was enhanced 60-80-fold independently of thrombomodulin. The anticoagulant activity of the activated protein C mutant was nearly eliminated as determined by a plasma-based clotting assay. However, the endothelial protein C receptor- and protease-activated receptor- l-dependent protective signaling properties of the mutant were minimally altered as determined by staurosporine-induced endothelial cell apoptosis, thrombin-induced endothelial cell permeability, and tumor necrosis-a-mediated neutrophil adhesion and migration assays. These results suggest that the mutant lost its ability to interact with the procoagulant cofactors but not with the protective signaling molecules; thus this mutant provides an important tool for in vivo studies to examine the role of anticoagulant versus anti-inflammatory function of activated protein C.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu	Bae, Jong-Sup/AAU-9724-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R01HL068571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62565, HL 68571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Che WY, 2002, CIRC RES, V90, P1222, DOI 10.1161/01.RES.0000021127.83364.7D; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Friedrich U, 2001, J BIOL CHEM, V276, P23105, DOI 10.1074/jbc.M103138200; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; HILL KAW, 1986, J BIOL CHEM, V261, P4991; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; LIU LW, 1994, J BIOL CHEM, V269, P11807; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Manithody C, 2003, BLOOD, V101, P4802, DOI 10.1182/blood-2003-01-0126; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Oganesyan V, 2002, J BIOL CHEM, V277, P24851, DOI 10.1074/jbc.C200163200; PERSSON E, 1993, J BIOL CHEM, V268, P22531; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STENFLO J, 1984, SEMIN THROMB HEMOST, V10, P109, DOI 10.1055/s-2007-1004413; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; Yang LK, 2006, P NATL ACAD SCI USA, V103, P879, DOI 10.1073/pnas.0507700103; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r	35	85	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9251	9259		10.1074/jbc.M610547200	http://dx.doi.org/10.1074/jbc.M610547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255099	hybrid			2022-12-27	WOS:000245780300072
J	Tu, YG; Wu, WP; Wu, TQ; Cao, ZM; Wilkins, R; Toh, BH; Cooper, ME; Chai, ZL				Tu, Yugang; Wu, Weiping; Wu, Tieqiao; Cao, Zemin; Wilkins, Richard; Toh, Ban-Hock; Cooper, Mark E.; Chai, Zhonglin			Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-1 TARGET DENTT; CELL-CYCLE ARREST; GROWTH-FACTOR; DNA-DAMAGE; DEPENDENT KINASES; CDK INHIBITORS; ERK ACTIVATION; PROTEIN SET; GENE; P21	We previously reported that overexpression of cell division autoantigen 1 ( CDA1) in HeLa cells arrests cell growth and inhibits DNA synthesis at S-phase ( 1). Here we show that CDA1-induced arrest of cell growth is accompanied by increases in protein and mRNA levels of the cyclin-dependent kinase ( Cdk) inhibitor protein, p21(Waf1/Cip1) ( p21). Both p21 induction and cell growth arrest are reversed when CDA1 expression is inhibited. CDA1 also increases p53 protein, but not its mRNA, in a time- and dose-dependent manner. MDM2, a ubiquitin ligase regulating p53 degradation, is inactivated by CDA1, suggesting that p53 protein accumulation is due to decreased protein degradation. Knockdown of p53, using siRNA targeting two sites of p53 mRNA, abrogates transcriptional induction of p21 by CDA1. Deletion of the p53 responsive element in the distal region of p21 promoter attenuates promoter activity in response to CDA1. DNA damage caused by camptothecin treatment increases mRNA and protein levels of CDA1, accompanied by induction of p53. The DNA damage-induced p53 induction is markedly attenuated by CDA1 knockdown. CDA1 induces phosphorylation of ERK1/2( p44/42), an activity blocked by PD98059 and U0126, inhibitors of the upstream kinase MEK1/2. The MEK inhibitors also block induction of p21 mRNA and abrogate p21 promoter activity stimulated by CDA1. Cell cycle kinases, Cdk1, -2, -4, and -6 are inhibited by CDA1 overexpression. We conclude that CDA1 induces p53- and MEK/ERK1/2 MAPK-dependent expression of p21 by acting through the p53 responsive element in the p21 promoter and that this contributes to its antiproliferative activity.	Baker Heart Res Inst, Cell Proliferat & Fibrosis Diabet Complicat Lab, Diabet & Metab Div, Melbourne, Vic 3004, Australia; Monash Univ, Autoimmun Lab, Ctr Inflammatory Dis, Dept Med, Clayton, Vic 3168, Australia; Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia	Baker Heart and Diabetes Institute; Monash University; Monash University	Chai, ZL (corresponding author), Baker Heart Res Inst, Cell Proliferat & Fibrosis Diabet Complicat Lab, Diabet & Metab Div, 75 Commercial Rd, Melbourne, Vic 3004, Australia.	zhonglin.chai@baker.edu.au	Cooper, Mark E/E-8680-2010; CHAI, ZHONGLIN/X-1342-2019; Cooper, Mark/AAC-5326-2020; Chai, Zhonglin/E-7482-2010	Cooper, Mark E/0000-0002-5953-642X; CHAI, ZHONGLIN/0000-0001-8182-8579; 				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Delbridge ML, 2004, CHROMOSOME RES, V12, P345, DOI 10.1023/B:CHRO.0000034134.91243.1c; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; Dotti G, 2005, BLOOD, V105, P4677, DOI 10.1182/blood-2004-08-3337; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eichmuller S, 2001, P NATL ACAD SCI USA, V98, P629, DOI 10.1073/pnas.021386498; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; GUPTA RS, 1988, CANCER RES, V48, P6404; HARPER JW, 1993, CELL, V75, P805; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Ito T, 2004, J BIOL CHEM, V279, P25204, DOI 10.1074/jbc.M402143200; Ito T, 1996, MOL CELL BIOL, V16, P3112; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim YK, 2006, CELL SIGNAL, V18, P236, DOI 10.1016/j.cellsig.2005.04.008; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee BY, 2005, ARCH BIOCHEM BIOPHYS, V443, P113, DOI 10.1016/j.abb.2005.09.005; Lee YH, 2001, BIOCHEM BIOPH RES CO, V280, P675, DOI 10.1006/bbrc.2000.4215; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu Y, 1996, CANCER RES, V56, P31; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Martinez A, 2002, DEV DYNAM, V224, P186, DOI 10.1002/dvdy.10096; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Okuwaki M, 2005, MOL CELL BIOL, V25, P10639, DOI 10.1128/MCB.25.23.10639-10651.2005; Ozbun LL, 2005, BBA-GENE STRUCT EXPR, V1728, P163, DOI 10.1016/j.bbaexp.2005.02.010; Ozbun LL, 2001, GENOMICS, V73, P179, DOI 10.1006/geno.2001.6505; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Seomun Y, 2005, MOL VIS, V11, P764; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun GF, 2002, BBA-MOL BASIS DIS, V1588, P241, DOI 10.1016/S0925-4439(02)00171-0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; VON LM, 1992, MOL CELL BIOL, V12, P3346; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang GS, 2004, NEURON, V42, P113, DOI 10.1016/S0896-6273(04)00139-4; WANG GS, 2004, NEURON, V43, P437; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	70	54	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11722	11731		10.1074/jbc.M609623200	http://dx.doi.org/10.1074/jbc.M609623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317670	hybrid			2022-12-27	WOS:000245941900014
J	Moretto, N; Bolchi, A; Rivetti, C; Imbimbo, BP; Villetti, G; Pietrini, V; Polonelli, L; Del Signore, S; Smith, KM; Ferrante, RJ; Ottonello, S				Moretto, Nadia; Bolchi, Angelo; Rivetti, Claudio; Imbimbo, Bruno P.; Villetti, Gino; Pietrini, Vladimiro; Polonelli, Luciano; Del Signore, Steven; Smith, Karen M.; Ferrante, Robert J.; Ottonello, Simone			Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; IMMUNE-RESPONSE; MOUSE MODEL; MEMORY LOSS; IN-VIVO; DISEASE; OLIGOMERS; IMMUNOTHERAPY; VACCINATION; PLAQUES	Immunotherapy against the amyloid-beta(A beta) peptide is a valuable potential treatment for Alzheimer disease ( AD). An ideal antigen should be soluble and nontoxic, avoid the C-terminally located T-cell epitope of A beta, and yet be capable of eliciting antibodies that recognize A beta fibrils and neurotoxic A beta oligomers but not the physiological monomeric species of A beta. We have described here the construction and immunological characterization of a recombinant antigen with these features obtained by tandem multimerization of the immunodominant B-cell epitope peptide A beta 1-15 (A beta 15) within the active site loop of bacterial thioredoxin (Trx). Chimeric Trx(A beta 15)(n) polypeptides bearing one, four, or eight copies of A beta 15 were constructed and injected into mice in combination with alum, an adjuvant approved for human use. All three polypeptides were found to be immunogenic, yet eliciting antibodies with distinct recognition specificities. The anti-Trx(A beta 15)(4) antibody, in particular, recognized A beta 42 fibrils and oligomers but not monomers and exhibited the same kind of conformational selectivity against transthyretin, an amyloidogenic protein unrelated in sequence to A beta. We have also demonstrated that anti-Trx(A beta 15)(4), which binds to human AD plaques, markedly reduces A beta pathology in transgenic AD mice. The data indicate that a conformational epitope shared by oligomers and fibrils can be mimicked by a thioredoxin- constrained A beta fragment repeat and identify Trx(A beta 15)(4) as a promising new tool for AD immunotherapy.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Chisi Farmaceut, R&D Dept, I-43100 Parma, Italy; Univ Parma, Dept Neurosci, Neurol Sect, I-43100 Parma, Italy; Univ Parma, Dept Pathol & Lab Med, I-43100 Parma, Italy; Bedford Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Bedford, MA 01730 USA; Boston Univ, Med Ctr, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Psychiat, Boston, MA 02118 USA	University of Parma; University of Parma; University of Parma; University of Parma; University Hospital of Parma; Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University	Ottonello, S (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Parco Area Sci 23-A, I-43100 Parma, Italy.	s.ottonello@unipr.it	Imbimbo, Bruno/E-2471-2013; Bolchi, Angelo/GOJ-9730-2022	Imbimbo, Bruno/0000-0002-0327-7262; Pietrini, Vladimiro/0000-0002-7521-8093; Rivetti, Claudio/0000-0003-3775-6779	NIA NIH HHS [AG13846] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013846] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agadjanyan MG, 2005, J IMMUNOL, V174, P1580, DOI 10.4049/jimmunol.174.3.1580; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Blum H, 1996, CYTOKINE, V8, P6, DOI 10.1006/cyto.1996.0002; Blum JH, 2000, P NATL ACAD SCI USA, V97, P2241, DOI 10.1073/pnas.040573397; Boche D, 2005, CURR OPIN NEUROL, V18, P720, DOI 10.1097/01.wco.0000191513.60368.a7; Bonifacio MJ, 1996, BBA-MOL BASIS DIS, V1316, P35, DOI 10.1016/0925-4439(96)00014-2; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Chubb C, 2006, NEUROBIOL AGING, V27, P1462, DOI 10.1016/j.neurobiolaging.2005.08.023; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Cribbs DH, 2003, INT IMMUNOL, V15, P505, DOI 10.1093/intimm/dxg049; DWULET FE, 1986, J CLIN INVEST, V78, P880, DOI 10.1172/JCI112675; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Gelinas DS, 2004, P NATL ACAD SCI USA, V101, P14657, DOI 10.1073/pnas.0404866101; Ghochikyan A, 2006, VACCINE, V24, P2275, DOI 10.1016/j.vaccine.2005.11.039; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Imbimbo BP, 2002, ANN NEUROL, V51, P794, DOI 10.1002/ana.10218; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HD, 2005, BIOCHEM BIOPH RES CO, V336, P84, DOI 10.1016/j.bbrc.2005.08.044; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Leverone JF, 2003, VACCINE, V21, P2197, DOI 10.1016/S0264-410X(02)00754-5; Lindgren M, 2005, BIOPHYS J, V88, P4200, DOI 10.1529/biophysj.104.049700; Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499; Maier M, 2006, J NEUROSCI, V26, P4717, DOI 10.1523/JNEUROSCI.0381-06.2006; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Robinson SR, 2003, BIOESSAYS, V25, P283, DOI 10.1002/bies.10236; Schenk D, 2004, CURR OPIN IMMUNOL, V16, P599, DOI 10.1016/j.coi.2004.07.012; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Solomon Beka, 2004, Current Alzheimer Research, V1, P149, DOI 10.2174/1567205043332126; Spooner ET, 2002, VACCINE, V21, P290, DOI 10.1016/S0264-410X(02)00464-4; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Thai R, 2004, J BIOL CHEM, V279, P50257, DOI 10.1074/jbc.M405738200; Town T, 2001, NEUROSCI LETT, V307, P101, DOI 10.1016/S0304-3940(01)01951-6; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zagorski MG, 1999, METHOD ENZYMOL, V309, P189; Zamora E, 2006, J IMMUNOL, V177, P2662, DOI 10.4049/jimmunol.177.4.2662; Zurbriggen R, 2005, J MOL NEUROSCI, V27, P157, DOI 10.1385/JMN:27:2:157	55	58	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11436	11445		10.1074/jbc.M609690200	http://dx.doi.org/10.1074/jbc.M609690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17267402	hybrid			2022-12-27	WOS:000245941500065
J	Saavalainen, K; Tammi, MI; Bowen, T; Schmitz, ML; Carlberg, C				Saavalainen, Katri; Tammi, Markku I.; Bowen, Timothy; Schmitz, M. Lienhard; Carlberg, Carsten			Integration of the activation of the human hyaluronan synthase 2 gene promoter by common cofactors of the transcription factors retinoic acid receptor and nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN SYNTHASE-2 GENE; INTRACELLULAR HYALURONAN; COMPLEX; EPIDERMIS; BINDING; ACCUMULATION; ACETYLATION; TARGETS; CANCER; MOTIF	Hyaluronan ( HA) is a polysaccharide of the vertebrate extracellular matrix, produced by three related HA synthases ( HASs) that influence numerous physiological processes. We screened the first 2250 bp of the HAS2 promoter for transcription factor response elements ( REs) in silico and found 1 cluster of 2 retinoic acid ( RA) REs, 3 discrete NF-kappa B factors, and 12 Sp1 REs. In parallel, we scanned nine overlapping promoter regions in HaCaT human immortalized keratinocytes using chromatin immunoprecipitation assays to identify binding of mediator, coactivator, and corepressor proteins and Sp1 transcription factor in response to all-trans-RA and tumor necrosis factor-alpha (TNF-alpha). We found that all-trans-RA modulated the binding of the RA receptor and several coregulators to the region containing the RARE cluster at position - 1230. The importance of this region is supported in reporter gene assays by the all-trans-RA induction of the respective promoter region. Similarly, we showed by chromatin immunoprecipitation assays as well as by gel-shift assays with nuclear extracts that TNF-alpha induced NF-kappa B binding to regions at positions -380, -1420, and -1890, demonstrated its association with RNA polymerase II and cofactor proteins, and confirmed the functionality of the respective promoter regions in vivo. These findings partially explain the induction of HAS2 mRNA by all-trans-RA and TNF-alpha and provide an example how the action of different transcription factor families can use the same cofactors.	Univ Luxembourg, Life Sci Res Unit, L-1511 Luxembourg, Luxembourg; Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland; Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, Wales; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	University of Luxembourg; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; Cardiff University; Justus Liebig University Giessen	Carlberg, C (corresponding author), Univ Luxembourg, Life Sci Res Unit, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	carsten.carlberg@uni.lu	Schmitz, M. Lienhard/D-9328-2017; Tammi, Markku/AAQ-7878-2021; Carlberg, Carsten/C-9075-2011	Schmitz, M. Lienhard/0000-0002-6984-7192; Carlberg, Carsten/0000-0003-2633-0684				BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Dunlop TW, 2004, J STEROID BIOCHEM, V89-90, P257, DOI 10.1016/j.jsbmb.2004.03.079; Glass CK, 2000, GENE DEV, V14, P121; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Karvinen S, 2003, J BIOL CHEM, V278, P49495, DOI 10.1074/jbc.M310445200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Monslow J, 2004, J BIOL CHEM, V279, P20576, DOI 10.1074/jbc.M312666200; Monslow J, 2003, INT J BIOCHEM CELL B, V35, P1272, DOI 10.1016/S1357-2725(03)00048-7; Monslow J, 2006, J BIOL CHEM, V281, P18043, DOI 10.1074/jbc.M510467200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nishida Y, 1999, J BIOL CHEM, V274, P21893, DOI 10.1074/jbc.274.31.21893; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Saavalainen K, 2005, J BIOL CHEM, V280, P14636, DOI 10.1074/jbc.M500206200; SCHMITZ ML, 1995, IMMUNOBIOLOGY, V193, P116, DOI 10.1016/S0171-2985(11)80534-6; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; Shaffer PL, 2002, EMBO J, V21, P2242, DOI 10.1093/emboj/21.9.2242; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TAMMI R, 1989, J INVEST DERMATOL, V92, P326, DOI 10.1111/1523-1747.ep12277125; Tammi R, 2005, J INVEST DERMATOL, V124, P898, DOI 10.1111/j.0022-202X.2005.23697.x; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001	37	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11530	11539		10.1074/jbc.M607871200	http://dx.doi.org/10.1074/jbc.M607871200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307735	hybrid			2022-12-27	WOS:000245941500074
J	Lloyd-Burton, SM; Yu, JCH; Irvine, RF; Schell, MJ				Lloyd-Burton, Samantha M.; Yu, Jowie C. H.; Irvine, Robin F.; Schell, Michael J.			Regulation of inositol 1,4,5-trisphosphate 3-kinases by calcium and localization in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; PHOSPHATE MULTIKINASE; CA2+ OSCILLATIONS; POLYPHOSPHATE 5-PHOSPHATASE; DROSOPHILA-MELANOGASTER; INS(1,4,5)P-3 3-KINASE; CRYSTAL-STRUCTURE; DENDRITIC SPINES; BINDING DOMAIN; HUMAN HOMOLOG	Inositol 1,4,5-trisphosphate (Ins(1,4,5)p3) 3-kinases (IP(3)Ks) are a group of calmodulin-regulated inositol polyphosphate kinases (IPKs) that convert the second messenger Ins(1,4,5)p3 into inositol 1,3,4,5-tetrakisphosphate. However, what they contribute to the complexities of Ca2+ signaling, and how, is still not fully understood. In this study, we have used a simple Ca2+ imaging assay to compare the abilities of various Ins (1,4,5)p3metabolizing enzymes to regulate a maximal histamine-stimulated Ca2+ signal in HeLa cells. Using transient transfection, we overexpressed green fluorescent protein-tagged versions of all three mammalian IP3K isoforms, including mutants with disrupted cellular localization or calmodulin regulation, and then imaged the Ca2+ release stimulated by 100 mu M histamine. Both localization to the F-actin cytoskeleton and calmodulin regulation enhance the efficiency of mammalian IP(3)Ks to dampen the Ins (1,4,5)P-3-mediated Ca2+ signals. We also compared the effects of the these IP(3)Ks with other enzymes that metabolize Ins(1,4,5)P-3, including the Type IIns(1,4,5)P(3)5-phosphatase, in both membrane-targeted and soluble forms, the human inositol polyphosphate multikinase, and the two isoforms of IP3K found in Drosophila. All reduce the Ca2+ signal but to varying degrees. We demonstrate that the activity of only one of two IP3K isoforms from Drosophila is positively regulated by calmodulin and that neither isoform associates with the cytoskeleton. Together the data suggest that IP(3)Ks evolved to regulate kinetic and spatial aspects of Ins (1,4,5)P-3 signals in increasingly complex ways in vertebrates, consistent with their probable roles in the regulation of higher brain and immune function.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	University of Cambridge; Uniformed Services University of the Health Sciences - USA	Irvine, RF (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	rfi20@cam.ac.uk		Schell, Michael/0000-0003-1553-3582	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALLA T, 1991, J BIOL CHEM, V266, P24719; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Brehm MA, 2004, BIOCHEM J, V382, P353, DOI 10.1042/BJ20031751; Bui YK, 2002, MOL BIOL CELL, V13, P1641, DOI 10.1091/mbc.02-01-0008; Chamberlain PP, 2005, BIOCHEMISTRY-US, V44, P14486, DOI 10.1021/bi051256q; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; Communi D, 1999, J BIOL CHEM, V274, P14734, DOI 10.1074/jbc.274.21.14734; Communi D, 2001, J BIOL CHEM, V276, P38738, DOI 10.1074/jbc.M105640200; Communi D, 1997, EMBO J, V16, P1943, DOI 10.1093/emboj/16.8.1943; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; Cozier GE, 2000, J BIOL CHEM, V275, P28261; Cullen PJ, 2006, CURR OPIN CELL BIOL, V18, P157, DOI 10.1016/j.ceb.2006.02.012; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; Dewaste V, 2003, BIOCHEM J, V374, P41, DOI 10.1042/BJ20021963; Dewaste V, 2002, BIOCHEM BIOPH RES CO, V291, P400, DOI 10.1006/bbrc.2002.6456; Dewaste V, 2000, BIOCHEM J, V352, P343, DOI 10.1042/0264-6021:3520343; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Dupont G, 2003, FEBS LETT, V534, P101, DOI 10.1016/S0014-5793(02)03789-4; Dupont G, 1997, CELL CALCIUM, V22, P321, DOI 10.1016/S0143-4160(97)90017-8; ERNEUX C, 1993, EUR J BIOCHEM, V214, P497, DOI 10.1111/j.1432-1033.1993.tb17947.x; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Frederick JP, 2005, P NATL ACAD SCI USA, V102, P8454, DOI 10.1073/pnas.0503706102; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; Holmes W, 2006, J BIOL CHEM, V281, P38109, DOI 10.1074/jbc.M606883200; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1984, BIOCHEM J, V222, P269, DOI 10.1042/bj2220269; Irvine RF, 1999, CHEM PHYS LIPIDS, V98, P49, DOI 10.1016/S0009-3084(99)00017-1; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Irvine RF, 2006, ADV ENZYME REGUL, V46, P314, DOI 10.1016/j.advenzreg.2006.01.009; Jun KS, 1998, LEARN MEMORY, V5, P317; Kim IH, 2004, MOL BRAIN RES, V124, P12, DOI 10.1016/j.molbrainres.2003.12.016; Kucharski R, 2002, MOL BRAIN RES, V99, P92, DOI 10.1016/S0169-328X(01)00325-4; LEYMAN AA, 2007, CELL SIGNAL; Millard TH, 2000, BIOCHEM J, V352, P709, DOI 10.1042/0264-6021:3520709; Miller GJ, 2004, MOL CELL, V15, P703, DOI 10.1016/j.molcel.2004.08.005; Monnier V, 2002, FREE RADICAL BIO MED, V33, P1250, DOI 10.1016/S0891-5849(02)01019-5; Nalaskowski MM, 2006, BIOL CHEM, V387, P583, DOI 10.1515/BC.2006.075; Nalaskowski MM, 2004, CURR MOL MED, V4, P277, DOI 10.2174/1566524043360726; Nalaskowski MM, 2003, J BIOL CHEM, V278, P19765, DOI 10.1074/jbc.M211059200; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; Pattni K, 2004, CELL SIGNAL, V16, P643, DOI 10.1016/j.cellsig.2003.10.009; Pattni K, 2003, BIOCHEM J, V375, P643, DOI 10.1042/BJ20030505; Pouillon V, 2003, NAT IMMUNOL, V4, P1136, DOI 10.1038/ni980; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Schell MJ, 2006, EUR J NEUROSCI, V24, P2491, DOI 10.1111/j.1460-9568.2006.05125.x; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; Soriano S, 1997, FEBS LETT, V403, P1, DOI 10.1016/S0014-5793(96)01516-5; Speed CJ, 1999, J CELL SCI, V112, P669; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Szinyei C, 1999, J PHYSIOL-LONDON, V516, P855, DOI 10.1111/j.1469-7793.1999.0855u.x; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; Tsubokawa H, 1996, J PHYSIOL-LONDON, V497, P67, DOI 10.1113/jphysiol.1996.sp021750; VERJANS B, 1994, BIOCHEM J, V304, P679, DOI 10.1042/bj3040679; Wen BG, 2004, P NATL ACAD SCI USA, V101, P5604, DOI 10.1073/pnas.0306907101; Woodring PJ, 1997, J BIOL CHEM, V272, P30447, DOI 10.1074/jbc.272.48.30447; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YU CHY, 2005, BIOCHEM J, V392, P435	68	15	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9526	9535		10.1074/jbc.M610253200	http://dx.doi.org/10.1074/jbc.M610253200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284449	hybrid			2022-12-27	WOS:000245421700025
J	Wang, YM; Singh, U; Mueller, DM				Wang, Yamin; Singh, Usha; Mueller, David M.			Mitochondrial genome integrity mutations uncouple the yeast Saccharomyces cerevisiae ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; KLUYVEROMYCES-LACTIS; ESCHERICHIA-COLI; OXIDATIVE-PHOSPHORYLATION; PERIPHERAL STALK; BETA-SUBUNIT; F-1-ATPASE; GENE; PROTEIN; PURIFICATION	The mitochondrial ATP synthase is a molecular motor, which couples the flow of protons with phosphorylation of ADP. Rotation of the central stalk within the core of ATP synthase effects conformational changes in the active sites driving the synthesis of ATP. Mitochondrial genome integrity (mgi) mutations have been previously identified in the alpha-, beta-, and gamma-subunits of ATP synthase in yeast Kluyveromyces lactis and trypanosome Trypanosoma brucei. These mutations reverse the lethality of the loss of mitochondrial DNA in petite negative strains. Introduction of the homologous mutations in Saccharomyces cerevisiae results in yeast strains that lose mitochondrial DNA at a high rate and accompanied decreases in the coupling of the ATP synthase. The structure of yeast F-1-ATPase reveals that the mgi residues cluster around the gamma-subunit and selectively around the collar region of F-1. These results indicate that residues within the mgi complementation group are necessary for efficient coupling of ATP synthase, possibly acting as a support to fix the axis of rotation of the central stalk.	Rosalind Franklin Univ Med & Sci, Dept Biochem & Mol Biol, Chicago Med Sch, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Mueller, DM (corresponding author), 3333 Greenbay Rd, N Chicago, IL USA.	David.Mueller@RosalindFranklin.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067091, R01GM066223] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066223, R01-GM067091, R01 GM066223-01, R01 GM066223-02, R01 GM066223-04, R01 GM067091, R01-GM066223, R01 GM066223-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Bald D, 1999, EUR J BIOCHEM, V262, P563, DOI 10.1046/j.1432-1327.1999.00410.x; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Cabezon E, 2003, NAT STRUCT BIOL, V10, P744, DOI 10.1038/nsb966; Cabezon E, 2001, EMBO J, V20, P6990, DOI 10.1093/emboj/20.24.6990; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chen XJ, 2000, INT REV CYTOL, V194, P197; CHEN XJ, 1995, EMBO J, V14, P3277, DOI 10.1002/j.1460-2075.1995.tb07331.x; Chen XJ, 1996, GENETICS, V144, P1445; Clark-Walker GD, 2003, MITOCHONDRION, V2, P257, DOI 10.1016/S1567-7249(02)00107-1; Clark-Walker GD, 2000, BBA-PROTEIN STRUCT M, V1478, P125, DOI 10.1016/S0167-4838(00)00003-0; DeLano W, 2002, PYMOL 0 99; Dickson VK, 2006, EMBO J, V25, P2911, DOI 10.1038/sj.emboj.7601177; Dunn CD, 2003, GENETICS, V165, P35; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green DW, 2000, BBA-BIOENERGETICS, V1458, P343, DOI 10.1016/S0005-2728(00)00085-2; Guerin B, 1979, Methods Enzymol, V55, P149; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; Jie LZ, 1999, EMBO J, V18, P58, DOI 10.1093/emboj/18.1.58; Kabaleeswaran V, 2006, EMBO J, V25, P5433, DOI 10.1038/sj.emboj.7601410; Kominsky DJ, 2000, GENETICS, V154, P147; Kominsky DJ, 2002, GENETICS, V162, P1595; KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2; KUKI M, 1988, J BIOL CHEM, V263, P17437; Mueller DM, 2004, PROTEIN EXPRES PURIF, V37, P479, DOI 10.1016/j.pep.2004.06.035; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; Mueller DM, 2000, J BIOENERG BIOMEMBR, V32, P391, DOI 10.1023/A:1005532104617; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; PITTMAN D, 1960, GENETICS, V45, P1023; PULLMAN ME, 1986, METHOD ENZYMOL, V126, P460; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; Schnaufer A, 2005, EMBO J, V24, P4029, DOI 10.1038/sj.emboj.7600862; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Silvester JA, 2006, ACTA CRYSTALLOGR F, V62, P530, DOI 10.1107/S1744309106015338; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Walker JE, 2006, BBA-BIOENERGETICS, V1757, P286, DOI 10.1016/j.bbabio.2006.01.001; WEBER ER, 1995, GENETICS, V140, P435; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	47	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8228	8236		10.1074/jbc.M609635200	http://dx.doi.org/10.1074/jbc.M609635200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244612	hybrid, Green Accepted			2022-12-27	WOS:000245081000055
J	Gwack, Y; Srikanth, S; Feske, S; Cruz-Guilloty, F; Oh-hora, M; Neems, DS; Hogan, PG; Rao, A				Gwack, Yousang; Srikanth, Sonal; Feske, Stefan; Cruz-Guilloty, Fernando; Oh-hora, Masatsugu; Neems, Daniel S.; Hogan, Patrick G.; Rao, Anjana			Biochemical and functional characterization of Orai proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED CA2+ ENTRY; PLASMA-MEMBRANE; CHANNEL FUNCTION; CALCIUM-ENTRY; CRAC CHANNEL; CENTRAL-SPINDLE; T-LYMPHOCYTES; RNAI SCREEN; STIM1; STORE	Stimulation of immune cells triggers Ca2+ entry through store-operated Ca2+ release-activated Ca2+ channels, promoting nuclear translocation of the transcription factor NFAT. Through genome-wide RNA interference screens in Drosophila, we and others identified olf186-F (Drosophila Orai, dOrai) and dStim as critical components of store-operated Ca2+ entry and showed that dOrai and its human homologue Orai1 are pore subunits of the Ca2+ release-activated Ca2+ channel. Here we report that Orai1 is predominantly responsible for store-operated Ca2+ influx in human embryonic kidney 293 cells and human T cells and fibroblasts, although its paralogue Orai3 can partly compensate in the absence of functional Orai1. All three mammalian Orai are widely expressed at the mRNA level, and all three are incorporated into the plasma membrane. In human embryonic kidney 293 cells, Orai1 is glycosylated at an asparagine residue in the predicted second extracellular loop, but mutation of the residue does not compromise function. STIM1 and Orai1 colocalize after store depletion, but Orai1 does not associate detectably with STIM1 in glycerol gradient centrifugation or coimmunoprecipitation experiments. Glutamine substitutions in two conserved glutamate residues, located within predicted transmembrane helices of Drosophila Orai and human Orai1, greatly diminish store-operated Ca2+ influx, and primary T cells ectopically expressing mutant E106Q and E190Q Orai1 proteins show reduced proliferation and cytokine secretion. Together, these data establish Orai1 as a predominant mediator of store-operated calcium entry, proliferation, and cytokine production in T cells.	Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Rao, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Rm 152,Warren Alpert Bldg,200 Longwood Ave, Boston, MA 02115 USA.	arao@cbr.med.harvard.edu	Feske, stefan/ABB-3554-2021	Feske, stefan/0000-0001-5431-8178	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040127, R01AI066128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075256] Funding Source: NIH RePORTER; NIAID NIH HHS [AI066128, AI40127] Funding Source: Medline; NIGMS NIH HHS [GM075256] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Ansel KM, 2004, NAT IMMUNOL, V5, P1251, DOI 10.1038/ni1135; Armknecht S, 2005, METHOD ENZYMOL, V392, P55, DOI 10.1016/S0076-6879(04)92004-6; Feske S, 2003, BIOCHEM BIOPH RES CO, V311, P1117, DOI 10.1016/j.bbrc.2003.09.174; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2005, J EXP MED, V202, P651, DOI 10.1084/jem.20050687; Flockhart I, 2006, NUCLEIC ACIDS RES, V34, pD489, DOI 10.1093/nar/gkj114; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Kulkarni MM, 2006, NAT METHODS, V3, P833, DOI 10.1038/nmeth935; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Oegema K, 2000, J CELL BIOL, V150, P539, DOI 10.1083/jcb.150.3.539; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Stathopulos PB, 2006, J BIOL CHEM, V281, P35855, DOI 10.1074/jbc.M608247200; Verni F, 2004, CURR BIOL, V14, P1569, DOI 10.1016/j.cub.2004.08.054; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; Wedel B, 2007, J PHYSIOL-LONDON, V579, P679, DOI 10.1113/jphysiol.2006.125641; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xu PY, 2006, BIOCHEM BIOPH RES CO, V350, P969, DOI 10.1016/j.bbrc.2006.09.134; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	34	287	297	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16232	16243		10.1074/jbc.M609630200	http://dx.doi.org/10.1074/jbc.M609630200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17293345	hybrid			2022-12-27	WOS:000246794300031
J	Caines, MEC; Vaughan, MD; Tarling, CA; Hancock, SM; Warren, RAJ; Withers, SG; Strynadka, NCJ				Caines, Matthew E. C.; Vaughan, Mark D.; Tarling, Chris A.; Hancock, Susan M.; Warren, R. Antony J.; Withers, Stephen G.; Strynadka, Natalie C. J.			Structural and mechanistic analyses of endo-glycoceramidase II, a membrane-associated family 5 glycosidase in the Apo and G(M3) ganglioside-bound forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BETA-GLUCOSIDASE; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; CERAMIDE-GLYCANASE; CRYSTALLOGRAPHIC STRUCTURE; GM1 GANGLIOSIDE; MOLECULAR-BASIS; HUMAN CD1B; GLYCOSPHINGOLIPIDS; PROTEIN	endo-Glycoceramidase, a membrane-associated family 5 glycosidase, deviates from the typical polysaccharide substrate specificity of other soluble members of the family, preferentially hydrolyzing glycosidic linkages between the oligosaccharide and ceramide moieties of gangliosides. Here we report the first x-ray crystal structures of an endo-glycoceramidase from Rhodococcus sp., in the apo form, in complex with the ganglioside G(M3) ( Svennerholm ganglioside nomenclature (Svennerholm, L. (1964) J. Lipid Res. 5, 145 - 155)), and trapped as a glycosyl-enzyme intermediate. These snapshots provide the first molecular insight into enzyme recognition and association with gangliosides, revealing the structural adaptations necessary for glycosidase-catalyzed hydrolysis and detailing a novel ganglioside binding topology. Consistent with the chemical duality of the substrate, the active site of endo-glycoceramidase is split into a wide, polar cavity to bind the polyhydroxylated oligosaccharide moiety and a narrow, hydrophobic tunnel to bind the ceramide lipid chains. The specific interactions with the ceramide polar head group manifest a surprising aglycone specificity, an observation substantiated by our kinetic analyses. Collectively, the reported structural and kinetic data provide insight toward rational redesign of the synthetic glycosynthase mutant of endo-glycoceramidase to enable facile synthesis of nonnatural, therapeutically useful gangliosides.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca	Withers, Stephen G/I-7229-2019	Withers, Stephen G/0000-0002-6722-5701				Ahn VE, 2003, P NATL ACAD SCI USA, V100, P38, DOI 10.1073/pnas.0136947100; Airenne TT, 2006, J MOL BIOL, V355, P224, DOI 10.1016/j.jmb.2005.10.031; Allende ML, 2002, CURR OPIN STRUC BIOL, V12, P587, DOI 10.1016/S0959-440X(02)00376-7; ASHIDA H, 1992, EUR J BIOCHEM, V205, P729, DOI 10.1111/j.1432-1033.1992.tb16836.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; Batuwangala T, 2004, J IMMUNOL, V172, P2382, DOI 10.4049/jimmunol.172.4.2382; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P1926, DOI 10.1021/bi972162m; DeLano W.L, PYMOL MOL GRAPHICS S; Dvir H, 2003, EMBO REP, V4, P704, DOI 10.1038/sj.embor.embor873; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; Giabbai B, 2005, J IMMUNOL, V175, P977, DOI 10.4049/jimmunol.175.2.977; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hancock SM, 2006, CURR OPIN CHEM BIOL, V10, P509, DOI 10.1016/j.cbpa.2006.07.015; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; Horibata Y, 2004, J BIOL CHEM, V279, P33379, DOI 10.1074/jbc.M401460200; Horibata Y, 2000, J BIOL CHEM, V275, P31297, DOI 10.1074/jbc.M003575200; ITO M, 1991, J BIOL CHEM, V266, P7919; ITO M, 1986, J BIOL CHEM, V261, P14278; Itoh M, 2001, GLYCOBIOLOGY, V11, P125, DOI 10.1093/glycob/11.2.125; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; Koch M, 2005, NAT IMMUNOL, V6, P819, DOI 10.1038/ni1225; Larson SB, 2003, BIOCHEMISTRY-US, V42, P8411, DOI 10.1021/bi034144c; LEATHERBARROW RJ, 2004, GRAFIT VERSION 4 0 2; Lemieux MJ, 2006, J MOL BIOL, V359, P913, DOI 10.1016/j.jmb.2006.04.004; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; Malinina L, 2004, NATURE, V430, P1048, DOI 10.1038/nature02856; Matsuoka Y, 2003, J NEUROSCI, V23, P29; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nojiri H, 2002, CANCER DETECT PREV, V26, P114, DOI 10.1016/S0361-090X(02)00033-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pope-Coleman A, 1998, RESTOR NEUROL NEUROS, V12, P255; Premkumar L, 2005, J BIOL CHEM, V280, P23815, DOI 10.1074/jbc.M502799200; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Sulzenbacher G, 2004, J BIOL CHEM, V279, P13119, DOI 10.1074/jbc.M313783200; Svennerholm L, 2002, DEMENT GERIATR COGN, V14, P128, DOI 10.1159/000063604; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tettamanti G, 2003, GLYCOCONJUGATE J, V20, P301, DOI 10.1023/B:GLYC.0000033627.02765.cc; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Vaughan MD, 2006, J AM CHEM SOC, V128, P6300, DOI 10.1021/ja058469n; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225; Wu D, 2006, P NATL ACAD SCI USA, V103, P3972, DOI 10.1073/pnas.0600285103; Zajonc DM, 2005, NAT IMMUNOL, V6, P810, DOI 10.1038/ni1224; Zajonc DM, 2005, IMMUNITY, V22, P209, DOI 10.1016/j.immuni.2004.12.009; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; Zajonc DM, 2005, J EXP MED, V202, P1517, DOI 10.1084/jem.20051625; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339; ZHOU B, 1989, J BIOL CHEM, V264, P12272	65	39	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14300	14308		10.1074/jbc.M611455200	http://dx.doi.org/10.1074/jbc.M611455200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17329247	hybrid			2022-12-27	WOS:000246245800041
J	Heinemeyer, J; Braun, HP; Boekema, EJ; Kouril, R				Heinemeyer, Jesco; Braun, Hans-Peter; Boekema, Egbert J.; Kouril, Roman			A structural model of the cytochrome c reductase/oxidase supercomplex from yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN SUPERCOMPLEXES; DIMERIC ATP SYNTHASE; OXIDATIVE-PHOSPHORYLATION; INNER MEMBRANE; COMPLEX-I; OXIDASE; ARCHITECTURE; CARDIOLIPIN; RESOLUTION; BC(1)	Mitochondrial respiratory chain complexes are arranged in supercomplexes within the inner membrane. Interaction of cytochrome c reductase ( complex III) and cytochrome c oxidase ( complex IV) was investigated in Saccharomyces cerevisiae. Projection maps at 15 angstrom resolution of supercomplexes III2 + IV1 and III2 + IV2 were obtained by electron microscopy. Based on a comparison of our maps with atomic x-ray structures for complexes III and IV we present a pseudo-atomic model of their precise interaction. Two complex IV monomers are specifically attached to dimeric complex III with their convex sides. The opposite sides, which represent the complex IV dimer interface in the x-ray structure, are open for complex IV-complex IV interactions. This could lead to oligomerization of III2 + IV2 supercomplexes, but this was not detected. Instead, binding of cytochrome c to the supercomplexes was revealed. It was calculated that cytochrome c has to move less than 40 angstrom at the surface of the supercomplex for electron transport between complex III2 and complex IV. Hence, the prime function of the supercomplex III2 + IV2 is proposed to be a scaffold for effective electron transport between complexes III and IV.	Univ Groningen, GBB, Dept Biophys Chem, NL-9747 AG Groningen, Netherlands; Leibniz Univ Hannover, Fac Nat Sci, Inst Plant Genet, D-30419 Hannover, Germany	University of Groningen; Leibniz University Hannover	Boekema, EJ (corresponding author), Univ Groningen, GBB, Dept Biophys Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	e.j.boekema@rug.nl; r.kouril@rug.nl	Braun, Hans-Peter/E-7149-2011; KOUŘIL, Roman/A-9587-2018	Braun, Hans-Peter/0000-0002-4459-9727; KOUŘIL, Roman/0000-0001-8211-3348				ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; DeLano W.L, PYMOL MOL GRAPHICS S; Dudkina NV, 2006, FEBS LETT, V580, P3427, DOI 10.1016/j.febslet.2006.04.097; Dudkina NV, 2006, TRENDS PLANT SCI, V11, P232, DOI 10.1016/j.tplants.2006.03.007; Dudkina NV, 2005, FEBS LETT, V579, P5769, DOI 10.1016/j.febslet.2005.09.065; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Giraud MF, 2002, BBA-BIOENERGETICS, V1555, P174, DOI 10.1016/S0005-2728(02)00274-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARRIS JR, 1994, MICRON, V25, P5; HEINEMEYER J, 2007, PLANT MITOCHONDRIA A; Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002; KIM CH, 1983, J BIOL CHEM, V258, P3543; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Lee SJ, 2001, ACTA CRYSTALLOGR D, V57, P941, DOI 10.1107/S0907444901005625; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mannella CA, 2006, BBA-MOL CELL RES, V1763, P542, DOI 10.1016/j.bbamcr.2006.04.006; Meisinger Chris, 2006, Methods Mol Biol, V313, P33; Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schafer E, 2006, J BIOL CHEM, V281, P15370, DOI 10.1074/jbc.M513525200; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHWERZMANN K, 1986, J CELL BIOL, V102, P97, DOI 10.1083/jcb.102.1.97; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; SUNDERHAU S, 2006, IN PRESS MITOCHONDRI; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; Wittig I, 2006, BBA-BIOENERGETICS, V1757, P1066, DOI 10.1016/j.bbabio.2006.05.006; Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	44	133	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12240	12248		10.1074/jbc.M610545200	http://dx.doi.org/10.1074/jbc.M610545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322303	Green Published, hybrid			2022-12-27	WOS:000245941900067
J	Mulherkar, N; Prasad, KV; Prabhakar, BS				Mulherkar, Nirupama; Prasad, Kanteti V.; Prabhakar, Bellur S.			MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation - Knockdown enhances trail-induced apoptosis of cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP/GTP EXCHANGE PROTEIN; DEATH DOMAIN PROTEIN; NECROSIS-FACTOR RECEPTOR; NEOPLASTIC-CELLS; DENN-SV; MADD; EXPRESSION; KINASE; SUSCEPTIBILITY; INHIBITION	The MADD variant of the IG20 gene is necessary and sufficient for cancer cell survival. Abrogation of MADD, but not the other IG20 splice variants, can render cancer cells more susceptible to spontaneous as well as TRAIL ( tumor necrosis factor alpha-related apoptosis-inducing ligand)-induced apoptosis. Both types of apoptosis in cells devoid of MADD can be inhibited by expression of CrmA or dominant-negative FADD, thereby suggesting that endogenous MADD may be targeting caspase-8 activation. Immunoprecipitation studies showed that MADD down-modulation could lead to caspase-8 activation at the death receptors without an apparent increase in the recruitment of death-inducing signaling complex components such as FADD. Further, we found that MADD can directly interact with death receptors, but not with either caspase-8 or FADD, and can inhibit caspase-8 activation. These results clearly demonstrate the importance of MADD in the control of cancer cell survival/death and in conferring significant resistance to TRAIL-induced apoptosis. In addition, our results indicate the therapeutic potential of MADD abrogation in enhancing TRAIL-induced selective apoptosis of cancer cells.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Prabhakar, BS (corresponding author), Rm E-705,835 S Wollcott Ave M-C 790, Chicago, IL 60610 USA.	bprabhak@uic.edu			NCI NIH HHS [5R01CA107506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Brown TL, 1998, CURR BIOL, V8, pR191; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Del Villar K, 2004, P NATL ACAD SCI USA, V101, P4210, DOI 10.1073/pnas.0307349101; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; Iwasaki K, 2000, EMBO J, V19, P4806, DOI 10.1093/emboj/19.17.4806; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Lim KM, 2004, INT J CANCER, V109, P24, DOI 10.1002/ijc.11660; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mulherkar N, 2006, ONCOGENE, V25, P6252, DOI 10.1038/sj.onc.1209650; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Ramaswamy M, 2004, ONCOGENE, V23, P6083, DOI 10.1038/sj.onc.1207804; RAMASWAMY M, 2004, THESIS U ILLINOIS CH; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Yamaguchi K, 2002, P NATL ACAD SCI USA, V99, P14536, DOI 10.1073/pnas.212511399; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	31	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11715	11721		10.1074/jbc.M701085200	http://dx.doi.org/10.1074/jbc.M701085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314102	hybrid			2022-12-27	WOS:000245941900013
J	Zhu, JQ; Boylan, B; Luo, BH; Newman, PJ; Springer, TA				Zhu, Jieqing; Boylan, Brian; Luo, Bing-Hao; Newman, Peter J.; Springer, Timothy A.			Tests of the extension and deadbolt models of integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-LIKE DOMAIN; ALPHA(L)BETA(2) HYBRID DOMAIN; PLATELET GLYCOPROTEIN-IIIA; INSIDE-OUT ACTIVATION; LOW-AFFINITY STATE; MONOCLONAL-ANTIBODY; STRUCTURAL BASIS; LIGAND-BINDING; SUBUNIT; COMPLEX	Despite extensive evidence that integrin conformational changes between bent and extended conformations regulate affinity for ligands, an alternative hypothesis has been proposed in which a "deadbolt" can regulate affinity for ligand in the absence of extension. Here, we tested both the deadbolt and the extension models. According to the deadbolt model, a hairpin loop in the beta 3 tail domain could act as a deadbolt to restrain the displacement of the beta 3 I domain beta 6-alpha 7 loop and maintain integrin in the low affinity state. We found that mutating or deleting the beta 3 tail domain loop has no effect on ligand binding by either alpha IIb beta 3 or alpha V beta 3 integrins. In contrast, we found that mutations that lock integrins in the bent conformation with disulfide bonds resist inside-out activation induced by cytoplasmic domain mutation. Furthermore, we demonstrated that extension is required for accessibility to fibronectin but not smaller fragments. The data demonstrate that integrin extension is required for ligand binding during integrin inside-out signaling and that the deadbolt does not regulate integrin activation.	Harvard Univ, Sch Med, CBR, Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Blood Ctr Wisconsin, Blood Res Inst, Milwaukee, WI 53201 USA; Med Coll Wisconsin, Dept Pharmacol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Cellular Biol, Milwaukee, WI 53226 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Springer, TA (corresponding author), Harvard Univ, Sch Med, CBR, Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu		Boylan, Brian/0000-0003-3930-4565	NHLBI NIH HHS [P01 HL048675, HL44612, P01 HL044612, HL48675] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048675, P01HL044612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Barton SJ, 2004, BIOCHEM J, V380, P401, DOI 10.1042/BJ20031973; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Ehirchiou D, 2005, J BIOL CHEM, V280, P8324, DOI 10.1074/jbc.M413525200; FARADAY N, 1994, J LAB CLIN MED, V123, P728; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GUPTA V, 2006, IN PRESS BLOOD; Hato T, 2006, J THROMB HAEMOST, V4, P2278, DOI 10.1111/j.1538-7836.2006.02137.x; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iwasaki K, 2005, J STRUCT BIOL, V150, P259, DOI 10.1016/j.jsb.2005.03.005; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1991, BLOOD, V78, P3215; Luo BH, 2005, P NATL ACAD SCI USA, V102, P3679, DOI 10.1073/pnas.0409440102; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Luo BH, 2004, J BIOL CHEM, V279, P27466, DOI 10.1074/jbc.M404354200; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Luo BH, 2006, CURR OPIN CELL BIOL, V18, P579, DOI 10.1016/j.ceb.2006.08.005; Mould AP, 2005, J BIOL CHEM, V280, P4238, DOI 10.1074/jbc.M412240200; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; NEWMAN PJ, 1985, BLOOD, V65, P227; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; Partridge AW, 2005, J BIOL CHEM, V280, P7294, DOI 10.1074/jbc.M412701200; Peterson JA, 2003, BLOOD, V101, P937, DOI 10.1182/blood-2002-07-2336; Shattil SJ, 2004, BLOOD, V104, P1606, DOI 10.1182/blood-2004-04-1257; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tang RH, 2005, J BIOL CHEM, V280, P29208, DOI 10.1074/jbc.M503239200; Tng E, 2004, J BIOL CHEM, V279, P54334, DOI 10.1074/jbc.M407818200; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200	44	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11914	11920		10.1074/jbc.M700249200	http://dx.doi.org/10.1074/jbc.M700249200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17301049	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000245941900034
J	During, U; Ossenbuhl, F; Wilde, A				Duehring, Ulf; Ossenbuehl, Friedrich; Wilde, Annegret			Late assembly steps and dynamics of the cyanobacterial photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP; CHLAMYDOMONAS-REINHARDTII; TARGETED INACTIVATION; STRUCTURAL ORGANIZATION; PROTEIN COMPLEXES; DEFICIENT MUTANT; MEMBRANE-PROTEIN; SUBUNIT; PLASTOCYANIN; ARABIDOPSIS	The dynamics of photosystem I assembly in cyanobacteria have been addressed using in vivo pulse-chase labeling of Synechocystis sp. PCC 6803 proteins in combination with blue native polyacrylamide gel electrophoresis. The analyses indicate the existence of three different monomeric photosystem I complexes and also the high stability of photosystem I trimers. We show that in addition to a complete photosystem I monomer, containing all 11 subunits, we detected a PsaK-less monomer and a short-lived PsaL/PsaK-less complex. The latter two monomers were missing in the ycf37 mutant of Synechocystis sp. PCC 6803 that accumulates also less trimers. Pulse-chase experiments suggest that the three monomeric complexes have different functions in the biogenesis of the trimer. Based on these findings we propose a model where PsaK is incorporated in the latest step of photosystem I assembly. The PsaK-less photosystem I monomer may represent an intermediate complex that is important for the exchange of the two PsaK variants during high light acclimation. Implications of the presented data with respect to Ycf37 function are discussed.	Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; Univ Ulm, Dept Mol Bot, D-89069 Ulm, Germany	Humboldt University of Berlin; Ulm University	Wilde, A (corresponding author), Humboldt Univ, Inst Biol Biochem Pflanzen, Chausseestr 117, D-10115 Berlin, Germany.	Annegret.Wilde@rz.hu-berlin.de						Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; CLARKE AK, 1993, P NATL ACAD SCI USA, V90, P9973, DOI 10.1073/pnas.90.21.9973; DUEHRING U, 2005, P 13 INT C PHOT, P802; DUEHRING U, 2006, BIOCHIM BIOPHYS ACTA, V1757, P3; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; Fromme P, 2004, PHOTOSYNTH RES, V80, P109, DOI 10.1023/B:PRES.0000030657.88242.e1; Fujimori T, 2005, J BIOL CHEM, V280, P22191, DOI 10.1074/jbc.M500369200; Giacomelli L, 2006, PLANT PHYSIOL, V141, P685, DOI 10.1104/pp.106.080150; Grotjohann I, 2005, PHOTOSYNTH RES, V85, P51, DOI 10.1007/s11120-005-1440-4; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; Hippler M, 2002, PROTIST, V153, P197, DOI 10.1078/1434-4610-00098; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jensen PE, 2003, PHYSIOL PLANTARUM, V119, P313, DOI 10.1034/j.1399-3054.2003.00157.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Karapetyan NV, 1999, FEBS LETT, V460, P395, DOI 10.1016/S0014-5793(99)01352-6; Khrouchtchova A, 2005, FEBS LETT, V579, P4808, DOI 10.1016/j.febslet.2005.07.061; Klinkert B, 2004, J BIOL CHEM, V279, P44639, DOI 10.1074/jbc.M405393200; Komenda J, 2004, J BIOL CHEM, V279, P48620, DOI 10.1074/jbc.M405725200; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Naithani S, 2000, PHOTOSYNTH RES, V63, P225, DOI 10.1023/A:1006463932538; Naver H, 2001, PLANT CELL, V13, P2731, DOI 10.1105/tpc.010253; Nishiyama Y, 2006, BBA-BIOENERGETICS, V1757, P742, DOI 10.1016/j.bbabio.2006.05.013; Ossenbuhl F, 2006, PLANT CELL, V18, P2236, DOI 10.1105/tpc.106.043646; Ossenbuhl F, 2004, PLANT CELL, V16, P1790, DOI 10.1105/tpc.023226; RIPPKA R, 1979, J GEN MICROBIOL, V11, P419; Rochaix JD, 2004, BIOCHEM SOC T, V32, P567, DOI 10.1042/BST0320567; Rochaix JD, 2002, FEBS LETT, V529, P34, DOI 10.1016/S0014-5793(02)03181-2; Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Setif P, 2002, BBA-BIOENERGETICS, V1555, P204, DOI 10.1016/S0005-2728(02)00279-7; Stockel J, 2006, PLANT PHYSIOL, V141, P870, DOI 10.1104/pp.106.078147; Varotto C, 2002, PLANT PHYSIOL, V129, P616, DOI 10.1104/pp.002089; Wilde A, 2001, BIOCHEM J, V357, P211, DOI 10.1042/0264-6021:3570211; WILDE A, 1995, PLANT CELL, V7, P649, DOI 10.1105/tpc.7.5.649; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU Q, 1995, PLANT PHYSIOL, V108, P1067, DOI 10.1104/pp.108.3.1067; Xu W, 2001, BBA-BIOENERGETICS, V1507, P32, DOI 10.1016/S0005-2728(01)00208-0; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898; Zygadlo A, 2005, BBA-BIOENERGETICS, V1708, P154, DOI 10.1016/j.bbabio.2005.02.003	46	37	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10915	10921		10.1074/jbc.M609206200	http://dx.doi.org/10.1074/jbc.M609206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303568	hybrid			2022-12-27	WOS:000245941500011
J	Fang, DX; Hawke, D; Zheng, YH; Xia, Y; Meisenhelder, J; Nika, H; Mills, GB; Kobayashi, R; Hunter, T; Lu, ZM				Fang, Dexing; Hawke, David; Zheng, Yanhua; Xia, Yan; Meisenhelder, Jill; Nika, Heinz; Mills, Gordon B.; Kobayashi, Ryuji; Hunter, Tony; Lu, Zhimin			Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; WNT SIGNALING PATHWAY; CELL-MIGRATION; HEPATOCELLULAR CARCINOMAS; TUMOR-FORMATION; E-CADHERIN; CYCLIN D1; EXON 3; CANCER	Increased transcriptional activity of beta-catenin resulting from Wnt/Wingless-dependent or -independent signaling has been detected in many types of human cancer, but the underlying mechanism of Wnt-independent regulation is poorly understood. We have demonstrated that AKT, which is activated downstream from epidermal growth factor receptor signaling, phosphorylates beta-catenin at Ser(552) in vitro and in vivo. AKT-mediated phosphorylation of beta-catenin causes its disassociation from cell-cell contacts and accumulation in both the cytosol and the nucleus and enhances its interaction with 14-3-3 zeta via a binding motif containing Ser(552). Phosphorylation of beta-catenin by AKT increases its transcriptional activity and promotes tumor cell invasion, indicating that AKT-dependent regulation of beta-catenin plays a critical role in tumor invasion and development.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA; Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Salk Institute	Lu, ZM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zhiminlu@mdanderson.org	yang, zheng/HGC-7753-2022		NCI NIH HHS [CA82683, P30 CA016672, R01 CA082683, R01 CA109035, CA55418, 1R01CA109035-01A1, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA055418, R01CA082683, R43CA055418, R01CA109035, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Ashihara Koji, 2002, Medical Electron Microscopy, V35, P9, DOI 10.1007/s007950200001; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Howe LR, 2003, CANCER RES, V63, P1906; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ihara A, 1996, HEPATOLOGY, V23, P1441, DOI 10.1053/jhep.1996.v23.pm0008675162; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Johnson JL, 2005, TRAFFIC, V6, P667, DOI 10.1111/j.1600-0854.2005.00308.x; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lu ZM, 2004, CELL CYCLE, V3, P571; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Meng Q, 2006, CELL SIGNAL, V18, P2262, DOI 10.1016/j.cellsig.2006.05.019; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Polakis P, 2000, GENE DEV, V14, P1837; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Semplici F, 2002, ONCOGENE, V21, P3978, DOI 10.1038/sj.onc.1205574; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song DH, 2003, J BIOL CHEM, V278, P24018, DOI 10.1074/jbc.M212260200; Stambolic V, 2006, TRENDS CELL BIOL, V16, P461, DOI 10.1016/j.tcb.2006.07.001; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian Q, 2004, P NATL ACAD SCI USA, V101, P15370, DOI 10.1073/pnas.0406499101; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200	72	656	678	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11221	11229		10.1074/jbc.M611871200	http://dx.doi.org/10.1074/jbc.M611871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17287208	hybrid, Green Accepted			2022-12-27	WOS:000245941500044
J	Jousset, H; Frieden, M; Demaurex, N				Jousset, Helene; Frieden, Maud; Demaurex, Nicolas			STIM1 knockdown reveals that store-operated Ca2+ channels located close to sarco/endoplasmic Ca2+ ATPases (SERCA) pumps silently refill the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CRAC CHANNELS; CALCIUM ENTRY; ACINAR-CELLS; MITOCHONDRIA; DEPLETION; ORAI1; SENSOR; HOMEOSTASIS; REGIONS	Stromal interaction molecule ( STIM) proteins are putative ER Ca2+ sensors that recruit and activate store-operated Ca2+ ( SOC) channels at the plasma membrane, a process triggered by the Ca2+ depletion of the endoplasmic reticulum ( ER). To test whether STIM1 is required for ER refilling, we used RNA interference and measured Ca2+ signals in the cytosol, the ER, and the mitochondria of HeLa cells. Knockdown of STIM1 ( mRNA levels, 73%) reducedSOCentry by 73% when sarco/ endoplasmic Ca2+ ATPases ( SERCA) were inhibited by thapsigargin but did not prevent Ca2+ stores refilling when cells were stimulated by physiological agonists. Stores could be fully refilled by increasing the external Ca2+ concentration above physiological values, but no cytosolic Ca2+ signals were detected during store refilling even at very high Ca2+ concentrations. [Ca2+](ER) measurements revealed that the basal activity of SERCA was not affected in STIM1 knockdown cells and that [ Ca2+](ER) levels were restored within 2 min in physiological saline following store depletion. Mitochondrial inhibitors reduced ER refilling in wild- type but not in STIM1 knockdown cells, indicating that ER refilling does not require functional mitochondria at low STIM1 levels. Our data show that ER refilling is largely preserved at reduced STIM1 levels, despite a drastic reduction of store- operated Ca2+ entry, because Ca2+ ions are directly transferred from SOC channels to SERCA. These findings are consistent with the formation of microdomains containing not only SOC channels on the plasma membrane and STIM proteins on the ER but also SERCA pumps and mitochondria to refill the ER without perturbing the cytosol.	Univ Geneva, Sch Med, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland	University of Geneva	Demaurex, N (corresponding author), Univ Geneva, Sch Med, Dept Cell Physiol & Metab, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.	Nicolas.Demaurex@medecine.unige.ch		Frieden, Maud/0000-0001-7135-0874; Demaurex, Nicolas/0000-0002-9933-6772				Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; BYRON KL, 1992, J BIOL CHEM, V267, P108; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Frieden M, 2005, J BIOL CHEM, V280, P43198, DOI 10.1074/jbc.M510279200; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Lemonnier L, 2006, FASEB J, V20, P503, DOI 10.1096/fj.05-4714fje; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; Lopez JJ, 2006, J BIOL CHEM, V281, P28254, DOI 10.1074/jbc.M604272200; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Malli R, 2007, CELL CALCIUM, V41, P63, DOI 10.1016/j.ceca.2006.05.001; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Montalvo GB, 2006, J BIOL CHEM, V281, P35616, DOI 10.1074/jbc.M603518200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Yan XH, 2006, J GEN PHYSIOL, V128, P443, DOI 10.1085/jgp.200609611; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; ZHANG SL, 2006, P NATL ACAD SCI US; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	33	115	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11456	11464		10.1074/jbc.M609551200	http://dx.doi.org/10.1074/jbc.M609551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17283081	hybrid			2022-12-27	WOS:000245941500067
J	McGinness, KE; Bolon, DN; Kaganovich, M; Baker, TA; Sauer, RT				McGinness, Kathleen E.; Bolon, Daniel N.; Kaganovich, Mark; Baker, Tania A.; Sauer, Robert T.			Altered tethering of the SspB adaptor to the ClpXP protease causes changes in substrate delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY-ENHANCING FACTOR; ZINC-BINDING DOMAIN; AAA PLUS PROTEASE; DEGRADATION MACHINE; STRUCTURAL BASIS; RECOGNITION; DESIGN; CHAPERONE; PROTEINS; ATP	SspB is a dimeric adaptor protein that increases the rate at which ssrA-tagged substrates are degraded by tethering them to the ClpXP protease. Each SspB subunit consists of a folded domain that forms the dimer interface and a flexible C-terminal tail. Ternary delivery complexes are stabilized by three sets of tethering interactions. The C-terminal XB peptide of each SspB subunit binds ClpX, the body of SspB binds one part of the ssrA-tag sequence, and ClpX binds another part of the tag. To test the functional importance of these tethering interactions, we engineered monomeric SspB variants and dimeric variants with different length linkers between the SspB body and the XB peptide and employed substrates with degradation tags that bind ClpX weakly and/or contain extensions between the binding sites for SspB and ClpX. We find that monomeric SspB variants can enhance ClpXP degradation of a subset of substrates, that doubling the number of tethering interactions stimulates degradation via changes in K-m and V-max, and that major alterations in the length of the 48-residue SspB linker cause only small changes in the efficiency of substrate delivery. These results indicate that the properties of the degradation tag and the number of SspB . ClpX tethering interactions are the major factors that determine the extent to which the substrate and ClpX are engaged in ternary delivery complexes.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	bobsauer@mit.edu		Bolon, Daniel/0000-0001-5857-6676; Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892] Funding Source: Medline; NIGMS NIH HHS [R01 GM049224-16, R01 GM049224, R01 GM049224-15, GM-48224] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049224, R01GM048224] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 2006, TRENDS BIOCHEM SCI, V31, P647, DOI 10.1016/j.tibs.2006.10.006; Bolon DN, 2004, MOL CELL, V16, P343, DOI 10.1016/j.molcel.2004.10.001; Bolon DN, 2004, MOL CELL, V13, P443, DOI 10.1016/S1097-2765(04)00027-9; Burton RE, 2003, PROTEIN SCI, V12, P893, DOI 10.1110/ps.0237603; Chivers PT, 1999, PROTEIN SCI, V8, P2494, DOI 10.1110/ps.8.11.2494; Dahiyat BI, 1997, P NATL ACAD SCI USA, V94, P10172, DOI 10.1073/pnas.94.19.10172; Dahiyat BI, 1997, PROTEIN SCI, V6, P1333, DOI 10.1002/pro.5560060622; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Donaldson LW, 2003, J BIOL CHEM, V278, P48991, DOI 10.1074/jbc.M307826200; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Flynn JM, 2004, GENE DEV, V18, P2292, DOI 10.1101/gad.1240104; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hersch GL, 2004, P NATL ACAD SCI USA, V101, P12136, DOI 10.1073/pnas.0404733101; Kenniston JA, 2005, P NATL ACAD SCI USA, V102, P1390, DOI 10.1073/pnas.0409634102; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 2003, MOL CELL, V12, P365, DOI 10.1016/j.molcel.2003.08.014; Marshall SA, 2002, J MOL BIOL, V316, P189, DOI 10.1006/jmbi.2001.5326; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; McGinness KE, 2006, MOL CELL, V22, P701, DOI 10.1016/j.molcel.2006.04.027; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Park EY, 2007, J MOL BIOL, V367, P514, DOI 10.1016/j.jmb.2007.01.003; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; Song HK, 2003, MOL CELL, V12, P75, DOI 10.1016/S1097-2765(03)00271-5; Thibault G, 2006, EMBO J, V25, P3367, DOI 10.1038/sj.emboj.7601223; Wah DA, 2003, MOL CELL, V12, P355, DOI 10.1016/S1097-2765(03)00272-7	34	24	24	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11465	11473		10.1074/jbc.M610671200	http://dx.doi.org/10.1074/jbc.M610671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17317664	hybrid			2022-12-27	WOS:000245941500068
J	Tailford, LE; Money, VA; Smith, NL; Dumon, C; Davies, GJ; Gilbert, HJ				Tailford, Louise E.; Money, Victoria A.; Smith, Nicola L.; Dumon, Claire; Davies, Gideon J.; Gilbert, Harry J.			Mannose foraging by Bacteroides thetaiotaomicron - Structure and specificity of the beta-mannosidase, BtMan2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENT CONFORMATIONAL ITINERARIES; CARBOHYDRATE-BINDING MODULES; GLYCOSIDE HYDROLASE FAMILY-5; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; SUBSTRATE-SPECIFICITY; MANNANASE; XYLANASES; CLASSIFICATION; GALACTOSIDASE	The human colonic bacterium Bacteroides thetaiotaomicron, which plays an important role in maintaining human health, produces an extensive array of exo-acting glycoside hydrolases ( GH), including 32 family GH2 glycoside hydrolases. Although it is likely that these enzymes enable the organism to utilize dietary and host glycans as major nutrient sources, the biochemical properties of these GH2 glycoside hydrolases are currently unclear. Here we report the biochemical properties and crystal structure of the GH2 B. thetaiotaomicron enzyme BtMan2A. Kinetic analysis demonstrates that BtMan2A is a beta-mannosidase in which substrate binding energy is provided principally by the glycone binding site, whereas aglycone recognition is highly plastic. The three-dimensional structure, determined to a resolution of 1.7 angstrom, reveals a five-domain structure that is globally similar to the Escherichia coli LacZ beta-galactosidase. The catalytic center is housed mainly within a ( beta/alpha)(8) barrel although the N-terminal domain also contributes to the active site topology. The nature of the substrate-binding residues is quite distinct from other GH2 enzymes of known structure, instead they are similar to other clan GH-A enzymes specific for manno-configured substrates. Mutagenesis studies, informed by the crystal structure, identified a WDW motif in the N-terminal domain that makes a significant contribution to catalytic activity. The observation that this motif is invariant in GH2 mannosidases points to a generic role for these residues in this enzyme class. The identification of GH-A clan and GH2 specific residues in the active site of BtMan2A explains why this enzyme is able to harness substrate binding at the proximal glycone binding site more efficiently than mannan-hydrolyzing glycoside hydrolases in related enzyme families. The catalytic properties of BtMan2A are consistent with the flexible nutrient acquisition displayed by the colonic bacterium.	Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England	Newcastle University - UK; University of York - UK	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	h.j.gilbert@ncl.ac.uk	Money, Victoria/E-8851-2013; Claire, Dumon/AAI-2553-2021; Davies, Gideon J/A-9042-2011	Claire, Dumon/0000-0003-4925-7336; Davies, Gideon J/0000-0002-7343-776X	Biotechnology and Biological Sciences Research Council [BBS/B/05974] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andrews SR, 2004, J BIOL CHEM, V279, P54369, DOI 10.1074/jbc.M409044200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Bourgault R, 2005, PROTEIN SCI, V14, P1233, DOI 10.1110/ps.041260905; Brett CT, 1996, PHYSL BIOCH PLANT CE; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; COUGLAN MP, 1985, BIOTECHNOL GENET ENG, P1; COWTANKD, 1996, ACTA CRYSTALLOGR D, V49, P148; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Dias FMV, 2004, J BIOL CHEM, V279, P25517, DOI 10.1074/jbc.M401647200; Ducros VMA, 2002, ANGEW CHEM INT EDIT, V41, P2824, DOI 10.1002/1521-3773(20020802)41:15<2824::AID-ANIE2824>3.0.CO;2-G; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FONTES CMGA, 1995, APPL MICROBIOL BIOT, V43, P52, DOI 10.1007/BF00170622; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; Hill J, 2006, P NATL ACAD SCI USA, V103, P11206, DOI 10.1073/pnas.0604600103; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Hogg D, 2001, J BIOL CHEM, V276, P31186, DOI 10.1074/jbc.M010290200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsson AM, 2006, J MOL BIOL, V357, P1500, DOI 10.1016/j.jmb.2006.01.044; Le Nours K, 2005, BIOCHEMISTRY-US, V44, P12700, DOI 10.1021/bi050779v; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, P1; Lillelund VH, 2003, ORG BIOMOL CHEM, V1, P282, DOI 10.1039/b208784g; Money VA, 2006, ANGEW CHEM INT EDIT, V45, P5136, DOI 10.1002/anie.200600802; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sabini E, 2000, ACTA CRYSTALLOGR D, V56, P3, DOI 10.1107/S0907444999013943; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Skalova T, 2005, J MOL BIOL, V353, P282, DOI 10.1016/j.jmb.2005.08.028; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; Stoll D, 2000, BIOCHEM J, V351, P833, DOI 10.1042/0264-6021:3510833; Vincent F, 2004, CHEMBIOCHEM, V5, P1596, DOI 10.1002/cbic.200400169; VOCADLO DJ, 2000, GLYCOSIDASE CATALYZE; Wen X, 2005, BIOCHEMISTRY-US, V44, P6729, DOI 10.1021/bi0500426; Williams SJ, 2000, J AM CHEM SOC, V122, P4229, DOI 10.1021/ja0002870; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; Zechel DL, 2003, BIOCHEMISTRY-US, V42, P7195, DOI 10.1021/bi034329j	46	57	57	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11291	11299		10.1074/jbc.M610964200	http://dx.doi.org/10.1074/jbc.M610964200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17287210	hybrid			2022-12-27	WOS:000245941500051
J	Tapley, TL; Eichner, T; Gleiter, S; Ballou, DP; Bardwell, JCA				Tapley, Timothy L.; Eichner, Timo; Gleiter, Stefan; Ballou, David P.; Bardwell, James C. A.			Kinetic characterization of the disulfide bond-forming enzyme DsbB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGE-TRANSFER COMPLEX; ESCHERICHIA-COLI; RESPIRATORY-CHAIN; FORMATION PATHWAY; REDOX POTENTIALS; DE-NOVO; PROTEIN; UBIQUINONE; CYSTEINES; MECHANISM	DsbB is an integral membrane protein responsible for the de novo synthesis of disulfide bonds in Escherichia coli and many other prokaryotes. In the process of transferring electrons from DsbA to a tightly bound ubiquinone cofactor, DsbB undergoes an unusual spectral transition at similar to 510 nm. We have utilized this spectral transition to study the kinetic cycle of DsbB in detail using stopped flow methods. We show that upon mixing of Dsb-B-ox and DsbA(red), there is a rapid increase in absorbance at 510 nm ( giving rise to a purple solution), followed by two slower decay phases. The rate of the initial phase is highly dependent upon DsbA concentration (k(1) similar to 5 similar to 10(5) M-1 s(-1)), suggesting this phase reflects the rate of DsbA binding. The rates of the subsequent decay phases are independent of DsbA concentration (k(2) similar to 2 s(-1); k(3) similar to 0.3 s(-1)), indicative of intramolecular reaction steps. Absorbance measurements at 275 nm suggest that k2 and k3 are associated with steps of quinone reduction. The rate of DsbA oxidation was found to be the same as the rate of quinone reduction, suggestive of a highly concerted reaction. The concerted nature of the reaction may explain why previous efforts to dissect the reaction mechanism of DsbB by examining individual pairs of cysteines yielded seemingly paradoxical results. Order of mixing experiments showed that the quinone must be pre-bound to DsbB to observe the purple intermediate as well as for efficient quinone reduction. These results are consistent with a kinetic model for DsbB action in which DsbA binding is followed by a rapid disulfide exchange event. This is followed by quinone reduction, which is rate-limiting in the overall reaction cycle.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	dballou@umich.edu, David P/A-1298-2007					Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; GENNIS RB, 1996, ESCHERICHIA COLI SAL, P222; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; Graige MS, 1998, P NATL ACAD SCI USA, V95, P11679, DOI 10.1073/pnas.95.20.11679; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Hennecke J, 1997, BIOCHEMISTRY-US, V36, P6391, DOI 10.1021/bi963017w; Inaba K, 2006, P NATL ACAD SCI USA, V103, P287, DOI 10.1073/pnas.0507570103; Inaba K, 2005, J BIOL CHEM, V280, P33035, DOI 10.1074/jbc.M506189200; Inaba K, 2004, J BIOL CHEM, V279, P6761, DOI 10.1074/jbc.M310765200; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; Inaba K, 2006, CELL, V127, P789, DOI 10.1016/j.cell.2006.10.034; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kadokura H, 2002, EMBO J, V21, P2354, DOI 10.1093/emboj/21.10.2354; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Nakamoto H, 2004, BBA-MOL CELL RES, V1694, P111, DOI 10.1016/j.bbamcr.2004.02.012; Regeimbal J, 2003, P NATL ACAD SCI USA, V100, P13779, DOI 10.1073/pnas.1935988100; Regeimbal J, 2002, J BIOL CHEM, V277, P32706, DOI 10.1074/jbc.M205433200; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Takahashi YH, 2004, J BIOL CHEM, V279, P47057, DOI 10.1074/jbc.M407153200; URBAN PF, 1969, EUR J BIOCHEM, V9, P519, DOI 10.1111/j.1432-1033.1969.tb00640.x; WAGNER GC, 1974, P NATL ACAD SCI USA, V71, P253, DOI 10.1073/pnas.71.2.253; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	31	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10263	10271		10.1074/jbc.M611541200	http://dx.doi.org/10.1074/jbc.M611541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17267399	hybrid			2022-12-27	WOS:000245941000016
J	Sun, YP; Oh, SF; Uddin, J; Yang, R; Gotlinger, K; Campbell, E; Colgan, SP; Petasis, NA; Serhan, CN				Sun, Yee-Ping; Oh, Sungwhan F.; Uddin, Jasim; Yang, Rong; Gotlinger, Katherine; Campbell, Eric; Colgan, Sean P.; Petasis, Nicos A.; Serhan, Charles N.			Resolvin D1 and its aspirin-triggered 17R epimer - Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOCOSAHEXAENOIC ACID; LIPOXIN A(4); FATTY-ACIDS; RESOLUTION; BRAIN; CELLS; TRANSMIGRATION; INFLAMMATION; METABOLISM; LEUKOCYTES	We recently uncovered two new families of potent docosahexaenoic acid-derived mediators, termed D series resolvins (Rv; resolution phase interaction products) and protectins. Here, we assign the stereochemistry of the conjugated double bonds and chirality of alcohols present in resolvin D1 (RvD1) and its aspirin-triggered 17R epimer (AT-RvDl) with compounds prepared by total organic synthesis. In addition, docosahexaenoic acid was converted by a single lipoxygenase in a "one-pot" reaction to RvD1 in vitro. The synthetic compounds matched the physical and biological properties of those enzymatically generated. RvD1 proved to be 7S,8R,17S-trihydroxy4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid, AT-RvD1 matched 7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid, and they both stopped transendothelial migration of human neutrophils (EC50 similar to 30 nm). In murine peritonitis in vivo, RvD1 and AT-RvD1 proved equipotent (at nanogram dosages), limiting polymorphonuclear leukocyte infiltration in a dose-dependent fashion. RvD1 was converted by eicosanoid oxidoreductase to novel 8-oxo- and 17-oxo-RvD1 that gave dramatically reduced bioactivity, whereas enzymatic conversion of AT-RvD1 was sharply reduced. These results establish the complete stereochemistry and actions of RvD1 and AT-RvDl as well as demonstrate the stereoselective basis for their enzymatic inactivation. RvD1 regulates human polymorphonuclear leukocyte transendothelial migration and is antiinflammatory. When its carbon 17S alcohol is enzymatically converted to 17-oxo-RvD1, it is essentially inactive, whereas the 17R alcohol configuration in its aspirin-triggered form (ATRvD1) resists rapid inactivation. These results maycontribute to the beneficial actions of aspirin and omega-3 fish oils in humans.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ So Calif, Dept Chem, Loker Hydrocarbon Res Inst, Los Angeles, CA 90089 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; University of Southern California	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Yang, Rong/ABA-7587-2021; Colgan, Sean P./B-4573-2009; Petasis, Nicos/B-3162-2009; Campbell, Eric/N-5357-2015	Petasis, Nicos/0000-0002-8864-4446; Campbell, Eric/0000-0003-0744-6577; Yang, Rong/0000-0001-8837-0089	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074448] Funding Source: NIH RePORTER; NIDCR NIH HHS [P50-DE16191] Funding Source: Medline; NIDDK NIH HHS [DK074448] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert CM, 2002, NEW ENGL J MED, V346, P1113, DOI 10.1056/NEJMoa012918; BANG HO, 1976, ACTA MED SCAND, V200, P69; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Bazan N. G., 1990, NUTR BRAIN, V8, P1; Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; BERGHOLTE JM, 1987, ARCH BIOCHEM BIOPHYS, V257, P444, DOI 10.1016/0003-9861(87)90589-3; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; Burr GO, 1929, J BIOL CHEM, V82, P345; Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; Collard CD, 2002, J BIOL CHEM, V277, P14801, DOI 10.1074/jbc.M110557200; COREY EJ, 1986, TETRAHEDRON LETT, V27, P5173, DOI 10.1016/S0040-4039(00)85161-8; Gallin J.I., 1999, INFLAMMATION BASIC P; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Hong S, 2005, PROSTAG OTH LIPID M, V78, P107, DOI 10.1016/j.prostaglandins.2005.04.004; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Lawrence DW, 2003, J EXP MED, V198, P999, DOI 10.1084/jem.20030380; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Lu Y, 2005, J LIPID RES, V46, P790, DOI 10.1194/jlr.D400020-JLR200; Lu Y, 2006, THESCIENTIFICWORLDJO, V6, P589, DOI 10.1100/tsw.2006.118; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; Majno G., 2004, CELLS TISSUES DIS PR; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Perretti Mauro, 2003, Methods Mol Biol, V225, P139; ROBINSON KA, 1995, ANGIOLOGY, V46, P107, DOI 10.1177/000331979504600203; Rodriguez AR, 2004, TETRAHEDRON LETT, V45, P8717, DOI 10.1016/j.tetlet.2004.09.129; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Schwarz K, 1998, BIOCHEMISTRY-US, V37, P15327, DOI 10.1021/bi9816204; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; SERHAN CN, 1990, METHOD ENZYMOL, V187, P167; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SERHAN CN, 2004, Patent No. 20040116408; SERHAN CN, 2003, Patent No. 6670396; Simopoulos AP, 1999, AM J CLIN NUTR, V70, p560S, DOI 10.1093/ajcn/70.3.560s; Tai HH, 2002, PROSTAG OTH LIPID M, V68-9, P483, DOI 10.1016/S0090-6980(02)00050-3; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5	43	385	397	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9323	9334		10.1074/jbc.M609212200	http://dx.doi.org/10.1074/jbc.M609212200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244615	hybrid, Green Published			2022-12-27	WOS:000245421700004
J	Elter, A; Hartel, A; Sieben, C; Hertel, B; Fischer-Schliebs, E; Luttge, U; Moroni, A; Thiel, G				Elter, Astrid; Hartel, Andreas; Sieben, Christian; Hertel, Brigitte; Fischer-Schliebs, Elke; Luttge, Ulrich; Moroni, Anna; Thiel, Gerhard			A plant homolog of animal chloride intracellular channels (CLICs) generates an ion conductance in heterologous systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE TRANSFERASE; FUNCTIONAL-CHARACTERIZATION; FAMILY; PROTEIN; NCC27; CELLS; IDENTIFICATION; ARABIDOPSIS; EXPRESSION; ACTIN	The genome of Arabidopsis thaliana contains unusual members of the glutathione S-transferase (GST) superfamily with a cysteine in place of a serine at the active site. Four of these genes (at-dhar 1-4) have an appreciable homology to intracellular Cl- channels (CLICs) from vertebrates and invertebrates. Transient expression of AtDHAR1 as wild type protein or as a chimera with GFP in mammalian HEK293 or Chinese hamster ovary cells generated a distinct inward rectifying conductance with a characteristic biphasic kinetics but no apparent ion selectivity. Analysis of the subcellular localization of AtDHRA1::GFP showed that the bulk of the protein was located as soluble form in the cytoplasm; however, an appreciable fraction of it could also be found in association with the non-soluble microsomal fraction. These data suggest that plant members of the GST superfamily have similar to those from animals multiple functions. The increase of ion conductance by AtDHAR1 is better explained by a CLIC-like channel activity than by a modification of endogenous channel proteins.	Tech Univ Darmstadt, Inst Bot, D-64287 Darmstadt, Germany; Univ Milan, Dipartimento Biol, I-20133 Milan, Italy; Univ Milan, CNR, IBF, I-20133 Milan, Italy; Univ Milan, INFM Unita, I-20133 Milan, Italy	Technical University of Darmstadt; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Milan; University of Milan	Thiel, G (corresponding author), Tech Univ Darmstadt, Inst Bot, D-64287 Darmstadt, Germany.	thiel@bio.tu-darmstadt.de	moroni, anna/H-2097-2014; Sieben, Christian/Z-6050-2019	moroni, anna/0000-0002-1860-406X; Sieben, Christian/0000-0002-2836-2623; Hartel, Andreas/0000-0002-2693-4472; Thiel, Gerhard/0000-0002-2335-1351				Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746; Barbier-Brygoo H, 2000, BBA-BIOMEMBRANES, V1465, P199, DOI 10.1016/S0005-2736(00)00139-5; Berry KL, 2006, J MOL BIOL, V359, P1316, DOI 10.1016/j.jmb.2006.04.046; Berry KL, 2003, SCIENCE, V302, P2134, DOI 10.1126/science.1087667; Berryman M, 2004, J BIOL CHEM, V279, P34794, DOI 10.1074/jbc.M402835200; Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Cromer BA, 2002, EUR BIOPHYS J BIOPHY, V31, P356, DOI 10.1007/s00249-002-0219-1; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Edwards R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Littler DR, 2004, J BIOL CHEM, V279, P9298, DOI 10.1074/jbc.M308444200; Moroni A, 2002, FEBS LETT, V530, P65, DOI 10.1016/S0014-5793(02)03397-5; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Sakmann B., 1985, SINGLE CHANNEL RECOR, P37; Singh H, 2006, BIOPHYS J, V90, P1628, DOI 10.1529/biophysj.105.072678; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Warton K, 2002, J BIOL CHEM, V277, P26003, DOI 10.1074/jbc.M203666200	25	27	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8786	8792		10.1074/jbc.M607241200	http://dx.doi.org/10.1074/jbc.M607241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17267397	hybrid			2022-12-27	WOS:000245780300025
J	Kim, SJ; Nian, C; McIntosh, CHS				Kim, Su-Jin; Nian, Cuilan; McIntosh, Christopher H. S.			Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes - A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; RAT ADIPOSE-TISSUE; 3T3-L1 ADIPOCYTES; BETA-CELL; PEPTIDE RECEPTOR; GLUCAGON; PHOSPHORYLATION; GIP; EXPRESSION; METABOLISM	Glucose-dependent insulinotropic polypeptide (GIP) has been mainly studied because of its glucose-dependent insulinotropic action and its ability to regulate beta-cell proliferation and survival. Considerably less is known about the effects of GIP on fat metabolism, and the present study was directed at identifying the mechanisms underlying its stimulatory action on lipoprotein lipase (LPL). In differentiated 3T3-L1 adipocytes, GIP, in the presence of insulin, increased LPL activity and triglyceride accumulation through a pathway involving increased phosphorylation of protein kinase B (PKB) and reductions in phosphorylated LKB1 and AMP-activated protein kinase (AMPK). Knockdown of AMPK using RNA interference and application of the AMPK inhibitor, Compound C, supported this conclusion. In contrast, the other major incretin hormone, glucagon-like peptide-1, exhibited no significant effects on LPL activity or PKB, LKB1, or AMPK phosphorylation. Cultured subcutaneous human adipocytes showed similar responses to GIP but with greater sensitivity. Chronic elevation of circulating GIP levels in the Vancouver diabetic fatty Zucker rat in vivo resulted in increased LPL activity and elevated triglyceride accumulation in epidydimal fat tissue, combined with a modulation of PKB, LKB1, and AMPK phosphorylation similar to that observed in vitro. This appears to be the first demonstration of a GIP-stimulated signal transduction pathway involved in increasing fat storage in adipocytes.	Univ British Columbia, Dept Cellular & Physiol Sci, Diabet Res Grp, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	McIntosh, CHS (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Diabet Res Grp, Inst Life Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; An D, 2005, AM J PHYSIOL-ENDOC M, V288, pE246, DOI 10.1152/ajpendo.00211.2004; BECK B, 1983, REGUL PEPTIDES, V7, P3, DOI 10.1016/0167-0115(83)90276-8; BERBO M, 2002, J BIOL CHEM, V277, P11927; BRAUN JEA, 1992, BIOCHEM J, V287, P337, DOI 10.1042/bj2870337; BROWN JC, 1989, HDB PHYSL 6, P403; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Carling D, 2006, TRENDS MOL MED, V12, P144, DOI 10.1016/j.molmed.2006.02.003; Daval M, 2005, J BIOL CHEM, V280, P25250, DOI 10.1074/jbc.M414222200; Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484; Drucker DJ, 2003, ENDOCRINOLOGY, V144, P5145, DOI 10.1210/en.2003-1147; DUPRE J, 1976, METABOLISM, V25, P1197, DOI 10.1016/S0026-0495(76)80002-9; ECKEL RH, 1981, INT J OBESITY, V5, P571; ECKEL RH, 1979, DIABETES, V28, P1141, DOI 10.2337/diabetes.28.12.1141; Ehses JA, 2003, ENDOCRINOLOGY, V144, P4433, DOI 10.1210/en.2002-0068; Ehses JA, 2002, J BIOL CHEM, V277, P37088, DOI 10.1074/jbc.M205055200; Ehses JA, 2001, J BIOL CHEM, V276, P23667, DOI 10.1074/jbc.M103023200; Fediuc S, 2006, J LIPID RES, V47, P412, DOI 10.1194/jlr.M500438-JLR200; Goldberg IJ, 1996, J LIPID RES, V37, P693; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; Hurley RL, 2006, J BIOL CHEM, V281, P36662, DOI 10.1074/jbc.M606676200; Kim SJ, 2005, J BIOL CHEM, V280, P22297, DOI 10.1074/jbc.M500540200; KIM WH, 2006, IN PRESS CELL SIGNAL; King TD, 2006, BIOCHEM PHARMACOL, V71, P1637, DOI 10.1016/j.bcp.2006.03.005; KNAPPER JME, 1995, J NUTR, V125, P183; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; McIntosh CHS, 1999, ENDOCRINOLOGY, V140, P398, DOI 10.1210/en.140.1.398; Meier JJ, 2005, DIABETES-METAB RES, V21, P91, DOI 10.1002/dmrr.538; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; MontroseRafizadeh C, 1997, J CELL PHYSIOL, V172, P275, DOI 10.1002/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L; Morgan LM, 1996, BIOCHEM SOC T, V24, P585, DOI 10.1042/bst0240585; OBEN J, 1991, J ENDOCRINOL, V130, P267, DOI 10.1677/joe.0.1300267; OHNEDA A, 1984, REGUL PEPTIDES, V8, P123, DOI 10.1016/0167-0115(84)90167-8; Pederson RA, 1993, GUT PEPTIDES, P217; PEDERSON RA, 2004, ENCY ENDOCRINE DIS, V2, P202; Pospisilik JA, 2002, DIABETES, V51, P943, DOI 10.2337/diabetes.51.4.943; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Sambandam N, 1999, ARTERIOSCL THROM VAS, V19, P1526, DOI 10.1161/01.ATV.19.6.1526; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; Sponarova J, 2005, FEBS LETT, V579, P6105, DOI 10.1016/j.febslet.2005.09.078; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WASADA T, 1981, J CLIN INVEST, V68, P1106, DOI 10.1172/JCI110335; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yip RGC, 1998, ENDOCRINOLOGY, V139, P4004, DOI 10.1210/en.139.9.4004; Yip RGC, 1999, LIFE SCI, V66, P91, DOI 10.1016/S0024-3205(99)00314-8; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	56	142	156	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8557	8567		10.1074/jbc.M609088200	http://dx.doi.org/10.1074/jbc.M609088200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244606	hybrid			2022-12-27	WOS:000245780300001
J	Oo, ML; Thangada, S; Wu, MT; Liu, CH; Macdonald, TL; Lynch, KR; Lin, CY; Hla, T				Oo, Myat Lin; Thangada, Shobha; Wu, Ming-Tao; Liu, Catherine H.; Macdonald, Timothy L.; Lynch, Kevin R.; Lin, Chen-Yong; Hla, Timothy			Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubipuitinylation and proteasomal degradation of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EXTRACELLULAR EXPORT; VASCULAR MATURATION; LYMPHOCYTE EGRESS; CELL-MIGRATION; BETA-ARRESTIN; T-CELLS; FTY720; SPHINGOSINE-1-PHOSPHATE; UBIQUITINATION	Sphingosine 1-phosphate (SIP), a multifunctional lipid mediator, regulates lymphocyte trafficking, vascular permeability, and angiogenesis by activation of the SIP1 receptor. This receptor is activated by FTY720-P, a phosphorylated derivative of the immunosuppressant and vasoactive compound FTY720. However, in contrast to the natural ligand SIP, FTY720-P appears to act as a functional antagonist, even though the mechanisms involved are poorly understood. In this study, we investigated the fate of endogenously expressed SIP1 receptor in agonist-activated human umbilical vein endothelial cells and human embryonic kidney 293 cells expressing green fluorescent protein-tagged SIP1. We show that FTY720-P is more potent than SIP at inducing receptor degradation. Pretreatment with an antagonist of S1P(1), VPC 44116, prevented receptor internalization and degradation. FTY720-P did not induce degradation of internalization-deficient SIP1 receptor mutants. Further, small interfering RNA-mediated down-regulation of G protein-coupled receptor kinase-2 and beta-arrestins abolished FTY720-P-induced SIP1 receptor degradation. These data suggest that agonist-induced phosphorylation of SIP1 and subsequent endocytosis are required for FTY720-P-induced degradation of the receptor. S1P(1) degradation is blocked by MG132, a proteasomal inhibitor. Indeed, FTY720-P strongly induced polyubiquitinylation of SIP1 receptor, whereas SIP at concentrations that induced complete internalization was not as efficient, suggesting that receptor internalization is required but not sufficient for ubiquitinylation and degradation. We propose that the ability of FTY720-P to target the S1P(1) receptor to the ubiquitinylation and proteasomal degradation pathway may at least in part underlie its immunosuppressive and anti-angiogenic properties.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Georgetown Univ, Sch Med, Lombardi Canc Ctr, Washington, DC 20007 USA	University of Connecticut; University of Virginia; University of Virginia; Georgetown University	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA.	hla@nso2.uchc.edu	Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NATIONAL CANCER INSTITUTE [R01CA096851, R01CA104944] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL067330, P01HL070694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067958] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA104944, R01-CA096851] Funding Source: Medline; NHLBI NIH HHS [R37-HL67330, P01 HL70694] Funding Source: Medline; NIGMS NIH HHS [R01-GM67958] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Bohler T, 2005, TRANSPLANTATION, V79, P492, DOI 10.1097/012.TP.0000151773.43266.17; Bolick DT, 2005, ARTERIOSCL THROM VAS, V25, P976, DOI 10.1161/01.ATV.0000162171.30089.f6; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2004, AM J TRANSPLANT, V4, P1019, DOI 10.1111/j.1600-6143.2004.00476.x; Chae SS, 2004, J CLIN INVEST, V114, P1082, DOI 10.1172/JCI200422716; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Chun J, 2006, CURR PHARM DESIGN, V12, P161, DOI 10.2174/138161206775193109; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; Drake MT, 2006, CIRC RES, V99, P570, DOI 10.1161/01.RES.0000242563.47507.ce; Foss FW, 2007, BIOORGAN MED CHEM, V15, P663, DOI 10.1016/j.bmc.2006.10.060; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; HLA T, 1990, J BIOL CHEM, V265, P9308; Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; LaMontagne K, 2006, CANCER RES, V66, P221, DOI 10.1158/0008-5472.CAN-05-2001; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Marchese Adriano, 2004, Methods Mol Biol, V259, P299; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Paik JH, 2004, GENE DEV, V18, P2392, DOI 10.1101/gad.1227804; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Singer II, 2005, J IMMUNOL, V175, P7151, DOI 10.4049/jimmunol.175.11.7151; TANG TK, 1993, J CELL SCI, V104, P237; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; Venkataraman K, 2006, BIOCHEM J, V397, P461, DOI 10.1042/BJ20060251; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074/jbc.M110647200; Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269; Welsch CA, 2003, J BIOL CHEM, V278, P26976, DOI 10.1074/jbc.M213144200; Whetzel AM, 2006, CIRC RES, V99, P731, DOI 10.1161/01.RES.0000244088.33375.52; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Zhan B, 2005, ATHEROSCLEROSIS, V178, P199, DOI 10.1016/j.atherosclerosis.2004.08.024	49	316	337	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9082	9089		10.1074/jbc.M610318200	http://dx.doi.org/10.1074/jbc.M610318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17237497	hybrid			2022-12-27	WOS:000245780300055
J	Jeon, Y; Lee, KY; Ko, MJ; Lee, YS; Kang, S; Hwang, DS				Jeon, Yesu; Lee, Kyung Yong; Ko, Min Ji; Lee, Yong Sun; Kang, Sukhyun; Hwang, Deog Su			Human TopBP1 participates in cyclin E/CDK2 activation and preinitiation complex assembly during G(1)/S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-BINDING-PROTEIN; CELL-CYCLE; S-PHASE; DNA-REPLICATION; KINASE COMPLEX; CDK INHIBITOR; XENOPUS CUT5; CDC7; ATR; PHOSPHORYLATION	Human TopBP1 with eight BRCA1 C terminus domains has been mainly reported to be involved in DNA damage response pathways. Here we show that TopBP1 is also required for G(1) to S progression in a normal cell cycle. TopBP1 deficiency inhibited cells from entering S phase by up-regulating p21 and p27, resulting in down-regulation of cyclin E/CDK2. Although co-depletion of p21 and p27 with TopBP1 restored the cyclin E/CDK2 kinase activity, however, cells remained arrested at the G(1)/S boundary, showing defective chromatin-loading of replication components. Based on these results, we suggest a dual role of TopBP1 necessary for the G(1)/S transition: one for activating cyclin E/CDK2 kinase and the other for loading replication components onto chromatin to initiate DNA synthesis.	Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Hwang, DS (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea.	dshwang@snu.ac.kr		Kang, Sukhyun/0000-0002-7567-0231				ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Dimitrova DS, 2000, EXP CELL RES, V254, P321, DOI 10.1006/excr.1999.4770; Dolan WP, 2004, CHROMOSOMA, V113, P145, DOI 10.1007/s00412-004-0302-8; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Greer DA, 2003, CANCER RES, V63, P4829; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harris S, 2003, J CELL SCI, V116, P3519, DOI 10.1242/jcs.00677; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Hashimoto Y, 2006, GENES CELLS, V11, P993, DOI 10.1111/j.1365-2443.2006.00998.x; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Jares P, 2000, GENE DEV, V14, P1528; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2006, EMBO J, V25, P4795, DOI 10.1038/sj.emboj.7601355; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Machida YJ, 2005, J BIOL CHEM, V280, P27624, DOI 10.1074/jbc.M502615200; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Ukomadu C, 2003, J BIOL CHEM, V278, P43586, DOI 10.1074/jbc.M307194200; Uto K, 2004, EMBO J, V23, P3386, DOI 10.1038/sj.emboj.7600328; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 2003, CANCER RES, V63, P3049; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yan S, 2006, J CELL BIOL, V173, P181, DOI 10.1083/jcb.200601076; You ZS, 2002, GENE DEV, V16, P1182, DOI 10.1101/gad.985302; Zeng L, 2005, J BIOL CHEM, V280, P29374, DOI 10.1074/jbc.M503016200; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747	55	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14882	14890		10.1074/jbc.M609116200	http://dx.doi.org/10.1074/jbc.M609116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17293600	hybrid			2022-12-27	WOS:000246589000025
J	Ramon, E; Cordomi, A; Bosch, L; Zernii, EY; Senin, II; Manyosa, J; Philippov, PP; Perez, JJ; Garriga, P				Ramon, Eva; Cordomi, Arnau; Bosch, Laia; Zernii, Eugeni Yu.; Senin, Ivan I.; Manyosa, Joan; Philippov, Pavel P.; Perez, Juan J.; Garriga, Pere			Critical role of electrostatic interactions of amino acids at the cytoplasmic region of helices 3 and 6 in rhodopsin conformational properties and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; CONSTITUTIVELY ACTIVE MUTANTS; PROTEIN-COUPLED RECEPTORS; MU-OPIOID RECEPTOR; BOVINE RHODOPSIN; BETA(2)-ADRENERGIC RECEPTOR; STRUCTURAL INSTABILITY; PHOSPHOLIPID-BILAYERS; CRYSTAL-STRUCTURE; METARHODOPSIN-I	The cytoplasmic sides of transmembrane helices 3 and 6 of G-protein-coupled receptors are connected by a network of ionic interactions that play an important role in maintaining its inactive conformation. To investigate the role of such a network in rhodopsin structure and function, we have constructed single mutants at position 134 in helix 3 and at positions 247 and 251 in helix 6, as well as combinations of these to obtain double mutants involving the two helices. These mutants have been expressed in COS-1 cells, immunopurified using the rho-1D4 antibody, and studied by UV-visible spectrophotometry. Most of the single mutations did not affect chromophore formation, but double mutants, especially those involving the T251K mutant, resulted in low yield of protein and impaired 11-cisretinal binding. Single mutants E134Q, E247Q, and E247A showed the ability to activate transducin in the dark, and E134Q and E247A enhanced activation upon illumination, with regard to wild-type rhodopsin. Mutations E247A and T251A (in E134Q/E247A and E134Q/T251A double mutants) resulted in enhanced activation compared with the single E134Q mutant in the dark. A role for Thr(251) in this network is proposed for the first time in rhodopsin. As a result of these mutations, alterations in the hydrogen bond interactions between the amino acid side chains at the cytoplasmic region of transmembrane helices 3 and 6 have been observed using molecular dynamics simulations. Our combined experimental and modeling results provide new insights into the details of the structural determinants of the conformational change ensuing photoactivation of rhodopsin.	Univ Politecn Catalunya, Dept Engn Quim, Ctr Biotecnol Mol, Terrassa 08222, Catalonia, Spain; Univ Politecn Catalunya, Ctr Biotecnol Mol, Dept Engn Quim, E-08028 Barcelona, Catalonia, Spain; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Dept Cell Signalling, Moscow 119992, Russia; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Biofis, Bellaterra 08193, Catalonia, Spain; Univ Autonoma Barcelona, Ctr Estudis Biofis, Bellaterra 08193, Catalonia, Spain	Universitat Politecnica de Catalunya; Universitat Politecnica de Catalunya; Lomonosov Moscow State University; Autonomous University of Barcelona; Autonomous University of Barcelona	Garriga, P (corresponding author), Univ Politecn Catalunya, Dept Engn Quim, Ctr Biotecnol Mol, Terrassa 08222, Catalonia, Spain.	pere.garriga@upc.edu	Cordomí, Arnau/A-1686-2009; Zernii, Evgeni Yu./D-9446-2012; Philippov, Pavel P/A-8939-2012; Garriga, Pere/C-1949-2017; Bosch-Presegué, Laia/Z-1351-2019; Perez, Juan J/E-3710-2010; Cordomí, Arnau/B-5257-2008; Senin, Ivan I/D-9163-2012	Cordomí, Arnau/0000-0002-3848-2928; Zernii, Evgeni Yu./0000-0002-3013-7863; Garriga, Pere/0000-0003-4234-8382; Bosch-Presegué, Laia/0000-0001-8025-2416; Perez, Juan J/0000-0002-0748-8147; 				Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; ARNIS S, 1994, J BIOL CHEM, V269, P23879; ARORA KK, 1997, MOL ENDOCRINOL, V11, P203; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Cordomi A, 2007, J COMPUT CHEM, V28, P1017, DOI 10.1002/jcc.20579; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Fahmy K, 2000, BIOCHEMISTRY-US, V39, P10607, DOI 10.1021/bi000912d; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Flanagan CA, 2005, MOL PHARMACOL, V68, P1, DOI 10.1124/mol.105.014183; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; Greasley PJ, 2002, MOL PHARMACOL, V61, P1025, DOI 10.1124/mol.61.5.1025; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Han M, 1997, J BIOL CHEM, V272, P23081, DOI 10.1074/jbc.272.37.23081; Hayashi S, 2002, BIOPHYS J, V83, P1281, DOI 10.1016/S0006-3495(02)73900-3; Hofsass C, 2003, BIOPHYS J, V84, P2192, DOI 10.1016/S0006-3495(03)75025-5; Huang P, 2001, BIOCHEMISTRY-US, V40, P13501, DOI 10.1021/bi010917q; JANSEN JJM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P68, DOI 10.1016/0167-4781(91)90086-2; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; Kim JM, 2004, P NATL ACAD SCI USA, V101, P12508, DOI 10.1073/pnas.0404519101; Kim JM, 1997, P NATL ACAD SCI USA, V94, P14273, DOI 10.1073/pnas.94.26.14273; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Kosugi S, 1998, MOL PHARMACOL, V53, P894; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lindahl E, 2000, BIOPHYS J, V79, P426, DOI 10.1016/S0006-3495(00)76304-1; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Nakamichi H, 2006, P NATL ACAD SCI USA, V103, P12729, DOI 10.1073/pnas.0601765103; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Oldham WM, 2006, Q REV BIOPHYS, V39, P117, DOI 10.1017/S0033583506004306; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; REN Q, 1993, J BIOL CHEM, V268, P16483; Ringkananont U, 2006, MOL ENDOCRINOL, V20, P893, DOI 10.1210/me.2005-0339; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Saam J, 2002, BIOPHYS J, V83, P3097, DOI 10.1016/S0006-3495(02)75314-9; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Salgado GFJ, 2006, J AM CHEM SOC, V128, P11067, DOI 10.1021/ja058738+; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Senin II, 2006, BIOCHEM BIOPH RES CO, V349, P345, DOI 10.1016/j.bbrc.2006.08.048; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Shi W, 1998, BIOCHEMISTRY-US, V37, P4869, DOI 10.1021/bi9731100; SHICHIDA Y, 2006, PHOTOCHEM PHOTOBIOL; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; Wohlert J, 2004, BIOPHYS J, V87, P2433, DOI 10.1529/biophysj.104.044222	62	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14272	14282		10.1074/jbc.M611091200	http://dx.doi.org/10.1074/jbc.M611091200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17322302	hybrid			2022-12-27	WOS:000246245800038
J	Isoo, N; Sato, C; Miyashita, H; Shinohara, M; Takasugi, N; Morohashi, Y; Tsuji, S; Tomita, T; Iwatsubo, T				Isoo, Noriko; Sato, Chihiro; Miyashita, Hiroyuki; Shinohara, Mitsuru; Takasugi, Nobumasa; Morohashi, Yuichi; Tsuji, Shoji; Tomita, Taisuke; Iwatsubo, Takeshi			A beta 42 overproduction associated with structural changes in the catalytic pore of gamma-secretase - Common effects of Pen-2 N-terminal elongation and fenofibrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOIDOGENIC A-BETA-42; TRANSMEMBRANE DOMAIN-4; C-TERMINUS; PRESENILIN; COMPLEX; STABILIZATION; SITE; ENDOPROTEOLYSIS; CLEAVAGE	gamma-Secretase is an atypical aspartyl protease that cleaves amyloid beta-precursor protein to generate A beta peptides that are causative for Alzheimer disease. gamma-Secretase is a multimeric membrane protein complex composed of presenilin ( PS), nicastrin, Aph-1, and Pen-2. Pen-2 directly binds to transmembrane domain 4 of PS and confers proteolytic activity on gamma-secretase, although the mechanism of activation and its role in catalysis remain unknown. Here we show that an addition of amino acid residues to the N terminus of Pen-2 specifically increases the generation of A beta 42, the longer and more aggregable species of A beta. The effect of the N- terminal elongation of Pen- 2 on A beta 42 generation was independent of the amino acid sequences, the expression system and the presenilin species. In vitro gamma-secretase assay revealed that Pen-2 directly affects the A beta 42- generating activity of gamma-secretase. The elongation of Pen-2N terminus caused a reduction in the water accessibility of the luminal side of the catalytic pore of PS1 in a similar manner to that caused by an A beta 42- raising gamma-secretase modulator, fenofibrate, as determined by substituted cysteine accessibility method. These data suggest a unique mechanism of A beta 42 overproduction associated with structural changes in the catalytic pore of presenilins caused commonly by the N-terminal elongation of Pen-2 and fenofibrate.	Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Neurol, Div Neurosci, Grad Sch Med,Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Tomita, T (corresponding author), Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	taisuke@mol.f.u-tokyo.ac.jp; iwatsubo@mol.f.u-tokyo.ac.jp	Naganawa, Shinji/I-1572-2012; Tomita, Taisuke/L-5427-2015	Naganawa, Shinji/0000-0002-0214-613X; Tomita, Taisuke/0000-0002-0075-5943; TAKASUGI, NOBUMASA/0000-0002-6059-2082; Sato, Chihiro/0000-0002-7639-8727				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Berezovska O, 2005, J NEUROSCI, V25, P3009, DOI 10.1523/JNEUROSCI.0364-05.2005; Berezovska O, 2003, J NEUROSCI, V23, P4560; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Hasegawa H, 2004, J BIOL CHEM, V279, P46455, DOI 10.1074/jbc.M406289200; Hayashi I, 2004, J BIOL CHEM, V279, P38040, DOI 10.1074/jbc.M405597200; Kim SH, 2005, J BIOL CHEM, V280, P41953, DOI 10.1074/jbc.M509070200; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lazarov VK, 2006, P NATL ACAD SCI USA, V103, P6889, DOI 10.1073/pnas.0602321103; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Morohashi Y, 2006, J BIOL CHEM, V281, P14670, DOI 10.1074/jbc.M513012200; Niimura M, 2005, J BIOL CHEM, V280, P12967, DOI 10.1074/jbc.M409829200; Ogura T, 2006, BIOCHEM BIOPH RES CO, V343, P525, DOI 10.1016/j.bbrc.2006.02.158; Okochi M, 2006, J BIOL CHEM, V281, P7890, DOI 10.1074/jbc.M513250200; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Prokop S, 2005, J NEUROCHEM, V94, P57, DOI 10.1111/j.1471-4159.2005.03165.x; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Sato C, 2006, J NEUROSCI, V26, P12081, DOI 10.1523/JNEUROSCI.3614-06.2006; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shiraishi H, 2004, J NEUROCHEM, V90, P1402, DOI 10.1111/j.1471-4159.2004.02597.x; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tomita T, 2006, CURR PHARM DESIGN, V12, P661, DOI 10.2174/138161206775474206; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Watanabe N, 2005, J BIOL CHEM, V280, P41967, DOI 10.1074/jbc.M509066200; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	42	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12388	12396		10.1074/jbc.M611549200	http://dx.doi.org/10.1074/jbc.M611549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329245	hybrid			2022-12-27	WOS:000245942800007
J	Velasco, LFR; Togashi, M; Walfish, PG; Pessanha, RP; Moura, FN; Barra, GB; Nguyen, P; Rebong, R; Yuan, C; Simeoni, LA; Ribeiro, RCJ; Baxter, JD; Webb, P; Neves, FAR				Velasco, Lara F. R.; Togashi, Marie; Walfish, Paul G.; Pessanha, Rutineia P.; Moura, Fanny N.; Barra, Gustavo B.; Nguyen, Phuong; Rebong, Rachelle; Yuan, Chaoshen; Simeoni, Luiz A.; Ribeiro, Ralff C. J.; Baxter, John D.; Webb, Paul; Neves, Francisco A. R.			Thyroid hormone response element organization dictates the composition of active receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; DNA-BINDING DOMAINS; HISTONE ACETYLATION; AUXILIARY PROTEIN; NUCLEAR RECEPTORS; ENHANCES BINDING; GENE ACTIVATION; DIRECT REPEATS; RXR-BETA; ACID	Thyroid hormone ( triiodothyronine, T-3) is known to activate transcription by binding heterodimers of thyroid hormone receptors ( TRs) and retinoid X receptors ( RXRs). RXR-TRs bind to T3 response elements ( TREs) composed of direct repeats of the sequence AGGTCA spaced by four nucleotides ( DR-4). In other TREs, however, the half-sites can be arranged as inverted palindromes and palindromes ( Pal). Here we show that TR homodimers and monomers activate transcription from representative TREs with alternate half-site placements. TR beta activates transcription more efficiently than TR alpha at an inverted palindrome ( F2), and this correlates with preferential TR beta homodimer formation at F2 in vitro. Furthermore, reconstruction of TR transcription complexes in yeast indicates that TR beta homodimers are active at F2, whereas RXR-TRs are active at DR-4 and Pal. Finally, analysis of TR beta mutations that block homodimer and/or heterodimer formation reveal TRE-selective requirements for these surfaces in mammalian cells, which suggest that TR beta homodimers are active at F2, RXR-TRs at DR-4, and TR monomers at Pal. TR beta requires higher levels of hormone for activation at F2 than other TREs, and this differential effect is abolished by a dimer surface mutation suggesting that it is related to composition of the TR center dot TRE complex. We propose that interactions of particular TR oligomers with different elements play unappreciated roles in TRE-selective actions of liganded TRs in vivo.	Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Brasilia, Mol Pharmacol Lab, Dept Pharmaceut Sci, Sch Hlth Sci, Brasilia, DF, Brazil; Univ Toronto, Mt Sinai Hosp, Sch Med, Dept Med,Endocrine Div, Toronto, ON M5G 1X5, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Webb, P (corresponding author), Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.	pwebb@diabetes.ucsf.edu	Simeoni, Luiz Alberto/A-9088-2008; Togashi, Marie/L-3092-2018; Barra, Gustavo/G-6137-2012	Simeoni, Luiz Alberto/0000-0003-3401-290X; Barra, Gustavo/0000-0002-2136-3471; Togashi, Marie/0000-0002-0886-8766	NIDDK NIH HHS [DK41482, DK51281, DK61468] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051281] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; Barros AC, 1998, NEUROREPORT, V9, P2933, DOI 10.1097/00001756-199809140-00003; Borngraeber S, 2003, P NATL ACAD SCI USA, V100, P15358, DOI 10.1073/pnas.2136689100; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; Diallo EM, 2005, PROTEIN EXPRES PURIF, V40, P292, DOI 10.1016/j.pep.2005.01.007; Diallo EM, 2007, MOL CELL ENDOCRINOL, V264, P149, DOI 10.1016/j.mce.2006.11.004; Glass CK, 2000, GENE DEV, V14, P121; Gloss B, 2005, ENDOCRINOLOGY, V146, P4926, DOI 10.1210/en.2005-0631; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Hsia SCV, 2002, MOL CELL BIOL, V22, P4043, DOI 10.1128/MCB.22.12.4043-4052.2002; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAUDET V, 2002, NUCL RECEPTOR FACTS, P87; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Leitman DC, 1996, J BIOL CHEM, V271, P21950, DOI 10.1074/jbc.271.36.21950; LENG XH, 1994, J BIOL CHEM, V269, P31436; Liang FQ, 2003, J BIOL CHEM, V278, P15073, DOI 10.1074/jbc.M207593200; Liu Y, 1998, ENDOCRINOLOGY, V139, P4197, DOI 10.1210/en.139.10.4197; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; Meng XW, 2005, P NATL ACAD SCI USA, V102, P6267, DOI 10.1073/pnas.0501491102; Meng XW, 2003, MOL ENDOCRINOL, V17, P1095, DOI 10.1210/me.2002-0294; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; O'Shea PJ, 2002, J ENDOCRINOL, V175, P553, DOI 10.1677/joe.0.1750553; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Ribeiro RCJ, 1998, J STEROID BIOCHEM, V65, P133, DOI 10.1016/S0960-0760(98)00029-6; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; Sachs LM, 2000, P NATL ACAD SCI USA, V97, P13138, DOI 10.1073/pnas.260141297; Santos GM, 2006, MOL PHARMACOL, V70, P793, DOI 10.1124/mol.106.025627; Shibusawa N, 2003, J BIOL CHEM, V278, P732, DOI 10.1074/jbc.M207264200; Shin DJ, 2006, NUCLEIC ACIDS RES, V34, P3853, DOI 10.1093/nar/gkl506; Togashi M, 2005, J BIOL CHEM, V280, P25665, DOI 10.1074/jbc.M501615200; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; Wu YF, 2001, J BIOL CHEM, V276, P3929, DOI 10.1074/jbc.M006743200; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, J BIOL CHEM, V267, P23248; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	58	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12458	12466		10.1074/jbc.M610700200	http://dx.doi.org/10.1074/jbc.M610700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17311926	Green Published, hybrid			2022-12-27	WOS:000245942800014
J	Peskin, AV; Low, FM; Paton, LN; Maghzal, GJ; Hampton, MB; Winterbourn, CC				Peskin, Alexander V.; Low, Felicia M.; Paton, Louise N.; Maghzal, Ghassan J.; Hampton, Mark B.; Winterbourn, Christine C.			The high reactivity of peroxiredoxin 2 with H2O2 is not reflected in its reaction with other oxidants and thiol reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; HYPOCHLOROUS ACID; MAMMALIAN PEROXIREDOXIN; TAURINE CHLORAMINE; OXIDATION; PROTEIN; CELL; MYELOPEROXIDASE; METHIONINE; THIOREDOXIN	Peroxiredoxin 2 is a member of the mammalian peroxiredoxin family of thiol proteins that is important in antioxidant defense and redox signaling. We have examined its reactivity with various biological oxidants, in order to assess its ability to act as a direct physiological target for these species. Human erythrocyte peroxiredoxin 2 was oxidized stoichiometrically to its disulfide-bonded homodimer by hydrogen peroxide, as monitored electrophoretically under nonreducing conditions. The protein was highly susceptible to oxidation by adventitious peroxide, which could be prevented by treating buffers with low concentrations of catalase. However, this did not protect peroxiredoxin 2 against oxidation by added H2O2. Experiments measuring inhibition of dimerization indicated that at pH 7.4 catalase and peroxiredoxin 2 react with hydrogen peroxide at comparable rates. A rate constant of 1.3 x 107 M-1 s(-1) for the peroxiredoxin reaction was obtained from competition kinetic studies with horseradish peroxidase. This is 100-fold faster than is generally assumed. It is sufficiently high for peroxiredoxin to be a favored cellular target for hydrogen peroxide, even in competition with catalase or glutathione peroxidase. Reactions of t-butyl and cumene hydroperoxides with peroxiredoxin were also fast, but amino acid chloramines reacted much more slowly. This contrasts with other thiol compounds that react many times faster with chloramines than with hydrogen peroxide. The alkylating agent iodoacetamide also reacted extremely slowly with peroxiredoxin 2. These results demonstrate that peroxiredoxin 2 has a tertiary structure that facilitates reaction of the active site thiol with hydrogen peroxide while restricting its reactivity with other thiol reagents.	Univ Otago, Dept Pathol, Free Rad Res Grp, Christchurch, New Zealand	University of Otago	Peskin, AV (corresponding author), Univ Otago, Dept Pathol, Free Rad Res Grp, POB 4345, Christchurch, New Zealand.	alexander.peskin@chmeds.ac.nz	Peskin, alexander/R-6457-2019; maghzal, ghassan/A-9692-2015; LOW, FELICIA/GRF-2704-2022; Hampton, Mark B/A-8490-2008	Hampton, Mark B/0000-0002-7349-3729; peskin, alexander/0000-0001-9890-6043; Paton, Louise N/0000-0002-7055-5170				Baty JW, 2002, PROTEOMICS, V2, P1261, DOI 10.1002/1615-9861(200209)2:9<1261::AID-PROT1261>3.0.CO;2-Q; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; DUNFORD HB, 1999, HEME PEROXIDASES, P439; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Johnson RM, 2005, FREE RADICAL BIO MED, V39, P1407, DOI 10.1016/j.freeradbiomed.2005.07.002; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; Kim JA, 2005, ANAL BIOCHEM, V338, P216, DOI 10.1016/j.ab.2004.12.008; Landar A, 2006, FREE RADICAL BIO MED, V40, P459, DOI 10.1016/j.freeradbiomed.2005.08.046; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Midwinter RG, 2004, J BIOL CHEM, V279, P32205, DOI 10.1074/jbc.M402070200; Midwinter RG, 2006, BIOCHEM J, V396, P71, DOI 10.1042/BJ20052026; Moon EY, 2006, FREE RADICAL BIO MED, V40, P2103, DOI 10.1016/j.freeradbiomed.2006.02.007; Moon EY, 2004, EUR J IMMUNOL, V34, P2119, DOI 10.1002/eji.200424962; MOORE RB, 1991, J BIOL CHEM, V266, P18964; MUNDAY R, 1985, J APPL TOXICOL, V5, P402, DOI 10.1002/jat.2550050613; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Ogusucu R, 2007, FREE RADICAL BIO MED, V42, P326, DOI 10.1016/j.freeradbiomed.2006.10.042; Parsonage D, 2005, BIOCHEMISTRY-US, V44, P10583, DOI 10.1021/bi050448i; Pattison DI, 2006, CURR MED CHEM, V13, P3271, DOI 10.2174/092986706778773095; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Peskin AV, 2006, FREE RADICAL BIO MED, V40, P45, DOI 10.1016/j.freeradbiomed.2005.08.019; Peskin AV, 2003, FREE RADICAL BIO MED, V35, P1252, DOI 10.1016/S0891-5849(03)00502-1; Puchades M, 1999, RAPID COMMUN MASS SP, V13, P344; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; SVENSSON BE, 1988, BIOCHEM J, V256, P751, DOI 10.1042/bj2560751; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Winterbourn CC, 2002, TOXICOLOGY, V181, P223, DOI 10.1016/S0300-483X(02)00286-X; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	34	296	306	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11885	11892		10.1074/jbc.M700339200	http://dx.doi.org/10.1074/jbc.M700339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329258	hybrid			2022-12-27	WOS:000245941900031
J	Urbanowicz, BR; Catala, C; Irwin, D; Wilson, DB; Ripoll, DR; Rose, JKC				Urbanowicz, Breeanna R.; Catala, Carmen; Irwin, Diana; Wilson, David B.; Ripoll, Daniel R.; Rose, Jocelyn K. C.			A tomato endo-beta-1,4-glucanase, SlCel9C1, represents a distinct subclass with a new family of carbohydrate binding modules (CBM49)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALLS; CELLULOMONAS-FIMI; ACTIVE ENZYMES; PROTEIN; DOMAIN; GENE; EXPRESSION; FRUIT; PURIFICATION; ENDO-1,4-BETA-GLUCANASE	A critical structural feature of many microbial endo-beta-1,4-glucanases( EGases, or cellulases) is a carbohydrate binding module ( CBM), which is required for effective crystalline cellulose degradation. However, CBMs are absent from plant EGases that have been biochemically characterized to date, and accordingly, plant EGases are not generally thought to have the capacity to degrade crystalline cellulose. We report the biochemical characterization of a tomato EGase, Solanum lycopersicum Cel8 ( SlCel9C1), with a distinct C-terminal noncatalytic module that represents a previously uncharacterized family of CBMs. In vitro binding studies demonstrated that this module indeed binds to crystalline cellulose and can similarly bind as part of a recombinant chimeric fusion protein containing an EGase catalytic domain from the bacterium Thermobifida fusca. Site-directed mutagenesis studies show that tryptophans 559 and 573 play a role in crystalline cellulose binding. The SlCel9C1 CBM, which represents a new CBM family ( CBM49), is a defining feature of a new structural subclass ( Class C) of plant EGases, with members present throughout the plant kingdom. In addition, the SlCel9C1 catalytic domain was shown to hydrolyze artificial cellulosic polymers, cellulose oligosaccharides, and a variety of plant cell wall polysaccharides.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Cornell Univ, Computat Biol Serv Unit, Cornell Theory Ctr, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Rose, JKC (corresponding author), Cornell Univ, Dept Plant Biol, 228 Plant Sci Bldg, Ithaca, NY 14853 USA.	jr286@cornell.edu	Urbanowicz, Breeanna/C-6488-2012; Catala, Carmen/E-7059-2012	, Breeanna/0000-0001-5247-4513				Arpat AB, 2004, PLANT MOL BIOL, V54, P911, DOI 10.1007/s11103-004-0392-y; Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; Boraston AB, 2003, J BIOL CHEM, V278, P6120, DOI 10.1074/jbc.M209554200; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Brummell DA, 2001, PLANT MOL BIOL, V47, P311, DOI 10.1023/A:1010656104304; BRUMMELL DA, 1994, ACS SYM SER, V566, P100; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Carrard G, 2000, P NATL ACAD SCI USA, V97, P10342, DOI 10.1073/pnas.160216697; Catala C., 1998, PLANT PHYSIOL, V118, P1535; Chen NJ, 2003, FUNCT PLANT BIOL, V30, P433, DOI 10.1071/FP02208; Coutinho PM, 1999, ROY SOC CH, P3; Davison A, 2005, MOL BIOL EVOL, V22, P1273, DOI 10.1093/molbev/msi107; Downes BP, 2001, PLANT PHYSIOL, V126, P244, DOI 10.1104/pp.126.1.244; Eckert K, 2002, APPL MICROBIOL BIOT, V60, P428, DOI 10.1007/s00253-002-1131-4; GHOSE TK, 1987, PURE APPL CHEM, V59, P257, DOI 10.1351/pac198759020257; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Harpster MH, 2002, PLANT MOL BIOL, V50, P345, DOI 10.1023/A:1019856929126; Henrissat B, 1998, FEBS LETT, V425, P352, DOI 10.1016/S0014-5793(98)00265-8; Henrissat B, 2001, PLANT MOL BIOL, V47, P55, DOI 10.1023/A:1010667012056; Hilden L, 2004, BIOTECHNOL LETT, V26, P1683, DOI 10.1007/s10529-004-4579-8; Irwin D, 1998, J BACTERIOL, V180, P1709, DOI 10.1128/JB.180.7.1709-1714.1998; IRWIN DC, 1993, BIOTECHNOL BIOENG, V42, P1002, DOI 10.1002/bit.260420811; Jahic M, 2003, J BIOTECHNOL, V102, P45, DOI 10.1016/S0168-1656(03)00003-8; JUNG ED, 1993, APPL ENVIRON MICROB, V59, P3032, DOI 10.1128/AEM.59.9.3032-3043.1993; Jung H, 2003, BIOTECHNOL BIOENG, V84, P151, DOI 10.1002/bit.10743; Kim JH, 2004, CAN J MICROBIOL, V50, P835, DOI 10.1139/W04-077; LEVER M, 1972, ANAL BIOCHEM, V47, P273, DOI 10.1016/0003-2697(72)90301-6; Libertini E, 2004, J MOL EVOL, V58, P506, DOI 10.1007/s00239-003-2571-x; Linder M, 1997, J BIOTECHNOL, V57, P15, DOI 10.1016/S0168-1656(97)00087-4; Lynd LR, 2005, CURR OPIN BIOTECH, V16, P577, DOI 10.1016/j.copbio.2005.08.009; Lynd LR, 2002, MICROBIOL MOL BIOL R, V66, P506, DOI 10.1128/MMBR.66.3.506-577.2002; MACLACHLAN G, 1988, METHOD ENZYMOL, V160, P382; Master ER, 2004, BIOCHEMISTRY-US, V43, P10080, DOI 10.1021/bi049453x; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Molhoj M, 2002, PLANT CELL PHYSIOL, V43, P1399, DOI 10.1093/pcp/pcf163; Molhoj M, 2001, PLANT PHYSIOL, V127, P674, DOI 10.1104/pp.010269; Pauly M, 1999, PLANT J, V20, P629, DOI 10.1046/j.1365-313X.1999.00630.x; Rabinovich ML, 2002, BIOCHEMISTRY-MOSCOW+, V67, P850, DOI 10.1023/A:1019958419032; Robert S, 2005, PLANT CELL, V17, P3378, DOI 10.1105/tpc.105.036228; Rose JK, 2003, PLANT CELL WALL, V8, P264, DOI DOI 10.1002/9781119312994.APR0075; Rose JKC, 1999, TRENDS PLANT SCI, V4, P176, DOI 10.1016/S1360-1385(99)01405-3; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SALMINEN O, 2002, THESIS CORNELL U ITH; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; SHOSEYOV O, 2001, Patent No. 6184440; Shpigel E, 1998, PLANT PHYSIOL, V117, P1185, DOI 10.1104/pp.117.4.1185; Trainotti L, 2006, J EXP BOT, V57, P589, DOI 10.1093/jxb/erj043; Trainotti L, 1999, PLANT MOL BIOL, V40, P323, DOI 10.1023/A:1006299821980; Wilson D. B., 1999, Advances in Biochemical Engineering/Biotechnology, V65, P1; Wolfgang DE, 1999, BIOCHEMISTRY-US, V38, P9746, DOI 10.1021/bi990401v; Woolley LC, 2001, PLANTA, V214, P11, DOI 10.1007/s004250100577; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; York WS, 1996, CARBOHYD RES, V285, P99, DOI 10.1016/0008-6215(96)00029-8	54	56	60	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12066	12074		10.1074/jbc.M607925200	http://dx.doi.org/10.1074/jbc.M607925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322304	hybrid			2022-12-27	WOS:000245941900049
J	Jang, SW; Kim, YS; Kim, YR; Sung, HJ; Ko, J				Jang, Sung-Wuk; Kim, Yoon Suk; Kim, Yoon Rim; Sung, Ho Joong; Ko, Jesang			Regulation of human LZIP expression by NF-kappa B and its involvement in monocyte cell migration induced by Lkn-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY RESPONSE GENES; NECROSIS-FACTOR-ALPHA; CC-CHEMOKINE; TRANSCRIPTION FACTORS; ADHESION MOLECULE-1; GROWTH-FACTORS; DNA-BINDING; HOS CELLS; IN-VITRO; CANCER	Human LZIP is a transcription factor that is involved in leukocyte cell mobility. Expression of LZIP is known to differentially regulate monocyte cell migration induced by CCR1-dependent chemokines. However, its transcriptional regulation has not been characterized. Our results indicate that Lkn-1 induces LZIP expression in a time- and dose-dependent manner, and the induction of LZIP shows an immediate early response to Lkn-1. We identified and cloned similar to 1.4 kb of the LZIP promoter from a human genomic DNA. To identify regulatory elements controlling restricted expression of LZIP, deletion mutants were constructed from the 1469-bp LZIP promoter region ( - 1219/ + 251) linked to the luciferase reporter gene. Maximal promoter activity was contained within 613 bp from the tentative transcription initiation site and was sharply reduced in a truncated construct ( - 338/ + 251). This promoter sequence contained consensus NF-kappa B- and Sp-1-binding sites. Results from an inhibitor assay showed that NF-kappa B is involved in Lkn-1-induced LZIP expression, but Sp-1 is not. We also demonstrated that NF-kappa B binds to the LZIP promoter and that the binding is specific, as revealed by an electrophoretic mobility shift assay and a mutation analysis. Chemotaxis analysis showed that LZIP expression because of the NF-kappa B subfamily is specifically involved in Lkn-1-induced chemotaxis. Our findings suggest that transcription factor NF-kappa B plays an important role in regulation of LZIP expression, and LZIP expression regulates the monocyte cell migration induced by Lkn-1.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Korea University	Ko, J (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	jesangko@korea.ac.kr						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bontemps Y, 2003, J BIOL CHEM, V278, P21566, DOI 10.1074/jbc.M209366200; BURBELO PD, 1994, GENE, V139, P241, DOI 10.1016/0378-1119(94)90763-3; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; FURIE MB, 1995, AM J PATHOL, V146, P1287; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grossmann M, 1999, INT J BIOCHEM CELL B, V31, P1209, DOI 10.1016/S1357-2725(99)00068-0; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Huang S, 2000, CANCER RES, V60, P5334; Hwang JS, 2004, FEBS LETT, V570, P47, DOI 10.1016/j.febslet.2004.06.023; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Karashima T, 2003, CLIN CANCER RES, V9, P2786; Karl E, 2005, CANCER RES, V65, P5063, DOI 10.1158/0008-5472.CAN-05-0140; Kim CH, 1999, FEBS LETT, V449, P28, DOI 10.1016/S0014-5793(99)00390-7; Kim IS, 2003, LIFE SCI, V73, P447, DOI 10.1016/S0024-3205(03)00312-6; Ko J, 2004, FASEB J, V18, P890, DOI 10.1096/fj.03-0867fje; Ko JS, 2002, FEBS LETT, V515, P159, DOI 10.1016/S0014-5793(02)02465-1; Lee BH, 2000, J CELL BIOCHEM, V76, P437, DOI 10.1002/(SICI)1097-4644(20000301)76:3<437::AID-JCB11>3.0.CO;2-2; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Lu RQ, 2002, J BIOL CHEM, V277, P16592, DOI 10.1074/jbc.M111440200; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; MATHEW S, 1993, ONCOGENE, V8, P191; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Oyama N, 1999, J INVEST DERMATOL, V113, P600, DOI 10.1046/j.1523-1747.1999.00734.x; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tolnay M, 2002, J IMMUNOL, V169, P6236, DOI 10.4049/jimmunol.169.11.6236; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Wu DQ, 2005, CELL RES, V15, P52, DOI 10.1038/sj.cr.7290265; Youn BS, 1997, J IMMUNOL, V159, P5201; Yu R, 2004, ATHEROSCLEROSIS, V174, P35, DOI 10.1016/j.atherosclerosis.2003.11.024	49	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11092	11100		10.1074/jbc.M607962200	http://dx.doi.org/10.1074/jbc.M607962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17296613	hybrid			2022-12-27	WOS:000245941500030
J	Miyashita, Y; Ozawa, M				Miyashita, Yayoi; Ozawa, Masayuki			Increased internalization of p120-uncoupled E-cadherin and a requirement for a dileucine motif in the cytoplasmic domain for endocytosis of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; MEMBRANE-PROXIMAL REGION; MOLECULE UVOMORULIN; MDCK CELLS; RAC; RHO; CATENIN; MORPHOGENESIS; P120-CATENIN; MODULATION	E-cadherin is a member of the cadherin family of Ca2+-dependent cell-cell adhesion molecules. E- cadherin associates with beta-catenin at the membrane-distal region of its cytosolic domain and with p120 at the membrane-proximal region of its cytoplasmic domain. It has been shown that a pool of cell surface E- cadherin is constitutively internalized and recycled back to the surface. Further, p120 knockdown by small interference RNA resulted in dose-dependent elimination of cell surface E- cadherin. Consistent with these observations, we found that selective uncoupling of p120 from E- cadherin by introduction of amino acid substitutions in the p120-binding site increased the level of E- cadherin endocytosis. The increased endocytosis was clathrin-dependent, because it was blocked by expression of a dominant-negative form of dynamin or by hypertonic shock. A dileucine motif in the juxtamembrane cytoplasmic domain is required for E-cadherin endocytosis, because substitution of these residues to alanine resulted in impaired internalization of the protein. The alanine substitutions in the p120- uncoupled construct reduced endocytosis of the protein, indicating that this motif was dominant to p120 binding in the control of E-cadherin endocytosis. Therefore, these results are consistent with the idea that p120 regulates E- cadherin endocytosis by masking the dileucine motif and preventing interactions with adaptor proteins required for internalization.	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 890, Japan	Kagoshima University	Ozawa, M (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 890, Japan.	mozawa@m.kufm.kagoshima-u.ac.jp						Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LEVINE E, 1994, DEVELOPMENT, V120, P901; Miranda KC, 2003, J BIOL CHEM, V278, P43480, DOI 10.1074/jbc.M305525200; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 2003, J BIOL CHEM, V278, P46014, DOI 10.1074/jbc.M307778200; Ozawa M, 2002, J BIOL CHEM, V277, P19600, DOI 10.1074/jbc.M202029200; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SHAPIRO L, 1995, NATURE, V374, P306; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Troyanovsky RB, 2006, MOL BIOL CELL, V17, P3484, DOI 10.1091/mbc.E06-03-0190; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046; Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Young P, 2003, EMBO J, V22, P5723, DOI 10.1093/emboj/cdg560	41	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11540	11548		10.1074/jbc.M608351200	http://dx.doi.org/10.1074/jbc.M608351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17298950	hybrid			2022-12-27	WOS:000245941500075
J	Siehl, DL; Castle, LA; Gorton, R; Keenan, RJ				Siehl, Daniel L.; Castle, Linda A.; Gorton, Rebecca; Keenan, Robert J.			The molecular basis of glyphosate resistance by an optimized microbial acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; SUPERFAMILY; EVOLUTION; ENZYME; ACID; RESIDUES	GAT is an N- acetyltransferase from Bacillus licheniformis that was optimized by gene shuffling for acetylation of the broad spectrum herbicide, glyphosate, forming the basis of a novel mechanism of glyphosate tolerance in transgenic plants ( Castle, L. A., Siehl, D. L., Gorton, R., Patten, P. A., Chen, Y. H., Bertain, S., Cho, H. J., Duck, N., Wong, J., Liu, D., and Lassner, M. W. ( 2004) Science 304, 1151 - 1154). The 1.6-angstrom resolution crystal structure of an optimized GAT variant in ternary complex with acetyl coenzyme A and a competitive inhibitor, 3-phosphoglyerate, defines GAT as a member of the GCN5- related family of N-acetyltransferases. Four active site residues ( Arg-21, Arg-73, Arg-111, and His-138) contribute to a positively charged substrate-binding site that is conserved throughout the GAT subfamily. Structural and kinetic data suggest that His-138 functions as a catalytic base via substrate-assisted deprotonation of the glyphosate secondary amine, whereas another active site residue, Tyr-118, functions as a general acid. Although the physiological substrate is unknown, native GAT acetylates D-2-amino-3- phosphonopropionic acid with a k(cat)/K-m of 1500 min(-1) mM(-1). Kinetic data show preferential binding of short analogs to native GAT and progressively better binding of longer analogs to optimized variants. Despite a 200-fold increase in k(cat) and a 5.4-fold decrease in K-m for glyphosate, only 4 of the 21 substitutions present in R7 GAT lie in the active site. Single-site revertants constructed at these positions suggest that glyphosate binding is optimized through substitutions that increase the size of the substrate- binding site. The large improvement in kcat is likely because of the cooperative effects of additional substitutions located distal to the active site.	Pioneer HiBred Int Inc, Redwood City, CA 94063 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	DuPont; University of Chicago	Keenan, RJ (corresponding author), Pioneer HiBred Int Inc, Redwood City, CA 94063 USA.	dan.siehl@pioneer.com; bkeenan@uchicago.edu		Keenan, Robert/0000-0003-1466-0889				Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Castle LA, 2004, SCIENCE, V304, P1151, DOI 10.1126/science.1096770; Cleland WW, 2000, ARCH BIOCHEM BIOPHYS, V382, P1, DOI 10.1006/abbi.2000.2011; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; DeLano W.L, PYMOL MOL GRAPHICS S; Draker KA, 2004, BIOCHEMISTRY-US, V43, P446, DOI 10.1021/bi035667n; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eschenburg S, 2002, PLANTA, V216, P129, DOI 10.1007/s00425-002-0908-0; Franz J. E., 1997, GLYPHOSATE UNIQUE GL; Hegde SS, 2001, J BIOL CHEM, V276, P45876, DOI 10.1074/jbc.M108810200; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Keenan RJ, 2005, P NATL ACAD SCI USA, V102, P8887, DOI 10.1073/pnas.0502497102; Kim KS, 2000, P NATL ACAD SCI USA, V97, P6373, DOI 10.1073/pnas.97.12.6373; KITTREDGE JS, 1964, BIOCHEMISTRY-US, V3, P991, DOI 10.1021/bi00895a026; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Nishina Y, 2003, J BIOCHEM, V134, P835, DOI 10.1093/jb/mvg209; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; Padgette SR, 1995, HERBICIDE RESISTANT, P53; Piana S, 2002, PROTEIN SCI, V11, P2393, DOI 10.1110/ps.0206702; Scheibner KA, 2002, J BIOL CHEM, V277, P18118, DOI 10.1074/jbc.M200595200; SCOPES RK, 1994, PROTEIN PURIFICATION, P46; Siehl DL, 2005, PEST MANAG SCI, V61, P235, DOI 10.1002/ps.1014; SMITH JD, 1970, BIOCHEMISTRY-US, V9, P2152, DOI 10.1021/bi00812a018; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Tomatis PE, 2005, P NATL ACAD SCI USA, V102, P13761, DOI 10.1073/pnas.0503495102; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; WALSH C, 1979, ENZYMATIC REACTION M, P34; WARREN WA, 1968, BIOCHIM BIOPHYS ACTA, V156, P340, DOI 10.1016/0304-4165(68)90263-8; Wybenga-Groot LE, 1999, STRUCTURE, V7, P497, DOI 10.1016/S0969-2126(99)80066-5	35	54	63	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11446	11455		10.1074/jbc.M610267200	http://dx.doi.org/10.1074/jbc.M610267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17272278	hybrid			2022-12-27	WOS:000245941500066
J	Heldring, N; Pawson, T; McDonnell, D; Treuter, E; Gustafsson, JA; Pike, ACW				Heldring, Nina; Pawson, Tanya; McDonnell, Donald; Treuter, Eckardt; Gustafsson, Jan-Ake; Pike, Ashley C. W.			Structural insights into corepressor recognition by antagonist-bound estrogen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; NUCLEAR RECEPTOR; N-COR; ER-ALPHA; BINDING; COMPLEX; RECRUITMENT; SURFACE; DOMAIN; IDENTIFICATION	Direct recruitment of transcriptional corepressors to estrogen receptors ( ER) is thought to contribute to the tissue-specific effects of clinically important ER antagonists. Here, we present the crystal structures of two affinity-selected peptides in complex with antagonist- bound ER alpha ligand-binding domain. Both peptides adopt helical conformations, bind along the activation function 2 coregulator interaction surface, and mimic corepressor ( CoRNR) sequence motif binding. Peptide binding is weak in a wild-type context but significantly enhanced by removal of ER helix 12. This region contains a previously unrecognized CoRNR motif that is able to compete with corepressors for binding to activation function 2, thereby providing a structural explanation for the poor ability of ER to directly interact with classical corepressors. Furthermore, the ability of other sequence motifs to mimic corepressor binding raises the possibility that coregulators do not necessarily require CoRNR motifs for direct recruitment to antagonist- bound ER.	Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden; Univ York, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Karolinska Institutet; University of York - UK; Duke University	Heldring, N (corresponding author), Univ Oxford, Botnar Res Ctr, Struct Genom Consortium, Oxford OX3 7LD, England.	nina.heldring@biosci.ki.se; ashley.pike@sgc.ox.ac.uk		Treuter, Eckardt/0000-0002-4147-8989	Wellcome Trust [064803] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bavner A, 2005, TRENDS ENDOCRIN MET, V16, P478, DOI 10.1016/j.tem.2005.10.005; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Dobrzycka KM, 2003, ENDOCR-RELAT CANCER, V10, P517, DOI 10.1677/erc.0.0100517; Dotzlaw H, 2003, MOL CELL ENDOCRINOL, V213, P79, DOI 10.1016/j.mce.2003.10.036; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Iannone MA, 2004, MOL ENDOCRINOL, V18, P1064, DOI 10.1210/me.2003-0432; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Kong EH, 2005, P NATL ACAD SCI USA, V102, P3593, DOI 10.1073/pnas.0407189102; Lalli E, 2003, MOL ENDOCRINOL, V17, P1445, DOI 10.1210/me.2003-0159; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Levenson AS, 1997, J STEROID BIOCHEM, V60, P261, DOI 10.1016/S0960-0760(96)00184-7; Levenson AS, 2001, J STEROID BIOCHEM, V76, P61, DOI 10.1016/S0960-0760(00)00143-6; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pike ACW, 2006, BEST PRACT RES CL EN, V20, P1, DOI 10.1016/j.beem.2005.09.002; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Wang DQ, 2005, MOL ENDOCRINOL, V19, P1483, DOI 10.1210/me.2005-0012; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Wu Y, 2006, MOL CELL BIOL, V26, P6633, DOI 10.1128/MCB.01534-05; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200; Yoon HG, 2006, MOL ENDOCRINOL, V20, P1048, DOI 10.1210/me.2005-0324; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	41	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10449	10455		10.1074/jbc.M611424200	http://dx.doi.org/10.1074/jbc.M611424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283072	hybrid			2022-12-27	WOS:000245941000036
J	Tai, SL; Daran-Lapujade, P; Luttik, MAH; Walsh, MC; Diderich, JA; Krijger, GC; van Gulik, WM; Pronk, JT; Daran, JM				Tai, Siew Leng; Daran-Lapujade, Pascale; Luttik, Marijke A. H.; Walsh, Michael C.; Diderich, Jasper A.; Krijger, Gerard C.; van Gulik, Walter M.; Pronk, Jack T.; Daran, Jean-Marc			Control of the glycolytic flux in Saccharomyces cerevisiae grown at low temperature - A multi-level analysis in anaerobic chemostat cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-SHOCK INDUCTION; GLUCOSE-TRANSPORT; SPERMOPHILUS-LATERALIS; CELLULAR-RESPONSES; GROUND-SQUIRREL; YEAST-CELLS; TRANSCRIPTOME; EXPRESSION; GENE; MEMBRANE	Growth temperature has a profound impact on the kinetic properties of enzymes in microbial metabolic networks. Activities of glycolytic enzymes in Saccharomyces cerevisiae were up to 7.5- fold lower when assayed at 12 degrees C than at 30 degrees C. Nevertheless, the in vivo glycolytic flux in chemostat cultures ( dilution rate: 0.03 h(-1)) grown at these two temperatures was essentially the same. To investigate how yeast maintained a constant glycolytic flux despite the kinetic challenge imposed by a lower growth temperature, a systems approach was applied that involved metabolic flux analysis, transcript analysis, enzyme activity assays, and metabolite analysis. Expression of hexosetransporter genes was affected by the growth temperature, as indicated by differential transcription of five HXT genes and changed zero trans-influx kinetics of [C-14] glucose transport. No such significant changes in gene expression were observed for any of the glycolytic enzymes. Fermentative capacity ( assayed off-line at 30 degrees C), which was 2- fold higher in cells grown at 12 degrees C, was therefore probably controlled predominantly by glucose transport. Massive differences in the intracellular concentrations of nucleotides ( resulting in an increased adenylate energy charge at low temperature) and glycolytic intermediates indicated a dominant role of metabolic control as opposed to gene expression in the adaptation of glycolytic enzyme activity to different temperatures. In evolutionary terms, this predominant reliance on metabolic control of a central pathway, which represents a significant fraction of the cellular protein of the organism, may be advantageous to limit the need for protein synthesis and degradation during adaptation to diurnal temperature cycles.	Delft Univ Technol, Dept Biochem, NL-2628 BC Delft, Netherlands; Heineken Supply Chain Res & Innovat, NL-2382 PH Zoeterwoude, Netherlands; Reactor Inst Delft, NL-2629 JB Delft, Netherlands	Delft University of Technology; Heineken; Delft University of Technology	Daran, JM (corresponding author), Delft Univ Technol, Dept Biochem, NL-2628 BC Delft, Netherlands.	j.g.daran@tudelft.nl	Tai, Siew L/E-6476-2016; Daran, Jean-Marc/X-8787-2019; Diderich, Jasper/AAH-3373-2019	Tai, Siew L/0000-0002-2148-3115; Luttik, Marijke/0000-0002-9798-8072; Daran-Lapujade, Pascale/0000-0002-4097-7831; Diderich, Jasper/0000-0003-2675-9712; Pronk, Jack/0000-0002-5617-4611; Daran, Jean-Marc/0000-0003-3136-8193				AHLERS J, 1981, BIOCHIM BIOPHYS ACTA, V649, P550, DOI 10.1016/0005-2736(81)90159-0; Al-Fageeh MB, 2006, BIOCHEM J, V397, P247, DOI 10.1042/BJ20060166; ARRHENIUS S, 1884, RES GALVANIC CONDUCT; Barnett J. A., 1983, YEASTS CHARACTERISTI; BLAZQUEZ MA, 1993, FEBS LETT, V329, P51, DOI 10.1016/0014-5793(93)80191-V; Boles E, 1998, J BACTERIOL, V180, P2875, DOI 10.1128/JB.180.11.2875-2882.1998; CAUBET R, 1988, ARCH MICROBIOL, V149, P324, DOI 10.1007/BF00411650; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; Daran-Lapujade P, 2004, J BIOL CHEM, V278, P3265; Dickinson JR, 1997, J BIOL CHEM, V272, P26871, DOI 10.1074/jbc.272.43.26871; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1016/S0168-6445(00)00059-0; HESS B, 1966, BIOCHEM BIOPH RES CO, V24, P824, DOI 10.1016/0006-291X(66)90322-6; Homma T, 2003, CRYOBIOLOGY, V46, P230, DOI 10.1016/S0011-2240(03)00028-2; HUNTER K, 1972, BIOCHIM BIOPHYS ACTA, V260, P639, DOI 10.1016/0005-2760(72)90013-6; Jansen MLA, 2005, MICROBIOL-SGM, V151, P1657, DOI 10.1099/mic.0.27577-0; Kandror O, 2004, MOL CELL, V13, P771, DOI 10.1016/S1097-2765(04)00148-0; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1991, J BIOL CHEM, V266, P17537; KOWALSKI LRZ, 1995, MOL MICROBIOL, V15, P341, DOI 10.1111/j.1365-2958.1995.tb02248.x; Kresnowati MTAP, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100083; KURGANOV BI, 1976, J THEOR BIOL, V60, P287, DOI 10.1016/0022-5193(76)90061-8; Kuyper M, 2003, FEMS YEAST RES, V4, P69, DOI 10.1016/S1567-1356(03)00141-7; LANGE HC, 2002, QUANTITATIVE PHYSL S; Larsson C, 1997, J BACTERIOL, V179, P7243, DOI 10.1128/jb.179.23.7243-7250.1997; MacDonald JA, 2005, FEBS J, V272, P120, DOI 10.1111/j.1432-1033.2004.04388.x; MacDonald JA, 2002, ARCH BIOCHEM BIOPHYS, V408, P279, DOI 10.1016/S0003-9861(02)00579-9; Maier A, 2002, FEMS YEAST RES, V2, P539, DOI 10.1016/S1567-1356(02)00140-X; Mashego MR, 2003, BIOTECHNOL BIOENG, V83, P395, DOI 10.1002/bit.10683; Panadero J, 2006, J BIOL CHEM, V281, P4638, DOI 10.1074/jbc.M512736200; Parrou JL, 1997, ANAL BIOCHEM, V248, P186, DOI 10.1006/abio.1997.2138; Petit T, 2000, J BACTERIOL, V182, P6815, DOI 10.1128/JB.182.23.6815-6818.2000; Piper MDW, 2002, J BIOL CHEM, V277, P37001, DOI 10.1074/jbc.M204490200; POSTMA E, 1989, APPL ENVIRON MICROB, V55, P468, DOI 10.1128/AEM.55.2.468-477.1989; Regenberg B, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-11-r107; Sahara T, 2002, J BIOL CHEM, V277, P50015, DOI 10.1074/jbc.M209258200; Schade B, 2004, MOL BIOL CELL, V15, P5492, DOI 10.1091/mbc.E04-03-0167; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Somero GN, 2004, COMP BIOCHEM PHYS B, V139, P321, DOI 10.1016/j.cbpc.2004.05.003; Stuckrath I, 2002, BIOTECHNOL BIOENG, V77, P61, DOI 10.1002/bit.10123; Tai SL, 2005, J BIOL CHEM, V280, P437, DOI 10.1074/jbc.M410573200; Teusink B, 1998, TRENDS BIOCHEM SCI, V23, P162, DOI 10.1016/S0968-0004(98)01205-5; Torija MJ, 2003, INT J FOOD MICROBIOL, V85, P127, DOI 10.1016/S0168-1605(02)00506-8; van Dam JC, 2002, ANAL CHIM ACTA, V460, P209, DOI 10.1016/S0003-2670(02)00240-4; van Dijken JP, 2000, ENZYME MICROB TECH, V26, P706, DOI 10.1016/S0141-0229(00)00162-9; Van Hoek P, 1998, APPL ENVIRON MICROB, V64, P4226; VANHOEK P, 2000, FERMENTATIVE CAPACIT; VERDUYN C, 1990, J GEN MICROBIOL, V136, P405, DOI 10.1099/00221287-136-3-405; Verduyn C, 1990, MICROBIOL REV, V58, P616; Vuralhan Z, 2005, APPL ENVIRON MICROB, V71, P3276, DOI 10.1128/AEM.71.6.3276-3284.2005; WALSH MC, 1994, J BACTERIOL, V176, P953, DOI 10.1128/JB.176.4.953-958.1994; Wu L, 2005, ANAL BIOCHEM, V336, P164, DOI 10.1016/j.ab.2004.09.001	51	47	51	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10243	10251		10.1074/jbc.M610845200	http://dx.doi.org/10.1074/jbc.M610845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17251183	Green Published, hybrid			2022-12-27	WOS:000245941000014
J	Connelly, L; Robinson-Benion, C; Chont, M; Saint-Jean, L; Li, HJ; Polosukhin, VV; Blackwell, TS; Yull, FE				Connelly, Linda; Robinson-Benion, Cheryl; Chont, Melissa; Saint-Jean, Leshana; Li, Haijing; Polosukhin, Vasiliy V.; Blackwell, Timothy S.; Yull, Fiona E.			A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; CYCLIN D1 EXPRESSION; TRANSCRIPTION FACTOR; GLAND DEVELOPMENT; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; GROWTH-FACTORS; IKK-ALPHA; ACTIVATION; PROTEINS	A regulated pattern of nuclear factor kappa B (NF-kappa B) activation is essential for normal development of the mammary gland. An increase in NF-kappa B activity has been implicated in breast cancer. We have generated a novel transgenic mouse model to investigate the role of the alternative NF-kappa B pathway in ductal development and identify possible mediators of tumorigenesis downstream of p100/p52. By overexpressing the NF-kappa B p100/p52 subunit in mammary epithelium using the beta-lactoglobulin milk protein promoter, we found that transgene expression resulted in increased overall NF-kappa B activity during late pregnancy. During pregnancy, p100/p52 expression resulted in delayed ductal development with impaired secondary branching and increased levels of Cyclin D1, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and cyclo-oxygenase-2 (COX-2) in the mammary gland. After multiple pregnancies the p100 transgenics exhibited a ductal thickening accompanied by small hyperplastic foci. In tumors from mice expressing the polyoma middle T oncoprotein (PyVT) in the mammary gland, increased levels of p100/p52 were present at the time of tumor development. These results show that increased p100/p52 disrupts normal ductal development and provides insight into the mechanism by which this may contribute to human breast cancer.	Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Yull, FE (corresponding author), Vanderbilt Univ, Dept Canc Biol, 771 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	Fiona.yull@vanderbilt.edu	Connelly, Linda/GVS-4612-2022					BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136-10147.2005; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Furth PA, 1999, J MAMMARY GLAND BIOL, V4, P123, DOI 10.1023/A:1018764922082; Geymayer S, 2000, FASEB J, V14, P1159, DOI 10.1096/fasebj.14.9.1159; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Han YP, 2001, J CELL SCI, V114, P131; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Heppner KJ, 1996, AM J PATHOL, V149, P273; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simian M, 2001, DEVELOPMENT, V128, P3117; Singh B, 2005, INT J ONCOL, V26, P1393; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Takahashi Y, 1999, FEBS LETT, V460, P145, DOI 10.1016/S0014-5793(99)01328-9; Wang DZ, 2004, SEMIN ONCOL, V31, P64, DOI 10.1053/j.seminoncol.2004.01.008; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; Witty Jean P., 1995, Molecular Biology of the Cell, V6, P1287	45	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10028	10035		10.1074/jbc.M611300200	http://dx.doi.org/10.1074/jbc.M611300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17261585	hybrid			2022-12-27	WOS:000245421700077
J	Matsushima, Y; Kaguni, LS				Matsushima, Yuichi; Kaguni, Laurie S.			Differential phenotypes of active site and human autosomal dominant progressive external ophthalmoplegia mutations in Drosophila mitochondrial DNA helicase expressed in Schneider cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; COPY NUMBER; MULTIPLE DELETIONS; CRYSTAL-STRUCTURE; MTDNA MAINTENANCE; PRIMASE-HELICASE; BACTERIOPHAGE T7; BINDING PROTEIN; LINKER REGION; TWINKLE	We report the cloning and molecular analysis of Drosophila mitochondrial DNA helicase (d-mtDNA helicase) homologous to human TWINKLE, which encodes one of the genes responsible for autosomal dominant progressive external ophthalmoplegia. An RNA interference construct was designed that reduces expression of d-mtDNA helicase to an undetectable level in Schneider cells. RNA interference knockdown of d-mtDNA helicase decreases the copy number of mitochondrial DNA (mtDNA) similar to 5-fold. In a corollary manner, overexpression of d-mtDNA helicase increases mtDNA levels 1.4-fold. Overexpression of helicase active site mutants K388A and D483A results in a severe depletion of mtDNA and a dominant negative lethal phenotype. Overexpression of mutants analogous to human autosomal dominant progressive external ophthalmoplegia mutations shows differential effects. Overexpression of 1334T and A442P mutants yields a dominant negative effect as for the active site mutants. In contrast, overexpression of A326T, R341Q, and W441C mutants results in increased mtDNA copy number, as observed with wild-type overexpression. Our dominant negative analysis of d-mtDNA helicase in cultured cells provides a tractable model for understanding human autosomal dominant progressive external ophthalmoplegia mutations.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	lskaguni@msu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295, R01 GM045295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arenas J, 2003, ANN NEUROL, V53, P278, DOI 10.1002/ana.10430; Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Farr CL, 2004, J BIOL CHEM, V279, P17047, DOI 10.1074/jbc.M400283200; Goto A, 2001, BIOCHEM J, V354, P243, DOI 10.1042/0264-6021:3540243; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890; Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257; Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200; Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200; Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9; Matsushima Y, 2005, J BIOL CHEM, V280, P16815, DOI 10.1074/jbc.M500569200; Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200; Matsushima Y, 2003, J BIOL CHEM, V278, P31149, DOI 10.1074/jbc.M303842200; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025; Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244; SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8; Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102; Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	37	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9436	9444		10.1074/jbc.M610550200	http://dx.doi.org/10.1074/jbc.M610550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272269	Green Accepted, hybrid			2022-12-27	WOS:000245421700016
J	Aoki, K; Perlman, M; Lim, JM; Cantu, R; Wells, L; Tiemeyer, M				Aoki, Kazuhiro; Perlman, Mindy; Lim, Jae-Min; Cantu, Rebecca; Wells, Lance; Tiemeyer, Michael			Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila melanogaster embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT CELLS; FUNCTIONAL-CHARACTERIZATION; HORSERADISH-PEROXIDASE; CAENORHABDITIS-ELEGANS; ACETYLNEURAMINIC ACID; SUBSTRATE-SPECIFICITY; PROTEIN GLYCOSYLATION; GRASSHOPPER EMBRYOS; MOLECULAR-CLONING; HEPARAN-SULFATE	The structural diversity of glycoprotein N-linked oligosaccharides is determined by the expression and regulation of glycosyltransferase activities and by the availability of the appropriate acceptor/donor substrates. Cells in different tissues and in different developmental stages utilize these control points to manifest unique glycan expression patterns in response to their surroundings. The activity of a Toll-like receptor, called Tollo/ Toll-8, induces a pattern of incompletely defined, but neural specific, glycan expression in the Drosophila embryo. Understanding the full extent of the changes in glycan expression that result from altered Tollo/Toll-8 signaling requires characterization of the complete N-linked glycan profile of both wild-type and mutant embryos. N-Linked glycans harvested from wildtype or mutant embryos were subjected to direct structural analysis by analytic and preparative high pressure liquid chromatography, by multidimensional mass spectrometry, and by exoglycosidase digestion, revealing a predominance of high mannose and paucimannose glycans. Di-, mono-, and nonfucosylated forms of hybrid, complex biantennary, and triantennary glycans account for 12% of the total wild-type glycan profile. Two sialylated glycans bearing N-acetylneuraminic acid were detected, the first direct demonstration of this modification in Drosophila. Glycan profiles change during normal development consistent with increasing a-mannosidase II and core fucosyltransferase enzyme activities, and with decreasing activity of the Fused lobes processing hexosaminidase. In tollo/toll-8 mutants, a dramatic, expected loss of difucosylated glycans is accompanied by unexpected decreases in monofucosylated and nonfucosylated hybrid glycans and increases in some nonfucosylated paucimannose and biantennary glycans. Therefore, tollo/toll-8 signaling influences flux through several processing steps that affect the maturation of N-linked glycans.	Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Tiemeyer, M (corresponding author), Complex Carbohydrate Res Ctr, 315 Riverband Rd, Athens, GA 30602 USA.	mtiemeyer@ccrc.uga.edu	Aoki, Kazuhiro/H-8283-2014; Wells, Lance/H-3118-2013	Aoki, Kazuhiro/0000-0003-0029-4291; Wells, Lance/0000-0003-4956-5363	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072839] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R01-GM072839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Ashline D, 2005, ANAL CHEM, V77, P6250, DOI 10.1021/ac050724z; Aumiller JJ, 2006, PROTEIN EXPRES PURIF, V47, P571, DOI 10.1016/j.pep.2005.11.026; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P672, DOI 10.1016/0005-2736(81)90097-3; CALLAERTS P, 1995, ROUX ARCH DEV BIOL, V204, P229, DOI 10.1007/BF00208490; Cipollo JF, 2005, J BIOL CHEM, V280, P26063, DOI 10.1074/jbc.M503828200; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; DAMICO P, 1995, TISSUE CELL, V27, P23, DOI 10.1016/S0040-8166(95)80005-0; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; Foe Victoria E., 1993, P149; FOSTER JM, 1995, GENE, V154, P183, DOI 10.1016/0378-1119(94)00867-R; FREDIEU JR, 1994, ACTA ANAT, V149, P89; Freeze HH, 2002, BBA-GEN SUBJECTS, V1573, P388, DOI 10.1016/S0304-4165(02)00408-7; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Haines N, 2005, GLYCOBIOLOGY, V15, P335, DOI 10.1093/glycob/cwi017; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Hanneman AJ, 2006, GLYCOBIOLOGY, V16, P874, DOI 10.1093/glycob/cwl011; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HASE S, 1981, J BIOCHEM-TOKYO, V90, P407, DOI 10.1093/oxfordjournals.jbchem.a133487; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHNSON SW, 1991, COMP BIOCHEM PHYS B, V99, P479, DOI 10.1016/0305-0491(91)90327-A; Kantor DB, 2004, NEURON, V44, P961, DOI 10.1016/j.neuron.2004.12.002; KERSCHER S, 1995, DEV BIOL, V168, P613, DOI 10.1006/dbio.1995.1106; Kim K, 2002, GLYCOBIOLOGY, V12, P73, DOI 10.1093/glycob/12.2.73; KOJIMA K, 1987, ANAL BIOCHEM, V165, P465, DOI 10.1016/0003-2697(87)90297-1; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; Landis G, 2001, GENETICS, V158, P1167; Leonard R, 2006, J BIOL CHEM, V281, P4867, DOI 10.1074/jbc.M511023200; Malykh YN, 1999, GLYCOCONJUGATE J, V16, P731, DOI 10.1023/A:1007115627708; Marchal I, 1999, GLYCOBIOLOGY, V9, P645, DOI 10.1093/glycob/9.7.645; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; Mechref Y, 2006, RAPID COMMUN MASS SP, V20, P1381, DOI 10.1002/rcm.2445; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Muller R, 2005, FEBS J, V272, P4295, DOI 10.1111/j.1742-4658.2005.04838.x; Muller R, 2002, J BIOL CHEM, V277, P32417, DOI 10.1074/jbc.C200381200; North SJ, 2006, GLYCOCONJUGATE J, V23, P345, DOI 10.1007/s10719-006-6693-4; OKU H, 1990, ANAL BIOCHEM, V185, P331, DOI 10.1016/0003-2697(90)90303-Q; PARKER GF, 1991, FEBS LETT, V290, P58, DOI 10.1016/0014-5793(91)81225-W; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; PATEL NH, 1994, DROSOPHILA MELANOGAS, P445; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; Rendic D, 2006, J BIOL CHEM, V281, P3343, DOI 10.1074/jbc.M508334200; Roberts DB, 1998, EUR J BIOCHEM, V253, P494, DOI 10.1046/j.1432-1327.1998.2530494.x; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; SAITO M, 1979, J BIOL CHEM, V254, P7845; Sarkar M, 2006, J BIOL CHEM, V281, P12776, DOI 10.1074/jbc.M512769200; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; Seppo A, 2003, DEVELOPMENT, V130, P1439, DOI 10.1242/dev.00347; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; SNOW PM, 1987, J NEUROSCI, V7, P4137; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TAKAHASHI N, 1995, ANAL BIOCHEM, V226, P139, DOI 10.1006/abio.1995.1201; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Tian E, 2006, GLYCOBIOLOGY, V16, P83, DOI 10.1093/glycob/cwj051; Tomiya N, 2004, GLYCOCONJUGATE J, V21, P343, DOI 10.1023/B:GLYC.0000046275.28315.87; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; Tomiya N, 2006, J BIOL CHEM, V281, P19545, DOI 10.1074/jbc.M603312200; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Vadaie N, 2004, J BIOL CHEM, V279, P33501, DOI 10.1074/jbc.M404925200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Viswanathan K, 2006, J BIOL CHEM, V281, P15929, DOI 10.1074/jbc.M512186200; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; Yano H, 2005, P NATL ACAD SCI USA, V102, P13467, DOI 10.1073/pnas.0506681102; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	78	210	216	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9127	9142		10.1074/jbc.M606711200	http://dx.doi.org/10.1074/jbc.M606711200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264077	hybrid			2022-12-27	WOS:000245780300060
J	Jasuja, R; Ge, GX; Voss, NG; Lyman-Gingerich, J; Branam, AM; Pelegri, FJ; Greenspan, DS				Jasuja, Reema; Ge, Gaoxiang; Voss, Nikolas G.; Lyman-Gingerich, Jamie; Branam, Amanda M.; Pelegri, Francisco J.; Greenspan, Daniel S.			Bone morphogenetic protein 1 prodomain specifically binds and regulates signaling by bone morphogenetic proteins 2 and 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWISTED GASTRULATION; GROWTH-FACTOR; VERTEBRATE DEVELOPMENT; ZEBRAFISH; EXPRESSION; CHORDIN; SKIN; METALLOPROTEINASES; XENOPUS; EMBRYO	Highly purified fractions of bone extracts capable of inducing ectopic bone formation have been reported to contain peptides corresponding to the mature active regions of the TGF-beta-like bone morphogenetic proteins (BMPs) 2-7, and to the prodomain region of the metalloproteinase BMP1. Co-purification of BMPs 2-7 with BMP1 prodomain sequences through the multiple biochemical steps used in these previous reports has suggested the possibility of interactions between the BMP1 prodomain and BMPs 2-7. Here we demonstrate that the BMP1 prodomain binds BMPs 2 and 4 with high specificity and with a K-D of similar to 11 nM, in the physiological range. It is further demonstrated that the BMP1 prodomain is capable of modulating signaling by BMPs 2 and 4 in vitro and in vivo, and that endogenous BMP1 prodomain-BMP4 complexes exist in cell culture media and in tissues.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.	dsgreens@wisc.edu		Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM71679] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746, R56AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071679] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Botchkarev VA, 2004, DIFFERENTIATION, V72, P512, DOI 10.1111/j.1432-0436.2004.07209005.x; Botchkarev VA, 2003, J INVEST DERMATOL, V120, P36, DOI 10.1046/j.1523-1747.2003.12002.x; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523-1755.2000.00081.x; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Ge GX, 2006, J CELL BIOL, V175, P111, DOI 10.1083/jcb.200606058; Ge Gaoxiang, 2006, Birth Defects Research, V78, P47, DOI 10.1002/bdrc.20060; Hillger F, 2005, J BIOL CHEM, V280, P14974, DOI 10.1074/jbc.M414413200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Jasuja R, 2004, J BIOL CHEM, V279, P51289, DOI 10.1074/jbc.M408129200; Jasuja R, 2006, MECH DEVELOP, V123, P548, DOI 10.1016/j.mod.2006.05.004; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; Kwan KM, 2004, GENESIS, V39, P10, DOI 10.1002/gene.20021; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Miller-Bertoglio VE, 1997, DEV BIOL, V192, P537, DOI 10.1006/dbio.1997.8788; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; Mullins MC, 1996, DEVELOPMENT, V123, P81; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Rentzsch F, 2006, DEVELOPMENT, V133, P801, DOI 10.1242/dev.02250; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; SOLNICAKREZEL L, 1995, BIOESSAYS, V17, P931, DOI 10.1002/bies.950171106; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	42	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9053	9062		10.1074/jbc.M610929200	http://dx.doi.org/10.1074/jbc.M610929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255107	hybrid			2022-12-27	WOS:000245780300052
J	Beierle, EA; Trujillo, A; Nagaram, A; Kurenova, EV; Finch, R; Ma, X; Vella, J; Cance, WG; Golubovskaya, VM				Beierle, Elizabeth A.; Trujillo, Angelica; Nagaram, Abhilasha; Kurenova, Elena V.; Finch, Richard; Ma, Xiaojie; Vella, Jennifer; Cance, William G.; Golubovskaya, Vita M.			N-MYC regulates focal adhesion kinase expression in human neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PROTEIN-TYROSINE KINASE; DNA-BINDING; NEURONAL DIFFERENTIATION; MEDIATED APOPTOSIS; TERMINAL DOMAIN; DEATH-DOMAIN; TUMOR-CELLS; C-MYC; GENE	N-MYC is a transcription factor that plays an important role in cellular survival in neuroblastoma, and amplification of the N-MYC oncogene is the primary adverse prognostic indicator for neuroblastoma. Focal adhesion kinase ( FAK) is a survival factor that has been shown to be overexpressed in many types of human cancers. In this study, we investigated the role of N-MYC regulation of FAK expression in neuroblastoma. We first found a correlation between N-MYC and FAK expression in neuroblastoma. Real time quantitative PCR demonstrated an increase in FAK mRNA abundance in the N-MYC-amplified IMR-32 compared with the nonamplified SK-N-AS neuroblastoma cell lines. FAK protein expression also correlated positively with N-MYC expression in the N-MYC-amplified IMR-32 versus nonamplified SK-N-AS neuroblastoma cell lines. The same results were seen with the isogenic N-MYC+ ( Tet(-)) and N-MYC+ ( Tet(-)) neuroblastoma cell lines. Promoter-reporter assays showed that activity of the FAK promoter was increased in the N-MYC-amplified IMR-32 cell line, in the N-MYC-transfected SK-N-AS nonamplified cell line, and in the isogenic N-MYC- ( Tet(+)) neuroblastoma cell lines compared with the nonamplified and N-MYC-nonexpressing cell lines. We also identified two N-MYC binding sites in the FAK promoter sequence and showed binding of N-MYC transcription factor to the FAK promoter through electrophoretic mobility shift, chromatin immunoprecipitation, and dual luciferase assays. Finally down-regulation of FAK expression in N-MYC-inducible neuroblastoma cell lines with FAK small interfering RNA or a dominant-negative FAK inhibitor ( AdFAK-CD) significantly decreased viability and increased apoptosis in the N-MYC+ ( Tet(-)) cells compared with the isogenic N-MYC- ( Tet(+)) cells, demonstrating the biological significance of FAK overexpression in the N-MYC-expressing cell lines. This is the first report linking N-MYC and FAK in neuroblastoma, and it clearly demonstrates that N-MYC induces FAK expression. The results indicate that N-MYC regulation of FAK expression can control cellular functions in isogenic N-MYC-/+ ( Tet(+/-)) neuroblastoma cell lines.	Univ Florida, Dept Surg, JHMHSC, Gainesville, FL 32610 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Beierle, EA (corresponding author), Univ Florida, Dept Surg, JHMHSC, POB 100286, Gainesville, FL 32610 USA.	beierea@surgery.ufl.edu; golubvi@surgery.ufl.edu	Kurenova, Elena/GQB-2333-2022	Beierle, Elizabeth/0000-0002-4613-0527				Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; BAUER J, 1990, NEOPLASMA, V37, P233; Beviglia L, 2003, BIOCHEM J, V373, P201, DOI 10.1042/BJ20021846; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brown A, 1998, CARCINOGENESIS, V19, P991, DOI 10.1093/carcin/19.6.991; Cance WG, 2000, CLIN CANCER RES, V6, P2417; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Earley S, 2006, BIOCHEM BIOPH RES CO, V350, P405, DOI 10.1016/j.bbrc.2006.09.056; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Giannini G, 2005, CANCER RES, V65, P8308, DOI 10.1158/0008-5472.CAN-05-0607; Golubovskaya V, 2004, BBA-GENE STRUCT EXPR, V1678, P111, DOI 10.1016/j.bbaexp.2004.03.002; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Golubovskaya VM, 2005, J BIOL CHEM, V280, P25008, DOI 10.1074/jbc.M414172200; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Goodman LA, 1997, CLIN EXP METASTAS, V15, P130, DOI 10.1023/A:1018448710006; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; Halder J, 2005, CLIN CANCER RES, V11, P8829, DOI 10.1158/1078-0432.CCR-05-1728; Han EKH, 2004, ANTICANCER RES, V24, P3899; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harris RG, 2002, J BIOL CHEM, V277, P34815, DOI 10.1074/jbc.M109609200; Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; Lark AL, 2003, CLIN CANCER RES, V9, P215; Lipinski CA, 2005, NEOPLASIA, V7, P435, DOI 10.1593/neo.04712; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Lutz W, 1996, ONCOGENE, V13, P803; MA A, 1993, ONCOGENE, V8, P1093; Manohar CF, 2004, ONCOGENE, V23, P753, DOI 10.1038/sj.onc.1207151; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; Nguyen T, 2003, BIOCHEM BIOPH RES CO, V302, P462, DOI 10.1016/S0006-291X(03)00177-3; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Ryu SJ, 2006, APOPTOSIS, V11, P303, DOI 10.1007/s10495-006-3978-9; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SHIN DM, 1987, ANTICANCER RES, V7, P117; Smith CS, 2005, MELANOMA RES, V15, P357, DOI 10.1097/00008390-200510000-00003; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; UCAR K, 1995, CANCER GENE THER, V2, P171; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; West AB, 2004, J BIOL CHEM, V279, P28896, DOI 10.1074/jbc.M400126200; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Zachary I, 1997, INT J BIOCHEM CELL B, V29, P929, DOI 10.1016/S1357-2725(97)00008-3; Zaizen Y, 1998, J PEDIATR SURG, V33, P1765, DOI 10.1016/S0022-3468(98)90281-0; Zhu XX, 2002, NEOPLASIA, V4, P432, DOI 10.1038/sj.neo.7900255	66	64	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12503	12516		10.1074/jbc.M701450200	http://dx.doi.org/10.1074/jbc.M701450200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327229	hybrid			2022-12-27	WOS:000245942800019
J	Hetz, C; Castilla, J; Soto, C				Hetz, Claudio; Castilla, Joaquin; Soto, Claudio			Perturbation of endoplasmic reticulum homeostasis facilitates prion replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; AMYOTROPHIC-LATERAL-SCLEROSIS; UBIQUITIN-PROTEASOME SYSTEM; ER STRESS; CELL-DEATH; TRANSCRIPTION FACTOR; MESSENGER-RNA; NEURODEGENERATIVE DISEASES; RETROGRADE TRANSPORT; TRANSGENIC MICE	Prion diseases are fatal and infectious neurodegenerative disorders characterized by the accumulation of an abnormally folded form of the prion protein ( PrP), termed PrPSc. Prion replication triggers endoplasmic reticulum ( ER) stress, neuronal dysfunction, and apoptosis. In this study we analyze the effect of perturbations in ER homeostasis on PrP biochemical properties and prion replication. ER stress led to the generation of a mis-folded PrP isoform, which is detergent-insoluble and protease-sensitive. To understand the mechanism by which ER stress generates PrP misfolding, we assessed the contribution of different signaling pathways implicated in the unfolded protein response. Expression of a dominant negative form of IRE1 alpha or XBP-1 significantly increased PrP aggregation, whereas overexpression of ATF4 or an active mutant form of XBP-1 and ATF6 had the opposite affect. Analysis of prion replication in vitro revealed that the PrP isoform generated after ER stress is more efficiently converted into PrPSc compared with the protein extracted from untreated cells. These findings indicate that ER-damaged cells might be more susceptible to prion replication. Because PrPSc induces ER stress, our data point to a vicious cycle accelerating prion replication, which may explain the rapid progression of the disease.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Chile, Inst Biomed Sci, Ctr Mol Studies Cell, Fondo Areas Prioritarias, Santiago, Chile	University of Texas System; University of Texas Medical Branch Galveston; Universidad de Chile	Hetz, C (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd, Galveston, TX 77555 USA.	chetz@med.uchile.cl; clsoto@utmb.edu	Hetz, Claudio/ABD-7514-2021; Hetz, Claudio/I-1900-2013; Longo, Kenneth A/A-5631-2010; Castilla, Joaquín/J-8414-2019; Castilla, Joaquin/D-5261-2011	Hetz, Claudio/0000-0001-7724-1767; Castilla, Joaquín/0000-0002-2216-1361; Castilla, Joaquin/0000-0002-2216-1361	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049173, R01NS050349] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS050349, R01 NS049173, NS049173, R01 NS049173-04, NS050349, R01 NS050349-03] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apodaca J, 2006, BIOCHEM BIOPH RES CO, V347, P319, DOI 10.1016/j.bbrc.2006.06.078; Bence NF, 2005, METHOD ENZYMOL, V399, P481, DOI 10.1016/S0076-6879(05)99033-2; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Beranger F, 2002, J BIOL CHEM, V277, P38972, DOI 10.1074/jbc.M205110200; Brown AR, 2005, BIOCHEM BIOPH RES CO, V334, P86, DOI 10.1016/j.bbrc.2005.06.060; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Campana V, 2006, J CELL SCI, V119, P433, DOI 10.1242/jcs.02768; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Dimcheff DE, 2003, TRENDS CELL BIOL, V13, P337, DOI 10.1016/S0962-8924(03)00125-9; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Ferreiro E, 2006, NEUROBIOL DIS, V23, P669, DOI 10.1016/j.nbd.2006.05.011; Gu YP, 2003, J NEUROCHEM, V84, P10, DOI 10.1046/j.1471-4159.2003.01255.x; Harris B, 2003, CLIO MED, V71, P85; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hegde RS, 2003, TRENDS NEUROSCI, V26, P337, DOI 10.1016/S0166-2236(03)00143-7; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hetz C, 2005, J NEUROSCI, V25, P2793, DOI 10.1523/JNEUROSCI.4090-04.2005; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hetz C, 2003, TRENDS MOL MED, V9, P237, DOI 10.1016/S1471-4914(03)00069-8; Hetz CA, 2006, CURR MOL MED, V6, P37, DOI 10.2174/156652406775574578; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kikuchi H, 2006, P NATL ACAD SCI USA, V103, P6025, DOI 10.1073/pnas.0509227103; Kristiansen M, 2005, J BIOL CHEM, V280, P38851, DOI 10.1074/jbc.M506600200; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oakes SA, 2006, CURR MOL MED, V6, P99, DOI 10.2174/156652406775574587; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Orsi A, 2006, J BIOL CHEM, V281, P30431, DOI 10.1074/jbc.M605320200; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Russelakis-Carneiro M, 2004, AM J PATHOL, V165, P1839, DOI 10.1016/S0002-9440(10)63439-6; Russelakis-Carneiro M, 2002, J BIOL CHEM, V277, P36872, DOI 10.1074/jbc.M202229200; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Saborio GP, 1999, BIOCHEM BIOPH RES CO, V258, P470, DOI 10.1006/bbrc.1999.0660; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sekine Y, 2006, CURR MOL MED, V6, P87, DOI 10.2174/156652406775574541; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Soto C, 2002, BIOCHEM SOC T, V30, P569, DOI 10.1042/bst0300569; Stewart LR, 2001, J NEUROSCI RES, V65, P565, DOI 10.1002/jnr.1186; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Tobisawa S, 2003, BIOCHEM BIOPH RES CO, V303, P496, DOI 10.1016/S0006-291X(03)00353-X; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Turner BJ, 2006, CURR MOL MED, V6, P79, DOI 10.2174/156652406775574550; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Vlug AS, 2005, EUR J NEUROSCI, V22, P1881, DOI 10.1111/j.1460-9568.2005.04389.x; Wootz H, 2004, BIOCHEM BIOPH RES CO, V322, P281, DOI 10.1016/j.bbrc.2004.07.118; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoo BC, 2002, NEUROSCI LETT, V334, P196, DOI 10.1016/S0304-3940(02)01071-6; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	71	55	56	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12725	12733		10.1074/jbc.M611909200	http://dx.doi.org/10.1074/jbc.M611909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329244	hybrid, Green Accepted			2022-12-27	WOS:000245942800042
J	Larson, HN; Zhou, JZ; Chen, ZQ; Stamler, JS; Weiner, H; Hurley, TD				Larson, Heather N.; Zhou, Jianzhong; Chen, Zhiqiang; Stamler, Jonathan S.; Weiner, Henry; Hurley, Thomas D.			Structural and functional consequences of coenzyme binding to the inactive Asian variant of mitochondrial aldehyde dehydrogenase - Roles of residues 475 and 487	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGLYCERIN; INTERFACE; MECHANISM; SUBUNIT; MODEL; SITE	The common mitochondrial aldehyde dehydrogenase (ALDH2) ALDH2*2 polymorphism is associated with impaired ethanol metabolism and decreased efficacy of nitroglycerin treatment. These physiological effects are due to the substitution of Lys for Glu-487 that reduces the k(cat) for these processes and increases the K-m for NAD(+), as compared with ALDH2. In this study, we sought to understand the nature of the interactions that give rise to the loss of structural integrity and low activity in ALDH2*2 even when complexed with coenzyme. Consequently, we have solved the crystal structure of ALDH2*2 complexed with coenzyme to 2.5 angstrom. We have also solved the structures of a mutated form of ALDH2 where Arg-475 is replaced by Gln (R475Q). The structural and functional properties of the R475Q enzyme are intermediate between those of wild-type and the ALDH2*2 enzymes. In both cases, the binding of coenzyme restores most of the structural deficits observed in the apoenzyme structures. The binding of coenzyme to the R475Q enzyme restores its structure and catalytic properties to near wild-type levels. In contrast, the disordered helix within the coenzyme binding pocket of ALDH2*2 is reordered, but the active site is only partially reordered. Consistent with the structural data, ALDH2*2 showed a concentration-dependent increase in esterase activity and nitroglycerin reductase activity upon addition of coenzyme, but the levels of activity do not approach those of the wild-type enzyme or that of the R475Q enzyme. The data presented shows that Glu-487 maintains a critical function in linking the structure of the coenzyme-binding site to that of the active site through its interactions with Arg-264 and Arg-475, and in doing so, creates the stable structural scaffold conducive to catalysis.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Duke University; Howard Hughes Medical Institute; Duke University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hurley, TD (corresponding author), 635 Barnhill Dr, Indianapolis, IN 46202 USA.	thurley@iupui.edu		Stamler, Jonathan/0000-0002-6866-1572; HURLEY, THOMAS/0000-0002-5942-1163	NIAAA NIH HHS [R01 AA11982, R01 AA011982] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011982] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		[Anonymous], 2004, PERS VIS RAYTR VERS; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen ZQ, 2005, P NATL ACAD SCI USA, V102, P12159, DOI 10.1073/pnas.0503723102; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; DeLano W.L, PYMOL MOL GRAPHICS S; FARRES J, 1994, J BIOL CHEM, V269, P13854; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FUNG HL, 1994, CARDIOVASC DRUG THER, V8, P489, DOI 10.1007/BF00877927; GOEDDE HW, 1979, HUM GENET, V51, P331; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammen PK, 2002, BIOCHEMISTRY-US, V41, P7156, DOI 10.1021/bi012197t; HIGUCHI S, 1992, J STUD ALCOHOL, V53, P170, DOI 10.15288/jsa.1992.53.170; Ho KK, 2005, BIOCHEMISTRY-US, V44, P8022, DOI 10.1021/bi050038u; Hurley TD, 2001, CHEM-BIOL INTERACT, V130, P3, DOI 10.1016/S0009-2797(00)00217-9; Hurley TD, 1999, ADV EXP MED BIOL, V463, P15; Hurley TD, 2002, PHARMACOGENOMICS SEA, P417, DOI DOI 10.1002/3527600752; Ignarro LJ, 2002, P NATL ACAD SCI USA, V99, P7816, DOI 10.1073/pnas.132271799; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Larson HN, 2005, J BIOL CHEM, V280, P30550, DOI 10.1074/jbc.M502345200; Li YF, 2006, J CLIN INVEST, V116, P506, DOI 10.1172/JCI26564; Mackenzie IS, 2005, ARTERIOSCL THROM VAS, V25, P1891, DOI 10.1161/01.ATV.0000179599.71086.89; Marchal S, 1999, BIOCHEMISTRY-US, V38, P12950, DOI 10.1021/bi990453k; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peng GS, 1999, PHARMACOGENETICS, V9, P463; Perez-Miller SJ, 2003, BIOCHEMISTRY-US, V42, P7100, DOI 10.1021/bi034182w; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Seitz HK, 2001, ALCOHOL CLIN EXP RES, V25, p137S, DOI 10.1097/00000374-200105051-00024; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Wei BX, 2000, BIOCHEMISTRY-US, V39, P5295, DOI 10.1021/bi000028n; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x; Zhou JZ, 2000, BIOCHEMISTRY-US, V39, P12019, DOI 10.1021/bi001221k	36	84	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12940	12950		10.1074/jbc.M607959200	http://dx.doi.org/10.1074/jbc.M607959200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327228	Green Accepted, hybrid			2022-12-27	WOS:000245942800065
J	Ma, BY; Nakamura, N; Dlabac, V; Naito, H; Yamaguchi, S; Ishikawa, M; Nonaka, M; Ishiguro, M; Kawasaki, N; Oka, S; Kawasaki, T				Ma, Bruce Yong; Nakamura, Natsuko; Dlabac, Vladimir; Naito, Haruna; Yamaguchi, Shinsuke; Ishikawa, Makiko; Nonaka, Motohiro; Ishiguro, Masaji; Kawasaki, Nobuko; Oka, Shogo; Kawasaki, Toshisuke			Isolation, cloning, and characterization of a novel phosphomannan-binding lectin from porcine serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE DEFENSE; 2 PARTS; PROTEIN; COMPLEMENT; PATHWAY; VIRUS; COLLECTINS; PROTECTION; INFECTION; SUSCEPTIBILITY	Mannan-binding protein (MBP) is a C-type serum lectin that is an important constituent of the innate immune defense because it activates the complement system via the lectin pathway. While the pig has been proposed to be an attractive source of xenotransplantable tissues and organs, little is known about porcine MBP. In our previous studies, phosphomannan, but not mannan, was found to be an effective inhibitor of the C1q-independent bactericidal activity of newborn piglet serum against some rough strains of Gram-negative bacteria. In contrast, the inhibitory activities of phosphomannan and mannan were very similar in the case of MBP-dependent bactericidal activity against rough strains of Escherichia coli K-12 and S-16. Based on these findings, we inferred that an MBP-like lectin with slightly or completely different carbohydrate binding specificity might exist in newborn piglet serum and be responsible for the C1-qindependent bactericidal activity. Herein we report that a novel phosphomannan-binding lectin (PMBL) of 33 kDa under reducing conditions was isolated from both newborn and adult porcine serum and characterized. Porcine PMBL functionally activated the complement system via the lectin pathway triggered by binding with both phosphomannan (P-mannan) and mannan, which, unlike MBP, was effectively inhibited by mannose 6-phosphate- or galatose-containing oligosaccharides. Our observations suggest that porcine PMBL plays a critical role in the innate immune defense from the newborn stage to adulthood, and the establishment of a newborn piglet experimental model for the innate immune system studies is a valuable step toward elucidation of the physiological function and molecular mechanism of lectin pathway.	Ritsumeikan Univ, Res Ctr Glycobiotechnol, Shiga 5258577, Japan; Kyoto Univ, Dept Biol Chem, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan; Kyoto Univ, Sch Hlth Sci, Fac Med, Kyoto 6068501, Japan; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic; Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan	Ritsumeikan University; Kyoto University; Kyoto University; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Suntory Holdings Ltd	Kawasaki, T (corresponding author), Ritsumeikan Univ, Res Ctr Glycobiotechnol, Nojishigashi 1-1-1, Shiga 5258577, Japan.	tkawasak@fc.ritsumei.ac.jp						Agah A, 2001, IMMUNOLOGY, V102, P338, DOI 10.1046/j.1365-2567.2001.01191.x; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; DLABAC V, 1994, IMMUNOBIOLOGY, V190, P399, DOI 10.1016/S0171-2985(11)80611-X; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; GADJEVA M, 2003, CURR PROT IMMUNOL, P1; Hansen S, 1998, IMMUNOBIOLOGY, V199, P165, DOI 10.1016/S0171-2985(98)80025-9; HARTLEY CA, 1992, J VIROL, V66, P4358, DOI 10.1128/JVI.66.7.4358-4363.1992; Hegele RA, 2000, J INVEST MED, V48, P198; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Jack DL, 2003, BIOCHEM SOC T, V31, P753, DOI 10.1042/BST0310753; Janeway Jr CA, 2001, IMMUNOBIOLOGY IMMUNE; JIN HK, 1995, J CLIN INVEST, V95, P1947, DOI 10.1172/JCI117877; Kawai T, 1998, GLYCOBIOLOGY, V8, P237, DOI 10.1093/glycob/8.3.237; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LU J, 1990, J IMMUNOL, V144, P2287; Ma Y, 1997, J BIOCHEM-TOKYO, V122, P810; Ma Y, 1999, P NATL ACAD SCI USA, V96, P371, DOI 10.1073/pnas.96.2.371; Miyatake T, 1998, J IMMUNOL, V160, P4114; Mogues T, 1996, GLYCOBIOLOGY, V6, P543, DOI 10.1093/glycob/6.5.543; Nagy A, 2003, J ALLERGY CLIN IMMUN, V112, P729, DOI 10.1016/S0091-6749(03)02010-4; Nauta AJ, 2004, J IMMUNOL, V173, P3044, DOI 10.4049/jimmunol.173.5.3044; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Sachs DH, 2001, ADV IMMUNOL, V79, P129, DOI 10.1016/S0065-2776(01)79004-9; SASTRY K, 1989, J EXP MED, V170, P1175, DOI 10.1084/jem.170.4.1175; SASTRY K, 1991, J IMMUNOL, V147, P692; Schwaeble W, 2002, IMMUNOBIOLOGY, V205, P455, DOI 10.1078/0171-2985-00146; SIMMS HH, 1990, J TRAUMA, V3, P1027; Suankratay C, 1998, J IMMUNOL, V160, P3006; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506	37	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12963	12975		10.1074/jbc.M611820200	http://dx.doi.org/10.1074/jbc.M611820200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324926	hybrid			2022-12-27	WOS:000245942800067
J	Oberstein, A; Jeffrey, PD; Shi, YG				Oberstein, Adam; Jeffrey, Philip D.; Shi, Yigong			Crystal structure of the Bcl-X-L-beclin 1 peptide complex - Beclin 1 is a novel BH3-only protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR; MOLECULAR-MECHANISMS; 3-KINASE COMPLEX; AUTOPHAGY GENE; X-RAY; APOPTOSIS; BCL-2; TUMORIGENESIS; MACROAUTOPHAGY	Bcl-2 family proteins are key regulators of apoptosis and have recently been shown to modulate autophagy. The tumor suppressor Beclin 1 has been proposed to coordinate both apoptosis and autophagy through direct interaction with anti-apoptotic family members Bcl-2 and/or Bcl-X-L. However, the molecular basis for this interaction remains enigmatic. Here we report that Beclin 1 contains a conserved BH3 domain, which is both necessary and sufficient for its interaction with Bcl-X-L. We also report the crystal structure of a Beclin BH3 peptide in complex with Bcl-X-L at 2.5 angstrom resolution. Reminiscent of previously determined Bcl-X-L-BH3 structures, the amphipathic BH3 helix of Beclin 1 bound to a conserved hydrophobic groove of Bcl-X-L. These results define Beclin 1 as a novel BH3-only protein, implying that Beclin 1 may have a direct role in initiating apoptotic signaling. We propose that this putative apoptotic function may be linked to the ability of Beclin 1 to suppress tumor formation in mammals.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA	Princeton University	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.	ygshi@princeton.edu		Jeffrey, Philip/0000-0002-4351-5341; Shi, Yigong/0000-0003-2030-168X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bursch W, 2004, FEMS YEAST RES, V5, P101, DOI 10.1016/j.femsyr.2004.07.006; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; DeLano WL, 2004, PYMOL MOL GRAPHICS S; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Fletcher JI, 2006, CELL DEATH DIFFER, V13, P1268, DOI 10.1038/sj.cdd.4401995; Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Jin SK, 2006, AUTOPHAGY, V2, P80, DOI 10.4161/auto.2.2.2460; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kundu M, 2005, CELL DEATH DIFFER, V12, P1484, DOI 10.1038/sj.cdd.4401780; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Thuduppathy GR, 2006, PROTEIN SCI, V15, P248, DOI 10.1110/ps.051807706; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wyllie A H, 1974, J Clin Pathol Suppl (R Coll Pathol), V7, P35; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	62	479	507	2	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13123	13132		10.1074/jbc.M700492200	http://dx.doi.org/10.1074/jbc.M700492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337444	hybrid			2022-12-27	WOS:000245942800080
J	Schmid, GM; Meda, P; Caille, D; Wargent, E; O'Dowd, J; Hochstrasser, DF; Cawthorne, MA; Sanchez, JC				Schmid, Gerhard M.; Meda, Paolo; Caille, Dorothee; Wargent, Ed; O'Dowd, Jacqueline; Hochstrasser, Denis F.; Cawthorne, Michael A.; Sanchez, Jean-Charles			Inhibition of insulin secretion by betagranin, an N-terminal chromogranin A fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOINHIBITORY ACTIVITY; PANCREATIC-ISLETS; MESSENGER-RNA; CELL-LINE; LEPTIN; PEPTIDES; RAT; EXPRESSION; VASOSTATINS; ACTIVATION	Betagranin, an N-terminal fragment of chromogranin A, results from a proteolytic processing, and is co-secreted with insulin. While other chromogranin A-derived peptides negatively modulate hormone secretion, the role of betagranin in pancreatic beta-cells is so far unknown. We have recently shown that pancreatic islet betagranin levels are down-regulated in obese, leptin-deficient mice. In the present study, we have investigated the distribution of betagranin in primary mouse islets and cells of the MIN6 line and have evaluated its effects on insulin secretion. We showed that betagranin co-localizes with insulin within secretory granules and strongly inhibited insulin secretion in response to both glucose and potassium, by blocking the influx of calcium. The data demonstrated a hitherto unknown inhibitory effect of betagranin on insulin secretion.	Univ Geneva, Dept Struct Biol & Bioinformat, BPRG, CH-1211 Geneva 4, Switzerland; Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Sanchez, JC (corresponding author), Univ Geneva, Dept Struct Biol & Bioinformat, BPRG, CH-1211 Geneva 4, Switzerland.	Jean-Charles.Sanchez@medecine.unige.ch		Wargent, Edward/0000-0002-8545-2430				AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ahren B, 1999, AM J PHYSIOL-REG I, V277, pR959, DOI 10.1152/ajpregu.1999.277.4.R959; Andrades JA, 2001, GROWTH FACTORS, V18, P261, DOI 10.3109/08977190109029115; ANGELETTI RH, 1994, ACTA PHYSIOL SCAND, V152, P11, DOI 10.1111/j.1748-1716.1994.tb09780.x; ARDEN SD, 1994, BIOCHEM J, V298, P521, DOI 10.1042/bj2980521; Blois A, 2006, REGUL PEPTIDES, V134, P30, DOI 10.1016/j.regpep.2005.11.003; Bosco D, 2005, DIABETOLOGIA, V48, P1523, DOI 10.1007/s00125-005-1816-1; Calabrese A, 2003, DIABETES, V52, P417, DOI 10.2337/diabetes.52.2.417; Cerra MC, 2006, BASIC RES CARDIOL, V101, P43, DOI 10.1007/s00395-005-0547-2; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; Fehmann HC, 1997, ACTA DIABETOL, V34, P249, DOI 10.1007/s005920050083; Feldman SA, 2003, ENDOCR PATHOL, V14, P3, DOI 10.1385/EP:14:1:3; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Ghia JE, 2004, REGUL PEPTIDES, V121, P31, DOI 10.1016/j.regpep.2004.04.003; Grodsky G M, 1975, Methods Enzymol, V39, P364; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; HENDY GN, 1995, CLIN INVEST MED, V18, P47; Houseknecht KL, 1998, J ANIM SCI, V76, P1405; HUTTON JC, 1987, BIOCHEM J, V244, P449, DOI 10.1042/bj2440449; HUTTON JC, 1985, FEBS LETT, V188, P336, DOI 10.1016/0014-5793(85)80398-7; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam NT, 2004, J MOL ENDOCRINOL, V32, P415, DOI 10.1677/jme.0.0320415; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Maget-Dana R, 2002, ANN NY ACAD SCI, V971, P352, DOI 10.1111/j.1749-6632.2002.tb04494.x; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; McVicar CM, 2001, J NEUROENDOCRINOL, V13, P588, DOI 10.1046/j.1365-2826.2001.00671.x; MEDA P, 1990, J CLIN INVEST, V86, P759, DOI 10.1172/JCI114772; Pallett AL, 1997, BIOCHEM BIOPH RES CO, V238, P267, DOI 10.1006/bbrc.1997.7274; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; Sanchez JC, 2002, MOL CELL PROTEOMICS, V1, P509, DOI 10.1074/mcp.M200033-MCP200; Scherl A, 2005, J MICROBIOL METH, V60, P247, DOI 10.1016/j.mimet.2004.09.017; Seufert J, 2004, DIABETES, V53, pS152, DOI 10.2337/diabetes.53.2007.S152; Sharp GWG, 1996, AM J PHYSIOL-CELL PH, V271, pC1781, DOI 10.1152/ajpcell.1996.271.6.C1781; Stridsberg M, 2000, ADV EXP MED BIOL, V482, P319; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Tota B, 2003, REGUL PEPTIDES, V114, P123, DOI 10.1016/S0167-0115(03)00112-5; Tsiotra PC, 2001, INT J OBESITY, V25, P1018, DOI 10.1038/sj.ijo.0801657; Vives-Pi M, 2003, CLIN EXP IMMUNOL, V133, P208, DOI 10.1046/j.1365-2249.2003.02211.x; Wang H, 2001, BIOCHEM BIOPH RES CO, V289, P161, DOI 10.1006/bbrc.2001.5915; WATKINSON A, 1991, BIOCHEM J, V276, P471, DOI 10.1042/bj2760471; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	47	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12717	12724		10.1074/jbc.M700788200	http://dx.doi.org/10.1074/jbc.M700788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17289672	hybrid			2022-12-27	WOS:000245942800041
J	Fijolek, A; Hofer, A; Thelander, L				Fijolek, Artur; Hofer, Anders; Thelander, Lars			Expression, purification, characterization, and in vivo targeting of trypanosome CTP synthetase for treatment of African sleeping sickness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE-TRIPHOSPHATE SYNTHETASE; ANTI-TUMOR AGENT; PHASE-I; CEREBROSPINAL-FLUID; ACID; ACIVICIN; GLUTAMINE; BRUCEI; ANTICANCER; METABOLISM	African sleeping sickness is a fatal disease caused by two parasite subspecies: Trypanosoma brucei gambiense and T.b. rhodesiense. We previously reported that trypanosomes have extraordinary low CTP pools compared with mammalian cells. Trypanosomes also lack salvage of cytidine/cytosine making the parasite CTP synthetase a potential target for treatment of the disease. In this study, we have expressed and purified recombinant T. brucei CTP synthetase. The enzyme has a higher K-m value for UTP than the mammalian CTP synthetase, which in combination with a lower UTP pool may account for the low CTP pool in trypanosomes. The activity of the trypanosome CTP synthetase is irreversibly inhibited by the glutamine analogue acivicin, a drug extensively tested as an antitumor agent. There is a rapid uptake of acivicin in mice both given intraperitoneally and orally by gavage. Daily injection of acivicin in trypanosome-infected mice suppressed the infection up to one month without any significant loss of weight. Experiments with cultured bloodstream T. brucei showed that acivicin is trypanocidal if present at 1 mu M concentration for at least 4 days. Therefore, acivicin may qualify as a drug with "desirable" properties, i.e. cure within 7 days, according to the current Target Product Profiles of WHO and DNDi.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Fijolek, A (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	artur.fijolek@medchem.umu.se		Hofer, Anders/0000-0003-2890-2957				AHLUWALIA GS, 1990, PHARMACOL THERAPEUT, V46, P243, DOI 10.1016/0163-7258(90)90094-I; Bacher G, 2001, J MASS SPECTROM, V36, P1038, DOI 10.1002/jms.208; Berrang-Ford L, 2006, EMERG INFECT DIS, V12, P813; Brun R, 2006, CURR OPIN INFECT DIS, V19, P415, DOI 10.1097/01.qco.0000244045.93016.b1; CHIKHALE EG, 1995, BIOCHEM PHARMACOL, V49, P941, DOI 10.1016/0006-2952(95)00005-K; Chittur SV, 2001, BIOCHEMISTRY-US, V40, P876, DOI 10.1021/bi0014047; COONEY DA, 1974, CANCER CHEMOTH REP 1, V58, P793; DOUGHERTY WG, 1988, EMBO J, V7, P1281, DOI 10.1002/j.1460-2075.1988.tb02942.x; EARHART RH, 1983, CANCER TREAT REP, V67, P683; EARHART RH, 1985, ADV ENZYME REGUL, V24, P179, DOI 10.1016/0065-2571(85)90076-7; Endrizzi JA, 2004, BIOCHEMISTRY-US, V43, P6447, DOI 10.1021/bi0496945; FISCHER PH, 1984, CANCER RES, V44, P3355; Goto M, 2004, STRUCTURE, V12, P1413, DOI 10.1016/j.str.2004.05.013; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; HANKA LJ, 1973, ANTIMICROB AGENTS CH, V3, P425, DOI 10.1128/AAC.3.3.425; Hatse S, 1999, BIOCHEM PHARMACOL, V58, P539, DOI 10.1016/S0006-2952(99)00035-0; HICKMAN CP, 1997, INTEGRATED PRINCIPLE, P225; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Hofer A, 2001, P NATL ACAD SCI USA, V98, P6412, DOI 10.1073/pnas.111139498; Huang M, 2003, CELL MOL LIFE SCI, V60, P321, DOI 10.1007/s000180300027; HURLBERT RB, 1960, J BIOL CHEM, V235, P443; Kaufman SL, 1998, ANAL BIOCHEM, V259, P195, DOI 10.1006/abio.1998.2644; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kursula P, 2006, ACTA CRYSTALLOGR F, V62, P613, DOI 10.1107/S1744309106018136; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; Livingston R B, 1970, Adv Pharmacol Chemother, V8, P57; LONG CW, 1970, J BIOL CHEM, V245, P80; LONG CW, 1967, J BIOL CHEM, V242, P4715; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Matthews KR, 2005, J CELL SCI, V118, P283, DOI 10.1242/jcs.01649; MCGOVREN JP, 1981, J PHARMACOL EXP THER, V216, P433; MCGOVREN JP, 1982, CANCER TREAT REP, V66, P1333; MCPARTLAND RP, 1976, J BIOL CHEM, V251, P4372; Neil G L, 1978, Adv Enzyme Regul, V17, P375; NEIL GL, 1979, CANCER RES, V39, P852; Pays E, 2004, CURR OPIN MICROBIOL, V7, P369, DOI 10.1016/j.mib.2004.05.001; PYE IF, 1978, ANAL CHEM, V50, P951, DOI 10.1021/ac50029a031; ROBERTSON JG, 1995, BIOCHEMISTRY-US, V34, P7533, DOI 10.1021/bi00022a029; Rofougaran R, 2006, J BIOL CHEM, V281, P27705, DOI 10.1074/jbc.M605573200; SAVAGE CR, 1970, J BIOL CHEM, V245, P2529; SULLIVAN MP, 1988, CANCER CHEMOTH PHARM, V21, P78, DOI 10.1007/BF00262746; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; WEISS GR, 1982, CANCER RES, V42, P3892; Welburn SC, 2006, TRENDS PARASITOL, V22, P123, DOI 10.1016/j.pt.2006.01.011; WHO Expert Comm, 1998, WHO TECH REP SER, V881, P1	47	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11858	11865		10.1074/jbc.M611580200	http://dx.doi.org/10.1074/jbc.M611580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17331943	hybrid			2022-12-27	WOS:000245941900028
J	Ghosh, S; Pendurthi, UR; Steinoe, A; Esmon, CT; Rao, LVM				Ghosh, Samit; Pendurthi, Usha R.; Steinoe, Anne; Esmon, Charles T.; Rao, L. Vijaya Mohan			Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; ACTIVATED FACTOR-VII; FACTOR-XA; BINDING; COAGULATION; EXPRESSION; PHARMACOKINETICS; INDIVIDUALS; GENERATION; TURNOVER	Although factor VII/factor VIIa ( FVII/FVIIa) is known to interact with many non-vascular cells, activated monocytes, and endothelial cells via its binding to tissue factor ( TF), the interaction of FVII/FVIIa with unperturbed endothelium and the role of this interaction in clearing FVII/FVIIa from the circulation are unknown. To investigate this, in the present study we examined the binding of radiolabeled FVIIa to endothelial cells and its subsequent internalization. I-125-FVIIa bound to non-stimulated human umbilical vein endothelial cells ( HUVEC) in time- and dose-dependent manner. The binding is specific and independent of TF and negatively charged phospholipids. Protein C and monoclonal antibodies to endothelial cell protein C receptor ( EPCR) blocked effectively I-125-FVIIa binding to HUVEC. FVIIa binding to EPCR is confirmed by demonstrating a marked increase in I-125-FVIIa binding to CHO cells that had been stably transfected with EPCR compared with the wild-type. Binding analysis revealed that FVII, FVIIa, protein C, and activated protein C(APC) bound to EPCR with similar affinity. FVIIa binding to EPCR failed to accelerate FVIIa activation of factor X or protease-activated receptors. FVIIa binding to EPCR was shown to facilitate FVIIa endocytosis. Pharmacological concentrations of FVIIa were found to impair partly the EPCR-dependent protein C activation and APC-mediated cell signaling. Overall, the present data provide convincing evidence that EPCR serves as a cellular binding site for FVII/FVIIa. Further studies are needed to evaluate the pathophysiological consequences and relevance of FVIIa binding to EPCR.	Univ Texas Hlth Ctr, Biomed Res Div, Tyler, TX 75708 USA; Univ Oklahoma, Hlth Sci Ctr, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Rao, LVM (corresponding author), Univ Texas Hlth Ctr, Biomed Res Div, 11937 US HWY 271, Tyler, TX 75708 USA.	Vijay.Rao@uthct.edu	Ghosh, Samit/F-1772-2015	Ghosh, Samit/0000-0002-3536-3077	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065500, R01HL058869] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58869, HL 65500, R01 HL065500, R01 HL058869, R01 HL058869-08, R01 HL065500-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Bjorkman S, 2001, CLIN PHARMACOKINET, V40, P815; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Erhardtsen E, 2000, SEMIN THROMB HEMOST, V26, P385, DOI 10.1055/s-2000-8457; FAIR DS, 1983, BLOOD, V62, P784; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Ghosh S, 2007, J THROMB HAEMOST, V5, P336, DOI 10.1111/j.1538-7836.2007.02308.x; Hackeng TM, 2006, P NATL ACAD SCI USA, V103, P3106, DOI 10.1073/pnas.0504240103; HASSELBACK R, 1960, J APPL PHYSIOL, V15, P945, DOI 10.1152/jappl.1960.15.5.945; Hjortoe G, 2005, J THROMB HAEMOST, V3, P2264, DOI 10.1111/j.1538-7836.2005.01542.x; Iakhiaev A, 2001, J BIOL CHEM, V276, P45895, DOI 10.1074/jbc.M107603200; Iakhiaev A, 1999, J BIOL CHEM, V274, P36995, DOI 10.1074/jbc.274.52.36995; LE DT, 1992, J BIOL CHEM, V267, P15447; LOELIGER EA, 1960, THROMB DIATH HAEMOST, V4, P196, DOI 10.1055/s-0038-1654496; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; NICOLAISEN EM, 1992, FEBS LETT, V306, P157, DOI 10.1016/0014-5793(92)80989-T; OREILLY RA, 1963, J CLIN INVEST, V42, P1542, DOI 10.1172/JCI104839; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; Preston RJS, 2006, J BIOL CHEM, V281, P28850, DOI 10.1074/jbc.M604966200; Qu D, 2006, J THROMB HAEMOST, V4, P229, DOI 10.1111/j.1538-7836.2005.01676.x; RAO LVM, 1988, BLOOD, V71, P791; Rao LVM, 2003, MOL CELL BIOCHEM, V253, P131, DOI 10.1023/A:1026004208822; RAO LVM, 1988, THROMB RES, V51, P373, DOI 10.1016/0049-3848(88)90373-8; REUNING U, 1993, THROMB HAEMOSTASIS, V69, P197; Riewald M, 2003, J ENDOTOXIN RES, V9, P317, DOI 10.1179/096805103225002584; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; RODGERS GM, 1984, BLOOD, V63, P434; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SELIGSOHN U, 1979, BLOOD, V53, P828; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STENFLO J, 1984, SEMIN THROMB HEMOST, V10, P109, DOI 10.1055/s-2007-1004413; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; STERN DM, 1984, J CLIN INVEST, V74, P1910, DOI 10.1172/JCI111611	37	122	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11849	11857		10.1074/jbc.M609283200	http://dx.doi.org/10.1074/jbc.M609283200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17327234	Green Accepted, hybrid			2022-12-27	WOS:000245941900027
J	Hasegawa, M; Kawasaki, A; Yang, K; Fujimoto, Y; Masumoto, J; Breukink, E; Nunez, G; Fukase, K; Inohara, N				Hasegawa, Mizuho; Kawasaki, Akiko; Yang, Kangkang; Fujimoto, Yukari; Masumoto, Junya; Breukink, Eefjan; Nunez, Gabriel; Fukase, Koichi; Inohara, Naohiro			A role of lipophilic peptidoglycan-related molecules in induction of Nod1-mediated immune responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; BACTERIAL PEPTIDOGLYCAN; HOST RECOGNITION; NOD1 VARIATION; ASSOCIATION; ACTIVATION; RECRUITMENT; CARD4/NOD1; RECEPTOR	Nod1 is an intracellular protein that is involved in recognition of bacterial molecules and whose genetic variation has been linked to several inflammatory diseases. Previous studies suggested that the recognition core of Nod1 stimulatory molecules is gamma-D-glutamyl-meso-diaminopimelic acid ( iE-DAP), but the identity of the major Nod1 stimulatory molecule produced by bacteria remains unknown. Here we show that bacteria produce lipophilic molecules capable of stimulating Nod1. Analysis of synthetic compounds revealed stereoselectivity of the DAP residue and that conjugation of lipophilic acyl residues specifically enhances the Nod1 stimulatory activity of the core iE-DAP. Furthermore, we demonstrate that lipophilic molecules induce and/or enhance the secretion of innate immune mediators from primary mouse mesothelial cells and human monocytic Mono-Mac6 cells, and this effect is mediated through Nod1. These results provide insight into the mechanism of immune recognition via Nod1, which might be useful in the design and testing of novel immunoregulators.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan; Univ Utrecht, Dept Biochem Membranes, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Osaka University; Utrecht University	Inohara, N (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	ino@umich.edu	Breukink, Eefjan/I-3039-2016; Nuñez, Gabriel/A-7160-2014; Fujimoto, Yukari/M-7282-2014	Breukink, Eefjan/0000-0002-7311-0660; Fujimoto, Yukari/0000-0001-5320-3192				Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153; Boughan PK, 2006, J BIOL CHEM, V281, P11637, DOI 10.1074/jbc.M510275200; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Eder W, 2006, ALLERGY, V61, P1117, DOI 10.1111/j.1398-9995.2006.01128.x; Gao Y, 1998, J ORG CHEM, V63, P2133, DOI 10.1021/jo972133h; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; GOTO T, 1987, IMMUNOSTIMULANTS NOW, P99; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hasegawa M, 2006, J BIOL CHEM, V281, P29054, DOI 10.1074/jbc.M602638200; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Hvorup RN, 2003, EUR J BIOCHEM, V270, P799, DOI 10.1046/j.1432-1033.2003.03418.x; Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Masumoto J, 2006, J EXP MED, V203, P203, DOI 10.1084/jem.20051229; McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Opitz B, 2006, J IMMUNOL, V176, P484, DOI 10.4049/jimmunol.176.1.484; Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Tanabe T, 2006, BBA-MOL BASIS DIS, V1762, P794, DOI 10.1016/j.bbadis.2006.07.006; TOMASIC J, 1980, BIOCHIM BIOPHYS ACTA, V629, P77, DOI 10.1016/0304-4165(80)90266-4; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034	31	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11757	11764		10.1074/jbc.M700846200	http://dx.doi.org/10.1074/jbc.M700846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322292	hybrid			2022-12-27	WOS:000245941900018
J	Lakshmipathy, SK; Tomic, S; Kaiser, CM; Chang, HC; Genevaux, P; Georgopoulos, C; Barral, JM; Johnson, AE; Hartl, FU; Etchells, SA				Lakshmipathy, Sathish K.; Tomic, Sladjana; Kaiser, Christian M.; Chang, Hung-Chun; Genevaux, Pierre; Georgopoulos, Costa; Barral, Jose M.; Johnson, Arthur E.; Hartl, F. Ulrich; Etchells, Stephanie A.			Identification of nascent chain interaction sites on trigger factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FACTOR-BINDING; POLYPEPTIDE-CHAINS; PROLYL ISOMERASE; RIBOSOME; CHAPERONE; PROTEIN; DNAK; DOMAIN; SPECIFICITY	The role of ribosome-binding molecular chaperones in protein folding is not yet well understood. Trigger factor (TF) is the first chaperone to interact with nascent polypeptides as they emerge from the bacterial ribosome. It binds to the ribosome as a monomer but forms dimers in free solution. Based on recent crystal structures, TF has an elongated shape, with the peptidylproly/cis/trans-isomerase (PPIase) domain and the N-terminal ribosome binding domain positioned at opposite ends of the molecule and the C-terminal domain, which forms two arms, positioned in between. By using site specifically labeled TF proteins, we have demonstrated that all three domains of TF interact with nascent chains during translation. Interactions with the PPIase domain were length-dependent but independent of PPIase activity. Interestingly, with free TF, these same sites were found to be involved in forming the dimer interface, suggesting that dimerization partially occludes TF-nascent chain binding sites. Our data indicate the existence of two regions on TF along which nascent chains can interact, the NC-domains as the main site and the PPIase domain as an auxiliary site.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Ctr Med Univ Geneva, Dept Microbiol & Med Mol, CH-1211 Geneva, Switzerland; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	Max Planck Society; University of Geneva; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.	uhartl@biochem.mpg.de; etchells@biochem.mpg.de	Genevaux, Pierre/A-4851-2015; Johnson, Arthur E/G-3457-2012; Hartl, F. Ulrich/Y-8206-2019	zhang, hong jun/0000-0003-0030-8323; GENEVAUX, Pierre/0000-0001-7539-3126				Agashe VR, 2004, CELL, V117, P199, DOI 10.1016/S0092-8674(04)00299-5; Baram D, 2005, P NATL ACAD SCI USA, V102, P12017, DOI 10.1073/pnas.0505581102; Blaha G, 2003, J MOL BIOL, V326, P887, DOI 10.1016/S0022-2836(02)01436-5; Chin JW, 2002, CHEMBIOCHEM, V3, P1135, DOI 10.1002/1439-7633(20021104)3:11<1135::AID-CBIC1135>3.0.CO;2-M; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Etchells SA, 2005, J BIOL CHEM, V280, P28118, DOI 10.1074/jbc.M504110200; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Hoffmann A, 2006, J BIOL CHEM, V281, P6539, DOI 10.1074/jbc.M512345200; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Kaiser CM, 2006, NATURE, V444, P455, DOI 10.1038/nature05225; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2004, J BIOL CHEM, V279, P14165, DOI 10.1074/jbc.M313635200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Kristensen O, 2003, STRUCTURE, V11, P1547, DOI 10.1016/j.str.2003.11.003; Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101; Maier R, 2003, J MOL BIOL, V326, P585, DOI 10.1016/S0022-2836(02)01427-4; Maier T, 2005, CURR OPIN STRUC BIOL, V15, P204, DOI 10.1016/j.sbi.2005.03.005; Merz F, 2006, J BIOL CHEM, V281, P31963, DOI 10.1074/jbc.M605164200; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Raine A, 2006, J BIOL CHEM, V281, P28033, DOI 10.1074/jbc.M605753200; Schlunzen F, 2005, STRUCTURE, V13, P1685, DOI 10.1016/j.str.2005.08.007; Scholz C, 1998, J MOL BIOL, V277, P723, DOI 10.1006/jmbi.1997.1604; Schulze-Gahmen U, 2005, ACTA CRYSTALLOGR D, V61, P1343, DOI [10.1107/S090744490502264X, 10.1107/S09074490502264X]; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tomic S, 2006, FEBS LETT, V580, P72, DOI 10.1016/j.febslet.2005.11.050; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; Ullers RS, 2004, P NATL ACAD SCI USA, V101, P7583, DOI 10.1073/pnas.0402398101; Vorderwulbecke S, 2004, FEBS LETT, V559, P181, DOI 10.1016/S0014-5793(04)00052-3	34	57	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12186	12193		10.1074/jbc.M609871200	http://dx.doi.org/10.1074/jbc.M609871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17296610	hybrid			2022-12-27	WOS:000245941900061
J	Lian, HY; Zhang, H; Zhang, ZR; Loovers, HM; Jones, GW; Rowling, PJE; Itzhaki, LS; Zhou, JM; Perrett, S				Lian, Hui-Yong; Zhang, Hong; Zhang, Zai-Rong; Loovers, Harriet M.; Jones, Gary W.; Rowling, Pamela J. E.; Itzhaki, Laura S.; Zhou, Jun-Mei; Perrett, Sarah			Hsp40 interacts directly with the native state of the yeast prion protein Ure2 and inhibits formation of amyloid-like fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; DNAJ HOMOLOG; IN-VITRO; ATPASE ACTIVITY; HSP70; DOMAIN; PROPAGATION; AGGREGATION; GLUTATHIONE	Ure2 is the protein determinant of the [ URE3] prion phenotype in Saccharomyces cerevisiae and consists of a flexible N-terminal prion-determining domain and a globular C-terminal glutathione transferase-like domain. Overexpression of the type I Hsp40 member Ydj1 in yeast cells has been found to result in the loss of [ URE3]. However, the mechanism of prion curing by Ydj1 remains unclear. Here we tested the effect of overexpression of Hsp40 members Ydj1, Sis1, and Apj1 and also Hsp70 co-chaperones Cpr7, Cns1, Sti1, and Fes1 in vivo and found that only Ydj1 showed a strong curing effect on [ URE3]. We also investigated the interaction of Ydj1 with Ure2 in vitro. We found that Ydj1 was able to suppress formation of amyloid-like fibrils of Ure2 by delaying the process of fibril formation, as monitored by thioflavin T binding and atomic force microscopy imaging. Controls using bovine serum albumin, Sis1, or the human Hsp40 homologues Hdj1 or Hdj2 showed no significant inhibitory effect. Ydj1 was only effective when added during the lag phase of fibril formation, suggesting that it interacts with Ure2 at an early stage in fibril formation and delays the nucleation process. Using surface plasmon resonance and size exclusion chromatography, we demonstrated a direct interaction between Ydj1 and both wild type and N-terminally truncated Ure2. In contrast, Hdj2, which did not suppress fibril formation, did not show this interaction. The results suggest that Ydj1 inhibits Ure2 fibril formation by binding to the native state of Ure2, thus delaying the onset of oligomerization.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Natl Univ Ireland Maynooth, Dept Biol, Maynooth, Kildare, Ireland; Hutchison Med Res Council, Res Ctr, Canc Cell Unit, Cambridge CB2 0XZ, England; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Maynooth University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Perrett, S (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	sarah.perrett@iname.com	Perrett, Sarah/AAS-9483-2020; Zhang, Zairong/G-1030-2013	Perrett, Sarah/0000-0003-0137-0997; ?, ??/0000-0003-0168-9201; Jones, Gary/0000-0002-7565-934X; ZHANG, ZAIRONG/0000-0001-9768-0548	Medical Research Council [MC_U105370180] Funding Source: Medline; MRC [MC_U105370180] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bai M, 2004, J BIOL CHEM, V279, P50025, DOI 10.1074/jbc.M406612200; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Bradley ME, 2002, P NATL ACAD SCI USA, V99, P16392, DOI 10.1073/pnas.152330699; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Catharino S, 2005, BIOL CHEM, V386, P633, DOI 10.1515/BC.2005.074; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; Edskes HK, 2002, P NATL ACAD SCI USA, V99, P16384, DOI 10.1073/pnas.162349599; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Galani D, 2002, J MOL BIOL, V315, P213, DOI 10.1006/jmbi.2001.5234; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gokhale KC, 2005, J BIOL CHEM, V280, P22809, DOI 10.1074/jbc.M500390200; Hainzl O, 2004, J BIOL CHEM, V279, P23267, DOI 10.1074/jbc.M402189200; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Jiang Y, 2004, J BIOL CHEM, V279, P3361, DOI 10.1074/jbc.M310494200; Johnson SM, 2005, ACCOUNTS CHEM RES, V38, P911, DOI 10.1021/ar020073i; Jones GW, 2005, BIOESSAYS, V27, P823, DOI 10.1002/bies.20267; Kryndushkin DS, 2002, J BIOL CHEM, V277, P23702, DOI 10.1074/jbc.M111547200; Krzewska J, 2006, EMBO J, V25, P822, DOI 10.1038/sj.emboj.7600985; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lian HY, 2006, BBA-PROTEINS PROTEOM, V1764, P535, DOI 10.1016/j.bbapap.2005.11.016; Loovers HM, 2007, GENETICS, V175, P621, DOI 10.1534/genetics.106.066019; Lopez N, 2003, MOL BIOL CELL, V14, P1172, DOI 10.1091/mbc.E02-09-0593; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Minami Y, 1999, GENES CELLS, V4, P721, DOI 10.1046/j.1365-2443.1999.00299.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Roberts BT, 2004, YEAST, V21, P107, DOI 10.1002/yea.1062; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlumpberger M, 2000, PROTEIN SCI, V9, P440; Schwimmer C, 2002, MOL CELL BIOL, V22, P3590, DOI 10.1128/MCB.22.11.3590-3598.2002; SILVER JM, 1969, BIOCHEM BIOPH RES CO, V34, P301, DOI 10.1016/0006-291X(69)90831-6; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhu L, 2003, J MOL BIOL, V328, P235, DOI 10.1016/S0022-2836(03)00249-3	63	52	52	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11931	11940		10.1074/jbc.M606856200	http://dx.doi.org/10.1074/jbc.M606856200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324933	hybrid			2022-12-27	WOS:000245941900036
J	Schelling, P; Guglielmi, KM; Kirchner, E; Paetzold, B; Dermody, TS; Stehle, T				Schelling, Pierre; Guglielmi, Kristen M.; Kirchner, Eva; Paetzold, Bernhard; Dermody, Terence S.; Stehle, Thilo			The reovirus sigma 1 aspartic acid sandwich - A trimerization motif poised for conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL ADHESION MOLECULE-1; CAPSID PROTEIN MU-1; ATTACHMENT PROTEIN; CRYSTAL-STRUCTURE; LOW-PH; SIALIC-ACID; PARTICLES; RECEPTOR; BINDING; HEMAGGLUTININ	Reovirus attachment protein sigma 1 mediates engagement of receptors on the surface of target cells and undergoes dramatic conformational rearrangements during viral disassembly in the endocytic pathway. The sigma 1 protein is a filamentous, trimeric molecule with a globular beta-barrel head domain. An unusual cluster of aspartic acid residues sandwiched between hydrophobic tyrosines is located at the sigma 1 subunit interface. A 1.75-angstrom structure of the sigma 1 head domain now reveals two water molecules at the subunit interface that are held strictly in position and interact with neighboring residues. Structural and biochemical analyses of mutants affecting the aspartic acid sandwich indicate that these residues and the corresponding chelated water molecules act as a plug to block the free flow of solvent and stabilize the trimer. This arrangement of residues at the sigma 1 head trimer interface illustrates a new protein design motif that may confer conformational mobility during cell entry.	Univ Tubingen, Interfakultares Inst Biochem, D-72076 Tubingen, Germany; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Eberhard Karls University of Tubingen; Vanderbilt University; Vanderbilt University; Vanderbilt University	Dermody, TS (corresponding author), Univ Tubingen, Interfakultares Inst Biochem, Hoppe Seyler Str 4, D-72076 Tubingen, Germany.	terry.dermody@vanderbilt.edu; thilo.stehle@uni-tuebingen.de	Ogden, Kristen/AAO-9276-2020	Ogden, Kristen/0000-0002-2670-4335	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067853, T32GM008554] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [T32 GM08554, R01 GM67853] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Baer GS, 1997, J VIROL, V71, P4921, DOI 10.1128/JVI.71.7.4921-4928.1997; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barton ES, 2001, J BIOL CHEM, V276, P2200, DOI 10.1074/jbc.M004680200; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Campbell JA, 2005, J VIROL, V79, P7967, DOI 10.1128/JVI.79.13.7967-7978.2005; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cavalli A, 2004, BIOPHYS J, V86, P3423, DOI 10.1529/biophysj.103.030825; Chandran K, 2003, J VIROL, V77, P13361, DOI 10.1128/JVI.77.24.13361-13375.2003; Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Chappell JD, 2002, EMBO J, V21, P1, DOI 10.1093/emboj/21.1.1; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; DeLano W.L, PYMOL MOL GRAPHICS S; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Forrest JC, 2003, J BIOL CHEM, V278, P48434, DOI 10.1074/jbc.M305649200; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIBERT ML, 1995, J VIROL, V69, P5057, DOI 10.1128/JVI.69.8.5057-5067.1995; Odegard AL, 2004, J VIROL, V78, P8732, DOI 10.1128/JVI.78.16.8732-8745.2004; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prota AE, 2003, P NATL ACAD SCI USA, V100, P5366, DOI 10.1073/pnas.0937718100; Roche S, 2006, SCIENCE, V313, P187, DOI 10.1126/science.1127683; SIBANDA BL, 1991, METHOD ENZYMOL, V202, P59; Stehle T, 2004, VIRAL IMMUNOL, V17, P129, DOI 10.1089/0882824041310621; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987	38	22	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11582	11589		10.1074/jbc.M610805200	http://dx.doi.org/10.1074/jbc.M610805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303562	Green Published, hybrid			2022-12-27	WOS:000245941500079
J	Agbulut, O; Huet, A; Niederlander, N; Puceat, M; Menasche, P; Coirault, C				Agbulut, Onnik; Huet, Alexis; Niederlander, Nicolas; Puceat, Michel; Menasche, Philippe; Coirault, Catherine			Green fluorescent protein impairs actin-myosin interactions by binding to the actin-binding site of myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRIATED-MUSCLE; SKELETAL-MUSCLE; MOTOR DOMAIN; CELLS; MODEL; SURFACE; CONTRACTION; EXPRESSION; ALGORITHM; FREQUENCY	Green fluorescent proteins ( GFP) are widely used in biology for tracking purposes. Although expression of GFP is considered to be innocuous for the cells, deleterious effects have been reported. We recently demonstrated that expression of eGFP in muscle impairs its contractile properties ( Agbulut, O., Coirault, C., Niederlander, N., Huet, A., Vicart, P., Hagege, A., Puceat, M., and Menasche, P. ( 2006) Nat. Meth. 3, 331). This prompted us to identify the molecular mechanisms linking eGFP expression to contractile dysfunction and, particularly, to test the hypothesis that eGFP could inhibit actin-myosin interactions. Therefore, we assessed the cellular, mechanical, enzymatic, biochemical, and structural properties of myosin in the presence of eGFP and F-actin. In vitro motility assays, the maximum actin-activated ATPase rate ( V-max) and the associated constant of myosin for actin ( K-m) were determined at 1:0.5, 1:1, and 1:3 myosin: eGFP molar ratios. At a myosin: eGFP ratio of 1: 0.5, there was a nearly 10-fold elevation of K-m. As eGFP concentration increased relative to myosin, the percentage of moving filaments, the myosin-based velocity, and V-max significantly decreased compared with controls. Moreover, myosin co-precipitated with eGFP. Crystal structures of myosin, actin, and GFP indicated that GFP and actin exhibited similar electrostatic surface patterns and the ClusPro docking model showed that GFP bound preferentially to the myosin head and especially to the actin-binding site. In conclusion, our data demonstrate that expression of eGFP in muscle resulted in the binding of eGFP to myosin, thereby disturbing the actin-myosin interaction and in turn the contractile function of the transduced cells. This potential adverse effect of eGFP should be kept in mind when using this marker to track cells following transplantation.	Univ Paris Diderot Paris 7, Dept Biochem, EA300, F-75005 Paris, France; INSERM U421 I Stem, F-91004 Evry, France; Hop Europeen Georges Pompidou, APHP, Dept Cardiovasc Surg, F-75014 Paris, France; Univ Paris 05, Fac Med, F-75014 Paris, France; INSERM U633, F-75014 Paris, France; Univ Paris 07, CRCIL, INSERM U689, F-75010 Paris, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Agbulut, O (corresponding author), 2 Pl Jussieu Case 7006, F-75005 Paris, France.	onnik.agbulut@univ-paris-diderot.fr	Coirault, Catherine/I-2979-2016; Huet, Alexis/AAU-5958-2021; PUCEAT, michel/R-6140-2017; Coirault, Catherine/S-2454-2019	Huet, Alexis/0000-0001-6069-4460; Coirault, Catherine/0000-0002-5594-1057; PUCEAT, michel/0000-0001-9055-7563; Niederlander, Nicolas/0000-0003-1323-8387; Agbulut, Onnik/0000-0003-1923-8871				Agbulut O, 2006, NAT METHODS, V3, P331, DOI 10.1038/nmeth0506-331; Al Attar N, 2003, CARDIOVASC RES, V58, P142, DOI 10.1016/S0008-6363(02)00790-3; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Bobkov AA, 1996, P NATL ACAD SCI USA, V93, P2285, DOI 10.1073/pnas.93.6.2285; Bobkova EA, 1999, BIOPHYS J, V76, P1001, DOI 10.1016/S0006-3495(99)77264-4; Brazelton TR, 2003, DEV BIOL, V262, P64, DOI 10.1016/S0012-1606(03)00357-9; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chow D, 2002, J BIOL CHEM, V277, P36799, DOI 10.1074/jbc.M204101200; Coirault C, 2002, AM J RESP CRIT CARE, V165, P250, DOI 10.1164/ajrccm.165.2.2105088; Comeau SR, 2004, NUCLEIC ACIDS RES, V32, pW96, DOI 10.1093/nar/gkh354; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hanazono Y, 1997, HUM GENE THER, V8, P1313, DOI 10.1089/hum.1997.8.11-1313; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Jesaitis AJ, 1999, PROTEIN SCI, V8, P760; Krestel HE, 2004, NEUROBIOL DIS, V17, P310, DOI 10.1016/j.nbd.2004.05.012; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; Smyczynski C, 1997, BIOCHEMISTRY-US, V36, P13201, DOI 10.1021/bi970746i; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Srikakulam R, 2004, J CELL SCI, V117, P641, DOI 10.1242/jcs.00899; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; Wang Q, 2003, J CELL SCI, V116, P4227, DOI 10.1242/jcs.00709; Zielske SP, 2004, MOL THER, V9, P923, DOI 10.1016/j.ymthe.2004.02.017	36	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10465	10471		10.1074/jbc.M610418200	http://dx.doi.org/10.1074/jbc.M610418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289667	hybrid			2022-12-27	WOS:000245941000038
J	Kanayama, T; Arito, M; So, K; Hachimura, S; Inoue, J; Sato, R				Kanayama, Tomohiko; Arito, Mitsumi; So, Kanako; Hachimura, Satoshi; Inoue, Jun; Sato, Ryuichiro			Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL HETERODIMER PARTNER; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; BILE-ACID BIOSYNTHESIS; COENZYME-A REDUCTASE; X-RECEPTOR; NUCLEAR RECEPTORS; DIFFERENTIAL REGULATION; PROTEASOME PATHWAY; 2 MECHANISMS; FATTY-ACIDS	In previous studies it was demonstrated that sterol regulatory element-binding proteins ( SREBPs) are able to interact with one of the nuclear receptors, hepatocyte nuclear receptor (HNF)-4, and that this interaction regulates transcriptional activities of these proteins (Misawa, K., Horiba, T., Arimura, N., Hirano, Y., Inoue, J., Emoto, N., Shimano, H., Shimizu, M., and Sato, R. (2003) J. Biol. Chem. 278, 36176 - 36182; Yamamoto, T., Shimano, H., Nakagawa, Y., Ide, T., Yahagi, N., Matsuzaka, T., Nakakuki, M., Takahashi, A., Suzuki, H., Sone, H., Toyoshima, H., Sato, R., and Yamada, N. ( 2004) J. Biol. Chem. 279, 12027 12035). In an attempt to identify other nuclear receptor family members affecting the SREBP transcriptional activities, we found that the liver receptor homolog (LRH)-1 suppresses them. Several types of luciferase assays revealed that coexpression of these two proteins (LRH- 1 and SREBP- 1a, - 1c, or - 2) results in reciprocal inhibition of the transcriptional activity of each protein. It was confirmed that suppression in endogenous LRH- 1 by small interference RNA stimulates the mRNA levels of certain SREBP target genes and that elevation in active SREBPs in the nucleus in response to cholesterol depletion suppresses the LRH- 1 activity. In vitro/ in vivo glutathione S-transferase pulldown experiments demonstrated that the basic helix-loop-helix-leucine zipper domain in SREBP- 2 binds to the ligand-binding domain in LRH- 1. Furthermore, we found that SREBP- 2 interferes with the recruitment of a coactivator of LRH-1, the peroxisome proliferator- activated receptor gamma coactivator-1 alpha, thereby leading to the inhibition of the LRH- 1 transcriptional activity. These results clearly indicate that the interaction between SREBPs and LRH-1 exerts a suppressive influence on their target gene expression responsible for cholesterol and bile acid metabolism.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Basic Res Activities Innovat Biosci, Tokyo 1050001, Japan	University of Tokyo	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, 1-1-1 Yayoi, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp	INOUE, Jun/O-7352-2016	INOUE, Jun/0000-0003-4145-3754				Agata Y, 2001, J EXP MED, V193, P873, DOI 10.1084/jem.193.7.873; Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Bengoechea-Alonso MT, 2005, P NATL ACAD SCI USA, V102, P11681, DOI 10.1073/pnas.0501494102; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Datta S, 2006, J BIOL CHEM, V281, P807, DOI 10.1074/jbc.M511050200; del Castillo-Olivares A, 2004, J BIOL CHEM, V279, P16813, DOI 10.1074/jbc.M400646200; Delerive P, 2004, MOL ENDOCRINOL, V18, P2378, DOI 10.1210/me.2004-0132; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kim HJ, 2004, J BIOL CHEM, V279, P28122, DOI 10.1074/jbc.M313302200; Kotzka J, 2004, J BIOL CHEM, V279, P22404, DOI 10.1074/jbc.M401198200; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lee YK, 2006, J BIOL CHEM, V281, P7850, DOI 10.1074/jbc.M509115200; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Li TG, 2006, J BIOL CHEM, V281, P28745, DOI 10.1074/jbc.M605815200; Li Y, 2005, P NATL ACAD SCI USA, V102, P9505, DOI 10.1073/pnas.0501204102; Li Y, 2005, MOL CELL, V17, P491, DOI 10.1016/j.molcel.2005.02.002; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Nakahara M, 2005, J BIOL CHEM, V280, P42283, DOI 10.1074/jbc.M507454200; Ngo TT, 2002, J BIOL CHEM, V277, P33901, DOI 10.1074/jbc.M202135200; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Qin J, 2004, MOL ENDOCRINOL, V18, P2424, DOI 10.1210/me.2004-0009; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Safi R, 2005, CANCER RES, V65, P11762, DOI 10.1158/0008-5472.CAN-05-2792; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Wang DP, 1996, J LIPID RES, V37, P1831; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Xu PL, 2004, MOL ENDOCRINOL, V18, P1887, DOI 10.1210/me.2003-0334; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Zhang YQ, 2003, J LIPID RES, V44, P356, DOI 10.1194/jlr.M200283-JLR200	43	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10290	10298		10.1074/jbc.M700270200	http://dx.doi.org/10.1074/jbc.M700270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283069	hybrid			2022-12-27	WOS:000245941000019
J	Malet, H; Egloff, MP; Selisko, B; Butcher, RE; Wright, PJ; Roberts, M; Gruez, A; Sulzenbacher, G; Vonrhein, C; Bricogne, G; Mackenzie, JM; Khromykh, AA; Davidson, AD; Canard, B				Malet, Helene; Egloff, Marie-Pierre; Selisko, Barbara; Butcher, Rebecca E.; Wright, Peter J.; Roberts, Michael; Gruez, Arnaud; Sulzenbacher, Gerlind; Vonrhein, Clemens; Bricogne, Gerard; Mackenzie, Jason M.; Khromykh, Alexander A.; Davidson, Andrew D.; Canard, Bruno			Crystal structure of the RNA polymerase domain of the West Nile Virus non-structural protein 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; NUCLEAR-LOCALIZATION; MAXIMUM-LIKELIHOOD; VIRAL HELICASE; NS5 PROTEIN; STRAND RNA; DENGUE; TYPE-2; NUCLEOTIDE; MECHANISM	Viruses of the family Flaviviridae are important human and animal pathogens. Among them, the Flaviviruses dengue ( DENV) and West Nile ( WNV) cause regular outbreaks with fatal outcomes. The RNA-dependent RNA polymerase ( RdRp) activity of the non-structural protein 5 ( NS5) is a key activity for viral RNA replication. In this study, crystal structures of enzymatically active and inactive WNV RdRp domains were determined at 3.0- and 2.35-angstrom resolution, respectively. The determined structures were shown to be mostly similar to the RdRps of the Flaviviridae members hepatitis C and bovine viral diarrhea virus, although with unique elements characteristic for the WNVRdRp. Using a reverse genetic system, residues involved in putative interactions between the RNA-cap methyltransferase ( MTase) and the RdRp domain of Flavivirus NS5 were identified. This allowed us to propose a model for the structure of the full-length WNV NS5 by in silico docking of the WNV MTase domain ( modeled from our previously determined structure of the DENV MTase domain) onto the RdRp domain. The Flavivirus RdRp domain structure determined here should facilitate both the design of anti-Flavivirus drugs and structure-function studies of the Flavivirus replication complex in which the multifunctional NS5 protein plays a central role.	CNRS, F-13288 Marseille, France; Univ Aix Marseille 1, F-13288 Marseille, France; Univ Aix Marseille 2, UMR 6098, F-13288 Marseille, France; Monash Univ, Dept Microbiol, Melbourne, Vic 3168, Australia; Global Phasing Ltd, Cambridge CB3 0AX, England; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia; Univ Bristol, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Monash University; Global Phasing Limited; University of Queensland; University of Bristol	Canard, B (corresponding author), CNRS, ESIL Case 925, F-13288 Marseille, France.	bruno.canard@afmb.univ-mrs.fr	Khromykh, Alexander/X-7200-2018; Sulzenbacher, Gerlind/A-6801-2018; Mackenzie, Jason/H-5632-2019	Khromykh, Alexander/0000-0001-6206-6935; Sulzenbacher, Gerlind/0000-0003-4844-2820; Mackenzie, Jason/0000-0001-6613-8350; MALET, Helene/0000-0002-2834-7386; Canard, Bruno/0000-0003-4924-1991				Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; Adachi T, 2002, BBA-PROTEINS PROTEOM, V1601, P38, DOI 10.1016/S1570-9639(02)00433-8; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartelma G, 2002, VIROLOGY, V299, P122, DOI 10.1006/viro.2002.1504; Benarroch D, 2004, VIROLOGY, V328, P208, DOI 10.1016/j.virol.2004.07.004; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brooks AJ, 2002, J BIOL CHEM, V277, P36399, DOI 10.1074/jbc.M204977200; Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCKLEY A, 1992, J GEN VIROL, V73, P1125, DOI 10.1099/0022-1317-73-5-1125; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferrer-Orta C, 2006, CURR OPIN STRUC BIOL, V16, P27, DOI 10.1016/j.sbi.2005.12.002; Ferrer-Orta C, 2004, J BIOL CHEM, V279, P47212, DOI 10.1074/jbc.M405465200; Gorbalenya AE, 2002, J MOL BIOL, V324, P47, DOI 10.1016/S0022-2836(02)01033-1; Gualano RC, 1998, J GEN VIROL, V79, P437, DOI 10.1099/0022-1317-79-3-437; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2; Hall RA, 2002, CURR TOP MICROBIOL, V267, P253; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johansson M, 2001, J GEN VIROL, V82, P735, DOI 10.1099/0022-1317-82-4-735; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Khromykh AA, 1999, J VIROL, V73, P10272, DOI 10.1128/JVI.73.12.10272-10280.1999; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Lanciotti RS, 2002, VIROLOGY, V298, P96, DOI 10.1006/viro.2002.1449; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Nomaguchi M, 2003, J VIROL, V77, P8831, DOI 10.1128/JVI.77.16.8831-8842.2003; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Pryor MJ, 1998, J GEN VIROL, V79, P2631, DOI 10.1099/0022-1317-79-11-2631; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Ray D, 2006, J VIROL, V80, P8362, DOI 10.1128/JVI.00814-06; Scherret JH, 2001, EMERG INFECT DIS, V7, P697, DOI 10.3201/eid0704.010418; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Selisko B, 2006, VIROLOGY, V351, P145, DOI 10.1016/j.virol.2006.03.026; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; Tao YZ, 2002, CELL, V111, P733, DOI 10.1016/S0092-8674(02)01110-8; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; Uchil PD, 2006, J VIROL, V80, P5451, DOI 10.1128/JVI.01982-05; van Dijk AA, 2004, J GEN VIROL, V85, P1077, DOI 10.1099/vir.0.19731-0; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; Yon C, 2005, J BIOL CHEM, V280, P27412, DOI 10.1074/jbc.M501393200	63	191	202	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10678	10689		10.1074/jbc.M607273200	http://dx.doi.org/10.1074/jbc.M607273200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287213	Green Published, hybrid			2022-12-27	WOS:000245941000062
J	Gutierrez, J; Paredes, R; Cruzat, F; Hill, DA; van Wijnen, AJ; Lian, JB; Stein, GS; Stein, JL; Imbalzano, AN; Montecino, M				Gutierrez, Jose; Paredes, Roberto; Cruzat, Fernando; Hill, David A.; van Wijnen, Andre J.; Lian, Jane B.; Stein, Gary S.; Stein, Janet L.; Imbalzano, Anthony N.; Montecino, Martin			Chromatin remodeling by SWI/SNF results in nucleosome mobilization to preferential positions in the rat osteocalcin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE OCTAMER; SWI-SNF; SEQUENCE MOTIFS; BINDING PROTEIN; DNA; COMPLEX; TRANSCRIPTION; ORGANIZATION; DISRUPTION; EXPRESSION	Changes in local chromatin structure accompany transcriptional activation of eukaryotic genes. In vivo these changes in chromatin organization can be catalyzed by ATP-dependent chromatin-remodeling complexes, such as SWI/SNF. These complexes alter the tight wrapping of DNA in the nucleosomes and can facilitate the mobilization of the histone octamer to adjacent DNA segments, leaving promoter regulatory elements exposed for transcription factor binding. To gain understanding of how the activity of SWI/SNF complexes may be modulated by the different DNA sequences within a natural promoter, we have reconstituted nucleosomes containing promoter segments of the transcriptionally active cell type-specific osteocalcin (OC) gene and determined how they affect the directional movements of the nucleosomes. Our results indicate that SWI/SNF complexes induce octamer sliding to preferential positions in the OC promoter, leading to a nucleosomal organization that resembles that described in intact cells expressing the OC gene. Our studies demonstrate that the position of the histone octamer is primarily determined by sequences within the OC promoter that include or exclude nucleosomes. We propose that these sequences are critical components of the regulatory mechanisms that mediate expression of this tissue-specific gene.	Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Concepcion 4079100, Chile; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Universidad de Concepcion; University of Massachusetts System; University of Massachusetts Worcester	Montecino, M (corresponding author), Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Barrio Univ S-N,Casilla 160-C, Concepcion 4079100, Chile.	mmonteci@udec.cl	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946; Gutierrez, Jose/0000-0002-0957-2297; Paredes, Roberto/0000-0002-6793-5404	FIC NIH HHS [5R03TW00990] Funding Source: Medline; NIAMS NIH HHS [R01 AR049069] Funding Source: Medline; NIGMS NIH HHS [GM56244] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JD, 2001, MOL CELL BIOL, V21, P3830, DOI 10.1128/MCB.21.11.3830-3839.2001; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Cao H, 1998, J MOL BIOL, V281, P253, DOI 10.1006/jmbi.1998.1925; Cloutier TE, 2004, MOL CELL, V14, P355, DOI 10.1016/S1097-2765(04)00210-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Flaus A, 2003, MOL CELL BIOL, V23, P7767, DOI 10.1128/MCB.23.21.7767-7779.2003; GRABIALAN A, 1996, FEBS LETT, V393, P65; Gutierrez J, 2000, BIOCHEMISTRY-US, V39, P13565, DOI 10.1021/bi0013896; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X; Kiyama R, 2002, FEBS LETT, V523, P7, DOI 10.1016/S0014-5793(02)02937-X; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Montecino M, 1996, J CELL BIOCHEM, V63, P221, DOI 10.1002/(SICI)1097-4644(19961101)63:2<221::AID-JCB9>3.0.CO;2-#; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; Studitsky VM, 1996, METHOD ENZYMOL, V274, P246; Thastrom A, 2004, J MOL BIOL, V338, P695, DOI 10.1016/j.jmb.2004.03.032; Thastrom A, 1999, J MOL BIOL, V288, P213, DOI 10.1006/jmbi.1999.2686; Villagra A, 2006, J BIOL CHEM, V281, P22695, DOI 10.1074/jbc.M511640200; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang YH, 1996, P NATL ACAD SCI USA, V93, P8863, DOI 10.1073/pnas.93.17.8863; Wang YH, 1996, J MOL BIOL, V263, P511, DOI 10.1006/jmbi.1996.0593; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	44	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9445	9457		10.1074/jbc.M609847200	http://dx.doi.org/10.1074/jbc.M609847200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272279	hybrid			2022-12-27	WOS:000245421700017
J	MacKenzie, DA; Schartner, J; Lin, J; Timmel, A; Jennens-Clough, M; Fathman, CG; Seroogy, CM				MacKenzie, Debra A.; Schartner, Jill; Lin, Jack; Timmel, Amanda; Jennens-Clough, Martha; Fathman, C. Garrison; Seroogy, Christine M.			GRAIL is up-regulated in CD4(+) CD25(+) T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; SUPPRESSOR FUNCTION; INDUCTION; TOLERANCE; ANTIGEN; SCURFIN; FOXP3; LYMPHOCYTES; POPULATIONS; MECHANISM	GRAIL (gene related to anergy in lymphocytes) is an ubiquitin-protein isopeptide ligase (E3) ubiquitin ligase necessary for the induction of CD4(+) T cell anergy in vivo. We have extended our previous studies to characterize the expression pattern of GRAIL in other murine CD4(+) T cell types with a described anergic phenotype. These studies revealed that GRAIL expression is increased in naturally occurring (thymically derived) CD4(+) CD25(+) T regulatory cells (mRNA levels 10-fold higher than naive CD25(-) T cells). Further investigation demonstrated that CD25(+) Foxp3(+) antigen-specific T cells were induced after a "tolerizing-administration" of antigen and that GRAIL expression correlated with the CD25(+) Foxp3(+) antigen-specific subset. Lastly, using retroviral transduction, we demonstrated that forced expression of GRAIL in a T cell line was sufficient for conversion of these cells to a regulatory phenotype in the absence of detectable Foxp3. These data demonstrate that GRAIL is differentially expressed in naturally occurring and peripherally induced CD25(+) T regulatory cells and that the expression of GRAIL is linked to their functional regulatory activity.	Univ Wisconsin, Dept Pediat, Div Allergy Immunol Rheumatol, Madison, WI 53792 USA; Stanford Univ, Dept Med, Div Immunol Rheumatol, Stanford, CA 94305 USA	University of Wisconsin System; University of Wisconsin Madison; Stanford University	Seroogy, CM (corresponding author), Univ Wisconsin, Dept Pediat, Div Immunol & Rheumatol, H4-474 CSC,600 Highland Ave, Madison, WI 53792 USA.	cmseroogy@wisc.edu						Anandasabapathy N, 2003, IMMUNITY, V18, P535, DOI 10.1016/S1074-7613(03)00084-0; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; DRESSER DW, 1961, NATURE, V191, P1169, DOI 10.1038/1911169a0; Ermann J, 2001, J IMMUNOL, V167, P4271, DOI 10.4049/jimmunol.167.8.4271; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; GVIN MA, 2006, P NATL ACAD SCI US; Heissmeyer V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Pape KA, 1998, J IMMUNOL, V160, P4719; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SCHWARTZ RH, 1989, COLD SH Q B, V54, P605; Seroogy CM, 2004, J IMMUNOL, V173, P79, DOI 10.4049/jimmunol.173.1.79; Soares L, 2004, NAT IMMUNOL, V5, P45, DOI 10.1038/ni1017; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tanchot C, 2001, J IMMUNOL, V167, P2030, DOI 10.4049/jimmunol.167.4.2030; Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188	29	57	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9696	9702		10.1074/jbc.M604192200	http://dx.doi.org/10.1074/jbc.M604192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259178	hybrid			2022-12-27	WOS:000245421700043
J	Haapasalo, A; Kim, DY; Carey, BW; Turunen, MK; Pettingell, WH; Kovacs, DM				Haapasalo, Annakaisa; Kim, Doo Yeon; Carey, Bryce W.; Turunen, Mari K.; Pettingell, Warren H.; Kovacs, Dora M.			Presenilin/gamma-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase with beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; HIPPOCAMPAL CHOLINERGIC INNERVATION; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; DISINTEGRIN-METALLOPROTEASE; NEURITE OUTGROWTH; NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; TERMINAL FRAGMENTS	Leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase regulates cell adhesion and formation of functional synapses and neuronal networks. Here we report that LAR is sequentially cleaved by alpha- and presenilin (PS)/gamma-secretases, which also affect signaling and/or degradation of type-I membrane proteins including the Alzheimer disease-related beta-amyloid precursor protein. Similar to the previously characterized PS/gamma-secretase substrates, inhibition of gamma-secretase activity resulted in elevated LAR C-terminal fragment (LAR-CTF) levels in stably LAR-overexpressing Chinese hamster ovary (CHO) cells, human neuroglioma cells, and mouse cortical neurons endogenously expressing LAR. Furthermore, LAR-CTF levels increased in cells lacking functional PS, indicating that gamma-secretase-mediated cleavage of LAR was PS-dependent. Inhibition of alpha-secretase activity by TAPI-1 treatment blocked LAR-CTF accumulation, demonstrating that prior ectodomain shedding was prerequisite for PS/gamma-secretase-mediated cleavage of LAR. Moreover, we identified the product of PS/gamma-secretase cleavage, LAR intracellular domain (LICD), both in vitro and in cells over-expressing full-length (FL) LAR or LAR-CTFs. LAR localizes to cadherin-beta-catenin-based cellular junctions. Assembly and disassembly of these junctions are regulated by tyrosine phosphorylation. We found that endogenous tyrosine-phosphorylated beta-catenin coimmunoprecipitated with LAR in CHO cells. However, when PS/gamma-secretase activity was inhibited, the association between LAR and beta-catenin significantly diminished. In addition to cell adhesion, beta-catenin is involved in transcriptional regulation. We observed that LICD significantly decreased transcription of cyclin D1, one of the beta-catenin target genes. Thus, our results show that PS/gamma-secretase-mediated cleavage of LAR controls LAR-beta-catenin interaction, suggesting an essential role for PS/gamma-secretase in the regulation of LAR signaling.	Massachusetts Gen Hosp, Neurobiol Dis Lab, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland	Harvard University; Massachusetts General Hospital; Harvard University; University of Eastern Finland	Kovacs, DM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,MIND, Neurobiol Dis Lab,Genet & Agine Res Unit,Dept Neu, 114 16th St, Charlestown, MA 02129 USA.	dora_kovacs@hms.harvard.edu		Haapasalo, Annakaisa/0000-0003-0959-2957				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Dunah AW, 2005, NAT NEUROSCI, V8, P458, DOI 10.1038/nn1416; Fox AN, 2005, CURR BIOL, V15, P1701, DOI 10.1016/j.cub.2005.08.035; Frade JM, 2005, J NEUROSCI, V25, P1407, DOI 10.1523/JNEUROSCI.3798-04.2005; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Honkaniemi J, 1998, MOL BRAIN RES, V60, P1, DOI 10.1016/S0169-328X(98)00151-X; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Johnson KG, 2006, NEURON, V49, P517, DOI 10.1016/j.neuron.2006.01.026; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Ko J, 2003, J NEUROSCI, V23, P1667; Kolkman MJM, 2004, BEHAV BRAIN RES, V154, P171, DOI 10.1016/j.bbr.2004.02.006; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Paul S, 2003, CELL MOL LIFE SCI, V60, P2465, DOI 10.1007/s00018-003-3123-7; POT DA, 1991, J BIOL CHEM, V266, P19688; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; Ruhe JE, 2006, CELL SIGNAL, V18, P1515, DOI 10.1016/j.cellsig.2005.12.003; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; Tsujikawa K, 2002, MOL CANCER RES, V1, P155; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Van der Zee CEEM, 2003, EUR J NEUROSCI, V17, P991, DOI 10.1046/j.1460-9568.2003.02516.x; Van Lieshout EMM, 2001, NEUROSCIENCE, V102, P833, DOI 10.1016/S0306-4522(00)00526-1; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Wang X, 2000, ONCOGENE, V19, P2346, DOI 10.1038/sj.onc.1203558; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Xie YM, 2001, J NEUROSCI, V21, P5130, DOI 10.1523/JNEUROSCI.21-14-05130.2001; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang T, 2005, EUR J NEUROSCI, V22, P2159, DOI 10.1111/j.1460-9568.2005.04403.x; Yang T, 2003, J NEUROSCI, V23, P3353; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; YU Q, 1992, ONCOGENE, V7, P1051; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	72	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9063	9072		10.1074/jbc.M611324200	http://dx.doi.org/10.1074/jbc.M611324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259169	hybrid			2022-12-27	WOS:000245780300053
J	Ellison, TI; Eckert, RL; MacDonald, PN				Ellison, Tara I.; Eckert, Richard L.; MacDonald, Paul N.			Evidence for 1,25-dihydroxyvitamin D-3-independent transactivation by the vitamin D receptor - Uncoupling the receptor and ligand in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PROTEIN COACTIVATOR COMPLEX; MINERAL ION HOMEOSTASIS; D-DEFICIENCY RICKETS; MEDIATED TRANSCRIPTION; 25-HYDROXYVITAMIN-D 1-ALPHA-HYDROXYLASE; INTERACTING PROTEIN; NUCLEAR-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; EPIDERMAL DIFFERENTIATION	The vitamin D endocrine system plays critical although poorly understood roles in skin. Vitamin D receptor (VDR) knock-out (VDRKO) mice have defects in hair follicle cycling and keratinocyte proliferation leading to epidermal thickening, dermal cyst formation, and alopecia. Surprisingly, skin defects are not apparent in mice lacking 25-hydroxyvitamin D 1 alpha-hydroxylase, the enzyme required for 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) hormone biosynthesis. These disparate phenotypes indicate that VDR effects in skin are independent of the 1,25(OH)(2)D-3 ligand. However, cellular or molecular data supporting this hypothesis are lacking. Here, we show transcriptional activation of the vitamin D-responsive 24-hydroxylase promoter by VDR in primary keratinocytes that is independent of the 1,25(OH)(2)D-3 ligand. This activity required functional vitamin D-responsive promoter elements as well as an intact VDR DNA binding domain and thus could not be distinguished from 1,25(OH)(2)D-3-dependent VDR transactivation. The 1,25(OH)(2)D-3-independent activation of VDR was also observed in keratinocytes from 1 alpha-hydroxylase knock-out mice, indicating that it is not due to endogenous 1,25(OH)(2)D-3 production. Mammalian two-hybrid studies showed strong, 1,25(OH)(2)D-3-independent interaction between VDR and retinoid X receptors in primary keratinocytes, indicating that enhanced heterodimerization of these receptors was involved. Indeed, this 1,25(OH)(2)D-3-independent VDR-RXR heterodimerization was sufficient to drive transactivation by VDR(L233S), an inactive ligand binding mutant of VDR that was previously shown to rescue the skin phenotype of VDR null mice. Cumulatively, these studies support the concept that transactivation by VDR in keratinocytes may be uncoupled from the 1,25(OH)(2)D-3 ligand.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	MacDonald, PN (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	pnm2@case.edu			NIAMS NIH HHS [P30 AR639750] Funding Source: Medline; NIDDK NIH HHS [R01DK53980] Funding Source: Medline; NIGMS NIH HHS [T32GM 08803] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008803] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Bergman R, 2005, ARCH DERMATOL, V141, P343, DOI 10.1001/archderm.141.3.343; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; Bikle DD, 2004, J INVEST DERMATOL, V122, P984, DOI 10.1111/j.0022-202X.2004.22424.x; BLUNT JW, 1968, P NATL ACAD SCI USA, V61, P717, DOI 10.1073/pnas.61.2.717; Brown AJ, 1999, J CELL BIOCHEM, V73, P106, DOI 10.1002/(SICI)1097-4644(19990401)73:1&lt;106::AID-JCB12&gt;3.0.CO;2-Q; Caldelari R, 2000, J INVEST DERMATOL, V114, P1064, DOI 10.1046/j.1523-1747.2000.00960-4.x; Chen CH, 2001, ENDOCRINOLOGY, V142, P5386, DOI 10.1210/en.142.12.5386; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; Chiba N, 2000, J BIOL CHEM, V275, P10719, DOI 10.1074/jbc.275.15.10719; Dardenne O, 2003, BONE, V32, P332, DOI 10.1016/S8756-3282(03)00023-1; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; Ellison TI, 2005, MOL ENDOCRINOL, V19, P2309, DOI 10.1210/me.2004-0382; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; GRAY RW, 1972, J BIOL CHEM, V247, P7528; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KNUTSON JC, 1974, BIOCHEMISTRY-US, V13, P1543, DOI 10.1021/bi00704a034; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; Lu JF, 2005, J INVEST DERMATOL, V124, P778, DOI 10.1111/j.0022-202X.2005.23641.x; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Miller WL, 2000, TRENDS ENDOCRIN MET, V11, P315, DOI 10.1016/S1043-2760(00)00287-3; ONATE SA, 1995, SCIENCE, V270, P1354; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Pinette KV, 2003, MINI-REV MED CHEM, V3, P193, DOI 10.2174/1389557033488204; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Sakai Y, 2001, J CLIN INVEST, V107, P961, DOI 10.1172/JCI11676; Skorija K, 2005, MOL ENDOCRINOL, V19, P855, DOI 10.1210/me.2004-0415; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Vanhooke JL, 2006, P NATL ACAD SCI USA, V103, P75, DOI 10.1073/pnas.0509734103; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhang C, 2003, J BIOL CHEM, V278, P35325, DOI 10.1074/jbc.M305191200; Zinser GM, 2002, CARCINOGENESIS, V23, P2103, DOI 10.1093/carcin/23.12.2103	49	33	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10953	10962		10.1074/jbc.M609717200	http://dx.doi.org/10.1074/jbc.M609717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17310066	hybrid			2022-12-27	WOS:000245941500015
J	Kang, JS; Kashtan, CE; Turner, AN; Heidet, L; Hudson, BG; Borza, DB				Kang, Jeong Suk; Kashtan, Clifford E.; Turner, A. Neil; Heidet, Laurence; Hudson, Billy G.; Borza, Dorin-Bogdan			The alloantigenic sites of alpha 3 alpha 4 alpha 5(IV) collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ALPORT SYNDROME; ANTI-GBM NEPHRITIS; IV COLLAGEN; GOODPASTURE AUTOANTIGEN; RENAL-TRANSPLANTATION; ALPHA-3(IV) COLLAGEN; CRYPTIC EPITOPES; BASEMENT-MEMBRANES; NC1 DOMAINS; ALLOANTIBODIES	Anti-glomerular basement membrane (GBM) antibody nephritis is caused by an autoimmune or alloimmune reaction to the NC1 domains of alpha 3 alpha 4 alpha 5(IV) collagen. Some patients with X-linked Alport syndrome (XLAS) develop post-transplant nephritis mediated by pathogenic anti-GBM alloantibodies to collagen IV chains present in the renal allograft but absent from the tissues of the patient. In this work, the epitopes targeted by alloantibodies from these patients were identified and characterized. All XLAS alloantibodies recognized conformational epitopes in the NC1 domain of alpha 5(IV) collagen, which were mapped using chimeric alpha 1/alpha 5NC1 domains expressed in mammalian cells. Allograft-eluted alloantibodies mainly targeted two conformational alloepitopes mapping to alpha 5NC1 residues 1-45 and 114-168. These regions also encompassed the major epitopes of circulating XLAS alloantibodies, which in some patients additionally targeted alpha 5NC1 residues 169-229. Both kidney-eluted and circulating alloantibodies to alpha 5NC1 distinctively targeted epitopes accessible in the alpha 3 alpha 4 alpha 5NC1 hexamers of human GBM, unlike anti-GBM autoantibodies, which targeted sequestered alpha 3NC1 epitopes. The results identify two immunodominant alpha 5NC1 epitopes as major alloantigenic sites of alpha 3 alpha 4 alpha 5(IV) collagen specifically implicated in the pathogenesis of post-transplant nephritis in XLAS patients. The contrast between the accessibility of these alloepitopes and the crypticity of autoepitopes indicates that distinct molecular forms of antigen may initiate the immunopathogenic processes in the two forms of anti-GBM disease.	Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Univ Edinburgh, MRC, Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland; Hop Necker Enfants Malad, INSERM, U574, F-75743 Paris 15, France	Vanderbilt University; University of Minnesota System; University of Minnesota Twin Cities; University of Edinburgh; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Borza, DB (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, S-3223 MCN, Nashville, TN 37232 USA.	Dorin-Bogdan.Borza@vanderbilt.edu	Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Turner, Neil/0000-0003-4547-873X; Hudson, Billy/0000-0002-5420-4100; Heidet, Laurence/0000-0002-1362-5515	NIDDK NIH HHS [P01 DK65123, R37 DK18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK065123, R37DK018381] Funding Source: NIH RePORTER; Medical Research Council [G9900991B] Funding Source: researchfish	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; Borza DB, 2005, J BIOL CHEM, V280, P27147, DOI 10.1074/jbc.M504050200; Borza DB, 2003, SPRINGER SEMIN IMMUN, V24, P345, DOI 10.1007/s00281-002-0103; Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Brainwood D, 1998, KIDNEY INT, V53, P762, DOI 10.1046/j.1523-1755.1998.00794.x; Browne G, 2004, KIDNEY INT, V65, P675, DOI 10.1111/j.1523-1755.2004.00428.x; Collins PW, 2006, HAEMOPHILIA, V12, P94, DOI 10.1111/j.1365-2516.2006.01372.x; Dehan P, 1996, NEPHROL DIAL TRANSPL, V11, P1983, DOI 10.1093/oxfordjournals.ndt.a027085; Gluckman J C, 1973, Clin Nephrol, V1, P40; Heidet L, 2000, AM J PATHOL, V156, P1901, DOI 10.1016/S0002-9440(10)65063-8; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; KALLURI R, 1995, KIDNEY INT, V47, P1199, DOI 10.1038/ki.1995.170; Kalluri R, 2000, TRANSPLANTATION, V69, P679, DOI 10.1097/00007890-200002270-00038; Kalluri R, 2000, J BIOL CHEM, V275, P20027, DOI 10.1074/jbc.M904549199; KASHTAN C, 1986, J CLIN INVEST, V78, P1035, DOI 10.1172/JCI112658; Kashtan CE, 2006, PEDIATR TRANSPLANT, V10, P651, DOI 10.1111/j.1399-3046.2006.00528.x; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Wang XP, 2005, J AM SOC NEPHROL, V16, P3563, DOI 10.1681/ASN.2005060670	22	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10670	10677		10.1074/jbc.M611892200	http://dx.doi.org/10.1074/jbc.M611892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293596	hybrid			2022-12-27	WOS:000245941000061
J	Chellaiah, MA; Kuppuswamy, D; Lasky, L; Linder, S				Chellaiah, Meenakshi A.; Kuppuswamy, Dhandapani; Lasky, Larry; Linder, Stefan			Phosphorylation of a Wiscott-Aldrich syndrome protein-associated signal complex is critical in osteoclast bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHATASE-PEST; CYTOSKELETAL-ASSOCIATED PROTEIN; FOCAL ADHESION KINASE; N-WASP; C-SRC; BETA-3 INTEGRIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIN POLYMERIZATION; INTERACTING PROTEIN; ARP2/3 COMPLEX	The activities of different kinases have been correlated to the phosphorylation of Wiscott-Aldrich syndrome protein (WASP) by studies in multiple cell systems. The purpose of this study was to elucidate the regulatory mechanisms involved in WASP phosphorylation and the resulting sealing ring formation in osteoclasts. The phosphorylation state of WASP and WASP-interacting proteins was determined in osteoclasts treated with osteopontin or expressing either constitutively active or kinase-defective Src by adenovirus-mediated delivery. In vitro kinase analysis of WASP immunoprecipitates exhibited phosphorylation of c-Src, PYK2, WASP, protein-tyrosine phosphatase (PTP)-PEST, and Pro-Ser-Thr phosphatase-interacting protein (PSTPIP). Phosphorylation of these proteins was increased in osteopontin-treated and constitutively active Src-expressing osteoclasts. Pulldown analysis with glutathione S-transferase-fused prohne-rich regions of PTP-PEST revealed coprecipitation of WASP, PYK2, c-Src, and PSTPIP proteins with the N-terminal region (amino acids 294 497) of PTP-PEST. Similarly, interaction of the same signaling proteins, as well as PTP-PEST, was observed with glutathione S-transferase-fused proline-rich regions of WASP. Furthermore, osteopontin stimulation or constitutively active Src expression resulted in serine phosphorylation and inhibition of WASP-associated PTP-PEST. The inhibition of PTP-PEST was accompanied by an increase in tyrosine phosphorylation of WASP and other associated signaling proteins. Experiments with an inhibitor to phosphatase and small interference RNA to PTP-PEST confirmed the involvement of PTP-PEST in sealing ring formation and bone resorption. WASP, which is identified in the sealing ring of resorbing osteoclasts, also demonstrates colocalization with c-Src, PYK2, PSTPIP, and PTP-PEST in immunostaining analyses. Our findings suggest that both tyrosine kinase(s) and the tyrosine phosphatase PTP-PEST coordinate the formation of the sealing ring and thus the bone-resorbing function of osteoclasts.	Univ Maryland, Sch Dent, Dept Biomed Sci, Baltimore, MD 21201 USA; Med Univ S Carolina, Div Cardiol, Cardiac Res Inst, Charleston, SC 29425 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94111 USA; Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, D-80336 Munich, Germany	University System of Maryland; University of Maryland Baltimore; Medical University of South Carolina; Roche Holding; Genentech; University of Munich	Chellaiah, MA (corresponding author), Univ Maryland, Sch Dent, Dept Biomed Sci, 650 W Baltimore St, Baltimore, MD 21201 USA.	mchellaiah@umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR046292, R01AR046292] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48788] Funding Source: Medline; NIAMS NIH HHS [AR46292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Banin S, 1999, MOL BIOL REP, V26, P173, DOI 10.1023/A:1006954206151; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER J A, 1992, P47; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; Cote JF, 2002, J BIOL CHEM, V277, P2973, DOI 10.1074/jbc.M106428200; Dowbenko D, 1998, J BIOL CHEM, V273, P989, DOI 10.1074/jbc.273.2.989; Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gupta A, 2003, J BONE MINER RES, V18, P669, DOI 10.1359/jbmr.2003.18.4.669; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hufner K, 2002, FEBS LETT, V514, P168, DOI 10.1016/S0014-5793(02)02358-X; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04-06-0522; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schulte RJ, 2003, BIOCHEMISTRY-US, V42, P9424, DOI 10.1021/bi034519u; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; TAYLOR ML, 1989, ANAT EMBRYOL, V180, P427, DOI 10.1007/BF00305117; TETI A, 1991, AM J PHYSIOL, V261, pC1, DOI 10.1152/ajpcell.1991.261.1.C1; Torres E, 2006, J BIOL CHEM, V281, P3513, DOI 10.1074/jbc.M509416200; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Violette SM, 2000, CHEM BIOL, V7, P225, DOI 10.1016/S1074-5521(00)00090-9; Willey CD, 2003, J MOL CELL CARDIOL, V35, P671, DOI 10.1016/S0022-2828(03)00112-3; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Wu Y, 1998, J BIOL CHEM, V273, P30487, DOI 10.1074/jbc.273.46.30487; Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756-3282(02)00834-7	57	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10104	10116		10.1074/jbc.M608957200	http://dx.doi.org/10.1074/jbc.M608957200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17283076	hybrid			2022-12-27	WOS:000245421700084
J	Chen, YG; Wang, Z; Ma, J; Zhang, L; Lu, ZX				Chen, Ye-Guang; Wang, Zhi; Ma, Jing; Zhang, Long; Lu, Zhongxian			Endofin, a FYVE domain protein, interacts with Smad4 and facilitates transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY ENDOSOMES; RECEPTOR INTERNALIZATION; CELL-MEMBRANE; SARA; ACTIVATION; APOPTOSIS; PATHWAYS; BINDING; TRANSDUCTION; ENDOCYTOSIS	Transforming growth factor-beta (TGF-beta) signaling is facilitated by scaffold proteins such as SARA (Smad anchor for receptor activation). Endofin, a member of the FYVE domain protein family, has been suggested to regulate membrane trafficking. In this study, we report that endofin functions as a scaffold protein to facilitate TGF-beta signaling. Overexpression of endofin FYVE domain-deletion mutants inhibited TGF-beta-induced expression of CAGA-luciferase. Knockdown of endogenous endofin expression by RNA interference specifically led to reduction of the transcriptional responses of TGF-beta, but had no effect on BMP-or Wnt1-induced reporter expression. Furthermore, in endofin small interfering RNA-expressing stable cells, TGF-beta-mediated expression of plasminogen activator inhibitor-1 andp21(Cip1) was significantly reduced, and TGF-beta-promoted apoptosis was also impaired. We further showed that endofin could interact with Smad4 and TGF-beta type I receptors. Reduction of endogenous endofin expression resulted in a decrease of TGF-beta-induced Smad2 phosphorylation and Smad2-Smad4 complex formation. Together, our findings suggest that endofin facilitates TGF-beta signaling as a scaffold protein to promote the R-Smad-Smad4 complex formation by bringing Smad4 to the proximity of the receptor complex.	Tsing Hua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Univ Calif Irvine, Coll Med, Dept Med & Biol Chem, Irvine, CA 92697 USA	Tsinghua University; University of California System; University of California Irvine	Chen, YG (corresponding author), Tsing Hua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	ygchen@tsinghua.edu.cn	Zhang, Long/AAT-6571-2021; Lu, ZX/G-4586-2010; Chen, Ye-Guang/L-6998-2019	Zhang, Long/0000-0001-8139-0474; 				Bennett D, 2002, NAT GENET, V31, P419, DOI 10.1038/ng938; Bokel C, 2006, SCIENCE, V314, P1135, DOI 10.1126/science.1132524; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Felici A, 2003, EMBO J, V22, P4465, DOI 10.1093/emboj/cdg428; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Hartung A, 2006, MOL CELL BIOL, V26, P7791, DOI 10.1128/MCB.00022-06; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Inman GJ, 2000, J IMMUNOL, V165, P2500, DOI 10.4049/jimmunol.165.5.2500; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kunzmann S, 2003, FASEB J, V17, P194, DOI 10.1096/fj.02-0550com; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Moustakas A, 2001, J CELL SCI, V114, P4359; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Seet LF, 2005, J CELL SCI, V118, P575, DOI 10.1242/jcs.01628; Seet LF, 2004, J BIOL CHEM, V279, P4670, DOI 10.1074/jbc.M311228200; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Yamakawa N, 2002, EMBO J, V21, P1684, DOI 10.1093/emboj/21.7.1684; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200; Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200; Zhou YL, 2004, MOL ENDOCRINOL, V18, P1818, DOI 10.1210/me.2004-0079	40	52	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9688	9695		10.1074/jbc.M611704200	http://dx.doi.org/10.1074/jbc.M611704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272273	hybrid			2022-12-27	WOS:000245421700042
J	Joshi, MB; Dwyer, DM				Joshi, Manju B.; Dwyer, Dennis M.			Molecular and functional analyses of a novel class I secretory nuclease from the human pathogen, Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; EUKARYOTIC HUMAN PATHOGENS; STRAND-SPECIFIC NUCLEASE; PARASITIC PROTOZOA; GENOME SEQUENCE; NUCLEOSIDE TRANSPORTERS; EXTRACELLULAR NUCLEASE; ENDOPLASMIC-RETICULUM; PENICILLIUM-CITRINUM; ASPERGILLUS-ORYZAE	The primitive protozoan pathogen of humans, Leishmania donovani, resides and multiplies in highly restricted micro-environments within their hosts (i.e. as promastigotes in the gut lumen of their sandfly vectors and as amastigotes in the phagolysosomal compartments of infected mammalian macrophages). Like other trypanosomatid parasites, they are purine auxotrophs (i.e. lack the ability to synthesize purines de novo) and therefore are totally dependent upon salvaging these essential nutrients from their hosts. In that context, in this study we identified a unique 35-kDa, dithiothreitol-sensitive nuclease and showed that it was constitutively released/secreted by both promastigote and amastigote developmental forms of this parasite. By using several different molecular approaches, we identified and characterized the structure of LdNuc(s), a gene that encodes this new 35-kDa class I nuclease family member in these organisms. Homologous episomal expression of an epitope-tagged LdNuc(s) chimeric construct was used in conjunction with an anti-LdNuc(s) peptide antibody to delineate the functional and biochemical properties of this unique 35-kDa parasite released/secreted enzyme. Results of coupled immunoprecipitation-enzyme activity analyses demonstrated that this "secretory" enzyme could hydrolyze a variety of synthetic polynucleotides as well as several natural nucleic acid substrates, including RNA and single- and double-stranded DNA. Based on these cumulative observations, we hypothesize that within the micro-environments of its host, this leishmanial "secretory" nuclease could function at a distance away from the parasite to harness (i.e. hydrolyze/access) host-derived nucleic acids to satisfy the essential purine requirements of these organisms. Thus, this enzyme might play an important role(s) in facilitating the survival, growth, and development of this important human pathogen.	NIAID, Cell Biol Sect, Lab Parasit Dis, Div Intramural Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dwyer, DM (corresponding author), NIAID, Cell Biol Sect, Lab Parasit Dis, Div Intramural Res,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	ddwyer@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000745, Z01AI000162, Z01AI000745] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BATES PA, 1993, FEMS MICROBIOL LETT, V107, P53, DOI 10.1111/j.1574-6968.1993.tb06003.x; Benedik MJ, 1998, FEMS MICROBIOL LETT, V165, P1; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; BROWN PH, 1987, EUR J BIOCHEM, V168, P357, DOI 10.1111/j.1432-1033.1987.tb13427.x; Campbell M, 2003, INFECT IMMUN, V71, P6270, DOI 10.1128/IAI.71.11.6270-6278.2003; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; Debrabant A, 2000, J BIOL CHEM, V275, P16366, DOI 10.1074/jbc.M908725199; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; Debrabant A, 2001, MOL CELL BIOCHEM, V220, P109, DOI 10.1023/A:1010809420104; Desai NA, 2003, FEMS MICROBIOL REV, V26, P457, DOI 10.1016/S0168-6445(02)00129-8; Desai NA, 2000, EUR J BIOCHEM, V267, P5123, DOI 10.1046/j.1432-1327.2000.01580.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DWYER DM, 1974, Z PARASITENKD, V43, P227, DOI 10.1007/BF00328879; DWYER DM, 1976, J IMMUNOL, V117, P2081; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Farajnia S, 2004, INT J PARASITOL, V34, P899, DOI 10.1016/j.ijpara.2004.03.005; FONG D, 1988, MOL BIOCHEM PARASIT, V31, P97, DOI 10.1016/0166-6851(88)90149-1; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GERBER LD, 1992, J BIOL CHEM, V267, P12168; Ghedin E, 2001, TRAFFIC, V2, P175, DOI 10.1034/j.1600-0854.2001.020304.x; GRAY HB, 1975, NUCLEIC ACIDS RES, V2, P1459, DOI 10.1093/nar/2.9.1459; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001; HASSAN HF, 1986, COMP BIOCHEM PHYS B, V84, P217, DOI 10.1016/0305-0491(86)90209-9; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; IWAMATSU A, 1991, J BIOCHEM-TOKYO, V110, P151, DOI 10.1093/oxfordjournals.jbchem.a123534; Joshi MB, 2005, J BIOL CHEM, V280, P3847, DOI 10.1074/jbc.M412299200; Kar S, 2000, J BIOL CHEM, V275, P37789, DOI 10.1074/jbc.M002149200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landfear SM, 2001, BIOCHEM PHARMACOL, V62, P149, DOI 10.1016/S0006-2952(01)00663-3; Landfear SM, 2004, EUKARYOT CELL, V3, P245, DOI 10.1128/EC.3.2.245-254.2004; Lee BR, 1995, APPL MICROBIOL BIOT, V44, P425; MAEKAWA K, 1991, EUR J BIOCHEM, V200, P651, DOI 10.1111/j.1432-1033.1991.tb16228.x; MCCARTHYBURKE C, 1991, EXP PARASITOL, V73, P385, DOI 10.1016/0014-4894(91)90112-A; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MUROPASTOR AM, 1992, MOL MICROBIOL, V6, P3021, DOI 10.1111/j.1365-2958.1992.tb01760.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Porter-Kelley JM, 2004, TRAFFIC, V5, P868, DOI 10.1111/j.1600-0854.2004.00229.x; PRZYKORSKA A, 1980, EUR J BIOCHEM, V108, P285, DOI 10.1111/j.1432-1033.1980.tb04722.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNEIDER A, 1993, J BIOL CHEM, V268, P21868; Shakarian AM, 2003, MOL CELL BIOCHEM, V245, P31, DOI 10.1023/A:1022851914014; Shakarian AM, 2002, J BIOL CHEM, V277, P17994, DOI 10.1074/jbc.M200114200; Sopwith WF, 2002, INT J PARASITOL, V32, P449, DOI 10.1016/S0020-7519(01)00372-1; STEVENS A, 1960, J BIOL CHEM, V235, P3016; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; TAKAHASHI M, 1978, J BIOCHEM-TOKYO, V83, P1521, DOI 10.1093/oxfordjournals.jbchem.a132063; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; *UNICEF UNDP WORLD, 2004, SPEC PROGR RES TRAIN, P19; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Yamage M, 2000, J BIOL CHEM, V275, P36369, DOI 10.1074/jbc.M004036200; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; ZLOTNICK GW, 1987, COMP BIOCHEM PHYS B, V87, P629, DOI 10.1016/0305-0491(87)90063-0	61	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10079	10095		10.1074/jbc.M610770200	http://dx.doi.org/10.1074/jbc.M610770200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276983	hybrid			2022-12-27	WOS:000245421700082
J	Nakamura, K; Moore, R; Negishi, M; Sueyoshi, T				Nakamura, Kouichi; Moore, Rick; Negishi, Masahiko; Sueyoshi, Tatsuya			Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BETA-OXIDATION; COA DESATURASE 1; GENE-EXPRESSION; XENOBIOTIC RECEPTORS; RESPONSE ELEMENT; ENHANCER MODULE; UGT1A1 GENE; CAR; TRANSCRIPTION; INSULIN	Upon drug activation, the nuclear pregnane X receptor (PXR) regulates not only hepatic drug but also energy metabolism. Using Pxr(-/-) mice, we have now investigated the PXR-mediated repression of lipid metabolism in the fasting livers. Treatment with PXR activator pregnenolone 16 alpha-carbonitrile (PCN) down-regulated the mRNA levels of carnitine palmitoyltransferase 1A (in beta-oxidation) and mitochondrial 3-hydroxy-3-methylglutarate-CoA synthase 2 (in ketogenesis) in wild-type (Pxr(+/+)) mice only. In contrast, the stearoyl-CoA desaturase 1 (in lipogenesis) mRNA was up-regulated in the PCN-treated Pxr(+/+) mice. Reflecting these up- and down-regulations and consistent with decreased energy metabolism, the levels of hepatic triglycerides and of serum 3-hydroxybutylate were increased and decreased, respectively, in the PCN-treated Pxr(+/+) mice. Using gel shift, glutathione S-transferase pull-down and cell-based reporter assays, we then examined whether PXR could cross-talk with the insulin response forkhead factor FoxA2 to repress the transcription of the Cpt1a and Hmgcs2 genes, because FoxA2 activates these genes in fasting liver. PXR directly bound to FoxA2 and repressed its activation of the Cpt1a and Hmgcs2 promoters. Moreover, ChIP assays showed that PCN treatment attenuated the binding of FoxA2 to these promoters in fasting Pxr(+/+) but not Pxr(-/-) mice. These results are consistent with the conclusion that PCN-activated PXR represses FoxA2-mediated transcription of Ctp1a and Hmgcs2 genes in fasting liver.	NIEHS, Pharmacogenet Sect, Lab Reprod & Dev Toxicol, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Lab Reprod & Dev Toxicol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928	Intramural NIH HHS [Z01 ES080040-22] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Bartlett K, 2004, EUR J BIOCHEM, V271, P462, DOI 10.1046/j.1432-1033.2003.03947.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Fukao T, 2004, PROSTAG LEUKOTR ESS, V70, P243, DOI 10.1016/j.plefa.2003.11.001; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Grefhorst A, 2005, AM J PHYSIOL-GASTR L, V289, pG592, DOI 10.1152/ajpgi.00063.2005; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Kakizaki S, 2002, DRUG METAB DISPOS, V30, P208, DOI 10.1124/dmd.30.2.208; Kiyosawa N, 2004, ARCH TOXICOL, V78, P435, DOI 10.1007/s00204-004-0565-0; Klaassen CD, 2005, CURR DRUG METAB, V6, P309, DOI 10.2174/1389200054633826; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kobayashi K, 2003, MOL PHARMACOL, V64, P1069, DOI 10.1124/mol.64.5.1069; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Louet JF, 2001, BIOCHEM SOC T, V29, P310, DOI 10.1042/0300-5127:0290310; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Mounier C, 2006, CAN J PHYSIOL PHARM, V84, P713, DOI 10.1139/Y05-152; Nyman LR, 2005, MOL GENET METAB, V86, P179, DOI 10.1016/j.ymgme.2005.07.021; Olpin SE, 2004, PROSTAG LEUKOTR ESS, V70, P293, DOI 10.1016/j.plefa.2003.06.003; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Rinaldo P, 2002, ANNU REV PHYSIOL, V64, P477, DOI 10.1146/annurev.physiol.64.082201.154705; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Runge-Morris M, 2005, CURR DRUG METAB, V6, P299, DOI 10.2174/1389200054633871; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; Squires EJ, 2004, J BIOL CHEM, V279, P49307, DOI 10.1074/jbc.M407281200; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2005, METHOD ENZYMOL, V400, P92, DOI 10.1016/S0076-6879(05)00006-6; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Wang HY, 2005, TRENDS MOL MED, V11, P262, DOI 10.1016/j.molmed.2005.04.003; WATERS KM, 1994, J BIOL CHEM, V269, P27773; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Yamamoto Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P207, DOI 10.1016/S0003-9861(02)00456-3; Zhou J, 2006, J BIOL CHEM, V281, P15013, DOI 10.1074/jbc.M511116200	47	143	155	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9768	9776		10.1074/jbc.M610072200	http://dx.doi.org/10.1074/jbc.M610072200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267396	hybrid, Green Accepted			2022-12-27	WOS:000245421700051
J	Sharma, A; Masri, J; Jo, OD; Bernath, A; Martin, J; Funk, A; Gera, J				Sharma, Anushree; Masri, Janine; Jo, Oak D.; Bernath, Andrew; Martin, Jheralyn; Funk, Alexander; Gera, Joseph			Protein kinase C regulates internal initiation of translation of the GATA-4 mRNA following vasopressin-induced hypertrophy of cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITES; TRANS-ACTING FACTORS; GENE-EXPRESSION; TRANSCRIPTION FACTORS; MEDIATED TRANSLATION; IN-VITRO; PRESSURE-OVERLOAD; AKT ACTIVITY; CYCLIN D1; PHOSPHORYLATION	GATA-4 is a key member of the GATA family of transcription factors involved in cardiac development and growth as well as in cardiac hypertrophy and heart failure. Our previous studies suggest that GATA-4 protein synthesis may be translationally regulated. We report here that the 518-nt long 5'-untransiated region (5'-UTR) of the GATA-4 mRNA, which is predicted to form stable secondary structures (-65 kcal/mol) such as to be inhibitory to cap-dependent initiation, confers efficient translation to monocistronic reporter mRNAs in cell-free extracts. Moreover, uncapped GATA-4 5'-UTR containing monocistronic reporter mRNAs continue to be well translated while capped reporters are insensitive to the inhibition of initiation by cap-analog, suggesting a capin-dependent mechanism of initiation. Utilizing a dicistronic luciferase mRNA reporter containing the GATA-4 5'-UTR within the intercistrionic region, we demonstrate that this leader sequence confers functional internal ribosome entry site (IRES) activity. The activity of the GATA-4 IRES is unaffected in trans - differentiating P19CL6 cells, however, is strongly stimulated immediately following arginine-vasopressin exposure of H9c2 ventricular myocytes. IRES activity is then maintained at submaximal levels during hypertrophic growth of these cells. Supraphysiological Ca2+ levels diminished stimulation of IRES activity immediately following exposure to vasopressin and inhibition of protein kinase C activity utilizing a pseudosubstrate peptide sequence blocked IRES activity during hypertrophy. Thus, our data suggest a mechanism for GATA-4 protein synthesis under conditions of reduced global cap-dependent translation, which is maintained at a submaximal level during hypertrophic growth and point to the regulation of GATA-4 IRES activity by sarco(ER)reticular Ca2+ stores and PKC.	Greater Los Angels Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gera, J (corresponding author), Greater Los Angels Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA.	gera@ucla.edu		Gera, Joseph/0000-0002-2908-6894	NATIONAL CANCER INSTITUTE [R01CA109312] Funding Source: NIH RePORTER; NCI NIH HHS [CA109312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; BOSSER R, 1995, MOL CELL BIOL, V15, P661; Brostrom MA, 2000, INT J BIOCHEM CELL B, V32, P993, DOI 10.1016/S1357-2725(00)00037-6; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Brostrom MA, 2001, J CELL BIOCHEM, V83, P204, DOI 10.1002/jcb.1219; Byrd MP, 2005, J BIOL CHEM, V280, P18610, DOI 10.1074/jbc.M414014200; CARROLL R, 1993, ANAL BIOCHEM, V212, P17, DOI 10.1006/abio.1993.1284; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Elango N, 2006, J CELL BIOCHEM, V99, P1108, DOI 10.1002/jcb.20909; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gerlitz G, 2002, EUR J BIOCHEM, V269, P2810, DOI 10.1046/j.1432-1033.2002.02974.x; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Grepin C, 1997, DEVELOPMENT, V124, P2387; HabaraOhkubo A, 1996, CELL STRUCT FUNCT, V21, P101, DOI 10.1247/csf.21.101; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HERSHEY J, 2000, PATHWAY MECH INITIAT; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Holcik M, 2005, RNA, V11, P1605, DOI 10.1261/rna.2158605; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; HUANG WY, 1995, GENE, V155, P219, DOI 10.1016/0378-1119(94)00893-W; IDRISS H, 1994, BIOCHEMISTRY-US, V33, P11382, DOI 10.1021/bi00203a037; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Krichevsky AM, 1999, J BIOL CHEM, V274, P14295, DOI 10.1074/jbc.274.20.14295; Lancaster AM, 2006, RNA, V12, P894, DOI 10.1261/rna.2342306; Lewis SM, 2005, CELL DEATH DIFFER, V12, P547, DOI 10.1038/sj.cdd.4401602; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; McMullen JR, 2004, CIRCULATION, V109, P3050, DOI 10.1161/01.CIR.0000130641.08705.45; Misquitta CM, 2006, CELL CALCIUM, V40, P329, DOI 10.1016/j.ceca.2006.04.004; Misquitta CM, 2001, MOL CELL BIOCHEM, V224, P53, DOI 10.1023/A:1011982932645; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Peterkin T, 2005, SEMIN CELL DEV BIOL, V16, P83, DOI 10.1016/j.semcdb.2004.10.003; Pikkarainen S, 2004, CARDIOVASC RES, V63, P196, DOI 10.1016/j.cardiores.2004.03.025; Reilly BA, 1998, J BIOL CHEM, V273, P3747, DOI 10.1074/jbc.273.6.3747; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; Saghir AN, 2001, BIOCHEM J, V356, P557, DOI 10.1042/0264-6021:3560557; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shioi T, 2003, CIRCULATION, V107, P1664, DOI 10.1161/01.CIR.0000057979.36322.88; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Thoma C, 2004, MOL CELL, V15, P925, DOI 10.1016/j.molcel.2004.08.021; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	57	17	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9505	9516		10.1074/jbc.M608874200	http://dx.doi.org/10.1074/jbc.M608874200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284439	hybrid			2022-12-27	WOS:000245421700023
J	Ball, JR; Dimaano, C; Bilak, A; Kurchan, E; Zundel, MT; Ullman, KS				Ball, Jennifer R.; Dimaano, Christian; Bilak, Amber; Kurchan, Eydiejo; Zundel, M. Tracy; Ullman, Katharine S.			Sequence preference in RNA recognition by the nucleoporin Nup153	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA; NUCLEOCYTOPLASMIC TRANSPORT; BINDING DOMAIN; PROTEIN NUP153; EXPORT; IMPORT; BETA; ORGANIZATION; CYTOPLASM	The vertebrate nuclear pore protein Nup153 contains a novel RNA binding domain. This 150-amino acid region was previously found to bind preferentially to a panel of mRNAs when compared with structured RNAs, such as tRNA, U snRNA, and double-stranded RNA. The ability to broadly recognize mRNA led to the conclusion that the Nup153 RNA binding domain confers a general affinity for single-stranded RNA. Here, we have probed Nup153 RNA recognition to decipher how this unique RNA binding domain discriminates between potential targets. We first mapped the binding determinant within an RNA fragment that associates relatively robustly with the Nup153 RNA binding domain. We next designed synthetic RNA oligonucleotides to systematically delineate the features within this minimal RNA fragment that are key to Nup153 RNA-binding domain binding and demonstrated that the binding preferences of Nup153 do not reflect general preferences of an mRNA/single-stranded RNA-binding protein. We further found that the association between Nup153 and a cellular mRNA can be attributed to an interaction with specific subregions of the RNA. These results indicate that Nup153 can discriminate between mRNA and other classes of RNA transcripts due in part to direct recognition of a loose sequence motif. This information adds a new dimension to the interfaces that can contribute to recognition in mRNA export cargo selection and fate.	Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Ullman, KS (corresponding author), Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	katharine.ullman@hci.utah.edu		Ullman, Katharine/0000-0003-3693-2830	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061275] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA421014] Funding Source: Medline; NIGMS NIH HHS [R01 GM061275-07, R01 GM061275, GM61275] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Ball JR, 2005, CHROMOSOMA, V114, P319, DOI 10.1007/s00412-005-0019-3; Ball JR, 2004, RNA, V10, P19, DOI 10.1261/rna.5109104; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Cabal GG, 2006, NATURE, V441, P770, DOI 10.1038/nature04752; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Cole CN, 2006, CURR OPIN CELL BIOL, V18, P299, DOI 10.1016/j.ceb.2006.04.006; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Dimaano C, 2004, MOL CELL BIOL, V24, P3069, DOI 10.1128/MCB.24.8.3069-3076.2004; Dimaano C, 2001, J BIOL CHEM, V276, P45349, DOI 10.1074/jbc.M102592200; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Griffis ER, 2004, MOL BIOL CELL, V15, P1991, DOI 10.1091/mbc.e03-10-0743; Hase ME, 2003, MOL BIOL CELL, V14, P1923, DOI 10.1091/mbc.E02-09-0620; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Lim RYH, 2006, CURR OPIN CELL BIOL, V18, P342, DOI 10.1016/j.ceb.2006.03.006; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Masuyama K, 2004, GENE DEV, V18, P2074, DOI 10.1101/gad.1216204; Menon BB, 2005, P NATL ACAD SCI USA, V102, P5749, DOI 10.1073/pnas.0501768102; Moroianu J, 1997, P NATL ACAD SCI USA, V94, P9699, DOI 10.1073/pnas.94.18.9699; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Ohno M, 2002, MOL CELL, V9, P659, DOI 10.1016/S1097-2765(02)00454-9; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Schmitt I, 2001, J BIOL CHEM, V276, P42355, DOI 10.1074/jbc.M103916200; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Smitherman M, 2000, MOL CELL BIOL, V20, P5631, DOI 10.1128/MCB.20.15.5631-5642.2000; Taddei A, 2006, NATURE, V441, P774, DOI 10.1038/nature04845; Tran EJ, 2006, CELL, V125, P1041, DOI 10.1016/j.cell.2006.05.027; Ullman KS, 2002, CURR BIOL, V12, pR461, DOI 10.1016/S0960-9822(02)00946-6; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vinciguerra P, 2004, CURR OPIN CELL BIOL, V16, P285, DOI 10.1016/j.ceb.2004.03.013; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451	42	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8734	8740		10.1074/jbc.M608477200	http://dx.doi.org/10.1074/jbc.M608477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242408	hybrid			2022-12-27	WOS:000245780300019
J	Otero-Cruz, JD; Baez-Pagan, CA; Caraballo-Gonzalez, IM; Lasalde-Dominicci, JA				David Otero-Cruz, Jose; Alberto Baez-Pagan, Carlos; Manuel Caraballo-Gonzalez, Ivan; Antonio Lasalde-Dominicci, Jose			Tryptophan-scanning mutagenesis in the alpha M3 transmembrane domain of the muscle-type acetylcholine receptor - A spring model revealed	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PROTEIN INTERFACE; GATED ION CHANNELS; SHAKER K+ CHANNEL; VOLTAGE-SENSING DOMAINS; CYTOCHROME-C-OXIDASE; TORPEDO-CALIFORNICA; ANGSTROM RESOLUTION; NICOTINIC RECEPTOR; CRYSTAL-STRUCTURE; HELICAL STRUCTURE	Membrane proteins constitute a large fraction of all proteins, yet very little is known about their structure and conformational transitions. A fundamental question that remains obscure is how protein domains that are in direct contact with the membrane lipids move during the conformational change of the membrane protein. Important structural and functional information of several lipid-exposed transmembrane domains of the acetylcholine receptor (AChR) and other ion channel membrane proteins have been provided by the tryptophan-scanning mutagenesis. Here, we use the tryptophan-scanning mutagenesis to monitor the conformational change of the aM3 domain of the muscle-type AChR. The perturbation produced by the systematic tryptophan substitution along the aM3 domain were characterized through two-electrode voltage clamp and I-125-labeled a-bungarotoxin binding. The periodicity profiles of the changes in AChR expression (closed state) and ACh EC50 (open-channel state) disclose two different helical structures; a thinner-elongated helix for the closed state and a thicker-shrunken helix for the open-channel state. The existence of two different helical structures suggest that the conformational transition of the aM3 domain between both states resembles a spring motion and reveals that the lipid-AChR interface plays a key role in the propagation of the conformational wave evoked by agonist binding. In addition, the present study also provides evidence about functional and structural differences between the aM3 domains of the Torpedo and muscle-type receptors AChR.	Univ Puerto Rico, Dept Biol, San Juan, PR 00931 USA; Univ Puerto Rico, Dept Chem, San Juan, PR 00931 USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Lasalde-Dominicci, JA (corresponding author), Univ Puerto Rico, Dept Biol, Rio Piedras Campus, San Juan, PR 00931 USA.	joseal@coqui.net			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056371, R25GM061151] Funding Source: NIH RePORTER; NIGMS NIH HHS [R25GM61151, GM08102-27, 2R01GM56371-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; Blanton MP, 1998, BIOCHEMISTRY-US, V37, P14545, DOI 10.1021/bi981435q; Bouzat C, 2000, J GEN PHYSIOL, V115, P663, DOI 10.1085/jgp.115.5.663; Bouzat C, 2002, BIOPHYS J, V82, P1920, DOI 10.1016/S0006-3495(02)75541-0; CamposCaro A, 1997, BIOCHEMISTRY-US, V36, P2709, DOI 10.1021/bi9623486; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Choe S, 1995, P NATL ACAD SCI USA, V92, P12046, DOI 10.1073/pnas.92.26.12046; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; COCKCROFT VB, 1990, MOL NEUROBIOL, V4, P129, DOI 10.1007/BF02780338; Collins A, 1997, P NATL ACAD SCI USA, V94, P5456, DOI 10.1073/pnas.94.10.5456; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Cruz-Martin A, 2001, J MEMBRANE BIOL, V183, P61, DOI 10.1007/s00232-001-0051-z; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; Cymes GD, 2005, NATURE, V438, P975, DOI 10.1038/nature04293; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; daCosta CJB, 2002, J BIOL CHEM, V277, P201, DOI 10.1074/jbc.M108341200; De Rosa MJ, 2002, MOL PHARMACOL, V62, P406, DOI 10.1124/mol.62.2.406; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; Engel AG, 2002, MOL NEUROBIOL, V26, P347, DOI 10.1385/MN:26:2-3:347; Garbus I, 2002, NEUROPHARMACOLOGY, V43, P65, DOI 10.1016/S0028-3908(02)00068-0; Guzman GR, 2003, BIOCHEMISTRY-US, V42, P12243, DOI 10.1021/bi034764d; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Harrenga A, 1999, J BIOL CHEM, V274, P33296, DOI 10.1074/jbc.274.47.33296; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; Honse Y, 2004, NEUROPHARMACOLOGY, V46, P647, DOI 10.1016/j.neuropharm.2003.11.006; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; IWATA T, 1994, J BIOL CHEM, V269, P4928; Jenkins A, 2002, NEUROPHARMACOLOGY, V43, P669, DOI 10.1016/S0028-3908(02)00175-2; Jung SW, 2005, J BIOL CHEM, V280, P308, DOI 10.1074/jbc.M409871200; Kandasamy SK, 2006, BIOPHYS J, V90, P2326, DOI 10.1529/biophysj.105.073395; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kashlan OB, 2006, J BIOL CHEM, V281, P30455, DOI 10.1074/jbc.M604615200; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2001, EUR J BIOCHEM, V268, P1820, DOI 10.1046/j.1432-1327.2001.02053.x; Lasalde JA, 1996, BIOCHEMISTRY-US, V35, P14139, DOI 10.1021/bi961583l; Le Novere N, 2002, J NEUROBIOL, V53, P447, DOI 10.1002/neu.10153; LEE YH, 1994, BIOPHYS J, V66, P646, DOI 10.1016/S0006-3495(94)80838-0; Leite JF, 2003, P NATL ACAD SCI USA, V100, P13054, DOI 10.1073/pnas.2133028100; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; LI L, 1990, BIOCHEMISTRY-US, V29, P5428, DOI 10.1021/bi00475a003; LI L, 1992, BIOPHYS J, V62, P61, DOI 10.1016/S0006-3495(92)81779-4; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Lugovskoy AA, 1998, EUR J BIOCHEM, V255, P455, DOI 10.1046/j.1432-1327.1998.2550455.x; MCINTOSH TJ, 1986, BIOCHEMISTRY-US, V25, P4058, DOI 10.1021/bi00362a011; Mitra A, 2004, STRUCTURE, V12, P1909, DOI 10.1016/j.str.2004.08.004; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; Navedo M, 2004, BIOCHEMISTRY-US, V43, P78, DOI 10.1021/bi0356496; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Ortiz-Acevedo A, 2004, J BIOL CHEM, V279, P42250, DOI 10.1074/jbc.M405132200; OrtizMiranda SI, 1997, J MEMBRANE BIOL, V158, P17, DOI 10.1007/s002329900240; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Panchenko VA, 2001, J GEN PHYSIOL, V117, P345, DOI 10.1085/jgp.117.4.345; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5713, DOI 10.1021/bi047338g; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; Santiago J, 2004, BIOCHEMISTRY-US, V43, P10064, DOI 10.1021/bi0362368; Santiago J, 2001, J BIOL CHEM, V276, P46523, DOI 10.1074/jbc.M104563200; Shen XM, 2006, ANN NEUROL, V60, P128, DOI 10.1002/ana.20861; Silberberg SD, 2005, J GEN PHYSIOL, V125, P347, DOI 10.1085/jgp.200409221; Smith DK, 2003, PROTEIN SCI, V12, P1060, DOI 10.1110/ps.0236203; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Subbiah RN, 2005, J PHYSIOL-LONDON, V569, P367, DOI 10.1113/jphysiol.2005.097386; Tamamizu S, 2000, BIOCHEMISTRY-US, V39, P4666, DOI 10.1021/bi992835w; Tamamizu S, 1999, J MEMBRANE BIOL, V170, P157, DOI 10.1007/s002329900545; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wang HL, 1999, NAT NEUROSCI, V2, P226, DOI 10.1038/6326; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; Wang SY, 2003, BIOPHYS J, V85, P911, DOI 10.1016/S0006-3495(03)74530-5; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798	82	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9162	9171		10.1074/jbc.M607492200	http://dx.doi.org/10.1074/jbc.M607492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242410	hybrid			2022-12-27	WOS:000245780300063
J	Gorlatova, NV; Tale, JM; Elokdah, H; Li, DH; Fan's, K; Warnock, M; Crandall, DL; Lawrence, DA				Gorlatova, Natalia V.; Tale, Jacqueline M.; Elokdah, Hassan; Li, Donghua; Fan's, Kristi; Warnock, Mark; Crandall, David L.; Lawrence, Daniel A.			Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY THROMBOSIS; ADIPOSE-TISSUE DEVELOPMENT; PAI-1 GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; IN-VIVO; BINDING-SITE; PHARMACOLOGICAL INHIBITION; CARDIOVASCULAR-DISEASE; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS	The inactivation of plasminogen activator inhibitor- 1(PAI-1) by the small molecule PAI-1 inhibitor PAI-039 (tiplaxtinin) has been investigated using enzymatic analysis, direct binding studies, site-directed mutagenesis, and molecular modeling studies. Previously PAI-039 has been shown to exhibit in vivo activity in various animal models, but the mechanism of inhibition is unknown. PAI-039 bound specifically to the active conformation of PAI-1 and exhibited reversible inactivation of PAI-1 in vitro. SDS-PAGE indicated that PAI-039 inactivated PAI-1 predominantly through induction of PAI-1 substrate behavior. Preincubation of PAI-1 with vitronectin, but not bovine serum albumin, blocked PAI-039 activity while analysis of the reciprocal experiment demonstrated that preincubation of PAI-1 with PAI-039 blocked the binding of PAI-1 to vitronectin. Together, these data suggest that the site of interaction of the drug on PAI-1 is inaccessible when PAI-1 is bound to vitronectin and may overlap with the PAI-1 vitronectin binding domain. This was confirmed by site-directed mutagenesis and molecular modeling studies, which suggest that the binding epitope for PAI-039 is localized adjacent to the previously identified interaction site for vitronectin. Thus, these studies provide a detailed characterization of the mechanism of inhibition of PAI-1 by PAI-039 against free, but not vitronectin-bound PAI-1, suggesting for the first time a novel pool of PAl-1 exists that is vulnerable to inhibition by inactivators that bind at the vitronectin binding site.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Wyeth Ayerst Res, Cardiovasc & Metab Dis Res, Collegeville, PA 19426 USA; Wyeth Ayerst Res, Chem & Screening Sci, Collegeville, PA 19426 USA; Univ Maryland, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	University of Michigan System; University of Michigan; Pfizer; Pfizer; American Red Cross	Lawrence, DA (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 7301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dlawrenc@umich.edu		Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, P01HL054710, R01HL055747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55374, HL55747, P01HL54710, P01 HL054710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BIEMOND BJ, 1995, CIRCULATION, V91, P1175, DOI 10.1161/01.CIR.91.4.1175; Bjorquist P, 1998, BIOCHEMISTRY-US, V37, P1227, DOI 10.1021/bi971554q; Cao CZ, 2006, EMBO J, V25, P1860, DOI 10.1038/sj.emboj.7601082; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; Crandall DL, 2006, ARTERIOSCL THROM VAS, V26, P2209, DOI 10.1161/01.ATV.0000235605.51400.9d; Crandall DL, 2004, J THROMB HAEMOST, V2, P1422, DOI 10.1111/j.1538-7836.2004.00829.x; Crandall DL, 2003, BIOCHEM BIOPH RES CO, V311, P904, DOI 10.1016/j.bbrc.2003.10.088; Crandall DL, 2000, J CLIN ENDOCR METAB, V85, P2609, DOI 10.1210/jc.85.7.2609; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; De Taeye B, 2005, CURR OPIN PHARMACOL, V5, P149, DOI 10.1016/j.coph.2005.01.007; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Durand MK, 2004, THROMB HAEMOSTASIS, V91, P438, DOI 10.1160/TH03-12-0784; Egelund R, 2001, J BIOL CHEM, V276, P13077, DOI 10.1074/jbc.M009024200; Elokdah H, 2004, J MED CHEM, V47, P3491, DOI 10.1021/jm049766q; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; FAY WP, 1994, BLOOD, V83, P351; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; Fearns C, 1997, AM J PATHOL, V150, P579; Fogo AB, 2003, J CLIN INVEST, V112, P326, DOI 10.1172/JCI200319375; Folkes A, 2002, BIOORG MED CHEM LETT, V12, P1063, DOI 10.1016/S0960-894X(02)00078-1; Gorlatova NV, 2003, J BIOL CHEM, V278, P16329, DOI 10.1074/jbc.M208420200; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Hennan JK, 2005, J PHARMACOL EXP THER, V314, P710, DOI 10.1124/jpet.105.084129; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; Huang YF, 2003, J CLIN INVEST, V112, P379, DOI 10.1172/JCI200318038; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Ingelfinger JR, 2003, NEW ENGL J MED, V349, P2265, DOI 10.1056/NEJMcibr032288; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Kannel WB, 2005, LIPIDS, V40, P1215, DOI 10.1007/s11745-005-1488-8; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Leik CE, 2006, J THROMB HAEMOST, V4, P2710, DOI 10.1111/j.1538-7836.2006.02244.x; Lijnen HR, 2005, J THROMB HAEMOST, V3, P1174, DOI 10.1111/j.1538-7836.2005.01390.x; LOSKUTOFF DJ, 1993, THROMB HAEMOSTASIS, V70, P135; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; Naessens D, 2003, J THROMB HAEMOST, V1, P1028, DOI 10.1046/j.1538-7836.2003.00206.x; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; PYKE C, 1991, CANCER RES, V51, P4067; Robbie LA, 1997, THROMB HAEMOSTASIS, V77, P510; Robbie LA, 1996, ARTERIOSCL THROM VAS, V16, P539, DOI 10.1161/01.ATV.16.4.539; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; Smith LH, 2006, BLOOD, V107, P132, DOI 10.1182/blood-2005-07-2681; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2004, J BIOL CHEM, V279, P29981, DOI 10.1074/jbc.M401913200; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STEFANSSON S, 2003, SCI STKE, pE24; Uchida Y, 2004, J BIOL CHEM, V279, P4075, DOI 10.1074/jbc.M304222200; Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Weisberg AD, 2005, ARTERIOSCL THROM VAS, V25, P365, DOI 10.1161/01.ATV.0000152356.85791.52; Xu Z, 2004, J BIOL CHEM, V279, P17914, DOI 10.1074/jbc.M314197200; Yepes M., 2006, HEMOSTASIS THROMBOSI, P365; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	67	78	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9288	9296		10.1074/jbc.M611642200	http://dx.doi.org/10.1074/jbc.M611642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17276980	hybrid			2022-12-27	WOS:000245780300076
J	Shiraishi, S; Zhou, C; Aoki, T; Sato, N; Chiba, T; Tanaka, K; Yoshida, S; Nabeshima, Y; Nabeshima, Y; Tamura, T				Shiraishi, Seiji; Zhou, Chang; Aoki, Tsutomu; Sato, Naruki; Chiba, Tomoki; Tanaka, Keiji; Yoshida, Shosei; Nabeshima, Yoko; Nabeshima, Yo-ichi; Tamura, Taka-aki			TBP-interacting protein 120B (TIP120B)/cullin-associated and neddylation-dissociated 2 (CAND2) inhibits SCF-dependent ubiquitination of myogenin and accelerates myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TBP-INTERACTING PROTEIN; LIGASE COMPLEX; MEDIATED DEGRADATION; NEDD8 MODIFICATION; SKELETAL-MUSCLE; E3 LIGASE; MYOD; GENE; CUL1; TRANSCRIPTION	Despite fast protein degradation in muscles, protein concentrations remain constant during differentiation and maintenance of muscle tissues. Myogenin, a basic helix-loop-helix-type myogenic transcription factor, plays a critical role through transcriptional activation in myogenesis as well as muscle maintenance. TBP-interacting protein 120/cullin-associated neddylation-dissociated (TIP 120/CAND) is known to bind to cullin and negatively regulate SCF (Skp1-Cullin1-F-box protein) ubiquitin ligase, although its physiological role has not been elucidated. We have identified a muscle-specific isoform of TIP120, named TIP120B/CAND2. In this study, we found that TIP120B is not only induced in association with myogenic differentiation but also actively accelerates the myogenic differentiation of C2C12 cells. Although myogenin is a short lived protein and is degraded by a ubiquitin-proteasome system, TIP120B suppressed its ubiquitination and subsequent degradation of myogenin. TIP120B bound to cullin family proteins, especially Cullin 1 (CULL), and was associated with SCF complex in cells. It was demonstrated that myogenin was also associated with SCF and that CULL small interference RNA treatment inhibited ubiquitination of myogenin and stabilized it. TIP120B was found to break down the SCF-myogenin complex. Consequently suppression of SCF-dependent ubiquitination of myogenin by TIP 120B, which leads to stabilization of myogenin, can account for the TIP1208-directed accelerated differentiation of C2C12 cells. TIP120B is proposed to be a novel regulator for myogenesis.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan; Kyoto Univ, Grad Sch Med, Kyoto 6068501, Japan	Chiba University; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Tamura, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoicho, Chiba 2638522, Japan.	ttamura@faculty.chiba-u.jp		Yoshida, Shosei/0000-0001-8861-1866				Aoki T, 2002, BIOCHEM BIOPH RES CO, V296, P1097, DOI 10.1016/S0006-291X(02)02031-4; Aoki T, 1999, BIOCHEM BIOPH RES CO, V261, P911, DOI 10.1006/bbrc.1999.1147; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Batonnet S, 2004, J BIOL CHEM, V279, P5413, DOI 10.1074/jbc.M310315200; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Cao Y, 2006, EMBO J, V25, P502, DOI 10.1038/sj.emboj.7600958; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Ciechanover A, 2006, EXP BIOL MED, V231, P1197; Di Carlo A, 2004, J BIOL CHEM, V279, P16332, DOI 10.1074/jbc.M313931200; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hatoum Ossama Abu, 1998, Molecular and Cellular Biology, V18, P5670; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; Kayukawa K, 2001, GENES CELLS, V6, P165, DOI 10.1046/j.1365-2443.2001.00407.x; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lo SC, 2006, MOL CELL BIOL, V26, P1235, DOI 10.1128/MCB.26.4.1235-1244.2006; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Makino Y, 1999, MOL CELL BIOL, V19, P7951; Min KW, 2005, BIOCHEM BIOPH RES CO, V334, P867, DOI 10.1016/j.bbrc.2005.06.188; Min KW, 2003, J BIOL CHEM, V278, P15905, DOI 10.1074/jbc.M213070200; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakadai T, 2004, J BIOL CHEM, V279, P7447, DOI 10.1074/jbc.M305412200; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Sato S, 2006, EMBO J, V25, P211, DOI 10.1038/sj.emboj.7600774; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; You JX, 2003, J BIOL CHEM, V278, P23369, DOI 10.1074/jbc.M212887200; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	50	35	35	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9017	9028		10.1074/jbc.M611513200	http://dx.doi.org/10.1074/jbc.M611513200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242400	hybrid			2022-12-27	WOS:000245780300049
J	Vaughan, RA; Sakrikar, DS; Parnas, ML; Adkins, S; Foster, JD; Duval, RA; Lever, JR; Kulkarni, SS; Hauck-Newman, A				Vaughan, Roxanne A.; Sakrikar, Dhananjay S.; Parnas, M. Laura; Adkins, Steven; Foster, James D.; Duval, Romain A.; Lever, John R.; Kulkarni, Santosh S.; Hauck-Newman, Amy			Localization of cocaine analog [I-125]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOAFFINITY LIGANDS; DOMAINS; RECOGNITION; RECEPTOR; SITE; ANTIDEPRESSANTS; ACCESSIBILITY; CONFORMATION; MUTAGENESIS; INHIBITORS	The site of cocaine binding on the dopamine transporter (DAT) was investigated using the photoactivatable irreversible cocaine analog [I-125]3 beta-(p-chlorophenyl)tropane-2 beta-carboxylic acid, 4'-azido-3'-iodophenylethyl ester ([I-125]RTI 82). The incorporation site of this compound was mapped to transmembrane domains (TMs) 4-6 using epitope-specific immunoprecipitation of trypsin fragments and further localized using cyanogen bromide (CNBr), which hydrolyzes proteins on the C-terminal side of methionine residues. CNBr hydrolysis of [I-125]RTI 82-labeled rat striatal and expressed human DATs produced fragments of similar to 5-10 kDa consistent with labeling between Met(271/272) or Met(290) in TM5 to Met(370/371) in TM7. To further define the incorporation site, substitution mutations were made that removed endogenous methionines and inserted exogenous methionines in combinations that would generate labeled CNBr fragments of distinct masses depending on the labeling site. The results obtained were consistent with the presence of TM6 but not TMs 4, 5, or 7 in the labeled fragments, with additional support for these conclusions obtained by epitopespecific immunoprecipitation and secondary digestion of CNBr fragments with endoproteinase Lys-C. The final localization of [I-125]RTI 82 incorporation to rat DAT Met(290)-Lys(336) and human DAT I291M to R344M provides positive evidence for the proximity of cocaine binding to TM6. Residues in and near DAT TM6 regulate transport and transport-dependent conformational states, and TM6 forms part of the substrate permeation pathway in the homologous Aquifex aeolicus leucine transporter. Cocaine binding near TM6 may thus overlap the dopamine translocation pathway and function to inhibit TM6 structural rearrangements necessary for transport.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; Univ Missouri, Dept Radiol, Columbia, MO 65212 USA; Univ Missouri, Dept Med Pharmacol, Columbia, MO 65212 USA; Univ Missouri, Dept Physiol, Columbia, MO 65212 USA; Harry S Truman Mem Vet Hosp, Columbia, MO 65212 USA; NIDA, Med Chem Sect, Intramural Res Program, Baltimore, MD 21224 USA	University of North Dakota Grand Forks; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Vaughan, RA (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, 501 N Columbia Rd, Grand Forks, ND 58203 USA.	rvaughan@medicine.nodak.edu	Duval, Romain A/K-2299-2016	Duval, Romain A/0000-0002-0125-506X; Sakrikar, Dhananjay/0000-0001-8430-0120	Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [P20 RR 016741] Funding Source: Medline; NIDA NIH HHS [DA15175] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015175] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CARROLL FI, 1992, J MED CHEM, V35, P1813, DOI 10.1021/jm00088a017; CARROLL FI, 1992, J MED CHEM, V35, P969, DOI 10.1021/jm00084a001; Chen NH, 2004, J NEUROCHEM, V89, P853, DOI 10.1111/j.1471-4159.2004.02386.x; Chen NH, 2004, J BIOL CHEM, V279, P5508, DOI 10.1074/jbc.M306294200; Chen NH, 1998, J NEUROSCI, V18, P10257; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Chen NH, 2001, J NEUROCHEM, V77, P1116, DOI 10.1046/j.1471-4159.2001.00312.x; CRIMMINS DL, 2005, CURRENT PROTOCOLS PR, V1, P2; ESHLEMAN AJ, 1995, J PHARMACOL EXP THER, V274, P276; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Gaffaney JD, 2004, MOL PHARMACOL, V65, P692, DOI 10.1124/mol.65.3.692; GIROS B, 1994, J BIOL CHEM, V269, P15985; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Henry LK, 2006, J BIOL CHEM, V281, P2012, DOI 10.1074/jbc.M505055200; Itokawa M, 2000, MOL PHARMACOL, V57, P1093; KOTZYBAHIBERT F, 1989, ANGEW CHEM INT EDIT, V34, P1296; Lee SH, 2002, EXP MOL MED, V34, P90, DOI 10.1038/emm.2002.13; Lever JR, 2005, BIOCONJUGATE CHEM, V16, P644, DOI 10.1021/bc0497214; LEVER JR, 1993, J LABELLED COMPD RAD, V33, P1131, DOI 10.1002/jlcr.2580331207; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Norgaard-Nielsen K, 2002, FEBS LETT, V524, P87, DOI 10.1016/S0014-5793(02)03008-9; PARNAS ML, 2006, ABSTR VIEW IT PLANN; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sen N, 2005, NEUROPHARMACOLOGY, V49, P780, DOI 10.1016/j.neuropharm.2005.08.014; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Smicun Y, 1999, J BIOL CHEM, V274, P36058, DOI 10.1074/jbc.274.51.36058; Surratt CK, 2005, AAPS J, V7, pE739, DOI 10.1208/aapsj070374; Varano F, 2002, J MED CHEM, V45, P1035, DOI 10.1021/jm010995b; Vaughan RA, 1996, J BIOL CHEM, V271, P21672, DOI 10.1074/jbc.271.35.21672; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; Vaughan RA, 2005, J NEUROSCI METH, V143, P33, DOI 10.1016/j.jneumeth.2004.09.022; Vaughan RA, 1999, J NEUROSCI, V19, P630; Vaughan RA, 2001, MOL PHARMACOL, V59, P1157, DOI 10.1124/mol.59.5.1157; Volz TJ, 2005, SYNAPSE, V58, P72, DOI 10.1002/syn.20183; Xing DX, 2000, J MED CHEM, V43, P639, DOI 10.1021/jm9902234; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zou MF, 2001, J MED CHEM, V44, P4453, DOI 10.1021/jm0101904	40	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8915	8925		10.1074/jbc.M610633200	http://dx.doi.org/10.1074/jbc.M610633200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255098	hybrid			2022-12-27	WOS:000245780300038
J	Wang, CH; Su, LH; Sun, CH				Wang, Chih-Hung; Su, Li-Hsin; Sun, Chin-Hung			A novel ARID/bright-like protein involved in transcriptional activation of cyst wall protein 1 gene in Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; DEAD RINGER GENE; PRIMITIVE EUKARYOTE; ARID FAMILY; ENCYSTATION; PROMOTER; SEQUENCE; EXPRESSION; IDENTIFICATION; COMPLEX	The capability of protozoan parasite Giardia lamblia to encyst is critical for survival outside the host and its transmission. AT-rich interaction domain (ARID) or Bright homologs constitute a large family of transcription factors in higher eukaryotes that regulate cell proliferation, development, and differentiation. We asked whether Giardia has ARID-like genes and whether they influence gene expression during Giardia encystation. Blast searches of the Giardia genome data base identified two genes with putative ARID/Bright domains (gARID1 and 2). Epitope-tagged gARID1 was found to localize to nuclei. Recombinant gARID1 specifically bound to the encystation-induced cyst wall protein (cwp) gene promoters. Mutation analysis revealed that AT-rich initiators were required for binding of gARID1 to the cwp promoters. gARID1 contains several key residues for DNA binding, and its binding sequences are similar to those of the known ARID family proteins. The gARID1 binding sequences were positive cis-acting elements of the cwp1 promoter during both vegetative growth and encystation. We also found that gARID1 transactivated the cwp1 promoter through its binding sequences in vivo. Our results suggest that the ARID family has been conserved during evolution and that gARID1 is an important transactivator in regulation of the Giardia cwp1 gene, which is key to Giardia differentiation into cysts.	Natl Taiwan Univ, Coll Med, Dept Parasitol, Taipei 100, Taiwan	National Taiwan University	Sun, CH (corresponding author), Natl Taiwan Univ, Coll Med, Dept Parasitol, Taipei 100, Taiwan.	chsun@ha.mc.ntu.edu.tw	Shin, Jerry/AAO-2515-2021	SUN, CHIN-HUNG/0000-0002-8604-8085				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Best AA, 2004, GENOME RES, V14, P1537, DOI 10.1101/gr.2256604; Bruderer T, 1996, MOL BIOCHEM PARASIT, V77, P225, DOI 10.1016/0166-6851(96)02605-9; BURATOWSKI S, 2000, CURRENT PROTOCOLS MO, P9; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Davis-Hayman SR, 2003, INT J PARASITOL, V33, P1005, DOI 10.1016/S0020-7519(03)00177-2; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Eichinger D, 2001, CURR OPIN MICROBIOL, V4, P421, DOI 10.1016/S1369-5274(00)00229-0; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; Erlandsen SL, 1996, J EUKARYOT MICROBIOL, V43, P416, DOI 10.1111/j.1550-7408.1996.tb05053.x; GILLIN FD, 1987, SCIENCE, V235, P1040, DOI 10.1126/science.3547646; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; HOLBERTON DV, 1995, NUCLEIC ACIDS RES, V23, P2945, DOI 10.1093/nar/23.15.2945; Inagaki Y, 2003, NUCLEIC ACIDS RES, V31, P4227, DOI 10.1093/nar/gkg440; Iwahara J, 2002, EMBO J, V21, P1197, DOI 10.1093/emboj/21.5.1197; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Kim TG, 2003, J BIOL CHEM, V278, P42247, DOI 10.1074/jbc.M307386200; Knodler LA, 1999, MOL MICROBIOL, V34, P327, DOI 10.1046/j.1365-2958.1999.01602.x; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; Nixon JC, 2004, J BIOL CHEM, V279, P52465, DOI 10.1074/jbc.M403028200; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Seshadri V, 2003, J BIOL CHEM, V278, P27804, DOI 10.1074/jbc.M303316200; Shandala T, 1999, DEVELOPMENT, V126, P4341; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sun CH, 2003, J BIOL CHEM, V278, P21701, DOI 10.1074/jbc.M302023200; Sun CH, 2006, MOL BIOCHEM PARASIT, V146, P45, DOI 10.1016/j.molbiopara.2005.10.017; Sun CH, 2005, MOL BIOCHEM PARASIT, V142, P1, DOI 10.1016/j.molbiopara.2005.03.003; Sun CH, 1999, J BIOL CHEM, V274, P19699, DOI 10.1074/jbc.274.28.19699; Sun CH, 2002, MOL MICROBIOL, V46, P971, DOI 10.1046/j.1365-2958.2002.03233.x; Sun CH, 1998, MOL BIOCHEM PARASIT, V92, P123, DOI 10.1016/S0166-6851(97)00239-9; Van Keulen H, 1998, J EUKARYOT MICROBIOL, V45, P637, DOI 10.1111/j.1550-7408.1998.tb04560.x; Watanabe M, 2002, CIRC RES, V91, P382, DOI 10.1161/01.RES.0000033593.05545.7B; Whitson RH, 1999, BIOCHEM BIOPH RES CO, V258, P326, DOI 10.1006/bbrc.1999.0643; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Wilsker D, 2004, NUCLEIC ACIDS RES, V32, P1345, DOI 10.1093/nar/gkh277; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95; WOLFE MS, 1992, CLIN MICROBIOL REV, V5, P93, DOI 10.1128/CMR.5.1.93-100.1992; Worgall TS, 2004, J LIPID RES, V45, P981, DOI 10.1194/jlr.M400024-JLR200; Yee J, 2000, J BIOL CHEM, V275, P11432, DOI 10.1074/jbc.275.15.11432	46	33	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8905	8914		10.1074/jbc.M611170200	http://dx.doi.org/10.1074/jbc.M611170200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244608	hybrid			2022-12-27	WOS:000245780300037
J	Gorner, K; Holtorf, E; Waak, J; Pham, TT; Vogt-Weisenhorn, DM; Wurst, W; Haass, C; Kahle, PJ				Goerner, Karin; Holtorf, Eve; Waak, Jens; Pham, Thu-Trang; Vogt-Weisenhorn, Daniela M.; Wurst, Wolfgang; Haass, Christian; Kahle, Philipp J.			Structural determinants of the C-terminal helix-kink-helix motif essential for protein stability and survival promoting activity of DJ-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL PARKINSONS-DISEASE; RESOLUTION CRYSTAL-STRUCTURE; EARLY-ONSET PARKINSONISM; TUMOR-SUPPRESSOR PTEN; OXIDATIVE STRESS; DROSOPHILA DJ-1; CELL-DEATH; ESCHERICHIA-COLI; ALPHA-SYNUCLEIN; APOPTOSIS	Mutations in the PARK7 gene encoding DJ-1 cause autosomal recessive Parkinson disease. The most deleterious point mutation is the L166P substitution, which resides in a structure motif comprising two alpha-helices (G and H) separated by a kink. Here we subjected the C-terminal helix-kink-helix motif to systematic site-directed mutagenesis, introducing helix-incompatible proline residues as well as conservative substitutions into the helical interface. Furthermore, we generated deletion mutants lacking the H-helix, the kink, and the entire C terminus. When transfected into neural and non-neural cell lines, steady-state levels of G-helix breaking and kink deletion mutants were dramatically lower than wildtype DJ-1. The effects of H-helix breakers were comparably smaller, and the non-helix breaking mutants only slightly destabilized DJ-1. The decreased steady-state levels were due to accelerated protein degradation involving in part the proteasome. G-helix breaking DJ-1 mutations abolished dimer formation. These structural perturbations had functional consequences on the cytoprotective activities of DJ-1. The destabilizing mutations conferred reduced cytoprotection against H2O2 in transiently retransfected DJ-1 knock-out mouse embryonic fibroblasts. The loss of survival promoting activity of the DJ-1 mutants with destabilizing C-terminal mutations correlated with impaired anti-apoptotic signaling. We found that wild-type, but not mutant DJ-1 facilitated the Akt pathway and simultaneously blocked the apoptosis signal-regulating kinase 1, with which DJ-1 interacted in a redox-dependent manner. Thus, the G-helix and kink are critical determinants of the C-terminal helix-kink-helix motif, which is absolutely required for stability and the regulation of survival-promoting redox signaling of the Parkinson disease-associated protein DJ-1.	Univ Clin Tubingen, Lab Funct Neurogenet, Dept Neurodegenerat, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; Univ Munich, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Dev Genet, D-85764 Neuherberg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Munich; Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Kahle, PJ (corresponding author), Univ Clin Tubingen, Lab Funct Neurogenet, Dept Neurodegenerat, Hertie Inst Clin Brain Res, Otfried Muller Str 27, D-72076 Tubingen, Germany.	Philipp.Kahle@uni-tuebingen.de		Wurst, Wolfgang/0000-0003-4422-7410; Vogt Weisenhorn, Daniela/0000-0002-4566-6506				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Bandyopadhyay S, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-6; Barthel A, 2005, BIOL CHEM, V386, P207, DOI 10.1515/BC.2005.026; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Cookson MR, 2003, P NATL ACAD SCI USA, V100, P9111, DOI 10.1073/pnas.1633722100; Gorner K, 2004, J BIOL CHEM, V279, P6943, DOI 10.1074/jbc.M309204200; Heales SJR, 2004, NEUROCHEM RES, V29, P513, DOI 10.1023/B:NERE.0000014822.69384.0f; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li HM, 2005, FREE RADICAL RES, V39, P1091, DOI 10.1080/10715760500260348; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Lockhart PJ, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011106; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; Menzies FM, 2005, CURR BIOL, V15, P1578, DOI 10.1016/j.cub.2005.07.036; Meulener M, 2005, CURR BIOL, V15, P1572, DOI 10.1016/j.cub.2005.07.064; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Neumann M, 2004, ACTA NEUROPATHOL, V107, P489, DOI 10.1007/s00401-004-0834-2; Nishinaga H, 2005, NEUROSCI LETT, V390, P54, DOI 10.1016/j.neulet.2005.07.053; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Okada M, 2002, BIOL PHARM BULL, V25, P853, DOI 10.1248/bpb.25.853; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Ooe H, 2005, TOXICOL SCI, V88, P114, DOI 10.1093/toxsci/kfi278; Rizzu P, 2004, ANN NEUROL, V55, P113, DOI 10.1002/ana.10782; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Shinbo YM, 2005, INT J ONCOL, V26, P641; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Wilson MA, 2005, J MOL BIOL, V353, P678, DOI 10.1016/j.jmb.2005.08.033; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Yang YF, 2005, P NATL ACAD SCI USA, V102, P13670, DOI 10.1073/pnas.0504610102; Zhou WB, 2006, J MOL BIOL, V356, P1036, DOI 10.1016/j.jmb.2005.12.030; Zhou WB, 2005, J BIOL CHEM, V280, P43150, DOI 10.1074/jbc.M507124200	52	59	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13680	13691		10.1074/jbc.M609821200	http://dx.doi.org/10.1074/jbc.M609821200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17331951	hybrid			2022-12-27	WOS:000246060300058
J	Schaub, MC; Lopez, SR; Caputi, M				Schaub, Michael C.; Lopez, Suzette R.; Caputi, Massimo			Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP-H; TAT EXON-2; REGULATORY ELEMENTS; A/B PROTEINS; SR PROTEINS; BINDING; SILENCER; A1; CLEAVAGE	In this study we analyzed members of the heterogeneous nuclear ribonucleoprotein ( hnRNP) H protein family to determine their RNA binding specificities and roles in splicing regulation. Our data indicate that hnRNPs H, H', F, 2H9, and GRSF-1 bind the consensus motif DGGGD (where D is U, G, or A) and aggregate in a multimeric complex. We analyzed the role of these proteins in the splicing of a substrate derived from the HIV-1 tat gene and have shown that hnRNP H family members are required for efficient splicing of this substrate. The hnRNP H protein family members activated splicing of the viral substrate by promoting the formation of ATP-dependent spliceosomal complexes. Mutational analysis of six consensus motifs present within the intron of the substrate indicated that only one of these motifs acts as an intronic splicing enhancer.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA	State University System of Florida; Florida Atlantic University	Caputi, M (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, 777 Glades Rd, Boca Raton, FL 33431 USA.	mcaputi@fau.edu			NIAID NIH HHS [R01AI052820] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052820] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkan SA, 2006, BIOCHEM J, V393, P361, DOI 10.1042/BJ20050538; AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; Bilodeau PS, 1999, J VIROL, V73, P9764, DOI 10.1128/JVI.73.12.9764-9772.1999; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; Buratti E, 2004, NUCLEIC ACIDS RES, V32, P4224, DOI 10.1093/nar/gkh752; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caputi M, 2004, J VIROL, V78, P6517, DOI 10.1128/JVI.78.12.6517-6526.2004; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Das R, 1999, RNA, V5, P1504, DOI 10.1017/S1355838299991501; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; Gamberi C, 1997, MOL CELL BIOL, V17, P2587, DOI 10.1128/MCB.17.5.2587; Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200; Hallay H, 2006, J BIOL CHEM, V281, P37159, DOI 10.1074/jbc.M603864200; Han K, 2005, PLOS BIOL, V3, P843, DOI 10.1371/journal.pbio.0030158; Hastings ML, 2001, RNA, V7, P859, DOI 10.1017/S1355838201002084; Honore B, 2004, EXP CELL RES, V294, P199, DOI 10.1016/j.yexcr.2003.11.011; House AE, 2006, NAT STRUCT MOL BIOL, V13, P937, DOI 10.1038/nsmb1149; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Kim DH, 2005, NUCLEIC ACIDS RES, V33, P3866, DOI 10.1093/nar/gki698; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; MARCUCCI R, 2006, NUCL ACIDS RES; Martinez-Contreras R, 2006, PLOS BIOL, V4, P172, DOI 10.1371/journal.pbio.0040021; Mayeda A, 1999, METH MOL B, V118, P309; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Park YW, 1999, P NATL ACAD SCI USA, V96, P6694, DOI 10.1073/pnas.96.12.6694; Sharma S, 2005, MOL CELL, V19, P485, DOI 10.1016/j.molcel.2005.07.014; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Tange TO, 2001, EMBO J, V20, P5748; Veraldi KL, 2001, MOL CELL BIOL, V21, P1228, DOI 10.1128/MCB.21.4.1228-1238.2001; Yeo G, 2004, P NATL ACAD SCI USA, V101, P15700, DOI 10.1073/pnas.0404901101; Yoshida T, 1999, GENES CELLS, V4, P707, DOI 10.1046/j.1365-2443.1999.00295.x; Yoshida T, 1999, FEBS LETT, V457, P251, DOI 10.1016/S0014-5793(99)01048-0; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; Zhang YZ, 2000, GENE, V257, P33, DOI 10.1016/S0378-1119(00)00372-3; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	44	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13617	13626		10.1074/jbc.M700774200	http://dx.doi.org/10.1074/jbc.M700774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337441	hybrid			2022-12-27	WOS:000246060300051
J	Campian, JL; Gao, XS; Qian, MW; Eaton, JW				Campian, Jian Li; Gao, Xueshan; Qian, Mingwei; Eaton, John W.			Cytochrome c oxidase activity and oxygen tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SUBUNIT-IV; MITOCHONDRIAL; CELLS; METABOLISM	Most cultured cells and intact animals die under hyperoxic conditions. However, a strain of HeLa cells that proliferates under 80% O-2, termed "HeLa-80," has been derived from wild-type HeLa cells ("HeLa-20") by selection for resistance to step-wise increases of oxygen partial pressure. The tolerance of HeLa-80 cells to hyperoxia is not associated with changes in antioxidant defenses or susceptibility to oxidant-mediated killing. Rather, under both 20 and 80% O-2, mitochondrial reactive oxygen species (ROS) production is similar to 2-fold less in HeLa-80 cells, likely related to a significantly higher cytochrome c oxidase (COX) activity (similar to 2-fold), which may act to deplete upstream electron-rich intermediates responsible for ROS generation. We now report that in HeLa-80 cells elevated COX activity is associated with a >2-fold increase in the regulatory subunit COX Vb, whereas expression levels of other subunits are very close to wild type. Small interfering RNA against Vb selectively lowers COX Vb expression in HeLa-80 cells, increases mitochondrial ROS generation, decreases COX activity 60-80%, and diminishes viability under 80% (but not 20%) O-2. In addition, overexpression of subunit Vb increases COX activity and decreases ROS production in wild-type HeLa-20 cells, along with some increase in tolerance to hyperoxia. Overall, our results indicate that it is possible to make cells tolerant of hyperoxia by manipulation of mitochondrial electron transport. These observations may suggest new pharmaceutical strategies to diminish oxygen-mediated cellular damage.	Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, Louisville, KY 40202 USA	University of Louisville	Eaton, JW (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, 580 S Preston St,Baxter Res Bldg 1,Rm 210, Louisville, KY 40202 USA.	EatonRedox@aol.com			NIDDK NIH HHS [DK58882] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058882] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beauchemin AMJ, 2001, BRAIN RES BULL, V56, P285, DOI 10.1016/S0361-9230(01)00583-4; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Bostek C C, 1989, AANA J, V57, P231; Campian JL, 2004, J BIOL CHEM, V279, P46580, DOI 10.1074/jbc.M406685200; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Castro L, 2001, NUTRITION, V17, P161, DOI 10.1016/S0899-9007(00)00570-0; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; Gerschman R, 2001, Nutrition, V17, P162; Grandjean F, 2002, BIOCHEM PHARMACOL, V63, P823, DOI 10.1016/S0006-2952(01)00865-6; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; Holthofer H, 1999, FASEB J, V13, P523, DOI 10.1096/fasebj.13.3.523; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0; JOENJE H, 1985, LAB INVEST, V52, P420; Jyonouchi H, 1998, AM J RESP CELL MOL, V19, P426, DOI 10.1165/ajrcmb.19.3.2862m; Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; Li J, 2004, FREE RADICAL BIO MED, V36, P1460, DOI 10.1016/j.freeradbiomed.2004.03.005; LIGHTOWLERS R, 1991, J BIOL CHEM, V266, P7688; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mantell LL, 2000, MOL GENET METAB, V71, P359, DOI 10.1006/mgme.2000.3046; Morris A H, 1994, New Horiz, V2, P19; O'Donovan DJ, 2000, MOL GENET METAB, V71, P352, DOI 10.1006/mgme.2000.3063; SANDERS SP, 1993, J CLIN INVEST, V91, P46, DOI 10.1172/JCI116198; Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214	30	44	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12430	12438		10.1074/jbc.M604547200	http://dx.doi.org/10.1074/jbc.M604547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17303578	hybrid			2022-12-27	WOS:000245942800011
J	Chen, L; Uchida, K; Endler, A; Shibasaki, F				Chen, Li; Uchida, Kazuyo; Endler, Alexander; Shibasaki, Futoshi			Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2 alpha for degradation by hypoxia- and pVHL-independent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL PAS DOMAIN; HIPPEL-LINDAU PROTEIN; FACTOR-I; GROWTH-FACTOR; HIF-ALPHA; TRANSACTIVATION DOMAIN; RECEPTOR-2 FLK-1; O-2 HOMEOSTASIS; TRANSGENIC MICE; CANCER-PATIENTS	The hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha are structurally similar as regards their DNA-binding and dimerization domains, but differ in their transactivation domains and, as is shown by experiments using hif-1 alpha(-/-) and hif-2 alpha(-/-) mice, in their functions. This implies that HIF-1 alpha and HIF-2 alpha may have unique target genes. To address this discrepancy and identify HIF-2 alpha-specific target genes, we performed yeast two-hybrid analysis and identified the tumor suppressor Int6/eIF3e/p48 as a novel target gene product involved in HIF-2 alpha regulation. The int6 gene was first identified from a screen in which the mouse mammary tumor virus was employed as an insertional mutagen to identify genes whose functions are critical for breast tumor formation. Here, by using two-hybrid analysis, immunoprecipitation in mammalian cells, and HRE-reporter assays, we report the specific interaction of HIF-2 alpha( but not HIF-1 alpha or HIF-3 alpha) with Int6. The results indicate that the direct interaction of Int6 induces proteasome inhibitor-sensitive HIF-2 alpha degradation. This degradation was clearly observed in renal cell carcinoma 786-O cells, and was found to be both hypoxia-and pVHL-independent. Furthermore, Int6 protein knockdown by int6-siRNA vectors or the dominant-negative mutant Int6-Delta C increased endogenous HIF-2 alpha expression, even under normoxia, and induced sets of critical angiogenic factors comprising vascular endoplasmic growth factor, angiopoietin, and basic fibroblast growth factor mRNA. These results indicate that Int6 is a novel and critical determinant of HIF-2-alpha dependent angiogenesis as well as cancer formation, and that int6-siRNA transfer may be an effective therapeutic strategy in pathological conditions such as heart and brain ischemia, hepatic cirrhosis, and obstructive vessel diseases.	Tokyo Metropolitan Inst Med Sci, Translat Res Project, Bunkyo Ku, Tokyo 1138613, Japan; Tongji Univ, Sch Basic Med, Dept Biol, Shanghai 2000092, Peoples R China	Tokyo Metropolitan Institute of Medical Science; Tongji University	Shibasaki, F (corresponding author), Tokyo Metropolitan Inst Med Sci, Translat Res Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	fshibasa@rinshoken.or.jp						Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bonicalzi ME, 2001, J BIOL CHEM, V276, P1407, DOI 10.1074/jbc.M008295200; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Duan LJ, 2005, CIRCULATION, V111, P2227, DOI 10.1161/01.CIR.0000163580.98098.A3; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Hara S, 1999, Mol Cell Biol Res Commun, V2, P119, DOI 10.1006/mcbr.1999.0160; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Maina EN, 2005, ONCOGENE, V24, P4549, DOI 10.1038/sj.onc.1208649; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; ONARNIM AG, 2003, CURR BIOL, V13, pR323; Ouiddir A, 1999, AM J RESP CELL MOL, V21, P710, DOI 10.1165/ajrcmb.21.6.3751; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sato M, 2002, AM J RESP CELL MOL, V26, P127, DOI 10.1165/ajrcmb.26.1.4319; Scortegagna M, 2003, BLOOD, V102, P1634, DOI 10.1182/blood-2003-02-0448; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Takahashi R, 2004, BIOCHEM BIOPH RES CO, V317, P84, DOI 10.1016/j.bbrc.2004.03.010; Takeda N, 2004, CIRC RES, V95, P146, DOI 10.1161/01.RES.0000134920.10128.b4; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yen HCS, 2003, CELL CYCLE, V2, P81, DOI 10.4161/cc.2.2.340; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu F, 2001, CANCER RES, V61, P4136	66	50	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12707	12716		10.1074/jbc.M700423200	http://dx.doi.org/10.1074/jbc.M700423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324924	hybrid			2022-12-27	WOS:000245942800040
J	Iwai, M; Michikawa, T; Bosanac, I; Ikura, M; Mikoshiba, K				Iwai, Miwako; Michikawa, Takayuki; Bosanac, Ivan; Ikura, Mitsuhiko; Mikoshiba, Katsuhiko			Molecular basis of the isoform-specific ligand-binding affinity of inositol 1,4,5-trisphosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR DOMAIN; XENOPUS OOCYTES; CALCIUM; SITE; SEQUENCE; COMPLEX; TYPE-3; CELLS	Three isoforms of the inositol 1,4,5-trisphosphate ( IP3) receptor ( IP3R), IP(3)R1, IP(3)R2, and IP(3)R3, have different IP3-binding affinities and cooperativities. Here we report that the amino-terminal 604 residues of three mouse IP3R types exhibited K-d values of 49.5 +/- 10.5, 14.0 +/- 3.5, and 163.0 +/- 44.4 nM, which are close to the intrinsic IP3-binding affinity previously estimated from the analysis of full-length IP(3)Rs. In contrast, residues 224-604 of IP(3)R1 and IP(3)R2 and residues 225-604 of IP(3)R3, which contain the IP3-binding core domain but not the suppressor domain, displayed an almost identical IP3-binding affinity with a K-d value of similar to 2 nM. Addition of 100-fold excess of the suppressor domain did not alter the IP3-binding affinity of the IP3-binding core domain. Artificial chimeric proteins in which the suppressor domain was fused to the IP3-binding core domain from different isoforms exhibited IP3-binding affinity significantly different from those of the proteins composed of the native combination of the suppressor domain and the IP3-binding core domain. Systematic mutagenesis analyses showed that amino acid residues critical for type-3 receptor-specific IP3-binding affinity are involved in Glu-39, Ala-41, Asp-46, Met-127, Ala-154, Thr-155, Leu-162, Trp-168, Asn-173, Asn-176, and Val-179. These results indicate that the IP3-binding affinity of IP(3)Rs is specifically tuned through the intramolecular attenuation of IP3-binding affinity of the IP3-binding core domain by the aminoterminal suppressor domain. Moreover, the functional diversity in ligand sensitivity among IP3R isoforms originates from at least the structural difference identified on the suppressor domain.	Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Div Signaling Biol, Toronto, ON M5G 1L7, Canada	University of Tokyo; RIKEN; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Michikawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	takamich@ims.u-tokyo.ac.jp; mikosiba@ims.u-tokyo.ac.jp	Mikoshiba, Katsuhiko/N-7943-2015	Ikura, Mitsuhiko/0000-0002-9524-1303				BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Bosanac I, 2004, BBA-MOL CELL RES, V1742, P89, DOI 10.1016/j.bbamcr.2004.09.016; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Iwai M, 2005, J BIOL CHEM, V280, P10305, DOI 10.1074/jbc.M413824200; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; Matsu-ura T, 2006, J CELL BIOL, V173, P755, DOI 10.1083/jcb.200512141; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Nerou EP, 2001, BIOCHEM J, V355, P59, DOI 10.1042/bj3550059; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Szlufcik K, 2006, CELL CALCIUM, V39, P325, DOI 10.1016/j.ceca.2005.11.007; Taylor Colin W., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P109; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498	24	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12755	12764		10.1074/jbc.M609833200	http://dx.doi.org/10.1074/jbc.M609833200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327232	hybrid			2022-12-27	WOS:000245942800046
J	Zhang, AS; Anderson, SA; Meyers, KR; Hernandez, C; Eisenstein, RS; Enns, CA				Zhang, An-Sheng; Anderson, Sheila A.; Meyers, Kathrin R.; Hernandez, Catalina; Eisenstein, Richard S.; Enns, Caroline A.			Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPULSIVE GUIDANCE MOLECULE; MORPHOGENETIC PROTEIN CORECEPTOR; JUVENILE HEMOCHROMATOSIS; EXPRESSION PATTERN; RAT-LIVER; MOUSE; GENE; HEPCIDIN; RGM; METABOLISM	Hemojuvelin ( HJV), encoded by the gene HFE2, is a critical upstream regulator of hepcidin expression. Hepcidin, the central iron regulatory hormone, is secreted from hepatocytes, whereas HFE2 is highly expressed in skeletal muscle and liver. Previous studies demonstrated that HJV is a GPI-anchored protein, binds the proteins neogenin and bone morphogenetic proteins ( BMP2 and BMP4), and can be released from the cell membrane ( shedding). In this study, we investigated the physiological significance and the underlying mechanism of HJV shedding. In acutely iron-deficient rats with markedly suppressed hepatic hepcidin expression, we detected an early phase increase of serum HJV with no significant change of either HFE2 mRNA or protein levels in gastrocnemius muscle. Studies in both C2C12 ( a mouse myoblast cell line) and HepG2 ( a human hepatoma cell line) cells showed active HJV shedding, implying that both skeletal muscle and liver could be the source of serum HJV. In agreement with the observations in iron-deficient rats, HJV shedding in these cell lines was down-regulated by holo-transferrin in a concentration-dependent manner. Our present study showing that knockdown of endogenous neogenin, a HJV receptor, in C2C12 cells suppresses HJV shedding and that overexpression of neogenin in HEK293 cells markedly enhances this process, suggests that membrane HJV shedding is mediated by neogenin. The finding that neither BMP4 nor its antagonist, noggin, was able to alter HJV shedding support the lack of involvement of BMP signaling pathway in this process.	Oregon Hlth & Sci Univ, Dept Cell & Dev Biol L215, Portland, OR 97239 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	Oregon Health & Science University; University of Wisconsin System; University of Wisconsin Madison	Zhang, AS (corresponding author), Oregon Hlth & Sci Univ, Dept Cell & Dev Biol L215, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhanga@ohsu.edu			NIDDK NIH HHS [DK066600, DK54488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK066600, R37DK054488, R01DK066600, R01DK054488] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2005, J BIOL CHEM, V280, P29820, DOI 10.1074/jbc.M503511200; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Camaschella C, 2002, SEMIN HEMATOL, V39, P242, DOI 10.1053/shem.2002.35635; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; De Gobbi M, 2002, BRIT J HAEMATOL, V117, P973, DOI 10.1046/j.1365-2141.2002.03509.x; Fairbanks VF, 1994, MODERN NUTR HLTH DIS, P185; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang FW, 2005, J CLIN INVEST, V115, P2187, DOI 10.1172/JCI25049; Johnson MB, 2004, BLOOD, V104, P4287, DOI 10.1182/blood-2004-06-2477; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225; Krijt J, 2004, BLOOD, V104, P4308, DOI 10.1182/blood-2004-06-2422; Kuninger D, 2004, GENOMICS, V84, P876, DOI 10.1016/j.ygeno.2004.07.013; Kuninger D, 2006, J CELL SCI, V119, P3273, DOI 10.1242/jcs.03074; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Lin L, 2005, BLOOD, V106, P2884, DOI 10.1182/blood-2005-05-1845; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Matsunaga E, 2004, DEV GROWTH DIFFER, V46, P481; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Niederkofler V, 2005, J CLIN INVEST, V115, P2180, DOI 10.1172/JCI25683; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Truksa J, 2006, P NATL ACAD SCI USA, V103, P10289, DOI 10.1073/pnas.0603124103; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010; Wilson NH, 2007, INT J BIOCHEM CELL B, V39, P874, DOI 10.1016/j.biocel.2006.10.023; Wilson NH, 2006, DEV BIOL, V296, P485, DOI 10.1016/j.ydbio.2006.06.018; Zhang AS, 2004, BLOOD, V103, P1509, DOI 10.1182/blood-2003-07-2378; Zhang AS, 2005, J BIOL CHEM, V280, P33885, DOI 10.1074/jbc.M506207200	42	94	102	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12547	12556		10.1074/jbc.M608788200	http://dx.doi.org/10.1074/jbc.M608788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331953	hybrid			2022-12-27	WOS:000245942800023
J	Gendra, E; Colgan, DF; Meany, B; Konarska, MM				Gendra, Elisenda; Colgan, Diana F.; Meany, Brendan; Konarska, Maria M.			A sequence motif in the simian virus 40 (SV40) early core promoter affects alternative splicing of transcribed mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; SITE SELECTION; IN-VIVO; ELONGATION-FACTORS; GENE-EXPRESSION; FACT COMPLEX; U6 SNRNA; INITIATION; PROTEIN; DNA	To identify new sequence elements in the promoter that affect splicing patterns of pre-mRNAs, we analyzed effects of different promoters on alternative splicing of model reporter genes. We compared the E1a alternative splicing pattern in transcripts expressed from the full-length cytomegalovirus, SV40 early, or a hybrid cytomegalovirus/SV40 early promoter and found that the hybrid promoter improved selection of the suboptimal E1a 5'SS-1. Expressing RNA from the hybrid promoter also enhanced selection of suboptimal splice sites in other alternatively spliced reporter genes, demonstrating the generality of this effect. Unlike previously defined promoter elements shown to affect alternative splicing, which were located in the enhancer/upstream activating sequences, the motif identified in this work is positioned within the core promoter; it is comprised of eight T-residues directly upstream of the SV40 early TATA box. This motif was previously implicated in DNA bending and negative regulation of transcription. Together, these results suggest that the identity of transcription complex assembled in the core promoter-dependent fashion can affect splice site selection during pre-mRNA splicing, perhaps by influencing the processivity of transcription elongation.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Konarska, MM (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	konarsk@mail.rockefeller.edu	Konarska, Maria/ABG-6405-2020; Konarska, Maria M./AAT-2572-2021	Konarska, Maria M./0000-0001-9235-1702	NCI NIH HHS [T32 CA009673] Funding Source: Medline; NIGMS NIH HHS [GM49044] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Biswas D, 2005, MOL CELL BIOL, V25, P5812, DOI 10.1128/MCB.25.14.5812-5822.2005; BONADIO J, 1990, J BIOL CHEM, V265, P2262; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; Buratowski S, 2005, CURR OPIN CELL BIOL, V17, P257, DOI 10.1016/j.ceb.2005.04.003; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Calvo O, 2005, EMBO J, V24, P1009, DOI 10.1038/sj.emboj.7600575; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; de la Mata M, 2006, NAT STRUCT MOL BIOL, V13, P973, DOI 10.1038/nsmb1155; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dowhan DH, 2005, MOL CELL, V17, P429, DOI 10.1016/j.molcel.2004.12.025; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203; HERTZ GZ, 1987, J VIROL, V61, P2322, DOI 10.1128/JVI.61.7.2322-2325.1987; Hirose Y, 2000, GENE DEV, V14, P1415; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kameoka S, 2004, EMBO J, V23, P1782, DOI 10.1038/sj.emboj.7600187; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lai MC, 1999, J BIOL CHEM, V274, P11832, DOI 10.1074/jbc.274.17.11832; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Muller F, 2004, EMBO J, V23, P2, DOI 10.1038/sj.emboj.7600027; Pagani F, 2003, J BIOL CHEM, V278, P1511, DOI 10.1074/jbc.M209676200; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; Prather D, 2005, MOL CELL BIOL, V25, P10122, DOI 10.1128/MCB.25.22.10122-10135.2005; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Robson-Dixon ND, 2004, J BIOL CHEM, V279, P29075, DOI 10.1074/jbc.M312747200; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Rosonina E, 2005, MOL CELL, V20, P167, DOI 10.1016/j.molcel.2005.10.004; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; Sun ZW, 1996, MOL CELL BIOL, V16, P1557; Takahara T, 2005, MOL CELL, V18, P245, DOI 10.1016/j.molcel.2005.03.018; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Ujvari A, 2004, J BIOL CHEM, V279, P49773, DOI 10.1074/jbc.M409087200; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029	65	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11648	11657		10.1074/jbc.M611126200	http://dx.doi.org/10.1074/jbc.M611126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17331949	hybrid			2022-12-27	WOS:000245941900006
J	Lerch-Gaggl, AF; Sun, K; Duncan, SA				Lerch-Gaggl, Alexandra F.; Sun, Kai; Duncan, Stephen A.			Light chain 1 of microtubule-associated protein 1B can negatively regulate the action of Pes1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME BIOGENESIS; CELL-PROLIFERATION; SACCHAROMYCES-CEREVISIAE; MITOTIC APPARATUS; YEAST PESCADILLO; MAMMALIAN-CELLS; BINDING DOMAIN; NERVOUS-SYSTEM; BRCT DOMAIN; RAT-BRAIN	Pes1 was first identified as the locus affected in the zebrafish mutant pescadillo, which exhibits severe defects in gut and liver development. It has since been demonstrated that loss of Pes1 expression in mammals and yeast affects ribosome biogenesis, resulting in a block in cell proliferation. Pes1 contains a BRCA1 C-terminal domain, a structural motif that has been shown to facilitate protein-protein interactions, suggesting that Pes1 has binding partners. We used a yeast two-hybrid screen to identify putative interacting proteins. We found that light chain 1 of the microtubule-associated protein 1B ( Mtap1b-LC1) could partner with Pes1, and deletion analyses revealed a specific interaction of Mtap1b-LC1 with the Pes1 BRCA1 C-terminal domain. We confirmed the integrity of the interaction between Pes1 and Mtap1b-LC1 by co-immunoprecipitation experiments. Protein localization studies in NIH3T3 cells revealed that exogenously expressed Pes1 was typically restricted to nuclei and nucleoli. However, exogenous Pes1 was found predominantly in the cytoplasm in cells that were forced to express Mtap1b-LC1. We also observed that the expression of endogenous Pes1 protein was significantly reduced or undetectable in nuclei when Mtap1b-LC1 was overexpressed, implying that a dynamic interaction exists between the two proteins and that Mtap1b-LC1 has the potential to negatively impact Pes1 function. Finally, we demonstrated that, as is the case when Pes1 expression is depleted by shRNA, overexpression of Mtap1b-LC1 resulted in diminished proliferation of NIH3T3 cells, suggesting that Mtap1b-LC1 has the potential to repress cell proliferation by modulating the nucleolar levels of Pes1.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Duncan, SA (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.	duncans@mcw.edu		Duncan, Stephen/0000-0002-2507-7827	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060064, R03DK054929] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK060064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; ANDERSON DF, 2002, INT J COMMUTATIVE RI, V1, P11; Battle MA, 2003, BIOCHEMISTRY-US, V42, P7270, DOI 10.1021/bi034081y; Borland G, 2006, MOL PHARMACOL, V69, P374, DOI 10.1124/mol.105.016337; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; Ding JQ, 2002, J CELL BIOL, V158, P427, DOI 10.1083/jcb.200202055; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; GOLDMAN RD, 1969, J CELL SCI, V4, P179; HAMILL D, 1994, J CELL BIOL, V127, P973, DOI 10.1083/jcb.127.4.973; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; Haque J, 2000, GENOMICS, V70, P201, DOI 10.1006/geno.2000.6375; HIROKAWA N, 1985, J CELL BIOL, V101, P1858, DOI 10.1083/jcb.101.5.1858; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Holzel M, 2005, J CELL BIOL, V170, P367, DOI 10.1083/jcb.200501141; Iouk TL, 2001, MOL CELL BIOL, V21, P1260, DOI 10.1128/MCB.21.4.1260-1271.2001; JESSUS C, 1984, CELL DIFFER DEV, V14, P295, DOI 10.1016/0045-6039(84)90018-6; Killian A, 2004, ONCOGENE, V23, P8597, DOI 10.1038/sj.onc.1207845; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Lapik YR, 2004, MOL CELL, V15, P17, DOI 10.1016/j.molcel.2004.05.020; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; LOOMIS PA, 1990, P NATL ACAD SCI USA, V87, P8422, DOI 10.1073/pnas.87.21.8422; Maiorana A, 2004, ONCOGENE, V23, P7116, DOI 10.1038/sj.onc.1207916; Mei X, 2000, BRAIN RES BULL, V53, P801, DOI 10.1016/S0361-9230(00)00416-0; Meixner A, 2000, J CELL BIOL, V151, P1169, DOI 10.1083/jcb.151.6.1169; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sakumoto N, 2001, BIOCHEM BIOPH RES CO, V289, P608, DOI 10.1006/bbrc.2001.6021; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; Schaper S, 2001, CURR BIOL, V11, P1885, DOI 10.1016/S0960-9822(01)00584-X; Sikorski EM, 2006, J BIOL CHEM, V281, P24423, DOI 10.1074/jbc.M602287200; SILVER RB, 1980, CELL, V19, P505, DOI 10.1016/0092-8674(80)90525-5; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SUPRENANT KA, 1993, J CELL SCI, V104, P445; SUPRENANT KA, 1989, CELL MOTIL CYTOSKEL, V14, P401, DOI 10.1002/cm.970140310; SUPRENANT KA, 1993, CELL MOTIL CYTOSKEL, V25, P1, DOI 10.1002/cm.970250102; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; Tretyakova I, 2005, J BIOL CHEM, V280, P31981, DOI 10.1074/jbc.M502736200; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753	48	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11308	11316		10.1074/jbc.M610977200	http://dx.doi.org/10.1074/jbc.M610977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308336	hybrid			2022-12-27	WOS:000245941500053
J	Mao, WF; Rupasinghe, SG; Zangerl, AR; Berenbaum, MR; Schuler, MA				Mao, Wenfu; Rupasinghe, Sanjeewa G.; Zangerl, Arthur R.; Berenbaum, May R.; Schuler, Mary A.			Allelic variation in the Depressaria pastinacella CYP6AB3 protein enhances metabolism of plant allelochemicals by altering a proximal surface residue and potential interactions with cytochrome P450 reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILIO-POLYXENES; INDUCIBLE CYTOCHROME-P450; MOLECULAR ANALYSIS; HELICOVERPA-ZEA; AMINO-ACIDS; SRS1 REGION; CYP6B1; IDENTIFICATION; SITE; XANTHOTOXIN	CYP6AB3v1, a cytochrome P450 monooxygenase in Depressaria pastinacella ( parsnip webworm), is highly specialized for metabolizing imperatorin, a toxic furanocoumarin in the apiaceous host plants of this insect. Cloning and heterologous expression of CYP6AB3v2, an allelic variant identified in D. pastinacella, reveals that it metabolizes imperatorin at a rate ( V-max of 10.02 pmol/min/pmol of cytochrome P450 monooxygenase ( P450)) significantly higher than CYP6AB3v1 ( V-max of 2.41 pmol/min/pmol) when supplemented with even low levels of cytochrome P450 reductase. Comparisons of the NADPH consumption rates for these variants indicate that CYP6AB3v2 utilizes this electron source at a faster rate than does CYP6AB3v1. Molecular modeling of the five amino acid differences between these variants and their potential interactions with P450 reductase suggests that replacement of Val(92) on the proximal face of CYP6AB3v1 with Ala(92) in CYP6AB3v2 affects interactions with P450 reductase so as to enhance its catalytic activity. Allelic variation at this locus potentially allows D. pastinacella to adapt to both intraspecific and interspecific variation in imperatorin concentrations in its host plants.	Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Entomol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Schuler, MA (corresponding author), Univ Illinois, Dept Cell & Dev Biol, 1201 W Gregory Dr,161 Edward R Madigan Lab, Urbana, IL 61801 USA.	maryschu@uiuc.edu			NIGMS NIH HHS [R01 GM071826] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071826] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amichot M, 2004, EUR J BIOCHEM, V271, P1250, DOI 10.1111/j.1432-1033.2004.04025.x; Baudry J, 2003, PROTEIN ENG, V16, P577, DOI 10.1093/protein/gzg075; Berenbaum MR, 2006, ECOLOGY, V87, P3070, DOI 10.1890/0012-9658(2006)87[3070:PWAHPA]2.0.CO;2; BERENBAUM MR, 1991, OIKOS, V62, P153, DOI 10.2307/3545260; Berenbaum MR, 1998, P NATL ACAD SCI USA, V95, P13743, DOI 10.1073/pnas.95.23.13743; BERENBAUM MR, 1995, P NATL ACAD SCI USA, V92, P2, DOI 10.1073/pnas.92.1.2; Berenbaum MR, 1996, RECENT ADV PHYTOCHEM, V30, P1; BERENBAUM MR, 1999, MOL BIOL TOXIC RESPO, P553; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Chen JS, 2002, INSECT MOL BIOL, V11, P175, DOI 10.1046/j.1365-2583.2002.00323.x; COHEN MB, 1992, P NATL ACAD SCI USA, V89, P10920, DOI 10.1073/pnas.89.22.10920; Feyereisen R, 2005, COMPREHENSIVE MOL IN, V4, P1; Graham SE, 1999, ARCH BIOCHEM BIOPHYS, V369, P24, DOI 10.1006/abbi.1999.1350; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; Hlavica P, 2003, J INORG BIOCHEM, V96, P279, DOI 10.1016/S0162-0134(03)00152-1; Humma LM, 2000, BIOTECHNIQUES, V29, P962, DOI 10.2144/00295bm07; Hung CF, 1997, INSECT BIOCHEM MOLEC, V27, P377, DOI 10.1016/S0965-1748(97)00009-X; HUNG CF, 1995, INSECT BIOCHEM MOLEC, V25, P89, DOI 10.1016/0965-1748(94)00038-J; Ingelman-Sundberg M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/sj.tpj.6500285; Ingelman-Sundberg M, 2002, TOXICOLOGY, V181, P447, DOI 10.1016/S0300-483X(02)00492-4; Jinno H, 2003, DRUG METAB DISPOS, V31, P398, DOI 10.1124/dmd.31.4.398; Kasai S, 2001, INSECT MOL BIOL, V10, P191, DOI 10.1046/j.1365-2583.2001.00256.x; Lee-Robichaud P, 1999, BIOCHEM J, V342, P309, DOI 10.1042/0264-6021:3420309; Lee-Robichaud P, 1998, BIOCHEM J, V332, P293, DOI 10.1042/bj3320293; Lehnerer M, 2000, J BIOCHEM, V127, P163, DOI 10.1093/oxfordjournals.jbchem.a022578; Li W, 2004, INSECT MOL BIOL, V13, P603, DOI 10.1111/j.0962-1075.2004.00518.x; Li W, 2002, INSECT MOL BIOL, V11, P543, DOI 10.1046/j.1365-2583.2002.00363.x; Li W, 2001, INSECT BIOCHEM MOLEC, V31, P999, DOI 10.1016/S0965-1748(01)00048-0; Li WM, 2003, P NATL ACAD SCI USA, V100, P14593, DOI 10.1073/pnas.1934643100; Li XC, 2000, J ECON ENTOMOL, V93, P18, DOI 10.1603/0022-0493-93.1.18; Li XC, 2004, P NATL ACAD SCI USA, V101, P2939, DOI 10.1073/pnas.0308691101; Li XC, 2002, INSECT BIOCHEM MOLEC, V32, P311, DOI 10.1016/S0965-1748(01)00092-3; Li XC, 2000, INSECT BIOCHEM MOLEC, V30, P75, DOI 10.1016/S0965-1748(99)00102-2; Li XC, 2007, ANNU REV ENTOMOL, V52, P231, DOI 10.1146/annurev.ento.51.110104.151104; Mao W, 2006, INSECT MOL BIOL, V15, P169, DOI 10.1111/j.1365-2583.2006.00623.x; Mao WF, 2006, J CHEM ECOL, V32, P523, DOI 10.1007/s10886-005-9018-3; Murray R. D. H., 1982, NATURAL COUMARINS OC; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NISIMOTO Y, 1988, BIOCHEMISTRY-US, V27, P5869, DOI 10.1021/bi00416a008; OMURA T, 1964, J BIOL CHEM, V239, P2379; Pan LP, 2004, ARCH BIOCHEM BIOPHYS, V422, P31, DOI 10.1016/j.abb.2003.09.047; Peterson JA, 1998, STRUCTURE, V6, P1079, DOI 10.1016/S0969-2126(98)00109-9; Sasabe M, 2004, GENE, V338, P163, DOI 10.1016/j.gene.2004.04.028; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; SHEN SJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P257, DOI 10.1006/abbi.1993.1347; SHEN SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P83, DOI 10.1016/0003-9861(92)90140-R; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; Wade RC, 2004, J INORG BIOCHEM, V98, P1175, DOI 10.1016/j.jinorgbio.2004.02.007; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wen ZM, 2006, MOL BIOL EVOL, V23, P2434, DOI 10.1093/molbev/msl118; Wen ZM, 2005, PROTEIN ENG DES SEL, V18, P191, DOI 10.1093/protein/gzi023; Wen ZM, 2003, INSECT BIOCHEM MOLEC, V33, P937, DOI 10.1016/S0965-1748(03)00100-0; Zangerl AR, 2003, EVOLUTION, V57, P806, DOI 10.1111/j.0014-3820.2003.tb00292.x; Zhu YC, 2003, INSECT MOL BIOL, V12, P39, DOI 10.1046/j.1365-2583.2003.00385.x	55	32	33	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10544	10552		10.1074/jbc.M607946200	http://dx.doi.org/10.1074/jbc.M607946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17244619	hybrid			2022-12-27	WOS:000245941000047
J	Zhu, WZ; Woo, AYH; Yang, DM; Cheng, HP; Crow, MT; Xiao, RP				Zhu, Weizhong; Woo, Anthony Yiu-Ho; Yang, Dongmei; Cheng, Heping; Crow, Michael T.; Xiao, Rui-Ping			Activation of CaMKII delta C is a common intermediate of diverse death stimuli- induced heart muscle cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; CALMODULIN KINASE; CARDIAC MYOCYTES; BETA(1)-ADRENERGIC STIMULATION; PHOSPHOLAMBAN PHOSPHORYLATION; DILATED CARDIOMYOPATHY; DEPENDENT FACILITATION; VENTRICULAR MYOCYTES; CALCIUM-CHANNELS; HYPERTROPHY	Ca2+-calmodulin-dependent protein kinase II ( CaMKII) is expressed in many mammalian cells, with the delta isoform predominantly expressed in cardiomyocytes. Previous studies have shown that inhibition of CaMKII protects cardiomyocytes against beta(1)-adrenergic receptor-mediated apoptosis. However, it is unclear whether activation of CaMKII is sufficient to cause cardiomyocyte apoptosis and whether CaMKII signaling is important in heart muscle cell apoptosis mediated by other stimuli. Here, we specifically enhanced or suppressed CaMKII activity using adenoviral gene transfer of constitutively active ( CA-CaMKII delta C) or dominant negative ( DN-CaMKII delta C) mutants of CaMKII delta C in cultured adult rat cardiomyocytes. Expression of CA-CaMKII delta C promoted cardiomyocyte apoptosis that was associated with increased mitochondrial cytochrome c release and attenuated by co-expression of Bcl-XL. Importantly, isoform-specific suppression of CaMKII delta C with the DN-CaMKII delta C mutant similar to nonselective CaMKII inhibition by the pharmacological inhibitors ( KN-93 or AIP) not only prevented CA-CaMKII delta C-mediated apoptosis but also protected cells from multiple death-inducing stimuli. Thus, activation of CaMKII delta C constitutes a common intermediate by which various death-inducing stimuli trigger cardiomyocyte apoptosis via the primary mitochondrial death pathway.	NIA, Cardiovasc Sci Lab, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China; Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Peking University; Johns Hopkins University	Xiao, RP (corresponding author), NIA, Cardiovasc Sci Lab, NIH, Gerontol Res Ctr, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	XiaoR@GRC.NIA.NIH.GOV	Woo, Anthony/D-4305-2014; cheng, heping/A-7299-2011; Heping, Cheng/AAE-2680-2019; Yimei, Wang/AAE-4083-2019; Xiao, Rui-Ping/AAE-2629-2019	Woo, Anthony/0000-0003-0662-698X; Heping, Cheng/0000-0002-9604-6702; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000287] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL073935] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ai X, 2005, CIRC RES, V97, P1314, DOI 10.1161/01.RES.0000194329.41863.89; Anderson ME, 2004, TRENDS CARDIOVAS MED, V14, P152, DOI 10.1016/j.tcm.2004.02.005; Anderson ME, 1998, J PHARMACOL EXP THER, V287, P996; BASSANI RA, 1995, AM J PHYSIOL-HEART C, V268, pH703, DOI 10.1152/ajpheart.1995.268.2.H703; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRUCE A, 1983, J BIOL CHEM, V258, P13587; Chen XW, 2005, CIRC RES, V97, P1009, DOI 10.1161/01.RES.0000189270.72915.D1; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; Grueter CE, 2006, MOL CELL, V23, P641, DOI 10.1016/j.molcel.2006.07.006; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hoch B, 2000, J CELL BIOCHEM, V79, P293, DOI 10.1002/1097-4644(20001101)79:2<293::AID-JCB120>3.3.CO;2-H; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Jiang H, 2005, FASEB J, V19, pA910; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Maier LS, 2003, CIRC RES, V92, P904, DOI 10.1161/01.RES.0000069685.20258.F1; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Sucharov CC, 2006, AM J PHYSIOL-HEART C, V291, pH1299, DOI 10.1152/ajpheart.00017.2006; Vinogradova TM, 2000, CIRC RES, V87, P760, DOI 10.1161/01.RES.87.9.760; Wang W, 2004, CIRC RES, V95, P798, DOI 10.1161/01.RES.0000145361.50017.aa; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Yang DM, 2007, CIRC RES, V100, P399, DOI 10.1161/01.RES.0000258022.13090.55; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982; Zhang R, 2005, NAT MED, V11, P409, DOI 10.1038/nm1215; Zhang T, 2004, CARDIOVASC RES, V63, P476, DOI 10.1016/j.cardiores.2004.04.026; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5; Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239; Zhu WZ, 2003, J CLIN INVEST, V111, P617, DOI 10.1172/JCI200316326	38	107	117	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10833	10839		10.1074/jbc.M611507200	http://dx.doi.org/10.1074/jbc.M611507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17296607	hybrid			2022-12-27	WOS:000245941000077
J	Nag, A; Germaniuk-Kurowska, A; Dimri, M; Sassack, MA; Gurumurthy, CB; Gao, QS; Dimri, G; Band, H; Band, V				Nag, Alo; Germaniuk-Kurowska, Aleksandra; Dimri, Manjari; Sassack, Michael A.; Gurumurthy, Channabasavaiah Basavaraju; Gao, Qingshen; Dimri, Goberdhan; Band, Hamid; Band, Vimla			An essential role of human Ada3 in p53 acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; IN-VIVO; MEDIATED TRANSACTIVATION; HISTONE; COMPLEX; BINDING; MDM2; COACTIVATOR; ACTIVATION; GENE	The p53 tumor suppressor protein functions as a critical component of genotoxic stress response by regulating the expression of effector gene products that control the fate of a cell following DNA damage. Unstressed cells maintain p53 at low levels through regulated degradation, and p53 levels and activity are rapidly elevated upon genotoxic stress. Biochemical mechanisms that control the levels and activity of p53 are therefore of great interest. We and others have recently identified hAda3 (human homologue of yeast alteration/deficiency in activation 3) as a p53-interacting protein and enhancer of p53 activity. Here, we show that endogenous levels of p53 and Ada3 interact with each other, and by using inducible overexpression and short hairpin RNA-mediated knockdown strategies we demonstrate that hAda3 stabilizes p53 protein by promoting its acetylation. Use of a p53 mutant with mutations of known p300/CREB-binding protein acetylation sites demonstrated that hAda3-dependent acetylation is required for increase in p53 stability and target gene induction. Importantly, we demonstrate that endogenous hAda3 is essential for DNA damage-induced acetylation and stabilization of p53 as well as p53 target gene induction. Overall, our results establish hAda3, a component of coactivator complexes that include histone acetyltransferase p300/CREB-binding protein, as a critical mediator of acetylation-dependent stabilization and activation of p53 upon genotoxic stress in mammalian cells.	Northwestern Univ, ENH Res Inst, Div Canc Biol, Evanston, IL 60201 USA; Northwestern Univ, ENH Res Inst, Div Mol Oncol, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Weinberg Coll arts, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60201 USA	Northwestern University; Northwestern University; Northwestern University; Feinberg School of Medicine; Northwestern University	Band, V (corresponding author), Northwestern Univ, ENH Res Inst, Div Canc Biol, 1001 Univ Pl, Evanston, IL 60201 USA.	v-band@northwestern.edu	Gurumurthy, Channabasavaiah B/E-7205-2011; Gurumurthy, Channabasavaiah B/H-8268-2016; Dimri, Goberdhan/AAO-4210-2021	Gurumurthy, Channabasavaiah B/0000-0002-8022-4033; 	NCI NIH HHS [R01 CA095221-01A1, CA99900, R01 CA096986-03, R01 CA096986-01A1, R01 CA096986-02, CA87986, R01 CA095221-04, R01 CA096986-05, CA99163, CA76118, R01 CA095221-03, R01 CA095221-02, CA96844, R01 CA096986-04, R01 CA095221-05, CA81076, CA94143] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095221, R01CA087986, R01CA081076, R01CA099900, R01CA099163, R01CA096986, R01CA096844, R01CA076118, R01CA094143] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Maki CG, 1996, CANCER RES, V56, P2649; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Meng GY, 2004, J BIOL CHEM, V279, P54230, DOI 10.1074/jbc.M404482200; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Pankotai T, 2005, MOL CELL BIOL, V25, P8215, DOI 10.1128/MCB.25.18.8215-8227.2005; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	45	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8812	8820		10.1074/jbc.M610443200	http://dx.doi.org/10.1074/jbc.M610443200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17272277	hybrid, Green Submitted			2022-12-27	WOS:000245780300028
J	Kraveka, JM; Li, L; Szulc, ZM; Bielawski, J; Ogretmen, B; Hannun, YA; Obeid, LM; Bielawska, A				Kraveka, Jacqueline M.; Li, Li; Szulc, Zdzislaw M.; Bielawski, Jacek; Ogretmen, Besim; Hannun, Yusuf A.; Obeid, Lina M.; Bielawska, Alicja			Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; TELOMERASE ACTIVITY; CERAMIDE; APOPTOSIS; ACTIVATION; INDUCTION; ACID; N-(4-HYDROXYPHENYL)RETINAMIDE; IDENTIFICATION; SPHINGOLIPIDS	The role of dihydroceramide desaturase as a key enzyme in the de novo pathway of ceramide generation was investigated in human neuroblastoma cells (SMS-KCNR). A novel assay using water-soluble analogs of dihydroceramide, dihydroceramidoids (D-erythro-dhCCPS analogs), was used to measure desaturase activity in situ. Conversion of D-erythro-2-N-[12 '-(1 ''-pyridinium)-dodecanoyl]- 4,5-dihydrosphingosine bromide (C-12-dhCCPS) to its 4,5-desaturated counterpart, D-erythro-2-N-[12 '-(1 ''-pyridinium) dodecanoyl]sphingosine bromide (C-12-CCPS), was determined by liquid chromatography/mass spectrometry analysis. The validity of the assay was confirmed using C-8-cyclopropenylceramide, a competitive inhibitor of dihydroceramide desaturase. A human homolog (DEGS-1) of the Drosophila melanogaster des-1 gene was recently identified and reported to have desaturase activity. Transfection of SMS-KCNR cells with small interfering RNA to DEGS-1 significantly blocked the conversion of C-12-dhCCPS to C-12-CCPS. The associated accumulation of endogenous dihydroceramides confirmed DEGS-1 as the main active dihydroceramide desaturase in these cells. The partial loss of DEGS-1 inhibited cell growth, with cell cycle arrest at G(0)/G(1). This was accompanied by a significant decrease in the amount of phosphorylated retinoblastoma protein. This hypophosphorylation was inhibited by tautomycin and not by okadaic acid, suggesting the involvement of protein phosphatase 1. Additionally, we found that treatment of SMS-KCNR cells with fenretinide inhibited desaturase activity in a dose-dependent manner. An increase in dihydroceramides (but not ceramides) paralleled this process as measured by liquid chromatography/mass spectrometry. There were no effects on the mRNA or protein levels of DEGS-1, suggesting that fenretinide acts at the post-translational level as an inhibitor of this enzyme. Tautomycin was also able to block the hypophosphorylation of the retinoblastoma protein observed upon fenretinide treatment. These findings suggest a novel biological function for dihydroceramides.	Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kraveka, JM (corresponding author), Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, 135 Rutledge Ave,POB 250558, Charleston, SC 29425 USA.	kravekjm@musc.edu		obeid, lina/0000-0002-0734-0847	NCI NIH HHS [L40 CA110721, K01 CA100767, P01 CA097132] Funding Source: Medline; NCRR NIH HHS [P20 RR017677, C06 RR018823] Funding Source: Medline; NIA NIH HHS [R01 AG016583] Funding Source: Medline; NIDCR NIH HHS [R01 DE016572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA100767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn EH, 2002, EXP BIOL MED, V227, P345, DOI 10.1177/153537020222700507; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Cadena DL, 1997, BIOCHEMISTRY-US, V36, P6960, DOI 10.1021/bi970091l; CARMICHAEL J, 1987, CANCER RES, V47, P943; Causeret C, 2000, LIPIDS, V35, P1117, DOI 10.1007/s11745-000-0627-6; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Clifford JL, 1999, CANCER RES, V59, P14; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DiPietrantonio AM, 1998, INT J CANCER, V78, P53, DOI 10.1002/(SICI)1097-0215(19980925)78:1<53::AID-IJC10>3.0.CO;2-6; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Geeraert L, 1997, BIOCHEM J, V327, P125, DOI 10.1042/bj3270125; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 1997, ADV EXP MED BIOL, V400, P305; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jiang Q, 2004, P NATL ACAD SCI USA, V101, P17825, DOI 10.1073/pnas.0408340102; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kraveka JM, 2003, ARCH BIOCHEM BIOPHYS, V419, P110, DOI 10.1016/j.abb.2003.08.034; Lee JY, 2000, EXP CELL RES, V261, P303, DOI 10.1006/excr.2000.5028; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Lovat PE, 2002, CANCER RES, V62, P5158; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mizutani Y, 2004, FEBS LETT, V563, P93, DOI 10.1016/S0014-5793(04)00274-1; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Omae F, 2004, BIOCHEM J, V379, P687, DOI 10.1042/BJ20031425; Osone S, 2004, INT J CANCER, V112, P219, DOI 10.1002/ijc.20412; Schulz A, 2006, J BIOL CHEM, V281, P2784, DOI 10.1074/jbc.M509483200; Schulze H, 2000, METHOD ENZYMOL, V311, P22; Seville LL, 2005, CURR CANCER DRUG TAR, V5, P159, DOI 10.2174/1568009053765816; Sugiki H, 2000, BRIT J DERMATOL, V143, P1154, DOI 10.1046/j.1365-2133.2000.03882.x; Szulc ZM, 2006, BIOORGAN MED CHEM, V14, P7083, DOI 10.1016/j.bmc.2006.07.016; Tamrakar S, 2000, FRONT BIOSCI-LANDMRK, V5, pD121, DOI 10.2741/Tamrakar; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; Triola G, 2004, MOL PHARMACOL, V66, P1671, DOI 10.1124/mol.104.003681; Triola G, 2003, J ORG CHEM, V68, P9924, DOI 10.1021/jo030141u; Tserng KY, 2004, BIOCHEM J, V380, P715, DOI 10.1042/BJ20031733; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wang HT, 2001, CANCER RES, V61, P5102; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621	43	127	130	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16718	16728		10.1074/jbc.M700647200	http://dx.doi.org/10.1074/jbc.M700647200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17283068	Green Accepted, hybrid			2022-12-27	WOS:000246946500003
J	St-Jean, M; Izard, T; Sygusch, J				St-Jean, Miguel; Izard, Tina; Sygusch, Jurgen			A hydrophobic pocket in the active site of glycolytic aldolase mediates interactions with Wiskott-Aldrich syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; F-ACTIN; N-WASP; WASP/SCAR PROTEINS; BINDING; POLYMERIZATION; ACTIVATION; ENZYMES; MUSCLE; MECHANISM	Aldolase plays essential catalytic roles in glycolysis and gluconeogenesis. However, aldolase is a highly abundant protein that is remarkably promiscuous in its interactions with other cellular proteins. In particular, aldolase binds to highly acidic amino acid sequences, including the C terminus of the Wiskott-Aldrich syndrome protein, an actin nucleation-promoting factor. Here we report the crystal structure of tetrameric rabbit muscle aldolase in complex with a C-terminal peptide of Wiskott-Aldrich syndrome protein. Aldolase recognizes a short, four-residue DEWD motif (residues 498 - 501), which adopts a loose hairpin turn that folds around the central aromatic residue, enabling its tryptophan side chain to fit into a hydrophobic pocket in the active site of aldolase. The flanking acidic residues in this binding motif provide further interactions with conserved aldolase active site residues Arg-42 and Arg-303, aligning their side chains and forming the sides of the hydrophobic pocket. The binding of Wiskott-Aldrich syndrome protein to aldolase precludes intramolecular interactions of its C terminus with its active site and is competitive with substrate as well as with binding by actin and cortactin. Finally, based on this structure, a novel naphthol phosphate-based inhibitor of aldolase was identified, and its structure in complex with aldolase demonstrated mimicry of the Wiskott-Aldrich syndrome protein-aldolase interaction. The data support a model whereby aldolase exists in distinct forms that regulate glycolysis or actin dynamics.	Univ Montreal, Stn Ctr Ville, Dept Biochem, Montreal, PQ H3C 3J7, Canada; St Jude Childrens Hosp, Dept Oncol, Memphis, TN 38105 USA	Universite de Montreal; St Jude Children's Research Hospital	Sygusch, J (corresponding author), Univ Montreal, Stn Ctr Ville, Dept Biochem, CP 6128, Montreal, PQ H3C 3J7, Canada.	Jurgen.Sygusch@UMontreal.CA		Sygusch, Jurgen/0000-0002-6629-2128	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071596] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM071596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antunes N, 2006, KIDNEY INT, V69, P68, DOI 10.1038/sj.ki.5000013; ARNOLD H, 1971, EUR J BIOCHEM, V22, P121, DOI 10.1111/j.1432-1033.1971.tb01522.x; ARNOLD H, 1968, EUR J BIOCHEM, V6, P163, DOI 10.1111/j.1432-1033.1968.tb00434.x; Atkinson SJ, 2004, J BIOL CHEM, V279, P5194, DOI 10.1074/jbc.M306973200; BARANOWSKI T, 1949, J BIOL CHEM, V180, P543; BERSHADSKY AD, 1983, CELL BIOL INT REP, V7, P173, DOI 10.1016/0309-1651(83)90218-7; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buscaglia CA, 2006, J BIOL CHEM, V281, P1324, DOI 10.1074/jbc.M506346200; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; CLARKE FM, 1976, BIOCHEM J, V159, P797, DOI 10.1042/bj1590797; DeLano WL, 2004, PYMOL MOL GRAPHICS S; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; KELLERMAN PS, 1990, AM J PHYSIOL, V259, pF279, DOI 10.1152/ajprenal.1990.259.2.F279; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; KUHNE W, 1993, AM J PHYSIOL, V264, pH1599, DOI 10.1152/ajpheart.1993.264.5.H1599; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Lundmark R, 2004, J BIOL CHEM, V279, P42694, DOI 10.1074/jbc.M407430200; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Maughan DW, 2005, MOL CELL PROTEOMICS, V4, P1541, DOI 10.1074/mcp.M500053-MCP200; Meyerhof O, 1936, BIOCHEM Z, V286, P301; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; Navarro-Lerida I, 2004, PROTEOMICS, V4, P339, DOI 10.1002/pmic.200300528; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; PENHOET E, 1967, BIOCHEMISTRY-US, V6, P2040; Pimentel G.C., 1960, HYDROGEN BOND; RACKER E, 1947, J BIOL CHEM, V167, P843; ROSE IA, 1965, J BIOL CHEM, V240, P1758; Schindler R, 2001, BIOCHEM CELL BIOL, V79, P719, DOI 10.1139/bcb-79-6-719; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; St-Jean M, 2005, J BIOL CHEM, V280, P27262, DOI 10.1074/jbc.M502413200; STRAPAZON E, 1976, BIOCHEMISTRY-US, V15, P1421, DOI 10.1021/bi00652a011; Sukumvanich P, 2004, CELL MOTIL CYTOSKEL, V59, P141, DOI 10.1002/cm.20030; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Volker KW, 1997, ARCH BIOCHEM BIOPHYS, V338, P237, DOI 10.1006/abbi.1996.9819; VOLKER KW, 1995, COMP BIOCHEM PHYS B, V112, P503, DOI 10.1016/0305-0491(95)00096-8; Wang J, 1997, EXP CELL RES, V237, P445, DOI 10.1006/excr.1997.3811; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	52	23	25	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14309	14315		10.1074/jbc.M611505200	http://dx.doi.org/10.1074/jbc.M611505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17329259	hybrid			2022-12-27	WOS:000246245800042
J	Koziczak-Holbro, M; Joyce, C; Gluck, A; Kinzel, B; Muller, M; Tschopp, C; Mathison, JC; Davis, CN; Gram, H				Koziczak-Holbro, Magdalena; Joyce, Claire; Glueck, Anton; Kinzel, Bernd; Mueller, Matthias; Tschopp, Claude; Mathison, John C.; Davis, Christopher N.; Gram, Hermann			IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; TOLL-LIKE RECEPTORS; NF-KAPPA-B; BACTERIAL-INFECTIONS; INNATE IMMUNITY; ACTIVATION; COMPLEX; FAMILY; AUTOPHOSPHORYLATION; PHOSPHORYLATION	IRAK-4 is an essential component of the signal transduction complex downstream of the IL-1- and Toll-like receptors. Although regarded as the first kinase in the signaling cascade, the role of IRAK-4 kinase activity versus its scaffold function is still controversial. To investigate the role of IRAK-4 kinase function in vivo, "knock- in" mice were generated by replacing the wild type IRAK-4 gene with a mutant gene encoding kinase-deficient IRAK-4 protein (IRAK-4 KD). IRAK-4 kinase was rendered inactive by mutating the conserved lysine residues in the ATP pocket essential for coordinating ATP. Analyses of embryonic fibroblasts and macrophages obtained from IRAK-4 KD mice demonstrate lack of cellular responsiveness to stimulation with IL-1 beta or a Toll- like receptor 7 (TLR7) agonist. IRAK-4 kinase deficiency prevents the recruitment of IRAK-1 to the IL-1 receptor complex and its subsequent phosphorylation and degradation. IRAK-4 KD cells are severely impaired in NF kappa B, JNK, and p38 activation in response to IL-1 beta or TLR7 ligand. As a consequence, IL-1 receptor/TLR7-mediated production of cytokines and chemokines is largely absent in these cells. Additionally, microarray analysis identified IL-1 beta response genes and revealed that the induction of IL-1 beta-responsive mRNAs is largely ablated in IRAK-4KDcells. In summary, our results suggest that IRAK-4 kinase activity plays a critical role in IL-1 receptor (IL-1R)/TLR7-mediated induction of inflammatory responses.	Novartis Inst BioMed Res, CH-4002 Basel, Switzerland; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Novartis; Scripps Research Institute	Gram, H (corresponding author), Novartis Inst BioMed Res, Kohlenstr 10,Bldg 386-9-27, CH-4002 Basel, Switzerland.	hermann.gram@novartis.com						Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Cheng H, 2007, BIOCHEM BIOPH RES CO, V352, P609, DOI 10.1016/j.bbrc.2006.11.068; Comalada N, 2003, AM J PHYSIOL-CELL PH, V285, pC1235, DOI 10.1152/ajpcell.00228.2003; Davis CN, 2006, J NEUROCHEM, V98, P1379, DOI 10.1111/j.1471-4159.2006.03951.x; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lye E, 2004, J BIOL CHEM, V279, P40653, DOI 10.1074/jbc.M402666200; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Medvedev AE, 2005, J IMMUNOL, V174, P6587, DOI 10.4049/jimmunol.174.11.6587; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Qin JZ, 2004, J BIOL CHEM, V279, P26748, DOI 10.1074/jbc.M400785200; Suzuki N, 2006, SCIENCE, V311, P1927, DOI 10.1126/science.1124256; Suzuki N, 2002, TRENDS IMMUNOL, V23, P503, DOI 10.1016/S1471-4906(02)02298-6; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang ZL, 2006, STRUCTURE, V14, P1835, DOI 10.1016/j.str.2006.11.001; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	33	64	87	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13552	13560		10.1074/jbc.M700548200	http://dx.doi.org/10.1074/jbc.M700548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337443	hybrid			2022-12-27	WOS:000246060300044
J	Yohe, ME; Rossman, KL; Gardner, OS; Karnoub, AE; Snyder, JT; Gershburg, S; Graves, LM; Der, CJ; Sondek, J				Yohe, Marielle E.; Rossman, Kent L.; Gardner, Olivia S.; Karnoub, Antoine E.; Snyder, Jason T.; Gershburg, Svetlana; Graves, Lee M.; Der, Channing J.; Sondek, John			Auto-inhibition of the Dbl family protein tim by an N-terminal helical motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; TYROSINE PHOSPHORYLATION; BIOLOGICAL-ACTIVITY; SIGNALING PATHWAY; GDP/GTP EXCHANGE; STRUCTURAL BASIS; RATIONAL DESIGN; ACTIVATION; VAV	Dbl-related oncoproteins are guanine nucleotide exchange factors specific for Rho-family GTPases and typically possess tandem Dbl homology (DH) and pleckstrin homology domains that act in concert to catalyze exchange. Because the ability of many Dbl-family proteins to catalyze exchange is constitutively activated by truncations N-terminal to their DH domains, it has been proposed that the activity of Dbl-family proteins is regulated by auto-inhibition. However, the exact mechanisms of regulation of Dbl- family proteins remain poorly understood. Here we show that the Dbl- family protein, Tim, is auto-inhibited by a short, helical motif immediately N-terminal to its DH domain, which directly occludes the catalytic surface of the DH domain to prevent GTPase activation. Similar to the distantly related Vav isozymes, auto-inhibition of Tim is relieved by truncation, mutation, or phosphorylation of the auto-inhibitory helix. A peptide comprising the helical motif inhibits the exchange activity of Tim in vitro. Furthermore, substitutions within the most highly conserved surface of the DH domain designed to disrupt interactions with the auto-inhibitory helix also activate the exchange process.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Sondek, J (corresponding author), CB 7365,1106 MEJ Bldg, Chapel Hill, NC 27599 USA.	Sondek@med.unc.edu	Graves, Lee/AAG-5470-2021	Sondek, John/0000-0002-1127-8310; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA92240, CA063071] Funding Source: Medline; NIGMS NIH HHS [GM62299, GM65533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092240, R01CA063071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299, P01GM065533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; CHAN AML, 1994, ONCOGENE, V9, P1057; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Debily MA, 2004, HUM MOL GENET, V13, P323, DOI 10.1093/hmg/ddh024; DeLano W.L, PYMOL MOL GRAPHICS S; Deprez C, 2005, J MOL BIOL, V346, P1047, DOI 10.1016/j.jmb.2004.12.028; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Llorca O, 2005, EMBO J, V24, P1330, DOI 10.1038/sj.emboj.7600617; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Miyamoto Y, 2006, P NATL ACAD SCI USA, V103, P10444, DOI 10.1073/pnas.0603914103; Ogita H, 2003, CIRC RES, V93, P23, DOI 10.1161/01.RES.0000079310.81429.C8; Rojas RJ, 2003, COMB CHEM HIGH T SCR, V6, P409; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Salojin KV, 2000, J BIOL CHEM, V275, P5966, DOI 10.1074/jbc.275.8.5966; Schiller MR, 2006, CELL SIGNAL, V18, P1834, DOI 10.1016/j.cellsig.2006.01.022; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schmidt S, 2002, FEBS LETT, V523, P35, DOI 10.1016/S0014-5793(02)02928-9; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Solski PA, 2004, J BIOL CHEM, V279, P25226, DOI 10.1074/jbc.M313792200; TAKAI S, 1995, CANCER GENET CYTOGEN, V83, P87, DOI 10.1016/S0165-4608(95)00017-8; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xie XZ, 2005, CELL SIGNAL, V17, P461, DOI 10.1016/j.cellsig.2004.09.012; Yamauchi J, 2002, BIOCHEM BIOPH RES CO, V296, P85, DOI 10.1016/S0006-291X(02)00839-2; Yoshizuka N, 2004, J BIOL CHEM, V279, P43998, DOI 10.1074/jbc.M406082200; Zeeh JC, 2006, J BIOL CHEM, V281, P11805, DOI 10.1074/jbc.M600149200; Zenke FT, 2004, J BIOL CHEM, V279, P18392, DOI 10.1074/jbc.M400084200; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	51	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13813	13823		10.1074/jbc.M700185200	http://dx.doi.org/10.1074/jbc.M700185200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337446	Green Published, hybrid			2022-12-27	WOS:000246060300071
J	Nusinow, DA; Hernandez-Munoz, I; Fazzio, TG; Shah, GM; Kraus, WL; Panning, B				Nusinow, Dmitri A.; Hernandez-Munoz, Inmaculada; Fazzio, Thomas G.; Shah, Girish M.; Kraus, W. Lee; Panning, Barbara			Poly(ADP-ribose) polymerase 1 is inhibited by a histone H2A variant, MacroH2A, and contributes to silencing of the inactive X chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; CHROMATIN-STRUCTURE; GENE-EXPRESSION; CORE HISTONE; TRANSCRIPTION; NUCLEOSOME; BINDING; PARP-1; DOMAINS; POLY(ADP-RIBOSYL)ATION	Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme that is involved in modulating chromatin structure, regulation of gene expression, and sensing DNA damage. Here, we report that PARP-1 enzymatic activity is inhibited by macroH2A, a vertebrate histone H2A variant that is enriched on facultative heterochromatin. MacroH2A family members have a large C-terminal non-histone domain (NHD) and H2A-like histone domain. MacroH2A1.2 and PARP-1 interact in vivo and in vitro via the NHD. The NHD of each macroH2A family member was sufficient to inhibit PARP-1 enzymatic activity in vitro. The NHD of macroH2A1.2 was a mixed inhibitor of PARP-1 catalytic activity, with affects on both catalytic activity and the substrate binding affinity of PARP-1. Depletion of PARP-1 by RNA interference caused reactivation of a reporter gene on the inactive X chromosome, demonstrating that PARP-1 participates in the maintenance of silencing. These results suggest that one function of macroH2A in gene silencing is to inhibit PARP-1 enzymatic activity, and this may affect PARP-1 association with chromatin.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain; Univ Laval, CHUL, Res Ctr, Lab Skin Canc Res, Quebec City, PQ G1V 4G2, Canada; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	University of California System; University of California San Francisco; Laval University; Cornell University	Panning, B (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Genentech Hall S372B,600 16th St, San Francisco, CA 94158 USA.	bpanning@biochem.ucsf.edu	Nusinow, Dmitri A/K-9129-2013	Nusinow, Dmitri A/0000-0002-0497-1723; Shah, Girish/0000-0002-9291-1164	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085186, R01GM063671] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK069710] Funding Source: Medline; NIGMS NIH HHS [R01 GM085186, R01 GM63671] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agelopoulos M, 2006, EMBO J, V25, P4843, DOI 10.1038/sj.emboj.7601364; Aguiar RCT, 2005, J BIOL CHEM, V280, P33756, DOI 10.1074/jbc.M505408200; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chadwick BP, 2001, NUCLEIC ACIDS RES, V29, P2699, DOI 10.1093/nar/29.13.2699; Chadwick BP, 2001, HUM MOL GENET, V10, P1101, DOI 10.1093/hmg/10.10.1101; Chakravarthy S, 2005, MOL CELL BIOL, V25, P7616, DOI 10.1128/MCB.25.17.7616-7624.2005; Changolkar LN, 2006, MOL CELL BIOL, V26, P4410, DOI 10.1128/MCB.02258-05; Chu FX, 2006, MOL CELL PROTEOMICS, V5, P194, DOI 10.1074/mcp.M500285-MCP200; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Costanzi C, 2001, J BIOL CHEM, V276, P21776, DOI 10.1074/jbc.M010919200; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Doyen CM, 2006, MOL CELL BIOL, V26, P1156, DOI 10.1128/MCB.26.3.1156-1164.2006; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Ouararhni K, 2006, GENE DEV, V20, P3324, DOI 10.1101/gad.396106; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; PEHRSON JR, 1992, SCIENCE, V257, P1398; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Shah RG, 2005, BIOCHEM BIOPH RES CO, V331, P167, DOI 10.1016/j.bbrc.2005.03.135; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	35	95	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12851	12859		10.1074/jbc.M610502200	http://dx.doi.org/10.1074/jbc.M610502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322296	hybrid			2022-12-27	WOS:000245942800057
J	Yoon, MK; Kim, HM; Choi, G; Lee, JO; Choi, BS				Yoon, Mi-Kyung; Kim, Ho-Min; Choi, Giltsu; Lee, Jie-Oh; Choi, Byong-Seok			Structural basis for the conformational integrity of the Arabidopsis thaliana HY5 leucine zipper homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURIED POLAR INTERACTION; COILED-COIL FORMATION; X-RAY-STRUCTURE; DIMERIZATION SPECIFICITY; AMINO-ACIDS; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; ALPHA-HELICES; BZIP PROTEIN; SALT-BRIDGES	The leucine zipper (LZ) domain of the HY5 transcription factor from Arabidopsis thaliana has unique primary structural properties, including major occupation by the Leu residues as well as two buried polar residues in the a positions and a localized distribution of charged and polar residues in the first three heptad repeats. In this study, we solved the crystal structure of the HY5 LZ domain and show that the peculiarities in the primary sequence yield unusual structural characteristics. For example, the HY5 LZ domain exhibits a bipartite charge distribution characterized by a highly negative electrostatic surface potential in its N-terminal half and a nearly neutral potential in its C-terminal half. The LZ N-terminal region also contains two consecutive putative trigger sites for dimerization of the coiled coils. In addition, two buried asparagines at a positions 19 and 33 in the HY5 LZ domain display distinct modes of polar interaction. Whereas Asn19 shows a conformational flip-flop, Asn33 is engaged in a permanent hydrogen bond network. CD spectropolarimetry and analytical ultracentrifugation experiments performed with versions of the HY5 LZ domain containing mutations in the a positions yielded further evidence that position a amino acid residues are crucial for achieving an oligomeric state and maintaining stability. However, a low correlation between position a amino acid preference, core packing geometry, and rotamer conformations suggests that the oligomeric state of the LZ domain is not governed entirely by known structural properties. Taken together, our results suggest structural factors conferring conformational integrity of the HY5 LZ homodimer that are more complicated than proposed previously.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Lee, JO (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, 373-1 Guseong Dong, Taejon 305701, South Korea.	jieoh.lee@kaist.ac.kr	Lee, Jie-Oh/AAG-4302-2020; Lee, Jie-Oh/C-1581-2011; Choi, Giltsu/C-1601-2011; Kim, Ho Min/G-2712-2011; Choi, Byong-Seok/C-1937-2011	Lee, Jie-Oh/0000-0001-6519-6049				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chattopadhyay S, 1998, PLANT CELL, V10, P673, DOI 10.1105/tpc.10.5.673; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Demeler B, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P210; Deppmann CD, 2004, NUCLEIC ACIDS RES, V32, P3435, DOI 10.1093/nar/gkh653; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hao Q, 2003, J APPL CRYSTALLOGR, V36, P1274, DOI 10.1107/S0021889803014031; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Ibarra-Molero B, 2004, J MOL BIOL, V336, P989, DOI 10.1016/j.jmb.2003.12.069; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; Jansson M, 1996, J BIOMOL NMR, V7, P131; JOHN M, 1994, J BIOL CHEM, V269, P16247; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Kammerer RA, 2001, J BIOL CHEM, V276, P13685, DOI 10.1074/jbc.M010492200; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kretsinger JK, 2003, J AM CHEM SOC, V125, P7907, DOI 10.1021/ja029892o; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; Mackay JP, 1996, BIOCHEMISTRY-US, V35, P4867, DOI 10.1021/bi952761y; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; Mittl PRE, 2000, P NATL ACAD SCI USA, V97, P2562, DOI 10.1073/pnas.97.6.2562; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Oyama T, 1997, GENE DEV, V11, P2983, DOI 10.1101/gad.11.22.2983; POTEKHIN SA, 1994, PROTEIN ENG, V7, P1097, DOI 10.1093/protein/7.9.1097; Spek EJ, 1998, PROTEIN SCI, V7, P2431, DOI 10.1002/pro.5560071121; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; Tchan MC, 2000, J BIOL CHEM, V275, P37454, DOI 10.1074/jbc.M004264200; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; Whitson SR, 2005, J MOL BIOL, V350, P319, DOI 10.1016/j.jmb.2005.05.002; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365; ZHU BY, 1993, PROTEIN SCI, V2, P383; Zhu H, 2000, J MOL BIOL, V300, P1377, DOI 10.1006/jmbi.2000.3936	60	13	16	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12989	13002		10.1074/jbc.M611465200	http://dx.doi.org/10.1074/jbc.M611465200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17261584	hybrid			2022-12-27	WOS:000245942800069
J	Gorman, MJ; Wang, Y; Jiang, HB; Kanost, MR				Gorman, Maureen J.; Wang, Yang; Jiang, Haobo; Kanost, Michael R.			Manduca sexta hemolymph proteinase 21 activates prophenoloxidase-activating proteinase 3 in an insect innate immune response proteinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLOTRICHIA-DIOMPHALIA LARVAE; PRO-PHENOL-OXIDASE; IN-VITRO ACTIVATION; COMPLEMENT FACTOR D; SERINE-PROTEASE; COLEOPTERAN INSECT; ANOPHELES-GAMBIAE; TOBACCO HORNWORM; CDNA CLONING; CLIP DOMAINS	Melanization, an insect immune response, requires a set of hemolymph proteins including pathogen recognition proteins that initiate the response, a cascade of mostly unknown serine proteinases, and phenoloxidase. Until now, only initial and final proteinases in the pathways have been conclusively identified. Four such proteinases have been purified from the larval hemolymph of Manduca sexta: hemolymph proteinase 14 ( HP14), which autoactivates in the presence of microbial surface components, and three prophenoloxidase-activating proteinases ( PAP1-3). In this study, we have used two complementary approaches to identify a serine proteinase that activates proPAP3. Partial purification from hemolymph of an activator of proPAP3 resulted in an active fraction with two abundant polypeptides of similar to 32 and similar to 37 kDa. Labeling of these polypeptides with a serine proteinase inhibitor, diisopropyl fluorophosphate, indicated that they were active serine proteinases. N-terminal sequencing revealed that both were cleaved forms of the previously identified hemolymph serine proteinase, HP21. Surprisingly, cleavage of proHP21 had occurred not at the predicted activation site but more N-terminal to it. In vitro reactions carried out with purified HP14 ( which activates proHP21), proHP21, proPAP3, and site-directed mutant forms of the latter two proteinases confirmed that HP21 activates proPAP3 by limited proteolysis. Like the HP21 products purified from hemolymph, HP21 that was activated by HP14 in the in vitro reactions was not cleaved at its predicted activation site.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA	Kansas State University; Oklahoma State University System; Oklahoma State University - Stillwater	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, 141 Chalmers Hall, Manhattan, KS 66506 USA.	kanost@ksu.edu	Jiang, Haobo/A-6519-2008	Gorman, Maureen/0000-0003-2005-6223; Jiang, Haobo/0000-0003-1357-1315; Kanost, Michael/0000-0002-6827-0061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R01GM041247, R01GM058634, R29GM041247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41247, R37 GM041247, R01 GM041247, R01 GM041247-18, R01 GM058634-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BC, 1991, BIOCHEM J, V279, P775, DOI 10.1042/bj2790775; Castillejo-Lopez C, 2005, BIOCHEM BIOPH RES CO, V338, P1075, DOI 10.1016/j.bbrc.2005.10.042; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Gal P, 2005, J BIOL CHEM, V280, P33435, DOI 10.1074/jbc.M506051200; Gupta S, 2005, INSECT BIOCHEM MOLEC, V35, P241, DOI 10.1016/j.ibmb.2004.12.003; Ji CY, 2004, J BIOL CHEM, V279, P34101, DOI 10.1074/jbc.M404584200; Ji CY, 2003, PROTEIN EXPRES PURIF, V29, P235, DOI 10.1016/S1046-5928(03)00020-2; Jiang HB, 2005, INSECT BIOCHEM MOLEC, V35, P931, DOI 10.1016/j.ibmb.2005.03.009; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804; Kanost Michael R, 2004, Immunol Rev, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Leclerc V, 2006, EMBO REP, V7, P231, DOI 10.1038/sj.embor.7400592; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; MORGAN PH, 1972, P NATL ACAD SCI USA, V69, P3312, DOI 10.1073/pnas.69.11.3312; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; Paskewitz SM, 2006, INSECT BIOCHEM MOLEC, V36, P701, DOI 10.1016/j.ibmb.2006.06.001; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; Stubbs MT, 1998, BIOL CHEM, V379, P95; Tang HP, 2006, J BIOL CHEM, V281, P28097, DOI 10.1074/jbc.M601642200; Tong YR, 2005, J BIOL CHEM, V280, P14932, DOI 10.1074/jbc.M500532200; Volanakis JE, 1996, PROTEIN SCI, V5, P553; VOLTZ J, 2006, CELL MICROBIOL, V8, P1392; Volz J, 2005, J BIOL CHEM, V280, P40161, DOI 10.1074/jbc.M506191200; Wang Y, 2006, J BIOL CHEM, V281, P9271, DOI 10.1074/jbc.M513797200; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P731, DOI 10.1016/j.ibmb.2004.03.008; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P387, DOI 10.1016/j.ibmb.2003.12.005; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200; Zou Z, 2005, INSECT MOL BIOL, V14, P433, DOI 10.1111/j.1365-2583.2005.00574.x; Zou Z, 2005, J BIOL CHEM, V280, P14341, DOI 10.1074/jbc.M500570200	39	90	94	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11742	11749		10.1074/jbc.M611243200	http://dx.doi.org/10.1074/jbc.M611243200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317663	hybrid, Green Accepted			2022-12-27	WOS:000245941900016
J	Kuhn, PH; Marjaux, E; Imhof, A; De Strooper, B; Haass, C; Lichtenthaler, SF				Kuhn, Peer-Hendrik; Marjaux, Els; Imhof, Axel; De Strooper, Bart; Haass, Christian; Lichtenthaler, Stefan F.			Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; RECEPTOR-TYPE-II; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; DECOY RECEPTOR; CLEAVAGE; BACE1; EXPRESSION; PRESENILIN; MICE	Ectodomain shedding and intramembrane proteolysis of the amyloid precursor protein ( APP) by alpha-, beta- and gamma-secretase are involved in the pathogenesis of Alzheimer disease ( AD). Increased proteolytic processing and secretion of another membrane protein, the interleukin-1 receptor II ( IL-1R2), have also been linked to the pathogenesis of AD. IL-1R2 is a decoy receptor that may limit detrimental effects of IL-1 in the brain. At present, the proteolytic processing of IL-1R2 remains little understood. Here we show that IL-1R2 can be proteolytically processed in a manner similar to APP. IL-1R2 expressed in human embryonic kidney 293 cells first undergoes ectodomain shedding in an alpha-secretase-like manner, resulting in secretion of the IL-1R2 ectodomain and the generation of an IL-1R2 C-terminal fragment. This fragment undergoes further intramembrane proteolysis by gamma-secretase, leading to the generation of the soluble intracellular domain of IL-1R2. Intramembrane cleavage of IL-1R2 was abolished by a highly specific inhibitor of gamma-secretase and was absent in mouse embryonic fibroblasts deficient in gamma-secretase activity. Surprisingly, the gamma-secretase BACE1 and its homolog BACE2 increased IL-1R2 secretion resulting in C-terminal fragments nearly identical to the ones generated by the alpha-secretase-like cleavage. This suggests that both proteases may act as alternative gamma-secretase-like proteases. Importantly, BACE1 and BACE2 did not cleave several other membrane proteins, demonstrating that both proteases do not contribute to general membrane protein turnover but only cleave specific proteins. This study reveals a similar proteolytic processing of IL-1R2 and APP and may provide an explanation for the increased IL-1R2 secretion observed in AD.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Catholic Univ Louvain, Ctr Human Genet, Dept Mol & Dev Genet, Flanders Interuniv Inst Biotehcnol, B-3000 Louvain, Belgium	University of Munich; Universite Catholique Louvain	Lichtenthaler, SF (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	Stefan.Lichtenthaler@med.uni-muenchen.de	de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012; Imhof, Axel/AAU-5313-2021; Lichtenthaler, Stefan F/B-6587-2016	De Strooper, Bart/0000-0001-5455-5819; Imhof, Axel/0000-0003-2993-8249; Lichtenthaler, Stefan F/0000-0003-2211-2575; Kuhn, Peer-Hendrik/0000-0001-7891-5102				Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 2004, TRENDS PHARMACOL SCI, V25, P92, DOI 10.1016/j.tips.2003.12.004; Cui XL, 2003, J IMMUNOL, V171, P6814, DOI 10.4049/jimmunol.171.12.6814; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; French RA, 1999, J NEUROIMMUNOL, V93, P194, DOI 10.1016/S0165-5728(98)00224-0; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Garlind A, 1999, BRAIN RES, V826, P112, DOI 10.1016/S0006-8993(99)01092-6; Griffin WST, 2000, EXP GERONTOL, V35, P481, DOI 10.1016/S0531-5565(00)00110-8; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hartwell DW, 1999, THROMB HAEMOSTASIS, V82, P850, DOI 10.1055/s-0037-1615922; Hebert SS, 2006, EMBO REP, V7, P739, DOI 10.1038/sj.embor.7400704; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kitazume S, 2005, J BIOL CHEM, V280, P8589, DOI 10.1074/jbc.M409417200; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lindberg C, 2005, NEUROCHEM INT, V46, P551, DOI 10.1016/j.neuint.2005.01.004; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Ma GZ, 2005, J NEUROSCI RES, V80, P683, DOI 10.1002/jnr.20515; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Neumann D, 2000, J IMMUNOL, V165, P3350, DOI 10.4049/jimmunol.165.6.3350; Neumann S, 2006, J BIOL CHEM, V281, P7583, DOI 10.1074/jbc.M508340200; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Orlando S, 1997, J BIOL CHEM, V272, P31764, DOI 10.1074/jbc.272.50.31764; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schobel S, 2006, INT J DEV NEUROSCI, V24, P141, DOI 10.1016/j.ijdevneu.2005.11.003; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Vardy ERLC, 2005, TRENDS MOL MED, V11, P464, DOI 10.1016/j.molmed.2005.08.004; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200	72	122	146	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11982	11995		10.1074/jbc.M700356200	http://dx.doi.org/10.1074/jbc.M700356200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17307738	hybrid			2022-12-27	WOS:000245941900041
J	Sugimoto, Y; Narumiya, S				Sugimoto, Yukihiko; Narumiya, Shuh			Prostaglandin E receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DISTINCT CELLULAR-LOCALIZATION; C-TERMINAL TAIL; PROSTANOID RECEPTORS; MICE LACKING; EP3 RECEPTOR; 2 ISOFORMS; MESSENGER-RNA; E-2 RECEPTORS; SUBTYPE; EXPRESSION	Prostaglandin ( PG) E-2 exerts its actions by acting on a group of G-protein-coupled receptors ( GPCRs). There are four GPCRs responding to PGE(2) designated subtypes EP1, EP2, EP3, and EP4 and multiple splicing isoforms of the subtype EP3. The EP subtypes exhibit differences in signal transduction, tissue localization, and regulation of expression. This molecular and biochemical heterogeneity of PGE receptors leads to PGE(2) being the most versatile prostanoid. Studies on knock-out mice deficient in each EP subtype have defined PGE(2) actions mediated by each subtype and identified the role each EP subtype plays in various physiological and pathophysiological responses. Here we review recent advances in PGE receptor research.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan; Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; Bilson HA, 2004, FEBS LETT, V572, P271, DOI 10.1016/j.febslet.2004.06.089; BREYER MD, 1993, KIDNEY INT, V44, P1372, DOI 10.1038/ki.1993.391; Breyer MD, 1996, AM J PHYSIOL-RENAL, V270, pF912, DOI 10.1152/ajprenal.1996.270.5.F912; Cha YI, 2006, GENE DEV, V20, P77, DOI 10.1101/gad.1374506; Chang SH, 2005, CANCER RES, V65, P4496, DOI 10.1158/0008-5472.CAN-05-0129; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Fujino H, 2006, MOL PHARMACOL, V69, P13, DOI 10.1124/mol.105.017749; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; Hasegawa H, 2000, FEBS LETT, V473, P76, DOI 10.1016/S0014-5793(00)01508-8; Herve M, 2003, EUR J IMMUNOL, V33, P2764, DOI 10.1002/eji.200324143; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; HONDA A, 1993, J BIOL CHEM, V268, P7759; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Ikegami R, 2001, J IMMUNOL, V166, P4689, DOI 10.4049/jimmunol.166.7.4689; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; Kabashima K, 2003, NAT IMMUNOL, V4, P694, DOI 10.1038/ni943; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; KATOH H, 1995, BBA-GEN SUBJECTS, V1244, P41, DOI 10.1016/0304-4165(94)00182-W; Katsuyama M, 1997, ENDOCRINOLOGY, V138, P344, DOI 10.1210/en.138.1.344; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; Katsuyama M, 1998, BIOCHEM BIOPH RES CO, V251, P727, DOI 10.1006/bbrc.1998.9540; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054; Liang XB, 2005, J NEUROSCI, V25, P10180, DOI 10.1523/JNEUROSCI.3591-05.2005; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Matsuoka Y, 2005, P NATL ACAD SCI USA, V102, P16066, DOI 10.1073/pnas.0504908102; Matsuoka Y, 2003, P NATL ACAD SCI USA, V100, P4132, DOI 10.1073/pnas.0633341100; Minami T, 2003, NEUROPHARMACOLOGY, V45, P96, DOI 10.1016/S0028-3908(03)00133-3; Moriyama T, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-3; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Mutoh M, 2002, CANCER RES, V62, P28; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; Ono K, 2003, BONE, V33, P798, DOI 10.1016/S8756-3282(03)00264-3; Pavlovic S, 2006, J BIOL CHEM, V281, P3321, DOI 10.1074/jbc.M506846200; Reinold H, 2005, J CLIN INVEST, V115, P673; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Segi E, 2003, BIOL REPROD, V68, P804, DOI 10.1095/biolreprod.102.003590; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, AM J PHYSIOL, V266, pF823, DOI 10.1152/ajprenal.1994.266.5.F823; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; Sugimoto Y, 2005, J IMMUNOL, V175, P2606, DOI 10.4049/jimmunol.175.4.2606; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Tabata H, 2002, BIOCHEM BIOPH RES CO, V298, P398, DOI 10.1016/S0006-291X(02)02455-5; Takasaki I, 2005, NEUROPHARMACOLOGY, V49, P283, DOI 10.1016/j.neuropharm.2004.12.025; Takeuchi K, 1999, GASTROENTEROLOGY, V117, P1128, DOI 10.1016/S0016-5085(99)70398-7; Timoshenko AV, 2003, EXP CELL RES, V289, P265, DOI 10.1016/S0014-4827(03)00269-6; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; Tsuchiya S, 2003, GENES CELLS, V8, P747, DOI 10.1046/j.1365-2443.2003.00672.x; Ueno A, 2001, BIOCHEM PHARMACOL, V62, P157, DOI 10.1016/S0006-2952(01)00654-2; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; WATABE A, 1993, J BIOL CHEM, V268, P20175; Yang L, 2003, J CLIN INVEST, V111, P727, DOI 10.1172/JCI200316492; Yokoyama U, 2006, J CLIN INVEST, V116, P3026, DOI 10.1172/JCI28639; Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399; Yuhki K, 2004, J PHARMACOL EXP THER, V311, P1218, DOI 10.1124/jpet.104.071548	65	883	926	4	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11613	11617		10.1074/jbc.R600038200	http://dx.doi.org/10.1074/jbc.R600038200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329241	hybrid			2022-12-27	WOS:000245941900002
J	Hills, R; Mazzarella, R; Fok, K; Liu, M; Nemirovskiy, O; Leone, J; Zack, MD; Arner, EC; Viswanathan, M; Abujoub, A; Muruganandam, A; Sexton, DJ; Bassill, GJ; Sato, AK; Malfait, AM; Tortorella, MD				Hills, Robert; Mazzarella, Richard; Fok, Kam; Liu, Min; Nemirovskiy, Olga; Leone, Joseph; Zack, Marc D.; Arner, Elizabeth C.; Viswanathan, Malini; Abujoub, Aida; Muruganandam, Arumugam; Sexton, Daniel J.; Bassill, Gary J.; Sato, Aaron K.; Malfait, Anne-Marie; Tortorella, Micky D.			Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; MATRIX METALLOPROTEINASES; AGGRECANASE-1 ADAMTS-4; OSTEOARTHRITIS; SPECIFICITY; RECOGNITION; DEGRADATION; SEQUENCES; ADAM-TS4; PROTEINS	ADAMTS-4 and ADAMTS-5 are aggrecanases responsible for the breakdown of cartilage aggrecan in osteoarthritis. Multiple ADAMTS-4 cleavage sites have been described in several matrix proteins including aggrecan, versican, and brevican, but no concise predictive cleavage motif has been identified for this protease. By screening a 13-mer peptide library with a diversity of 10(8), we have identified the ADAMTS-4 cleavage motif E-(AFVLMY)-X( 0,1)-( RK)-X( 2,3)-( ST)-(VYIFWMLA), with Glu representing P1. Several 13-mer peptides containing this motif, including DVQEFRGVTAVIR and HNEFRQRETYMVF, were shown to be substrates for ADAMTS-4. These peptides were found to be specific substrates for ADAMTS-4 as they were not cleaved by ADAMTS-5. Modification of these peptides with donor ( 6-FAM) and acceptor ( QSY-9) molecules resulted in the development of fluorescence-based substrates with a K-m of similar to 35 mu M. Furthermore, the role of Glu at P1 and Phe at P1' in binding and catalysis was studied by exploring substitution of these amino acids with the D-isomeric forms. Substitution of P1 with dGlu was tolerable for binding, but not catalysis, whereas substitution of P1' with dPhe precluded both binding and catalysis. Similarly, replacement of Glu with Asp at P1 abolished recognition and cleavage of the peptide. Finally, BLAST results of the ADAMTS-4 cleavage motif identified matrilin-3 as a new substrate for ADAMTS-4. When tested, recombinant ADAMTS-4 effectively cleaved intact matrilin-3 at the predicted motif at Glu435/Ala436 generating two species of 45 and 5 kDa.	Pfizer Global Res & Dev, St Louis, MO 63017 USA; Dynax Corp, Cambridge, MA 02139 USA	Pfizer	Hills, R (corresponding author), 700 Chesterfield Pkwy, Chesterfield, MO 63017 USA.	Robert.L.Hills@Pfizer.com		Malfait, Anne-Marie/0000-0003-1428-0384; Sexton, Daniel J/0000-0001-9604-5948				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Brazma A, 1996, Proc Int Conf Intell Syst Mol Biol, V4, P34; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; Cloutier SM, 2002, EUR J BIOCHEM, V269, P2747, DOI 10.1046/j.1432-1033.2002.02960.x; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Dickinson SC, 2003, MATRIX BIOL, V22, P267, DOI 10.1016/S0945-053X(03)00034-9; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Karlson L, 2002, J BIOL CHEM, V277, P18579, DOI 10.1074/jbc.M110356200; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEY CA, 2001, Patent No. 6906176; McCarter JD, 2004, J BACTERIOL, V186, P5919, DOI 10.1128/JB.186.17.5919-5925.2004; Melching LI, 2006, OSTEOARTHR CARTILAGE, V14, P1147, DOI 10.1016/j.joca.2006.05.014; Miller JA, 2003, ANAL BIOCHEM, V314, P260, DOI 10.1016/S0003-2697(02)00638-3; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Pan WJ, 2003, J BIOL CHEM, V278, P27820, DOI 10.1074/jbc.M304436200; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Song RH, 2007, ARTHRITIS RHEUM-US, V56, P575, DOI 10.1002/art.22334; Stefansson SE, 2003, AM J HUM GENET, V72, P1448, DOI 10.1086/375556; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2004, J BIOL CHEM, V279, P17554, DOI 10.1074/jbc.M313041200; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; van der Weyden L, 2006, AM J PATHOL, V169, P515, DOI 10.2353/ajpath.2006.050981; Wagener R, 2005, FEBS LETT, V579, P3323, DOI 10.1016/j.febslet.2005.03.018; WANG Z, 2004, P 50 ANN M ORTH RES; ZENG W, 2004, P 50 ANN M ORTH RES	36	36	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11101	11109		10.1074/jbc.M611588200	http://dx.doi.org/10.1074/jbc.M611588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311924	hybrid			2022-12-27	WOS:000245941500031
J	Singh, RK; Iyappan, S; Scheffner, M				Singh, Rajesh K.; Iyappan, Saravanakumar; Scheffner, Martin			Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE; DNA-DAMAGE; EMBRYONIC LETHALITY; P53 DEGRADATION; IN-VIVO; COMPLEX; UBIQUITINATION; DOMAIN; PHOSPHORYLATION; ONCOPROTEIN	Mdm2 is a member of the RING finger family of ubiquitin ligases and is best known for its role in targeting the tumor suppressor p53 for ubiquitination and degradation. Mdm2 can bind to itself and to the structurally related protein MdmX, and these interactions involve the RING finger domain of Mdm2 and MdmX, respectively. In this study, we performed a mutational analysis of the RING finger domain of Mdm2, and we identified several amino acid residues that are important for Mdm2 to exert its ubiquitin ligase function. Mutation of some of these residues interfered with the Mdm2-Mdm2 interaction indicating that a homomeric complex represents the active form of Mdm2. Mutation of other residues did not detectably affect the ability of Mdm2 to interact with itself but reduced the ability of Mdm2 to interact with UbcH5. Remarkably, MdmX efficiently rescued the ubiquitin ligase activity of the latter Mdm2 mutants in vitro and within cells. Because the interaction of Mdm2 with MdmX is more stable than the Mdm2-Mdm2 interaction, this suggests that Mdm2-MdmX complexes play a prominent role in p53 ubiquitination in vivo. Furthermore, we show that, similar to Mdm2, the Mdm2-MdmX complex has Nedd8 ligase activity and that all mutations that affect the ubiquitin ligase activity of Mdm2 also affect its Nedd8 ligase activity. From a mechanistic perspective, this suggests that the actual function of Mdm2 and Mdm2-MdmX, respectively, in p53 ubiquitination and in p53 neddylation is similar for both processes.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Scheffner, M (corresponding author), Univ Konstanz, Dept Biol, Box M642, D-78457 Constance, Germany.	martin.scheffner@uni-konstanz.de	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Grier JD, 2006, MOL CELL BIOL, V26, P192, DOI 10.1128/MCB.26.1.192-198.2006; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Linares LK, 2003, FEBS LETT, V554, P73, DOI 10.1016/S0014-5793(03)01108-6; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; LUNA RMD, 1995, NATURE, V378, P203; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; OPYUROVSKY MV, 2007, EMBO J, V26, P90; Ozkan E, 2005, P NATL ACAD SCI USA, V102, P18890, DOI 10.1073/pnas.0509418102; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Steinman HA, 2005, ONCOGENE, V24, P7935, DOI 10.1038/sj.onc.1208930; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vander Kooi CW, 2006, BIOCHEMISTRY-US, V45, P121, DOI 10.1021/bi051787e; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Xu Z, 2006, BIOCHEMISTRY-US, V45, P4749, DOI 10.1021/bi0601508; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10901	10907		10.1074/jbc.M610879200	http://dx.doi.org/10.1074/jbc.M610879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17301054	hybrid, Green Published			2022-12-27	WOS:000245941500009
J	Lunn, JA; Jacamo, R; Rozengurt, E				Lunn, J. Adrian; Jacamo, Rodrigo; Rozengurt, Enrique			Preferential phosphorylation of focal adhesion kinase tyrosine 861 is critical for mediating an anti-apoptotic response to hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; SRC FAMILY KINASES; SALTED FOOD-INTAKE; GASTRIC-CANCER; DEPENDENT PHOSPHORYLATION; CORTICAL CYTOSKELETON; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; PROTEIN	The results presented here demonstrate that focal adhesion kinase ( FAK) Tyr-861 is the predominant tyrosine phosphorylation site stimulated by hyperosmotic stress in a variety of cell types, including epithelial cell lines (ileum-derived IEC-18, colon-derived Caco2, and stomach-derived NCI-N87), FAK null fibroblasts re-expressing FAK, and Src family kinase triple null fibroblasts ( SYF cells) in which c-Src has been restored ( YF cells). We show that hyperosmotic stress-stimulated FAK phosphorylation in epithelial cells is inhibited by Src family kinase inhibitors PP2 and SU6656 and that it does not occur in SYF cells. Unexpectedly, hyperosmotic stress-induced phosphorylation of FAK at Tyr-397, Tyr-576, and most dramatically at Tyr-861 was completely insensitive to the F-actin-disrupting agents, latrunculin A and cytochalasin D. Finally, we show that in FAK null cells exposed to hyperosmotic stress or growth factor withdrawal, re-expression of wild type FAK restored cell survival, whereas re-expression of FAK mutated from tyrosine to phenylalanine at position 861 (FAKY861F) did not. Our results indicate that FAK Tyr- 861 phosphorylation is required for mammalian cell survival of hyperosmotic stress. Furthermore, the results suggest that FAK is an upstream regulator ( rather than downstream effector) of F-actin reorganization in response to hyperosmotic stress. We propose that FAK/c-Src bipartite enzyme is a sensor of cytoplasmic shrinkage, and that the phosphorylation on FAK Tyr-861 by Src and subsequent reorganization of F-actin can initiate an anti- apoptotic signaling pathway that protects cells from hyperosmotic stress.	Univ Calif Los Angeles, Dept Med, David Geffen Sch Med,Digest Dis Res Ctr, Div Digest Dis,CURE, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Dept Med, David Geffen Sch Med,Digest Dis Res Ctr, Div Digest Dis,CURE, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NCI NIH HHS [K08CA104039-01] Funding Source: Medline; NIDDK NIH HHS [DK 56930, DK 55003, P30 DK41301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA104039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK056930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Bellas RE, 2002, AM J PHYSIOL-LUNG C, V282, pL1135, DOI 10.1152/ajplung.00174.2001; Cary LA, 1996, J CELL SCI, V109, P1787; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Di Ciano C, 2002, AM J PHYSIOL-CELL PH, V283, pC850, DOI 10.1152/ajpcell.00018.2002; Di Ciano-Oliveira C, 2003, AM J PHYSIOL-CELL PH, V285, pC555, DOI 10.1152/ajpcell.00086.2003; Duxbury MS, 2004, SURGERY, V135, P555, DOI 10.1016/j.surg.2003.10.017; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Fox JG, 2003, CANCER RES, V63, P942; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Garces CA, 2006, CANCER RES, V66, P1446, DOI 10.1158/0008-5472.CAN-05-1661; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; Gustavsson A, 2004, J BIOL CHEM, V279, P22893, DOI 10.1074/jbc.M309693200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Joossens JV, 1996, INT J EPIDEMIOL, V25, P494, DOI 10.1093/ije/25.3.494; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lunn JA, 2004, J BIOL CHEM, V279, P45266, DOI 10.1074/jbc.M314132200; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; QUARONI A, 1981, J NATL CANCER I, V67, P1353; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHILLI R, 1982, GUT, V23, P326, DOI 10.1136/gut.23.4.326; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Sun GQ, 2002, ARCH BIOCHEM BIOPHYS, V397, P11, DOI 10.1006/abbi.2001.2627; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; Tohyama Y, 2004, CURR PHARM DESIGN, V10, P835, DOI 10.2174/1381612043452947; Tsugane S, 2005, CANCER SCI, V96, P1, DOI 10.1111/j.1349-7006.2005.00006.x; Tsugane S, 2004, BRIT J CANCER, V90, P128, DOI 10.1038/sj.bjc.6601511; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VERNIA P, 1988, DIGEST DIS SCI, V33, P1353, DOI 10.1007/BF01536987; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zaidel-Bar R, 2005, J CELL SCI, V118, P3997, DOI 10.1242/jcs.02523; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200	62	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10370	10379		10.1074/jbc.M607780200	http://dx.doi.org/10.1074/jbc.M607780200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289681	hybrid			2022-12-27	WOS:000245941000027
J	Pannu, J; Nakerakanti, S; Smith, E; ten Dijke, P; Trojanowska, M				Pannu, Jaspreet; Nakerakanti, Sashidhar; Smith, Edwin; ten Dijke, Peter; Trojanowska, Maria			Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; TGF-BETA; HUMAN FIBROBLASTS; LUNG FIBROBLASTS; MESANGIAL CELLS; SKIN FIBROSIS; SCLERODERMA; EXPRESSION; KINASE; MODEL	The transforming growth factor (TGF)- beta/Smad3 signaling pathway is considered a central mediator of pathological organ fibrosis; however, contribution of Smad2/3-independent TGF-beta signaling has not been fully explored. The present study utilized previously a described model of scleroderma (SSc) fibrosis based on forced expression of the TGF-beta RI ( ALK5) ( Pannu, J., Gardner, H., Shearstone, J. R., Smith, E., and Trojanowska, M. ( 2006) Arthritis Rheum. 54, 3011 - 3021). This study was aimed at determining the molecular mechanisms underlying the profibrotic program in this model. We demonstrate that the TGF-beta RI-dependent up-regulation of collagen and CCN2 ( CTGF) does not involve Smad2/3 activation but is mediated by ALK1/Smad1 and ERK1/2 pathways. The following findings support this conclusion: (i) Smad2 and - 3 were not phosphorylated in response to TGF-beta RI, ( ii) a TGF- beta RI mutant defective in Smad2/3 activation, ALK5( 3A), potently stimulated collagen production, (iii) elevation of TGF-beta RI triggered sustained association of ALK5 with ALK1 and high levels of Smad1 phosphorylation, (iv) blockade of Smad1 via small interfering RNA abrogated collagen and CCN2 up-regulation in this model, ( v) elevated TGF-beta RI led to a prolonged activation of ERK1/2, ( vi) the pharmacologic inhibitor of ERK1/2 inhibited Smad1 phosphorylation and abrogated profibrotic effects of elevated TGF beta-RI. Additional experiments demonstrated that a GC- rich response element located -6 to -16 ( upstream of the transcription start site) in the CCN2 promoter mediated Smad1- dependent increased promoter activity in this model. This element was shown previously to mediate up- regulation of the CCN2 promoter in SSc fibroblasts. In conclusion, this study defines a novel ALK1/Smad1- and ERK1/2-dependent, Smad3-independent mode of TGF-beta signaling that may operate during chronic stages of fibrosis in SSc.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA; Leiden Univ, Med Ctr, NL-2300 RC Leiden, Netherlands	Medical University of South Carolina; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Trojanowska, M (corresponding author), CSB 912,96 Jonathan Lucas St, Charleston, SC 29425 USA.	trojanme@musc.edu	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Trojanowska, Maria/0000-0001-9550-7178	NIAMS NIH HHS [AR-44883, AR-42334] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044883, R01AR042334] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe H, 2004, J BIOL CHEM, V279, P14201, DOI 10.1074/jbc.M310427200; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Chen YL, 2006, ARTHRITIS RHEUM-US, V54, P1309, DOI 10.1002/art.21725; Falanga V, 2004, WOUND REPAIR REGEN, V12, P320, DOI 10.1111/j.1067-1927.2004.012316.x; Fan JG, 2006, J CELL PHYSIOL, V207, P499, DOI 10.1002/jcp.20593; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gardner H, 2006, ARTHRITIS RHEUM-US, V54, P1961, DOI 10.1002/art.21894; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hill C, 2000, ENDOCRINOLOGY, V141, P1196, DOI 10.1210/en.141.3.1196; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; ISHIKAWA O, 1990, J CELL PHYSIOL, V145, P181, DOI 10.1002/jcp.1041450124; Isono M, 2000, AM J PHYSIOL-RENAL, V278, pF830, DOI 10.1152/ajprenal.2000.278.5.F830; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Izumi M, 2006, J MOL CELL CARDIOL, V40, P224, DOI 10.1016/j.yjmcc.2005.11.007; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsubara T, 2006, LAB INVEST, V86, P357, DOI 10.1038/labinvest.3700400; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Mori Y, 2003, ARTHRITIS RHEUM-US, V48, P1964, DOI 10.1002/art.11157; Nagashio Y, 2004, LAB INVEST, V84, P1610, DOI 10.1038/labinvest.3700191; Nakamura H, 2004, MOL VIS, V10, P703; Nakamuta M, 2005, INT J MOL MED, V16, P59; Pannu J, 2004, ARTHRITIS RHEUM-US, V50, P1566, DOI 10.1002/art.20225; Pannu J, 2006, ARTHRITIS RHEUM-US, V54, P3011, DOI 10.1002/art.22063; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Querfeld C, 1999, J DERMATOL SCI, V21, P13, DOI 10.1016/S0923-1811(99)00008-0; Roulot D, 1999, HEPATOLOGY, V29, P1730, DOI 10.1002/hep.510290622; SILVERSTEIN JL, 1988, ARCH DERMATOL, V124, P1379, DOI 10.1001/archderm.124.9.1379; Svegliati S, 2005, J BIOL CHEM, V280, P36474, DOI 10.1074/jbc.M502851200; Takahashi T, 2005, J BIOL CHEM, V280, P7100, DOI 10.1074/jbc.M411064200; Tourkina E, 2005, J BIOL CHEM, V280, P13879, DOI 10.1074/jbc.M412551200; Wiercinska E, 2006, HEPATOLOGY, V43, P1032, DOI 10.1002/hep.21135; Xu SW, 2004, J BIOL CHEM, V279, P23098, DOI 10.1074/jbc.M311430200; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2003, J INVEST DERMATOL, V121, P713, DOI 10.1046/j.1523-1747.2003.12517.x	46	155	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10405	10413		10.1074/jbc.M611742200	http://dx.doi.org/10.1074/jbc.M611742200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17317656	hybrid			2022-12-27	WOS:000245941000031
J	Zhao, YT; He, DH; Zhao, J; Wang, LX; Leff, AR; Spannhake, EW; Georas, S; Natarajan, V				Zhao, Yutong; He, Donghong; Zhao, Jing; Wang, Lixin; Leff, Alan R.; Spannhake, Ernst Wm.; Georas, Steve; Natarajan, Viswanathan			Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha 2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-D; ALPHA-2 CHAIN; GENE-EXPRESSION; ALLERGEN CHALLENGE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; (IL)-13 RESPONSES; INTERFERON-GAMMA; BINDING SUBUNIT	Interleukin-13 (IL-13), a Th2 cytokine, plays a pivotal role in pathogenesis of bronchial asthma via IL-13 receptor alpha 1 ( IL-13R alpha 1) and IL-4 receptor alpha(IL-4R alpha). Recent studies show that a decoy receptor for IL-13, namely IL-13R alpha 2, mitigates IL-13 signaling and function. This study provides evidence for regulation of IL-13R alpha 2 production and release and IL-13-dependent signaling by lysophosphatidic acid(LPA) in primary cultures of human bronchial epithelial cells( HBEpCs). LPA treatment of HBEpCs in a time dependent fashion increased IL-13R alpha 2 gene expression without altering the mRNA levels of IL-13R alpha 1 and IL-4R alpha. Pretreatment with pertussis toxin (100 ng/ml, 4 h) or transfection of c-Jun small interference RNA or an inhibitor of JNK attenuated LPA-induced IL-13R alpha 2 gene expression and secretion of soluble IL-13R alpha 2. Overexpression of catalytically inactive mutants of phospholipase D(PLD) 1 or 2 attenuated LPA-induced IL-13R alpha 2 gene expression and protein secretion as well as phosphorylation of JNK. Pretreatment of HBEpCs with 1 mu m LPA for 6 h attenuated IL-13 but not IL-4 induced phosphorylation of STAT6. Transfection of HBEpCs with IL-13R alpha 2 small interference RNA blocked the effect of LPA on IL-13-induced phosphorylation of STAT6. Furthermore, pretreatment with LPA (1 mu m, 6 h) attenuated IL-13-induced eotaxin-1 and SOCS-1 gene expression. These results demonstrate that LPA induces IL-13R alpha 2 expression and release via PLD and JNK/AP-1 signal transduction and that pretreatment with LPA down-regulates IL-13 signaling in HBEpCs. Our data suggest a novel mechanism of regulation of IL-13R alpha 2 and IL-13 signaling that may be of physiological relevance to airway inflammation and remodeling.	Berlex Biosci, Dept Gene Technol, Richmond, CA 94806 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Rochester, Dept Med, Div Pulm & Crit Care, Rochester, NY 14627 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Rochester	Zhao, YT (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, Ctr Integrat Sci Bldg,Room W403M,929 E 57th St, Chicago, IL 60637 USA.	yzhao@medicine.bsd.uchicago.edu	wang, xl/Y-8251-2019; Wang, Lai-Xi/E-8755-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071152] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071152, HL71152, R01 HL071152-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi T, 1996, HEPATOLOGY, V24, P1274; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; Budnik LT, 2002, BIOL REPROD, V66, P859, DOI 10.1095/biolreprod66.4.859; CAR BD, 1994, AM J RESP CRIT CARE, V149, P655, DOI 10.1164/ajrccm.149.3.8118632; Casas-Gonzalez P, 2003, BBA-MOL CELL BIOL L, V1633, P75, DOI 10.1016/S1388-1981(03)00089-1; Cazzolli R, 2006, IUBMB LIFE, V58, P457, DOI 10.1080/15216540600871142; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Chou CH, 2005, CARCINOGENESIS, V26, P45, DOI 10.1093/carcin/bgh301; Chun J, 2006, CURR PHARM DESIGN, V12, P161, DOI 10.2174/138161206775193109; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Folkard SG, 1997, EUR RESPIR J, V10, P2097, DOI 10.1183/09031936.97.10092097; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; GEORAS SN, 2007, IN PRESS CLIN EXP AL; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Heller NM, 2004, AM J RESP CELL MOL, V31, P573, DOI 10.1165/rcmb.2004-0195OC; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HUANG SK, 1995, J IMMUNOL, V155, P2688; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; Kawakami K, 2006, CANCER RES, V66, P4434, DOI 10.1158/0008-5472.CAN-05-1265; Kawakami K, 2001, CANCER GENE THER, V8, P861, DOI 10.1038/sj.cgt.7700373; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kawakami M, 2003, CLIN CANCER RES, V9, P6381; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kogut MH, 2003, INT IMMUNOPHARMACOL, V3, P693, DOI 10.1016/S1567-5769(03)00057-2; Kotowicz K, 1996, INT IMMUNOL, V8, P1915, DOI 10.1093/intimm/8.12.1915; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Malabarba MG, 1996, BIOCHEM J, V319, P865, DOI 10.1042/bj3190865; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1998, INT J MOL MED, V1, P551; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Rahaman SO, 2002, CANCER RES, V62, P1103; Rubenfeld J, 2006, AM J PHYSIOL-LUNG C, V290, pL66, DOI 10.1152/ajplung.00473.2004; Saatian B, 2006, BIOCHEM J, V393, P657, DOI 10.1042/BJ20050791; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Snyder MD, 2006, TRAFFIC, V7, P993, DOI 10.1111/j.1600-0854.2006.00450.x; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Wang LX, 2003, J BIOL CHEM, V278, P39931, DOI 10.1074/jbc.M302896200; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Wu AH, 2003, NEURO-ONCOLOGY, V5, P179, DOI 10.1215/S1152851702000510; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu YJ, 2005, CELL CALCIUM, V38, P569, DOI 10.1016/j.ceca.2005.08.001; Yasunaga S, 2003, CYTOKINE, V24, P293, DOI 10.1016/j.cyto.2003.08.006; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	60	33	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10172	10179		10.1074/jbc.M611210200	http://dx.doi.org/10.1074/jbc.M611210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287216	hybrid, Green Accepted			2022-12-27	WOS:000245941000007
J	Huang, Y; Breitwieser, GE				Huang, Ying; Breitwieser, Gerda E.			Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; EXTRACELLULAR CA2+-SENSING RECEPTOR; METABOTROPIC GLUTAMATE RECEPTORS; N-LINKED GLYCOSYLATION; HUMAN CA2+ RECEPTOR; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; SECONDARY HYPERPARATHYROIDISM; PHARMACOLOGICAL CHAPERONES; AMINOGLYCOSIDE ANTIBIOTICS	The calcium-sensing receptor (CaR), a member of G protein-coupled receptor family C, regulates systemic calcium homeostasis by activating G(q)- and G(i)-linked signaling in the parathyroid, kidney, and intestine. CaR is ubiquitinated by the E3 ligase dorfin and degraded via the endoplasmic reticulum-associated degradation pathway (Huang, Y., Niwa, J., Sobue, G., and Breitwieser, G. E. (2006) J. BioL Chem. 281,11610 -11617). Here we provide evidence for a conformational or functional checkpoint in CaR biogenesis using two complementary approaches. First we characterized the sensitivity of loss- or gain-of-function CaR mutants to proteasome inhibition by MG132. The stabilization of loss-of-function mutants and insensitivity of gain-of-function mutants to MG132 suggests that receptor sensitivity to calcium influences susceptibility to proteasomal degradation. Second, we used the allosteric activator NPS R-568 and antagonist NPS 2143 to promote the active and inactive conformations of wild type CaR, respectively. Overnight culture in NPS R-568 increased expression of CaR, whereas NPS 2143 had the opposite effect. NPS R-568 and NPS 2143 differentially regulated maturation and cell surface expression of wild type CaR, directly affecting maximal signaling responses. NPS R-568 rescued expression of loss-of-function CaR mutants, increasing plasma membrane expression and ERK1/2 phosphorylation in response to 5 mM Ca2+. Disorders of calcium homeostasis caused by CaR mutations may therefore result from altered receptor biogenesis independent of receptor function, i.e. a protein folding disorder. The allosteric modulators NPS R-568 and NPS 2143 not only alter CaR sensitivity to calcium and hence signaling but also modulate receptor expression.	Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA; Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	Geisinger Medical Center; Syracuse University	Breitwieser, GE (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	gebreitwieser@geisinger.edu		Breitwieser, Gerda/0000-0001-9081-0362	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077563] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM077563] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai M, 1997, J CLIN INVEST, V99, P88, DOI 10.1172/JCI119137; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Baron J, 1996, HUM MOL GENET, V5, P601, DOI 10.1093/hmg/5.5.601; Breitwieser GE, 2004, CELL CALCIUM, V35, P209, DOI 10.1016/j.ceca.2003.10.013; Chakravarthi S, 2006, EMBO REP, V7, P271, DOI 10.1038/sj.embor.7400645; Chattopadhyay N, 2006, MOL GENET METAB, V89, P189, DOI 10.1016/j.ymgme.2006.07.003; Dupre DJ, 2006, J BIOL CHEM, V281, P34561, DOI 10.1074/jbc.M605012200; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; Hebert SC, 2006, ANNU REV MED, V57, P349, DOI 10.1146/annurev.med.57.121304.131328; Holstein DM, 2004, J BIOL CHEM, V279, P10060, DOI 10.1074/jbc.M312039200; Hu JX, 2005, J BIOL CHEM, V280, P5113, DOI 10.1074/jbc.M413403200; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Huang Y, 2006, J BIOL CHEM, V281, P11610, DOI 10.1074/jbc.M513552200; Jong YJI, 2005, J BIOL CHEM, V280, P30469, DOI 10.1074/jbc.M501775200; KATZ CL, 1992, ENDOCRINOLOGY, V131, P903, DOI 10.1210/en.131.2.903; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512; Mah SJ, 2005, J NEUROSCI, V25, P2215, DOI 10.1523/JNEUROSCI.4573-04.2005; McLarnon SJ, 2002, BIOCHEM BIOPH RES CO, V297, P71, DOI 10.1016/S0006-291X(02)02133-2; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Miedlich S, 2002, J BIOL CHEM, V277, P49691, DOI 10.1074/jbc.M205578200; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Mizobuchi M, 2004, J AM SOC NEPHROL, V15, P2579, DOI 10.1097/01.ASN.0000141016.20133.33; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nagano N, 2006, PHARMACOL THERAPEUT, V109, P339, DOI 10.1016/j.pharmthera.2005.06.019; Nemeth EF, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290015; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pidasheva S, 2006, HUM MOL GENET, V15, P2200, DOI 10.1093/hmg/ddl145; Ramasamy I, 2006, CLIN CHEM LAB MED, V44, P237, DOI 10.1515/CCLM.2006.046; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Sato K, 2002, J CLIN ENDOCR METAB, V87, P3068, DOI 10.1210/jc.87.7.3068; Tfelt-Hansen J, 2005, CRIT REV CL LAB SCI, V42, P35, DOI 10.1080/10408360590886606; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Wang MH, 2006, J BIOL CHEM, V281, P8864, DOI 10.1074/jbc.M512865200; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; Zhang ML, 2005, J BIOL CHEM, V280, P11140, DOI 10.1074/jbc.M412242200	45	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9517	9525		10.1074/jbc.M609045200	http://dx.doi.org/10.1074/jbc.M609045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284438	hybrid			2022-12-27	WOS:000245421700024
J	Kajino, T; Omori, E; Ishii, S; Matsumoto, K; Ninomiya-Tsuji, J				Kajino, Taisuke; Omori, Emily; Ishii, Shunsuke; Matsumoto, Kunihiro; Ninomiya-Tsuji, Jun			TAK1 MAPK kinase kinase mediates transforming growth factor-beta signaling by targeting SnoN oncoprotein for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; RECEPTOR; ACTIVATION; EXPRESSION; CELLS; SMAD3; GENE; SKI; TRANSDUCTION; PATHWAY	Transforming growth factor-beta (TGF-beta) regulates a variety of physiologic processes through essential intracellular mediators Smads. The SnoN oncoprotein is an inhibitor of TGF-beta signaling. SnoN recruits transcriptional repressor complex to block Smad-dependent transcriptional activation of TGF-beta-responsive genes. Following TGF-beta stimulation, SnoN is rapidly degraded, thereby allowing the activation of TGF-beta target genes. Here, we report the role of TAK1 as a SnoN protein kinase. TAK1 interacted with and phosphorylated SnoN, and this phosphorylation regulated the stability of SnoN. Inactivation of TAK1. prevented TGF-beta-induced SnoN degradation and impaired induction of the TGF-beta-responsive genes. These data suggest that TAK1 modulates TGF-beta-dependent cellular responses by targeting SnoN for degradation.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Biol Mol, Nagoya, Aichi 4648602, Japan; RIKEN, Tsukuba Inst, Genet Mol Lab, Ibaraki 3050074, Japan	University of North Carolina; North Carolina State University; Nagoya University; RIKEN	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478; Ninomiya-Tsuji, Jun/0000-0002-5584-0176	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812] Funding Source: NIH RePORTER; NIAMS NIH HHS [R21 AR050972-02, R21 AR050972, AR050972] Funding Source: Medline; NIGMS NIH HHS [R01 GM068812-04, R01 GM068812, GM068812] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Jadrich JL, 2006, DEVELOPMENT, V133, P1529, DOI 10.1242/dev.02333; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 2004, CURR OPIN GENET DEV, V14, P65, DOI 10.1016/j.gde.2003.11.003; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	28	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9475	9481		10.1074/jbc.M700875200	http://dx.doi.org/10.1074/jbc.M700875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276978	Green Accepted, hybrid			2022-12-27	WOS:000245421700020
J	Silva, RAGD; Schneeweis, LA; Krishnan, SC; Zhang, XQ; Axelsen, PH; Davidson, WS				Silva, R. A. Gangani D.; Schneeweis, Lumelle A.; Krishnan, Srinivasan C.; Zhang, Xiuqi; Axelsen, Paul H.; Davidson, W. Sean			The structure of apolipoprotein A-II in discoidal high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; ORGANIZATION; ASSOCIATION; PARTICLES	It is well accepted that high levels of high density lipoproteins (HDL) reduce the risk of atherosclerosis in humans. Apolipoprotein A-I (apoA-I) and apoA-II are the first and second most common protein constituents of HDL. Unlike apoA-I, detailed structural models for apoA-II in HDL are not available. Here, we present a structural model of apoA-II in reconstituted HDL (rHDL) based on two well established experimental approaches: chemical cross-linking/mass spectrometry (MS) and internal reflection infrared spectroscopy. Homogeneous apoA-II rHDL were reacted with a cross-linking agent to link proximal lysine residues. Upon trypitic digestion, cross-linked peptides were identified by electrospray mass spectrometry. 14 cross-links were identified and confirmed by tandem mass spectrometry (MS/MS). Infrared spectroscopy indicated a beltlike molecular arrangement for apoA-II in which the protein helices wrap around the lipid bilayer rHDL disc. The cross-links were then evaluated on three potential belt arrangements. The data clearly refute a parallel model but support two antiparallel models, especially a "double hairpin" form. These models form the basis for understanding apoA-II structure in more complex HDL particles.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Mass Spectrometry Applicat Lab, Framingham, MA 01701 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University System of Ohio; University of Cincinnati; University of Pennsylvania; University of Pennsylvania; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 2120 Galbraith Rd, Cincinnati, OH 45237 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067093, R01HL068186] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL67093, R01-HL68186] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allayee H, 2003, CIRC RES, V92, P1262, DOI 10.1161/01.RES.0000075600.87675.16; Axelsen PH, 1996, PROG BIOPHYS MOL BIO, V66, P227, DOI 10.1016/S0079-6107(97)00007-2; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; Boucher J, 2004, J LIPID RES, V45, P849, DOI 10.1194/jlr.M300431-JLR200; Castellani LW, 1997, J CLIN INVEST, V100, P464, DOI 10.1172/JCI119554; Clay MA, 2000, J BIOL CHEM, V275, P9019, DOI 10.1074/jbc.275.12.9019; Davidson WS, 2005, CURR OPIN LIPIDOL, V16, P295, DOI 10.1097/01.mol.0000169349.38321.ad; Davidson WS, 2003, J BIOL CHEM, V278, P27199, DOI 10.1074/jbc.M302764200; DECOEN JL, 1988, P NATL ACAD SCI USA, V85, P5669; Durbin DM, 1997, J BIOL CHEM, V272, P31333, DOI 10.1074/jbc.272.50.31333; Escola-Gil JC, 1998, J LIPID RES, V39, P457; Gillard BK, 2005, BIOCHEMISTRY-US, V44, P471, DOI 10.1021/bi048591j; Hedrick CC, 2001, J LIPID RES, V42, P563; Hime NJ, 2006, J LIPID RES, V47, P115, DOI 10.1194/jlr.M500284-JLR200; Jahangiri A, 2005, J LIPID RES, V46, P896, DOI 10.1194/jlr.M400212-JLR200; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Koppaka V, 2001, CELL MOL LIFE SCI, V58, P885, DOI 10.1007/PL00000908; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Kumar MS, 2002, BIOCHEMISTRY-US, V41, P11681, DOI 10.1021/bi026069w; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; Maiorano JN, 2004, BIOCHEMISTRY-US, V43, P11717, DOI 10.1021/bi0496642; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASSEY JB, 1989, BIOCHIM BIOPHYS ACTA, V999, P121, DOI 10.1016/0167-4838(89)90208-2; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Pliszka B, 2001, BIOCHEM BIOPH RES CO, V281, P924, DOI 10.1006/bbrc.2001.4454; Schneeweis LA, 2005, BIOCHEMISTRY-US, V44, P12525, DOI 10.1021/bi050872j; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P8600, DOI 10.1021/bi050421z; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+; SPARKS DL, 1992, J LIPID RES, V33, P123; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912	33	27	27	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9713	9721		10.1074/jbc.M610380200	http://dx.doi.org/10.1074/jbc.M610380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17264082	hybrid			2022-12-27	WOS:000245421700045
J	Sun, Y; Breydo, L; Makarava, N; Yang, QY; Bocharova, OV; Baskakov, IV				Sun, Ying; Breydo, Leonid; Makarava, Natallia; Yang, Qingyuan; Bocharova, Olga V.; Baskakov, Ilia V.			Site-specific conformational studies of prion protein (PrP) amyloid fibrils revealed two cooperative folding domains within amyloid structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO CONVERSION; SYNTHETIC PRIONS; SCRAPIE PRIONS; M-VALUES; STRAIN; THERMODYNAMICS; DENATURATION; STABILITY; DISEASE; POLYMORPHISM	Despite the ability of most proteins to form amyloid, very little is know about amyloid fibril structures and the factors that govern their stability. Using amyloid fibrils produced from full-length prion protein (PrP), we describe a reliable approach for determining both site-specific and global conformational stability of the fibrillar form. To measure site-specific stability, we produced six variants of PrP by replacing the residues at positions 88, 98, 127, 144, 196, and 230 with cysteine, labeled the new cysteines with the fluorescent dye acrylodan, and investigated their conformational status within the amyloid form in guanidine hydrochloride-induced denaturation experiments. We found that the fibrils labeled at positions 127, 144, 196, and 230 displayed cooperative unfolding and showed a very high C-1/2 value similar to that observed for the global unfolding of the amyloid structure. The unfolding at residue 98 was also cooperative; however, it showed a C-1/2 value substantially lower than that of global unfolding, whereas the unfolding of fibrils labeled at residue 88 was non-cooperative. These data illustrate that there are at least two independent cooperative folding domains within the amyloid structure of the full-length PrP. In addition, kinetic experiments revealed only a partial overlap between the region that constituted the fibrillar cross-beta core and the regions that were involved in nucleation. This result illustrates that separate PrP regions accounted for the nucleation and for the formation of the conformationally most stable fibrillar core.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Baskakov, IV (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu	Breydo, Leo/AAJ-7996-2020; Bocharova, Olga V./J-8284-2018; Breydo, Leonid/E-6119-2010	Bocharova, Olga V./0000-0002-5056-1506; Breydo, Leonid/0000-0003-4666-2301				Anderson M, 2006, J MOL BIOL, V358, P580, DOI 10.1016/j.jmb.2006.02.007; Baskakov IV, 2005, BIOCHEMISTRY-US, V44, P2339, DOI 10.1021/bi048322t; Baskakov IV, 2004, PROTEIN SCI, V13, P586, DOI 10.1110/ps.03457204; Baskakov IV, 1998, BIOCHEMISTRY-US, V37, P18010, DOI 10.1021/bi981849j; BASKAKOV IV, 2007, IN PRESS BIOCH BIOPH; Bocharova OV, 2006, J BIOL CHEM, V281, P2373, DOI 10.1074/jbc.M510840200; Bocharova OV, 2005, BIOCHEMISTRY-US, V44, P6776, DOI 10.1021/bi050251q; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Breydo L, 2005, BIOCHEMISTRY-US, V44, P15534, DOI 10.1021/bi051369+; Breydo L, 2007, BIOCHEMISTRY-US, V46, P852, DOI 10.1021/bi061923v; Carra JH, 1996, FASEB J, V10, P67, DOI 10.1096/fasebj.10.1.8566550; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Dima RI, 2004, P NATL ACAD SCI USA, V101, P15335, DOI 10.1073/pnas.0404235101; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Englander SW, 1997, PROTEIN SCI, V6, P1101, DOI 10.1002/pro.5560060517; Ferreon ACM, 2004, BIOCHEMISTRY-US, V43, P13357, DOI 10.1021/bi048666j; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; Haire LF, 2004, J MOL BIOL, V336, P1175, DOI 10.1016/j.jmb.2003.12.059; Hosszu LLP, 2005, BIOCHEMISTRY-US, V44, P16649, DOI 10.1021/bi051277k; Iconomidou VA, 2000, FEBS LETT, V479, P141, DOI 10.1016/S0014-5793(00)01888-3; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Legname G, 2005, P NATL ACAD SCI USA, V102, P2168, DOI 10.1073/pnas.0409079102; Legname G, 2006, P NATL ACAD SCI USA, V103, P19105, DOI 10.1073/pnas.0608970103; Leliveld SR, 2006, J BIOL CHEM, V281, P3268, DOI 10.1074/jbc.M510606200; Moore RA, 2006, PROTEIN SCI, V15, P609, DOI 10.1110/ps.051822606; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Narimoto T, 2004, FEBS LETT, V576, P313, DOI 10.1016/j.febslet.2004.09.024; Novitskaya V, 2006, J BIOL CHEM, V281, P15536, DOI 10.1074/jbc.M601349200; O'Nuallain B, 2005, BIOCHEMISTRY-US, V44, P12709, DOI 10.1021/bi050927h; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Podrabsky JE, 2001, AM J PHYSIOL-REG I, V280, pR123, DOI 10.1152/ajpregu.2001.280.1.R123; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Williams AD, 2006, J MOL BIOL, V357, P1283, DOI 10.1016/j.jmb.2006.01.041; Ziegler J, 2003, J BIOL CHEM, V278, P50175, DOI 10.1074/jbc.M305234200	49	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9090	9097		10.1074/jbc.M608623200	http://dx.doi.org/10.1074/jbc.M608623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244617	hybrid			2022-12-27	WOS:000245780300056
J	von Holst, A; Egbers, U; Prochiantz, A; Faissner, A				von Holst, Alexander; Egbers, Ursula; Prochiantz, Alain; Faissner, Andreas			Neural stem/progenitor cells express 20 Tenascin C isoforms that are differentially regulated by Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGODENDROCYTE PRECURSOR CELLS; ALTERNATIVELY SPLICED REGION; NGF-DEPENDENT SURVIVAL; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; NEURITE OUTGROWTH; GENE-EXPRESSION; SYMPATHETIC NEURONS; TRKA EXPRESSION; MOUSE TENASCIN	Tenascin C (Tnc) is an alternatively spliced, multimodular extracellular matrix glycoprotein present in the ventricular zone of the developing brain. Pax6-deficient small eye (sey) mouse mutants show an altered Tnc expression pattern. Here, we investigated the expression of Tnc isoforms in neural stem/progenitor cells and their regulation by the paired-box transcription factor Pax6. Neural stem/progenitor cells cultured as neurospheres strongly expressed Tnc on the protein level. The Tnc isoform expression in neural stem/progenitor cells was analyzed by reverse transcriptase-PCR and dot blot Southern hybridization: In total, 20 different Tnc isoforms were detected in neurospheres derived from embryonic forebrain cell suspensions. The Tnc isoform containing the fibronectin type III domains A1A4BD is novel and might be neural stem/progenitor cell-specific. Transient overexpression of Pax6 in neurospheres of the medial ganglionic eminence did not alter the total Tnc mRNA expression level but showed a pronounced regulative effect on different Tnc isoforms. The larger Tnc isoforms containing four, five, and six additional alternatively spliced fibronectin type III domains were up-regulated, whereas the small Tnc isoforms without any or with one additional domain were down-regulated. Thus, Pax6 is a homeodomain protein that also modulates the splicing machinery. We conclude that the combinatorial code of Tnc isoform expression in the neural stem/progenitor cell is complex and regulated by Pax6. These findings suggest a functional significance for individual Tnc isoforms in neural stem/progenitor cells.	Ruhr Univ Bochum, Dept Cell Morphol & Mol Neurobiol, D-44780 Bochum, Germany; Ecole Normale Super, CNRS UMR 8542, F-75005 Paris, France	Ruhr University Bochum; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	von Holst, A (corresponding author), Univ Str 150,NDEF 05-339, D-44780 Bochum, Germany.	Alexander.vonHolst@ruhr-uni-bochum.de; Andreas.Faissner@ruhr-uni-bochum.de	Faissner, Andreas/A-5314-2008; von Holst, Alexander/I-3061-2014	Faissner, Andreas/0000-0002-2211-8259; 				Ba-Charvet KTN, 1998, DEVELOPMENT, V125, P4273; Bard JBL, 1998, MECH DEVELOP, V74, P111, DOI 10.1016/S0925-4773(98)00069-0; BARTSCH S, 1992, J NEUROSCI, V12, P736; Campos LS, 2004, DEVELOPMENT, V131, P3433, DOI 10.1242/dev.01199; Carnemolla B, 1999, AM J PATHOL, V154, P1345, DOI 10.1016/S0002-9440(10)65388-6; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Copertino DW, 1997, P NATL ACAD SCI USA, V94, P1846, DOI 10.1073/pnas.94.5.1846; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Dirks PB, 2006, NATURE, V444, P687, DOI 10.1038/444687a; DORRIES U, 1994, J NEUROSCI RES, V37, P336, DOI 10.1002/jnr.490370306; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Garcion E, 2001, DEVELOPMENT, V128, P2485; Garwood J, 2004, EUR J NEUROSCI, V20, P2524, DOI 10.1111/j.1460-9568.2004.03727.x; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; GELLER HM, 1988, J CELL BIOL, V107, P1977, DOI 10.1083/jcb.107.5.1977; Gherzi R, 1997, DNA CELL BIOL, V16, P559, DOI 10.1089/dna.1997.16.559; Gotz M, 1998, NEURON, V21, P1031, DOI 10.1016/S0896-6273(00)80621-2; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Gotz M, 1997, EUR J NEUROSCI, V9, P496, DOI 10.1111/j.1460-9568.1997.tb01627.x; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Hack MA, 2005, NAT NEUROSCI, V8, P865, DOI 10.1038/nn1479; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; Haubst N, 2004, DEVELOPMENT, V131, P6131, DOI 10.1242/dev.01524; Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828; Hu JG, 2004, J NEUROSCI RES, V78, P637, DOI 10.1002/jnr.20317; Joester A, 2001, MATRIX BIOL, V20, P13, DOI 10.1016/S0945-053X(00)00136-0; Joester A, 1999, J BIOL CHEM, V274, P17144, DOI 10.1074/jbc.274.24.17144; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; KAPLONY A, 1991, DEVELOPMENT, V112, P605; Leone DP, 2005, J CELL SCI, V118, P2589, DOI 10.1242/jcs.02396; Meiners S, 2001, J NEUROSCI, V21, P7215, DOI 10.1523/JNEUROSCI.21-18-07215.2001; Mercado MLT, 2004, J NEUROSCI, V24, P238, DOI 10.1523/JNEUROSCI.4519-03.2004; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rigato F, 2002, J NEUROSCI, V22, P6596; Stoykova A, 2000, J NEUROSCI, V20, P8042; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; TUCKER RP, 1993, DEVELOPMENT, V117, P347; von Holst A, 2006, J NEUROSCI, V26, P4082, DOI 10.1523/JNEUROSCI.0422-06.2006; VONHOLST A, 1995, MOL CELL NEUROSCI, V6, P185; vonHolst A, 1997, EUR J NEUROSCI, V9, P2169; Wain HM, 2002, NUCLEIC ACIDS RES, V30, P169, DOI 10.1093/nar/30.1.169; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; Yuasa S, 2001, ARCH HISTOL CYTOL, V64, P119, DOI 10.1679/aohc.64.119	48	70	71	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9172	9181		10.1074/jbc.M608067200	http://dx.doi.org/10.1074/jbc.M608067200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264084	hybrid			2022-12-27	WOS:000245780300064
J	de Oliveira, SK; Hoffmeister, M; Gambaryan, S; Muller-Esterl, W; Guimaraes, JA; Smolenski, AP				de Oliveira, Simone Kobe; Hoffmeister, Meike; Gambaryan, Stepan; Mueller-Esterl, Werner; Guimaraes, Jorge A.; Smolenski, Albert P.			Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; PROTEIN; CAMP; CGMP; BINDING; TRANSACTIVATION; ACTIVATION; DETERMINANTS; LOCALIZATION; MECHANISMS	Phosphodiesterase type 2A (PDE2A) hydrolyzes cyclic nucleotides cAMP and cGMP, thus efficiently controlling cAMP-dependent signaling pathways. PDE2A is composed of an amino-terminal region, two regulatory GAF domains, and a catalytic domain. Cyclic nucleotide hydrolysis is known to be activated by cGMP binding to GAF-B; however, other mechanisms may operate to fine-tune local cyclic nucleotide levels. In a yeast two-hybrid screening we identified XAP2, a crucial component of the aryl hydrocarbon receptor (AhR) complex, as a major PDE2A-interacting protein. We mapped the XAP2 binding site to the GAF-B domain of PDE2A. PDE assays with purified proteins showed that XAP2 binding does not change the enzymatic activity of PDE2A. To analyze whether PDE2A could affect the function of XAP2, we studied nuclear translocation of AhR, i.e. the master transcription factor controlling the expression of multiple detoxification genes. Notably, regulation of AhR target gene expression is initiated by tetrachlorodibenzodioxin (TCDD) binding to AhR and by a poorly understood cAMP-dependent pathway followed by the translocation of AhR from the cytosol into the nucleus. Binding of PDE2A to XAP2 inhibited TCDD- and cAMP-induced nuclear translocation of AhR in Hepa1c1c7 hepatocytes. Furthermore, PDE2A attenuated TCDD- induced transcription in reporter gene assays. We conclude that XAP2 targets PDE2A to the AhR complex, thereby restricting AhR mobility, possibly by a local reduction of cAMP levels. Our results provide first insights into the elusive cAMP-dependent regulation of AhR.	Univ Frankfurt Klinikum, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Fed Rio Grande do Sul, Ctr Biotechnol, BR-91501970 Porto Alegre, RS, Brazil; Univ Wurzburg, Ins Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Russian Acad Sci, Sechenov Inst Evolut Physiol & Biochem, St Petersburg 194223, Russia	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Universidade Federal do Rio Grande do Sul; University of Wurzburg; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry	Smolenski, AP (corresponding author), Univ Frankfurt Klinikum, Sch Med, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	smolenski@biochem2.de	Gambaryan, Stepan/I-3940-2016	Gambaryan, Stepan/0000-0002-1470-0791; Guimaraes, Jorge A./0000-0001-6354-6789; Smolenski, Albert/0000-0001-9210-9406				Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; Bentley JK, 2001, J NEUROCHEM, V76, P1252, DOI 10.1046/j.1471-4159.2001.00133.x; Bock KW, 2006, BIOCHEM PHARMACOL, V72, P393, DOI 10.1016/j.bcp.2006.01.017; Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Froidevaux MSC, 2006, EMBO REP, V7, P1035, DOI 10.1038/sj.embor.7400778; Fujii-Kuriyama Y, 2005, BIOCHEM BIOPH RES CO, V338, P311, DOI 10.1016/j.bbrc.2005.08.162; Gross-Langenhoff M, 2006, J BIOL CHEM, V281, P2841, DOI 10.1074/jbc.M511468200; Harper PA, 2006, BIOCHEM PHARMACOL, V72, P267, DOI 10.1016/j.bcp.2006.01.007; Iffland A, 2005, BIOCHEMISTRY-US, V44, P8312, DOI 10.1021/bi047313h; Kashuba EV, 2006, J BIOL CHEM, V281, P1215, DOI 10.1074/jbc.M509036200; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Ma Q, 1997, J BIOL CHEM, V272, P8878; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Meurer S, 2005, J BIOL CHEM, V280, P33149, DOI 10.1074/jbc.M507565200; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Mongillo M, 2006, CIRC RES, V98, P226, DOI 10.1161/01.RES.0000200178.34179.93; Oesch-Bartlomowicz B, 2005, P NATL ACAD SCI USA, V102, P9218, DOI 10.1073/pnas.0503488102; Petrulis JR, 2003, J BIOL CHEM, V278, P2677, DOI 10.1074/jbc.M209331200; Ramadoss P, 2005, BIOCHEMISTRY-US, V44, P11148, DOI 10.1021/bi050948b; Ramadoss Preeti, 2005, Expert Opin Drug Metab Toxicol, V1, P9, DOI 10.1517/17425255.1.1.9; Rosman GJ, 1997, GENE, V191, P89, DOI 10.1016/S0378-1119(97)00046-2; Schultess J, 2005, BLOOD, V105, P3185, DOI 10.1182/blood-2004-09-3605; Seybold J, 2005, BLOOD, V105, P3569, DOI 10.1182/blood-2004-07-2729; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Vierimaa O, 2006, SCIENCE, V312, P1228, DOI 10.1126/science.1126100; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; Zaccolo M, 2006, BIOCHEM SOC T, V34, P495, DOI 10.1042/BST0340495	34	83	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13656	13663		10.1074/jbc.M610942200	http://dx.doi.org/10.1074/jbc.M610942200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17329248	Green Submitted, hybrid			2022-12-27	WOS:000246060300055
J	Berndt, A; Kottke, T; Breitkreuz, H; Dvorsky, R; Hennig, S; Alexander, M; Wolf, E				Berndt, Alex; Kottke, Tilman; Breitkreuz, Helena; Dvorsky, Radovan; Hennig, Sven; Alexander, Michael; Wolf, Eva			A novel photoreaction mechanism for the circadian blue light photoreceptor Drosophila cryptochrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; INDUCED ELECTRON-TRANSFER; ESCHERICHIA-COLI; ARABIDOPSIS CRYPTOCHROME-1; CRYSTAL-STRUCTURE; CHOLINE OXIDASE; FLAVIN RADICALS; ACTION SPECTRUM; CLOCK PROTEIN; PHASE-SHIFTS	Cryptochromes are flavoproteins that are evolutionary related to the DNA photolyases but lack DNA repair activity. Drosophila cryptochrome (dCRY) is a blue light photoreceptor that is involved in the synchronization of the circadian clock with the environmental light-dark cycle. Until now, spectroscopic and structural studies on this and other animal cryptochromes have largely been hampered by difficulties in their recombinant expression. We have therefore established an expression and purification scheme that enables us to purify mg amounts of monomeric dCRY from Sf21 insect cell cultures. Using UV-visible spectroscopy, mass spectrometry, and reversed phase high pressure liquid chromatography, we show that insect cell-purified dCRY contains flavin adenine dinucleotide in its oxidized state (FAD(ox)) and residual amounts of methenyltetrahydrofolate. Upon blue light irradiation, dCRY undergoes a reversible absorption change, which is assigned to the conversion of FAD(ox) to the red anionic FAD(-.) radical. Our findings lead us to propose a novel photoreaction mechanism for dCRY, in which FAD(ox) corresponds to the ground state, whereas the FAD(-.) radical represents the light-activated state that mediates resetting of the Drosophila circadian clock.	Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany; Res Ctr Julich, IBI 2, D-52425 Julich, Germany; Univ Bielefeld, Dept Chem, D-33615 Bielefeld, Germany	Max Planck Society; Helmholtz Association; Research Center Julich; University of Bielefeld	Wolf, E (corresponding author), Max Planck Inst Mol Physiol, Dept Biol Struct, Otto Hahn Str 11, D-44227 Dortmund, Germany.	eva.wolf@mpi-dortmund.mpg.de	Dvorsky, Radovan/ABE-3042-2020; Hennig, Sven/GYU-3381-2022; Kottke, Tilman/B-7102-2011; Wolf, Eva/G-7340-2014	Kottke, Tilman/0000-0001-8080-9579; Hennig, Sven/0000-0002-8297-6845				Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Busza A, 2004, SCIENCE, V304, P1503, DOI 10.1126/science.1096973; Cashmore AR, 2003, CELL, V114, P537, DOI 10.1016/j.cell.2003.08.004; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FRANK KD, 1969, SCIENCE, V163, P688, DOI 10.1126/science.163.3868.688; Froy O, 2002, CURR BIOL, V12, P147, DOI 10.1016/S0960-9822(01)00656-X; Ghanem M, 2006, BIOCHEMISTRY-US, V45, P3437, DOI 10.1021/bi052514m; Ghanem M, 2003, BIOCHEMISTRY-US, V42, P15179, DOI 10.1021/bi035435o; Giovani B, 2003, NAT STRUCT BIOL, V10, P489, DOI 10.1038/nsb933; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; Huang YH, 2006, P NATL ACAD SCI USA, V103, P17701, DOI 10.1073/pnas.0608554103; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Jung A, 2005, P NATL ACAD SCI USA, V102, P12350, DOI 10.1073/pnas.0500722102; Kottke T, 2006, BIOCHEMISTRY-US, V45, P2472, DOI 10.1021/bi051964b; Lin CT, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-5-220; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; MALHOTRA K, 1994, BIOCHEMISTRY-US, V33, P8712, DOI 10.1021/bi00195a012; MASSEY V, 1964, FED PROC, V23, P18; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MEDINA M, 1994, EUR J BIOCHEM, V222, P941, DOI 10.1111/j.1432-1033.1994.tb18943.x; MULLER F, 1987, FREE RADICAL BIO MED, V3, P215, DOI 10.1016/0891-5849(87)90009-8; MULLER F, 1972, EUR J BIOCHEM, V25, P573, DOI 10.1111/j.1432-1033.1972.tb01730.x; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Okano S, 1999, PHOTOCHEM PHOTOBIOL, V69, P108; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Partch CL, 2005, PHOTOCHEM PHOTOBIOL, V81, P1291, DOI 10.1562/2005-07-08-IR-607; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Sang Y, 2005, PLANT CELL, V17, P1569, DOI 10.1105/tpc.104.029645; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; Song SH, 2006, J PHOTOCH PHOTOBIO B, V85, P1, DOI 10.1016/j.jphotobiol.2006.03.007; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sullivan JA, 2003, DEV BIOL, V260, P289, DOI 10.1016/S0012-1606(03)00212-4; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; UYEDA K, 1963, ANAL BIOCHEM, V6, P100, DOI 10.1016/0003-2697(63)90012-5; Wagner MA, 2000, BIOCHEMISTRY-US, V39, P8813, DOI 10.1021/bi000349z; Worthington EN, 2003, J BIOL CHEM, V278, P39143, DOI 10.1074/jbc.M305792200; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zeugner A, 2005, J BIOL CHEM, V280, P19437, DOI 10.1074/jbc.C500077200; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580; Zhu HS, 2005, CURR BIOL, V15, pR953, DOI 10.1016/j.cub.2005.11.030	52	156	159	4	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13011	13021		10.1074/jbc.M608872200	http://dx.doi.org/10.1074/jbc.M608872200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17298948	hybrid			2022-12-27	WOS:000245942800071
J	Ekberg, J; Schuetz, F; Boase, NA; Conroy, SJ; Manning, J; Kumar, S; Poronnik, P; Adams, DJ				Ekberg, Jenny; Schuetz, Friderike; Boase, Natasha A.; Conroy, Sarah-Jane; Manning, Jantina; Kumar, Sharad; Poronnik, Philip; Adams, David J.			Regulation of the voltage-gated K+ channels KCNQ2/3 and KCNQ3/5 by ubiquitination - Novel role for Nedd4-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DETERMINANTS; POTASSIUM CHANNELS; LIGASE NEDD4-2; ION CHANNELS; PROTEIN; BRAIN; SUPPRESSION; PHYSIOLOGY; EXPRESSION; INTERACTS	The muscarine-sensitive K+ current (M-current) stabilizes the resting membrane potential in neurons, thus limiting neuronal excitability. The M-current is mediated by heteromeric channels consisting of KCNQ3 subunits in association with either KCNQ2 or KCNQ5 subunits. The role of KCNQ2/3/5 in the regulation of neuronal excitability is well established; however, little is known about the mechanisms that regulate the cell surface expression of these channels. Ubiquitination by the Nedd4/Nedd4-2 ubiquitin ligases is known to regulate a number of membrane ion channels and transporters. In this study, we investigated whether Nedd4/Nedd4-2 could regulate KCNQ2/3/5 channels. We found that the amplitude of the K+ currents mediated by KCNQ2/3 and KCNQ3/5 were reduced by Nedd4-2 (but not Nedd4) in a Xenopus oocyte expression system. Deletion experiments showed that the C-terminal region of the KCNQ3 subunit is required for the Nedd4-2-mediated regulation of the heteromeric channels. Glutathione S-transferase fusion pulldowns and co-immunoprecipitations demonstrated a direct interaction between KCNQ2/3 and Nedd4-2. Furthermore, Nedd4-2 could ubiquitinate KCNQ2/3 in transfected cells. Taken together, these data suggest that Nedd4-2 is potentially an important regulator of M-current activity in the nervous system.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia	University of Queensland; Hanson Institute; Institute Medical & Veterinary Science Australia	Poronnik, P (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	p.poronnik@uq.edu.au; dadams@uq.edu.au	Ekberg, Jenny/AAV-2006-2020; Adams, David John/K-3578-2019; Manning, Jantina/AAP-3810-2020; Adams, David/J-9125-2014; Kumar, Sharad/AAX-7787-2020	Adams, David John/0000-0002-7030-2288; Manning, Jantina/0000-0001-9142-6135; Adams, David/0000-0002-7030-2288; Kumar, Sharad/0000-0001-7126-9814; Ekberg, Jenny/0000-0001-5151-4966; Poronnik, Philip/0000-0002-6246-528X				Abriel H, 2005, PHYSIOLOGY, V20, P398, DOI 10.1152/physiol.00033.2005; Blackburn-Munro G, 2003, EUR J PHARMACOL, V460, P109, DOI 10.1016/S0014-2999(02)02924-2; Boehmer C, 2006, J NEUROCHEM, V97, P911, DOI 10.1111/j.1471-4159.2006.03629.x; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; Calabresi P, 2003, ANN NEUROL, V53, P693, DOI 10.1002/ana.10603; Delmas P, 2005, NAT REV NEUROSCI, V6, P850, DOI 10.1038/nrn1785; DIBBENS LM, 2007, IN PRESS GENES BRAIN; Etxeberria A, 2004, J NEUROSCI, V24, P9146, DOI 10.1523/JNEUROSCI.3194-04.2004; Fotia AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gordon E, 2006, BIOPHYS J, V90, P1223, DOI 10.1529/biophysj.105.072504; Gribkoff VK, 2005, EXPERT OPIN INV DRUG, V14, P579, DOI 10.1517/13543784.14.5.579; Gutman GA, 2003, PHARMACOL REV, V55, P583, DOI 10.1124/pr.55.4.9; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Hettema EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137; Hryciw DH, 2004, J BIOL CHEM, V279, P54996, DOI 10.1074/jbc.M411491200; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Keleman K, 2005, NAT NEUROSCI, V8, P156, DOI 10.1038/nn1388; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1994, J BIOL CHEM, V269, P11318; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Layfield R, 2001, NEUROPATH APPL NEURO, V27, P171, DOI 10.1046/j.1365-2990.2001.00335.x; Lerche H, 2001, AM J MED GENET, V106, P146, DOI 10.1002/ajmg.1582; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Palmada M, 2004, BIOCHEM BIOPH RES CO, V321, P1001, DOI 10.1016/j.bbrc.2004.07.064; Passmore GM, 2003, J NEUROSCI, V23, P7227, DOI 10.1523/JNEUROSCI.23-18-07227.2003; Peters HC, 2005, NAT NEUROSCI, V8, P51, DOI 10.1038/nn1375; Robbins J, 2001, PHARMACOL THERAPEUT, V90, P1, DOI 10.1016/S0163-7258(01)00116-4; Roche JP, 2002, BRIT J PHARMACOL, V137, P1173, DOI 10.1038/sj.bjp.0704989; Schroeder BC, 2000, J BIOL CHEM, V275, P24089, DOI 10.1074/jbc.M003245200; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Schwake M, 2006, J NEUROSCI, V26, P3757, DOI 10.1523/JNEUROSCI.5017-05.2006; Schwake M, 2003, EMBO REP, V4, P76, DOI 10.1038/sj.embor.embor715; Shearwin-Whyatt L, 2006, BIOESSAYS, V28, P617, DOI 10.1002/bies.20422; Sorkina T, 2006, J NEUROSCI, V26, P8195, DOI 10.1523/JNEUROSCI.1301-06.2006; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Yi JJ, 2005, NEURON, V47, P629, DOI 10.1016/j.neuron.2005.07.008; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200	49	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12135	12142		10.1074/jbc.M609385200	http://dx.doi.org/10.1074/jbc.M609385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322297	hybrid, Green Published			2022-12-27	WOS:000245941900056
J	Xie, HQ; Choi, RCY; Leung, KW; Siow, NL; Kong, LW; Lau, FTC; Peng, HB; Tsim, KWK				Xie, Heidi Q.; Choi, Roy C. Y.; Leung, K. Wing; Siow, Nina L.; Kong, Ling W.; Lau, Faye T. C.; Peng, H. Benjamin; Tsim, Karl W. K.			Regulation of a transcript encoding the proline-rich membrane anchor of globular muscle acetylcholinesterase - The suppressive roles of myogenesis and innervating nerves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; FAST-TWITCH MUSCLE; CYCLIC-AMP; NEUROMUSCULAR-JUNCTION; CHICK MYOTUBES; COLLAGEN COLQ; T-PEPTIDE; EXPRESSION; SLOW; EXERCISE	The transcriptional regulation of proline-rich membrane anchor ( PRiMA), an anchoring protein of tetrameric globular form acetylcholinesterase ( G(4) AChE), was revealed in muscle during myogenic differentiation under the influence of innervation. During myotube formation of C2C12 cells, the expression of AChE(T) protein and the enzymatic activity were dramatically increased, but the level of G(4) AChE was relatively decreased. This G(4) AChE in C2C12 cells was specifically recognized by anti-PRiMA antibody, suggesting the association of this enzyme with PRiMA. Reverse transcription-PCR analysis revealed that the level of PRiMA mRNA was reduced during the myogenic differentiation of C2C12 cells. Overexpression of PRiMA in C2C12 myotubes significantly increased the production of G(4) AChE. The oligomerization of G(4) AChE, however, did not require the intracellular cytoplasmic tail of PRiMA. After overexpressing the muscle regulatory factors, myogenin and MyoD, the expressions of PRiMA and G(4) AChE in cultured myotubes were markedly reduced. In addition, calcitonin gene-related peptide, a known motor neuron-derived factor, and muscular activity were able to suppress PRiMA expression in muscle; the suppression was mediated by the phosphorylation of a cAMP-responsive element-binding protein. In accordance with the in vitro results, sciatic nerve denervation transiently increased the expression of PRiMA mRNA and decreased the phosphorylation of cAMP-responsive element-binding protein as well as its activator calcium/calmodulin-dependent protein kinase II in muscles. Our results suggest that the expression of PRiMA, as well as PRiMA-associated G(4) AChE, in muscle is suppressed by muscle regulatory factors, muscular activity, and nerve-derived trophic factor(s).	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay Rd, Hong Kong, Hong Kong, Peoples R China.	BOTSIM@UST.HK		Leung, Ka Wing/0000-0002-6137-3877; Tsim, Karl/0000-0003-4808-1674				Angus LM, 2001, J BIOL CHEM, V276, P17603, DOI 10.1074/jbc.M100916200; BACOU F, 1982, NATURE, V296, P661, DOI 10.1038/296661a0; Belbeoc'h S, 2003, EMBO J, V22, P3536, DOI 10.1093/emboj/cdg360; Boudreau-Lariviere C, 1999, FEBS LETT, V444, P22, DOI 10.1016/S0014-5793(99)00015-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choi RCY, 1998, J NEUROCHEM, V71, P152; Choi RCY, 2001, MOL CELL NEUROSCI, V17, P732, DOI 10.1006/mcne.2001.0968; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Dvir H, 2004, EMBO J, V23, P4394, DOI 10.1038/sj.emboj.7600425; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Falasca C, 2005, J BIOL CHEM, V280, P878, DOI 10.1074/jbc.M409201200; FERNANDEZ HL, 1994, NEUROCHEM RES, V19, P1369, DOI 10.1007/BF00972465; Fernandez HL, 1996, J APPL PHYSIOL, V80, P357, DOI 10.1152/jappl.1996.80.1.357; FERNANDEZ HL, 1988, J APPL PHYSIOL, V65, P2245, DOI 10.1152/jappl.1988.65.5.2245; GISIGER V, 1994, EUR J NEUROSCI, V6, P673, DOI 10.1111/j.1460-9568.1994.tb00979.x; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; HODGESSAVOLA CA, 1991, J NEUROCHEM, V56, P1423, DOI 10.1111/j.1471-4159.1991.tb11441.x; Inestrosa NC, 1998, J PHYSIOLOGY-PARIS, V92, P341, DOI 10.1016/S0928-4257(99)80002-3; JASMIN BJ, 1990, J NEUROSCI, V10, P1444; JENNINGS CGB, 1989, BRAIN RES, V504, P199, DOI 10.1016/0006-8993(89)91357-7; Krejci E, 1999, J NEUROSCI, V19, P10672, DOI 10.1523/JNEUROSCI.19-24-10672.1999; Lee HHC, 2004, J BIOL CHEM, V279, P27098, DOI 10.1074/jbc.M402596200; Liang D, 2003, NEUROSCIENCE, V121, P999, DOI 10.1016/S0306-4522(03)00483-4; Lu JT, 1999, MOL CELL NEUROSCI, V14, P99, DOI 10.1006/mcne.1999.0767; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; Massoulie J, 2005, CHEM-BIOL INTERACT, V157, P3, DOI 10.1016/j.cbi.2005.10.002; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; Perrier NA, 2003, EUR J NEUROSCI, V18, P1837, DOI 10.1046/j.1460-9568.2003.02914.x; Pick M, 2004, ANN NY ACAD SCI, V1018, P85, DOI 10.1196/annals.1296.010; Rossi SG, 2003, J BIOL CHEM, V278, P24994, DOI 10.1074/jbc.M211379200; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Tang HB, 2004, CELL SIGNAL, V16, P551, DOI 10.1016/j.cellsig.2003.09.006; Ting AKL, 2005, CHEM-BIOL INTERACT, V157, P63, DOI 10.1016/j.cbi.2005.10.009; Tsim KWK, 1997, J NEUROCHEM, V68, P479; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	40	48	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11765	11775		10.1074/jbc.M608265200	http://dx.doi.org/10.1074/jbc.M608265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324938	hybrid			2022-12-27	WOS:000245941900019
J	Baran, Y; Salas, A; Senkal, CE; Gunduz, U; Bielawski, J; Obeid, LM; Ogretmen, B				Baran, Yusuf; Salas, Arelis; Senkal, Can E.; Gunduz, Ufuk; Bielawski, Jacek; Obeid, Lina M.; Ogretmen, Besim			Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; LONGEVITY ASSURANCE GENE-1; HUMAN ACID CERAMIDASE; SPHINGOSINE 1-PHOSPHATE; TYROSINE KINASE; DIHYDROCERAMIDE SYNTHASE; FAMILY-MEMBERS; CANCER-THERAPY; HUMAN HEAD; PROTEIN	In this study, mechanisms of resistance to imatinib-induced apoptosis in human K562 cells were examined. Continuous exposure to stepwise increasing concentrations of imatinib resulted in the selection of K562/IMA-0.2 and -1 cells, which expressed similar to 2.3- and 19-fold resistance, respectively. Measurement of endogenous ceramides by high performance liquid chromatography/mass spectroscopy showed that treatment with imatinib increased the generation of ceramide, mainly C-18-ceramide, which is generated by the human longevity assurance gene 1 (hLASS1), in sensitive, but not in resistant cells. Inhibition of hLASS1 by small interfering RNA partially prevented imatinib-induced cell death in sensitive cells. In reciprocal experiments, overexpression of hLASS1, and not hLASS6, in drug-resistant cells caused a marked increase in imatinib-induced C-18-ceramide generation, and enhanced apoptosis. Interestingly, there were no defects in the levels of mRNA and enzyme activity levels of hLASS1 for ceramide generation in K562/IMA-1 cells. However, expression levels of sphingosine kinase-1 (SK1) and generation of sphingosine 1-phosphate (S1P) were increased significantly in K562/IMA-1 cells, channeling sphingoid bases to the sphingosine kinase pathway. The partial inhibition of SK1 expression by small interference RNA modulated S1P levels and increased sensitivity to imatinib-induced apoptosis in resistant cells. On the other hand, forced expression of SK1 in K562 cells increased the ratio between total S1P/C-18-ceramide levels similar to 6-fold and prevented apoptosis significantly in response to imatinib. Additional data indicated a role for SK1/S1P signaling in the up-regulation of the Bcr-Abl expression at the post-transcriptional level, which suggested a possible mechanism for resistance to imatinib-mediated apoptosis. In conclusion, these data suggest a role for endogenous C-18-ceramide synthesis mainly via hLASS1 in imatinib-induced apoptosis in sensitive cells, whereas in resistant cells, alterations of the balance between the levels of ceramide and S1P by overexpression of SK1 result in resistance to imatinib-induced apoptosis.	Med Univ S Carolina, Div Gen Internal Med, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Middle E Tech Univ, Dept Biol, TR-06531 Ankara, Turkey	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Middle East Technical University	Ogretmen, B (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, 173 Ashley Ave, Charleston, SC 29425 USA.	ogretmen@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [P01CA097132, R01CA088932] Funding Source: NIH RePORTER; NCI NIH HHS [CA88932, CA097132] Funding Source: Medline; NIDCR NIH HHS [DE01657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Buchdunger E, 1996, CANCER RES, V56, P100; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; Deininger Michael, 2005, J Natl Compr Canc Netw, V3, P757; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Foss FW, 2007, BIOORGAN MED CHEM, V15, P663, DOI 10.1016/j.bmc.2006.10.060; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Galadari S, 2006, BIOCHEM J, V393, P687, DOI 10.1042/BJ20050682; Gambacorti-Passerini CB, 2003, LANCET ONCOL, V4, P75, DOI 10.1016/S1470-2045(03)00979-3; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; He XX, 2003, J BIOL CHEM, V278, P32978, DOI 10.1074/jbc.M301936200; Hegedus T, 2002, BBA-MOL BASIS DIS, V1587, P318, DOI 10.1016/S0925-4439(02)00095-9; Illmer T, 2004, LEUKEMIA, V18, P401, DOI 10.1038/sj.leu.2403257; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Johnson KR, 2005, J HISTOCHEM CYTOCHEM, V53, P1159, DOI 10.1369/jhc.4A6606.2005; KANTARJIAN HM, 1988, CANCER, V61, P1441, DOI 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kitatani K, 2006, J BIOL CHEM, V281, P36793, DOI 10.1074/jbc.M608137200; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Krystal GW, 2001, DRUG RESIST UPDATE, V4, P16, DOI 10.1054/drup.2000.0176; Lahiri S, 2005, J BIOL CHEM, V280, P33735, DOI 10.1074/jbc.M506485200; Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Park JH, 2006, BBA-BIOMEMBRANES, V1758, P2133, DOI 10.1016/j.bbamem.2006.08.019; Pchejetski D, 2005, CANCER RES, V65, P11667, DOI 10.1158/0008-5472.CAN-05-2702; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Schulz A, 2006, J BIOL CHEM, V281, P2784, DOI 10.1074/jbc.M509483200; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Sultan I, 2006, BIOCHEM J, V393, P513, DOI 10.1042/BJ20051083; Taha TA, 2005, FASEB J, V19, P482, DOI 10.1096/fj.05-4412fje; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Walz C, 2006, CRIT REV ONCOL HEMAT, V57, P145, DOI 10.1016/j.critrevonc.2005.06.007; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xu RJ, 2006, FASEB J, V20, P1813, DOI 10.1096/fj.05-5689com	56	175	191	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10922	10934		10.1074/jbc.M610157200	http://dx.doi.org/10.1074/jbc.M610157200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303574	hybrid, Green Submitted			2022-12-27	WOS:000245941500012
J	Kaustov, L; Lukin, J; Lemak, A; Duan, SL; Ho, M; Doherty, R; Penn, LZ; Arrowsmith, CH				Kaustov, Lilia; Lukin, Jonathan; Lemak, Alexander; Duan, Shili; Ho, Melissa; Doherty, Ryan; Penn, Linda Z.; Arrowsmith, Cheryl H.			The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; OLIGOMERIZATION; IDENTIFICATION; COUPLINGS; SYSTEM; FAMILY; CANCER; SITE	Cul7 is a member of the Cullin Ring Ligase ( CRL) family and is required for normal mouse development and cellular proliferation. Recently, a region of Cul7 that is highly conserved in the p53-associated, Parkin-like cytoplasmic protein PARC, was shown to bind p53 directly. Here we identify the CPH domains ( conserved domain within Cul7, PARC, and HERC2 proteins) of both Cul7 and PARC as p53 interaction domains using size exclusion chromatography and NMR spectroscopy. We present the first structure of the evolutionarily conserved CPH domain and provide novel insight into the Cul7-p53 interaction. The NMRstructure of the Cul7-CPH domain reveals a fold similar to peptide interaction modules such as the SH3, Tudor, and KOW domains. The p53 interaction surface of both Cul7 and PARC CPH domains was mapped to a conserved surface distinct from the analogous peptide-binding regions of SH3, KOW, and Tudor domains, suggesting a novel mode of interaction. The CPH domain interaction surface of p53 resides in the tetramerization domain and is formed by residues contributed by at least two subunits.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L5, Canada; Univ Toronto, NE Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; Structural Genomics Consortium	Arrowsmith, CH (corresponding author), Rm 4-803,TMDT,MaRS,101 Coll St, Toronto, ON M5G 1L7, Canada.	carrow@uhnres.utoronto.ca		Arrowsmith, Cheryl/0000-0002-4971-3250; Penn, Linda/0000-0001-8133-5459; Kaustov, Lilia/0000-0002-8474-559X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50-GM62413-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews P, 2006, ONCOGENE, V25, P4534, DOI 10.1038/sj.onc.1209490; Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; Bhattacharya A, 2007, PROTEINS, V66, P778, DOI 10.1002/prot.21165; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Charier G, 2004, STRUCTURE, V12, P1551, DOI 10.1016/j.str.2004.06.014; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Davison TS, 2001, J MOL BIOL, V307, P605, DOI 10.1006/jmbi.2001.4450; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; Grishaev A, 2005, PROTEINS, V61, P36, DOI 10.1002/prot.20457; Grishaev A, 2004, J BIOMOL NMR, V28, P1, DOI 10.1023/B:JNMR.0000012846.56763.f7; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hochrainer K, 2005, GENOMICS, V85, P153, DOI 10.1016/j.ygeno.2004.10.006; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kasper JS, 2006, BIOCHEM BIOPH RES CO, V348, P132, DOI 10.1016/j.bbrc.2006.07.013; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee AS, 2003, J MOL BIOL, V327, P699, DOI 10.1016/S0022-2836(03)00175-X; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Schwartz AL, 1999, ANNU REV MED, V50, P57; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Steiner T, 2002, EMBO J, V21, P4641, DOI 10.1093/emboj/cdf455; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Tsunematsu R, 2006, MOL CELL BIOL, V26, P6157, DOI 10.1128/MCB.00595-06; Tugarinov V, 2003, J MOL BIOL, V327, P1121, DOI 10.1016/S0022-2836(03)00238-9; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; Zweckstetter M, 2001, J AM CHEM SOC, V123, P9490, DOI 10.1021/ja016496h	45	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11300	11307		10.1074/jbc.M611297200	http://dx.doi.org/10.1074/jbc.M611297200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17298945	hybrid			2022-12-27	WOS:000245941500052
J	Xu, K; Zhang, Y; Ilalov, K; Carlson, CS; Feng, JQ; Di Cesare, PE; Liu, CJ				Xu, Ke; Zhang, Yan; Llalov, Kirill; Carlson, Cathy S.; Feng, Jian Q.; Di Cesare, Paul E.; Liu, Chuan-ju			Cartilage oligomeric matrix protein associates with granulin-epithelin precursor (GEP) and potentiates GEP-stimulated chondrocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; HOMOLOGOUS FACTOR 1B; GROWTH-FACTOR PCDGF; CELL-LINE; IN-VITRO; GRANULIN/EPITHELIN PRECURSOR; MYOBLAST DIFFERENTIATION; BONE METABOLISM; GENE-EXPRESSION; SYNOVIAL-FLUID	Mutations in human cartilage oligomeric matrix protein ( COMP) have been linked to the development of pseudoachondroplasia and multiple epiphyseal dysplasia; however, the functions of both wild-type and mutant COMP in the skeletogenesis remain unknown. In an effort to define the biological functions of COMP, a functional genetic screen based on the yeast two-hybrid system was performed. This led to the identification of granulin-epithelin precursor ( GEP), an autocrine growth factor, as a COMP-associated partner. COMP directly binds to GEP both in vitro and in vivo, as revealed by in vitro pull down and co-immunoprecipitation assays. GEP selectively interacts with the epidermal growth factor repeat domain of COMP but not with the other three functional domains of COMP. The granulin A repeat unit of GEP is required and sufficient for association with COMP. COMP co-localizes with GEP predominantly in the pericellular matrix of transfected rat chondrosarcoma cell and primary human chondrocytes. Staining of musculoskeletal tissues of day 19 mouse embryo with antibodies to GEP is restricted to chondrocytes in the lower proliferative and upper hypertrophic zones. Overexpression of GEP stimulates the proliferation of chondrocytes, and this stimulation is enhanced by COMP. In addition, COMP appears to be required for GEP-mediated chondrocyte proliferation, since chondrocyte proliferation induced by GEP is dramatically inhibited by an anti-COMP antibody. findings provide the first evidence linking the association of COMP and GEP and identifying a previously unrecognized growth factor ( i.e. GEP) in cartilage.	NYU, Sch Med, Dept Orthopaed Surg, Hosp Joint Dis, New York, NY 10003 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Baylor Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA; Shandong Univ, Sch Med, Inst Pathogen Biol, Jinan 250012, Shandong, Peoples R China	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; University of Minnesota System; University of Minnesota Twin Cities; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Shandong University	Liu, CJ (corresponding author), NYU, Sch Med, Dept Orthopaed Surg, 301 E 17th St, New York, NY 10003 USA.	Chuanju.liu@med.nyu.edu	Liu, Chuan-ju/AAT-8165-2021	liu, chuanju/0000-0002-7181-8032; Xu, Ke Kate/0000-0002-2453-4475	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR052022] Funding Source: NIH RePORTER; NCRR NIH HHS [RR14099] Funding Source: Medline; NIAMS NIH HHS [AR050620, AR052022] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANAKWE OO, 1990, BIOL REPROD, V42, P317, DOI 10.1095/biolreprod42.2.317; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P727, DOI 10.1016/j.dci.2003.11.005; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen FH, 2005, J BIOL CHEM, V280, P32655, DOI 10.1074/jbc.M504778200; CHEN FHT, 2004, 50 ANN M ORTH RES SO; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506; Di Cesare PE, 1999, J ORTHOPAED RES, V17, P437; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; Duke J, 2003, APOPTOSIS, V8, P191, DOI 10.1023/A:1022926811397; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hoque M, 2005, J BIOL CHEM, V280, P13648, DOI 10.1074/jbc.M409575200; Hoque M, 2003, MOL CELL BIOL, V23, P1688, DOI 10.1128/MCB.23.5.1688-1702.2003; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; Jones MB, 2003, GYNECOL ONCOL, V88, pS136, DOI 10.1006/gyno.2002.6704; Justen H P, 2000, Mol Cell Biol Res Commun, V3, P165, DOI 10.1006/mcbr.2000.0211; Kipnes J, 2003, OSTEOARTHR CARTILAGE, V11, P442, DOI 10.1016/S1063-4584(03)00055-4; Koelling S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1922; Kraus VB, 2002, ARTHRITIS RHEUM-US, V46, P420, DOI 10.1002/art.10124; Kuhne SAM, 1998, RHEUMATOL INT, V18, P21, DOI 10.1007/s002960050049; Liu CJ, 2006, FASEB J, V20, P988, DOI 10.1096/fj.05-3877fje; Liu CJ, 2006, J BIOL CHEM, V281, P15800, DOI 10.1074/jbc.M513433200; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2003, J BIOL CHEM, V278, P1029, DOI 10.1074/jbc.M207074200; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; Lohmander LS, 1999, ARTHRITIS RHEUM, V42, P534, DOI 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; MANSSON B, 1995, J CLIN INVEST, V95, P1071, DOI 10.1172/JCI117753; Misumi K, 2002, EQUINE VET J, V34, P602, DOI 10.2746/042516402776180205; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; Neidhart M, 1996, J RHEUMATOL, V23, P476; Ozbek S, 2002, EMBO J, V21, P5960, DOI 10.1093/emboj/cdf628; Petersson IF, 1998, BRIT J RHEUMATOL, V37, P46; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SAXNE T, 1992, BRIT J RHEUMATOL, V31, P583; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Sun XJ, 2004, AM J RESP CELL MOL, V30, P510, DOI 10.1165/rcmb.2003-0266OC; Susic S, 1997, CLIN GENET, V51, P219; Suzuki M, 2002, MOL GENET METAB, V75, P31, DOI 10.1006/mgme.2001.3274; Thornburg NJ, 2004, J VIROL, V78, P12848, DOI 10.1128/JVI.78.23.12848-12856.2004; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Wang WG, 2003, CLIN CANCER RES, V9, P2221; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	70	107	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11347	11355		10.1074/jbc.M608744200	http://dx.doi.org/10.1074/jbc.M608744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307734	hybrid			2022-12-27	WOS:000245941500057
J	Hauser, M; Kauffman, S; Lee, BK; Naider, F; Becker, JM				Hauser, Melinda; Kauffman, Sarah; Lee, Byung-Kwon; Naider, Fred; Becker, Jeffrey M.			The first extracellular loop of the Saccharomyces cerevisiae G protein-coupled receptor Ste2p undergoes a conformational change upon ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; C5A RECEPTOR; TRANSMEMBRANE DOMAIN; PHEROMONE RECEPTOR; MATING PHEROMONE; STRUCTURAL BASIS; PEPTIDE ANALOGS; RESIDUES; ACTIVATION; IDENTIFICATION	In this study of the Saccharomyces cerevisiae G protein-coupled receptor Ste2p, we present data indicating that the first extracellular loop (EL1) of the alpha-factor receptor has tertiary structure that limits solvent accessibility and that its conformation changes in a ligand- dependent manner. The substituted cysteine accessibility method was used to probe the solvent exposure of single cysteine residues engineered to replace residues Tyr(101) through Gln(135) of EL1 in the presence and absence of the tridecapeptide alpha-factor and a receptor antagonist. Surprisingly, many residues, especially those at the N-terminal region, were not solvent-accessible, including residues of the binding-competent yet signal transduction- deficient mutants L102C, N105C, S108C, Y111C, and T114C. In striking contrast, two N- terminal residues, Y101C and Y106C, were readily solventaccessible, but upon incubation with alpha-dfactor labeling was reduced, suggesting a pheromone-dependent conformational change limiting solvent accessibility had occurred. Labeling in the presence of the antagonist, which binds Ste2p but does not initiate signal transduction, did not significantly alter reactivity with the Y101C and Y106C receptors, suggesting that the alpha-factor-dependent decrease in solvent accessibility was not because of steric hindrance that prevented the labeling reagent access to these residues. Based on these and previous observations, we propose a model in which the N terminus of EL1 is structured such that parts of the loop are buried in a solvent-inaccessible environment interacting with the extracellular part of the transmembrane domain bundle. This study highlights the essential role of an extracellular loop in activation of a G proteincoupled receptor upon ligand binding.	Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA; CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA; CUNY Coll Staten Isl, Macromol Assemblies Inst, Staten Isl, NY 10314 USA; CUNY Grad Sch & Univ Ctr, Staten Isl, NY 10314 USA	University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) Graduate School	Becker, JM (corresponding author), Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA.	jbecker@utk.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022086, R56GM022086, R01GM022087, R56GM022087] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22087, GM22086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MG, 1998, BBA-MOL CELL RES, V1448, P12, DOI 10.1016/S0167-4889(98)00109-8; Abel MG, 1998, J PEPT RES, V52, P95; Akal-Strader A, 2002, J BIOL CHEM, V277, P30581, DOI 10.1074/jbc.M204089200; AKALSTRADER A, 2004, THESIS U TENNESSEE K, P181; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Baneres JL, 2005, J BIOL CHEM, V280, P20253, DOI 10.1074/jbc.M412009200; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Burlison JA, 2006, J AM CHEM SOC, V128, P15529, DOI 10.1021/ja065793p; Celic Andjelka, 2003, V237, P105; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Choi Y, 2006, BIOCHEMISTRY-US, V45, P15310, DOI 10.1021/bi0614939; David NE, 1997, J BIOL CHEM, V272, P15553, DOI 10.1074/jbc.272.24.15553; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; ERIOTOUBARGIOTA E, 1992, BIOCHEMISTRY-US, V31, P551, DOI 10.1021/bi00117a036; Feng YH, 1999, J BIOL CHEM, V274, P35546, DOI 10.1074/jbc.274.50.35546; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 2002, PHARMACOL TOXICOL, V91, P304, DOI 10.1034/j.1600-0773.2002.910607.x; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Henry LK, 2002, BIOCHEMISTRY-US, V41, P6128, DOI 10.1021/bi015863z; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hill SJ, 2006, BRIT J PHARMACOL, V147, pS27, DOI 10.1038/sj.bjp.0706455; Javitch JA, 2002, METHOD ENZYMOL, V343, P137; Jenness DD, 1997, MOL CELL BIOL, V17, P6236, DOI 10.1128/MCB.17.11.6236; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; Lawson Z, 2004, BIOCHEM SOC T, V32, P1048, DOI 10.1042/BST0321048; Lee BK, 2002, BIOCHEMISTRY-US, V41, P13681, DOI 10.1021/bi026100u; Lee BK, 2001, J BIOL CHEM, V276, P37950; Lee YH, 2006, J BIOL CHEM, V281, P2263, DOI 10.1074/jbc.M509987200; Lin JC, 2004, MOL CELL BIOL, V24, P2041, DOI 10.1128/MCB.24.5.2041-2051.2004; Lin JC, 2003, BIOCHEMISTRY-US, V42, P293, DOI 10.1021/bi026766o; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Mentesana PE, 2001, BIOCHEMISTRY-US, V40, P9685, DOI 10.1021/bi0108507; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; POCKLINGTON MJ, 1994, BBA-MOL CELL RES, V1224, P401, DOI 10.1016/0167-4889(94)90275-5; RATHS SK, 1988, J BIOL CHEM, V263, P17333; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; Schlyer S, 2006, DRUG DISCOV TODAY, V11, P481, DOI 10.1016/j.drudis.2006.04.008; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Son CD, 2005, J PEPT RES, V65, P418, DOI 10.1111/j.1399-3011.2005.00248.X; Son CD, 2004, BIOCHEMISTRY-US, V43, P13193, DOI 10.1021/bi0496889; Stitham J, 2004, BIOCHEMISTRY-US, V43, P8974, DOI 10.1021/bi0496788; Ward SDC, 2006, BIOCHEMISTRY-US, V45, P676, DOI 10.1021/bi051503q	52	37	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10387	10397		10.1074/jbc.M608903200	http://dx.doi.org/10.1074/jbc.M608903200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293349	hybrid			2022-12-27	WOS:000245941000029
J	Hoffmann, C; Aktories, K; Schmidt, G				Hoffmann, Claudia; Aktories, Klaus; Schmidt, Gudula			Change in substrate specificity of cytotoxic necrotizing factor unmasks proteasome-independent down-regulation of constitutively active RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE TRANSLOCATION; SWISS-MODEL; CNF1; GTPASES; DOMAIN; TOXIN; DEAMIDATION; ACTIVATION; MECHANISM; GLUTAMINE	Cytotoxic necrotizing factors CNF1 and CNF2 are produced by pathogenic Escherichia coli strains. They constitutively activate small GTPases of the Rho family by deamidation of a glutamine, which is crucial for GTP hydrolysis. Recently, a novel CNF ( CNFY) encompassing 65% identity to CNF1 has been identified in Yersinia pseudotuberculosis. In contrast to the E. coli toxins, which activate several isoforms of Rho family GTPases, CNFY is a strong and selective activator of RhoA in vivo. By constructing chimeras between CNF1 and CNFY, we show that this substrate specificity is based on differences in the catalytic domains, whereas the receptor binding and translocation domains have no influence. We further define a loop element ( L8) on the surface of the catalytic domains as important for substrate recognition. A single amino acid exchange in L8 is sufficient to shift substrate specificity of CNF1. Moreover, it is shown that RhoA activation by CNF1 is transient, which may be the consequence of the broader substrate specificity of the E. coli toxin, leading to cross-talk between the activated GTPases.	Univ Freiburg, Inst Expt Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Schmidt, G (corresponding author), Univ Freiburg, Inst Expt Klin Pharmakol & Toxikol, Albert Str 25, D-79104 Freiburg, Germany.	Gudula.Schmidt@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Buetow L, 2003, BIOCHEMISTRY-US, V42, P12784, DOI 10.1021/bi035123l; Buetow L, 2001, NAT STRUCT BIOL, V8, P584, DOI 10.1038/89610; Contamin S, 2000, MOL BIOL CELL, V11, P1775, DOI 10.1091/mbc.11.5.1775; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Fabbri A, 1999, MOL MICROBIOL, V33, P108, DOI 10.1046/j.1365-2958.1999.01453.x; Flatau G, 2000, BIOCHEM BIOPH RES CO, V267, P588, DOI 10.1006/bbrc.1999.1904; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hoffmann C, 2004, J BIOL CHEM, V279, P16026, DOI 10.1074/jbc.M313556200; Hoffmann C, 2005, REV PHYSIOL BIOCH P, V152, P49, DOI 10.1007/s10254-004-0026-4; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Lerm M, 1999, J BIOL CHEM, V274, P28999, DOI 10.1074/jbc.274.41.28999; Lockman HA, 2002, INFECT IMMUN, V70, P2708, DOI 10.1128/IAI.70.5.2708-2714.2002; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Moreau V, 2003, MOL CELL BIOL, V23, P6809, DOI 10.1128/MCB.23.19.6809-6822.2003; Pei S, 2001, MOL MICROBIOL, V41, P1237, DOI 10.1046/j.1365-2958.2001.02596.x; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797	25	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10826	10832		10.1074/jbc.M610451200	http://dx.doi.org/10.1074/jbc.M610451200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17296609	hybrid			2022-12-27	WOS:000245941000076
J	Singh, K; Srivastava, A; Patel, SS; Modak, MJ				Singh, Kamalendra; Srivastava, Aashish; Patel, Smita S.; Modak, Mukund J.			Participation of the fingers subdomain of Escherichia coli DNA polymerase I in the strand displacement synthesis of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; CRYSTAL-STRUCTURE; PROTEOLYTIC FRAGMENT; TERNARY COMPLEXES; TEMPLATE-PRIMER; ACTIVE-SITE; REPLICATION; MECHANISM; STABILIZATION; EXONUCLEASE	The replication of the genome requires the removal of RNA primers from the Okazaki fragments and their replacement by DNA. In prokaryotes, this process is completed by DNA polymerase I by means of strand displacement DNA synthesis and 5'-nuclease activity. Here, we demonstrate that the strand displacement DNA synthesis is facilitated by the collective participation of Ser(769), Phe(771), and Arg(841) present in the fingers subdomain of DNA polymerase I. The steady and presteady state kinetic analysis of the properties of appropriate mutant enzymes suggest that: ( a) Ser(769) and Phe(771) together are involved in the strand separation via the formation of a flap structure, and ( b) Arg(841) interacts with the template strand to achieve the optimal strand separation and DNA synthesis. The amino acid residues Ser(769) and Phe(771) are constituents of the O1-helix, which together with O and O2 helices form a 3-helix bundle structure. We note that this 3-helix bundle motif also exists in prokaryotic RNA polymerase. Thus in both DNA and RNA polymerases, this motif may have been adopted to achieve the strand separation function.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Singh, K (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	ksingh@umdnj.edu			NIGMS NIH HHS [GM55310, GM 36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SETLOW P, 1972, J BIOL CHEM, V247, P232; Singh K, 2003, J BIOL CHEM, V278, P11289, DOI 10.1074/jbc.M211496200; Srivastava A, 2003, BIOCHEMISTRY-US, V42, P3645, DOI 10.1021/bi026699y; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Turner RM, 2003, BIOCHEMISTRY-US, V42, P2373, DOI 10.1021/bi026566c; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Yuan YC, 1998, NAT STRUCT BIOL, V5, P959, DOI 10.1038/2934	28	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10594	10604		10.1074/jbc.M611242200	http://dx.doi.org/10.1074/jbc.M611242200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17259182	hybrid			2022-12-27	WOS:000245941000053
J	Thompson, BD; Jin, YZ; Wu, KH; Colvirl, RA; Luster, AD; Birnbaumer, L; Wu, MX				Thompson, Brian D.; Jin, Yongzhu; Wu, Kevin H.; Colvirl, Richard A.; Luster, Andrew D.; Birnbaumer, Lutz; Wu, Mei X.			Inhibition of G alpha(i2) activation by G alpha(i3) in CXCR3-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ACUTE ALLOGRAFT-REJECTION; PERTUSSIS-TOXIN; T-CELLS; G-ALPHA-I2(-/-) MICE; MULTIGENE FAMILY; ALPHA-SUBUNIT; BINDING; CXCR3; LYMPHOCYTES	G protein-coupled receptors (GPCRs) convey extracellular stimulation into dynamic intracellular action, leading to the regulation of cell migration and differentiation. T lymphocytes express G alpha(12), and G alpha(i3), two members of the G alpha(i/o). protein family, but whether these two G alpha(i) proteins have distinguishable roles guiding T cell migration remains largely unknown because of a lack of member-specific inhibitors. This study details distinct G alpha(i2) and G alpha(i3) effects on chemokine receptor CXCR3-mediated signaling. Our data showed that Gai, was indispensable for T cell responses to three CXCR3 ligands, CXCL9, CXCL10, and CXCL11, as the lack of G alpha(i2) abolished CXCR3-stimulated migration and guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) incorporation. In sharp contrast, T cells isolated from G alpha(i3) knock-out mice displayed a significant increase in both GTP gamma S incorporation and migration as compared with wild type T cells when stimulated with CXCR3 agonists. The increased GTP gamma S incorporation was blocked by G alpha(i3) protein in a dose-dependent manner. G alpha(i3)-mediated blockade of Gai, activation did not result from Gai3 activation, but instead resulted from competition or steric hindrance of Gai, interaction with the CXCR3 receptor via the N terminus of the second intracellular loop. A mutation in this domain abrogated not only G alpha(i2) activation induced by a CXCR3 agonist but also the interaction of Gai3 to the CXCR3 receptor. These findings reveal for the first time an interplay of Gai proteins in transmitting G protein-coupled receptor signals. This interplay has heretofore been masked by the use of pertussis toxin, a broad inhibitor of the G alpha(i/o) protein family.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA; NIEHS, Transmembrane Signaling Grp, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wu, MX (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, 55 Fruit St,Edwards 222, Boston, MA 02114 USA.	mwu2@partners.org	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	Intramural NIH HHS [Z01 ES101643-05] Funding Source: Medline; NIAID NIH HHS [R01 AI050822, AI070785, K02 AI070785, AI050822] Funding Source: Medline; NIAMS NIH HHS [T32 AR007098, T32 AR07098-31] Funding Source: Medline; NIDDK NIH HHS [DK43351, DK074449, R01 DK074449, P30 DK043351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI070785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK074449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101643] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Colvin RA, 2004, J BIOL CHEM, V279, P30219, DOI 10.1074/jbc.M403595200; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Duffner U, 2003, EXP HEMATOL, V31, P897, DOI 10.1016/S0301-472X(03)00198-X; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gonsiorek W, 2003, J IMMUNOL METHODS, V273, P15, DOI 10.1016/S0022-1759(02)00415-5; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Han SB, 2005, IMMUNITY, V22, P343, DOI 10.1016/j.immuni.2005.01.017; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001; Hornquist CE, 1997, J IMMUNOL, V158, P1068; Huang TT, 2003, INT IMMUNOL, V15, P1359, DOI 10.1093/intimm/dxg135; Hwang JI, 2004, P NATL ACAD SCI USA, V101, P488, DOI 10.1073/pnas.0307549100; Jiang MS, 2002, METHOD ENZYMOL, V344, P277; KASLOW HR, 1992, FASEB J, V6, P2684, DOI 10.1096/fasebj.6.9.1612292; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Khan IA, 2000, IMMUNITY, V12, P483, DOI 10.1016/S1074-7613(00)80200-9; KIM S, 1988, P NATL ACAD SCI USA, V85, P4153, DOI 10.1073/pnas.85.12.4153; Liu LP, 2005, CURR TOP DEV BIOL, V68, P149, DOI 10.1016/S0070-2153(05)68006-4; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Lu B, 1999, EUR J IMMUNOL, V29, P3804, DOI 10.1002/(SICI)1521-4141(199911)29:11<3804::AID-IMMU3804>3.0.CO;2-9; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; PALMER TM, 1995, J BIOL CHEM, V270, P16895, DOI 10.1074/jbc.270.28.16895; Papadakis KA, 2004, CURR ALLERGY ASTHM R, V4, P83, DOI 10.1007/s11882-004-0048-7; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; Roberts DJ, 2004, BIOCHEM PHARMACOL, V68, P799, DOI 10.1016/j.bcp.2004.05.044; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Sklar LA, 2000, BIOTECHNIQUES, V28, P976, DOI 10.2144/00285rr03; Smit MJ, 2003, BLOOD, V102, P1959, DOI 10.1182/blood-2002-12-3945; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; SUNYER T, 1989, MOL ENDOCRINOL, V3, P1115, DOI 10.1210/mend-3-7-1115; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Whiting D, 2004, J IMMUNOL, V172, P7417, DOI 10.4049/jimmunol.172.12.7417; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Wise A, 2002, DRUG DISCOV TODAY, V7, P235, DOI 10.1016/S1359-6446(01)02131-6; Wu JY, 2005, J IMMUNOL, V174, P6122, DOI 10.4049/jimmunol.174.10.6122; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699; Zhang YJ, 2005, INT IMMUNOL, V17, P233, DOI 10.1093/intimm/dxh204; Zhang Z, 2002, J IMMUNOL, V168, P3205, DOI 10.4049/jimmunol.168.7.3205	46	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9547	9555		10.1074/jbc.M610931200	http://dx.doi.org/10.1074/jbc.M610931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17289675	Green Accepted, hybrid			2022-12-27	WOS:000245421700027
J	Adachi, R; Yamaguchi, K; Yagi, H; Sakurai, K; Naiki, H; Goto, Y				Adachi, Rumi; Yamaguchi, Kei-ichi; Yagi, Hisashi; Sakurai, Kazumasa; Naiki, Hironobu; Goto, Yuji			Flow-induced alignment of amyloid protofilaments revealed by linear dichroism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; BETA(2)-MICROGLOBULIN FRAGMENT; PHYSIOLOGICAL CONDITIONS; PROTEIN; BETA-2-MICROGLOBULIN; ORIENTATION; MATURATION; SUGGESTS	uAmyloid fibrils underlying various serious amyloidoses including Alzheimer and prion diseases form characteristic deposits in which linear fibrils with an unbranched and rigid morphology associate laterally or radially, e.g. radial senile amyloid plaques of amyloid beta. To clarify the formation of these high order amyloid deposits, studying the rheology is important. A 22-residue K3 peptide fragment of beta(2)-microglobulin, a protein responsible for dialysis-related amyloidosis, forms long and homogeneous protofilament-like fibrils in 20% (v/v) 2,2,2-trifluoroethanol and 10 mM HCI (pH similar to 2). Here, using circular dichroism and linear dichroism, we observed the flow-induced alignment of fibrils. Analysis of far- and near-UV linear dichroism spectra suggested that both the net pi-pi transition moment of the backbone carbonyl group and L-b transition moment of the Tyr(26) side chain are oriented in parallel to the fibril axis, revealing the structural details of amyloid protofilaments. Moreover, the intensities of flow-induced circular dichroism or linear dichroism signals depended critically on the length and type of fibrils, suggesting that they are useful for detecting and characterizing amyloid fibrils.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; CREST, Japan Sci & Technol Agcy, Suita, Osaka 5650871, Japan; Univ Fukui, Fac Med Sci, Dept Pathol Sci, Matsuoka, Fukui 9101193, Japan; CREST, Japan Sci & Technol Agcy, Matsuoka, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Dafforn TR, 2004, CURR OPIN STRUC BIOL, V14, P541, DOI 10.1016/j.sbi.2004.08.005; Dafforn TR, 2004, BIOPHYS J, V86, P404, DOI 10.1016/S0006-3495(04)74116-8; DAVIDSSON A, 1980, CHEM PHYS LETT, V70, P313, DOI 10.1016/0009-2614(80)85341-3; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Eakin CM, 2006, NAT STRUCT MOL BIOL, V13, P202, DOI 10.1038/nsmb1068; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Iwata K, 2006, P NATL ACAD SCI USA, V103, P18119, DOI 10.1073/pnas.0607180103; Jahn TR, 2005, AMYLOID PROTEINS: THE BETA SHEET CONFORMATION AND DISEASE, VOLS 1 AND 2, P667, DOI 10.1002/9783527619344.ch26; Jahn TR, 2006, NAT STRUCT MOL BIOL, V13, P195, DOI 10.1038/nsmb1058; Jin LW, 2003, P NATL ACAD SCI USA, V100, P15294, DOI 10.1073/pnas.2534647100; Kihara M, 2005, J BIOL CHEM, V280, P12012, DOI 10.1074/jbc.M411949200; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Lansbury PT, 2004, NAT MED, V10, pS51, DOI 10.1038/nrn1435; Marrington R, 2004, BIOPHYS J, V87, P2002, DOI 10.1529/biophysj.103.035022; Marrington R, 2006, CHIRALITY, V18, P680, DOI 10.1002/chir.20305; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Ohhashi Y, 2004, J BIOL CHEM, V279, P10814, DOI 10.1074/jbc.M310334200; Petkova AT, 2006, BIOCHEMISTRY-US, V45, P498, DOI 10.1021/bi051952q; Relini A, 2006, J BIOL CHEM, V281, P16521, DOI 10.1074/jbc.M513827200; Rodger A, 2002, PHYS CHEM CHEM PHYS, V4, P4051, DOI 10.1039/b205080n; Rodger A., 1997, CIRCULAR DICHROISM L; Smith JF, 2006, P NATL ACAD SCI USA, V103, P15806, DOI 10.1073/pnas.0604035103; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2; Yamaguchi K, 2005, J MOL BIOL, V352, P952, DOI 10.1016/j.jmb.2005.07.061; Yamaguchi K, 2006, J MOL BIOL, V363, P279, DOI 10.1016/j.jmb.2006.08.030	29	30	31	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8978	8983		10.1074/jbc.M611738200	http://dx.doi.org/10.1074/jbc.M611738200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264078	hybrid, Green Published			2022-12-27	WOS:000245780300044
J	Boggs, K; Reisman, D				Boggs, Kristy; Reisman, David			C/EBP beta participates in regulating transcription of the p53 gene in response to mitogen stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEINS; SIGNAL-TRANSDUCTION; EXPRESSION; DIFFERENTIATION; PROMOTER; ISOFORMS; PROLIFERATION; DEFICIENT; MUTATION; ANTIGEN	The tightly regulated expression of p53 contributes to genomic stability, and transcription of the p53 gene is induced prior to cells entering S phase, possibly as a mechanism to ensure a rapid p53 response in the event of DNA damage. We have previously described the cloning of an additional 1000 bp of upstream p53 sequences that we have demonstrated play a role in the regulated expression of p53. As described in an earlier report, we preliminarily identified that a member of the CAAT/enhancer-binding protein (C/EPB) family of transcription factors may play a role in regulating p53. Here we have demonstrated that a particular C/EB beta isoform, C/EB beta 6-2, efficiently binds to the p53 promoter and induces its expression in a fashion that reflects the pattern of p53 expression seen as cells are induced to enter S phase and is absent from cells that are defective in proper p53 regulation. We conclude from these findings that C/EBP beta-2 plays a central role in the regulating of p53 transcription during the transition into S phase.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Reisman, D (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.	reisman@biol.sc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016461] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR16461] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Boggs K, 2006, ONCOGENE, V25, P555, DOI 10.1038/sj.onc.1209076; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen XN, 1997, BLOOD, V90, P156; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Freedman DA, 1999, CANCER RES, V59, P1; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Ghosh M, 2003, BIOCHEMISTRY-US, V42, P2291, DOI 10.1021/bi0271291; GINSBERG D, 1990, ONCOGENE, V5, P1285; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hussain SP, 1998, CANCER RES, V58, P4023; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Reisman D, 2001, GENE, V274, P129, DOI 10.1016/S0378-1119(01)00623-0; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	50	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7982	7990		10.1074/jbc.M611675200	http://dx.doi.org/10.1074/jbc.M611675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244625	hybrid			2022-12-27	WOS:000245081000028
J	Wang, CH; Mao, XM; Wang, LX; Liu, ML; Wetzel, MD; Guan, KL; Dong, LQ; Liu, F				Wang, Changhua; Mao, Xuming; Wang, Lixin; Liu, Meilian; Wetzel, Michael D.; Guan, Kun-Liang; Dong, Lily Q.; Liu, Feng			Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE-1; SKELETAL-MUSCLE; RHEB GTPASE; MTOR; ACTIVATION; INHIBITION; RESISTANCE; TSC1/TSC2; ADIPOCYTE; TARGET	Adiponectin functions as an insulin sensitizer, and yet the underlying molecular mechanism(s) remains largely unknown. We found that treating C2C12 myotubes with adiponectin or rapamycin enhanced the ability of insulin to stimulate IRS-1 tyrosine phosphorylation and Akt phosphorylation, concurrently with reduced p70 S6 kinase phosphorylation at Thr(389) as well as IRS-1 phosphorylation at Ser(302) and Ser(636/639). Overexpression of dominant-negative AMP kinase (AMPK), but not dominant-negative p38 MAPK, reduced the insulin-sensitizing effect of adiponectin. Rapamycin, but not adiponectin, enhanced insulin-stimulated Akt phosphorylation in HeLa cells, which lack LKB1, and exogenous expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin. Finally, overexpression of wild-type Rheb (Ras homology-enriched in brain) or the TSC2 mutant lacking the AMPK phosphorylation. site (TSC2(S1345A)) inhibited the insulin-sensitizing effect of adiponectin in C2C12 cells. These results indicate that activation of the LKB1/AMPK/TSC1/2 pathway alleviates the p70 S6 kinase-mediated negative regulation of insulin signaling, providing a mechanism by which adiponectin increases insulin sensitivity in cells.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Michigan System; University of Michigan	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Guan, Kun-Liang/ADK-7088-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069930] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK069930] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Bouskila M, 2005, INT J OBESITY, V29, pS17, DOI 10.1038/sj.ijo.0802908; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Danielsson A, 2005, J BIOL CHEM, V280, P34389, DOI 10.1074/jbc.C500230200; Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005; Faried LS, 2006, EUR J CANCER, V42, P934, DOI 10.1016/j.ejca.2005.12.018; Fujii R, 2000, J CELL BIOL, V150, P1335, DOI 10.1083/jcb.150.6.1335; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; HARDIE D, 2007, ANN REV PHARM TOXICO, V47; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ju JS, 2007, AM J PHYSIOL-CELL PH, V292, pC564, DOI 10.1152/ajpcell.00269.2006; Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005; Lindsay RS, 2002, LANCET, V360, P57, DOI 10.1016/S0140-6736(02)09335-2; Mao XM, 2006, NAT CELL BIOL, V8, P516, DOI 10.1038/ncb1404; Nawrocki AR, 2006, J BIOL CHEM, V281, P2654, DOI 10.1074/jbc.M505311200; Nawrocki AR, 2005, DRUG DISCOV TODAY, V10, P1219, DOI 10.1016/S1359-6446(05)03569-5; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Ueno M, 2005, DIABETOLOGIA, V48, P506, DOI 10.1007/s00125-004-1662-6; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yang Q, 2006, P NATL ACAD SCI USA, V103, P6811, DOI 10.1073/pnas.0602282103; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	36	161	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7991	7996		10.1074/jbc.M700098200	http://dx.doi.org/10.1074/jbc.M700098200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244624	hybrid			2022-12-27	WOS:000245081000029
J	Bulanova, E; Budagian, V; Duitman, E; Orinska, Z; Krause, H; Ruckert, R; Reiling, N; Bulfone-Paus, S				Bulanova, Elena; Budagian, Vadim; Duitman, Erwin; Orinska, Zane; Krause, Hans; Rueckert, Rene; Reiling, Norbert; Bulfone-Paus, Silvia			RETRACTED: Soluble interleukin (IL)-15R alpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15 (Retracted Article. See vol 286, pg 5934, 2011)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							RECEPTOR-ALPHA-CHAIN; T-CELLS; IN-VIVO; IDENTIFICATION; INFLAMMATION; ACTIVATION; EXPRESSION; PREVENTS; ISOFORMS; CLONING	Interleukin 15 (IL-15) is a pleiotropic cytokine that is hardly detectable in biological fluids. Here, we show that IL-15 forms functional heterocomplexes with soluble high affinity IL-15 receptor alpha (IL-15R alpha) chain in mouse serum and cell-conditioned medium, which prevents IL-15 detection by ELISA. We also demonstrate that two soluble IL-15R alpha (sIL-15R alpha) sushi domain isoforms are generated through a novel alternative splicing mechanism within the IL-15R alpha gene. These isoforms potentiate IL-15 action by promoting the IL-15-mediated proliferation of the CTLL cell line and interferon gamma production by murine NK cells, which suggests a role in IL-15 transpresentation. Conversely, a full-length sIL-15R alpha ectodomain released by tumor necrosis factor-alpha-converting enzyme (TACE)-dependent proteolysis inhibits IL-15 activity. Thus, a dual mechanism of sIL-15R alpha generation exists in mice, giving rise to polypeptides with distinct properties, which regulate IL-15 function.	Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany; Res Ctr Borstel, Dept Immunochem & Biochem Microbiol, D-23845 Borstel, Germany; Charite, Dept Urol, D-12200 Berlin, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bulanova, E (corresponding author), Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.	ebulanova@fz-borstel.de		Krause, Hans/0000-0001-8713-8229				ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Becknell B, 2005, ADV IMMUNOL, V86, P209, DOI 10.1016/S0065-2776(04)86006-1; Bernard J, 2004, J BIOL CHEM, V279, P24313, DOI 10.1074/jbc.M312458200; Blum H, 1996, J IMMUNOL, V157, P1846; Brandt K, 2003, BLOOD, V102, P4090, DOI 10.1182/blood-2003-03-0669; Budagian V, 2005, EMBO J, V24, P4260, DOI 10.1038/sj.emboj.7600874; Budagian V, 2006, CYTOKINE GROWTH F R, V17, P259, DOI 10.1016/j.cytogfr.2006.05.001; Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; Burkett PR, 2004, J EXP MED, V200, P825, DOI 10.1084/jem.20041389; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Fernandez-Botran R, 2000, EXPERT OPIN INV DRUG, V9, P497, DOI 10.1517/13543784.9.3.497; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Mortier E, 2006, J BIOL CHEM, V281, P1612, DOI 10.1074/jbc.M508624200; Mortier E, 2004, J IMMUNOL, V173, P1681, DOI 10.4049/jimmunol.173.3.1681; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Nishimura H, 2005, FASEB J, V19, P19, DOI 10.1096/fj.04-2633com; Onu A, 1997, J IMMUNOL, V158, P255; Ruchatz H, 1998, J IMMUNOL, V160, P5654; Ruckert R, 2005, J IMMUNOL, V174, P5507, DOI 10.4049/jimmunol.174.9.5507; Vamosi G, 2004, P NATL ACAD SCI USA, V101, P11082, DOI 10.1073/pnas.0403916101; van Heel DA, 2006, GUT, V55, P444, DOI 10.1136/gut.2005.079335; Waldmann TA, 2004, ARTHRITIS RES THER, V6, P174, DOI 10.1186/ar1202; Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200; Wei XQ, 2001, J IMMUNOL, V167, P277, DOI 10.4049/jimmunol.167.1.277	30	53	56	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13167	13179		10.1074/jbc.M610036200	http://dx.doi.org/10.1074/jbc.M610036200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17327231	hybrid			2022-12-27	WOS:000246060300005
J	Weber, ANR; Gangloff, M; Moncrieffe, MC; Hyvert, Y; Imler, JL; Gay, NJ				Weber, Alexander N. R.; Gangloff, Monique; Moncrieffe, Martin C.; Hyvert, Yann; Imler, Jean-Luc; Gay, Nicholas J.			Role of the Spatzle pro-domain in the generation of an active toll receptor ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-VENTRAL POLARITY; NERVE GROWTH-FACTOR; DROSOPHILA EMBRYO; SIGNALING PATHWAY; INNATE IMMUNITY; CELL FATE; ACTIVATION; PROTEIN; GRADIENT; SEQUENCE	The cytokine Spatzle is the ligand for Drosophila Toll, the prototype of an important family of membrane receptors that function in embryonic patterning and innate immunity. A dimeric precursor of Spatzle is processed by an endoprotease to produce a form (C-106) that cross-links Toll receptor ectodomains and establishes signaling. Here we show that before processing the pro-domain of Spatzle is required for correct biosynthesis and secretion. We mapped two loss-of-function mutations of Spatzle to a discrete site in the pro-domain and showed that the phenotype arises because of a defect in biosynthesis rather than signaling. We also report that the pro-domain and C-106 remain associated after cleavage and that this processed complex signals with the same characteristics as the C-terminal fragment. These results suggest that before activation the determinants on C-106 that bind specifically to Toll are sequestered by the pro-domain and that proteolytic processing causes conformational rearrangements that expose these determinants and enables binding to Toll. Furthermore, we show that the pro-domain is released when the Toll extracellular domain binds to the complex, a finding that has implications for the generation of a signaling-competent Toll dimer.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; CNRS, UPR 9022, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; German Canc Res Ctr, D-69242 Heidelberg, Germany	University of Cambridge; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; German Cancer Research Center (DKFZ)	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	njg11@mole.bio.cam.ac.uk	Imler, Jean-Luc/GXH-4323-2022	Weber, Alexander/0000-0002-8627-7056; Gangloff, Monique/0000-0001-6131-0115	MRC [G0400007] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044220] Funding Source: NIH RePORTER; Medical Research Council [G1000133, G0400007] Funding Source: Medline; NIAID NIH HHS [P01 AI44220] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; CARROLL SB, 1987, DEVELOPMENT, V99, P327; Chang AJ, 2002, DEVELOPMENT, V129, P5635, DOI 10.1242/dev.00161; CHASAN R, 1992, DEVELOPMENT, V115, P607; DeLotto Y, 2001, MOL GEN GENET, V264, P643, DOI 10.1007/s004380000350; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; Dissing M, 2001, EMBO J, V20, P2387, DOI 10.1093/emboj/20.10.2387; DOUGHERTY WG, 1989, VIROLOGY, V172, P145, DOI 10.1016/0042-6822(89)90116-5; Gay NJ, 2006, NAT REV IMMUNOL, V6, P693, DOI 10.1038/nri1916; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Kirk P, 2005, IMMUNITY, V23, P347, DOI 10.1016/j.immuni.2005.09.008; KLIEMANNEL M, 2007, IN PRESS PROTEIN SCI; Lawrence DA, 2001, MOL CELL BIOCHEM, V219, P163, DOI 10.1023/A:1010819716023; LeMosy EK, 2001, P NATL ACAD SCI USA, V98, P5055, DOI 10.1073/pnas.081026598; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Morisato D, 2001, DEVELOPMENT, V128, P2309; Moussian B, 2005, CURR BIOL, V15, pR887, DOI 10.1016/j.cub.2005.10.026; Paoletti F, 2006, BIOCHEM SOC T, V34, P605, DOI 10.1042/BST0340605; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Rattenholl A, 2001, J MOL BIOL, V305, P523, DOI 10.1006/jmbi.2000.4295; Rose T, 2003, J BIOL CHEM, V278, P11320, DOI 10.1074/jbc.M211820200; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; Taylor WR, 1997, J MOL BIOL, V269, P902, DOI 10.1006/jmbi.1997.1008; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; Weber ANR, 2005, J BIOL CHEM, V280, P22793, DOI 10.1074/jbc.M502074200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955	36	39	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13522	13531		10.1074/jbc.M700068200	http://dx.doi.org/10.1074/jbc.M700068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17324925	hybrid			2022-12-27	WOS:000246060300041
J	Fufezan, C; Gross, CM; Sjodin, M; Rutherford, AW; Krieger-Liszkay, A; Kirilovsky, D				Fufezan, Christian; Gross, Christine M.; Sjodin, Martin; Rutherford, A. William; Krieger-Liszkay, Anja; Kirilovsky, Diana			Influence of the redox potential of the primary quinone electron acceptor on photoinhibition in photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM THERMOSYNECHOCOCCUS-ELONGATUS; PHOTOSYNTHETIC OXYGEN EVOLUTION; CHARGE RECOMBINATION; REACTION CENTERS; SINGLET OXYGEN; D1 PROTEIN; THERMOLUMINESCENCE BANDS; RHODOPSEUDOMONAS-VIRIDIS; LOW-TEMPERATURE; LOW-LIGHT	We report the characterization of the effects of the A249S mutation located within the binding pocket of the primary quinone electron acceptor, Q(A), in the D-2 subunit of photosystem II in Thermosynechococcus elongatus. This mutation shifts the redox potential of Q(A) by similar to-60 mV. This mutant provides an opportunity to test the hypothesis, proposed earlier from herbicide-induced redox effects, that photoinhibition ( light-induced damage of the photosynthetic apparatus) is modulated by the potential of Q(A). Thus the influence of the redox potential of Q(A) on photoinhibition was investigated in vivo and in vitro. Compared with the wild-type, the A249S mutant showed an accelerated photoinhibition and an increase in singlet oxygen production. Measurements of thermoluminescence and of the fluorescence yield decay kinetics indicated that the charge-separated state involving Q(A) was destabilized in the A249S mutant. These findings support the hypothesis that a decrease in the redox potential of Q(A) causes an increase in singlet oxygen-mediated photoinhibition by favoring the back-reaction route that involves formation of the reaction center chlorophyll triplet. The kinetics of charge recombination are interpreted in terms of a dynamic structural heterogeneity in photosystem II that results in high and low potential forms of Q(A). The effect of the A249S mutation seems to reflect a shift in the structural equilibrium favoring the low potential form.	CEA Saclay, Serv Bioenerget, Dept Biol, CNRS,Unite Rech Associe 2096, F-91191 Gif Sur Yvette, France; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Freiburg	Fufezan, C (corresponding author), CUNY City Coll, Dept Phys J419, 160 Convent Ave, New York, NY 10031 USA.	christian@fufezan.net	Rutherford, Alfred W/A-7831-2019; Kirilovsky, Diana/I-2359-2014	Rutherford, Alfred W/0000-0002-3124-154X; Fufezan, Christian/0000-0002-7048-6822; Krieger-Liszkay, Anja/0000-0001-7141-4129; Kirilovsky, Diana/0000-0003-2146-3103				ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BOUGESBOCQUET B, 1973, BIOCHIM BIOPHYS ACTA, V314, P250, DOI 10.1016/0005-2728(73)90140-0; Boussac A, 2004, J BIOL CHEM, V279, P22809, DOI 10.1074/jbc.M401677200; Britt R.D, 1996, ADV PHOTOSYNTHESIS O; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; Cuni A, 2004, PHYS CHEM CHEM PHYS, V6, P4825, DOI 10.1039/b407511k; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; Ducruet JM, 2003, J EXP BOT, V54, P2419, DOI 10.1093/jxb/erg268; El Bissati K, 2000, BBA-BIOENERGETICS, V1457, P229, DOI 10.1016/S0005-2728(00)00104-3; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Fufezan C, 2005, BIOCHEMISTRY-US, V44, P12780, DOI 10.1021/bi051000k; Fufezan C, 2005, BIOCHEMISTRY-US, V44, P5931, DOI 10.1021/bi050055j; Fufezan C, 2002, FEBS LETT, V532, P407, DOI 10.1016/S0014-5793(02)03724-9; GOPHER A, 1985, BIOPHYS J, V48, P311, DOI 10.1016/S0006-3495(85)83784-X; Goussias C, 2002, PHILOS T R SOC B, V357, P1369, DOI 10.1098/rstb.2002.1134; Gunner M.R., 1982, FUNCTION QUINONES EN, P265; Hakala M, 2005, BBA-BIOENERGETICS, V1706, P68, DOI 10.1016/j.bbabio.2004.09.001; HIDEG E, 1994, BBA-BIOENERGETICS, V1186, P143, DOI 10.1016/0005-2728(94)90173-2; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; JOHNSON GN, 1995, BBA-BIOENERGETICS, V1229, P202, DOI 10.1016/0005-2728(95)00003-2; JOHNSON GN, 1994, BBA-BIOENERGETICS, V1184, P85, DOI 10.1016/0005-2728(94)90157-0; JOLIOT A, 1964, CR HEBD ACAD SCI, V258, P4622; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; KANAZAWA A, 1992, RES PHOTOSYNTHESIS, V2, P131; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; KEREN N, 1995, J BIOL CHEM, V270, P806, DOI 10.1074/jbc.270.2.806; Kirilovsky D, 2004, J BIOL CHEM, V279, P52869, DOI 10.1074/jbc.M408206200; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; Komenda J, 2000, PHOTOSYNTH RES, V63, P135, DOI 10.1023/A:1006307417977; KRIEGER A, 1993, PHOTOSYNTH RES, V37, P117, DOI 10.1007/BF02187470; KRIEGER A, 1995, BBA-BIOENERGETICS, V1229, P193, DOI 10.1016/0005-2728(95)00002-Z; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAVERGNE J, 1995, BIOPHYS J, V68, P2474, DOI 10.1016/S0006-3495(95)80429-7; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MIRANDA T, 1995, PHOTOSYNTH RES, V43, P251, DOI 10.1007/BF00029938; Nakajima Y, 1996, PLANT CELL PHYSIOL, V37, P673, DOI 10.1093/oxfordjournals.pcp.a028997; Olesen K, 2003, BIOCHEMISTRY-US, V42, P2025, DOI 10.1021/bi026175y; PALLETT KE, 1980, J EXP BOT, V31, P1051, DOI 10.1093/jxb/31.4.1051; PAROT P, 1987, BIOCHIM BIOPHYS ACTA, V893, P534, DOI 10.1016/0005-2728(87)90105-8; PICKETT SD, 1993, J MOL BIOL, V231, P825, DOI 10.1006/jmbi.1993.1329; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; Querol E, 1996, PROTEIN ENG, V9, P265, DOI 10.1093/protein/9.3.265; Rappaport F, 2005, BIOPHYS J, V88, P1948, DOI 10.1529/biophysj.104.050237; Rappaport F, 2002, BIOCHEMISTRY-US, V41, P8518, DOI 10.1021/bi025725p; Roncel M, 2003, J BIOL INORG CHEM, V8, P206, DOI 10.1007/s00775-002-0406-7; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; Rutherford AW, 2001, TRENDS BIOCHEM SCI, V26, P648, DOI 10.1016/S0968-0004(01)01953-3; RUTHERFORD AW, 1981, BIOCHIM BIOPHYS ACTA, V635, P205, DOI 10.1016/0005-2728(81)90020-7; SCHOEPP B, 1992, NATO ADV SCI INST SE, V237, P331; SEBBAN P, 1989, BIOCHIM BIOPHYS ACTA, V974, P54, DOI 10.1016/S0005-2728(89)80165-3; SEBBAN P, 1991, BIOCHIM BIOPHYS ACTA, V1057, P109, DOI 10.1016/S0005-2728(05)80090-8; SEBBAN P, 1988, BIOCHIM BIOPHYS ACTA, V936, P128; SHOPES RJ, 1987, BIOCHIM BIOPHYS ACTA, V893, P409, DOI 10.1016/0005-2728(87)90093-4; Sugiura M, 1999, PLANT CELL PHYSIOL, V40, P1219, DOI 10.1093/oxfordjournals.pcp.a029510; Trebst A, 2002, FEBS LETT, V516, P156, DOI 10.1016/S0014-5793(02)02526-7; VANGORKOM HJ, 1985, PHOTOSYNTH RES, V6, P97, DOI 10.1007/BF00032785; VANMIEGHEM F, 1995, BIOCHEMISTRY-US, V34, P4798, DOI 10.1021/bi00014a038; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VELTHUYS BR, 1974, BIOCHIM BIOPHYS ACTA, V333, P85, DOI 10.1016/0005-2728(74)90165-0; VELTHUYS BR, 1981, FEBS LETT, V126, P277, DOI 10.1016/0014-5793(81)80260-8; Wincencjusz H, 1999, BIOCHEMISTRY-US, V38, P3719, DOI 10.1021/bi982295n; WOODBURY NW, 1986, BIOCHIM BIOPHYS ACTA, V851, P6, DOI 10.1016/0005-2728(86)90243-4; WRAIGHT CA, 1981, ISRAEL J CHEM, V21, P348	68	67	68	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12492	12502		10.1074/jbc.M610951200	http://dx.doi.org/10.1074/jbc.M610951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327225	hybrid			2022-12-27	WOS:000245942800018
J	Sanz-Rodriguez, CE; Concepcion, JL; Pekerar, S; Oldfield, E; Urbina, JA				Sanz-Rodriguez, Carlos E.; Concepcion, Juan L.; Pekerar, Sara; Oldfield, Eric; Urbina, Julio A.			Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase - Kinetic and metabolic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAGAS-DISEASE; SCHIZOTRYPANUM CRUZI; IN-VITRO; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLUCOKINASE ACTIVATORS; FUMARATE REDUCTASE; ENERGY-METABOLISM; DIABETES THERAPY; EPIMASTIGOTES; GROWTH	Trypanosoma cruzi, the etiologic agent of Chagas disease, has an unusual ATP-dependent hexokinase (TcHK) that is not affected by D-glucose 6-phosphate, but is non-competitively inhibited by inorganic pyrophosphate (PPi), suggesting a heterotropic modulator effect. In a previous study we identified a novel family of bisphosphonates, metabolically stable analogs of PPi, which are potent and selective inhibitors of TcHK as well as the proliferation of the clinically relevant intracellular amastigote form of the parasite in vitro ( Hudock, M. P., Sanz-Rodriguez, C. E., Song, Y., Chan, J. M., Zhang, Y., Odeh, S., Kosztowski, T., Leon-Rossell, A., Concepcion, J. L., Yardley, V., Croft, S. L., Urbina, J. A., and Oldfield, E. ( 2006) J. Med. Chem. 49, 215 - 223). In this work, we report a detailed kinetic analysis of the effects of three of these bisphosphonates on homogeneous TcHK, as well as on the enzyme in purified intact glycosomes, peroxisome-like organelles that contain most of the glycolytic pathway enzymes in this organism. We also investigated the effects of the same compounds on glucose consumption by intact and digitonin-permeabilized T. cruzi epimastigotes, and on the growth of such cells in liver-infusion tryptose medium. The bisphosphonates investigated were several orders of magnitude more active than PPi as non-competitive or mixed inhibitors of TcHK and blocked the use of glucose by the epimastigotes, inducing a metabolic shift toward the use of amino acids as carbon and energy sources. Furthermore, there was a significant correlation between the IC50 values for TcHK inhibition and those for epi-mastigote growth inhibition for the 12 most potent compounds of this series. Finally, these bisphosphonates did not affect the sterol composition of the treated cells, indicating that they do not act as inhibitors of farnesyl diphosphate synthase. Taken together, our results suggest that these novel bisphosphonates act primarily as specific inhibitors of TcHK and may represent a novel class of selective anti-T. cruzi agents.	Inst Venezolano Invest Cient, Lab Quim Biol, Ctr Biofis & Bioquim, Caracas 1020, Venezuela; Univ Los Andes, Fac Ciencias, Dept Biol, Lab Enzimol Parasitos, Merida 5101, Venezuela; Inst Venezolano Invest Cient, Ctr Quim, Caracas 1020, Venezuela; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	Venezuelan Institute Science Research; University of Los Andes Venezuela; Venezuelan Institute Science Research; University of Illinois System; University of Illinois Urbana-Champaign	Urbina, JA (corresponding author), Inst Venezolano Invest Cient, Lab Quim Biol, Ctr Biofis & Bioquim, Caracas 1020, Venezuela.	jurbina@mac.com	Sanz-Rodriguez, Carlos/AAF-6746-2020	Sanz-Rodriguez, Carlos/0000-0002-6759-1955	NIGMS NIH HHS [GM-65307] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065307] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acosta H, 2004, COMP BIOCHEM PHYS B, V138, P347, DOI 10.1016/j.cbpc.2004.04.017; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; Caceres AJ, 2003, MOL BIOCHEM PARASIT, V126, P251, DOI 10.1016/S0166-6851(02)00294-3; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Cazzulo Juan Jose, 1992, V18, P235; Concepcion JL, 1998, ARCH BIOCHEM BIOPHYS, V352, P114, DOI 10.1006/abbi.1998.0577; Coura JR, 2002, MEM I OSWALDO CRUZ, V97, P3, DOI 10.1590/S0074-02762002000100001; de Maio A., 1984, Acta Cientifica Venezolana, V35, P136; Dias JCP, 2002, MEM I OSWALDO CRUZ, V97, P603, DOI 10.1590/S0074-02762002000500002; Docampo R, 2005, NAT REV MICROBIOL, V3, P251, DOI 10.1038/nrmicro1097; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo Roberto, 2001, Current Drug Targets - Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191; FRYDMAN B, 1990, EUR J BIOCHEM, V192, P363, DOI 10.1111/j.1432-1033.1990.tb19235.x; Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Hudock MP, 2006, J MED CHEM, V49, P215, DOI 10.1021/jm0582625; HUDSON L, 1983, T ROY SOC TROP MED H, V77, P416, DOI 10.1016/0035-9203(83)90176-1; Kita K, 2003, CURR MED CHEM, V10, P2535, DOI 10.2174/0929867033456549; KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010; Leighton B, 2005, BIOCHEM SOC T, V33, P371, DOI 10.1042/BST0330371; Lemercier G, 2004, J BIOL CHEM, V279, P3420, DOI 10.1074/jbc.M309974200; Lemercier G, 2002, J BIOL CHEM, V277, P37369, DOI 10.1074/jbc.M204744200; Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404; Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578; Martinez R, 2002, MOL BIOCHEM PARASIT, V120, P205, DOI 10.1016/S0166-6851(01)00456-X; Matschinsky FM, 2006, DIABETES, V55, P1; Moreno B, 2002, FEBS LETT, V523, P207, DOI 10.1016/S0014-5793(02)02977-0; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Quinones W, 2004, EXP PARASITOL, V106, P135, DOI 10.1016/j.exppara.2004.03.006; RACAGNI GE, 1983, MOL BIOCHEM PARASIT, V9, P181, DOI 10.1016/0166-6851(83)90108-1; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rodrigues CO, 2001, J EUKARYOT MICROBIOL, V48, P588, DOI 10.1111/j.1550-7408.2001.tb00195.x; TAYLOR M, 1986, FEBS LETT, V201, P262, DOI 10.1016/0014-5793(86)80620-2; TAYLOR MB, 1987, EXP PARASITOL, V63, P84, DOI 10.1016/0014-4894(87)90081-6; Turrens JF, 1999, FEMS MICROBIOL LETT, V175, P217, DOI 10.1111/j.1574-6968.1999.tb13623.x; URBINA JA, 1984, MOL BIOCHEM PARASIT, V11, P241, DOI 10.1016/0166-6851(84)90069-0; URBINA JA, 1984, MOL BIOCHEM PARASIT, V11, P225, DOI 10.1016/0166-6851(84)90068-9; URBINA JA, 1994, PARASITOL TODAY, V10, P107, DOI 10.1016/0169-4758(94)90010-8; Urbina JA, 2003, INT J ANTIMICROB AG, V21, P39, DOI 10.1016/S0924-8579(02)00274-1; Urbina JA, 2003, INT J ANTIMICROB AG, V21, P27, DOI 10.1016/S0924-8579(02)00273-X; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001; URBINA JA, 1987, ARCH BIOCHEM BIOPHYS, V258, P186, DOI 10.1016/0003-9861(87)90335-3; URBINA JA, 1990, ARCH BIOCHEM BIOPHYS, V282, P91, DOI 10.1016/0003-9861(90)90091-C; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; [No title captured]	49	55	57	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12377	12387		10.1074/jbc.M607286200	http://dx.doi.org/10.1074/jbc.M607286200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329254	hybrid			2022-12-27	WOS:000245942800006
J	Textoris-Taube, K; Henklein, P; Pollmann, S; Bergann, T; Weisshoff, H; Seifert, U; Drung, I; Mugge, C; Sijts, A; Kloetzel, PM; Kuckelkorn, U				Textoris-Taube, Kathrin; Henklein, Peter; Pollmann, Sylvie; Bergann, Theresa; Weisshoff, Hardy; Seifert, Ulrike; Drung, Ilse; Muegge, Clemens; Sijts, Alice; Kloetzel, Peter-Michael; Kuckelkorn, Ulrike			The N-terminal flanking region of the TRP2(360-368) melanoma antigen determines proteasome activator PA28 requirement for epitope liberation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTE EPITOPE; CTL EPITOPE; DEGRADATION; EXPRESSION	Proteasomes are known to produce major histocompatibility complex ( MHC) class I ligands from endogenous antigens. The interferon-gamma-inducible proteasome activator PA28 plays an important role in the generation of MHC ligands by proteasomes. Generation of the HLA-A*0201 restricted melanoma antigen TRP2(360-368) by the proteasome has been shown to be dependent on the function of PA28 in vitro and in vivo ( Sun, Y., Sijts, A. J., Song, M., Janek, K., Nussbaum, A. K., Kral, S., Schirle, M., Stevanovic, S., Paschen, A., Schild, H., Kloetzel, P. M., and Schadendorf, D. ( 2002) Cancer Res. 62, 2875-2882). Here we analyzed the role of the epitope sequence environment in determining this PA28 dependence. Experiments using the melanoma TRP2(288-296) epitope and the murine cytomegalovirus-derived pp89 epitope precursor peptide for epitope replacement revealed that the TRP2(360-368) flanking sequences can transfer PA28 dependence onto otherwise PA28 independent epitopes. Moreover, the N-terminal flanking sequence is sufficient to establish PA28 dependence of an epitope by allowing PA28-induced coordinated dual cleavages. These results show that N-terminal flanking sequences strongly influence epitope generation efficiency and that PA28 function is particularly relevant for the generation of normally poorly excised peptide products.	Charite Univ Med Berlin, Inst Biochem, D-10117 Berlin, Germany; Humboldt Univ, Inst Chem, D-12489 Berlin, Germany; Univ Utrecht, Fac Vet Med, Div Infect Dis & Immunol, NL-3584 CL Utrecht, Netherlands	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Utrecht University	Kloetzel, PM (corresponding author), Monbijoustr 2, D-10117 Berlin, Germany.	p-m.kloetzel@charite.de		Sijts, Alice/0000-0003-3815-4788; Kuckelkorn, Ulrike/0000-0002-3085-9161				Beekman NJ, 2000, J IMMUNOL, V164, P1898, DOI 10.4049/jimmunol.164.4.1898; Braun HA, 2005, J BIOL CHEM, V280, P28394, DOI 10.1074/jbc.M502453200; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; Hill CP, 2002, CURR TOP MICROBIOL, V268, P73; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Knuehl C, 2001, J IMMUNOL, V167, P1515, DOI 10.4049/jimmunol.167.3.1515; Kuckelkorn U, 2002, EUR J IMMUNOL, V32, P1368, DOI 10.1002/1521-4141(200205)32:5<1368::AID-IMMU1368>3.0.CO;2-Z; Kuehn L, 1996, ARCH BIOCHEM BIOPHYS, V329, P87, DOI 10.1006/abbi.1996.0195; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Schwarz K, 2000, EUR J IMMUNOL, V30, P3672, DOI 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Seifert U, 2004, J CLIN INVEST, V114, P250, DOI 10.1172/JCI200420985; Shimbara N, 1997, GENES CELLS, V2, P785, DOI 10.1046/j.1365-2443.1997.1610359.x; Stohwasser R, 2003, BIOL CHEM, V384, P39, DOI 10.1515/BC.2003.005; Sun Y, 2002, CANCER RES, V62, P2875; Theobald M, 1998, J EXP MED, V188, P1017, DOI 10.1084/jem.188.6.1017; van Hall T, 2000, J EXP MED, V192, P483, DOI 10.1084/jem.192.4.483	20	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12749	12754		10.1074/jbc.M611644200	http://dx.doi.org/10.1074/jbc.M611644200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17308306	hybrid, Green Published			2022-12-27	WOS:000245942800045
J	Islam, MM; Wallin, R; Wynn, RM; Conway, M; Fujii, H; Mobley, JA; Chuang, DT; Hutson, SM				Islam, Mohammad Mainul; Wallin, Reidar; Wynn, R. Max; Conway, Myra; Fujii, Hisao; Mobley, James A.; Chuang, David T.; Hutson, Susan M.			A novel branched-chain amino acid metabolon - Protein-protein interactions in a supramolecular complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOACID DEHYDROGENASE; HUMAN MITOCHONDRIAL; ESCHERICHIA-COLI; ACTIVE-SITES; AMINOTRANSFERASE ISOENZYMES; MULTIENZYME COMPLEX; CRYSTAL-STRUCTURE; BINDING DOMAIN; E1 COMPONENT; CXXC MOTIF	The catabolic pathways of branched-chain amino acids have two common steps. The first step is deamination catalyzed by the vitamin B-6-dependent branched-chain aminotransferase isozymes ( BCATs) to produce branched-chain alpha-keto acids ( BCKAs). The second step is oxidative decarboxylation of the BCKAs mediated by the branched-chain alpha-keto acid dehydrogenase enzyme complex ( BCKD complex). The BCKD complex is organized around a cubic core consisting of 24 lipoate-bearing dihydrolipoyl transacylase ( E2) subunits, associated with the branched-chain alpha-keto acid decarboxylase/ dehydrogenase ( E1), dihydrolipoamide dehydrogenase ( E3), BCKD kinase, and BCKD phosphatase. In this study, we provide evidence that human mitochondrial BCAT ( hBCATm) associates with the E1 decarboxylase component of the rat or human BCKD complex with a K-D of 2.8 mu M. NADH dissociates the complex. The E2 and E3 components do not interact with hBCATm. In the presence of hBCATm, k(cat) values for E1-catalyzed decarboxylation of the BCKAs are enhanced 12-fold. Mutations of hBCATm proteins in the catalytically important CXXC center or E1 proteins in the phosphorylation loop residues prevent complex formation, indicating that these regions are important for the interaction between hBCATm and E1. Our results provide evidence for substrate channeling between hBCATm and BCKD complex and formation of a metabolic unit ( termed branched-chain amino acid metabolon) that can be influenced by the redox state in mitochondria.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA	Wake Forest University; Wake Forest University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Alabama System; University of Alabama Birmingham	Hutson, SM (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.	shutson@wfubmc.edu		Wynn, Richard/0000-0002-1879-2136	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034738, R56DK034738, R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26758, DK34738] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; Brautigam CA, 2005, J MOL BIOL, V350, P543, DOI 10.1016/j.jmb.2005.05.014; CATE RL, 1980, J BIOL CHEM, V255, P7556; Chang CF, 2006, J BIOL CHEM, V281, P28345, DOI 10.1074/jbc.M605005200; CHUANG DI, 2001, METABOLIC BASIS INHE, P1239; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Conway ME, 2000, METHOD ENZYMOL, V324, P355; Conway ME, 2004, BIOCHEMISTRY-US, V43, P7356, DOI 10.1021/bi0498050; Conway ME, 2002, BIOCHEMISTRY-US, V41, P9070, DOI 10.1021/bi020200i; DAMUNI Z, 1985, BIOCHEM BIOPH RES CO, V133, P878, DOI 10.1016/0006-291X(85)91217-3; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DANSON MJ, 1978, P NATL ACAD SCI USA, V75, P5386, DOI 10.1073/pnas.75.11.5386; Davoodi J, 1998, J BIOL CHEM, V273, P4982, DOI 10.1074/jbc.273.9.4982; FAHIEN LA, 1993, J BIOL CHEM, V268, P17935; Figeys D, 2002, CURR OPIN MOL THER, V4, P210; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; Fries M, 2003, EUR J BIOCHEM, V270, P861, DOI 10.1046/j.1432-1033.2003.03444.x; Goto M, 2005, J BIOL CHEM, V280, P37246, DOI 10.1074/jbc.M506486200; HALL TR, 1993, J BIOL CHEM, V268, P3092; HARPER AE, 1989, ANN NY ACAD SCI, V573, P267, DOI 10.1111/j.1749-6632.1989.tb15003.x; HARRIS RA, 1994, J NUTR, V124, pS1499, DOI 10.1093/jn/124.suppl_8.1499S; Harris RA, 2004, BIOCHEM BIOPH RES CO, V313, P391, DOI 10.1016/j.bbrc.2003.11.007; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HARRIS RA, 1985, ARCH BIOCHEM BIOPHYS, V243, P542, DOI 10.1016/0003-9861(85)90531-4; HTUSON SM, 1981, METABOLISM CLIN IMPL, P245; HUTSON SM, 1981, AM J CLIN NUTR, V34, P173, DOI 10.1093/ajcn/34.2.173; HUTSON SM, 1992, J BIOL CHEM, V267, P15681; HUTSON SM, 1978, J BIOL CHEM, V253, P8126; Hutson SM, 2005, J NUTR, V135, p1557S, DOI 10.1093/jn/135.6.1557S; HUTSON SM, 1989, ANN NY ACAD SCI, V573, P230, DOI 10.1111/j.1749-6632.1989.tb15000.x; Hutson SM, 2001, J NUTR, V131, p839S, DOI 10.1093/jn/131.3.839S; Hutson SM, 1998, J NEUROCHEM, V71, P863; ICHIHARA A, 1985, TRANSAMINASES, V2, P430; Kato M, 2006, EMBO J, V25, P5983, DOI 10.1038/sj.emboj.7601444; Kimball SR, 2004, BIOCHEM BIOPH RES CO, V313, P423, DOI 10.1016/j.bbrc.2003.07.014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li J, 2004, J BIOL CHEM, V279, P32968, DOI 10.1074/jbc.M403611200; Li J, 2007, J BIOL CHEM, V282, P11904, DOI 10.1074/jbc.M610843200; LORIDAN L, 1971, J PEDIATR-US, V78, P53, DOI 10.1016/S0022-3476(71)80263-9; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Lynch CJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE854, DOI 10.1152/ajpendo.00153.2003; Machius M, 2006, STRUCTURE, V14, P287, DOI 10.1016/j.str.2005.10.009; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; MALAISSE WJ, 1984, BIOCHIM BIOPHYS ACTA, V797, P194, DOI 10.1016/0304-4165(84)90122-3; MALAISSE WJ, 1986, ADV ENZYME REGUL, V25, P203, DOI 10.1016/0065-2571(86)90015-4; ODESSEY R, 1974, J BIOL CHEM, V249, P7623; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; Prod'homme M, 2004, CURR OPIN CLIN NUTR, V7, P71, DOI 10.1097/00075197-200401000-00012; REED LJ, 1990, J BIOL CHEM, V265, P8971; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; Seifert F, 2006, BIOCHEMISTRY-US, V45, P12775, DOI 10.1021/bi061582l; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; Srere PA, 2000, TRENDS BIOCHEM SCI, V25, P150, DOI 10.1016/S0968-0004(00)01550-4; Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Sweatt AJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE64, DOI 10.1152/ajpendo.00276.2003; TELLER JK, 1990, J BIOL CHEM, V265, P19486; Wynn RM, 2000, METHOD ENZYMOL, V324, P179; Wynn RM, 2004, STRUCTURE, V12, P2185, DOI 10.1016/j.str.2004.09.013; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200; Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200; Yennawar N, 2001, ACTA CRYSTALLOGR D, V57, P506, DOI 10.1107/S0907444901001925; Yennawar NH, 2006, J BIOL CHEM, V281, P39660, DOI 10.1074/jbc.M607552200; Yennawar NH, 2002, BIOCHEMISTRY-US, V41, P11592, DOI 10.1021/bi020221c; Yoshizawa F, 2004, BIOCHEM BIOPH RES CO, V313, P417, DOI 10.1016/j.bbrc.2003.07.013; Zimmerman LJ, 2005, J PROTEOME RES, V4, P1672, DOI 10.1021/pr050138m	70	81	81	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11893	11903		10.1074/jbc.M700198200	http://dx.doi.org/10.1074/jbc.M700198200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314104	hybrid			2022-12-27	WOS:000245941900032
J	Yamamoto, T; Shimano, H; Inoue, N; Nakagawa, Y; Matsuzaka, T; Takahashi, A; Yahagi, N; Sone, H; Suzuki, H; Toyoshima, H; Yamada, N				Yamamoto, Takashi; Shimano, Hitoshi; Inoue, Noriyuki; Nakagawa, Yoshimi; Matsuzaka, Takashi; Takahashi, Akimitsu; Yahagi, Naoya; Sone, Hirohito; Suzuki, Hiroaki; Toyoshima, Hideo; Yamada, Nobuhiro			Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; LIPOGENIC GENE-EXPRESSION; CHOLESTEROL-METABOLISM; TRANSGENIC MICE; LXR-ALPHA; TRANSCRIPTION FACTOR; ADIPOSE-TISSUE; ACTIVATION; PROMOTER; INHIBITION	Sterol regulatory element-binding protein ( SREBP)-1c is a transcription factor that controls synthesis of fatty acids and triglycerides in the liver and is highly regulated by nutrition and hormones. In the current studies we show that protein kinase A ( PKA), a mediator of glucagon/cAMP, a fasting signaling, suppresses SREBP-1c by modulating the activity of liver X receptor alpha( LXR alpha), a dominant activator of SREBP-1c expression. Activation of PKA repressed LXR-induced SREBP-1c expression both in rat primary hepatocytes and mouse livers. Promoter analyses revealed that the LXR alpha-binding site in the SREBP-1c promoter is responsible for PKA inhibitory effect on SREBP-1c transcription. In vitro and in vivo PKA directly phosphorylated LXR alpha, and the two consensus PKA target sites ( 195, 196 serines and 290, 291 serines) in its ligand binding/heterodimerization domain were crucial for the inhibition of LXR signaling. PKA phosphorylation of LXR alpha caused impaired DNA binding activity by preventing LXR alpha/RXR dimerization and decreased its transcription activity by inhibiting recruitment of coactivator SCR-1 and enhancing recruitment of corepressor NcoR1. These results indicate that LXR alpha is regulated not only by oxysterol derivatives but also by PKA-mediated phosphorylation, which suggests that nutritional regulation of SREBP-1c and lipogenesis could be regulated at least partially through modulation of LXR.	Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba	Shimano, H (corresponding author), Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019; Sone, Hirohito/ABC-9346-2021; Shimano, Hitoshi/AAI-5648-2020	Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572; Sone, Hirohito/0000-0003-1263-2817; 				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Chen MY, 2006, FEBS LETT, V580, P4835, DOI 10.1016/j.febslet.2006.07.074; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Costet P, 2000, J BIOL CHEM, V275, P28240; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Harish S, 2000, BIOCHEM BIOPH RES CO, V279, P853, DOI 10.1006/bbrc.2000.4043; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Hu X, 2003, MOL ENDOCRINOL, V17, P1019, DOI 10.1210/me.2002-0399; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Ono H, 2003, DIABETES, V52, P2905, DOI 10.2337/diabetes.52.12.2905; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Sone H, 2004, BIOCHEM BIOPH RES CO, V316, P790, DOI 10.1016/j.bbrc.2004.02.121; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Yu LQ, 2005, J BIOL CHEM, V280, P8742, DOI 10.1074/jbc.M411080200	43	83	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11687	11695		10.1074/jbc.M611911200	http://dx.doi.org/10.1074/jbc.M611911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17296605	hybrid			2022-12-27	WOS:000245941900010
J	Zeidan, YH; Hannun, YA				Zeidan, Youssef H.; Hannun, Yusuf A.			Activation of acid sphingomyelinase by protein kinase C delta-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; NIEMANN-PICK-DISEASE; LEUKEMIA-CELL LINE; CERAMIDE PRODUCTION; PKC-DELTA; TYROSINE PHOSPHORYLATION; MITOCHONDRIAL-MEMBRANE; CANCER CELLS; TRANSLOCATION; DIFFERENTIATION	Although important for cellular stress signaling pathways, the molecular mechanisms of acid sphingomyelinase (ASMase) activation remain poorly understood. Previous studies showed that treatment of MCF-7 mammary carcinoma cells with the potent protein kinase C (PKC) agonist, phorbol 12-myristate 13-acetate ( PMA), induces a transient drop in sphingomyelin concomitant with an increase in cellular ceramide levels ( Becker, K. P., Kitatani, K., Idkowiak- Baldys, J., Bielawski, J., and Hannun, Y. A. ( 2005) J. Biol. Chem. 280, 2606 - 2612). Here we show that PMA selectively activates ASMase and that ASMase accounts for the majority of PMA- induced ceramide. Pharmacologic inhibition and RNA interference experiments indicated that the novel PKC, PKC delta, is required for ASMase activation. Immunoprecipitation experiments revealed the formation of a novel PKC delta-ASMase complex after PMA stimulation, and PKC delta was able to phosphorylate ASMase in vitro and in cells. Using site-directed mutagenesis, we identify serine 508 as the key residue phosphorylated in response to PMA. Phosphorylation of Ser(508) proved to be an indispensable step for ASMase activation and membrane translocation in response to PMA. The relevance of the proposed mechanism of ASMase regulation is further validated in a model of UV radiation. UV radiation also induced phosphorylation of ASMase at serine 508. Moreover, when transiently overexpressed, ASMase(S508A) blocked the ceramide formation after PMA treatment, suggesting a dominant negative function for this mutant. Taken together, these results establish a novel direct biochemical mechanism for ASMase activation in which PKC delta serves as a key upstream kinase.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 175 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Zeidan, Youssef H./H-7578-2019	Zeidan, Youssef H./0000-0002-1951-8585	NCI NIH HHS [P01-CA97132] Funding Source: Medline; NCRR NIH HHS [C06 RR018823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Becker KP, 2005, J BIOL CHEM, V280, P2606, DOI 10.1074/jbc.M409066200; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Charruyer A, 2005, J BIOL CHEM, V280, P19196, DOI 10.1074/jbc.M412867200; Church LD, 2005, J LEUKOCYTE BIOL, V78, P266, DOI 10.1189/jlb.1003456; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568; Enomoto A, 2000, CANCER LETT, V155, P137, DOI 10.1016/S0304-3835(00)00422-5; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; Ferlinz K, 1999, CHEM PHYS LIPIDS, V102, P35, DOI 10.1016/S0009-3084(99)00073-0; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; Garzotto M, 1998, CANCER RES, V58, P2260; Ginzburg L, 2005, J NEUROCHEM, V95, P1619, DOI 10.1111/j.1471-4159.2005.03534.x; Giuliano M, 2006, INT J MOL MED, V17, P811; Grant S, 2002, J CLIN INVEST, V109, P717, DOI 10.1172/JCI200215302; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kuemmel TA, 1997, PATHOL RES PRACT, V193, P663, DOI 10.1016/S0344-0338(97)80025-8; Langmann T, 1999, J LIPID RES, V40, P870; Li LW, 1999, MOL CELL BIOL, V19, P8547; Linke T, 2001, BIOL CHEM, V382, P283, DOI 10.1515/BC.2001.035; Liu JH, 2003, CANCER RES, V63, P1153; Liu X, 2006, MOL THER, V14, P627, DOI 10.1016/j.ymthe.2006.07.001; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Mimeault M, 2003, PROSTATE, V56, P1, DOI 10.1002/pros.10190; Murate T, 2002, J BIOL CHEM, V277, P9936, DOI 10.1074/jbc.M111594200; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Rehman F, 2004, BRIT J CANCER, V91, P1821, DOI 10.1038/sj.bjc.6602212; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Sikora J, 2003, ANN HUM GENET, V67, P63, DOI 10.1046/j.1469-1809.2003.00009.x; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Takahashi E, 2006, J RADIAT RES, V47, P19, DOI 10.1269/jrr.47.19; Tettamanti G, 1996, J LIPID MEDIAT CELL, V14, P263, DOI 10.1016/0929-7855(96)00535-4; YAMAGUCHI S, 1977, J BIOL CHEM, V252, P3805; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zeidan YH, 2006, J BIOL CHEM, V281, P24695, DOI 10.1074/jbc.M604713200	56	112	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11549	11561		10.1074/jbc.M609424200	http://dx.doi.org/10.1074/jbc.M609424200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303575	hybrid			2022-12-27	WOS:000245941500076
J	de Silva, U; Choudhury, S; Bailey, SL; Harvey, S; Perrino, FW; Hollis, T				de Silva, Udesh; Choudhury, Sumana; Bailey, Suzanna L.; Harvey, Scott; Perrino, Fred W.; Hollis, Thomas			The crystal structure of TREX1 explains the 3 ' nucleotide specificity and reveals a polyproline II helix for protein partnering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; AICARDI-GOUTIERES-SYNDROME; STRAND BREAK REPAIR; PROOFREADING EXONUCLEASE; RECOMBINANT PROTEINS; MICE DEFICIENT; MECHANISM; IDENTIFICATION; CHROMOSOME; SEQUENCES	The TREX1 enzyme processes DNA ends as the major 3'-> 5' exonuclease activity in human cells. Mutations in the TREX1 gene are an underlying cause of the neurological brain disease Aicardi-Goutieres syndrome implicating TREX1 dysfunction in an aberrant immune response. TREX1 action during apoptosis likely prevents autoimmune reaction to DNA that would otherwise persist. To understand the impact of TREX1 mutations identified in patients with Aicardi-Goutieres syndrome on structure and activity we determined the x-ray crystal structure of the dimeric mouse TREX1 protein in substrate and product complexes containing single-stranded DNA and deoxyadenosine monophosphate, respectively. The structures show the specific interactions between the bound nucleotides and the residues lining the binding pocket of the 3' terminal nucleotide within the enzyme active site that account for specificity, and provide the molecular basis for understanding mutations that lead to disease. Three mutant forms of TREX1 protein identified in patients with Aicardi-Goutieres syndrome were prepared and the measured activities show that these specific mutations reduce enzyme activity by 4-35,000-fold. The structure also reveals an 8-amino acid polyproline II helix within the TREX1 enzyme that suggests a mechanism for interactions of this exonuclease with other protein complexes.	Wake Forest Univ Hlth Sci, Dept Biochem, Ctr Struct Biol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine	Hollis, T (corresponding author), Med Ctr Blvd, Winston Salem, NC 27157 USA.	thollis@wfubmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM069962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AICARDI J, 1984, ANN NEUROL, V15, P49, DOI 10.1002/ana.410150109; Alarcon-Riquelme ME, 2006, NAT GENET, V38, P866, DOI 10.1038/ng0806-866; BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; DeRose EF, 2002, BIOCHEMISTRY-US, V41, P94, DOI 10.1021/bi0114170; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Goldsby RE, 2002, P NATL ACAD SCI USA, V99, P15560, DOI 10.1073/pnas.232340999; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Goutieres F, 2005, BRAIN DEV-JPN, V27, P201, DOI 10.1016/j.braindev.2003.12.011; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Inamdar KV, 2002, RADIAT RES, V157, P306, DOI 10.1667/0033-7587(2002)157[0306:ROPDET]2.0.CO;2; Karasinska JM, 2006, CLIN GENET, V70, P457, DOI 10.1111/j.1399-0004.2006.00709_1.x; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lee-Kirsch MA, 2006, AM J HUM GENET, V79, P731, DOI 10.1086/507848; Longacre A, 2003, INT IMMUNOL, V15, P477, DOI 10.1093/intimm/dxg047; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mazur DJ, 2001, J BIOL CHEM, V276, P17022, DOI 10.1074/jbc.M100623200; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McElhinny SAN, 2006, CELL CYCLE, V5, P958, DOI 10.4161/cc.5.9.2736; Miller H, 1996, BIOCHEMISTRY-US, V35, P12919, DOI 10.1021/bi960326d; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Perrino FW, 2004, ADV ENZYME REGUL, V44, P37, DOI 10.1016/j.advenzreg.2003.11.010; Perrino FW, 2005, J BIOL CHEM, V280, P15212, DOI 10.1074/jbc.M500108200; Perry JJP, 2006, NAT STRUCT MOL BIOL, V13, P414, DOI 10.1038/nsmb1088; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	44	82	88	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10537	10543		10.1074/jbc.M700039200	http://dx.doi.org/10.1074/jbc.M700039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293595	hybrid			2022-12-27	WOS:000245941000046
J	Hsu, SC; Hung, MC				Hsu, Sheng-Chieh; Hung, Mien-Chie			Characterization of a novel tripartite nuclear localization sequence in the EGFR family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; RECEPTOR TYROSINE KINASES; IMPORTIN BETA; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; GENE-EXPRESSION; IN-VITRO; PATHWAY; DNA	Aberrant expression of epidermal growth factor receptor ( EGFR) is present in many human tumors. Several reports have shown that EGFR is translocated into the nucleus during liver regeneration and in several types of cells and tissues such as placenta and thyroid. Nuclear EGFR is associated with transcription, DNA synthesis, and DNA repair activity and serves as a prognostic marker in breast carcinoma and oropharyngeal squamous cell cancer. However, the nuclear localization sequence ( NLS) of EGFR has not been extensively examined. In this study, we have shown that the juxtamembrane region of EGFR harbors a putative NLS with three clusters of basic amino acids ( RRRHIVRKRTLRR ( amino acids 645 - 657)) that mediates the nuclear localization of EGFR. We found that this newly characterized tripartite NLS is conserved among the EGFR family members ( EGFR, ErbB2, ErbB3, and ErbB4) and is able to move each to the nucleus. Further, this tripartite NLS could also mediate the nuclear localization of other known cytoplasmic proteins such as pyruvate kinase. We have demonstrated that mutating one of the three basic amino acid clusters ( R or K3A) leads to significant impairment of the nuclear localization of EGFR and that of a green fluorescent protein-pyruvate kinase-NLS reporter protein. Our results show that this tripartite NLS is distinct from the traditional mono- and bipartite NLS and reveal a mechanism that could account for the nuclear localization of membrane receptors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 79,1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA109311] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA109311] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aifa S, 2005, EXP CELL RES, V302, P108, DOI 10.1016/j.yexcr.2004.08.032; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; BADER T, 1994, P NATL ACAD SCI USA, V91, P11831, DOI 10.1073/pnas.91.25.11831; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; CAO H, 1995, ENDOCRINOLOGY, V136, P3163, DOI 10.1210/en.136.7.3163; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007; Chen QQ, 2005, CELL RES, V15, P504, DOI 10.1038/sj.cr.7290320; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CURTIS BM, 1990, J IMMUNOL, V144, P1295; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Friedmann BJ, 2006, MOL CANCER THER, V5, P209, DOI 10.1158/1535-7163.MCT-05-0239; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Johnson HM, 1998, P SOC EXP BIOL MED, V218, P149; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMIO T, 1990, HUM PATHOL, V21, P277, DOI 10.1016/0046-8177(90)90227-V; Larkin J, 2000, J INTERF CYTOK RES, V20, P565, DOI 10.1089/10799900050044769; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Marti U, 2001, THYROID, V11, P137, DOI 10.1089/105072501300042785; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Peters Reiner, 2006, V322, P235; Pillai G, 2005, HISTOPATHOLOGY, V46, P209, DOI 10.1111/j.1365-2559.2005.02081.x; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RAKOWICZSZULCZYNSKA EM, 1988, CANCER RES, V48, P7200; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; TERVAHAUTA A, 1994, INT J GYNECOL PATHOL, V13, P234, DOI 10.1097/00004347-199407000-00007; Truant R, 1999, MOL CELL BIOL, V19, P1210; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VILLALOBO A, 2003, REV ONCOL, V5, P381; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yan Duen-Hwa, 2004, V245, P125; Zwaagstra JC, 2000, EXP CELL RES, V258, P121, DOI 10.1006/excr.2000.4905	69	184	195	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10432	10440		10.1074/jbc.M610014200	http://dx.doi.org/10.1074/jbc.M610014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283074	hybrid			2022-12-27	WOS:000245941000034
J	Johnson, CL; Owen, DM; Gale, M				Johnson, Cynthia L.; Owen, David M.; Gale, Michael, Jr.			Functional and therapeutic analysis of hepatitis C virus NS3 center dot 4A protease control of antiviral immune defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-3; NONSTRUCTURAL PROTEIN-3 NS3; NF-KAPPA-B; RIG-I; CRYSTAL-STRUCTURE; ADAPTER PROTEIN; SIGNALING PROTEIN; HELICASE ACTIVITY; BETA PROMOTER; CELL-LINES	Chronic hepatitis C virus ( HCV) infection is a major global public health problem. HCV infection is supported by viral strategies to evade the innate antiviral response wherein the viral NS3.4A protease complex targets and cleaves the interferon promoter stimulator-1 ( IPS-1) adaptor protein to ablate signaling of interferon alpha/beta immune defenses. Here we examined the structural requirements of NS3.4A and the therapeutic potential of NS3.4A inhibitors to control the innate immune response against virus infection. The structural composition of NS3 includes an amino-terminal serine protease domain and a carboxyl-terminal RNA helicase domain. NS3 mutants lacking the helicase domain retained the ability to control virus signaling initiated by retinoic acid-inducible gene-I ( RIG-I) or melanoma differentiation antigen 5 and suppressed the downstream activation of interferon regulatory factor-3 ( IRF-3) and nuclear factor kappa B ( NF-kappa B) through the targeted proteolysis of IPS-1. This regulation was abrogated by truncation of the NS3 protease domain or by point mutations that ablated protease activity. NS3.4A protease control of antiviral immune signaling was due to targeted proteolysis of IPS-1 by the NS3 protease domain and minimal NS4A cofactor. Treatment of HCV-infected cells with an NS3 protease inhibitor prevented IPS-1 proteolysis by the HCV protease and restored RIG-I immune defense signaling during infection. Thus, the NS3.4A protease domain can target IPS-1 for cleavage and is essential for blocking RIG-I signaling to IRF-3 and NF-kappa B, whereas the helicase domain is dispensable for this action. Our results indicate that NS3.4A protease inhibitors have immunomodulatory potential to restore innate immune defenses to HCV infection.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gale, M (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA.	Michael.Gale@UTSouthwestern.edu		Owen, David/0000-0002-5724-0342; Monaco, Cynthia/0000-0003-3093-5563; Gale, Michael/0000-0002-6332-7436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060389, U19AI040035] Funding Source: NIH RePORTER; NIAID NIH HHS [U19AI40035, R01AI060389] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Bartenschlager R, 1999, J VIRAL HEPATITIS, V6, P165, DOI 10.1046/j.1365-2893.1999.00152.x; Borowski P, 1997, J VIROL, V71, P2838, DOI 10.1128/JVI.71.4.2838-2843.1997; Borowski P, 1999, J BIOL CHEM, V274, P30722, DOI 10.1074/jbc.274.43.30722; Brown RS, 2005, NATURE, V436, P973, DOI 10.1038/nature04083; De Francesco R, 1998, ANTIVIR THER, V3, P99; Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082; Ferreon JC, 2005, J BIOL CHEM, V280, P20483, DOI 10.1074/jbc.M500422200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fredericksen B, 2002, VIRAL IMMUNOL, V15, P29, DOI 10.1089/088282402317340215; Fukuda K, 2004, BIOCHEM BIOPH RES CO, V325, P670, DOI 10.1016/j.bbrc.2004.10.089; Fukuda K, 2001, Nucleic Acids Res Suppl, P147; Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Gu BH, 2005, PROTEIN PEPTIDE LETT, V12, P315, DOI 10.2174/0929866053765716; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Johnson CL, 2006, TRENDS IMMUNOL, V27, P1, DOI 10.1016/j.it.2005.11.004; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kuang WF, 2004, BIOCHEM BIOPH RES CO, V317, P211, DOI 10.1016/j.bbrc.2004.03.032; Kwong AD, 2000, CURR TOP MICROBIOL, V242, P171; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Love RA, 1998, CLIN DIAGN VIROL, V10, P151, DOI 10.1016/S0928-0197(98)00036-1; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Ni ZJ, 2004, CURR OPIN DRUG DISC, V7, P446; Nishikawa F, 2003, NUCLEIC ACIDS RES, V31, P1935, DOI 10.1093/nar/gkg291; Nomura-Takigawa Y, 2006, J GEN VIROL, V87, P1935, DOI 10.1099/vir.0.81701-0; Pflugheber J, 2002, P NATL ACAD SCI USA, V99, P4650, DOI 10.1073/pnas.062055699; Reed KE, 1998, CURR STUD HEMATOL BL, P1; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104; Saito T, 2007, CURR OPIN IMMUNOL, V19, P17, DOI 10.1016/j.coi.2006.11.003; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Sumpter R, 2004, J VIROL, V78, P11591, DOI 10.1128/JVI.78.21.11591-11604.2004; Tan SL, 2004, CURR OPIN PHARMACOL, V4, P465, DOI 10.1016/j.coph.2004.07.003; Taremi SS, 1998, PROTEIN SCI, V7, P2143, DOI 10.1002/pro.5560071011; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang CF, 2003, J VIROL, V77, P3898, DOI 10.1128/JVI.77.7.3898-3912.2003; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000; Wyss DF, 2004, J MED CHEM, V47, P2486, DOI 10.1021/jm0305117; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yoneyama M, 2002, J INTERF CYTOK RES, V22, P73, DOI 10.1089/107999002753452674; Zhang C, 2005, J VIROL, V79, P8687, DOI 10.1128/JVI.79.14.8687-8697.2005	60	74	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10792	10803		10.1074/jbc.M610361200	http://dx.doi.org/10.1074/jbc.M610361200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289677	hybrid			2022-12-27	WOS:000245941000073
J	Kinoshita, A; Tsukada, K; Soga, T; Hishiki, T; Ueno, Y; Nakayama, Y; Tomita, M; Suematsu, M				Kinoshita, Ayako; Tsukada, Kosuke; Soga, Tomoyoshi; Hishiki, Takako; Ueno, Yuki; Nakayama, Yoichi; Tomita, Masaru; Suematsu, Makoto			Roles of hemoglobin allostery in hypoxia-induced metabolic alterations in erythrocytes - Simulation and its verification by metabolome analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELL; ENZYME-KINETIC EQUATIONS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; 2,3-BISPHOSPHOGLYCERATE METABOLISM; GLUCOSE-METABOLISM; MUSCULAR EXERCISE; MASS-SPECTROMETRY; OXYGEN-BINDING; MEMBRANE; BAND-3	When erythrocytes are exposed to hypoxia, hemoglobin ( Hb) stabilizes in the T-state by capturing 2,3-bisphosphoglycerate. This process could reduce the intracellular pool of glycolytic substrates, jeopardizing cellular energetics. Recent observations suggest that hypoxia-induced activation of glycolytic enzymes is correlated with their release from Band III ( BIII) on the cell membrane. Based on these data, we developed a mathematical model of erythrocyte metabolism and compared hypoxia-induced differences in predicted activities of the enzymes, their products, and cellular energetics between models with and without the interaction of Hb with BIII. The models predicted that the allostery-dependent Hb interaction with BIII accelerates consumption of upstream glycolytic substrates such as glucose 6-phosphate and increases downstream products such as phosphoenolpyruvate. This prediction was consistent with metabolomic data from capillary electrophoresis mass spectrometry. The hypoxia-induced alterations in the metabolites resulted from acceleration of glycolysis, as judged by increased conversion of [ C-13] glucose to [ C-13] lactate. The allostery-dependent interaction of Hb with BIII appeared to contribute not only to maintenance of energy charge but also to further synthesis of 2,3-bisphosphoglycerate, which could help sustain stabilization of T-state Hb during hypoxia. Furthermore, such an activation of glycolysis was not observed when Hb was stabilized in R-state by treating the cells with CO. These results suggest that Hb allostery in erythrocytes serves as an O-2-sensing trigger that drives glycolytic acceleration to stabilize intracellular energetics and promote the ability to release O-2 from the cells.	Keio Univ, Inst Adv Biosci, Yamagata 9970017, Japan; Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University	Suematsu, M (corresponding author), Keio Univ, Inst Adv Biosci, Yamagata 9970017, Japan.	msuem@sc.itc.keio.ac.jp	Suematsu, Makoto/I-8135-2013; Soga, Tomoyoshi/B-8105-2014; Suematsu, Makoto/O-5762-2018; Tsukada, Kosuke/C-9986-2014	Suematsu, Makoto/0000-0002-7165-6336; Soga, Tomoyoshi/0000-0001-9502-2509; Suematsu, Makoto/0000-0002-7165-6336; Tsukada, Kosuke/0000-0003-1463-2204; Yachie, Ayako/0000-0003-2032-227X				ATKINSON DE, 1967, J BIOL CHEM, V242, P3239; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; Chu HY, 2006, BIOCHEM J, V400, P143, DOI 10.1042/BJ20060792; COSTA LE, 1976, ACTA PHYSIOL LAT AM, V26, P115; Dash RK, 2004, ANN BIOMED ENG, V32, P1676, DOI 10.1007/s10439-004-7821-6; Ellsworth ML, 2004, MED SCI SPORT EXER, V36, P35, DOI 10.1249/01.MSS.0000106284.80300.B2; Ellsworth ML, 1995, AM J PHYSIOL-HEART C, V269, pH2155, DOI 10.1152/ajpheart.1995.269.6.H2155; HARRIS SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P306, DOI 10.1016/0167-4838(90)90242-8; Hauck EF, 2004, J CEREBR BLOOD F MET, V24, P383, DOI 10.1097/00004647-200404000-00003; HIGASHI T, 1979, J BIOL CHEM, V254, P9542; Jagger JE, 2001, AM J PHYSIOL-HEART C, V280, pH2833, DOI 10.1152/ajpheart.2001.280.6.H2833; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; Jensen FB, 2004, ACTA PHYSIOL SCAND, V182, P215, DOI 10.1111/j.1365-201X.2004.01361.x; JOSHI A, 1990, J THEOR BIOL, V142, P69, DOI 10.1016/S0022-5193(05)80013-X; JOSHI A, 1989, J THEOR BIOL, V141, P529, DOI 10.1016/S0022-5193(89)80234-6; JOSHI A, 1990, J THEOR BIOL, V142, P41, DOI 10.1016/S0022-5193(05)80012-8; JOSHI A, 1989, J THEOR BIOL, V141, P515, DOI 10.1016/S0022-5193(89)80233-4; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; Komarova SV, 1999, BLOOD CELL MOL DIS, V25, P171, DOI 10.1006/bcmd.1999.0243; LENFANT C, 1968, J CLIN INVEST, V47, P2652, DOI 10.1172/JCI105948; MACPHEE PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG692, DOI 10.1152/ajpgi.1995.269.5.G692; MAGNANI M, 1983, BLOOD, V61, P915; Messana I, 1996, FEBS LETT, V390, P25, DOI 10.1016/0014-5793(96)00624-2; MILLS GC, 1976, P NATL ACAD SCI USA, V73, P2867, DOI 10.1073/pnas.73.8.2867; MOORE LG, 1980, AM J PHYS ANTHROPOL, V53, P11, DOI 10.1002/ajpa.1330530104; Mulquiney PJ, 1999, BIOCHEM J, V342, P581, DOI 10.1042/0264-6021:3420581; Mulquiney PJ, 1999, BIOCHEM J, V342, P567, DOI 10.1042/0264-6021:3420567; MURPHY JR, 1960, J LAB CLIN MED, V55, P286; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; Qian H, 2005, BIOPHYS CHEM, V114, P213, DOI 10.1016/j.bpc.2004.12.001; RAPOPORT TA, 1975, BIOSYSTEMS, V7, P120, DOI 10.1016/0303-2647(75)90049-0; RAPOPORT TA, 1976, BIOCHEM J, V154, P449, DOI 10.1042/bj1540449; SHIMIZU T, 1988, BLOOD, V71, P1130; Soga T, 2002, ANAL CHEM, V74, P2233, DOI 10.1021/ac020064n; Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m; Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; Sprague RS, 1996, AM J PHYSIOL-HEART C, V271, pH2717, DOI 10.1152/ajpheart.1996.271.6.H2717; Suganuma K, 2006, ANTIOXID REDOX SIGN, V8, P1847, DOI 10.1089/ars.2006.8.1847; Takahashi K, 2002, IEEE INTELL SYST, V17, P64, DOI 10.1109/MIS.2002.1039834; Tomita M, 1999, BIOINFORMATICS, V15, P72, DOI 10.1093/bioinformatics/15.1.72; Tsai AG, 2003, PHYSIOL REV, V83, P933, DOI 10.1152/physrev.00034.2002; TSUNESHIGE A, 1987, J BIOCHEM-TOKYO, V101, P695, DOI 10.1093/jb/101.3.695; von Ruckmann B, 2002, BBA-BIOMEMBRANES, V1559, P43, DOI 10.1016/S0005-2736(01)00435-7; WALDER JA, 1984, J BIOL CHEM, V259, P238; YAMAMOTO T, 1994, HORM METAB RES, V26, P504, DOI 10.1055/s-2007-1001744; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323	49	75	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10731	10741		10.1074/jbc.M610717200	http://dx.doi.org/10.1074/jbc.M610717200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289676	hybrid			2022-12-27	WOS:000245941000067
J	Sharp, KH; Schneider, S; Cockayne, A; Paoli, M				Sharp, Katherine H.; Schneider, Sabine; Cockayne, Alan; Paoli, Max			Crystal structure of the heme-IsdC complex, the central conduit of the isd iron/heme uptake system in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; IRON; BINDING; TRANSPORT; ACQUISITION; METABOLISM; PROTEINS; DOMAIN; NEAT; SITE	Pathogens such as Staphylococcus aureus require iron to survive and have evolved specialized proteins to steal heme from their host. IsdC is the central conduit of the Isd ( iron-regulated surface determinant) multicomponent heme uptake machinery; staphylococcal cell-surface proteins such as IsdA, IsdB, and IsdH are thought to funnel their molecular cargo to IsdC, which then mediates the transfer of the iron-containing nutrient to the membrane translocation system IsdDEF. The structure of the heme-IsdC complex reveals a novel heme site within an immunoglobulin-like domain and sheds light on its binding mechanism. The folding topology is reminiscent of the architecture of cytochrome f, cellobiose dehydrogenase, and ethylbenzene dehydrogenase; in these three proteins, the heme is bound in an equivalent position, but interestingly, IsdC features a distinct binding pocket with the ligand located next to the hydrophobic core of the beta-sandwich. The iron is coordinated with a tyrosine surrounded by several non-polar side chains that cluster into a tightly packed proximal side. On the other hand, the distal side is relatively exposed with a short helical peptide segment that acts as a lip clasping onto almost half of the porphyrin plane. This structural feature is argued to play a role in the mechanism of binding and release by switching to an open conformation and thus loosening the interactions holding the heme. The structure of the heme-IsdC complex provides a template for the understanding of other proteins, such as IsdA, IsdB, and IsdH, that contain the same heme-binding module as IsdC, known as the NEAT ( near transporter) domain.	Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; Univ Nottingham, Inst Infect Immun & Inflammat, Ctr Biomol Sci, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Paoli, M (corresponding author), Univ Nottingham, Sch Pharm, Univ Pk, Nottingham NG7 2RD, England.	max.paoli@nottingham.ac.uk	Schneider, Sabine/G-2908-2013	Schneider, Sabine/0000-0003-1054-8689				Abraham BD, 2001, BIOCHEMISTRY-US, V40, P2251, DOI 10.1021/bi002121h; Andrade MA, 2002, GENOME BIOL, V3; Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROWETT WR, 1979, BIOCHIM BIOPHYS ACTA, V577, P291, DOI 10.1016/0005-2795(79)90033-3; Chan ACK, 2006, J MOL BIOL, V362, P1108, DOI 10.1016/j.jmb.2006.08.001; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Clarke SR, 2006, J INFECT DIS, V193, P1098, DOI 10.1086/501471; Clarke SR, 2004, MOL MICROBIOL, V51, P1509, DOI 10.1111/j.1365-2958.2003.03938.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans W, 1997, CHEM BRIT, V33, P22; Faraldo-Gomez JD, 2003, NAT REV MOL CELL BIO, V4, P105, DOI 10.1038/nrm1015; Friedman DB, 2006, PLOS PATHOG, V2, P777, DOI 10.1371/journal.ppat.0020087; Grigg JC, 2007, MOL MICROBIOL, V63, P139, DOI 10.1111/j.1365-2958.2006.05502.x; Hallberg BM, 2000, STRUCT FOLD DES, V8, P79, DOI 10.1016/S0969-2126(00)00082-4; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kloer DP, 2006, STRUCTURE, V14, P1377, DOI 10.1016/j.str.2006.07.001; Kuklin NA, 2006, INFECT IMMUN, V74, P2215, DOI 10.1128/IAI.74.4.2215-2223.2006; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Mack J, 2004, BIOCHEM BIOPH RES CO, V320, P781, DOI 10.1016/j.bbrc.2004.06.025; Maresso AW, 2006, BIOMETALS, V19, P193, DOI 10.1007/s10534-005-4863-7; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ochsner UA, 2000, MICROBIOL-UK, V146, P185, DOI 10.1099/00221287-146-1-185; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Paoli M, 1999, NAT STRUCT BIOL, V6, P926; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Pilpa RM, 2006, J MOL BIOL, V360, P435, DOI 10.1016/j.jmb.2006.05.019; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; Schneider S, 2006, J BIOL CHEM, V281, P32606, DOI 10.1074/jbc.M607516200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Skaar EP, 2004, MICROBES INFECT, V6, P390, DOI 10.1016/j.micinf.2003.12.008; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; Stojiljkovic I, 2002, DNA CELL BIOL, V21, P281, DOI 10.1089/104454902753759708; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Vliet AHM, 2002, FEMS MICROBIOL REV, V26, P173, DOI 10.1111/j.1574-6976.2002.tb00609.x; Vermeiren CL, 2006, BIOCHEMISTRY-US, V45, P12867, DOI 10.1021/bi0607711; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215	42	105	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10625	10631		10.1074/jbc.M700234200	http://dx.doi.org/10.1074/jbc.M700234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287214	hybrid			2022-12-27	WOS:000245941000056
J	Lao, DH; Yusoff, P; Chandramouli, S; Philp, RJ; Fong, CW; Jackson, RA; Saw, TY; Yu, CY; Guy, GR				Lao, Dieu-Hung; Yusoff, Permeen; Chandramouli, Sumana; Philp, Robin J.; Fong, Chee Wai; Jackson, Rebecca A.; Saw, Tzuen Yih; Yu, Chye Yun; Guy, Graeme R.			Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; TYROSINE PHOSPHORYLATION; KINASE; ACTIVATION; PATHWAY; FAMILY; RAF-1; CBL	In the context of fibroblast growth factor (FGF) signaling, Sprouty2 (Spry2) is the most profound inhibitor of the Ras/ERK pathway as compared with other Spry isoforms. An exclusive, necessary, but cryptic PXXPXR motif in the C terminus of Spry2 is revealed upon stimulation. The activation of Spry2 appears to be linked to sequences in the N-terminal half of the protein and correlated with a bandshifting seen on SDS-PAGE. The bandshifting is likely caused by changes in the phosphorylation status of key Ser and Thr residues following receptor stimulation. Dephosphorylation of at least two conserved Ser residues (Ser112 and Ser-115) within a conserved Ser/Thr sequence is accomplished upon stimulation by a phosphatase that binds to Spry2 around residues 50-60. We show that human Spry2 coimmunoprecipitates with both the catalytic and the regulatory subunits of protein phosphatase 2A (PP2A-C and PP2A-A, respectively) in cells upon FGF receptor (FGFR) activation. PP2A-A binds directly to Spry2, but not to Spry2 Delta 50 - 60 (Delta 50-60), and the activity of PP2A increases with both FGF treatment and FGFR1 overexpression. c-Cb1 and PP2A-A compete for binding centered around Tyr-55 on Spry2. We show that there are at least two distinct pools of Spry2, one that binds PP2A and another that binds c-Cb1. c-Cb1 binding likely targets Spry2 for ubiquitin-linked destruction, whereas the phosphatase binding and activity are necessary to dephosphorylate specific Ser/Thr residues. The resulting change in tertiary structure enables the Pro-rich motif to be revealed with subsequent binding of Grb2, a necessary step for Spry2 to act as a Ras/ERK pathway inhibitor in FGF signaling.	Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 138673, Singapore; Bioproc Technol Inst, Singapore 138668, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Bioprocessing Technology Institute (BTI)	Guy, GR (corresponding author), Inst Mol & Cell Biol, Signal Transduct Lab, Rm 6-01A,61 Biopolis Dr, Singapore 138673, Singapore.	mcbgg@imcb.a-star.edu.sg		Chandramouli, Sumana/0000-0001-6994-506X				BOS JL, 1989, CANCER RES, V49, P4682; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hu JJ, 2005, J BIOL CHEM, V280, P18943, DOI 10.1074/jbc.M414157200; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Lao DH, 2006, J BIOL CHEM, V281, P29993, DOI 10.1074/jbc.M604044200; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Mason JM, 2004, MOL BIOL CELL, V15, P2176, DOI 10.1091/mbc.E03-07-0503; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Rubin C, 2005, J BIOL CHEM, V280, P9735, DOI 10.1074/jbc.M408308200; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	27	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9117	9126		10.1074/jbc.M607563200	http://dx.doi.org/10.1074/jbc.M607563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255109	hybrid			2022-12-27	WOS:000245780300059
J	Pagano, JM; Farley, BM; McCoig, LM; Ryder, SP				Pagano, John M.; Farley, Brian M.; McCoig, Lisa M.; Ryder, Sean P.			Molecular basis of RNA recognition by the embryonic polarity determinant MEX-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS EMBRYOS; GLP-1 MESSENGER-RNA; ZINC-FINGER DOMAIN; CAENORHABDITIS-ELEGANS; TRANSLATIONAL REGULATION; GERMLINE SPECIFICATION; PIE-1 PROTEIN; CELL POLARITY; BINDING; TRISTETRAPROLIN	Embryonic development requires maternal proteins and RNA. In Caenorhabditis elegans, a gradient of CCCH tandem zinc finger (TZF) proteins coordinates axis polarization and germline differentiation. These proteins govern expression from maternal mRNAs by an unknown mechanism. Here we show that the TZF protein MEX-5, a primary anterior determinant, is an RNA-binding protein that recognizes linear RNA sequences with high affinity but low specificity. The minimal binding site is a tract of six or more uridines within a 9-13-nucleotide window. This sequence is remarkably abundant in the 3'-untranslated region of C. elegans transcripts, demonstrating that MEX-5 alone cannot specify mRNA target selection. In contrast, human TZF homologs tristetraprolin and ERF-2 bind with high specificity to UUAUUUAUU elements. We show that mutation of a single amino acid in each MEX-5 zinc finger confers tristetraprolin-like specificity to this protein. We propose that divergence of this discriminator residue modulates the RNA-binding specificity in this protein class. This residue is variable in nematode TZF proteins, but is invariant in other metazoans. Therefore, the divergence of TZF proteins and their critical role in early development is likely a nematode-specific adaptation.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Ryder, SP (corresponding author), 364 Plantat St,Lazare Res Bldg,Rm 906, Worcester, MA 01605 USA.	sean.ryder@umassmed.edu		Farley, Brian/0000-0002-8400-9306				Alliegro MC, 2006, P NATL ACAD SCI USA, V103, P9034, DOI 10.1073/pnas.0602859103; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Auweter SD, 2006, NUCLEIC ACIDS RES, V34, P4943, DOI 10.1093/nar/gkl620; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; BRENNER S, 1974, GENETICS, V77, P71; Brewer BY, 2004, J BIOL CHEM, V279, P27870, DOI 10.1074/jbc.M402551200; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; Curtis D, 1997, EMBO J, V16, P834, DOI 10.1093/emboj/16.4.834; D'Agostino I, 2006, DEV BIOL, V292, P244, DOI 10.1016/j.ydbio.2005.11.046; DeRenzo C, 2003, NATURE, V424, P685, DOI 10.1038/nature01887; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Dsouza M, 1997, TRENDS GENET, V13, P497, DOI 10.1016/S0168-9525(97)01347-4; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; Forbes A, 1998, DEVELOPMENT, V125, P679; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Goldstein B, 1996, DEVELOPMENT, V122, P1467; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Huang NN, 2002, DEVELOPMENT, V129, P747; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Johnstone O, 2001, ANNU REV GENET, V35, P365, DOI 10.1146/annurev.genet.35.102401.090756; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; Maduro MF, 2005, DEV BIOL, V285, P510, DOI 10.1016/j.ydbio.2005.06.022; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Ogura K, 2003, DEVELOPMENT, V130, P2495, DOI 10.1242/dev.00469; Pellettieri J, 2002, SCIENCE, V298, P1946, DOI 10.1126/science.1072162; Pitt JN, 2000, DEV BIOL, V219, P315, DOI 10.1006/dbio.2000.9607; Rambo RP, 2004, BIOCHEMISTRY-US, V43, P6486, DOI 10.1021/bi049912u; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; REINES SA, 1974, NUCLEIC ACIDS RES, V1, P767, DOI 10.1093/nar/1.6.767; Ryder SP, 2004, RNA, V10, P1449, DOI 10.1261/rna.7780504; Schubert CM, 2000, MOL CELL, V5, P671, DOI 10.1016/S1097-2765(00)80246-4; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seydoux G, 2006, CELL, V127, P891, DOI 10.1016/j.cell.2006.11.016; Tabara H, 1999, DEVELOPMENT, V126, P1; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Tenlen JR, 2006, GENETICS, V174, P1933, DOI 10.1534/genetics.105.052621; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; Wallenfang MR, 2000, NATURE, V408, P89, DOI 10.1038/35040562; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	50	78	79	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8883	8894		10.1074/jbc.M700079200	http://dx.doi.org/10.1074/jbc.M700079200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264081	hybrid			2022-12-27	WOS:000245780300035
J	Solt, LA; Madge, LA; Orange, JS; May, MJ				Solt, Laura A.; Madge, Lisa A.; Orange, Jordan S.; May, Michael J.			Interleukin-1-induced NF-kappa B activation is NEMO-dependent but does not require IKK beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; GENE-EXPRESSION; INCONTINENTIA PIGMENTI; SELECTIVE-INHIBITION; KINASE-ALPHA; PATHWAYS; SUBUNIT; LACKING; DOMAIN	Activation of NF-kappa B by the pro-inflammatory cytokines tumor necrosis factor (TNF) and interleukin-1 (IL-1) requires the I kappa B kinase (IKK) complex, which contains two kinases named IKK alpha and IKK beta and a critical regulatory subunit named NEMO. Although we have previously demonstrated that NEMO associates with both IKKs, genetic studies reveal that only its interaction with IKK beta is required for TNF-induced NF-kappa B activation. To determine whether NEMO and IKK alpha can form a functional IKK complex capable of activating the classical NF-kappa B pathway in the absence of IKK beta, we utilized a panel of mouse embryonic fibroblasts (MEFs) lacking each of the IKK complex subunits. This confirmed that TNF-induced I kappa B alpha degradation absolutely requires NEMO and IKK beta. In contrast, we consistently observed intact I kappa B alpha degradation and NF-kappa B activation in response to IL-1 in two separate cell lines lacking IKK beta. Furthermore, exogenously expressed, catalytically inactive IKK beta blocked TNF- but not IL-1-induced I kappa B alpha degradation in wild-type MEFs, and reconstitution of IKK alpha/beta double knockout cells with IKK alpha rescued IL-1- but not TNF-induced NF-kappa B activation. Finally, we have shown that incubation of IKK beta-deflcient MEFs with a cell-permeable peptide that blocks the interaction of NEMO with the IKKs inhibits IL-1-induced NF-kappa B activation. Our results therefore demonstrate that NEMO and IKK alpha can form a functional IKK complex that activates the classical NF-kappa B pathway in response to IL-1 but not TNF. These findings further suggest NEMO differentially regulates the fidelity of the IKK subunits activated by distinct upstream signaling pathways.	Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	May, MJ (corresponding author), Univ Penn, Sch Vet Med, Dept Biol Anim, 3800 Spruce St OVH 200E, Philadelphia, PA 19104 USA.	maym@vet.upenn.edu	Orange, Jordan S/D-5239-2009	May, Michael/0000-0002-2485-3716; orange, jordan/0000-0001-7117-7725	NHLBI NIH HHS [R01 HL080612-01A1, R01 HL080612, 1R01HL080612-01A1] Funding Source: Medline; NIAID NIH HHS [T32 AI055428, R01 AI022070, N01AI-22070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022070, T32AI055428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Correa RG, 2005, CURR BIOL, V15, P1291, DOI 10.1016/j.cub.2005.06.023; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hong X, 2001, FEBS LETT, V499, P133, DOI 10.1016/S0014-5793(01)02535-2; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2004, J BIOL CHEM, V279, P45528, DOI 10.1074/jbc.M408579200; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schmidt-Supprian M, 2003, IMMUNITY, V19, P377, DOI 10.1016/S1074-7613(03)00237-1; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	39	65	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8724	8733		10.1074/jbc.M609613200	http://dx.doi.org/10.1074/jbc.M609613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244613	hybrid, Green Accepted			2022-12-27	WOS:000245780300018
J	Duca, L; Blanchevoye, C; Cantarelli, B; Ghoneim, C; Dedieu, S; Delacoux, F; Hornebeck, W; Hinek, A; Martiny, L; Debelle, L				Duca, Laurent; Blanchevoye, Charlotte; Cantarelli, Benoit; Ghoneim, Christelle; Dedieu, Stephane; Delacoux, Frederic; Hornebeck, William; Hinek, Aleksander; Martiny, Laurent; Debelle, Laurent			The elastin receptor complex transduces signals through the catalytic activity of its Neu-1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; SMOOTH-MUSCLE CELLS; LYSOSOMAL MULTIENZYME COMPLEX; BINDING-PROTEIN; BETA-GALACTOSIDASE; CULTURED FIBROBLASTS; ENDOTHELIAL-CELLS; HUMAN-LEUKOCYTES; PLASMA-MEMBRANE; GENE-EXPRESSION	The binding of elastin peptides on the elastin receptor complex leads to the formation of intracellular signals but how this is achieved remains totally unknown. Using pharmacological inhibitors of the enzymatic activities of its subunits, we show here that the elastin peptide-driven ERK1/2 activation and subsequent pro-MMP-1 production, observed in skin fibroblasts when they are cultured in the presence of these peptides, rely on a membrane-bound sialidase activity. As lactose blocked this effect, the elastin receptor sialidase subunit, Neu-1, seemed to be involved. The use of a catalytically inactive form of Neu-1 and the small interfering RNA-mediated decrease of Neu-1 expression strongly support this view. Finally, we report that N-acetyl neuraminic acid can reproduce the effects of elastin peptides on both ERK1/2 activation and pro-MMP-1 production. Altogether, our results indicate that the enzymatic activity of the Neu-1 subunit of the elastin receptor complex is responsible for its signal transduction, presumably through sialic acid generation from undetermined substrates.	CNRS, Fac Sci, UMR 6198, IFR 53,Lab Biochim, F-51687 Reims 2, France; Univ Toronto, Hosp Sick Children, Lab Med & Pathobiol, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Debelle, L (corresponding author), CNRS, Fac Sci, UMR 6198, IFR 53,Lab Biochim, Moulin Housse,BP 1039, F-51687 Reims 2, France.	laurent.debelle@univ-reims.fr	MARTINY, Laurent/ABI-5531-2020; Hinek, Aleksander/V-8790-2019	DUCA, Laurent/0000-0002-6035-4906; Dedieu, Stephane/0000-0003-1447-5640				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Caciotti A, 2005, AM J PATHOL, V167, P1689, DOI 10.1016/S0002-9440(10)61251-5; Caciotti A, 2007, HUM MUTAT, V28, DOI 10.1002/humu.9475; Callahan JW, 1999, BBA-MOL BASIS DIS, V1455, P85, DOI 10.1016/S0925-4439(99)00075-7; Chen XP, 1997, J IMMUNOL, V158, P3070; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; Debret R, 2005, ARTERIOSCL THROM VAS, V25, P1353, DOI 10.1161/01.ATV.0000168412.50855.9f; Duca L, 2005, MOL PHARMACOL, V67, P1315, DOI 10.1124/mol.104.002725; Duca L, 2004, CRIT REV ONCOL HEMAT, V49, P235, DOI 10.1016/j.critrevonc.2003.09.007; Duca L, 2002, FEBS LETT, V524, P193, DOI 10.1016/S0014-5793(02)03057-0; FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084; Faury G, 1998, CIRC RES, V82, P328, DOI 10.1161/01.RES.82.3.328; GROSSO LE, 1993, MATRIX, V13, P157, DOI 10.1016/S0934-8832(11)80074-0; Hauck M, 1995, BIOCHEM MOL BIOL INT, V37, P45; HINEK A, 1995, EXP CELL RES, V220, P312, DOI 10.1006/excr.1995.1321; Hinek A, 2006, J BIOL CHEM, V281, P3698, DOI 10.1074/jbc.M508736200; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; Hinek A, 1996, BIOL CHEM, V377, P471; ITOH K, 1993, J BIOL CHEM, V268, P1180; JACOB MP, 1987, P NATL ACAD SCI USA, V84, P995, DOI 10.1073/pnas.84.4.995; Jin L, 2002, J EXP MED, V195, P1199, DOI 10.1084/jem.20011796; Kamoun A, 1995, CELL ADHES COMMUN, V3, P273, DOI 10.3109/15419069509081013; Kelm S, 2002, J EXP MED, V195, P1207, DOI 10.1084/jem.20011783; Kielty CM, 2002, J CELL SCI, V115, P2817; Liang F, 2006, J BIOL CHEM, V281, P27526, DOI 10.1074/jbc.M605633200; LONG MM, 1989, J CELL PHYSIOL, V140, P512, DOI 10.1002/jcp.1041400316; LONG MM, 1988, BIOCHIM BIOPHYS ACTA, V968, P300, DOI 10.1016/0167-4889(88)90021-3; Lukong KE, 2000, HUM MOL GENET, V9, P1075, DOI 10.1093/hmg/9.7.1075; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Lukong KE, 2001, J BIOL CHEM, V276, P17286, DOI 10.1074/jbc.M100460200; Malvagia S, 2004, MOL GENET METAB, V82, P48, DOI 10.1016/j.ymgme.2004.02.007; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Mizuno T, 2005, AM J PHYSIOL-HEART C, V288, pH2819, DOI 10.1152/ajpheart.00862.2004; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; MORREAU H, 1989, J BIOL CHEM, V264, P20655; OGURA K, 1992, EXP CELL RES, V199, P169, DOI 10.1016/0014-4827(92)90475-N; OOYAMA T, 1987, ARTERIOSCLEROSIS, V7, P593, DOI 10.1161/01.ATV.7.6.593; Ostuni A, 2002, INT J BIOCHEM CELL B, V34, P130, DOI 10.1016/S1357-2725(01)00115-7; Peterszegi G, 1999, EUR J CLIN INVEST, V29, P166, DOI 10.1046/j.1365-2362.1999.00423.x; Privitera S, 1998, J BIOL CHEM, V273, P6319, DOI 10.1074/jbc.273.11.6319; Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; Seyrantepe V, 2003, HUM MUTAT, V22, P343, DOI 10.1002/humu.10268; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; Stamatos NM, 2004, J LEUKOCYTE BIOL, V75, P307, DOI 10.1189/jlb.0503241; Tajima S, 1997, ARCH DERMATOL RES, V289, P489, DOI 10.1007/s004030050227; Traving C, 1998, CELL MOL LIFE SCI, V54, P1330, DOI 10.1007/s000180050258; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; USUKI S, 1988, J BIOL CHEM, V263, P10595; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VARGA Z, 1989, FEBS LETT, V258, P5, DOI 10.1016/0014-5793(89)81602-3; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; WACHI H, 1995, FEBS LETT, V368, P215, DOI 10.1016/0014-5793(95)00641-L	58	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12484	12491		10.1074/jbc.M609505200	http://dx.doi.org/10.1074/jbc.M609505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327233	hybrid			2022-12-27	WOS:000245942800017
J	Olson, GE; Winfrey, VP; NagDas, SK; Hill, KE; Burk, RF				Olson, Gary E.; Winfrey, Virginia P.; NagDas, Subir K.; Hill, Kristina E.; Burk, Raymond F.			Apolipoprotein E receptor-2 (ApoER2) mediates selenium uptake from selenoprotein P by the mouse testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; E RECEPTOR 2; LIPOPROTEIN RECEPTOR; SPERM DEVELOPMENT; RAT PLASMA; PROTEIN; BINDING; SELENOCYSTEINE; REELIN; SPERMATOZOA	Selenium is a micronutrient that is essential for the production of normal spermatozoa. The selenium-rich plasma protein selenoprotein P ( Sepp1) is required for maintenance of testis selenium and for fertility of the male mouse. Sepp1 trafficking in the seminiferous epithelium was studied using conventional methods and mice with gene deletions. Immunocytochemistry demonstrated that Sepp1 is present in vesicle-like structures in the basal region of Sertoli cells, suggesting that the protein is taken up intact. Sepp1 affinity chromatography of a testicular extract followed by mass spectrometry-based identification of bound proteins identified apolipoprotein E receptor 2 ( ApoER2) as a candidate testis Sepp1 receptor. In situ hybridization analysis identified Sertoli cells as the only cell type in the seminiferous epithelium with detectable ApoER2 expression. Testis selenium levels in apoER2(-/-) males were sharply reduced from those in apoER2(-/-) males and were comparable with the depressed levels found in Sepp1(-/-) males. However, liver selenium levels were unchanged by deletion of apoER2. Immunocytochemistry did not detect Sepp1 in the Sertoli cells of apoER2(-/-) males, consistent with a defect in the receptor-mediated Sepp1 uptake pathway. Phase contrast microscopy revealed identical sperm defects in apoER2(-/-) and Sepp1(-/-) mice. Co-immunoprecipitation analysis demonstrated an interaction of testis ApoER2 with Sepp1. These data demonstrate that Sertoli cell ApoER2 is a Sepp1 receptor and a component of the selenium delivery pathway to spermatogenic cells.	Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Olson, GE (corresponding author), Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.	gary.olson@vanderbilt.edu			NICHD NIH HHS [HD044863] Funding Source: Medline; NIEHS NIH HHS [ES02497] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497, R37ES002497] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andersen OM, 2003, BIOCHEMISTRY-US, V42, P9355, DOI 10.1021/bi034475p; Andersen OM, 2003, J BIOL CHEM, V278, P23989, DOI 10.1074/jbc.M302157200; Beckett GJ, 2005, J ENDOCRINOL, V184, P455, DOI 10.1677/joe.1.05971; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; BURK RF, 1987, METHOD ENZYMOL, V143, P307; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Foresta C, 2002, BIOL REPROD, V67, P967, DOI 10.1095/biolreprod.102.003822; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; Imai H, 2001, BIOL REPROD, V64, P674, DOI 10.1095/biolreprod64.2.674; KANALAS JJ, 1993, J BIOL CHEM, V268, P8188; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kim HJ, 1998, J BIOCHEM-TOKYO, V124, P451, DOI 10.1093/oxfordjournals.jbchem.a022134; KOH TS, 1983, J ASSOC OFF ANA CHEM, V66, P918; Kohrle J, 2000, BIOL CHEM, V381, P849, DOI 10.1515/BC.2000.107; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Maiorino M, 1999, BIOFACTORS, V10, P251, DOI 10.1002/biof.5520100224; Maiorino M, 2003, BIOL REPROD, V68, P1134, DOI 10.1095/biolreprod.102.007500; May P, 2005, CELL MOL LIFE SCI, V62, P2325, DOI 10.1007/s00018-005-5231-z; Mihara H, 2000, J BIOL CHEM, V275, P6195, DOI 10.1074/jbc.275.9.6195; Moschos MP, 2000, CELL MOL LIFE SCI, V57, P1836, DOI 10.1007/PL00000665; Olson GE, 2005, BIOL REPROD, V73, P201, DOI 10.1095/biolreprod.105.040360; Olson GE, 2004, J BIOL CHEM, V279, P51266, DOI 10.1074/jbc.M410485200; READ R, 1990, J BIOL CHEM, V265, P17899; Schneider WJ, 2003, CELL MOL LIFE SCI, V60, P892, DOI 10.1007/s00018-003-2183-z; SHEEHAN TMT, 1990, CLIN CHEM, V36, P2124; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; URSINI F, 1999, SCIENCE, V277, P225; WILSON DS, 1993, J INORG BIOCHEM, V51, P707, DOI 10.1016/0162-0134(93)85003-Q	37	167	177	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12290	12297		10.1074/jbc.M611403200	http://dx.doi.org/10.1074/jbc.M611403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314095	hybrid			2022-12-27	WOS:000245941900071
J	Wong, ESP; Tan, JMM; Wang, C; Zhang, ZS; Tay, SP; Zaiden, N; Ko, HS; Dawson, VL; Dawson, TM; Lim, KL				Wong, Esther S. P.; Tan, Jeanne M. M.; Wang, Cheng; Zhang, Zhenshui; Tay, Shiam-Peng; Zaiden, Norazean; Ko, Han Seok; Dawson, Valina L.; Dawson, Ted M.; Lim, Kah-Leong			Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE; MUTATIONS; DOMAIN; DOPAMINE; ASSOCIATION; COMPLEX; GENE; RING	Loss of parkin function is a predominant cause of familial Parkinsonism. Emerging evidence also suggests that parkin expression variability may confer a risk for sporadic Parkinson disease. We have recently demonstrated that a wide variety of Parkinson disease-linked stressors, including dopamine ( DA), induce parkin solubility alterations and promote its aggregation within the cell, a phenomenon that may underlie the progressive susceptibility of the brain to degeneration. The vulnerability of parkin to stress-induced modification is likely due to its abundance of cysteine residues. Here, we performed a comprehensive mutational analysis and demonstrate that Cys residues residing both within and outside of the RING-IBR ( (i) under barn (b) under bar etween (R) under bar ING fingers)-RING domain of parkin are important in maintaining its solubility. The majority of these Cys residues are highly conserved in parkin across different species and potentially fulfil important structural roles. Further, we found that both parkin and HHARI ( human homologue of Drosophila ariadne), another RING-IBR-RING- type ubiquitin ligase, are comparably more susceptible to solubility alterations induced by oxidative and nitrosative stress when compared with other non RING-IBR-RING Cys-containing enzymes. However, parkin appears to be uniquely sensitive to DA-mediated stress, the specificity of which is likely due to DA modification of 2 Cys residues on parkin ( Cys-268 and Cys-323) that are distinct from other RING-IBR-RING members.	Natl Inst Neurosci, Neurodegenerat Res Lab, Singapore 308433, Singapore; Natl Inst Neurosci, Parkinsons Dis & Movement Disorders Ctr, Singapore 308433, Singapore; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Natl Univ Singapore, Dept Sci Biol, Singapore 119077, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 119077, Singapore	National Neuroscience Institute (NNI); National Neuroscience Institute (NNI); Johns Hopkins University; Johns Hopkins University; National University of Singapore; National University of Singapore	Lim, KL (corresponding author), Natl Inst Neurosci, Neurodegenerat Res Lab, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	Kah_Leong_Lim@nni.com.sg	Tan, Jeanne/GQI-3612-2022; Lim, Kah/L-5426-2019; Wong, Esther/E-1344-2011; Lim, Kah-Leong/AAY-3308-2020; Dawson, Valina/Y-9757-2019	Lim, Kah-Leong/0000-0002-5440-2588; Dawson, Valina/0000-0002-2915-3970; Wong, Esther/0000-0003-2421-7346	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377, R01NS048206] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38377, R01 NS048206, P50 NS038377, NS48206] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Capili AD, 2004, J MOL BIOL, V340, P1117, DOI 10.1016/j.jmb.2004.05.035; Cookson MR, 2003, CURR BIOL, V13, pR522, DOI 10.1016/S0960-9822(03)00446-9; Feany MB, 2003, NEURON, V38, P13, DOI 10.1016/S0896-6273(03)00201-0; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Klein C, 2003, ANN NEUROL, V54, P415, DOI 10.1002/ana.10737; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; Lim KL, 2003, ANN NY ACAD SCI, V991, P80; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Oliveira SA, 2003, ANN NEUROL, V53, P624, DOI 10.1002/ana.10524; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Savitt JM, 2006, J CLIN INVEST, V116, P1744, DOI 10.1172/JCI29178; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Wang C, 2005, HUM MOL GENET, V14, P3885, DOI 10.1093/hmg/ddi413; Wang C, 2005, J NEUROCHEM, V93, P422, DOI 10.1111/j.1471-4159.2005.03023.x; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; West AB, 2002, HUM MOL GENET, V11, P2787, DOI 10.1093/hmg/11.22.2787; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	22	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12310	12318		10.1074/jbc.M609466200	http://dx.doi.org/10.1074/jbc.M609466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329252	hybrid			2022-12-27	WOS:000245941900073
J	Ha, SW; Korbas, M; Klepsch, M; Meyer-Klaucke, W; Meyer, O; Svetlitchnyi, V				Ha, Seung-Wook; Korbas, Malgorzata; Klepsch, Mirjam; Meyer-Klaucke, Wolfram; Meyer, Ortwin; Svetlitchnyi, Vitali			Interaction of potassium cyanide with the [Ni-4Fe-5S] active site cluster of CO dehydrogenase from Carboxydothermus hydrogenoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; RAY-ABSORPTION SPECTROSCOPY; CLOSTRIDIUM-THERMOACETICUM; RHODOSPIRILLUM-RUBRUM; NICKEL; COMPLEXES; SYNTHASE; ENDOR; AZIDE; LIFE	The Ni-Fe carbon monoxide ( CO) dehydrogenase II ( CODHIICh) from the anaerobic CO-utilizing hydrogenogenic bacterium Carboxydothermus hydrogenoformans catalyzes the oxidation of CO, presumably at the Ni-(mu S-2)-Fe1 subsite of the [ Ni-4S-5S] cluster in the active site. The CO oxidation mechanism proposed on the basis of several CODHIICh crystal structures involved the apical binding of CO at the nickel ion and the activation of water at the Fe1 ion of the cluster. To understand how CO interacts with the active site, we have studied the reactivity of the cluster with potassium cyanide and analyzed the resulting type of nickel coordination by x-ray absorption spectroscopy. Cyanide acts as a competitive inhibitor of reduced CODHIICh with respect to the substrate CO and is therefore expected to mimic the substrate. It inhibits the enzyme reversibly, forming a nickel cyanide. In this reaction, one of the four square-planar sulfur ligands of nickel is replaced by the carbon atom of cyanide, suggesting removal of the mu S-2 from the Ni-(mu S-2)-Fe1 subsite. Upon reactivation of the inhibited enzyme, cyanide is released, and the square-planar coordination of nickel by 4S ligands is recovered, which includes the reformation of the Ni-(mu S-2)-Fe1 bridge. The results are summarized in a model of the CO oxidation mechanism at the [ Ni-4Fe-5S] active site cluster of CODHIICh from C. hydrogenoformans.	Univ Bayreuth, Lehrstuhl Mikrobiol, D-95440 Bayreuth, Germany; Univ Bayreuth, BZMB, D-95440 Bayreuth, Germany; DESY, EMBL, D-22603 Hamburg, Germany	University of Bayreuth; University of Bayreuth; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Svetlitchnyi, V (corresponding author), Univ Bayreuth, Lehrstuhl Mikrobiol, Univ Str 30, D-95440 Bayreuth, Germany.	vitali.svetlitchnyi@uni-bayreuth.de	Meyer-Klaucke, Wolfram/G-1148-2010; Korbas, Malgorzata/B-4024-2009	Korbas, Malgorzata/0000-0003-3064-0132				ANDERSON ME, 1993, J AM CHEM SOC, V115, P12204, DOI 10.1021/ja00078a085; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASTAIN BB, 1968, J AM CHEM SOC, V90, P3994, DOI 10.1021/ja01017a015; COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; Darnault C, 2003, NAT STRUCT BIOL, V10, P271, DOI 10.1038/nsb912; DeRose VJ, 1998, J AM CHEM SOC, V120, P8767, DOI 10.1021/ja9731480; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Dobbek H, 2004, J AM CHEM SOC, V126, P5382, DOI 10.1021/ja037776v; Dobbek H, 2002, P NATL ACAD SCI USA, V99, P15971, DOI 10.1073/pnas.212640899; Doukov TI, 2002, SCIENCE, V298, P567, DOI 10.1126/science.1075843; Drennan CL, 2001, P NATL ACAD SCI USA, V98, P11973, DOI 10.1073/pnas.211429998; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4973, DOI 10.1021/bi00438a011; Fan Y, 2004, CHEM-EUR J, V10, P1805, DOI 10.1002/chem.200304840; Feng J, 2004, J AM CHEM SOC, V126, P9094, DOI 10.1021/ja048811g; Gnida M, 2003, BIOCHEMISTRY-US, V42, P222, DOI 10.1021/bi026514n; Gu WW, 2004, BIOCHEMISTRY-US, V43, P9029, DOI 10.1021/bi036104e; HALCROW MA, 1994, CHEM REV, V94, P2421, DOI 10.1021/cr00032a008; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; Kim EJ, 2004, BIOCHEMISTRY-US, V43, P5728, DOI 10.1021/bi036062u; Korbas M, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2209954; LAX E, 1967, DANS LAX TASCHENBUCH, V1, P1; MEYER O, 1982, J BIOL CHEM, V257, P1333; Ragsdale SW, 2004, CRIT REV BIOCHEM MOL, V39, P165, DOI 10.1080/10409230490496577; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; Resch M, 2005, J BIOL INORG CHEM, V10, P518, DOI 10.1007/s00775-005-0006-4; Sellmann D, 2000, CHEM-EUR J, V6, P4279, DOI 10.1002/1521-3765(20001201)6:23<4279::AID-CHEM4279>3.0.CO;2-S; Shores MP, 2002, J AM CHEM SOC, V124, P2279, DOI 10.1021/ja011645h; STERN EA, 1993, PHYS REV B, V48, P9825, DOI 10.1103/PhysRevB.48.9825; SVETLICHNY VA, 1991, SYST APPL MICROBIOL, V14, P254, DOI 10.1016/S0723-2020(11)80377-2; Svetlitchnyi V, 2004, P NATL ACAD SCI USA, V101, P446, DOI 10.1073/pnas.0304262101; Svetlitchnyi V, 2001, J BACTERIOL, V183, P5134, DOI 10.1128/JB.183.17.5134-5144.2001; Volbeda A, 2005, DALTON T, P3443, DOI 10.1039/b508403b	33	35	36	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10639	10646		10.1074/jbc.M610641200	http://dx.doi.org/10.1074/jbc.M610641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17277357	hybrid			2022-12-27	WOS:000245941000058
J	Rigby, K; Zhang, LM; Cobine, PA; George, GN; Winge, DR				Rigby, Kevin; Zhang, Limei; Cobine, Paul A.; George, Graham N.; Winge, Dennis R.			Characterization of the cytochrome c oxidase assembly factor Cox19 of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER METALLOCHAPERONE COX17; THIOLATE POLYNUCLEAR CLUSTER; MITOCHONDRIAL INNER MEMBRANE; INTERMEMBRANE SPACE; STRUCTURAL CHEMISTRY; PROTEIN IMPORT; BIOGENESIS; BINDING; EXPRESSION; OXIDATION	Cox19 is an important accessory protein in the assembly of cytochrome c oxidase in yeast. The protein is functional when tethered to the mitochondrial inner membrane, suggesting its functional role within the intermembrane space. Cox19 resembles Cox17 in having a twin CX9C sequence motif that adopts a helical hairpin in Cox17. The function of Cox17 appears to be a Cu(I) donor protein in the assembly of the copper centers in cytochrome c oxidase. Cox19 also resembles Cox17 in its ability to coordinate Cu(I). Recombinant Cox19 binds 1 mol eq of Cu(I) per monomer and exists as a dimeric protein. Cox19 isolated from the mitochondrial intermembrane space contains variable quantities of copper, suggesting that Cu(I) binding may be a transient property. Cysteinyl residues important for Cu(I) binding are also shown to be important for the in vivo function of Cox19. Thus, a correlation exists in the ability to bind Cu(I) and in vivo function.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84312 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84312 USA; Univ Saskatchewan, Saskatoon, SK S7N 5E2, Canada	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Saskatchewan	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Cobine, Paul A/G-3107-2011; George, Graham N/E-3290-2013; Cobine, Paul/AAH-6619-2020; Winge, Dennis/G-3611-2010	Cobine, Paul A/0000-0001-6012-0985; Cobine, Paul/0000-0001-6012-0985; George, Graham/0000-0002-0420-7493	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057375] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03817] Funding Source: Medline; NIGMS NIH HHS [GM57375] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abajian C, 2004, J BIOL CHEM, V279, P53584, DOI 10.1074/jbc.M408099200; Arnesano F, 2005, STRUCTURE, V13, P713, DOI 10.1016/j.str.2005.02.015; Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Barros MH, 2004, J BIOL CHEM, V279, P31943, DOI 10.1074/jbc.M405014200; BOWMAKER GA, 1984, POLYHEDRON, V3, P535, DOI 10.1016/S0277-5387(00)88084-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown KR, 2002, BIOCHEMISTRY-US, V41, P6469, DOI 10.1021/bi0160664; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; DANCE IG, 1986, POLYHEDRON, V5, P1037, DOI 10.1016/S0277-5387(00)84307-7; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Herrmann JM, 2005, GENE, V354, P43, DOI 10.1016/j.gene.2005.03.017; Horng YC, 2005, J BIOL CHEM, V280, P34113, DOI 10.1074/jbc.M506801200; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; REHR JJ, 1992, PHYS REV LETT, V69, P3397, DOI 10.1103/PhysRevLett.69.3397; Rissler M, 2005, J MOL BIOL, V353, P485, DOI 10.1016/j.jmb.2005.08.051; Terziyska N, 2005, FEBS LETT, V579, P179, DOI 10.1016/j.febslet.2004.11.072; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Winge DR, 1997, J BIOL INORG CHEM, V2, P2, DOI 10.1007/s007750050100; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350	30	48	49	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10233	10242		10.1074/jbc.M610082200	http://dx.doi.org/10.1074/jbc.M610082200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17237235	hybrid			2022-12-27	WOS:000245941000013
J	Islam, A; Shen, XY; Hiroi, T; Moss, J; Vaughan, M; Levine, SJ				Islam, Aminul; Shen, Xiaoyan; Hiroi, Toyoko; Moss, Joel; Vaughan, Martha; Levine, Stewart J.			The brefeldin A-inhibited guanine nucleotide-exchange protein, BIG2, regulates the constitutive release of TNFR1 exosome-like vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ADP-RIBOSYLATION FACTOR; FACTOR-BINDING-PROTEIN; TRANS-GOLGI NETWORK; FACTOR RECEPTOR; ENDOPLASMIC-RETICULUM; RECYCLING ENDOSOMES; CELL-SURFACE; SOLUBLE FORM; TRAFFICKING	The type 1, 55-kDa tumor necrosis factor receptor (TNFR1) is released from cells to the extracellular space where it can bind and modulate TNF bioactivity. Extracellular TNFR1 release occurs by two distinct pathways: the inducible proteolytic cleavage of TNFR1 ectodomains and the constitutive release of full-length TNFR1 in exosome-like vesicles. Regulation of both TNFR1 release pathways appears to involve the trafficking of cytoplasmic TNFRI vesicles. Vesicular trafficking is controlled by ADP-ribosylation factors (ARFs), which are active in the GTP-bound state and inactive when bound to GDP. ARF activation is enhanced by guanine nucleotide-exchange factors that catalyze replacement of GDP by GTP. We investigated whether the brefeldin A (BFA)-inhibited guanine nucleotide-exchange proteins, BIG1 and/or BIG2, are required for TNFRI release from human umbilical vein endothelial cells. Effects of specific RNA interference (RNAi) showed that BIG2, but not BIG1, regulated the release of TNFR1 exosome-like vesicles, whereas neither BIG2 nor BIG1 was required for the IL-1 beta-induced proteolytic cleavage of TNFRI ectodomains. BIG2 co-localized with TNFRI in diffusely distributed cytoplasmic vesicles, and the association between BIG2 and TNFRI was disrupted by BFA. Consistent with the preferential activation of class I ARFs by BIG2, ARF1 and ARF3 participated in the extracellular release of TNFR1 exosome-like vesicles in a nonredundant and additive fashion. We conclude that the association between BIG2 and TNFRI selectively regulates the extracellular release of TNFR1 exosome-like vesicles from human vascular endothelial cells via an ARF1- and ARF3-dependent mechanism.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, SJ (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 6D03,MSC 1590, Bethesda, MD 20892 USA.	levines@nhlbi.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002544, Z01HL000627, ZIAHL000627, Z01HL002544] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALCH WE, 1992, J BIOL CHEM, V267, P13053; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Denzer K, 2000, J CELL SCI, V113, P3365; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; Islam A, 2006, J BIOL CHEM, V281, P6860, DOI 10.1074/jbc.M509397200; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; Levine SJ, 2005, AM J PHYSIOL-LUNG C, V289, pL233, DOI 10.1152/ajplung.00469.2004; Levine SJ, 1996, AM J RESP CELL MOL, V14, P254, DOI 10.1165/ajrcmb.14.3.8845176; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; Sheen VL, 2004, NAT GENET, V36, P69, DOI 10.1038/ng1276; Shen XY, 2006, P NATL ACAD SCI USA, V103, P2635, DOI 10.1073/pnas.0510599103; Shin HW, 2004, MOL BIOL CELL, V15, P5283, DOI 10.1091/mbc.E04-05-0388; Shinotsuka C, 2002, BIOCHEM BIOPH RES CO, V294, P254, DOI 10.1016/S0006-291X(02)00456-4; Shinotsuka C, 2002, J BIOL CHEM, V277, P9468, DOI 10.1074/jbc.M112427200; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; Volpicelli-Daley LA, 2005, MOL BIOL CELL, V16, P4495, DOI 10.1091/mbc.E04-12-1042; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WALLACH D, 1991, TUMOR NECROSIS FACTO, P47; Wang J, 2003, J BIOL CHEM, V278, P21751, DOI 10.1074/jbc.M212662200; Xu KF, 2005, P NATL ACAD SCI USA, V102, P2784, DOI 10.1073/pnas.0409871102; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567	41	43	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9591	9599		10.1074/jbc.M607122200	http://dx.doi.org/10.1074/jbc.M607122200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276987	hybrid			2022-12-27	WOS:000245421700032
J	ter Haar, E; Prabakhar, P; Liu, X; Lepre, C				ter Haar, Ernst; Prabakhar, Prakash; Liu, Xun; Lepre, Christopher			Crystal structure of the P38 alpha-MAPKAP kinase 2 heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; HIGH-AFFINITY BINDING; DOCKING SITES; NUCLEAR EXPORT; SUBSTRATE-SPECIFICITY; CELLULAR STRESSES; PATHWAY; SIGNAL; PROTEIN-KINASE-2	The p38 signaling pathway is activated in response to cell stress and induces production of proinflammatory cytokines. P38 alpha is phosphorylated and activated in response to cell stress by MKK3 and MKK6 and in turn phosphorylates a number of substrates, including MAPKAP kinase 2 (MK2). We have determined the crystal structure of the unphosphorylated p38 alpha-MK2 heterodimer. The C-terminal regulatory domain of MK2 binds in the docking groove of p38 alpha, and the ATP-binding sites of both kinases are at the heterodimer interface. The conformation suggests an extra mechanism in addition to the regulation of the p38 alpha and MK2 phosphorylation states that prevents phosphorylation of substrates in the absence of cell stress. Addition of constitutively active MKK6-DD results in rapid phosphorylation of the p38 alpha-MK2 heterodimer.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	ter Haar, E (corresponding author), Vertex Pharmaceut Inc, 130 Waverly St, Cambridge, MA 02139 USA.	ernst_terhaar@vrtx.com						Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Force T, 2004, CIRCULATION, V109, P1196, DOI 10.1161/01.CIR.0000118538.21306.A9; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lukas SM, 2004, BIOCHEMISTRY-US, V43, P9950, DOI 10.1021/bi049508v; Meng WY, 2002, J BIOL CHEM, V277, P37401, DOI 10.1074/jbc.C200418200; Neininger A, 2001, EMBO REP, V2, P703, DOI 10.1093/embo-reports/kve157; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Salituro FG, 1999, CURR MED CHEM, V6, P807; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Underwood KW, 2003, STRUCTURE, V11, P627, DOI 10.1016/S0969-2126(03)00092-3; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566; ZU YL, 1995, J BIOL CHEM, V270, P202, DOI 10.1074/jbc.270.1.202	40	72	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9733	9739		10.1074/jbc.M611165200	http://dx.doi.org/10.1074/jbc.M611165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17255097	hybrid			2022-12-27	WOS:000245421700047
J	Wu, L; Xiao, BT; Jia, XL; Zhang, Y; Lu, SQ; Chen, J; Long, M				Wu, Li; Xiao, Botao; Jia, Xiaoling; Zhang, Yan; Lu, Shouqin; Chen, Juan; Long, Mian			Impact of carrier stiffness and microtopology on two-dimensional kinetics of P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; BINDING; ADHESION; AFFINITY; RATES	Mechanics and surface microtopology of the molecular carrier influence cell adhesion, but the mechanisms underlying these effects are not well understood. We used a micropipette adhesion frequency assay to quantify how the carrier stiffness and microtopology affected two-dimensional kinetics of interacting adhesion molecules on two apposing surfaces. Interactions of P-selectin with P-selectin glycoprotein ligand-1 (PSGL-1) were used to demonstrate such effects by presenting the molecules on three carrier systems: human red blood cells (RBCs), human promyelocytic leukemia HL-60 cells, and polystyrene beads. Stiffening the carrier alone or in cooperation with roughing the surface lowered the two-dimensional affinity of interacting molecules by reducing the forward rate but not the reverse rate, whereas softening the carrier and roughing the surface had opposing effects in affecting two-dimensional kinetics. In contrast, the soluble antibody bound with similar three-dimensional affinity to surface-anchored P-selectin or PSGL-1 constructs regardless of carrier stiffness and microtopology. These results demonstrate that the carrier stiffness and microtopology of a receptor influences its rate of encountering and binding a surface ligand but does not subsequently affect the stability of binding. This provides new insights into understanding the rolling and tethering mechanism of leukocytes onto endothelium in both physiological and pathological processes.	Chinese Acad Sci, Inst Mech, Natl Micrograv Lab, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Mech, Ctr Biomech & Bioengn, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Mechanics, CAS; Chinese Academy of Sciences; Institute of Mechanics, CAS	Long, M (corresponding author), Chinese Acad Sci, Inst Mech, Natl Micrograv Lab, Beijing 100080, Peoples R China.	mlong@imech.ac.cn	Xiao, Botao/F-4667-2010	Xiao, Botao/0000-0002-0785-1006				Chesla SE, 2000, J BIOL CHEM, V275, P10235, DOI 10.1074/jbc.275.14.10235; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Dumaswala UJ, 1996, BLOOD, V88, P697, DOI 10.1182/blood.V88.2.697.bloodjournal882697; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; Finger EB, 1996, J IMMUNOL, V157, P5085; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GRETCH DR, 1987, ANAL BIOCHEM, V163, P270, DOI 10.1016/0003-2697(87)90123-0; Hanley W, 2003, J BIOL CHEM, V278, P10556, DOI 10.1074/jbc.M213233200; Huang J, 2004, J BIOL CHEM, V279, P44915, DOI 10.1074/jbc.M407039200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KOFLER R, 1977, J IMMUNOL METHODS, V16, P201, DOI 10.1016/0022-1759(77)90198-3; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; LI SH, 1994, J BIOL CHEM, V269, P4431; Long M, 2001, ANN BIOMED ENG, V29, P935, DOI 10.1114/1.1415529; Long MA, 1999, BIOPHYS J, V76, P1112, DOI 10.1016/S0006-3495(99)77276-0; Long M, 2006, BIOPHYS J, V91, P352, DOI 10.1529/biophysj.106.082909; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Merkel R, 2001, PHYS REP, V346, P344; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NAGARAJAN S, 1995, J BIOL CHEM, V270, P25762, DOI 10.1074/jbc.270.43.25762; Park EYH, 2002, BIOPHYS J, V82, P1835, DOI 10.1016/S0006-3495(02)75534-3; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; Shao JY, 1998, P NATL ACAD SCI USA, V95, P6797, DOI 10.1073/pnas.95.12.6797; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Williams TE, 2000, BIOPHYS J, V79, P1858, DOI 10.1016/S0006-3495(00)76435-6; Williams TE, 2001, J BIOL CHEM, V276, P13283, DOI 10.1074/jbc.M010427200; Zhu C, 2002, ANN BIOMED ENG, V30, P305, DOI 10.1114/1.1467923	29	48	54	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9846	9854		10.1074/jbc.M609219200	http://dx.doi.org/10.1074/jbc.M609219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267403	hybrid, Green Published			2022-12-27	WOS:000245421700059
J	Hou, YZ; Gao, FQ; Wang, QH; Zhao, JF; Flagg, T; Zhang, YD; Deng, XM				Hou, Yongzhong; Gao, Fengqin; Wang, Qinhong; Zhao, Jinfeng; Flagg, Tammy; Zhang, Yangde; Deng, Xingming			Bcl2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERPHASE NUCLEI; EXCISION-REPAIR; PROTEIN; EXPRESSION; APOPTOSIS; CELLS; MICE; PHOSPHORYLATION; RECOMBINATION; SUPPRESSION	Bcl2 has been reported to suppress DNA mismatch repair (MMR) with promotion of mutagenesis, but the mechanism(s) is not fully understood. MutS alpha is the hMSH2-hMSH6 heterodimer that primarily functions to correct mutations that escape the proofreading activity of DNA polymerase. Here we have discovered that Bc12 potently suppresses MMR in association with decreased MutSa activity and increased mutagenesis. Exposure of cells to nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone results in accumulation of Bc12 in the nucleus, which interacts with hMSH6 but not hMSH2 via its BH4 domain. Deletion of the BH4 domain from Bcl2 abrogates the ability of Bcl2 to interact with hMSH6 and is associated with enhanced MMR efficiency and decreased mutation frequency. Overexpression of Bcl2 reduces formation of the hMSH2-hMSH6 complex in cells, and purified Bcl2 protein directly disrupts the hMSH2-hMSH6 complex and suppresses MMR in vitro. Importantly, depletion of endogenous Bcl2 by RNA interference enhances formation of the hMSH2-hMSH6 complex in association with increased MMR and decreased mutagenesis. Thus, Bc12 suppression of MMR may occur in a novel mechanism by directly regulating the heterodimeric hMSH2-hMSH6 complex, which potentially contributes to genetic instability and carcinogenesis.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1376 Mowry Rd,Canc Genet Res Complex,Rm 262,POB 1, Gainesville, FL 32610 USA.	xdeng@ufl.edu	hou, yongzhong/E-4658-2011; hou, YONGZHONG/K-7771-2013	Hou, Yongzhong/0000-0003-2019-8686	NCI NIH HHS [R01 CA112183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Castrilli G, 2001, J ORAL PATHOL MED, V30, P305, DOI 10.1034/j.1600-0714.2001.300508.x; Chang IY, 2005, NUCLEIC ACIDS RES, V33, P5073, DOI 10.1093/nar/gki829; CHEBONNELLASSER.C, 1996, ONCOGENE, V13, P1489; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Jin ZH, 2006, J BIOL CHEM, V281, P14446, DOI 10.1074/jbc.M511914200; JORQUERA R, 1994, CARCINOGENESIS, V15, P389, DOI 10.1093/carcin/15.2.389; Kaklamanis L, 1996, J PATHOL, V179, P10; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Kuo ML, 1999, MOL PHARMACOL, V55, P894; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Liu YF, 1997, CANCER RES, V57, P1650; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Mijal RS, 2004, CHEM RES TOXICOL, V17, P424, DOI 10.1021/tx0342417; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Raffoul JJ, 2004, J BIOL CHEM, V279, P18425, DOI 10.1074/jbc.M313983200; ROTH EP, 2005, MOL CELL BIOL, V25, P3596; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P151, DOI 10.1177/002215549904700204; Shin KH, 2004, CLIN CANCER RES, V10, P2551, DOI 10.1158/1078-0432.CCR-0669-3; Snowden T, 2004, MOL CELL, V15, P437, DOI 10.1016/j.molcel.2004.06.040; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	36	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9279	9287		10.1074/jbc.M608523200	http://dx.doi.org/10.1074/jbc.M608523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259174	hybrid			2022-12-27	WOS:000245780300075
J	Zegarra-Moran, O; Monteverde, M; Galietta, LJV; Moran, O				Zegarra-Moran, Olga; Monteverde, Martino; Galietta, Luis J. V.; Moran, Oscar			Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators - Interaction between activation and inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE CORRECTORS; CL-CHANNELS; DELTA-F508 MUTATION; CRYSTAL-STRUCTURE; CFTR CHANNEL; WILD-TYPE; GENISTEIN; DOMAIN; PHOSPHORYLATION; MECHANISM	An increasing number of compounds able to potentiate the activity of mutants of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel have been identified by high throughput screening or by individual search of derivatives of known active compounds. Several lines of evidence suggest that most CFTR potentiators act through the same mechanism, probably by binding to the nucleotide binding domains to promote the activity of the protein and then, with lower affinity, to an inhibitory site. With the aim of identifying the activating binding site, we recently modeled the nucleotide binding domain dimer and predicted a common binding site for potentiators in its interface. To validate this model experimentally, we mutated some of the residues involved in the putative binding site, i.e. Arg(553), Ala(554), and Val(1293). The activity of CFTR potentiators was measured as apical membrane currents on polarized cells stably expressing wild type or mutated proteins. CFTR activity was elicited by application of a membrane-permeable cAMP analogue followed by increasing concentrations of potentiators. We found that all three mutants responded to cAMP, although the affinity of R553Q was higher than that of wild type CFTR. In R553Q and V1293G mutants, the dissociation constant of potentiators for the activating site was increased, whereas the dissociation constant for the inhibitory site was reduced. Our results show that the mutated residues are part of the activating binding site for potentiators, as suggested by the molecular model. In addition, these results suggest that the activating and inhibitory sites are not independent of each other.	Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy; CNR, Inst Biofis, I-16149 Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; Consiglio Nazionale delle Ricerche (CNR)	Zegarra-Moran, O (corresponding author), Ist Giannina Gaslini, Genet Mol Lab, Largo Gerolamo Gaslini 5, I-16148 Genoa, Italy.	ozegarra@unige.it	Moran, Oscar/W-4277-2019; Galietta, Luis JV/HCG-8692-2022	Monteverde, Martino/0000-0003-2623-414X; Galietta, Luis/0000-0001-8686-3461				Ai T, 2004, MOL PHARMACOL, V65, P1415, DOI 10.1124/mol.65.6.1415; Al-Nakkash L, 2001, J PHARMACOL EXP THER, V296, P464; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Caci E, 2003, AM J PHYSIOL-LUNG C, V285, pL180, DOI 10.1152/ajplung.00351.2002; Cai ZW, 2006, J BIOL CHEM, V281, P1970, DOI 10.1074/jbc.M510576200; Cai ZW, 2002, J BIOL CHEM, V277, P19546, DOI 10.1074/jbc.M108023200; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Derand R, 2001, AM J PHYSIOL-CELL PH, V281, pC1657, DOI 10.1152/ajpcell.2001.281.5.C1657; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Galietta LJV, 2001, J BIOL CHEM, V276, P19723, DOI 10.1074/jbc.M101892200; Lansdell KA, 2000, J PHYSIOL-LONDON, V524, P317, DOI 10.1111/j.1469-7793.2000.t01-1-00317.x; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Ma TH, 2002, J BIOL CHEM, V277, P37235, DOI 10.1074/jbc.M205932200; Marivingt-Mounir C, 2004, J MED CHEM, V47, P962, DOI 10.1021/jm0308848; Mense M, 2006, EMBO J, V25, P4728, DOI 10.1038/sj.emboj.7601373; Moran O, 2005, FEBS LETT, V579, P3979, DOI 10.1016/j.febslet.2005.06.026; Moran O, 2005, CELL MOL LIFE SCI, V62, P446, DOI 10.1007/s00018-004-4422-3; Pedemonte N, 2005, MOL PHARMACOL, V68, P1736, DOI 10.1124/mol.105.015149; Pedemonte N, 2005, MOL PHARMACOL, V67, P1797, DOI 10.1124/mol.105.010959; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; Springsteel MF, 2003, BIOORGAN MED CHEM, V11, P4113, DOI 10.1016/S0968-0896(03)00435-8; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Taddei A, 2004, FEBS LETT, V558, P52, DOI 10.1016/S0014-5793(04)00011-0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; Weinreich F, 1997, PFLUG ARCH EUR J PHY, V434, P484, DOI 10.1007/s004240050424; Yang H, 2003, J BIOL CHEM, V278, P35079, DOI 10.1074/jbc.M303098200; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zegarra-Moran O, 2002, BRIT J PHARMACOL, V137, P504, DOI 10.1038/sj.bjp.0704882	34	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9098	9104		10.1074/jbc.M611411200	http://dx.doi.org/10.1074/jbc.M611411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244607	hybrid			2022-12-27	WOS:000245780300057
J	Ding, HG; Yang, JJ; Coleman, LC; Yeung, S				Ding, Huangen; Yang, Juanjuan; Coleman, Liana C.; Yeung, Simon			Distinct iron binding property of two putative iron donors for the iron-sulfur cluster assembly - IscA and the bacterial frataxin ortholog CyaY under physiological and oxidative stress conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLET-REPEAT EXPANSION; ESCHERICHIA-COLI CYAY; FRIEDREICH ATAXIA; YEAST FRATAXIN; CRYSTAL-STRUCTURE; THIOREDOXIN REDUCTASE; 2FE-2S CLUSTERS; SACCHAROMYCES-CEREVISIAE; AZOTOBACTER-VINELANDII; TRANSCRIPTION FACTOR	Frataxin, a small mitochondrial protein linked to the neurodegenerative disease Friedreich ataxia, has recently been proposed as an iron donor for the iron-sulfur cluster assembly. An analogous function has also been attributed to IscA, a key member of the iron-sulfur cluster assembly machinery found in bacteria, yeast, and humans. Here we have compared the iron binding property of IscA and the frataxin ortholog CyaY from Escherichia coli under physiological and oxidative stress conditions. In the presence of the thioredoxin reductase system, which emulates the intracellular redox potential, CyaY fails to bind any iron even at a 10-fold excess of iron in the incubation solution. Under the same physiologically relevant conditions, IscA efficiently recruits iron and transfers the iron for the iron-sulfur cluster assembly in a proposed scaffold IscU. In the presence of hydrogen peroxide, however, IscA completely loses its iron binding activity, whereas CyaY becomes a competent iron-binding protein and attenuates the iron-mediated production of hydroxyl free radicals. Hydrogen peroxide appears to oxidize the iron binding thiol groups in IscA, thus blocking the iron binding in the protein. Once the oxidized thiol groups in IscA are re-reduced with the thioredoxin reductase system, the iron binding activity of IscA is fully restored. On the other hand, hydrogen peroxide has no effect on the iron binding carboxyl groups in CyaY, allowing the protein to bind iron under oxidative stress conditions. The results suggest that IscA is capable of recruiting intracellular iron for the iron-sulfur cluster assembly under normal physiological conditions, whereas CyaY may serve as an iron chaperon to sequester redox active free iron and alleviate cellular oxidative damage under oxidative stress conditions.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Ding, HG (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	hding@lsu.edu	Ding, Huangen/AAJ-8550-2020	Ding, Huangen/0000-0002-4815-7336	NATIONAL CANCER INSTITUTE [R01CA107494] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA107494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Adinolfi S, 2002, HUM MOL GENET, V11, P1865, DOI 10.1093/hmg/11.16.1865; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; AISEN P, 1978, J BIOL CHEM, V253, P1930; Aloria K, 2004, EMBO REP, V5, P1096, DOI 10.1038/sj.embor.7400272; Aslund F, 1999, J BACTERIOL, V181, P1375; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Balasubramanian R, 2006, J BACTERIOL, V188, P3182, DOI 10.1128/JB.188.9.3182-3191.2006; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bilder PW, 2004, BIOCHEMISTRY-US, V43, P133, DOI 10.1021/bi035440s; Bou-Abdallah F, 2004, J MOL BIOL, V341, P605, DOI 10.1016/j.jmb.2004.05.072; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Campanella A, 2004, HUM MOL GENET, V13, P2279, DOI 10.1093/hmg/ddh232; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Condo I, 2006, J BIOL CHEM, V281, P16750, DOI 10.1074/jbc.M511960200; Cook JD, 2006, BIOCHEMISTRY-US, V45, P7767, DOI 10.1021/bi060424r; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; COWART RE, 1993, ANAL BIOCHEM, V211, P151, DOI 10.1006/abio.1993.1246; Cozar-Castellano I, 2004, BBA-PROTEINS PROTEOM, V1700, P179, DOI 10.1016/j.bbapap.2004.05.004; Cupp-Vickery JR, 2004, J MOL BIOL, V338, P127, DOI 10.1016/j.jmb.2004.02.027; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Ding BJ, 2005, BIOCHEM J, V389, P797, DOI 10.1042/BJ20050405; Ding H, 2004, J BIOL CHEM, V279, P37499, DOI 10.1074/jbc.M404533200; Ding HG, 2005, J BIOL CHEM, V280, P30432, DOI 10.1074/jbc.M504638200; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fontecave M, 2006, NAT CHEM BIOL, V2, P171, DOI 10.1038/nchembio0406-171; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3; He YN, 2004, BIOCHEMISTRY-US, V43, P16254, DOI 10.1021/bi0488193; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Irazusta V, 2006, J BIOL CHEM, V281, P12227, DOI 10.1074/jbc.M511649200; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Johnson DC, 2006, J BACTERIOL, V188, P7551, DOI 10.1128/JB.00596-06; Karthikeyan G, 2003, HUM MOL GENET, V12, P3331, DOI 10.1093/hmg/ddg349; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; Keyer K, 1997, J BIOL CHEM, V272, P27652, DOI 10.1074/jbc.272.44.27652; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Layer G, 2006, J BIOL CHEM, V281, P16256, DOI 10.1074/jbc.M513569200; Li DS, 1999, FEBS LETT, V456, P13, DOI 10.1016/S0014-5793(99)00896-0; Morimoto K, 2006, J MOL BIOL, V360, P117, DOI 10.1016/j.jmb.2006.04.067; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Nair M, 2004, STRUCTURE, V12, P2037, DOI 10.1016/j.str.2004.08.012; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; O'Neill HA, 2005, J MOL BIOL, V345, P433, DOI 10.1016/j.jmb.2004.10.074; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Veine DM, 1998, PROTEIN SCI, V7, P1441, DOI 10.1002/pro.5560070621; Ventura N, 2005, AGING CELL, V4, P109, DOI 10.1111/j.1474-9726.2005.00149.x; VIVAS E, 2006, J BACTERIOL, V188, P1475; Wollenberg M, 2003, EUR J BIOCHEM, V270, P1662, DOI 10.1046/j.1432-1033.2003.03522.x; Yang JJ, 2006, J BIOL CHEM, V281, P27956, DOI 10.1074/jbc.M601356200; Yang WY, 2002, J BIOL CHEM, V277, P12868, DOI 10.1074/jbc.M109485200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	72	39	45	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7997	8004		10.1074/jbc.M609665200	http://dx.doi.org/10.1074/jbc.M609665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244611	hybrid			2022-12-27	WOS:000245081000030
J	Saita, Y; Takagi, T; Kitahara, K; Usui, M; Miyazono, K; Ezura, Y; Nakashima, K; Kurosawa, H; Ishii, S; Noda, M				Saita, Yoshitomo; Takagi, Tsuyoshi; Kitahara, Keiichiro; Usui, Michihiko; Miyazono, Kohei; Ezura, Yoichi; Nakashima, Kazuhisa; Kurosawa, Hisashi; Ishii, Shunsuke; Noda, Masaki			Lack of Schnurri-2 expression associates with reduced bone remodeling and osteopenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; NEGATIVE REGULATION; SIGNALING PATHWAY; MINERAL DENSITY; GENE; DIFFERENTIATION; OSTEOBLASTS; MASS; OSTEOPOROSIS	Regulation of bone remodeling determines the levels of bone mass and its imbalance causes major skeletal diseases such as osteoporosis. A zinc finger protein, Schnurri-2 (SHN-2), was recently demonstrated to regulate bone morphogenetic protein-dependent adipogenesis and lymphogenesis. However, the role of SHN-2 in bone is not known. Here, we investigated the effects of Shn-2 deficiency on bone metabolism and cell function in Shn-2-null mice. Lack of SHN-2 expression reduced bone remodeling by suppressing both osteoblastic bone formation and osteoclastic bone resorption activities in vivo. Shn-2 deficiency suppressed osterix and osteocalcin expression as well as in vitro mineralization. Conversely, Shn-2 overexpression enhanced osteocalcin promoter activity and bone morphogenetic protein-dependent osteoblastic differentiation. Shn-2 deficiency suppressed Nfatc1 and c-fos expression leading to reduction of tartrate-resistant acid phosphatase-positive cell development in vivo as well as in the cultures of bone marrow cells. These studies demonstrate that SHN-2 regulates the activities of critical transcription factors required for normal bone remodeling.	Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 1010062, Japan; RIKEN, Genet Mol Lab, Tsukuba Inst, Ibaraki 3050074, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Juntendo Univ, Sch Med, Dept Orthoped, Tokyo 1138421, Japan; Tokyo Med & Dent Univ, 21st Century Ctr Excellence Program Frontier Res, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Adv Bone & Joint Sci Integrated Act Initiat JSPS, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1010062, Japan	Tokyo Medical & Dental University (TMDU); RIKEN; University of Tokyo; Juntendo University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Noda, M (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Chiyoda Ku, 3-10 Kanda Surugadai,2 Chome, Tokyo 1010062, Japan.	noda.mph@mri.tmd.ac.jp	Ezura, Yoichi/L-9485-2016; Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478; Nakashima, Kazuhisa/0000-0003-0491-2149; Usui, Michihiko/0000-0002-5208-1848				Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Bleul CC, 2005, J IMMUNOL, V175, P5213, DOI 10.4049/jimmunol.175.8.5213; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Dai H, 2000, DEV BIOL, V227, P373, DOI 10.1006/dbio.2000.9901; Durr U, 2004, EUR J BIOCHEM, V271, P1135, DOI 10.1111/j.1432-1033.2004.04017.x; Epstein S, 2005, MAYO CLIN PROC, V80, P379, DOI 10.4065/80.3.379; Felsenberg D, 2005, CLIN THER, V27, P1, DOI 10.1016/j.clinthera.2004.12.020; Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005-1235; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; HOGAN B, 1994, MANIPULATING MOUSE E, P379; Jin WZ, 2006, DEV CELL, V10, P461, DOI 10.1016/j.devcel.2006.02.016; Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313; Kimura MY, 2005, J EXP MED, V201, P397, DOI 10.1084/jem.20040733; Kitahara K, 2003, ENDOCRINOLOGY, V144, P2132, DOI 10.1210/en.2002-220996; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Maeda Y, 2004, J CELL BIOCHEM, V93, P337, DOI 10.1002/jcb.20154; Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411; Oukka M, 2004, J EXP MED, V199, P15, DOI 10.1084/jem.20030421; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014-4827(03)00107-1; Shen ZJ, 2002, J BIOL CHEM, V277, P29840, DOI 10.1074/jbc.M203157200; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; Takagi T, 2001, NAT IMMUNOL, V2, P1048, DOI 10.1038/ni728; Takeuchi Y, 2002, J BIOL CHEM, V277, P49011, DOI 10.1074/jbc.M207804200; Tsuji K, 2004, J BONE MINER RES, V19, P1481, DOI 10.1359/JBMR.040601; Udagawa Y, 2000, GENES CELLS, V5, P359, DOI 10.1046/j.1365-2443.2000.00328.x; Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006; Wu LC, 2002, GENE EXPRESSION, V10, P137, DOI 10.3727/000000002783992479; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659	42	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12907	12915		10.1074/jbc.M611203200	http://dx.doi.org/10.1074/jbc.M611203200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17311925	hybrid			2022-12-27	WOS:000245942800062
J	Guo, BC; Cheng, GH				Guo, Beichu; Cheng, Genhong			Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEPATITIS-C VIRUS; MEDIATED SIGNAL-TRANSDUCTION; INDUCIBLE GENE-I; RIG-I; IKK-EPSILON; VIRAL-INFECTION; ACTIVATION; PATHWAY; KINASE	Induction of type I interferons can be triggered by viral components through Toll-like receptors or intracellular viral receptors such as retinoic acid-inducible gene I. Here, we demonstrate that the TRAF ( tumor necrosis factor receptor-associated factor) family member-associated NF-kappa B activator ( TANK) plays an important role in interferon induction through both retinoic acid-inducible gene I- and Toll-like receptor-dependent pathways. TANK forms complexes with both upstream signal mediators, such as Cardif/MAVS/IPS-1/VISA, TRIF ( Toll-interleukin-1 receptor domain-containing adaptor inducing interferon-beta), and TRAF3 and downstream mediators TANK-binding kinase 1, inducible I kappa B kinase, and interferon regulatory factor 3. In addition, it synergizes with these signaling components in interferon induction. Specific knockdown of TANK results in reduced type I interferon production, increased viral titers, and enhanced cell sensitivity to viral infection. Thus, TANK may be a critical adaptor that regulates the assembly of the TANK-binding kinase 1-inducible I kappa B kinase complex with upstream signaling molecules in multiple antiviral pathways.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Cheng, GH (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 8-240 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	genhongc@microbio.ucla.edu			NATIONAL CANCER INSTITUTE [T32CA009120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069120, R01AI056154] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA009120] Funding Source: Medline; NIAID NIH HHS [R01 AI069120, R01 AI056154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Breiman A, 2005, J VIROL, V79, P3969, DOI 10.1128/JVI.79.7.3969-3978.2005; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chin AID, 1999, MOL CELL BIOL, V19, P6665; Chung JY, 2002, J CELL SCI, V115, P679; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Heim MH, 2005, J HEPATOL, V42, P431, DOI 10.1016/j.jhep.2004.12.016; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Jefferies CA, 2005, TRENDS MOL MED, V11, P403, DOI 10.1016/j.molmed.2005.07.006; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Le Page C, 2000, Rev Immunogenet, V2, P374; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Nomura F, 2000, GENES CELLS, V5, P191; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/BST0310643; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Sasai M, 2005, J IMMUNOL, V174, P27, DOI 10.4049/jimmunol.174.1.27; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	48	163	167	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11817	11826		10.1074/jbc.M700017200	http://dx.doi.org/10.1074/jbc.M700017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17327220	hybrid			2022-12-27	WOS:000245941900024
J	Sanchez-Magraner, L; Viguera, AR; Garcia-Pacios, M; Garcillan, MP; Arrondo, JLR; de la Cruz, F; Goni, FM; Ostolaza, H				Sanchez-Magraner, Lissete; Viguera, Ana R.; Garcia-Pacios, Marcos; Garcillan, M. Pilar; Arrondo, Jose-Luis R.; de la Cruz, Fernando; Goni, Felix M.; Ostolaza, Helena			The calcium-binding c-terminal domain of Escherichia coli alpha-hemolysin is a major determinant in the surface-active properties of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE TOXIN; CRYSTAL-STRUCTURE; PSEUDOMONAS-AERUGINOSA; INFRARED-SPECTROSCOPY; ALKALINE PROTEASE; SELF-AGGREGATION; LIPID-BILAYERS; TARGET-CELLS; INSERTION; RECEPTOR	alpha-Hemolysin ( HlyA) from Escherichia coli is a protein toxin ( 1024 amino acids) that targets eukaryotic cell membranes, causing loss of the permeability barrier. HlyA consists of two main regions, an N-terminal domain rich in amphipathic helices, and a C-terminal Ca2+-binding domain containing a Gly- and Asp-rich nonapeptide repeated in tandem 11-17 times. The latter is called the RTX domain and gives its name to the RTX protein family. It had been commonly assumed that membrane interaction occurred mainly if not exclusively through the amphipathic helix domain. However, we have cloned and expressed the C-terminal region of HlyA, containing the RTX domain plus a few stabilizing sequences, and found that it is a potent surface-active molecule. The isolated domain binds Ca2+ with about the same affinity ( apparent K-0.5 approximate to 150 mu M) as the parent protein HlyA, and Ca2+ binding induces in turn a more compact folding with an increased proportion of beta-sheet structure. Both with and without Ca2+ the C-terminal region of HlyA can interact with lipid monolayers spread at an air-water interface. However, the C-terminal domain by itself is devoid of membrane lytic properties. The present results can be interpreted in the light of our previous studies that involved in receptor binding a peptide in the C-terminal region of HlyA. We had also shown experimentally the distinction between reversible membrane adsorption and irreversible lytic insertion of the toxin. In this context, the present data allow us to propose that both major domains of HlyA are directly involved in membrane-toxin interaction, the nonapeptide repeat, calcium-binding RTX domain being responsible for the early stages of HlyA docking to the target membrane.	Univ Basque Country, Unidad Biofis, Ctr Mixto, CSIC,EHU, Bilbao 48080, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Univ Cantabria, CSIC, Dept Biol Mol, Unidad Asociada Ctr Invest Biol, Santander 39011, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria	Ostolaza, H (corresponding author), Univ Basque Country, Unidad Biofis, Ctr Mixto, CSIC,EHU, Aptdo 644, Bilbao 48080, Spain.	gbzoseth@ehu.es	Garcillan, Maria Pilar/L-3125-2014; Viguera, Ana R/L-8248-2014; de la Cruz, Fernando/L-2812-2014; Garcillán-Barcia, María Pilar/G-5812-2016; Goni, Felix M/M-5425-2015	Viguera, Ana R/0000-0002-7688-8099; de la Cruz, Fernando/0000-0003-4758-6857; Garcillán-Barcia, María Pilar/0000-0001-7058-5428; Goni, Felix M/0000-0001-6270-9216; OSTOLAZA ECHABE, ELENA AMAYA/0000-0003-2933-9975				Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; Bauche C, 2006, J BIOL CHEM, V281, P16914, DOI 10.1074/jbc.M601594200; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Cortajarena AL, 2003, J BIOL CHEM, V278, P19159, DOI 10.1074/jbc.M208552200; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; Dalla Serra M, 1999, BIOCHEM BIOPH RES CO, V263, P516, DOI 10.1006/bbrc.1999.1400; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FELMLEE T, 1988, P NATL ACAD SCI USA, V85, P5269, DOI 10.1073/pnas.85.14.5269; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; Hamada K, 1996, J BIOCHEM, V119, P844, DOI 10.1093/oxfordjournals.jbchem.a021320; Holland IB, 2005, MOL MEMBR BIOL, V22, P29, DOI 10.1080/09687860500042013; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Ligi F, 1998, COMP BIOCHEM PHYS B, V121, P265, DOI 10.1016/S0305-0491(98)10099-8; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Martin C, 2004, J BACTERIOL, V186, P3760, DOI 10.1128/JB.186.12.3760-3765.2004; MIYATAKE H, 1995, J BIOCHEM, V118, P474, DOI 10.1093/oxfordjournals.jbchem.a124932; Moayeri M, 1997, INFECT IMMUN, V65, P2233, DOI 10.1128/IAI.65.6.2233-2239.1997; OSTOLAZA H, 1995, EUR J BIOCHEM, V228, P39, DOI 10.1111/j.1432-1033.1995.tb20225.x; OSTOLAZA H, 1991, FEBS LETT, V280, P195, DOI 10.1016/0014-5793(91)80291-A; Sanchez-Magraner L, 2006, J BIOL CHEM, V281, P5461, DOI 10.1074/jbc.M512897200; Soloaga A, 1998, BIOCHEMISTRY-US, V37, P6387, DOI 10.1021/bi9730994; Soloaga A, 1999, MOL MICROBIOL, V31, P1013, DOI 10.1046/j.1365-2958.1999.01225.x; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Valeva A, 2005, J BIOL CHEM, V280, P36657, DOI 10.1074/jbc.M507690200; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85	30	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11827	11835		10.1074/jbc.M700547200	http://dx.doi.org/10.1074/jbc.M700547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324923	hybrid			2022-12-27	WOS:000245941900025
J	Girnita, L; Shenoy, SK; Sehat, B; Vasilcanu, R; Vasilcanu, D; Girnita, A; Lefkowitz, RJ; Larsson, O				Girnita, Leonard; Shenoy, Sudha K.; Sehat, Bita; Vasilcanu, Radu; Vasilcanu, Daiana; Girnita, Ada; Lefkowitz, Robert J.; Larsson, Olle			beta-Arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PROTEIN-COUPLED RECEPTORS; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; G1 PHASE; GROWTH; INSULIN; UBIQUITINATION; SIGNAL; ENDOCYTOSIS; EXPRESSION	beta-Arrestin1, which regulates many aspects of seven transmembrane receptor (7TMR) biology, has also been shown to serve as an adaptor, which brings Mdm2, an E3 ubiquitin ligase to the insulin-like growth factor-1 receptor (IGF-1R), leading to its proteasome- dependent destruction. Here we demonstrate that IGF-1R stimulation also leads to ubiquitination of beta-arrestin1, which regulates vesicular trafficking and activation of ERK1/2. This beta-arrestin1-dependent ERK activity can occur even when the classical tyrosine kinase signaling is impaired. siRNA- mediated suppression of beta-arrestin1 in human melanoma cells ablates IGF-1-stimulated ERK and prolongs the G1 phase of the cell cycle. These data suggest that beta-arrestin-dependent ERK signaling by the IGF-1R regulates cell cycle progression and may thus be an important regulator of the growth of normal and malignant cells.	Karolinska Hosp, Dept Pathol & Oncol, Div Cellular & Mol Tumor Pathol, CCK, SE-17176 Stockholm, Sweden; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Karolinska Institutet; Karolinska University Hospital; Duke University; Howard Hughes Medical Institute; Duke University	Girnita, L (corresponding author), Karolinska Hosp, Dept Pathol & Oncol, Div Cellular & Mol Tumor Pathol, CCK, R8-04, SE-17176 Stockholm, Sweden.	Leonard.Girnita@ki.se; Olle.Larsson@ki.se	Girnita, Ada/AAC-4518-2020; Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021; Girnita, Leonard/A-4168-2008	Shenoy, Sudha/0000-0002-2565-4663; Girnita, Leonard/0000-0003-0280-9500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, R01HL080525, R01HL070631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL080525, HL16037, HL70631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BASERGA R, 1995, CANCER RES, V55, P249; Carter RS, 2005, J BIOL CHEM, V280, P43272, DOI 10.1074/jbc.M508656200; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lefkowitz RJ, 2004, TRENDS PHARMACOL SCI, V25, P413, DOI 10.1016/j.tips.2004.06.006; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McMasters KM, 1996, ONCOGENE, V13, P1731; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044	42	106	112	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11329	11338		10.1074/jbc.M611526200	http://dx.doi.org/10.1074/jbc.M611526200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303558	hybrid			2022-12-27	WOS:000245941500055
J	Hobbs, MD; Sakai, A; Cox, MM				Hobbs, Michael D.; Sakai, Akiko; Cox, Michael M.			SSB protein limits RecOR binding onto single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECF; STALLED REPLICATION FORKS; PHAGE-LAMBDA ORF; GENETIC-RECOMBINATION; C-TERMINUS; DEINOCOCCUS-RADIODURANS; CRYSTAL-STRUCTURE; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; RAD51 RECOMBINASE	The RecO and RecR proteins form a complex that promotes the nucleation of RecA protein filaments onto SSB protein-coated single-stranded DNA ( ssDNA). However, even when RecO and RecR proteins are provided at optimal concentrations, the loading of RecA protein is surprisingly slow, typically proceeding with a lag of 10 min or more. The rate-limiting step in RecOR-promoted RecA nucleation is the binding of RecOR protein to ssDNA, which is inhibited by SSB protein despite the documented interaction between RecO and SSB. Full activity of RecOR is seen only when RecOR is preincubated with ssDNA prior to the addition of SSB. The slow binding of RecOR to SSB-coated ssDNA involves the C terminus of SSB. When an SSB variant that lacks the C-terminal 8 amino acids is used, the capacity of RecOR to facilitate RecA loading onto the ssDNA is largely abolished. The results are used in an expanded model for RecOR action.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu	SAKAI, AKIKO/AAC-9814-2020	SAKAI, AKIKO/0000-0002-1258-1725	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725, T32GM007215] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007215, GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya N, 2002, J MOL BIOL, V318, P1251, DOI 10.1016/S0022-2836(02)00053-0; ALONSO JC, 1993, J BIOL CHEM, V268, P1424; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bernstein DA, 2004, P NATL ACAD SCI USA, V101, P8575, DOI 10.1073/pnas.0401331101; BIANCO PR, 1998, FRONT BIOSCI, V3, P560; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Cadman CJ, 2004, NUCLEIC ACIDS RES, V32, P6378, DOI 10.1093/nar/gkh980; Carrasco B, 2005, NUCLEIC ACIDS RES, V33, P3942, DOI 10.1093/nar/gki713; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Curth U, 1996, NUCLEIC ACIDS RES, V24, P2706, DOI 10.1093/nar/24.14.2706; DAVIS RW, 1980, ADV BACTERIAL GENET, P116; Drees JC, 2004, J BIOL CHEM, V279, P52991, DOI 10.1074/jbc.M409050200; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; Eggington JM, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-2; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; Gulbis JM, 2004, EUR J BIOCHEM, V271, P439, DOI 10.1046/j.1432-1033.2003.03944.x; Handa P, 2001, J BIOL CHEM, V276, P16992, DOI 10.1074/jbc.M100393200; Honda M, 2006, J BIOL CHEM, V281, P18549, DOI 10.1074/jbc.M512658200; Kantake N, 2002, P NATL ACAD SCI USA, V99, P15327, DOI 10.1073/pnas.252633399; Kinebuchi T, 1997, BIOCHEMISTRY-US, V36, P6732, DOI 10.1021/bi961647s; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; Lee BI, 2004, EMBO J, V23, P2029, DOI 10.1038/sj.emboj.7600222; Leiros I, 2005, EMBO J, V24, P906, DOI 10.1038/sj.emboj.7600582; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; Liu YL, 2000, EMBO REP, V1, P85, DOI 10.1093/embo-reports/kvd002; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; Lusetti SL, 2006, MOL CELL, V21, P41, DOI 10.1016/j.molcel.2005.11.011; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P55073, DOI 10.1074/jbc.M410371200; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; Maxwell KL, 2005, P NATL ACAD SCI USA, V102, P11260, DOI 10.1073/pnas.0503399102; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOREAU PL, 1988, J BACTERIOL, V170, P2493, DOI 10.1128/jb.170.6.2493-2500.1988; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Richard DJ, 2004, NUCLEIC ACIDS RES, V32, P1065, DOI 10.1093/nar/gkh259; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROCHA EPC, 2005, PLOS GENET; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; SAWITZKE JA, 1992, GENETICS, V130, P7; SAWITZKE JA, 1994, J BACTERIOL, V176, P6730, DOI 10.1128/JB.176.21.6730-6737.1994; Schlacher K, 2006, CHEM REV, V106, P406, DOI 10.1021/cr0404951; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SMITH GR, 1989, GENOME, V31, P520, DOI 10.1139/g89-100; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Walker GC, 2000, BACTERIAL STRESS RESPONSES, P131; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Webb BL, 1999, J BIOL CHEM, V274, P15367, DOI 10.1074/jbc.274.22.15367; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; WHITBY MC, 1995, MOL GEN GENET, V246, P174, DOI 10.1007/BF00294680; Witte G, 2003, NUCLEIC ACIDS RES, V31, P4434, DOI 10.1093/nar/gkg498; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	81	67	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11058	11067		10.1074/jbc.M611007200	http://dx.doi.org/10.1074/jbc.M611007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17272275	hybrid			2022-12-27	WOS:000245941500026
J	Dhawan, L; Liu, B; Blaxall, BC; Taubman, MB				Dhawan, Latika; Liu, Bin; Blaxall, Burns C.; Taubman, Mark B.			A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CHOLESTEROL-FED RABBITS; BALLOON ARTERIAL INJURY; GENE-EXPRESSION; ATHEROSCLEROTIC LESIONS; MACROPHAGE ACCUMULATION; NEOINTIMAL HYPERPLASIA; INTIMAL HYPERPLASIA; MCP-1 DEFICIENCY; DNA-BINDING	Monocyte chemoattractant protein-1 (MCP-1) plays an important role in attracting monocytes to sites of inflammation and is the dominant mediator of macrophage accumulation in atherosclerotic plaques. We have previously shown that glucocorticoids inhibit the secretion of MCP-1 in arterial smooth muscle cells (SMC) by markedly decreasing MCP-1 mRNA stability. We now report that the destabilization of MCP-1 mRNA is mediated by the glucocorticoid receptor (GR). The GR antagonist, RU486, blocked the effect of the glucocorticoid dexamethasone (Dex) on MCP-1 mRNA stability in SMC culture. Using a previously reported in vitro mRNA gel shift and stability assay, antibodies to the GR blocked the ability of cytoplasmic extracts from Dex-treated SMC to decay MCP-1 mRNA. Recombinant human GR (rhGR) bound in a concentration dependent manner to in vitro transcribed MCP-1 mRNA, whereas other members of the steroid hormone receptor family did not. Binding of GR to MCP-1 mRNA was specific as it was not found to bind other mRNAs. Immunoprecipitation of GR in extracts from Dex-treated SMC followed by real-time reverse transcription-PCR demonstrated that endogenous GR was bound specifically to MCP-1 mRNA. The addition of exogenous rhGR blocked the ability of extracts from Dex-treated SMC to degrade MCP-1 mRNA, suggesting that exogenous rhGR can compete with an endogenous GR-containing degradative complex. These data suggest a novel role for the GR in binding to and facilitating mRNA degradation. These results provide novel insights into GR function and may provide a new approach to attenuate the inflammatory response mediated by MCP-1.	Univ Rochester, Sch Med & Dent, Rochester, NY 14620 USA; Univ Rochester, Cardiovasc Res Inst, Rochester, NY 14620 USA	University of Rochester; University of Rochester	Taubman, MB (corresponding author), Univ Rochester, Sch Med & Dent, 601 Elmwood Ave,Box 678 CVRI, Rochester, NY 14620 USA.	mark_taubman@urmc.rochester.edu	Blaxall, Burns/ABD-8289-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL077789, R01HL077669] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL77669, P01 HL77789] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alcorn JL, 2004, AM J PHYSIOL-LUNG C, V286, pL767, DOI 10.1152/ajplung.00280.2003; ALI M, 1987, J BIOL CHEM, V262, P6778; ASAI K, 1993, ARTERIOSCLER THROMB, V13, P892, DOI 10.1161/01.ATV.13.6.892; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERK BC, 1991, J AM COLL CARDIOL, V17, pB111; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Cooper JAD, 1998, AM J RESP CELL MOL, V18, P521, DOI 10.1165/ajrcmb.18.4.2786; DAVIES GJ, 1995, EUR HEART J, V16, P31, DOI 10.1093/eurheartj/16.suppl_I.31; de Silanes IL, 2005, MOL CELL BIOL, V25, P9520, DOI 10.1128/MCB.25.21.9520-9531.2005; Egashira K, 2002, CIRC RES, V90, P1167, DOI 10.1161/01.RES.0000020561.03244.7E; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Gao ZL, 2003, CHEM REV, V103, P3733, DOI 10.1021/cr020474b; Garcia-Gras EA, 2000, J BIOL CHEM, V275, P22001, DOI 10.1074/jbc.M001048200; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 1999, Chem Immunol, V72, P7, DOI 10.1159/000058723; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Kim WJH, 2003, BIOCHEM BIOPH RES CO, V310, P936, DOI 10.1016/j.bbrc.2003.09.088; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Liu B, 2006, J MOL CELL CARDIOL, V41, P160, DOI 10.1016/j.yjmcc.2006.03.426; MCGUIRE J, 1988, ANN NY ACAD SCI, V548, P283, DOI 10.1111/j.1749-6632.1988.tb18816.x; NAITO M, 1992, J NUTR SCI VITAMINOL, V38, P255, DOI 10.3177/jnsv.38.255; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Newton R, 2000, THORAX, V55, P603, DOI 10.1136/thorax.55.7.603; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; Poon M, 1999, MOL CELL BIOL, V19, P6471; POON M, 1991, J BIOL CHEM, V266, P22375; Poon M, 1999, LAB INVEST, V79, P1369; Poon M, 2001, ATHEROSCLEROSIS, V155, P371, DOI 10.1016/S0021-9150(00)00605-5; Poon M, 1996, AM J PATHOL, V149, P307; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Roque M, 2002, ARTERIOSCL THROM VAS, V22, P554, DOI 10.1161/hq0402.105720; ROSSINI GP, 1987, BIOCHEM BIOPH RES CO, V147, P1188, DOI 10.1016/S0006-291X(87)80195-X; RUSSOMARIE F, 1992, J NEUROIMMUNOL, V40, P281, DOI 10.1016/0165-5728(92)90144-A; Sakai M, 1999, ARTERIOSCL THROM VAS, V19, P1726, DOI 10.1161/01.ATV.19.7.1726; SLAVIN J, 1995, GROWTH FACTORS, V12, P151, DOI 10.3109/08977199509028961; Stellato Cristiana, 2004, Proc Am Thorac Soc, V1, P255, DOI 10.1513/pats.200402-015MS; Steube Klaus G., 2000, Molecular Cell Biology Research Communications, V3, P60, DOI 10.1006/mcbr.2000.0190; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; TYMOCZKO JL, 1985, BIOCHIM BIOPHYS ACTA, V846, P193, DOI 10.1016/0167-4889(85)90065-5; VanPut DJM, 1995, EUR J PHARMACOL, V294, P753, DOI 10.1016/0014-2999(95)00635-4; Wang JM, 1999, AM J PHYSIOL-LUNG C, V276, pL175, DOI 10.1152/ajplung.1999.276.1.L175; Wysocki SJ, 1996, J CELL BIOCHEM, V62, P303, DOI 10.1002/(SICI)1097-4644(199609)62:3<303::AID-JCB1>3.0.CO;2-V; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953	50	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10146	10152		10.1074/jbc.M605925200	http://dx.doi.org/10.1074/jbc.M605925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17276989	hybrid			2022-12-27	WOS:000245941000004
J	Duurkens, RH; Tol, MB; Geertsma, ER; Permentier, HP; Slotboom, DJ				Duurkens, Ria H.; Tol, Menno B.; Geertsma, Eric R.; Permentier, Hjalmar P.; Slotboom, Dirk Jan			Flavin binding to the high affinity riboflavin transporter RibU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOCOCCUS-LACTIS; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; SCHIZOSACCHAROMYCES-POMBE; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; PROTEIN; BIOSYNTHESIS; MEMBRANE; SYSTEMS	The first biochemical and spectroscopic characterization of a purified membrane transporter for riboflavin ( vitamin B-2) is presented. The riboflavin transporter RibU from the bacterium Lactococcus lactis was overexpressed, solubilized, and purified. The purified transporter was bright yellow when the cells had been cultured in rich medium. We used a detergent- compatible matrix- assisted laser desorption ionization time-of-flight mass spectrometry method ( Cadene, M., and Chait, B. T. ( 2000) Anal. Chem. 72, 5655 - 5658) to show that the source of the yellow color was riboflavin that had been co-purified with the transporter. The method appears generally applicable for substrate identification of purified membrane proteins. Substrate- free RibU was produced by expressing the protein in cells cultured in chemically defined medium. Riboflavin, FMN, and roseoflavin bound to RibU with high affinity and 1: 1 stoichiometry ( K-d for riboflavin is 0.6 nM), but FAD did not bind to the transporter. The absorption spectrum of riboflavin changed dramatically when the substrate bound to RibU. Well resolved bands appeared at 441, 464, and 486 nm, indicating a hydrophobic binding pocket. The fluorescence of riboflavin was almost completely quenched upon binding to RibU, and also the tryptophan fluorescence of the transporter was quenched when flavins bound. The results indicate that riboflavin is stacked with one or more tryptophan residues in the binding pocket of RibU. Mutagenesis experiments showed that Trp-68 was involved directly in the riboflavin binding. The structural properties of the binding site and mechanistic consequences of the exceptionally high affinity of RibU for its substrate are discussed in relation to soluble riboflavin- binding proteins of known structure.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Slotboom, DJ (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	d.j.slotboom@rug.nl	Permentier, Hjalmar P/H-4190-2016	Permentier, Hjalmar P/0000-0001-7317-8887; Geertsma, Eric R./0000-0002-2789-5444				Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; Bieger B, 2003, STRUCTURE, V11, P375, DOI 10.1016/S0969-2126(03)00048-0; BOWMAN BB, 1989, ANNU REV NUTR, V9, P187, DOI 10.1146/annurev.nu.09.070189.001155; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgess C, 2004, APPL ENVIRON MICROB, V70, P5769, DOI 10.1128/AEM.70.10.5769-5777.2004; Burgess CM, 2006, J BACTERIOL, V188, P2752, DOI 10.1128/JB.188.8.2752-2760.2006; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; CECCHINI G, 1979, J BIOL CHEM, V254, P7295; CHOI JD, 1980, ARCH BIOCHEM BIOPHYS, V204, P41, DOI 10.1016/0003-9861(80)90005-3; Eitinger T, 2000, ARCH MICROBIOL, V173, P1, DOI 10.1007/s002030050001; Fischer M, 2002, EUR J BIOCHEM, V269, P519, DOI 10.1046/j.0014-2956.2001.02674.x; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Gerhardt S, 2002, J MOL BIOL, V318, P1317, DOI 10.1016/S0022-2836(02)00116-X; GHISLA S, 1986, BIOCHEM J, V239, P1; HARBURY HA, 1959, P NATL ACAD SCI USA, V45, P1708, DOI 10.1073/pnas.45.12.1708; Kreneva RA, 2000, RUSS J GENET+, V36, P972; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; MOLENAAR D, 1993, J BACTERIOL, V175, P5438, DOI 10.1128/JB.175.17.5438-5444.1993; Monaco HL, 1997, EMBO J, V16, P1475, DOI 10.1093/emboj/16.7.1475; NISHIKIMI M, 1973, J BIOCHEM, V73, P1233, DOI 10.1093/oxfordjournals.jbchem.a130196; Ohashi Y, 2003, CURR ORG CHEM, V7, P1605, DOI 10.2174/1385272033486288; OTTO MK, 1981, P NATL ACAD SCI-BIOL, V78, P266, DOI 10.1073/pnas.78.1.266; Reihl P, 2005, J BIOL CHEM, V280, P39809, DOI 10.1074/jbc.M505002200; Sahin-Toth M, 2000, BIOCHEMISTRY-US, V39, P5097, DOI 10.1021/bi0000263; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; Veldhuis G, 2004, BIOPHYS J, V86, P1959, DOI 10.1016/S0006-3495(04)74259-9; VELDHUIS G, 2006, THESIS U GRONINGEN; WHITE HB, 1988, ANNU REV NUTR, V8, P279, DOI 10.1146/annurev.nu.08.070188.001431; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	29	75	78	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10380	10386		10.1074/jbc.M608583200	http://dx.doi.org/10.1074/jbc.M608583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289680	hybrid			2022-12-27	WOS:000245941000028
J	Li, ZY; Agellon, LB; Vance, DE				Li, Zhaoyu; Agellon, Luis B.; Vance, Dennis E.			Choline redistribution during adaptation to choline deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; PHOSPHATIDYLCHOLINE; LIVER; PHOSPHOLIPIDS; BIOSYNTHESIS; DISRUPTION; SECRETION; S-100B; DAMAGE	Choline is an important nutrient for mammals. Choline can also be generated by the catabolism of phosphatidylcholine synthesized in the liver by the methylation of phosphatidylethanolamine by phosphatidylethanolamine N- methyltransferase ( PEMT). Complete choline deprivation is achieved by feeding Pemt(-/-) mice a choline-deficient diet and is lethal due to liver failure. Mice that lack both PEMT and MDR2 ( multiple drug-resistant protein 2) successfully adapt to choline deprivation via hepatic choline recycling. We now report another mechanism involved in this adaptation, choline redistribution. Normal levels of choline-containing metabolites were maintained in the brains of choline-deficient Mdr2(-/-)/Pemt(-/-) mice for 90 days despite continued choline consumption via oxidation. Choline oxidase activity had not been previously detected in the brain. Plasma levels of choline were also maintained for 90 days, whereas plasma phosphatidylcholine levels decreased by > 60%. The injection of [H-3] choline into Mdr2(-/-) /Pemt(-/-) mice revealed a redistribution of choline among tissues. Although CD-Pemt(-/-) mice failed to adapt to choline deprivation, choline redistribution was also initiated in these mice. The data suggest that adaptation to choline deprivation is not restricted to liver via choline recycling but also occurs in the whole animal via choline redistribution.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Li, Zhaoyu/0000-0002-1136-2758				BANNERMAN R, 1983, MOUSE BIOMEDICAL RES, V3; Best CH, 1932, J PHYSIOL-LONDON, V75, P405, DOI 10.1113/jphysiol.1932.sp002899; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; FIELDING PE, 2002, BIOCH LIPIDS LIPOPRO, P527; HISE MK, 1983, ANAL BIOCHEM, V135, P78, DOI 10.1016/0003-2697(83)90733-9; KENNEDY EP, 1956, CAN J BIOCHEM PHYS, V34, P334, DOI 10.1139/o56-036; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Lang DH, 2005, J BONE MINER RES, V20, P748, DOI 10.1359/JBMR.041224; Li ZY, 2006, CELL METAB, V3, P321, DOI 10.1016/j.cmet.2006.03.007; Li ZY, 2005, J BIOL CHEM, V280, P37798, DOI 10.1074/jbc.M508575200; Lockman PR, 2002, DRUG DEV IND PHARM, V28, P749, DOI 10.1081/DDC-120005622; MCCLUER RH, 1986, ADV CHROMATOGR, V25, P309; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; PELECH SL, 1981, J BIOL CHEM, V256, P8283; Sarter M, 2005, NAT REV NEUROSCI, V6, P48, DOI 10.1038/nrn1588; SIDRANSKY H, 1959, Bull Tulane Univ Med Fac, V19, P11; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; VANCE JE, 2002, BIOCH LIPIDS LIPOPRO, P505; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Zeisel SH, 2000, NUTRITION, V16, P669, DOI 10.1016/S0899-9007(00)00349-X; Zeisel SH, 2004, J AM COLL NUTR, V23, p621S, DOI 10.1080/07315724.2004.10719433	27	35	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10283	10289		10.1074/jbc.M611726200	http://dx.doi.org/10.1074/jbc.M611726200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283071	hybrid			2022-12-27	WOS:000245941000018
J	Meray, RK; Lansbury, PT				Meray, Robin K.; Lansbury, Peter T., Jr.			Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HYDROLASES; DEUBIQUITINATING ENZYMES; CONFORMATIONAL PLASTICITY; BINDING PROTEINS; STRUCTURAL BASIS; CELL APOPTOSIS; BETA-ARRESTIN; IN-VIVO; PGP 9.5; SUBSTRATE	Deubiquitinating enzymes ( DUBs) are negative regulators of protein ubiquitination and play an important role in ubiquitin-dependent processes. Recent studies have found that diverse cellular mechanisms are employed to control the activity of DUBs. Ubiquitin C-terminal hydrolase-L1 ( UCH-L1) is a highly expressed neuronal DUB linked to Parkinson disease; however, little is known about its specific functions or modes of regulation. Here, we demonstrate that UCH-L1 is post-translationally modified by monoubiquitin in cells, at lysine residues near the active site. This modification restricts enzyme activity by preventing binding to ubiquitinated targets, and permanent monoubiquitination, as mimicked by a ubiquitin-UCH-L1 fusion, inhibits UCH-L1 in its capacity to increase free ubiquitin levels in cells. Interestingly, UCH-L1 catalyzes its own deubiquitination in an intramolecular manner, thereby regulating the lifetime of this modification. Our results illustrate monoubiquitination as a reversible regulatory mechanism for DUB activity involving auto-deubiquitination.	Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Cambridge, MA 02139 USA	Harvard University; Harvard University; Brigham & Women's Hospital	Lansbury, PT (corresponding author), Ctr Neurol Dis, 65 Landsdowne St,4th Floor, Cambridge, MA 02139 USA.	plansbury@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS047420] Funding Source: NIH RePORTER; NINDS NIH HHS [R21NS047420] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Das C, 2006, P NATL ACAD SCI USA, V103, P4675, DOI 10.1073/pnas.0510403103; DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317; DICKSON DW, 1994, ACTA NEUROPATHOL, V87, P269; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Facheris M, 2005, NEUROSCI LETT, V381, P131, DOI 10.1016/j.neulet.2005.02.008; Gong B, 2006, CELL, V126, P775, DOI 10.1016/j.cell.2006.06.046; Harada T, 2004, AM J PATHOL, V164, P59, DOI 10.1016/S0002-9440(10)63096-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kwon J, 2004, AM J PATHOL, V165, P1367, DOI 10.1016/S0002-9440(10)63394-9; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Luchansky SJ, 2006, BIOCHEMISTRY-US, V45, P14717, DOI 10.1021/bi061406c; Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Misaghi S, 2005, J BIOL CHEM, V280, P1512, DOI 10.1074/jbc.M410770200; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Reiley W, 2005, MOL CELL BIOL, V25, P3886, DOI 10.1128/MCB.25.10.3886-3895.2005; Satoh J, 2001, J NEUROL SCI, V189, P113, DOI 10.1016/S0022-510X(01)00555-X; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Shen CL, 2005, J BIOL CHEM, V280, P35967, DOI 10.1074/jbc.M505220200; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Xue SF, 2006, BRAIN RES, V1087, P28, DOI 10.1016/j.brainres.2006.02.121; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; Zhu QZ, 2005, EXP CELL RES, V307, P436, DOI 10.1016/j.yexcr.2005.03.031	48	78	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10567	10575		10.1074/jbc.M611153200	http://dx.doi.org/10.1074/jbc.M611153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17259170	hybrid			2022-12-27	WOS:000245941000050
J	Ricciardelli, C; Russell, DL; Ween, MP; Mayne, K; Suwiwat, S; Byers, S; Marshall, VR; Tilley, WD; Horsfall, DJ				Ricciardelli, Carmela; Russell, Darryl L.; Ween, Miranda P.; Mayne, Keiko; Suwiwat, Supaporn; Byers, Sharon; Marshall, Villis R.; Tilley, Wayne D.; Horsfall, David J.			Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CHONDROITIN SULFATE; REACTIVE STROMA; ELEVATED LEVELS; BREAST-CANCER; TUMOR-CELLS; EXPRESSION; MIGRATION; GROWTH; INVASION	Previous studies have demonstrated that high levels of hyaluronan ( HA) and the chondroitin sulfate proteoglycan, versican in the peritumoral stroma are associated with metastatic spread of clinical prostate cancer. In vitro integration of HA and versican into a pericellular sheath is a prerequisite for proliferation and migration of vascular smooth muscle cells. In this study, a particle exclusion assay was used to determine whether human prostate cancer cell lines are capable of assembling a pericellular sheath following treatment with versican-containing medium and whether formation of a pericellular sheath modulated cell motility. PC3 and DU145, but not LNCaP cells formed prominent polarized pericellular sheaths following treatment with prostate fibroblast-conditioned medium. The capacity to assemble a pericellular sheath correlated with the ability to express membranous HA receptor, CD44. HA and versican histochemical staining were observed surrounding PC3 and DU145 cells following treatment with prostatic fibroblast-conditioned medium. The dependence on HA for integrity of the pericellular sheath was demonstrated by its removal following treatment with hyaluronidase. Purified versican or conditioned medium from Chinese hamster ovary K1 cells overexpressing versican V1, but not conditioned medium from parental cells, promoted pericellular sheath formation and motility of PC3 cells. Using time lapse microscopy, motile PC3 cells treated with versican but not non-motile cells exhibited a polar pericellular sheath. Polar pericellular sheath was particularly evident at the trailing edge but was excluded from the leading edge of PC3 cells. These studies indicate that prostate cancer cells recruit stromal components to remodel their pericellular environment and promote their motility.	Univ Adelaide, Discipline Obstet & Gynaecol, Res Ctr Reprod Hlth, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Reprod Hlth, Adelaide, SA 5005, Australia; Univ Adelaide, Hanson Inst, Dame Roma Mitchell Canc Res Labs, Adelaide, SA 5001, Australia; Womens & Childrens Hosp, Dept Med Genet, Matrix Biol Unit, Adelaide, SA 5006, Australia; Royal Adelaide Hosp, Surg Special Serv, Adelaide, SA 5000, Australia	University of Adelaide; University of Adelaide; Hanson Institute; University of Adelaide; Womens & Childrens Hospital Australia; Royal Adelaide Hospital	Ricciardelli, C (corresponding author), Univ Adelaide, Discipline Obstet & Gynaecol, Res Ctr Reprod Hlth, Frome Rd, Adelaide, SA 5005, Australia.	carmela.ricciardelli@adelaide.edu.au	Ricciardelli, Carmela/U-1814-2019; Russell, Darryl L/I-6654-2012; Ween, Miranda/C-3828-2011; Ricciardelli, Carmela/K-2212-2015	Ricciardelli, Carmela/0000-0001-7415-1854; Russell, Darryl L/0000-0002-4930-7658; Ricciardelli, Carmela/0000-0001-7415-1854; Tilley, Wayne/0000-0003-1893-2626; Byers, Sharon/0000-0001-5576-3636; ween, miranda/0000-0002-0600-4585				Aaltomaa S, 2002, UROL INT, V69, P266, DOI 10.1159/000066123; ALBINI A, 1987, CANCER RES, V47, P3239; Alstergren P, 2004, CELL IMMUNOL, V231, P146, DOI 10.1016/j.cellimm.2005.01.007; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Gakunga P, 1997, DEVELOPMENT, V124, P3987; Henderson DJ, 1998, CIRC RES, V83, P523, DOI 10.1161/01.RES.83.5.523; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; KNAPP PE, 1992, J HISTOCHEM CYTOCHEM, V40, P1405, DOI 10.1177/40.9.1506676; KNUDSON W, 1991, J CELL SCI, V99, P227; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Kosaki R, 1999, CANCER RES, V59, P1141; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lebaron RG, 1996, PERSPECT DEV NEUROBI, V3, P261; Lipponen P, 2001, EUR J CANCER, V37, P849, DOI 10.1016/S0959-8049(00)00448-2; Olumi AF, 1998, CANCER RES, V58, P4525; PASSANITI A, 1992, INT J CANCER, V51, P318, DOI 10.1002/ijc.2910510224; Ricciardelli C, 1997, CLIN CANCER RES, V3, P983; Ricciardelli C, 1999, CANCER RES, V59, P2324; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Sakko AJ, 2003, CANCER RES, V63, P4786; Sakko AJ, 2001, CANCER RES, V61, P926; SHEVRIN DH, 1989, PROSTATE, V15, P187, DOI 10.1002/pros.2990150212; Simpson MA, 2001, J BIOL CHEM, V276, P17949, DOI 10.1074/jbc.M010064200; Suwiwat S, 2004, CLIN CANCER RES, V10, P2491, DOI 10.1158/1078-0432.CCR-03-0146; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Voutilainen K, 2003, INT J CANCER, V107, P359, DOI 10.1002/ijc.11423; Wight TN, 2002, CURR OPIN CELL BIOL, V14, P617, DOI 10.1016/S0955-0674(02)00375-7; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	42	123	124	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10814	10825		10.1074/jbc.M606991200	http://dx.doi.org/10.1074/jbc.M606991200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293599	hybrid			2022-12-27	WOS:000245941000075
J	DiCara, D; Rapisarda, C; Sutcliffe, JL; Violette, SM; Weinreb, PH; Hart, IR; Howard, MJ; Marshall, JF				DiCara, Danielle; Rapisarda, Chiara; Sutcliffe, Julie L.; Violette, Shelia M.; Weinreb, Paul H.; Hart, Ian R.; Howard, Mark J.; Marshall, John F.			Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE-VIRUS; TRANSFER DIFFERENCE NMR; SQUAMOUS CARCINOMA-CELLS; NEUTRALIZING ANTIBODY; EXPRESSION; RECEPTOR; PROTEIN; LOOP; RECOGNITION; BINDING	Data relating to the structural basis of ligand recognition by integrins are limited. Here we describe the physical requirements for high affinity binding of ligands to alpha v beta 6. By combining a series of structural analyses with functional testing, we show that 20-mer peptide ligands, derived from high affinity ligands of alpha v beta 6 (foot-and-mouth-disease virus, latency associated peptide), have a common structure comprising an Arg-Gly-Asp motif at the tip of a hairpin turn followed immediately by a C-terminal helix. This arrangement allows two conserved Leu/Ile residues at Asp(+1) and Asp(+4) to be presented on the outside face of the helix enabling a potential hydrophobic interaction with the alpha v beta 6 integrin, in addition to the Arg-Gly-Asp interaction. The extent of the helix determines peptide affinity for alpha v beta 6 and potency as an alpha v beta 6 antagonist. A major role of this C-terminal helix is likely to be the correct positioning of the Asp(+1) and Asp(+4) residues. These data suggest an explanation for several biological functions of alpha v beta 6 and provide a structural platform for design of alpha v beta 6 antagonists.	Univ Kent, Prot Sci Grp, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Queen Marys Coll, Tumor Biol Ctr, Canc Res UK Clin Ctr, London EC1M 6BQ, England; London Med & Dent Sch, John Vane Sci Ctr, London EC1M 6BQ, England; Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; Biogen Idec Inc, Cambridge Ctr, Cambridge, MA 02142 USA	University of Kent; Cancer Research UK; University of London; Queen Mary University London; University of London; Queen Mary University London; University of California System; University of California Davis; Biogen	Howard, MJ (corresponding author), Univ Kent, Prot Sci Grp, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	m.j.howard@kent.ac.uk; john.marshall@cancer.org.uk	Rapisarda, Chiara/E-8028-2013	Rapisarda, Chiara/0000-0002-1867-1385; Weinreb, Paul/0000-0002-0802-0052; Howard, Mark/0000-0002-0762-2887				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Annes JP, 2002, FEBS LETT, V511, P65, DOI 10.1016/S0014-5793(01)03280-X; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; BREUSS JM, 1995, J CELL SCI, V108, P2241; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Burman A, 2006, J VIROL, V80, P9798, DOI 10.1128/JVI.00577-06; Cavanagh John, 1996, P532; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; Goodman SL, 2002, J MED CHEM, V45, P1045, DOI 10.1021/jm0102598; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hakkinen L, 2004, AM J PATHOL, V164, P229, DOI 10.1016/S0002-9440(10)63113-6; Jackson T, 2000, J VIROL, V74, P4949, DOI 10.1128/JVI.74.11.4949-4956.2000; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kraft S, 1999, J BIOL CHEM, V274, P1979, DOI 10.1074/jbc.274.4.1979; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; Mateu MG, 1996, J BIOL CHEM, V271, P12814, DOI 10.1074/jbc.271.22.12814; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meinecke R, 2001, J MED CHEM, V44, P3059, DOI 10.1021/jm0109154; Monaghan P, 2005, J GEN VIROL, V86, P2769, DOI 10.1099/vir.0.81172-0; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Ochoa WF, 2000, J GEN VIROL, V81, P1495, DOI 10.1099/0022-1317-81-6-1495; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Thomas GJ, 2006, J ORAL PATHOL MED, V35, P1, DOI 10.1111/j.1600-0714.2005.00374.x; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722; VANGUNSTEREN WF, 1994, METHOD ENZYMOL, V239, P619; Verdaguer N, 1998, J VIROL, V72, P739, DOI 10.1128/JVI.72.1.739-748.1998; VERDAGUER N, 1995, EMBO J, V14, P1690, DOI 10.1002/j.1460-2075.1995.tb07158.x; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Weinreb PH, 2004, J BIOL CHEM, V279, P17875, DOI 10.1074/jbc.M312103200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan JL, 2003, J MAGN RESON, V163, P270, DOI 10.1016/S1090-7807(03)00106-X	41	72	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9657	9665		10.1074/jbc.M610461200	http://dx.doi.org/10.1074/jbc.M610461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244604	hybrid			2022-12-27	WOS:000245421700039
J	Hernandez, E; Leite, MF; Guerra, MT; Kruglov, EA; Bruna-Romero, O; Rodrigues, MA; Gomes, DA; Giordano, FJ; Dranoff, JA; Nathanson, MH				Hernandez, Erick; Leite, M. Fatima; Guerra, Mateus T.; Kruglov, Emma A.; Bruna-Romero, Oscar; Rodrigues, Michele A.; Gomes, Dawidson A.; Giordano, Frank J.; Dranoff, Jonathan A.; Nathanson, Michael H.			Spatial distribution of inositol 1,4,5-trisphosphate receptor isoforms shapes Ca2+ waves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTE COUPLETS; PANCREATIC ACINAR-CELLS; BILE-DUCT EPITHELIA; GENE-EXPRESSION; XENOPUS OOCYTES; CALCIUM WAVES; TRISPHOSPHATE RECEPTOR; LIVER; OSCILLATIONS; VASOPRESSIN	Cytosolic Ca2+ is a versatile second messenger that can regulate multiple cellular processes simultaneously. This is accomplished in part through Ca2+ waves and other spatial patterns of Ca2+ signals. To investigate the mechanism responsible for the formation of Ca2+ waves, we examined the role of inositol 1,4,5-trisphosphate receptor (InsP3R) isoforms in Ca2+ wave formation. Ca2+ signals were examined in hepatocytes, which express the type I and II InsP3R in a polarized fashion, and in AR4-2J cells, a nonpolarized cell line that expresses type I and II InsP3R in a ratio similar to what is found in hepatocytes but homogeneously throughout the cell. Expression of type I or II InsP3R was selectively suppressed by isoform-specific DNA antisense in an adenoviral delivery system, which was delivered to AR4-2J cells in culture and to hepatocytes in vivo. Loss of either isoform inhibited Ca2+ signals to a similar extent in AR4-2J cells. In contrast, loss of the basolateral type I InsP3R decreased the sensitivity of hepatocytes to vasopressin but had little effect on the initiation or spread of Ca2+ waves across hepatocytes. Loss of the apical type II isoform caused an even greater decrease in the sensitivity of hepatocytes to vasopressin and resulted in Ca2+ waves that were much slower and delayed in onset. These findings provide evidence that the apical concentration of type II InsP3Rs is essential for the formation of Ca2+ waves in hepatocytes. The subcellular distribution of InsP3R isoforms may critically determine the repertoire of spatial patterns of Ca2+ signals.	Yale Univ, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Dept Med, New Haven, CT 06520 USA; Univ Fed Minas Gerais, Dept Physiol & Biophys, BR-31270901 Belo Horizonte, MG, Brazil	Yale University; Yale University; Universidade Federal de Minas Gerais	Nathanson, MH (corresponding author), Yale Univ, Sch Med, Rm TAC S241D,1 Gilbert St, New Haven, CT 06520 USA.	michael.nathanson@yale.edu	de Fatima Leite, Maria/AAK-2555-2021; BRUNA-ROMERO, OSCAR/B-3918-2010; Gomes, Dawidson Assis/O-1372-2013	BRUNA-ROMERO, OSCAR/0000-0002-8855-4969; Gomes, Dawidson Assis/0000-0001-7714-991X	FIC NIH HHS [R03 TW001451, TW01451] Funding Source: Medline; NIDDK NIH HHS [DK57751, R01 DK045710-06A2, R01 DK061747, DK34989, DK07356, DK45710, DK61747, R01 DK045710, P30 DK034989-169004, P01 DK057751, P01 DK057751-01A1, P30 DK034989, T32 DK007356] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007356, R01DK045710, P30DK034989, P01DK057751, R01DK061747, R29DK045710] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GAUTAM A, 1987, HEPATOLOGY, V7, P216, DOI 10.1002/hep.1840070203; Gilland E, 1999, P NATL ACAD SCI USA, V96, P157, DOI 10.1073/pnas.96.1.157; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hattori M, 2004, J BIOL CHEM, V279, P11967, DOI 10.1074/jbc.M311456200; Hirata K, 1999, INVEST OPHTH VIS SCI, V40, P2046; Hirata K, 1998, P NATL ACAD SCI USA, V95, P8381, DOI 10.1073/pnas.95.14.8381; Hirata K, 2002, HEPATOLOGY, V36, P284, DOI 10.1053/jhep.2002.34432; Hirata K, 2002, GASTROENTEROLOGY, V122, P1088, DOI 10.1053/gast.2002.32363; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; JOSEPH SK, 1994, J BIOL CHEM, V269, P5673; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEITE MF, 2001, LIVER BIOL PATHOBIOL, P537; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Lu CY, 1996, J MOL CELL CARDIOL, V28, P1703, DOI 10.1006/jmcc.1996.0160; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Morel JL, 2003, ARTERIOSCL THROM VAS, V23, P1567, DOI 10.1161/01.ATV.0000089013.82552.5D; Nathanson MH, 1999, J EXP BIOL, V202, P3049; NATHANSON MH, 1992, J BIOL CHEM, V267, P23282; Nathanson MH, 1996, AM J PHYSIOL-REG I, V270, pR561, DOI 10.1152/ajpregu.1996.270.3.R561; Nathanson MH, 1999, GASTROENTEROLOGY, V116, P1176, DOI 10.1016/S0016-5085(99)70021-1; NATHANSON MH, 1995, AM J PHYSIOL-GASTR L, V269, pG167, DOI 10.1152/ajpgi.1995.269.1.G167; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NATHANSON MH, 1994, AM J PHYSIOL, V267, pG338, DOI 10.1152/ajpgi.1994.267.3.G338; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Onoue H, 2000, BIOCHEM BIOPH RES CO, V267, P928, DOI 10.1006/bbrc.1999.2065; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARYS JB, 1995, CELL CALCIUM, V18, P353, DOI 10.1016/0143-4160(95)90051-9; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Shibao K, 2003, GASTROENTEROLOGY, V125, P1175, DOI 10.1016/S0016-5085(03)01201-0; Sugiyama T, 1996, J HISTOCHEM CYTOCHEM, V44, P1237, DOI 10.1177/44.11.8918898; Swillens S, 1999, P NATL ACAD SCI USA, V96, P13750, DOI 10.1073/pnas.96.24.13750; Tordjmann T, 1998, EMBO J, V17, P4695, DOI 10.1093/emboj/17.16.4695; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Yule DI, 1997, J BIOL CHEM, V272, P9093	51	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10057	10067		10.1074/jbc.M700746200	http://dx.doi.org/10.1074/jbc.M700746200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284437	Green Accepted, hybrid			2022-12-27	WOS:000245421700080
J	Lim, EJ; Sampath, S; Coll-Rodriguez, J; Schmidt, J; Ray, K; Rodgers, DW				Lim, Eun Jeong; Sampath, Sowmya; Coll-Rodriguez, Jerry; Schmidt, Jack; Ray, Kallol; Rodgers, David W.			Swapping the substrate specificities of the neuropeptidases neurolysin and thimet oligopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOENDOPEPTIDASE EC 3.4.24.15; SENSITIVE NEUTRAL ENDOPEPTIDASE; ANGIOTENSIN-CONVERTING ENZYME; CRYSTAL-STRUCTURE; RAT-BRAIN; SOLUBLE METALLOENDOPEPTIDASE; CONTAINING PEPTIDES; ANTIGENIC PEPTIDES; MOLECULAR-CLONING; ACTIVE-SITE	Thimet oligopeptidase (EC 3.4.24.15) and neurolysin (EC 3.4.24.16) are closely related zinc-dependent metallopeptidases that metabolize small bioactive peptides. They cleave many substrates at the same sites, but they recognize different positions on others, including neurotensin, a 13-residue peptide involved in modulation of dopaminergic circuits, pain perception, and thermoregulation. On the basis of crystal structures and previous mapping studies, four sites (Glu-469/Arg-470, Met-490/Arg-491, His-495/Asn-496, and Arg-498/Thr-499; thimet oligopeptidase residues listed first) in their substrate-binding channels appear positioned to account for differences in specificity. Thimet oligopeptidase mutated so that neurolysin residues are at all four positions cleaves neurotensin at the neurolysin site, and the reverse mutations in neurolysin switch hydrolysis to the thimet oligopeptidase site. Using a series of constructs mutated at just three of the sites, it was determined that mutations at only two (Glu-469/Arg-470 and Arg-498/Thr-499) are required to swap specificity, a result that was confirmed by testing the two-mutant constructs. If only either one of the two sites is mutated in thimet oligopeptidase, then the enzyme cleaves almost equally at the two hydrolysis positions. Crystal structures of both two-mutant constructs show that the mutations do not perturb local structure, but side chain conformations at the Arg-498/Thr-499 position differ from those of the mimicked enzyme. A model for differential recognition of neurotensin based on differences in surface charge distribution in the substrate binding sites is proposed. The model is supported by the finding that reducing the positive charge on the peptide results in cleavage at both hydrolysis sites.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Ctr Struct Biol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Rodgers, DW (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, 741 S Limestone, Lexington, KY 40536 USA.	david.rodgers@uky.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS038041, R01NS038041] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR20171] Funding Source: Medline; NINDS NIH HHS [NS38041] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; Arndt JW, 2002, STRUCTURE, V10, P215, DOI 10.1016/S0969-2126(02)00698-6; BARELLI H, 1988, EUR J BIOCHEM, V175, P481, DOI 10.1111/j.1432-1033.1988.tb14220.x; BARELLI H, 1994, BRIT J PHARMACOL, V112, P127, DOI 10.1111/j.1476-5381.1994.tb13041.x; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; Bevington P. R., 2002, DATA REDUCTION ERROR; Brown CK, 2001, P NATL ACAD SCI USA, V98, P3127, DOI 10.1073/pnas.051633198; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; CHABRY J, 1990, J NEUROSCI, V10, P3916, DOI 10.1523/JNEUROSCI.10-12-03916.1990; CHECLER F, 1986, J BIOL CHEM, V261, P1274; CHECLER F, 1995, METHOD ENZYMOL, V248, P593; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; Comellas-Bigier M, 2005, J MOL BIOL, V349, P99, DOI 10.1016/j.jmb.2005.03.016; Crack PJ, 1999, BRAIN RES, V835, P113, DOI 10.1016/S0006-8993(99)01494-8; CSUHAI E, 1998, MOL B INT U, V2, P173; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; DeSantis G, 1999, BIOCHEMISTRY-US, V38, P13391, DOI 10.1021/bi990861o; EIPPER BA, 1986, TRENDS NEUROSCI, V9, P463, DOI 10.1016/0166-2236(86)90149-9; Ferro ES, 2004, PROTEIN PEPTIDE LETT, V11, P415, DOI 10.2174/0929866043406706; Ferro ES, 1999, DNA CELL BIOL, V18, P781, DOI 10.1089/104454999314926; GOEDERT M, 1984, TRENDS NEUROSCI, V7, P3, DOI 10.1016/S0166-2236(84)80176-9; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671; Gutfreund H., 1995, KINETICS LIFE SCI RE; HEALY DP, 1992, BRAIN RES, V571, P121, DOI 10.1016/0006-8993(92)90517-D; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; Jeske NA, 2004, J NEUROCHEM, V90, P819, DOI 10.1111/j.1471-4159.2004.02557.x; Jeske NA, 2003, J NEUROSCI RES, V74, P468, DOI 10.1002/jnr.10778; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Judice WAS, 2005, MOL BIOCHEM PARASIT, V144, P36, DOI 10.1016/j.molbiopara.2005.07.004; KASCKOW J, 1991, REGUL PEPTIDES, V36, P153, DOI 10.1016/0167-0115(91)90053-J; Kato A, 1997, J BIOL CHEM, V272, P15313, DOI 10.1074/jbc.272.24.15313; Kim SI, 2003, BIOCHEM J, V375, P111, DOI 10.1042/BJ20030490; Kinkead B, 2004, INT REV NEUROBIOL, V59, P327; KNIGHT CG, 1995, BIOCHEM J, V308, P145, DOI 10.1042/bj3080145; Konkoy CS, 1996, TRENDS PHARMACOL SCI, V17, P288, DOI 10.1016/0165-6147(96)10036-5; Lian W, 2000, ACTA CRYSTALLOGR D, V56, P1644, DOI 10.1107/S0907444900012683; LITTLEWOOD GM, 1988, NEUROCHEM INT, V12, P383, DOI 10.1016/0197-0186(88)90178-7; MCKELVY JF, 1986, ANNU REV NEUROSCI, V9, P415; MENTLEIN R, 1994, J NEUROCHEM, V62, P27; Moodie SL, 1996, J MOL BIOL, V263, P486, DOI 10.1006/jmbi.1996.0591; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; Oefner C, 2004, ACTA CRYSTALLOGR D, V60, P392, DOI 10.1107/S0907444903027410; Oliveira V, 2001, BIOCHEMISTRY-US, V40, P4417, DOI 10.1021/bi002715k; Oliveira V, 2001, ANAL BIOCHEM, V292, P257, DOI 10.1006/abio.2001.5083; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; Portaro FCV, 1999, BIOCHEM BIOPH RES CO, V255, P596, DOI 10.1006/bbrc.1999.0251; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Ray K, 2004, J BIOL CHEM, V279, P20480, DOI 10.1074/jbc.M400795200; Ray K, 2002, PROTEIN SCI, V11, P2237, DOI 10.1110/ps.0216302; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; Saric T, 2004, J BIOL CHEM, V279, P46723, DOI 10.1074/jbc.M406537200; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; Silva CL, 1999, BIOCHEM BIOPH RES CO, V255, P591, DOI 10.1006/bbrc.1999.0250; Szeltner Z, 2003, J BIOL CHEM, V278, P48786, DOI 10.1074/jbc.M309555200; Tzakos AG, 2003, PROTEIN ENG, V16, P993, DOI 10.1093/protein/gzg122; Varadarajan N, 2005, P NATL ACAD SCI USA, V102, P6855, DOI 10.1073/pnas.0500063102; Villa JP, 2003, J BIOL CHEM, V278, P42545, DOI 10.1074/jbc.M303718200; Vincent B, 1996, J NEUROSCI, V16, P5049; VINCENT B, 1995, BRIT J PHARMACOL, V115, P1053, DOI 10.1111/j.1476-5381.1995.tb15918.x; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1982, J CHROMATOGR, V249, P121, DOI 10.1016/S0021-9673(00)80238-1; WILK S, 1979, LIFE SCI, V24, P457, DOI 10.1016/0024-3205(79)90218-2; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; York IA, 2003, IMMUNITY, V18, P429, DOI 10.1016/S1074-7613(03)00058-X	77	20	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9722	9732		10.1074/jbc.M609897200	http://dx.doi.org/10.1074/jbc.M609897200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251185	hybrid			2022-12-27	WOS:000245421700046
J	Liu, SW; Jing, WG; Cheung, B; Lu, H; Sun, J; Yan, XX; Niu, JK; Farmar, J; Wu, SG; Jiang, SB				Liu, Shuwen; Jing, Weiguo; Cheung, Byron; Lu, Hong; Sun, Jane; Yan, Xuxia; Niu, Jinkui; Farmar, James; Wu, Shuguang; Jiang, Shibo			HIV gp41 C-terminal heptad repeat contains multifunctional domains - Relation to mechanisms of action of anti-HIV peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; 6-HELIX BUNDLE FORMATION; ENV-MEDIATED FUSION; MEMBRANE-FUSION; ENVELOPE GLYCOPROTEIN; INHIBITORY-ACTION; ENTRY INHIBITORS; COILED-COIL; BINDING; CONFORMATION	T20 (Fuzeon), a novel anti-human immunodeficiency virus (HIV) drug, is a peptide derived from HIV-1 gp41 C-terminal heptad repeat (CHR). Its mechanism of action has not yet been defined. We applied Pepscan strategy to determine the relationship between functional domains and mechanisms of action of five 36-mer overlapping peptides with a shift of five amino acids (aa): CHR-1 (aa 623-658), C36 (aa 628-663), CHR-3 (aa 633-668), T20 (aa 638 - 673), and CHR-5 (aa 643- 678). C36 is a peptide with addition of two aa to the N terminus of C34. Peptides CHR-1 and C36 contain N-terminal heptad repeat (NHR)- and pocket-binding domains. They inhibited HIV-1 fusion by interacting with gp41 NHR, forming stable six-helix bundles and blocking gp41 core formation. Peptide T20 containing partial NHR- and lipid-binding domains, but lacking pocket-binding domain, blocked viral fusion by binding its N- and C-terminal sequences with gp41 NHR and cell membrane, respectively. Peptide CHR-3, which is located in the middle between C36 and T20, overlaps > 86% of the sequences of these two peptides, and lacks pocket- and lipid-binding domains, exhibited marginal anti-HIV-1 activity. These results suggest that T20 and C36 contain different functional domains, through which they inhibit HIV-1 entry with distinct mechanisms of action. The multiple functional domains in gp41 CHR and their binding partners may serve as targets for rational design of new anti-HIV-1 drugs and vaccines.	So Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China; New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA	Southern Medical University - China; New York Blood Center	Liu, SW (corresponding author), So Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China.	liusw269@gmail.com; sjiang@nybloodcenter.org	Jiang, Shibo/L-4500-2014	Jiang, Shibo/0000-0001-8283-7135; Liu, Shuwen/0000-0001-6346-5006	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046221] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI46221] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Armand-Ugon M, 2003, ANTIVIR RES, V59, P137, DOI 10.1016/S0166-3542(03)00071-8; Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428-12437.2004; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHOU TC, 1991, CALCUSYN; Cohen FS, 2004, J MEMBRANE BIOL, V199, P1, DOI 10.1007/s00232-004-0669-8; Dwyer JJ, 2003, BIOCHEMISTRY-US, V42, P4945, DOI 10.1021/bi027283n; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallo SA, 2006, J BIOL CHEM, V281, P18787, DOI 10.1074/jbc.M602422200; Hildinger M, 2001, J VIROL, V75, P3038, DOI 10.1128/JVI.75.6.3038-3042.2001; Hong LA, 2003, J VIROL METHODS, V107, P155, DOI 10.1016/S0166-0934(02)00213-6; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG S, 2000, P SOC PHOTO-OPT INS, V3926, P212, DOI DOI 10.1117/12.380514; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013; Liu SW, 2003, J BIOMOL SCREEN, V8, P685, DOI 10.1177/1087057103259155; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Peisajovich SG, 2003, J BIOL CHEM, V278, P21012, DOI 10.1074/jbc.M212773200; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Shnaper S, 2004, J BIOL CHEM, V279, P18526, DOI 10.1074/jbc.M304950200; Shu W, 2000, J BIOL CHEM, V275, P1839, DOI 10.1074/jbc.275.3.1839; Trivedi VD, 2003, PROTEIN ENG, V16, P311, DOI 10.1093/proeng/gzg036; Veiga AS, 2004, J AM CHEM SOC, V126, P14758, DOI 10.1021/ja0459882; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wexler-Cohen Y, 2006, J BIOL CHEM, V281, P9005, DOI 10.1074/jbc.M512475200; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	43	123	137	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9612	9620		10.1074/jbc.M609148200	http://dx.doi.org/10.1074/jbc.M609148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276993	hybrid			2022-12-27	WOS:000245421700034
J	Ohnuma, K; Uchiyama, M; Yamochi, T; Nishibashi, K; Hosono, O; Takahashi, N; Kina, S; Tanaka, H; Lin, X; Dang, NH; Morimoto, C				Ohnuma, Kei; Uchiyama, Masahiko; Yamochi, Tadanori; Nishibashi, Kunika; Hosono, Osamu; Takahashi, Nozomu; Kina, Shinichiro; Tanaka, Hirotoshi; Lin, Xin; Dang, Nam H.; Morimoto, Chikao			Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DIPEPTIDYL PEPTIDASE-IV; ANTIGEN-PRESENTING CELLS; MAGUK FAMILY; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; PERIPHERAL-BLOOD; SURFACE-MOLECULE; SYNOVIAL-FLUID; PROTEIN-KINASE	CD26 is a widely distributed 110-kDa cell surface glycoprotein with an important role in T-cell costimulation. We demonstrated previously that CD26 binds to caveolin-1 in antigen-presenting cells, and following exogenous CD26 stimulation, Tollip and IRAK-1 disengage from caveolin-1 in antigen-presenting cells. IRAK-1 is then subsequently phosphorylated to up-regulate CD86 expression, resulting in subsequent T-cell proliferation. However, it is unclear whether caveolin-1 is a costimulatory ligand for CD26 in T-cells. Using soluble caveolin-1-Fc fusion protein, we now show that caveolin-1 is the costimulatory ligand for CD26, and that ligation of CD26 by caveolin-1 induces T-cell proliferation and NF-kappa B activation in a T-cell receptor/CD3-dependent manner. We also demonstrated that the cytoplasmic tail of CD26 interacts with CARMAI in T-cells, resulting in signaling events that lead to NF-kappa B activation. Ligation of CD26 by caveolin-1 recruits a complex consisting of CD26, CARMAI, Bcl10, and I kappa B kinase to lipid rafts. Taken together, our findings provide novel insights into the regulation of T-cell costimulation via the CD26 molecule.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Nevada Canc Inst, Dept Hematol Malignancies, Las Vegas, NV 89135 USA	University of Tokyo; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego	Morimoto, C (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	morimoto@ims.u-tokyo.ac.jp						Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; Chen CY, 2003, B MATH BIOL, V65, P933, DOI 10.1016/S0092-8240(03)00055-7; Chien CH, 2004, J BIOL CHEM, V279, P52338, DOI 10.1074/jbc.M406185200; CICCIMARRA F, 1976, J CLIN INVEST, V57, P1386, DOI 10.1172/JCI108407; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; DANG NH, 1990, J IMMUNOL, V145, P3963; DANG NH, 1990, J IMMUNOL, V144, P4092; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dong RP, 1998, MOL IMMUNOL, V35, P13, DOI 10.1016/S0161-5890(98)00015-7; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; EGUCHI K, 1989, J IMMUNOL, V142, P4233; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; FOX DA, 1984, J IMMUNOL, V133, P1250; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Gerli R, 1996, CLIN IMMUNOL IMMUNOP, V80, P31, DOI 10.1006/clin.1996.0091; Hara H, 2004, J EXP MED, V200, P1167, DOI 10.1084/jem.20032246; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hegen M, 1997, IMMUNOLOGY, V90, P257, DOI 10.1046/j.1365-2567.1997.00053.x; Ishii T, 2001, P NATL ACAD SCI USA, V98, P12138, DOI 10.1073/pnas.211439098; Kahne T, 1999, INT J MOL MED, V4, P3; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Lin X, 2004, SEMIN IMMUNOL, V16, P429, DOI 10.1016/j.smim.2004.08.022; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Mizokami A, 1996, J RHEUMATOL, V23, P2022; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MUSCAT C, 1994, CLIN EXP IMMUNOL, V98, P252; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohnuma K, 2005, MOL CELL BIOL, V25, P7743, DOI 10.1128/MCB.25.17.7743-7757.2005; Ohnuma K, 2004, P NATL ACAD SCI USA, V101, P14186, DOI 10.1073/pnas.0405266101; Ohnuma K, 2002, IMMUNOLOGY, V107, P325, DOI 10.1046/j.1365-2567.2002.01510.x; Ohnuma K, 2001, J IMMUNOL, V167, P6745, DOI 10.4049/jimmunol.167.12.6745; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Tanaka J, 1999, BIOCHEM BIOPH RES CO, V264, P938, DOI 10.1006/bbrc.1999.1617; TANAKA T, 1994, P NATL ACAD SCI USA, V91, P3082, DOI 10.1073/pnas.91.8.3082; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1992, J IMMUNOL, V149, P481; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; von Bonin A, 1998, IMMUNOL REV, V161, P43; vonBonin A, 1997, IMMUNOL LETT, V55, P179, DOI 10.1016/S0165-2478(97)02705-3; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wegener E, 2006, MOL CELL, V23, P13, DOI 10.1016/j.molcel.2006.05.027; Yan SL, 2003, EUR J IMMUNOL, V33, P1519, DOI 10.1002/eji.200323469; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	53	94	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10117	10131		10.1074/jbc.M609157200	http://dx.doi.org/10.1074/jbc.M609157200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17287217	hybrid			2022-12-27	WOS:000245421700085
J	Wang, GY; Strang, C; Pfaffinger, PJ; Covarrubias, M				Wang, Guangyu; Strang, Candace; Pfaffinger, Paul J.; Covarrubias, Manuel			Zn2+-dependent redox switch in the intracellular T1-T1 interface of a Kv channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SULFENIC ACIDS; DEPENDENT K+ CURRENTS; NITRIC-OXIDE; OXIDATIVE MODULATION; ZINC HOMEOSTASIS; CYSTEINE; COMPLEX; KCHIP3; ZN2+	The thiol-based redox regulation of proteins plays a central role in cellular signaling. Here, we investigated the redox regulation at the Zn2+ binding site (HX5CX20CC) in the intracellular T1-T1 inter-subunit interface of a Kv4 channel. This site undergoes conformational changes coupled to voltage-dependent gating, which may be sensitive to oxidative stress. The main results show that internally applied nitric oxide (NO) inhibits channel activity profoundly. This inhibition is reversed by reduced glutathione and suppressed by intracellular Zn2+, and at least two Zn2+ site cysteines are required to observe the NO-induced inhibition (Cys-110 from one subunit and Cys-132 from the neighboring subunit). Biochemical evidence suggests strongly that NO induces a disulfide bridge between Cys-110 and Cys-132 in intact cells. Finally, further mutational studies suggest that intra-subunit Zn2+ coordination involving His-104, Cys-131, and Cys-132 protects against the formation of the inhibitory disulfide bond. We propose that the interfacial T1 Zn2+ site of Kv4 channels acts as a Zn2+-dependent redox switch that may regulate the activity of neuronal and cardiac A-type K+ currents under physiological and pathological conditions.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Jefferson University; Baylor College of Medicine	Wang, GY (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, 1020 Lucust St,JAH241, Philadelphia, PA 19107 USA.	Guang-yu.Wang@jefferson.edu; Manuel.Covarrubias@jefferson.edu		Wang, Guangyu/0000-0002-5581-6926; Covarrubias, Manuel/0000-0002-0881-4143	NIAAA NIH HHS [T32 AA007463, T32 AA07463] Funding Source: Medline; NINDS NIH HHS [R01 NS032337, R01 NS032337-06, R01 NS032337-12, R01 NS032337-07, R01 NS032337-08, R01 NS032337-09A1, P01 NS037444, R01 NS032337-10, R01 NS032337-11] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS037444, R01NS032337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Akar FG, 2004, AM J PHYSIOL-HEART C, V286, pH602, DOI 10.1152/ajpheart.00673.2003; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Capasso M, 2005, J ALZHEIMERS DIS, V8, P93; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Colvin RA, 2003, EUR J PHARMACOL, V479, P171, DOI 10.1016/j.ejphar.2003.08.067; Crane EJ, 1997, BIOCHEMISTRY-US, V36, P8611, DOI 10.1021/bi9707990; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Fitzhugh AL, 2000, FREE RADICAL BIO MED, V28, P1463, DOI 10.1016/S0891-5849(00)00251-3; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; Gow A, 2002, AM J PHYSIOL-LUNG C, V282, pL183, DOI 10.1152/ajplung.00424.2001; Han NLR, 2006, J NEUROPHYSIOL, V95, P2167, DOI 10.1152/jn.01185.2004; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; HEINEMANN SH, 2006, SCI STKE, pE33; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Ilbert M, 2006, ANTIOXID REDOX SIGN, V8, P835, DOI 10.1089/ars.2006.8.835; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; Jahng AW, 2002, J BIOL CHEM, V277, P47885, DOI 10.1074/jbc.M208416200; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Jerng HH, 2005, J PHYSIOL-LONDON, V568, P767, DOI 10.1113/jphysiol.2005.087858; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Knipp M, 2003, J BIOL CHEM, V278, P3410, DOI 10.1074/jbc.M209088200; Kunjilwar K, 2004, J BIOL CHEM, V279, P54542, DOI 10.1074/jbc.M409721200; Lipton SA, 2002, TRENDS NEUROSCI, V25, P474, DOI 10.1016/S0166-2236(02)02245-2; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Maret W, 2006, ANTIOXID REDOX SIGN, V8, P1419, DOI 10.1089/ars.2006.8.1419; Muller W, 2002, J NEUROPHYSIOL, V87, P2990, DOI 10.1152/jn.00790.2001; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nanao MH, 2003, P NATL ACAD SCI USA, V100, P8670, DOI 10.1073/pnas.1432840100; Neculai AM, 2005, J BIOL CHEM, V280, P2826, DOI 10.1074/jbc.C400517200; Noguchi T, 2003, BIOCHEMISTRY-US, V42, P11642, DOI 10.1021/bi035260i; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Pioletti M, 2006, NAT STRUCT MOL BIOL, V13, P987, DOI 10.1038/nsmb1164; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Prasad M, 2004, AM J PHYSIOL-CELL PH, V286, pC671, DOI 10.1152/ajpcell.00137.2003; Rozanski GJ, 2002, J MOL CELL CARDIOL, V34, P1623, DOI 10.1006/jmcc.2002.2112; Rozanski GJ, 2002, AM J PHYSIOL-HEART C, V282, pH2346, DOI 10.1152/ajpheart.00894.2001; Ruschenschmidt C, 2006, EUR J NEUROSCI, V23, P675, DOI 10.1111/j.1460-9568.2006.04608.x; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Strang C, 2003, J BIOL CHEM, V278, P31361, DOI 10.1074/jbc.M304268200; Takeda A, 2001, BIOMETALS, V14, P343, DOI 10.1023/A:1012982123386; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Wang GY, 2006, J GEN PHYSIOL, V127, P391, DOI 10.1085/jgp.200509442; Wang GY, 2005, J GEN PHYSIOL, V126, P55, DOI 10.1085/jgp.200509288; Wang HY, 2007, NAT NEUROSCI, V10, P32, DOI 10.1038/nn1822; Wilcox DE, 2001, ANTIOXID REDOX SIGN, V3, P549, DOI 10.1089/15230860152542925; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821	53	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13637	13647		10.1074/jbc.M609182200	http://dx.doi.org/10.1074/jbc.M609182200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17331952	Green Accepted, hybrid			2022-12-27	WOS:000246060300053
J	Dehennaut, V; Lefebvre, T; Sellier, C; Leroy, Y; Gross, B; Walker, S; Cacan, R; Michalski, JC; Vilain, JP; Bodart, JF				Dehennaut, Vanessa; Lefebvre, Tony; Sellier, Chantal; Leroy, Yves; Gross, Benjamin; Walker, Suzanne; Cacan, Rene; Michalski, Jean-Claude; Vilain, Jean-Pierre; Bodart, Jean-Francois			O-linked N-acetylglucosaminyltransferase inhibition prevents G(2)/M transition in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEIOTIC MATURATION; CELL-CYCLE; PROTEIN-KINASE; REDOX REGULATION; RANA PIPIENS; MAP KINASE; GLCNAC; PHOSPHORYLATION; ACTIVATION; MPF	Full-grown Xenopus oocytes are arrested at the prophase of the first meiotic division in a G(2)-like state. Progesterone triggers meiotic resumption also called the G(2)/M transition. This event is characterized by germinal vesicle breakdown ( GVBD) and by a burst in phosphorylation level that reflects activation of M-phase-promoting factor ( MPF) and MAPK pathways. Besides phosphorylation and ubiquitin pathways, increasing evidence has suggested that the cytosolic and nucleus-specific O-GlcNAc glycosylation also contributes to cell cycle regulation. To investigate the relationship between O-GlcNAc and cell cycle, Xenopus oocyte, in which most of the M-phase regulators have been discovered, was used. Alloxan, an O-GlcNAc transferase inhibitor, blocked G(2)/M transition in a concentration-dependent manner. Alloxan prevented GVBD and both MPF and MAPK activations, either triggered by progesterone or by egg cytoplasm injection. The addition of detoxifying enzymes ( SOD and catalase) did not rescue GVBD, indicating that the alloxan effect did not occur through reactive oxygen species production. These results were strengthened by the use of a benzoxazolinone derivative ( XI), a new O-GlcNAc transferase inhibitor. Conversely, injection of O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate, an O-GlcNAcase inhibitor, accelerated the maturation process. Glutamine: fructose-6-phosphate amidotransferase inhibitors, azaserine and 6-diazo-5-ox-onorleucine, failed to prevent GVBD. Such a strategy appeared to be inefficient; indeed, UDP-GlcNAc assays in mature and immature oocytes revealed a constant pool of the nucleotide sugar. Finally, we observed that cyclin B2, the MPF regulatory subunit, was associated with an unknown O-GlcNAc partner. The present work underlines a crucial role for O-GlcNAc in G(2)/M transition and strongly suggests that its function is required for cell cycle regulation.	Univ Sci & Technol Lille, EA 4020, Lab Regulat Signaux Div, SN3,IFR147, F-59655 Villeneuve Dascq, France; CNRS, Unite Glycobiol Struct & Fonct, UMR 8576, IFR147, F-59655 Villeneuve Dascq, France; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Harvard University; Harvard Medical School	Bodart, JF (corresponding author), Univ Sci & Technol Lille, EA 4020, Lab Regulat Signaux Div, SN3,IFR147, F-59655 Villeneuve Dascq, France.	jean-francois.bodart@univ-lille1.fr	Bodart, Jean-François Laurent/AAZ-2075-2021; Lefebvre, Tony/AAW-9169-2021; dehennaut, vanessa/I-7435-2018; Lefebvre, Tony/AAZ-1724-2021	Bodart, Jean-François Laurent/0000-0002-6113-7700; dehennaut, vanessa/0000-0001-6421-0793; Lefebvre, Tony/0000-0001-9883-2240				Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Baert F, 2003, J BIOL CHEM, V278, P49714, DOI 10.1074/jbc.M308067200; Bodart JFL, 2005, DEV BIOL, V283, P373, DOI 10.1016/j.ydbio.2005.04.031; Bodart JFL, 2002, DEV BIOL, V245, P348, DOI 10.1006/dbio.2002.0647; Cakir Y, 2005, ANTIOXID REDOX SIGN, V7, P726, DOI 10.1089/ars.2005.7.726; Champattanachai V, 2007, AM J PHYSIOL-CELL PH, V292, pC178, DOI 10.1152/ajpcell.00162.2006; Chesnel F, 1997, DEV BIOL, V188, P122, DOI 10.1006/dbio.1997.8631; Dupre A, 2002, ONCOGENE, V21, P6425, DOI 10.1038/sj.onc.1205827; DWORKIN MB, 1992, MOL REPROD DEV, V32, P354, DOI 10.1002/mrd.1080320408; DWORKIN MB, 1989, DEV BIOL, V132, P512, DOI 10.1016/0012-1606(89)90246-7; Fang B, 2001, EXP CELL RES, V263, P243, DOI 10.1006/excr.2000.5110; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Fisher DL, 1999, DEVELOPMENT, V126, P4537; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hochegger H, 2001, DEVELOPMENT, V128, P3795; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Iyer SPN, 2003, BIOCHEMISTRY-US, V42, P2493, DOI 10.1021/bi020685a; Kim YH, 2006, J CELL PHYSIOL, V207, P689, DOI 10.1002/jcp.20609; Konrad RJ, 2002, BIOCHEM BIOPH RES CO, V293, P207, DOI 10.1016/S0006-291X(02)00200-0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lefebvre T, 2004, J CELL BIOCHEM, V93, P999, DOI 10.1002/jcb.20242; Liu J, 2006, J MOL CELL CARDIOL, V40, P303, DOI 10.1016/j.yjmcc.2005.11.003; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; Masui Y, 2001, DIFFERENTIATION, V69, P1, DOI 10.1046/j.1432-0436.2001.690101.x; MASUI Y, 1967, J EXP ZOOL, V166, P365, DOI 10.1002/jez.1401660309; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; Rudolph J, 2005, ANTIOXID REDOX SIGN, V7, P761, DOI 10.1089/ars.2005.7.761; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schmitt A, 2002, J CELL SCI, V115, P2457; Slawson C, 2006, J CELL BIOCHEM, V97, P71, DOI 10.1002/jcb.20676; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Slawson C, 2002, BBA-GEN SUBJECTS, V1573, P121, DOI 10.1016/S0304-4165(02)00369-0; SMITH LD, 1968, DEV BIOL, V17, P627, DOI 10.1016/0012-1606(68)90010-9; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Szkudelski T, 2001, PHYSIOL RES, V50, P537; Walsh S, 2003, MOL CANCER RES, V1, P280; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017; Wu G, 2006, BIOCHEMISTRY-US, V45, P5319, DOI 10.1021/bi0601149; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	47	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12527	12536		10.1074/jbc.M700444200	http://dx.doi.org/10.1074/jbc.M700444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329255	hybrid			2022-12-27	WOS:000245942800021
J	Ghosh, M; Loper, R; Ghomashchi, F; Tucker, DE; Bonventre, JV; Gelb, MH; Leslie, CC				Ghosh, Moumita; Loper, Robyn; Ghomashchi, Farideh; Tucker, Dawn E.; Bonventre, Joseph V.; Gelb, Michael H.; Leslie, Christina C.			Function, activity, and membrane targeting of cytosolic phospholipase A(2)zeta in mouse lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; SMOOTH-MUSCLE-CELLS; GROUP-IIA; GROUP-IV; MAMMALIAN-CELLS; GROUP-X; PHOSPHORYLATION SITES; EICOSANOID PRODUCTION; NUCLEAR-ENVELOPE; BINDING DOMAIN	Group IVA cytosolic phospholipase A(2) ( cPLA(2)alpha) initiates eicosanoid production; however, this pathway is not completely ablated in cPLA(2)alpha(-/-) lung fibroblasts stimulated with A23187 or serum. cPLA(2)alpha(-/-) fibroblasts preferentially released arachidonic acid, but A23187-stimulated cPLA(2)alpha(-/-) fibroblasts nonspecifically released multiple fatty acids. Arachidonic acid release from cPLA2 alpha(-/-) fibroblasts was inhibited by the cPLA(2)alpha inhibitors pyrrolidine-2 ( IC50, 0.03 mu M) and Wyeth-1 ( IC50, 0.1 mu M), implicating another C2 domain-containing group IV PLA(2). cPLA(2)alpha(-/-) fibroblasts contain cPLA(2)beta and cPLA(2)zeta but not cPLA(2)epsilon or cPLA(2)delta. Purified cPLA(2)zeta exhibited much higher lysophospholipase and PLA(2) activity than cPLA(2)beta and was potently inhibited by pyrrolidine-2 and Wyeth-1, which did not inhibit cPLA(2)beta. In contrast to cPLA(2)beta, cPLA(2)zeta expressed in Sf9 cells mediated A23187-induced arachidonic acid release, which was inhibited by pyrrolidine-2 and Wyeth-1. cPLA(2)zeta exhibits specific activity, inhibitor sensitivity, and low micromolar calcium dependence similar to cPLA(2)alpha and has been identified as the PLA(2) responsible for calcium-induced fatty acid release and prostaglandin E-2 production from cPLA(2)alpha(-/-) lung fibroblasts. In response to ionomycin, EGFP-cPLA(2)zeta translocated to ruffles and dynamic vesicular structures, whereas EGFP-cPLA(2)alpha translocated to the Golgi and endoplasmic reticulum, suggesting distinct mechanisms of regulation for the two enzymes.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Univ Colorado, Sch Med, Dept Pathol, Aurora, CO 80045 USA; Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	National Jewish Health; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org		gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL50040, HL34303, R01 HL050040, P01 HL034303, HL61378, R01 HL050040-14, R01 HL061378] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378, R01HL050040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Chiba H, 2004, J BIOL CHEM, V279, P12890, DOI 10.1074/jbc.M305801200; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Downey P, 2001, AM J PHYSIOL-RENAL, V280, pF607, DOI 10.1152/ajprenal.2001.280.4.F607; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Ghosh M, 2004, AM J RESP CELL MOL, V30, P91, DOI 10.1165/rcmb.2003-0005OC; Ghosh M, 2006, J BIOL CHEM, V281, P16615, DOI 10.1074/jbc.M601770200; Ghosh M, 2006, PROG LIPID RES, V45, P487, DOI 10.1016/j.plipres.2006.05.003; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Girotti M, 2004, J BIOL CHEM, V279, P19113, DOI 10.1074/jbc.M313867200; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; Jenkins CM, 2003, BIOCHEMISTRY-US, V42, P11798, DOI 10.1021/bi034611q; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; Leslie Christina C, 2004, Methods Mol Biol, V284, P229; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Ni Z, 2006, J BIOL CHEM, V281, P16245, DOI 10.1074/jbc.M513874200; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Seno K, 2000, J MED CHEM, V43, P1041, DOI 10.1021/jm9905155; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; Tucker DE, 2005, J LIPID RES, V46, P2122, DOI 10.1194/jlr.M500230-JLR200; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Vitale A, 2005, DEV BIOL, V282, P374, DOI 10.1016/j.ydbio.2005.03.018; Wong DA, 2002, J EXP MED, V196, P349, DOI 10.1084/jem.20011443; Yokota Y, 1999, BBA-MOL CELL BIOL L, V1438, P213, DOI 10.1016/S1388-1981(99)00053-0	45	47	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11676	11686		10.1074/jbc.M608458200	http://dx.doi.org/10.1074/jbc.M608458200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17293613	Green Accepted, hybrid			2022-12-27	WOS:000245941900009
J	Li, J; Machius, M; Chuang, JL; Wynn, RM; Chuang, DT				Li, Jun; Machius, Mischa; Chuang, Jacinta L.; Wynn, R. Max; Chuang, David T.			The two active sites in human branched-chain alpha-keto acid dehydrogenase operate independently without an obligatory alternating-site mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PYRUVATE DECARBOXYLASE; THIAMIN DIPHOSPHATE BINDING; PHOSPHORYLATION SITES; MULTIENZYME COMPLEX; CRYSTAL-STRUCTURE; TRANSKETOLASE; RECONSTITUTION; REACTIVITY; SUBUNIT; ENZYMES	A long standing controversy is whether an alternating active-site mechanism occurs during catalysis in thiamine diphosphate ( ThDP)-dependent enzymes. We address this question by investigating the ThDP-dependent decarboxylase/dehydrogenase ( E1b) component of the mitochondrial branched-chain alpha-keto acid dehydrogenase complex ( BCKDC). Our crystal structure reveals that conformations of the two active sites in the human E1b heterotetramer harboring the reaction intermediate are identical. Acidic residues in the core of the E1b heterotetramer, which align with the proton-wire residues proposed to participate in active-site communication in the related pyruvate dehydrogenase from Bacillus stearothermophilus, are mutated. Enzyme kinetic data show that, except in a few cases because of protein misfolding, these alterations are largely without effect on overall activity of BCKDC, ruling out the requirement of a proton-relay mechanism in E1b. BCKDC overall activity is nullified at 50% phosphorylation of E1b, but it is restored to nearly half of the pre-phosphorylation level after dissociation and reconstitution of BCKDC with the same phosphorylated E1b. The results suggest that the abolition of overall activity likely results from the specific geometry of the half-phosphorylated E1b in the BCKDC assembly and not due to a disruption of the alternating active-site mechanism. Finally, we show that a mutant E1b containing only one functional active site exhibits half of the wild-type BCKDC activity, which directly argues against the obligatory communication between active sites. The above results provide evidence that the two active sites in the E1b heterotetramer operate independently during the ThDP-dependent decarboxylation reaction.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.chuang@utsouthwestern.edu		Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK26758, DK62306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062306, R01DK026758, R56DK062306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chang CF, 2006, J BIOL CHEM, V281, P28345, DOI 10.1074/jbc.M605005200; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; EGAN RM, 1981, J BIOL CHEM, V256, P4877; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Jordan F, 2005, ACCOUNTS CHEM RES, V38, P755, DOI 10.1021/ar040244e; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KOCHETOV GA, 1976, BIOCHEM BIOPH RES CO, V69, P839, DOI 10.1016/0006-291X(76)90450-2; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; Kovina MV, 1998, FEBS LETT, V440, P81, DOI 10.1016/S0014-5793(98)01423-9; Kovina MV, 1997, FEBS LETT, V418, P11, DOI 10.1016/S0014-5793(97)01331-8; Li J, 2004, J BIOL CHEM, V279, P32968, DOI 10.1074/jbc.M403611200; Lu GG, 2000, EUR J BIOCHEM, V267, P861, DOI 10.1046/j.1432-1327.2000.01070.x; Machius M, 2006, STRUCTURE, V14, P287, DOI 10.1016/j.str.2005.10.009; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Meshalkina L, 1997, EUR J BIOCHEM, V244, P646, DOI 10.1111/j.1432-1033.1997.t01-1-00646.x; Milne JLS, 2002, EMBO J, V21, P5587, DOI 10.1093/emboj/cdf574; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 2004, J MOL BIOL, V337, P1011, DOI 10.1016/j.jmb.2004.02.011; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; Seifert F, 2006, BIOCHEMISTRY-US, V45, P12775, DOI 10.1021/bi061582l; Sergienko EA, 2000, BIOCHEMISTRY-US, V39, P13862, DOI 10.1021/bi001214w; Sergienko EA, 2002, BIOCHEMISTRY-US, V41, P6164, DOI 10.1021/bi0121712; Song JL, 2001, J BIOL CHEM, V276, P40241, DOI 10.1074/jbc.M107242200; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wynn RM, 2004, STRUCTURE, V12, P2185, DOI 10.1016/j.str.2004.09.013; Wynn RM, 2003, J BIOL CHEM, V278, P43402, DOI 10.1074/jbc.M306204200; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200; ZHAO Y, 1994, J BIOL CHEM, V269, P18583; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698	41	9	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11904	11913		10.1074/jbc.M610843200	http://dx.doi.org/10.1074/jbc.M610843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329260	hybrid			2022-12-27	WOS:000245941900033
J	Hill, KE; Zhou, JD; Austin, LM; Motley, AK; Ham, AJL; Olson, GE; Atkins, JF; Gesteland, RF; Burk, RF				Hill, Kristina E.; Zhou, Jiadong; Austin, Lori M.; Motley, Amy K.; Ham, Amy-Joan L.; Olson, Gary E.; Atkins, John F.; Gesteland, Raymond F.; Burk, Raymond F.			The selenium-rich C-terminal domain of mouse selenoprotein P is necessary for the supply of selenium to brain and testis but not for the maintenance of whole body selenium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; UGA CODONS; RAT PLASMA; PROTEIN; EXPRESSION; INSERTION; DELETION; ACID; GENE; SELENOCYSTEINES	Selenoprotein P (Sepp1) has two domains with respect to selenium content: the N-terminal, selenium-poor domain and the C-terminal, selenium-rich domain. To assess domain function, mice with deletion of the C-terminal domain have been produced and compared with Sepp1(-/-) and Sepp1(-)/(-) mice. All mice studied were males fed a semipurified diet with defined selenium content. The Sepp1 protein in the plasma of mice with the C-terminal domain deleted was determined by mass spectrometry to terminate after serine 239 and thus was designated Sepp1 Delta 240 - 361. Plasma Sepp1 and selenium concentrations as well as glutathione peroxidase activity were determined in the three types of mice. Glutathione peroxidase and Sepp1(Delta 240-361) accounted for over 90% of the selenium in the plasma of Sepp1(Delta 240-361) mice. Calculations using results from Sepp1(-/-) mice revealed that Sepp1, with a potential for containing 10 selenocysteine residues, contained an average of 5 selenium atoms per molecule, indicating that shortened and/or selenium-depleted forms of the protein were present in these wild-type mice. Sepp1(Delta 240 - 361) mice had low brain and testis selenium concentrations that were similar to those in Sepp1(-/-) mice but they better maintained their whole body selenium. Sepp1(Delta 240-361) mice had depressed fertility, even when they were fed a high selenium diet, and their spermatozoa were defective and morphologically indistinguishable from those of selenium-deficient mice. Neurological dysfunction and death occurred when Sepp1(Delta 240-361) mice were fed selenium-deficient diet. These phenotypes were similar to those of Sepp1(-/-) mice but had later onset or were less severe. The results of this study demonstrate that the C terminus of Sepp1 is critical for the maintenance of selenium in brain and testis but not for the maintenance of whole body selenium.	Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA; Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Natl Univ Ireland Univ Coll Cork, Biosci Inst, Cork, Ireland	Vanderbilt University; Vanderbilt University; Vanderbilt University; Utah System of Higher Education; University of Utah; University College Cork	Burk, RF (corresponding author), Vanderbilt Univ Sch Med, 1030C Med Res Bldg 4, Nashville, TN 37232 USA.	raymond.burk@vanderbilt.edu		Atkins, John/0000-0001-7933-0165	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES002497, R37ES002497] Funding Source: NIH RePORTER; NICHD NIH HHS [HD44863] Funding Source: Medline; NIEHS NIH HHS [ES00267, ES02497] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Burk RF, 2006, BBA-GEN SUBJECTS, V1760, P1789, DOI 10.1016/j.bbagen.2006.08.010; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Greer JM, 2002, NEURON, V33, P23, DOI 10.1016/S0896-6273(01)00564-5; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; HILL KE, 1991, J BIOL CHEM, V266, P10050; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; Howard MT, 2005, EMBO J, V24, P1596, DOI 10.1038/sj.emboj.7600642; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; KOH TS, 1983, J ASSOC OFF ANA CHEM, V66, P918; Kryukov GV, 2000, GENES CELLS, V5, P1049, DOI 10.1046/j.1365-2443.2000.00392.x; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Ma SG, 2003, BIOCHEMISTRY-US, V42, P9703, DOI 10.1021/bi0346300; Ma SG, 2002, J BIOL CHEM, V277, P12749, DOI 10.1074/jbc.M111462200; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; Olson GE, 2005, BIOL REPROD, V73, P201, DOI 10.1095/biolreprod.105.040360; READ R, 1990, J BIOL CHEM, V265, P17899; SAIJOH K, 1995, MOL BRAIN RES, V30, P301, DOI 10.1016/0169-328X(94)00007-2; Saito Y, 2004, BIOCHEM J, V381, P841, DOI 10.1042/BJ20040328; Schweizer U, 2005, BIOCHEM J, V386, P221, DOI 10.1042/BJ20041973; SHEEHAN TMT, 1990, CLIN CHEM, V36, P2124; Stoytcheva Z, 2006, MOL CELL BIOL, V26, P9177, DOI 10.1128/MCB.00856-06; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Xia YM, 2005, AM J CLIN NUTR, V81, P829, DOI 10.1093/ajcn/81.4.829; Yang XG, 2000, BBA-GEN SUBJECTS, V1474, P390, DOI 10.1016/S0304-4165(00)00035-0	30	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10972	10980		10.1074/jbc.M700436200	http://dx.doi.org/10.1074/jbc.M700436200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311913	hybrid			2022-12-27	WOS:000245941500017
J	Baker, BY; Epand, RF; Epand, RM; Miller, WL				Baker, Bo Y.; Epand, Raquel F.; Epand, Richard M.; Miller, Walter L.			Cholesterol binding does not predict activity of the steroidogenic acute regulatory protein, StAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; MOLTEN-GLOBULE; MITOCHONDRIAL-MEMBRANE; SYNTHETIC MEMBRANES; CELLS; MECHANISM; GENE; TRANSPORT; COMPLEX; IMPORT	Steroidogenic acute regulatory protein ( StAR) stimulates adrenal and gonadal steroidogenesis by increasing the influx of cholesterol into mitochondria, where it is converted to pregnenolone to initiate steroidogenesis. StAR acts on the outer mitochondrial membrane where each molecule stimulates the mitochondrial import of several hundred molecules of cholesterol, but the precise mechanism of the action of StAR remains uncertain. StAR has a sterol-binding pocket that can accommodate one molecule of cholesterol. Direct assays show that StAR can bind cholesterol with stoichiometry approaching 1: 1, and several disease- causing mutants with decreased or absent activity have correspondingly decreased cholesterol binding. We show that the StAR mutant R182L, which causes severe disease and is devoid of measurable activity in transfected cells or with isolated steroidogenic mitochondria, nevertheless, can bind as much [C-14]- or NBD-cholesterol as wild-type StAR under equilibrium conditions and can transfer cholesterol between liposomes in vitro. Similarly, the artificial mutant S195A had 46.5% of the activity of wild-type StAR but bound cholesterol indistinguishably from wild- type. Competition assays showed that the rate of binding (t(1/2on)) for R182L was only 36% of the wild- type and the rate of dissociation (t(1/2off)) was 57% of wild- type, whereas the t(1/2on) and t(1/2off) for S195A and S195D were essentially the same for wild- type. These data indicate that cholesterol binding and transfer activities are distinct from its activity to induce steroidogenesis. StAR appears to act by other mechanisms in addition to cholesterol binding.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; McMaster University	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Room HSE1427, San Francisco, CA 94143 USA.	wlmlab@ucsf.edu	Miller, Walter L/J-3696-2012; , Richard/R-2316-2019; Baker, Bo/C-1466-2010	, Richard/0000-0002-9602-9558; 	NIDDK NIH HHS [DK37922] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; Baker BY, 2006, J CLIN ENDOCR METAB, V91, P4781, DOI 10.1210/jc.2006-1565; Baker BY, 2005, J BIOL CHEM, V280, P41753, DOI 10.1074/jbc.M510241200; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Bose HS, 2000, J CLIN ENDOCR METAB, V85, P3636, DOI 10.1210/jc.85.10.3636; Chen X, 2005, J CLIN ENDOCR METAB, V90, P835, DOI 10.1210/jc.2004-1323; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Ewing TJA, 1997, J COMPUT CHEM, V18, P1175, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O; Fleury A, 2004, J STEROID BIOCHEM, V91, P259, DOI 10.1016/j.jsbmb.2004.04.010; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; Hauet T, 2005, MOL ENDOCRINOL, V19, P540, DOI 10.1210/me.2004-0307; Im YJ, 2005, NATURE, V437, P154, DOI 10.1038/nature03923; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Li XM, 2002, J CELL BIOL, V157, P63, DOI 10.1083/jcb.200201037; Li ZG, 2006, J ORG CHEM, V71, P1718, DOI 10.1021/jo052029x; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Mathieu AP, 2002, J MOL ENDOCRINOL, V29, P327, DOI 10.1677/jme.0.0290327; Miller WL, 2007, MOL ENDOCRINOL, V21, P589, DOI 10.1210/me.2006-0303; Miller WL, 1999, J STEROID BIOCHEM, V69, P131, DOI 10.1016/S0960-0760(98)00153-8; Miller WL, 1997, J MOL ENDOCRINOL, V19, P227, DOI 10.1677/jme.0.0190227; Murcia M, 2006, J LIPID RES, V47, P2614, DOI 10.1194/jlr.M600232-JLR200; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PON LA, 1986, J BIOL CHEM, V261, P3309; Raychaudhuri S, 2006, J CELL BIOL, V173, P107, DOI 10.1083/jcb.200510084; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Shaw JE, 2006, BIOPHYS J, V90, P2170, DOI 10.1529/biophysj.105.073510; Soccio RE, 2005, J BIOL CHEM, V280, P19410, DOI 10.1074/jbc.M501778200; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Song MS, 2001, BIOCHEM J, V356, P151, DOI 10.1042/0264-6021:3560151; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; West LA, 2001, ENDOCRINOLOGY, V142, P502, DOI 10.1210/en.142.1.502; Yaworsky DC, 2005, J BIOL CHEM, V280, P2045, DOI 10.1074/jbc.M410937200	46	61	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10223	10232		10.1074/jbc.M611221200	http://dx.doi.org/10.1074/jbc.M611221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17301050	hybrid			2022-12-27	WOS:000245941000012
J	Hellbusch, CC; Sperandio, M; Frommhold, D; Yakubenia, S; Wild, MK; Popovici, D; Vestweber, D; Grone, HJ; von Figura, K; Lubke, T; Korner, C				Hellbusch, Christina C.; Sperandio, Markus; Frommhold, David; Yakubenia, Sviatlana; Wild, Martin K.; Popovici, Diana; Vestweber, Dietmar; Grone, Hermann-Josef; von Figura, Kurt; Lubke, Torben; Korner, Christian			Golgi GDP-fucose transporter-deficient mice mimic congenital disorder of glycosylation IIc/leukocyte adhesion deficiency II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SELECTIN; GLYCOPROTEIN SYNDROME; FUCT-VII; DEFECT; IDENTIFICATION; FUCOSYLATION; RECRUITMENT; INTEGRINS; MUTATION; REVEALS	Modification of glycoproteins by the attachment of fucose residues is widely distributed in nature. The importance of fucosylation has recently been underlined by identification of the monogenetic inherited human disease "congenital disorder of glycosylation IIc," also termed "leukocyte adhesion deficiency II." Due to defective Golgi GDP-fucose transporter ( SLC35C1) activity, patients show a hypofucosylation of glycoproteins and present clinically with mental and growth retardation, persistent leukocytosis, and severe infections. To investigate effects induced by the loss of fucosylated structures in different organs, we generated a mouse model for the disease by inactivating the Golgi GDP-transporter gene ( Slc35c1). Lectin binding studies revealed a tremendous reduction of fucosylated glycoconjugates in tissues and isolated cells from Slc35c1(-/-) mice. Fucose treatment of cells from different organs led to partial normalization of the fucosylation state of glycoproteins, thereby indicating an alternative GDP-fucose transport mechanism. Slc35c1-deficient mice presented with severe growth retardation, elevated postnatal mortality rate, dilatation of lung alveoles, and hypocellular lymph nodes. In vitro and in vivo leukocyte adhesion and rolling assays revealed a severe impairment of P-, E-, and L-selectin ligand function. The diversity of these phenotypic aspects demonstrates the broad general impact of fucosylation in the mammalian organism.	Univ Childrens Hosp, Dept Pediat, Div Inborn Metab Dis, D-69120 Heidelberg, Germany; Univ Childrens Hosp, Dept Pediat, Sect Neonatol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Biomed, D-48149 Munster, Germany; German Canc Res Ctr, Dept Cellular & Mol Pathol, D-69120 Heidelberg, Germany; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Abt Biochem 2, D-37073 Gottingen, Germany	Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ); University of Gottingen	Korner, C (corresponding author), Univ Childrens Hosp, Dept Pediat, Div Inborn Metab Dis, Neuenheimer Feld 153, D-69120 Heidelberg, Germany.	christian.koerner@med.uni-heidelberg.de	Lübke, Torben/B-6019-2012	Lubke, Torben/0000-0002-3342-0090; Vestweber, Dietmar/0000-0002-3517-732X; Sperandio, Markus/0000-0002-7689-3613				BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; Domino SE, 2001, MOL CELL BIOL, V21, P8336, DOI 10.1128/MCB.21.24.8336-8345.2001; Gotsch U, 1997, J CELL SCI, V110, P583; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helmus Y, 2006, BLOOD, V107, P3959, DOI 10.1182/blood-2005-08-3334; Hidalgo A, 2003, BLOOD, V101, P1705, DOI 10.1182/blood-2002-09-2840; HOGAN B, 1986, MANIPULATING MOUSE E, P188; HOGAN B, 1994, MANIPULATING MOUSE E, P89; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Klyscz T, 1997, BIOMED TECH, V42, P168, DOI 10.1515/bmte.1997.42.6.168; Korner C, 1999, J LEUKOCYTE BIOL, V66, P95; Korner C, 1998, GLYCOCONJUGATE J, V15, P499, DOI 10.1023/A:1006939104442; KRAKOWER CA, 1951, AMA ARCH PATHOL, V51, P629; Kudo T, 2004, MOL CELL BIOL, V24, P4221, DOI 10.1128/MCB.24.10.4221-4228.2004; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEY K, 1988, PFLUG ARCH EUR J PHY, V412, P93, DOI 10.1007/BF00583736; LEY K, 1989, AM J PHYSIOL, V256, pH85, DOI 10.1152/ajpheart.1989.256.1.H85; LIPOWSKY HH, 1978, MICROVASC RES, V15, P93, DOI 10.1016/0026-2862(78)90009-2; Long DS, 2004, P NATL ACAD SCI USA, V101, P10060, DOI 10.1073/pnas.0402937101; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; Martinez-Duncker I, 2003, GLYCOBIOLOGY, V13, p1C, DOI 10.1093/glycob/cwg113; MEREDITH MJ, 1988, CELL BIOL TOXICOL, V4, P405, DOI 10.1007/BF00117769; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Sears P, 1998, CELL MOL LIFE SCI, V54, P223, DOI 10.1007/s000180050146; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Smith ML, 2003, BIOPHYS J, V85, P637, DOI 10.1016/S0006-3495(03)74507-X; Smith PL, 2002, J CELL BIOL, V158, P801, DOI 10.1083/jcb.200203125; Sperandio M, 2001, J IMMUNOL, V167, P2268, DOI 10.4049/jimmunol.167.4.2268; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4	48	55	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10762	10772		10.1074/jbc.M700314200	http://dx.doi.org/10.1074/jbc.M700314200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17276979	hybrid			2022-12-27	WOS:000245941000070
J	Bruneau, E; Akaaboune, M				Bruneau, Emile; Akaaboune, Mohammed			The dynamics of the rapsyn scaffolding protein at individual acetylcholine receptor clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; NEUROMUSCULAR-JUNCTIONS; POSTSYNAPTIC PROTEINS; REQUIRES RAPSYN; IN-VIVO; PHOSPHORYLATION; AGRIN; TRAFFICKING; STARGAZIN; PSD-95	Rapsyn, a cytoplasmic receptor-associated protein, is required for the clustering of acetylcholine receptors (AChRs). Although AChR dynamics have been extensively studied, little is known about the dynamics of rapsyn. Here, we used a rapsyn-green fluorescent protein (GFP) fusion protein and quantitative fluorescent imaging to study the dynamics of rapsyn in transfected C2C12 myotubes. First, we found that rapsyn-GFP expression at clusters did not alter AChR aggregation, function, or turnover. Quantification of rapsyn immunofluorescence indicated that the expression of rapsyn-GFP proteins at clusters does not increase the overall rapsyn density compared with untransfected myotube clusters. Using time lapse imaging and fluorescence recovery after photobleaching, we demonstrated that the recovery of rapsyn-GFP fluorescence at clusters was very fast, with a halftime of about similar to 1.5 h (similar to 3 times faster than AChRs). Inhibition of protein kinase C significantly altered receptor insertion, but it had no effect on rapsyn insertion. When cells were treated with the broad spectrum kinase inhibitor staurosporine, receptor insertion was decreased even further. However, inhibition of protein kinase A had no effect on insertion of either rapsyn or receptors. Finally, when cells were treated with neural agrin, rapsyn and AChRs were both directed away from preexisting clusters and accumulated together in new small clusters. These results demonstrate the remarkable dynamism of rapsyn, which may underlie the stability and maintenance of the postsynaptic scaffold and suggest that the insertion of different postsynaptic proteins may be operating independently.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Neurosci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Akaaboune, M (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	makaabou@umich.edu		Bruneau, Emile/0000-0001-7294-8675	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS056748, R01NS047332] Funding Source: NIH RePORTER; NINDS NIH HHS [NS047332, NS056748] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEL DE, 2002, CELL, V108, P849; Akaaboune M, 2002, NEURON, V34, P865, DOI 10.1016/S0896-6273(02)00739-0; Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Brune JN, 2006, GEOLOGY, V34, P137, DOI 10.1130/G22127.1; Bruneau EG, 2005, DEV BIOL, V288, P248, DOI 10.1016/j.ydbio.2005.09.041; Cai CL, 2006, J BIOL CHEM, V281, P4267, DOI 10.1074/jbc.M505886200; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FRAIL DE, 1989, NEURON, V2, P1077, DOI 10.1016/0896-6273(89)90232-8; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Fuhrer C, 1996, J BIOL CHEM, V271, P32474, DOI 10.1074/jbc.271.50.32474; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gervasio OL, 2005, J PHYSIOL-LONDON, V562, P673, DOI 10.1113/jphysiol.2004.077685; Grady RM, 2003, J CELL BIOL, V160, P741, DOI 10.1083/jcb.200209045; Henley JM, 2003, NEUROSCI RES, V45, P243, DOI 10.1016/S0168-0102(02)00229-8; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kummer TT, 2004, J CELL BIOL, V164, P1077, DOI 10.1083/jcb.200401115; Lanuza MA, 2002, J NEUROSCI RES, V67, P607, DOI 10.1002/jnr.10122; Marangi PA, 2001, EMBO J, V20, P7060, DOI 10.1093/emboj/20.24.7060; Marangi PA, 2002, J CELL BIOL, V157, P883, DOI 10.1083/jcb.200202110; Marchand S, 2002, J NEUROSCI, V22, P8891; Marchand S, 2000, J NEUROSCI, V20, P521, DOI 10.1523/JNEUROSCI.20-02-00521.2000; McConville J, 2002, CURR OPIN PHARMACOL, V2, P296, DOI 10.1016/S1471-4892(02)00156-X; Mittaud P, 2001, J BIOL CHEM, V276, P14505, DOI 10.1074/jbc.M007024200; Mohamed AS, 1999, J BIOL CHEM, V274, P20529, DOI 10.1074/jbc.274.29.20529; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; Muller JS, 2006, NEUROLOGY, V67, P1159, DOI 10.1212/01.wnl.0000233837.79459.40; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; Ohno K, 2002, AM J HUM GENET, V70, P875, DOI 10.1086/339465; Ono F, 2001, J NEUROSCI, V21, P5439, DOI 10.1523/JNEUROSCI.21-15-05439.2001; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Rasse TM, 2005, NAT NEUROSCI, V8, P898, DOI 10.1038/nn1484; Rutter AR, 2000, J NEUROCHEM, V75, P2501, DOI 10.1046/j.1471-4159.2000.0752501.x; Sadasivam G, 2005, J NEUROSCI, V25, P10479, DOI 10.1523/JNEUROSCI.2103-05.2005; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sharma K, 2006, MOL CELL NEUROSCI, V31, P702, DOI 10.1016/j.mcn.2006.01.010; Si JT, 1998, LIFE SCI, V62, P1497, DOI 10.1016/S0024-3205(98)00096-4; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2; VALENZUELA IMP, 2005, J BIOL CHEM, V280, P31801; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; Wang JQ, 2005, MOL NEUROBIOL, V32, P237, DOI 10.1385/MN:32:3:237	49	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9932	9940		10.1074/jbc.M608714200	http://dx.doi.org/10.1074/jbc.M608714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17283077	Green Published, hybrid			2022-12-27	WOS:000245421700068
J	Moncoq, K; Trieber, CA; Young, HS				Moncoq, Karine; Trieber, Catharine A.; Young, Howard S.			The molecular basis for cyclopiazonic acid inhibition of the sarcoplasmic reticulum calcium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; ACTIVE-SITE; CA2+-ATPASE; CA2+; THAPSIGARGIN; MECHANISM; RESIDUES; PROTEIN	The sarcoplasmic reticulum Ca2+-ATPase is essential for calcium reuptake in the muscle contraction-relaxation cycle. Here we present structures of a calcium-free state with bound cyclopiazonic acid (CPA) and magnesium fluoride at 2.65 angstrom resolution and a calcium-free state with bound CPA and ADP at 3.4 angstrom resolution. In both structures, CPA occupies the calcium access channel delimited by transmembrane segments M1-M4. Inhibition of Ca2+-ATPase is stabilized by a polar pocket that surrounds the tetramic acid of CPA and a hydrophobic platform that cradles the inhibitor. The calcium pump residues involved include Gln(56), Leu(61), Val(62), and Asn(101). We conclude that CPA inhibits the calcium pump by blocking the calcium access channel and immobilizing a subset of transmembrane helices. In the E2(CPA) structure, ADP is bound in a distinct orientation within the nucleotide binding pocket. The adenine ring is sandwiched between Arg(489) of the nucleotide-binding domain and Arg(678) of the phosphorylation domain. This mode of binding conforms to an adenine recognition motif commonly found in ATP-dependent proteins.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Young, HS (corresponding author), Univ Alberta, Dept Biochem, Bldg 327, Edmonton, AB T6G 2H7, Canada.	hyoung@ualberta.ca		Trieber, Catharine/0000-0002-1336-1126; Young, Howard/0000-0002-5990-8422				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biot C, 2003, J AM CHEM SOC, V125, P13988, DOI 10.1021/ja035223e; Denessiouk KA, 2001, PROTEINS, V44, P282, DOI 10.1002/prot.1093; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; HOLZAPFE.CW, 1968, TETRAHEDRON, V24, P2101, DOI 10.1016/0040-4020(68)88113-X; Inesi G, 2006, BIOCHEMISTRY-US, V45, P13769, DOI 10.1021/bi061255d; Jensen AML, 2006, EMBO J, V25, P2305, DOI 10.1038/sj.emboj.7601135; Kimura K, 1996, J BIOL CHEM, V271, P28933, DOI 10.1074/jbc.271.46.28933; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LU YZ, 1994, BIOCHEMISTRY-US, V33, P5056, DOI 10.1021/bi00183a008; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; Mao LS, 2003, J AM CHEM SOC, V125, P14216, DOI 10.1021/ja036096p; MARTINS OB, 1985, J BIOL CHEM, V260, P6776; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Missiaen L, 2002, J BIOL CHEM, V277, P6898, DOI 10.1074/jbc.M110939200; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; MURPHY AJ, 1976, BIOCHEM BIOPH RES CO, V70, P1048, DOI 10.1016/0006-291X(76)91008-1; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Picard M, 2006, J BIOL CHEM, V281, P3360, DOI 10.1074/jbc.M511385200; RAESS BU, 1985, MOL PHARMACOL, V27, P444; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Reddy LG, 2003, BIOCHEMISTRY-US, V42, P4585, DOI 10.1021/bi026995a; RILEY RT, 1992, TOXICOL APPL PHARM, V114, P261, DOI 10.1016/0041-008X(92)90076-5; ROSS DC, 1991, J BIOL CHEM, V266, P4613; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Soler F, 1998, BIOCHEMISTRY-US, V37, P4266, DOI 10.1021/bi971455c; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sousa MC, 1998, BIOCHEMISTRY-US, V37, P15392, DOI 10.1021/bi981510x; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; Stewart RC, 1998, BIOCHEMISTRY-US, V37, P12269, DOI 10.1021/bi980970n; STOKES D, 2003, ANNU REV BIOPH BIOM, V32, P425; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; Tetko IV, 2005, J COMPUT AID MOL DES, V19, P453, DOI 10.1007/s10822-005-8694-y; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Venkatesh PK, 2005, MYCOPATHOLOGIA, V159, P393, DOI 10.1007/s11046-004-6271-x; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; Wilson DM, 2002, ADV EXP MED BIOL, V504, P3; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wootton LL, 2006, J BIOL CHEM, V281, P6970, DOI 10.1074/jbc.M510978200; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; Young HS, 2004, J MEMBRANE BIOL, V198, P55, DOI 10.1007/s00232-004-0666-y; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	53	110	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9748	9757		10.1074/jbc.M611653200	http://dx.doi.org/10.1074/jbc.M611653200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259168	hybrid			2022-12-27	WOS:000245421700049
J	Suzuki, T; Nishi, T; Nagino, T; Sasaki, K; Aizawa, K; Kada, N; Sawaki, D; Munemasa, Y; Matsumura, T; Muto, S; Sata, M; Miyagawa, K; Horikoshi, M; Nagai, R				Suzuki, Toru; Nishi, Toshiya; Nagino, Tomoko; Sasaki, Kana; Aizawa, Kenichi; Kada, Nanae; Sawaki, Daigo; Munemasa, Yoshiko; Matsumura, Takayoshi; Muto, Shinsuke; Sata, Masataka; Miyagawa, Kiyoshi; Horikoshi, Masami; Nagai, Ryozo			Functional interaction between the transcription factor Kruppel-like factor 5 and poly(ADP-ribose) polymerase-1 in cardiovascular apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ACETYLATION; P300; MICE; EXPRESSION; REGULATOR; PATHWAY; PROTEIN; REPAIR; DOMAIN	Kruppel-like factor 5 (KLF5) is a transcription factor important in regulation of the cardiovascular response to external stress. KLF5 regulates pathological cell growth, and its acetylation is important for this effect. Its mechanisms of action, however, are still unclear. Analysis in KLF5-deficient mice showed that KLF5 confers apoptotic resistance in vascular lesions. Mechanistic analysis further showed that it specifically interacts with poly(ADP-ribose) polymerase-1 (PARP-1), a nuclear enzyme important in DNA repair and apoptosis. KLF5 interacted with a proteolytic fragment of PARP-1, and acetylation of KLF5 under apoptotic conditions increased their affinity. Moreover, KLF5 wild-type (but not a non-acetylatable point mutant) inhibited apoptosis as induced by the PARP-1 fragment. Collectively, we have found that KLF5 regulates apoptosis and targets PARP-1, and further, for acetylation to regulate these effects. Our findings thus implicate functional interaction between the transcription factor KLF5 and PARP-1 in cardiovascular apoptosis.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Clin Bioinformat, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Radiat Biol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Lab Dev Biol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	torusuzu-tky@umin.ac.jp; nagai-tky@umin.ac.jp	SAWAKI, Daigo/T-6871-2018	SAWAKI, Daigo/0000-0003-1417-2033; Nishi, Toshiya/0000-0002-9451-2423; Suzuki, Toru/0000-0002-8371-664X				Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; Kim JW, 2000, J CELL SCI, V113, P955; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Miyamoto S, 2006, CIRCULATION, V113, P679, DOI 10.1161/CIRCULATIONAHA.105.585182; Miyamoto S, 2003, MOL CELL BIOL, V23, P8528, DOI 10.1128/MCB.23.23.8528-8541.2003; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Suzuki T, 2005, TRENDS CARDIOVAS MED, V15, P125, DOI 10.1016/j.tcm.2005.04.003; Suzuki T, 2005, ARTERIOSCL THROM VAS, V25, P1135, DOI 10.1161/01.ATV.0000165656.65359.23; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; Suzuki T, 1998, J BIOCHEM, V124, P389, DOI 10.1093/oxfordjournals.jbchem.a022124; Torigoe T, 2005, J BIOL CHEM, V280, P1179, DOI 10.1074/jbc.M410499200; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Yang L, 2003, CANCER RES, V63, P6815; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	32	25	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9895	9901		10.1074/jbc.M608098200	http://dx.doi.org/10.1074/jbc.M608098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17283079	hybrid			2022-12-27	WOS:000245421700064
J	Kim, M; Hersh, LB; Leissring, MA; Ingelsson, M; Matsui, T; Farris, W; Lu, A; Hyman, BT; Selkoe, DJ; Bertram, L; Tanzi, RE				Kim, Minji; Hersh, Louis B.; Leissring, Malcolm A.; Ingelsson, Martin; Matsui, Toshifumi; Farris, Wesley; Lu, Alice; Hyman, Bradley T.; Selkoe, Dennis J.; Bertram, Lars; Tanzi, Rudolph E.			Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; NEURODEGENERATIVE DISEASES; EXTRACELLULAR LEVELS; APOLIPOPROTEIN-E; PEPTIDE LEVELS; IN-VIVO; BRAIN; DEGRADATION; PROTEOLYSIS; INSULYSIN	Insulin-degrading enzyme (IDE) is a zinc metalloprotease that degrades the amyloid beta-peptide, the key component of Alzheimer disease (AD)-associated senile plaques. We have previously reported evidence for genetic linkage and association of AD on chromosome 10q23-24 in the region harboring the IDE gene. Here we have presented the first functional assessment of IDE in AD families showing the strongest evidence of the genetic linkage. We have examined the catalytic activity and expression of IDE in lymphoblast samples from 12 affected and unaffected members of three chromosome 10-linked AD pedigrees in the National Institute of Mental Health AD Genetics Initiative family sample. We have shown that the catalytic activity of cytorsolic IDE to degrade insulin is reduced in affected versus unaffected subjects of these families. Further, we have shown the decrease in activity is not due to reduced IDE expression, suggesting the possible defects in IDE function in these AD families. In attempts to find potential mutations in the IDE gene in these families, we have found no coding region substitutions or alterations in splicing of the canonical exons and exon 15b of IDE. We have also found that total IDE mRNA levels are not significantly different in sporadic AD versus age-matched control brains. Collectively, our data suggest that the genetic linkage of AD in this set of chromosome 10-linked AD families may be the result of systemic defects in IDE activity in the absence of altered IDE expression, further supporting a role for IDE in AD pathogenesis.	Massachusetts Gen Hosp, Inst Neurodegenerat, Genet & Aging Res Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02129 USA; Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Inst Neurodegenerat, Alzheimer Res Unit, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Kentucky; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Tanzi, RE (corresponding author), Massachusetts Gen Hosp, Inst Neurodegenerat, Genet & Aging Res Unit, Bldg 114,16th St,C3009, Boston, MA 02129 USA.	tanzi@helix.mgh.harvard.edu	Bertram, Lars/K-3889-2015; LEISSRING, MALCOLM/AAW-5361-2021; Tanzi, Rudolph/AAE-9622-2019	Bertram, Lars/0000-0002-0108-124X; LEISSRING, MALCOLM/0000-0001-7185-4255; Tanzi, Rudolph/0000-0002-7032-1454; Matsui, Toshifumi/0000-0002-8478-2809				BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; Bennett RG, 2000, J BIOL CHEM, V275, P36621, DOI 10.1074/jbc.M006170200; Bernstein HG, 1999, NEUROSCI LETT, V263, P161, DOI 10.1016/S0304-3940(99)00135-4; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934; Blacker D, 2003, HUM MOL GENET, V12, P23, DOI 10.1093/hmg/ddg007; Blomqvist MEL, 2004, NEUROGENETICS, V5, P115, DOI 10.1007/s10048-004-0173-4; Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013; Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; Edland SD, 2003, NEUROSCI LETT, V345, P21, DOI 10.1016/S0304-3940(03)00488-9; Farris W, 2005, BIOCHEMISTRY-US, V44, P6513, DOI 10.1021/bi0476578; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Farris W, 2004, AM J PATHOL, V164, P1425, DOI 10.1016/S0002-9440(10)63229-4; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Gutala RV, 2004, J NEUROSCI METH, V132, P101, DOI 10.1016/j.jneumeth.2003.09.005; Hamel FG, 2003, ENDOCRINOLOGY, V144, P2404, DOI 10.1210/en.2002-0007; Huang J, 2004, NEUROSCI LETT, V367, P85, DOI 10.1016/j.neulet.2004.05.085; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; INGELSSON M, 2006, ACTA NEUROPATHOL BER; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; LOWE J, 1993, BRAIN PATHOL, V3, P55, DOI 10.1111/j.1750-3639.1993.tb00726.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morelli L, 2004, J BIOL CHEM, V279, P56004, DOI 10.1074/jbc.M407283200; OGAWA W, 1992, J BIOL CHEM, V267, P1310; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; Prince JA, 2003, HUM MUTAT, V22, P363, DOI 10.1002/humu.10282; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Saric T, 2003, MOL CELL ENDOCRINOL, V204, P11, DOI 10.1016/S0303-7207(03)00154-0; Savage MJ, 1998, J NEUROSCI, V18, P1743; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Song ES, 2005, J MOL NEUROSCI, V25, P201, DOI 10.1385/JMN:25:3:201; Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200; Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Udrisar Daniel Pedro, 1992, Acta Physiologica Pharmacologica et Therapeutica Latinoamericana, V42, P183; Vekrellis K, 2000, J NEUROSCI, V20, P1657	47	83	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7825	7832		10.1074/jbc.M609168200	http://dx.doi.org/10.1074/jbc.M609168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244626	hybrid			2022-12-27	WOS:000245081000011
J	Shi, R; Lamb, SS; Bhat, S; Sulea, T; Wright, GD; Matte, A; Cygler, M				Shi, Rong; Lamb, Sherry S.; Bhat, Sathesh; Sulea, Traian; Wright, Gerard D.; Matte, Allan; Cygler, Miroslaw			Crystal structure of StaL, a glycopeptide antibiotic sulfotransferase from Streptomyces toyocaensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-SPECIFICITY; MOLECULAR-BASIS; MODEL; BIOSYNTHESIS; SUBSTRATE; SULFATION; REFINEMENT; GENERATION; DOPAMINE; PROTEINS	Over the past decade, antimicrobial resistance has emerged as a major public health crisis. Glycopeptide antibiotics such as vancomycin and teicoplanin are clinically important for the treatment of Gram-positive bacterial infections. StaL is a 3'-phosphoadenosine 5'-phosphosulfate-dependent sulfotransferase capable of sulfating the cross-linked heptapeptide substrate both in vivo and in vitro, yielding the product A47934, a unique teicoplanin-class glycopeptide antibiotic. The sulfonation reaction catalyzed by StaL constitutes the final step in A47934 biosynthesis. Here we report the crystal structure of StaL and its complex with the cofactor product 3'-phosphoadenosine 5'-phosphate. This is only the second prokaryotic sulfotransferase to be structurally characterized. StaL belongs to the large sulfotransferase family and shows higher similarity to cytosolic sulfotransferases (ST) than to the bacterial ST (Stf0). StaL has a novel dimerization motif, different from any other STs that have been structurally characterized. We have also applied molecular modeling to investigate the binding mode of the unique substrate, desulfo-A47934. Based on the structural analysis and modeling results, a series of residues was mutated and kinetically characterized. In addition to the conserved residues (Lys(12), His(67), and Ser(98)), molecular modeling, fluorescence quenching experiments, and mutagenesis studies identified several other residues essential for substrate binding and/or activity, including Trp(34), His(43), Phe(77), Trp(13)2, and Glu(205).	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McMaster Univ, Dept Biochem & Biomed Sci, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	National Research Council Canada; McGill University; McMaster University	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				Bal AM, 2005, EXPERT OPIN PHARMACO, V6, P2257, DOI 10.1517/14656566.6.13.2257; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhat S, 2006, PROTEINS, V62, P244, DOI 10.1002/prot.20682; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; BOECK LD, 1986, J ANTIBIOT, V39, P1533, DOI 10.7164/antibiotics.39.1533; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chang HJ, 2004, J BIOL CHEM, V279, P2689, DOI 10.1074/jbc.M310446200; Chapman E, 2004, ANGEW CHEM INT EDIT, V43, P3526, DOI 10.1002/anie.200300631; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Dombrovski L, 2006, PROTEINS, V64, P1091, DOI 10.1002/prot.21048; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Gamage NU, 2003, J BIOL CHEM, V278, P7655, DOI 10.1074/jbc.M207246200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hanin M, 1997, MOL MICROBIOL, V24, P1119, DOI 10.1046/j.1365-2958.1997.3981777.x; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kahne D, 2005, CHEM REV, V105, P425, DOI 10.1021/cr030103a; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Lamb SS, 2006, CHEM BIOL, V13, P171, DOI 10.1016/j.chembiol.2005.12.003; Lee KA, 2003, J BIOL CHEM, V278, P44593, DOI 10.1074/jbc.M308312200; Lehrer S S, 1978, Methods Enzymol, V49, P222; Lu JH, 2005, BIOCHEM BIOPH RES CO, V335, P417, DOI 10.1016/j.bbrc.2005.07.091; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McGann MR, 2003, BIOPOLYMERS, V68, P76, DOI 10.1002/bip.10207; Moon AF, 2004, J BIOL CHEM, V279, P45185, DOI 10.1074/jbc.M405013200; Mougous JD, 2002, CHEM BIOL, V9, P767, DOI 10.1016/S1074-5521(02)00175-8; Mougous JD, 2006, P NATL ACAD SCI USA, V103, P4258, DOI 10.1073/pnas.0510861103; Mougous JD, 2004, NAT STRUCT MOL BIOL, V11, P721, DOI 10.1038/nsmb802; Murray BE, 2000, NEW ENGL J MED, V342, P710, DOI 10.1056/NEJM200003093421007; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Nicolaou KC, 1999, ANGEW CHEM INT EDIT, V38, P2096, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Petrotchenko EV, 2001, FEBS LETT, V490, P39, DOI 10.1016/S0014-5793(01)02129-9; Pootoolal J, 2002, P NATL ACAD SCI USA, V99, P8962, DOI 10.1073/pnas.102285099; Purisima EO, 1998, J COMPUT CHEM, V19, P1494, DOI 10.1002/(SICI)1096-987X(199810)19:13<1494::AID-JCC6>3.0.CO;2-L; Rath VL, 2004, DRUG DISCOV TODAY, V9, P1003, DOI 10.1016/S1359-6446(04)03273-8; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; Schafer M, 1996, HELV CHIM ACTA, V79, P1916, DOI 10.1002/hlca.19960790714; Smith DW, 2004, PROTEINS, V57, P854, DOI 10.1002/prot.20258; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Townsend GE, 2006, J BACTERIOL, V188, P8560, DOI 10.1128/JB.01035-06; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; ZMIJEWSKI MJ, 1987, ANTIMICROB AGENTS CH, V31, P1497, DOI 10.1128/AAC.31.10.1497	58	19	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13073	13086		10.1074/jbc.M611912200	http://dx.doi.org/10.1074/jbc.M611912200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329243	hybrid			2022-12-27	WOS:000245942800076
J	Sjostrand, D; Carlsson, J; Paratcha, G; Persson, B; Ibanez, CF				Sjostrand, Dan; Carlsson, Jonas; Paratcha, Gustavo; Persson, Bengt; Ibanez, Carlos F.			Disruption of the GDNF binding site in NCAM dissociates ligand binding and homophilic cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NEUROTROPHIC FACTOR; MOLECULE NCAM; RET; DOMAINS; FAMILY; GFR-ALPHA-1; ACTIVATION; IDENTIFICATION; SPECIFICITY	Most plasma membrane proteins are capable of sensing multiple cell-cell and cell-ligand interactions, but the extent to which this functional versatility is founded on their modular design is less clear. We have identified the third immunoglobulin domain of the Neural Cell Adhesion Molecule ( NCAM) as the necessary and sufficient determinant for its interaction with Glial Cell Line-derived Neurotrophic Factor ( GDNF). Four charged contacts were identified by molecular modeling as the main contributors to binding energy. Their mutation abolished GDNF binding to NCAM but left intact the ability of NCAM to mediate cell adhesion, indicating that the two functions are genetically separable. The GDNF-NCAM interface allows complex formation with the GDNF family receptor alpha 1, shedding light on the molecular architecture of a multicomponent GDNF receptor.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Linkoping Univ, IFM Bioinformat, S-58183 Linkoping, Sweden	Karolinska Institutet; Karolinska Institutet; Linkoping University	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden.	carlos.ibanez@ki.se	Almlöf, Jonas/E-1608-2017	Almlöf, Jonas/0000-0002-1211-9821; Paratcha, Gustavo/0000-0002-0804-4433; Persson, Bengt/0000-0003-3165-5344				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Albach C, 2004, ANAL BIOANAL CHEM, V378, P1129, DOI 10.1007/s00216-003-2383-2; Anders J, 2001, J BIOL CHEM, V276, P35808, DOI 10.1074/jbc.M104968200; Atkins AR, 2004, J BIOL CHEM, V279, P49633, DOI 10.1074/jbc.M409159200; Baloh RH, 2000, J BIOL CHEM, V275, P3412, DOI 10.1074/jbc.275.5.3412; Baloh RH, 1998, P NATL ACAD SCI USA, V95, P5801, DOI 10.1073/pnas.95.10.5801; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Barker RA, 2006, LANCET NEUROL, V5, P285, DOI 10.1016/S1474-4422(06)70386-6; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; Davies AM, 1997, NEURON, V19, P485; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eigenbrot C, 1997, NAT STRUCT BIOL, V4, P435, DOI 10.1038/nsb0697-435; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Gardell LR, 2003, NAT MED, V9, P1383, DOI 10.1038/nm944; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; HALL AK, 1987, J CELL BIOL, V104, P1579, DOI 10.1083/jcb.104.6.1579; Iwase T, 2005, J NEUROCHEM, V94, P1488, DOI 10.1111/j.1471-4159.2005.03290.x; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johnson CP, 2004, P NATL ACAD SCI USA, V101, P6963, DOI 10.1073/pnas.0307567100; Ledda F, 2007, NAT NEUROSCI, V10, P293, DOI 10.1038/nn1855; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; Natarajan D, 2002, DEVELOPMENT, V129, P5151; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; Paratcha G, 2006, MOL CELL NEUROSCI, V31, P505, DOI 10.1016/j.mcn.2005.11.007; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Sainio K, 1997, DEVELOPMENT, V124, P4077; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; Soroka V, 2003, STRUCTURE, V11, P1291, DOI 10.1016/j.str.2003.09.006; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Wang XQ, 2006, STRUCTURE, V14, P1083, DOI 10.1016/j.str.2006.05.010; Wieland JA, 2005, J BIOL CHEM, V280, P41037, DOI 10.1074/jbc.M503975200	37	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12734	12740		10.1074/jbc.M701588200	http://dx.doi.org/10.1074/jbc.M701588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322291	hybrid			2022-12-27	WOS:000245942800043
J	Ivanovic, T; Agosto, MA; Chandran, K; Nibert, ML				Ivanovic, Tijana; Agosto, Melina A.; Chandran, Kartik; Nibert, Max L.			A role for molecular chaperone Hsc70 in reovirus outer capsid disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ENTRY; MAMMALIAN REOVIRUSES; NONENVELOPED VIRUS; PROTEIN MU-1; PUTATIVE AUTOCLEAVAGE; PEPTIDE-BINDING; PARTICLES; ATPASE; POLYOMAVIRUS; ACTIVATION	After crossing the cellular membrane barrier during cell entry, most animal viruses must undergo further disassembly before initiating viral gene expression. In many cases, these disassembly mechanisms remain poorly defined. For this report, we examined a final step in disassembly of the mammalian reovirus outer capsid: cytoplasmic release of the central, delta fragment of membrane penetration protein mu 1 to yield the transcriptionally active viral core particle. An in vitro assay with reticulocyte lysate recapitulated the release of intact delta molecules. Requirements for activity in this system were shown to include a protein factor, ATP, and Mg2+ and K+ ions, consistent with involvement of a molecular chaperone such as Hsc70. Immunodepletion of Hsc70 and Hsp70 impaired delta release, which was then rescued by addition of purified Hsc70. Hsc70 was associated with released delta molecules not only in the lysate but also during cell entry. We conclude that Hsc70 plays a defined role in reovirus outer capsid disassembly, during or soon after membrane penetration, to prepare the entering particle for gene expression and replication.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Training Program Virol, Boston, MA 02115 USA; Harvard Univ, Training Programs Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University	Nibert, ML (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	mnibert@hms.harvard.edu	Chandran, Kartik/I-2232-2012	Agosto, Melina/0000-0002-3647-1926	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046440, T32AI007245, F31AI064142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007226] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI046440, R01 AI46440, T32 AI07245, F31 AI064142, F31 AI064142-01] Funding Source: Medline; NIGMS NIH HHS [T32 GM07226] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agosto MA, 2006, P NATL ACAD SCI USA, V103, P16496, DOI 10.1073/pnas.0605835103; BODKIN DK, 1989, J VIROL, V63, P4676, DOI 10.1128/JVI.63.11.4676-4681.1989; BORSA J, 1973, J VIROL, V11, P552, DOI 10.1128/JVI.11.4.552-564.1973; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Broering TJ, 2005, J VIROL, V79, P6194, DOI 10.1128/JVI.79.10.6194-6206.2005; Chandran K, 2003, J VIROL, V77, P13361, DOI 10.1128/JVI.77.24.13361-13375.2003; Chandran K, 2003, TRENDS MICROBIOL, V11, P374, DOI 10.1016/S0966-842X(03)00178-1; Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002; Chromy LR, 2006, J VIROL, V80, P5086, DOI 10.1128/JVI.80.10.5086-5091.2006; CRIPE TP, 1995, J VIROL, V69, P7807, DOI 10.1128/JVI.69.12.7807-7813.1995; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Guerrero CA, 2002, J VIROL, V76, P4096, DOI 10.1128/JVI.76.8.4096-4102.2002; Gurer C, 2002, J VIROL, V76, P4666, DOI 10.1128/JVI.76.9.4666-4670.2002; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; JOKLIK WK, 1972, VIROLOGY, V49, P700, DOI 10.1016/0042-6822(72)90527-2; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Nibert ML, 2005, J MOL BIOL, V345, P461, DOI 10.1016/j.jmb.2004.10.026; NIBERT ML, 1991, J VIROL, V65, P1960, DOI 10.1128/JVI.65.4.1960-1967.1991; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; Odegard AL, 2004, J VIROL, V78, P8732, DOI 10.1128/JVI.78.16.8732-8745.2004; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Perez-Vargas J, 2006, J VIROL, V80, P3322, DOI 10.1128/JVI.80.7.3322-3331.2006; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SAGARA J, 1992, VIROLOGY, V190, P845, DOI 10.1016/0042-6822(92)90923-D; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; Sullivan CS, 2001, VIROLOGY, V287, P1, DOI 10.1006/viro.2001.1038; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zarate S, 2003, J VIROL, V77, P7254, DOI 10.1128/JVI.77.13.7254-7260.2003	36	51	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12210	12219		10.1074/jbc.M610258200	http://dx.doi.org/10.1074/jbc.M610258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17284448	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000245941900064
J	Partridge, JD; Sanguinetti, G; Dibden, DP; Roberts, RE; Poole, RK; Green, J				Partridge, Jonathan D.; Sanguinetti, Guido; Dibden, David P.; Roberts, Ruth E.; Poole, Robert K.; Green, Jeffrey			Transition of Escherichia coli from aerobic to micro-aerobic conditions involves fast and slow reacting regulatory components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE CYDAB OPERON; OUTER-MEMBRANE; SACCHAROMYCES-CEREVISIAE; ANAEROBIC GROWTH; GENE-EXPRESSION; FNR PROTEIN; TRANSCRIPTION; ACTIVATION; ARCA; ROLES	Understanding life at a systems level is a major aim of biology. The bacterium Escherichia coli offers one of the best opportunities to achieve this goal. It is a metabolically versatile bacterium able to respond to changes in oxygen availability. This ability is a crucial component of its lifestyle, allowing it to thrive in aerobic external environments and under the oxygen-starved conditions of a host gut. The controlled growth conditions of chemostat culture were combined with transcript profiling to investigate transcriptome dynamics during the transition from aerobic to micro-aerobic conditions. In addition to predictable changes in transcripts encoding proteins of central metabolism, the abundances of transcripts involved in homeostasis of redox-reactive metals ( Cu and Fe), and cell envelope stress were significantly altered. To gain further insight into the responses of the regulatory networks, the activities of key transcription factors during the transition to micro-aerobic conditions were inferred using a probabilistic modeling approach, which revealed that the response of the direct oxygen sensor FNR was rapid and overshot, whereas the indirect oxygen sensor ArcA reacted more slowly. Similarly, the cell envelope stress sensors RpoE and CpxR reacted rapidly and more slowly, respectively. Thus, it is suggested that combining rapid and slow reacting components in regulatory networks might be a feature of systems in which a signal is perceived by two or more functionally related transcription factors controlling overlapping regulons.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Dept Comp Sci, Sheffield S1 4DP, S Yorkshire, England	University of Sheffield; University of Sheffield	Green, J (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	jeff.green@sheffield.ac.uk	Partridge, Jonathan/GSD-6795-2022	Partridge, Jonathan/0000-0003-2536-5404	BBSRC [BB/F003463/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F003463/1, P19192] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Anderson LA, 2000, J BACTERIOL, V182, P7035, DOI 10.1128/JB.182.24.7035-7043.2000; COMPAN I, 1994, MOL MICROBIOL, V11, P955, DOI 10.1111/j.1365-2958.1994.tb00374.x; Constantinidou C, 2006, J BIOL CHEM, V281, P4802, DOI 10.1074/jbc.M512312200; Cotter PA, 1997, MOL MICROBIOL, V25, P605, DOI 10.1046/j.1365-2958.1997.5031860.x; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Dartigalongue C, 2001, J BIOL CHEM, V276, P20866, DOI 10.1074/jbc.M100464200; De Wulf P, 2002, J BIOL CHEM, V277, P26652, DOI 10.1074/jbc.M203487200; Dmello R, 1996, MICROBIOL-UK, V142, P755, DOI 10.1099/00221287-142-4-755; Evans C. G. T., 1970, METHODS MICROBIOLOGY, V2, DOI [10.1016/S0580-9517(08)70227-7, DOI 10.1016/S0580-9517(08)70227-7]; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Govantes F, 2000, MOL MICROBIOL, V38, P1061, DOI 10.1046/j.1365-2958.2000.02215.x; GREEN J, 1998, MOL MICROBIOL, P17; Guest John R., 1996, P317; Hayes A, 2002, METHODS, V26, P281, DOI 10.1016/S1046-2023(02)00032-4; Hondorp ER, 2004, PLOS BIOL, V2, P1738, DOI 10.1371/journal.pbio.0020336; Hong HD, 2006, J BIOL CHEM, V281, P7568, DOI 10.1074/jbc.M512365200; Hoskisson PA, 2005, MICROBIOL-SGM, V151, P3153, DOI 10.1099/mic.0.27924-0; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; King T, 2005, FEMS MICROBIOL LETT, V244, P323, DOI 10.1016/j.femsle.2005.02.002; King T, 2004, J BACTERIOL, V186, P5614, DOI 10.1128/JB.186.17.5614-5620.2004; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Marshall FA, 2001, MOL MICROBIOL, V39, P747, DOI 10.1046/j.1365-2958.2001.02262.x; Miller J. H, 1972, EXPT MOL GENETICS; Nandi B, 2005, MICROBIOL-SGM, V151, P2975, DOI 10.1099/mic.0.27995-0; Outten FW, 2001, J BIOL CHEM, V276, P30670, DOI 10.1074/jbc.M104122200; Partridge JD, 2006, J BIOL CHEM, V281, P27806, DOI 10.1074/jbc.M603450200; Pilsl H, 1999, J BACTERIOL, V181, P3578, DOI 10.1128/JB.181.11.3578-3581.1999; Piper MDW, 2002, J BIOL CHEM, V277, P37001, DOI 10.1074/jbc.M204490200; Rhodius VA, 2006, PLOS BIOL, V4, P43, DOI 10.1371/journal.pbio.0040002; Salmon KA, 2005, J BIOL CHEM, V280, P15084, DOI 10.1074/jbc.M414030200; Sambrook J., 2001, MOL CLONING LAB MANU; SAWERS G, 1993, MOL MICROBIOL, V10, P737, DOI 10.1111/j.1365-2958.1993.tb00944.x; Wagner AFV, 2001, BIOCHEM BIOPH RES CO, V285, P456, DOI 10.1006/bbrc.2001.5186; Wainwright LM, 2005, MICROBIOL-SGM, V151, P4079, DOI 10.1099/mic.0.28266-0; WING HJ, 1995, J BACTERIOL, V177, P6704, DOI 10.1128/jb.177.23.6704-6710.1995; Wyborn NR, 2002, MICROBIOL-SGM, V148, P1015, DOI 10.1099/00221287-148-4-1015; Yamamoto K, 2005, MOL MICROBIOL, V56, P215, DOI 10.1111/j.1365-2958.2005.04532.x	42	101	102	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11230	11237		10.1074/jbc.M700728200	http://dx.doi.org/10.1074/jbc.M700728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307737	hybrid			2022-12-27	WOS:000245941500045
J	Vecchiarelli, AG; Schumacher, MA; Funnell, BE				Vecchiarelli, Anthony G.; Schumacher, Maria A.; Funnell, Barbara E.			P1 partition complex assembly involves several modes of protein-DNA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; P7 PLASMID PARTITION; PARB PROTEIN; DAUGHTER CELLS; BINDING; SITE; RECOMBINATION; SEGREGATION; SPECIFICITY; CENTROMERE	Assembly of P1 plasmid partition complexes at the partition site, parS, is nucleated by a dimer of P1 ParB and Escherichia coli integration host factor (IHF), which promotes loading of more ParB dimers and the pairing of plasmids during the cell cycle. ParB binds several copies of two distinct recognition motifs, known as A- and B-boxes, which flank a bend in parS created by IHF binding. The recent crystal structure of ParB bound to a partial parS site revealed two relatively independent DNA-binding domains and raised the question of how a dimer of ParB recognizes its complicated arrangement of recognition motifs when it loads onto the full parS site in the presence of IHF. In this study, we addressed this question by examining ParB binding activities to parS mutants containing different combinations of the A- and B- box motifs in parS. Binding was measured to linear and supercoiled DNA in electrophoretic and filter binding assays, respectively. ParB showed preferences for certain motifs that are dependent on position and on plasmid topology. In the simplest arrangement, one motif on either side of the bend was sufficient to form a complex, although affinity differed depending on the motifs. Therefore, a ParB dimer can load onto parS in different ways, so that the initial ParB-IHF-parS complex consists of a mixture of different orientations of ParB. This arrangement supports a model in which parS motifs are available for inter-as well as intramolecular parS recognition.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Toronto; University of Texas System; UTMD Anderson Cancer Center	Funnell, BE (corresponding author), Univ Toronto, Dept Mol & Med Genet, Rm 4182,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	b.funnell@utoronto.ca	Vecchiarelli, Anthony/H-5978-2019	Vecchiarelli, Anthony/0000-0002-6198-3245; Funnell, Barbara/0000-0002-1828-6567	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074815] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM074815] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEK DP, 1994, P NATL ACAD SCI USA, V91, P8027, DOI 10.1073/pnas.91.17.8027; Biswas T, 2005, NATURE, V435, P1059, DOI 10.1038/nature03657; Bouet JY, 2000, J BIOL CHEM, V275, P8213, DOI 10.1074/jbc.275.11.8213; Bouet JY, 1999, EMBO J, V18, P1415, DOI 10.1093/emboj/18.5.1415; Davis MA, 1996, MOL MICROBIOL, V21, P1029, DOI 10.1046/j.1365-2958.1996.721423.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DAVIS MA, 1990, EMBO J, V9; Edgar R, 2001, MOL MICROBIOL, V42, P1363, DOI 10.1046/j.1365-2958.2001.02717.x; Erdmann N, 1999, P NATL ACAD SCI USA, V96, P14905, DOI 10.1073/pnas.96.26.14905; Funnell BE, 2004, PLASMID BIOLOGY, P81; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; Hayes F, 2006, NAT REV MICROBIOL, V4, P133, DOI 10.1038/nrmicro1342; HAYES F, 1994, J MOL BIOL, V243, P190, DOI 10.1006/jmbi.1994.1646; HAYES F, 1994, MOL MICROBIOL, V11, P249, DOI 10.1111/j.1365-2958.1994.tb00305.x; Higgins NP, 2004, PLASMID BIOLOGY, P181; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LARSSON A, 1991, J IMMUNOL METHODS, V137, P253, DOI 10.1016/0022-1759(91)90031-A; Li YF, 2002, MOL MICROBIOL, V46, P63, DOI 10.1046/j.1365-2958.2002.03156.x; Ma YM, 2001, BIOCHEMISTRY-US, V40, P9638, DOI 10.1021/bi010932v; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Radman-Livaja M, 2006, CURR OPIN STRUC BIOL, V16, P42, DOI 10.1016/j.sbi.2005.12.003; Radnedge L, 1996, EMBO J, V15, P1155, DOI 10.1002/j.1460-2075.1996.tb00454.x; Reichheld SE, 2006, J MOL BIOL, V361, P382, DOI 10.1016/j.jmb.2006.06.035; Rodionov O, 2004, MOL MICROBIOL, V52, P1215, DOI 10.1111/j.1365-2958.2004.04055.x; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Schumacher MA, 2005, NATURE, V438, P516, DOI 10.1038/nature04149; Surtees JA, 1999, J BACTERIOL, V181, P5898, DOI 10.1128/JB.181.19.5898-5908.1999; Surtees JA, 2001, J BIOL CHEM, V276, P12385, DOI 10.1074/jbc.M009370200	32	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10944	10952		10.1074/jbc.M611250200	http://dx.doi.org/10.1074/jbc.M611250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308337	hybrid			2022-12-27	WOS:000245941500014
J	Pust, S; Hochmann, H; Kaiser, E; von Figura, G; Heine, K; Aktories, K; Barth, H				Pust, Sascha; Hochmann, Henrike; Kaiser, Eva; von Figura, Guido; Heine, Karin; Aktories, Klaus; Barth, Holger			A cell-permeable fusion toxin as a tool to study the consequences of actin-ADP-ribosylation caused by the Salmonella enterica virulence factor SpvB in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM C2 TOXIN; III SECRETION SYSTEM; CLOSTRIDIUM-BOTULINUM; HOST-CELLS; PLASMID; PROTEIN; GENES; TRANSLOCATION; INFECTION; BINDING	The virulence factor SpvB is a crucial component for the intracellular growth and infection process of Salmonella enterica. The SpvB protein mediates the ADP-ribosylation of actin in infected cells and is assumed to be delivered directly from the engulfed bacteria into the host cell cytosol. Here we used the binary Clostridium botulinum C2 toxin as a transport system for the catalytic domain of SpvB (C/SpvB) into the host cell cytosol. A recombinant fusion toxin composed of the enzymatically inactive N-terminal domain of C. botulinum C2 toxin (C2IN) and C/SpvB was cloned, expressed, and characterized in vitro and in intact cells. When added together with C2II, the C2IN-C/SpvB fusion toxin was efficiently delivered into the host cell cytosol and ADP-ribosylated actin in various cell lines. The cellular uptake of the fusion toxin requires translocation from acidic endosomes into the cytosol and is facilitated by Hsp90. The N- and C- terminal domains of SpvB are linked by 7 proline residues. To elucidate the function of this proline region, fusion toxins containing none, 5, 7, and 9 proline residues were constructed and analyzed. The existence of the proline residues was essential for the translocation of the fusion toxins into host cell cytosol and thereby determined their cytopathic efficiency. No differences concerning the mode of action of the C2IN-C/SpvB fusion toxin and the C2 toxin were obvious as both toxins induced depolymerization of actin filaments, resulting in cell rounding. The acute cellular responses following ADP- ribosylation of actin did not immediately induce cell death of J774.A1 macrophage- like cells.	Univ Ulm, Inst Pharmacol & Toxicol, D-89081 Ulm, Germany; Univ Freiburg, Inst Expt & Clin Pharmacol & Tocicol, D-79104 Freising Weihenstephan, Germany	Ulm University; University of Freiburg	Barth, H (corresponding author), Univ Ulm, Inst Pharmacol & Toxicol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	holger.barth@uni-ulm.de	Aktories, Klaus/CAJ-5682-2022; Pust, Sascha/M-3201-2013; Barth, Holger/E-7920-2013	Aktories, Klaus/0000-0002-5397-0436; Pust, Sascha/0000-0002-0178-2206; 				Aktories K, 2004, INT J MED MICROBIOL, V293, P557, DOI 10.1078/1438-4221-00305; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Barth H, 2002, J BIOL CHEM, V277, P5074, DOI 10.1074/jbc.M109167200; Barth H, 1999, INFECT IMMUN, V67, P5083, DOI 10.1128/IAI.67.10.5083-5090.1999; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Blocker D, 2001, INFECT IMMUN, V69, P2980, DOI 10.1128/IAI.69.5.2980-2987.2001; Chakravortty D, 2005, EMBO J, V24, P2043, DOI 10.1038/sj.emboj.7600676; FANG FC, 1991, J BACTERIOL, V173, P6783, DOI 10.1128/jb.173.21.6783-6789.1991; Fierer J, 2001, J CLIN INVEST, V107, P775, DOI 10.1172/JCI12561; Grob P, 1996, J BACTERIOL, V178, P1813, DOI 10.1128/jb.178.7.1813-1820.1996; Guiney DG, 2005, CLIN IMMUNOL, V114, P248, DOI 10.1016/j.clim.2004.07.014; GUINEY DG, 1995, TRENDS MICROBIOL, V3, P275, DOI 10.1016/S0966-842X(00)88944-1; Gulig PA, 1998, INFECT IMMUN, V66, P2471, DOI 10.1128/IAI.66.6.2471-2485.1998; Haug G, 2003, BIOCHEMISTRY-US, V42, P15284, DOI 10.1021/bi0354278; Haug G, 2003, J BIOL CHEM, V278, P32266, DOI 10.1074/jbc.M303980200; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; Hippenstiel S, 1997, AM J PHYSIOL-LUNG C, V272, pL38, DOI 10.1152/ajplung.1997.272.1.L38; Hippenstiel S, 2002, BIOCHEM PHARMACOL, V64, P971, DOI 10.1016/S0006-2952(02)01162-0; Hochmann H, 2006, BIOCHEMISTRY-US, V45, P1271, DOI 10.1021/bi051810w; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Libby SJ, 1997, INFECT IMMUN, V65, P1786, DOI 10.1128/IAI.65.5.1786-1792.1997; Libby SJ, 2000, CELL MICROBIOL, V2, P49, DOI 10.1046/j.1462-5822.2000.00030.x; Linseman DA, 2001, J BIOL CHEM, V276, P39123, DOI 10.1074/jbc.M103959200; Margarit SM, 2006, STRUCTURE, V14, P1219, DOI 10.1016/j.str.2006.05.022; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Otto H, 2000, MOL MICROBIOL, V37, P1106, DOI 10.1046/j.1365-2958.2000.02064.x; Pollard Thomas D, 2002, Harvey Lect, V98, P1; Rodriguez M, 1998, J CLIN MICROBIOL, V36, P3291; Schleberger C, 2006, J MOL BIOL, V364, P705, DOI 10.1016/j.jmb.2006.09.002; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Tezcan-Merdol D, 2001, MOL MICROBIOL, V39, P606, DOI 10.1046/j.1365-2958.2001.02258.x; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZEPEDA H, 1988, J PHARMACOL EXP THER, V246, P1183	36	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10272	10282		10.1074/jbc.M610254200	http://dx.doi.org/10.1074/jbc.M610254200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283073	hybrid			2022-12-27	WOS:000245941000017
J	Sheftel, AD; Kim, SF; Ponka, P				Sheftel, Alex D.; Kim, Sangwon F.; Ponka, Prem			Non-heme induction of heme oxygenase-1 does not alter cellular iron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; OXIDASE ACTIVITY; EXPRESSION; GENE; INTERLEUKIN-10; IDENTIFICATION; RETICULOCYTES; FIBROBLASTS; SUPPRESSES; INHIBITION	The catabolism of heme is carried out by members of the heme oxygenase ( HO) family. The products of heme catabolism by HO-1 are ferrous iron, biliverdin ( subsequently converted to bilirubin), and carbon monoxide. In addition to its function in the recycling of hemoglobin iron, this microsomal enzyme has been shown to protect cells in various stress models. Implicit in the reports of HO-1 cytoprotection to date are its effects on the cellular handling of heme/iron. However, the limited amount of uncommitted heme in non-erythroid cells brings to question the source of substrate for this enzyme in non-hemolytic circumstances. In the present study, HO-1 was induced by either sodium arsenite ( reactive oxygen species producer) or hemin or overexpressed in the murine macrophage-like cell line, RAW 264.7. Both of the inducers elicited an increase in active HO-1; however, only hemin exposure caused an increase in the synthesis rate of the iron storage protein, ferritin. This effect of hemin was the direct result of the liberation of iron from heme by HO. Cells stably overexpressing HO-1, although protected from oxidative stress, did not display elevated basal ferritin synthesis. However, these cells did exhibit an increase in ferritin synthesis, compared with untransfected controls, in response to hemin treatment, suggesting that heme levels, and not HO-1, limit cellular heme catabolism. Our results suggest that the protection of cells from oxidative insult afforded by HO-1 is not due to the catabolism of significant amounts of cellular heme as thought previously.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA	Lady Davis Institute; McGill University; McGill University; Johns Hopkins University	Ponka, P (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	prem.ponka@mcgill.ca	Ponka, Prem/A-4123-2011; Sheftel, Alex/GZL-8530-2022; Sheftel, Alex D/G-1043-2010	Sheftel, Alex D/0000-0002-3126-5066; Ponka, Prem/0000-0001-5835-1477	NATIONAL INSTITUTE OF MENTAL HEALTH [K99MH079614] Funding Source: NIH RePORTER; NIMH NIH HHS [K99 MH079614-02, K99 MH079614] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abraham NG, 2005, FREE RADICAL BIO MED, V39, P1, DOI 10.1016/j.freeradbiomed.2005.03.010; ALBORES A, 1992, XENOBIOTICA, V22, P591, DOI 10.3109/00498259209053122; Balla J, 2005, MOL NUTR FOOD RES, V49, P1030, DOI 10.1002/mnfr.200500076; BALLA J, 1992, T ASSOC AM PHYSICIAN, V105, P1; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; BOROVA J, 1973, BIOCHIM BIOPHYS ACTA, V320, P143, DOI 10.1016/0304-4165(73)90174-8; BOTHWELL TH, 1979, IRON METABOLISM MAN, P2; Bouchet D, 2002, TRANSPL IMMUNOL, V9, P235, DOI 10.1016/S0966-3274(02)00037-0; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; BUNN HF, 1968, J BIOL CHEM, V243, P465; Camara NOS, 2005, FREE RADICAL BIO MED, V38, P426, DOI 10.1016/j.freeradbiomed.2004.11.019; Chen SF, 2005, P NATL ACAD SCI USA, V102, P7251, DOI 10.1073/pnas.0502407102; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Graca-Souza AV, 2006, INSECT BIOCHEM MOLEC, V36, P322, DOI 10.1016/j.ibmb.2006.01.009; HAILE DJ, 1990, J BIOL CHEM, V265, P12786; Hori R, 2002, J BIOL CHEM, V277, P10712, DOI 10.1074/jbc.M107749200; Jacobs J, 1998, TOXICOL APPL PHARM, V150, P376, DOI 10.1006/taap.1998.8436; Jeong JS, 2004, J BIOL CHEM, V279, P45450, DOI 10.1074/jbc.M407562200; Kim S, 1999, J BIOL CHEM, V274, P33035, DOI 10.1074/jbc.274.46.33035; Kim YS, 2005, FREE RADICAL BIO MED, V39, P558, DOI 10.1016/j.freeradbiomed.2005.04.009; LABBE RF, 1957, BIOCHIM BIOPHYS ACTA, V26, P437, DOI 10.1016/0006-3002(57)90033-1; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; LEFF JA, 1991, J LAB CLIN MED, V118, P352; LOSONCZY G, 1982, NEPHRON, V32, P180, DOI 10.1159/000182840; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; MARTINEZ.J, 1972, BIOCHIM BIOPHYS ACTA, V264, P272, DOI 10.1016/0304-4165(72)90291-7; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; PONKA P, 1979, BIOCHIM BIOPHYS ACTA, V586, P278, DOI 10.1016/0304-4165(79)90100-4; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; SARDANA MK, 1981, PHARMACOLOGY, V23, P247, DOI 10.1159/000137557; Sassa S, 2004, ANTIOXID REDOX SIGN, V6, P819, DOI 10.1089/ars.2004.6.819; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; SNYDER WS, 1974, 23 INT COMM RAD PROT; Srisook K, 2004, BIOCHEM PHARMACOL, V68, P1709, DOI 10.1016/j.bcp.2004.07.001; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; Tsui TY, 2003, CIRCULATION, V107, P2623, DOI 10.1161/01.CIR.0000066911.03770.8D; VILE GF, 1993, J BIOL CHEM, V268, P14678; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; Woo CH, 2004, J IMMUNOL, V173, P6973, DOI 10.4049/jimmunol.173.11.6973; Wyckoff EE, 2005, J BACTERIOL, V187, P5658, DOI 10.1128/JB.187.16.5658-5664.2005; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952; Zhang AS, 2005, BLOOD, V105, P368, DOI 10.1182/blood-2004-06-2226	51	39	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10480	10486		10.1074/jbc.M700240200	http://dx.doi.org/10.1074/jbc.M700240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17242398	hybrid			2022-12-27	WOS:000245941000040
J	Rass, U; Ahel, I; West, SC				Rass, Ulrich; Ahel, Ivan; West, Stephen C.			Actions of aprataxin in multiple DNA repair pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; HISTIDINE TRIAD SUPERFAMILY; PROTEIN APRATAXIN; ATAXIA; GENE; MUTATIONS; APRAXIA; DAMAGE	Mutations in the Aptx gene lead to a neurological disorder known as ataxia oculomotor apraxia-1. The product of Aptx is Aprataxin (Aptx), a DNA-binding protein that resolves abortive DNA ligation intermediates. Aprataxin catalyzes the nucleophilic release of adenylate groups covalently linked to 5' phosphate termini, resulting in termini that can again serve as substrates for DNA ligases. Here we show that Aprataxin acts preferentially on adenylated nicks and double-strand breaks rather than on single-stranded DNA. Moreover, we show that whereas the catalytic activity of Aptx resides within the HIT domain, the C-terminal zinc finger domain provides stabilizing contacts that lock the enzyme onto its high affinity AMP-DNA target site. Both domains are therefore required for efficient AMP-DNA hydrolase activity. Additionally, we find a role for Aprataxin in base excision repair, specifically in the removal of adenylates that arise from abortive ligation reactions that take place at incised abasic sites in DNA. We suggest that Aprataxin may have a general proofreading function in DNA repair, removing DNA adenylates as they arise during single-strand break repair, double-strand break repair, and in base excision repair.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk		Rass, Ulrich/0000-0001-9275-9062; West, Stephen/0000-0001-8848-9418; Ahel, Ivan/0000-0002-9446-3756				Ahel I, 2006, NATURE, V443, P713, DOI 10.1038/nature05164; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Bogenhagen DF, 1998, J BIOL CHEM, V273, P7888, DOI 10.1074/jbc.273.14.7888; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; GOFFIN C, 1987, NUCLEIC ACIDS RES, V15, P875; Gueven N, 2004, HUM MOL GENET, V13, P1081, DOI 10.1093/hmg/ddh122; Kijas AW, 2006, J BIOL CHEM, V281, P13939, DOI 10.1074/jbc.M507946200; Le Ber I, 2003, BRAIN, V126, P2761, DOI 10.1093/brain/awg283; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Mosesso P, 2005, CELL MOL LIFE SCI, V62, P485, DOI 10.1007/s00018-004-4441-0; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Sano Y, 2004, ANN NEUROL, V55, P241, DOI 10.1002/ana.10808; Seidle HF, 2005, J BIOL CHEM, V280, P20927, DOI 10.1074/jbc.M502889200; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002	19	70	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9469	9474		10.1074/jbc.M611489200	http://dx.doi.org/10.1074/jbc.M611489200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276982	Green Accepted, hybrid			2022-12-27	WOS:000245421700019
J	Shang, X; Moon, SY; Zheng, Y				Shang, Xun; Moon, Sun Young; Zheng, Yi			p200 RhoGAP promotes cell proliferation by mediating cross-talk between Ras and Rho signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; C-SRC; TRANSFORMATION; FAMILY; DOMAIN; CDC42; RAC1; P190; RECEPTOR; CANCER	p200 RhoGAP, a member of the Rho GTPase-activating protein (RhoGAP) family, was previously implicated in the regulation of neurite outgrowth through its RhoGAP activity. Here we show that ectopic expression of p200 RhoGAP stimulates fibroblast cell proliferation and cell cycle progression, leading to transformation. The morphology of the foci induced by p200 RhoGAP is distinct from that formed by Rac or Rho activation but similar to that induced by oncogenic Ras, raising the possibility that p200 RhoGAP may engage Ras signaling. Expression of p200 RhoGAP results in a significant increase of Ras-GTP and the activation of two downstream signaling pathways of Ras, ERK1/2 and phosphatidylinositol 3-kinase. Inhibition of Ras or ERK1/2, but not phosphatidylinositol 3-kinase, effectively suppresses the foci formation induced by p200 RhoGAP, suggesting that the Ras-ERK pathway is required for p200 RhoGAP-mediated cell transformation. p200 RhoGAP co-localizes with p120 RasGAP in cells and forms a complex with p120 RasGAP, and this interaction is mediated by the C-terminal region and the Src homology 3 domain of p200 RhoGAP and p120 RasGAP, respectively. Mutations of p200 RhoGAP that disrupt interaction with p120 RasGAP abolish its Ras activation and cell transforming activities. Interestingly, the RhoGAP activity of the N-terminal RhoGAP domain in p200 RhoGAP is also required for its full transforming activity, and expression of a dominant negative RhoA mutant that blocks RhoA cycling between the GDP- and GTP-bound states suppresses p200 RhoGAP transformation. These results suggest that a Rho GTPase-activating protein may have a positive input to cell proliferation and provide evidence that p200 RhoGAP can mediate cross-talks between Ras- and Rho-regulated signaling pathways in cell growth regulation.	Univ Cincinnati, Childrens Hosp, Med Ctr, Childrens Hosp Res Fdn,Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Childrens Hosp Res Fdn,Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL CANCER INSTITUTE [R01CA105117] Funding Source: NIH RePORTER; NCI NIH HHS [CA105117] Funding Source: Medline; NIGMS NIH HHS [GM53943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jaffe AB, 2003, SCIENCE, V302, P1690, DOI 10.1126/science.1092874; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Moon SY, 2003, J BIOL CHEM, V278, P4151, DOI 10.1074/jbc.M207789200; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nakazawa T, 2003, MOL BIOL CELL, V14, P2921, DOI 10.1091/mbc.e02-09-0623; Nasu-Nishimura Y, 2006, GENES CELLS, V11, P607, DOI 10.1111/j.1365-2443.2006.00966.x; Okabe T, 2003, J BIOL CHEM, V278, P9920, DOI 10.1074/jbc.M208872200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Roof RW, 2000, FEBS LETT, V472, P117, DOI 10.1016/S0014-5793(00)01439-3; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Tcherkezian J, 2005, MOL CELL BIOL, V25, P6314, DOI 10.1128/MCB.25.15.6314-6329.2005; VAN AL, 1997, GENE DEV, V11, P2295; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wang DZM, 1997, CANCER RES, V57, P2478; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhao CM, 2003, J BIOL CHEM, V278, P34641, DOI 10.1074/jbc.M304594200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	42	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8801	8811		10.1074/jbc.M609375200	http://dx.doi.org/10.1074/jbc.M609375200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17272280	hybrid			2022-12-27	WOS:000245780300027
J	Vinci, CR; Clarke, SG				Vinci, Chris R.; Clarke, Steven G.			Recognition of age-damaged (R,S)-adenosyl-L-methionine by two methyltransferases in the yeast Saccharomyces cervisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; S-ADENOSYLMETHIONINE; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; PROTEIN METHYLATION; SULFONIUM CENTER; TRANS-ACONITATE; SPECIFICITY; REPAIR; CONFIGURATION; BIOSYNTHESIS	The biological methyl donor S-adenosylmethionine (AdoMet) can exist in two diastereoisomeric states with respect to its sulfonium ion. The S configuration, (SS)-AdoMet, is the only form that is produced enzymatically as well as the only form used in almost all biological methylation reactions. Under physiological conditions, however, the sulfonium ion can spontaneously racemize to the R form, producing (R,S)AdoMet. As of yet, (R,S)-AdoMet has no known physiological function and may inhibit cellular reactions. In this study, we found two Saccharomyces cerevisiae enzymes that are capable of recognizing (R,S)-AdoMet and using it to methylate homocysteine to form methionine. These enzymes are the products of the SAM4 and MHT1 genes, identified previously as homocysteine methyltransferases dependent upon AdoMet and S-methylmethionine, respectively. We found here that Sam4 recognizes both (S,S)- and (R,S)-AdoMet, but that its activity is much higher with the R,S form. Mht1 reacts with only the R,S form of AdoMet, whereas no activity is seen with the SS form. R,S-Specific homocysteine methyltransferase activity is also shown here to occur in extracts of A rabidopsis thaliana, Drosophila melanogaster, and Caenorhabditis elegans, but has not been detected in several tissue extracts of Mus musculus. Such activity may function to prevent the accumulation of (R,S)-AdoMet in these organisms.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, SG (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018000] Funding Source: NIH RePORTER; NIA NIH HHS [AG018000] Funding Source: Medline; NIGMS NIH HHS [GM026020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BEAUDOUIN C, 1993, J NEUROCHEM, V61, P928, DOI 10.1111/j.1471-4159.1993.tb03604.x; Bentley R, 2005, CHEM SOC REV, V34, P609, DOI 10.1039/b418284g; BORCHARDT RT, 1976, J MED CHEM, V19, P1099, DOI 10.1021/jm00231a004; Bottiglieri T, 2002, AM J CLIN NUTR, V76, p1151S, DOI 10.1093/ajcn/76.5.1151S; Cai H, 2001, BIOCHEMISTRY-US, V40, P2210, DOI 10.1021/bi0022902; Cannon LM, 2002, ANAL BIOCHEM, V308, P358, DOI 10.1016/S0003-2697(02)00267-1; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Castro C, 2004, BIOCHEMISTRY-US, V43, P5341, DOI 10.1021/bi049821x; Clarke S, 2003, AGEING RES REV, V2, P263, DOI 10.1016/S1568-1637(03)00011-4; CORNFORTH JW, 1977, J AM CHEM SOC, V99, P7292, DOI 10.1021/ja00464a032; CREASON GL, 1985, PHYTOCHEMISTRY, V24, P1151, DOI 10.1016/S0031-9422(00)81092-4; DELAHABA G, 1959, J AM CHEM SOC, V81, P3975, DOI 10.1021/ja01524a039; Evans JC, 2002, STRUCTURE, V10, P1159, DOI 10.1016/S0969-2126(02)00796-7; Fellner T, 2003, METHOD ENZYMOL, V366, P187; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Friguet B, 2006, FEBS LETT, V580, P2910, DOI 10.1016/j.febslet.2006.03.028; Garrow TA, 2006, FASEB J, V20, pA606; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; GRUESORENSEN G, 1984, J CHEM SOC PERK T 1, P1091, DOI 10.1039/p19840001091; Hanna GM, 2004, PHARMAZIE, V59, P251; Hernebring M, 2006, P NATL ACAD SCI USA, V103, P7700, DOI 10.1073/pnas.0510944103; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Jiracek J, 2006, J MED CHEM, V49, P3982, DOI 10.1021/jm050885v; KAGAN RM, 1995, BIOCHEMISTRY-US, V34, P10794, DOI 10.1021/bi00034a012; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Loenen WAM, 2006, BIOCHEM SOC T, V34, P330, DOI 10.1042/BST0340330; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; LOUGHLIN RE, 1964, J BIOL CHEM, V239, P2888; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; McCarthy DL, 2001, BIOCHEMISTRY-US, V40, P12276, DOI 10.1021/bi011050z; Miranda TB, 2004, FEBS LETT, V577, P181, DOI 10.1016/j.febslet.2004.09.080; Neuhierl B, 1999, J BIOL CHEM, V274, P5407, DOI 10.1074/jbc.274.9.5407; Peariso K, 1998, J AM CHEM SOC, V120, P8410, DOI 10.1021/ja980581g; Porras-Yakushi TR, 2005, J BIOL CHEM, V280, P34590, DOI 10.1074/jbc.M507672200; Ranocha P, 2000, J BIOL CHEM, V275, P15962, DOI 10.1074/jbc.M001116200; Ranocha P, 2001, PLANT J, V25, P575, DOI 10.1046/j.1365-313x.2001.00988.x; REBHOLZ KL, 1994, ARCH BIOCHEM BIOPHYS, V312, P227, DOI 10.1006/abbi.1994.1303; SATOH S, 1989, PLANT PHYSIOL, V91, P1036, DOI 10.1104/pp.91.3.1036; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; SHAPIRO SK, 1964, J BIOL CHEM, V239, P1551; Thomas D, 2000, J BIOL CHEM, V275, P40718, DOI 10.1074/jbc.M005967200; Urdiales JL, 2001, EUR J GASTROEN HEPAT, V13, P1015, DOI 10.1097/00042737-200109000-00003; Veiga-Da-Cunha M, 2006, BIOCHEM J, V399, P257, DOI 10.1042/BJ20060684; Villa ST, 2006, PHYSIOL PLANTARUM, V128, P581, DOI 10.1111/j.1399-3054.2006.00772.x; WU SE, 1983, BIOCHEMISTRY-US, V22, P2828, DOI 10.1021/bi00281a009; ZAPPIA V, 1969, BIOCHIM BIOPHYS ACTA, V178, P185, DOI 10.1016/0005-2744(69)90147-8	52	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8604	8612		10.1074/jbc.M610029200	http://dx.doi.org/10.1074/jbc.M610029200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264075	hybrid			2022-12-27	WOS:000245780300006
J	Zhang, CK; Ng, KL; Li, JD; He, F; Anderson, DJ; Sun, YE; Zhou, QY				Zhang, Chengkang; Ng, Kwan L.; Li, Jia-Da; He, Fei; Anderson, David J.; Sun, Yi E.; Zhou, Qun-Yong			Prokineticin 2 is a target gene of proneural basic helix-loop-helix factors for olfactory bulb neurogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ADULT MAMMALIAN BRAIN; SUBVENTRICULAR ZONE; MIGRATION; EXPRESSION; RECEPTORS; NEURONS; CELLS; IDENTIFICATION; PROGENITORS	Prokineticin 2, a cysteine-rich secreted protein, regulates diverse biological functions including the neurogenesis of olfactory bulb. Here we show that the PK2 gene is a functional target gene of proneural basic helix-loop-helix (bHLH) factors. Neurogenin 1 and MASH1 activate PK2 transcription by binding to E-box motifs on the PK2 promoter with the same set of E-boxes critical for another pair of bHLH factors, CLOCK and BMAL1, in the regulation of circadian clock. Our results establish PK2 as a common functional target gene for different bHLH transcriptional factors in mediating their respective functions.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Pharmacol, Los Angeles, CA 90095 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Zhou, QY (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.	qzhou@uci.edu	ZHANG, CHENGKANG/A-8141-2008	Li, Jia-Da/0000-0002-4236-3518; Zhang, Chengkang/0000-0002-3746-2095				Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Cheng MY, 2006, J COMP NEUROL, V498, P796, DOI 10.1002/cne.21087; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Ge WH, 2006, P NATL ACAD SCI USA, V103, P1319, DOI 10.1073/pnas.0510419103; Hand R, 2005, NEURON, V48, P45, DOI 10.1016/j.neuron.2005.08.032; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; LeCouter J, 2004, P NATL ACAD SCI USA, V101, P16813, DOI 10.1073/pnas.0407697101; LeCouter J, 2003, P NATL ACAD SCI USA, V100, P2685, DOI 10.1073/pnas.0337667100; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lin DCH, 2002, J BIOL CHEM, V277, P19276, DOI 10.1074/jbc.M202139200; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Ma QF, 1999, GENE DEV, V13, P1717, DOI 10.1101/gad.13.13.1717; Murray RC, 2003, J NEUROSCI, V23, P1769; Ng KL, 2005, SCIENCE, V308, P1923, DOI 10.1126/science.1112103; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Pattyn A, 2004, NAT NEUROSCI, V7, P589, DOI 10.1038/nn1247; RICHARDSON A, 2001, PROTOCOLS NEURAL CEL, P173; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Zhang CK, 2005, BIOCHEM J, V386, P161, DOI 10.1042/BJ20041514	29	32	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6917	6921		10.1074/jbc.C600290200	http://dx.doi.org/10.1074/jbc.C600290200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17259180	hybrid, Green Accepted			2022-12-27	WOS:000245080900002
J	Li, SY; Gruschow, S; Dordick, JS; Sherman, DH				Li, Shengying; Gruschow, Sabine; Dordick, Jonathan S.; Sherman, David H.			Molecular analysis of the role of tyrosine 224 in the active site of Streptomyces coelicolor RppA, a bacterial type III polyketide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; CHALCONE SYNTHASE; SUBSTRATE-SPECIFICITY; PSEUDOMONAS-FLUORESCENS; BIOSYNTHESIS; PATHWAY; ANTIBIOTICS; MANIPULATION; SUPERFAMILY; METABOLITES	Streptomyces coelicolor RppA (Sc-RppA), a bacterial type III polyketide synthase, utilizes malonyl-CoA as both starter and extender unit substrate to form 1,3,6,8-tetrahydroxynaphthalene (THN) (therefore RppA is also known as THN synthase (THNS)). The significance of the active site Tyr224 for substrate specificity has been established previously, and its aromatic ring is believed to be essential for RppA to select malonyl-CoA as starter unit. Herein, we describe a series of Tyr224 mutants of Sc-RppA including Y224F, Y224L, Y224C, Y224M, and Y224A that were able to catalyze a physiological assembly of THN, albeit with lower efficiency, challenging the necessity for the Tyr224 aromatic ring. Steady-state kinetics and radioactive substrate binding analysis of the mutant enzymes corroborated these unexpected results. Functional examination of the Tyr224 series of RppA mutants using diverse unnatural acyl-CoA substrates revealed the unique role of malonyl-CoA as starter unit substrate for RppA, leading to the development of a novel steric-electronic constraint model.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Rensselaer Polytech Inst, Dept Biol & Chem Engn, Troy, NY 12180 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Rensselaer Polytechnic Institute	Sherman, DH (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	davidhs@umich.edu			PHS HHS [M66712] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abe I, 2005, J AM CHEM SOC, V127, P12709, DOI 10.1021/ja053945v; Abe I, 2005, J AM CHEM SOC, V127, P1362, DOI 10.1021/ja0431206; Abe I, 2004, FEBS LETT, V562, P171, DOI 10.1016/S0014-5793(04)00230-3; Achkar J, 2005, J AM CHEM SOC, V127, P5332, DOI 10.1021/ja042340g; Akiyama T, 1999, EUR J BIOCHEM, V263, P834, DOI 10.1046/j.1432-1327.1999.00562.x; Austin MB, 2004, J BIOL CHEM, V279, P45162, DOI 10.1074/jbc.M406567200; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Bangera MG, 1999, J BACTERIOL, V181, P3155, DOI 10.1128/JB.181.10.3155-3163.1999; Eckermann S, 1998, NATURE, V396, P387, DOI 10.1038/24652; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2002, J BIOL CHEM, V277, P4628, DOI 10.1074/jbc.M110357200; Funa N, 2002, BIOCHEM J, V367, P781, DOI 10.1042/BJ20020953; Gerth K, 2003, J BIOTECHNOL, V106, P233, DOI 10.1016/j.jbiotec.2003.07.015; Gross F, 2006, ARCH MICROBIOL, V185, P28, DOI 10.1007/s00203-005-0059-3; HAHLBROCK K, 1972, H-S Z PHYSIOL CHEM, V353, P1522; HELARIUTTA Y, 1995, PLANT MOL BIOL, V28, P47, DOI 10.1007/BF00042037; HELLER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P617, DOI 10.1016/0003-9861(80)90395-1; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Izumikawa M, 2003, J IND MICROBIOL BIOT, V30, P510, DOI 10.1007/s10295-003-0075-8; Jeong JC, 2005, J AM CHEM SOC, V127, P64, DOI 10.1021/ja0441559; Jez JM, 2000, CHEM BIOL, V7, P919, DOI 10.1016/S1074-5521(00)00041-7; Jez JM, 2001, BIOCHEMISTRY-US, V40, P14829, DOI 10.1021/bi015621z; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Li TL, 2001, CHEM COMMUN, P2156, DOI 10.1039/b106638b; Moore BS, 2001, CHEMBIOCHEM, V2, P35, DOI 10.1002/1439-7633(20010105)2:1<35::AID-CBIC35>3.3.CO;2-T; Paniego NB, 1999, EUR J BIOCHEM, V262, P612, DOI 10.1046/j.1432-1327.1999.00444.x; Pfeifer V, 2001, J BIOL CHEM, V276, P38370, DOI 10.1074/jbc.M106580200; Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; Seshime Y, 2005, BIOCHEM BIOPH RES CO, V331, P253, DOI 10.1016/j.bbrc.2005.03.160; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Tseng CC, 2004, BIOCHEMISTRY-US, V43, P970, DOI 10.1021/bi035714b; Zha WJ, 2006, J BIOL CHEM, V281, P32036, DOI 10.1074/jbc.M606500200	33	14	15	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12765	12772		10.1074/jbc.M700393200	http://dx.doi.org/10.1074/jbc.M700393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331946	hybrid			2022-12-27	WOS:000245942800047
J	Theiss, AL; Obertone, TS; Merlin, D; Sitaraman, SV				Theiss, Arianne L.; Obertone, Tracy S.; Merlin, Didier; Sitaraman, Shanthi V.			Interleukin-6 transcriptionally regulates prohibitin expression in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTIC ACTIVATION; INFLAMMATORY RESPONSES; ULCERATIVE-COLITIS; ORAL INTERLEUKIN-6; HEMORRHAGIC-SHOCK; PROTECTIVE ROLE; CROHNS-DISEASE; GROWTH-FACTOR; IL-6; GENE	Prohibitin (PHB) is a highly conserved protein that has multiple functions in the cell. We recently demonstrated that PHB plays an important role in combating oxidative stress and its expression is down-regulated in human and animal models of inflammatory bowel disease. Little is known regarding the regulation of PHB expression in intestine or other tissues. In this study we examined the regulation of PHB expression in intestinal epithelial cells using the model cell line Caco2-BBE. We successfully cloned the 1192-bp human PHB promoter region and identified the transcription start site 1594 bp upstream from the translation start site due to an intervening intron. We show that the acute phase cytokine interleukin-6 (IL-6) increases PHB protein and mRNA abundance and induces PHB promoter activation. The IL-6 response element site in the PHB promoter is required for maximal basal promoter activity and responsiveness to IL-6. IL-6 also increases binding of nuclear proteins to the IL-6 response element in the PHB promoter that are super-shifted by a STAT3 antibody. Both basal promoter activity and IL-6 responsiveness are attenuated by signal transducer and activator of transcription 3 short interference RNA, suggesting that signal transducer and activator of transcription 3 mediates PHB activity by IL-6. Confirming these in vitro results, IL-6(-/-) mice exhibit reduced PHB expression in the colon compared with wild-type mice. These results suggest that IL-6 modulates PHB expression in cultured intestinal epithelial cells and in the intestine in vivo.	Emory Univ, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA	Emory University	Theiss, AL (corresponding author), Emory Univ, Dept Med, Div Digest Dis, 615 Michael St,Whitehead Biomed Res Bldg 265, Atlanta, GA 30322 USA.	atheiss@emory.edu		Theiss, Arianne/0000-0003-2862-0933	NIDDK NIH HHS [F32-DK076243-01, R01-DK061941-02, R01-DK06411, R24-DK064399] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061941, F32DK076243, R24DK064399] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256; Chen JC, 2005, PLANT J, V44, P16, DOI 10.1111/j.1365-313X.2005.02505.x; DellOrco RT, 1996, EXP GERONTOL, V31, P245, DOI 10.1016/0531-5565(95)02009-8; Dignass AU, 2004, ALIMENT PHARM THER, V20, P9, DOI 10.1111/j.1365-2036.2004.02047.x; Dube PH, 2004, INFECT IMMUN, V72, P3561, DOI 10.1128/IAI.72.6.3561-3570.2004; El-Assal O, 2004, CELL MOL IMMUNOL, V1, P205; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; Fujii H, 2003, CRIT CARE MED, V31, P893, DOI 10.1097/01.CCM.0000050442.54044.06; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Hack V, 1996, FASEB J, V10, P1219, DOI 10.1096/fasebj.10.10.8751725; He QY, 2004, PROTEOMICS, V4, P3276, DOI 10.1002/pmic.200300916; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Hsieh SY, 2006, PROTEOMICS, V6, P5322, DOI 10.1002/pmic.200500541; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; Joshi B, 2007, BIOCHEM J, V401, P155, DOI 10.1042/BJ20060364; Kasutani K, 1998, TOXICOL APPL PHARM, V151, P143, DOI 10.1006/taap.1998.8452; Kida H, 2005, AM J PHYSIOL-LUNG C, V288, pL342, DOI 10.1152/ajplung.00016.2004; Kimizuka K, 2004, AM J TRANSPLANT, V4, P482, DOI 10.1111/j.1600-6143.2004.00368.x; Kojima H, 1996, ONCOGENE, V12, P547; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; LEGGETT B, 1995, BRIT J CANCER, V71, P1070, DOI 10.1038/bjc.1995.206; Louis E, 1997, EUR J GASTROEN HEPAT, V9, P939, DOI 10.1097/00042737-199710000-00004; Manjeshwar S, 2003, CANCER RES, V63, P5251; Nakajima A, 2002, FREE RADICAL BIO MED, V32, P1324, DOI 10.1016/S0891-5849(02)00845-6; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Panja A, 1998, J IMMUNOL, V161, P3675; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rastogi S, 2006, J BIOL CHEM, V281, P2951, DOI 10.1074/jbc.M508669200; Reinisch W, 1999, AM J GASTROENTEROL, V94, P2156; Rockman SP, 2001, J GASTROEN HEPATOL, V16, P991, DOI 10.1046/j.1440-1746.2001.02588.x; Rollwagen FM, 1996, CYTOKINE, V8, P121, DOI 10.1006/cyto.1996.0017; Rollwagen FM, 1997, MIL MED, V162, P366, DOI 10.1093/milmed/162.5.366; Russell DL, 1996, BIOL REPROD, V55, P1029, DOI 10.1095/biolreprod55.5.1029; Ryu JW, 2003, J KOREAN MED SCI, V18, P505, DOI 10.3346/jkms.2003.18.4.505; SATO M, 1995, ARCH BIOCHEM BIOPHYS, V316, P738, DOI 10.1006/abbi.1995.1098; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Theiss AL, 2007, FASEB J, V21, P197, DOI 10.1096/fj.06-6801com; Tsai HW, 2006, HUM PATHOL, V37, P198, DOI 10.1016/j.humpath.2005.10.012; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Yamamoto M, 2000, J IMMUNOL, V164, P4878, DOI 10.4049/jimmunol.164.9.4878; Yeo M, 2006, PROTEOMICS, V6, P1158, DOI 10.1002/pmic.200500390; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	48	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12804	12812		10.1074/jbc.M609031200	http://dx.doi.org/10.1074/jbc.M609031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324931	hybrid			2022-12-27	WOS:000245942800052
J	Hong, S; Wang, LC; Gao, X; Kuo, YL; Liu, BY; Merling, R; Kung, HJ; Shih, HM; Giam, CZ				Hong, Sohee; Wang, Ling-Chi; Gao, Xiang; Kuo, Yu-Liang; Liu, Baoying; Merling, Randall; Kung, Hsing-Jien; Shih, Hsiu-Ming; Giam, Chou-Zen			Heptad repeats regulate protein phosphatase 2A recruitment to I-kappa B kinase gamma/NF-kappa B essential modulator and are targeted by human T-lymphotropic virus type 1 tax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-GAMMA; PERSISTENT ACTIVATION; TRANSFORMING PROTEIN; COMPLEX ACTIVITY; TNF-ALPHA; NEMO; UBIQUITINATION; PHOSPHORYLATION; OLIGOMERIZATION; IDENTIFICATION	The switching on-and-off of I-kappa B kinase (IKK) and NF-kappa B occurs rapidly after signaling. How activated IKK becomes down-regulated is not well understood. Here we show that following tumor necrosis factor-alpha stimulation, protein phosphatase 2A (PP2A) association with IKK is increased. A heptad repeat in IKK gamma, helix 2 (HLX2), mediates PP2A recruitment. Two other heptad repeats downstream of HLX2, termed coiled-coil region 2 (CCR2) and leucine zipper (LZ), bind HLX2 and negatively regulate HLX2 interaction with PP2A. HTLV-1 transactivator Tax also binds HLX2, and this interaction is enhanced by CCR2 but reduced by LZ. In the presence of Tax, PP2A-IKK gamma binding is greatly strengthened. Interestingly, peptides spanning CCR2 and/or LZ disrupt IKK gamma Tax and IKK gamma-PP2A interactions and potently inhibit NF-kappa B activation by Tax and tumor necrosis factor-alpha. We propose that when IKK is resting, HLX2, CCR2, and LZ form a helical bundle in which HLX2 is sequestered. The HLX2-CCR2-LZ bundle becomes unfolded by signal-induced modifications of IKK gamma or after Tax binding. In this conformation, IKK becomes activated. IKK gamma then recruits PP2A via the exposed HLX2 domain for rapid down-regulation of IKK. Tax-PP2A interaction, however, renders PP2A inactive, thus maintaining Tax-PP2A-IKK in an active state. Finally, CCR2 and LZ possibly inhibit IKK activation by stabilizing the HLX2-CCR2-LZ bundle.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	Uniformed Services University of the Health Sciences - USA; National Health Research Institutes - Taiwan; University of California System; University of California Davis	Giam, CZ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	cgiam@usuhs.mil	Kung, Hsing-Jien/C-7651-2013; Shih, Hsiu-Ming/S-7023-2018					Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Cheong R, 2006, J BIOL CHEM, V281, P2945, DOI 10.1074/jbc.M510085200; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McDonnell AV, 2006, BIOINFORMATICS, V22, P356, DOI 10.1093/bioinformatics/bti797; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SUNG SSJ, 1992, J EXP MED, V176, P897, DOI 10.1084/jem.176.3.897; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	35	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12119	12126		10.1074/jbc.M610392200	http://dx.doi.org/10.1074/jbc.M610392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314097	hybrid			2022-12-27	WOS:000245941900054
J	Kobayashi, N; Kostka, G; Garbe, JHO; Keene, DR; Bachinger, HP; Hanisch, FG; Markova, D; Tsuda, T; Timpl, R; Chu, ML; Sasaki, T				Kobayashi, Naoyuki; Kostka, Guenter; Garbe, Joerg H. O.; Keene, Douglas R.; Baechinger, Hans Peter; Hanisch, Franz-Georg; Markova, Dessislava; Tsuda, Takeshi; Timpl, Rupert; Chu, Mon-Li; Sasaki, Takako			A comparative analysis of the fibulin protein family - Biochemical characterization, binding interactions, and tissue localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; HONEYCOMB RETINAL DYSTROPHY; MESSENGER-RNA EXPRESSION; COLLAGEN TYPE-IV; CALCIUM-BINDING; CUTIS LAXA; IN-VIVO; STRUCTURAL CHARACTERIZATION; PERINATAL LETHALITY; ADHESIVE PROPERTIES	Fibulins are a family of five extracellular matrix proteins characterized by tandem arrays of epidermal growth factor-like domains and a C-terminal fibulin-type module. They are widely distributed and often associated with vasculature and elastic tissues. In this study, we expressed the three more recently identified family members, fibulin-3, fibulin-4, and fibulin-5, as recombinant proteins in mammalian cells. The purified proteins showed short rod structures of similar to 20 nm with a globule at one end, after rotary shadowing and electron microscopy. Two forms of mouse fibulin-3 were purified, and the O-glycan profiles of the larger form were characterized. Polyclonal antibodies raised against the purified proteins did not show any cross-reactivity with other family members and were used to assess the levels and localization of the fibulins in mouse tissues. Their binding interactions, cell adhesive properties, and tissue localization were analyzed in parallel with the previously characterized fibulin-1 and -2. Binding to tropoelastin was strong for fibulin-2 and -5, moderate for fibulin-4 and -1, and relatively weak for fibulin-3. Fibulin-4, but not fibulin-3 and -5, exhibited distinct interactions with collagen IV and nidogen-2 and moderate binding to the endostatin domain from collagen XV. Cell adhesive activities were not observed for all fibulins, except mouse fibulin-2, with various cell lines tested. All five fibulins were found in perichondrium and various regions of the lungs. Immunoelectron microscopy localized fibulin-4 and -5 to fibrillin microfibrils at distinct locations. Our studies suggest there are unique and redundant functions shared by these structurally related proteins.	Shriners Hosp Children, Portland, OR 97239 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Cologne, Inst Biochem 2, Fac Med, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Alfred I DuPont Hosp Children, Nemours Cardiac Ctr & Nemours Biomed Res, Wilmington, DE 19899 USA	Max Planck Society; Oregon Health & Science University; University of Cologne; University of Cologne; Jefferson University; Nemours Alfred I. duPont Hospital for Children	Sasaki, T (corresponding author), Shriners Hosp Children, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	txs@shcc.org			NIGMS NIH HHS [GM55625] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055625] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albig AR, 2006, CANCER RES, V66, P2621, DOI 10.1158/0008-5472.CAN-04-4096; Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; AUMAILLEY M, 1991, EXP CELL RES, V196, P177, DOI 10.1016/0014-4827(91)90248-S; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BarShavit R, 1996, J CELL BIOCHEM, V61, P278, DOI 10.1002/(SICI)1097-4644(19960501)61:2<278::AID-JCB11>3.0.CO;2-I; Blackburn J, 2003, INVEST OPHTH VIS SCI, V44, P4613, DOI 10.1167/iovs.03-0112; BODE W, 1992, PROTEIN SCI, V1, P426; Chu Mon-Li, 2004, Birth Defects Res C Embryo Today, V72, P25, DOI 10.1002/bdrc.20003; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Ehlermann J, 2003, GENE EXPR PATTERNS, V3, P441, DOI 10.1016/S1567-133X(03)00084-X; El-Hallous E, 2007, J BIOL CHEM, V282, P8935, DOI 10.1074/jbc.M608204200; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; Engelmann K, 2005, GLYCOBIOLOGY, V15, P1111, DOI 10.1093/glycob/cwi099; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Freeman LJ, 2005, BIOCHEM J, V388, P1, DOI 10.1042/BJ20050368; Gallagher WM, 1999, ONCOGENE, V18, P3608, DOI 10.1038/sj.onc.1202937; Gallagher WM, 2001, FEBS LETT, V489, P59, DOI 10.1016/S0014-5793(00)02389-9; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Hucthagowder V, 2006, AM J HUM GENET, V78, P1075, DOI 10.1086/504304; Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kostka G, 2001, MOL CELL BIOL, V21, P7025, DOI 10.1128/MCB.21.20.7025-7034.2001; Kowal RC, 1999, CIRC RES, V84, P1166, DOI 10.1161/01.RES.84.10.1166; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113; Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; McLaughlin PJ, 2006, MOL CELL BIOL, V26, P1700, DOI 10.1128/MCB.26.5.1700-1709.2006; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PFAFF M, 1995, EXP CELL RES, V219, P87, DOI 10.1006/excr.1995.1208; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611; Sasaki T, 1996, J CELL SCI, V109, P2895; Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9; Sasaki T, 2000, J MOL BIOL, V301, P1179, DOI 10.1006/jmbi.2000.3996; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; Schulz BL, 2002, ANAL CHEM, V74, P6088, DOI 10.1021/ac025890a; Schulze B, 1996, MATRIX BIOL, V15, P349, DOI 10.1016/S0945-053X(96)90138-9; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833; TIMPL R, 1987, METHOD ENZYMOL, V145, P363; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Tsuda T, 2001, DEV DYNAM, V222, P89, DOI 10.1002/dvdy.1172; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zhang HY, 1996, DEV DYNAM, V205, P348, DOI 10.1002/(SICI)1097-0177(199603)205:3<348::AID-AJA13>3.0.CO;2-0; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	64	188	196	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11805	11816		10.1074/jbc.M611029200	http://dx.doi.org/10.1074/jbc.M611029200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324935	hybrid			2022-12-27	WOS:000245941900023
J	Wu, ATH; Sutovsky, P; Manandhar, G; Xu, W; Katayama, M; Day, BN; Park, KW; Yi, YJ; Xi, YW; Prather, RS; Oko, R				Wu, Alexander T. H.; Sutovsky, Peter; Manandhar, Gaurishankar; Xu, Wei; Katayama, Mika; Day, Billy N.; Park, Kwang-Wook; Yi, Young-Joo; Xi, Yan Wei; Prather, Randall S.; Oko, Richard			PAWP, a sperm-specific WW domain-binding protein, promotes meiotic resumption and pronuclear development during fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; TRIGGERS CA2+ OSCILLATIONS; PROLINE-RICH MOTIFS; PERINUCLEAR THECA; OOCYTE ACTIVATION; CELL-CYCLE; BOVINE SPERMIOGENESIS; BETA-DYSTROGLYCAN; PHOSPHOLIPASE-C; LIDDLE SYNDROME	We report a novel alkaline extractable protein of the sperm head that exclusively resides in the post-acrosomal sheath region of the perinuclear theca (PT) and is expressed and assembled in elongating spermatids. It is a protein that shares sequence homology to the N-terminal half of WW domain-binding protein 2, while the C-terminal half is unique and rich in proline. A functional PPXY consensus binding site for group-I WW domain-containing proteins, and numerous unique repeating motifs, YGXPPXG, are identified in the proline-rich region. Considering these molecular characteristics, we designated this protein PAWP for postacrosomal sheath WW domain-binding protein. Microinjection of recombinant PAWP or alkaline PT extract into metaphase II-arrested porcine, bovine, macaque, and Xenopus oocytes induced a high rate of pronuclear formation, which was prevented by co-injection of a competitive PPXY motif containing peptide derived from PAWP but not by co-injection of the point-mutated peptide. Intracytoplasmic sperm injection (ICSI) of porcine oocytes combined with co-injection of the competitive PPXY peptide or an anti-recombinant PAWP antiserum prevented pronuclear formation and arrested fertilization. Conversely, co-injection of the modified PPXY peptide, when the tyrosine residue of PPXY was either phosphorylated or substituted with phenylalanine, did not prevent ICSI-induced fertilization. This study uncovers a group IWW domain module signal transduction event within the fertilized egg that appears compulsory for meiotic resumption and pronuclear development during egg activation and provides compelling evidence that a PPXY motif of sperm-contributed PAWP can trigger these events.	Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Obstet & Gynecol, Columbia, MO 65211 USA; Univ Ottawa, Dept Biol, Ctr Adv Res Environm Genom, Ottawa, ON K1N 6N5, Canada	Queens University - Canada; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Ottawa	Oko, R (corresponding author), Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada.	ro3@post.queensu.ca	Prather, Randall S/B-4528-2012	Sutovsky, Peter/0000-0002-9231-2823; Prather, Randall/0000-0002-6012-4035; Wu, Alexander/0000-0002-0178-6530				Abeydeera LR, 1997, BIOL REPROD, V57, P729, DOI 10.1095/biolreprod57.4.729; Adenot PG, 1997, DEVELOPMENT, V124, P4615; Aul RB, 2002, DEV BIOL, V242, P268, DOI 10.1006/dbio.2002.0575; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cox LJ, 2002, REPRODUCTION, V124, P611, DOI 10.1530/rep.0.1240611; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Heid HW, 2002, EXP CELL RES, V279, P177, DOI 10.1006/excr.2002.5603; Herrada G, 1997, J CELL SCI, V110, P1543; Heyers S, 2000, MOL CELL ENDOCRINOL, V166, P51, DOI 10.1016/S0303-7207(00)00297-5; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Ilsley JL, 2001, CELL SIGNAL, V13, P625, DOI 10.1016/S0898-6568(01)00188-7; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kimura Y, 1998, BIOL REPROD, V58, P1407, DOI 10.1095/biolreprod58.6.1407; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; Kurokawa M, 2005, DEV BIOL, V285, P376, DOI 10.1016/j.ydbio.2005.06.029; Lecuyer C, 2000, BIOL REPROD, V63, P1801, DOI 10.1095/biolreprod63.6.1801; Ma CQ, 2006, CURR BIOL, V16, P214, DOI 10.1016/j.cub.2005.11.067; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; OKO R, 1995, MICROSC RES TECHNIQ, V32, P520, DOI 10.1002/jemt.1070320605; OKO R, 1994, BIOL REPROD, V50, P1000, DOI 10.1095/biolreprod50.5.1000; OKO R, 2001, ANDROLOGY 21 CENTURY, P37; Perry ACF, 1999, BIOL REPROD, V60, P747, DOI 10.1095/biolreprod60.3.747; Rousseaux-Preost R, 2003, BIOCHEM BIOPH RES CO, V303, P182, DOI 10.1016/S0006-291X(03)00317-6; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Schultz RM, 2002, HUM REPROD UPDATE, V8, P323, DOI 10.1093/humupd/8.4.323; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Sette C, 1997, DEVELOPMENT, V124, P2267; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sutovsky P, 1999, HUM REPROD, V14, P2301, DOI 10.1093/humrep/14.9.2301; Sutovsky P, 1998, J CELL SCI, V111, P2841; Sutovsky P, 1997, DEV BIOL, V188, P75, DOI 10.1006/dbio.1997.8618; Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P362, DOI 10.1002/jemt.10350; Swann K, 2004, REPRODUCTION, V127, P431, DOI 10.1530/rep.1.00169; Talmor-Cohen A, 2004, REPRODUCTION, V127, P455, DOI 10.1530/rep.1.00104; Tovich PR, 2004, BIOL REPROD, V71, P1182, DOI 10.1095/biolreprod.104.030445; Tovich PR, 2003, J BIOL CHEM, V278, P32431, DOI 10.1074/jbc.M303786200; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; Whitaker M, 2006, PHYSIOL REV, V86, P25, DOI 10.1152/physrev.00023.2005; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551	45	129	138	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12164	12175		10.1074/jbc.M609132200	http://dx.doi.org/10.1074/jbc.M609132200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17289678	hybrid			2022-12-27	WOS:000245941900059
J	Jansen, S; Callewaert, N; Dewerte, I; Andries, M; Ceulemans, H; Bollen, M				Jansen, Silvia; Callewaert, Nico; Dewerte, Isabelle; Andries, Maria; Ceulemans, Hugo; Bollen, Mathieu			An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; NUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE; I-ALPHA/AUTOTAXIN; N-GLYCOSYLATION; PROTEIN; IDENTIFICATION; MOTILITY; CELLS; PYROPHOSPHATASES/PHOSPHODIESTERASES; PHOSPHODIESTERASE	Autotaxin/NPP2, a secreted lysophospholipase-D, promotes cell proliferation, survival, and motility by generating the signaling molecule lysophosphatidic acid. Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 ( NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524. Mutagenesis and deglycosylation experiments revealed that only the glycosylation of Asn-524 is essential for the expression of the catalytic and motility-stimulating activities of NPP2. The N-glycan on Asn-524 was identified as Man(8/9)GlcNAc(2), which is rarely present on mature eukaryotic glycoproteins. Additional studies show that this Asn-524-linked glycan is not accessible to alpha-1,2-mannosidase, suggesting that its non-reducing termini are buried inside the folded protein. Consistent with a structural role for the Asn-524-linked glycan, only the mutation of Asn-524 augmented the sensitivity of NPP2 to proteolysis and increased its mobility during Blue Native PAGE. Asn-524 is phylogenetically conserved and maps to the catalytic domain of NPP2, but a structural model of this domain suggests that Asn-524 is remote from the catalytic site. Our study defines an essential role for the Asn-524-linked glycan chain of NPP2.	Katholieke Univ Leuven, Fac Med, Lab Biosignaling & Therapeut, Dept Mol Cellular Biol, B-3000 Louvain, Belgium; Univ Ghent VIB, Unit Mol Glycobiol, DMBRVIB & LProbe, B-9052 Ghent, Belgium	KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University	Bollen, M (corresponding author), Katholieke Univ Leuven, Afdeling Biochem, Campus Gasthuisberg,Here Str 49, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.kuleuven.be	Nabi, Ambreen/AED-3676-2022	Nabi, Ambreen/0000-0003-1899-363X; Callewaert, Nico/0000-0003-2069-6917; Ceulemans, Hugo/0000-0002-7059-4399				Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Cimpean A, 2004, BIOCHEM J, V381, P71, DOI 10.1042/BJ20040465; Clark RAC, 1998, J NEUROCHEM, V70, P2594; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fox MA, 2004, MOL CELL NEUROSCI, V27, P140, DOI 10.1016/j.mcn.2004.06.002; Fox MA, 2003, MOL CELL NEUROSCI, V23, P507, DOI 10.1016/S1044-7431(03)00073-3; Gijsbers R, 2003, BIOCHEM J, V371, P321, DOI 10.1042/BJ20021943; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; Jansen S, 2005, J CELL SCI, V118, P3081, DOI 10.1242/jcs.02438; Koike S, 2006, GENES CELLS, V11, P133, DOI 10.1111/j.1365-2443.2006.00924.x; Laroy W, 2006, NAT PROTOC, V1, P397, DOI 10.1038/nprot.2006.60; Maras M, 2000, J BIOTECHNOL, V77, P255, DOI 10.1016/S0168-1656(99)00222-9; Meerson NR, 2000, J CELL SCI, V113, P4193; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; OBE Y, 2003, BIOCHEM BIOPH RES CO, V308, P719; Roth J, 2002, CHEM REV, V102, P285, DOI 10.1021/cr000423j; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SKIPPER R, 1989, J HISTOTECHNOL, V12, P303; Stefan C, 2005, TRENDS BIOCHEM SCI, V30, P542, DOI 10.1016/j.tibs.2005.08.005; STRACKE ML, 1995, MELANOMA RES, V5, P203, DOI 10.1097/00008390-199508000-00001; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Tyagarajan K, 1997, BIOCHEMISTRY-US, V36, P10200, DOI 10.1021/bi9706125; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2005, J BIOL CHEM, V280, P21155, DOI 10.1074/jbc.M413183200; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Wu J, 2005, BIOCHEM J, V386, P153, DOI 10.1042/BJ20041455; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Zalatan JG, 2006, BIOCHEMISTRY-US, V45, P9788, DOI 10.1021/bi060847t	34	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11084	11091		10.1074/jbc.M611503200	http://dx.doi.org/10.1074/jbc.M611503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307740	hybrid			2022-12-27	WOS:000245941500029
J	Umeda-Kameyama, Y; Tsuda, M; Ohkura, C; Matsuo, T; Namba, Y; Ohuchi, Y; Aigaki, T				Umeda-Kameyama, Yumi; Tsuda, Manabu; Ohkura, Chiaki; Matsuo, Takashi; Namba, Yoshio; Ohuchi, Yasuyoshi; Aigaki, Toshiro			Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; PROTEIN; STRESS; MODEL; DISEASE; CELLS; DEGENERATION; DEGRADATION; SUBSTRATE; APOPTOSIS	Parkin-associated endothelin receptor-like receptor ( Pael-R) is a substrate of the E3 ubiquitin ligase Parkin, which has been implicated in the pathogenesis of Parkinson disease. Misexpression of human Pael-R in Drosophila has been shown to induce selective loss of dopaminergic neurons, a symptom of Parkinson disease. Using this model, we investigated whether thioredoxin ( TRX), an evolutionarily conserved antioxidant and molecular chaperone, could suppress the neurotoxicity induced by Pael-R. The Drosophila genome contains three TRX-encoding genes, namely TrxT, Trx-2, and dhd. When each of the TRX genes was overexpressed together with Pael-R in all neurons, the number of dopaminergic neurons and level of locomotor activity were significantly increased compared with control flies. To assess the role of the antioxidant activity of TRX in this context, we generated redox-defective mutants, TrxT( C35A) and TrxT( D26A/K57I), and coexpressed each of them with Pael-R. The mutants suppressed the Pael-R neurotoxicity similarly to wild-type TrxT, although the extent of the rescue was slightly reduced for the locomotor activity. We confirmed that both mutants remained active as chaperones, suggesting that this activity may be the major cause of the suppression. In the absence of Pael-R, overexpression of TRX in all neurons increased the level of locomotor activity in aged flies and extended the mean longevity by 15%. Furthermore, overexpression of TRX suppressed neurotoxicity in a Drosophila model of Machado-Joseph disease expressing polyglutamine. These results establish that Drosophila TRX can function as an anti-aging agent and as a suppressor of Pael-R- and polyglutamine-induced neurotoxicity.	Tokyo Metropolitan Univ, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Biol Informat Consortium, Tokyo 1358073, Japan	Tokyo Metropolitan University; University of Tokyo	Aigaki, T (corresponding author), Tokyo Metropolitan Univ, Dept Biol Sci, 1-1 Minami Osawa, Hachioji, Tokyo 1920397, Japan.	aigaki-toshiro@c.metro-u.ac.jp	Matsuo, Takashi/AAR-8291-2021	Matsuo, Takashi/0000-0002-4185-6740				Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bauer H, 2002, J BIOL CHEM, V277, P17457, DOI 10.1074/jbc.M200636200; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cha GH, 2005, P NATL ACAD SCI USA, V102, P10345, DOI 10.1073/pnas.0500346102; Chan HYE, 2000, CELL DEATH DIFFER, V7, P1075, DOI 10.1038/sj.cdd.4400757; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; ENDOH M, 1993, BIOCHEM BIOPH RES CO, V192, P760, DOI 10.1006/bbrc.1993.1479; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; GIBB WRG, 1988, NEUROLOGY, V38, P1402, DOI 10.1212/WNL.38.9.1402; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Haywood AFM, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-14; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HORI K, 1994, BRAIN RES, V652, P304, DOI 10.1016/0006-8993(94)90241-0; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kern R, 2003, BIOCHEM J, V371, P965, DOI 10.1042/BJ20030093; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koutsillieri E, 2002, J NEUROL S2, V249, P1, DOI DOI 10.1007/S00415-002-1201-7; Le Bourg E, 1999, EXP GERONTOL, V34, P157, DOI 10.1016/S0531-5565(98)00077-1; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; Neckameyer WS, 2000, NEUROBIOL AGING, V21, P145, DOI 10.1016/S0197-4580(99)00109-8; Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Quigney DJ, 2003, BRAIN RES, V993, P133, DOI 10.1016/j.brainres.2003.09.004; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SALZ HK, 1994, GENETICS, V136, P1075; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; SPINA MB, 1989, P NATL ACAD SCI USA, V86, P1398, DOI 10.1073/pnas.86.4.1398; Sulzer D, 1999, NEUROTOX RES, V1, P181, DOI 10.1007/BF03033289; Svensson MJ, 2003, CHROMOSOMA, V112, P133, DOI 10.1007/s00412-003-0253-5; Van Duijn CM, 2001, AM J HUM GENET, V69, P505; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Whitworth AJ, 2005, P NATL ACAD SCI USA, V102, P8024, DOI 10.1073/pnas.0501078102; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	49	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11180	11187		10.1074/jbc.M700937200	http://dx.doi.org/10.1074/jbc.M700937200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17301052	hybrid			2022-12-27	WOS:000245941500039
J	Takahashi, H; Arai, M; Takenawa, T; Sota, H; Xie, QH; Wakura, M				Takahashi, Hisashi; Arai, Munehito; Takenawa, Tatsuyuki; Sota, Hiroyuki; Xie, Qui Hong; Wakura, Masahiro			Stabilization of hyperactive dihydrofolate reductase by cyanocysteine-mediated backbone cyclization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; GLOBULAR-PROTEINS; IN-VIVO; UNPROTECTED PEPTIDES; THERMAL-DENATURATION; PYROCOCCUS-FURIOSUS; CRYSTAL-STRUCTURES; SUBSTRATE BINDING; SULFHYDRYL GROUPS	Stabilization of an enzyme while maintaining its activity has been a major challenge in protein chemistry. Although it is difficult to simultaneously improve stability and activity of a protein by amino acid substitutions due to the activity-stability trade-off, backbone cyclization by connecting the N and C termini with a linker is promising as a general method of stabilizing a protein without affecting its activity. Recently, we created a hyperactive, methionine- and cysteine-free mutant of dihydrofolate reductase from Escherichia coli, called ANLYF, by introducing seven amino acid substitutions, which, however, destabilized the protein. Here we show that ANLYF is stabilized without a loss of its high activity by a novel backbone cyclization method for unprotected proteins. The method is based on the in vitro cyanocysteine-mediated intramolecular ligation reaction, which can be conducted with relatively high efficiency by a simple procedure and under mild conditions. We also show that the reversibility of thermal denaturation is highly improved by the cyclization. Thus, activity and stability of the protein can be separately improved by amino acid substitutions and backbone cyclization, respectively. We suggest that the cyanocysteine-mediated cyclization method is complementary to the intein-mediated cyclization method in stabilizing a protein without affecting its activity.	Natl Inst Adv Ind Sci & Technol, Prot Design Res Grp, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Wakura, M (corresponding author), Natl Inst Adv Ind Sci & Technol, Prot Design Res Grp, Inst Biol Resources & Funct, Tsukuba Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	masa-iwakura@aist.go.jp	Takenawa, Tatsuyuki/M-5439-2018; Arai, Munehito/A-1258-2012	Takenawa, Tatsuyuki/0000-0001-5642-0117; Arai, Munehito/0000-0002-1223-2242				Aita T, 2001, PROTEIN ENG, V14, P633, DOI 10.1093/protein/14.9.633; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; Arai M, 2005, J MOL BIOL, V347, P337, DOI 10.1016/j.jmb.2005.01.033; Arai M, 2003, J MOL BIOL, V329, P779, DOI 10.1016/S0022-2836(03)00511-4; Arai M, 2003, J MOL BIOL, V328, P273, DOI 10.1016/S0022-2836(03)00212-2; Arnold FH, 2001, NATURE, V409, P253, DOI 10.1038/35051731; ARNOLD FH, 2000, ADV PROTEIN CHEM, V55, P1; Beadle BM, 2002, J MOL BIOL, V321, P285, DOI 10.1016/S0022-2836(02)00599-5; BETZ SF, 1993, PROTEIN SCI, V2, P1551, DOI 10.1002/pro.5560021002; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; Blaschke UK, 2000, METHOD ENZYMOL, V328, P478, DOI 10.1016/S0076-6879(00)28414-0; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; Camarero JA, 1998, ANGEW CHEM INT EDIT, V37, P347, DOI 10.1002/(SICI)1521-3773(19980216)37:3<347::AID-ANIE347>3.0.CO;2-5; Camarero JA, 1999, J AM CHEM SOC, V121, P5597, DOI 10.1021/ja990929n; Camarero JA, 2001, J MOL BIOL, V308, P1045, DOI 10.1006/jmbi.2001.4631; Camarero JA, 1997, CHEM COMMUN, P1369, DOI 10.1039/a702083j; Cantor C., 1980, BIOPHYS CHEM; CATSIMPOOLAS N, 1966, J BIOL CHEM, V241, P1790; Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200; Declerck N, 2003, PROTEIN ENG, V16, P287, DOI 10.1093/proeng/gzg032; Deechongkit S, 2002, J AM CHEM SOC, V124, P4980, DOI 10.1021/ja0123608; DEGANI Y, 1971, J ORG CHEM, V36, P2727; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; Eijsink VGH, 2004, J BIOTECHNOL, V113, P105, DOI 10.1016/j.jbiotec.2004.03.026; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FLORY PJ, 1956, J AM CHEM SOC, V78, P5222, DOI 10.1021/ja01601a025; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; Gangopadhyay JP, 2003, BBA-GEN SUBJECTS, V1619, P193, DOI 10.1016/S0304-4165(02)00495-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDENBERG DP, 1983, J MOL BIOL, V165, P407, DOI 10.1016/S0022-2836(83)80265-4; Gonzalez C, 2000, P NATL ACAD SCI USA, V97, P11221, DOI 10.1073/pnas.210301097; Guo CY, 2004, PROTEIN EXPRES PURIF, V37, P361, DOI 10.1016/j.pep.2004.06.037; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; Ishihama Y, 1999, TETRAHEDRON LETT, V40, P3415, DOI 10.1016/S0040-4039(99)00504-3; Iwai H, 1999, FEBS LETT, V459, P166, DOI 10.1016/S0014-5793(99)01220-X; Iwai H, 2001, J BIOL CHEM, V276, P16548, DOI 10.1074/jbc.M011639200; Iwakura M, 2006, J BIOL CHEM, V281, P13234, DOI 10.1074/jbc.M508823200; IWAKURA M, 1995, J BIOCHEM, V117, P480, DOI 10.1093/oxfordjournals.jbchem.a124733; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P37, DOI 10.1093/oxfordjournals.jbchem.a123715; Iwakura M, 2000, NAT STRUCT BIOL, V7, P580, DOI 10.1038/76811; Iwakura M, 1996, J BIOCHEM-TOKYO, V119, P414; Iwakura M, 2001, PROTEIN ENG, V14, P583, DOI 10.1093/protein/14.8.583; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korkegian A, 2005, SCIENCE, V308, P857, DOI 10.1126/science.1107387; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; MEIERING EM, 1992, J MOL BIOL, V225, P585, DOI 10.1016/0022-2836(92)90387-Y; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; Ota M, 2003, J MOL BIOL, V327, P1053, DOI 10.1016/S0022-2836(03)00207-9; Pace C N, 1986, Methods Enzymol, V131, P266; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Pfeil W., 1998, PROTEIN STABILITY FO; POLAND DC, 1965, BIOPOLYMERS, V3, P379, DOI 10.1002/bip.1965.360030404; PRESS WH, 1992, NUMERICAL RECIPES; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; Schnell JR, 2004, ANNU REV BIOPH BIOM, V33, P119, DOI 10.1146/annurev.biophys.33.110502.133613; SCHREIBER C, 1994, STRUCTURE, V2, P945, DOI 10.1016/S0969-2126(94)00096-4; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; SHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452, DOI 10.1073/pnas.92.2.452; Siebold C, 2002, BIOPHYS CHEM, V96, P163, DOI 10.1016/S0301-4622(02)00012-1; Sota H, 1998, ANAL CHEM, V70, P2019, DOI 10.1021/ac9713666; Sun ZY, 2005, PROTEIN EXPRES PURIF, V43, P26, DOI 10.1016/j.pep.2005.05.005; Sydor JR, 2002, BIOCONJUGATE CHEM, V13, P707, DOI 10.1021/bc025534z; Takenawa T, 1998, J BIOCHEM-TOKYO, V123, P1137; THORNTON JM, 1983, J MOL BIOL, V167, P443, DOI 10.1016/S0022-2836(83)80344-1; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; TSUNASAWA S, 1987, J BIOCHEM, V101, P111, DOI 10.1093/oxfordjournals.jbchem.a121882; UWAJIMA T, 1990, BIOCHEM BIOPH RES CO, V171, P684, DOI 10.1016/0006-291X(90)91200-C; Valiyaveetil FI, 2002, J AM CHEM SOC, V124, P9113, DOI 10.1021/ja0266722; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; Wang XJ, 2002, J MOL BIOL, V320, P85, DOI 10.1016/S0022-2836(02)00400-X; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187; Zhou HX, 2003, J MOL BIOL, V332, P257, DOI 10.1016/S0022-2836(03)00886-6	82	15	16	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9420	9429		10.1074/jbc.M610983200	http://dx.doi.org/10.1074/jbc.M610983200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17264073	hybrid			2022-12-27	WOS:000245421700014
J	Tani, M; Hannun, YA				Tani, Motohiro; Hannun, Yusuf A.			Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues - Role of palmitoylation in subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NECROSIS-FACTOR-ALPHA; SIGNALING PROTEINS; BACILLUS-CEREUS; PHOSPHOLIPASE-C; ACID-RESIDUES; DISTINCT POOL; CELL-SURFACE; ACTIVATION; EXPRESSION	The neutral sphingomyelinases (nSMases) are considered major candidates for mediating the stress-induced production of ceramide. nSMase2, which has two hydrophobic segments near the NH2-terminal region, has been reported to be located at the plasma membrane and play important roles in ceramide-mediated signaling. In this study, we found that nSMase2 is palmitoylated on multiple cysteine residues via thioester bonds. Site-directed mutagenesis of cysteine residues to alanine indicated that two cysteine clusters of the enzyme are multiply palmitoylated; one cluster is located between the two hydrophobic segments, and the second one is located in the middle of the catalytic region of the protein. When overexpressed in the confluent phase of MCF-7 cells, wild-type nSMase2 was strictly localized in the plasma membranes, and the cysteine mutants of each palmitoylated cysteine cluster were seen not only at the plasma membrane but also in some punctate structures. Furthermore, mutation of all potential palmitoylation sites resulted in a dramatic reduction in the plasma membrane distribution and an increase in the punctate structures. The palmitoylation-deficient mutant was directed to lysosomes and rapidly degraded. Palmitoylation had no effect on enzyme activity but affected membrane-association properties of the protein. Finally, the catalytic region of nSMase2 where palmitoylation occurs was found to be localized at the inner leaflet of the plasma membrane. In summary, the results from this study reveal for the first time the palmitoylation of nSMase2 via thioester bonds and its importance in the subcellular localization and stability of this protein.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu		Tani, Motohiro/0000-0003-4316-8260	NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Ago H, 2006, J BIOL CHEM, V281, P16157, DOI 10.1074/jbc.M601089200; Aubin I, 2005, NAT GENET, V37, P803, DOI 10.1038/ng1603; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; Clarke CJ, 2007, J BIOL CHEM, V282, P1384, DOI 10.1074/jbc.M609216200; Clarke CJ, 2006, BIOCHEMISTRY-US, V45, P11247, DOI 10.1021/bi061307z; De Palma C, 2006, ARTERIOSCL THROM VAS, V26, P99, DOI 10.1161/01.ATV.0000194074.59584.42; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hayashi Y, 1997, J BIOL CHEM, V272, P18082, DOI 10.1074/jbc.272.29.18082; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Jana A, 2004, J BIOL CHEM, V279, P51451, DOI 10.1074/jbc.M404635200; Jiang LW, 2002, TRENDS CELL BIOL, V12, P362, DOI 10.1016/S0962-8924(02)02322-X; Karakashian AA, 2004, FASEB J, V18, P968, DOI 10.1096/fj.03-0875fje; Krut O, 2006, J BIOL CHEM, V281, P13784, DOI 10.1074/jbc.M511306200; Lane SR, 1997, J NEUROCHEM, V69, P1864; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levy M, 2006, BIOCHEM BIOPH RES CO, V344, P900, DOI 10.1016/j.bbrc.2006.04.013; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Miura GI, 2006, CELL CYCLE, V5, P1184, DOI 10.4161/cc.5.11.2804; Nagata Y, 2006, J CELL BIOL, V174, P245, DOI 10.1083/jcb.200605028; Okamoto Y, 2003, BIOCHEMISTRY-US, V42, P7855, DOI 10.1021/bi0341354; Openshaw AEA, 2005, J BIOL CHEM, V280, P35011, DOI 10.1074/jbc.M506800200; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Rodrigues-Lima F, 2000, J BIOL CHEM, V275, P28316; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Stoffel W, 2005, P NATL ACAD SCI USA, V102, P4554, DOI 10.1073/pnas.0406380102; TAMURA H, 1995, BIOCHEM J, V309, P757, DOI 10.1042/bj3090757; Tani M, 2004, J BIOL CHEM, V279, P29351, DOI 10.1074/jbc.M404012200; Tani M, 2007, CELL SIGNAL, V19, P229, DOI 10.1016/j.cellsig.2006.07.001; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Valdez-Taubas J, 2005, EMBO J, V24, P2524, DOI 10.1038/sj.emboj.7600724; Van Itallie CM, 2005, J CELL SCI, V118, P1427, DOI 10.1242/jcs.01735; VENIEN C, 1988, BIOCHIM BIOPHYS ACTA, V942, P159, DOI 10.1016/0005-2736(88)90285-4; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zumbansen M, 2002, MOL CELL BIOL, V22, P3633, DOI 10.1128/MCB.22.11.3633-3638.2002	45	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10047	10056		10.1074/jbc.M611249200	http://dx.doi.org/10.1074/jbc.M611249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272284	hybrid			2022-12-27	WOS:000245421700079
J	Tarze, A; Dauplais, M; Grigoras, I; Lazard, M; Ha-Duong, NT; Barbier, F; Blanquet, S; Plateau, P				Tarze, Agathe; Dauplais, Marc; Grigoras, Ioana; Lazard, Myriam; Ha-Duong, Nguyet-Thanh; Barbier, Frederique; Blanquet, Sylvain; Plateau, Pierre			Extracellular production of hydrogen selenide accounts for thiol-assisted toxicity of selenite against Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GROWTH-INHIBITION; BRUSH-BORDER MEMBRANE; ESCHERICHIA-COLI; SODIUM SELENITE; SUPEROXIDE-DISMUTASE; SMALL-INTESTINE; D-CYSTEINE; GLUTATHIONE; CELLS; MECHANISM	Administration of selenium in humans has anticarcinogenic effects. However, the boundary between cancer-protecting and toxic levels of selenium is extremely narrow. The mechanisms of selenium toxicity need to be fully understood. In Saccharomyces cerevisiae, selenite in the millimolar range is well tolerated by cells. Here we show that the lethal dose of selenite is reduced to the micromolar range by the presence of thiols in the growth medium. Glutathione and selenite spontaneously react to produce several selenium-containing compounds (selenodiglutathione, glutathioselenol, hydrogen selenide, and elemental selenium) as well as reactive oxygen species. We studied which compounds in the reaction pathway between glutathione and sodium selenite are responsible for this toxicity. Involvement of selenodiglutathione, elemental selenium, or reactive oxygen species could be ruled out. In contrast, extracellular formation of hydrogen selenide can fully explain the exacerbation of selenite toxicity by thiols. Indeed, direct production of hydrogen selenide with D-cysteine desulfhydrase induces high mortality. Selenium uptake by S. cerevisiae is considerably enhanced in the presence of external thiols, most likely through internalization of hydrogen selenide. Finally, we discuss the possibility that selenium exerts its toxicity through consumption of intracellular reduced glutathione, thus leading to severe oxidative stress.	Ecole Polytech, Dept Biol, CNRS, UMR 7654,Lab Biochim, F-91128 Palaiseau, France; CNRS, Serv Cent Anal, USR 59, F-69390 Vernaison, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS)	Plateau, P (corresponding author), Ecole Polytech, Dept Biol, CNRS, UMR 7654,Lab Biochim, F-91128 Palaiseau, France.	plateau@bioc.polytechnique.fr	Grigoras, Ioana/G-4426-2011; Ha-Duong, Nguyet-Thanh/N-5907-2018; Tarze, Agathe/R-4379-2018	Grigoras, Ioana/0000-0003-2547-8935; Lazard, Myriam/0000-0002-7154-1352; Tarze, Agathe/0000-0001-6101-069X; Bessueille, Frederique/0000-0002-3786-6225				ANJARIA KB, 1988, MUTAT RES, V204, P605, DOI 10.1016/0165-1218(88)90063-8; ANUNDI I, 1984, ACTA PHARMACOL TOX, V54, P273; Bansal M. P., 2002, Journal of Medicinal Food, V5, P85, DOI 10.1089/109662002760178168; Bansal MP, 1999, BIOL TRACE ELEM RES, V70, P21, DOI 10.1007/BF02783846; BATIST G, 1986, CANCER RES, V46, P5482; Bebien M, 2002, J BACTERIOL, V184, P1556, DOI 10.1128/JB.184.6.1556-1564.2002; Bendich A, 2001, DIETARY REFERENCE IN, DOI [10.1016/s0899-9007(00)00596-7, DOI 10.1016/S0899-9007(00)00596-7]; BERGMEYER HU, 1955, BIOCHEM Z, V327, P255; BJORNSTEDT M, 1995, METHOD ENZYMOL, V252, P209; Bjornstedt M, 1996, BIOCHEMISTRY-US, V35, P8511, DOI 10.1021/bi9528762; Bronzetti G, 2001, MUTAT RES-GEN TOX EN, V496, P105, DOI 10.1016/S1383-5718(01)00213-3; BYARD JL, 1969, ARCH BIOCHEM BIOPHYS, V130, P556, DOI 10.1016/0003-9861(69)90070-8; CAFFREY PB, 1991, MOL PHARMACOL, V39, P281; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X; COSTE H, 1987, J BIOL CHEM, V262, P12096; de Leon CAP, 2002, J APPL MICROBIOL, V92, P602, DOI 10.1046/j.1365-2672.2002.01562.x; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; Diwadkar-Navsariwala V, 2004, J NUTR, V134, P2899, DOI 10.1093/jn/134.11.2899; Diwadkar-Navsariwala V, 2006, P NATL ACAD SCI USA, V103, P8179, DOI 10.1073/pnas.0508218103; DUDLEY H. C., 1941, Journal of Industrial Hygiene and Toxicology, V23, P470; Eghbal MA, 2004, TOXICOLOGY, V203, P69, DOI 10.1016/j.tox.2004.05.020; FALCONE G, 1963, J BACTERIOL, V85, P754, DOI 10.1128/JB.85.4.754-762.1963; GANTHER HE, 1971, BIOCHEMISTRY-US, V10, P4089, DOI 10.1021/bi00798a013; GANTHER HE, 1968, BIOCHEMISTRY-US, V7, P2898, DOI 10.1021/bi00848a029; GANTHER HE, 1987, J AM COLL TOXICOL, V5, P1; Gharieb MM, 2004, MYCOL RES, V108, P1415, DOI 10.1017/S0953756204001418; Gharieb MM, 2004, BIOMETALS, V17, P183, DOI 10.1023/B:BIOM.0000018402.22057.62; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; HSIEH HS, 1977, BIOCHIM BIOPHYS ACTA, V497, P205; Imura N., 1989, SE BIOL MED, P70, DOI [10.1007/978-3-642-74421-1_14, DOI 10.1007/978-3-642-74421-1_14]; IVES DJG, 1948, J CHEM SOC, P766, DOI 10.1039/jr9480000766; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; JIANG XR, 1992, LEUKEMIA RES, V16, P347, DOI 10.1016/0145-2126(92)90136-U; Kessi J, 2004, J BIOL CHEM, V279, P50662, DOI 10.1074/jbc.M405887200; KICE JL, 1980, J AM CHEM SOC, V102, P4448, DOI 10.1021/ja00533a025; Kim TS, 2003, BIOCHEM PHARMACOL, V66, P2301, DOI 10.1016/j.bcp.2003.08.021; KITAHARA J, 1993, ARCH TOXICOL, V67, P497, DOI 10.1007/BF01969921; Kobayashi Y, 2001, J CHROMATOGR B, V760, P73, DOI 10.1016/S0378-4347(01)00252-3; KRAMER GF, 1988, MUTAT RES, V201, P169, DOI 10.1016/0027-5107(88)90123-6; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; KUCHAN MJ, 1991, CANCER LETT, V57, P181, DOI 10.1016/0304-3835(91)90213-2; KUCHAN MJ, 1992, CANCER RES, V52, P1091; Leblondel G, 2001, BIOL TRACE ELEM RES, V83, P191, DOI 10.1385/BTER:83:3:191; LIN Y, 1993, BIOCHEM PHARMACOL, V45, P429, DOI 10.1016/0006-2952(93)90080-G; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MCCONNELL KP, 1952, J BIOL CHEM, V195, P277; Mihara H, 2000, J BIOL CHEM, V275, P6195, DOI 10.1074/jbc.275.9.6195; MYKKANEN HM, 1990, J NUTR, V120, P882, DOI 10.1093/jn/120.8.882; NAGASAWA T, 1985, EUR J BIOCHEM, V153, P541, DOI 10.1111/j.1432-1033.1985.tb09335.x; Ogra Y, 2002, J CHROMATOGR B, V767, P301, DOI 10.1016/S1570-0232(01)00581-5; ONEIL MJ, 2001, MERCK INDEX ENCY CHE, P1512; Painter EP, 1941, CHEM REV, V28, P179, DOI 10.1021/cr60090a001; Park YC, 2004, BIOL TRACE ELEM RES, V98, P143, DOI 10.1385/BTER:98:2:143; Pinson B, 2000, MOL MICROBIOL, V36, P679, DOI 10.1046/j.1365-2958.2000.01890.x; PITTMAN RW, 1949, J CHEM SOC, P1811, DOI 10.1039/jr9490001811; Rayman MP, 2004, BRIT J NUTR, V92, P557, DOI 10.1079/BJN20041251; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; ROSIN MP, 1981, CANCER LETT, V13, P7, DOI 10.1016/0304-3835(81)90080-X; Schrauzer Gerhard Norbert, 2003, Adv Food Nutr Res, V47, P73, DOI 10.1016/S1043-4526(03)47002-2; Seko Y, 1997, BIOMED ENVIRON SCI, V10, P333; Seo YR, 2002, ONCOGENE, V21, P3663, DOI 10.1038/sj.onc.1205468; SHAMBERGER RJ, 1969, CAN MED ASSOC J, V100, P682; Shen HM, 2000, FREE RADICAL BIO MED, V28, P1115, DOI 10.1016/S0891-5849(00)00206-9; Shen HM, 2001, FREE RADICAL BIO MED, V30, P9, DOI 10.1016/S0891-5849(00)00421-4; SLONIMSKI PP, 1949, ANN I PASTEUR PARIS, V76, P510; Soutourina J, 2001, J BIOL CHEM, V276, P40864, DOI 10.1074/jbc.M102375200; SPALLHOLZ JE, 1994, FREE RADICAL BIO MED, V17, P45, DOI 10.1016/0891-5849(94)90007-8; Sutherland MW, 1997, FREE RADICAL RES, V27, P283, DOI 10.3109/10715769709065766; Suzuki KT, 2006, TOXICOL APPL PHARM, V217, P43, DOI 10.1016/j.taap.2006.07.006; WHITING RF, 1980, MUTAT RES, V78, P159, DOI 10.1016/0165-1218(80)90095-6; WOLFFRAM S, 1989, J NUTR, V119, P706, DOI 10.1093/jn/119.5.706; YU SY, 1985, BIOL TRACE ELEM RES, V7, P21, DOI 10.1007/BF02916544; Zuo L, 2004, ANN HEMATOL, V83, P751, DOI 10.1007/s00277-004-0920-5	74	99	105	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8759	8767		10.1074/jbc.M610078200	http://dx.doi.org/10.1074/jbc.M610078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17261587	hybrid			2022-12-27	WOS:000245780300022
J	Sun, XX; Dai, MS; Lu, H				Sun, Xiao-Xin; Dai, Mu-Shui; Lu, Hua			5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINES; AUTOREGULATORY FEEDBACK LOOP; HCT116 COLON-CANCER; COLORECTAL-CANCER; ANTICANCER AGENTS; ONCOPROTEIN MDM2; RIBOSOMAL-RNA; INHIBITION; CYCLE; L11	5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug for the treatment of a variety of solid tumors. The antitumor activity of 5-FU has been attributed in part to its ability to induce p53-dependent cell growth arrest and apoptosis. However, the molecular mechanisms underlying p53 activation by 5-FU remain largely obscure. Here we report that 5-FU treatment leads to p53 stabilization and activation by blocking MDM2 feedback inhibition through ribosomal proteins. 5-FU treatment increased the fraction of ribosome-free L5, L11, and L23 ribosomal proteins and their interaction with MDM2, leading to p53 activation and G,/S arrest. Conversely, individual knockdown of these ribosomal proteins by small interfering RNA prevented the 5-FU-induced p53 activation and reversed the 5-FU-induced G(1)/S arrest. These results demonstrate that 5-FU treatment triggers a ribosomal stress response so that ribosomal proteins L5, L11, and L23 are released from ribosome to activate p53 by ablating the MDM2-p53 feedback circuit.	Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Lu, H (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR USA.	luh@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA079721, R01CA095441, R01CA093614] Funding Source: NIH RePORTER; NCI NIH HHS [CA079721, CA93614, CA095441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnen DJ, 1998, CANCER RES, V58, P1149; ASCHROFT M, 2000, MOL CELL BIOL, V20, P3224; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; De Angelis PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-20; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; GEOFFROY FJ, 1994, ONCOL RES, V6, P581; GHOSHAL K, 1994, CANCER RES, V54, P632; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hernandez-Vargas H, 2006, INT J CANCER, V119, P1164, DOI 10.1002/ijc.21938; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Houghton JA, 1995, CLIN CANCER RES, V1, P723; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; KANAMARU R, 1986, CANCER CHEMOTH PHARM, V17, P43, DOI 10.1007/BF00299864; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li MH, 2004, ORAL ONCOL, V40, P63, DOI 10.1016/S1368-8375(03)00136-2; Liang JT, 2002, INT J CANCER, V101, P519, DOI 10.1002/ijc.10643; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAYBAUM J, 1980, CANCER RES, V40, P4209; OConnor PM, 1997, CANCER RES, V57, P4285; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PIZZORNO G, 1995, BIOCHEM PHARMACOL, V49, P553, DOI 10.1016/0006-2952(94)00444-Q; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WILKINSON DS, 1973, J BIOL CHEM, V248, P63; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	41	133	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8052	8059		10.1074/jbc.M610621200	http://dx.doi.org/10.1074/jbc.M610621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17242401	hybrid			2022-12-27	WOS:000245081000037
J	Johnson, J; Albarani, V; Nguyen, M; Goldman, M; Willems, F; Aksoy, E				Johnson, Jolyn; Albarani, Valentina; Nguyen, Muriel; Goldman, Michel; Willems, Fabienne; Aksoy, Ezra			Protein kinase C alpha is involved in interferon regulatory factor 3 activation and type I interferon-beta synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTOR-3; NF-KAPPA-B; REGULATORY FACTOR-3; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DENDRITIC CELLS; VIRUS INDUCTION; ANTIVIRAL RESPONSE; SIGNALING PATHWAY	Protein kinase C ( PKC) isoforms are critically involved in the regulation of innate immune responses. Herein, we investigated the role of conventional PKC alpha in the regulation of IFN-beta gene expression mediated by the Toll-like receptor 3 ( TLR3) signaling pathway. Inhibition of conventional PKC ( cPKC) activity in monocyte-derived dendritic cells or TLR3-expressing cells by an isoform-specific inhibitor, Go "6976, selectively inhibited IFN-beta synthesis induced by double-stranded RNA polyinosine-polycytidylic acid. Furthermore, reporter gene assays confirmed that PKC alpha regulates IFN-beta promoter activity, since overexpression of dominant negative PKC alpha but not PKC beta(I) repressed interferon regulatory factor 3 ( IRF-3)-dependent but not NF-kappa B-mediated promoter activity upon TLR3 engagement in HEK 293 cells. Dominant negative PKC alpha inhibited IRF-3 transcriptional activity mediated by overexpression of TIR domain-containing adapter inducing IFN-beta and Tank-binding kinase-1. Additional biochemical analysis demonstrated that Go "6976-treated dendritic cells exhibited IRF-3 phosphorylation, dimerization, nuclear translocation, and DNA binding activity analogous to their control counterparts in response to polyinosine-polycytidylic acid. In contrast, co-immunoprecipitation experiments revealed that TLR3-induced cPKC activity is essential for mediating the interaction of IRF-3 but not p65/RelA with the coactivator CREB-binding protein. Furthermore, PKC alpha knockdown with specific small interfering RNA inhibited IFN-beta expression and down-regulated IRF-3-dependent promoter activity, establishing PKC alpha as a component of TLR3 signaling that regulates IFN-beta gene expression by targeting IRF-3-CREB-binding protein interaction. Finally, we analyzed the involvement of cPKCs in other signaling pathways leading to IFN-beta synthesis. These experiments revealed that cPKCs play a role in the synthesis of IFN-beta induced via both TLR-dependent and -independent pathways.	Univ Libre Bruxelles, Inst Med Immunol, B-6041 Charleroi, Belgium	Universite Libre de Bruxelles	Willems, F (corresponding author), Univ Libre Bruxelles, Inst Med Immunol, 8 Rue Adrienne Bolland, B-6041 Charleroi, Belgium.	fwillems@ulb.ac.be	Aksoy, Ezra/ABH-1337-2021	Aksoy, Ezra/0000-0002-6962-1572				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aksoy E, 2002, EUR J IMMUNOL, V32, P3040, DOI 10.1002/1521-4141(200211)32:11<3040::AID-IMMU3040>3.0.CO;2-M; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bach JF, 2005, NAT MED, V11, P120, DOI 10.1038/nm0205-120; Banchereau J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074-7613(04)00108-6; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; GESSANI S, 1989, J INTERFERON RES, V9, P543, DOI 10.1089/jir.1989.9.543; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kontny E, 2000, J LEUKOCYTE BIOL, V67, P249, DOI 10.1002/jlb.67.2.249; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McGettrick AF, 2006, P NATL ACAD SCI USA, V103, P9196, DOI 10.1073/pnas.0600462103; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mochly-Rosen D, 1998, FASEB J, V12, P35; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Panne D, 2004, EMBO J, V23, P4384, DOI 10.1038/sj.emboj.7600453; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Shapira L, 1997, BIOCHEM BIOPH RES CO, V240, P629, DOI 10.1006/bbrc.1997.7717; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; SHINJI H, 1994, J IMMUNOL, V153, P5760; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Tan SL, 2003, BIOCHEM J, V376, P545, DOI 10.1042/BJ20031406; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; THACORE HR, 1990, J GEN VIROL, V71, P2833, DOI 10.1099/0022-1317-71-12-2833; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	62	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15022	15032		10.1074/jbc.M700421200	http://dx.doi.org/10.1074/jbc.M700421200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17296604	hybrid			2022-12-27	WOS:000246589000041
J	Hrmova, M; Farkas, V; Lahnstein, J; Fincher, GB				Hrmova, Maria; Farkas, Vladimir; Lahnstein, Jelle; Fincher, Geoffrey B.			A barley xyloglucan xyloglucosyl transferase covalently links xyloglucan, cellulosic substrates, and (1,3;1,4)-beta-D-glucans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELL WALL; CARBOHYDRATE-ACTIVE ENZYMES; HORDEUM-VULGARE L.; ENDOTRANSGLYCOSYLASE; BIOSYNTHESIS; ARABIDOPSIS; EXPRESSION; XTH; TRANSGLYCOSYLATION; OLIGOSACCHARIDES	Molecular interactions between wall polysaccharides, which include cellulose and a range of noncellulosic polysaccharides such as xyloglucans and (1,3;1,4)-beta-D-glucans, are fundamental to cell wall properties. These interactions have been assumed to be noncovalent in nature in most cases. Here we show that a highly purified barley xyloglucan xyloglucosyl transferase HvXET5 (EC 2.4.1.207), a member of the GH16 group of glycoside hydrolases, catalyzes the in vitro formation of covalent linkages between xyloglucans and cellulosic substrates and between xyloglucans and (1,3;1,4)-beta-D-glucans. The rate of covalent bond formation catalyzed by HvXET5 with hydroxyethylcellulose (HEC) is comparable with that on tamarind xyloglucan, whereas that with (1,3;1,4)-beta-D-glucan is significant but slower. Matrix-assisted laser desorption ionization time-of-flight mass spectrometric analyses showed that oligosaccharides released from the fluorescent HEC:xyloglucan conjugate by a specific (1,4)-beta-Dglucan endohydrolase consisted of xyloglucan substrate with one, two, or three glucosyl residues attached. Ancillary peaks contained hydroxyethyl substituents (m/z 45) and confirmed that the parent material consisted of HEC covalently linked with xyloglucan. Similarly, partial hydrolysis of the (1,3;1,4)-beta-D-glucan:xyloglucan conjugate by a specific (1,3;1,4)-beta-Dglucan endohydrolase revealed the presence of a series of fluorescent oligosaccharides that consisted of the fluorescent xyloglucan acceptor substrate linked covalently with 2-6 glucosyl residues. These findings raise the possibility that xyloglucan endo-transglucosylases could link different polysaccharides in vivo and hence influence cell wall strength, flexibility, and porosity.	Univ Adelaide, Sch Agr Food & Wine, Glen Osmond, SA 5064, Australia; Univ Adelaide, Australian Ctr Plant Funct Genom, Glen Osmond, SA 5064, Australia; Slovak Acad Sci, Inst Chem, Ctr Excellence GLYCOBIOS, Bratislava 84538, Slovakia	University of Adelaide; University of Adelaide; Slovak Academy of Sciences	Fincher, GB (corresponding author), Univ Adelaide, Sch Agr Food & Wine, Waite Campus, Glen Osmond, SA 5064, Australia.	maria.hrmova@adelaide.edu.au; geoff.fincher@adelaide.edu.au	Hrmova, Maria/AAH-3951-2020	Farkas, Vladimir/0000-0002-8219-4288; Hrmova, Maria/0000-0002-3545-0605				Bacic A., 1988, BIOCHEM PLANT, V14, P297, DOI [DOI 10.1016/B978-0-08-092615-5.50014-X, 10.1016/B978-0-08-092615-5.50014-X]; Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938; Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844; Carpita NC, 2001, PLANT PHYSIOL, V127, P551, DOI 10.1104/pp.010146; Cohen A, 2004, J CHROMATOGR A, V1029, P87, DOI 10.1016/j.chroma.2003.12.010; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Coutinho PM, 1999, ROY SOC CH, P3; Cumming CM, 2005, PLANTA, V222, P546, DOI 10.1007/s00425-005-1560-2; FARKAS V, 1992, ARCH BIOCHEM BIOPHYS, V298, P365, DOI 10.1016/0003-9861(92)90423-T; Farkas V, 2005, PLANT PHYSIOL BIOCH, V43, P431, DOI 10.1016/j.plaphy.2005.03.006; Farrokhi N, 2006, PLANT BIOTECHNOL J, V4, P145, DOI 10.1111/j.1467-7652.2005.00169.x; FRY SC, 1992, BIOCHEM J, V282, P821, DOI 10.1042/bj2820821; Fry SC, 1997, PLANT J, V11, P1141, DOI 10.1046/j.1365-313X.1997.11051141.x; Geisler-Lee J, 2006, PLANT PHYSIOL, V140, P946, DOI 10.1104/pp.105.072652; Gibeaut DM, 2005, PLANTA, V221, P729, DOI 10.1007/s00425-005-1481-0; Gomez-Esquer F, 2004, MICROBIOL-SGM, V150, P3269, DOI 10.1099/mic.0.27314-0; HAHN M, 1995, EUR J BIOCHEM, V232, P849, DOI 10.1111/j.1432-1033.1995.tb20883.x; HOJ PB, 1995, PLANT J, V7, P367, DOI 10.1046/j.1365-313X.1995.7030367.x; Hrmova M, 1996, J BIOL CHEM, V271, P5277, DOI 10.1074/jbc.271.9.5277; Hrmova M, 2006, BIOCHEM J, V399, P77, DOI 10.1042/BJ20060170; Ishii T, 1999, J BIOL CHEM, V274, P13098, DOI 10.1074/jbc.274.19.13098; Jin ZF, 2006, BIOPOLYMERS, V83, P103, DOI 10.1002/bip.20533; Johansson P, 2004, PLANT CELL, V16, P874, DOI 10.1105/tpc.020065; Kallas AM, 2005, BIOCHEM J, V390, P105, DOI 10.1042/BJ20041749; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KEEGSTRA K, 1973, PLANT PHYSIOL, V51, P188, DOI 10.1104/pp.51.1.188; Kerr EM, 2003, PLANTA, V217, P327, DOI 10.1007/s00425-003-1027-2; Knogge W, 2002, MYCOTA, V11, P289; Mohand FA, 2006, CARBOHYD RES, V341, P577, DOI 10.1016/j.carres.2006.01.018; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P225; Popper ZA, 2005, ANN BOT-LONDON, V96, P91, DOI 10.1093/aob/mci153; Purugganan MM, 1997, PLANT PHYSIOL, V115, P181, DOI 10.1104/pp.115.1.181; Rose JKC, 2002, PLANT CELL PHYSIOL, V43, P1421, DOI 10.1093/pcp/pcf171; Saladie M, 2006, PLANT J, V47, P282, DOI 10.1111/j.1365-313X.2006.02784.x; Saura-Valls M, 2006, BIOCHEM J, V395, P99, DOI 10.1042/BJ20051396; Schroder R, 1998, PLANTA, V204, P242, DOI 10.1007/s004250050253; Schunmann PHD, 1997, PLANT CELL ENVIRON, V20, P1439, DOI 10.1046/j.1365-3040.1997.d01-49.x; Somerville C, 2004, SCIENCE, V306, P2206, DOI 10.1126/science.1102765; Steele NM, 1999, BIOCHEM J, V340, P207, DOI 10.1042/0264-6021:3400207; Strohmeier M, 2004, PROTEIN SCI, V13, P3200, DOI 10.1110/ps.04828404; Suurnakki A, 2000, CELLULOSE, V7, P189, DOI 10.1023/A:1009280109519; Thompson JE, 2000, PLANTA, V211, P275, DOI 10.1007/s004250000287; Trethewey JAK, 2002, NEW PHYTOL, V154, P347, DOI 10.1046/j.1469-8137.2002.00383.x; Vincken JP, 1997, PLANT PHYSIOL, V114, P9, DOI 10.1104/pp.114.1.9; Yokoyama R, 2004, PLANT CELL PHYSIOL, V45, P1111, DOI 10.1093/pcp/pch151; Yokoyama R, 2004, PLANT PHYSIOL, V134, P1088, DOI 10.1104/pp.103.035261	46	121	125	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12951	12962		10.1074/jbc.M611487200	http://dx.doi.org/10.1074/jbc.M611487200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329246	hybrid			2022-12-27	WOS:000245942800066
J	Moseley, JB; Bartolini, F; Okada, K; Wen, Y; Gundersen, GG; Goode, BL				Moseley, James B.; Bartolini, Francesca; Okada, Kyoko; Wen, Ying; Gundersen, Gregg G.; Goode, Bruce L.			Regulated binding of adenomatous polyposis coli protein to actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; MICROTUBULES IN-VIVO; FORMIN PROTEINS; CROSS-LINKING; APC PROTEIN; EB1; ASSOCIATION; FILAMENTS; ENDS; LOCALIZATION	Adenomatous polyposis coli ( APC) protein is a large tumor suppressor that is truncated in most colorectal cancers. The carboxyl-terminal third of APC protein mediates direct interactions with microtubules and the microtubule plus-end tracking protein EB1. In addition, APC has been localized to actin-rich regions of cells, but the mechanism and functional significance of this localization have remained unclear. Here we show that purified carboxyl-terminal basic domain of human APC protein ( APC-basic) bound directly to and bundled actin filaments and associated with actin stress fibers in microinjected cells. Actin filaments and microtubules competed for binding to APC-basic, but APC-basic also could cross-link actin filaments and microtubules at specific concentrations, suggesting a possible role in cytoskeletal cross-talk. APC interactions with actin in vitro were inhibited by its ligand EB1, and co-microinjection of EB1 prevented APC association with stress fibers. Point mutations in EB1 that disrupted APC binding relieved the inhibition in vitro and restored APC localization to stress fibers in vivo, demonstrating that EB1-APC regulation is direct. Because tumor formation and metastasis involve coordinated changes in the actin and microtubule cytoskeletons, this novel function for APC and its regulation by EB1 may have direct implications	Brandeis Univ, Rosentiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA	Brandeis University; Brandeis University; Columbia University; Columbia University	Goode, BL (corresponding author), Brandeis Univ, Rosentiel Basic Med Sci Res Ctr, 415 South St, Waltham, MA 02454 USA.	goode@brandeis.edu			NIGMS NIH HHS [GM63691, R01 GM062939, GM062939] Funding Source: Medline; Telethon [GFP03006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062939, R01GM063691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Barth AIM, 2002, J CELL SCI, V115, P1583; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; BROWN SS, 1979, J CELL BIOL, V80, P499, DOI 10.1083/jcb.80.2.499; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; ERICKSON HP, 1976, P NATL ACAD SCI USA, V73, P2813, DOI 10.1073/pnas.73.8.2813; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9135; JACOBS M, 1975, NATURE, V257, P707, DOI 10.1038/257707a0; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Kita K, 2006, MOL BIOL CELL, V17, P2331, DOI 10.1091/mbc.E05-06-0498; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; Langford KJ, 2006, CELL MOTIL CYTOSKEL, V63, P483, DOI 10.1002/cm.20139; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; LEE JC, 1978, BIOCHEMISTRY-US, V17, P2783, DOI 10.1021/bi00607a013; Li ZY, 2005, CANCER RES, V65, P5195, DOI 10.1158/0008-5472.CAN-04-4609; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Moseley JB, 2005, J BIOL CHEM, V280, P28023, DOI 10.1074/jbc.M503094200; Moseley JB, 2006, METHOD ENZYMOL, V406, P215, DOI 10.1016/S0076-6879(06)06016-2; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Oshima H, 1997, CANCER RES, V57, P1644; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Slep KC, 2005, J CELL BIOL, V168, P587, DOI 10.1083/jcb.200410114; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Wolff J, 1998, BIOCHEMISTRY-US, V37, P10722, DOI 10.1021/bi980400n; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	45	83	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12661	12668		10.1074/jbc.M610615200	http://dx.doi.org/10.1074/jbc.M610615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17293347	hybrid			2022-12-27	WOS:000245942800035
J	Filomeni, G; Cerchiaro, G; Ferreira, AMD; De Martino, A; Pedersen, JZ; Rotilio, G; Ciriolo, MR				Filomeni, Giuseppe; Cerchiaro, Giselle; Da Costa Ferreira, Ana Maria; De Martino, Angelo; Pedersen, Jens Z.; Rotilio, Giuseppe; Ciriolo, Maria R.			Pro-apoptotic activity of novel isatin-Schiff base copper(II) complexes depends on oxidative stress induction and organelle-selective damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; ANTICANCER DRUGS; CANCER-TREATMENT; KINASE PATHWAYS; CELLS; IRON; INHIBITION; BLEOMYCIN; TARGETS; DNA	We characterized the pro-apoptotic activity of two new synthesized isatin- Schiff base copper(II) complexes, obtained from isatin and 1,3- diaminopropane or 2-(2-aminoethyl)pyridine: (Cu(isapn)) and (Cu(isaepy)(2)), respectively. We demonstrated that these compounds trigger apoptosis via the mitochondrial pathway. The early induction of the p53/p21 system indicates a role for p53 in cell death, however, experiments carried out with small interfering RNA against p53, or with cells lacking p53, support that a p53-independent mechanism can also occur. The extent of apoptosis mirrors the kinetics of intracellular copper uptake. Particularly, Cu(isaepy())2 enters the cells more efficiently and specifically damages nuclei and mitochondria, as evidenced by atomic absorption analysis of copper content and by the extent of nuclear and mitochondrial integrity. Conversely, Cu(isapn), although less permeable, induces a widespread oxidative stress, as demonstrated by analyses of reactive oxygen species concentration, and oxidation of proteins and lipids. The increase of the antioxidant defense, through the overexpression of Cu,Zn-SOD, partially counteracts cell death; whereas retinoic acid-mediated differentiation completely rescues cells from apoptosis induced by both compounds. The activation of JNK- and Akt-mediated phosphorylative pathways has been found to be not functional for apoptosis induction. On the contrary, apoptosis significantly decreased when the analogous zinc complex was used or when Cu(isaepy)(2) was incubated in the presence of a copper chelator. Altogether, our data provide evidence for a dual role of these copper(II) complexes: they are able to vehicle copper into the cell, thus producing reactive oxygen species, and could behave as delocalized lipophilic cation-like molecules, thus specifically targeting organelles.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Sao Paulo, Inst Quim, Dept Quim Fundamental, BR-05513970 Sao Paulo, Brazil	University of Rome Tor Vergata; Universidade de Sao Paulo	Ciriolo, MR (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	ciriolo@bio.uniroma2.it	Da Costa Ferreira, Ana Maria/C-2244-2012; Ciriolo, Maria Rosa/K-6572-2016; Cerchiaro, Giselle/B-8424-2013	Da Costa Ferreira, Ana Maria/0000-0001-9898-1692; Ciriolo, Maria Rosa/0000-0002-7863-9029; Cerchiaro, Giselle/0000-0001-8606-5400; Filomeni, Giuseppe/0000-0002-2719-1412				ANTHOLINE WE, 1976, J MED CHEM, V19, P339, DOI 10.1021/jm00224a030; Biaglow JE, 2005, CANCER BIOL THER, V4, P6; Blagosklonny MV, 2001, CANCER RES, V61, P4301; Cerchiaro G, 2005, J INORG BIOCHEM, V99, P1433, DOI 10.1016/j.jinorgbio.2005.03.013; Cerchiaro G, 2004, J MOL CATAL A-CHEM, V221, P29, DOI 10.1016/j.molcata.2004.06.017; Chen D, 2005, FRONT BIOSCI-LANDMRK, V10, P2932, DOI 10.2741/1749; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; CIRIOLO MR, 1989, J BIOL CHEM, V264, P1443; Cleveland JL, 2000, NATURE, V407, P309, DOI 10.1038/35030277; Daniel KG, 2004, BIOCHEM PHARMACOL, V67, P1139, DOI 10.1016/j.bcp.2003.10.031; DAVIS S, 1985, J BIOL CHEM, V260, P3844; Engel RH, 2006, FRONT BIOSCI-LANDMRK, V11, P300, DOI 10.2741/1798; Filomeni G, 2005, CELL DEATH DIFFER, V12, P1555, DOI 10.1038/sj.cdd.4401754; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Filomeni G, 2002, FASEB J, V16, P64, DOI 10.1096/fj.02-0105fje; Filomeni G, 2003, CANCER RES, V63, P5940; Gaetke LM, 2003, TOXICOLOGY, V189, P147, DOI 10.1016/S0300-483X(03)00159-8; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gius D, 2006, ANTIOXID REDOX SIGN, V8, P1249, DOI 10.1089/ars.2006.8.1249; Griguer CE, 2006, CANCER RES, V66, P2257, DOI 10.1158/0008-5472.CAN-05-3364; Harsch A, 2000, NUCLEIC ACIDS RES, V28, P1978, DOI 10.1093/nar/28.9.1978; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; Katsaros N, 2002, CRIT REV ONCOL HEMAT, V42, P297, DOI 10.1016/S1040-8428(01)00222-0; Kotamraju S, 2004, METHOD ENZYMOL, V378, P362; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Martin V, 2006, CANCER RES, V66, P1081, DOI 10.1158/0008-5472.CAN-05-2354; Miller RA, 2001, CLIN CANCER RES, V7, P3215; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; MODICANAPOLITANO JS, 1987, CANCER RES, V47, P4361; Na HK, 2006, MOL CARCINOGEN, V45, P368, DOI 10.1002/mc.20225; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Prusty BK, 2005, INT J CANCER, V113, P951, DOI 10.1002/ijc.20668; Radulovic S, 2002, CURR MED CHEM, V9, P1611, DOI 10.2174/0929867023369376; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Rossi L, 2004, NATO SCI SER I LIFE, V358, P207; SARYAN LA, 1979, J MED CHEM, V22, P1218, DOI 10.1021/jm00196a013; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Townsend DM, 2005, METHOD ENZYMOL, V401, P287, DOI 10.1016/S0076-6879(05)01019-0; Wang T, 2006, CURR MED CHEM, V13, P525, DOI 10.2174/092986706776055742; Wilson L, 2004, J CHEMOTHERAPY, V16, P83, DOI 10.1179/joc.2004.16.Supplement-1.83	41	124	128	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12010	12021		10.1074/jbc.M610927200	http://dx.doi.org/10.1074/jbc.M610927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17327230	hybrid			2022-12-27	WOS:000245941900043
J	Genini, D; Catapano, CV				Genini, Davide; Catapano, Carlo V.			Block of nuclear receptor ubiquitination - A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME SYSTEM CONTROLS; PPAR-DELTA; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; COLON CARCINOGENESIS; COLORECTAL-CANCER; EPITHELIAL-CELLS; ADENOMA GROWTH; ROLES; ALPHA	Peroxisome proliferator-activated receptor delta ( PPAR delta) is a ligand-activated transcription factor involved in many physiological and pathological processes. PPAR delta is a promising therapeutic target for metabolic, chronic inflammatory, and neuro-degenerative disorders. However, limited information is available about the mechanisms that control the activity of this nuclear receptor. Here, we examined the role of the ubiquitin-proteasome system in PPAR delta turnover. The receptor was ubiquitinated and subject to rapid degradation by the 26 S proteasome. Unlike most nuclear receptors that are degraded upon ligand binding, PPAR delta ligands inhibited the ubiquitination of the receptor, thereby preventing its degradation. Ligand binding was required for inhibition of the ubiquitination since disruption of the ligand binding domain abolished the effect. Site-directed mutagenesis showed that the DNA binding domain was also required, indicating that ligands preferentially stabilized the DNA-bound receptor. In contrast, the activation function-2 domain and co-repressor binding site were not involved in ligand-induced stabilization. Block of ubiquitination by ligands may be an essential step to avoid rapid degradation of a receptor, like PPAR delta, with a very short half-life and sustain its transcriptional activity once it is engaged in transcriptional activation complexes.	Oncol Inst So Switzerland, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland	Institute of Oncology Research (IOR)	Catapano, CV (corresponding author), Oncol Inst So Switzerland, Expt Oncol Lab, Via Vela 6, CH-6500 Bellinzona, Switzerland.	carlo.catapano@irb.unisi.ch		Catapano, Carlo V./0000-0002-7079-557X				Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; Blanquart C, 2004, BIOCHEM BIOPH RES CO, V319, P663, DOI 10.1016/j.bbrc.2004.05.035; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Cutler NS, 2003, CANCER RES, V63, P1748; Dennis AP, 2005, J STEROID BIOCHEM, V94, P337, DOI 10.1016/j.jsbmb.2004.11.009; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2005, J BIOL CHEM, V280, P38700, DOI 10.1074/jbc.M507782200; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Glinghammar B, 2003, BIOCHEM BIOPH RES CO, V308, P361, DOI 10.1016/S0006-291X(03)01384-6; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hirotani M, 2001, BIOCHEM BIOPH RES CO, V288, P106, DOI 10.1006/bbrc.2001.5739; Jaeckel EC, 2001, ARCH OTOLARYNGOL, V127, P1253, DOI 10.1001/archotol.127.10.1253; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Reed KR, 2004, ONCOGENE, V23, P8992, DOI 10.1038/sj.onc.1208143; Rochette-Egly C, 2005, J BIOL CHEM, V280, P32565, DOI 10.1074/jbc.R500008200; Rodriguez-Vilarino S, 2000, J BIOL CHEM, V275, P6592, DOI 10.1074/jbc.275.9.6592; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Shao JY, 2002, CANCER RES, V62, P3282; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Tong BJ, 2000, NEOPLASIA, V2, P483, DOI 10.1038/sj.neo.7900119; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Yin YZ, 2005, CANCER RES, V65, P3950, DOI 10.1158/0008-5472.CAN-04-3990	46	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11776	11785		10.1074/jbc.M609149200	http://dx.doi.org/10.1074/jbc.M609149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324937	hybrid			2022-12-27	WOS:000245941900020
J	Hait, NC; Bellamy, A; Milstien, S; Kordula, T; Spiegel, S				Hait, Nitai C.; Bellamy, Andrea; Milstien, Sheldon; Kordula, Tomasz; Spiegel, Sarah			Sphingosine kinase type 2 activation by ERK-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOMODULATORY DRUG FTY720; PLASMA-MEMBRANE; GROWTH-FACTOR; FUNCTIONAL-CHARACTERIZATION; DEPENDENT TRANSLOCATION; CELL-PROLIFERATION; MOLECULAR-CLONING; BINDING SITE; PROTEIN; SPHINGOSINE-1-PHOSPHATE	Sphingosine 1-phosphate ( S1P), a potent lipid mediator, is a ligand for a family of five G protein-coupled receptors ( S1P1-5) that have been shown to regulate a variety of biological responses important for cancer progression. The cellular level of S1P is low and tightly regulated in a spatio-temporal manner through its synthesis catalyzed by two sphingosine kinases, denoted SphK1 and SphK2. Many stimuli activate and translocate SphK1 to the plasma membrane by mechanisms that are dependent on its phosphorylation. Much less is known about activation of SphK2. Here we demonstrate that epidermal growth factor ( EGF) as well as the protein kinase C activator, phorbol ester, induce rapid phosphorylation of hSphK2 which was markedly reduced by inhibition of MEK1/ERK pathway. Down-regulation of ERK1 blocked EGF-induced phosphorylation of SphK2. Recombinant ERK1 phosphorylated hSphK2 in vitro and increased its enzymatic activity. ERK1 also was found to be in a complex with hSphK2 in vivo. Site-directed mutagenesis indicated that hSphK2 is phosphorylated on Ser-351 and Thr-578 by ERK1 and that phosphorylation of these residues is important for EGF-stimulated migration of MDA-MB-453 cells. These studies provide the first clues to the mechanism of agonist-mediated SphK2 activation and enhance understanding of the regulation of SphK2 activity by phosphorylation and its role in movement of human breast cancer cells toward EGF.	Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem, 1101 E Marshall St,2-011 Sanger Hall,Box 980614, Richmond, VA 23298 USA.	sspiegel@vcu.edu			NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01CA61774] Funding Source: Medline; NIGMS NIH HHS [R37GM043880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007; Hla T, 2005, SCIENCE, V309, P1682, DOI 10.1126/science.1118340; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Milstien S, 2006, CANCER CELL, V9, P148, DOI 10.1016/j.ccr.2006.02.025; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Sutherland CM, 2006, J BIOL CHEM, V281, P11693, DOI 10.1074/jbc.M601042200; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Tedesco-Silva H, 2005, TRANSPLANTATION, V79, P1553, DOI 10.1097/01.TP.0000121761.02129.A6; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Urtz N, 2004, MOL CELL BIOL, V24, P8765, DOI 10.1128/MCB.24.19.8765-8777.2004; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Wattenberg BW, 2006, J LIPID RES, V47, P1128, DOI 10.1194/jlr.R600003-JLR200; Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628	40	120	122	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12058	12065		10.1074/jbc.M609559200	http://dx.doi.org/10.1074/jbc.M609559200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17311928	hybrid			2022-12-27	WOS:000245941900048
J	Harrison, D; Hussain, SA; Combs, AC; Ervasti, JM; Yurchenco, PD; Hohenester, E				Harrison, David; Hussain, Sadaf-Ahmahni; Combs, Ariana C.; Ervasti, James M.; Yurchenco, Peter D.; Hohenester, Erhard			Crystal structure and cell surface anchorage sites of laminin alpha 1LG4-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-DYSTROGLYCAN BINDING; SULFATIDE BINDING; RECEPTOR; CHAIN; HEPARIN; MODULE; DOMAIN; REQUIREMENTS; PERLECAN	The laminin G-like ( LG) domains of laminin-111, a glycoprotein widely expressed during embryogenesis, provide cell anchoring and receptor binding sites that are involved in basement membrane assembly and cell signaling. We now report the crystal structure of the laminin alpha 1LG4-5 domains and provide a mutational analysis of heparin, alpha-dystroglycan, and galactosyl-sulfatide binding. The two domains of alpha 1LG4-5 are arranged in a V-shaped fashion similar to that observed with laminin alpha 2 LG4-5 but with a substantially different interdomain angle. Recombinant alpha 1LG4-5 binding to heparin, alpha-dystroglycan, and sulfatides was dependent upon both shared and unique contributions from basic residues distributed in several clusters on the surface of LG4. For heparin, the greatest contribution was detected from two clusters, (RKR)-R-2719 and (KRK)-K-2791. Binding to alpha-dystroglycan was particularly dependent on basic residues within (RKR)-R-2719, (2831)RAR, and (KDR)-K-2858. Binding to galactosyl-sulfatide was most affected by mutations in (2831)RAR and (2766)KGRTK but not in (RKR)-R-2719. The combined analysis of structure and activities reveal differences in LG domain interactions that should enable dissection of biological roles of different laminin ligands.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Div Cell & Mol Biol, London SW7 2AZ, England; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	Imperial College London; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Wisconsin System; University of Wisconsin Madison	Hohenester, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Div Cell & Mol Biol, Prince Consort Rd, London SW7 2AZ, England.	e.hohenester@imperial.ac.uk	Ervasti, James/AAZ-4786-2020	Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425] Funding Source: NIH RePORTER; BBSRC [BB/D524840/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D524840/1, BBD5248401] Funding Source: Medline; NIDDK NIH HHS [R37-DK36425, R37 DK036425] Funding Source: Medline; Wellcome Trust [054334] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Combs AC, 2005, BIOCHEM J, V390, P303, DOI 10.1042/BJ20050375; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Hozumi K, 2006, J BIOL CHEM, V281, P32929, DOI 10.1074/jbc.M605708200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; McDearmon EL, 2003, J BIOL CHEM, V278, P44868, DOI 10.1074/jbc.M307026200; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Sasaki T, 2002, EXP CELL RES, V275, P185, DOI 10.1006/excr.2002.5499; Scheele S, 2005, P NATL ACAD SCI USA, V102, P1502, DOI 10.1073/pnas.0405095102; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tseng CN, 2003, J BIOL CHEM, V278, P17236, DOI 10.1074/jbc.M300282200; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; Wizemann H, 2003, J MOL BIOL, V332, P635, DOI 10.1016/S0022-2836(03)00848-9; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006; Yurchenco PD, 2002, METHOD CELL BIOL, V69, P111, DOI 10.1016/S0091-679X(02)69010-7	33	53	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11573	11581		10.1074/jbc.M610657200	http://dx.doi.org/10.1074/jbc.M610657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307732	Green Accepted, hybrid			2022-12-27	WOS:000245941500078
J	Heinz, K; Marx, A				Heinz, Kathrin; Marx, Andreas			Lesion bypass activity of DNA polymerase a from the extremely radioresistant organism Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; REPLICATION; FIDELITY; RESISTANT; RADIATION; GENOME; REPAIR; SPECIFICITY; MANGANESE	The bacterium Deinococcus radiodurans survives extremely high exposure to ionizing radiation and extended periods of desiccation. Radiation at the survival doses is known to cause numerous DNA damage, such as hundreds of double strand breaks and single strand breaks, as well as damage of the nucleobases. The mechanisms of D. radiodurans to survive the depicted threats are still only beginning to be understood. DNA polymerase A (PolA) has been shown to be crucially involved in irradiation resistance mechanisms of D. radiodurans. We expressed and characterized the DNA polymerase domain of PolA for the first time in vitro. The obtained enzyme is able to efficiently catalyze DNA-dependent DNA synthesis requiring Mg(II) as divalent metal ion. Additionally, strand displacement synthesis of the DNA polymerase, which is required in several repair processes, could be detected. We further found that DNA polymerase function of PolA is modulated by the presence of Mn(II). Whereas proceeding DNA synthesis of PolA was blocked by certain DNA damage that occurs through radiation of DNA, bypass was facilitated by Mn(II). Our results suggest an enzyme modulator function of Mn(II). These observations parallel reports that D. radiodurans accumulates intracellular Mn(II) in cases of irradiation and that the level of irradiation protection correlates with Mn(II) concentrations.	Univ Konstanz, Dept Chem, Chair Organ Chem Cellular Chem, D-78457 Constance, Germany	University of Konstanz	Marx, A (corresponding author), Univ Str 10, D-78457 Constance, Germany.	andreas.marx@uni-konstanz.de						ANDERSON AW, 1956, FOOD TECHNOL-CHICAGO, V10, P575; BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; Battista JR, 1999, TRENDS MICROBIOL, V7, P362, DOI 10.1016/S0966-842X(99)01566-8; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; Blasius M, 2006, MOL MICROBIOL, V60, P165, DOI 10.1111/j.1365-2958.2006.05077.x; CHOU FI, 1990, J BACTERIOL, V172, P2029, DOI 10.1128/jb.172.4.2029-2035.1990; Cox MM, 2005, NAT REV MICROBIOL, V3, P882, DOI 10.1038/nrmicro1264; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Daly MJ, 2004, SCIENCE, V306, P1025, DOI 10.1126/science.1103185; DIAZ A, 1992, MOL MICROBIOL, V6, P3009, DOI 10.1111/j.1365-2958.1992.tb01759.x; Englander J, 2004, J BACTERIOL, V186, P5973, DOI 10.1128/jb.186.18.5973-5977.2004; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GUTMAN PD, 1993, J BACTERIOL, V175, P3581, DOI 10.1128/jb.175.11.3581-3590.1993; GUTMAN PD, 1994, MUTAT RES, V314, P87, DOI 10.1016/0921-8777(94)90064-7; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1979, J BIOL CHEM, V254, P5718; Lecointe F, 2004, MOL MICROBIOL, V53, P1721, DOI 10.1111/j.1365-2958.2004.04233.x; Levin-Zaidman S, 2003, SCIENCE, V299, P254, DOI 10.1126/science.1077865; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; MILDVAN AS, 1972, CRIT REV BIOCH, V6, P219; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; RABKIN SD, 1983, P NATL ACAD SCI-BIOL, V80, P1541, DOI 10.1073/pnas.80.6.1541; Scharer OD, 2003, ANGEW CHEM INT EDIT, V42, P2946, DOI 10.1002/anie.200200523; SETLOW P, 1972, J BIOL CHEM, V247, P224; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; SIROVER MA, 1979, J BIOL CHEM, V254, P107; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; Villani G, 2002, NUCLEIC ACIDS RES, V30, P3323, DOI 10.1093/nar/gkf463; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Zahradka K, 2006, NATURE, V443, P569, DOI 10.1038/nature05160	38	17	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10908	10914		10.1074/jbc.M611404200	http://dx.doi.org/10.1074/jbc.M611404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303573	Green Submitted, hybrid			2022-12-27	WOS:000245941500010
J	Blanes, MG; Oubaha, M; Rautureau, Y; Gratton, JP				Blanes, Mariela Garcia; Oubaha, Malika; Rautureau, Yohann; Gratton, Jean-Philippe			Phosphorylation of tyrosine 801 of vascular endothelial growth factor receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEGF RECEPTOR-2; ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; ACTIN REORGANIZATION; FLK-1/KDR ACTIVATION; KINASE-ACTIVITY; PLC-GAMMA; KDR; ANGIOGENESIS; MIGRATION	Vascular endothelial growth factor ( VEGF)-stimulated nitric oxide ( NO) release from endothelial cells is mediated through the activation of VEGF receptor-2 ( VEGFR-2). Herein, we have attempted to determine which autophosphorylated tyrosine residue on the VEGFR-2 is essential for VEGF-mediated endothelial nitric-oxide synthase ( eNOS) activation and NO production from endothelial cells. Tyrosine residues 801, 1175, and 1214 of the VEGFR-2 were mutated to phenylalanine, and the mutated receptors were analyzed for their ability to stimulate NO production. We show, both in COS-7 cells cotransfected with the VEGFR-2 mutants and eNOS and in bovine aortic endothelial cells, that the Y801F-VEGFR-2 mutant is unable to stimulate NO synthesis and eNOS activation in contrast to the wild type, Y1175F-VEGFR-2, and Y1214F-VEGFR-2. However, the Y801F mutant retains the capacity to activate phospholipase C-gamma in contrast to the Y1175F-VEGFR-2. Interestingly, the Y801F-VEGFR-2, in contrast to the wild type receptor, does not fully activate phosphatidylinositol 3-kinase or recruit the p85 subunit upon receptor activation. This results in a complete incapacity of the Y801F-VEGFR-2 to stimulate Akt activation and eNOS phosphorylation on serine 1179 in endothelial cells. In addition, constitutive activation of Akt or a phosphomimetic mutant of eNOS ( S1179D) fully rescues the inability of the Y801F-VEGFR-2 to induce NO release. Finally, we generated an antibody that specifically recognizes the phosphorylated form of tyrosine 801 of the VEGFR-2 and demonstrate that this residue is actively phosphorylated in response to VEGF stimulation of endothelial cells. We thus conclude that autophosphorylation of tyrosine residue 801 of the VEGFR-2 is essential for VEGF-stimulated NO production from endothelial cells, and this is primarily accomplished via the activation of phosphatidylinositol 3-kinase and Akt signaling to eNOS.	Univ Montreal, IRCM, Lab Endothelial Cell Biol, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Gratton, JP (corresponding author), Univ Montreal, IRCM, Lab Endothelial Cell Biol, 110 Pins Ave W, Montreal, PQ H2W 1R7, Canada.	jean-philippe.gratton@ircm.qc.ca		Gratton, Jean-Philippe/0000-0001-9877-8520				Ahmad S, 2006, CIRC RES, V99, P715, DOI 10.1161/01.RES.0000243989.46006.b9; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Dance M, 2006, J BIOL CHEM, V281, P23285, DOI 10.1074/jbc.M600987200; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Duval M, 2003, J BIOL CHEM, V278, P20091, DOI 10.1074/jbc.M301410200; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gampel A, 2006, BLOOD, V108, P2624, DOI 10.1182/blood-2005-12-007484; Gelinas DS, 2002, BRIT J PHARMACOL, V137, P1021, DOI 10.1038/sj.bjp.0704956; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Knight EL, 2000, ONCOGENE, V19, P5398, DOI 10.1038/sj.onc.1203915; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Lampugnani MG, 2006, J CELL BIOL, V174, P593, DOI 10.1083/jcb.200602080; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; MORBIDELLI L, 1996, AM J PHYSIOL, V270, P411; Munoz-Chapuli R, 2004, CELL MOL LIFE SCI, V61, P2224, DOI 10.1007/s00018-004-4070-7; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Ng YS, 2006, EXP CELL RES, V312, P527, DOI 10.1016/j.yexcr.2005.11.008; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Ratcliffe KE, 2002, ONCOGENE, V21, P6307, DOI 10.1038/sj.onc.1205781; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	50	56	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10660	10669		10.1074/jbc.M609048200	http://dx.doi.org/10.1074/jbc.M609048200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17303569	hybrid			2022-12-27	WOS:000245941000060
J	Justino, MC; Almeida, CC; Teixeira, M; Saraiva, LM				Justino, Marta C.; Almeida, Claudia C.; Teixeira, Miguel; Saraiva, Ligia M.			Escherichia coli di-iron YtfE protein is necessary for the repair of stress-damaged iron-sulfur clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; NITRIC-OXIDE; CYSTEINE DESULFURASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; ACONITASE; BIOGENESIS; MECHANISMS; OPERON; INACTIVATION	DNA microarray experiments showed that the expression of the Escherichia coli ytfE gene is highly increased upon exposure to nitric oxide. We also reported that deletion of ytfE significantly alters the phenotype of E. coli, generating a strain with enhanced susceptibility to nitrosative stress and defective in the activity of several iron- sulfur- containing proteins. In this work, it is shown that the E. coli ytfE confers protection against oxidative stress. Furthermore, we found that the damage of the [ 4Fe-4S](2+) clusters of aconitase B and fumarase A caused by exposure to hydrogen peroxide and nitric oxide stress occurs at higher rates in the absence of ytfE. The ytfE null mutation also abolished the recovery of aconitase and fumarase activities, which is observed in wild type E. coli once the stress is scavenged. Notably, upon the addition of purified holo- YtfE protein to the mutant cell extracts, the enzymatic activities of fumarase and aconitase are fully recovered and at rates similar to the wild type strain. We concluded that YtfE is critical for the repair of iron- sulfur clusters damaged by oxidative and nitrosative stress conditions.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780157 Oeiras, Portugal	Universidade Nova de Lisboa	Saraiva, LM (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Ave Republ, P-2780157 Oeiras, Portugal.	lst@itqb.unl.pt	Teixeira, Miguel/M-1509-2019; Saraiva, Ligia M/H-8537-2012; DE ALMEIDA, CARLOS CAETANO/K-4265-2016; Teixeira, Miguel/A-9098-2011	Teixeira, Miguel/0000-0003-4124-6237; Saraiva, Ligia M/0000-0002-0675-129X; DE ALMEIDA, CARLOS CAETANO/0000-0002-3215-5731; Teixeira, Miguel/0000-0003-4124-6237; Justino, Marta/0000-0002-9310-9456				Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bodenmiller DM, 2006, J BACTERIOL, V188, P874, DOI 10.1128/JB.188.3.874-881.2006; Bradbury AJ, 1996, MICROBIOL-SGM, V142, P389, DOI 10.1099/13500872-142-2-389; Djaman O, 2004, J BIOL CHEM, V279, P44590, DOI 10.1074/jbc.M406487200; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; Fontecave M, 2005, J BIOL INORG CHEM, V10, P713, DOI 10.1007/s00775-005-0025-1; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Han D, 2005, BIOCHEMISTRY-US, V44, P11986, DOI 10.1021/bi0509393; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Imlay JA, 2006, MOL MICROBIOL, V59, P1073, DOI 10.1111/j.1365-2958.2006.05028.x; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Johnson DC, 2006, J BACTERIOL, V188, P7551, DOI 10.1128/JB.00596-06; Justino MC, 2006, FEMS MICROBIOL LETT, V257, P278, DOI 10.1111/j.1574-6968.2006.00179.x; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Lee JH, 2004, MOL MICROBIOL, V51, P1745, DOI 10.1111/j.1365-2958.2003.03946.x; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; MASSEY V, 1953, BIOCHEM J, V53, P72, DOI 10.1042/bj0530072; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Rogers PA, 2003, DNA REPAIR, V2, P809, DOI 10.1016/S1568-7864(03)00065-X; Rogers PA, 2001, J BIOL CHEM, V276, P30980, DOI 10.1074/jbc.M101037200; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Varghese S, 2003, J BACTERIOL, V185, P221, DOI 10.1128/JB.185.1.221-230.2003; Woodmansee AN, 2002, METHOD ENZYMOL, V349, P3, DOI 10.1016/S0076-6879(02)49316-0; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7; Yang WY, 2002, J BIOL CHEM, V277, P12868, DOI 10.1074/jbc.M109485200; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	39	99	104	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10352	10359		10.1074/jbc.M610656200	http://dx.doi.org/10.1074/jbc.M610656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289666	hybrid			2022-12-27	WOS:000245941000025
J	Salamat-Miller, N; Fang, JW; Seidel, CW; Assenov, Y; Albrecht, M; Middaugh, CR				Salamat-Miller, Nazila; Fang, Jianwen; Seidel, Christopher W.; Assenov, Yassen; Albrecht, Mario; Middaugh, C. Russell			A network-based analysis of polyanion-binding proteins utilizing human protein arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; INTRINSIC DISORDER; SULFATED GLYCOSAMINOGLYCANS; HEPARAN-SULFATE; SCALE; DATABASE; CELLS; SITES; PHOSPHORYLATION; COMPLEXES	The existence of interactions between many cellular proteins and various polyanionic surfaces within a cell is now well established. The functional role of such interactions, however, remains to be clearly defined. The existence of protein arrays, with a large selection of different kinds of proteins, provides a way to better address a number of aspects of this question. We have therefore investigated the interaction between five cellular polyanions (actin, tubulin, heparin, heparan sulfate, and DNA) and similar to 5,000 human proteins using protein microarrays in an attempt to better understand the functional nature of such interaction(s). We demonstrate that a large number of polyanion-binding proteins exist that contain multiple positively charged regions, are often disordered, are involved in phosphorylation processes, and appear to play a role in protein-protein interaction networks. Considering the crowded nature of cellular interiors, we propose that polyanion-binding proteins interact with a wide variety of polyanionic surfaces in cells in a functionally significant manner.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Univ Kansas, Bioinformat Core Facil, Lawrence, KS 66047 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA; Max Planck Inst Informat, D-66123 Saarbrucken, Germany	University of Kansas; University of Kansas; Stowers Institute for Medical Research; Max Planck Society	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2030 Becker Dr, Lawrence, KS 66047 USA.	middaugh@ku.edu	Albrecht, Mario/B-6694-2008	Albrecht, Mario/0000-0002-3103-9624	NCRR NIH HHS [P20 RR016475] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albert R, 2005, J CELL SCI, V118, P4947, DOI 10.1242/jcs.02714; Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Chantalat S, 2003, MOL BIOL CELL, V14, P2357, DOI 10.1091/mbc.E02-10-0693; Conrad H. E., 1998, HEPARIN BINDING PROT; DABORA JM, 1991, J BIOL CHEM, V266, P23637; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; Deleault NR, 2005, J BIOL CHEM, V280, P26873, DOI 10.1074/jbc.M503973200; Diella F, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-79; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Fang JW, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-277; Fitzgerald J, 2000, BRAIN RES, V877, P110, DOI 10.1016/S0006-8993(00)02692-5; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Jones LS, 2004, MOL CELL PROTEOMICS, V3, P746, DOI 10.1074/mcp.R400008-MCP200; Kueltzo LA, 2000, J BIOL CHEM, V275, P33213, DOI 10.1074/jbc.M002476200; Kueltzo LA, 2000, EXPERT OPIN INV DRUG, V9, P2039, DOI 10.1517/13543784.9.9.2039; Kurakin A, 2005, DEV GENES EVOL, V215, P46, DOI 10.1007/s00427-004-0448-7; Li JP, 2005, P NATL ACAD SCI USA, V102, P6473, DOI 10.1073/pnas.0502287102; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Liu JG, 2006, BIOCHEMISTRY-US, V45, P6873, DOI 10.1021/bi0602718; MACH H, 1993, BIOCHEMISTRY-US, V32, P7703, DOI 10.1021/bi00081a015; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Miteva MA, 2005, NUCLEIC ACIDS RES, V33, pW372, DOI 10.1093/nar/gki365; Mitsi M, 2006, BIOCHEMISTRY-US, V45, P10319, DOI 10.1021/bi060974p; Mulder NJ, 2005, NUCLEIC ACIDS RES, V33, pD201, DOI 10.1093/nar/gki106; O'Brien KP, 2005, NUCLEIC ACIDS RES, V33, pD476, DOI 10.1093/nar/gki107; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Rentzeperis D, 1999, NAT STRUCT BIOL, V6, P569; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Salamat-Miller N, 2006, MOL CELL PROTEOMICS, V5, P2263, DOI 10.1074/mcp.M600240-MCP200; Samanta MP, 2003, P NATL ACAD SCI USA, V100, P12579, DOI 10.1073/pnas.2132527100; Schweitzer B, 2003, PROTEOMICS, V3, P2190, DOI 10.1002/pmic.200300610; Sedlak E, 1998, BIOPOLYMERS, V46, P145, DOI 10.1002/(SICI)1097-0282(199809)46:3<145::AID-BIP2>3.0.CO;2-L; Spitzer JJ, 2005, TRENDS BIOCHEM SCI, V30, P536, DOI 10.1016/j.tibs.2005.08.002; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Tang C, 2006, NATURE, V444, P383, DOI 10.1038/nature05201; TEMPLETON DM, 1988, INT J BIOL MACROMOL, V10, P131, DOI 10.1016/0141-8130(88)90038-4; TSAI PK, 1993, PHARMACEUT RES, V10, P649, DOI 10.1023/A:1018939228201; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; WOLLIN A, 1973, Thrombosis Research, V2, P377, DOI 10.1016/0049-3848(73)90048-0; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; YU Q, 1995, BIOTECHNIQUES, V19, P122	56	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10153	10163		10.1074/jbc.M610957200	http://dx.doi.org/10.1074/jbc.M610957200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17276992	hybrid			2022-12-27	WOS:000245941000005
J	Wright, CW; Rumble, JM; Duckett, CS				Wright, Casey W.; Rumble, Julie M.; Duckett, Colin S.			CD30 activates both the canonical and alternative NF-kappa B pathways in anaplastic large cell lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; REED-STERNBERG CELLS; NEGATIVE SELECTION; NF-KAPPA-B1 P105; HODGKINS-LYMPHOMA; TNF RECEPTOR-1; FACTOR FAMILY; CYCLE ARREST; T-CELLS; NPM-ALK	CD30 is a member of the tumor necrosis factor receptor superfamily whose expression is up-regulated on anaplastic large cell lymphoma ( ALCL) and Hodgkin lymphoma ( HL) cells. Many different outcomes of CD30 stimulation have been reported, including cell cycle arrest, apoptosis, and activation of the prosurvival transcription factor, NF-kappa B, although this last activity is much less well defined in ALCL cells. In order to better understand the signaling properties of CD30 in cancer, we established a system for the stimulation of CD30 with its physiological ligand. Using this system, CD30 was stimulated on ALCL and HL cells, and the subsequent CD30 signaling properties were characterized. We show that a fraction of ALCL cells rapidly underwent apoptosis following CD30 stimulation, whereas HL cells were unaffected. The surviving ALCL cells exhibited robust activation of both the canonical and alternative NF-kappa B pathways as measured by nuclear translocation of RelA, p50, RelB, and p52, and this culminated in the transactivation of classical NF-kappa B-responsive genes. With prolonged CD30 stimulation, ALCL cells underwent cell cycle arrest that correlated with expression of the cell cycle inhibitor p21(waf1). Furthermore, p21(waf1) expression and cell cycle arrest were found to depend predominantly on the canonical NF-kappa B pathway, since it was reversed byRNAinterference- mediated suppression of RelA. In contrast, suppression of the p100/ p52 NF-kappa B subunit had little effect on p21(waf1). These data reveal that in ALCL cells, in contrast to other cell types, CD30 stimulation elicits p21(waf1)-mediated arrest through the canonical but not the alternative NF-kappa B pathway.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Mol Mech Dis Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Duckett, CS (corresponding author), Univ Michigan, Dept Pathol, 2057 BSRB, Ann Arbor, MI 48109 USA.	colind@umich.edu		Wright, Casey/0000-0002-9512-1264; Duckett, Colin/0000-0001-9413-2263	NHLBI NIH HHS [T32 HL07517] Funding Source: Medline; NIAID NIH HHS [T32 AI007413-12] Funding Source: Medline; NIGMS NIH HHS [GM067827] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067827] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa S, 1997, J BIOL CHEM, V272, P2042; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chiarle R, 1999, CLIN IMMUNOL, V90, P157, DOI 10.1006/clim.1998.4636; Chiarle R, 1999, J IMMUNOL, V163, P194; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; DeYoung AL, 2000, J IMMUNOL, V165, P6170, DOI 10.4049/jimmunol.165.11.6170; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Harper J.V., 2005, CELL CYCLE CONTROL, P113; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Horie R, 2004, CANCER CELL, V5, P353, DOI 10.1016/S1535-6108(04)00084-4; Hubinger G, 2001, ONCOGENE, V20, P590, DOI 10.1038/sj.onc.1204128; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Levi E, 2001, BLOOD, V98, P1630, DOI 10.1182/blood.V98.5.1630; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Mir SS, 2000, BLOOD, V96, P4307; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nishikori M, 2005, CANCER SCI, V96, P487, DOI 10.1111/j.1349-7006.2005.00078.x; Nonaka M, 2005, ONCOGENE, V24, P3976, DOI 10.1038/sj.onc.1208564; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; STEIN H, 1985, BLOOD, V66, P848; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watanabe M, 2005, CANCER RES, V65, P7628, DOI 10.1158/0008-5472.CAN-05-0925; Younes A, 1999, INT J BIOL MARKER, V14, P135, DOI 10.1177/172460089901400303; Younes A, 2003, CANCER-AM CANCER SOC, V98, P458, DOI 10.1002/cncr.11524; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2005, ONCOGENE, V24, P7114, DOI 10.1038/sj.onc.1208853; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	43	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10252	10262		10.1074/jbc.M608817200	http://dx.doi.org/10.1074/jbc.M608817200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17261581	hybrid			2022-12-27	WOS:000245941000015
J	Ishiguro, A; Ideta, M; Mikoshiba, K; Chen, DJ; Aruga, J				Ishiguro, Akira; Ideta, Maki; Mikoshiba, Katsuhiko; Chen, David J.; Aruga, Jun			ZIC2-dependent transcriptional regulation is mediated by DNA-dependent protein kinase, poly(ADP-ribose) polymerase, and RNA helicase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSACTIVATION DOMAIN; NEURAL CREST DEVELOPMENT; XENOPUS-ZIC FAMILY; V(D)J RECOMBINATION; KU-AUTOANTIGEN; MOLECULAR-PROPERTIES; IN-VITRO; GENE; MOUSE; BINDING	The Zic family of zinc finger proteins is essential for animal development, as demonstrated by the holoprosencephaly caused by mammalian Zic2 mutation. To determine the molecular mechanism of Zic-mediated developmental control, we characterized two types of high molecular weight complexes, including Zic2. Complex I was composed of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), Ku70/80, and poly(ADP-ribose) polymerase; complex II contained Ku70/80 and RNA helicase A; all the components interacted directly with Zic2 protein. Immunoprecipitation, submiclear localization, and in vitro phosphorylation analyses revealed that the DNAPKcs in complex I played an essential role in the assembly of complex II. Stepwise exchange from complex I to complex II depended on phosphorylation of Zic2 by DNA-PK and poly(ADP-ribose) polymerase. Phosphorylated Zic2 protein made a stable complex with RNA helicase A, and complex II could interact with RNA polymerase II. Phosphorylation-dependent transformation of Zic2-containing molecular complexes may occur in transcriptional regulation.	RIKEN, Brain Sci Inst, Lab Comparat Neurogenesis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Dev Neurobiol, Wako, Saitama 3510198, Japan; Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA	RIKEN; RIKEN; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ishiguro, A (corresponding author), RIKEN, Brain Sci Inst, Lab Comparat Neurogenesis, Wako, Saitama 3510198, Japan.	akiraishiguro@brain.riken.go.jp; jaruga@brain.riken.go.jp	Aruga, Jun/H-5837-2011; Mikoshiba, Katsuhiko/N-7943-2015	Aruga, Jun/0000-0001-7936-1375; Ishiguro, Akira/0000-0003-1867-3134				Ame JC, 2001, J BIOL CHEM, V276, P11092, DOI 10.1074/jbc.M007870200; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Aratani S, 2003, INT J MOL MED, V12, P175; Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Aruga J, 2002, J NEUROSCI, V22, P218, DOI 10.1523/JNEUROSCI.22-01-00218.2002; Aruga J, 2002, DEV BIOL, V244, P329, DOI 10.1006/dbio.2002.0598; Aruga J, 2004, MOL CELL NEUROSCI, V26, P205, DOI 10.1016/j.mcn.2004.01.004; Aruga J, 2006, GENOMICS, V87, P783, DOI 10.1016/j.ygeno.2006.02.011; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; DVIR A, 1993, J BIOL CHEM, V268, P10440; Fukumura R, 1998, J BIOL CHEM, V273, P13058, DOI 10.1074/jbc.273.21.13058; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grinberg I, 2005, CLIN GENET, V67, P290, DOI 10.1111/j.1399-0004.2005.00418.x; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Hoshino J, 2003, MOL BRAIN RES, V120, P57, DOI 10.1016/j.molbrainres.2003.10.004; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; Inoue T, 2004, DEV BIOL, V270, P146, DOI 10.1016/j.ydbio.2004.02.017; Ishiguro A, 2004, BIOCHEM BIOPH RES CO, V324, P302, DOI 10.1016/j.bbrc.2004.09.052; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Koike M, 1999, J CELL SCI, V112, P4031; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lebrun P, 2005, J BIOL CHEM, V280, P38203, DOI 10.1074/jbc.M504842200; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; LIU SH, 1993, J BIOL CHEM, V268, P21147; Minakawa M, 1998, BRAIN RES, V813, P172, DOI 10.1016/S0006-8993(98)00979-2; Mizugishi K, 2004, BIOCHEM BIOPH RES CO, V320, P233, DOI 10.1016/j.bbrc.2004.05.158; Mizugishi K, 2001, J BIOL CHEM, V276, P2180, DOI 10.1074/jbc.M004430200; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; Nakata K, 2000, MECH DEVELOP, V99, P83, DOI 10.1016/S0925-4773(00)00480-9; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Salero E, 2001, J BIOL CHEM, V276, P1881, DOI 10.1074/jbc.M007008200; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Schild-Poulter C, 2003, DNA CELL BIOL, V22, P65, DOI 10.1089/104454903321515887; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Tetsuka T, 2004, EUR J BIOCHEM, V271, P3741, DOI 10.1111/j.1432-1033.2004.04314.x; Tzung TY, 1998, INT J RADIAT BIOL, V73, P469; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yagi K, 2004, DEV BIOL, V274, P478, DOI 10.1016/j.ydbio.2004.07.013; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426; Zhang QM, 2005, RADIAT RES, V164, P497, DOI 10.1667/RR3366.1; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933	65	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9983	9995		10.1074/jbc.M610821200	http://dx.doi.org/10.1074/jbc.M610821200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251188	hybrid			2022-12-27	WOS:000245421700073
J	Losasso, C; Cretaio, E; Palle, K; Pattarello, L; Bjornsti, MA; Benedetti, P				Losasso, Carmen; Cretaio, Erica; Palle, Komaraiah; Pattarello, Luca; Bjornsti, Mary-Ann; Benedetti, Piero			Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPTOTHECIN RESISTANCE; SINGLE MUTATION; ACTIVE-SITE; YEAST; SENSITIVITY; DOMAIN; RELAXATION; MECHANISMS; BINDING; ENZYME	Eukaryotic DNA topoisomerase I (Top1p) catalyzes changes in DNA topology via the formation of a covalent enzyme-DNA intermediate, which is reversibly stabilized by the anticancer agent camptothecin (CPT). Crystallographic studies of the 70-kDa C terminus of human Top1p bound to duplex DNA describe a monomeric protein clamp circumscribing the DNA helix. The structures, which lack the N-terminal domain, comprise the conserved clamp, an extended linker domain, and the conserved C-terminal active site Tyr domain. CPT bound to the covalent Top1p-DNA complex limits linker flexibility, allowing structural determination of this domain. We previously reported that mutation of Ala 653 to Pro in the linker increases the rate of enzyme-catalyzed DNA religation, thereby rendering Top1A653Pp resistant to CPT (Fiorani, P., Bruselles, A., Falconi, M., Chillemi, G., Desideri, A., and Benedetti P. (2003) J. Biol. Chem. 278, 43268 - 43275). Molecular dynamics studies suggested mutation-induced increases in linker flexibility alter Top1p catalyzed DNA religation. To address the functional consequences of linker flexibility on enzyme catalysis and drug sensitivity, we investigated the interactions of the A653P linker mutation with a self-poisoning T718A mutation within the active site of Top1p. The A653P mutation suppressed the lethal phenotype of Top1T718Ap in yeast, yet did not restore enzyme sensitivity to CPT. However, the specific activity of the double mutant was decreased in vivo and in vitro, consistent with a decrease in DNA binding. These findings support a model where changes in the flexibility or orientation of the linker alter the geometry of the active site and thereby the kinetics of DNA cleavage/religation catalyzed by Top1p.	Univ Padua, Dept Biol, I-35131 Padua, Italy; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38104 USA	University of Padua; St Jude Children's Research Hospital	Benedetti, P (corresponding author), Univ Padua, Dept Biol, Via U Bassi 58-B, I-35131 Padua, Italy.	pietro.benedetti@unipd.it	losasso, carmen/C-2928-2013; Losasso, Carmen/AAC-9790-2022; Losasso, Carmen/AAC-9734-2022	losasso, carmen/0000-0002-8234-1292; Losasso, Carmen/0000-0002-8234-1292; Losasso, Carmen/0000-0002-8234-1292; Cretaio, Erica/0000-0001-9654-5563	NATIONAL CANCER INSTITUTE [R01CA058755, P30CA021765, R01CA111542] Funding Source: NIH RePORTER; NCI NIH HHS [CA111542, CA21765, CA58755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEDETTI P, 1993, CANCER RES, V53, P4343; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chillemi G, 2005, NUCLEIC ACIDS RES, V33, P3339, DOI 10.1093/nar/gki642; Chillemi G, 2004, BIOPHYS J, V87, P4087, DOI 10.1529/biophysj.104.044925; Colley WC, 2004, J BIOL CHEM, V279, P54069, DOI 10.1074/jbc.M409764200; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2003, J BIOL CHEM, V278, P43268, DOI 10.1074/jbc.M303899200; Fiorani P, 2000, METH MOL B, V95, P291; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Ireton GC, 2000, J BIOL CHEM, V275, P25820, DOI 10.1074/jbc.M002144200; Jacquiau HR, 2005, J BIOL CHEM, V280, P23566, DOI 10.1074/jbc.M500947200; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; KAISER C, 1994, METHODS YEAST GENETI, P133; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; LEVIN NA, 1993, GENETICS, V133, P799; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Li TK, 2003, CANCER RES, V63, P8400; MCCONAUGHY BL, 1981, BIOCHIM BIOPHYS ACTA, V655, P1, DOI 10.1016/0005-2787(81)90059-9; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; van Waardenburg RCAM, 2006, MOL CELL BIOL, V26, P4958, DOI 10.1128/MCB.00160-06; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100	44	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9855	9864		10.1074/jbc.M608200200	http://dx.doi.org/10.1074/jbc.M608200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276985	hybrid			2022-12-27	WOS:000245421700060
J	Persson, M; Letts, JA; Hosseini-Maaf, B; Borisova, SN; Palcic, MM; Evans, SV; Olsson, ML				Persson, Mattias; Letts, James A.; Hosseini-Maaf, Bahram; Borisova, Svetlana N.; Palcic, Monica M.; Evans, Stephen V.; Olsson, Martin L.			Structural effects of naturally occurring human blood group B galactosyltransferase mutations adjacent to the DXD motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOR SUBSTRATE-SPECIFICITY; SINGLE-POINT MUTATION; MOLECULAR-GENETIC ANALYSIS; ENZYME-ACTIVITY; GROUP SYSTEM; GROUP-A; GLYCOSYLTRANSFERASES; BETA-1,4-GALACTOSYLTRANSFERASE-I; MUTAGENESIS; PROTEINS	Human blood group A and B antigens are produced by two closely related glycosyltransferase enzymes. An N-acetylgalactosaminyltransferase (GTA) utilizes UDP-GalNAc to extend H antigen acceptors (Fuc alpha(1-2)Gal beta-OR) producing A antigens, whereas a galactosyltransferase (GTB) utilizes UDP-Gal as a donor to extend H structures producing B antigens. GTA and GTB have a characteristic (DVD213)-D-211 motif that coordinates to a Mn2+ ion shown to be critical in donor binding and catalysis. Three GTB mutants, M214V, M214T, and M214R, with alterations adjacent to the (211)DVD213 motif have been identified in blood banking laboratories. From serological phenotyping, individuals with the M214R mutation show the B,1 variant expressing very low levels of B antigens, whereas those with M214T and M214V mutations give rise to A(weak)B phenotypes. Kinetic analysis of recombinant mutant GTB enzymes revealed that M214R has a 1200-fold decrease in k(cat) compared with wild type GTB. The crystal structure of M214R showed that DVD motif coordination to Mn2+ was disrupted by Arg-214 causing displacement of the metal by a water molecule. Kinetic characterizations of the M214T and M214V mutants revealed they both had GTA and GTB activity consistent with the serology. The crystal structure of the M214T mutant showed no change in DVD coordination to Mn2+. Instead a critical residue, Met-266, which is responsible for determining donor specificity, had adopted alternate conformations. The conformation with the highest occupancy opens up the active site to accommodate the larger A-specific donor, UDP-GalNAc, accounting for the dual specificity.	Carlsberg Lab, DK-2500 Copenhagen, Denmark; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Lund Univ, Div Hematol & Transfus Med, Dept Lab Med, SE-22185 Lund, Sweden; Univ Lund Hosp, Blood Ctr, SE-22185 Lund, Sweden	University of Victoria; Lund University; Lund University; Skane University Hospital	Palcic, MM (corresponding author), Carlsberg Lab, Gamle Carlsberg Vej 10, DK-2500 Copenhagen, Denmark.	monica@crc.dk; Martin_L.Olsson@med.lu.se	Letts, James Anthony/AAN-6632-2020	Letts, James Anthony/0000-0002-9864-3586; Olsson, Martin L/0000-0003-1647-9610; Evans, Stephen/0000-0002-0366-4027				Angulo J, 2006, J AM CHEM SOC, V128, P13529, DOI 10.1021/ja063550r; Blumenfeld OO, 2004, HUM MUTAT, V23, P8, DOI 10.1002/humu.10296; Breton C, 2006, GLYCOBIOLOGY, V16, p29R, DOI 10.1093/glycob/cwj016; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Butterfoss GL, 2003, PROTEIN SCI, V12, P2719, DOI 10.1110/ps.03273303; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; Deng ZH, 2005, VOX SANG, V89, P251, DOI 10.1111/j.1423-0410.2005.00697.x; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gotting C, 2004, J BIOL CHEM, V279, P42566, DOI 10.1074/jbc.M401340200; Gulberti S, 2003, J BIOL CHEM, V278, P32219, DOI 10.1074/jbc.M207899200; Hancock SM, 2006, CURR OPIN CHEM BIOL, V10, P509, DOI 10.1016/j.cbpa.2006.07.015; Hu YN, 2002, CHEM BIOL, V9, P1287, DOI 10.1016/S1074-5521(02)00295-8; Jank T, 2005, J BIOL CHEM, V280, P37833, DOI 10.1074/jbc.M506836200; Kubo A, 2004, ARCH BIOCHEM BIOPHYS, V429, P198, DOI 10.1016/j.abb.2004.06.021; Lee HJ, 2005, J BIOL CHEM, V280, P525, DOI 10.1074/jbc.M410245200; Li JG, 2001, GLYCOBIOLOGY, V11, P217, DOI 10.1093/glycob/11.3.217; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ogasawara K, 1996, BLOOD, V88, P2732, DOI 10.1182/blood.V88.7.2732.bloodjournal8872732; Olsson ML, 2001, BLOOD, V98, P1585, DOI 10.1182/blood.V98.5.1585; Ouzzine M, 2002, J BIOL CHEM, V277, P25439, DOI 10.1074/jbc.M201912200; Pak JE, 2006, J BIOL CHEM, V281, P26693, DOI 10.1074/jbc.M603534200; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Rajagopal S, 2005, FEBS J, V272, P1819, DOI 10.1111/j.1742-4658.2005.04604.x; Ramakrishnan B, 2005, BIOCHEMISTRY-US, V44, P3202, DOI 10.1021/bi0479454; Ramakrishnan B, 2002, J BIOL CHEM, V277, P20833, DOI 10.1074/jbc.M111183200; Roubinet F, 2002, TRANSFUSION, V42, P239, DOI 10.1046/j.1537-2995.2002.00030.x; Seltsam A, 2003, BLOOD, V102, P3035, DOI 10.1182/blood-2003-03-0955; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	38	17	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9564	9570		10.1074/jbc.M610998200	http://dx.doi.org/10.1074/jbc.M610998200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259183	hybrid			2022-12-27	WOS:000245421700029
J	Maegawa, GHB; Tropak, M; Buttner, J; Stockley, T; Kok, F; Clarke, JTR; Mahuran, DJ				Maegawa, Gustavo H. B.; Tropak, Michael; Buttner, Justin; Stockley, Tracy; Kok, Fernando; Clarke, Joe T. R.; Mahuran, Don J.			Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-HEXOSAMINIDASE; TAY-SACHS-DISEASE; SANDHOFF-DISEASE; MOLECULAR-BASIS; ALPHA-SUBUNIT; ADULT FORM; GM2-GANGLIOSIDOSIS-B1 VARIANT; ENHANCEMENT THERAPIES; ENZYME REPLACEMENT; ACTIVATOR PROTEIN	Late-onset GM2 gangliosidosis is composed of two related, autosomal recessive, neurodegenerative diseases, both resulting from deficiency of lysosomal, heterodimeric beta-hexosaminidase A (Hex A, alpha beta). Pharmacological chaperones (PC) are small molecules that can stabilize the conformation of a mutant protein, allowing it to pass the quality control system of the endoplasmic reticulum. To date all successful PCs have also been competitive inhibitors. Screening for Hex A inhibitors in a library of 1040 Food Drug Administration-approved compounds identified pyrimethamine (PYR (2,4-diamino 5-(4-chlorophenyl)-6-ethylpyrimidine)) as the most potent inhibitor. Cell lines from 10 late-onset Tay-Sachs (11 a-mutations, 2 novel) and 7 Sandhoff (9 beta-mutations, 4 novel) disease patients, were cultured with PYR at concentrations corresponding to therapeutic doses. Cells carrying the most common late-onset mutation, alpha G269S, showed significant increases in residual Hex A activity, as did all 7 of the beta-mutants tested. Cells responding to PC treatment included those carrying mutants resulting in reduced Hex heat stability and partial splice junction mutations of the inherently less stable a-subunit. PYR, which binds to the active site in domain II, was able to function as PC even to domain I beta-mutants. We concluded that PYR functions as a mutation-specific PC, variably enhancing residual lysosomal Hex A levels in late-onset GM2 gangliosidosis patient cells.	Hosp Sick Children, Res Inst, Div Clin & Metab Genet, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 1L5, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Sao Paulo, Fac Med, Dept Neurol, BR-01246903 Sao Paulo, Brazil	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Universidade de Sao Paulo	Mahuran, DJ (corresponding author), Rm 9146,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hex@sickkids.ca	Stockley, Tracy/AAW-6561-2021	Stockley, Tracy/0000-0002-4476-9722; Maegawa, Gustavo/0000-0001-6933-4138	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS051214] Funding Source: NIH RePORTER; NINDS NIH HHS [R21 NS051214-01, R21 NS051214-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akerman B. R., 1992, Human Mutation, V1, P303, DOI 10.1002/humu.1380010407; AKLI S, 1993, HUM MOL GENET, V2, P61, DOI 10.1093/hmg/2.1.61; Apic G, 2001, Bioinformatics, V17 Suppl 1, pS83; ARNOLD LA, 2006, SCI STKE, P13; BOLHUIS PA, 1993, BIOCHIM BIOPHYS ACTA, V1182, P142, DOI 10.1016/0925-4439(93)90134-M; BROWN CA, 1993, AM J HUM GENET, V53, P497; Buxton IL, 2006, GOODMAN GILMANS PHAR; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; DAZZO A, 1984, J BIOL CHEM, V259, P1070; Desnick RJ, 2004, J INHERIT METAB DIS, V27, P385, DOI 10.1023/B:BOLI.0000031101.12838.c6; Desnick RJ, 2002, NAT REV GENET, V3, P954, DOI 10.1038/nrg963; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; Hou YM, 1998, J BIOL CHEM, V273, P21386, DOI 10.1074/jbc.273.33.21386; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; Kaback MM, 2000, EUR J PEDIATR, V159, pS192, DOI 10.1007/PL00014401; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; Lemieux MJ, 2006, J MOL BIOL, V359, P913, DOI 10.1016/j.jmb.2006.04.004; Leport C, 1996, J INFECT DIS, V173, P91, DOI 10.1093/infdis/173.1.91; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maegawa GHB, 2006, PEDIATRICS, V118, pE1550, DOI 10.1542/peds.2006-0588; MAHURAN D, 1980, CAN J BIOCHEM CELL B, V58, P287, DOI 10.1139/o80-038; Mark BL, 2003, J MOL BIOL, V327, P1093, DOI 10.1016/S0022-2836(03)00216-X; Matsuda J, 2003, P NATL ACAD SCI USA, V100, P15912, DOI 10.1073/pnas.2536657100; MCINNES B, 1992, J CLIN INVEST, V90, P306, DOI 10.1172/JCI115863; Mules Emilie H., 1992, Human Mutation, V1, P298, DOI 10.1002/humu.1380010406; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAKANO T, 1989, J BIOL CHEM, V264, P5155; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; NEOTE K, 1990, J CLIN INVEST, V86, P1524, DOI 10.1172/JCI114871; Neudorfer O, 2005, GENET MED, V7, P119, DOI 10.1097/01.GIM.0000154300.84107.75; OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x; PAW BH, 1990, J BIOL CHEM, V265, P9452; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RODRIGUEZPARIS JM, 1993, J BIOL CHEM, V268, P9110; SAGHERIAN C, 1994, BIOCHEM BIOPH RES CO, V204, P135, DOI 10.1006/bbrc.1994.2436; SAGHERIAN C, 1993, BIOCHEM CELL BIOL, V71, P340, DOI 10.1139/o93-051; Sambrook J., 2001, MOL CLONING LAB MANU; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Sharma R, 2003, BBA-MOL BASIS DIS, V1637, P113, DOI 10.1016/S0925-4439(02)00221-1; SmiljanicGeorgijev N, 1997, BBA-PROTEIN STRUCT M, V1339, P192, DOI 10.1016/S0167-4838(97)00002-2; TANAKA A, 1990, AM J HUM GENET, V46, P329; Teichmann SA, 2001, TRENDS BIOTECHNOL, V19, P482, DOI 10.1016/S0167-7799(01)01813-3; Tominaga L, 2001, BRAIN DEV-JPN, V23, P284, DOI 10.1016/S0387-7604(01)00216-9; Tropak MB, 2004, J BIOL CHEM, V279, P13478, DOI 10.1074/jbc.M308523200; Verkman AS, 2006, CURR PHARM DESIGN, V12, P2235, DOI 10.2174/138161206777585148; WAKAMATSU N, 1992, J BIOL CHEM, V267, P2406; WEISS LM, 1988, J INFECT DIS, V157, P580, DOI 10.1093/infdis/157.3.580; WEISS LM, 1992, AM J TROP MED HYG, V46, P288, DOI 10.4269/ajtmh.1992.46.288; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	54	126	127	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9150	9161		10.1074/jbc.M609304200	http://dx.doi.org/10.1074/jbc.M609304200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17237499	Green Accepted, hybrid			2022-12-27	WOS:000245780300062
J	Miller, S; Kastner, S; Krijnse-Locker, J; Buhler, S; Bartenschlager, R				Miller, Sven; Kastner, Stefan; Krijnse-Locker, Jacomine; Buehler, Sandra; Bartenschlager, Ralf			The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEST-NILE-VIRUS; RNA REPLICATION; NS3 PROTEIN; NS2B-3 PROTEINASE; FLAVIVIRUS KUNJIN; NS4B PROTEIN; STRANDED-RNA; IDENTIFICATION; INTERFERON; CURVATURE	Dengue virus (DV) is a positive sense RNA virus replicating in the cytoplasm in membranous compartments that are induced by viral infection. The non-structural protein (NS) 4A is one of the least characterized DV proteins. It is highly hydrophobic with its C-terminal region (designated 2K fragment) serving as a signal sequence for the translocation of the adjacent NS4B into the endoplasmic reticulum (ER) lumen. In this report, we demonstrate that NS4A associates with membranes via 4 internal hydrophobic regions, which are all able to mediate membrane targeting of a cytosolic reporter protein. We also developed a model for the membrane topology of NS4A in which the N-terminal third of NS4A localizes to the cytoplasm, while the remaining part contains three transmembrane segments, with the C-terminal end localized in the ER lumen. Subcellular localization experiments in DV-infected cells revealed that NS4A resides primarily in ER-derived cytoplasmic dot-like structures that also contain dsRNA and other DV proteins, suggesting that NS4A is a component of the membrane-bound viral replication complex (RC). Interestingly, the individual expression of DV NS4A lacking the 2K fragment resulted in the induction of cytoplasmic membrane alterations resembling virus-induced structures, whereas expression of full-length NS4A does not induce comparable membrane alterations. Thus, proteolytic removal of the 2K peptide appears to be important for induction of membrane alterations that may harbor the viral RC. These results shed new light on the role of NS4A in the DV replication cycle and provide a model of how this protein induces membrane rearrangements and how this property may be regulated.	Univ Heidelberg, Dept Mol Virol, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL)	Buhler, S (corresponding author), Univ Heidelberg, Dept Mol Virol, Bergheimer Str 58, D-69120 Heidelberg, Germany.	sandra_sparacio@med.uni-heidelberg.de; ralf_bartenschlager@med.uni-heidelberg.de	Locker, Jacomine Krijnse/E-1009-2016; Locker, Jacomine Krijnse/AAX-1185-2020; Bartenschlager, Ralf/L-2582-2015	Bartenschlager, Ralf/0000-0001-5601-9307				AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994; AnandaRao R, 2005, VIRUS RES, V112, P60, DOI 10.1016/j.virusres.2005.03.022; Appel N, 2005, J VIROL, V79, P3187, DOI 10.1128/JVI.79.5.3187-3194.2005; BONIFACINO JS, 2000, CHARACTERIZATION CEL; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHU PWG, 1992, ARCH VIROL, V125, P177, DOI 10.1007/BF01309636; CHU PWG, 1992, J VIROL METHODS, V37, P219, DOI 10.1016/0166-0934(92)90049-J; CLEAVES GR, 1979, VIROLOGY, V96, P159, DOI 10.1016/0042-6822(79)90181-8; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; Guo JT, 2005, J VIROL, V79, P1343, DOI 10.1128/JVI.79.3.1343-1350.2005; Kaariainen L, 2002, PROG NUCLEIC ACID RE, V71, P187, DOI 10.1016/S0079-6603(02)71044-1; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; LEARY K, 1980, J ULTRA MOL STRUCT R, V72, P123, DOI 10.1016/S0022-5320(80)90050-7; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999; Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997; Liu WJ, 2005, J VIROL, V79, P1934, DOI 10.1128/JVI.79.3.1934-1942.2005; Mackenzie J, 2005, TRAFFIC, V6, P967, DOI 10.1111/j.1600-0854.2005.00339.x; Mackenzie JM, 1998, VIROLOGY, V245, P203, DOI 10.1006/viro.1998.9156; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; MILLER S, 2006, J BIOL CHEM; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Munoz-Jordan JL, 2005, J VIROL, V79, P8004, DOI 10.1128/JVI.79.13.8004-8013.2005; Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100; Muylaert IR, 1997, J VIROL, V71, P291, DOI 10.1128/JVI.71.1.291-298.1997; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NG ML, 1989, ARCH VIROL, V106, P103, DOI 10.1007/BF01311042; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Roosendaal J, 2006, J VIROL, V80, P4623, DOI 10.1128/JVI.80.9.4623-4632.2006; SAMBROOK J, 2001, MOL CLONIGN LAB MANU; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; Umareddy I, 2006, J GEN VIROL, V87, P2605, DOI 10.1099/vir.0.81844-0; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997; Yu GY, 2006, J VIROL, V80, P6013, DOI 10.1128/JVI.00053-06; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	41	320	327	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8873	8882		10.1074/jbc.M609919200	http://dx.doi.org/10.1074/jbc.M609919200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17276984	hybrid			2022-12-27	WOS:000245780300034
J	Shelton, MD; Kern, TS; Mieyal, JJ				Shelton, Melissa D.; Kern, Timothy S.; Mieyal, John J.			Glutaredoxin regulates nuclear factor kappa-B and intercellular adhesion molecule in Muller cells - Model of diabetic retinopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYMES; OXIDATIVE STRESS; S-GLUTATHIONYLATION; REDOX REGULATION; GLIAL-CELLS; THIOLTRANSFERASE GLUTAREDOXIN; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; 20S PROTEASOME; COMPLEX-I	Reversible S-glutathionylation of proteins is a focal point of redox signaling and cellular defense against oxidative stress. This post-translational modification alters protein function, and its reversal ( deglutathionylation) is catalyzed specifically and efficiently by glutaredoxin ( GRx, thioltransferase), a thioldisulfide oxidoreductase. We hypothesized that changes in glutaredoxin might be important in the development of diabetic retinopathy, a condition characterized by oxidative stress. Indeed, GRx protein and activity were increased in retinal homogenates from streptozotocin-diabetic rats. Also, incubation of rat retinal Muller cells ( rMC-1) in normal glucose ( 5 mM) or diabetic-like glucose ( 25 mM) medium led to selective up-regulation of GRx in contrast to thioredoxin, the other thioldisulfide oxidoreductase system. Under analogous conditions, NF-kappa B ( p50-p65) translocated to the nucleus, and expression of ICAM-1 ( intercellular adhesion molecule-1), a transcriptional product of NF-kappa B, increased. Proinflammatory ICAM-1 is increased in diabetic retinae, and it is implicated in pathogenesis of retinopathy. To evaluate the role of GRx in mediating these changes, intracellular GRx content and activity in rMC-1cells were increased independently under normal glucose via infection with an adenoviral GRx1 construct ( Ad-GRx). rMC-1 cells exhibited adenovirus concentration-dependent increases in GRx and corresponding increases in NF-kappa B nuclear translocation, NF-kappa B luciferase reporter activity, and ICAM-1 expression. Blocking the increase in GRx1 via small interfering RNA in rMC-1 cells in high glucose prevented the increased ICAM-1 expression. These data suggest that redox regulation by glutaredoxin in retinal glial cells is perturbed by hyperglycemia, leading to NF-kappa B activation and a pro-inflammatory response. Thus, GRx may represent a novel therapeutic target to inhibit diabetic retinopathy.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Mieyal, JJ (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 2109 Adelbert Rd,WRT300-9, Cleveland, OH 44106 USA.	JJM5@case.edu			NEI NIH HHS [5 T32 EY07157] Funding Source: Medline; NIA NIH HHS [P01 AG15885, R01 AG024413] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024413, P01AG015885] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Akterin S, 2006, CELL DEATH DIFFER, V13, P1454, DOI 10.1038/sj.cdd.4401818; BALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P681; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Biaglow JE, 2000, ANAL BIOCHEM, V281, P77, DOI 10.1006/abio.2000.4533; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Gerhardinger C, 2005, INVEST OPHTH VIS SCI, V46, P349, DOI 10.1167/iovs.04-0860; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRAVINA SA, 1993, THESIS CASE W RESERV; Hamnell-Pamment Y, 2005, BIOCHEM BIOPH RES CO, V332, P362, DOI 10.1016/j.bbrc.2005.04.130; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jeon KI, 2003, EXP MOL MED, V35, P61, DOI 10.1038/emm.2003.9; Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kenchappa RS, 2003, FASEB J, V17, P717, DOI 10.1096/fj.02-0771fje; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Li X, 2005, AM J PHYSIOL-HEART C, V288, pH1417, DOI 10.1152/ajpheart.00559.2004; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Miklossy J, 2006, EXP NEUROL, V197, P275, DOI 10.1016/j.expneurol.2005.10.034; Moorthy AK, 2006, EMBO J, V25, P1945, DOI 10.1038/sj.emboj.7601081; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Peltoniemi MJ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-133; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; POW DV, 1995, NEUROSCI LETT, V193, P25, DOI 10.1016/0304-3940(95)11657-I; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sawada M, 2006, J NEURAL TRANSM-SUPP, P373; Schutte M, 1998, NEUROSCI LETT, V246, P53, DOI 10.1016/S0304-3940(98)00229-8; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Shrikant P, 1996, J IMMUNOL, V156, P1307; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; THOMSON JJ, 1903, CONDUCTION ELECT GAS, P258; Wang J, 2003, P NATL ACAD SCI USA, V100, P5103, DOI 10.1073/pnas.0931345100; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; Zheng L, 2004, DIABETES, V53, P2960, DOI 10.2337/diabetes.53.11.2960	56	100	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12467	12474		10.1074/jbc.M610863200	http://dx.doi.org/10.1074/jbc.M610863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324929	hybrid			2022-12-27	WOS:000245942800015
J	Xu, L; Chong, YH; Hwang, IY; D'Onofrio, A; Amore, K; Beardsley, GP; Li, CL; Olson, AJ; Boger, DL; Wilson, IA				Xu, Lan; Chong, Youhoon; Hwang, Inkyu; D'Onofrio, Anthony; Amore, Kristen; Beardsley, G. Peter; Li, Chenglong; Olson, Arthur J.; Boger, Dale L.; Wilson, Ian A.			Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN AICAR TRANSFORMYLASE; IMP CYCLOHYDROLASE; RIBONUCLEOTIDE TRANSFORMYLASE; CATALYTIC MECHANISM; PURIFICATION; ENZYME; EXPRESSION; INSIGHTS; COMPLEX; BINDING	The inosine monophosphate cyclohydrolase (IMPCH) component (residues 1-199) of the bifunctional enzyme aminoimidazole-4-carboxamide ribonucleotide transformylase (AICAR Tfase, residues 200-593)/IMPCH (ATIC) catalyzes the final step in the de novo purine biosynthesis pathway that produces IMP. As a potential target for antineoplastic intervention, we designed IMPCH inhibitors, 1,5-dihydroimidazo[4,5-c][1,2,6] thiadiazin-4(3H)-one 2,2-dioxide (heterocycle, 1), the corresponding nucleoside (2), and the nucleoside monophosphate (nucleotide) (3), as mimics of the tetrahedral intermediate in the cyclization reaction. All compounds are competitive inhibitors against IMPCH (K-i values = 0.13-0.23 mu M) with the simple heterocycle 1 exhibiting the most potent inhibition (K-i = 0.13 nM). Crystal structures of bifunctional ATIC in complex with nucleoside 2 and nucleotide 3 revealed IMPCH binding modes similar to that of the IMPCH feedback inhibitor, xanthosine 5'-monophosphate. Surprisingly, the simpler heterocycle 1 had a completely different IMPCH binding mode and was relocated to the phosphate binding pocket that was identified from previous xanthosine 5'-monophosphate structures. The aromatic imidazole ring interacts with a helix dipole, similar to the interaction with the phosphate moiety of 3. The crystal structures not only revealed the mechanism of inhibition of these compounds, but they now serve as a platform for future inhibitor improvements. Importantly, the nucleoside-complexed structure supports the notion that inhibitors lacking a negatively charged phosphate can still inhibit IMPCH activity with comparable potency to phosphate-containing inhibitors. Provocatively, the nucleotide inhibitor 3 also binds to the AICAR Tfase domain of ATIC, which now provides a lead compound for the design of inhibitors that simultaneously target both active sites of this bifunctional enzyme.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Yale Univ, Sch Med, Dept Pediat & Pharmacol, New Haven, CT 06520 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Yale University	Boger, DL (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	boger@scripps.edu; wilson@scripps.edu	Li, Chenglong/E-7182-2010	Li, Chenglong/0000-0003-3174-8719; Hwang, Inkyu/0000-0001-8997-6090	NATIONAL CANCER INSTITUTE [P01CA063536, R24CA095830] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008605] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA063536, R24 CA95830, P01 CA63536] Funding Source: Medline; NCRR NIH HHS [P41 RR08605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEARDSLEY GP, 1997, PURINE PYRIMIDINE ME, P221; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulock KG, 2002, J BIOL CHEM, V277, P22168, DOI 10.1074/jbc.M111964200; Cheong CG, 2004, J BIOL CHEM, V279, P18034, DOI 10.1074/jbc.M313691200; Christopherson RI, 2002, ACCOUNTS CHEM RES, V35, P961, DOI 10.1021/ar0000509; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Efferth T, 2003, BIOCHEM PHARMACOL, V66, P613, DOI 10.1016/S0006-2952(03)00341-1; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; IMAI KI, 1969, J ORG CHEM, V34, P1547, DOI 10.1021/jo01258a004; Jackson RC., 1981, NUCLEOSIDES CANC TRE, P18; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CL, 2004, J MED CHEM, V47, P6681, DOI 10.1021/jm049504o; MEYER RB, 1979, J MED CHEM, V22, P944, DOI 10.1021/jm00194a011; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JD, 2002, J MED CHEM, V45, P5295, DOI 10.1021/jm020258v; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; Shim JH, 2001, J AM CHEM SOC, V123, P4687, DOI 10.1021/ja010014k; SRIVASTAVA PC, 1974, J MED CHEM, V17, P1207, DOI 10.1021/jm00257a600; SZABADOS E, 1994, BIOCHEMISTRY-US, V33, P14237, DOI 10.1021/bi00251a036; Szabados E, 1998, BIOCHEM MOL BIOL INT, V44, P617; Vergis JM, 2004, BIOCHEMISTRY-US, V43, P1184, DOI 10.1021/bi035139b; Wall M, 2000, BIOCHEMISTRY-US, V39, P11303, DOI 10.1021/bi0007268; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wolan DW, 2004, BIOCHEMISTRY-US, V43, P1171, DOI 10.1021/bi030162i; Wolan DW, 2003, BIOCHEMISTRY-US, V42, P10904, DOI 10.1021/bi030106h; Wolan DW, 2002, BIOCHEMISTRY-US, V41, P15505, DOI 10.1021/bi020505x; Xu L, 2004, J BIOL CHEM, V279, P50555, DOI 10.1074/jbc.M406801200	35	16	16	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13033	13046		10.1074/jbc.M607293200	http://dx.doi.org/10.1074/jbc.M607293200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324932	hybrid			2022-12-27	WOS:000245942800073
J	Zhang, Y; Deng, Q; Barbieri, JT				Zhang, Yue; Deng, Qing; Barbieri, Joseph T.			Intracellular localization of type III-delivered Pseudomonas ExoS with endosome vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA EXOENZYME-S; GTPASE-ACTIVATING PROTEIN; TRANS-GOLGI NETWORK; IMPORTANT VIRULENCE MECHANISM; PLASMA-MEMBRANE; ADP-RIBOSYLATION; IN-VIVO; TERMINAL DOMAIN; EARLY/RECYCLING ENDOSOMES; EUKARYOTIC CELLS	ExoS (453 amino acids) is a bi-functional type III cytotoxin produced by Pseudomonas aeruginosa. Residues 96-219 include the Rho GTPase- activating protein (RhoGAP) domain, and residues 234-453 include the 14-3-3-dependent ADP-ribosyltransferase domain. Earlier studies also identified an N-terminal domain (termed the membrane localization domain) that comprises residues 51-77 and includes a novel leucine-rich motif that targets ExoS to the perinuclear region of cultured cells. There is limited information on how ExoS or other type III cytotoxins enter and target intracellular host proteins. Type III-delivered ExoS localized to both plasma membrane and perinuclear region, whereas ExoS(Delta MLD) was localized to the cytosol. Plasma membrane localization of ExoS was transient and had a half-life of similar to 20 min. Type III-delivered ExoS co-immunoprecipitated 14-3-3 proteins and Rab9, Rab6, and Rab5. Immunofluorescence experiments showed that ExoS colocalized with Rab9, Rab6, and Rab5. Fluorescent energy transfer was detected between ExoS and 14-3-3 proteins but not between ExoS and Rabs proteins. Together, these results indicate that type III-delivered ExoS localizes on the host endosomes and utilizes multiple pathways to traffic from the plasma membrane to the perinuclear region of intoxicated host cells.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jtb01@mcw.edu	Deng, Qing/AAC-1123-2020; Deng, Qing/G-3923-2011	Deng, Qing/0000-0002-9254-9951; 	NIAID NIH HHS [AI030162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHNERTHILGER G, 1992, BIOCHEM J, V284, P321, DOI 10.1042/bj2840321; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O; Barbieri JT, 2000, INT J MED MICROBIOL, V290, P381; Benabdillah R, 2004, MICROB PATHOGENESIS, V36, P247, DOI 10.1016/j.micpath.2003.12.006; BODEY GP, 1983, REV INFECT DIS, V5, P279; Boutros R, 2003, J MOL BIOL, V332, P675, DOI 10.1016/S0022-2836(03)00944-6; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Centonze VE, 2003, METHOD ENZYMOL, V360, P542; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Del Nery E, 2006, TRAFFIC, V7, P394, DOI 10.1111/j.1600-0854.2006.00395.x; Deleuil F, 2003, CELL MICROBIOL, V5, P53, DOI 10.1046/j.1462-5822.2003.00236.x; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; Frithz-Lindsten E, 1998, MOL MICROBIOL, V29, P1155, DOI 10.1046/j.1365-2958.1998.00994.x; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Henriksson ML, 2002, BIOCHEM J, V367, P617, DOI 10.1042/BJ20020714; Henriksson ML, 2002, EUR J BIOCHEM, V269, P4921, DOI 10.1046/j.1432-1033.2002.03191.x; Hoja MR, 2000, EXP CELL RES, V259, P239, DOI 10.1006/excr.2000.4948; IGLEWSKI BH, 1978, P NATL ACAD SCI USA, V75, P3211, DOI 10.1073/pnas.75.7.3211; Iversen TG, 2001, MOL BIOL CELL, V12, P2099, DOI 10.1091/mbc.12.7.2099; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Krall R, 2004, J BIOL CHEM, V279, P2747, DOI 10.1074/jbc.M301963200; Krall R, 2002, INFECT IMMUN, V70, P360, DOI 10.1128/IAI.70.1.360-367.2002; KULICH SM, 1995, INFECT IMMUN, V63, P1; Lencer WI, 2005, BBA-MOL CELL RES, V1746, P314, DOI 10.1016/j.bbamcr.2005.07.007; Letzelter M, 2006, EMBO J, V25, P3223, DOI 10.1038/sj.emboj.7601202; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Massol RH, 2004, MOL BIOL CELL, V15, P3631, DOI 10.1091/mbc.E04-04-0283; McDonald C, 2003, J BIOL CHEM, V278, P18514, DOI 10.1074/jbc.M301226200; MELBY EL, 1991, J CELL BIOCHEM, V47, P251, DOI 10.1002/jcb.240470311; MENDELSON MH, 1994, CLIN INFECT DIS, V18, P886, DOI 10.1093/clinids/18.6.886; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Pederson KJ, 1998, MOL MICROBIOL, V30, P751, DOI 10.1046/j.1365-2958.1998.01106.x; Pederson KJ, 1999, MOL MICROBIOL, V32, P393, DOI 10.1046/j.1365-2958.1999.01359.x; Pederson KJ, 2002, MOL MICROBIOL, V46, P1381, DOI 10.1046/j.1365-2958.2002.03256.x; Pederson KJ, 2000, MOL MICROBIOL, V37, P287, DOI 10.1046/j.1365-2958.2000.01990.x; Persson C, 1999, MOL MICROBIOL, V33, P828, DOI 10.1046/j.1365-2958.1999.01529.x; Rabin SDP, 2006, INFECT IMMUN, V74, P2552, DOI 10.1128/IAI.74.5.2552-2561.2006; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Riese MJ, 2002, INFECT IMMUN, V70, P2230, DOI 10.1128/IAI.70.4.2230-2232.2002; Rodman JS, 2000, J CELL SCI, V113, P183; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; Smith DC, 2006, TRAFFIC, V7, P379, DOI 10.1111/j.1600-0854.2006.00391.x; Stirling FR, 2006, CELL MICROBIOL, V8, P1294, DOI 10.1111/j.1462-5822.2006.00710.x; Sun JJ, 2003, J BIOL CHEM, V278, P32794, DOI 10.1074/jbc.M304290200; Utskarpen A, 2006, TRAFFIC, V7, P663, DOI 10.1111/j.1600-0854.2006.00418.x; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Willumsen BM, 1996, ONCOGENE, V13, P1901; Yahr TL, 1997, J BACTERIOL, V179, P7165, DOI 10.1128/jb.179.22.7165-7168.1997; Zhang Y, 2005, INFECT IMMUN, V73, P7938, DOI 10.1128/IAI.73.12.7938-7945.2005	64	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13022	13032		10.1074/jbc.M606305200	http://dx.doi.org/10.1074/jbc.M606305200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17311921	hybrid			2022-12-27	WOS:000245942800072
J	Akoachere, M; Squires, RC; Nour, AM; Angelov, L; Brojatsch, J; Abel-Santos, E				Akoachere, Monique; Squires, Raynal C.; Nour, Adel M.; Angelov, Ludmyl; Brojatsch, Jurgen; Abel-Santos, Ernesto			Identification of an in vivo inhibitor of Bacillus anthracis spore germination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSPORES REQUIRES; CEREUS-T; RESISTANCE; RECEPTORS; ENZYMES; TOXINS; HEAT	Germination of Bacillus anthracis spores into the vegetative form is an essential step in anthrax pathogenicity. This process can be triggered in vitro by the common germinants inosine and alanine. Kinetic analysis of B. anthracis spore germination revealed synergy and a sequential mechanism between inosine and alanine binding to their cognate receptors. Because inosine is a critical germinant in vitro, we screened inosine analogs for the ability to block in vitro germination of B. anthracis spores. Seven analogs efficiently blocked this process in vitro. This led to the identification of 6-thioguanosine, which also efficiently blocked spore germination in macrophages and prevented killing of these cells mediated by B. anthracis spores. 6-Thioguanosine shows potential as an anti-anthrax therapeutic agent.	Univ Nevada, Dept Chem, Las Vegas, NV 89154 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Brojatsch, J (corresponding author), Univ Nevada, Dept Chem, 4505 Maryland Pwy,Box 454003, Las Vegas, NV 89154 USA.	brojatsc@aecom.yu.edu		brojatsch, jurgen/0000-0002-7424-365X	NIAID NIH HHS [AI057158] Funding Source: Medline; PHS HHS [1R01AIGM053212] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057158] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alileche A, 2006, CELL CYCLE, V5, P100, DOI 10.4161/cc.5.1.2283; Alileche A, 2005, PLOS PATHOG, V1, P150, DOI 10.1371/journal.ppat.0010019; Banks DJ, 2005, CELL MICROBIOL, V7, P1173, DOI 10.1111/j.1462-5822.2005.00545.x; BARANKIEWICZ J, 1985, EUR J IMMUNOL, V15, P627, DOI 10.1002/eji.1830150618; Bonuccelli G, 2005, AM J PHYSIOL-CELL PH, V288, pC1402, DOI 10.1152/ajpcell.00582.2004; BOSCHWITZ H, 1983, J BACTERIOL, V153, P700, DOI 10.1128/JB.153.2.700-708.1983; BOSCHWITZ H, 1985, J BACTERIOL, V164, P302, DOI 10.1128/JB.164.1.302-309.1985; Brittingham KC, 2005, J IMMUNOL, V174, P5545, DOI 10.4049/jimmunol.174.9.5545; Cheng HC, 2001, J PHARMACOL TOX MET, V46, P61, DOI 10.1016/S1056-8719(02)00166-1; Cortezzo DE, 2004, J APPL MICROBIOL, V96, P725, DOI 10.1111/j.1365-2672.2004.02196.x; Coulthard S, 2005, INVEST NEW DRUG, V23, P523, DOI 10.1007/s10637-005-4020-8; Derijks LJJ, 2003, EUR J GASTROEN HEPAT, V15, P63, DOI 10.1097/00042737-200301000-00011; Dixon TC, 2000, CELL MICROBIOL, V2, P453, DOI 10.1046/j.1462-5822.2000.00067.x; Fisher N, 2005, J BACTERIOL, V187, P8055, DOI 10.1128/JB.187.23.8055-8062.2005; FOSTER SJ, 1986, BIOCHEM J, V237, P865, DOI 10.1042/bj2370865; FRANCIS JE, 1991, J MED CHEM, V34, P2570, DOI 10.1021/jm00112a035; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; Guidi-Rontani C, 2001, MOL MICROBIOL, V42, P931, DOI 10.1046/j.1365-2958.2001.02695.x; Hanna PC, 1999, TRENDS MICROBIOL, V7, P180, DOI 10.1016/S0966-842X(99)01507-3; HILLS GM, 1949, BIOCHEM J, V45, P353, DOI 10.1042/bj0450353; Hornstra LM, 2006, APPL ENVIRON MICROB, V72, P44, DOI 10.1128/AEM.72.1.44-53.2006; Ireland JAW, 2002, J BACTERIOL, V184, P1296, DOI 10.1128/JB.184.5.1296-1303.2002; Ireland JAW, 2002, INFECT IMMUN, V70, P5870, DOI 10.1128/IAI.70.10.5870-5872.2002; Kaina B, 2004, CYTOGENET GENOME RES, V104, P77, DOI 10.1159/000077469; Massa M R, 1975, Nuovi Ann Ig Microbiol, V26, P450; MITCHELL C, 1986, FEMS MICROBIOL LETT, V34, P211; Moayeri M, 2003, J CLIN INVEST, V112, P670, DOI [10.1172/JCI200317991, 10.1172/JCI17991]; Mock M, 2003, CELL MICROBIOL, V5, P15, DOI 10.1046/j.1462-5822.2003.00253.x; Moir A, 2002, CELL MOL LIFE SCI, V59, P403, DOI 10.1007/s00018-002-8432-8; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; Presta M, 1999, CANCER RES, V59, P2417; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; RODBARD D, 1974, CLIN CHEM, V20, P1255; Segel IH., 1993, ENZYME KINETICS BEHA; Setlow P, 2006, J APPL MICROBIOL, V101, P514, DOI 10.1111/j.1365-2672.2005.02736.x; SPLITTST.DF, 1966, J BACTERIOL, V92, P995, DOI 10.1128/JB.92.4.995-1001.1966; Tournier JN, 2006, B ACAD NAT MED PARIS, V190, P155, DOI 10.1016/S0001-4079(19)33358-8; TRUJILLO R, 1970, APPL MICROBIOL, V20, P620, DOI 10.1128/AEM.20.4.620-623.1970; WARREN SC, 1968, BIOCHIM BIOPHYS ACTA, V170, P341, DOI 10.1016/0304-4165(68)90014-7; Weiner M, 2003, J BACTERIOL, V185, P1462, DOI 10.1128/JB.185.4.1462-1464.2003; Weiner MA, 2003, INFECT IMMUN, V71, P3954, DOI 10.1128/IAI.71.7.3954-3959.2003; WOESE CR, 1968, P NATL ACAD SCI USA, V59, P869, DOI 10.1073/pnas.59.3.869; WOLGAMOT.GD, 1971, CAN J MICROBIOL, V17, P1043, DOI 10.1139/m71-165; YOUSTEN AA, 1975, CAN J MICROBIOL, V21, P1192, DOI 10.1139/m75-178	44	56	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12112	12118		10.1074/jbc.M611432200	http://dx.doi.org/10.1074/jbc.M611432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17296608	hybrid			2022-12-27	WOS:000245941900053
J	Seong, HA; Jung, H; Ha, H				Seong, Hyun-A; Jung, Haiyoung; Ha, Hyunjung			NM23-H1 tumor suppressor physically interacts with serine-threonine kinase receptor-associated protein, a transforming growth factor-beta (TGF-beta) receptor-interacting protein, and negatively regulates TGF-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; MIGRATION INHIBITORY FACTOR; X-RAY STRUCTURE; IN-VITRO; IDENTIFICATION; METASTASIS; ENZYME; CELLS; GENE; DIFFERENTIATION	NM23-H1 is a member of the NM23/NDP kinase gene family and a putative metastasis suppressor. Previously, a screen for NM23-H1-interacting proteins that could potentially modulate its activity identified serine-threonine kinase receptor-associated protein (STRAP), a transforming growth factor (TGF)-beta receptor-interacting protein. Through the use of cysteine to serine amino acid substitution mutants of NM23-H1 (C4S, C109S, and C145S) and STRAP (C152S, C270S, and C152S/C270S), we demonstrated that the association between these two proteins is dependent on Cys(145) of NM23-H1 and Cys(152) and Cys(270) of STRAP but did not appear to involve Cys(4) and Cys(109) of NM23-H1, suggesting that a disulfide linkage involving Cys(145) of NM23-H1 and Cys(152) or Cys(270) of STRAP mediates complex formation. The interaction was dependent on the presence of dithiothreitol or beta-mercaptoethanol but not H2O2. Ectopic expression of wild-type NM23-H1, but not NM23-H1(C145S), negatively regulated TGF-beta signaling in a dose-dependent manner, enhanced stable association between the TGF-beta receptor and Smad7, and prevented nuclear translocation of Smad3. Similarly, wild-type NM23-H1 inhibited TGF-beta induced apoptosis and growth inhibition, whereas NM23H1(C145S) had no effect. Knockdown of NM23-H1 by small interfering RNA stimulated TGF-beta signaling. Coexpression of wild-type STRAP, but not STRAP(C152S/C270S), significantly stimulated NM23-H1-induced growth of HaCaT cells. These results suggest that the direct interaction of NM23-H1 and STRAP is important for the regulation of TGF-beta-dependent biological activity as well as NM23-H1 activity.	Chungbuk Natl Univ, Dept Biochem, Sch Life Sci, Res Ctr Bioresource & Hlth,Biotechnol Res Inst, Cheongju 361763, South Korea	Chungbuk National University	Ha, H (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Life Sci, Res Ctr Bioresource & Hlth,Biotechnol Res Inst, Cheongju 361763, South Korea.	hyunha@chungbuk.ac.kr						Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; Ishikawa N, 2003, J BIOENERG BIOMEMBR, V35, P7, DOI 10.1023/A:1023433504713; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; KANTOR JD, 1993, CANCER RES, V53, P1971; KIMURA N, 1988, J BIOL CHEM, V263, P4647; Kimura N, 2000, J BIOENERG BIOMEMBR, V32, P309, DOI 10.1023/A:1005549315846; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Lombardi D, 2003, J BIOENERG BIOMEMBR, V35, P67, DOI 10.1023/A:1023445907439; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; Nosaka K, 1998, BIOCHEM BIOPH RES CO, V243, P342, DOI 10.1006/bbrc.1997.8097; Otero AD, 1997, J BIOL CHEM, V272, P14690, DOI 10.1074/jbc.272.23.14690; Otero AD, 2000, J BIOENERG BIOMEMBR, V32, P269, DOI 10.1023/A:1005589029959; Paravicini G, 1996, BIOCHEM BIOPH RES CO, V227, P82, DOI 10.1006/bbrc.1996.1471; Postel EH, 2003, P NATL ACAD SCI USA, V100, P13247, DOI 10.1073/pnas.2333230100; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Rochdi MD, 2004, J BIOL CHEM, V279, P18981, DOI 10.1074/jbc.M312621200; Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690; Seong HA, 2005, J BIOL CHEM, V280, P42897, DOI 10.1074/jbc.M507539200; Seong HA, 2003, J BIOL CHEM, V278, P9655, DOI 10.1074/jbc.M207478200; Song EJ, 2000, BIOCHEMISTRY-US, V39, P10090, DOI 10.1021/bi000267a; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Timmons L, 1997, ADV GENET, V35, P207, DOI 10.1016/S0065-2660(08)60451-4; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; Yao KS, 2005, CLIN CANCER RES, V11, P7264, DOI 10.1158/1078-0432.CCR-05-0135; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	43	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12075	12096		10.1074/jbc.M609832200	http://dx.doi.org/10.1074/jbc.M609832200			22	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314099	hybrid			2022-12-27	WOS:000245941900050
J	Gassanov, N; Jankowski, M; Danalache, B; Wang, D; Grygorczyk, R; Hoppe, UC; Gutkowska, J				Gassanov, Natig; Jankowski, Marek; Danalache, Bogdan; Wang, Donghao; Grygorczyk, Ryszard; Hoppe, Uta C.; Gutkowska, Jolanta			Arginine vasopressin-mediated cardiac differentiation - Insights into the role of its receptors and nitric oxide signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; INDUCED RELEASE; ES CELLS; EXPRESSION; CARDIOMYOCYTES; SYNTHASE; ATRIAL; SSR149415	Despite the existence of a functional arginine vasopressin ( AVP) system in the adult heart and evidence that AVP induces myogenesis, its significance in cardiomyogenesis is currently unknown. In the present study, we hypothesized a role for AVP in cardiac differentiation of D3 and lineage-specific embryonic stem ( ES) cells expressing green fluorescent protein under the control of atrial natriuretic peptide ( Anp) or myosin light chain-2V ( Mlc-2V) promoters. Furthermore, we investigated the nitric oxide ( NO) involvement in AVP-mediated pathways. AVP exposure increased the number of beating embryoid bodies, fluorescent cells, and expression of Gata-4 and other cardiac genes. V1a and V2 receptors ( V1aR and V2R) differentially mediated these effects in transgenic ES cells, and exhibited a distinct developmentally regulated mRNA expression pattern. A NO synthase inhibitor, L-NAME, powerfully antagonized the AVP-induced effects on cardiogenic differentiation, implicating NO signaling in AVP-mediated pathways. Indeed, AVP elevated the mRNA and protein levels of endothelial NO synthase ( eNOS) through V2R stimulation. Remarkably, increased beating activity was found in AVP-treated ES cells with down-regulated eNOS expression, indicating the significant involvement of additional pathways in cardiomyogenic effects of AVP. Finally, patch clamp recordings revealed specific AVP-induced changes of action potentials and increased L-type Ca2+ ( I-Ca,I- L) current densities in differentiated ventricular phenotypes. Thus, AVP promotes cardiomyocyte differentiation of ES cells and involves Gata-4 and NO signaling. AVP-induced action potential prolongation appears likely to be linked to the increased I-Ca,I- L current in ventricular cells. In conclusion, this report provides new evidence for the essential role of the AVP system in ES cell-derived cardiomyogenesis.	Univ Cologne, Dept Internal Med 3, D-50924 Cologne, Germany; Univ Montreal, CHUM Hotel Dieu, Res Ctr, Montreal, PQ H2W 1T8, Canada	University of Cologne; Universite de Montreal	Gutkowska, J (corresponding author), Pavillon Mason,3850 St Urbain, Montreal, PQ H2W 1T8, Canada.	jolanta.gutkowska@umontreal.ca	Jankowski, Marek/AAF-7643-2019; Danalache, Bogdan Alexandru 1/B-3958-2010	Jankowski, Marek/0000-0002-1245-0733; Grygorczyk, Ryszard/0000-0002-9798-7651				Bani-Yaghoub M, 2004, DEVELOPMENT, V131, P4287, DOI 10.1242/dev.01295; Bernat A, 1997, J PHARMACOL EXP THER, V282, P597; Bloch W, 1999, CARDIOVASC RES, V43, P675, DOI 10.1016/S0008-6363(99)00160-1; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; Gassanov N, 2006, CELL CALCIUM, V39, P175, DOI 10.1016/j.ceca.2005.10.008; Gassanov N, 2004, FASEB J, V18, P1710, DOI 10.1096/fj.04-1619fje; Griffante C, 2005, BRIT J PHARMACOL, V146, P744, DOI 10.1038/sj.bjp.0706383; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hirata Y, 1997, HYPERTENSION, V29, P58, DOI 10.1161/01.HYP.29.1.58; Holmes CL, 2003, CRIT CARE, V7, P427, DOI 10.1186/cc2337; Hupf H, 1999, CIRC RES, V84, P365, DOI 10.1161/01.RES.84.3.365; Jankowski M, 2001, P NATL ACAD SCI USA, V98, P11765, DOI 10.1073/pnas.201394198; Kanno S, 2004, P NATL ACAD SCI USA, V101, P12277, DOI 10.1073/pnas.0401557101; Kaufmann JE, 2000, J CLIN INVEST, V106, P107, DOI 10.1172/JCI9516; Kaufmann JE, 2003, J THROMB HAEMOST, V1, P821, DOI 10.1046/j.1538-7836.2003.00197.x; Kofidis T, 2004, STEM CELLS, V22, P1239, DOI 10.1634/stemcells.2004-0127; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; Krumenacker JS, 2006, NITRIC OXIDE-BIOL CH, V14, P1, DOI 10.1016/j.niox.2005.06.010; Lagumdzija A, 2005, PEPTIDES, V26, P1661, DOI 10.1016/j.peptides.2005.02.007; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Laugwitz KL, 1999, CIRCULATION, V99, P925, DOI 10.1161/01.CIR.99.7.925; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; McDevitt TC, 2005, J MOL CELL CARDIOL, V39, P865, DOI 10.1016/j.yjmcc.2005.09.007; Menard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moore JC, 2004, INT J DEV BIOL, V48, P47, DOI 10.1387/ijdb.15005574; Mouillac B, 1995, ADV EXP MED BIOL, V395, P301; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Nakamura Y, 2000, EUR J PHARMACOL, V391, P39, DOI 10.1016/S0014-2999(99)00775-X; NERVI C, 1995, CELL GROWTH DIFFER, V6, P81; Oshikawa S, 2004, MOL PHARMACOL, V65, P623, DOI 10.1124/mol.65.3.623; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; Park F, 1998, HYPERTENSION, V32, P896, DOI 10.1161/01.HYP.32.5.896; Scicchitano BM, 2005, MOL BIOL CELL, V16, P3632, DOI 10.1091/mbc.E05-01-0055; Scicchitano BM, 2002, MOL ENDOCRINOL, V16, P1407, DOI 10.1210/me.16.6.1407; Serradeil-Le Gal C, 2002, J PHARMACOL EXP THER, V300, P1122; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; Tahara A, 2005, PHARMACOL RES, V51, P275, DOI 10.1016/j.phrs.2004.09.006; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; XU YJ, 1991, CIRC RES, V69, P239, DOI 10.1161/01.RES.69.1.239; ZHANG ST, 1995, CIRC RES, V76, P592, DOI 10.1161/01.RES.76.4.592; Zou GM, 2003, BIOL CELL, V95, P365, DOI 10.1016/S0248-4900(03)00079-0	43	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11255	11265		10.1074/jbc.M610769200	http://dx.doi.org/10.1074/jbc.M610769200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17298949	hybrid			2022-12-27	WOS:000245941500048
J	Lasbury, ME; Merali, S; Durant, PJ; Tschang, D; Ray, CA; Lee, CH				Lasbury, Mark E.; Merali, Salim; Durant, Pamela J.; Tschang, Dennis; Ray, Chad A.; Lee, Chao-Hung			Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHOALVEOLAR LAVAGE FLUID; NF-KAPPA-B; CARINII-PNEUMONIA; BORDETELLA-PERTUSSIS; CYTOLOGICAL EXAMINATION; INCREASED EXPRESSION; PHAGOCYTIC-ACTIVITY; CASPASE ACTIVATION; HYDROGEN-PEROXIDE; CYTOCHROME-C	The number of alveolar macrophages is decreased during Pneumocystis pneumonia (Pcp), partly because of activation of apoptosis in these cells. This apoptosis occurs in both rat and mouse models of Pcp. Bronchoalveolar lavage (BAL) fluids from Pneumocystis-infected animals were found to contain high levels of polyamines, including spermidine, N1-acetylspermine, and N-1-acetylspermidine. These BAL fluids and exogenous polyamines were able to induce apoptosis in alveolar macrophages. Apoptosis of alveolar macrophages during infection, after incubation with BAL fluids from Pneumocystis-infected animals, or after incubation with polyamines was marked by an increase in intracellular reactive oxygen species, activation of caspases-3 and -9, DNA fragmentation, and leakage of mitochondrial cytochrome c into the cytoplasm. When polyamines were depleted from the BAL fluids of infected animals, the ability of these BAL fluids to induce apoptosis was lost. Interestingly, the apoptosis inducing activity of the polyamine-depleted BAL fluids was restored when polyamines were added back. The results of this study suggested that Pneumocystis infection results in accumulation of high levels of polyamines in the lung. These polyamines activate apoptosis of alveolar macrophages, perhaps because of the ROS that are produced during polyamine metabolism.	Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Amgen	Lasbury, ME (corresponding author), Indiana Univ, Sch Med, Dept Pathol & Lab Med, 1120 S Dr,Fesler Hall,Rm 406, Indianapolis, IN 46202 USA.	melasbur@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062259] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL65170] Funding Source: Medline; NIAID NIH HHS [R01 AI062259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Atochina EN, 2000, AM J PHYSIOL-LUNG C, V278, pL599, DOI 10.1152/ajplung.2000.278.3.L599; Atochina EN, 2001, J LAB CLIN MED, V137, P429, DOI 10.1067/mlc.2001.115220; Balcewicz-Sablinska MK, 1998, J IMMUNOL, V161, P2636; BARTLETT MS, 1988, J CLIN MICROBIOL, V26, P1100, DOI 10.1128/JCM.26.6.1100-1102.1988; BARTLETT MS, 1994, CLIN DIAGN LAB IMMUN, V1, P511, DOI 10.1128/CDLI.1.5.511-516.1994; BARTLETT MS, 1992, DIAGN MICR INFEC DIS, V15, P129, DOI 10.1016/0732-8893(92)90036-S; Beers MF, 1999, J LAB CLIN MED, V133, P423, DOI 10.1016/S0022-2143(99)90019-7; Benfield TL, 1997, CHEST, V111, P1193, DOI 10.1378/chest.111.5.1193; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen Y, 2003, CANCER RES, V63, P3619; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; FLEURY J, 1985, ACTA CYTOL, V29, P721; FLEURYFEITH J, 1989, CHEST, V95, P1198, DOI 10.1378/chest.95.6.1198; Fraser IP, 2000, MICROBES INFECT, V2, P1305, DOI 10.1016/S1286-4579(00)01283-1; GAJDUSEK DC, 1957, PEDIATRICS, V19, P543; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Goebel S, 1999, MED MICROBIOL IMMUN, V187, P221, DOI 10.1007/s004300050096; Goebel Stefan, 1998, Tokai Journal of Experimental and Clinical Medicine, V23, P351; Gueirard P, 1998, INFECT IMMUN, V66, P1718, DOI 10.1128/IAI.66.4.1718-1725.1998; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HAMPERL H, 1956, AM J PATHOL, V32, P1; Hawel L, 2002, ANAL BIOCHEM, V311, P127, DOI 10.1016/S0003-2697(02)00423-2; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; Kolls JK, 1999, J IMMUNOL, V162, P2890; Koziel H, 1998, J CLIN INVEST, V102, P1332, DOI 10.1172/JCI560; Kuramoto N, 2003, BRAIN RES, V967, P170, DOI 10.1016/S0006-8993(02)04268-3; Lasbury ME, 2006, J IMMUNOL, V176, P6443, DOI 10.4049/jimmunol.176.11.6443; Lasbury ME, 2003, J EUKARYOT MICROBIOL, V50, P637, DOI 10.1111/j.1550-7408.2003.tb00662.x; Lasbury ME, 2004, INFECT IMMUN, V72, P2140, DOI 10.1128/IAI.72.4.2140-2147.2004; Lasbury ME, 2003, INFECT IMMUN, V71, P4943, DOI 10.1128/IAI.71.9.4943-4952.2003; Lasbury ME, 2003, CLIN DIAGN LAB IMMUN, V10, P293, DOI 10.1128/CDLI.10.2.293-302.2003; LAURSEN AL, 1993, J INFECT DIS, V168, P1466, DOI 10.1093/infdis/168.6.1466; MATSUMOTO Y, 1989, J PROTOZOOL, V36, pS21, DOI 10.1111/j.1550-7408.1989.tb05814.x; Merali S, 1999, J BIOL CHEM, V274, P21017, DOI 10.1074/jbc.274.30.21017; Merali S, 1996, J CHROMATOGR B, V675, P321, DOI 10.1016/0378-4347(95)00363-0; Merali S, 1996, ANTIMICROB AGENTS CH, V40, P973, DOI 10.1128/AAC.40.4.973; Meyer TF, 1999, CLIN INFECT DIS, V28, P433, DOI 10.1086/515160; Molestina RE, 2003, J CELL SCI, V116, P4359, DOI 10.1242/jcs.00683; Muller A, 1999, EMBO J, V18, P339, DOI 10.1093/emboj/18.2.339; NIELSEN H, 1987, ACTA PATH MICRO IM C, V95, P81; OHNO Y, 1985, J BIOL CHEM, V260, P8438; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; Payne TM, 2003, J CELL SCI, V116, P4345, DOI 10.1242/jcs.00756; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; ROGEL A, 1992, J BIOL CHEM, V267, P22599; SADAGHDAR H, 1992, CHEST, V102, P63, DOI 10.1378/chest.102.1.63; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; Skelly M, 2003, LANCET, V361, P1267, DOI 10.1016/S0140-6736(03)12984-4; SMITH RL, 1988, CHEST, V93, P60, DOI 10.1378/chest.93.1.60; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Stefanelli C, 1999, FEBS LETT, V451, P95, DOI 10.1016/S0014-5793(99)00549-9; Stefanelli C, 2000, BIOCHEM J, V347, P875, DOI 10.1042/0264-6021:3470875; Stefanelli C, 2002, FEBS LETT, V527, P223, DOI 10.1016/S0014-5793(02)03242-8; SU TH, 1994, ANNU REV MED, V45, P261, DOI 10.1146/annurev.med.45.1.261; Sukumaran SK, 2004, INFECT IMMUN, V72, P6012, DOI 10.1128/IAI.72.10.6012-6022.2004; Tang X, 2000, INFECT IMMUN, V68, P4720, DOI 10.1128/IAI.68.8.4720-4724.2000; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; YOUNG JA, 1986, J CLIN PATHOL, V39, P945, DOI 10.1136/jcp.39.9.945; YOUNG JA, 1984, J CLIN PATHOL, V37, P390, DOI 10.1136/jcp.37.4.390; YOUNG KR, 1985, ANN INTERN MED, V103, P522, DOI 10.7326/0003-4819-103-4-522; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	67	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11009	11020		10.1074/jbc.M611686200	http://dx.doi.org/10.1074/jbc.M611686200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17314093	hybrid			2022-12-27	WOS:000245941500021
J	Muylaert, I; Elias, P				Muylaert, Isabella; Elias, Per			Knockdown of DNA ligase IV/XRCC4 by RNA interference inhibits herpes simplex virus type I DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT LIGATION; REPAIR PROTEINS; GENOME; RECOMBINATION; CIRCULARIZATION; MUTATIONS; GENE; LIFE	Herpes simplex virus has a linear double-stranded DNA genome with directly repeated terminal sequences needed for cleavage and packaging of replicated DNA. In infected cells, linear genomes rapidly become endless. It is currently a matter of discussion whether the endless genomes are circles supporting rolling circle replication or arise by recombination of linear genomes forming concatemers. Here, we have examined the role of mammalian DNA ligases in the herpes simplex virus, type I (HSV-1) life cycle by employing RNA interference (RNAi) in human 1BR.3.N fibroblasts. We find that RNAi-mediated knockdown of DNA ligase IV and its co-factor XRCC4 causes a hundred-fold reduction of virus yield, a small plaque phenotype, and reduced DNA synthesis. The effect is specific because RNAi against DNA ligase I or DNA ligase III fail to reduce HSV-1 replication. Furthermore, RNAi against DNA ligase IV and XRCC4 does not affect replication of adenovirus. In addition, high multiplicity infections of HSV-1 in human DNA ligase IV-deficient cells reveal a pronounced delay of production of infectious virus. Finally, we demonstrate that formation of endless genomes is inhibited by RNAi-mediated depletion of DNA ligase IV and XRCC4. Our results suggests that DNA ligase IV/XRCC4 serves an important role in the replication cycle of herpes viruses and is likely to be required for the formation of the endless genomes early during productive infection.	Gothenburg Univ, Inst Biomed, Dept Med Biochem & Cell Biol, SE-40530 Gothenburg, Sweden	University of Gothenburg	Elias, P (corresponding author), Gothenburg Univ, Inst Biomed, Dept Med Biochem & Cell Biol, Box 440, SE-40530 Gothenburg, Sweden.	per.elias@medkem.gu.se						Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Bentley DJ, 2002, J CELL SCI, V115, P1551; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896; GARBER DA, 1993, VIROLOGY, V197, P459, DOI 10.1006/viro.1993.1612; Girard PM, 2004, HUM MOL GENET, V13, P2369, DOI 10.1093/hmg/ddh274; Goldstein JN, 1998, VIROLOGY, V244, P442, DOI 10.1006/viro.1998.9129; Hammarsten O, 1996, J VIROL, V70, P4523, DOI 10.1128/JVI.70.7.4523-4529.1996; Jackson SA, 2003, P NATL ACAD SCI USA, V100, P7871, DOI 10.1073/pnas.1230643100; Kysela B, 2005, P NATL ACAD SCI USA, V102, P1877, DOI 10.1073/pnas.0401179102; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Lilley CE, 2005, P NATL ACAD SCI USA, V102, P5844, DOI 10.1073/pnas.0501916102; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; Martin IV, 2002, GENOME BIOL, V3; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Pitcher RS, 2006, MOL CELL, V23, P743, DOI 10.1016/j.molcel.2006.07.009; POFFENBERGER KL, 1985, J VIROL, V53, P587, DOI 10.1128/JVI.53.2.587-595.1985; Porter IM, 2004, J GEN VIROL, V85, P583, DOI 10.1099/vir.0.19657-0; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Sandri-Goldin RM, 2003, P NATL ACAD SCI USA, V100, P7428, DOI 10.1073/pnas.1432875100; Schildgen O, 2005, J VIROL, V79, P7273, DOI 10.1128/JVI.79.11.7273-7278.2005; Severini A, 2003, VIROLOGY, V314, P443, DOI 10.1016/S0042-6822(03)00451-3; Shirata N, 2005, J BIOL CHEM, V280, P30336, DOI 10.1074/jbc.M500976200; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Strang BL, 2005, J VIROL, V79, P12487, DOI 10.1128/JVI.79.19.12487-12494.2005; Su YH, 2002, J GEN VIROL, V83, P2943, DOI 10.1099/0022-1317-83-12-2943; Su YH, 2006, J VIROL, V80, P11589, DOI 10.1128/JVI.01869-06; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; WEBER PC, 1988, CELL, V54, P369, DOI 10.1016/0092-8674(88)90200-0; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Wilkinson DE, 2004, J VIROL, V78, P4783, DOI 10.1128/JVI.78.9.4783-4796.2004; Yao XD, 1997, J VIROL, V71, P6842, DOI 10.1128/JVI.71.9.6842-6849.1997; Yao XD, 2001, J BIOL CHEM, V276, P2905, DOI 10.1074/jbc.M005627200	44	46	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10865	10872		10.1074/jbc.M611834200	http://dx.doi.org/10.1074/jbc.M611834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17296606	hybrid			2022-12-27	WOS:000245941500005
J	Weyer, K; Boldt, HB; Poulsen, CB; Kjaer-Sorensen, K; Gyrup, C; Oxvig, C				Weyer, Kathrin; Boldt, Henning B.; Poulsen, Christine B.; Kjaer-Sorensen, Kasper; Gyrup, Claus; Oxvig, Claus			A substrate specificity-determining unit of three Lin12-Notch repeat modules is formed in trans within the pappalysin-1 dimer and requires a sequence stretch C-terminal to the third module	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-PROTEIN-A; MAJOR BASIC-PROTEIN; PHYSIOLOGICAL INHIBITOR; PROTEOLYTIC ACTIVATION; DROSOPHILA NOTCH; PAPP-A; DOMAIN; PROFORM; COMPLEX; EXPRESSION	Members of the pappalysin family of metzincin metalloproteinases, pregnancy-associated plasma protein-A (PAPP-A, pappalysin-1) and PAPP-A2 (pappalysin-2), regulate the bioavailability of insulin-like growth factors (IGFs) by specific proteolytic inactivation of IGF-binding proteins (IGFBPs). PAPP-A cleaves IGFBP-4 and IGFBP-5, whereas PAPP-A2 cleaves only IGFBP-5. The pappalysins contain three Lin12-Notch repeat (LNR1-3) modules, previously considered unique to the Notch receptor family in which they function to regulate receptor cleavage. In contrast to the Notch receptor where three LNR modules are tandemly arranged, LNR3 is separated by more than 1000 residues from LNR1-2 in the pappalysin sequence. Each of the three LNR modules of PAPP-A is required for proteolysis of IGFBP-4, but not IGFBP-5. However, we here find that a C-terminal truncated variant of PAPP-A, which lacks LNR3 and therefore activity against IGFBP-4, cleaves IGFBP-4 when co-expressed with a PAPP-A variant, which is mutated in the active site. This suggests that LNR3 from the inactive subunit interacts in trans with LNR1-2 of the truncated PAPP-A subunit to form a functional trimeric LNR unit. We also show that formation of such a functional LNR unit depends on dimerization, as dissociation of a mutated non-covalent PAPP-A dimer results in reduced activity against IGFBP-4, but not IGFBP-5. Using PAPP-A/PAPP-A2 chimeras, we demonstrate that PAPP-A2 LNR1-2, but not LNR3, are functionally conserved with respect to IGFBP proteolysis. Additionally, we find that a sequence stretch C-terminal to LNR3 and single residues (Asp(1521), Arg(1529), and Asp(1530)) within this are required for LNR functionality.	Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus, Denmark	Aarhus University	Oxvig, C (corresponding author), Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.	co@mb.au.dk	Kjaer-Sorensen, Kasper/AAF-1457-2020	Oxvig, Claus/0000-0002-4715-9719; Weyer, Kathrin/0000-0002-8473-7987				Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Boldt HB, 2004, J BIOL CHEM, V279, P38525, DOI 10.1074/jbc.M405222200; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; Boldt HB, 2006, PROTEIN EXPRES PURIF, V48, P261, DOI 10.1016/j.pep.2006.01.024; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Chen BK, 2003, J CLIN ENDOCR METAB, V88, P4465, DOI 10.1210/jc.2003-030193; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; Cosin-Sales J, 2004, CIRCULATION, V109, P1724, DOI 10.1161/01.CIR.0000124716.67921.D2; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Giudice LC, 2002, J CLIN ENDOCR METAB, V87, P2359, DOI 10.1210/jc.87.5.2359; Glerup S, 2005, J BIOL CHEM, V280, P9823, DOI 10.1074/jbc.M413228200; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 2003, J BIOL CHEM, V278, P2106, DOI 10.1074/jbc.M208777200; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; OXVIG C, 2004, HDB PROTEOLYTIC ENZY, P754; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qin QP, 1997, CLIN CHEM, V43, P2323; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tallant C, 2006, J BIOL CHEM, V281, P17920, DOI 10.1074/jbc.M600907200; Vardar D, 2003, BIOCHEMISTRY-US, V42, P7061, DOI 10.1021/bi034156y; Wald NJ, 1999, NEW ENGL J MED, V341, P461, DOI 10.1056/NEJM199908123410701; Weyer K, 2004, EUR J BIOCHEM, V271, P1525, DOI 10.1111/j.1432-1033.2004.04061.x	43	30	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10988	10999		10.1074/jbc.M607903200	http://dx.doi.org/10.1074/jbc.M607903200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17314100	hybrid			2022-12-27	WOS:000245941500019
J	Jiang, LI; Collins, J; Davis, R; Lin, KM; DeCamp, D; Roach, T; Hsueh, R; Rebres, RA; Ross, EM; Taussig, R; Fraser, I; Sternweis, PC				Jiang, Lily I.; Collins, Julie; Davis, Richard; Lin, Keng-Mean; DeCamp, Dianne; Roach, Tamara; Hsueh, Robert; Rebres, Robert A.; Ross, Elliott M.; Taussig, Ronald; Fraser, Iain; Sternweis, Paul C.			Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G(13) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; MULTIPLE SIGNALING PATHWAYS; PROTEIN-COUPLED RECEPTORS; RESONANCE ENERGY-TRANSFER; BETA-GAMMA-SUBUNITS; ADENYLYL-CYCLASE; FLUORESCENT INDICATORS; EPAC ACTIVATION; CROSS-TALK; CELL-LINE	Regulation of intracellular cyclic adenosine 3',5'-monophosphate ( cAMP) is integral in mediating cell growth, cell differentiation, and immune responses in hematopoietic cells. To facilitate studies of cAMP regulation we developed a BRET ( (b) under bar ioluminescence (r) under bar esonance (e) under bar nergy (t) under bar ransfer) sensor for cAMP, CAMYEL ( (cAMP) under bar sensor using (Y) under bar FP-(E) under bar pac-R (L) under bar uc), which can quantitatively and rapidly monitor intracellular concentrations of cAMP in vivo. This sensor was used to characterize three distinct pathways for modulation of cAMP synthesis stimulated by presumed G(s)-dependent receptors for isoproterenol and prostaglandin E-2. Whereas two ligands, uridine 5'-diphosphate and complement C5a, appear to use known mechanisms for augmentation of cAMP via G(q)/calcium and G(i), the action of sphingosine 1-phosphate ( S1P) is novel. In these cells, S1P, a biologically active lysophospholipid, greatly enhances increases in intracellular cAMP triggered by the ligands for G(s)-coupled receptors while having only a minimal effect by itself. The enhancement of cAMP by S1P is resistant to pertussis toxin and independent of intracellular calcium. Studies with RNAi and chemical perturbations demonstrate that the effect of S1P is mediated by the S1P(2) receptor and the heterotrimeric G(13) protein. Thus in these macrophage cells, all four major classes of G proteins can regulate intracellular cAMP.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Calif San Francisco, Vet Adm Med Ctr, San Francisco, CA 94121 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); California Institute of Technology	Jiang, LI (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	lily.jiang@utsouthwestern.edu; paul.sternweis@utsouthwestern.edu	Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907	NIGMS NIH HHS [R01 GM030355, U54 GM062114, U54 GM062114-07, GM 62114] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, U54GM062114] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Boute N, 2002, TRENDS PHARMACOL SCI, V23, P351, DOI 10.1016/S0165-6147(02)02062-X; BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Castro A, 2005, MED RES REV, V25, P229, DOI 10.1002/med.20020; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chin KV, 2002, ANN NY ACAD SCI, V968, P49, DOI 10.1111/j.1749-6632.2002.tb04326.x; DiPilato LM, 2004, P NATL ACAD SCI USA, V101, P16513, DOI 10.1073/pnas.0405973101; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Haslauer M, 1998, MOL PHARMACOL, V53, P837; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lania A, 2001, EUR J ENDOCRINOL, V145, P543, DOI 10.1530/eje.0.1450543; Lerner A, 2006, BIOCHEM J, V393, P21, DOI 10.1042/BJ20051368; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Movsesian MA, 2005, CURR TOP DEV BIOL, V68, P25, DOI 10.1016/S0070-2153(05)68002-7; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Natarajan M, 2006, NAT CELL BIOL, V8, P571, DOI 10.1038/ncb1418; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Ponsioen B, 2004, EMBO REP, V5, P1176, DOI 10.1038/sj.embor.7400290; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rehmann H, 2006, NATURE, V439, P625, DOI 10.1038/nature04468; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Sunahara Roger K, 2002, Mol Interv, V2, P168, DOI 10.1124/mi.2.3.168; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TURNER JT, 1992, J PHARMACOL EXP THER, V263, P708; Wang HB, 2003, MOL PHARMACOL, V63, P463, DOI 10.1124/mol.63.3.463; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885	47	222	228	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10576	10584		10.1074/jbc.M609695200	http://dx.doi.org/10.1074/jbc.M609695200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283075	hybrid, Green Accepted			2022-12-27	WOS:000245941000051
J	Maertens, B; Hopkins, D; Franzke, CW; Keene, DR; Bruckner-Tuderman, L; Greenspan, DS; Koch, M				Maertens, Barbara; Hopkins, Delana; Franzke, Claus-Werner; Keene, Douglas R.; Bruckner-Tuderman, Leena; Greenspan, Daniel S.; Koch, Manuel			Cleavage and oligomerization of gliomedin, a transmembrane collagen required for node of Ranvier formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; OPEN-ANGLE GLAUCOMA; OLFACTOMEDIN-DOMAIN; XIII COLLAGEN; MOLECULAR-CLONING; ADHESION PROTEIN; HUMAN MYOCILIN; FURIN; EXPRESSION; GLYCOPROTEIN	Gliomedin, which has been implicated as a major player in genesis of the nodes of Ranvier, contains two collagenous domains and an olfactomedin-like domain and belongs to the group of type II transmembrane collagens that includes collagens XIII and XVII and ectodysplasin A. One characteristic of this protein family is that constituent proteins can exist in both transmembrane and soluble forms. Recently, gliomedin expressed at the tips of Schwann cell microvilli was found to bind axonal adhesion molecules neurofascin and NrCAM in interactions essential for Na+-channel clustering at the nodes of Ranvier in myelinating peripheral nerves. Interestingly, exogenously added olfactomedin domain was found to have the same effect as intact gliomedin. Here we analyze the tissue form of gliomedin and demonstrate that the molecule not only exists as full-length gliomedin but also as a soluble form shed from the cell surface in a furin-dependent manner. In addition, gliomedin can be further proteolytically processed by bone morphogenetic protein 1/Tolloid-like enzymes, resulting in release of the olfactomedin domain from the collagen domains. Interestingly, the later cleavage induces formation of higher order, insoluble molecular aggregates that may play important roles in Na+-channel clustering.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Dept Dermatol, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med Cologne, D-50931 Cologne, Germany; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Shriners Hosp Children, Res Ctr, Portland, OR 97239 USA	University of Cologne; University of Cologne; University of Cologne; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Freiburg	Koch, M (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	Manuel.Koch@uni-koeln.de	Koch, Manuel/AAG-9914-2021	Koch, Manuel/0000-0002-2962-7814; Greenspan, Daniel/0000-0001-8096-7446	NIGMS NIH HHS [R01 GM71679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aroca-Aguilar JD, 2005, J BIOL CHEM, V280, P21043, DOI 10.1074/jbc.M501340200; Barembaum M, 2000, NAT CELL BIOL, V2, P219, DOI 10.1038/35008643; Bosio A, 1998, J NEUROCHEM, V70, P308; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Eshed Y, 2005, NEURON, V47, P215, DOI 10.1016/j.neuron.2005.06.026; Feltri ML, 2005, J PERIPHER NERV SYST, V10, P128, DOI 10.1111/j.1085-9489.2005.0010204.x; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Furutani Y, 2005, BIOCHEM J, V389, P675, DOI 10.1042/BJ20050120; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Ge Gaoxiang, 2006, Birth Defects Research, V78, P47, DOI 10.1002/bdrc.20060; Ge GX, 2005, MOL CELL BIOL, V25, P5846, DOI 10.1128/MCB.25.14.5846-5858.2005; Girault JA, 2002, CURR OPIN NEUROBIOL, V12, P476, DOI 10.1016/S0959-4388(02)00370-7; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Henrich S, 2005, J MOL BIOL, V345, P211, DOI 10.1016/j.jmb.2004.10.050; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hillier BJ, 2006, ACTA CRYSTALLOGR F, V62, P16, DOI 10.1107/S1744309105038996; Hillier BJ, 2003, J CELL BIOL, V160, P597, DOI 10.1083/jcb.200210053; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Koch M, 2004, J BIOL CHEM, V279, P22514, DOI 10.1074/jbc.M400536200; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; Kubota R, 1998, BIOCHEM BIOPH RES CO, V242, P396, DOI 10.1006/bbrc.1997.7972; Lambert S, 1997, J NEUROSCI, V17, P7025; Latvanlehto A, 2003, J BIOL CHEM, V278, P37590, DOI 10.1074/jbc.M305974200; Loria PM, 2004, J NEUROSCI, V24, P2191, DOI 10.1523/JNEUROSCI.5462-03.2004; Moreno TA, 2005, DEV BIOL, V288, P434, DOI 10.1016/j.ydbio.2005.09.050; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nagy I, 2003, BIOCHEM BIOPH RES CO, V302, P554, DOI 10.1016/S0006-291X(03)00198-0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Ricard CS, 2005, EXP EYE RES, V81, P501, DOI 10.1016/j.exer.2005.06.014; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; SNYDER DA, 1991, BIOCHEMISTRY-US, V30, P9143, DOI 10.1021/bi00102a004; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Torrado M, 2002, HUM MOL GENET, V11, P1291, DOI 10.1093/hmg/11.11.1291; Tsuda H, 2002, NEURON, V33, P515, DOI 10.1016/S0896-6273(02)00590-1; Vabnick I, 1996, J NEUROSCI, V16, P4914; Vaisanen MR, 2004, BIOCHEM J, V380, P685, DOI 10.1042/BJ20031974; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; YOKOE H, 1993, P NATL ACAD SCI USA, V90, P4655, DOI 10.1073/pnas.90.10.4655	46	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10647	10659		10.1074/jbc.M611339200	http://dx.doi.org/10.1074/jbc.M611339200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293346	hybrid			2022-12-27	WOS:000245941000059
J	Palmer, D; Jimmo, SL; Raymond, DR; Wilson, LS; Carter, RL; Maurice, DH				Palmer, Daniel; Jimmo, Sandra L.; Raymond, Daniel R.; Wilson, Lindsay S.; Carter, Rhonda L.; Maurice, Donald H.			Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; MEDIATED ACTIVATION; EXPRESSION; HEART; CAMP; LOCALIZATION; ISOFORMS; DOMAINS; PDE3B	Recent studies confirm that intracellular cAMP concentrations are nonuniform and that localized subcellular cAMP hydrolysis by cyclic nucleotide phosphodiesterases (PDEs) is important in maintaining these cAMP compartments. Human phosphodiesterase 313 (HSPDE3B), a member of the PDE3 family of PDEs, represents the dominant particulate cAMP-PDE activity in many cell types, including adipocytes and cells of hematopoietic lineage. Although several previous reports have shown that phosphorylation of HSPDE3B by either protein kinase A (PKA) or protein kinase B (PKB) activates this enzyme, the mechanisms that allow cells to distinguish these two activated forms of HSPDE3B are unknown. Here we report that PKA phosphorylates HSPDE3B at several distinct sites (Ser-73, Ser-296, and Ser-318), and we show that phosphorylation of HSPDE3B at Ser-318 activates this PDE and stimulates its interaction with 14-3-3 proteins. In contrast, although PKB-catalyzed phosphorylation of HSPDE3B activates this enzyme, it does not promote 14-3-3 protein binding. Interestingly, we report that the PKA-phosphorylated, 14-3-3 protein-bound, form of HSPDE3B is protected from phosphatase-dependent dephosphorylation and inactivation. In contrast, PKA-phosphorylated HSPDE3B that is not bound to 14-3-3 proteins is readily dephosphorylated and inactivated. Our data are presented in the context that a selective interaction between PKA-activated HSPDE3B and 14-3-3 proteins represents a mechanism by which cells can protect this enzyme from deactivation. Moreover, we propose that this mechanism may allow cells to distinguish between PKA- and PKB-activated HSPDE3B.	Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada	Maurice, DH (corresponding author), Queens Univ, Dept Pharmacol & Toxicol, Botterell Hall,Rm 229, Kingston, ON K7L 3N6, Canada.	mauriced@post.queensu.ca	Palmer, Daniel/Q-7595-2016; Maurice, Donald/AAE-9332-2019; Palmer, Daniel/J-2967-2014	Palmer, Daniel/0000-0002-7954-9332; Palmer, Daniel/0000-0002-7954-9332				Antoni FA, 2000, FRONT NEUROENDOCRIN, V21, P103, DOI 10.1006/frne.1999.0193; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Dodge-Kafka KL, 2006, CIRC RES, V98, P993, DOI 10.1161/01.RES.0000218273.91741.30; Elbatarny HS, 2005, AM J PHYSIOL-ENDOC M, V289, pE695, DOI 10.1152/ajpendo.00125.2005; FELDMAN RD, 1993, BRIT J PHARMACOL, V110, P1640, DOI 10.1111/j.1476-5381.1993.tb14013.x; Feng SJ, 2000, BLOOD, V95, P551, DOI 10.1182/blood.V95.2.551; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hambleton R, 2005, J BIOL CHEM, V280, P39168, DOI 10.1074/jbc.M506760200; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Hutchins JRA, 2002, FEBS LETT, V528, P267, DOI 10.1016/S0014-5793(02)03327-6; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; MASTERS SC, 1999, BIOCHEM J, V38, P12499; Maurice DH, 2003, MOL PHARMACOL, V64, P533, DOI 10.1124/mol.64.3.533; McConnachie G, 2006, TRENDS MOL MED, V12, P317, DOI 10.1016/j.molmed.2006.05.008; Nilsson R, 2006, CELL SIGNAL, V18, P1713, DOI 10.1016/j.cellsig.2006.01.010; Onuma H, 2002, DIABETES, V51, P3362, DOI 10.2337/diabetes.51.12.3362; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Pawson T, 2005, TRENDS BIOCHEM SCI, V30, P286, DOI 10.1016/j.tibs.2005.04.013; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; Rose RJ, 1997, BRIT J PHARMACOL, V122, P233, DOI 10.1038/sj.bjp.0701376; Rubio MP, 2005, BIOCHEM J, V392, P163, DOI 10.1042/BJ20051103; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; TAYLOR P, 1988, PRINCIPLES DRUG ACTI, P144; Voigt P, 2006, J BIOL CHEM, V281, P9977, DOI 10.1074/jbc.M512502200; Wechsler J, 2002, J BIOL CHEM, V277, P38072, DOI 10.1074/jbc.M203647200; Zmuda-Trzebiatowska E, 2007, CELL SIGNAL, V19, P81, DOI 10.1016/j.cellsig.2006.05.024	41	40	45	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9411	9419		10.1074/jbc.M606936200	http://dx.doi.org/10.1074/jbc.M606936200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17255105	hybrid			2022-12-27	WOS:000245421700013
J	Schumacher, J; Joly, N; Rappas, M; Bradley, D; Wigneshweraraj, SR; Zhang, XD; Buck, M				Schumacher, Jorg; Joly, Nicolas; Rappas, Mathieu; Bradley, Dominic; Wigneshweraraj, Siva R.; Zhang, Xiaodong; Buck, Martin			Sensor I threonine of the AAA plus ATPase transcriptional activator PspF is involved in coupling nucleoticle triphosphate hydrolysis to the restructuring of sigma(54)-RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE FTSH; ENHANCER-BINDING PROTEINS; BACTERIAL RNA-POLYMERASE; PROMOTER DNA COMPLEX; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DOMAIN; MECHANISM; COMMUNICATION; SUBUNIT	Transcriptional initiation invariably involves the transition from a closed RNA polymerase (RNAP) promoter complex to a transcriptional competent open complex. Activators of the bacterial sigma(54)-RNAP are AAA+ proteins that couple ATP hydrolysis to restructure the sigma(54)-RNAP promoter complex. Structures of the sigma(54) activator PspF AAA+ domain (PspF(1-275)) bound to sigma(54) show two loop structures proximal to sigma(54) as follows: the w` contacting the GAFTGA loop 1 structure and loop 2 that classifies sigma(54) activators as pre-sensor 1 beta-hairpin AAA+ proteins. We report activities for PspF(1-275) mutated in the AAA+ conserved served sensor I threonine/asparagine motif (PspF(1-275)(T148A), PspF(1-275)(N149A), and PspF(1-275)(N149S)) within the second region of homology. We show that sensor I asparagine plays a direct role in ATP hydrolysis. However, low hydrolysis rates are sufficient for functional output in vitro. In contrast, PspF(1-275)(T148A) has severe defects at the distinct step of 0,54 promoter restructuring. This defect is not because of the failure of PspF(1-275)(T148A) to stably engage with the closed sigma(54) promoter, indicating (i) an important role in ATP hydrolysis-associated motions during energy coupling for remodeling and (ii) distinguishing PspF(1-275)(T148A) from PspF(1-275) variants involved in signaling to the GAFTGA loop I,which fail to stably engage with the promoter. Activities of loop 2 PspF(1-275) variants are similar to those of PspF(1-275)(T148A) suggesting a functional signaling link between Thr(148) and loop 2. In PspF(1-275) this link relies on the conserved nucleotide state-dependent interaction between the Walker B residue Glu(108) and Thr(148). We propose that hydrolysis is relayed via Thr(148) to loop 2 creating motions that provide mechanical force to the GAFTGA loop 1 that contacts sigma(54).	Univ London Imperial Coll Sci & Technol, Div Biol, London SW7 2AZ, England; Univ London Imperial Coll Sci & Technol, Div Mol Biosci, London SW7 2AZ, England	Imperial College London; Imperial College London	Schumacher, J (corresponding author), Univ London Imperial Coll Sci & Technol, Div Biol, London SW7 2AZ, England.	j.schumacher@imperial.ac.uk; m.buck@imperial.ac.uk		Wigneshweraraj, Sivaramesh/0000-0002-1418-4029				Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Besche H, 2004, FEBS LETT, V574, P161, DOI 10.1016/j.febslet.2004.08.021; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Bordes P, 2004, MOL MICROBIOL, V54, P489, DOI 10.1111/j.1365-2958.2004.04280.x; Burrows PC, 2004, EMBO J, V23, P4253, DOI 10.1038/sj.emboj.7600406; Cannon W, 2002, NUCLEIC ACIDS RES, V30, P886, DOI 10.1093/nar/30.4.886; Cannon W, 2001, J BIOL CHEM, V276, P386, DOI 10.1074/jbc.M007779200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Cannon WV, 2004, NUCLEIC ACIDS RES, V32, P4596, DOI 10.1093/nar/gkh755; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Darwin AJ, 2005, MOL MICROBIOL, V57, P621, DOI 10.1111/j.1365-2958.2005.04694.x; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Gerega A, 2005, J BIOL CHEM, V280, P42856, DOI 10.1074/jbc.M510592200; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Han YW, 2001, J BIOL CHEM, V276, P35024, DOI 10.1074/jbc.M103611200; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hsu LLM, 2003, BIOCHEMISTRY-US, V42, P3777, DOI 10.1021/bi026954e; Huo YX, 2006, MOL MICROBIOL, V59, P168, DOI 10.1111/j.1365-2958.2005.04943.x; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; Joly N, 2006, J BIOL CHEM, V281, P34997, DOI 10.1074/jbc.M606628200; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; Jovanovic G, 2006, J BIOL CHEM, V281, P21147, DOI 10.1074/jbc.M602323200; Kapanidis AN, 2006, SCIENCE, V314, P1144, DOI 10.1126/science.1131399; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; Leach RN, 2006, J BIOL CHEM, V281, P33717, DOI 10.1074/jbc.M605731200; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lin YC, 2005, NAT STRUCT MOL BIOL, V12, P603, DOI 10.1038/nsmb949; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Rappas M, 2006, J MOL BIOL, V357, P481, DOI 10.1016/j.jmb.2005.12.052; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; SARKAR G, 1985, J BIOL CHEM, V260, P3831; Schumacher J, 2004, J MOL BIOL, V338, P863, DOI 10.1016/j.jmb.2004.02.071; Schumacher J, 2006, J STRUCT BIOL, V156, P190, DOI 10.1016/j.jsb.2006.01.006; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Studholme DJ, 2003, J BACTERIOL, V185, P1757, DOI 10.1128/JB.185.6.1757-1767.2003; Suno R, 2006, MOL CELL, V22, P575, DOI 10.1016/j.molcel.2006.04.020; Wigneshweraraj SR, 2004, EMBO J, V23, P4264, DOI 10.1038/sj.emboj.7600407; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	47	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9825	9833		10.1074/jbc.M611532200	http://dx.doi.org/10.1074/jbc.M611532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17242399	hybrid			2022-12-27	WOS:000245421700057
J	Stauffer, D; Chang, B; Huang, J; Dunn, A; Thayer, M				Stauffer, Daniel; Chang, Bill; Huang, Jing; Dunn, Andrew; Thayer, Mathew			p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DAMAGE CHECKPOINT; S-PHASE; HISTONE ACETYLTRANSFERASE; COACTIVATOR P300; KINASE ATR; GENE; ACETYLATION; P53; ACTIVATION	The highly related acetyltransferases, p300 and CREB-binding protein (CBP) are coactivators of signal-responsive transcriptional activation. In addition, recent evidence suggests that p300/CBP also interacts directly with complexes that mediate DNA replication and repair. In this report, we show that loss of p300/CBP in mammalian cells results in a defect in the cell cycle arrest induced by stalled DNA replication. We demonstrate that complexes containing p300/CBP and ATR can be detected in mammalian cells, and that the downstream kinase CHK1 fails to be phosphorylated in response to stalled DNA replication in cells that lack p300/CBP. These observations broaden the roles for the p300/CBP acetyltransferases to include the modulation of chromatin structure and function during DNA metabolic events as well as for transcription.	Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97201 USA	Oregon Health & Science University	Thayer, M (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	thayerm@ohsu.edu		Chang, Bill/0000-0003-3783-1820	NATIONAL CANCER INSTITUTE [R01CA097021, R01CA104693] Funding Source: NIH RePORTER; NCI NIH HHS [CA97021, CA104693] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chan HM, 2001, J CELL SCI, V114, P2363; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Friedrich-Heineken F, 2005, J MOL BIOL, V353, P980, DOI 10.1016/j.jmb.2005.09.018; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; Goodman RH, 2000, GENE DEV, V14, P1553; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hasan S, 2002, MOL CELL, V10, P1213, DOI 10.1016/S1097-2765(02)00745-1; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Ho CC, 2006, CANCER RES, V66, P2233, DOI 10.1158/0008-5472.CAN-05-1790; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kung AL, 2000, GENE DEV, V14, P272; Kuninger D, 2004, HUM GENE THER, V15, P1287, DOI 10.1089/hum.2004.15.1287; Liu QH, 2000, GENE DEV, V14, P1448; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Naryzhny SN, 2004, J BIOL CHEM, V279, P20194, DOI 10.1074/jbc.M312850200; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Pichierri P, 2004, BIOESSAYS, V26, P306, DOI 10.1002/bies.10411; Pichierri P, 2003, ONCOGENE, V22, P1491, DOI 10.1038/sj.onc.1206169; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shiomi Y, 2002, GENES CELLS, V7, P861, DOI 10.1046/j.1365-2443.2002.00566.x; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Smolik S, 2007, MOL CELL BIOL, V27, P135, DOI 10.1128/MCB.01283-06; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	58	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9678	9687		10.1074/jbc.M609261200	http://dx.doi.org/10.1074/jbc.M609261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272271	hybrid			2022-12-27	WOS:000245421700041
J	Umate, P; Schwenkert, S; Karbat, I; Dal Bosco, C; Mlcochova, L; Volz, S; Zer, H; Herrmann, RG; Ohad, I; Meurer, J				Umate, Pavan; Schwenkert, Serena; Karbat, Izhar; Dal Bosco, Cristina; Mlcochova, Lada; Volz, Stefanie; Zer, Hagit; Herrmann, Reinhold G.; Ohad, Itzhak; Meurer, Joerg			Deletion of PsbM in tobacco alters the Q(B) site properties and the electron flow within photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING-COMPLEX; MOLECULAR-MASS SUBUNITS; THERMO-LUMINESCENCE; CHLAMYDOMONAS-REINHARDTII; PROTEIN-PHOSPHORYLATION; CHARGE ACCUMULATION; CYTOCHROME B(559); CRYSTAL-STRUCTURE; PLASTOQUINONE; OXIDATION	Photosystem II, the oxygen-evolving complex of photosynthetic organisms, includes an intriguingly large number of low molecular weight polypeptides, including PsbM. Here we describe the first knock-out of psbM using a transplastomic, reverse genetics approach in a higher plant. Homoplastomic Delta psbM plants exhibit photoautotrophic growth. Biochemical, biophysical, and immunological analyses demonstrate that PsbM is not required for biogenesis of higher order photosystem 11 complexes. However, photosystem 11 is highly light-sensitive, and its activity is significantly decreased in ApsbM, whereas kinetics of plastid protein synthesis, reassembly of photosystem 11, and recovery of its activity are comparable with the wild type. Unlike wild type, phosphorylation of the reaction center proteins D1 and D2 is severely reduced, whereas the redox-controlled phosphorylation of photosystem 11 light-harvesting complex is reversely regulated in ApsbM plants because of accumulation of reduced plastoquinone in the dark and a limited photosystem II-mediated electron transport in the light. Charge recombination in ApsbM measured by thermoluminescence oscillations significantly differs from the 2/6 patterns in the wild type. A simulation program of thermoluminescence oscillations indicates a higher Q(B)/Q(B)(-) ratio in dark-adapted mutant thylakoids relative to the wild type. The interaction of the Q(A)/Q(B) sites estimated by shifts in the maximal thermoluminescence emission temperature of the Q band, induced by binding of different herbicides to the Q(B) site, is changed indicating alteration of the activation energy for back electron flow. We conclude that PsbM is primarily involved in the interaction of the redox components important for the electron flow within, outward, and backward to photosystem II.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany; Tel Aviv Univ, Dept Plant Sci, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Even Ari Ctr Photosynthesis Res, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Biol Chem, Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	University of Munich; Tel Aviv University; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Meurer, J (corresponding author), Univ Munich, Dept Biol 1, Menzingerstr 67, D-80638 Munich, Germany.	joerg.meurer@lrz.uni-muenchen.de	Meurer, Jörg/F-8479-2010; Schwenkert, Serena/F-8564-2012	Meurer, Jörg/0000-0003-2973-9514; Dal Bosco, Cristina/0000-0002-0280-5369				Adir N, 2003, PHOTOSYNTH RES, V76, P343, DOI 10.1023/A:1024969518145; Allen JF, 2005, CURR BIOL, V15, pR929, DOI 10.1016/j.cub.2005.10.061; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Bondarava N, 2003, J BIOL CHEM, V278, P13554, DOI 10.1074/jbc.M212842200; Clausen J, 2004, BBA-BIOENERGETICS, V1655, P184, DOI 10.1016/j.bbabio.2003.06.001; CORANA A, 1987, ACM T MATH SOFTWARE, V13, P262, DOI 10.1145/29380.29864; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; DEMETER S, 1984, BIOCHIM BIOPHYS ACTA, V764, P24, DOI 10.1016/0005-2728(84)90136-1; DEVAULT D, 1983, P NATL ACAD SCI-BIOL, V80, P983, DOI 10.1073/pnas.80.4.983; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; Ducruet JM, 2003, J EXP BOT, V54, P2419, DOI 10.1093/jxb/erg268; Feild TS, 1998, PLANT PHYSIOL, V116, P1209, DOI 10.1104/pp.116.4.1209; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Gomez SM, 2002, MOL CELL PROTEOMICS, V1, P46, DOI 10.1074/mcp.M100007-MCP200; Granvogl B, 2006, PROTEOMICS, V6, P3681, DOI 10.1002/pmic.200500924; Hankamer B, 2001, J STRUCT BIOL, V135, P262, DOI 10.1006/jsbi.2001.4405; Haumann M, 2005, SCIENCE, V310, P1019, DOI 10.1126/science.1117551; Ikeuchi M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P297; IKEUCHI M, 1989, FEBS LETT, V253, P178, DOI 10.1016/0014-5793(89)80954-8; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; KLESS H, 1993, Z NATURFORSCH C, V48, P185; KLUGHAMMER C, 1994, PLANTA, V192, P261, DOI 10.1007/BF01089043; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; Minagawa J, 2004, PHOTOSYNTH RES, V82, P241, DOI 10.1007/s11120-004-2079-2; Munekage Y, 2002, CELL, V110, P361, DOI 10.1016/S0092-8674(02)00867-X; Nelson N, 2004, NAT REV MOL CELL BIO, V5, P971, DOI 10.1038/nrm1525; Nelson N, 2006, ANNU REV PLANT BIOL, V57, P521, DOI 10.1146/annurev.arplant.57.032905.105350; Ohad I, 2004, BIOCHEMISTRY-US, V43, P2297, DOI 10.1021/bi0348260; Ohnishi N, 2007, J BIOL CHEM, V282, P7107, DOI 10.1074/jbc.M606763200; Ossenbuhl F, 2006, PLANT CELL, V18, P2236, DOI 10.1105/tpc.106.043646; Peng LW, 2006, PLANT CELL, V18, P955, DOI 10.1105/tpc.105.037689; Regel RE, 2001, J BIOL CHEM, V276, P41473, DOI 10.1074/jbc.M102007200; Rochaix JD, 2001, PLANT PHYSIOL, V125, P142, DOI 10.1104/pp.125.1.142; Ruban AV, 2006, J BIOL CHEM, V281, P14981, DOI 10.1074/jbc.M511415200; RUTHERFORD AW, 1984, P NATL ACAD SCI-BIOL, V81, P1107, DOI 10.1073/pnas.81.4.1107; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; Rutherford AW, 2001, TRENDS BIOCHEM SCI, V26, P648, DOI 10.1016/S0968-0004(01)01953-3; Schreiber U., 1998, P320; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P411, DOI 10.1111/j.1432-1033.1988.tb14390.x; Schwenkert S, 2006, J BIOL CHEM, V281, P34227, DOI 10.1074/jbc.M604888200; Shi LX, 2004, BBA-BIOENERGETICS, V1608, P75, DOI 10.1016/j.bbabio.2003.12.004; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; SUGIURA M, 1986, PLANT SCI, V44, P211, DOI 10.1016/0168-9452(86)90093-2; Swiatek M, 2003, CURR GENET, V43, P45, DOI 10.1007/s00294-003-0369-4; Swiatek M, 2003, MOL GENET GENOMICS, V268, P699, DOI 10.1007/s00438-002-0791-1; Swiatek M, 2001, PLANT CELL, V13, P1347, DOI 10.1105/tpc.13.6.1347; Szilard A, 2005, PHOTOSYNTH RES, V84, P15, DOI 10.1007/s11120-004-7161-2; Thornton LE, 2005, ADV PHOTO RESPIRAT, V22, P121; Vass I, 2003, PHOTOSYNTH RES, V76, P303, DOI 10.1023/A:1024989519054; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; Vrettos JS, 2002, PHILOS T R SOC B, V357, P1395, DOI 10.1098/rstb.2002.1136; WHITMARSH I, 1996, OXYGENIC PHOTOSYNTHE, P249; ZER H, 1994, J BIOL CHEM, V269, P17670; Zer H, 1999, P NATL ACAD SCI USA, V96, P8277, DOI 10.1073/pnas.96.14.8277; Zer H, 2003, BIOCHEMISTRY-US, V42, P728, DOI 10.1021/bi020451r	61	34	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9758	9767		10.1074/jbc.M608117200	http://dx.doi.org/10.1074/jbc.M608117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17261590	Green Published, hybrid			2022-12-27	WOS:000245421700050
J	Wu, Y; Song, P; Xu, J; Zhang, M; Zou, MH				Wu, Yong; Song, Ping; Xu, Jian; Zhang, Miao; Zou, Ming-Hui			RETRACTED: Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase (Retracted article. See vol. 294, pg. 10741, 2019)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							ACETYL-COA CARBOXYLASE; NITRIC-OXIDE SYNTHESIS; INSULIN-RESISTANCE; SKELETAL-MUSCLE; SIGNAL-TRANSDUCTION; MALONYL-COA; C-ZETA; PHOSPHORYLATION; ACID; CERAMIDE	Elevated levels of free fatty acids contribute to cardiovascular diseases, but the mechanisms remain poorly understood. The present study was aimed to determine if free fatty acid inhibits the AMP-activated kinase (AMPK). Exposure of cultured bovine aortic endothelial cells (BAECs) to palmitate (0.4 mM) but not to palmitoleic or oleic acid (0.4 mm) for 40 h significantly reduced the Thr(172) phosphorylation of AMPK-a without altering its protein expression or the phosphorylation of LKB1-Ser(428), a major AMPK kinase in BAECs. Further, in LKB1-deficient cells, palmitate suppressed AMPK-Thr(172) implying that the inhibitory effects of palmitate on AMPK might be independent of LKB1. In contrast, 2-bromopalmitate, a non-metabolizable analog of palmitate, did not alter the phosphorylation of AMPK and acetyl-CoA carboxylase. Further, palmitate significantly increased the activity of protein phosphatase (PP)2A. Inhibition of PP2A with either okadaic acid, a selective PP2A inhibitor, or PP2A small interference RNA abolished palmitate-induced inhibition on AMPK-Thr(172) phosphorylation. Exposure of BAECs to C-2-ceramide, a cell-permeable analog of ceramide, mimicked the effects of palmitate. Conversely, fumonisin B I, which selectively inhibits ceramide synthase and decreases de novo formation of ceramide, abolished the effects of palmitate on both PP2A and AMPK. Inhibition of AMPK in parallel with increased PP2A activity was founded in C57BL/6J mice fed with high fat diet (HFD) rich in palmitate but not in mice fed with HFD rich in oleate. Moreover, inhibition of PP2A with PP2A-specific siRNA but not scrambled siRNA reversed HFD-induced inhibition on the phosphorylation of AMPK-Thr(172) and endothelial nitric-oxide synthase (eNOS)-Ser(1177) in mice fed with high fat diets. Taken together, we conclude that palmitate inhibits the phosphorylation of both AMPK and endothelial nitric-oxide synthase in endothelial cells via ceramide-dependent PP2A activation.	Univ Oklahoma, Hlth Sci Ctr, Div Endocrinol & Diabet, Dept Med, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Zou, MH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Div Endocrinol & Diabet, Dept Med, 941 Stanton L Young Blvd,BSEB 325, Oklahoma City, OK 73104 USA.	ming-hui-zou@ouhsc.edu	Song, Ping/N-8456-2018; Song, Ping/D-6972-2011	Song, Ping/0000-0002-6143-4270; Song, Ping/0000-0002-2654-6162	NHLBI NIH HHS [HL074399, HL079584, HL080499] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074399, R01HL080499, R01HL079584] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; Carling D, 2005, BIOCHIMIE, V87, P87, DOI 10.1016/j.biochi.2004.10.017; CHASE JFA, 1972, BIOCHEM J, V129, P55, DOI 10.1042/bj1290055; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; Davis BJ, 2006, DIABETES, V55, P496, DOI 10.2337/diabetes.55.02.06.db05-1064; Fayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724; Fediuc S, 2006, J LIPID RES, V47, P412, DOI 10.1194/jlr.M500438-JLR200; Gimeno-Alcaniz JV, 2003, J MOL BIOL, V333, P201, DOI 10.1016/j.jmb.2003.08.022; Gonzalez J, 2003, BIOCHEM J, V374, P647, DOI 10.1042/BJ20030215; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; Jiang BB, 2004, J BIOL CHEM, V279, P20363, DOI 10.1074/jbc.M314172200; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; KELLEY DE, 1994, J CLIN INVEST, V94, P2349, DOI 10.1172/JCI117600; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Lee WJ, 2005, ARTERIOSCL THROM VAS, V25, P2488, DOI 10.1161/01.ATV.0000190667.33224.4c; Lessard SJ, 2006, AM J PHYSIOL-ENDOC M, V290, pE251, DOI 10.1152/ajpendo.00096.2005; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; McCarty MF, 2005, MED HYPOTHESES, V64, P1211, DOI 10.1016/j.mehy.2004.01.042; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Muse ED, 2004, J CLIN INVEST, V114, P232, DOI 10.1172/JCI200421270; Musi N, 2006, CURR MED CHEM, V13, P583, DOI 10.2174/092986706776055724; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Powell DJ, 2004, BIOCHEM J, V382, P619, DOI 10.1042/BJ20040139; Ravnskjaer K, 2006, J MOL ENDOCRINOL, V36, P289, DOI 10.1677/jme.1.01965; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Ruderman NB, 2003, BIOCHEM SOC T, V31, P202, DOI 10.1042/bst0310202; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Suchankova G, 2005, BIOCHEM BIOPH RES CO, V326, P851, DOI 10.1016/j.bbrc.2004.11.114; Summers SA, 2006, PROG LIPID RES, V45, P42, DOI 10.1016/j.plipres.2005.11.002; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; Taylor EB, 2005, AM J PHYSIOL-ENDOC M, V288, pE1055, DOI 10.1152/ajpendo.00516.2004; Wang MY, 2005, AM J PHYSIOL-ENDOC M, V288, pE216, DOI 10.1152/ajpendo.00004.2004; Wilkes JJ, 2005, AM J PHYSIOL-ENDOC M, V289, pE1015, DOI 10.1152/ajpendo.00169.2005; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200	49	218	228	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9777	9788		10.1074/jbc.M608310200	http://dx.doi.org/10.1074/jbc.M608310200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17255104	hybrid			2022-12-27	WOS:000245421700052
J	Oh, J; Kim, JG; Jeon, E; Yoo, CH; Moon, JS; Rhee, S; Hwang, I				Oh, Jonghee; Kim, Jung-Gun; Jeon, Eunkyung; Yoo, Chang-Hyuk; Moon, Jae Sun; Rhee, Sangkee; Hwang, Ingyu			Amyloidogenesis of type III-dependent harpins from plant pathogenic bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; LEAF APOPLASTIC FLUID; HYPERSENSITIVE RESPONSE; BIOLOGICAL-ACTIVITY; HYDROPHOBIC PROTEINS; ERWINIA-AMYLOVORA; IRON-DEFICIENCY; HRP PATHWAY; ELICITOR; FORMS	Harpins are heat-stable, glycine-rich type III-secreted proteins produced by plant pathogenic bacteria, which cause a hypersensitive response (HR) when infiltrated into the intercellular space of tobacco leaves; however, the biochemical mechanisms by which harpins cause plant cell death remain unclear. In this study, we determined the biochemical characteristics of HpaG, the first harpin identified from a Xanthomonas species, under plant apoplast-like conditions using electron microscopy and circular dichroism spectroscopy. We found that His(6)-HpaG formed biologically active spherical oligomers, protofibrils, and beta-sheet-rich fibrils, whereas the null HR mutant His(6)HpaG(L50P) did not. Biochemical analysis and HR assay of various forms of HpaG demonstrated that the transition from an beta-helix to beta-sheet-rich fibrils is important for the biological activity of protein. The fibrillar form of His(6)-HpaG is an amyloid protein based on positive staining with Congo red to produce green birefringence under polarized light, increased protease resistance, and beta-sheet fibril structure. Other harpins, such as HrpN from Erwinia amylovora and HrpZ from Pseudomonas syringae pv. syringae, also formed curvilinear protofibrils or fibrils under plant apoplast-like conditions, suggesting that amyloidogenesis is a common feature of harpins. Missense and deletion mutagenesis of HpaG indicated that the rate of HpaG fibril formation is modulated by a motif present in the C terminus. The plant cytotoxicity of HpaG is unique among the amyloid-forming proteins that occur in several microorganisms. Structural and morphological analogies between HpaG and disease-related amyloidogenic proteins, such as A beta protein, suggest possible common biochemical characteristics in the induction of plant and animal cell death.	Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Seoul 151921, South Korea; Korea Res Biosci & Biotechnol, Plant Genome Res Ctr, Taejon 305633, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Hwang, I (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea.	ingyu@snu.ac.kr						Ahmad M, 2001, MOL PLANT MICROBE IN, V14, P1223, DOI 10.1094/MPMI.2001.14.10.1223; Alfano JR, 1996, MOL MICROBIOL, V19, P715, DOI 10.1046/j.1365-2958.1996.415946.x; Alfano JR, 2004, ANNU REV PHYTOPATHOL, V42, P385, DOI 10.1146/annurev.phyto.42.040103.110731; ARLAT M, 1994, EMBO J, V13, P543, DOI 10.1002/j.1460-2075.1994.tb06292.x; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BAUER DW, 1995, MOL PLANT MICROBE IN, V8, P484, DOI 10.1094/MPMI-8-0484; Bieler S, 2005, J BIOL CHEM, V280, P26880, DOI 10.1074/jbc.M502031200; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Charkowski AO, 1998, J BACTERIOL, V180, P5211, DOI 10.1128/JB.180.19.5211-5217.1998; Claessen D, 2003, GENE DEV, V17, P1714, DOI 10.1101/gad.264303; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fandrich M, 2003, P NATL ACAD SCI USA, V100, P15463, DOI 10.1073/pnas.0303758100; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; Greenberg JT, 1997, ANNU REV PLANT PHYS, V48, P525, DOI 10.1146/annurev.arplant.48.1.525; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hoyos ME, 1996, MOL PLANT MICROBE IN, V9, P608, DOI 10.1094/MPMI-9-0608; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim JF, 1998, J BACTERIOL, V180, P5203, DOI 10.1128/JB.180.19.5203-5210.1998; Kim JG, 2004, J BACTERIOL, V186, P6239, DOI 10.1128/JB.186.18.6239-6247.2004; Kim JG, 2003, J BACTERIOL, V185, P3155, DOI 10.1128/JB.185.10.3155-3166.2003; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kourie JI, 2002, CLIN EXP PHARMACOL P, V29, P741, DOI 10.1046/j.1440-1681.2002.03737.x; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; Lee J, 2001, P NATL ACAD SCI USA, V98, P289, DOI 10.1073/pnas.011265298; Lopez-Millan AF, 2000, PLANT PHYSIOL, V124, P873, DOI 10.1104/pp.124.2.873; Lopez-Millan AF, 2001, J EXP BOT, V52, P1489, DOI 10.1093/jexbot/52.360.1489; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Pike SM, 1998, PHYSIOL MOL PLANT P, V53, P39, DOI 10.1006/pmpp.1998.0167; Qahwash I, 2003, J BIOL CHEM, V278, P23187, DOI 10.1074/jbc.M213298200; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Racape J, 2005, MOL MICROBIOL, V58, P1406, DOI 10.1111/j.1365-2958.2004.04910.x; Resende CG, 2003, MOL MICROBIOL, V49, P1005, DOI 10.1046/j.1365-2958.2003.03608.x; SCHULTE R, 1992, PLANT CELL, V4, P79, DOI 10.1105/tpc.4.1.79; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Thompson A, 2000, J NEUROSCI RES, V62, P293, DOI 10.1002/1097-4547(20001015)62:2<293::AID-JNR14>3.0.CO;2-Y; Tossi A, 2000, BIOPOLYMERS, V55, P4; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; Wengelnik K, 1996, J BACTERIOL, V178, P1061, DOI 10.1128/jb.178.4.1061-1069.1996; Wickner RB, 2004, GENE DEV, V18, P470, DOI 10.1101/gad.1177104	48	85	91	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13601	13609		10.1074/jbc.M602576200	http://dx.doi.org/10.1074/jbc.M602576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17314101	hybrid			2022-12-27	WOS:000246060300049
J	Grubina, R; Huang, Z; Shiva, S; Joshi, MS; Azarov, I; Basu, S; Ringwood, LA; Jiang, A; Hogg, N; Kim-Shapiro, DB; Gladwin, MT				Grubina, Rozalina; Huang, Zhi; Shiva, Sruti; Joshi, Mahesh S.; Azarov, Ivan; Basu, Swati; Ringwood, Lorna A.; Jiang, Alice; Hogg, Neil; Kim-Shapiro, Daniel B.; Gladwin, Mark T.			Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy- and oxyhemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; BLOOD-FLOW REGULATION; S-NITROSOHEMOGLOBIN; AUTOCATALYTIC OXIDATION; ISCHEMIA-REPERFUSION; HYPOXIC CONDITIONS; LIGAND-BINDING; OXYGEN-BINDING; HEMOGLOBIN; NO	Recent studies reveal a novel role for hemoglobin as an allosterically regulated nitrite reductase that may mediate nitric oxide (NO)-dependent signaling along the physiological oxygen gradient. Nitrite reacts with deoxyhemoglobin in an allosteric reaction that generates NO and oxidizes deoxyhemoglobin to methemoglobin. NO then reacts at a nearly diffusion-limited rate with deoxyhemoglobin to form iron-nitrosyl-hemoglobin, which to date has been considered a highly stable adduct and, thus, not a source of bioavailable NO. However, under physiological conditions of partial oxygen saturation, nitrite will also react with oxyhemoglobin, and although this complex autocatalytic reaction has been studied for a century, the interaction of the oxy- and deoxy-reactions and the effects on NO disposition have never been explored. We have now characterized the kinetics of hemoglobin oxidation and NO generation at a range of oxygen partial pressures and found that the deoxy-reaction runs in parallel with and partially inhibits the oxy-reaction. In fact, intermediates in the oxy-reaction oxidize the heme iron of iron nitrosyl hemoglobin, a product of the deoxy-reaction, which releases NO from the iron-nitrosyl. This oxidative denitrosylation is particularly striking during cycles of hemoglobin deoxygenation and oxygenation in the presence of nitrite. These chemistries may contribute to the oxygen-dependent disposition of nitrite in red cells by limiting oxidative inactivation of nitrite by oxyhemoglobin, promoting nitrite reduction to NO by deoxyhemoglobin, and releasing free NO from iron-nitrosyl-hemoglobin.	NHLBI, Vasc Med Branch, Dept Crit Care Med, Ctr Clin,NIH, Bethesda, MD 20892 USA; Howard Hughes Med Inst, Natl Inst Hlth, Res Scholars Program, Bethesda, MD 20814 USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Heart Lung & Blood Institute (NHLBI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Wake Forest University; Medical College of Wisconsin	Gladwin, MT (corresponding author), NHLBI, Vasc Med Branch, Dept Crit Care Med, Ctr Clin,NIH, Bldg 10 CRC,Rm 5-5140,10 Ctr Dr, Bethesda, MD 20892 USA.	mgladwin@nih.gov	Kim-Shapiro, Daniel/HGA-2682-2022	Azarov, Ivan/0000-0002-9886-3298	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL58091, R37 HL058091, R01 HL058091, HL078706] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL058091, R01HL058091, R29HL058091, K02HL078706] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angelo M, 2006, P NATL ACAD SCI USA, V103, P8366, DOI 10.1073/pnas.0600942103; Boccini F, 2006, J PHYS CHEM A, V110, P3927, DOI 10.1021/jp056452l; Brooks J, 1937, PROC R SOC SER B-BIO, V123, P368, DOI 10.1098/rspb.1937.0057; Bryan NS, 2005, NAT CHEM BIOL, V1, P290, DOI 10.1038/nchembio734; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; Castello PR, 2006, CELL METAB, V3, P277, DOI 10.1016/j.cmet.2006.02.011; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; Duranski MR, 2005, J CLIN INVEST, V115, P1232, DOI 10.1172/JCI200522493; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Ford PC, 2005, CHEM REV, V105, P2439, DOI 10.1021/cr0307289; Gardner PR, 2005, J INORG BIOCHEM, V99, P247, DOI 10.1016/j.jinorgbio.2004.10.003; Gautier C, 2006, BIOCHEM BIOPH RES CO, V341, P816, DOI 10.1016/j.bbrc.2006.01.031; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gladwin MT, 2004, FREE RADICAL BIO MED, V36, P707, DOI 10.1016/j.freeradbiomed.2003.11.032; Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Hataishi R, 2006, AM J PHYSIOL-HEART C, V291, pH379, DOI 10.1152/ajpheart.01172.2005; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Herold S, 2006, INORG CHEM, V45, P6933, DOI 10.1021/ic060469g; Huang KT, 2005, J BIOL CHEM, V280, P31126, DOI 10.1074/jbc.M501496200; Huang KT, 2006, BLOOD, V107, P2602, DOI 10.1182/blood-2005-10-4104; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Huang Z, 2003, BIOPHYS J, V85, P2374, DOI 10.1016/S0006-3495(03)74661-X; Hunter CJ, 2004, NAT MED, V10, P1122, DOI 10.1038/nm1109; Jeffers A, 2005, COMP BIOCHEM PHYS A, V142, P130, DOI 10.1016/j.cbpb.2005.04.016; Keszler A, 2006, FREE RADICAL BIO MED, V40, P507, DOI 10.1016/j.freeradbiomed.2005.09.005; Kim-Shapiro DB, 2005, J INORG BIOCHEM, V99, P237, DOI 10.1016/j.jinorgbio.2004.10.034; Kim-Shapiro DB, 2004, FREE RADICAL BIO MED, V36, P402, DOI 10.1016/j.freeradbiomed.2003.10.030; KOSAKA H, 1982, BIOCHIM BIOPHYS ACTA, V702, P237; Kozlov AV, 2005, ANTIOXID REDOX SIGN, V7, P515, DOI 10.1089/ars.2005.7.515; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Lissi E, 1998, FREE RADICAL BIO MED, V24, P1535, DOI 10.1016/S0891-5849(98)00004-5; Luchsinger BP, 2003, P NATL ACAD SCI USA, V100, P461, DOI 10.1073/pnas.0233287100; Luchsinger BP, 2005, J INORG BIOCHEM, V99, P912, DOI 10.1016/j.jinorgbio.2004.12.010; Lundberg JO, 2005, ARTERIOSCL THROM VAS, V25, P915, DOI 10.1161/01.ATV.0000161048.72004.c2; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Modin A, 2001, ACTA PHYSIOL SCAND, V171, P9, DOI 10.1046/j.1365-201x.2001.171001009.x; MORRIS RJ, 1980, J BIOL CHEM, V255, P8050; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Nohl H, 2000, ACTA BIOCHIM POL, V47, P913, DOI 10.18388/abp.2000_3946; Piknova B, 2005, J BIOL CHEM, V280, P40583, DOI 10.1074/jbc.M506292200; Roche CJ, 2006, J BIOL CHEM, V281, P36874, DOI 10.1074/jbc.M603914200; SHIVA S, 2007, IN PRESS CIRC RES; Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Tsuchiya K, 2005, AM J PHYSIOL-HEART C, V288, pH2163, DOI 10.1152/ajpheart.00525.2004; Wang Y, 1995, Adv Pharmacol, V34, P71; Webb A, 2004, P NATL ACAD SCI USA, V101, P13683, DOI 10.1073/pnas.0402927101; Xu XL, 2003, P NATL ACAD SCI USA, V100, P11303, DOI 10.1073/pnas.2033883100; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	60	128	130	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12916	12927		10.1074/jbc.M700546200	http://dx.doi.org/10.1074/jbc.M700546200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322300	hybrid			2022-12-27	WOS:000245942800063
J	Han, YP; Yan, CL; Zhou, L; Qin, L; Tsukamoto, H				Han, Yuan-Ping; Yan, Chunli; Zhou, Ling; Qin, Lan; Tsukamoto, Hidekazu			A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; NECROSIS FACTOR-ALPHA; NF-KAPPA-B; RAT-LIVER; HUMAN SKIN; PROTEOLYTIC ACTIVATION; INFLAMMATORY CYTOKINES; MEDIATED INDUCTION; GROWTH-FACTORS; KUPFFER CELLS	Hepatic stellate cells (HSCs) undergo myofibroblastic transdifferentiation in liver fibrogenesis. We previously showed that dual stimulation with three-dimensional type-I collagen and interleukin-1 (IL-1) synergistically induces HSC trans-differentiation in a manner dependent on the activation of matrix metallopreinase-9 (MMP-9). The present study is aimed to determine the mechanism of MMP-9 activation in this model. The pro-MMP-9-converting activities expressed by trans-differentiating HSCs are characterized as secreted factors that are sensitive to MMP inhibitor and have apparent molecular masses of 50 and 25 kDa. This is in sharp contrast to the pro-MMP-9 activator from mouse and human skin, which is a chymotrypsin-like proteinase. Among multiple MMPs induced in HSCs by the dual stimulation, MMP-13 is most conspicuously up-regulated and meets all criteria as the pro-MMP-9 activator. HSC cultured in three- dimensional type-I collagen, but not in Matrigel, IL-1 induces expression of MMP-13 and its matured form at 50 and 25 kDa, respectively. In vitro reconstitution experiment proves that MMP-13, but not its zymogen, activates pro-MMP-9. Further, short hairpin RNA targeting MMP-13 abolishes proMMP-9 activation and HSC trans-differentiation. We further demonstrate that pro-MMP-13 activation is facilitated with a membrane-associated factor, inhibited with tissue inhibitor of metalloproteinase-2, and abolished with short hairpin RNA against MMP-14. Moreover, pro-MMP-13 is also activated by a secreted factor, which is absorbed by gelatin-Sepharose and reconstituted with MMP-9. Thus, IL-1-induced trans-differentiation of HSCs in three-dimensional extracellular matrix is facilitated by an MMP activation cascade (MMP-14 > MMP13 > MMP-9) and a positive feedback loop of MMP-9 > MMP13, suggesting their critical roles in liver injury and repair.	Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Han, YP (corresponding author), Univ So Calif, Keck Sch Med, Dept Surg, 2011 Zonal Ave,HMR 813, Los Angeles, CA 90033 USA.	yhan@surgery.usc.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R24AA012885, P50AA011999] Funding Source: NIH RePORTER; NIAAA NIH HHS [P50 AA11999, R24 AA012885, R24AA12885, P50 AA011999] Funding Source: Medline; NIAMS NIH HHS [AR051558, R01 AR051558, R01 AR051558-01] Funding Source: Medline; NIDDK NIH HHS [DK069418, R01 DK069418-01, R01 DK069418] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Corbel M, 2001, INFLAMM RES, V50, P129, DOI 10.1007/s000110050736; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; Dreier R, 2004, EXP CELL RES, V297, P303, DOI 10.1016/j.yexcr.2004.02.027; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; Friedman SL, 1999, SEMIN LIVER DIS, V19, P129, DOI 10.1055/s-2007-1007105; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; GEERTS A, 1989, J HEPATOL, V9, P59, DOI 10.1016/0168-8278(89)90076-7; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hahn-Dantona E, 1999, ANN NY ACAD SCI, V878, P372, DOI 10.1111/j.1749-6632.1999.tb07696.x; Han YP, 2005, SURGERY, V138, P932, DOI 10.1016/j.surg.2005.05.003; Han YP, 2004, J BIOL CHEM, V279, P4820, DOI 10.1074/jbc.M310999200; Han YP, 2002, J BIOL CHEM, V277, P27319, DOI 10.1074/jbc.M202842200; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; Han YP, 2001, J CELL SCI, V114, P131; Han YP, 2006, J GASTROEN HEPATOL, V21, pS88, DOI 10.1111/j.1440-1746.2006.04586.x; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; HERBST H, 1991, VIRCHOWS ARCH B, V60, P295, DOI 10.1007/BF02899560; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Itoh Y, 2006, MOL BIOL CELL, V17, P5390, DOI 10.1091/mbc.e06-08-0740; JEZEQUEL AM, 1987, J HEPATOL, V5, P174, DOI 10.1016/S0168-8278(87)80570-6; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; Kossakowska AE, 1998, AM J PATHOL, V153, P1895, DOI 10.1016/S0002-9440(10)65703-3; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; MATSUOKA M, 1989, LIVER, V9, P71; MILANI S, 1994, AM J PATHOL, V144, P528; MINATO Y, 1983, HEPATOLOGY, V3, P559; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKANOUE T, 1983, ARCH PATHOL LAB MED, V107, P459; OKAZAKI I, 1974, NATURE, V252, P49, DOI 10.1038/252049a0; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; SATO H, 1993, J BIOL CHEM, V268, P23460; Selvarajan S, 2001, NAT CELL BIOL, V3, P267, DOI 10.1038/35060059; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; TAKAHARA T, 1988, LAB INVEST, V59, P509; Tchougounova E, 2005, J BIOL CHEM, V280, P9291, DOI 10.1074/jbc.M410396200; TSUKADA S, 2006, CLIN CHIM ACTA, V364, P33, DOI DOI 10.1016/J.CCA.2005.06.014; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Uchinami H, 2006, HEPATOLOGY, V44, P420, DOI 10.1002/hep.21268; Wake K, 1980, Int Rev Cytol, V66, P303; Watanabe T, 2001, J HEPATOL, V35, P465, DOI 10.1016/S0168-8278(01)00177-5	56	70	73	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12928	12939		10.1074/jbc.M700554200	http://dx.doi.org/10.1074/jbc.M700554200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322299	Green Accepted, hybrid			2022-12-27	WOS:000245942800064
J	Budman, J; Kim, SA; Chu, G				Budman, Joe; Kim, Sunny A.; Chu, Gilbert			Processing of DNA for nonhomologous end-joining is controlled by kinase activity and XRCC4/Ligase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; POLYMERASE-LAMBDA; LIGASE-IV; MAMMALIAN-CELLS; COMPLEX; KU; AUTOPHOSPHORYLATION	Nonhomologous end-joining ( NHEJ) repairs DNA double-strand breaks created by ionizing radiation and V(D)J recombination. To repair the broken ends, NHEJ processes noncompatible ends into a ligatable form but suppresses processing of compatible ends. It is not known how NHEJ controls polymerase and nuclease activities to act exclusively on noncompatible ends. Here, we analyzed processing independently of ligation by using a two-stage assay with extracts that recapitulated the properties of NHEJ in vivo. Processing of noncompatible ends required wortmannin-sensitive kinase activity. Since DNA-dependent protein kinase catalytic subunit ( DNA-PKcs) brings the ends together before undergoing activation of its kinase, this suggests that processing occurred after synapsis of the ends. Surprisingly, all polymerase and most nuclease activity required XRCC4/Ligase IV. This suggests a mechanism for how NHEJ suppresses processing to optimize the preservation of DNA sequence.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Stanford University	Chu, G (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR Bldg,Rm 1145,269 Campus Dr, Stanford, CA 94305 USA.	chu@stanford.edu						Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Budman J, 2005, EMBO J, V24, P849, DOI 10.1038/sj.emboj.7600563; Budman J, 2006, METHOD ENZYMOL, V408, P430, DOI 10.1016/S0076-6879(06)08027-X; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Fan W, 2004, BIOCHEM BIOPH RES CO, V323, P1328, DOI 10.1016/j.bbrc.2004.09.002; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; OKADA T, 1994, J BIOL CHEM, V269, P3563; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Sarkaria JN, 1998, CANCER RES, V58, P4375; Schlissel MS, 1998, MOL CELL BIOL, V18, P2029, DOI 10.1128/MCB.18.4.2029; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001	38	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11950	11959		10.1074/jbc.M610058200	http://dx.doi.org/10.1074/jbc.M610058200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17272270	hybrid			2022-12-27	WOS:000245941900038
J	Cabello, N; Remelli, R; Canela, L; Soriguera, A; Mallol, J; Canela, EI; Robbins, MJ; Lluis, C; Franco, R; McIlhinney, RAJ; Ciruela, F				Cabello, Nuria; Remelli, Rosaria; Canela, Laia; Soriguera, Ana; Mallol, Josefa; Canela, Enric I.; Robbins, Melanie J.; Lluis, Carme; Franco, Rafael; McIlhinney, R. A. Jeffrey; Ciruela, Francisco			Actin-binding protein alpha-actinin-1 interacts with the metabotropic glutamate receptor type 5b and modulates the cell surface expression and function of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT INACTIVATION; ALPHA-ACTININ; NMDA-RECEPTOR; FILAMIN-A; MASS-SPECTROMETRY; KINASE-II; TYPE-1-ALPHA RECEPTOR; SENSING RECEPTOR; ADENOSINE A(2A); PLASMA-MEMBRANE	Receptors for neurotransmitters require scaffolding proteins for membrane microdomain targeting and for regulating receptor function. Using a yeast two-hybrid screen, alpha-actinin-1, a major F-actin cross-linking protein, was identified as a binding partner for the C-terminal domain of metabotropic glutamate receptor type 5b (mGlu(5b) receptor). Co-expression, co-immunoprecipitation, and pull-down experiments showed a close and specific interaction between mGlu(5b) receptor and alpha-actinin-1 in both transfected HEK293 cells and rat striatum. The interaction of alpha-actinin-1 with mGlu(5b) receptor modulated the cell surface expression of the receptor. This was dependent on the binding of alpha-actinin-1 to the actin cytoskeleton. In addition, the alpha-actinin-1/mGlu(5b) receptor interaction regulated receptor-mediated activation of the mitogen-activated protein kinase pathway. Together, these findings indicate that there is an alpha-actinin-1-dependent mGlu(5b) receptor association with the actin cytoskeleton modulating receptor cell surface expression and functioning.	Univ Barcelona, Fac Biol, Inst Invest Biomed August Pi Sunyer, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; GlaxoSmithKline, Psychiat Ctr Excellence Drug Discovery, Dept Schizophrenia & Bipolar Neurophysiol & Pharm, Harlow CM19 5AW, Essex, England	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; GlaxoSmithKline	Ciruela, F (corresponding author), Univ Barcelona, Fac Biol, Inst Invest Biomed August Pi Sunyer, Avda Diagonal 645, E-08028 Barcelona, Spain.	fciruela@ub.edu	Franco, Rafael/C-3694-2015; Mallol, Josefa/I-4194-2015; Ciruela, F./A-5096-2013; Canela, Enric I./M-8726-2013	Franco, Rafael/0000-0003-2549-4919; Mallol, Josefa/0000-0002-2479-4162; Ciruela, F./0000-0003-0832-3739; Canela, Enric I./0000-0003-4992-7440	MRC [MC_U138162357] Funding Source: UKRI; Medical Research Council [MC_U138162357] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Attucci S, 2001, BRIT J PHARMACOL, V132, P799, DOI 10.1038/sj.bjp.0703904; Au YH, 2004, STRUCTURE, V12, P611, DOI 10.1016/j.str.2004.02.019; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; Benquet P, 2002, J NEUROSCI, V22, P9679; Bouhamdan M, 2006, J NEUROSCI, V26, P2522, DOI 10.1523/JNEUROSCI.4083-05.2006; Burgueno J, 2004, EXP CELL RES, V300, P23, DOI 10.1016/j.yexcr.2004.06.013; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Burgueno J, 2003, J NEUROCHEM, V86, P785, DOI 10.1046/j.1471-4159.2003.01842.x; Canals M, 2003, J BIOL CHEM, V278, P46741, DOI 10.1074/jbc.M306451200; CASADO V, 1990, J NEUROSCI RES, V26, P461, DOI 10.1002/jnr.490260409; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Chan WY, 2001, MOL CELL NEUROSCI, V17, P577, DOI 10.1006/mcne.2001.0965; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Ciruela F, 1999, BIOCHEM J, V341, P795, DOI 10.1042/0264-6021:3410795; Ciruela F, 2004, ANAL CHEM, V76, P5354, DOI 10.1021/ac049295f; Ciruela F, 2005, J MOL NEUROSCI, V26, P277, DOI 10.1385/JMN:26:2-3:277; Cukovic D, 2001, FEBS LETT, V498, P87, DOI 10.1016/S0014-5793(01)02505-4; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; Dunah AW, 2000, MOL BRAIN RES, V79, P77, DOI 10.1016/S0169-328X(00)00102-9; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Enz R, 2002, FEBS LETT, V514, P184, DOI 10.1016/S0014-5793(02)02361-X; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Ferre S, 2002, P NATL ACAD SCI USA, V99, P11940, DOI 10.1073/pnas.172393799; Heidinger V, 2002, J NEUROSCI, V22, P5452; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Huang CF, 2006, FEBS LETT, V580, P1795, DOI 10.1016/j.febslet.2006.02.035; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kremerskothen J, 2002, BIOCHEM BIOPH RES CO, V295, P678, DOI 10.1016/S0006-291X(02)00734-9; Krupp JJ, 1999, J NEUROSCI, V19, P1165; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lin RW, 2002, PHARMACOLOGY, V66, P173, DOI 10.1159/000065531; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Lujan R, 2001, NEUROREPORT, V12, P1285, DOI 10.1097/00001756-200105080-00046; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nakagawa T, 2004, NEUROPHARMACOLOGY, V47, P734, DOI 10.1016/j.neuropharm.2004.07.022; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pisani A, 1997, BRIT J PHARMACOL, V120, P1007, DOI 10.1038/sj.bjp.0700999; Robison AJ, 2005, J BIOL CHEM, V280, P39316, DOI 10.1074/jbc.M508189200; Robison AJ, 2005, J BIOL CHEM, V280, P35329, DOI 10.1074/jbc.M502191200; Romano C, 2002, NEUROSCIENCE, V111, P693, DOI 10.1016/S0306-4522(02)00042-8; Rycroft BK, 2004, J PHYSIOL-LONDON, V557, P795, DOI 10.1113/jphysiol.2003.059212; Sarrio S, 2000, MOL CELL BIOL, V20, P5164, DOI 10.1128/MCB.20.14.5164-5174.2000; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; Sessoms-Sikes S, 2005, MOL CELL NEUROSCI, V29, P139, DOI 10.1016/j.mcn.2005.01.006; Sorimachi H, 1997, J MOL BIOL, V270, P688, DOI 10.1006/jmbi.1997.1145; TRAVE G, 1995, EUR J BIOCHEM, V227, P35, DOI 10.1111/j.1432-1033.1995.tb20357.x; Ugolini A, 1997, NEUROPHARMACOLOGY, V36, P1047, DOI 10.1016/S0028-3908(97)00103-2; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Wirkner K, 2007, CEREB CORTEX, V17, P621, DOI 10.1093/cercor/bhk012; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Yang L, 2004, J NEUROSCI, V24, P10846, DOI 10.1523/JNEUROSCI.2496-04.2004; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zhang ML, 2005, J BIOL CHEM, V280, P11140, DOI 10.1074/jbc.M412242200; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092; Zimmermann T, 2002, FEBS LETT, V531, P245, DOI 10.1016/S0014-5793(02)03508-1	70	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12143	12153		10.1074/jbc.M608880200	http://dx.doi.org/10.1074/jbc.M608880200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17311919	Green Published, hybrid			2022-12-27	WOS:000245941900057
J	Cottrell, GS; Padilla, B; Pikios, S; Roosterman, D; Steinhoff, M; Grady, EF; Bunnett, NW				Cottrell, Graeme S.; Padilla, Benjamin; Pikios, Stella; Roosterman, Dirk; Steinhoff, Martin; Grady, Eileen F.; Bunnett, Nigel W.			Post-endocytic sorting of calcitonin receptor-like receptor and receptor activity-modifying protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; BETA(2)-ADRENERGIC RECEPTOR; NEUROKININ-1 RECEPTOR; COUPLED RECEPTOR; MEDIATES UBIQUITINATION; BINDING-SPECIFICITY; DOWN-REGULATION; BETA-ARRESTIN; SPINAL-CORD; RAB GTPASES	Calcitonin receptor-like receptor ( CLR) and the receptor activity-modifying protein 1 ( RAMP1) comprise a receptor for calcitonin gene-related peptide ( CGRP). Although CGRP induces endocytosis of CLR/RAMP1, little is known about post-endocytic sorting of these proteins. We observed that the duration of stimulation with CGRP markedly affected post-endocytic sorting of CLR/RAMP1. In HEK and SK-N-MC cells, transient stimulation ( 10(-7) M CGRP, 1 h), induced CLR/RAMP1 recycling with similar kinetics ( 2-6 h), demonstrated by labeling receptors in living cells with antibodies to extracellular epitopes. Recycling of CLR/RAMP1 correlated with resensitization of CGRP-induced increases in [ Ca2+](i). Cycloheximide did not affect resensitization, but bafilomycin A(1), an inhibitor of vacuolar H+-ATPases, abolished resensitization. Recycling CLR and RAMP1 were detected in endosomes containing Rab4a and Rab11a, and expression of GTPase-defective Rab4aS22N and Rab11aS25N inhibited resensitization. After sustained stimulation ( 10(-7) M CGRP,> 2 h), CLR/RAMP1 trafficked to lysosomes. RAMP1 was degraded similar to 4-fold more rapidly than CLR ( RAMP1, 45% degradation, 5 h; CLR, 54% degradation, 16 h), determined by Western blotting. Inhibitors of lysosomal, but not proteasomal, proteases prevented degradation. Sustained stimulation did not induce detectable mono- or polyubiquitination of CLR or RAMP1, determined by immunoprecipitation and Western blotting. Moreover, a RAMP1 mutant lacking the only intracellular lysine ( RAMP1K142R) internalized and was degraded normally. Thus, after transient stimulation with CGRP, CLR and RAMP1 traffic from endosomes to the plasma membrane, which mediates resensitization. After sustained stimulation, CLR and RAMP1 traffic from endosomes to lysosomes by ubiquitin-independent mechanisms, where they are degraded at different rates.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Interdisziplinares Zentrum Klin Forsch Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Immunobiol Skin, D-48149 Munster, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Munster	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.	nigel.bunnett@ucsf.edu	Steinhoff, Martin/F-6312-2013	Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627; Steinhoff, Martin/0000-0002-7090-2187	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052388, R56DK043207, R01DK039957, R01DK043207, R01DK057840, R37DK039957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52388, DK57840, DK39957, DK43207] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bomberger JM, 2005, J BIOL CHEM, V280, P23926, DOI 10.1074/jbc.M501751200; Bomberger JM, 2005, J BIOL CHEM, V280, P9297, DOI 10.1074/jbc.M413786200; Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Cottrell GS, 2006, J BIOL CHEM, V281, P27773, DOI 10.1074/jbc.M603369200; Cottrell GS, 2005, J COMP NEUROL, V490, P239, DOI 10.1002/cne.20669; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Garland AM, 1996, MOL PHARMACOL, V49, P438; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hilaire S, 2001, J BIOL CHEM, V276, P42182, DOI 10.1074/jbc.M107323200; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Kuwasako K, 2006, J BIOL CHEM, V281, P7205, DOI 10.1074/jbc.M511147200; Kuwasako K, 2003, J BIOL CHEM, V278, P22623, DOI 10.1074/jbc.M302571200; Kuwasako K, 2002, FEBS LETT, V519, P113, DOI 10.1016/S0014-5793(02)02721-7; Li JG, 2003, J PHARMACOL EXP THER, V305, P531, DOI 10.1124/jpet.102.045559; LONGMORE J, 1994, EUR J PHARMACOL, V265, P53, DOI 10.1016/0014-2999(94)90222-4; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; ROSENFELD MG, 1984, SCIENCE, V225, P1315, DOI 10.1126/science.6089345; Schmidlin F, 2003, AM J PHYSIOL-CELL PH, V285, pC945, DOI 10.1152/ajpcell.00541.2002; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1	40	64	65	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12260	12271		10.1074/jbc.M606338200	http://dx.doi.org/10.1074/jbc.M606338200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17310067	hybrid			2022-12-27	WOS:000245941900069
J	Hung, CL; Liu, JH; Chiu, WC; Huang, SW; Hwang, JK; Wang, WC				Hung, Chiu-Lien; Liu, Jia-Hsin; Chiu, Wei-Chun; Huang, Shao-Wei; Hwang, Jenn-Kang; Wang, Wen-Ching			Crystal structure of Helicobacter pylori formamidase AmiF reveals a cysteine-glutamate-lysine catalytic triad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACID AMIDOHYDROLASE; ALIPHATIC AMIDASE; SERINE PROTEASES; SEQUENCE; PROGRAM; PURIFICATION; DYNAMICS	Helicobacter pylori AmiF formamidase that hydrolyzes formamide to produce formic acid and ammonia belongs to a member of the nitrilase superfamily. The crystal structure of AmiF was solved to 1.75 angstrom resolution using single-wavelength anomalous dispersion methods. The structure consists of a homohexamer related by 3-fold symmetry in which each subunit has an alpha-beta-beta-alpha four-layer architecture characteristic of the nitrilase superfamily. One exterior alpha layer faces the solvent, whereas the other one associates with that of the neighbor subunit, forming a tight alpha-beta-beta-alpha-alpha-beta-beta-alpha dimer. The apo and liganded crystal structures of an inactive mutant C166S were also determined to 2.50 and 2.30 angstrom, respectively. These structures reveal a small formamide-binding pocket that includes Cys(166), Glu(60), and Lys(133) catalytic residues, in which Cys166 acts as a nucleophile. Analysis of the liganded AmiF and N-carbamoyl D-amino acid amidohydrolase binding pockets reveals a common Cys-Glu-Lys triad, another conserved glutamate, and different subsets of ligand-binding residues. Molecular dynamic simulations show that the conserved triad has minimal fluctuations, catalyzing the hydrolysis of a specific nitrile or amide in the nitrilase superfamily efficiently.	Natl Chiao Tung Univ, Inst Bioinformat, Hsinchu 300, Taiwan; Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu 300, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	National Yang Ming Chiao Tung University; National Tsing Hua University; National Tsing Hua University	Hwang, JK (corresponding author), Natl Chiao Tung Univ, Inst Bioinformat, Hsinchu 300, Taiwan.	jkhwang@faculty.nctu.edu.tw; wcwang@life.nthu.edu.tw	Wang, Wen-Ching/ABI-2253-2020	Wang, Wen-Ching/0000-0002-7422-3667				Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BORK P, 1994, PROTEIN SCI, V3, P1344, DOI 10.1002/pro.5560030821; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bury-Mone S, 2004, MOL MICROBIOL, V53, P623, DOI 10.1111/j.1365-2958.2004.04137.x; Chen CY, 2003, J BIOL CHEM, V278, P26194, DOI 10.1074/jbc.M302384200; Chiu WC, 2006, J MOL BIOL, V359, P741, DOI 10.1016/j.jmb.2006.03.063; DeLano W.L, PYMOL MOL GRAPHICS S; EICHINGE.BE, 1972, MACROMOLECULES, V5, P496, DOI 10.1021/ma60028a028; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grifantini R, 1996, J BIOL CHEM, V271, P9326, DOI 10.1074/jbc.271.16.9326; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holm L, 1999, NUCLEIC ACIDS RES, V27, P244, DOI 10.1093/nar/27.1.244; Ikenaka Y, 1998, BIOSCI BIOTECH BIOCH, V62, P1672, DOI 10.1271/bbb.62.1672; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Kumaran D, 2003, PROTEINS, V52, P283, DOI 10.1002/prot.10417; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 2000, STRUCTURE, V8, P729, DOI 10.1016/S0969-2126(00)00160-X; OGAWA J, 1993, EUR J BIOCHEM, V212, P685, DOI 10.1111/j.1432-1033.1993.tb17706.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Pace HC, 2001, GENOME BIOL, V2; Sakai N, 2004, PROTEINS, V57, P869, DOI 10.1002/prot.20259; Skouloubris S, 2001, MOL MICROBIOL, V40, P596, DOI 10.1046/j.1365-2958.2001.02400.x; Skouloubris S, 1997, MOL MICROBIOL, V25, P989, DOI 10.1111/j.1365-2958.1997.mmi536.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Vliet AHM, 2004, INFECT IMMUN, V72, P766, DOI 10.1128/IAI.72.2.766-773.2004; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wang WC, 2001, J MOL BIOL, V306, P251, DOI 10.1006/jmbi.2000.4380; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; WILLISON JC, 1993, FEMS MICROBIOL LETT, V104, P1; Yang LW, 2005, STRUCTURE, V13, P893, DOI 10.1016/j.str.2005.03.015; YANG W, 1990, J BIOL CHEM, V265, P13553	42	40	40	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12220	12229		10.1074/jbc.M609134200	http://dx.doi.org/10.1074/jbc.M609134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17307742	hybrid			2022-12-27	WOS:000245941900065
J	Jiang, SX; Seng, S; Avraham, HK; Fu, YG; Avraham, S				Jiang, Shuxian; Seng, Seyha; Avraham, Hava Karsenty; Fu, Yigong; Avraham, Shalom			Process elongation of oligodendrocytes is promoted by the kelch-related protein MRP2/KLHL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MATRIX PROTEIN; RAT OPTIC-NERVE; NEURITE OUTGROWTH; INTERACTION MOTIF; PRECURSOR CELLS; SPINAL-CORD; LINEAGE; DROSOPHILA; BINDING; EXPRESSION	Oligodendrocytes ( OLGs) are generated by progenitor cells that are committed to differentiating into myelin-forming cells of the central nervous system. Rearrangement of the cytoskeleton leading to the extension of cellular processes is essential for the myelination of axons by OLGs. Here, we have characterized a new member of the Kelch-related protein family termed MRP2 ( for Mayven-related protein 2) that is specifically expressed in brain. MRP2/KLHL1 is expressed in oligodendrocyte precursors and mature OLGs, and its expression is up-regulated during OLG differentiation. MRP2/KLHL1 expression was abundant during the specific stages of oligodendrocyte development, as identified by A2B5-, O4-, and O1-specific oligodendrocyte markers. MRP2/KLHL1 was localized in the cytoplasm and along the cell processes. Moreover, a direct endogenous association of MRP2/KLHL1 with actin was observed, which was significantly increased in differentiated OLGs compared with undifferentiated OLGs. Overexpression of MRP2/KLHL1 resulted in a significant increase in the process extension of rat OLGs, whereas MRP2/KLHL1 antisense reduced the process length of primary rat OLGs. Furthermore, murine OLGs isolated from MRP2/KLHL1 transgenic mice showed a significant increase in the process extension of OLGs compared with control wild-type murine OLGs. These studies provide insights into the role of MRP2/KLHL1, through its interaction with actin, in the process elongation of OLGs.	Harvard Univ, Sch Med, Div Expt Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039558] Funding Source: NIH RePORTER; NCI NIH HHS [CA 096805] Funding Source: Medline; NHLBI NIH HHS [K18 PAR-HL-02-069] Funding Source: Medline; NINDS NIH HHS [NS 39558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ARMSTRONG R, 1991, ANN NY ACAD SCI, V633, P520; AVRAHAM S, 2003, RECENT RES DEV BIOL, V1, P231; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1992, J NEUROBIOL, V23, P1221, DOI 10.1002/neu.480230912; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Barry C, 1996, DEV NEUROSCI-BASEL, V18, P233, DOI 10.1159/000111413; Benzow KA, 2002, MAMM GENOME, V13, P134, DOI 10.1007/s0033501-2105-2; Benzow KA, 2002, LEUKEMIA LYMPHOMA, V43, P1987, DOI 10.1080/1042819021000015943; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; GARD AL, 1990, NEURON, V5, P615, DOI 10.1016/0896-6273(90)90216-3; GODT D, 1993, DEVELOPMENT, V119, P799; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; He Y, 2006, J NEUROSCI, V26, P9975, DOI 10.1523/JNEUROSCI.2595-06.2006; Jiang S, 2005, J NEUROCHEM, V92, P1191, DOI 10.1111/j.1471-4159.2004.02946.x; KENNEDY PGE, 1980, LAB INVEST, V43, P342; Kim TA, 2000, GENE, V255, P105, DOI 10.1016/S0378-1119(00)00297-3; Kim TA, 2005, J CELL SCI, V118, P5537, DOI 10.1242/jcs.02643; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; LEVITON A, 1973, J NEUROL SCI, V18, P53, DOI 10.1016/0022-510X(73)90020-8; Ludwin SK, 1997, J NEUROPATH EXP NEUR, V56, P111, DOI 10.1097/00005072-199702000-00001; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; Nemes JP, 2000, HUM MOL GENET, V9, P1543, DOI 10.1093/hmg/9.10.1543; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Richter-Landsberg C, 2000, J NEUROSCI RES, V59, P11, DOI 10.1002/(SICI)1097-4547(20000101)59:1<11::AID-JNR2>3.0.CO;2-O; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; Seng S, 2000, PARASITOL RES, V86, P263, DOI 10.1007/s004360050041; Seng S, 2006, MOL CELL BIOL, V26, P8371, DOI 10.1128/MCB.02167-05; Shi JY, 1998, J NEUROSCI, V18, P4627; SMALL RK, 1987, NATURE, V328, P155, DOI 10.1038/328155a0; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; TIMSIT S, 1995, J NEUROSCI, V15, P1012; Vartanian T, 1999, P NATL ACAD SCI USA, V96, P731, DOI 10.1073/pnas.96.2.731; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; WARF BC, 1991, J NEUROSCI, V11, P2477; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Williams SK, 2005, J NEUROSCI RES, V81, P622, DOI 10.1002/jnr.20588; WILSON R, 1989, J NEUROSCI RES, V22, P439, DOI 10.1002/jnr.490220409; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	45	18	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12319	12329		10.1074/jbc.M701019200	http://dx.doi.org/10.1074/jbc.M701019200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324934	hybrid			2022-12-27	WOS:000245941900074
J	Miki, T; Takegami, Y; Okawa, K; Muraguchi, T; Noda, M; Takahashi, C				Miki, Takao; Takegami, Yujiro; Okawa, Katsuya; Muraguchi, Teruyuki; Noda, Makoto; Takahashi, Chiaki			The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase n and modulates their endocytic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; HUMAN ENDOTHELIAL-CELLS; AMINOPEPTIDASE-N; DOWN-REGULATION; INHIBITOR RECK; LUNG-CANCER; LIPID RAFTS; MT1-MMP; CAVEOLAE; INVASION	The reversion-inducing cysteine-rich protein with Kazal motifs ( RECK) is anchored to the cell surface via glycosylphosphatidylinositol. This molecule antagonizes the function of membrane type 1 matrix metalloproteinase ( MT1-MMP) to promote proMMP-2 maturation. Here, we attempt to clarify the mechanism underlying RECK functions. First, we found that RECK forms a complex with MT1-MMP and inhibits its proteolytic activity. Notably, RECK increases the amount of MT1-MMP that associates with detergent-resistant membranes during sucrose gradient ultracentrifugation. Furthermore, perturbation of membrane cholesterol significantly affected the function of RECK in suppressing MT1-MMP function. These findings indicate that RECK possibly regulates MT1-MMP function by modulating its behavior on the cell surface as well as by enzymatic action; this prompted us to find another molecule whose behavior in detergent-resistant membranes is influenced by RECK. Subsequently, we found that RECK interacts with CD13/aminopeptidase N. Further, we found that RECK inhibits the proteolytic activity of CD13 in a cholesterol perturbation-sensitive manner. Finally, we examined whether RECK influences the behavior of MT1-MMP and CD13 during their internalization from the cell surface. In the absence of RECK, MT1-MMP and CD13 were internalized along with the markers of clathrin- or caveolae-dependent endocytosis. However, interestingly, in the presence of RECK these molecules were internalized preferentially with an endocytic marker that is neither clathrin- nor caveolae-dependent, indicating that RECK modulates endocytic pathways of MT1-MMP and CD13. This modulation was correlated with the accelerated internalization and decay of MT1-MMP and CD13. This study unveils the novel function and target molecules of RECK.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, 21st Century Ctr Excellence Format, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Kyoto University	Takahashi, C (corresponding author), Kyoto Univ, Grad Sch Med, 21st Century COE Format, Sakyo Ku, Kyoto 6068501, Japan.	chtakaha@virus.kyoto-u.ac.jp						Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Aozuka Y, 2004, CANCER LETT, V216, P35, DOI 10.1016/j.canlet.2004.06.050; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Bhagwat SV, 2003, BLOOD, V101, P1818, DOI 10.1182/blood-2002-05-1422; Bigg HF, 2001, CANCER RES, V61, P3610; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Chang HC, 2007, CANCER SCI, V98, P169, DOI 10.1111/j.1349-7006.2006.00367.x; Chang YW, 2005, INT J CANCER, V116, P243, DOI 10.1002/ijc.21089; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Echizenya M, 2005, ONCOGENE, V24, P5850, DOI 10.1038/sj.onc.1208733; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nomura R, 2004, J VIROL, V78, P8701, DOI 10.1128/JVI.78.16.8701-8708.2004; Oda A, 2005, BLOOD, V105, P3141, DOI 10.1182/blood-2003-04-1319; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Paulissen G, 2006, MOL MED, V12, P171, DOI 10.2119/2006-00028.Paulissen; Rabien A, 2007, EUR UROL, V51, P1259, DOI 10.1016/j.eururo.2006.05.050; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; SAIKI I, 1993, INT J CANCER, V54, P137, DOI 10.1002/ijc.2910540122; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suenaga N, 2005, ONCOGENE, V24, P859, DOI 10.1038/sj.onc.1208258; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; van Lent PLEM, 2005, ANN RHEUM DIS, V64, P368, DOI 10.1136/ard.2004.027870; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Zhang Z, 2005, PEPTIDES, V26, P2182, DOI 10.1016/j.peptides.2005.03.049	42	70	74	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12341	12352		10.1074/jbc.M610948200	http://dx.doi.org/10.1074/jbc.M610948200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329256	hybrid			2022-12-27	WOS:000245941900076
J	Wagner, JR; Zhang, JR; Brunzelle, JS; Vierstra, RD; Forest, KT				Wagner, Jeremiah R.; Zhang, Junrui; Brunzelle, Joseph S.; Vierstra, Richard D.; Forest, Katrina T.			High resolution structure of Deinococcus bacteriophytochrome yields new insights into phytochrome architecture and evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; X-RAY-SCATTERING; HISTIDINE KINASES; CPH1 PHYTOCHROME; CHROMOPHORE; DOMAIN; CYANOBACTERIAL; REVEALS; SYNECHOCYSTIS; MODEL	Phytochromes are red/far red light photochromic photoreceptors that direct many photosensory behaviors in the bacterial, fungal, and plant kingdoms. They consist of an N-terminal domain that covalently binds a bilin chromophore and a C-terminal region that transmits the light signal, often through a histidine kinase relay. Using x-ray crystallography, we recently solved the first three-dimensional structure of a phytochrome, using the chromophore-binding domain of Deinococcus radiodurans bacterial phytochrome assembled with its chromophore, biliverdin IX alpha. Now, by engineering the crystallization interface, we have achieved a significantly higher resolution model. This 1.45 angstrom resolution structure helps identify an extensive buried surface between crystal symmetry mates that may promote dimerization in vivo. It also reveals that upon ligation of the C3(2) carbon of biliverdin to Cys(24), the chromophore A-ring assumes a chiral center at C2, thus becoming 2(R),3(E)-phytochromobilin, a chemistry more similar to that proposed for the attached chromophores of cyanobacterial and plant phytochromes than previously appreciated. The evolution of bacterial phytochromes to those found in cyanobacteria and higher plants must have involved greater fitness using more reduced bilins, such as phycocyanobilin, combined with a switch of the attachment site from a cysteine near the N terminus to one conserved within the cGMP phosphodiesterase/adenyl cyclase/FhlA domain. From analysis of site-directed mutants in the D. radiodurans phytochrome, we show that this bilin preference was partially driven by the change in binding site, which ultimately may have helped photosynthetic organisms optimize shade detection. Collectively, these three-dimensional structural results better clarify bilin/protein interactions and help explain how higher plant phytochromes evolved from prokaryotic progenitors.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Northwestern Univ, Life Sci Collaborat Access Team, Argonne, IL 60439 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Northwestern University	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Genet, 425-G Henry Mall, Madison, WI 53706 USA.	vierstra@wisc.edu; forest@bact.wisc.edu	Zhang, Junrui/J-2684-2012					Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Book AJ, 2005, PLANT PHYSIOL, V138, P1046, DOI 10.1104/pp.104.057406; Borucki B, 2005, J BIOL CHEM, V280, P34358, DOI 10.1074/jbc.M505493200; CHERRY JR, 1993, PLANT CELL, V5, P565, DOI 10.1105/tpc.5.5.565; Cramer P, 1997, FEBS LETT, V405, P373, DOI 10.1016/S0014-5793(97)00217-2; Dasgupta S, 1997, PROTEINS, V28, P494, DOI 10.1002/(SICI)1097-0134(199708)28:4<494::AID-PROT4>3.0.CO;2-A; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; EDGERTON MD, 1992, PLANT CELL, V4, P161, DOI 10.1105/tpc.4.2.161; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esteban B, 2005, BIOCHEMISTRY-US, V44, P450, DOI 10.1021/bi0484365; Evans K, 2006, J MOL BIOL, V364, P655, DOI 10.1016/j.jmb.2006.09.045; Fischer AJ, 2005, BIOCHEMISTRY-US, V44, P15203, DOI 10.1021/bi051633z; FOREST K, 1992, CURR OPIN STRUC BIOL, V2, P576; Froehlich AC, 2005, EUKARYOT CELL, V4, P2140, DOI 10.1128/EC.4.12.2140-2152.2005; Garrard SM, 2001, PROTEIN EXPRES PURIF, V21, P412, DOI 10.1006/prep.2001.1392; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Inomata K, 2006, J BIOL CHEM, V281, P28162, DOI 10.1074/jbc.M603983200; JONES AM, 1989, PHOTOCHEM PHOTOBIOL, V49, P479, DOI 10.1111/j.1751-1097.1989.tb09198.x; JONES AM, 1986, BIOCHEMISTRY-US, V25, P2987, DOI 10.1021/bi00358a038; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Jorissen HJMM, 2002, EUR J BIOCHEM, V269, P2662, DOI 10.1046/j.1432-1033.2002.02928.x; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; Karniol B, 2004, J BACTERIOL, V186, P445, DOI 10.1128/JB.186.2.445-453.2004; KIEFHABER T, 1992, J MOL BIOL, V224, P231, DOI 10.1016/0022-2836(92)90586-9; Krall L, 2000, P NATL ACAD SCI USA, V97, P8169, DOI 10.1073/pnas.140520097; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; Lamparter T, 2003, J BIOL CHEM, V278, P33786, DOI 10.1074/jbc.M305563200; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Lamparter T, 1997, P NATL ACAD SCI USA, V94, P11792, DOI 10.1073/pnas.94.22.11792; Mallam AL, 2005, J MOL BIOL, V346, P1409, DOI 10.1016/j.jmb.2004.12.055; Matsushita T, 2003, NATURE, V424, P571, DOI 10.1038/nature01837; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy F., 2006, PHOTOMORPHOGENESIS P, P65; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otto H, 2003, BIOCHEMISTRY-US, V42, P5885, DOI 10.1021/bi026946y; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park CM, 2000, BIOCHEMISTRY-US, V39, P6349, DOI 10.1021/bi992916s; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; Rockwell NC, 2006, ANNU REV PLANT BIOL, V57, P837, DOI 10.1146/annurev.arplant.56.032604.144208; Rohmer T, 2006, J PHYS CHEM B, V110, P20580, DOI 10.1021/jp062454+; Strauss HM, 2005, FEBS LETT, V579, P3970, DOI 10.1016/j.febslet.2005.06.025; TERRY MJ, 1993, J BIOL CHEM, V268, P26099; TOKUTOMI S, 1989, FEBS LETT, V247, P139, DOI 10.1016/0014-5793(89)81257-8; Vierstra RD, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P171, DOI 10.1002/352760510X.ch8; Virnau P, 2006, PLOS COMPUT BIOL, V2, P1074, DOI 10.1371/journal.pcbi.0020122; von Stetten D, 2007, J BIOL CHEM, V282, P2116, DOI 10.1074/jbc.M608878200; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	53	195	205	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12298	12309		10.1074/jbc.M611824200	http://dx.doi.org/10.1074/jbc.M611824200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322301	hybrid			2022-12-27	WOS:000245941900072
J	Ogawa, C; Usui, K; Aoki, M; Ito, F; Itoh, M; Kai, C; Kanamori-Katayama, M; Hayashizaki, Y; Suzuki, H				Ogawa, Chihiro; Usui, Kengo; Aoki, Makoto; Ito, Fuyu; Itoh, Masayoshi; Kai, Chikatoshi; Kanamori-Katayama, Mutsumi; Hayashizaki, Yoshihide; Suzuki, Harukazu			Gemin2 plays an important role in stabilizing the survival of motor neuron complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; SMN COMPLEX; GENE-PRODUCT; U SNRNPS; PROTEIN; COMPONENT; IDENTIFICATION; LOCALIZATION; EXPRESSION; ZPR1	The survival of motor neuron ( SMN) protein, responsible for the neurodegenerative disease spinal muscular atrophy ( SMA), oligomerizes and forms a stable complex with seven other major components, the Gemin proteins. Besides the SMN protein, Gemin2 is a core protein that is essential for the formation of the SMN complex, although the mechanism by which it drives formation is unclear. We have found a novel interaction, a Gemin2 self-association, using the mammalian two-hybrid system and the in vitro pull-down assays. Using in vitro dissociation assays, we also found that the self-interaction of the amino-terminal SMN protein, which was confirmed in this study, became stable in the presence of Gemin2. In addition, Gemin2 knockdown using small interference RNA treatment revealed a drastic decrease in SMN oligomer formation and in the assembly activity of spliceosomal small nuclear ribonucleoprotein ( snRNP). Taken together, these results indicate that Gemin2 plays an important role in snRNP assembly through the stabilization of the SMN oligomer/complex via novel self-interaction. Applying the results/techniques to amino-terminal SMN missense mutants that were recently identified from SMA patients, we successfully showed that amino-terminal self-association, Gemin2 binding, the stabilization effect of Gemin2, and snRNP assembly activity were all lowered in the mutant SMN( D44V), suggesting that instability of the amino-terminal SMN self-association may cause SMA in patients carrying this allele.	RIKEN, Yokohama Inst, Genom Sci Ctr, Genome Explorat Res Grp,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Yokohama City Univ, Int Grad Sch Arts & Sci, Div Genom Informat Resource Supramol Biol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; RIKEN, Wako Inst, Discovery Res Inst, Genome Sci Lab, Wako, Saitama 3510198, Japan	RIKEN; Yokohama City University; Japan Science & Technology Agency (JST); RIKEN	Suzuki, H (corresponding author), RIKEN, Yokohama Inst, Genom Sci Ctr, Genome Explorat Res Grp,Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	rgscerg@gsc.riken.jp	Usui, Kengo/A-7203-2016; Hayashizaki, Yoshihide/N-6590-2015; Itoh, Masayoshi/N-5363-2015; Suzuki, Harukazu/N-9553-2015	Itoh, Masayoshi/0000-0002-1772-318X; Suzuki, Harukazu/0000-0002-8087-0836				Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Battle DJ, 2006, MOL CELL, V23, P273, DOI 10.1016/j.molcel.2006.05.036; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; Carissimi C, 2006, J BIOL CHEM, V281, P8126, DOI 10.1074/jbc.M512243200; Carissimi C, 2006, J BIOL CHEM, V281, P37009, DOI 10.1074/jbc.M607505200; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010; Feng WQ, 2005, HUM MOL GENET, V14, P1605, DOI 10.1093/hmg/ddi168; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Gangwani L, 2005, MOL CELL BIOL, V25, P2744, DOI 10.1128/MCB.25.7.2744-2756.2005; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; Gubitz AK, 2004, EXP CELL RES, V296, P51, DOI 10.1016/j.yexcr.2004.03.022; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hua Y, 2004, CELL MOL LIFE SCI, V61, P2658, DOI 10.1007/s00018-004-4300-z; Jablonka S, 2002, P NATL ACAD SCI USA, V99, P10126, DOI 10.1073/pnas.152318699; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Ma YL, 2005, STRUCTURE, V13, P883, DOI 10.1016/j.str.2005.03.014; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Mouaikel J, 2003, EMBO REP, V4, P616, DOI 10.1038/sj.embor.embor863; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Ogino S, 2004, EXPERT REV MOL DIAGN, V4, P15, DOI 10.1586/14737159.4.1.15; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Rochette CF, 1997, NEUROGENETICS, V1, P141, DOI 10.1007/s100480050021; Shpargel KB, 2005, P NATL ACAD SCI USA, V102, P17372, DOI 10.1073/pnas.0508947102; Sun Y, 2005, HUM MUTAT, V25, P64, DOI 10.1002/humu.20111; Suzuki H, 2001, GENOME RES, V11, P1758, DOI 10.1101/gr.180101; Suzuki H, 2004, BIOTECHNIQUES, V37, P918, DOI 10.2144/04376BM06; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Wan LL, 2005, MOL CELL BIOL, V25, P5543, DOI 10.1128/MCB.25.13.5543-5551.2005; Wirth B, 2006, HUM GENET, V119, P422, DOI 10.1007/s00439-006-0156-7; Yong JS, 2004, TRENDS CELL BIOL, V14, P226, DOI 10.1016/j.tcb.2004.03.010; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869; ZERRES K, 1995, ARCH NEUROL-CHICAGO, V52, P518, DOI 10.1001/archneur.1995.00540290108025	43	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11122	11134		10.1074/jbc.M609297200	http://dx.doi.org/10.1074/jbc.M609297200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308308	hybrid			2022-12-27	WOS:000245941500033
J	van der Veer, E; Ho, C; O'Neil, C; Barbosa, N; Scott, R; Cregan, SP; Pickering, JG				van der Veer, Eric; Ho, Cynthia; O'Neil, Caroline; Barbosa, Nicole; Scott, Robert; Cregan, Sean P.; Pickering, J. Geoffrey			Extension of human cell lifespan by nicotinamide phosphoribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; COLONY-ENHANCING FACTOR; NAD BIOSYNTHESIS; APOPTOSIS; SIRT1; P53; ATHEROSCLEROSIS; INHIBITION; ACTIVATION; EXPRESSION	Extending the productive lifespan of human cells could have major implications for diseases of aging, such as atherosclerosis. We identified a relationship between aging of human vascular smooth muscle cells (SMCs) and nicotinamide phosphoribosyltransferase (Nampt/PBEF/Visfatin), the rate-limiting enzyme for NAD(+) salvage from nicotinamide. Replicative senescence of SMCs was preceded by a marked decline in the expression and activity of Nampt. Furthermore, reducing Nampt activity with the antagonist FK866 induced premature senescence in SMCs, assessed by serial quantification of the proportion of cells with senescence-associated beta-galactosidase activity. In contrast, introducing the Nampt gene into aging human SMCs delayed senescence and substantially lengthened cell lifespan, together with enhanced resistance to oxidative stress. Nampt-mediated SMClifespan extension was associated with increased activity of the NAD(+)-dependent longevity enzyme SIRT1 and was abrogated in Nampt-overexpressing cells transduced with a dominant-negative form of SIRT1 (H363Y). Nampt overexpression also reduced the fraction of p53 that was acetylated on lysine 382, a target of SIRT1, suppressed an age-related increase in p53 expression, and increased the rate of p53 degradation. Moreover, add-back of p53 with recombinant adenovirus blocked the anti-aging effects of Nampt. These data indicate that Nampt is a longevity protein that can add stress-resistant life to human SMCs by optimizing SIRT1-mediated p53 degradation.	Univ Western Ontario, London Hlth Sci Ctr, Dept Med Cardiol, London, ON N6A 5K8, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Biochem, London, ON N6A 5K8, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Med Biophys, London, ON N6A 5K8, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Biol, London, ON N6A 5K8, Canada; Univ Western Ontario, Robarts Res Inst, London, ON N6A 5K8, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Pickering, JG (corresponding author), London Hlth Sci Ctr, 339 Windermere Rd, London, ON N6A 5A5, Canada.	gpickering@robarts.ca	Pickering, J. Geoffrey/G-3341-2011; Cregan, Sean/M-3205-2013	Pickering, J. Geoffrey/0000-0001-6474-3274; 				Al-Shali KZ, 2004, ARTERIOSCL THROM VAS, V24, P1591, DOI 10.1161/01.ATV.0000136392.59656.8b; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bauer JH, 2006, AGING CELL, V5, P437, DOI 10.1111/j.1474-9726.2006.00228.x; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Cregan SP, 2000, GENE THER, V7, P1200, DOI 10.1038/sj.gt.3301208; de Boer VCJ, 2006, MECH AGEING DEV, V127, P618, DOI 10.1016/j.mad.2006.02.007; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fera E, 2004, J BIOL CHEM, V279, P35573, DOI 10.1074/jbc.M400711200; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Hasmann M, 2003, CANCER RES, V63, P7436; Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI [10.1172/JCI19930, 10.1172/JCI200419930]; Khan JA, 2006, NAT STRUCT MOL BIOL, V13, P582, DOI 10.1038/nsmb1105; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Li SH, 2001, CIRC RES, V89, P517, DOI 10.1161/hh1801.097165; Matthews C, 2006, CIRC RES, V99, P156, DOI 10.1161/01.RES.0000233315.38086.bc; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Rocnik EF, 2002, J BIOL CHEM, V277, P38571, DOI 10.1074/jbc.M206689200; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; van der Veer E, 2005, CIRC RES, V97, P25, DOI 10.1161/01.RES.0000173298.38808.27; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yang HY, 2006, EXP GERONTOL, V41, P718, DOI 10.1016/j.exger.2006.06.003	25	251	257	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10841	10845		10.1074/jbc.C700018200	http://dx.doi.org/10.1074/jbc.C700018200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307730	hybrid			2022-12-27	WOS:000245941500002
J	Adlerz, L; Holback, S; Multhaup, G; Iverfeldt, K				Adlerz, Linda; Holback, Sofia; Multhaup, Gerd; Iverfeldt, Kerstin			IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; HUMAN NEUROBLASTOMA-CELLS; CYCLIN-DEPENDENT KINASE-5; RETINOIC-ACID; ALZHEIMERS-DISEASE; IGF-I; INSULIN; APLP2; BRAIN; APP	The mammalian amyloid precursor protein (APP) protein family consists of the APP and the amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2). The neurotoxic amyloid ss-peptide (A ss) originates from APP, which is the only member of this protein family implicated in Alzheimer disease. However, the three homologous proteins have been proposed to be processed in similar ways and to have essential and overlapping functions. Therefore, it is also important to take into account the effects on the processing and function of the APP- like proteins in the development of therapeutic drugs aimed at decreasing the production of A ss. Insulin and insulin-like growth factor-1 (IGF-1) have been shown to regulate APP processing and the levels of A ss in the brain. In the present study, we show that IGF-1 increases alpha-secretase processing of endogenous APP and also increases ectodomain shedding of APLP1 and APLP2 in human SH-SY5Y neuroblastoma cells. We also investigated the role of different IGF-1-induced signaling pathways, using specific inhibitors for phosphatidylinositol 3- kinase and mitogenactivated protein kinase (MAPK). Our results indicate that phosphatidylinositol 3-kinase is involved in ectodomain shedding of APP and APLP1, but not APLP2, and that MAPK is involved only in the ectodomain shedding of APLP1.	Univ Stockholm, Dept Neurochem, SE-10691 Stockholm, Sweden; Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany	Stockholm University; Free University of Berlin	Iverfeldt, K (corresponding author), Univ Stockholm, Dept Neurochem, SE-10691 Stockholm, Sweden.	kerstin@neurochem.su.se						Adlerz L, 2003, MOL BRAIN RES, V119, P62, DOI 10.1016/j.molbrainres.2003.08.014; ALLSOP D, 1983, BRAIN RES, V259, P348, DOI 10.1016/0006-8993(83)91273-8; Beckman M, 1997, NEUROSCI LETT, V221, P73, DOI 10.1016/S0304-3940(96)13292-4; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cappai R, 1999, FEBS LETT, V442, P95, DOI 10.1016/S0014-5793(98)01635-4; Carro E, 2006, NEUROBIOL AGING, V27, P1250, DOI 10.1016/j.neurobiolaging.2005.06.015; Carro E, 2004, EUR J PHARMACOL, V490, P127, DOI 10.1016/j.ejphar.2004.02.050; Carro E, 2002, NAT MED, V8, P1390, DOI 10.1038/nm793; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Dupont J, 2003, RECENT PROG HORM RES, V58, P325, DOI 10.1210/rp.58.1.325; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Endres K, 2005, FEBS J, V272, P5808, DOI 10.1111/j.1742-4658.2005.04976.x; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Han P, 2005, J NEUROSCI, V25, P11542, DOI 10.1523/JNEUROSCI.3831-05.2005; Heber S, 2000, J NEUROSCI, V20, P7951; Holback S, 2005, J NEUROCHEM, V95, P1059, DOI 10.1111/j.1471-4159.2005.03440.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim B, 2004, ONCOGENE, V23, P130, DOI 10.1038/sj.onc.1206924; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Lee JH, 2004, J NEUROCHEM, V91, P634, DOI 10.1111/j.1471-4159.2004.02770.x; Leyssen M, 2005, EMBO J, V24, P2944, DOI 10.1038/sj.emboj.7600757; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Liu F, 2003, FEBS LETT, V547, P193, DOI 10.1016/S0014-5793(03)00714-2; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattsson MEK, 1990, GROWTH FACTORS, V2, P251, DOI 10.3109/08977199009078013; Navarro I, 1999, COMP BIOCHEM PHYS B, V122, P137, DOI 10.1016/S0305-0491(98)10163-3; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; Pastorino L, 2004, MOL CELL NEUROSCI, V25, P642, DOI 10.1016/j.mcn.2003.12.013; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; Ryder J, 2003, BIOCHEM BIOPH RES CO, V312, P922, DOI 10.1016/j.bbrc.2003.11.014; Sakai T, 2006, CELL BIOL INT, V30, P952, DOI 10.1016/j.cellbi.2006.06.018; Solano DC, 2000, FASEB J, V14, P1015, DOI 10.1096/fasebj.14.7.1015; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Vardy ERLC, 2005, TRENDS MOL MED, V11, P464, DOI 10.1016/j.molmed.2005.08.004; Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; Watanabe T, 2005, J AM GERIATR SOC, V53, P1748, DOI 10.1111/j.1532-5415.2005.53524.x; WEBSTER MT, 1995, BIOCHEM J, V310, P95, DOI 10.1042/bj3100095; Xu KP, 2001, AM J PHYSIOL-CELL PH, V281, pC603, DOI 10.1152/ajpcell.2001.281.2.C603	46	61	68	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10203	10209		10.1074/jbc.M611183200	http://dx.doi.org/10.1074/jbc.M611183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17301053	hybrid			2022-12-27	WOS:000245941000010
J	Gleason, CE; Lu, DH; Witters, LA; Newgard, CB; Birnbaum, MJ				Gleason, Catherine E.; Lu, Danhong; Witters, Lee A.; Newgard, Christopher B.; Birnbaum, Morris J.			The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; STIMULATED INSULIN-SECRETION; CHAIN AMINO-ACIDS; P70 S6 KINASE; MAMMALIAN TARGET; GLUCOSE-HOMEOSTASIS; SIGNALING PATHWAY; SKELETAL-MUSCLE; GENE-EXPRESSION; PHAS-I	The AMP- activated protein kinase ( AMPK) is a central regulator of the energy status of the cell, based on its unique ability to respond directly to fluctuations in the ratio of AMP: ATP. Because glucose and amino acids stimulate insulin release from pancreatic beta- cells by the regulation of metabolic intermediates, AMPK represents an attractive candidate for control of beta- cell function. Here, we show that inhibition of AMPK in beta- cells by high glucose inversely correlates with activation of the mammalian Target of Rapamycin ( mTOR) pathway, another cellular sensor for nutritional conditions. Forced activation of AMPK by AICAR, phenformin, or oligomycin significantly blocked phosphorylation of p70S6K, a downstream target of mTOR, in response to the combination of glucose and amino acids. Amino acids also suppressed the activity of AMPK, and this at a minimum required the presence of leucine and glutamine. It is unlikely that the ability of AMPK to sense both glucose and amino acids plays a role in regulation of insulin secretion, as inhibition of AMPK by amino acids did not influence insulin secretion. Moreover, activation of AMPK by AICAR or phenformin did not antagonize glucose- stimulated insulin secretion, and insulin secretion was also unaffected in response to suppression ofAMPKactivity by expression of a dominant negative AMPK construct ( K45R). Taken together, these results suggest that the inhibition ofAMPKactivity by glucose and amino acids might be an important component of the mechanism for nutrientstimulated mTOR activity but not insulin secretion in the beta- cell.	Univ Penn, Howard Hughes Med Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Med & Biochem, Durham, NC 27704 USA; Dartmouth Coll, Dept Med, Dartmouth Med Sch, Hanover, NH 03755 USA; Dartmouth Coll, Dept Biochem, Dartmouth Med Sch, Hanover, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Duke University; Duke University; Duke University; Dartmouth College; Dartmouth College; Dartmouth College	Birnbaum, MJ (corresponding author), Univ Penn, Howard Hughes Med Inst, Sch Med, 415 Curie Blvd,CRB Room 320, Philadelphia, PA 19104 USA.	birnbaum@mail.med.upenn.edu		Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK42583, DK019525, DK049210] Funding Source: Medline; NIGMS NIH HHS [T32-GM07229] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, P01DK049210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahren B, 2005, CURR MOL MED, V5, P275, DOI 10.2174/1566524053766004; Akkan A G, 1994, Diabetes Res, V25, P13; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bolea S, 1997, PFLUG ARCH EUR J PHY, V433, P699, DOI 10.1007/s004240050334; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chan AYM, 2004, J BIOL CHEM, V279, P32771, DOI 10.1074/jbc.M403528200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Doyle ME, 2003, PHARMACOL REV, V55, P105, DOI 10.1124/pr.55.1.7; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; Gomez E, 2004, J BIOL CHEM, V279, P53937, DOI 10.1074/jbc.M408682200; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Hurley RL, 2006, J BIOL CHEM, V281, P36662, DOI 10.1074/jbc.M606676200; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Jensen MV, 2006, J BIOL CHEM, V281, P22342, DOI 10.1074/jbc.M604350200; Kimball S R, 2001, Prog Mol Subcell Biol, V26, P155; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; Leclerc I, 2004, DIABETES, V53, pS67, DOI 10.2337/diabetes.53.suppl_3.S67; Leclerc I, 2004, AM J PHYSIOL-ENDOC M, V286, pE1023, DOI 10.1152/ajpendo.00532.2003; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; Malaisse W J, 1994, Diabetes Res, V25, P25; MAY ME, 1989, DIABETES METAB REV, V5, P227, DOI 10.1002/dmr.5610050303; McDaniel ML, 2002, DIABETES, V51, P2877, DOI 10.2337/diabetes.51.10.2877; Meijer AJ, 2004, BIOCHEM BIOPH RES CO, V313, P397, DOI 10.1016/j.bbrc.2003.07.012; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; NEWGARD CB, 2001, SUBSTRATE CONTROL IN, P125; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Raile K, 2005, DIABETOLOGIA, V48, P1798, DOI 10.1007/s00125-005-1860-x; Reiter AK, 2005, AM J PHYSIOL-ENDOC M, V288, pE980, DOI 10.1152/ajpendo.00333.2004; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; SENER A, 1981, EUR J CLIN INVEST, V11, P455, DOI 10.1111/j.1365-2362.1981.tb02013.x; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Xavier GD, 2003, BIOCHEM J, V371, P761; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Xu G, 2001, DIABETES, V50, P353, DOI 10.2337/diabetes.50.2.353; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Yoshizawa F, 2004, BIOCHEM BIOPH RES CO, V313, P417, DOI 10.1016/j.bbrc.2003.07.013; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	57	149	154	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10341	10351		10.1074/jbc.M610631200	http://dx.doi.org/10.1074/jbc.M610631200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287212	hybrid			2022-12-27	WOS:000245941000024
J	Li, FM; Luo, ZM; Huang, WY; Lu, QS; Wilcox, CS; Jose, PA; Chen, SY				Li, Fengmin; Luo, Zaiming; Huang, Wenyan; Lu, Quansheng; Wilcox, Christopher S.; Jose, Pedro A.; Chen, Shiyou			Response gene to complement 32, a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; STEM-CELLS; IN-VITRO; ACTIN EXPRESSION; SMAD PROTEINS; CARG ELEMENTS; MYOCARDIN; TRANSCRIPTION; PROLIFERATION; ACTIVATION	We previously developed a robust in vitro model system for vascular smooth muscle cell ( VSMC) differentiation from neural crest cell line Monc-1 upon transforming growth factor-ss ( TGF-ss) induction. Further studies demonstrated that both Smad and RhoA signaling are critical for TGF-ss- induced VSMC development. To identify downstream targets, we performed Affymetrix cDNA array analysis of Monc-1 cells and identified a gene named response gene to complement 32 (RGC-32) to be important for the VSMC differentiation. RGC-32 expression was increased 5-fold after 2 h and 50- fold after 24 h of TGF-ss induction. Knockdown of RGC-32 expression in Monc-1 cells by small interfering RNA significantly inhibited the expression of multiple smooth muscle marker genes, including SM alpha-actin (alpha-SMA), SM22 alpha, and calponin. Of importance, the inhibition of RGC-32 expression correlated with the reduction of alpha-SMA while not inhibiting smooth muscle- unrelated c-fos gene expression, suggesting that RGC-32 is an important protein factor for VSMC differentiation from neural crest cells. Moreover, RGC-32 overexpression significantly enhanced TGF-ss-induced alpha-SMA, SM22 alpha, and SM myosin heavy chain promoter activities in both Monc-1 and C3H10T1/2 cells. The induction of VSMC gene promoters by RGC-32 appears to be CArG- dependent. These data suggest that RGC-32 controls VSMC differentiation by regulating marker gene transcription in a CArG- dependent manner. Further studies revealed that both Smad and RhoA signaling are important for RGC-32 activation.	Georgetown Univ, Med Ctr, Dept Pediat, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20057 USA	Georgetown University; Georgetown University	Chen, SY (corresponding author), Georgetown Univ, Med Ctr, Dept Pediat, Bldg D,Room 363,4000 Reservoir Rd NW, Washington, DC 20057 USA.	sc229@georgetown.edu	Li, Fengmin/K-8740-2012; LI, feng/HIR-1703-2022; Li, Fengmin/J-5721-2013	Li, Fengmin/0000-0002-2144-3498; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68686] Funding Source: Medline; NIDDK NIH HHS [DK52612] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Badea T, 2002, J BIOL CHEM, V277, P502, DOI 10.1074/jbc.M109354200; Badea TC, 1998, J BIOL CHEM, V273, P26977, DOI 10.1074/jbc.273.41.26977; Baldwin H. Scott, 1999, Current Opinion in Pediatrics, V11, P413, DOI 10.1097/00008480-199910000-00008; Brand-Saberi B, 2000, CURR TOP DEV BIOL, V48, P1; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Chen SY, 2006, J BIOL CHEM, V281, P1765, DOI 10.1074/jbc.M507771200; Chen SY, 2004, CIRC RES, V94, P1195, DOI 10.1161/01.RES.0000126897.41658.81; Chen SY, 2003, NUCLEIC ACIDS RES, V31, P1302, DOI 10.1093/nar/gkg224; Choudhary B, 2006, DEV BIOL, V289, P420, DOI 10.1016/j.ydbio.2005.11.008; Ding RB, 2004, STEM CELLS DEV, V13, P509, DOI 10.1089/1547328042417336; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Epstein J. A., 2001, TRENDS GENET, V17, pS13; Epstein JA, 2000, DEVELOPMENT, V127, P1869; Etchevers HC, 2001, DEVELOPMENT, V128, P1059; Fosbrink M, 2005, EXP MOL PATHOL, V78, P116, DOI 10.1016/j.yexmp.2004.11.001; Fosbrink M, 2005, IMMUNOL RES, V31, P37, DOI 10.1385/IR:31:1:37; Gittenberger-de Groot AC, 1999, ARTERIOSCL THROM VAS, V19, P1589; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; Hagedorn L, 1999, DEVELOPMENT, V126, P3781; Hirschi KK, 2004, ANAT REC PART A, V276A, P22, DOI 10.1002/ar.a.10128; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Hirschi KK, 2002, J BIOL CHEM, V277, P6287, DOI 10.1074/jbc.M106649200; Hungerford JE, 1999, J VASC RES, V36, P2, DOI 10.1159/000025622; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Lilly B, 2001, DEV BIOL, V240, P531, DOI 10.1006/dbio.2001.0507; Liu CY, 2002, DEVELOPMENT, V129, P5081; Mack CP, 1999, CIRC RES, V84, P852; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Niederreither K, 2001, DEVELOPMENT, V128, P1019; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Parmacek MS, 2001, CURR TOP DEV BIOL, V51, P69, DOI 10.1016/S0070-2153(01)51002-9; Qiu P, 2003, J MOL CELL CARDIOL, V35, P1407, DOI 10.1016/j.yjmcc.2003.09.002; Rao MS, 1997, J NEUROBIOL, V32, P722, DOI 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6; SCHWARTZ SM, 1983, P SOC EXP BIOL MED, V173, P1; Schwartz SM, 1998, ANNU REV MED, V49, P437; Schwartz SM, 1997, J CLIN INVEST, V100, P87; Shah NM, 1997, P NATL ACAD SCI USA, V94, P11369, DOI 10.1073/pnas.94.21.11369; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shanahan CM, 1998, ARTERIOSCL THROM VAS, V18, P333, DOI 10.1161/01.ATV.18.3.333; Tallquist MD, 2003, DEVELOPMENT, V130, P507, DOI 10.1242/dev.00241; Vitelli F, 2002, HUM MOL GENET, V11, P915, DOI 10.1093/hmg/11.8.915; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wu JL, 2003, TRENDS NEUROSCI, V26, P40, DOI 10.1016/S0166-2236(02)00011-5; Wurdak H, 2005, GENE DEV, V19, P530, DOI 10.1101/gad.317405; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698; Yoshida T, 2004, ARTERIOSCL THROM VAS, V24, P1596, DOI 10.1161/01.ATV.0000137190.63214.c5; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhou JL, 2005, J BIOL CHEM, V280, P10861, DOI 10.1074/jbc.M411586200	57	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10133	10137		10.1074/jbc.C600225200	http://dx.doi.org/10.1074/jbc.C600225200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17327222	hybrid			2022-12-27	WOS:000245941000002
J	Ritter, E; Elgeti, M; Hofmann, KP; Bartl, FJ				Ritter, Eglof; Elgeti, Matthias; Hofmann, Klaus Peter; Bartl, Franz J.			Deactivation and proton transfer in light-induced metarhodopsin II/metarhodopsin III conversion - A time-resolved fourier transform infrared spectroscopic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MI-MII EQUILIBRIUM; ARRESTIN-RHODOPSIN INTERACTIONS; PROTEIN-COUPLED RECEPTOR; FTIR SPECTROSCOPY; SIGNALING STATES; RECOMBINANT MEMBRANES; RETINAL CHROMOPHORE; VISUAL EXCITATION; BOVINE RHODOPSIN; PH-DEPENDENCE	Vertebrate rhodopsin shares with other retinal proteins the 11-cis-retinal chromophore and the light-induced 11-cis/trans isomerization triggering its activation pathway. However, only in rhodopsin the retinylidene Schiff base bond to the apoprotein is eventually hydrolyzed, making a complex regeneration pathway necessary. Metabolic regeneration cannot be short-cut, and light absorption in the active metarhodopsin ( Meta) II intermediate causes anti/syn isomerization around the retinylidene linkage rather than reversed trans/cis isomerization. A new deactivating pathway is thereby triggered, which ends in the Meta III "retinal storage" product. Using time-resolved Fourier transform infrared spectroscopy, we show that the identified steps of receptor activation, including Schiff base deprotonation, protein structural changes, and proton uptake by the apoprotein, are all reversed. However, Schiff base reprotonation is much faster than the activating deprotonation, whereas the protein structural changes are slower. The final proton release occurs with pK approximate to 4.5, similar to the pK of a free Glu residue and to the pK at which the isolated opsin apoprotein becomes active. A forced deprotonation, equivalent to the forced protonation in the activating pathway, which occurs against the unfavorable pH of the medium, is not observed. This explains properties of the final Meta III product, which displays much higher residual activity and is less stable than rhodopsin arising from regeneration with 11-cis-retinal. We propose that the anti/syn conversion can only induce a fast reorientation and distance change of the Schiff base but fails to build up the full set of dark ground state constraints, presumably involving the Glu(134)/Arg(135) cluster.	Univ Med Berlin, Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Humboldt Univ, Zentrum Biophys & Bioinformat, D-10015 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Bartl, FJ (corresponding author), Univ Med Berlin, Charite, Inst Med Phys & Biophys, Charitepl 1, D-10098 Berlin, Germany.	franz.bartl@charite.de						ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; ATTWOOD PV, 1980, FEBS LETT, V119, P323, DOI 10.1016/0014-5793(80)80281-X; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; Bartl FJ, 2001, J BIOL CHEM, V276, P30161, DOI 10.1074/jbc.M101506200; Bartl FJ, 2005, J BIOL CHEM, V280, P34259, DOI 10.1074/jbc.M505260200; Bartl FJ, 2007, PHYS CHEM CHEM PHYS, V9, P1648, DOI 10.1039/b616365c; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; Calvert PD, 2006, TRENDS CELL BIOL, V16, P560, DOI 10.1016/j.tcb.2006.09.001; COOPER A, 1979, NATURE, V282, P531, DOI 10.1038/282531a0; Crognale MA, 1999, VISION RES, V39, P707, DOI 10.1016/S0042-6989(98)00140-0; Dickopf S, 1998, BIOCHEMISTRY-US, V37, P16888, DOI 10.1021/bi981879m; Fahmy K, 1998, BIOPHYS J, V75, P1306, DOI 10.1016/S0006-3495(98)74049-4; Fahmy K, 2000, BIOCHEMISTRY-US, V39, P10607, DOI 10.1021/bi000912d; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gartner W., 2000, HDB BIOL PHYS, V3, P297; GIBSON NJ, 1990, BIOCHEM BIOPH RES CO, V169, P1028, DOI 10.1016/0006-291X(90)91997-7; GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040; GIBSON NJ, 1991, BIOCHEM BIOPH RES CO, V176, P915, DOI 10.1016/S0006-291X(05)80273-6; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hofmann K P, 2001, Z Med Phys, V11, P217; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HUBBARD R, 1952, SCIENCE, V115, P60, DOI 10.1126/science.115.2977.60; HUBBARD R, 1952, J GEN PHYSIOL, V36, P269, DOI 10.1085/jgp.36.2.269; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Kim JE, 2001, BIOCHEMISTRY-US, V40, P13774, DOI 10.1021/bi0116137; KROFP A, 1967, VISION RES, V7, P811, DOI 10.1016/0042-6989(67)90001-6; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; LANYI JK, 1992, ACTA PHYSIOL SCAND, V146, P245; Ludeke S, 2005, J MOL BIOL, V353, P345, DOI 10.1016/j.jmb.2005.08.039; Mahalingam M, 2006, BIOCHEMISTRY-US, V45, P15624, DOI 10.1021/bi061970n; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; Mendez A, 2003, J NEUROSCI, V23, P3124; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; MONTAG ED, 1987, VISION RES, V27, P2153, DOI 10.1016/0042-6989(87)90129-5; Nishimura S, 1998, BIOCHEMISTRY-US, V37, P15816, DOI 10.1021/bi981451n; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; Patel AB, 2005, J MOL BIOL, V347, P803, DOI 10.1016/j.jmb.2005.01.069; PAULSEN R, 1975, VISION RES, V15, P1325, DOI 10.1016/0042-6989(75)90184-4; Ritter E, 2004, J BIOL CHEM, V279, P48102, DOI 10.1074/jbc.M406857200; Sachs K, 2000, METHOD ENZYMOL, V315, P238; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Siebert F, 1995, ISRAEL J CHEM, V35, P309; SIEBERT F, 1983, EUR J BIOCHEM, V136, P119, DOI 10.1111/j.1432-1033.1983.tb07714.x; Sommer ME, 2006, VISION RES, V46, P4532, DOI 10.1016/j.visres.2006.08.031; Sommer ME, 2006, J BIOL CHEM, V281, P9407, DOI 10.1074/jbc.M510037200; Sommer ME, 2005, J BIOL CHEM, V280, P6861, DOI 10.1074/jbc.M411341200; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; Vogel R, 2005, BIOCHEMISTRY-US, V44, P11684, DOI 10.1021/bi0508587; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0; Zimmermann K, 2004, J BIOL CHEM, V279, P48112, DOI 10.1074/jbc.M406856200	60	13	13	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10720	10730		10.1074/jbc.M610658200	http://dx.doi.org/10.1074/jbc.M610658200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287211	hybrid			2022-12-27	WOS:000245941000066
J	Chung, I; Karpf, AR; Muindi, JR; Conroy, JM; Nowak, NJ; Johnson, CS; Trump, DL				Chung, Ivy; Karpf, Adam R.; Muindi, Josephia R.; Conroy, Jeffrey M.; Nowak, Norma J.; Johnson, Candace S.; Trump, Donald L.			Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; VITAMIN-D-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; CANDIDATE ONCOGENE; D ANALOGS; IN-VITRO; METHYLATION; EXPRESSION; PREVENTION; THERAPY	Calcitriol (1,25-dihydroxycholecalciferol), the most active form of vitamin D, has selective anti-proliferative effects on tumor-derived endothelial cells (TDEC) compared with Matrigel-derived endothelial cells (MDEC). Although both cell types have an intact vitamin D receptor-signaling axis, this study demonstrates that upon treatment with calcitriol, 24-hydroxylase (CYP24) mRNA, protein and enzymatic activity were markedly induced in MDEC in a time-dependent manner but not in TDEC. Furthermore, treatment of MDEC with a CYP24 small interfering RNA restored sensitivity to calcitriol. To investigate the lack of CYP24 induction in TDEC, we examined methylation patterns in the promoter regions of the CYP24 gene in these two cell types. We identified two putative CpG island regions located at the 5' end. Using methylation-specific PCR and bisulfite sequencing, we determined that these CpG islands were hypermethylated in TDEC but not in MDEC. These data may explain the recruitment of vitamin D receptor to the promoter region in MDEC but not TDEC, as revealed by chromatin immunoprecipitation analyses. Treatment of TDEC with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine restored calcitriol-mediated induction of CYP24, which led to loss of sensitivity to calcitriol growth inhibitory effects. CYP24 promoter hypermethylation was also observed in endothelial cells isolated from other tumors but not in endothelial cells isolated from normal mouse tissues. These observations indicate that the methylation status of the CYP24 promoter differs in endothelial cells isolated from different microenvironments (tumor versus normal) and that methylation silencing of CYP24 contributes to selective calcitriol-mediated growth inhibition in endothelial cells.	Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Prevent, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Trump, DL (corresponding author), Roswell Pk Canc Inst, Dept Med, Elm & Carlton Sts, Buffalo, NY 14263 USA.	donald.trump@roswellpark.org	Chung, Ivy/C-3804-2012	Karpf, Adam/0000-0002-0866-0666	NATIONAL CANCER INSTITUTE [R01CA085142, R01CA067267, R01CA095045, R01CA116674] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116674-02, CA95045, CA67267, R01 CA116674, CA85142] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Anderson MG, 2006, CANCER CHEMOTH PHARM, V57, P234, DOI 10.1007/s00280-005-0059-7; Banwell CM, 2006, CLIN CANCER RES, V12, P2004, DOI 10.1158/1078-0432.CCR-05-1218; Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508; CHOUVET C, 1986, J STEROID BIOCHEM, V24, P373, DOI 10.1016/0022-4731(86)90085-3; Chung I, 2006, CANCER RES, V66, P8565, DOI 10.1158/0008-5472.CAN-06-0905; Cross HS, 2004, J NUTR, V134, p1207S, DOI 10.1093/jn/134.5.1207S; Diaz GD, 2000, CANCER RES, V60, P2304; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fradette C, 2004, CURR DRUG METAB, V5, P257, DOI 10.2174/1389200043335577; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Grover AC, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-13; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Hershberger PA, 1999, CANCER RES, V59, P2644; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; HONDA A, 1993, BIOCHEM J, V295, P509, DOI 10.1042/bj2950509; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Johnson CS, 2006, ANTICANCER RES, V26, P2543; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu Y, 2005, J BONE MINER RES, V20, P1680, DOI 10.1359/JBMR.050410; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; Mimori K, 2004, ANN ONCOL, V15, P236, DOI 10.1093/annonc/mdh056; MODZELEWSKI RA, 1994, CANCER RES, V54, P336; Muindi JR, 2007, CANCER CHEMOTH PHARM, V59, P97, DOI 10.1007/s00280-006-0247-0; OHYAMA Y, 2002, NUCL ACIDS RES S, V2, P249; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005; Sergeev IN, 2004, J STEROID BIOCHEM, V89-90, P419, DOI 10.1016/j.jsbmb.2004.03.010; Shen Q, 2005, J BIOL CHEM, V280, P40589, DOI 10.1074/jbc.M504166200; Trump DL, 2006, ANTICANCER RES, V26, P2551; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	32	60	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8704	8714		10.1074/jbc.M608894200	http://dx.doi.org/10.1074/jbc.M608894200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244627	hybrid			2022-12-27	WOS:000245780300016
J	Dinh, M; Grunberger, D; Ho, HD; Tsing, SY; Shaw, D; Lee, S; Barnett, J; Hill, RJ; Swinney, DC; Bradshaw, JM				Dinh, Marie; Grunberger, Dorit; Ho, Hoangdung; Tsing, Stan Y.; Shaw, David; Lee, Simon; Barnett, Jim; Hill, Ronald J.; Swinney, David C.; Bradshaw, J. Michael			Activation mechanism and steady state kinetics of Bruton's tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DEVELOPMENT; X-LINKED AGAMMAGLOBULINEMIA; TEC FAMILY KINASES; PHOSPHORYL TRANSFER; CATALYTIC MECHANISM; PROTEIN-KINASES; BTK FUNCTION; SH3 DOMAIN; MAP KINASE; AUTOPHOSPHORYLATION	Bruton's tyrosine kinase (BTK) is a member of the Tec nonreceptor tyrosine kinase family that is involved in regulating B cell proliferation. To better understand the enzymatic mechanism of the Tec family of kinases, the kinetics of BTK substrate phosphorylation were characterized using a radioactive enzyme assay. We first examined whether autophosphorylation regulates BTK activity. Western blotting with a phosphospecific antibody revealed that BTK rapidly autophosphorylates at Tyr(551) within its activation loop in vitro. Examination of a Y55 IF BTK mutant indicated that phosphorylation of Tyr(551) causes a 10-fold increase in BTK activity. We then proceeded to characterize the steady state kinetic mechanism of BTK. Varying the concentrations of ATP and S1 peptide (biotin-Aca-AAAEEIYGEI-NH2) revealed that BTK employs a ternary complex mechanism with K-mATP = 84 +/- 20 mu m and K-mS1 = 37 +/- 8 mu m. Inhibition studies were also performed to examine the order of substrate binding. The inhibitors ADP and staurosporine were both found to be competitive with ATP and non-competitive with S1, indicating binding of ATP and S1 to BTK is either random or ordered with ATP binding first. Negative cooperativity was also found between the S1 and ATP binding sites. Unlike ATP site inhibitors, substrate analog inhibitors did not inhibit BTK at concentrations less than 1 mm, suggesting that BTK may employ a "substrate clamping" type of kinetic mechanism whereby the substrate K-d is weaker than K-m. This investigation of BTK provides the first detailed kinetic characterization of a Tec family kinase.	Roche Palo Alto LLC, Dept Biochem Pharmacol, Palo Alto, CA 94304 USA; Roche Palo Alto LLC, Dept Mol & Prot Sci, Palo Alto, CA 94304 USA; Roche Palo Alto LLC, Dept Inflammat Autoimmun & Transplantat Therapy A, Palo Alto, CA 94304 USA	Roche Holding; Roche Holding; Roche Holding	Bradshaw, JM (corresponding author), 3431 Hillview Ave,Mailstop R2-101, Palo Alto, CA 94304 USA.	Michael.bradshaw@roche.com						BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Berg LJ, 2005, ANNU REV IMMUNOL, V23, P549, DOI 10.1146/annurev.immunol.22.012703.104743; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; Chen GJ, 2000, BIOCHEMISTRY-US, V39, P2079, DOI 10.1021/bi9919495; COLE PA, 1994, J BIOL CHEM, V269, P30880; Copeland R. A., 2005, EVALUATION ENZYME IN; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Desiderio S, 1997, CURR OPIN IMMUNOL, V9, P534, DOI 10.1016/S0952-7915(97)80107-0; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Levitzki A, 2006, ANNU REV BIOCHEM, V75, P93, DOI 10.1146/annurev.biochem.75.103004.142657; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Lieser SA, 2005, BBA-PROTEINS PROTEOM, V1754, P191, DOI 10.1016/j.bbapap.2005.07.024; Lieser SA, 2005, J BIOL CHEM, V280, P7769, DOI 10.1074/jbc.M411736200; Lindvall JM, 2005, IMMUNOL REV, V203, P200, DOI 10.1111/j.0105-2896.2005.00225.x; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Parast CV, 1998, BIOCHEMISTRY-US, V37, P16788, DOI 10.1021/bi981291f; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Partik G, 1999, J CANCER RES CLIN, V125, P379, DOI 10.1007/s004320050290; POSNER I, 1992, J BIOL CHEM, V267, P20638; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Segel I.H., 1975, ENZYME KINETICS; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Takesono A, 2002, J CELL SCI, V115, P3039; Trauger JW, 2002, BIOCHEMISTRY-US, V41, P8948, DOI 10.1021/bi0258243; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Vassilev AO, 2006, CURR DRUG TARGETS, V7, P327, DOI 10.2174/138945006776054997; Vassilev AO, 2004, CURR PHARM DESIGN, V10, P1757, DOI 10.2174/1381612043384475; Vihinen M, 2000, FRONT BIOSCI-LANDMRK, V5, pD917, DOI 10.2741/vihinen; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Wu H, 2003, BIOCHEMISTRY-US, V42, P1129, DOI 10.1021/bi026857l	40	37	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8768	8776		10.1074/jbc.M609920200	http://dx.doi.org/10.1074/jbc.M609920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264076	hybrid			2022-12-27	WOS:000245780300023
J	Taricani, L; Wang, TSF				Taricani, Lorena; Wang, Teresa S. F.			Rad4(TopBP1) associates with Srr2, an Spc1 MAPK-regulated protein, in response to environmental stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATF1 TRANSCRIPTION FACTOR; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; S-PHASE; KINASE; ACTIVATION; EXPRESSION; TOPBP1; PHOSPHORYLATION; REPLICATION	Rad4(TopBP1) is a scaffold in a protein complex containing both replication proteins and checkpoint proteins and plays essential roles in both replication and checkpoint responses. We have previously identified four novel fission yeast mutants of rad4(+TopBP1) to explore how Rad4(TopBP1), a single protein, can play multiple roles in genomic integrity maintenance. Among the four novel mutants, rad4-c17(TopBP1) is a thermosensitive mutant. Here, we characterized rad4-c17(TopBP1) and identified a rad4-c17(TopBP1) allele specific suppressor named srr2(+) (suppressor of Rad4(TopBP1) R2 domain). srr2(+) has previously been identified as an environmental stress-responsive gene (GenBank (TM) accession number AL049644.1, locus spcc191.01). srr2(+) null cells are sensitive to hydroxyurea (HU) at elevated temperatures. Deletion of srr2(+) in rad4-c17(TopBP1) exacerbates the HU sensitivity of the mutant. Overexpression of srr2(+) suppresses the rad4-c17(TopBP1) mutant sensitivity to temperature and HU and restores the compromised ability of rad4-c17(TopBP1) to activating Cds1 kinase in response to HU treatment. Furthermore, stress-activated MAPK, Spc1 (also known as StyI or Phh1), induces the expression and phosphorylation of the Srr2 protein. Significantly, environmental stress induces co-precipitation of Srr2 protein with Rad4(TopBP1), and the co-precipitation is compromised in the rad4-c17(TopBP1) mutant. These results have led us to propose a model; Rad4(TopBP1) exists in a large protein complex to coordinate genomic perturbations with checkpoint responses to maintain genomic integrity. In addition, when cells experience environmental stress, Rad4(TopBP1) associates with Srr2, an Spc1 MAPK-responsive protein, to survive the stress, potentially by providing a link of the Spc1 MAPK response to checkpoint responses.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Wang, TSF (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	tswang@stanford.edu			NATIONAL CANCER INSTITUTE [R01CA054415] Funding Source: NIH RePORTER; NCI NIH HHS [CA54415] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Degols G, 1996, MOL CELL BIOL, V16, P2870; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Garcia V, 2005, DNA REPAIR, V4, P1227, DOI 10.1016/j.dnarep.2005.04.001; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sawin KE, 1998, J CELL BIOL, V142, P457, DOI 10.1083/jcb.142.2.457; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; Shiozaki K, 1998, MOL BIOL CELL, V9, P1339, DOI 10.1091/mbc.9.6.1339; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Taricani L, 2002, J BIOL CHEM, V277, P10562, DOI 10.1074/jbc.M110686200; Taricani L, 2001, NUCLEIC ACIDS RES, V29, P3030, DOI 10.1093/nar/29.14.3030; Taricani L, 2006, MOL BIOL CELL, V17, P3456, DOI 10.1091/mbc.E06-01-0056; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x	25	2	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8793	8800		10.1074/jbc.M609282200	http://dx.doi.org/10.1074/jbc.M609282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17272281	hybrid			2022-12-27	WOS:000245780300026
J	Yap, LL; Samoilova, RI; Gennis, RB; Dikanov, SA				Yap, Lai Lai; Samoilova, Rimma I.; Gennis, Robert B.; Dikanov, Sergei A.			Characterization of mutants that change the hydrogen bonding of the semiquinone radical at the Q(H) site of the cytochrome bo(3) from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; NUCLEAR-QUADRUPOLE RESONANCE; ECHO ENVELOPE MODULATION; PRIMARY ACCEPTOR QUINONE; UBIQUINONE BINDING-SITE; Q(H)(CENTER-DOT-) UBISEMIQUINONE; BOUND UBIQUINONE; REACTION CENTERS; PHOTOSYSTEM-II; SPIN SYSTEMS	The cytochrome bo(3) ubiquinol oxidase catalyzes the two-electron oxidation of ubiquinol in the cytoplasmic membrane of Escherichia coli, and reduces O-2 to water. This enzyme has a high affinity quinone binding site (Q(H)), and the quinone bound to this site acts as a cofactor, necessary for rapid electron transfer from substrate ubiquinol, which binds at a separate site (Q(L)), to heme b. Previous pulsed EPR studies have shown that a semiquinone at the Q(H) site formed during the catalytic cycle is a neutral species, with two strong hydrogen bonds to Asp-75 and either Arg-71 or Gln-101. In the current work, pulsed EPR studies have been extended to two mutants at the Q(H) site. The D75E mutation has little influence on the catalytic activity, and the pattern of hydrogen bonding is similar to the wild type. In contrast, the D75H mutant is virtually inactive. Pulsed EPR revealed significant structural changes in this mutant. The hydrogen bond to Arg-71 or Gln-101 that is present in both the wild type and D75E mutant oxidases is missing in the D75H mutant. Instead, the D75H has a single, strong hydrogen bond to a histidine, likely His-75. The D75H mutant stabilizes an anionic form of the semiquinone as a result of the altered hydrogen bond network. Either the redistribution of charge density in the semiquinone species, or the altered hydrogen bonding network is responsible for the loss of catalytic function.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Clin Vet Med, Urbana, IL 61801 USA; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS	Gennis, RB (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.	r-gennis@uiuc.edu; dikanov@uiuc.edu	Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487	FIC NIH HHS [1 R03 TW 01495] Funding Source: Medline; NCRR NIH HHS [S10-RR15878] Funding Source: Medline; NIGMS NIH HHS [GM62954] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062954] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; ASHBY CIH, 1978, J AM CHEM SOC, V100, P6057, DOI 10.1021/ja00487a014; ASTASHKIN AV, 1995, J CHEM PHYS, V102, P5583, DOI 10.1063/1.469289; Deligiannakis Y, 1999, J AM CHEM SOC, V121, P7653, DOI 10.1021/ja984209c; DIKANOV SA, 1995, J MAGN RESON SER A, V116, P125, DOI 10.1006/jmra.1995.1199; DIKANOV SA, 1982, CHEM PHYS LETT, V90, P149, DOI 10.1016/0009-2614(82)83630-0; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; Flores M, 2003, CHEM PHYS, V294, P401, DOI 10.1016/S0301-0104(03)00321-5; Grimaldi S, 2003, BIOCHEMISTRY-US, V42, P5632, DOI 10.1021/bi034010z; Grimaldi S, 2001, BIOCHEMISTRY-US, V40, P1037, DOI 10.1021/bi001641+; Hastings SF, 2000, EUR J BIOCHEM, V267, P5638, DOI 10.1046/j.1432-1327.2000.01643.x; Hellwig P, 1999, BIOCHEMISTRY-US, V38, P14683, DOI 10.1021/bi991267h; Hellwig P, 2002, BIOCHEMISTRY-US, V41, P10675, DOI 10.1021/bi012146w; Hellwig P, 2001, BIOCHEMISTRY-US, V40, P1077, DOI 10.1021/bi002154x; HOFER P, 1986, CHEM PHYS LETT, V132, P279, DOI 10.1016/0009-2614(86)80124-5; HUNT MJ, 1976, J MAGN RESON, V22, P295, DOI 10.1016/0022-2364(76)90304-8; HUNT MJ, 1975, CHEM PHYS LETT, V34, P473, DOI 10.1016/0009-2614(75)85542-4; JIANG F, 1990, J AM CHEM SOC, V112, P9035, DOI 10.1021/ja00181a002; Joela H, 1997, ACTA CHEM SCAND, V51, P233, DOI 10.3891/acta.chem.scand.51-0233; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P15620, DOI 10.1021/bi0014094; Lendzian F, 1996, BER BUNSEN PHYS CHEM, V100, P2036, DOI 10.1002/bbpc.19961001219; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; MACMILLAN F, 1995, MAGN RESON CHEM, V33, P581; MCCONNELL HM, 1956, J CHEM PHYS, V24, P764, DOI 10.1063/1.1742605; MCDOWELL CA, 1986, J MAGN RESON, V69, P283, DOI 10.1016/0022-2364(86)90079-X; MIMS WB, 1978, J CHEM PHYS, V69, P4921, DOI 10.1063/1.436479; Mogi T, 1999, FEBS LETT, V457, P223, DOI 10.1016/S0014-5793(99)01047-9; Musser SM, 1997, BIOCHEMISTRY-US, V36, P894, DOI 10.1021/bi961723r; OMALLEY PJ, 1986, J AM CHEM SOC, V108, P3995, DOI 10.1021/ja00274a024; Puustinen A, 1996, P NATL ACAD SCI USA, V93, P1545, DOI 10.1073/pnas.93.4.1545; REIJERSE EJ, 1991, J CHEM PHYS, V95, P836, DOI 10.1063/1.461091; Rumbley JN, 1997, BBA-PROTEIN STRUCT M, V1340, P131, DOI 10.1016/S0167-4838(97)00036-8; SAMOILOVA RI, 1994, J CHEM SOC P1, V2, P609; Schultz BE, 1998, BIOCHEMISTRY-US, V37, P4160, DOI 10.1021/bi971714y; Schweiger A., 2001, PRINCIPLES PULSE ELE, P359; Sinnecker S, 2004, J AM CHEM SOC, V126, P3280, DOI 10.1021/ja0392014; Spoyalov AP, 1996, CHEM PHYS LETT, V263, P715, DOI 10.1016/S0009-2614(96)01255-9; Tsubaki M, 2000, J INORG BIOCHEM, V82, P19, DOI 10.1016/S0162-0134(00)00140-9; Veselov AV, 2000, BIOCHEMISTRY-US, V39, P3169, DOI 10.1021/bi9926835; Wiertz FGM, 2004, FEBS LETT, V575, P127, DOI 10.1016/j.febslet.2004.08.048; Yap LL, 2006, J BIOL CHEM, V281, P16879, DOI 10.1074/jbc.M602544200	42	27	28	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8777	8785		10.1074/jbc.M611595200	http://dx.doi.org/10.1074/jbc.M611595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17267395	hybrid			2022-12-27	WOS:000245780300024
J	Wei, EH; Gao, WH; Lehner, R				Wei, Enhui; Gao, Wenhui; Lehner, Richard			Attenuation of adipocyte triacylglycerol hydrolase activity decreases basal fatty acid efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; CHOLESTERYL ESTER HYDROLASE; ADIPOSE-TISSUE; INSULIN-RESISTANCE; EXPRESSION; MOBILIZATION; IDENTIFICATION; LIPOLYSIS; CLONING; PHOSPHORYLATION	Fatty acids released from adipose triacylglycerol stores by lipolysis provide vertebrates with an important source of energy. We investigated the role of microsomal triacylglycerol hydrolase (TGH) in the mobilization of adipocyte triacylglycerols through inactivation of the TGH activity by RNA interference or chemical inhibition. Attenuation of TGH activity resulted in decreased basal but not isoproterenol-stimulated efflux of fatty acids from 3T3-L1 adipocytes. Lack of TGH activity was accompanied by accumulation of cellular triacylglycerols and cholesteryl esters without any changes in the expression of enzymes catalyzing triacylglycerol synthesis (diacylglycerol acyltransferases 1 and 2) or degradation (adipose triglyceride lipase and hormone-sensitive lipase). Inhibition of TGH-mediated lipolysis also did not affect insulin-stimulated Glut4 translocation from intracellular compartments to the plasma membrane or glucose uptake into adipocytes. These data suggest that TGH plays a role in adipose tissue triacylglycerol. metabolism and may be a suitable pharmacological target for lowering fatty acid efflux from adipose tissue without altering glucose import.	Univ Alberta, Res Grp Mol & Cell Biol Lipids, Canadian Inst Hlth, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Res Grp Mol & Cell Biol Lipids, Canadian Inst Hlth, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Lehner, R (corresponding author), Univ Alberta, Res Grp Mol & Cell Biol Lipids, Canadian Inst Hlth, Dept Pediat, 328 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	richard.lehner@ualberta.ca		Lehner, Richard/0000-0002-6008-1805				Alam M, 2002, BIOCHEMISTRY-US, V41, P6679, DOI 10.1021/bi0255625; Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Birner-Gruenberger R, 2005, MOL CELL PROTEOMICS, V4, P1710, DOI 10.1074/mcp.M500062-MCP200; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Dolinsky VW, 2004, BIOCHEM J, V378, P967, DOI 10.1042/BJ20031320; Dolinsky VW, 2003, BBA-MOL CELL BIOL L, V1635, P20, DOI 10.1016/j.bbalip.2003.09.007; Dolinsky VW, 2001, BBA-MOL CELL BIOL L, V1532, P162, DOI 10.1016/S1388-1981(01)00133-0; Frayn KN, 2002, DIABETOLOGIA, V45, P1201, DOI 10.1007/s00125-002-0873-y; Ghosh S, 2003, J LIPID RES, V44, P1833, DOI 10.1194/jlr.M300162-JLR200; Gilham D, 2005, BBA-MOL CELL BIOL L, V1736, P189, DOI 10.1016/j.bbalip.2005.08.013; Gilham D, 2005, METHODS, V36, P139, DOI 10.1016/j.ymeth.2004.11.003; Gilham D, 2005, MOL BIOL CELL, V16, P984, DOI 10.1091/mbc.e04-03-0224; Gilham D, 2003, FASEB J, V17, P1685, DOI 10.1096/fj.02-0728fje; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Horowitz JF, 2003, TRENDS ENDOCRIN MET, V14, P386, DOI 10.1016/S1043-2760(03)00143-7; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kershaw EE, 2006, DIABETES, V55, P148, DOI 10.2337/diabetes.55.01.06.db05-0982; Kraemer FB, 2002, ENDOCRINOLOGY, V143, P801, DOI 10.1210/en.143.3.801; Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200; Langin D, 2005, DIABETES, V54, P3190, DOI 10.2337/diabetes.54.11.3190; Langston TB, 2005, LIPIDS, V40, P31, DOI 10.1007/s11745-005-1357-5; Lee W, 2000, J BIOL CHEM, V275, P10041, DOI 10.1074/jbc.275.14.10041; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Milad-Kodsi E, 2005, BBA-MOL CELL BIOL L, V1734, P62, DOI 10.1016/j.bbalip.2005.02.008; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Sahoo D, 2004, J LIPID RES, V45, P1122, DOI 10.1194/jlr.M300529-JLR200; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 2001, J BIOL CHEM, V276, P49443, DOI 10.1074/jbc.M104095200; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Soni KG, 2004, J BIOL CHEM, V279, P40683, DOI 10.1074/jbc.M400541200; Su CL, 2003, J BIOL CHEM, V278, P43615, DOI 10.1074/jbc.M301809200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei E, 2005, BIOCHEM J, V388, P959, DOI 10.1042/BJ20041442; World Health Organization, 1997, OB PREV MAN GLOB EP; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747; Zimmermann R, 2003, J LIPID RES, V44, P2089, DOI 10.1194/jlr.M300190-JLR200	46	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8027	8035		10.1074/jbc.M605789200	http://dx.doi.org/10.1074/jbc.M605789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17237500	hybrid			2022-12-27	WOS:000245081000034
J	Schauble, S; King, CC; Darshi, M; Koller, A; Shah, K; Taylor, SS				Schauble, Sharmin; King, Charles C.; Darshi, Manjula; Koller, Antonius; Shah, Kavita; Taylor, Susan S.			Identification of ChChd3 as a novel substrate of the cAMP-dependent protein kinase (PKA) using an analog-sensitive catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNNATURAL NUCLEOTIDE SPECIFICITY; TYROSINE KINASE; CHEMICAL GENETICS; ESCHERICHIA-COLI; V-SRC; PHOSPHORYLATION; ACTIVATION; FAMILY; AUTOPHOSPHORYLATION; INHIBITOR	Due to the numerous kinases in the cell, many with overlapping substrates, it is difficult to find novel substrates for a specific kinase. To identify novel substrates of cAMP- dependent protein kinase ( PKA), the PKA catalytic subunit was engineered to accept bulky N-6-substituted ATP analogs, using a chemical genetics approach initially pioneered with v-Src ( 1). Methionine 120 was mutated to glycine in the ATP-binding pocket of the catalytic subunit. To express the stable mutant C-subunit in Escherichia coli required co-expression with PDK1. This mutant protein was active and fully phosphorylated on Thr(197) and Ser(338). Based on its kinetic properties, the engineered C-subunit preferred N-6( benzyl)-ATP and N-6( phenethyl)-ATP over other ATP analogs, but still retained a 30 mu M K-m for ATP. This mutant recombinant C-subunit was used to identify three novel PKA substrates. One protein, a novel mitochondrial ChChd protein, ChChd3, was identified, suggesting that PKA may regulate mitochondria proteins.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Taylor, SS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, La Jolla, CA 92093 USA.	staylor@ucsd.edu	Shah, Kavita/Y-9755-2019	Shah, Kavita/0000-0002-0451-1305	NCI NIH HHS [T32 CA009523] Funding Source: Medline; NIDDK NIH HHS [DK5441, DK071228] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK071228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Dephoure N, 2005, P NATL ACAD SCI USA, V102, P17940, DOI 10.1073/pnas.0509080102; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Grant BD, 1998, BIOCHEMISTRY-US, V37, P7708, DOI 10.1021/bi972987w; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; Iyer GH, 2005, J BIOL CHEM, V280, P8800, DOI 10.1074/jbc.M407586200; Juris SJ, 2006, FEBS LETT, V580, P179, DOI 10.1016/j.febslet.2005.11.071; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee I, 2005, J BIOL CHEM, V280, P6094, DOI 10.1074/jbc.M411335200; Lew J, 1997, BIOCHEMISTRY-US, V36, P6717, DOI 10.1021/bi963164u; Liu Y, 1998, BIOORGAN MED CHEM, V6, P1219, DOI 10.1016/S0968-0896(98)00099-6; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Moore MJ, 2002, J BIOL CHEM, V277, P47878, DOI 10.1074/jbc.M204970200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niswender CM, 2002, J BIOL CHEM, V277, P28916, DOI 10.1074/jbc.M203327200; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Rider MH, 2004, BIOCHEM J, V381, P561, DOI 10.1042/BJ20040752; Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; SLICE LW, 1989, J BIOL CHEM, V264, P20940; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915	28	33	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14952	14959		10.1074/jbc.M609221200	http://dx.doi.org/10.1074/jbc.M609221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17242405	hybrid			2022-12-27	WOS:000246589000033
J	Bohl, CE; Wu, ZR; Miller, DD; Bell, CE; Dalton, JT				Bohl, Casey E.; Wu, Zengru; Miller, Duane D.; Bell, Charles E.; Dalton, James T.			Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL LIGANDS; PROSTATE-CANCER; WITHDRAWAL SYNDROME; LNCAP CELLS; ANTAGONISM; BICALUTAMIDE; ACCOMMODATION; RECOGNITION; MODULATORS; MUTATIONS	Cyproterone acetate (CPA) is a steroidal antiandrogen used clinically in the treatment of prostate cancer. Compared with steroidal agonists for the androgen receptor (AR) (e. g. dihydrotestosterone, R1881), CPA is bulkier in structure and therefore seemingly incompatible with the binding pockets observed in currently available x-ray crystal structures of the AR ligand-binding domain (LBD). We solved the x-ray crystal structure of the human AR LBD bound to CPA at 1.8 angstrom in the T877A variant, a mutation known to increase the agonist activity of CPA and therefore facilitate purification and crystal formation of the receptor drug complex. The structure demonstrates that bulk from the 17 alpha-acetate group of CPA induces movement of the Leu-701 side chain, which results in partial unfolding of the C-terminal end of helix 11 and displacement of the loop between helices 11 and 12 in comparison to all other AR LBD crystal structures published to date. This structural alteration leads to an expansion of the AR binding cavity to include an additional pocket bordered by Leu-701, Leu-704, Ser-778, Met-780, Phe-876, and Leu-880. Further, we found that CPA invokes transcriptional activation in the L701A AR at low nanomolar concentrations similar to the T877A mutant. Analogous mutations in the glucocorticoid receptor (GR) and progesterone receptor were constructed, and we found that CPA was also converted into a potent agonist in the M560A GR. Altogether, these data offer information for structure-based drug design, elucidate flexible regions of the AR LBD, and provide insight as to how CPA antagonizes the AR and GR.	Ohio State Univ, Dept Pharmaceut, Coll Pharm, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Univ Tennessee, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center	Dalton, JT (corresponding author), Ohio State Univ, Dept Pharmaceut, Coll Pharm, 500 W 12th Ave, Columbus, OH 43210 USA.	dalton.1@osu.edu		Dalton, James T/0000-0002-3915-7326	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059800, R01DK065227] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK059800-07, R01 DK59800, R01 DK065227, R01 DK059800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balog A, 2004, BIOORG MED CHEM LETT, V14, P6107, DOI 10.1016/j.bmcl.2004.09.049; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; Bohl CE, 2004, J MED CHEM, V47, P3765, DOI 10.1021/jm0499007; Bohl CE, 2005, J BIOL CHEM, V280, P37747, DOI 10.1074/jbc.M507464200; Borngraeber S, 2003, P NATL ACAD SCI USA, V100, P15358, DOI 10.1073/pnas.2136689100; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen JY, 2005, ENDOCRINOLOGY, V146, P5444, DOI 10.1210/en.2005-0732; Dalton JT, 1998, BIOCHEM BIOPH RES CO, V244, P1, DOI 10.1006/bbrc.1998.8209; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; Hara T, 2003, CANCER RES, V63, P149; He YL, 2002, EUR J MED CHEM, V37, P619, DOI 10.1016/S0223-5234(02)01335-1; Honer C, 2003, MOL PHARMACOL, V63, P1012, DOI 10.1124/mol.63.5.1012; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; Kim J, 2005, J PHARMACOL EXP THER, V315, P230, DOI 10.1124/jpet.105.088344; Lill MA, 2005, J MED CHEM, V48, P5666, DOI 10.1021/jm050403f; Marhefka CA, 2004, J MED CHEM, V47, P993, DOI 10.1021/jm030336u; Marhefka CA, 2001, J MED CHEM, V44, P1729, DOI 10.1021/jm0005353; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Poujol N, 2000, J BIOL CHEM, V275, P24022, DOI 10.1074/jbc.M001999200; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Soderholm AA, 2005, J MED CHEM, V48, P917, DOI 10.1021/jm0495879; Suzuki H, 1996, PROSTATE, V29, P153, DOI 10.1002/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Yin DH, 2003, MOL PHARMACOL, V63, P211, DOI 10.1124/mol.63.1.211; Yoshida T, 2005, CANCER RES, V65, P9611, DOI 10.1158/0008-5472.CAN-05-0817	29	88	107	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13648	13655		10.1074/jbc.M611711200	http://dx.doi.org/10.1074/jbc.M611711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17311914	Green Accepted, hybrid			2022-12-27	WOS:000246060300054
J	Guo, NX; Kanter, D; Funderburgh, ML; Mann, MM; Du, YQ; Funderburgh, JL				Guo, Naxin; Kanter, David; Funderburgh, Martha L.; Mann, Mary M.; Du, Yiqin; Funderburgh, James L.			A rapid transient increase in hyaluronan synthase-2 mRNA initiates secretion of hyaluronan by corneal keratocytes in response to transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; TGF-BETA; INTRACELLULAR HYALURONAN; PROTEOGLYCAN EXPRESSION; ARTICULAR-CARTILAGE; ENDOTHELIAL-CELLS; ACCUMULATION; FIBROBLASTS; GENE; GROWTH-FACTOR-BETA-1	Keratocytes of the corneal stroma produce transparent extracellular matrix devoid of hyaluronan ( HA); however, in corneal pathologies and wounds, HA is abundant. We previously showed primary keratocytes cultured under serum-free conditions to secrete matrix similar to that of normal stroma, but serum and transforming growth factor beta ( TGF beta) induced secretion of fibrotic matrix components, including HA. This study found HA secretion by primary bovine keratocytes to increase rapidly in response to TGF beta, reaching a maximum in 12 h and then decreasing to < 5% of the maximum by 48 h. Cell-free biosynthesis of HAby cell extracts also exhibited a transient peak at 12 h after TGF beta treatment. mRNA for hyaluronan synthase enzymes HAS1 and HAS2 increased > 10- and > 50-fold, respectively, in 4-6 h, decreasing to near original levels after 24-48 h. Small interfering RNA against HAS2 inhibited the transient increase of HAS2 mRNA and completely blocked HA induction, but small interfering RNA to HAS1 had no effect on HA secretion. HAS2 mRNA was induced by a variety of mitogens, and TGF beta acted synergistically to induce HAS2 by as much as 150-fold. In addition to HA synthesis, treatment with TGF beta induced degradation of fluorescein-HA added to culture medium. These results show HA secretion by keratocytes to be initiated by a rapid transient increase in the HAS2 mRNA pool. The very rapid induction of HA expression in keratocytes suggests a functional role of this molecule in the fibrotic response of keratocytes to wound healing.	Univ Pittsburgh, Dept Ophthalmol, Eye & Ear Inst 1009,Ophthalmol & Visual Sci Res C, Sch Med,UPMC Eye Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Funderburgh, JL (corresponding author), Univ Pittsburgh, Dept Ophthalmol, Eye & Ear Inst 1009,Ophthalmol & Visual Sci Res C, Sch Med,UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.	jlfunder@pitt.edu	Du, Yiqin/A-7727-2018; DU, YIQIN/AAO-1566-2020	DU, YIQIN/0000-0002-4330-0957	NEI NIH HHS [EY09368, R01 EY009368, P30 EY008098, R01 EY009368-15A1, P30-EY08098, P30 EY008098-179003] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008098, R01EY009368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamia Sophia, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P3, DOI 10.2174/1568006053005056; Arici M, 2002, NEPHROL DIAL TRANSPL, V17, P1751, DOI 10.1093/ndt/17.10.1751; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; FITZSIMMONS TD, 1994, INVEST OPHTH VIS SCI, V35, P2774; Funderburgh JL, 2003, J BIOL CHEM, V278, P45629, DOI 10.1074/jbc.M303292200; Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200; Funderburgh ML, 2005, FASEB J, V19, P1371, DOI 10.1096/fj.04-2770fje; Haase HR, 2001, J PERIODONTOL, V72, P341, DOI 10.1902/jop.2001.72.3.341; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; HAUBECK HD, 1995, ARTHRITIS RHEUM-US, V38, P669, DOI 10.1002/art.1780380515; Hirsch M, 2001, EXP EYE RES, V72, P123, DOI 10.1006/exer.2000.0935; Hiscock DRR, 2000, OSTEOARTHR CARTILAGE, V8, P120, DOI 10.1053/joca.1999.0280; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Jenkins RH, 2004, J BIOL CHEM, V279, P41453, DOI 10.1074/jbc.M401678200; Jia Y, 2004, EXP BIOL MED, V229, P676, DOI 10.1177/153537020422900712; LAFON C, 1995, BBA-MOL CELL RES, V1266, P288, DOI 10.1016/0167-4889(95)00023-L; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; Meek KM, 2003, EYE, V17, P927, DOI 10.1038/sj.eye.6700574; Monslow J, 2004, J BIOL CHEM, V279, P20576, DOI 10.1074/jbc.M312666200; Nishida Y, 2000, OSTEOARTHR CARTILAGE, V8, P127, DOI 10.1053/joca.1999.0281; Oguchi T, 2004, CONNECT TISSUE RES, V45, P197, DOI 10.1080/03008200490523031; Pasonen-Seppanen S, 2003, J INVEST DERMATOL, V120, P1038, DOI 10.1046/j.1523-1747.2003.12249.x; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Plaas A H, 2001, Methods Mol Biol, V171, P117; Recklies AD, 2001, BIOCHEM J, V354, P17, DOI 10.1042/0264-6021:3540017; Saavalainen K, 2005, J BIOL CHEM, V280, P14636, DOI 10.1074/jbc.M500206200; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Shimabukuro Y, 2005, J CELL PHYSIOL, V203, P557, DOI 10.1002/jcp.20256; Spicer Andrew P, 2004, Birth Defects Res C Embryo Today, V72, P89, DOI 10.1002/bdrc.20006; Stephan JP, 2004, AM J NEPHROL, V24, P14, DOI 10.1159/000075347; Stuhlmeier KM, 2004, J BIOL CHEM, V279, P8753, DOI 10.1074/jbc.M303945200; Stuhlmeier KM, 2004, RHEUMATOLOGY, V43, P164, DOI 10.1093/rheumatology/keh014; Suzuki K, 2003, JPN J OPHTHALMOL, V47, P557, DOI 10.1016/j.jjo.2003.09.001; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Usui T, 2000, INVEST OPHTH VIS SCI, V41, P3261; Usui T, 2003, BRIT J OPHTHALMOL, V87, P357, DOI 10.1136/bjo.87.3.357; Wilkinson TS, 2004, AM J RESP CELL MOL, V31, P92, DOI 10.1165/rcmb.2003-0380OC	40	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12475	12483		10.1074/jbc.M609280200	http://dx.doi.org/10.1074/jbc.M609280200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327235	Green Accepted, hybrid			2022-12-27	WOS:000245942800016
J	Jones, BW; Song, GJ; Greuber, EK; Hinkle, PM				Jones, Brian W.; Song, Gyun Jee; Greuber, Emileigh K.; Hinkle, Patricia M.			Phosphorylation of the endogenous thyrotropin-releasing hormone receptor in pituitary GH3 cells and pituitary tissue revealed by phosphosite-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT PHOSPHORYLATION; A(3) ADENOSINE RECEPTOR; PROTEIN PHOSPHATASE 2A; BETA-ARRESTIN; DESENSITIZATION; KINASE; DEPHOSPHORYLATION; INTERNALIZATION; SITES; VISUALIZATION	To study phosphorylation of the endogenous type I thyrotropin-releasing hormone receptor in the anterior pituitary, generated phosphosite-specific polyclonal antibodies. The major phosphorylation site of receptor endogenously expressed in pituitary GH3 cells was Thr(365) in the receptor tail; distal sites were more phosphorylated in some heterologous models. beta-Arrestin 2 reduced thyrotropin-releasing hormone (TRH)-stimulated inositol phosphate production and accelerated internalization of the wild type receptor but not receptor mutants where the critical phosphosites were mutated to Ala. Phosphorylation peaked within seconds and was maximal at 100 nM TRH. Based on dominant negative kinase and small interfering RNA approaches, phosphorylation was mediated primarily by G protein-coupled receptor kinase 2. Phosphorylated receptor, visualized by immunofluorescence microscopy, was initially at the plasma membrane, and over 5-30 min it moved to intracellular vesicles in GH3 cells. Dephosphorylation was rapid (t(1/2) alpha 1 min) if agonist was removed while receptor was at the surface. Dephosphorylation was slower (t(1/2) similar to 4 min) if agonist was withdrawn after receptor had internalized. After agonist removal and dephosphorylation, a second pulse of agonist caused extensive rephosphorylation, particularly if most receptor was still on the plasma membrane. Phosphorylated receptor staining was visible in prolactin- and thyrotropin-producing cells in rat pituitary tissue from untreated rats and much stronger in tissue from animals injected with TRH. Our results show that the TRH receptor can rapidly cycle between a phosphorylated and nonphosphorylated state in response to changing agonist concentrations and that phosphorylation can be used as an indicator of receptor activity in vivo.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Hinkle, PM (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Box 711, Rochester, NY 14642 USA.	Patricia_Hinkle@urmc.rochester.edu		Jones, Brian/0000-0002-3277-4735	NIDDK NIH HHS [DK19974, R01 DK019974] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams RA, 2003, BIOCHEM J, V374, P537, DOI 10.1042/BJ20030408; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Cook LB, 2004, ENDOCRINOLOGY, V145, P3095, DOI 10.1210/en.2004-0304; DELAPENA P, 1992, J BIOL CHEM, V267, P25703; Drmota T, 2000, BIOCHEM J, V346, P711, DOI 10.1042/0264-6021:3460711; Du DY, 2005, MOL PHARMACOL, V68, P204, DOI 10.1124/mol.105.012641; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; HALPERN J, 1981, P NATL ACAD SCI-BIOL, V78, P587, DOI 10.1073/pnas.78.1.587; HINKLE PM, 1973, J BIOL CHEM, V248, P6180; IMAI A, 1985, J BIOL CHEM, V260, P536; Iyer V, 2006, BRIT J PHARMACOL, V147, P249, DOI 10.1038/sj.bjp.0706551; JinsiParimoo A, 1997, ENDOCRINOLOGY, V138, P1471, DOI 10.1210/en.138.4.1471; Jones BW, 2005, J BIOL CHEM, V280, P38346, DOI 10.1074/jbc.M502918200; Kageyama K, 2006, ENDOCRINOLOGY, V147, P441, DOI 10.1210/en.2005-0376; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Langkabel P, 1999, EUR J IMMUNOL, V29, P3035, DOI 10.1002/(SICI)1521-4141(199909)29:09<3035::AID-IMMU3035>3.0.CO;2-Z; LUTZ MP, 1993, J BIOL CHEM, V268, P12136; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Mao LM, 2005, J BIOL CHEM, V280, P12602, DOI 10.1074/jbc.M411709200; MARTIN TFJ, 1986, J BIOL CHEM, V261, P2918; McLaughlin JP, 2004, J BIOL CHEM, V279, P1810, DOI 10.1074/jbc.M305796200; McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200; Neill JD, 1998, ENDOCRINOLOGY, V139, P1781, DOI 10.1210/en.139.4.1781; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; PALMER TM, 1995, J BIOL CHEM, V270, P29607, DOI 10.1074/jbc.270.49.29607; PERRONE MH, 1978, J BIOL CHEM, V253, P5168; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Pollok-Kopp B, 2003, J BIOL CHEM, V278, P2190, DOI 10.1074/jbc.M209844200; Pollok-Kopp B, 2007, J BIOL CHEM, V282, P4345, DOI 10.1074/jbc.M601317200; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Rabeler R, 2004, MOL ENDOCRINOL, V18, P1450, DOI 10.1210/me.2004-0017; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Spurney RF, 2001, J PHARMACOL EXP THER, V296, P592; Tachibanaki S, 2005, P NATL ACAD SCI USA, V102, P9329, DOI 10.1073/pnas.0501875102; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Woerner BM, 2005, CANCER RES, V65, P11392, DOI 10.1158/0008-5472.CAN-05-0847; Yamada M, 1997, P NATL ACAD SCI USA, V94, P10862, DOI 10.1073/pnas.94.20.10862; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737; Yu R, 1998, THYROID, V8, P887, DOI 10.1089/thy.1998.8.887; Zhu CC, 2002, J BIOL CHEM, V277, P28228, DOI 10.1074/jbc.M204221200	52	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12893	12906		10.1074/jbc.M610854200	http://dx.doi.org/10.1074/jbc.M610854200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329249	hybrid			2022-12-27	WOS:000245942800061
J	Bhattacharyya, G; Grove, A				Bhattacharyya, Gargi; Grove, Anne			The N-terminal extensions of Deinococcus radiodurans Dps-1 mediate DNA major groove interactions as well as assembly of the dodecamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PROTEIN; ESCHERICHIA-COLI DPS; BINDING PROTEIN; CRYSTAL-STRUCTURE; FERRITIN HOMOLOG; IRON; PROTECTION; STRATEGIES; REVEALS; SITE	Dps ( (D) under bar NA (p) under bar rotection during (s) under bar tarvation) proteins play an important role in the protection of prokaryotic macromolecules from damage by reactive oxygen species. Previous studies have suggested that the lysine-rich N-terminal tail of Dps proteins participates in DNA binding. In comparison with other Dps proteins, Dps-1 from Deinococcus radiodurans has an extended N terminus comprising 55 amino acids preceding the first helix of the 4-helix bundle monomer. In the crystal structure of Dps-1, the first similar to 30 N-terminal residues are invisible, and the remaining 25 residues form a loop that harbors a novel metal-binding site. We show here that deletion of the flexible N-terminal tail obliterates DNA/Dps-1 interaction. Surprisingly, deletion of the entire N terminus also abolishes dodecameric assembly of the protein. Retention of the N-terminal metal site is necessary for formation of the dodecamer, and metal binding at this site facilitates oligomerization of the protein. Electrophoretic mobility shift assays using DNA modified with specific major/minor groove reagents further show that Dps-1 interacts through the DNA major groove. DNA cyclization assays suggest that dodecameric Dps-1 does not wrap DNA about itself. A significant decrease in DNA binding affinity accompanies a reduction in duplex length from 22 to 18 bp, but only for dodecameric Dps-1. Our data further suggest that high affinity DNA binding depends on occupancy of the N-terminal metal site. Taken together, the mode of DNA interaction by dodecameric Dps-1 suggests interaction of two metal-anchored N-terminal tails in successive DNA major grooves, leading to DNA compaction by formation of stacked protein-DNA layers.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Grove, A (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	agrove@lsu.edu	Grove, Anne/O-5998-2015	Grove, Anne/0000-0002-4390-0354				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; BOYD D, 1985, J BIOL CHEM, V260, P1755; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; Ceci P, 2005, J BIOL CHEM, V280, P34776, DOI 10.1074/jbc.M502343200; Ceci P, 2004, NUCLEIC ACIDS RES, V32, P5935, DOI 10.1093/nar/gkh915; Ceci P, 2003, J BIOL CHEM, V278, P20319, DOI 10.1074/jbc.M302114200; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; Crichton RR, 2002, J INORG BIOCHEM, V91, P9, DOI 10.1016/S0162-0134(02)00461-0; Daly MJ, 2004, SCIENCE, V306, P1025, DOI 10.1126/science.1103185; Frenkiel-Krispin D, 2004, MOL MICROBIOL, V51, P395, DOI 10.1046/j.1365-2958.2003.03855.x; Gauss GH, 2006, BIOCHEMISTRY-US, V45, P10815, DOI 10.1021/bi060782u; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Grove A, 2005, J MOL BIOL, V347, P495, DOI 10.1016/j.jmb.2005.01.055; Grove A, 2001, J MOL BIOL, V311, P491, DOI 10.1006/jmbi.2001.4763; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; Ilari A, 2002, J BIOL CHEM, V277, P37619, DOI 10.1074/jbc.M206186200; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; Kim SG, 2006, J MOL BIOL, V361, P105, DOI 10.1016/j.jmb.2006.06.010; LATHAM KA, 1995, J BIOL CHEM, V270, P3765, DOI 10.1074/jbc.270.8.3765; Liu XF, 2006, J BIOL CHEM, V281, P27827, DOI 10.1074/jbc.M601398200; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; Papinutto E, 2002, J BIOL CHEM, V277, P15093, DOI 10.1074/jbc.M112378200; Romao CV, 2006, J BIOL INORG CHEM, V11, P891, DOI 10.1007/s00775-006-0142-5; Sabatini R, 2002, J BIOL CHEM, V277, P28150, DOI 10.1074/jbc.M201487200; Stillman TJ, 2005, MOL MICROBIOL, V57, P1101, DOI 10.1111/j.1365-2958.2005.04757.x; Surguladze N, 2004, J BIOL CHEM, V279, P14694, DOI 10.1074/jbc.M313348200; Theil EC, 2006, J BIOL INORG CHEM, V11, P803, DOI 10.1007/s00775-006-0125-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; Wilson DM, 2003, FRONT BIOSCI-LANDMRK, V8, pD963, DOI 10.2741/1109; Zanotti G, 2002, J MOL BIOL, V323, P125, DOI 10.1016/S0022-2836(02)00879-3; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	37	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11921	11930		10.1074/jbc.M611255200	http://dx.doi.org/10.1074/jbc.M611255200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17331944	Green Published, hybrid			2022-12-27	WOS:000245941900035
J	Zhao, YT; Katzman, RB; Delmolino, LM; Bhat, I; Zhang, Y; Gurumurthy, CB; Germaniuk-Kurowska, A; Reddi, HV; Solomon, A; Zeng, MS; Kung, A; Ma, H; Gao, QS; Dimri, G; Stanculescu, A; Miele, L; Wu, LZ; Griffin, JD; Wazer, DE; Band, H; Band, V				Zhao, Yongtong; Katzman, Rebecca B.; Delmolino, Laurie M.; Bhat, Ishfaq; Zhang, Ying; Gurumurthy, Channabasavaiah B.; Germaniuk-Kurowska, Aleksandra; Reddi, Honey V.; Solomon, Aharon; Zeng, Mu-Sheng; Kung, Aisha; Ma, Hui; Gao, Qingshen; Dimri, Goberdhan; Stanculescu, Adina; Miele, Lucio; Wu, Lizi; Griffin, James D.; Wazer, David E.; Band, Hamid; Band, Vimla			The Notch regulator MAML1 interacts with p53 and functions as a coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; TUMOR-SUPPRESSOR; DNA-DAMAGE; HUMAN ADA3; TRANSCRIPTIONAL COACTIVATORS; MEDIATED TRANSACTIVATION; CELL FATE; MASTERMIND; APOPTOSIS; TUMORIGENESIS	Members of the evolutionarily conserved Mastermind (MAM) protein family, including the three related mammalian Master-mind-like (MAML) proteins MAML1-3, function as crucial coactivators of Notch-mediated transcriptional activation. Given the recent evidence of cross-talk between the p53 and Notch signal transduction pathways, we have investigated whether MAML1 may also be a transcriptional coactivator of p53. Indeed, we show here that MAML1 is able to interact with p53. We show that MAML1-p53 interaction involves the N-terminal region of MAML1 and the DNA-binding domain of p53, and we use a chromatin immunoprecipitation assay to show that MAML1 is part of the activator complex that binds to native p53-response elements within the promoter of the p53 target genes. Overexpression of wild-type MAML1 as well as a mutant, defective in Notch signaling, enhanced the p53-dependent gene induction in mammalian cells, whereas MAML1 knockdown reduced the p53-dependent gene expression. MAML1 increases the half-life of p53 protein and enhances its phosphorylation/acetylation upon DNA damage of cells. Finally, RNA interference-mediated knockdown of the single Caenorhabditis elegans MAML homolog, Lag-3, led to substantial abrogation of p53-mediated germ-cell apoptotic response to DNA damage and markedly reduced the expression of Ced-13 and Egl-1, downstream pro-apoptotic targets of the C. elegans p53 homolog Cep-1. Thus, we present evidence for a novel coactivator function of MAML1 for p53, independent of its function as a coactivator of Notch signaling pathway.	Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Div Canc Biol,Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Div Mol Oncol,Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60201 USA; Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Loyola Univ, Med Ctr, Breast Canc Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pharmacol & Expt Therapeut, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Tufts Medical Center; Loyola University Chicago; Loyola University Chicago; Harvard University; Dana-Farber Cancer Institute	Band, V (corresponding author), Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Div Canc Biol,Dept Med, 1001 Univ Pl, Evanston, IL 60201 USA.	v-band@northwestern.edu	Gurumurthy, Channabasavaiah B/H-8268-2016; Gurumurthy, Channabasavaiah B/E-7205-2011	Gurumurthy, Channabasavaiah B/0000-0002-8022-4033; Miele, Lucio/0000-0002-5853-7287; zeng, musheng/0000-0003-3509-5591	NATIONAL CANCER INSTITUTE [R01CA081076, T32CA070085, R01CA097148, R01CA076118, R01CA096986, R01CA099900, R01CA087986, R01CA096844, R01CA095221, R01CA094143, R01CA099163] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA70085, R01 CA095221-05, R01 CA097148, R01 CA096986-05, R01 CA096986-02, R01 CA096986-01A1, R01 CA095221-01A1, CA81076, R01 CA096986-04, CA94143, R01 CA095221-02, R01 CA095221-04, CA87986, CA99900, R01 CA096986-03, CA96844, R01 CA095221-03, CA76118, CA99163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BRENNER S, 1974, GENETICS, V77, P71; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DORMAN JB, 1995, GENETICS, V141, P1399; Doyle TG, 2000, P NATL ACAD SCI USA, V97, P7877, DOI 10.1073/pnas.97.14.7877; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lathion S, 2003, CANCER RES, V63, P8687; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Meng GY, 2004, J BIOL CHEM, V279, P54230, DOI 10.1074/jbc.M404482200; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu LZ, 2004, SEMIN CANCER BIOL, V14, P348, DOI 10.1016/j.semcancer.2004.04.014; Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200	49	62	70	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11969	11981		10.1074/jbc.M608974200	http://dx.doi.org/10.1074/jbc.M608974200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317671	hybrid, Green Submitted			2022-12-27	WOS:000245941900040
J	Greenstein, AE; Echols, N; Lombana, TN; King, DS; Alber, T				Greenstein, Andrew E.; Echols, Nathaniel; Lombana, T. Noelle; King, David S.; Alber, Tom			Allosteric activation by dimerization of the PknD receptor Ser/Thr protein kinase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE KINASES; CRYSTAL-STRUCTURE; DOMAIN; SUBSTRATE; PHOSPHORYLATION; RECOGNITION; EMBR; AUTOPHOSPHORYLATION; IDENTIFICATION; PHOSPHATASE	To define how extracellular signals activate bacterial receptor Ser/Thr protein kinases, we characterized the regulatory functions of a weak dimer interface identified in the Mycobacterium tuberculosis PknB and PknE receptor kinases. Sequence comparisons revealed that the analogous interface is conserved in PknD orthologs from diverse bacterial species. To analyze the roles of dimerization, we constructed M. tuberculosis PknD kinase domain ( KD) fusion proteins that formed dimers upon addition of rapamycin. Dimerization of unphosphorylated M. tuberculosis PknD KD fusions stimulated phosphorylation activity. Mutations in the dimer interface reduced this activation, limited autophosphorylation, and altered substrate specificity. In contrast, an inactive catalytic site mutant retained the ability to stimulate the wild-type KD by dimerization. These results support the idea that dimer formation allosterically activates unphosphorylated PknD. The phosphorylated PknD KD was fully active even in the absence of dimerization, suggesting that phosphorylation provides an additional regulatory mechanism. The conservation of analogous dimers in diverse prokaryotic and eukaryotic Ser/Thr protein kinases implies that this mechanism of protein kinase regulation is ancient and broadly distributed.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Mass Spectrometry Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Alber, T (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 339 Hildebrand Hall 3206, Berkeley, CA 94720 USA.	tom@ucxray.berkeley.edu		Greenstein, Andrew/0000-0002-1470-1970	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM70962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderwick LJ, 2006, P NATL ACAD SCI USA, V103, P2558, DOI 10.1073/pnas.0507766103; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Boitel B, 2003, MOL MICROBIOL, V49, P1493, DOI 10.1046/j.1365-2958.2003.03657.x; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Dey M, 2005, CELL, V122, P901, DOI 10.1016/j.cell.2005.06.041; Duran R, 2005, BIOCHEM BIOPH RES CO, V333, P858, DOI 10.1016/j.bbrc.2005.05.173; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P380, DOI 10.1093/nar/gkh180; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Gay LM, 2006, J MOL BIOL, V360, P409, DOI 10.1016/j.jmb.2006.05.015; Good MC, 2004, J MOL BIOL, V339, P459, DOI 10.1016/j.jmb.2004.03.063; Greenstein AE, 2005, J MOL MICROB BIOTECH, V9, P167, DOI 10.1159/000089645; GREENSTEIN AE, 2007, IN PRESS PLOS PATHOG; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kang CM, 2005, GENE DEV, V19, P1692, DOI 10.1101/gad.1311105; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Madec E, 2002, MOL MICROBIOL, V46, P571, DOI 10.1046/j.1365-2958.2002.03178.x; Molle V, 2003, BIOCHEMISTRY-US, V42, P15300, DOI 10.1021/bi035150b; Ortiz-Lombardia M, 2003, J BIOL CHEM, V278, P13094, DOI 10.1074/jbc.M300660200; Padyana AK, 2005, J BIOL CHEM, V280, P29289, DOI 10.1074/jbc.M504096200; Perez J, 2006, BIOCHEM BIOPH RES CO, V348, P6, DOI 10.1016/j.bbrc.2006.06.164; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Pullen KE, 2004, STRUCTURE, V12, P1947, DOI 10.1016/j.str.2004.09.008; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sharma K, 2006, FEBS J, V273, P2711, DOI 10.1111/j.1742-4658.2006.05289.x; Villarino A, 2005, J MOL BIOL, V350, P953, DOI 10.1016/j.jmb.2005.05.049; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Young TA, 2003, NAT STRUCT BIOL, V10, P168, DOI 10.1038/nsb897; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	31	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11427	11435		10.1074/jbc.M610193200	http://dx.doi.org/10.1074/jbc.M610193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17242402	hybrid			2022-12-27	WOS:000245941500064
J	Bertola, A; Bonnafous, S; Cormont, M; Anty, R; Tanti, JF; Tran, A; Le Marchand-Brustel, Y; Gual, P				Bertola, Adeline; Bonnafous, Stephanie; Cormont, Mireille; Anty, Rodolphe; Tanti, Jean-Francois; Tran, Albert; Le Marchand-Brustel, Yannick; Gual, Philippe			Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through A Gab1/phosphatidylinositol 3-kinase/Glut4 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY LIVER-DISEASE; ADIPOSE-TISSUE; INSULIN; MET; EXPRESSION; ADIPOKINES; SECRETION; CANCER; LEADS; GAB1	Adipose tissue is a source of hepatocyte growth factor ( HGF), and circulating HGF levels have been associated with elevated body mass index in human. However, the effects of HGF on adipocyte functions have not yet been investigated. We show here that in 3T3-L1 adipocytes HGF stimulates the phosphatidylinositol (PI) 3-kinase-dependent protein kinase B (PKB) activity, AS160 phosphorylation, Glut4 translocation, and consequently, glucose uptake. The initial steps involved in HGF- and insulin-induced glucose uptake are different. HGF enhanced the tyrosine phosphorylation of Gab1, leading to the recruitment of the p85-regulated subunit of PI 3-kinase, whereas p85 was exclusively recruited by IRS1 in response to insulin. In adipocytes rendered insulin-resistant by a long-lasting tumor necrosis factor alpha treatment, the protein level of Gab1 was strongly decreased, and HGF- stimulated PKB activation and glucose uptake were also altered. Moreover, treatment of 3T3-L1 adipocytes with thiazolidinedione, an anti- diabetic drug, enhanced the expression of both HGF and its receptor. These data provide the first evidence that in vitro HGF promotes glucose uptake through a Gab1/PI 3-kinase/ PKB/ AS160 pathway which was altered in tumor necrosis factor alpha-treated adipocytes.	INSERM, U568, Fac Med, F-06107 Nice 02, France; Univ Nice, F-06107 Nice, France; CHU, Federat Hepatol, F-06202 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Gual, P (corresponding author), INSERM, U568, Fac Med, Ave Valombrose, F-06107 Nice 02, France.	gual@unice.fr	Gual, Philippe/P-9833-2019; Gual, Philippe/M-8787-2017	Gual, Philippe/0000-0001-7393-8356; Gual, Philippe/0000-0001-7393-8356; Tanti, Jean-Francois/0000-0003-1782-1318; CORMONT, Mireille/0000-0001-6918-2410; Anty, Rodolphe/0000-0002-8053-1957; Anty, Rodolphe/0000-0001-8194-9805; Bertola, Adeline/0000-0002-4885-8423				Arner P, 2003, TRENDS ENDOCRIN MET, V14, P137, DOI 10.1016/S1043-2760(03)00024-9; Bard-Chapeau EA, 2005, NAT MED, V11, P567, DOI 10.1038/nm1227; Bell LN, 2006, AM J PHYSIOL-ENDOC M, V291, pE843, DOI 10.1152/ajpendo.00174.2006; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; Dugani CB, 2005, EMBO REP, V6, P1137, DOI 10.1038/sj.embor.7400584; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Gual P, 2002, J BIOL CHEM, V277, P43980, DOI 10.1074/jbc.M203042200; Gual P, 2003, DIABETES METAB, V29, P566, DOI 10.1016/S1262-3636(07)70071-X; Guerre-Millo M, 2004, DIABETES METAB, V30, P13, DOI 10.1016/S1262-3636(07)70084-8; Haukeland JW, 2006, J HEPATOL, V44, P1167, DOI 10.1016/j.jhep.2006.02.011; Hiratsuka A, 2005, J CLIN ENDOCR METAB, V90, P2927, DOI 10.1210/jc.2004-1588; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Janez A, 2000, J BIOL CHEM, V275, P26870; Kaplan O, 2000, NEOPLASIA, V2, P365, DOI 10.1038/sj.neo.7900103; Kataoka H, 2003, CANCER METAST REV, V22, P223, DOI 10.1023/A:1023051500010; Kato Y, 1998, J PEDIATR SURG, V33, P13, DOI 10.1016/S0022-3468(98)90351-7; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Mari M, 2006, J CELL SCI, V119, P1297, DOI 10.1242/jcs.02850; NAKAMURA Y, 1995, BIOCHEM BIOPH RES CO, V215, P483, DOI 10.1006/bbrc.1995.2490; Pagano C, 2006, J CLIN ENDOCR METAB, V91, P1081, DOI 10.1210/jc.2005-1056; Patel N, 2006, PFLUG ARCH EUR J PHY, V451, P499, DOI 10.1007/s00424-005-1475-6; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; Rehman J, 2003, J AM COLL CARDIOL, V41, P1408, DOI 10.1016/S0735-1097(03)00231-6; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Roccisana J, 2005, DIABETES, V54, P2090, DOI 10.2337/diabetes.54.7.2090; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Saiki A, 2006, INT J OBESITY, V30, P1676, DOI 10.1038/sj.ijo.0803316; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Swierczynski J, 2005, OBES SURG, V15, P803, DOI 10.1381/0960892054222678; Tomita K, 2004, GASTROENTEROLOGY, V126, P873, DOI 10.1053/j.gastro.2003.12.008; WANG M, 2006, AM J PHYSIOL-REG I, V29, pE880	38	36	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10325	10332		10.1074/jbc.M611770200	http://dx.doi.org/10.1074/jbc.M611770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284447	hybrid			2022-12-27	WOS:000245941000022
J	Huang, JS; Dong, L; Kozasa, T; Le Breton, GC				Huang, Jin-Sheng; Dong, Lanlan; Kozasa, Tohru; Le Breton, Guy C.			Signaling through G alpha(13) switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPDUCIN-BASED INTERVENTION; ENDOTHELIAL-CELL MIGRATION; THROMBOXANE A(2) RECEPTORS; INTACT HUMAN-PLATELETS; BETA-GAMMA-SUBUNITS; G-ALPHA-Q; PHOSPHOLIPASE-C; INTEGRIN ALPHA(IIB)BETA(3); MOLECULAR-MECHANISM; THROMBIN RECEPTORS	This study investigated the involvement of G alpha(13) switch region I (SRI) in protease-activated receptor 1 (PAR1)-mediated platelet function and signaling. To this end, myristoylated peptides representing the G alpha(13) SRI (Myr-G(13)SRI(pep)) and its random counterpart were evaluated for their effects on PAR1 activation. Initial studies demonstrated that (Myr-G(13)SRI(pep)) and Myr-G(13)SRI(Random-pep) pep were equally taken up by human platelets and did not interfere with PAR1-ligand interaction. Subsequent experiments revealed that Myr-G(13)SRI(pep) specifically bound to platelet RhoA guanine nucleotide exchange factor (p115RhoGEF) and blocked PAR1-mediated RhoA activation in platelets and human embryonic kidney cells. These results suggest a direct interaction of G alpha(13) SRI with p115RhoGEF and a mechanism for Myr-G13SRIpep inhibition of RhoA activation. Platelet function studies demonstrated that Myr-G13SRIpep specifically inhibited PAR1- stimulated shape change, aggregation, and secretion in a dose-dependent manner but did not inhibit platelet activation induced by either ADP or A23187. It was also found that Myr-G(13)SRI(pep) inhibited low dose, but not high dose, thrombin-induced aggregation. Additional experiments showed that PAR1- mediated calcium mobilization was partially blocked by Myr-G(13)SRI(pep) but not by the Rho kinase inhibitor Y-27632. Finally, Myr-G(13)SRI(pep) effectively inhibited PAR1-induced stress fiber formation and cell contraction in endothelial cells. Collectively, these results suggest the following: 1) interaction of G alpha(13) SRI with p115RhoGEF is required for G13-mediated RhoA activation in platelets; 2) signaling through the G(13) pathway is critical for PAR1- mediated human platelet functional changes and low dose thrombin-induced aggregation; and 3) G13 signaling elicits calcium mobilization in human platelets through a Rho kinase-independent mechanism.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Le Breton, GC (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,MC 868, Chicago, IL 60612 USA.	gcl@uic.edu			NHLBI NIH HHS [HL-24530-23] Funding Source: Medline; NIGMS NIH HHS [GM061454] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; D'Ursi AM, 2006, MOL PHARMACOL, V69, P727, DOI 10.1124/mol.105.017715; Djellas Y, 1999, J BIOL CHEM, V274, P14325, DOI 10.1074/jbc.274.20.14325; Dorsam RT, 2002, J BIOL CHEM, V277, P47588, DOI 10.1074/jbc.M208778200; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FEINBERG H, 1974, J LAB CLIN MED, V84, P926; Flaumenhaft R, 2005, BLOOD, V105, P3879, DOI 10.1182/blood-2004-04-1392; Freissmuth M, 1999, TRENDS PHARMACOL SCI, V20, P237, DOI 10.1016/S0165-6147(99)01337-1; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; HAMILTON JR, 2004, J THROMB HAEMOST, V2, P1538; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Huang JS, 2006, CELL SIGNAL, V18, P564, DOI 10.1016/j.cellsig.2005.06.011; Huang JS, 2004, CELL SIGNAL, V16, P521, DOI 10.1016/j.cellsig.2003.10.008; JHON DY, 1993, J BIOL CHEM, V268, P6654; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; KATTELMAN EJ, 1986, THROMB RES, V41, P471, DOI 10.1016/0049-3848(86)91692-0; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kuliopulos A, 2003, LIFE SCI, V74, P255, DOI 10.1016/j.lfs.2003.09.012; Lee BS, 2005, RAPID COMMUN MASS SP, V19, P1545, DOI 10.1002/rcm.1956; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; Manganello JM, 2003, J BIOL CHEM, V278, P124, DOI 10.1074/jbc.M209219200; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Mazzoni MR, 2000, MOL PHARMACOL, V58, P226, DOI 10.1124/mol.58.1.226; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Moers A, 2004, J BIOL CHEM, V279, P45354, DOI 10.1074/jbc.M408962200; Moers A, 2003, NAT MED, V9, P1418, DOI 10.1038/nm943; Murugappan S, 2005, BLOOD, V106, P550, DOI 10.1182/blood-2004-12-4866; MUSTARD JF, 1975, AM J PHYSIOL, V228, P1757, DOI 10.1152/ajplegacy.1975.228.6.1757; Nakamura S, 2004, MOL PHARMACOL, V66, P1029, DOI 10.1124/mol.104.002287; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; OBRIAN CA, 1991, INVEST NEW DRUG, V9, P169, DOI 10.1007/BF00175084; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Otterdal K, 2001, THROMB RES, V103, P411, DOI 10.1016/S0049-3848(01)00334-6; PARK DG, 1993, J BIOL CHEM, V268, P4573; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; RINK TJ, 1988, EXPERIENTIA, V44, P97, DOI 10.1007/BF01952188; Simoncini T, 2006, MOL ENDOCRINOL, V20, P1756, DOI 10.1210/me.2005-0259; Suzuki Y, 1999, BLOOD, V93, P3408, DOI 10.1182/blood.V93.10.3408.410k37_3408_3417; Vaidyula VR, 2003, BRIT J HAEMATOL, V121, P491, DOI 10.1046/j.1365-2141.2003.04296.x; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Watanabe Y, 2001, BLOOD, V97, P3798, DOI 10.1182/blood.V97.12.3798	55	29	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10210	10222		10.1074/jbc.M605678200	http://dx.doi.org/10.1074/jbc.M605678200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17298951	hybrid			2022-12-27	WOS:000245941000011
J	Storozhenko, S; Navarrete, O; Ravanel, S; De Brouwer, V; Chaerle, P; Zhang, GF; Bastien, O; Lambert, W; Rebeille, F; Van Der Straeten, D				Storozhenko, Sergei; Navarrete, Oscar; Ravanel, Stephane; De Brouwer, Veerle; Chaerle, Peter; Zhang, Guo-Fang; Bastien, Olivier; Lambert, Willy; Rebeille, Fabrice; Van Der Straeten, Dominique			Cytosolic hydroxymethyldihydropterin pyrophosphokinase/dihydropteroate synthase from Arabidopsis thaliana - A specific role in early development and stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; P-AMINOBENZOATE BRANCH; CELL-FREE-EXTRACTS; FOLIC-ACID; FOLATE SYNTHESIS; ENDOTHELIAL FUNCTION; HIGHER-PLANTS; BIOSYNTHESIS; DIHYDROPTEROATE; MITOCHONDRIA	In plants, 6-hydroxymethyl-7, 8-dihydropterin pyrophosphokinase/7, 8-dihydropteroate synthase ( mitHPPK/DHPS) is a bifunctional mitochondrial enzyme, which catalyzes the first two consecutive steps of tetrahydrofolate biosynthesis. Mining the Arabidopsis genome data base has revealed a second gene encoding a protein that lacks a potential transit peptide, suggesting a cytosolic localization of the isoenzyme ( cytHPPK/DHPS). When the N-terminal part of the cytHPPK/DHPS was fused to green fluorescent protein, the fusion protein appeared only in the cytosol, confirming the above prediction. Functionality of cytHPPK/DHPS was addressed by two parallel approaches: first, the cytHPPK/DHPS was able to rescue yeast mutants lacking corresponding activities; second, recombinant cytHPPK/DHPS expressed and purified from Escherichia coli displayed both HPPK and DHPS activities in vitro. In contrast to mitHPPK/DHPS, which was ubiquitously expressed, the cytHPPK/DHPS gene was exclusively expressed in reproductive tissue, more precisely in developing seeds as revealed by histochemical analysis of a transgenic cytHPPK/DHPS promoter-GUS line. In addition, it was observed that expression of cytHPPK/DHPS mRNA was induced by salt stress, suggesting a potential role of the enzyme in stress response. This was supported by the phenotype of a T-DNA insertion mutant in the cytHPPK/DHPS gene, resulting in lower germination rates as compared with the wild-type upon application of oxidative and osmotic stress.	Univ Ghent, Dept Mol Genet, Unit Plant Hormone Signaling & Bioimaging, B-9000 Ghent, Belgium; CEA Grenoble, Lab Physiol Cellulaire Vegetale, Dept Dynam Cellulaire, F-38054 Grenoble 9, France; Univ Ghent, Toxicol Lab, B-9000 Ghent, Belgium	Ghent University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Ghent University	Van Der Straeten, D (corresponding author), Univ Ghent, Dept Mol Genet, Unit Plant Hormone Signaling & Bioimaging, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	dominique.vanderstraeten@ugent.be	Bastien, Olivier/B-9723-2008; Van Der Straeten, Dominique/E-7385-2016	Van Der Straeten, Dominique/0000-0002-7755-1420; Chaerle, Peter/0000-0002-8216-0299; Ravanel, Stephane/0000-0001-9475-4222				APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Basset G, 2002, P NATL ACAD SCI USA, V99, P12489, DOI 10.1073/pnas.192278499; Basset GJC, 2004, PLANT J, V40, P453, DOI 10.1111/j.1365-313X.2004.02231.x; Basset GJC, 2004, P NATL ACAD SCI USA, V101, P1496, DOI 10.1073/pnas.0308331100; Baxter CJ, 2007, PLANT PHYSIOL, V143, P312, DOI 10.1104/pp.106.090431; Bayly AM, 2002, FEMS MICROBIOL LETT, V213, P189; Beeckman T., 1994, Plant Molecular Biology Reporter, V12, P37, DOI 10.1007/BF02668662; Bowers JE, 2003, NATURE, V422, P433, DOI 10.1038/nature01521; BROWN GM, 1961, J BIOL CHEM, V236, P2534; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Doshi SN, 2001, ARTERIOSCL THROM VAS, V21, P1196, DOI 10.1161/hq0701.092000; EVANS IH, 1976, GENETIC FUNCTION MIT, P209; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Goyer A, 2004, PLANT PHYSIOL, V135, P103, DOI 10.1104/pp.103.038430; Guldener U, 2004, MOL BIOL CELL, V15, P3811, DOI 10.1091/mbc.E03-09-0680; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; Hanson AD, 2001, ANNU REV PLANT PHYS, V52, P119, DOI 10.1146/annurev.arplant.52.1.119; He XL, 2005, GENETICS, V169, P1157, DOI 10.1534/genetics.104.037051; IWAI K, 1968, J VITAMINOL, V14, P160, DOI 10.5925/jnsv1954.14.160; Jabrin S, 2003, PLANT PHYSIOL, V131, P1431, DOI 10.1104/pp.016915; Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Magome H, 2004, PLANT J, V37, P720, DOI 10.1111/j.1365-313X.2003.01998.x; Mouillon JM, 2002, BIOCHEM J, V363, P313, DOI 10.1042/0264-6021:3630313; Neuburger M, 1996, J BIOL CHEM, V271, P9466, DOI 10.1074/jbc.271.16.9466; Orsomando G, 2006, PLANT J, V46, P426, DOI 10.1111/j.1365-313X.2006.02685.x; Orsomando G, 2005, J BIOL CHEM, V280, P28877, DOI 10.1074/jbc.M504306200; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; Rebeille F, 1997, EMBO J, V16, P947, DOI 10.1093/emboj/16.5.947; Scott J, 2000, J SCI FOOD AGR, V80, P795, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;795::AID-JSFA599&gt;3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000515)80:7<795::AID-JSFA599>3.0.CO;2-K]; Seki M, 2002, PLANT J, V31, P279, DOI 10.1046/j.1365-313X.2002.01359.x; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Storozhenko S, 2005, TRENDS FOOD SCI TECH, V16, P271, DOI 10.1016/j.tifs.2005.03.007; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verhaar MC, 1999, CIRCULATION, V100, P335, DOI 10.1161/01.CIR.100.4.335; Wang RC, 2003, PLANT PHYSIOL, V132, P556, DOI 10.1104/pp.103.021253; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang GF, 2005, J CHROMATOGR A, V1078, P59, DOI 10.1016/j.chroma.2005.04.085; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0	41	28	33	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10749	10761		10.1074/jbc.M701158200	http://dx.doi.org/10.1074/jbc.M701158200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289662	hybrid, Green Published			2022-12-27	WOS:000245941000069
J	Tanaka, S; Ishii, K; Kasai, K; Yoon, SO; Saeki, Y				Tanaka, Shigeru; Ishii, Ken; Kasai, Kazue; Yoon, Sung Ok; Saeki, Yoshinaga			Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; AXONAL REGENERATION; NEURONAL SURVIVAL; MEIOTIC ARREST; GROWTH-FACTOR; CAMP; INHIBITION; OOCYTES	Cyclic AMP regulates multiple neuronal functions, including neurite outgrowth and axonal regeneration. GPR3, GPR6, and GPR12 make up a family of constitutively active G protein-coupled receptors ( GPCRs) that share greater than 50% identity and 65% similarity at the amino acid level. They are highly expressed in the central nervous system, and their expression in various cell lines results in constitutive stimulation of cAMP production. When the constitutively active GPCRs were overexpressed in rat cerebellar granule neurons in culture, the transfected neurons exhibited significantly enhanced neurite outgrowth and overcame growth inhibition caused by myelin-associated glycoprotein. GPR12-mediated neurite outgrowth was the most prominent and was shown to depend on G(s) and cAMP-dependent protein kinase. Moreover, the GPR12-mediated rescue from myelin- associated glycoprotein inhibition was attributable to cAMP-dependent protein kinase-mediated inhibition of the small GTPase, RhoA. Among the three receptors, GPR3 was revealed to be enriched in the developing rat cerebellar granule neurons. When the endogenous GPR3 was knocked down, significant reduction of neurite growth was observed, which was reversed by expression of either GPR3 or GPR12. Taken together, our results indicate that expression of the constitutively active GPCRs up-regulates cAMP production in neurons, stimulates neurite outgrowth, and counteracts myelin inhibition. Further characterization of the GPCRs in developing and injured mammalian neurons should provide insights into how basal cAMP levels are regulated in neurons and could establish a firm scientific foundation for applying receptor biology to treatment of various neurological disorders.	Ohio State Univ, Med Ctr, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Neurobiol, Columbus, OH 43210 USA; Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo 1608582, Japan	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Keio University	Saeki, Y (corresponding author), Ohio State Univ, Med Ctr, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci, 385B Wiseman Hall CCC,400 W 12th Ave, Columbus, OH 43210 USA.	saeki.6@osu.edu	Tanaka, Shigeru/O-3908-2015; Yoon, Sung Ok/C-5992-2012	Tanaka, Shigeru/0000-0003-3247-9098; 	NINDS NIH HHS [R21 NS44514] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS044514] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200; Bhatt DH, 2004, SCIENCE, V305, P254, DOI 10.1126/science.1098439; Bresnick JN, 2003, ASSAY DRUG DEV TECHN, V1, P239, DOI 10.1089/15406580360545053; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; EGGERICKX D, 1995, BIOCHEM J, V309, P837, DOI 10.1042/bj3090837; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Freudzon L, 2005, J CELL BIOL, V171, P255, DOI 10.1083/jcb.200506194; Gao Y, 2003, J NEUROSCI, V23, P11770; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Hinckley M, 2005, DEV BIOL, V287, P249, DOI 10.1016/j.ydbio.2005.08.019; Ignatov A, 2003, BIOCHEM BIOPH RES CO, V311, P329, DOI 10.1016/j.bbrc.2003.10.006; Ignatov A, 2003, J NEUROSCI, V23, P907; IISMAA TP, 1994, GENOMICS, V24, P391, DOI 10.1006/geno.1994.1635; Kao HT, 2002, NAT NEUROSCI, V5, P431, DOI 10.1038/nn840; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Komuro H, 2003, CELL MOL LIFE SCI, V60, P1084, DOI 10.1007/s00018-003-2248-z; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Leclere PG, 2005, J NEUROSCI METH, V142, P137, DOI 10.1016/j.jneumeth.2004.08.012; Ledent C, 2005, P NATL ACAD SCI USA, V102, P8922, DOI 10.1073/pnas.0503840102; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; LIESI P, 1983, NATURE, V306, P265, DOI 10.1038/306265a0; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; Mehlmann LM, 2004, SCIENCE, V306, P1947, DOI 10.1126/science.1103974; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Qiu J, 2002, PROG BRAIN RES, V137, P381; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SAEKI Y, 1993, FEBS LETT, V336, P317, DOI 10.1016/0014-5793(93)80828-I; Saeki Yoshinaga, 2003, Methods Mol Med, V76, P51; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SONG ZH, 1995, GENOMICS, V28, P347, DOI 10.1006/geno.1995.1154; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Wang Q, 1998, J NEUROSCI, V18, P4973; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	46	87	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10506	10515		10.1074/jbc.M700911200	http://dx.doi.org/10.1074/jbc.M700911200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284443	hybrid			2022-12-27	WOS:000245941000043
J	Wohlwend, D; Strasser, A; Dickmanns, A; Doenecke, D; Ficner, R				Wohlwend, Daniel; Strasser, Anja; Dickmanns, Achim; Doenecke, Detlef; Ficner, Ralf			Thermodynamic analysis of H1 nuclear import - Receptor tuning of importin beta/importin7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN IMPORT; LOCALIZATION SIGNAL; STRUCTURAL BASIS; MAMMALIAN-CELLS; BETA; ALPHA; COMPLEX; RANGTP; DOMAIN	The nuclear import of H1 linker histones is mediated by a heterodimer of transport receptors, known as importin beta and importin7. Interestingly, both importins separately interact with H1, but only as a dimer they facilitate the translocation through the nuclear pore. We identified the H1 binding site of importin7, comprising two extended acidic loops near the C terminus of importin7. The analysis of the H1 import complex assembly by means of isothermal titration calorimetry revealed that the formation of a receptor heterodimer in vitro is an enthalpy-driven process, whereas subsequent binding of H1 to the heterodimer is entropy-driven. Furthermore, we show that the importin beta binding domain of importin7 plays a key role in the activation of importin7 by importin beta. This process is allosterically regulated by importin beta and accounts for a specific tuning of the activity of the importin beta center dot importin7 heterodimer. The results presented here provide new insights into cellular strategies to even energy balances in nuclear import and point toward a general regulation of importin beta-related nuclear import processes.	Univ Gottingen, Abt Mol Strukturbiol, Inst Microbiol & Genet, D-37077 Gottingen, Germany; Univ Gottingen, GZMB, D-37077 Gottingen, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Gottingen, Inst Biochem & Mol Zellbiol, Abt Mol Biol, D-37073 Gottingen, Germany	University of Gottingen; University of Gottingen; European Molecular Biology Laboratory (EMBL); University of Gottingen	Ficner, R (corresponding author), Univ Gottingen, Abt Mol Strukturbiol, Inst Microbiol & Genet, Justus Von Liebig Weg 11, D-37077 Gottingen, Germany.	rficner@gwdg.de						ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bauerle M, 2002, J BIOL CHEM, V277, P32480, DOI 10.1074/jbc.M202765200; Bednenko J, 2003, J CELL BIOL, V162, P391, DOI 10.1083/jcb.200303085; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 2006, CURR OPIN STRUC BIOL, V16, P237, DOI 10.1016/j.sbi.2006.03.010; Conti Elena, 2002, Results Probl Cell Differ, V35, P93; Fassati A, 2003, EMBO J, V22, P3675, DOI 10.1093/emboj/cdg357; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Fukuhara N, 2004, J BIOL CHEM, V279, P2176, DOI 10.1074/jbc.M309112200; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Huber J, 2002, J CELL BIOL, V156, P467, DOI 10.1083/jcb.200108114; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Madrid AS, 2006, CHROMOSOMA, V115, P98, DOI 10.1007/s00412-005-0043-3; Matsuura Y, 2004, NATURE, V432, P872, DOI 10.1038/nature03144; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x	29	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10707	10719		10.1074/jbc.M610409200	http://dx.doi.org/10.1074/jbc.M610409200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17259172	hybrid			2022-12-27	WOS:000245941000065
J	Chen, S; Kim, JJP; Barbieri, JT				Chen, Sheng; Kim, Jung-Ja P.; Barbieri, Joseph T.			Mechanism of substrate recognition by botulinum neurotoxin serotype A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN; CRYSTAL-STRUCTURE; STRUCTURAL-ANALYSIS; CLOSTRIDIUM-BOTULINUM; ANGSTROM RESOLUTION; TETANUS NEUROTOXIN; CATALYTIC DOMAIN; TOXIN; IDENTIFICATION; INHIBITORS	Botulinum neurotoxins (BoNTs) are zinc proteases that cleave SNARE proteins to elicit flaccid paralysis by inhibiting neurotransmitter-carrying vesicle fusion to the plasma membrane of peripheral neurons. Unlike other zinc proteases, BoNTs recognize extended regions of SNAP25 for cleavage; however, the molecular basis for this extended substrate recognition is unclear. Here, we define a multistep mechanism for recognition and cleavage of SNAP25 by BoNT/A. SNAP25 initially binds along the belt region of BoNT/A, which aligns the P5 residue to the S5 pocket at the periphery of the active site. Although the exact order of each step of recognition of SNAP25 by BoNT/A at the active site is not clear, the initial binding could subsequently orient the P4'-residue of SNAP25 to form a salt bridge with the S4'-residue, which opens the active site allowing the P1'-residue access to the S1'-pocket. Subsequent hydrophobic interactions between the P3 residue of SNAP25 and the S3 pocket optimize alignment of the scissile bond for cleavage. This explains how the BoNTs recognize and cleave specific coiled SNARE substrates and provides insight into the development of inhibitors to prevent botulism.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA.	jtb01@mcw.edu		Chen, Sheng/0000-0003-3526-7808	NIAID NIH HHS [U54 AI057153] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057153] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal R, 2005, BIOCHEMISTRY-US, V44, P11758, DOI 10.1021/bi0510072; Agarwal R, 2005, BIOCHEMISTRY-US, V44, P8291, DOI 10.1021/bi050253a; Agarwal R, 2004, BIOCHEMISTRY-US, V43, P6637, DOI 10.1021/bi036278w; Ahmed SA, 2001, J PROTEIN CHEM, V20, P221, DOI 10.1023/A:1010952025677; Arndt JW, 2005, BIOCHEMISTRY-US, V44, P9574, DOI 10.1021/bi0505924; ARNON SS, 1978, LANCET, V1, P1273; Ascher B, 2004, Ann Chir Plast Esthet, V49, P537, DOI 10.1016/j.anplas.2004.09.002; Bajohrs M, 2004, EMBO REP, V5, P1090, DOI 10.1038/sj.embor.7400278; Baldwin MR, 2004, PROTEIN EXPRES PURIF, V37, P187, DOI 10.1016/j.pep.2004.05.009; Bhidayasiri R, 2005, J NEUROL SCI, V235, P1, DOI 10.1016/j.jns.2005.04.017; Binz T, 2002, BIOCHEMISTRY-US, V41, P1717, DOI 10.1021/bi0157969; Boldt GE, 2006, J COMB CHEM, V8, P513, DOI 10.1021/cc060010h; Breidenbach MA, 2005, BIOCHEMISTRY-US, V44, P7450, DOI 10.1021/bi050262j; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Chen S, 2006, J BIOL CHEM, V281, P10906, DOI 10.1074/jbc.M513032200; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Fu ZJ, 2006, BIOCHEMISTRY-US, V45, P8903, DOI 10.1021/bi060786z; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; Klein AW, 2004, DERMATOL CLIN, V22, P197, DOI 10.1016/S0733-8635(03)00122-0; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Mandal A, 2001, EUR J GASTROEN HEPAT, V13, P603, DOI 10.1097/00042737-200105000-00024; Marvaud JC, 2002, CR BIOL, V325, P863, DOI 10.1016/S1631-0691(02)01498-1; Middlebrook JL, 1995, ADV EXP MED BIOL, V383, P93; Min D, 2004, P NATL ACAD SCI USA, V101, P14701, DOI 10.1073/pnas.0404107101; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Parpura V, 2005, CROAT MED J, V46, P491; Poulain B., 2003, Annales de Readaptation et de Medecine Physique, V46, P265, DOI 10.1016/S0168-6054(03)00114-4; Rao KN, 2005, TOXICON, V45, P929, DOI 10.1016/j.toxicon.2005.02.032; Robinson RF, 2003, ANN PHARMACOTHER, V37, P127, DOI 10.1345/aph.1C034; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; Schiavo G, 1995, CURR TOP MICROBIOL, V195, P257; Schmidt JJ, 2005, BIOCHEMISTRY-US, V44, P4067, DOI 10.1021/bi0477642; Segelke B, 2004, P NATL ACAD SCI USA, V101, P6888, DOI 10.1073/pnas.0400584101; Shapiro RL, 1998, ANN INTERN MED, V129, P221, DOI 10.7326/0003-4819-129-3-199808010-00011; Sikorra S, 2006, J MOL BIOL, V357, P574, DOI 10.1016/j.jmb.2005.12.075; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8	39	67	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9621	9627		10.1074/jbc.M611211200	http://dx.doi.org/10.1074/jbc.M611211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244603	hybrid			2022-12-27	WOS:000245421700035
J	Jeyakumar, M; Liu, XF; Erdjument-Bromage, H; Tempst, P; Bagchi, MK				Jeyakumar, M.; Liu, Xue-feng; Erdjument-Bromage, Hediye; Tempst, Paul; Bagchi, Milan K.			Phosphorylation of thyroid hormone receptor-associated nuclear receptor corepressor holocomplex by the DNA-dependent protein kinase enhances its histone deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; N-COR; PROGESTERONE-RECEPTOR; CATALYTIC SUBUNIT; BINDING DOMAIN; LIGASE-III; IN-VITRO; COMPLEX; TRANSCRIPTION; REPRESSION	It is well documented that unliganded thyroid hormone receptor (TR) functions as a transcriptional repressor of specific cellular target genes by acting in concert with a corepressor complex harboring histone deacetylase (HDAC) activity. To fully explore the cofactors that interact with the transcriptionally repressive form of TR, we biochemically isolated a multiprotein complex that assembles on a TR-retinoid X receptor (RXR) heterodimer in HeLa nuclear extracts and identified its polypeptide components by mass spectrometry. A subset of TR-RXRassociated polypeptides included NCoR, SMRT, TBLI, and HDAC3, which represent the core components of a previously described NCoR/SMRT corepressor complex. We also identified several polypeptides that constitute a DNA-dependent protein kinase (DNA-PK) enzyme complex, a regulator of DNA repair, recombination, and transcription. These polypeptides included the catalytic subunit DNA-PKcs, the regulatory subunits Ku70 and Ku86, and the poly(ADP-ribose) polymerase 1. Density gradient fractionation and immunoprecipitation analyses provided evidence for the existence of a high molecular weight TR-RXR-corepressor holocomplex containing both NCoR/SMRT and DNA-PK complexes. Chromatin immunoprecipitation studies confirmed that unliganded TR-RXR recruits both complexes to the triiodothyronine-responsive region of growth hormone gene in vivo. Interestingly, DNAPKcs, a member of the phosphatidylinositol 3-kinase family, was found to phosphorylate HDAC3 when the purified TR-RXR-corepressor holocomplex was incubated with ATP. This phosphorylation was accompanied by a significant enhancement of the HDAC activity of this complex. Collectively, our results indicated that DNA-PK promotes the establishment of a repressive chromatin at a TR target promoter by enhancing the HDAC activity of the receptor-bound NCoR/SMRT corepressor complex.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Illinois System; University of Illinois Urbana-Champaign; Memorial Sloan Kettering Cancer Center	Bagchi, MK (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 534 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	mbagchi@life.uiuc.edu		Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIDDK NIH HHS [DK50257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li QX, 2004, J BIOL CHEM, V279, P11570, DOI 10.1074/jbc.M311773200; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Mortusewicz O, 2006, NUCLEIC ACIDS RES, V34, P3523, DOI 10.1093/nar/gkl492; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Soubeyrand S, 2004, EUR J BIOCHEM, V271, P3776, DOI 10.1111/j.1432-1033.2004.04319.x; Soubeyrand S, 2003, CANCER RES, V63, P1198; SUEN CS, 1994, J BIOL CHEM, V269, P1314; Tong GX, 1996, MOL CELL BIOL, V16, P1909; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; Watrin E, 2006, EXP CELL RES, V312, P2687, DOI 10.1016/j.yexcr.2006.06.024; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; Weinfeld M, 1997, RADIAT RES, V148, P22, DOI 10.2307/3579534; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Yen PM, 2006, MOL CELL ENDOCRINOL, V246, P121, DOI 10.1016/j.mce.2005.11.030; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005	59	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9312	9322		10.1074/jbc.M609009200	http://dx.doi.org/10.1074/jbc.M609009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17242407	hybrid			2022-12-27	WOS:000245421700003
J	Rajala, A; Anderson, RE; Ma, JX; Lem, J; Al-Ubaidi, MR; Rajala, RVS				Rajala, Ammaji; Anderson, Robert E.; Ma, Jian-Xing; Lem, Janis; Al-Ubaidi, Muayyad R.; Rajala, Raju V. S.			G-protein-coupled receptor rhodopsin regulates the phosphorylation of retinal insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR EXPRESSION; TYROSINE PHOSPHORYLATION; CELL-DEATH; PHOTORECEPTOR DEGENERATION; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; ROD PHOTORECEPTORS; IMPAIRED INSULIN; BOUND PROTEIN-14	We have shown previously that phosphoinositide 3-kinase in the retina is activated in vivo through light-induced tyrosine phosphorylation of the insulin receptor (IR). The light effect is localized to photoreceptor neurons and is independent of insulin secretion (Rajala, R. V., McClellan, M. E., Ash, J. D., and Anderson, R. E. (2002) J. Biol. Chem, 277,43319 - 43326). These results suggest that there exists a cross-talk between phototransduction and other signal transduction pathways. In this study, we examined the stage of phototransduction that is coupled to the activation of the IR. We studied IR phosphorylation in mice lacking the rod-specific a-subunit of transducin to determine if phototransduction events are required for IR activation. To confirm that light-induced tyrosine phosphorylation of the IR is signaled through bleachable rhodopsin, we examined IR activation in retinas from RPE65(-/-) mice that are deficient in opsin chromophore. We observed that IR phosphorylation requires the photobleaching of rhodopsin but not transducin signaling. To determine whether the light-dependent activation of IR is mediated through the rod or cone transduction pathway, we studied the IR activation in mice lacking opsin, a mouse model of pure cone function. No light-dependent activation of the IR was found in the retinas of these mice. We provide evidence for the existence of a light-mediated IR pathway in the retina that is different from the known insulin-mediated pathway in nonneuronal tissues. These results suggest that IR phosphorylation in rod photoreceptors is signaled through the G-protein-coupled receptor rhodopsin. This is the first study demonstrating that rhodopsin can initiate signaling pathway(s) in addition to its classical photortransduction.	Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA; Tufts Univ New England Med Ctr, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Tufts Medical Center; Tufts University	Rajala, RVS (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, 608 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	raju-rajala@ouhsc.edu	Gimenez, Luis E Diaz/D-9291-2011		NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017703] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY012190, R01EY000871, R01EY016507, R01EY004149] Funding Source: NIH RePORTER; NCRR NIH HHS [RR17703, P20 RR017703] Funding Source: Medline; NEI NIH HHS [EY016507, EY04149, P30 EY012190, EY00871, EY12190] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alfinito PD, 2002, P NATL ACAD SCI USA, V99, P5655, DOI 10.1073/pnas.072557799; ARSHAVSKY VY, 2003, SCI STKE, pE43; Balasubramanian N, 2003, CURR BIOL, V13, P1306, DOI 10.1016/S0960-9822(03)00511-6; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; BASINGER S, 1976, SCIENCE, V194, P1074, DOI 10.1126/science.1086510; Bell MW, 2000, J NEUROCHEM, V75, P2006, DOI 10.1046/j.1471-4159.2000.0752006.x; Bell MW, 1999, J NEUROCHEM, V73, P2331, DOI 10.1046/j.1471-4159.1999.0732331.x; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; BROEKHUYSE RM, 1985, CURR EYE RES, V4, P613, DOI 10.3109/02713688508999993; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang HY, 2000, SCIENCE, V290, P1978, DOI 10.1126/science.290.5498.1978; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COOK B, 1995, INVEST OPHTH VIS SCI, V36, P990; Cooney GJ, 2004, EMBO J, V23, P582, DOI 10.1038/sj.emboj.7600082; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; de la Monte SM, 2005, J ALZHEIMERS DIS, V7, P45; de la Monte SM, 2004, J ALZHEIMERS DIS, V6, P231; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Ghalayini AJ, 1998, EXP EYE RES, V66, P817, DOI 10.1006/exer.1998.0498; Ghalayini AJ, 2002, J BIOL CHEM, V277, P1469, DOI 10.1074/jbc.M011432200; Hamada J, 2004, FEBS LETT, V557, P204, DOI 10.1016/S0014-5793(03)01493-5; Hardie RC, 2003, CURR BIOL, V13, pR775, DOI 10.1016/j.cub.2003.09.021; HOLLYFIELD JG, 1979, INVEST OPHTH VIS SCI, V18, P117; Hong DH, 2003, INVEST OPHTH VIS SCI, V44, P2413, DOI 10.1167/iovs.02-1206; Jaissle GB, 2001, INVEST OPHTH VIS SCI, V42, P506; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kasahara T, 2002, J NEUROSCI, V22, P7321; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Lev S, 1999, MOL CELL BIOL, V19, P2278; Li F, 2003, INVEST OPHTH VIS SCI, V44, P4968, DOI 10.1167/iovs.03-0140; Li GY, 2007, J NEUROSCI, V27, P203, DOI 10.1523/JNEUROSCI.0445-06.2007; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; *NIH, 1985, GUID CAR US LAB AN; Nouaille S, 2006, EMBO REP, V7, P512, DOI 10.1038/sj.embor.7400668; Nouaille S, 2006, BIOCHEM PHARMACOL, V72, P1355, DOI 10.1016/j.bcp.2006.07.018; ORGANISCIAK DT, 1991, EXP EYE RES, V53, P773, DOI 10.1016/0014-4835(91)90113-S; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; PENN JS, 1987, EXP EYE RES, V44, P779, DOI 10.1016/S0014-4835(87)80041-6; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RAJALA RV, 2006, INVEST OPHTH VIS SCI, V47, P52; Rajala RVS, 2005, BIOCHEMISTRY-US, V44, P15461, DOI 10.1021/bi0513148; Rajala RVS, 2005, BIOCHEMISTRY-US, V44, P7929, DOI 10.1021/bi0500271; Rajala RVS, 2004, BIOCHEMISTRY-US, V43, P5637, DOI 10.1021/bi035913v; Rajala RVS, 2003, MOL NEUROBIOL, V28, P123, DOI 10.1385/MN:28:2:123; Rajala RVS, 2002, J BIOL CHEM, V277, P43319, DOI 10.1074/jbc.M206355200; Rajala RVS, 2001, INVEST OPHTH VIS SCI, V42, P3110; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Reiter CEN, 2006, DIABETES, V55, P1148, DOI 10.2337/diabetes.55.04.06.db05-0744; Reiter CEN, 2003, AM J PHYSIOL-ENDOC M, V285, pE763, DOI 10.1152/ajpendo.00507.2002; Reiter CEN, 2003, PROG RETIN EYE RES, V22, P545, DOI 10.1016/S1350-9462(03)00035-1; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schubert M, 2004, P NATL ACAD SCI USA, V101, P3100, DOI 10.1073/pnas.0308724101; SMITH HG, 1982, METHOD ENZYMOL, V81, P57; Sokolov M, 2004, J BIOL CHEM, V279, P19149, DOI 10.1074/jbc.M311058200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203; Spear N, 1997, J NEUROCHEM, V69, P53; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Strissel KJ, 2005, J BIOL CHEM, V280, P29250, DOI 10.1074/jbc.M501789200; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; Yi XJ, 2005, J NEUROSCI, V25, P1240, DOI 10.1523/JNEUROSCI.3664-04.2005; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200; Zheng LX, 2006, INVEST OPHTH VIS SCI, V47, P5583, DOI 10.1167/iovs.06-0163; ZIMMERMAN WF, 1982, METHOD ENZYMOL, V81, P52	78	37	38	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9865	9873		10.1074/jbc.M608845200	http://dx.doi.org/10.1074/jbc.M608845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272282	hybrid			2022-12-27	WOS:000245421700061
J	Dupont, E; Prochiantz, A; Joliot, A				Dupont, Edmond; Prochiantz, Alain; Joliot, Alain			Identification of a signal peptide for unconventional secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PENETRATING PEPTIDES; ISCHEMIC BRAIN INJURY; PLASMA-MEMBRANE; ANTENNAPEDIA HOMEODOMAIN; 3RD HELIX; PROTEIN; TRANSCYTOSIS; PERMEATION; DELIVERY; PATHWAY	Homeoproteins are a class of transcription factors defined by the structure of their DNA-binding domain, the homeodomain. In addition to their nuclear cell-autonomous activities, homeoproteins transfer between cells, thanks to two separate steps of secretion and internalization, which both rely on unconventional mechanisms. Internalization is driven by the third helix of the homeodomain (Penetratin) through a non-vesicular and endocytosis-independent mechanism. In contrast, homeoprotein secretion involves vesicular compartments and requires the presence of a sequence of 11 amino acids (Sec sequence) spanning between the second and third helix of the homeodomain. In this study, we report that the SecPen polypeptide, which combines the two identified domains, Penetratin and Sec, bears all of the necessary information to go in and out of cells. We have analyzed key mechanisms and demonstrated that this peptide can efficiently cross a tight junction epithelium.	Ecole Normale Super, CNRS, UMR8542, Homeoprot Cell Biol Grp, F-75230 Paris 05, France; Ecole Normale Super, CNRS, UMR8542, Dev & Neuropharmacol Grp, F-75230 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS)	Joliot, A (corresponding author), Ecole Normale Super, CNRS, UMR8542, Homeoprot Cell Biol Grp, 46 Rue Ulm, F-75230 Paris 05, France.	joliot@biologie.ens.fr						Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299; Brunet I, 2005, NATURE, V438, P94, DOI 10.1038/nature04110; Cao GD, 2002, J NEUROSCI, V22, P5423; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DUPONT E, 2002, PHARM TOXIC, P23; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Joliot A, 1998, CURR BIOL, V8, P856, DOI 10.1016/S0960-9822(07)00346-6; Joliot A, 1997, DEVELOPMENT, V124, P1865; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200; Lindgren ME, 2004, BIOCHEM J, V377, P69, DOI 10.1042/BJ20030760; Maizel A, 2002, DEVELOPMENT, V129, P3545; Maizel A, 1999, DEVELOPMENT, V126, P3183; Nedelec S, 2004, P NATL ACAD SCI USA, V101, P10815, DOI 10.1073/pnas.0403824101; NIBBERING PH, 1996, FRONT BIOSCI, V1, P25; Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124; Schafer T, 2004, J BIOL CHEM, V279, P6244, DOI 10.1074/jbc.M310500200; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SUGIYAMA S, 2005, SOC NEUROSCI; Tasssetto M, 2005, EMBO REP, V6, P885, DOI 10.1038/sj.embor.7400487; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Trehin R, 2004, PHARM RES-DORDR, V21, P1248, DOI 10.1023/B:PHAM.0000033013.45204.c3; Tuma PL, 2003, PHYSIOL REV, V83, P871, DOI 10.1152/physrev.00001.2003; Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e; WAN JS, 1992, J BIOL CHEM, V267, P13446; Zhang XP, 2004, MOL PHARMACEUT, V1, P145, DOI 10.1021/mp034014y	29	63	64	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8994	9000		10.1074/jbc.M609246200	http://dx.doi.org/10.1074/jbc.M609246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242404	hybrid			2022-12-27	WOS:000245780300046
J	East, CJ; Stanton, H; Golub, SB; Rogerson, FM; Fosang, AJ				East, Charlotte J.; Stanton, Heather; Golub, Suzanne B.; Rogerson, Fraser M.; Fosang, Amanda J.			ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-INDUCED ARTHRITIS; HUMAN ARTICULAR-CARTILAGE; HUMAN SYNOVIAL-FLUID; MATRIX-METALLOPROTEINASE; INTERGLOBULAR DOMAIN; EXTRACELLULAR-MATRIX; PIVOTAL ROLE; IN-VITRO; PROTEOGLYCAN; DEGRADATION	In the mouse, proteolysis in the aggrecan interglobular domain is driven by ADAMTS-5, and mice deficient in ADAMTS-5 catalytic activity are protected against aggrecan loss and cartilage damage in experimental models of arthritis. Here we show that despite ablation of ADAMTS-5 activity, aggrecanolysis can still occur at two preferred sites in the chondroitin sulfate-rich region. Retinoic acid was more effective than interleukin-1 alpha (IL) in promoting cleavage at these sites in ADAMTS-5-deficient cartilage. These results suggest that cleavage at preferred sites in the chondroitin sulfate-rich region is mediated by ADAMTS-4 or an aggrecanase other than ADAMTS-5. Following retinoic acid or IL-1 alpha stimulation of cartilage explants, aggrecan fragments in medium and extracts contained SELE1279 orFREEE(1467) C-terminal sequences. Some SELE1279 and FREEE1467 fragments were retained in the cartilage, with intact G1 domains. Other SELE1279 fragments were released into the medium and co-migrated with the (374)ALGS neoepitope, indicating they were aggrecanase-derived fragments. In contrast none of the FREEE1467 fragments released into the medium co-migrated with the (374)ALGS neoepitope, suggesting that, despite their size, these fragments were not products of aggrecanase cleavage in the interglobular domain. ADAMTS-5, but not ADAMTS-1, -4, or -9, was up-regulated 8-fold by retinoic acid and 17-fold by IL-1 alpha treatment. The data show that whereas ADAMTS-5 is entirely responsible for cleavage in the interglobular domain, cleavage in the chondroitin sulfate-rich region is driven either by ADAMTS-4, which compensates for loss of ADAMTS-5 in this experimental system, or possibly by another aggrecanase. The data show that there are differential aggrecanase activities with preferences for separate regions of the core protein.	Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Fosang, AJ (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia.	amanda.fosang@mcri.edu.au		Fosang, Amanda/0000-0002-5523-5427; STANTON, HEATHER/0000-0002-3427-5614				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Chockalingam PS, 2004, ARTHRITIS RHEUM-US, V50, P2839, DOI 10.1002/art.20496; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; DENNIS JE, 1990, J BIOL CHEM, V265, P12098; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; Fosang AJ, 2000, J BIOL CHEM, V275, P33027, DOI 10.1074/jbc.M910207199; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; Hui W, 2005, ANN RHEUM DIS, V64, P1624, DOI 10.1136/ard.2004.028191; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Jones GC, 2005, ARTHRITIS RES THER, V7, P160, DOI 10.1186/ar1783; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; Little CB, 2005, ARTHRITIS RHEUM-US, V52, P1461, DOI 10.1002/art.21022; Little CB, 2005, MOL CELL BIOL, V25, P3388, DOI 10.1128/MCB.25.8.3388-3399.2005; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Mercuri FA, 2000, J BIOL CHEM, V275, P33038, DOI 10.1074/jbc.275.42.33038; Mittaz L, 2004, BIOL REPROD, V70, P1096, DOI 10.1095/biolreprod.103.023911; Mort JS, 2003, BIOCHEM SOC SYMP, V70, P107, DOI 10.1042/bss0700107; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; Roughley PJ, 2003, BIOCHEM J, V375, P183, DOI 10.1042/BJ20030609; Sandy J.D., 2000, BIOCHEM J, V351, P1, DOI [10.1042/bj3510161, DOI 10.1042/BJ3510161]; Sandy JD, 1998, BIOCHEM J, V335, P59, DOI 10.1042/bj3350059; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Schmidt EE, 2000, P NATL ACAD SCI USA, V97, P13702, DOI 10.1073/pnas.240471297; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Singer II, 1997, OSTEOARTHR CARTILAGE, V5, P407, DOI 10.1016/S1063-4584(97)80045-3; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Stewart MC, 2006, OSTEOARTHR CARTILAGE, V14, P392, DOI 10.1016/j.joca.2005.11.009; Sugimoto K, 2004, OSTEOARTHR CARTILAGE, V12, P1006, DOI 10.1016/j.joca.2004.09.003; Sztrolovics R, 2002, BIOCHEM J, V362, P473, DOI 10.1042/0264-6021:3620473; Sztrolovics R, 2002, BIOCHEM J, V362, P465, DOI 10.1042/0264-6021:3620465; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; van Meurs J, 1999, J IMMUNOL, V163, P5633; van Meurs JBJ, 1998, ARTHRITIS RHEUM, V41, P647, DOI 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2	55	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8632	8640		10.1074/jbc.M605750200	http://dx.doi.org/10.1074/jbc.M605750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255106	hybrid			2022-12-27	WOS:000245780300009
J	Ivarsson, Y; Travaglini-Allocatelli, C; Jemth, P; Malatesta, F; Brunori, M; Gianni, S				Ivarsson, Ylva; Travaglini-Allocatelli, Carlo; Jemth, Per; Malatesta, Francesco; Brunori, Maurizio; Gianni, Stefano			An on-pathway intermediate in the folding of a PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPSIN INHIBITOR-2; TRANSITION-STATES; KINETIC-ANALYSIS; MECHANISM; BARNASE; BINDING; PROTEINS; EXCHANGE; REVEAL; MODEL	The folding pathways of some proteins include the population of partially structured species en route to the native state. Identification and characterization of these folding intermediates are particularly difficult as they are often only transiently populated and play different mechanistic roles, being either on-pathway productive species or off-pathway kinetic traps. To define the role of folding intermediates, a quantitative analysis of the folding and unfolding rate constants over a wide range of denaturant concentration is often required. Such a task is further complicated by the reversible nature of the folding reaction, which implies the observed kinetics to be governed by a complex combination of different microscopic rate constants. Here, we tackled this problem by measuring directly the folding rate constant under highly denaturing conditions, namely by inducing the folding of a PDZ domain through a quasi-irreversible binding reaction with a specific peptide. In analogy with previous works based on hydrogen exchange experiments, we present evidence that the folding pathway of the PDZ domain involves the formation of an obligatory on-pathway intermediate. The results presented exemplify a novel type of kinetic test to detect an on-pathway folding intermediate.	Univ Roma La Sapienza, Ist Biol & Patol Mol, CNR, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Univ Aquila, Dept Pure & Appl Biol, I-67010 Coppito, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Uppsala University; University of L'Aquila	Gianni, S (corresponding author), Univ Roma La Sapienza, Ist Biol & Patol Mol, CNR, Dipartimento Sci Biochim A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	stefano.gianni@uniromal.it	Malatesta, Francesco/AAT-4757-2020; Ivarsson, Ylva/HGE-0283-2022; gianni, stefano/C-8536-2009	Ivarsson, Ylva/0000-0002-7081-3846; Gianni, Stefano/0000-0003-1653-1925; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126; Brunori, Maurizio/0000-0002-7795-1635				BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; Feng HQ, 2005, J MOL BIOL, V346, P345, DOI 10.1016/j.jmb.2004.11.040; Ferraro DM, 2004, BIOCHEMISTRY-US, V43, P587, DOI 10.1021/bi035943y; Fersht AR, 2000, P NATL ACAD SCI USA, V97, P14121, DOI 10.1073/pnas.260502597; Gianni S, 2005, J BIOL CHEM, V280, P34805, DOI 10.1074/jbc.M506017200; Gianni S, 2005, PROTEIN ENG DES SEL, V18, P389, DOI 10.1093/protein/gzi047; Gianni S, 2007, P NATL ACAD SCI USA, V104, P128, DOI 10.1073/pnas.0602770104; Gianni S, 2006, STRUCTURE, V14, P1801, DOI 10.1016/j.str.2006.10.010; Hedberg L, 2004, P NATL ACAD SCI USA, V101, P7606, DOI 10.1073/pnas.0308497101; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; Khan F, 2003, J MOL BIOL, V333, P169, DOI 10.1016/j.jmb.2003.08.024; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Krantz BA, 2002, J MOL BIOL, V324, P359, DOI 10.1016/S0022-2836(02)01029-X; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OLSON ST, 1981, J BIOL CHEM, V256, P1073; Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; RODER H, 1985, BIOCHEMISTRY-US, V24, P7396, DOI 10.1021/bi00346a055; Sanchez IE, 2003, J MOL BIOL, V325, P367, DOI 10.1016/S0022-2836(02)01230-5; SANZ JM, 1994, FEBS LETT, V344, P216, DOI 10.1016/0014-5793(94)00384-X; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Takei L, 2000, P NATL ACAD SCI USA, V97, P10796, DOI 10.1073/pnas.190265797; Teilum K, 2002, P NATL ACAD SCI USA, V99, P9807, DOI 10.1073/pnas.152321499; Ternstrom T, 1999, P NATL ACAD SCI USA, V96, P14854, DOI 10.1073/pnas.96.26.14854	30	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8568	8572		10.1074/jbc.M611026200	http://dx.doi.org/10.1074/jbc.M611026200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17251182	hybrid			2022-12-27	WOS:000245780300002
J	Melchers, J; Dirdjaja, N; Ruppert, T; Krauth-Siegel, RL				Melchers, Johannes; Dirdjaja, Natalie; Ruppert, Thomas; Krauth-Siegel, R. Luise			Glutathionylation of trypanosomal thiol redox proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MONOTHIOL GLUTAREDOXIN; THIOLTRANSFERASE GLUTAREDOXIN; TRYPAREDOXIN PEROXIDASES; TRYPANOTHIONE REDUCTASE; CRITHIDIA-FASCICULATA; THIOREDOXIN REDUCTASE; AFRICAN TRYPANOSOMES; BRUCEI TRYPAREDOXIN; S-THIOLATION	Trypanosomatids, the causative agents of several tropical diseases, lack glutathione reductase and thioredoxin reductase but have a trypanothione reductase instead. The main low molecular weight thiols are trypanothione (N-1,N-8-bis(glutathionyl)spermidine) and glutathionyl-spermidine, but the parasites also contain free glutathione. To elucidate whether trypanosomes employ S-thiolation for regulatory or protection purposes, six recombinant parasite thiol redox proteins were studied by ESI-MS and MALDI-TOF-MS for their ability to form mixed disulfides with glutathione or glutathionylspermidine. Trypanosoma brucei mono-Cys-glutaredoxin 1 is specifically thiolated at Cys(181). Thiolation of this residue induced formation of an intramolecular disulfide bridge with the putative active site Cys(104). This contrasts with mono-Cys-glutaredoxins from other sources that have been reported to be glutathionylated at the active site cysteine. Both disulfide forms of the T. brucei protein were reduced by tryparedoxin and trypanothione, whereas glutathione cleaved only the protein disulfide. In the glutathione peroxidase-type tryparedoxin peroxidase III of T. brucei, either Cys(47) or Cys(95) became glutathionylated but not both residues in the same protein molecule. T. brucei thioredoxin contains a third cysteine (Cys(68)) in addition to the redox active dithiol/disulfide. Treatment of the reduced protein with GSSG caused glutathionylation of Cys(68), which did not affect its capacity to catalyze reduction of insulin disulfide. Reduced T. brucei tryparedoxin possesses only the redox active Cys(32)-Cys(35) couple, which upon reaction with GSSG formed a disulfide. Also glyoxalase II and Trypanosoma cruzi trypanothione reductase were not sensitive to thiolation at physiological GSSG concentrations.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 504, D-69120 Heidelberg, Germany.	krauth-siegel@bzh.uni-heidelberg.de	Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266				Alves R, 2004, PROTEINS, V57, P481, DOI 10.1002/prot.20228; Andersen JF, 1997, BIOCHEMISTRY-US, V36, P13979, DOI 10.1021/bi971004s; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Budde H, 2003, BIOL CHEM, V384, P1305, DOI 10.1515/BC.2003.146; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; Comini M, 2005, J BIOL CHEM, V280, P6850, DOI 10.1074/jbc.M404486200; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Deponte M, 2005, BIOL CHEM, V386, P33, DOI 10.1515/BC.2005.005; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Fernandes AP, 2005, J BIOL CHEM, V280, P24544, DOI 10.1074/jbc.M500678200; Fladvad M, 2005, J BIOL CHEM, V280, P24553, DOI 10.1074/jbc.M500679200; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Friemann R, 2003, FEBS LETT, V554, P301, DOI 10.1016/S0014-5793(03)01173-6; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Irsch T, 2004, J BIOL CHEM, V279, P22209, DOI 10.1074/jbc.M401240200; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Krauth-Siegel RL, 2005, ANGEW CHEM INT EDIT, V44, P690, DOI 10.1002/anie.200300639; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; Michelet L, 2005, P NATL ACAD SCI USA, V102, P16478, DOI 10.1073/pnas.0507498102; Motyka SA, 2006, J BIOL CHEM, V281, P18499, DOI 10.1074/jbc.M602880200; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Onn I, 2004, EUKARYOT CELL, V3, P277, DOI 10.1128/EC.3.2.277-287.2004; Oza SL, 2003, MOL BIOCHEM PARASIT, V131, P25, DOI 10.1016/S0166-6851(03)00176-2; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; Reckenfelderbaumer N, 2002, J BIOL CHEM, V277, P17548, DOI 10.1074/jbc.M112115200; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rist W, 2005, ANAL BIOCHEM, V342, P160, DOI 10.1016/j.ab.2004.11.043; Schlecker T, 2005, J BIOL CHEM, V280, P14385, DOI 10.1074/jbc.M413338200; Schmidt H, 2003, J BIOL CHEM, V278, P46329, DOI 10.1074/jbc.M305338200; Shahi SK, 2002, MOL MICROBIOL, V43, P1129, DOI 10.1046/j.1365-2958.2002.02831.x; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; SHIM H, 1988, J GEN MICROBIOL, V134, P807; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; TABOR H, 1975, J BIOL CHEM, V250, P2648; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Wilkinson SR, 2003, J BIOL CHEM, V278, P31640, DOI 10.1074/jbc.M303035200; Wyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504	54	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8678	8694		10.1074/jbc.M608140200	http://dx.doi.org/10.1074/jbc.M608140200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242409	hybrid			2022-12-27	WOS:000245780300014
J	Yueh, MF; Tukey, RH				Yueh, Mei-Fei; Tukey, Robert H.			Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT RESPONSE ELEMENT; ARYL-HYDROCARBON RECEPTOR; GLUTAMATE-CYSTEINE LIGASE; OXIDATIVE STRESS; X-RECEPTOR; UDP-GLUCURONOSYLTRANSFERASES; HEPATIC EXPRESSION; NUCLEAR RECEPTOR; AH RECEPTOR	The formation of beta-D-glucopyranosides (glucuronides) by the UDP-glucuronosyltransferases (UGTs) is a significant metabolic pathway that facilitates the elimination of small hydrophobic molecules such as drugs, dietary constituents, steroids, and bile acids. We elucidate here that an anti-oxidative response leads to induction of UGT1A1 through the Nrf2-Keap1 pathway. When human HepG2 cells were treated with the prooxidants tent-butylhydroquinone and beta-naphthoflavone, cellular UGT1A1 glucuronidation activities were increased. The induction of UGT1A1 proceeded following the overexpression of Nrf2 and was blocked following overexpression of Keap1, demonstrating that Keap1 suppresses Nrf2 activation of the UGT1A1 gene. Loss of function analysis for Nrf2 conducted by small interfering RNA revealed that induction of UGT1A1 was not seen in Nrf2 knock-out cells. To examine the contribution of oxidants toward the regulation of human UGT1A1 in vivo, transgenic mice bearing the human UGT1 locus (Tg-UGT1) were treated with tert-butylhydroquinone. Human UGT1A1 was markedly increased in small and large intestines as well as in liver. Gene mapping experiments including transfections of UGT1A1 reporter gene constructs into HepG2 cells coupled with functional analysis of Nrf2 expression and binding to antioxidant-response elements (ARE) resulted in identification of an ARE in the phenobarbital-response enhancer module region of the UGT1A1 gene. The ARE flanks the recently identified Ah receptor xenobiotic-responsive element. The results suggest that Nrf2-Keap1-dependent UGT1A1 induction by prooxidants might represent a key adaptive response to cellular oxidative stress that defends against a variety of environmental insults, including electrophile attacks and chemical carcinogenesis.	Univ Calif San Diego, Lab Environm Toxicol, Dept Biochem & Chem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Tukey, RH (corresponding author), Univ Calif San Diego, Lab Environm Toxicol, Dept Biochem & Chem, Leichtag Biomed Res Bldg,9500 Gilman Dr, La Jolla, CA 92093 USA.	rtukey@ucsd.edu			NIEHS NIH HHS [ES10337] Funding Source: Medline; NIGMS NIH HHS [GM49135] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS NH, 1993, CHEM-BIOL INTERACT, V86, P255, DOI 10.1016/0009-2797(93)90101-4; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Auyeung DJ, 2003, MOL PHARMACOL, V63, P119, DOI 10.1124/mol.63.1.119; BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; Barbier O, 2003, J BIOL CHEM, V278, P32852, DOI 10.1074/jbc.M305361200; Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen SJ, 2005, J BIOL CHEM, V280, P37547, DOI 10.1074/jbc.M506683200; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Frank C, 2003, J BIOL CHEM, V278, P43299, DOI 10.1074/jbc.M305186200; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gregory PA, 2004, TOXICOL APPL PHARM, V199, P354, DOI 10.1016/j.taap.2004.01.008; Holtzclaw WD, 2004, ADV ENZYME REGUL, V44, P335, DOI 10.1016/j.advenzreg.2003.11.013; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Ma Q, 2004, BIOCHEM J, V377, P205, DOI 10.1042/BJ20031123; Mackenzie PI, 2005, PHARMACOGENET GENOM, V15, P677, DOI 10.1097/01.fpc.0000173483.13689.56; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; Ritter JK, 1999, HEPATOLOGY, V30, P476, DOI 10.1002/hep.510300205; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Sugatani J, 2005, MOL PHARMACOL, V67, P845, DOI 10.1124/mol.104.007161; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Verreault M, 2006, HEPATOLOGY, V44, P368, DOI 10.1002/hep.21259; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xu CJ, 2006, MOL CANCER THER, V5, P1918, DOI 10.1158/1535-7163.MCT-05-0497; Yang HP, 2002, J BIOL CHEM, V277, P35232, DOI 10.1074/jbc.M203812200; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; Yueh MF, 2005, METHOD ENZYMOL, V400, P75, DOI 10.1016/S0076-6879(05)00005-4; Yueh MF, 2003, J BIOL CHEM, V278, P15001, DOI 10.1074/jbc.M300645200	42	112	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8749	8758		10.1074/jbc.M610790200	http://dx.doi.org/10.1074/jbc.M610790200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259171	hybrid			2022-12-27	WOS:000245780300021
J	Jones, RJ; Dickerson, S; Bhende, PM; Delecluse, HJ; Kenney, SC				Jones, Richard J.; Dickerson, Sarah; Bhende, Prassana M.; Delecluse, Henri-Jacque; Kenney, Shannon C.			Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY PROTEIN; EPITHELIAL-CELLS; VITAMIN-A; HUMAN CYTOMEGALOVIRUS; ZTA TRANSACTIVATOR; LATENT INFECTION; PLASMA-CELLS; EXPRESSION; DIFFERENTIATION; REPLICATION	Lytic Epstein-Barr virus (EBV) replication occurs in differentiated, but not undifferentiated, epithelial cells. Retinoic acid (RA) induces epithelial cell differentiation. The conversion of retinol into its active form, retinoic acid, requires retinol dehydrogenase enzymes. Here we show that AGS gastric carcinoma cells containing the lytic form of EBV infection have enhanced expression of a gene (DHRS9) encoding an enzyme that mediates conversion of retinol into RA. DHRS9 expression is also increased following induction of lytic viral infection in EBVpositive Burkitt lymphoma cells. We demonstrate that the EBV immediate-early protein, BZLF1, activates the DHRS9 promoter through a direct DNA binding mechanism. Furthermore, BZLF1 expression in AGS cells is sufficient to activate DHRS9 gene expression and increases the ability of retinol to induce the RA-responsive gene, CYP26A1. Production of RA during the lytic form of EBV infection may enhance viral replication by promoting keratinocyte differentiation.	Univ Wisconsin, McArdle Lab Canc Res, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA; Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA; German Canc Res Ctr, D-69009 Heidelberg, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Helmholtz Association; German Cancer Research Center (DKFZ)	Kenney, SC (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Dept Med, Rm 421A,1400 Univ Ave, Madison, WI 53706 USA.	skenney@wisc.edu		Delecluse, Henri-Jacques/0000-0002-1744-6274	NCI NIH HHS [P01-CA19014, R01-CA66519, R01-CA58853] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066519, R01CA058853, P01CA019014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGULO A, 1995, J VIROL, V69, P3831, DOI 10.1128/JVI.69.6.3831-3837.1995; Bhende PM, 2004, NAT GENET, V36, P1099, DOI 10.1038/ng1424; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Faluhelyi Z, 2004, ANTICANCER RES, V24, P807; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; Feng WH, 2004, JNCI-J NATL CANCER I, V96, P1691, DOI 10.1093/jnci/djh313; Feng WH, 2004, J VIROL, V78, P1893, DOI 10.1128/JVI.78.4.1893-1902.2004; Ghazal P, 1997, REV MED VIROL, V7, P21, DOI 10.1002/(SICI)1099-1654(199704)7:1<21::AID-RMV179>3.0.CO;2-Q; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GONCZOL E, 1984, SCIENCE, V224, P159, DOI 10.1126/science.6322309; GREENSPAN D, 1984, LANCET, V2, P831; GUDAS LJ, 1994, RETINOIDS BIOL CHEM; Hong GK, 2005, J VIROL, V79, P13993, DOI 10.1128/JVI.79.22.13993-14003.2005; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; KARIMI L, 1995, J GEN VIROL, V76, P759, DOI 10.1099/0022-1317-76-4-759; Klaassen I, 2001, BRIT J CANCER, V85, P630, DOI 10.1054/bjoc.2001.1952; Laichalk LL, 2005, J VIROL, V79, P1296, DOI 10.1128/JVI.79.2.1296-1307.2005; Lampen A, 2000, J PHARMACOL EXP THER, V295, P979; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; Li YL, 2004, J VIROL, V78, P4197, DOI 10.1128/JVI.78.8.4197-4206.2004; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; Marill J, 2003, CURR DRUG METAB, V4, P1, DOI 10.2174/1389200033336900; Morikawa K, 2005, INT IMMUNOPHARMACOL, V5, P1830, DOI 10.1016/j.intimp.2005.06.002; Morrison TE, 2004, VIROLOGY, V328, P219, DOI 10.1016/j.virol.2004.07.020; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Neuhierl B, 2006, J VIROL, V80, P5078, DOI 10.1128/JVI.80.10.5078-5081.2006; Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769; Ozpolat B, 2002, AM J HEMATOL, V70, P39, DOI 10.1002/ajh.10099; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; RICKINSON AB, 2001, FIELDS VIROLOGY; Sarisky RT, 1996, J VIROL, V70, P8340, DOI 10.1128/JVI.70.12.8340-8347.1996; Shimizu N, 1996, J VIROL, V70, P7260, DOI 10.1128/JVI.70.10.7260-7263.1996; SHYU RY, 1995, EUR J CANCER, V31A, P237, DOI 10.1016/0959-8049(94)00481-J; SISTA ND, 1993, P NATL ACAD SCI USA, V90, P3894, DOI 10.1073/pnas.90.9.3894; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIZEMORE N, 1993, CANCER RES, V53, P4511; Soref CM, 2001, J BIOL CHEM, V276, P24194, DOI 10.1074/jbc.M100332200; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; WOLFF D, 1994, VIROLOGY, V204, P101, DOI 10.1006/viro.1994.1514; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200	48	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8317	8324		10.1074/jbc.M608667200	http://dx.doi.org/10.1074/jbc.M608667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244623	hybrid			2022-12-27	WOS:000245081000065
J	Briggs, GS; McEwan, PA; Yu, J; Moore, T; Emsley, J; Lloyd, RG				Briggs, Geoffrey S.; McEwan, Paul A.; Yu, Jing; Moore, Timothy; Emsley, Jonas; Lloyd, Robert G.			Ring structure of the Escherichia coli DNA-binding protein RdgC associated with recombination and replication fork repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT GROWTH; RECA; BETA; STRAINS; CLAMP	The DNA-binding protein, RdgC, is associated with recombination and replication fork repair in Escherichia coli and with the virulence- associated, pilin antigenic variation mediated by RecA and other recombination proteins in Neisseria species. We solved the structure of the E. coli protein and refined it to 2.4 angstrom. RdgC crystallizes as a dimer with a head-to-head, tail-to-tail organization forming a ring with a 30 angstrom diameter hole at the center. The protein fold is unique and reminiscent of a horseshoe with twin gates closing the open end. The central hole is lined with positively charged residues and provides a highly plausible DNA binding channel consistent with the nonspecific mode of binding detected in vitro and with the ability of RdgC to modulate RecA function in vivo.	Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England; Univ Nottingham, Ctr Biomol Sci, Sch Pharm, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Lloyd, RG (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England.	bob.lloyd@nottingham.ac.uk	emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030; mcewan, paul/0000-0001-6097-1528; Briggs, Geoff/0000-0002-4149-8752; Yu, Jing/0000-0001-8001-8494	MRC [G9806167] Funding Source: UKRI; Medical Research Council [G9806167] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cox MM, 2007, NAT REV MOL CELL BIO, V8, P127, DOI 10.1038/nrm2099; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Drees JC, 2006, J BIOL CHEM, V281, P4708, DOI 10.1074/jbc.M513592200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; EVANS P, 1993, CCP4 DARESBURY STUDY, P114; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Mahdi AA, 2006, GENE DEV, V20, P2135, DOI 10.1101/gad.382306; Mehr IJ, 2000, GENETICS, V154, P523; Moore T, 2004, J BACTERIOL, V186, P870, DOI 10.1128/JB.186.3.870-874.2004; Moore T, 2003, EMBO J, V22, P735, DOI 10.1093/emboj/cdg048; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ryder L, 1996, GENETICS, V143, P1101; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tessmer I, 2005, J MOL BIOL, V350, P254, DOI 10.1016/j.jmb.2005.04.043; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999	24	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12353	12357		10.1074/jbc.C700023200	http://dx.doi.org/10.1074/jbc.C700023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17308310	hybrid			2022-12-27	WOS:000245942800002
J	Gong, Q; Weide, M; Huntsman, C; Xu, ZJ; Jan, LY; Ma, D				Gong, Qiang; Weide, Michael; Huntsman, Christopher; Xu, Zhuojin; Jan, Lily Y.; Ma, Dzwokai			Identification and characterization of a new class of trafficking motifs for controlling clathrin-independent internalization and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; EXCHANGE FACTOR; K+ CHANNEL; CELLS; ARF6; PROTEINS; DISTINCT; EFA6; MACROPINOCYTOSIS	Plasma membrane proteins such as receptors and ion channels allow a cell to communicate with its environment and regulate many intracellular activities. Thus, the proper control of the surface number of these proteins is essential for maintaining the structural and functional homeostasis of a cell. Internalization and recycling plays a key role in determining the surface density of receptors and channels. Whereas the clathrin-mediated internalization and its associated recycling have been the focus of research in this field, recent studies have revealed that an increasing number of receptors and channels enter a cell via clathrin-independent pathways. However, little is known about the trafficking motifs involved in controlling clathrin-independent internalization and various associated recycling pathways. By using a potassium channel as a model system, we identified a class of trafficking motifs that function along a clathrin-independent pathway to increase the surface density of a membrane protein by preventing its rapid internalization and/or facilitating its recycling via the ADP-ribosylation factor 6-dependent recycling pathway. Moreover our data suggest that these motifs may enhance the association of membrane proteins with the EFA6 family of guanine nucleotide exchange factors for ADP-ribosylation factor	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Ma, D (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	ma@lifesci.ucsb.edu	Gong, Qiang/D-5337-2009; Gong, Qiang/H-3234-2014	/0000-0002-6129-2938; Jan, Lily/0000-0003-3938-8498				Benmerah A, 1999, J CELL SCI, V112, P1303; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Cardelli J, 2001, TRAFFIC, V2, P311, DOI 10.1034/j.1600-0854.2001.002005311.x; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Crump CM, 2001, EMBO J, V20, P2191, DOI 10.1093/emboj/20.9.2191; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Decressac S, 2004, EMBO REP, V5, P1171, DOI 10.1038/sj.embor.7400292; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Derrien V, 2002, J CELL SCI, V115, P2867; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Dobrzynski H, 2001, J HISTOCHEM CYTOCHEM, V49, P1221, DOI 10.1177/002215540104901004; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Hu KL, 2003, NEURON, V38, P417, DOI 10.1016/S0896-6273(03)00256-3; Kass RS, 2005, J CLIN INVEST, V115, P1986, DOI 10.1172/JCI26011; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Peters M, 2003, KIDNEY INT, V64, P923, DOI 10.1046/j.1523-1755.2003.00153.x; RACOOSIN EL, 1993, J CELL BIOL, V121, P1011, DOI 10.1083/jcb.121.5.1011; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Richards DA, 2003, NEURON, V39, P529, DOI 10.1016/S0896-6273(03)00405-7; Rodman JS, 2000, J CELL SCI, V113, P183; Sakagami H, 2006, BRAIN RES, V1093, P1, DOI 10.1016/j.brainres.2006.02.058; SANDVIG K, 1991, CELL BIOL INT REP, V15, P3, DOI 10.1016/0309-1651(91)90077-V; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wilkinson RS, 2004, TRENDS NEUROSCI, V27, P171, DOI 10.1016/j.tins.2004.01.011; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	42	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13087	13097		10.1074/jbc.M700767200	http://dx.doi.org/10.1074/jbc.M700767200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331948	hybrid			2022-12-27	WOS:000245942800077
J	Pauff, JM; Hemann, CF; Junemann, N; Leimkuhler, S; Hille, R				Pauff, James M.; Hemann, Craig F.; Juenemann, Nora; Leimkuehler, Silke; Hille, Russ			The role of arginine 310 in catalysis and substrate specificity in xanthine dehydrogenase from Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-MECHANISM; CRYSTAL-STRUCTURES; MOLYBDENUM; OXIDASE	The rapid reaction kinetics of wild-type xanthine dehydrogenase from Rhodobacter capsulatus and variants at Arg-310 in the active site have been characterized for a variety of purine substrates. With xanthine as substrate, k(red) (the limiting rate of enzyme reduction by substrate at high [S]) decreased similar to 20-fold in an R310K variant and 2 x 10(4)-fold in an R310M variant. Although Arg-310 lies on the opposite end of the substrate from the C-8 position that becomes hydroxylated, its interaction with substrate still contributed similar to 4.5 kcal/mol toward transition state stabilization. The other purines examined fell into two distinct groups: members of the first were effectively hydroxylated by the wild-type enzyme but were strongly affected by the exchange of Arg-310 to methionine (with a reduction in kred greater than 10(3)), whereas members of the second were much less effectively hydroxylated by wild-type enzyme but also much less significantly affected by the amino acid exchanges (with a reduction in kred less than 50-fold). The effect was such that the 4000-fold range in kred seen with wild-type enzyme was reduced to a mere 4-fold in the R310M variant. The data are consistent with a model in which "good" substrates are bound "correctly" in the active site in an orientation that allows Arg-310 to stabilize the transition state for the first step of the overall reaction via an electrostatic interaction at the C-6 position, thereby accelerating the reaction rate. On the other hand, "poor" substrates bound upside down relative to this "correct" orientation. In so doing, they are unable to avail themselves of the additional catalytic power provided by Arg-310 in wild-type enzyme but, for this reason, are significantly less affected by mutations at this position. The kinetic data thus provide a picture of the specific manner in which the physiological substrate xanthine is oriented in the active site relative to Arg-310 and how this residue is used catalytically to accelerate the reaction rate (rather than simply bind substrate) despite being remote from the position that is hydroxylated.	Univ Potsdam, Inst Biochem & Biol, D-14476 Potsdam, Germany; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University of Potsdam; University System of Ohio; Ohio State University	Leimkuhler, S (corresponding author), Univ Potsdam, Inst Biochem & Biol, D-14476 Potsdam, Germany.	sleim@uni-potsdam.de; hille.1@osu.edu		Hemann, Craig/0000-0002-7380-4072; Leimkuhler, Silke/0000-0003-3238-2122	NIGMS NIH HHS [GM 075036] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075036] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonin I, 2004, STRUCTURE, V12, P1425, DOI 10.1016/j.str.2004.05.014; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Hille R, 2005, ARCH BIOCHEM BIOPHYS, V433, P107, DOI 10.1016/j.abb.2004.08.012; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Hille R, 2002, TRENDS BIOCHEM SCI, V27, P360, DOI 10.1016/S0968-0004(02)02107-2; Hille R, 2006, EUR J INORG CHEM, P1913, DOI 10.1002/ejic.200600087; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 2004, J BIOL CHEM, V279, P40437, DOI 10.1074/jbc.M405778200; Leimkuhler S, 2003, J BIOL CHEM, V278, P20802, DOI 10.1074/jbc.M303091200; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; Okamoto K, 2004, P NATL ACAD SCI USA, V101, P7931, DOI 10.1073/pnas.0400973101; Stockert AL, 2002, J AM CHEM SOC, V124, P14554, DOI 10.1021/ja027388d; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; Yamaguchi Y, 2007, J BIOCHEM, V141, P513, DOI 10.1093/jb/mvm053	16	33	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12785	12790		10.1074/jbc.M700364200	http://dx.doi.org/10.1074/jbc.M700364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327224	hybrid			2022-12-27	WOS:000245942800049
J	Cowart, LA; Hannun, YA				Cowart, L. Ashley; Hannun, Yusuf A.			Selective substrate supply in the regulation of yeast de novo sphingolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STRESS RESPONSE; MEMBRANE H+-ATPASE; LONG-CHAIN BASES; SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; PLASMA-MEMBRANE; INDUCE APOPTOSIS; FREE SPHINGOSINE; PALMITIC ACID; STEARIC-ACID	The heat stress response of Saccharomyces cerevisiae is characterized by transient cell cycle arrest, altered gene expression, degradation of nutrient permeases, trehalose accumulation, and translation initiation of heat shock proteins. Importantly heat stress also induces de novo sphingolipid synthesis upon which many of these subprograms of the heat stress response depend. Despite extensive data addressing the roles for sphingolipids in heat stress, the mechanism( s) by which heat induces sphingolipid synthesis remains unknown. This study was undertaken to determine the events and/or factors required for heat stress-induced sphingolipid synthesis. Data presented indicate that heat does not directly alter the in vitro activity of serine palmitoyltransferase ( SPT), the enzyme responsible for initiating de novo sphingolipid synthesis. Moreover deletion of the small peptide Tsc3p, which is thought to maximize SPT activity, specifically reduced production of C-20 sphingolipid species by over 70% but did not significantly decrease overall sphingoid base production. In contrast, the fatty-acid synthase inhibitor cerulenin nearly completely blocked sphingoid base production after heat, indicating a requirement for endogenous fatty acids for heat-mediated sphingoid base synthesis. Consistent with this, genetic studies show that fatty acid import does not contribute to heat-induced de novo synthesis under normal conditions. Interestingly the absence of medium serine also ameliorated heat-induced sphingoid base production, indicating a requirement for exogenous serine for the response, and consistent with this finding, disruption of synthesis of endogenous serine did not affect heat-induced sphingolipid synthesis. Serine uptake assays indicated that heat increased serine uptake from medium by 100% during the first 10 min of heat stress. Moreover treatments that increase serine uptake in the absence of heat including acute medium acidification and glucose treatment also enhanced de novo sphingoid base synthesis equivalent to that induced by heat stress. These data agree with findings from mammalian systems that availability of substrates is a key determinant of flux through sphingolipid synthesis. Moreover data presented here indicate that SPT activity can be driven by several factors that increase serine uptake in the absence of heat. These findings may provide insights into the many systems in which de novo synthesis is increased in the absence of elevated in vitro SPT activity.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	hannun@musc.edu			NIGMS NIH HHS [GM63265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albers E, 2003, J BIOL CHEM, V278, P10264, DOI 10.1074/jbc.M211692200; Aouida M, 2005, J BIOL CHEM, V280, P24267, DOI 10.1074/jbc.M503071200; Assimacopoulos-Jeannet F, 2004, INT J OBESITY, V28, pS53, DOI 10.1038/sj.ijo.0802857; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Cowart LA, 2006, BIOCHEM J, V393, P733, DOI 10.1042/BJ20050643; Cowart LA, 2003, J BIOL CHEM, V278, P30328, DOI 10.1074/jbc.M300656200; Dickson RC, 2000, METHOD ENZYMOL, V311, P3; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Dickson RC, 2006, PROG LIPID RES, V45, P447, DOI 10.1016/j.plipres.2006.03.004; Ferguson-Yankey SR, 2002, YEAST, V19, P573, DOI 10.1002/yea.861; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hans MA, 2003, BIOTECHNOL BIOENG, V82, P143, DOI 10.1002/bit.10553; Inuzuka M, 2005, J BIOL CHEM, V280, P35776, DOI 10.1074/jbc.M505712200; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Jenkins GM, 2002, J BIOL CHEM, V277, P42572, DOI 10.1074/jbc.M207346200; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; KOTYK A, 1994, J MEMBRANE BIOL, V138, P29; Lecchi S, 2005, BIOCHEMISTRY-US, V44, P16624, DOI 10.1021/bi051555f; Lu ZH, 2003, BIOCHEM BIOPH RES CO, V303, P1002, DOI 10.1016/S0006-291X(03)00449-2; Meier KD, 2006, MOL BIOL CELL, V17, P1164, DOI 10.1091/mbc.E05-11-1039; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Monaghan E, 2002, YEAST, V19, P659, DOI 10.1002/yea.864; Moskvina E, 1999, MOL MICROBIOL, V32, P1263, DOI 10.1046/j.1365-2958.1999.01438.x; Mu YM, 2001, ENDOCRINOLOGY, V142, P3590, DOI 10.1210/en.142.8.3590; Nagura M, 2004, LIPIDS, V39, P43, DOI 10.1007/s11745-004-1200-z; Obeid LA, 2002, BBA-MOL CELL BIOL L, V1585, P163, DOI 10.1016/S1388-1981(02)00337-2; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Perry DK, 2002, BBA-MOL CELL BIOL L, V1585, P146, DOI 10.1016/S1388-1981(02)00335-9; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; PIPER PW, 1993, FEMS MICROBIOL REV, V11, P339, DOI 10.1016/0168-6445(93)90005-T; REICH JG, 1981, ENERGY METABOLISM CE; SAHEKI S, 1985, ANAL BIOCHEM, V148, P277, DOI 10.1016/0003-2697(85)90229-5; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Sims KJ, 2004, BIOCHEM CELL BIOL, V82, P45, DOI 10.1139/o03-086; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; SYCHROVA H, 1985, FEBS LETT, V183, P21, DOI 10.1016/0014-5793(85)80945-5; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; VIEGAS CA, 1995, APPL ENVIRON MICROB, V61, P1904, DOI 10.1128/AEM.61.5.1904-1909.1995; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	52	60	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12330	12340		10.1074/jbc.M700685200	http://dx.doi.org/10.1074/jbc.M700685200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322298	hybrid			2022-12-27	WOS:000245941900075
J	Loh, E; Choe, J; Loeb, LA				Loh, Ern; Choe, Juno; Loeb, Lawrence A.			Highly tolerated amino acid substitutions increase the fidelity of Escherichia coli DNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; ACTIVE-SITE; DEOXYRIBONUCLEIC ACID; NUCLEOTIDE SELECTION; REPLICATION FIDELITY; BIOCHEMICAL BASIS; O-HELIX; MUTANTS; MUTATIONS; MECHANISM	Fidelity of DNA synthesis, catalyzed by DNA polymerases, is critical for the maintenance of the integrity of the genome. Mutant polymerases with elevated accuracy ( antimutators) have been observed, but these mainly involve increased exonuclease proofreading or large decreases in polymerase activity. We have determined the tolerance of DNA polymerase for amino acid substitutions in the active site and in different segments of E. coli DNA polymerase I and have determined the effects of these substitutions on the fidelity of DNA synthesis. We established a DNA polymerase I mutant library, with random substitutions throughout the polymerase domain. This random library was first selected for activity. The essentiality of DNA polymerases and their sequence and structural conservation suggests that few amino acid substitutions would be tolerated. However, we report that two-thirds of single base substitutions were tolerated without loss of activity, and plasticity often occurs at evolutionarily conserved regions. We screened 408 members of the active library for alterations in fidelity of DNA synthesis in Escherichia coli expressing the mutant polymerases and carrying a second plasmid containing a beta-lactamase reporter. Mutation frequencies varied from 1/1000- to 1000-fold greater compared with wild type. Mutations that produced an antimutator phenotype were distributed throughout the polymerase domain, with 12% clustered in the M-helix. We confirmed that a single mutation in this segment results in increased base discrimination. Thus, this work identifies the M-helix as a determinant of fidelity and suggests that polymerases can tolerate many substitutions that alter fidelity without incurring major changes in activity.	Univ Washington, Joseph Gottstein Mem Canc Res Lab, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Joseph Gottstein Mem Canc Res Lab, Dept Pathol, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NCI NIH HHS [CA102029] Funding Source: Medline; NIA NIH HHS [AG01751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beard WA, 2003, STRUCTURE, V11, P489, DOI 10.1016/S0969-2126(03)00051-0; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Camps M, 2003, P NATL ACAD SCI USA, V100, P9727, DOI 10.1073/pnas.1333928100; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Ciccarelli FD, 2006, SCIENCE, V311, P1283, DOI 10.1126/science.1123061; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FIJALKOWSKA IJ, 1993, GENETICS, V134, P1023; GILLIN FD, 1976, J BIOL CHEM, V251, P5225; Glick E, 2002, BIOTECHNIQUES, V33, P1136, DOI 10.2144/02335dd08; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo HH, 2004, P NATL ACAD SCI USA, V101, P9205, DOI 10.1073/pnas.0403255101; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kim TW, 2005, P NATL ACAD SCI USA, V102, P15803, DOI 10.1073/pnas.0505113102; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V21, P197, DOI 10.1016/0006-3002(56)90127-5; Kornberg A., 1992, DNA REPLICATION; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Loh E, 2005, DNA REPAIR, V4, P1390, DOI 10.1016/j.dnarep.2005.09.006; Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Miller JH, 1999, J BACTERIOL, V181, P1576, DOI 10.1128/JB.181.5.1576-1584.1999; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; Plosky BS, 2004, CURR OPIN GENET DEV, V14, P113, DOI 10.1016/j.gde.2004.02.002; Rattray AJ, 2003, ANNU REV GENET, V37, P31, DOI 10.1146/annurev.genet.37.042203.132748; REHAKRANTZ LJ, 1977, J MOL BIOL, V116, P99, DOI 10.1016/0022-2836(77)90121-8; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; Shinkai A, 2001, J BIOL CHEM, V276, P46759, DOI 10.1074/jbc.M104780200; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; Singh K, 2003, J BIOL CHEM, V278, P11289, DOI 10.1074/jbc.M211496200; Summerer D, 2005, ANGEW CHEM INT EDIT, V44, P4712, DOI 10.1002/anie.200500047; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Turner RM, 2003, BIOCHEMISTRY-US, V42, P2373, DOI 10.1021/bi026566c; WITKIN EM, 1992, J BACTERIOL, V174, P4166, DOI 10.1128/jb.174.12.4166-4168.1992; Yoshikuni Y, 2006, NATURE, V440, P1078, DOI 10.1038/nature04607; Zheng WJ, 2005, STRUCTURE, V13, P565, DOI 10.1016/j.str.2005.01.017	60	37	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12201	12209		10.1074/jbc.M611294200	http://dx.doi.org/10.1074/jbc.M611294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17301051	hybrid			2022-12-27	WOS:000245941900063
J	Oktay, Y; Dioum, E; Matsuzaki, S; Ding, K; Yan, LJ; Haller, RG; Szweda, LI; Garcia, JA				Oktay, Yavuz; Dioum, Elhadji; Matsuzaki, Satoshi; Ding, Kan; Yan, Liang-Jun; Haller, Ronald G.; Szweda, Luke I.; Garcia, Joseph A.			Hypoxia-inducible factor 2 alpha regulates expression of the mitochondrial aconitase chaperone protein frataxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; ALPHA-KETOGLUTARATE DEHYDROGENASE; REDOX-DEPENDENT MODULATION; HYPOXIA-INDUCIBLE FACTOR; OXIDATIVE DAMAGE; HYDROGEN-PEROXIDE; MAMMALIAN-CELLS; TUMOR-CELLS; MUTANT MICE; IRON	Mice lacking Epas1, encoding the transcription factor Hypoxia-inducible Factor 2 alpha (HIF-2 alpha), exhibit an apparent mitochondrial disease state. Similarities between knock-outs of Epas1 and of Sod2, encoding the mitochondrial antioxidant enzyme manganese superoxide dismutase, led to the identification of Sod2 as a HIF-2 alpha target gene. However, Sod2 levels in Epas1(-/-) liver are intermediate between that of Sod(-/-) and Sod2(-/-) mice, which have subtle or severe phenotypes, respectively. This suggests that additional HIF-2 alpha target genes besides Sod2 contribute to the Epas1(-/-) mitochondrial disease state. To define the nature of the mitochondrial defect in Epas1(-/-) liver, we performed biophysical, biochemical, and molecular studies. In the setting of decreased Sod2 levels and increased oxidative stress, we found reduced respiration, sensitized mitochondrial permeability transition pore opening, intact electron transport chain activities, and impaired mitochondrial aconitase activity. Mitochondrial aconitase protein levels were preserved, whereas mRNA and protein levels for frataxin, the oxidative stress-regulated mitochondrial aconitase chaperone protein, were markedly reduced in Epas1(-/-) livers. The mouse Fxn promoter was preferentially activated by HIF-2 alpha through a consensus HIF-responsive enhancer element. In summary, the studies reveal that Fxn, like Sod2, is a nuclear-encoded, mitochondrial-localized HIF-2 alpha target gene required for optimal mitochondrial homeostasis. These findings expand upon the previously defined role of HIF-2 alpha in the cellular response to oxidative stress and identify a novel link of HIF-2 alpha with mitochondrial homeostasis.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Inst Exercise & Environm Med, Dallas, TX 75231 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Arlington; Oklahoma Medical Research Foundation	Garcia, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joseph.garcia@utsouthwestern.edu	Oktay, Yavuz/G-4794-2015	Oktay, Yavuz/0000-0002-0158-2693; Garcia, Joseph/0000-0002-5621-7538; , Kan/0000-0003-3485-8200; Yan, Liang-Jun/0000-0002-5815-5430	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067154] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL067154] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Armstrong JS, 2004, BIOESSAYS, V26, P894, DOI 10.1002/bies.20071; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Boveris A, 2002, METHOD ENZYMOL, V349, P280, DOI 10.1016/S0076-6879(02)49342-1; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bulteau AL, 2005, P NATL ACAD SCI USA, V102, P5987, DOI 10.1073/pnas.0501519102; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Bulteau AL, 2003, BIOCHEMISTRY-US, V42, P14846, DOI 10.1021/bi0353979; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FISCHER JC, 1985, CLIN CHIM ACTA, V153, P23, DOI 10.1016/0009-8981(85)90135-4; Fiske CH, 1925, J BIOL CHEM, V66, P375; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gong YQ, 2005, AM J PHYSIOL-CELL PH, V288, pC1023, DOI 10.1152/ajpcell.00443.2004; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Greene E, 2005, GENOMICS, V85, P221, DOI 10.1016/j.ygeno.2004.10.013; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; KREBS HA, 1952, BIOCHEM J, V52, P527, DOI 10.1042/bj0520527; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LEE CP, 1995, BBA-MOL BASIS DIS, V1271, P21, DOI 10.1016/0925-4439(95)00005-O; LEE CP, 1968, EUR J BIOCHEM, V3, P385, DOI 10.1111/j.1432-1033.1967.tb19541.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Matecki S, 2002, AM J RESP CELL MOL, V26, P239, DOI 10.1165/ajrcmb.26.2.4581; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Munnich A, 1996, EUR J PEDIATR, V155, P262; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; RACKER E, 1950, BIOCHIM BIOPHYS ACTA, V4, P211, DOI 10.1016/0006-3002(50)90026-6; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sadek HA, 2004, BIOCHEMISTRY-US, V43, P8494, DOI 10.1021/bi049803f; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; SRERE PA, 1969, METHOD ENZYMOL, V13, P245; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Sturm B, 2005, J BIOL CHEM, V280, P6701, DOI 10.1074/jbc.M408717200; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; TAYLOR RW, 1997, ORGANELLE DIS, P341; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Wharton DC., 1967, METHOD ENZYMOL, P245; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yan LJ, 2002, EMBO J, V21, P5164, DOI 10.1093/emboj/cdf528	57	67	67	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11750	11756		10.1074/jbc.M611133200	http://dx.doi.org/10.1074/jbc.M611133200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322295	hybrid			2022-12-27	WOS:000245941900017
J	Tsytsykova, AV; Falvo, JV; Schmidt-Supprian, M; Courtois, G; Thanos, D; Goldfeld, AE				Tsytsykova, Alla V.; Falvo, James V.; Schmidt-Supprian, Marc; Courtois, Gilles; Thanos, Dimitris; Goldfeld, Anne E.			Post-induction, stimulus-specific regulation of tumor necrosis factor mRNA expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NF-KAPPA-B; FACTOR-ALPHA GENE; BRUTONS TYROSINE KINASE; HUMAN MONOCYTIC CELLS; CREB-BINDING-PROTEIN; TOLL-LIKE RECEPTORS; ACTIVATED T-CELLS; IFN-BETA-GENE; TRANSCRIPTION FACTOR; DNA-BINDING	The tumor necrosis factor ( TNF) gene is activated by multiple extracellular signals in a stimulus- and cell type-specific fashion. Based on the presence of kappa B-like DNA motifs in the region upstream of the TNF gene, some have proposed a direct role for NF-kappa B in lipopolysaccharide ( LPS)-induced TNF gene transcription in cells of the monocyte/macrophage lineage. However, we have previously demonstrated a general and critical role for a minimal TNF promoter region bearing only one of the kappa B-like motifs, kappa 3, which is bound by nuclear factor of activated T cell proteins in lymphocytes and fibroblasts in response to multiple stimuli and Ets proteins in LPS-stimulated macrophages. Here, in an effort to resolve these contrasting findings, we used a combination of site-directed mutagenesis of the TNF promoter, quantitative DNase I footprinting, and analysis of endogenous TNF mRNA production in response to multiple stimuli under conditions that inhibit NF-kappa B activation ( using the proteasome inhibitor lactacystin and using cells lacking either functional NF-kappa B essential modulator, which is the I kappa B kinase regulatory subunit, or the Nemo gene itself). We find that TNF mRNA production in response to ionophore is NF-kappa B-independent, but inhibition of NF-kappa B activation attenuates virus- and LPS-induced TNF mRNA levels after initial induction. We conclude that induction of TNF gene transcription by virus or LPS does not depend upon NF-kappa B binding to the proximal promoter; rather, a stimulus- specific post-induction mechanism involving NF-kappa B, yet to be characterized, is involved in the maintenance of maximal TNF mRNA levels.	CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Hop St Louis, INSERM, F-75015 Paris, France; Biomed Sci Res Ctr Alexander Fleming, Inst Mol Biol & Genet, Athens, Greece; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Alexander Fleming Biomedical Sciences Research Center; Columbia University	Goldfeld, AE (corresponding author), CBR Inst Biomed Res, 800 Huntington Ave, Boston, MA 02115 USA.	goldfeld@cbrinstitute.org	Schmidt-Supprian, Marc/F-5893-2011; Goldfeld, Anne/AAF-1818-2019; Thanos, Dimitris/AAE-5720-2019	Schmidt-Supprian, Marc/0000-0002-8543-6166; COURTOIS, Gilles/0000-0003-3117-9595	NIGMS NIH HHS [GM076685] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076685] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADERKA D, 1986, J IMMUNOL, V136, P2938; Aggarwal B.B., 1995, HUMAN CYTOKINES THEI; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Andreakos E, 2004, BLOOD, V103, P2229, DOI 10.1182/blood-2003-04-1356; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Berkowitz B, 2002, J BIOL CHEM, V277, P24694, DOI 10.1074/jbc.M200006200; BEUTLER B, 1991, J CLIN INVEST, V87, P1336, DOI 10.1172/JCI115137; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; BOUSSIOTIS VA, 1994, P NATL ACAD SCI USA, V91, P7007, DOI 10.1073/pnas.91.15.7007; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de Diego RP, 2006, J ALLERGY CLIN IMMUN, V117, P1462, DOI 10.1016/j.jaci.2006.01.037; Diaz B, 2000, J INTERF CYTOK RES, V20, P741, DOI 10.1089/10799900050116453; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; DROUET C, 1991, J IMMUNOL, V147, P1694; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Escalante CR, 2002, STRUCTURE, V10, P383, DOI 10.1016/S0969-2126(02)00723-2; Falvo JV, 2000, P NATL ACAD SCI USA, V97, P3925, DOI 10.1073/pnas.97.8.3925; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; Frankenberger M, 1997, IMMUNOBIOLOGY, V198, P81, DOI 10.1016/S0171-2985(97)80029-0; GEPPERT TD, 1994, MOL MED, V1, P93; GOLDFELD AE, 1992, P NATL ACAD SCI USA, V89, P12198, DOI 10.1073/pnas.89.24.12198; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; Jefferies CA, 2004, IMMUNOL LETT, V92, P15, DOI 10.1016/j.imlet.2003.11.017; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kuprash DV, 1999, J IMMUNOL, V162, P4045; KUPRASH DV, 1995, ONCOGENE, V11, P97; Leung JY, 2000, P NATL ACAD SCI USA, V97, P6614, DOI 10.1073/pnas.97.12.6614; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; MAINS PE, 1983, SOMAT CELL GENET, V9, P699, DOI 10.1007/BF01539475; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Donnell PM, 2002, J INTERF CYTOK RES, V22, P539, DOI 10.1089/10799900252982016; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREDE NS, 1995, J IMMUNOL, V155, P902; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Tsytsykova AV, 2000, J EXP MED, V192, P581, DOI 10.1084/jem.192.4.581; Tsytsykova AV, 2002, MOL CELL BIOL, V22, P2620, DOI 10.1128/MCB.22.8.2620-2631.2002; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	102	27	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11629	11638		10.1074/jbc.M611418200	http://dx.doi.org/10.1074/jbc.M611418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17303559	hybrid			2022-12-27	WOS:000245941900004
J	Chen, WJ; Lam, SS; Srinath, H; Schiffer, CA; Royer, WE; Lin, K				Chen, Weijun; Lam, Suvana S.; Srinath, Hema; Schiffer, Celia A.; Royer, William E., Jr.; Lin, Kai			Competition between Ski and CREB-binding protein for binding to Smad proteins in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; CRYSTAL-STRUCTURE; CELL-MEMBRANE; CO-REPRESSOR; RECEPTOR; ONCOPROTEIN; ACTIVATION; PHOSPHORYLATION; DOMAIN; COACTIVATORS	The family of Smad proteins mediates transforming growth factor-beta (TGF-beta) signaling in cell growth and differentiation. Smads repress or activate TGF-beta signaling by interacting with corepressors ( e. g. Ski) or coactivators ( e. g. CREB-binding protein (CBP)), respectively. Specifically, Ski has been shown to interfere with the interaction between Smad3 and CBP. However, it is unclear whether Ski competes with CBP for binding to Smads and whether they can interact with Smad3 at the same binding surface on Smad3. We investigated the interactions among purified constructs of Smad, Ski, and CBP in vitro by size-exclusion chromatography, isothermal titration calorimetry, and mutational studies. Here, we show that Ski-(16 - 192) interacted directly with a homotrimer of receptor-regulated Smad protein ( R-Smad), e. g. Smad2 or Smad3, to form a hexamer; Ski-( 16 - 192) interacted with an R- Smad . Smad4 heterotrimer to form a pentamer. CBP-(1941 - 1992) was also found to interact directly with an R- Smad homotrimer to form a hexamer and with an R- Smad . Smad4 heterotrimer to form a pentamer. Moreover, these domains of Ski and CBP competed with each other for binding to Smad3. Our mutational studies revealed that domains of Ski and CBP interacted with Smad3 at a portion of the binding surface of the Smad anchor for receptor activation. Our results suggest that Ski negatively regulates TGF-beta signaling by replacing CBP in R-Smad complexes. Our working model suggests that Smad protein activity is delicately balanced by Ski and CBP in the TGF-beta pathway.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Chen, WJ (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, 364 Plantat St, Worcester, MA 01605 USA.	Weijun.Chen@umassmed.edu; William.Royer@umassmed.edu	Chen, Wei/GZK-7348-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056080] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 056080, R01 AI056080] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Inoue Y, 2007, ONCOGENE, V26, P500, DOI 10.1038/sj.onc.1209826; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Warner DR, 2003, CELL SIGNAL, V15, P235, DOI 10.1016/S0898-6568(02)00082-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	38	28	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11365	11376		10.1074/jbc.M700186200	http://dx.doi.org/10.1074/jbc.M700186200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17283070	hybrid			2022-12-27	WOS:000245941500059
J	Lee, WL; Cosio, G; Ireton, K; Grinstein, S				Lee, Warren L.; Cosio, Gabriela; Ireton, Keith; Grinstein, Sergio			Role of CrkII in Fc gamma receptor-mediated phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; ADAPTER PROTEINS; APOPTOTIC CELLS; RHO-GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLSERINE RECEPTOR; RAC-GEF; ACTIVATION; MEMBRANE; COMPLEX	Phagocytosis of IgG-opsonized pathogens by Fc gamma receptors requires extensive remodeling of the actin cytoskeleton, a process regulated by the small GTPase Rac. Vav was thought to be the guanine nucleotide exchange factor responsible for the activation of Rac, but recent evidence indicates that Fc gamma receptor-mediated phagocytosis is unaffected in macrophages lacking all three isoforms of Vav. We therefore tested whether another GEF, DOCK180, participates in Fc gamma receptor-initiated phagocytosis. DOCK180 associates with the adaptor protein Crk, which mediates recruitment of the GEF to sites of tyrosine phosphorylation. CrkII and DOCK180 were found to accumulate at the phagocytic cup. Knockdown of Crk or DOCK180 in murine macrophages using small interfering RNA inhibited phagocytosis of IgG-opsonized particles. Moreover, transfection of dominant negative CrkII prevented both recruitment of DOCK180 and the activation of Rac at the phagocytic cup. This is the first report of a role for either Crk or DOCK180 in Fc gamma receptor-mediated phagocytosis. The Crk-DOCK180 complex is involved in the clearance of apoptotic cells, which unlike the ingestion of IgG-opsonized particles, is an anti-inflammatory process. The finding that CrkII-DOCK180 is also responsible, at least in part, for the effects of Fc gamma receptors implies that additional, parallel pathways must account for the associated pro-inflammatory effect.	Hosp Sick Children, Programme Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Interdept Div Crit Care Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Div Respirol, Toronto, ON M5S 1A8, Canada; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; State University System of Florida; University of Central Florida	Grinstein, S (corresponding author), Hosp Sick Children, Programme Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca		Lee, Warren/0000-0002-1788-6587				Akakura S, 2005, J CELL PHYSIOL, V204, P344, DOI 10.1002/jcp.20288; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Castellano F, 2000, J CELL SCI, V113, P2955; Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P1092; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Hall AB, 2006, IMMUNITY, V24, P305, DOI 10.1016/j.immuni.2006.02.005; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Maderna P, 2003, BBA-MOL BASIS DIS, V1639, P141, DOI 10.1016/j.bbadis.2003.09.004; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scott CC, 2005, J CELL BIOL, V169, P139, DOI 10.1083/jcb.200412162; Sun H, 2005, CELL MICROBIOL, V7, P443, DOI 10.1111/j.1462-5822.2004.00475.x; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Wang XC, 2003, SCIENCE, V302, P1563, DOI 10.1126/science.1087641; YAMAMOTO K, 1984, J EXP MED, V159, P405, DOI 10.1084/jem.159.2.405	37	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11135	11143		10.1074/jbc.M700823200	http://dx.doi.org/10.1074/jbc.M700823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308335	hybrid			2022-12-27	WOS:000245941500034
J	Lippert, U; Diao, D; Barak, NN; Ferrari, DM				Lippert, Undine; Diao, Daojun; Barak, Naomi N.; Ferrari, David M.			Conserved structural and functional properties of D-domain containing redox-active and -inactive protein disulfide isomerase-related protein chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING SITE; RETICULUM-LUMENAL PROTEIN; QUALITY-CONTROL; B' DOMAIN; ERP29; FAMILY; IDENTIFICATION; LOCALIZATION; MEMBER; WIND	The structure and mode of binding of the endoplasmic reticulum protein disulfide isomerase-related proteins to their substrates is currently a focus of intensive research. We have recently determined the crystal structure of the Drosophila melanogaster protein disulfide isomerase-related protein Wind and have described two essential substrate binding sites within the protein, one within the thioredoxin b-domain and another within the C-terminal D-domain. Although a mammalian ortholog of Wind ( ERp29/28) is known, conflicting interpretations of its structure and putative function have been postulated. Here, we have provided evidence indicating that ERp29 is indeed similar in both structure and function to its Drosophila ortholog. Using a site-directed mutagenesis approach, we have demonstrated that homodimerization of the b-domains is significantly reduced in vitro upon replacement of key residues at the predicted dimerization interface. Investigation of Wind-ERp29 fusion constructs showed that mutants of the D-domain of ERp29 prevent transport of a substrate protein ( Pipe) in a manner consistent with the presence of a discrete, conserved peptide binding site in the D-domain. Finally, we have highlighted the general applicability of these findings by showing that the D-domain of a redox-active disulfide isomerase, from the slime mold Dictyostelium discoideum, can also functionally replace the Wind D-domain in vivo.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany; Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Univ Gottingen, Dept Cardiol & Pneumol, D-37075 Gottingen, Germany	Max Planck Society; Max Planck Society; University of Gottingen	Ferrari, DM (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle, Germany.	ferrari@enzyme-halle.mpg.de						Barnewitz K, 2004, J BIOL CHEM, V279, P39829, DOI 10.1074/jbc.M406839200; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FERRARI DM, 1999, ISOLATION CHARACTERI; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Hermann VM, 2005, J BIOL CHEM, V280, P13529, DOI 10.1074/jbc.M410889200; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Ma QJ, 2003, J BIOL CHEM, V278, P44600, DOI 10.1074/jbc.M307966200; Mayer M, 2003, J MOL BIOL, V330, P137, DOI 10.1016/S0022-2836(03)00556-4; Mkrtchiana S, 1998, FEBS LETT, V431, P322, DOI 10.1016/S0014-5793(98)00786-8; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Monnat J, 2000, MOL BIOL CELL, V11, P3469, DOI 10.1091/mbc.11.10.3469; Monnat J, 1997, FEBS LETT, V418, P357, DOI 10.1016/S0014-5793(97)01415-4; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sargsyan E, 2002, J BIOL CHEM, V277, P17009, DOI 10.1074/jbc.M200539200; Sen J, 2000, DEVELOPMENT, V127, P5541; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P191, DOI 10.1080/10409230591008161	26	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11213	11220		10.1074/jbc.M604440200	http://dx.doi.org/10.1074/jbc.M604440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17296603	hybrid, Green Published			2022-12-27	WOS:000245941500043
J	Shalak, V; Guigou, L; Kaminska, M; Wautier, MP; Wautier, JL; Mirande, M				Shalak, Vyacheslav; Guigou, Ludovic; Kaminska, Monika; Wautier, Marie-Paule; Wautier, Jean-Luc; Mirande, Marc			Characterization of p43(ARF), a derivative of the p43 component of multiaminoacyl-tRNA synthetase complex released during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-POLYPEPTIDE-II; ENDOTHELIAL-CELLS; MULTISYNTHETASE COMPLEX; CYTOKINE; PROTEIN; TRANSLATION; MECHANISMS; EXPRESSION; PRECURSOR; DOMAIN	In human, nine aminoacyl tRNA synthetases are associated with the three auxiliary proteins, p18, p38, and p43, to form a stable multiprotein complex. The p43 component, which has a potent tRNA binding capacity, is associated to the complex via its N-terminal moiety. This protein is also the precursor of the endothelial monocyte-activating polypeptide II (p43(EMAPII), corresponding to the C-terminal moiety of p43), a cytokine generated during apoptosis. Here we examined the cellular pathway that, starting from the p43 subunit of the complex, leads to this extracellular cytokine. We identified a new intermediate in this pathway, named p43(ARF) for Apoptosis-released Factor. This intermediate is produced in cellulo by proteolytic cleavage of endogenous p43 and is rapidly recovered in the culture medium. This p43 derivative was purified from the medium of human U937 cells subjected to serum starvation. It contains 40 additional N-terminal amino acid residues as compared with the cytokine p43(EMAPII) and may be generated by a member of the matrix metalloproteinase family. Recombinant p43(ARF) is a monomer in solution and binds tRNA with a K-d of similar to 6 nM, 30-fold lower than that of p43. Highly purified p43(ARF) or p43(EMAPII) do not stimulate the expression of E-selectin by human umbilical vein endothelial cells. Our results suggest that the cleavage of p43 and its cellular delocalization, and thus the release of this tRNA binding subunit from the complex, is one of the molecular mechanisms leading to the shut down of protein synthesis in apoptosis.	CNRS, Lab Enzymol & Biochim Struct, F-91190 Gif Sur Yvette, France; Univ Paris 07, Inst Natl Transfus Sanguine, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Mirande, M (corresponding author), CNRS, Lab Enzymol & Biochim Struct, 1 Ave Terrasse, F-91190 Gif Sur Yvette, France.	Marc.Mirande@lebs.cnrs-gif.fr	Shalak, Vyacheslav F/D-3707-2015; wautier, marie/ABC-4444-2020; Wautier, Jean-Luc/T-9851-2019	Shalak, Vyacheslav F/0000-0001-6114-6482; WAUTIER, Marie-Paule/0000-0002-9353-5180; WAUTIER, Jean-Luc/0000-0001-6826-2312				Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Barnett G, 2000, CANCER RES, V60, P2850; DELOMENIE C, 1993, EXP CELL RES, V207, P122, DOI 10.1006/excr.1993.1170; Guigou L, 2004, BIOCHEMISTRY-US, V43, P4592, DOI 10.1021/bi036150e; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Kaminska M, 2001, BIOCHEMISTRY-US, V40, P14309, DOI 10.1021/bi015670b; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; KERJAN P, 1994, BBA-GEN SUBJECTS, V1199, P293, DOI 10.1016/0304-4165(94)90009-4; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Ko YG, 2001, J BIOL CHEM, V276, P23028, DOI 10.1074/jbc.M101544200; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Liu J, 2006, EXP CELL RES, V312, P2231, DOI 10.1016/j.yexcr.2006.03.024; MIRANDE M, 2003, AMINOACYL TRNA SYNTH, P298; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Park SG, 2002, J BIOL CHEM, V277, P45243, DOI 10.1074/jbc.M207934200; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; POPENKO VI, 1994, EUR J CELL BIOL, V65, P60; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Renault L, 2001, EMBO J, V20, P570, DOI 10.1093/emboj/20.3.570; Saelens X, 2005, J CELL BIOL, V168, P545, DOI 10.1083/jcb.200407162; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Sampath P, 2004, CELL, V119, P195, DOI 10.1016/j.cell.2004.09.030; Schwarz MA, 1999, J EXP MED, V190, P341, DOI 10.1084/jem.190.3.341; Shalak V, 2001, J BIOL CHEM, V276, P23769, DOI 10.1074/jbc.M100489200; WAUTIER JL, 1981, NEW ENGL J MED, V305, P237, DOI 10.1056/NEJM198107303050501; Wautier MP, 1999, CELL BIOL TOXICOL, V15, P153, DOI 10.1023/A:1007629403123; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403	32	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10935	10943		10.1074/jbc.M611737200	http://dx.doi.org/10.1074/jbc.M611737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303557	hybrid			2022-12-27	WOS:000245941500013
J	Piao, SF; Kim, S; Kim, JH; Park, JW; Lee, BL; Ha, NC				Piao, Shunfu; Kim, Seulki; Kim, Jung Hyun; Park, Ji Won; Lee, Bok Leul; Ha, Nam-Chul			Crystal structure of the serine protease domain of prophenoloxidase activating factor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTALLOGRAPHIC ANALYSIS; COLEOPTERAN INSECT; BINDING; PROTEINASE; REFINEMENT; THROMBIN; MODELS; SYSTEM; TOLL	A family of serine proteases ( SPs) mediates the proteolytic cascades of embryonic development and immune response in invertebrates. These proteases, called easter-type SPs, consist of clip and chymotrypsin-like SP domains. The SP domain of easter-type proteases differs from those of typical SPs in its primary structure. Herein, we report the first crystal structure of the SP domain of easter-type proteases, presented as that of prophenoloxidase activating factor ( PPAF)-I in zymogen form. This structure reveals several important structural features including a bound calcium ion, an additional loop with a unique disulfide linkage, a canyon-like deep active site, and an exposed activation loop. We subsequently show the role of the bound calcium and the proteolytic susceptibility of the activation loop, which occurs in a clip domain-independent manner. Based on biochemical study in the presence of heparin, we suggest that PPAF-III, highly homologous to PPAF-I, contains a surface patch that is responsible for enhancing the catalytic activity through interaction with a nonsubstrate region of a target protein. These results provide insights into an activation mechanism of easter-type proteases in proteolytic cascades, in comparison with the well studied blood coagulation enzymes in mammals.	Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea; Pusan Natl Univ, Res Inst Drug Dev, Pusan 609735, South Korea	Pusan National University; Pusan National University	Ha, NC (corresponding author), Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea.	hnc@pusan.ac.kr						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; DeLano W.L, PYMOL MOL GRAPHICS S; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; O'Brien D., 1993, NATURAL IMMUNE SYSTE, P257; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pechik I, 2006, BIOCHEMISTRY-US, V45, P3588, DOI 10.1021/bi0525369; Pechik I, 2004, P NATL ACAD SCI USA, V101, P2718, DOI 10.1073/pnas.0303440101; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Piao S, 2005, BBA-PROTEINS PROTEOM, V1752, P103, DOI 10.1016/j.bbapap.2005.05.008; Piao SF, 2006, ACTA CRYSTALLOGR F, V62, P771, DOI 10.1107/S1744309106025851; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rose T, 2003, J BIOL CHEM, V278, P11320, DOI 10.1074/jbc.M211820200; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; SIPOS T, 1970, BIOCHEMISTRY-US, V9, P2766, DOI 10.1021/bi00816a003; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9	32	25	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10783	10791		10.1074/jbc.M611556200	http://dx.doi.org/10.1074/jbc.M611556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287215	hybrid			2022-12-27	WOS:000245941000072
J	Fischer, T; Lu, L; Haigler, HT; Langen, R				Fischer, Torsten; Lu, Lucy; Haigler, Harry T.; Langen, Ralf			Annexin B12 is a sensor of membrane curvature and undergoes major curvature-dependent structural changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; MILDLY ACIDIC PH; CRYSTAL-STRUCTURE; HELICAL HAIRPIN; BAR DOMAIN; PHOSPHATIDYLCHOLINE VESICLES; PHOSPHOLIPID-VESICLES; TRANSMEMBRANE HELIX; V BINDING; CALCIUM	The regulation of membrane curvature plays an important role in many membrane trafficking and fusion events. Recent studies have begun to identify some of the proteins involved in controlling and sensing the curvature of cellular membranes. A mechanistic understanding of these processes is limited, however, as structural information for the membrane-bound forms of these proteins is scarce. Here, we employed a combination of biochemical and biophysical approaches to study the interaction of annexin B12 with membranes of different curvatures. We observed selective and Ca2+-independent binding of annexin B12 to negatively charged vesicles that were either highly curved or that contained lipids with negative intrinsic curvature. This novel curvature-dependent membrane interaction induced major structural rearrangements in the protein and resulted in a backbone fold that was different from that of the well characterized Ca2+-dependent membrane-bound form of annexin B12. Following curvature-dependent membrane interaction, the protein retained a predominantly a-helical structure but EPR spectroscopy studies of nitroxide side chains placed at selected sites on annexin B12 showed that the protein underwent inside-out refolding that brought previously buried hydrophobic residues into contact with the membrane. These structural changes were reminiscent of those previously observed following Ca2+- independent interaction of annexins with membranes at mildly acidic pH, yet they occurred at neutral pH in the presence of curved membranes. The present data demonstrate that annexin B12 is a sensor of membrane curvature and that membrane curvature can trigger large scale conformational changes. We speculate that membrane curvature could be a physiological signal that induces the previously reported Ca2+-independent membrane interaction of annexins in vivo.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90033 USA	University of California System; University of California Irvine; University of Southern California	Haigler, HT (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	hhaigler@uci.edu; langen@usc.edu	Haigler, Harry/C-3788-2011		NIGMS NIH HHS [GM 55651, GM 63915] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063915, R01GM055651] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Avila-Sakar AJ, 1998, BBA-PROTEIN STRUCT M, V1387, P103, DOI 10.1016/S0167-4838(98)00111-3; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Crowley JJ, 2005, MOL PHARMACOL, V68, P4, DOI 10.1124/mol.105.012971; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gallop JL, 2006, EMBO J, V25, P2898, DOI 10.1038/sj.emboj.7601174; Gennis R. B., 1989, BIOMEMBRANES MOL STR, DOI [10.1007/978-1-4757-2065-5, DOI 10.1007/978-1-4757-2065-5]; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Golczak Marcin, 2001, FASEB Journal, V15, P1083; GREENHUT SF, 1986, J BIOL CHEM, V261, P3670; Hegde BG, 2006, BIOCHEMISTRY-US, V45, P934, DOI 10.1021/bi052143+; Hofmann A, 2000, J BIOL CHEM, V275, P8072, DOI 10.1074/jbc.275.11.8072; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; Huang H, 2001, BIOCHEMISTRY-US, V40, P4169, DOI 10.1021/bi002346s; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Isas JM, 2005, BIOCHEMISTRY-US, V44, P16435, DOI 10.1021/bi051751m; Isas JM, 2004, J BIOL CHEM, V279, P32492, DOI 10.1074/jbc.M402568200; Isas JM, 2003, J BIOL CHEM, V278, P30227, DOI 10.1074/jbc.M301228200; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jost M, 1997, J CELL SCI, V110, P221; Kim YE, 2005, J BIOL CHEM, V280, P32398, DOI 10.1074/jbc.M505017200; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Ladokhin AS, 2005, BIOCHEMISTRY-US, V44, P3402, DOI 10.1021/bi047805u; Ladokhin AS, 2002, BIOCHEMISTRY-US, V41, P13617, DOI 10.1021/bi0264418; Lambert O, 2004, J BIOL CHEM, V279, P10872, DOI 10.1074/jbc.M313657200; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Lecat S, 2000, J CELL SCI, V113, P2607; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; MACHIDA K, 1980, BIOCHIM BIOPHYS ACTA, V596, P201, DOI 10.1016/0005-2736(80)90355-7; Masuda M, 2006, EMBO J, V25, P2889, DOI 10.1038/sj.emboj.7601176; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; MEERS P, 1994, BIOCHEMISTRY-US, V33, P5829, DOI 10.1021/bi00185a022; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; MEERS P, 1993, BIOCHEMISTRY-US, V32, P11711, DOI 10.1021/bi00094a030; Mukhopadhyay P, 2004, BIOPHYS J, V86, P1601, DOI 10.1016/S0006-3495(04)74227-7; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Patel DR, 2001, BIOCHEMISTRY-US, V40, P7054, DOI 10.1021/bi010345+; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245; Rety S, 2005, J MOL BIOL, V345, P1131, DOI 10.1016/j.jmb.2004.11.015; Rosengarth A, 1998, FEBS LETT, V438, P279, DOI 10.1016/S0014-5793(98)01318-0; Seaton B. A., 1996, ANNEXINS MOL STRUCTU; Sopkova J, 1998, BIOCHEMISTRY-US, V37, P11962, DOI 10.1021/bi980773o; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Turpin E, 1998, BBA-MOL CELL RES, V1402, P115, DOI 10.1016/S0167-4889(97)00151-1; van den Brink-van der Laan E, 2001, BIOCHEMISTRY-US, V40, P9677, DOI 10.1021/bi002903a; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; Weissenhorn W, 2005, J MOL BIOL, V351, P653, DOI 10.1016/j.jmb.2005.06.013; WENG XW, 1993, PROTEIN SCI, V2, P448; Zanotti G, 1998, BIOCHEM J, V329, P101, DOI 10.1042/bj3290101	64	19	20	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9996	10004		10.1074/jbc.M611180200	http://dx.doi.org/10.1074/jbc.M611180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267400	hybrid			2022-12-27	WOS:000245421700074
J	Garcia-Saez, I; DeBonis, S; Lopez, R; Trucco, F; Rousseau, B; Thuery, P; Kozielski, F				Garcia-Saez, Isabel; DeBonis, Salvatore; Lopez, Roman; Trucco, Fernando; Rousseau, Bernard; Thuery, Pierre; Kozielski, Frank			Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE PROTEIN KSP; DIFFRACTION DATA; KINESIN EG5; DESIGN; CONFORMATION; ACTIVATION; MECHANISM; PROGRAM; POTENT	Drugs that target mitotic spindle proteins have been proven useful for tackling tumor growth. Eg5, a kinesin-5 family member, represents a potential target, since its inhibition leads to prolonged mitotic arrest through the activation of the mitotic checkpoint and apoptotic cell death. Monastrol, a specific dihydropyrimidine inhibitor of Eg5, shows stereo-specificity, since predominantly the (S)-, but not the (R)-, enantiomer has been shown to be the biologically active compound in vitro and in cell-based assays. Here, we solved the crystal structure (2.7 angstrom) of the complex between human Eg5 and a new keto derivative of monastrol (named mon-97), a potent antimitotic inhibitor. Surprisingly, we identified the (R)-enantiomer bound in the active site, and not, as for monastrol, the (S)-enantiomer. The absolute configuration of this more active (R)-enantiomer has been unambiguously determined via chemical correlation and x-ray analysis. Unexpectedly, both the R- and the S-forms inhibit Eg5 ATPase activity with IC50 values of 110 and 520 nM (basal assays) and 150 nm and 650 nm (microtubule-stimulated assays), respectively. However, the difference was large enough for the protein to select the (R)- over the (S)-enantiomer. Taken together, these results show that in this new monastrol family, both (R)- and (S)-enantiomers can be active as Eg5 inhibitors. This considerably broadens the alternatives for rational drug design.	UJF, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Moteurs Mol, F-38027 Grenoble, France; CEA Saclay, Grp Chim Combinatoire & Criblage Haut Debit, Serv Marquage Mol & Chim Bioorgan, F-91191 Gif Sur Yvette, France; CEA Saclay, Serv Chim Mol, DSM, DRECAM, F-91191 Gif Sur Yvette, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Kozielski, F (corresponding author), UJF, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Moteurs Mol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	frank.kozielski@ibs.fr	Thuery, Pierre/A-7429-2009					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bergnes G, 2005, CURR TOP MED CHEM, V5, P127, DOI 10.2174/1568026053507697; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Cochran JC, 2005, J BIOL CHEM, V280, P12658, DOI 10.1074/jbc.M413140200; Cochran JC, 2005, BIOCHEMISTRY-US, V44, P16633, DOI 10.1021/bi051724w; Cox CD, 2006, BIOORG MED CHEM LETT, V16, P3175, DOI 10.1016/j.bmcl.2006.03.040; Cox CD, 2005, BIOORG MED CHEM LETT, V15, P2041, DOI 10.1016/j.bmcl.2005.02.055; Crevel IMTC, 2004, CURR BIOL, V14, pR411, DOI 10.1016/j.cub.2004.05.030; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; DeLano W.L, PYMOL MOL GRAPHICS S; Dondoni A, 2002, TETRAHEDRON LETT, V43, P5913, DOI 10.1016/S0040-4039(02)01269-8; FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762; Fraley ME, 2006, BIOORG MED CHEM LETT, V16, P1775, DOI 10.1016/j.bmcl.2006.01.030; Gartner M, 2005, CHEMBIOCHEM, V6, P171, DOI 10.1002/cbic.200400195; Huang YJ, 2005, J AM CHEM SOC, V127, P16386, DOI 10.1021/ja056092f; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kappe CO, 2000, EUR J MED CHEM, V35, P1043, DOI 10.1016/S0223-5234(00)01189-2; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kim KS, 2006, BIOORG MED CHEM LETT, V16, P3937, DOI 10.1016/j.bmcl.2006.05.037; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leizerman I, 2004, CELL MOL LIFE SCI, V61, P2060, DOI 10.1007/s00018-004-4074-3; LOPEZ R, 2005, Patent No. 02518; Luo LS, 2004, BIOCHEMISTRY-US, V43, P15258, DOI 10.1021/bi048282t; Maiti R, 2004, NUCLEIC ACIDS RES, V32, pW590, DOI 10.1093/nar/gkh477; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Maliga Z, 2006, J BIOL CHEM, V281, P7977, DOI 10.1074/jbc.M511955200; Manju K, 1998, TETRAHEDRON-ASYMMETR, V9, P3365, DOI 10.1016/S0957-4166(98)00347-4; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nitta R, 2004, SCIENCE, V305, P678, DOI 10.1126/science.1096621; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rosenfeld SS, 2005, J BIOL CHEM, V280, P35684, DOI 10.1074/jbc.M506561200; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V81; Sheldrick G.M., 1997, SHELXS97 SHELXL97; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Tarby CM, 2006, BIOORG MED CHEM LETT, V16, P2095, DOI 10.1016/j.bmcl.2006.01.056; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074	44	66	68	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9740	9747		10.1074/jbc.M608883200	http://dx.doi.org/10.1074/jbc.M608883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251189	hybrid			2022-12-27	WOS:000245421700048
J	Stevens, C; Lin, Y; Sanchez, M; Amin, E; Copson, E; White, H; Durston, V; Eccles, DM; Hupp, T				Stevens, Craig; Lin, Yao; Sanchez, Maria; Amin, Eliana; Copson, Ellen; White, Helen; Durston, Vicky; Eccles, Diana M.; Hupp, Ted			A germ line mutation in the death domain of DAPK-1 inactivates ERK-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-DEATH; P53 PATHWAY; EXPRESSION; POLYMORPHISM; TRANSCRIPTION; RECEPTOR; CANCER; PHOSPHORYLATION; ACETYLATION	p53 is activated genetically by a set of kinases that are components of the calcium calmodulin kinase superfamily, including CHK2, AMP kinase, and DAPK-1. In dissecting the mechanism of DAPK-1 control, a novel mutation (N1347S) was identified in the death domain of DAPK-1. The N1347S mutation prevented the death domain module binding stably to ERK in vitro and in vivo. Gel filtration demonstrated that the N1347S mutation disrupted the higher order oligomeric nature of the purified recombinant death domain miniprotein. Accordingly, the N1347S death domain module is defective in vivo in the formation of high molecular weight oligomeric intermediates after crosslinking with ethylene glycol bis(succinimidylsuccinate). Full-length DAPK-1 protein harboring a N1347S mutation in the death domain was also defective in binding to ERK in cells and was defective in formation of an ethylene glycol bis(succinimidylsuccinate)cross-linked intermediate in vivo. Full-length DAPK-1 encoding the N1347S mutation was attenuated in tumor necrosis factor receptor-induced apoptosis. However, the N1347S mutation strikingly prevented ERK: DAPK-1-dependent apoptosis as defined by poly(ADP-ribose) polymerase cleavage, Annexin V staining, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling imaging. Significant penetrance of the N1347S allele was identified in normal genomic DNA indicating the mutation is germ line, not tumor derived. The frequency observed in genomic DNA was from 37 to 45% for homozygous wild-type, 41 to 47% for heterozygotes, and 12 to 15% for homozygous mutant. These data highlight a naturally occurring DAPK-1 mutation that alters the oligomeric structure of the death domain, de-stabilizes DAPK-1 binding to ERK, and prevents ERK: DAPK-1-dependent apoptosis.	Univ Edinburgh, Canc Res UK P53 Signal Transduct Grp, Edinburgh EH4 2XR, Midlothian, Scotland; Univ Southampton, Southampton SO16 6YD, Hants, England; Salisbury District Hosp, Natl Genet Reference Lab Wessex, Salisbury SP2 8BJ, Wilts, England	University of Edinburgh; University of Southampton; Salisbury District Hospital	Hupp, T (corresponding author), Univ Edinburgh, Canc Res UK P53 Signal Transduct Grp, S Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland.	ted.hupp@ed.ac.uk	Eccles, Diana/K-6327-2019	Eccles, Diana/0000-0002-9935-3169; , yao/0000-0002-0493-0155				Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bialik S, 2004, CELL DEATH DIFFER, V11, P631, DOI 10.1038/sj.cdd.4401386; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brooks LA, 2000, CANCER RES, V60, P6875; Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; Craig AL, 2004, ONCOGENE, V23, P8411, DOI 10.1038/sj.onc.1208035; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie JJ, 2005, CANCER LETT, V217, P221, DOI 10.1016/j.canlet.2004.06.025; Harris SL, 2005, P NATL ACAD SCI USA, V102, P16297, DOI 10.1073/pnas.0508390102; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane DR, 2003, DRUG DISCOV TODAY, V8, P347, DOI 10.1016/S1359-6446(03)02669-2; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Levy D, 2004, CLIN CANCER RES, V10, P3124, DOI 10.1158/1078-0432.CCR-03-0213; Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; Murphy ME, 2006, CELL DEATH DIFFER, V13, P916, DOI 10.1038/sj.cdd.4401907; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Velentza AV, 2003, BIOORG MED CHEM LETT, V13, P3465, DOI 10.1016/S0960-894X(03)00733-9; VELENTZA AV, 2002, EXPERT OPIN THER TAR, V6, P497; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wethkamp N, 2006, EUR J CANCER, V42, P264, DOI 10.1016/j.ejca.2005.10.019; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	44	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13791	13803		10.1074/jbc.M605649200	http://dx.doi.org/10.1074/jbc.M605649200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17244621	hybrid			2022-12-27	WOS:000246060300069
J	Blundell, CD; Mahoney, DJ; Cordell, MR; Almond, A; Kahmann, JD; Perczel, A; Taylor, JD; Campbell, ID; Day, AJ				Blundell, Charles D.; Mahoney, David J.; Cordell, Martin R.; Almond, Andrew; Kahmann, Jan D.; Perczel, Andras; Taylor, Jonathan D.; Campbell, Iain D.; Day, Anthony J.			Determining the molecular basis for the pH-dependent interaction between the link module of human TSG-6 and hyaluronan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTER-ALPHA-INHIBITOR; FACTOR-STIMULATED GENE-6; EXTRACELLULAR-MATRIX; PROTEIN TSG-6; ESCHERICHIA-COLI; CHROMOSOMAL LOCALIZATION; INDUCED ARTHRITIS; CELL-INTERACTIONS; BINDING-PROTEINS; HEAVY-CHAINS	TSG-6 is an inflammation-associated hyaluronan (HA)-binding protein that has anti-inflammatory and protective functions in arthritis and asthma as well as a critical role in mammalian ovulation. The interaction between TSG-6 and HA is pH-dependent, with a marked reduction in affinity on increasing the pH from 6.0 to 8.0. Here we have investigated the mechanism underlying this pH dependence using a combined approach of site-directed mutagenesis, NMR, isothermal titration calorimetry and microtiter plate assays. Analysis of single-site mutants of the TSG-6 Link module indicated that the loss in affinity above pH 6.0 is mediated by the change in ionization state of a histidine residue (His(4)) that is not within the HA-binding site. To understand this in molecular terms, the pH-dependent folding profile and the pK(a) values of charged residues within the Link module were determined using NMR. These data indicated that His(4) makes a salt bridge to one side-chain oxygen atom of a buried aspartate residue (Asp(89)), whereas the other oxygen is simultaneously hydrogen-bonded to a key HA-binding residue (Tyr(12)). This molecular network transmits the change in ionization state of His(4) to the HA-binding site, which explains the loss of affinity at high pH. In contrast, simulations of the pH affinity curves indicate that another histidine residue, His(45), is largely responsible for the gain in affinity for HA between pH 3.5 and 6.0. The pH-dependent interaction of TSG-6 with HA (and other ligands) provides a means of differentially regulating the functional activity of this protein in different tissue microenvironments.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Eotvos Lorand Univ, Inst Chem, Prot Modelling Grp, H-1117 Budapest, Hungary; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester; University of Oxford; University of Oxford; Eotvos Lorand University; Hungarian Academy of Sciences; University of Manchester	Day, AJ (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	anthony.day@manchester.ac.uk	Taylor, Jonathan/A-1416-2013; Day, Anthony/O-1658-2015	Taylor, Jonathan/0000-0003-0119-433X; Day, Anthony/0000-0002-1415-3134; Almond, Andrew/0000-0001-7471-6333; Taylor, Jonathan/0000-0002-9797-3989; Blundell, Charles/0000-0002-1439-9126	Wellcome Trust [058154, 063822/Z/01/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Blundell C. D., 2002, HYALURONAN, P161; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; Blundell CD, 2006, BIOCHEM J, V396, P487, DOI 10.1042/BJ20060085; Blundell CD, 2006, ANAL BIOCHEM, V353, P236, DOI 10.1016/j.ab.2006.03.013; Cao TV, 2004, MICROCIRCULATION, V11, P615, DOI 10.1080/10739680490503438; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2005, TRENDS IMMUNOL, V26, P637, DOI 10.1016/j.it.2005.09.009; Day AJ, 1998, WENN GR INT, V72, P141; Day AJ, 2001, CURR OPIN STRUC BIOL, V11, P617, DOI 10.1016/S0959-440X(00)00256-6; FENG P, 1993, J BIOL CHEM, V268, P9387; Forteza R, 2007, AM J RESP CELL MOL, V36, P20, DOI 10.1165/rcmb.2006-0018OC; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; Kahmann JD, 1997, PROTEIN EXPRES PURIF, V9, P315, DOI 10.1006/prep.1996.0694; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Kuznetsova SA, 2005, J BIOL CHEM, V280, P30899, DOI 10.1074/jbc.M500701200; Kuznetsova SA, 2006, J CELL SCI, V119, P4499, DOI 10.1242/jcs.03171; LADBURY JE, 1993, BIOCHEMISTRY-US, V32, P7526, DOI 10.1021/bi00080a026; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Maroudas A., 1980, JOINTS SYNOVIAL FLUI, P239; Milner CM, 2006, BIOCHEM SOC T, V34, P446, DOI 10.1042/BST0340446; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PELTON JG, 1993, PROTEIN SCI, V2, P543; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; SIMKIN PA, 1992, J RHEUMATOL, V19, P1017; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 2005, J BIOL CHEM, V280, P14476, DOI 10.1074/jbc.M411734200; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200	54	28	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12976	12988		10.1074/jbc.M611713200	http://dx.doi.org/10.1074/jbc.M611713200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17307731	hybrid			2022-12-27	WOS:000245942800068
J	DeMorrow, S; Glaser, S; Francis, H; Venter, J; Vaculin, B; Vaculin, S; Alpini, G				DeMorrow, Sharon; Glaser, Shannon; Francis, Heather; Venter, Julie; Vaculin, Bradley; Vaculin, Shelley; Alpini, Gianfranco			Opposing actions of endocannabinoids on cholangiocarcinoma growth - Recruitment of Fas and Fas ligand to lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA(9)-TETRAHYDROCANNABINOL INDUCES APOPTOSIS; RECEPTOR-INDEPENDENT MECHANISM; CANNABINOID CB2 RECEPTOR; SIGNAL-REGULATED KINASE; HUMAN NEUROGLIOMA CELLS; BREAST-CANCER CELLS; MEMBRANE DOMAINS; PROTEIN-KINASE; DEATH RECEPTOR; TUMOR-GROWTH	Cholangiocarcinomas are devastating cancers of biliary origin with limited treatment options. Modulation of the endocannabinoid system is being targeted to develop possible therapeutic strategies for a number of cancers; therefore, we evaluated the effects of the two major endocannabinoids, anandamide and 2-arachidonylglycerol, on numerous cholangiocarcinoma cell lines. Although anandamide was antiproliferative and proapoptotic, 2-arachidonylglycerol stimulated cholangiocarcinoma cell growth. Specific inhibitors for each of the cannabinoid receptors did not prevent either of these effects nor did pretreatment with pertussis toxin, a G(i/o) protein inhibitor, suggesting that anandamide and 2-arachidonylglycerol did not exert their diametric effects through any known cannabinoid receptor or through any other G(i/o) protein-coupled receptor. Using the lipid raft disruptors methyl-beta- cyclodextrin and filipin, we demonstrated that anandamide, but not 2-arachidonylglycerol, requires lipid raft-mediated events to inhibit cellular proliferation. Closer inspection of the lipid raft structures within the cell membrane revealed that although anandamide treatment had no observable effect 2-arachidonylglycerol treatment effectively dissipated the lipid raft structures and caused the lipid raft-associated proteins lyn and flotillin-1 to disperse into the surrounding membrane. In addition, anandamide, but not 2-arachidonylglycerol, induced an accumulation of ceramide, which was required for anandamide-induced suppression of cell growth. Finally we demonstrated that anandamide and ceramide treatment of cholangiocarcinoma cells recruited Fas and Fas ligand into the lipid rafts, subsequently activating death receptor pathways. These findings suggest that modulation of the endocannabinoid system may be a target for the development of possible therapeutic strategies for the treatment of this devastating cancer.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med, Coll Med, Temple, TX 76504 USA; Cent Texas Vet Hlth Care Syst, Temple, TX USA; Scott & White Hosp, Dept Med, Temple, TX USA; Scott & White Hosp, Dept Syst Biol & Translat Med, Temple, TX USA; Scott & White Hosp, Div Res & Educ, Temple, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Alpini, G (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med, Coll Med, Med Res Bldg,702 SWHK Dodgen Loop, Temple, TX 76504 USA.	galpini@tamu.edu			NIDDK NIH HHS [DK062975, K01 DK078532] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK078532, R01DK062975] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Alpini G, 2001, LIVER BIOL PATHOBIOL, V4E, P421; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; ARANCIA G, 1991, PHARMACOL RES, V24, P205, DOI 10.1016/1043-6618(91)90083-A; Arenz C, 2000, ANGEW CHEM INT EDIT, V39, P1440, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1440::AID-ANIE1440>3.0.CO;2-R; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashton JC, 2006, NEUROSCI LETT, V396, P113, DOI 10.1016/j.neulet.2005.11.038; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Bifulco M, 2004, FASEB J, V18, P1606, DOI 10.1096/fj.04-1754fje; Bisogno T, 2005, PHARMACOL BIOCHEM BE, V81, P224, DOI 10.1016/j.pbb.2005.01.027; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; Bollinger CR, 2005, BBA-MOL CELL RES, V1746, P284, DOI 10.1016/j.bbamcr.2005.09.001; BURNS CP, 1988, CANCER INVEST, V6, P439, DOI 10.3109/07357908809080073; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cowart LA, 2002, J LIPID RES, V43, P2042, DOI 10.1194/jlr.M200241-JLR200; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, NEUROBIOL DIS, V5, P386, DOI 10.1006/nbdi.1998.0214; Doherty EM, 2005, J MED CHEM, V48, P71, DOI 10.1021/jm049485i; Fava G, 2005, CANCER RES, V65, P11437, DOI 10.1158/0008-5472.CAN-05-1470; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; GAONI Y, 1971, J AM CHEM SOC, V93, P217, DOI 10.1021/ja00730a036; Gardner B, 2003, FASEB J, V17, P2157, DOI 10.1096/fj.03-0254fje; Giuliano M, 2006, INT J MOL MED, V17, P811; Griffin G, 1999, EUR J PHARMACOL, V377, P117, DOI 10.1016/S0014-2999(99)00402-1; GRUBMAN SA, 1994, AM J PHYSIOL, V266, pG1060, DOI 10.1152/ajpgi.1994.266.6.G1060; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Hinz B, 2004, BIOCHEM BIOPH RES CO, V324, P621, DOI 10.1016/j.bbrc.2004.09.095; Ishii I, 2002, NEUROREPORT, V13, P593, DOI 10.1097/00001756-200204160-00011; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kanno N, 2002, HEPATOLOGY, V35, P1329, DOI 10.1053/jhep.2002.33330; Kanno N, 2001, J HEPATOL, V34, P284, DOI 10.1016/S0168-8278(00)00025-8; Kern A, 2006, J BIOL CHEM, V281, P2405, DOI 10.1074/jbc.M505625200; KNUTH A, 1985, J HEPATOL, V1, P579, DOI 10.1016/S0168-8278(85)80002-7; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kusaka Y, 1988, Hum Cell, V1, P92; LeSage G, 1999, GASTROENTEROLOGY, V117, P191, DOI 10.1016/S0016-5085(99)70567-6; Manzanares J, 1999, TRENDS PHARMACOL SCI, V20, P287, DOI 10.1016/S0165-6147(99)01339-5; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Melck D, 1999, FEBS LETT, V463, P235, DOI 10.1016/S0014-5793(99)01639-7; Mimeault M, 2003, PROSTATE, V56, P1, DOI 10.1002/pros.10190; MIYAGIWA M, 1989, IN VITRO CELL DEV B, V25, P503; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; O'Reilly LA, 2004, CELL DEATH DIFFER, V11, P724, DOI 10.1038/sj.cdd.4401408; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Pickens A, 1999, J GASTROINTEST SURG, V3, P374, DOI 10.1016/S1091-255X(99)80053-5; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Ruiz L, 1999, FEBS LETT, V458, P400, DOI 10.1016/S0014-5793(99)01073-X; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sarnataro D, 2005, FEBS LETT, V579, P6343, DOI 10.1016/j.febslet.2005.10.016; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Shoemaker JL, 2005, J PHARMACOL EXP THER, V315, P828, DOI 10.1124/jpet.105.089474; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sirica AE, 2005, HEPATOLOGY, V41, P5, DOI 10.1002/hep.20537; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; STORTO PD, 1990, GENE CHROMOSOME CANC, V2, P300, DOI 10.1002/gcc.2870020408; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P99; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; Tanaka S, 2000, HEPATOLOGY, V32, P523, DOI 10.1053/jhep.2000.9716; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRITTON TR, 1990, CANCER CELL-MON REV, V2, P95; Vaccani A, 2005, BRIT J PHARMACOL, V144, P1032, DOI 10.1038/sj.bjp.0706134; Voth EA, 1997, ANN INTERN MED, V126, P791, DOI 10.7326/0003-4819-126-10-199705150-00008; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	84	88	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13098	13113		10.1074/jbc.M608238200	http://dx.doi.org/10.1074/jbc.M608238200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329257	hybrid			2022-12-27	WOS:000245942800078
J	Fox, TE; Houck, KL; O'Neill, SM; Nagarajan, M; Stover, TC; Pomianowski, PT; Unal, O; Yun, JK; Naides, SJ; Kester, M				Fox, Todd E.; Houck, Kristy L.; O'Neill, Sean M.; Nagarajan, Murali; Stover, Thomas C.; Pomianowski, Pawel T.; Unal, Onur; Yun, Jong K.; Naides, Stanley J.; Kester, Mark			Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTUMOR CELL-LINES; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; DOMAIN; RAS; INHIBITION; SUPPRESSOR; COMPLEX; BINDING; DIGLYCERIDES	We have previously demonstrated that hexanoyl-D-erythrosphingosine ( C-6-ceramide), an anti-mitogenic cell-permeable lipid metabolite, limited vascular smooth muscle growth by abrogating trauma-induced Akt activity in a stretch injury model of neointimal hyperplasia. Furthermore, ceramide selectively and directly activated protein kinase C zeta ( PKC zeta) to suppress Akt-dependent mitogenesis. To further analyze the interaction between ceramide and PKC zeta, the ability of ceramide to localize within highly structured lipid microdomains ( rafts) and activate PKC zeta was investigated. Using rat aorta vascular smooth muscle cells ( A7r5), we now demonstrate that C-6-ceramide treatment results in an increased localization and phosphorylation of PKC zeta within caveolin-enriched lipid microdomians to inactivate Akt. In addition, ceramide specifically reduced the association of PKC zeta with 14-3-3, a scaffold protein localized to less structured regions within membranes. Pharmacological disruption of highly structured lipid microdomains resulted in abrogation of ceramide-activated, PKC zeta-dependent Akt inactivation, whereas molecular strategies suggest that ceramide-dependent PKC zeta phosphorylation of Akt3 at Ser(34) was necessary for ceramide-induced vascular smooth muscle cell growth arrest. Taken together, these data demonstrate that structured membrane microdomains are necessary for ceramide-induced activation of PKC zeta and resultant diminished Akt activity, leading to vascular smooth muscle cell growth arrest.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol H078, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kester, M (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol H078, Hershey, PA 17033 USA.	mkester@psu.edu	Kester, Mark/ABG-4615-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076789, R01HL066371] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL76789, R01HL66371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; BRIDGES D, 2005, SCI STKE, pRE10, DOI DOI 10.1126/STKE.2962005RE10; Bridges D, 2004, SCI STKE, pre10; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Charles R, 2000, CIRC RES, V87, P282, DOI 10.1161/01.RES.87.4.282; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Christian AE, 1997, J LIPID RES, V38, P2264; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Goswami R, 2005, J NEUROSCI RES, V81, P541, DOI 10.1002/jnr.20550; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Heinrich M, 2000, ADV EXP MED BIOL, V477, P305; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Huwiler A, 2001, FASEB J, V15, P7; Kaga S, 1998, J IMMUNOL, V160, P4182; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kilkus J, 2003, J NEUROSCI RES, V72, P65, DOI 10.1002/jnr.10549; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leroy I, 2005, CELL SIGNAL, V17, P1149, DOI 10.1016/j.cellsig.2004.12.013; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Mandal A, 1997, J BIOL CHEM, V272, P20306, DOI 10.1074/jbc.272.32.20306; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; Rosenfeldt HM, 2001, BIOCHEM SOC T, V29, P836, DOI 10.1042/0300-5127:0290836; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; Sandirasegarane L, 2001, BIOCHEM BIOPH RES CO, V283, P158, DOI 10.1006/bbrc.2001.4739; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200; Tanabe F, 1998, BIOCHEM BIOPH RES CO, V242, P129, DOI 10.1006/bbrc.1997.7934; Wang GH, 2005, J BIOL CHEM, V280, P26415, DOI 10.1074/jbc.M501492200; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	39	134	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12450	12457		10.1074/jbc.M700082200	http://dx.doi.org/10.1074/jbc.M700082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17308302	hybrid			2022-12-27	WOS:000245942800013
J	Steiner, T; Lamerz, AC; Hess, P; Breithaupt, C; Krapp, S; Bourenkov, G; Huber, R; Gerardy-Schahn, R; Jacob, U				Steiner, Thomas; Lamerz, Anne-Christin; Hess, Petra; Breithaupt, Constanze; Krapp, Stephan; Bourenkov, Gleb; Huber, Robert; Gerardy-Schahn, Rita; Jacob, Uwe			Open and closed structures of the UDP-glucose pyrophosphorylase from Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; POTATO-TUBER; BIOCHEMICAL-CHARACTERIZATION; PURIFICATION; TRANSLATION; RESIDUES; CLONING; CDNA	Uridine diphosphate-glucose pyrophosphorylase (UGPase) represents a ubiquitous enzyme, which catalyzes the formation of UDP-glucose, a key metabolite of the carbohydrate pathways of all organisms. In the protozoan parasite Leishmania major, which causes a broad spectrum of diseases and is transmitted to humans by sand fly vectors, UGPase represents a virulence factor because of its requirement for the synthesis of cell surface glycoconjugates. Here we present the crystal structures of the L. major UGPase in its uncomplexed apo form (open conformation) and in complex with UDP-glucose (closed conformation). The UGPase consists of three distinct domains. The N-terminal domain exhibits species-specific differences in length, which might permit distinct regulation mechanisms. The central catalytic domain resembles a Rossmann-fold and contains key residues that are conserved in many nucleotidyltransferases. The C-terminal domain forms a left-handed parallel beta-helix (L beta H), which represents a rarely observed structural element. The presented structures together with mutagenesis analyses provide a basis for a detailed analysis of the catalytic mechanism and for the design of species-specific UGPase inhibitors.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Hannover Med Sch, Abt Zellulare Chem, Zentrum Biochem, D-30625 Hannover, Germany; DESY, MPG, ASMB, Grp Prot Dynam, D-22603 Hamburg, Germany; Salzburg Univ, Forschungszentrum Biowissensch & Gesundheit, A-5020 Salzburg, Austria; Cardiff Univ, Sch Biosci & Chem, Cardiff CF10 3TL, Wales	Max Planck Society; Hannover Medical School; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Salzburg University; Cardiff University	Steiner, T (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18, D-82152 Martinsried, Germany.	steiner@biochem.mpg.de	Bourenkov, Gleb P/C-7794-2017	Bourenkov, Gleb P/0000-0002-2617-5920				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Bonofiglio L, 2005, CURR MICROBIOL, V51, P217, DOI 10.1007/s00284-005-4466-0; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang HY, 1996, EUR J BIOCHEM, V236, P723, DOI 10.1111/j.1432-1033.1996.t01-1-00723.x; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; ELLING L, 1994, J BIOTECHNOL, V34, P157, DOI 10.1016/0168-1656(94)90085-X; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; Geisler M, 2004, PLANT MOL BIOL, V56, P783, DOI 10.1007/s11103-004-4953-x; Genevaux P, 1999, ARCH MICROBIOL, V172, P1, DOI 10.1007/s002030050732; Jin XS, 2005, EMBO J, V24, P694, DOI 10.1038/sj.emboj.7600551; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATSUBE T, 1991, BIOCHEMISTRY-US, V30, P8546, DOI 10.1021/bi00099a008; Krapp S, 2003, J MOL BIOL, V334, P625, DOI 10.1016/j.jmb.2003.09.080; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamerz AC, 2006, J BIOL CHEM, V281, P16314, DOI 10.1074/jbc.M600076200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; Martz F, 2002, BIOCHEM J, V367, P295, DOI 10.1042/BJ20020772; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P528, DOI 10.1093/oxfordjournals.jbchem.a122886; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; ORDIN L, 1968, PLANT PHYSIOL, V43, P473, DOI 10.1104/pp.43.3.473; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Roeben A, 2006, J MOL BIOL, V364, P551, DOI 10.1016/j.jmb.2006.08.079; Rutter J, 2002, CELL, V111, P17, DOI 10.1016/S0092-8674(02)00974-1; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sivaraman J, 2002, J BIOL CHEM, V277, P44214, DOI 10.1074/jbc.M206932200	36	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13003	13010		10.1074/jbc.M609984200	http://dx.doi.org/10.1074/jbc.M609984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17303565	hybrid			2022-12-27	WOS:000245942800070
J	Lande-Diner, L; Zhang, JM; Ben-Porath, I; Amariglio, N; Keshet, I; Hecht, M; Azuara, V; Fisher, AG; Rechavi, G; Cedar, H				Lande-Diner, Laura; Zhang, Jianmin; Ben-Porath, Ittai; Amariglio, Ninette; Keshet, Ilana; Hecht, Merav; Azuara, Veronique; Fisher, Amanda G.; Rechavi, Gideon; Cedar, Howard			Role of DNA methylation in stable gene repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-STRUCTURE; DEVELOPMENTAL PATTERN; TRANSCRIPTION; DEMETHYLATION; INHIBITION; OCT-3/4	A large fraction of the animal genome is maintained in a transcriptionally repressed state throughout development. By generating viable Dnmt1(-/-) mouse cells we have been able to study the effect of DNA methylation on both gene expression and chromatin structure. Our results confirm that the underlying methylation pattern has a profound effect on histone acetylation and is the major effector of me-H3(K4) in the animal genome. We demonstrate that many methylated genes are subject to additional repression mechanisms that also impact on histone acetylation, and the data suggest that late replication timing may play an important role in this process.	Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Ctr Canc Res, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Safra Childrens Hosp, IL-69978 Tel Aviv, Israel; Hammersmith Hosp, Lymphocytes Dev Grp, MRC,Sch Med, Clin Sci Ctr,Imperial Coll, London W12 0NN, England	Hebrew University of Jerusalem; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Imperial College London	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel.	cedar@md.huji.ac.il		Azuara, Veronique/0000-0003-4608-3713	MRC [MC_U120027516] Funding Source: UKRI; Medical Research Council [MC_U120027516] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Azuara V, 2003, NAT CELL BIOL, V5, P668, DOI 10.1038/ncb1006; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; Goren A, 2003, NAT REV MOL CELL BIO, V4, P25, DOI 10.1038/nrm1008; Gribnau J, 2003, GENE DEV, V17, P759, DOI 10.1101/gad.1059603; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Hiratani I, 2004, P NATL ACAD SCI USA, V101, P16861, DOI 10.1073/pnas.0406687101; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Lande-Diner L, 2004, COLD SPRING HARB SYM, V69, P131, DOI 10.1101/sqb.2004.69.131; LANDEDINER L, 2005, NAT REV GENET, V6, P648; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Perry P, 2004, CELL CYCLE, V3, P1645; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; REYNAUD C, 1992, CANCER LETT, V61, P255, DOI 10.1016/0304-3835(92)90296-8; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Zhang JM, 2002, NATURE, V420, P198, DOI 10.1038/nature01150	40	110	117	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12194	12200		10.1074/jbc.M607838200	http://dx.doi.org/10.1074/jbc.M607838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17311920	hybrid			2022-12-27	WOS:000245941900062
J	Rickman, C; Medine, CN; Bergmann, A; Duncan, RR				Rickman, Colin; Medine, Claire N.; Bergmann, Axel; Duncan, Rory R.			Functionally and spatially distinct modes of munc18-syntaxin 1 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE FUSION; SNARE COMPLEX-FORMATION; REGULATED EXOCYTOSIS; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; VPS45P BINDS; PC12 CELLS; SYNTAXIN; PROTEIN; MUNC18	Eukaryotic membrane trafficking is a conserved process under tight temporal and spatial regulation in which the fusion of membranes is driven by the formation of the ternary SNARE complex. Syntaxin 1a, a core component of the exocytic SNARE complex in neurons and neuroendocrine cells, is regulated directly by munc18-1, its cognate Sec1p/munc18 ( SM) protein. SM proteins show remarkable structural conservation throughout evolution, indicating a common binding mechanism and function. However, SM proteins possess disparate binding mechanisms and regulatory effects with munc18-1, the major brain isoform, classed as atypical in both its binding specificity and its mode. We now show that munc18-1 interacts with syntaxin 1a through two mechanistically distinct modes of binding, both in vitro and in living cells, in contrast to current models. Furthermore, these functionally divergent interactions occur at distinct cellular locations. These findings provide a molecular explanation for the multiple, spatially distinct roles of munc18-1.	Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; Becker & Hickl GmbH, D-12277 Berlin, Germany	University of Edinburgh; Becker & Hickl	Duncan, RR (corresponding author), Univ Edinburgh, Ctr Integrat Physiol, George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.	rory.duncan@ed.ac.uk		Rickman, Colin/0000-0001-8938-524X; Duncan, Rory/0000-0003-0693-910X	Wellcome Trust [074146] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Bracher A, 2002, EMBO J, V21, P6114, DOI 10.1093/emboj/cdf608; Bracher A, 2000, STRUCTURE, V8, P685, DOI 10.1016/S0969-2126(00)00156-8; BRENNER S, 1974, GENETICS, V77, P71; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Carpp LN, 2006, J CELL BIOL, V173, P927, DOI 10.1083/jcb.200512024; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Duncan RR, 2004, J MICROSC-OXFORD, V215, P1, DOI 10.1111/j.0022-2720.2004.01343.x; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Grabowski R, 1997, FEBS LETT, V411, P169, DOI 10.1016/S0014-5793(97)00720-5; Graham ME, 1997, J NEUROCHEM, V69, P2369; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Latham CF, 2006, TRAFFIC, V7, P1408, DOI 10.1111/j.1600-0854.2006.00474.x; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nichols BJ, 1998, EUR J CELL BIOL, V77, P263, DOI 10.1016/S0171-9335(98)80084-8; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rickman C, 2005, CHEM BIOL, V12, P545, DOI 10.1016/j.chembiol.2005.03.004; Rickman C, 2006, MOL BIOL CELL, V17, P283, DOI 10.1091/mbc.E05-07-0620; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Rowe J, 1999, J CELL SCI, V112, P1865; Schutz D, 2005, EUR J NEUROSCI, V21, P2419, DOI 10.1111/j.1460-9568.2005.04095.x; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Toonen RF, 2006, EMBO J, V25, P3725, DOI 10.1038/sj.emboj.7601256; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zilly FE, 2006, PLOS BIOL, V4, P1789, DOI 10.1371/journal.pbio.0040330	40	100	105	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12097	12103		10.1074/jbc.M700227200	http://dx.doi.org/10.1074/jbc.M700227200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17264080	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000245941900051
J	Yang, B; Chen, KY; Zhang, C; Huang, S; Zhang, H				Yang, Bin; Chen, Keyang; Zhang, Chune; Huang, Sophia; Zhang, Hui			Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE TRANSCRIPTION; NONPERMISSIVE CELLS; INHIBITOR PROTEIN; POTENT INHIBITORS; VIF PROTEIN; VIRAL-DNA; VPR; REPLICATION; INFECTION	Cellular cytidine deaminases APOBEC3 family is a group of potent inhibitors for many exogenous and endogenous retroviruses. It has been demonstrated that they induce G to A hypermutations in the nascent retroviral DNA, resulting from the cytosine ( C) to uracil ( U) conversions in minus-stranded viral DNA. In this report, we have demonstrated that the result of C to U conversion in minus-stranded DNA of human immunodeficiency virus type 1 ( HIV-1) could trigger a degradation of nascent viral DNA mediated by uracil DNA glycosylases-2 ( UNG2) and apurinic/apyrimidinic endonuclease ( APE). Since antiviral activity of APOBEC3G is partially affected by UNG2 inhibitor Ugi or UNG2-specific short-interfering RNA in virus-producing cells but not target cells, the virion-associated UNG2 most likely mediates this process. Interestingly, as APE-specific short-interfering RNA can also partially inhibit the anti-HIV-1 activity of APOBEC3G in virus-producing cells but not in target cells and APE molecules can be detected within HIV-1 virions, it seems that the required APE is also virion-associated. Furthermore, the in vitro cleavage experiment using uracil-containing single-stranded DNA as a template has demonstrated that the uracil-excising catalytic activity of virion-associated UNG2 can remove dU from the uracil-containing viral DNA and leave an abasic site, which could be further cleaved by virion-associated APE. Based upon our observations, we propose that the degradation of APOBEC3G-edited viral DNA mediated by virion-associated UNG2 and APE during or after reverse transcription could be partially responsible for the potent anti-HIV-1 effect by APOBEC3G in the absence of vif.	Thomas Jefferson Univ, Ctr Human Virol, Div Infect Dis, Dept Med, Philadelphia, PA 19107 USA	Jefferson University	Zhang, H (corresponding author), Thomas Jefferson Univ, Ctr Human Virol, Div Infect Dis, Dept Med, JAH334,1020 Locust St, Philadelphia, PA 19107 USA.	hui.zhang@jefferson.edu	Yang, Bin/W-7014-2019; Yang, Bin/J-4044-2015	Yang, Bin/0000-0003-1180-6184; Yang, Bin/0000-0003-4110-1513	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047720, R01AI047720, R01AI058798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI047720, AI058798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acharya N, 2003, MICROBIOL-SGM, V149, P1647, DOI 10.1099/mic.0.26228-0; Acharya N, 2002, J MOL BIOL, V321, P579, DOI 10.1016/S0022-2836(02)00654-X; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2006, NUCLEIC ACIDS RES, V34, P89, DOI 10.1093/nar/gkj416; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; Chen KY, 2006, J VIROL, V80, P7645, DOI 10.1128/JVI.00206-06; Chen RX, 2004, J BIOL CHEM, V279, P28419, DOI 10.1074/jbc.M403875200; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; DOEHLE BP, 2005, VIROLOGY, V80, P12102; Dornadula G, 2000, J VIROL, V74, P2594, DOI 10.1128/JVI.74.6.2594-2602.2000; Esnault C, 2005, NATURE, V433, P430, DOI 10.1038/nature03238; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Handa P, 2002, NUCLEIC ACIDS RES, V30, P3086, DOI 10.1093/nar/gkf425; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Holmes RK, 2007, J BIOL CHEM, V282, P2587, DOI 10.1074/jbc.M607298200; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; Iwatani Y, 2006, J VIROL, V80, P5992, DOI 10.1128/JVI.02680-05; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kaiser SM, 2006, J VIROL, V80, P875, DOI 10.1128/JVI.80.2.875-882.2006; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mansky LM, 2000, J VIROL, V74, P7039, DOI 10.1128/JVI.74.15.7039-7047.2000; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Navaratnam N, 2006, INT J HEMATOL, V83, P195, DOI 10.1532/IJH97.06032; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Noguchi C, 2005, HEPATOLOGY, V41, P626, DOI 10.1002/hep.20580; Petersen-Mahrt SK, 2003, J BIOL CHEM, V278, P19583, DOI 10.1074/jbc.C300114200; Pion M, 2006, J EXP MED, V203, P2887, DOI 10.1084/jem.20061519; Priet S, 2005, MOL CELL, V17, P479, DOI 10.1016/j.molcel.2005.01.016; Rosler C, 2005, HEPATOLOGY, V42, P301, DOI 10.1002/hep.20801; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Schrofelbauer B, 2005, J VIROL, V79, P10978, DOI 10.1128/JVI.79.17.10978-10987.2005; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WANG ZG, 1991, GENE, V99, P31; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Yu Q, 2004, J BIOL CHEM, V279, P53379, DOI 10.1074/jbc.M408802200; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	52	111	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11667	11675		10.1074/jbc.M606864200	http://dx.doi.org/10.1074/jbc.M606864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17272283	hybrid			2022-12-27	WOS:000245941900008
J	Zhang, LG; Nephew, KP; Gallagher, PJ				Zhang, Liguo; Nephew, Kenneth P.; Gallagher, Patricia J.			Regulation of death-associated protein kinase - Stabilization by HSP90 heterocomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE CHIP; HEAT-SHOCK PROTEINS; PROTEASOMAL DEGRADATION; ANDROGEN RECEPTOR; DAP-KINASE; E3 LIGASE; PHOSPHORYLATION; TARGET; HYPERMETHYLATION; IDENTIFICATION	Death-associated protein kinase ( DAPK) has been found associated with HSP90, and inhibition of HSP90 with 17-alkylamino-17-demethoxygeldanamycin reduced expression of DAPK. These results were extended to determine whether the degradation of DAPK in the absence of HSP90 activity is dependent on the ubiquitin-proteasome pathway. Our results show that treatment of cells with geldanamycin ( GA) leads to degradation of DAPK, and this degradation is attenuated by the proteasome inhibitor, lactacystin. GA-induced DAPK degradation is also dependent on phosphorylation of DAPK at Ser(308), and the cellular levels of phospho( Ser(308))-DAPK dramatically increase in response to GA treatment. Expression of two distinct ubiquitin E3 ligases, carboxyl terminus of HSC70-interacting protein ( CHIP) or DIP1/Mib1, enhanced DAPK degradation, and conversely, short interfering RNA depletion of either CHIP or DIP1/Mib1 attenuated DAPK degradation. In vitro ubiquitination assays confirmed that DAPK is targeted for ubiquitination by both CHIP and DIP. Consistent with these results, DAPK is found in two distinct immune complexes, one containing HSP90 and CHIP and a second complex containing only DIP1/Mib. Collectively, these results indicate that strict modulation of DAPK activities is critical for regulation of apoptosis and cellular homeostasis.	Indiana Univ, Sch Med, Dept Cellular & Integrated Physiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Bloomington, IN 47405 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrated Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pgallag@iupui.edu	Zhang, Liguo/E-2804-2014		NATIONAL CANCER INSTITUTE [R01CA085289] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062810] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085289, CA085289] Funding Source: Medline; NHLBI NIH HHS [HL54118, R01 HL054118, R01 HL054118-08] Funding Source: Medline; NIDDK NIH HHS [R01 DK062810-03, DK062810, R01 DK062810] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Bondar T, 2006, MOL CELL BIOL, V26, P2531, DOI 10.1128/MCB.26.7.2531-2539.2006; Bonvini P, 2004, CANCER RES, V64, P3256, DOI 10.1158/0008-5472.CAN-03-3531; Chan AWH, 2005, ONCOL REP, V13, P937; Chen GM, 2006, OPHTHAL EPIDEMIOL, V13, P199, DOI 10.1080/09286580500477440; Chim CS, 2006, J HUM GENET, V51, P832, DOI 10.1007/s10038-006-0029-x; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Collins Y, 2006, INT J GYNECOL CANCER, V16, P195, DOI 10.1111/j.1525-1438.2006.00506.x; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Doucet Christine, 2005, BMC Biochem, V6, P27, DOI 10.1186/1471-2091-6-27; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Georgakis Georgios V, 2005, Future Oncol, V1, P273; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jin YJ, 2006, J BIOL CHEM, V281, P39033, DOI 10.1074/jbc.M605097200; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Kuo JC, 2006, J CELL BIOL, V172, P619, DOI 10.1083/jcb.200505138; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Morishima Y, 2005, BIOCHEMISTRY-US, V44, P16333, DOI 10.1021/bi0515570; Peng HM, 2004, J BIOL CHEM, V279, P52970, DOI 10.1074/jbc.M406926200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Rees I, 2006, BBA-PROTEINS PROTEOM, V1764, P1073, DOI 10.1016/j.bbapap.2006.03.013; Schneider-Stock R, 2005, INT J BIOCHEM CELL B, V37, P1763, DOI 10.1016/j.biocel.2005.02.019; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; VOSO MT, 2006, HAEMATOLOGICA, V91, P1108; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	35	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11795	11804		10.1074/jbc.M610430200	http://dx.doi.org/10.1074/jbc.M610430200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324930	Green Accepted, hybrid			2022-12-27	WOS:000245941900022
J	Zhao, TB; Zhang, HL; Guo, YM; Fan, ZS				Zhao, Tongbiao; Zhang, Honglian; Guo, Yuming; Fan, Zusen			Granzyme K directly processes bid to release cytochrome c and endonuclease g leading to mitochondria-dependent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE SERINE PROTEASES; ASSEMBLY PROTEIN SET; DNA FRAGMENTATION; IN-VIVO; PERMEABILITY TRANSITION; MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR; ACTIVATED DNASE; KILLER-CELLS; A-DEFICIENT	Granule-mediated cytolysis is the major pathway for killer lymphocytes to kill pathogens and tumor cells. Little is known about how granzyme K functions in killer lymphocyte-mediated cytolysis. We previously showed that human GzmK triggers rapid cell death independently of caspase activation with single-stranded DNA nicks, similar to GzmA. In this study we found that GzmK can induce rapid reactive oxygen species generation and collapse of mitochondrial inner membrane potential (Delta psi(m)). Blockade of reactive oxygen species production by antioxidant N-acetylcysteine or superoxide scavenger Tiron inhibits GzmK-induced cell death. Moreover GzmK targets mitochondria by cleaving Bid to generate its active form tBid, which disrupts the outer mitochondrial membrane leading to the release of cytochrome c and endonuclease G. Thus, we showed herein that GzmK-induced caspase-independent death occurs through Bid-dependent mitochondrial damage that is different from GzmA.	Chinese Acad Sci, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Ctr Infect & Immun, Inst Biophys, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; Institute of Biophysics, CAS	Fan, ZS (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	fanz@moon.ibp.ac.cn	Zhao, Tongbiao/C-5761-2011	Zhao, Tongbiao/0000-0003-1429-5818				Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Bade B, 2005, EUR J IMMUNOL, V35, P2940, DOI 10.1002/eji.200526249; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bratke K, 2005, EUR J IMMUNOL, V35, P2608, DOI 10.1002/eji.200526122; Carter CRD, 1996, CELL IMMUNOL, V172, P235, DOI 10.1006/cimm.1996.0238; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis JE, 2001, EUR J IMMUNOL, V31, P39, DOI 10.1002/1521-4141(200101)31:1<39::AID-IMMU39>3.0.CO;2-1; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fan ZS, 2005, CELL MOL IMMUNOL, V2, P259; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Grossman WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2; HAMEED A, 1988, J IMMUNOL, V141, P3142; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lu HX, 2006, J IMMUNOL, V177, P1171, DOI 10.4049/jimmunol.177.2.1171; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shresta S, 1997, J BIOL CHEM, V272, P20236, DOI 10.1074/jbc.272.32.20236; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhao T, 2007, CELL DEATH DIFFER, V14, P489, DOI 10.1038/sj.cdd.4402040; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12104	12111		10.1074/jbc.M611006200	http://dx.doi.org/10.1074/jbc.M611006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17308307	hybrid			2022-12-27	WOS:000245941900052
J	Lu, HH; Pannicke, U; Schwarz, K; Lieber, MR				Lu, Haihui; Pannicke, Ulrich; Schwarz, Klaus; Lieber, Michael R.			Length-dependent binding of human XLF to DNA and stimulation of XRCC4 center dot DNA ligase IV activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINED IMMUNE-DEFICIENCY; CLASS SWITCH RECOMBINATION; KINASE CATALYTIC SUBUNIT; END-JOINING FACTOR; V(D)J RECOMBINATION; XRCC4 PROTEIN; COMPLEX; INTERACTS; CERNUNNOS; MECHANISM	An XRCC4-like factor, called XLF or Cernunnos, was recently identified as another important factor in the non-homologous DNA end joining ( NHEJ) process. NHEJ is the major pathway for the repair of double-strand DNA breaks. The similarity in the putative secondary structures of XLF and XRCC4 as well as the association of XLF with XRCC4.DNA ligase IV in vivo suggested a role in the final ligation step of NHEJ. Here, we find that purified XLF directly interacts with purified XRCC4.DNA ligase IV complex and stimulates the ligase complex in a direct assay for ligation activity. Purified XLF has DNA binding activity, but this binding is dependent on DNA length in a manner most consistent with orientation of the C-terminal alpha helices parallel to the DNA helix. To better understand the function of XLF, we purified an XLF mutant ( R57G), which was identified in patients with NHEJ deficiency and severe combined immunodeficiency. Surprisingly, the mutant protein retained its ability to stimulate XRCC4.DNA ligase IV but failed to translocate to the nucleus, and this appears to be the basis for the NHEJ defect in this patient.	Univ Ulm, Dept Transfus Med, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany; Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA; Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem, Los Angeles, CA 90089 USA; Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Biol, Los Angeles, CA 90089 USA; Kenneth Norris Jr Comprehens Canc Ctr, Dept Biol Sci, Los Angeles, CA 90089 USA; Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	Ulm University	Schwarz, K (corresponding author), Univ Ulm, Dept Transfus Med, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany.	klaus.schwarz@medizin.uni-ulm.de; lieber@usc.edu	Pannicke, Ulrich/D-7348-2014	Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Callebaut I, 2006, J BIOL CHEM, V281, P13857, DOI 10.1074/jbc.C500473200; Drouet J, 2006, J BIOL CHEM, V281, P27784, DOI 10.1074/jbc.M603047200; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hentges P, 2006, J BIOL CHEM, V281, P37517, DOI 10.1074/jbc.M608727200; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Lieber MR, 2006, DNA REPAIR, V5, P1234, DOI 10.1016/j.dnarep.2006.05.013; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Pavlicek A, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-15; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; Schwarz K, 2003, BIOESSAYS, V25, P1061, DOI 10.1002/bies.10344; Tomkinson AE, 2006, CHEM REV, V106, P687, DOI 10.1021/cr040498d	18	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11155	11162		10.1074/jbc.M609904200	http://dx.doi.org/10.1074/jbc.M609904200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17317666	hybrid			2022-12-27	WOS:000245941500036
J	Mazon, H; Gabor, K; Leys, D; Heck, AJR; van der Oost, J; van den Heuvel, RHH				Mazon, Hortense; Gabor, Krisztina; Leys, David; Heck, Albert J. R.; van der Oost, John; van den Heuvel, Robert H. H.			Transcriptional activation by CprK1 is regulated by protein structural changes induced by effector binding and redox state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR COMPLEXES; REDUCTIVE DEHALOGENASE; CONFORMATIONAL-CHANGES; LIMITED PROTEOLYSIS; MASS-SPECTROMETRY; SP-NOV; FLIGHT; DEHALORESPIRATION; HALORESPIRATION; PURIFICATION	The transcriptional activator CprK1 from Desulfitobacterium-hafniense, a member of the ubiquitous cAMP receptor protein/fumarate nitrate reduction regulatory protein family, activates transcription of genes encoding proteins involved in reductive dehalogenation of chlorinated aromatic compounds. 3-Chloro-4-hydroxyphenylacetate is a known effector for CprK1, which interacts tightly with the protein, and induces binding to a specific DNA sequence ("dehalobox," TTAAT--ATTAA) located in the promoter region of chlorophenol reductive dehalogenase genes. Despite the availability of recent x-ray structures of two CprK proteins in distinct states, the mechanism by which CprK1 activates transcription is poorly understood. In the present study, we have investigated the mechanism of CprK1 activation and its effector specificity. By using macromolecular native mass spectrometry and DNA binding assays, analogues of 3-chloro-4-hydroxypheny-lacetate that have a halogenated group at the ortho position and a chloride or acetic acid group at the para position were found to be potent effectors for CprK1. By using limited proteolysis it was demonstrated that CprK1 requires a cascade of structural events to interact with dehalobox dsDNA. Upon reduction of the intermolecular disulfide bridge in oxidized CprK1, the protein becomes more dynamic, but this alone is not sufficient for DNA binding. Activation of CprK1 is a typical example of allosteric regulation; the binding of a potent effector molecule to reduced CprK1 induces local changes in the N-terminal effector binding domain, which subsequently may lead to changes in the hinge region and as such to structural changes in the DNA binding domain that are required for specific DNA binding.	Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Wageningen & Res Ctr, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; Univ Manchester, Manchester Interdisciplinary Bioctr, Fac Life Sci, Manchester M60 1QD, Lancs, England	Utrecht University; Utrecht University; Wageningen University & Research; University of Manchester	van den Heuvel, RHH (corresponding author), Organon Int BV, NL-5340 BH Oss, Netherlands.	r.h.h.vandenheuvel@chem.uu.nl	van+der+Oost, John/Y-2548-2019; Heck, Albert/D-7098-2011	Heck, Albert/0000-0002-2405-4404	Biotechnology and Biological Sciences Research Council [BB/C00521X/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Akashi S, 2006, MED RES REV, V26, P339, DOI 10.1002/med.20051; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandes HK, 1998, ARCH BIOCHEM BIOPHYS, V352, P130, DOI 10.1006/abbi.1998.0580; Christiansen N, 1998, FEBS LETT, V436, P159, DOI 10.1016/S0014-5793(98)01114-4; Christiansen N, 1996, INT J SYST BACTERIOL, V46, P442, DOI 10.1099/00207713-46-2-442; Clark A.R., 1996, ENZYMOLOGY LABFAX, P199; Eiting M, 2005, MOL MICROBIOL, V56, P433, DOI 10.1111/j.1365-2958.2005.04561.x; El Fantroussi S, 1998, BIOTECHNOL PROGR, V14, P167, DOI 10.1021/bp980011k; Fic E, 2006, BIOCHEMISTRY-US, V45, P373, DOI 10.1021/bi051586a; Gabor K, 2006, J BACTERIOL, V188, P2604, DOI 10.1128/JB.188.7.2604-2613.2006; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; Hanson CL, 2004, J BIOL CHEM, V279, P24907, DOI 10.1074/jbc.R300037200; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; Holliger C, 1998, FEMS MICROBIOL REV, V22, P383, DOI 10.1016/S0168-6445(98)00030-8; Joyce MG, 2006, J BIOL CHEM, V281, P28318, DOI 10.1074/jbc.M602654200; Krutchinsky AN, 1998, J AM SOC MASS SPECTR, V9, P569, DOI 10.1016/S1044-0305(98)00027-0; Loo JA, 1997, MASS SPECTROM REV, V16, P1; MADSEN T, 1992, APPL ENVIRON MICROB, V58, P2874, DOI 10.1128/AEM.58.9.2874-2878.1992; McDonald C, 2005, ANAL CHIM ACTA, V534, P3, DOI 10.1016/j.aca.2004.04.017; Myers SL, 2006, RAPID COMMUN MASS SP, V20, P1628, DOI 10.1002/rcm.2482; Pop SM, 2004, J BIOL CHEM, V279, P49910, DOI 10.1074/jbc.M409435200; Pop SM, 2006, J BIOL CHEM, V281, P26382, DOI 10.1074/jbc.M602158200; Robinson CV, 1996, J AM CHEM SOC, V118, P8646, DOI 10.1021/ja960211x; Rogniaux H, 2001, ANAL BIOCHEM, V291, P48, DOI 10.1006/abio.2000.4975; Smidt H, 2004, ANNU REV MICROBIOL, V58, P43, DOI 10.1146/annurev.micro.58.030603.123600; Smidt H, 2000, J BACTERIOL, V182, P5683, DOI 10.1128/JB.182.20.5683-5691.2000; Sobott F, 2005, PHILOS T R SOC A, V363, P379, DOI 10.1098/rsta.2004.1498; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; UTKIN I, 1995, APPL ENVIRON MICROB, V61, P346, DOI 10.1128/AEM.61.1.346-351.1995; UTKIN I, 1994, INT J SYST BACTERIOL, V44, P612, DOI 10.1099/00207713-44-4-612; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; van den Heuvel RH, 2004, CURR OPIN CHEM BIOL, V8, P519, DOI 10.1016/j.cbpa.2004.08.006; Villemur R, 2002, CAN J MICROBIOL, V48, P697, DOI 10.1139/w02-057; WEBER IT, 1987, J BIOL CHEM, V262, P5630; WENDT H, 1995, PROTEIN SCI, V4, P1563, DOI 10.1002/pro.5560040814	35	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11281	11290		10.1074/jbc.M611177200	http://dx.doi.org/10.1074/jbc.M611177200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303561	Green Published, hybrid			2022-12-27	WOS:000245941500050
J	Naji, S; Grunberg, S; Thomm, M				Naji, Souad; Gruenberg, Sebastian; Thomm, Michael			The RPB7 orthologue E ' is required for transcriptional activity of a reconstituted archaeal core enzyme at low temperatures and stimulates open complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TFIIE-ALPHA; IN-VITRO; BASAL TRANSCRIPTION; PYROCOCCUS-FURIOSUS; ABC TRANSPORTER; INITIATION; PROMOTER; SUBUNIT; REGULATOR	RNA polymerases from Archaea and Eukaryotes consist of a core enzyme associated with a dimeric E'F ( Rpb7/Rpb4) sub-complex but the functional contribution of the two subunit subcomplexes to the transcription process is poorly understood. Here we report the reconstitution of the 11-subunit RNA polymerase and of the core enzyme from the hyperthermophilic Archaeon Pyrococcus furiosus. The core enzyme showed significant activity between 70 and 80 degrees C but was almost inactive at 60 degrees C. E' stimulated the activity of the core enzyme at 60 degrees C, dramatically suggesting an important role of this subunit at low growth temperatures. Subunit F did not contribute significantly to catalytic activity. Permanganate footprinting at low temperatures dissected the contributions of the core enzyme, subunit E', and of archaeal TFE to open complex formation. Opening in the -2 and -4 region could be achieved by the core enzyme, subunit E' stimulated bubble formation in general and opening at the upstream end of the transcription bubble was preferably stimulated by TFE. Analyses of the kinetic stabilities of open complexes revealed an unexpected E'-independent role of TFE in the stabilization of open complexes.	Univ Regensburg, Lehrstuhl Mikrobiol, D-93053 Regensburg, Germany; Univ Regensburg, Archaeenzentrum, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg	Thomm, M (corresponding author), Univ Str 31, D-93053 Regensburg, Germany.	michael.thomm@biologie.uni-regensburg.de		Grunberg, Sebastian/0000-0002-5694-0574				Armache KJ, 2005, J BIOL CHEM, V280, P7131, DOI 10.1074/jbc.M413038200; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Choder M, 2004, TRENDS BIOCHEM SCI, V29, P674, DOI 10.1016/j.tibs.2004.10.007; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Darcy TJ, 1999, J BACTERIOL, V181, P4424, DOI 10.1128/JB.181.14.4424-4429.1999; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; Geiduschek EP, 2005, MOL MICROBIOL, V56, P1397, DOI 10.1111/j.1365-2958.2005.04627.x; Goede B, 2006, J BIOL CHEM, V281, P30581, DOI 10.1074/jbc.M605209200; Goodchild A, 2004, MOL MICROBIOL, V53, P309, DOI 10.1111/j.1365-2958.2004.04130.x; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; Jasiak AJ, 2006, MOL CELL, V23, P71, DOI 10.1016/j.molcel.2006.05.013; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Lee SJ, 2005, MOL MICROBIOL, V57, P1797, DOI 10.1111/j.1365-2958.2005.04804.x; Lee SJ, 2003, J BIOL CHEM, V278, P983, DOI 10.1074/jbc.M210236200; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; Orlicky SM, 2001, J BIOL CHEM, V276, P10097, DOI 10.1074/jbc.M003165200; Ouhammouch M, 2004, J BIOL CHEM, V279, P51719, DOI 10.1074/jbc.C400446200; Peyroche E, 2002, P NATL ACAD SCI USA, V99, P14670, DOI 10.1073/pnas.232580799; SADHALE PP, 1994, MOL CELL BIOL, V14, P6164, DOI 10.1128/MCB.14.9.6164; Shpakovski GV, 1999, BIOORG KHIM+, V25, P791; Siaut M, 2003, MOL CELL BIOL, V23, P195, DOI 10.1128/MCB.23.1.195-205.2003; Spitalny P, 2003, J BIOL CHEM, V278, P30497, DOI 10.1074/jbc.M303633200; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; THOMM M, 2006, ARCHAEA EVOLUTION PH, P185; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Toulokhonov I, 2006, J MOL BIOL, V361, P644, DOI 10.1016/j.jmb.2006.06.071; Vierke G, 2003, J BIOL CHEM, V278, P18, DOI 10.1074/jbc.M209250200; Werner F, 2000, NUCLEIC ACIDS RES, V28, P4299, DOI 10.1093/nar/28.21.4299; Werner F, 2005, MOL CELL BIOL, V25, P8344, DOI 10.1128/MCB.25.18.8344-8355.2005; Werner F, 2002, MOL CELL, V10, P635, DOI 10.1016/S1097-2765(02)00629-9; WETTACH J, 1995, P NATL ACAD SCI USA, V92, P472, DOI 10.1073/pnas.92.2.472; Zaros C, 2005, MOL MICROBIOL, V55, P104, DOI 10.1111/j.1365-2958.2004.04375.x	42	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11047	11057		10.1074/jbc.M611674200	http://dx.doi.org/10.1074/jbc.M611674200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311916	hybrid			2022-12-27	WOS:000245941500025
J	Taguchi, N; Ishihara, N; Jofuku, A; Oka, T; Mihara, K				Taguchi, Naoko; Ishihara, Naotada; Jofuku, Akihiro; Oka, Toshihiko; Mihara, Katsuyoshi			Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT OPTIC ATROPHY; MAMMALIAN-CELLS; OUTER-MEMBRANE; BUDDING YEAST; FUSION; PROTEIN; MORPHOLOGY; INHERITANCE; DIVISION; CYCLE	Organelles are inherited to daughter cells beyond dynamic changes of the membrane structure during mitosis. Mitochondria are dynamic entities, frequently dividing and fusing with each other, during which dynamin-related GTPase Drp1 is required for the fission reaction. In this study, we analyzed mitochondrial dynamics in mitotic mammalian cells. Although mitochondria in interphase HeLa cells are long tubular network structures, they are fragmented in early mitotic phase, and the filamentous network structures are subsequently reformed in the daughter cells. In marked contrast, tubular mitochondrial structures are maintained during mitosis in Drp1 knockdown cells, indicating that the mitochondrial fragmentation in mitosis requires mitochondrial fission by Drp1. Drp1 was specifically phosphorylated in mitosis by Cdk1/cyclin B on Ser-585. Exogenous expression of unphosphorylated mutant Drp1(S585A) led to reduced mitotic mitochondrial fragmentation. These results suggest that phosphorylation of Drp1 on Ser-d585 promotes mitochondrial fission in mitotic cells.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	mihara@cell.med.kyushu-u.ac.jp		Ishihara, Naotada/0000-0002-6305-7149				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Barni S, 1996, BIOTECH HISTOCHEM, V71, P66, DOI 10.3109/10520299609117135; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Boldogh IR, 2001, TRAFFIC, V2, P368, DOI 10.1034/j.1600-0854.2001.002006368.x; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2004, CURR TOP DEV BIOL, V59, P119, DOI 10.1016/S0070-2153(04)59005-1; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Gorsich SW, 2004, MOL BIOL CELL, V15, P4369, DOI 10.1091/mbc.E03-12-0875; Griffin EE, 2005, J CELL BIOL, V170, P237, DOI 10.1083/jcb.200503148; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; Itoh T, 2004, EMBO J, V23, P2520, DOI 10.1038/sj.emboj.7600271; Jofuku A, 2005, BIOCHEM BIOPH RES CO, V333, P650, DOI 10.1016/j.bbrc.2005.05.154; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Karbowski M, 2001, J CELL SCI, V114, P281; Karren MA, 2005, J CELL BIOL, V171, P291, DOI 10.1083/jcb.200506158; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Margineantu DH, 2002, MITOCHONDRION, V1, P425, DOI 10.1016/S1567-7249(02)00006-5; Mozdy AD, 2003, NAT REV MOL CELL BIO, V4, P468, DOI 10.1038/nrm1125; Naylor K, 2006, J BIOL CHEM, V281, P2177, DOI 10.1074/jbc.M507943200; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Solomaha E, 2005, J BIOL CHEM, V280, P23147, DOI 10.1074/jbc.M501745200; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Uchiyama K, 2003, J CELL BIOL, V161, P1067, DOI 10.1083/jcb.200303048; Westermann B, 2003, BBA-MOL CELL RES, V1641, P195, DOI 10.1016/S0167-4889(03)00091-0; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	49	831	861	3	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11521	11529		10.1074/jbc.M607279200	http://dx.doi.org/10.1074/jbc.M607279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17301055	hybrid			2022-12-27	WOS:000245941500073
J	Hitosugi, T; Sasaki, K; Sato, M; Suzuki, Y; Umezawa, Y				Hitosugi, Taro; Sasaki, Kazuki; Sato, Moritoshi; Suzuki, Yoshiko; Umezawa, Yoshio			Epidermal growth factor directs sex-specific steroid signaling through Src activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; BINDING-SITES; ESTRADIOL; SHC; COMPLEX; CELLS	Estrogens and androgens exert many biological effects that do not require interactions of their receptors with chromosomal DNA. However, it has been a long-standing question how the sex steroid receptors provoke signal transduction outside the nucleus. Here we have shown that epidermal growth factor ( EGF) directs sex-specific steroid signaling through Src activation. We have revealed that estrogen ( E2)-induced Src activation takes place in, not only plasma, but also endomembranes. This was found ascribed to the existence of EGF and the occurrence of EGF receptor ( EGFR)-involved endocytosis of estrogen receptor together with Src. EGFR, estrogen receptor, and Src were found to form a complex upon E2 stimulation. The cell growth of breast cancer-derived MCF-7 cells was found to remarkably increase through the above EGF-involved estrogen-signaling process. In contrast, the androgen 5 alpha-dihydrotestosterone-induced Src activation occurs only in the plasma membrane free from the interaction of EGFR with androgen receptor, irrespective of EGF. The cell growth occurred only moderately as a result. The spatial difference in Src activation between E2 and 5 alpha-dihydrotestosterone may be responsible for the different extent of observed cell growth.	Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Umezawa, Y (corresponding author), Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan.	sato@chem.s.u-tokyo.ac.jp; umezawa@chem.s.u-tokyo.ac.jp	Sato, Moritoshi/O-2735-2018	Sato, Moritoshi/0000-0002-3095-5831				Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7; Hom YK, 1998, ENDOCRINOLOGY, V139, P913, DOI 10.1210/en.139.3.913; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; VANZOELEN EJJ, 1985, J CELL PHYSIOL, V123, P151, DOI 10.1002/jcp.1041230202; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; Zheng JB, 1996, J PSYCHIATR NEUROSCI, V21, P187	26	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10697	10706		10.1074/jbc.M610444200	http://dx.doi.org/10.1074/jbc.M610444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284441	hybrid			2022-12-27	WOS:000245941000064
J	Lee, JH; Richter, W; Namkung, W; Kim, KH; Kim, E; Conti, M; Lee, MG				Lee, Ji Hyun; Richter, Wito; Namkung, Wan; Kim, Kyung Hwan; Kim, Eunjoon; Conti, Marco; Lee, Min Goo			Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; SHANK FAMILY; DIFFERENTIAL EXPRESSION; POSTSYNAPTIC DENSITY; EPITHELIAL-CELLS; EMERGING ROLE; CAMP; CFTR; PHOSPHODIESTERASES; MEMBRANE	Disorganized ion transport caused by hypo- or hyperfunctioning of the cystic fibrosis transmembrane conductance regulator ( CFTR) can be detrimental and may result in life-threatening diseases such as cystic fibrosis or secretory diarrhea. Thus, CFTR is controlled by elaborate positive and negative regulations for an efficient homeostasis. It has been shown that expression and activity of CFTR can be regulated either positively or negatively by PDZ ( PSD-95/ discs large/ ZO-1) domain-based adaptors. Although a positive regulation by PDZ domain-based adaptors such as EBP50/NHERF1 is established, the mechanisms for negative regulation of the CFTR by Shank2, as well as the effects of multiple adaptor interactions, are not known. Here we demonstrate a physical and physiological competition between EBP50-CFTR and Shank2-CFTR associations and the dynamic regulation of CFTR activity by these positive and negative interactions using the surface plasmon resonance assays and consecutive patch clamp experiments. Furthermore whereas EBP50 recruits a cAMP-dependent protein kinase ( PKA) complex to CFTR, Shank2 was found to be physically and functionally associated with the cyclic nucleotide phosphodiesterase PDE4D that precludes cAMP/PKA signals in epithelial cells and mouse brains. These findings strongly suggest that balanced interactions between the membrane transporter and multiple PDZ-based adaptors play a critical role in the homeostatic regulation of epithelial transport and possibly the membrane transport in other tissues.	Yonsei Univ, Coll Med, Dept Pharmacol, Inst Gastroenterol, Seoul 120752, South Korea; Stanford Univ, Sch Med, Div Reprod Biol, Dept Obstet & Gynecol, Stanford, CA 94305 USA; Korea Adv Inst Sci & Technol, Creat Res Ctr Synaptogenesis, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Yonsei University; Yonsei University Health System; Stanford University; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Lee, MG (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Inst Gastroenterol, 134 Sinchon Dong, Seoul 120752, South Korea.	mlee@yumc.yonsei.ac.kr	Lee, Min Goo/AAS-4636-2020; Kim, Eunjoon/C-1566-2011; Lee, Min Goo/D-5635-2012	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X; Richter, Wito/0000-0001-5588-9060	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Barnes AP, 2005, J BIOL CHEM, V280, P7997, DOI 10.1074/jbc.M407521200; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Donowitz M, 2005, J PHYSIOL-LONDON, V567, P3, DOI 10.1113/jphysiol.2005.090399; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Han W, 2006, J BIOL CHEM, V281, P1461, DOI 10.1074/jbc.M509786200; Im YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kim JY, 2004, J BIOL CHEM, V279, P10389, DOI 10.1074/jbc.M312871200; Lamprecht G, 2006, AM J PHYSIOL-GASTR L, V291, pG766, DOI 10.1152/ajpgi.00135.2006; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Liu SS, 2005, J PHARMACOL EXP THER, V314, P846, DOI 10.1124/jpet.105.083519; McWilliams RR, 2004, BIOCHEM J, V380, P181, DOI 10.1042/BJ20031577; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Namkung W, 2005, GASTROENTEROLOGY, V129, P1979, DOI 10.1053/j.gastro.2005.08.049; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Richter W, 2005, BIOCHEM J, V388, P803, DOI 10.1042/BJ20050030; Sheng M, 2000, J CELL SCI, V113, P1851; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Taouil K, 2003, J BIOL CHEM, V278, P17320, DOI 10.1074/jbc.M212227200; Tateyama M, 2006, P NATL ACAD SCI USA, V103, P1124, DOI 10.1073/pnas.0505925103; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	35	73	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10414	10422		10.1074/jbc.M610857200	http://dx.doi.org/10.1074/jbc.M610857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17244609	hybrid			2022-12-27	WOS:000245941000032
J	Necula, M; Kayed, R; Milton, S; Glabe, CG				Necula, Mihaela; Kayed, Rakez; Milton, Saskia; Glabe, Charles G.			Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TAU-FILAMENT FORMATION; ATOMIC-FORCE MICROSCOPY; FIBRILS IN-VITRO; ALZHEIMERS-DISEASE; A-BETA; CONGO RED; ALPHA-SYNUCLEIN; PROTEIN FIBRILLOGENESIS; TEMPERATURE-DEPENDENCE; INSULIN FIBRILLATION	Alzheimer disease is characterized by the abnormal aggregation of amyloid beta peptide into extracellular fibrillar deposits known as amyloid plaques. Soluble oligomers have been observed at early time points preceding fibril formation, and these oligomers have been implicated as the primary pathological species rather than the mature fibrils. A significant issue that remains to be resolved is whether amyloid oligomers are an obligate intermediate on the pathway to fibril formation or represent an alternate assembly pathway that may or may not lead to fiber formation. To determine whether amyloid beta oligomers are obligate intermediates in the fibrillization pathway, we characterized the mechanism of action of amyloid beta aggregation inhibitors in terms of oligomer and fibril formation. Based on their effects, the small molecules segregated into three distinct classes: compounds that inhibit oligomerization but not fibrillization, compounds that inhibit fibrillization but not oligomerization, and compounds that inhibit both. Several compounds selectively inhibited oligomerization at substoichiometric concentrations relative to amyloid beta monomer, with some active in the low nanomolar range. These results indicate that oligomers are not an obligate intermediate in the fibril formation pathway. In addition, these data suggest that small molecule inhibitors are useful for clarifying the mechanisms underlying protein aggregation and may represent potential therapeutic agents that target fundamental disease mechanisms.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3438 McGaugh Hall, Irvine, CA 92697 USA.	cglabe@uci.edu			NINDS NIH HHS [NS-38298] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038298] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad A, 2005, J BIOL CHEM, V280, P42669, DOI 10.1074/jbc.M504298200; Ahmad A, 2004, J BIOL CHEM, V279, P14999, DOI 10.1074/jbc.M313134200; Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; Bloom GS, 2005, BBA-MOL BASIS DIS, V1739, P116, DOI 10.1016/j.bbadis.2004.08.008; Bohrmann B, 2000, J STRUCT BIOL, V130, P232, DOI 10.1006/jsbi.2000.4241; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; Chen YR, 2006, J BIOL CHEM, V281, P24414, DOI 10.1074/jbc.M602363200; Cheng X, 2005, ANAL CHEM, V77, P7012, DOI 10.1021/ac050556a; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; Chirita CN, 2005, BIOCHEMISTRY-US, V44, P5862, DOI 10.1021/bi0500123; Chirita CN, 2004, BIOCHEMISTRY-US, V43, P1704, DOI 10.1021/bi036034b; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; D'Andrea MR, 2003, NEUROSCI LETT, V342, P114, DOI 10.1016/S0304-3940(03)00252-0; De Felice FG, 2004, FASEB J, V18, P1366, DOI 10.1096/fj.04-1764com; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Ferrao-Gonzales AD, 2005, J BIOL CHEM, V280, P34747, DOI 10.1074/jbc.M501651200; Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167; Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009; Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017; Gorman PM, 2003, J MOL BIOL, V325, P743, DOI 10.1016/S0022-2836(02)01279-2; Gosal WS, 2005, J MOL BIOL, V351, P850, DOI 10.1016/j.jmb.2005.06.040; Gosal WS, 2004, BIOMACROMOLECULES, V5, P2408, DOI 10.1021/bm049659d; Green JD, 2004, J BIOL CHEM, V279, P12206, DOI 10.1074/jbc.M312452200; Grudzielanek S, 2006, J MOL BIOL, V356, P497, DOI 10.1016/j.jmb.2005.11.075; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Hepler RW, 2006, BIOCHEMISTRY-US, V45, P15157, DOI 10.1021/bi061850f; Howlett D, 1997, FEBS LETT, V417, P249, DOI 10.1016/S0014-5793(97)01290-8; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; Howlett DR, 1999, BIOCHEM J, V343, P419, DOI 10.1042/0264-6021:3430419; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Hurshman AR, 2004, BIOCHEMISTRY-US, V43, P7365, DOI 10.1021/bi049621l; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kim YS, 2003, J BIOL CHEM, V278, P10842, DOI 10.1074/jbc.M212540200; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Klunk WE, 2001, LIFE SCI, V69, P1471, DOI 10.1016/S0024-3205(01)01232-2; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Morozova-Roche LA, 2004, BIOCHEMISTRY-US, V43, P9610, DOI 10.1021/bi0494121; Naiki H, 1998, BIOCHEMISTRY-US, V37, P17882, DOI 10.1021/bi980550y; Naiki H, 1996, LAB INVEST, V74, P374; Necula M, 2005, BIOCHEMISTRY-US, V44, P10227, DOI 10.1021/bi050387o; Necula M, 2004, ANAL BIOCHEM, V329, P238, DOI 10.1016/j.ab.2004.02.023; Netland EE, 1998, NEUROBIOL AGING, V19, P201, DOI 10.1016/S0197-4580(98)00047-5; Nilsson KPR, 2005, BIOCHEMISTRY-US, V44, P3718, DOI 10.1021/bi047402u; Nybo M, 1999, SCAND J IMMUNOL, V49, P219; Oddo S, 2006, J BIOL CHEM, V281, P1599, DOI 10.1074/jbc.M507892200; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; Ono K, 2004, BBA-MOL BASIS DIS, V1690, P193, DOI 10.1016/j.bbadis.2004.06.008; Padrick SB, 2002, BIOCHEMISTRY-US, V41, P4694, DOI 10.1021/bi0160462; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Pertinhez TA, 2002, FEBS LETT, V529, P193, DOI 10.1016/S0014-5793(02)03333-1; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; Porat Y, 2004, BIOCHEMISTRY-US, V43, P14454, DOI 10.1021/bi048582a; Sabate R, 2005, LANGMUIR, V21, P6944, DOI 10.1021/la050472x; Sabate R, 2005, INT J BIOL MACROMOL, V35, P9, DOI 10.1016/j.ijbiomac.2004.11.001; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Skovronsky DM, 2000, P NATL ACAD SCI USA, V97, P7609, DOI 10.1073/pnas.97.13.7609; Smith DL, 2001, NEUROBIOL DIS, V8, P1017, DOI 10.1006/nbdi.2001.0438; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Souillac PO, 2003, BIOCHEMISTRY-US, V42, P8094, DOI 10.1021/bi034652m; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; Taniguchi S, 2005, J BIOL CHEM, V280, P7614, DOI 10.1074/jbc.M408714200; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang J, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-1; Williams AD, 2005, P NATL ACAD SCI USA, V102, P7115, DOI 10.1073/pnas.0408582102; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0; Yu JX, 2002, J MOL NEUROSCI, V19, P51, DOI 10.1007/s12031-002-0010-x; Zhu M, 2004, J BIOL CHEM, V279, P26846, DOI 10.1074/jbc.M403129200	106	557	575	1	174	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10311	10324		10.1074/jbc.M608207200	http://dx.doi.org/10.1074/jbc.M608207200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284452	hybrid			2022-12-27	WOS:000245941000021
J	Schumacher, MA; Mansoor, A; Funnell, BE				Schumacher, Maria A.; Mansoor, Andre; Funnell, Barbara E.			Structure of a four-way bridged ParB-DNA complex provides insight into P1 segrosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID PARTITION COMPLEX; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; BACTERIAL SEGROSOME; PROTEIN; SPECIFICITY; BINDING; SITE; CENTROMERE; DOMAINS	The plasmid partition process is essential for plasmid propagation and is mediated by par systems, consisting of centromere-like sites and two proteins, ParA and ParB. In the first step of partition by the archetypical P1 system, ParB binds a complicated centromere-like site to form a large nucleoprotein segrosome. ParB is a dimeric DNA-binding protein that can bridge between both A-boxes and B-boxes located on the centromere. Its helix-turn-helix domains bind A-boxes and the dimer domain binds B-boxes. Binding of the first ParB dimer nucleates the remaining ParB molecules onto the centromere site, which somehow leads to the formation of a condensed segrosome superstructure. To further understand this unique DNA spreading capability of ParB, we crystallized and determined the structure of a 1: 2 ParB-(142-333):A3-B2-box complex to 3.35 angstrom resolution. The structure reveals a remarkable four-way, protein-DNA bridged complex in which both ParB helix-turn-helix domains simultaneously bind adjacent A-boxes and the dimer domain bridges between two B-boxes. The multibridging capability and the novel dimer domain-B-box interaction, which juxtaposes the DNA sites close in space, suggests a mechanism for the formation of the wrapped solenoid-like segrosome superstructure. This multibridging capability of ParB is likely critical in its partition complex formation and pairing functions.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University; University of Toronto	Schumacher, MA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000,1515 Holcombe Blvd, Houston, TX 77030 USA.	maschuma@mdanderson.org		Funnell, Barbara/0000-0002-1828-6567	NIGMS NIH HHS [GM074815] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074815] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biswas T, 2005, NATURE, V435, P1059, DOI 10.1038/nature03657; Bouet JY, 2000, J BIOL CHEM, V275, P8213, DOI 10.1074/jbc.275.11.8213; Bradley CM, 2005, NAT STRUCT MOL BIOL, V12, P935, DOI 10.1038/nsmb989; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davey MJ, 1997, J BIOL CHEM, V272, P15286, DOI 10.1074/jbc.272.24.15286; DAVIS MA, 1990, EMBO J, V9, P991, DOI 10.1002/j.1460-2075.1990.tb08201.x; DeLano W.L, PYMOL MOL GRAPHICS S; Edgar R, 2001, MOL MICROBIOL, V42, P1363, DOI 10.1046/j.1365-2958.2001.02717.x; Erdmann N, 1999, P NATL ACAD SCI USA, V96, P14905, DOI 10.1073/pnas.96.26.14905; Fung E, 2001, EMBO J, V20, P4901, DOI 10.1093/emboj/20.17.4901; Funnell BE, 2005, PLASMID, V53, P119, DOI 10.1016/j.plasmid.2004.12.009; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; FUNNELL BE, 2004, PLASMID BIOL; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hayes F, 2006, NAT REV MICROBIOL, V4, P133, DOI 10.1038/nrmicro1342; HAYES F, 1993, P NATL ACAD SCI USA, V90, P9228, DOI 10.1073/pnas.90.19.9228; HAYES F, 1994, J MOL BIOL, V243, P190, DOI 10.1006/jmbi.1994.1646; Hayes F, 2006, TRENDS BIOCHEM SCI, V31, P247, DOI 10.1016/j.tibs.2006.03.002; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khare D, 2004, NAT STRUCT MOL BIOL, V11, P656, DOI 10.1038/nsmb773; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lobocka M, 1996, J MOL BIOL, V259, P366, DOI 10.1006/jmbi.1996.0326; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; PRENTKI P, 1977, MOL GEN GENET, V152, P71, DOI 10.1007/BF00264942; Radnedge L, 1998, EMBO J, V17, P6076, DOI 10.1093/emboj/17.20.6076; Radnedge L, 1996, EMBO J, V15, P1155, DOI 10.1002/j.1460-2075.1996.tb00454.x; Rodionov O, 2004, MOL MICROBIOL, V52, P1215, DOI 10.1111/j.1365-2958.2004.04055.x; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Schumacher MA, 2005, NATURE, V438, P516, DOI 10.1038/nature04149; Surtees JA, 2003, CURR TOP DEV BIOL, V56, P145, DOI 10.1016/S0070-2153(03)01010-X; Surtees JA, 1999, J BACTERIOL, V181, P5898, DOI 10.1128/JB.181.19.5898-5908.1999; Surtees JA, 2001, J BIOL CHEM, V276, P12385, DOI 10.1074/jbc.M009370200; Vlieghe D, 1999, ACTA CRYSTALLOGR D, V55, P1495, DOI 10.1107/S0907444999007933	40	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10456	10464		10.1074/jbc.M610603200	http://dx.doi.org/10.1074/jbc.M610603200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293348	hybrid			2022-12-27	WOS:000245941000037
J	Duffy, HS; Iacobas, I; Hotchkiss, K; Hirst-Jensen, BJ; Bosco, A; Dandachi, N; Dermietzel, R; Sorgen, PL; Spray, DC				Duffy, Heather S.; Iacobas, Ionela; Hotchkiss, Kylie; Hirst-Jensen, Bethany J.; Bosco, Alejandra; Dandachi, Nadine; Dermietzel, Rolf; Sorgen, Paul L.; Spray, David C.			The gap junction protein connexin32 interacts with the Src homology 3/Hook domain of discs large homolog 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 GLIOMA-CELLS; POSSIBLE MECHANISM; EXPRESSION; COLOCALIZATION; IDENTIFICATION; COMMUNICATION; TRANSCRIPTION; MEMBRANE; ELEMENTS; GROWTH	Scaffolding of membrane proteins is a common strategy for forming complexes of proteins, including some connexins, within membrane microdomains. Here we describe studies indicating that Cx32 interacts with a PDZ-containing scaffolding protein, Dlgh1 (Discs Large homolog 1). Initial screens of liver lysates using antibody arrays indicated an interaction between Cx32 and Dlgh1 that was confirmed using coimmunoprecipitation studies. Yeast two-hybrid complementation determined that the Cx32 bound via interaction with the SH3/Hook domain of Dlgh1. Confocal microscopy of liver sections revealed that Cx32 and Dlgh1 could colocalize in hepatocyte membranes in wild type mice. Examination of levels and localization of Dlgh1 in livers from Cx32 null mice indicate that, in the absence of Cx32, Dlgh1 was decreased, and the remainder was translocated from the hepatocyte membrane to the nucleus with some remaining in cytoplasmic compartments. This translocation was confirmed by Western blots comparing Dlgh1 levels in nuclear extracts from wild type and Cx32 null murine livers. Using SKHep cells stably transfected with Cx32 under the control of a tet-off promoter, we found that acute removal of Cx32 led to a decrease of membrane-localized Dlgh1 and an increase in the nuclear localization of this tumor suppressor protein. Together, these results suggest that loss of Cx32 alters the levels, localization, and interactions of the tumor suppressor protein Dlgh1, events known in other systems to alter cell cycle and increase tumorigenicity.	Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Univ Nebraska, Dept Biochem & Mol Biol, Omaha, NE 68918 USA; Univ Bochum, Dept Neurosci & Mol Brain Res, D-44780 Bochum, Germany	Columbia University; Yeshiva University; Albert Einstein College of Medicine; University of Nebraska System; Ruhr University Bochum	Duffy, HS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	hsd2102@columbia.edu		BOSCO, ALEJANDRA/0000-0003-3743-5414; Spray, David/0000-0001-8368-5073	NIDDK NIH HHS [DK41918] Funding Source: Medline; NIGMS NIH HHS [R01 GM072631] Funding Source: Medline; PHS HHS [M072631] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072631] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad S, 2001, EUR J BIOCHEM, V268, P4544, DOI 10.1046/j.1432-1327.2001.02380.x; Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Dagli MLZ, 2004, CARCINOGENESIS, V25, P483, DOI 10.1093/carcin/bgh050; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; Duffy HS, 2002, J PHYSIOL-PARIS, V96, P243, DOI 10.1016/S0928-4257(02)00012-8; Duffy HS, 2005, PRACTICAL METHODS IN CARDIOVASCULAR RESEARCH, P916, DOI 10.1007/3-540-26574-0_46; Fishman GI, 1995, CELL ADHES COMMUN, V3, P353, DOI 10.3109/15419069509081019; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Gellhaus A, 2004, J BIOL CHEM, V279, P36931, DOI 10.1074/jbc.M404073200; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Hsueh YP, 2006, CURR MED CHEM, V13, P1915, DOI 10.2174/092986706777585040; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kojima T, 1999, BIOCHEM BIOPH RES CO, V266, P222, DOI 10.1006/bbrc.1999.1778; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Lauf U, 2002, P NATL ACAD SCI USA, V99, P10446, DOI 10.1073/pnas.162055899; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Naus CCG, 2002, CAN J PHYSIOL PHARM, V80, P136, DOI 10.1139/Y02-009; Naus CCG, 2000, BRAIN RES REV, V32, P259, DOI 10.1016/S0165-0173(99)00087-9; Neijssen J, 2005, NATURE, V434, P83, DOI 10.1038/nature03290; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Penes MC, 2005, EUR J NEUROSCI, V22, P404, DOI 10.1111/j.1460-9568.2005.04225.x; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; PITTS JD, 1988, BRIT J CANCER, V58, P52; Scemes E, 2000, J NEUROSCI, V20, P1435; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Stains Joseph P, 2005, Birth Defects Res C Embryo Today, V75, P72, DOI 10.1002/bdrc.20034; Stains JP, 2005, MOL BIOL CELL, V16, P64, DOI 10.1091/mbc.E04-04-0339; Stains JP, 2003, J BIOL CHEM, V278, P24377, DOI 10.1074/jbc.M212554200; Suadicani SO, 2003, GLIA, V42, P160, DOI 10.1002/glia.10197; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Valiunas V, 2005, J PHYSIOL-LONDON, V568, P459, DOI 10.1113/jphysiol.2005.090985; Xu X, 2001, CELL COMMUN ADHES, V8, P321, DOI 10.3109/15419060109080746	34	54	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9789	9796		10.1074/jbc.M605261200	http://dx.doi.org/10.1074/jbc.M605261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284442	hybrid			2022-12-27	WOS:000245421700053
J	Hoos, MD; Ahmed, M; Smith, SO; van Nostrand, WE				Hoos, Michael D.; Ahmed, Mahiuddin; Smith, Steven O.; van Nostrand, William E.			Inhibition of familial cerebral amyloid angiopathy mutant amyloid beta-protein fibril assembly by myelin basic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE BRAIN; HUMAN APOLIPOPROTEIN-E; DUTCH-TYPE; A-BETA; PRECURSOR PROTEIN; TRANSGENIC MICE; MUSCLE-CELLS; IN-VITRO; HEMORRHAGE	Deposition of fibrillar amyloid beta-protein (A beta) in the brain is a prominent pathological feature of Alzheimer disease and related disorders, including familial forms of cerebral amyloid angiopathy (CAA). Mutant forms of A beta, including Dutch- and Iowa-type A beta, which are responsible for familial CAA, deposit primarily as fibrillar amyloid along the cerebral vasculature and are either absent or present only as diffuse non-fibrillar plaques in the brain parenchyma. Despite the lack of parenchymal fibril formation in vivo, these CAA mutant A beta peptides exhibit a markedly increased rate and extent of fibril formation in vitro compared with wild-type A beta. Based on these conflicting observations, we sought to determine whether brain parenchymal factors that selectively interact with and modulate CAA mutant A beta fibril assembly exist. Using a combination of immunoaffinity chromatography and mass spectrometry, we identified myelin basic protein (MBP) as a prominent brain parenchymal factor that preferentially binds to CAA mutant A beta compared with wild-type A beta. Surface plasmon resonance measurements confirmed that MBP bound more tightly to Dutch/Iowa CAA double mutant A beta than to wild-type A beta. Using a combination of biochemical and ultrastructural techniques, we found that MBP inhibited the fibril assembly of CAA mutant A beta. Together, these findings suggest a possible role for MBP in regulating parenchymal fibrillar A beta deposition in familial CAA.	SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	van Nostrand, WE (corresponding author), SUNY Stony Brook, Dept Med, HSC T-15-083, Stony Brook, NY 11794 USA.	William.VanNostrand@stonybrook.edu	Smith, Steven/HDM-9496-2022		NIA NIH HHS [R01 AG027317] Funding Source: Medline; NIGMS NIH HHS [T32 GM008444] Funding Source: Medline; NINDS NIH HHS [NS35781] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027317] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abdo WF, 2006, NEUROLOGY, V67, P474, DOI 10.1212/01.wnl.0000227891.25592.8c; Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; Attems J, 2004, ACTA NEUROPATHOL, V107, P83, DOI 10.1007/s00401-003-0796-9; Bailey TL, 2004, NEUROL RES, V26, P573, DOI 10.1179/016164104225016272; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Beems T, 2003, ACTA NEUROCHIR, V145, P37, DOI 10.1007/s00701-002-1019-1; Bentley NM, 2002, BIOCHEM J, V366, P273, DOI 10.1042/BJ20020207; BERLET HH, 1994, NEUROSCI LETT, V179, P75, DOI 10.1016/0304-3940(94)90938-5; Bornebroek M, 1996, ALZ DIS ASSOC DIS, V10, P224, DOI 10.1097/00002093-199601040-00008; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAMPAGNONI AT, 1993, J BIOL CHEM, V268, P4930; CHAN KC, 1988, BIOCHEM BIOPH RES CO, V152, P1468, DOI 10.1016/S0006-291X(88)80451-0; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; CHOU FCH, 1976, J BIOL CHEM, V251, P2671; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Cotman SL, 2000, MOL CELL NEUROSCI, V15, P183, DOI 10.1006/mcne.1999.0816; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Esiri MM, 2001, LANCET, V357, P169; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Givogri MI, 2000, J NEUROSCI RES, V59, P153, DOI 10.1002/(SICI)1097-4547(20000115)59:2<153::AID-JNR1>3.3.CO;2-6; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; HENDRIKSL, 1992, NAT GENET, V1, P218; Hill CMD, 2005, BIOCHEM BIOPH RES CO, V329, P362, DOI 10.1016/j.bbrc.2005.01.151; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; John V, 2003, J MED CHEM, V46, P4625, DOI 10.1021/jm030247h; Kakio A, 2001, J BIOL CHEM, V276, P24985, DOI 10.1074/jbc.M100252200; KAMINO K, 1992, AM J HUM GENET, V51, P998; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; Kokubo H, 2005, BRAIN RES, V1031, P222, DOI 10.1016/j.brainres.2004.10.041; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Maat-Schieman MLC, 2004, ACTA NEUROPATHOL, V107, P389, DOI 10.1007/s00401-004-0824-4; MAATSCHIEMAN MLC, 1992, ACTA NEUROPATHOL, V84, P674, DOI 10.1007/BF00227745; MaatSchieman MLC, 1997, J NEUROPATH EXP NEUR, V56, P273, DOI 10.1097/00005072-199703000-00006; Manelli AM, 2004, J MOL NEUROSCI, V23, P235, DOI 10.1385/JMN:23:3:235; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mastrangelo IA, 2006, J MOL BIOL, V358, P106, DOI 10.1016/j.jmb.2006.01.042; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; Miravalle L, 2000, J BIOL CHEM, V275, P27110; MOSCARELLO MA, 1990, PROG CLIN BIOL RES, V336, P25; Mucke L, 2000, AM J PATHOL, V157, P2003, DOI 10.1016/S0002-9440(10)64839-0; Natte R, 2001, ANN NEUROL, V50, P765, DOI 10.1002/ana.10040; Pillot T, 1999, J NEUROCHEM, V72, P230, DOI 10.1046/j.1471-4159.1999.0720230.x; PIROLLET F, 1992, BIOCHEMISTRY-US, V31, P8849, DOI 10.1021/bi00152a022; Polverini E, 2004, J STRUCT BIOL, V148, P353, DOI 10.1016/j.jsb.2004.08.004; Potter H, 2001, NEUROBIOL AGING, V22, P923, DOI 10.1016/S0197-4580(01)00308-6; Pribyl TM, 1996, J COMP NEUROL, V374, P342, DOI 10.1002/(SICI)1096-9861(19961021)374:3<342::AID-CNE3>3.0.CO;2-1; PRIBYL TM, 1993, P NATL ACAD SCI USA, V90, P10695, DOI 10.1073/pnas.90.22.10695; Richter-Landsberg C, 2000, J NEUROSCI RES, V59, P11, DOI 10.1002/(SICI)1097-4547(20000101)59:1<11::AID-JNR2>3.0.CO;2-O; ROTH HJ, 1987, J NEUROSCI RES, V17, P321, DOI 10.1002/jnr.490170402; ROZEMULLER AJM, 1993, AM J PATHOL, V142, P1449; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Schwarzman AL, 2004, AMYLOID, V11, P1, DOI 10.1080/13506120410001667458; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shin Y, 2002, ANN NY ACAD SCI, V977, P245, DOI 10.1111/j.1749-6632.2002.tb04822.x; SMITH R, 1992, J NEUROCHEM, V59, P1589, DOI 10.1111/j.1471-4159.1992.tb10989.x; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Tagliavini F., 1999, ALZHEIMERS REP, V2, pS28; Thal DR, 2003, J NEUROPATH EXP NEUR, V62, P1287, DOI 10.1093/jnen/62.12.1287; Tosic M, 2002, GLIA, V37, P219, DOI 10.1002/glia.10028; Tsuzuki K, 2000, NEUROSCI LETT, V281, P171, DOI 10.1016/S0304-3940(00)00834-X; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verbeek MM, 1997, J NEUROCHEM, V68, P1135; Vinters Harry V, 2003, Adv Neurol, V92, P105; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WATTENDORFF AR, 1995, J NEUROL NEUROSUR PS, V59, P699; WISNIEWSKI HM, 1994, AMYLOID, V1, P8, DOI 10.3109/13506129409148619; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WOOD DD, 1989, J BIOL CHEM, V264, P5121; Yamamoto N, 2005, FEBS LETT, V579, P2185, DOI 10.1016/j.febslet.2005.03.013; Yang DS, 2001, AMYLOID, V8, P10; Zand R, 1998, BIOCHEMISTRY-US, V37, P2441, DOI 10.1021/bi972347t	83	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9952	9961		10.1074/jbc.M603494200	http://dx.doi.org/10.1074/jbc.M603494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259179	hybrid			2022-12-27	WOS:000245421700070
J	Phartiyal, P; Jones, EMC; Robertson, GA				Phartiyal, Pallavi; Jones, Eugenia M. C.; Robertson, Gail A.			Heteromeric assembly of human ether-a-go-go-related gene (hERG) 1a/1b channels occurs cotranslationally via N-terminal interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; DEFECTIVE PROTEIN TRAFFICKING; GATED POTASSIUM CHANNELS; K+ CHANNEL; ENDOPLASMIC-RETICULUM; CARDIAC-ARRHYTHMIA; I-KR; PHARMACOLOGICAL RESCUE; SURFACE EXPRESSION; MUTANT CHANNELS	Alternate transcripts of the human ether-A-go-go-related gene (hERG1) encode two subunits, hERG 1a and 1b, which form potassium channels regulating cardiac repolarization, neuronal firing frequency, and neoplastic cell growth. The la and 1b subunits are identical except for their unique, cytoplasmic N termini, and they readily co-assemble in heterologous and native systems. We tested the hypothesis that interactions of nascent N termini promote heteromeric assembly of 1a and 1b subunits. We found that 1a and 1b N-terminal fragments bind in a direct and dose-dependent manner. hERG1 hetero-oligomerization occurs in the endoplasmic reticulum where co-expression of N-terminal fragments with hERG1 subunits disrupted oligomerization and core glycosylation. The disruption of core glycosylation, a cotranslational event, allows us to pinpoint these N-terminal interactions to the earliest steps in biogenesis. Thus, N-terminal interactions mediate hERG 1a/1b assembly, a process whose perturbation may represent a new mechanism for disease.	Univ Wisconsin, Satellite Labs, Dept Physiol, Madison, WI 53711 USA; Univ Wisconsin, Satellite Labs, Cellular & Mol Biol Program, Madison, WI 53711 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Robertson, GA (corresponding author), Univ Wisconsin, Satellite Labs, Dept Physiol, 601 Sci Dr, Madison, WI 53711 USA.	robertson@physiology.wisc.edu		Robertson, Gail/0000-0003-4694-5790	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081780] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL081780] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson CL, 2006, CIRCULATION, V113, P365, DOI 10.1161/CIRCULATIONAHA.105.570200; Arcangeli A, 2004, BIOCHEM SOC T, V32, P826, DOI 10.1042/BST0320826; Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Arcangeli Annarosa, 2005, V266, P225; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; Bianchi L, 1998, CANCER RES, V58, P815; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Cherubini A, 2005, MOL BIOL CELL, V16, P2972, DOI 10.1091/mbc.E04-10-0940; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; Crociani O, 2003, J BIOL CHEM, V278, P2947, DOI 10.1074/jbc.M210789200; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Deutsch C, 2003, NEURON, V40, P265, DOI 10.1016/S0896-6273(03)00506-3; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Farrelly AM, 2003, AM J PHYSIOL-GASTR L, V284, pG883, DOI 10.1152/ajpgi.00394.2002; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Fitzgerald PT, 2005, HEART RHYTHM, V2, pS30, DOI 10.1016/j.hrthm.2005.08.007; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; Gong QM, 2005, J BIOL CHEM, V280, P19419, DOI 10.1074/jbc.M502327200; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; Gullo F, 2002, FASEB J, V16, P330, DOI 10.1096/fj.02-0200fje; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; January CT, 2000, J CARDIOVASC ELECTR, V11, P1413, DOI 10.1046/j.1540-8167.2000.01413.x; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Jones EMC, 2004, J BIOL CHEM, V279, P44690, DOI 10.1074/jbc.M408344200; Jordan M, 2004, METHODS, V33, P136, DOI 10.1016/j.ymeth.2003.11.011; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kosolapov A, 2003, J BIOL CHEM, V278, P4305, DOI 10.1074/jbc.M209422200; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; Lees-Miller JP, 2003, MOL CELL BIOL, V23, P1856, DOI 10.1128/MCB.23.6.1856-1862.2003; LeesMiller JP, 1997, CIRC RES, V81, P719; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; London B, 1997, CIRC RES, V81, P870; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Lu JL, 2001, BIOCHEMISTRY-US, V40, P13288, DOI 10.1021/bi0107647; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Ohya S, 2002, AM J PHYSIOL-CELL PH, V283, pC866, DOI 10.1152/ajpcell.00099.2002; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pillozzi S, 2002, LEUKEMIA, V16, P1791, DOI 10.1038/sj.leu.2402572; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; Robertson GA, 2006, HANDB EXP PHARMACOL, V171, P349; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; SHAHLA V, 1992, CELL, V68, P23; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Tu L, 2000, BIOCHEMISTRY-US, V39, P824, DOI 10.1021/bi991740r; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; WIRTH PJ, 1995, J CHROMATOGR A, V698, P123, DOI 10.1016/0021-9673(94)00879-E; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	64	51	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9874	9882		10.1074/jbc.M610875200	http://dx.doi.org/10.1074/jbc.M610875200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272276	hybrid			2022-12-27	WOS:000245421700062
J	Boucher, N; Dacheux, D; Giroud, C; Baltz, T				Boucher, Nathalie; Dacheux, Denis; Giroud, Christiane; Baltz, Theo			An essential cell cycle-regulated nucleolar protein relocates to the mitotic spindle where it is involved in mitotic progression in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; RNA INTERFERENCE; RIBOSOME BIOGENESIS; BINDING PROTEIN; GENE-EXPRESSION; PROCYCLIC FORM; AURORA KINASE; CYTOKINESIS; HOMOLOG; MITOSIS	TbNOP86 and TbNOP66 are two novel nucleolar proteins isolated in Trypanosoma brucei. They share 92.6% identity, except for an additional C-terminal domain of TbNOP86 of 182 amino acids in length. Both proteins are found in Trypanosomatidae, but similarity to other eukaryotic proteins could not be found. TbNOP86 and TbNOP66 are expressed at similar level in procyclic and bloodstream forms, although the relative level of expression of TbNOP66 is 11 times lower. TbNOP86 undergoes post-translational modifications, as it is found predominantly at 110 kDa compared with the predicted 86 kDa. Immunofluorescence of overexpressed ty-tagged TbNOP86 and TbNOP66 showed that both proteins accumulated in the nucleolus of G(1) cells. This was confirmed by the co-localization of an endogenous TbNOP86-myc with the nucleolar protein Nopp140. TbNOP86-ty localization is cell cycle-regulated, because it co-localizes with the mitotic spindle in mitotic cells. TbNOP86 is required for mitotic progression in both life stages as depleted cells are enriched in the G2/M phase. In procyclic cells, a reduced growth rate is accompanied by an accumulation of zoids (0N1K), 2N1K, and multinucleated cells (xNyK). The 2N1K cells are blocked in late mitosis as nucleolar segregation is completed. TbNOP86 depletion in bloodstream form caused a drastic growth inhibition producing cells bearing two kinetoplasts and an enlarged nucleus (1N*2K), followed by an accumulation of 2N2K cells with connected nuclei and xNyK cells. These studies of TbNOP86 provide a more comprehensive account of proteins involved in mitotic events in trypanosomes and should lead to the identification of partners with similar function.	Univ Bordeaux 2, UMR 5234, CNRS, Lab Microbiol Cellulaire & Mol, F-33076 Bordeaux, France; Univ Bordeaux 2, UMR 5234, CNRS, Lab Pathogenet, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Boucher, N (corresponding author), Univ Bordeaux 2, UMR 5234, CNRS, Lab Microbiol Cellulaire & Mol, F-33076 Bordeaux, France.	nathalie.boucher@parasitmol.u-bordeaux2.fr	Dacheux, Denis/AGF-5359-2022	DACHEUX, Denis/0000-0002-9956-4839				Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Bakalara N, 2000, J BIOL CHEM, V275, P8863, DOI 10.1074/jbc.275.12.8863; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Blanc JF, 2005, PROTEOMICS, V5, P3778, DOI 10.1002/pmic.200401194; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Das A, 1996, J BIOL CHEM, V271, P15675, DOI 10.1074/jbc.271.26.15675; Dubessay P, 2006, MOL MICROBIOL, V59, P1162, DOI 10.1111/j.1365-2958.2005.05013.x; Durand-Dubief M, 2003, BMC BIOL, V1, DOI 10.1186/1741-7007-1-2; Elias MCQB, 2001, MOL BIOCHEM PARASIT, V112, P79, DOI 10.1016/S0166-6851(00)00349-2; Ersfeld K, 1997, SCIENCE, V276, P611, DOI 10.1126/science.276.5312.611; Hammarton TC, 2005, MOL MICROBIOL, V56, P104, DOI 10.1111/j.1365-2958.2005.04542.x; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Harlow E., 1988, ANTIBODIES LAB MANUA; Hoek M, 2000, J CELL SCI, V113, P3959; Jensen BC, 2005, EUKARYOT CELL, V4, P30, DOI 10.1128/EC.4.1.30-35.2005; Jensen BC, 2003, J BIOL CHEM, V278, P32204, DOI 10.1074/jbc.M304198200; Jensen BC, 2007, MOL BIOCHEM PARASIT, V151, P28, DOI 10.1016/j.molbiopara.2006.10.002; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kelly S, 2006, EUKARYOT CELL, V5, P876, DOI 10.1128/EC.5.5.876-879.2006; Kumar P, 2006, EUKARYOT CELL, V5, P92, DOI 10.1128/EC.5.1.92-102.2006; Kumar P, 2005, J BIOL CHEM, V280, P31783, DOI 10.1074/jbc.M504326200; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Li B, 2005, MOL CELL BIOL, V25, P5011, DOI 10.1128/MCB.25.12.5011-5021.2005; Li ZY, 2006, EUKARYOT CELL, V5, P1026, DOI 10.1128/EC.00129-06; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; McKean PG, 2003, CURR OPIN MICROBIOL, V6, P600, DOI 10.1016/j.mib.2003.10.010; Nazar RN, 2004, IUBMB LIFE, V56, P457, DOI 10.1080/15216540400010867; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Oberholzer M, 2006, MOL BIOCHEM PARASIT, V145, P117, DOI 10.1016/j.molbiopara.2005.09.002; Ogbadoyi E, 2000, CHROMOSOMA, V108, P501, DOI 10.1007/s004120050402; Park JH, 2002, MOL BIOCHEM PARASIT, V119, P97, DOI 10.1016/S0166-6851(01)00407-8; Ploubidou A, 1999, J CELL SCI, V112, P4641; Pradel LC, 2006, J CELL SCI, V119, P1852, DOI 10.1242/jcs.02900; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Rothberg KG, 2006, J BIOL CHEM, V281, P9781, DOI 10.1074/jbc.M600133200; SASSE R, 1988, J CELL SCI, V90, P577; SEYFANG A, 1993, EUR J BIOCHEM, V214, P593, DOI 10.1111/j.1432-1033.1993.tb17958.x; Trautmann S, 2004, DEV CELL, V7, P755, DOI 10.1016/j.devcel.2004.10.006; Tu XM, 2006, J BIOL CHEM, V281, P9677, DOI 10.1074/jbc.M511504200; Tu XM, 2004, J BIOL CHEM, V279, P20519, DOI 10.1074/jbc.M312862200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835; WOODWARD R, 1990, J CELL SCI, V95, P49	47	13	13	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13780	13790		10.1074/jbc.M700780200	http://dx.doi.org/10.1074/jbc.M700780200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17322293	hybrid			2022-12-27	WOS:000246060300068
J	Ferrai, C; Munari, D; Luraghi, P; Pecciarini, L; Cangi, MG; Doglioni, C; Blasi, F; Crippa, MP				Ferrai, Carmelo; Munari, Davide; Luraghi, Paolo; Pecciarini, Lorenza; Cangi, Maria Giulia; Doglioni, Claudio; Blasi, Francesco; Crippa, Massimo P.			A transcription-dependent micrococcal nuclease-resistant fragment of the urokinase-type plasminogen activator promoter interacts with the enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; IN-VIVO; GENE-EXPRESSION; HISTONE MODIFICATIONS; ALPHA-AMANITIN; SP1; UPA; PROTEINS; DISTANCE; LINKING	We show the interaction between the enhancer and the minimal promoter of urokinase-type plasminogen activator gene during active transcription by coupling micrococcal nuclease digestion of cross-linked, sonicated chromatin, and chromatin immunoprecipitation. This approach allowed the precise identification of the interacting genomic fragments, one of which is resistant to micrococcal nuclease cleavage. The interacting fragments form a single transcriptional control unit, as indicated by their common protein content. Furthermore, we show that the enhancer-MP interaction persists during the early stages of transcription and is lost upon alpha-amanitin treatment, indicating the requirement for active transcription. Our results support a looping model of interaction between the enhancer and the MP of the urokinase-type plasminogen activator gene.	Ist Sci San Raffaele, Mol Genet Lab, I-20132 Milan, Italy; Ist Sci San Raffaele, Anat Pathol Unit, I-20132 Milan, Italy; Univ Vita Salute S Raffaele, I-20132 Milan, Italy; FIRC Inst Mol Oncol, I-20139 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IFOM - FIRC Institute of Molecular Oncology	Crippa, MP (corresponding author), Ist Sci San Raffaele, Mol Genet Lab, Via Olgettina 58, I-20132 Milan, Italy.	crippa.massimo@hsr.it	Ferrai, Carmelo/GVS-7378-2022; Cangi, M.Giulia/CAF-1459-2022; crippa, massimo/J-6514-2016; Pecciarini, Lorenza/GQI-3544-2022	Cangi, M.Giulia/0000-0002-9472-0935; crippa, massimo/0000-0003-3214-9670; Ferrai, Carmelo/0000-0002-8088-2757; DOGLIONI, Claudio/0000-0002-4969-5216; Blasi, Francesco/0000-0001-9406-1784				Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; Chan HM, 2001, J CELL SCI, V114, P2363; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; DECESARE D, 1995, ONCOGENE, V11, P365; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; Helenius MA, 2001, CANCER RES, V61, P5340; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Ibanez-Tallon I, 2002, BLOOD, V100, P3325, DOI 10.1182/blood.V100.9.3325; Ibanez-Tallon I, 1999, ONCOGENE, V18, P2836, DOI 10.1038/sj.onc.1202644; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Levsky JM, 2002, SCIENCE, V297, P836, DOI 10.1126/science.1072241; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Patrinos GP, 2004, GENE DEV, V18, P1495, DOI 10.1101/gad.289704; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; ROSS IL, 1994, IMMUNOL CELL BIOL, V72, P177, DOI 10.1038/icb.1994.26; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Turner B., 2001, CHROMATIN GENE REGUL; Turner BM, 2005, NAT STRUCT MOL BIOL, V12, P110, DOI 10.1038/nsmb0205-110; van Holde KE., 1989, SPRINGER SERIES MOL; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371	47	16	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12537	12546		10.1074/jbc.M700867200	http://dx.doi.org/10.1074/jbc.M700867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331942	hybrid			2022-12-27	WOS:000245942800022
J	Singhirunnusorn, P; Ueno, Y; Matsuo, M; Suzuki, S; Saiki, I; Sakurai, H				Singhirunnusorn, Pattama; Ueno, Yoko; Matsuo, Mitsuhiro; Suzuki, Shunsuke; Saiki, Ikuo; Sakurai, Hiroaki			Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-alpha through the TAK1-p38 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; EPITHELIAL-CELLS; TYROSINE KINASE; ERBB RECEPTORS; LUNG-CANCER; HB-EGF; STRESS; TRANSACTIVATION; PHOSPHORYLATION; TRANSDUCTION	Epidermal growth factor receptor ( EGFR) has been shown to be activated by specific ligands as well as other cellular stimuli including tumor necrosis factor-alpha ( TNF-alpha). In the present study, we found that cellular stress suppressed ligand-mediated EGFR activity. Both TNF-alpha and osmotic stress rapidly induced phosphorylation of EGFR. This phosphorylation of EGFR and the activation of mitogen-activated protein kinases and NF-kappa B occurred independently of the shedding of extracellular membrane-bound EGFR ligands and intracellular EGFR tyrosine kinase activity. Transforming growth factor-beta-activated kinase 1 ( TAK1) was involved in the TNF-alpha-induced signaling pathway to EGFR. In addition, experiments using chemical inhibitors and small interfering RNA demonstrated that p38 alpha is a common mediator for the cellular stress-induced phosphorylation of EGFR. Surprisingly, the modified EGFR was not able to respond to its extracellular ligand due to transient internalization through the clathrin-mediated mechanism. Furthermore, turnover of p38 activation led to dephosphorylation and recycling back to the cell surface of EGFR. These results demonstrated that TNF-alpha has opposite bifunctional activities in modulating the function of the EGFR.	Toyama Univ, Grad Sch Med & Pharmaceut Sci, Inst Nat Med, Div Pathogen Biochem, Toyama 9300194, Japan; Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Anat, Toyama 9300194, Japan; Toyama Univ, Century Ctr Excellence Program 21st, Toyama 9300194, Japan	University of Toyama; University of Toyama; University of Toyama	Sakurai, H (corresponding author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Inst Nat Med, Div Pathogen Biochem, 2630 Sugitani, Toyama 9300194, Japan.	hsakurai@inm.u-toyama.ac.jp	Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Argast GM, 2004, J BIOL CHEM, V279, P34530, DOI 10.1074/jbc.M405703200; Blackledge G, 2004, BRIT J CANCER, V90, P566, DOI 10.1038/sj.bjc.6601550; CARPENTER G, 1986, EXP CELL RES, V164, P1, DOI 10.1016/0014-4827(86)90449-0; Chan SK, 2006, EUR J CANCER, V42, P17, DOI 10.1016/j.ejca.2005.07.031; Chen WNU, 2004, J BIOL CHEM, V279, P18488, DOI 10.1074/jbc.M310874200; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Cheng H, 2002, J CELL PHYSIOL, V192, P234, DOI 10.1002/jcp.10134; Chobotova K, 2005, J CLIN ENDOCR METAB, V90, P913, DOI 10.1210/jc.2004-0476; Choo MK, 2006, INT J CANCER, V118, P2758, DOI 10.1002/ijc.21734; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; GarciaLloret MI, 1996, J CELL PHYSIOL, V167, P324, DOI 10.1002/(SICI)1097-4652(199605)167:2<324::AID-JCP17>3.0.CO;2-7; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hart S, 2005, BIOL CHEM, V386, P845, DOI 10.1515/BC.2005.099; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Iwamoto R, 2006, CELL STRUCT FUNCT, V31, P1, DOI 10.1247/csf.31.1; Janes KA, 2006, CELL, V124, P1225, DOI 10.1016/j.cell.2006.01.041; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Matsuo M, 2006, CANCER SCI, V97, P155, DOI 10.1111/j.1349-7006.2006.00152.x; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shinohara H, 2005, J EXP MED, V202, P1423, DOI 10.1084/jem.20051591; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Sweeney C, 2000, ONCOGENE, V19, P5568, DOI 10.1038/sj.onc.1203913; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Ueno Y, 2005, BRIT J CANCER, V92, P1690, DOI 10.1038/sj.bjc.6602548; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Vergarajauregui S, 2006, TRAFFIC, V7, P686, DOI 10.1111/j.1600-0854.2006.00420.x; Wan YSY, 2006, NAT IMMUNOL, V7, P851, DOI 10.1038/ni1355; Wan YS, 2001, CELL SIGNAL, V13, P139, DOI 10.1016/S0898-6568(00)00146-7; Winograd-Katz SE, 2006, ONCOGENE, V25, P7381, DOI 10.1038/sj.onc.1209737; Xu YR, 2006, AM J PATHOL, V169, P823, DOI 10.2353/ajpath.2006.050449; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zwang Y, 2006, EMBO J, V25, P4195, DOI 10.1038/sj.emboj.7601297	52	38	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12698	12706		10.1074/jbc.M608723200	http://dx.doi.org/10.1074/jbc.M608723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327237	hybrid			2022-12-27	WOS:000245942800039
J	Cannistraro, VJ; Taylor, JS				Cannistraro, Vincent J.; Taylor, John-Stephen			Ability of polymerase eta and T7 DNA polymerase to bypass bulge structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; SYN THYMINE DIMER; CRYSTAL-STRUCTURE; ERROR-PRONE; CIS-SYN; SULFOLOBUS-SOLFATARICUS; REPLICATION FIDELITY; PHOSPHATE BACKBONE; INSERTION OPPOSITE; REACTION-MECHANISM	DNA misalignment occurs in homopolymer tracts during replication and can lead to frameshift mutations. Polymerase ( pol) recognition of primer-templates containing bulge structures and the transmission of a bulge through a polymerase binding site or replication complex are important components of frameshift mutagenesis. In this report, we describe the interaction of the catalytic core of pol eta with primer-templates containing bulge structures by single round primer extension. We found that pol eta could stabilize a frayed primer terminus, which enhances its ability to extend primer-templates containing bulges. Based on methylphosphonate-DNA mapping, pol eta interacts with the single strand template but not appreciably with the template strand of the DNA stem greater than two nucleotides from the primer terminus. These latter characteristics, combined with the ability to stabilize a frayed primer terminus, may explain why primer-templates containing template bulges are extended so efficiently by pol eta. Although pol eta could accommodate large bulges and continue synthesis without obstruction, bulge structures in the template, but not in the primer, caused termination of the T7 DNA replication complex. Terminations occurred when the template bulge neared the helix-loop-helix domain of the polymerase thumb. Terminations were not observed, however, when bulge structures approached the site of interaction of the DNA with the extended thumb and thioredoxin. At low temperature, however, terminations did occur at this site.	Washington Univ, Dept Chem, St Louis, MO 63103 USA	Washington University (WUSTL)	Taylor, JS (corresponding author), Washington Univ, Dept Chem, 1 Brookings Dr,Campus Box 1134, St Louis, MO 63103 USA.	taylor@wuchem.wustl.edu	Taylor, John-Stephen/AAA-3218-2020	Taylor, John-Stephen/0000-0002-8615-7257	NATIONAL CANCER INSTITUTE [R37CA040463, R01CA040463] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40463, R01 CA040463, R01 CA040463-23] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bassett E, 2002, DNA REPAIR, V1, P1003, DOI 10.1016/S1568-7864(02)00150-7; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354; Cannistraro VJ, 1999, BBA-PROTEIN STRUCT M, V1433, P170, DOI 10.1016/S0167-4838(99)00136-3; Cannistraro VJ, 2004, J BIOL CHEM, V279, P18288, DOI 10.1074/jbc.M400282200; CANNISTRARO VJ, 1994, J MOL BIOL, V243, P930, DOI 10.1006/jmbi.1994.1693; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fortune JM, 2005, J BIOL CHEM, V280, P29980, DOI 10.1074/jbc.M505236200; Fortune JM, 2006, NUCLEIC ACIDS RES, V34, P4335, DOI 10.1093/nar/gkl403; Garcia-Diaz M, 2006, CELL, V124, P331, DOI [10.1016/j.cell.2005.10.039, 10.1016/j.cel.2005.10.039]; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Hamelberg D, 2002, NUCLEIC ACIDS RES, V30, P3615, DOI 10.1093/nar/gkf472; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Hwang HS, 2005, BIOCHEMISTRY-US, V44, P4850, DOI 10.1021/bi048244+; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; Lam WC, 1999, BIOCHEMISTRY-US, V38, P2661, DOI 10.1021/bi9820762; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; LEBLANC DA, 1991, BIOCHEMISTRY-US, V30, P4042, DOI 10.1021/bi00230a031; Lee JB, 2006, NATURE, V439, P621, DOI 10.1038/nature04317; Li Y, 2004, NAT STRUCT MOL BIOL, V11, P784, DOI 10.1038/nsmb792; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; MASKER W, 1993, MUTAT RES, V301, P235, DOI 10.1016/0165-7992(93)90063-2; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; MORDEN KM, 1990, BIOCHEMISTRY-US, V29, P8835, DOI 10.1021/bi00489a047; Okonogi TM, 2002, P NATL ACAD SCI USA, V99, P4156, DOI 10.1073/pnas.072067799; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4004, DOI 10.1021/bi00131a016; Schweitzer M, 1999, J BIOMOL STRUCT DYN, V16, P1177, DOI 10.1080/07391102.1999.10508326; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; StraussSoukup JK, 1997, BIOCHEMISTRY-US, V36, P8692, DOI 10.1021/bi9705467; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Sun LP, 2000, BIOCHEMISTRY-US, V39, P14603, DOI 10.1021/bi001446v; TABOR S, 1987, J BIOL CHEM, V262, P16212; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Turner RM, 2003, BIOCHEMISTRY-US, V42, P2373, DOI 10.1021/bi026566c; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	58	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11188	11196		10.1074/jbc.M608478200	http://dx.doi.org/10.1074/jbc.M608478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303570	hybrid			2022-12-27	WOS:000245941500040
J	Kooijman, EE; Tieleman, DP; Testerink, C; Munnik, T; Rijkers, DTS; Burger, KNJ; de Kruijff, B				Kooijman, Edgar E.; Tieleman, D. Peter; Testerink, Christa; Munnik, Teun; Rijkers, Dirk T. S.; Burger, Koert N. J.; de Kruijff, Ben			An electrostatic/hydrogen bond switch as the basis for the specific interaction of phosphatidic acid with proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; ALPHA-HELICAL PEPTIDES; LYSOPHOSPHATIDIC ACID; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-D; PHOSPHOGLUCOSE ISOMERASE; HYDROPHOBIC MISMATCH; CATALYTIC MECHANISM; MOLECULAR-DYNAMICS; ESCHERICHIA-COLI	Phosphatidic acid ( PA) is a minor but important phospholipid that, through specific interactions with proteins, plays a central role in several key cellular processes. The simple yet unique structure of PA, carrying just a phosphomonoester head group, suggests an important role for interactions with the positively charged essential residues in these proteins. We analyzed by solid- state magic angle spinning P-31 NMR and molecular dynamics simulations the interaction of low concentrations of PA in model membranes with positively charged side chains of membrane- interacting peptides. Surprisingly, lysine and arginine residues increase the charge of PA, predominantly by forming hydrogen bonds with the phosphate of PA, thereby stabilizing the protein-lipid interaction. Our results demonstrate that this electrostatic/ hydrogen bond switch turns the phosphate of PA into an effective and preferred docking site for lysine and arginine residues. In combination with the special packing properties of PA, PA may well be nature's preferred membrane lipid for interfacial insertion of positively charged membrane protein domains.	Univ Utrecht, Bijvoet Ctr, Dept Biochem Membranes, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Amsterdam, Swammerdam Inst Life Sci, Sect Plant Physiol, NL-1098 SM Amsterdam, Netherlands; Univ Utrecht, Dept Med Chem, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Dept Biochem Physiol, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; University of Calgary; University of Amsterdam; Utrecht University; Utrecht University	Kooijman, EE (corresponding author), Kent State Univ, Dept Phys, Smith Hall 105, Kent, OH 44242 USA.	e.e.kooijman@gmail.com	Munnik, Teun/G-8624-2012; Munnik, Teun/N-2778-2019; Tieleman, D. Peter/A-4790-2011	Munnik, Teun/0000-0002-4919-4913; Munnik, Teun/0000-0002-4919-4913; Tieleman, D. Peter/0000-0001-5507-0688; Rijkers, Dirk T.S./0000-0002-8874-7576; Testerink, Christa/0000-0001-6738-115X				Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; Aliste MP, 2003, BIOCHEMISTRY-US, V42, P8976, DOI 10.1021/bi027001j; Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Bruno IJ, 2002, ACTA CRYSTALLOGR B, V58, P389, DOI 10.1107/S0108768102003324; Burger KNJ, 2000, BIOCHEMISTRY-US, V39, P12485, DOI 10.1021/bi000971r; *CCDC, 1994, VIST PROGR AN DISPL; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; de Planque MRR, 2002, BIOCHEMISTRY-US, V41, P8396, DOI 10.1021/bi0257686; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; DEKRUIJFF B, 1985, BIOCHIM BIOPHYS ACTA, V820, P295, DOI 10.1016/0005-2736(85)90124-5; Deol SS, 2006, BIOPHYS J, V90, P822, DOI 10.1529/biophysj.105.071407; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ellson CD, 2002, J CELL SCI, V115, P1099; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Freyberg Z, 2003, TRENDS CELL BIOL, V13, P540, DOI 10.1016/j.tcb.2003.08.004; Ghosh S, 2003, J BIOL CHEM, V278, P45690, DOI 10.1074/jbc.M302933200; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAUSER H, 1989, P NATL ACAD SCI USA, V86, P5351, DOI 10.1073/pnas.86.14.5351; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Kooijman EE, 2005, BIOCHEMISTRY-US, V44, P17007, DOI 10.1021/bi0518794; Kooijman EE, 2005, BIOCHEMISTRY-US, V44, P2097, DOI 10.1021/bi0478502; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; KOTER M, 1978, BIOCHIM BIOPHYS ACTA, V514, P255, DOI 10.1016/0005-2736(78)90296-1; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Lee DC, 2003, J BIOL CHEM, V278, P31412, DOI 10.1074/jbc.M213154200; Lee JH, 2005, PROTEIN SCI, V14, P727, DOI 10.1110/ps.041070205; Lee SA, 2005, P NATL ACAD SCI USA, V102, P13052, DOI 10.1073/pnas.0503900102; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P289, DOI 10.1016/S1388-1981(02)00183-X; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Oliva G, 1995, STRUCTURE, V3, P1323, DOI 10.1016/S0969-2126(01)00270-2; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5873, DOI 10.1021/bi047439e; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Solomons JTG, 2004, J MOL BIOL, V342, P847, DOI 10.1016/j.jmb.2004.07.085; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	55	180	184	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11356	11364		10.1074/jbc.M609737200	http://dx.doi.org/10.1074/jbc.M609737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17277311	Green Published, hybrid			2022-12-27	WOS:000245941500058
J	Sato, Y; Okuyama, S; Hori, K				Sato, Yuichiro; Okuyama, Satomi; Hori, Kanji			Primary structure and carbohydrate binding specificity of a potent anti-HIV lectin isolated from the filamentous cyanobacterium Oscillatoria agardhii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRESH-WATER CYANOBACTERIUM; MYXOBACTERIAL HEMAGGLUTININ; CONCANAVALIN-A; MICROCYSTIS-AERUGINOSA; INACTIVATING PROTEIN; MYXOCOCCUS-XANTHUS; PLANT-LECTINS; CYANOVIRIN-N; MANNOSE; RECOGNITION	The primary structure of a lectin, designated Oscillatoria agardhii agglutinin (OAA), isolated from the freshwater cyanobacterium O. agardhii NIES-204 was determined by the combination of Edman degradation and electron spray ionization-mass spectrometry. OAA is a polypeptide (M-r 13,925) consisting of two tandem repeats. Interestingly, each repeat sequence of OAA showed a high degree of similarity to those of a myxobacterium, Myxococcus xanthus hemagglutinin, and a marine red alga Eucheuma serra lectin. A systematic binding assay with pyridylaminated oligosaccharides revealed that OAA exclusively binds to high mannose (HM)-typeN-glycans but not to other N-glycans, including complex types, hybrid types, and the pentasaccharide core or oligosaccharides from glycolipids. OAA did not interact with any of free mono- and oligomannoses that are constituents of the branched oligomannosides. These results suggest that the core disaccharide, GlcNAc-GlcNAc, is also essential for binding to OAA. The binding activity of OAA to HM type N-glycans was dramatically decreased when alpha 1 - 2 Man was attached to alpha 1 - 3 Man branched from the alpha 1 - 6 Man of the pentasaccharide core. This specificity of OAA for HM- type oligosaccharides is distinct from other HM- binding lectins. Kinetic analysis with an HM heptasaccharide revealed that OAA possesses two carbohydrate binding sites per molecule, with an association constant of 2.41 x 10(8) M-1. Furthermore, OAA potently inhibits human immunodeficiency virus replication in MT-4 cells (EC50 = 44.5 nM). Thus, we have found a novel lectin family sharing similar structure and carbohydrate binding specificity among bacteria, cyanobacteria, and marine algae.	Hiroshima Univ, Grad Sch Biosphere Sci, Higashihiroshima 7398528, Japan	Hiroshima University	Hori, K (corresponding author), Hiroshima Univ, Grad Sch Biosphere Sci, Kagamiyama 1-4-4, Higashihiroshima 7398528, Japan.	kanhori@hiroshima-u.ac.jp						BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; Balzarini J, 2004, J VIROL, V78, P10617, DOI 10.1128/JVI.78.19.10617-10627.2004; Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200; Barre A, 1996, PLANT PHYSIOL, V112, P1531, DOI 10.1104/pp.112.4.1531; Barre A, 2001, BIOCHIMIE, V83, P645, DOI 10.1016/S0300-9084(01)01315-3; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698; Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200; Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102; Chisholm JRM, 1996, NATURE, V381, P382, DOI 10.1038/381382a0; CUMSKY M, 1979, P NATL ACAD SCI USA, V76, P5505, DOI 10.1073/pnas.76.11.5505; CUMSKY MG, 1981, J BIOL CHEM, V256, P2596; Dam TK, 1998, J BIOL CHEM, V273, P5528, DOI 10.1074/jbc.273.10.5528; Dworkin M, 1996, MICROBIOL REV, V60, P70, DOI 10.1128/MMBR.60.1.70-102.1996; Fourans A, 2004, FEMS MICROBIOL ECOL, V51, P55, DOI 10.1016/j.femsec.2004.07.012; Gupta D, 1996, EUR J BIOCHEM, V242, P320, DOI 10.1111/j.1432-1033.1996.0320r.x; Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004; Hester G, 1996, J MOL BIOL, V262, P516, DOI 10.1006/jmbi.1996.0532; HORI K, 1990, HYDROBIOLOGIA, V204, P561, DOI 10.1007/BF00040287; Jimbo M, 2000, BIOCHEM BIOPH RES CO, V273, P499, DOI 10.1006/bbrc.2000.2961; KATOH H, 1993, J BIOCHEM-TOKYO, V113, P118, DOI 10.1093/oxfordjournals.jbchem.a123994; Kawakubo A, 1999, J APPL PHYCOL, V11, P149, DOI 10.1023/A:1008062127564; Kawakubo AL, 1997, J APPL PHYCOL, V9, P331, DOI 10.1023/A:1007915006334; Kehr JC, 2006, MOL MICROBIOL, V59, P893, DOI 10.1111/j.1365-2958.2005.05001.x; Liener I.E., 1986, LECTINS PROPERTIES F; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; MEGA T, 1992, J BIOCHEM-TOKYO, V111, P396, DOI 10.1093/oxfordjournals.jbchem.a123768; MISQUITH S, 1994, J BIOL CHEM, V269, P30393; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; NELSON DR, 1981, J BIOL CHEM, V256, P2589; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; ROMEO JM, 1986, P NATL ACAD SCI USA, V83, P6332, DOI 10.1073/pnas.83.17.6332; Sato Y, 2000, COMP BIOCHEM PHYS B, V125, P169, DOI 10.1016/S0305-0491(99)00164-9; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; Skvortsov IM, 1998, FEMS MICROBIOL LETT, V165, P223, DOI 10.1111/j.1574-6968.1998.tb13150.x; Tateno H, 2003, J BIOL CHEM, V278, P10891, DOI 10.1074/jbc.M211840200; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Williams DC, 2005, J BIOL CHEM, V280, P29269, DOI 10.1074/jbc.M504642200; Yamaguchi M, 1999, BIOCHEM BIOPH RES CO, V265, P703, DOI 10.1006/bbrc.1999.1749	41	84	87	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11021	11029		10.1074/jbc.M701252200	http://dx.doi.org/10.1074/jbc.M701252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17314091	hybrid, Green Submitted			2022-12-27	WOS:000245941500022
J	Han, Y; Joosten, HJ; Niu, WL; Zhao, ZM; Mariano, PS; McCalman, M; van Kan, J; Schaap, PJ; Dunaway-Mariano, D				Han, Ying; Joosten, Henk-Jan; Niu, Weiling; Zhao, Zhiming; Mariano, Patrick S.; McCalman, Melisa; van Kan, Jan; Schaap, Peter J.; Dunaway-Mariano, Debra			Oxaloacetate hydrolase, the C-C bond lyase of oxalate secreting fungi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXALIC-ACID BIOSYNTHESIS; PETAL DEATH PROTEIN; ASPERGILLUS-NIGER; CRYSTAL-STRUCTURE; ISOCITRATE LYASE; MYCOBACTERIUM-TUBERCULOSIS; SCLEROTINIA-SCLEROTIORUM; 2-METHYLISOCITRATE LYASE; OXALACETATE; CATALYSIS	Oxalate secretion by fungi is known to be associated with fungal pathogenesis. In addition, oxalate toxicity is a concern for the commercial application of fungi in the food and drug industries. Although oxalate is generated through several different biochemical pathways, oxaloacetate acetylhydrolase (OAH)-catalyzed hydrolytic cleavage of oxaloacetate appears to be an especially important route. Below, we report the cloning of the Botrytis cinerea oahA gene and the demonstration that the disruption of this gene results in the loss of oxalate formation. In addition, through complementation we have shown that the intact B. cinerea oahA gene restores oxalate production in an Aspergillus niger mutant strain, lacking a functional oahA gene. These observations clearly indicate that oxalate production in A. niger and B. cinerea is solely dependent on the hydrolytic cleavage of oxaloacetate catalyzed by OAH. In addition, the B. cinera oahA gene was overexpressed in Escherichia coli and the purified OAH was used to define catalytic efficiency, substrate specificity, and metal ion activation. These results are reported along with the discovery of the mechanism-based, tight binding OAH inhibitor 3,3-difluorooxaloacetate (K-i = 68 nm). Finally, we propose that cellular uptake of this inhibitor could reduce oxalate production.	Univ Wageningen & Res Ctr, Microbiol Lab, Sect Fungal Genom, NL-6703 HA Wageningen, Netherlands; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Univ Wageningen & Res Ctr, Lab Phytopathol, NL-6709 PD Wageningen, Netherlands	Wageningen University & Research; University of New Mexico; Wageningen University & Research	Schaap, PJ (corresponding author), Univ Wageningen & Res Ctr, Microbiol Lab, Sect Fungal Genom, Dreijenlaan 2, NL-6703 HA Wageningen, Netherlands.	peter.schaap@wur.nl; dd39@unm.edu	Han, Ying/G-3278-2012; Niu, Weiling/B-2997-2011	van Kan, Jan/0000-0003-3563-1550; Schaap, Peter/0000-0002-4346-6084	NIGMS NIH HHS [GM 28688] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERG DG, 1992, J AM CHEM SOC, V114, P3535, DOI 10.1021/ja00035a058; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BALMFORTH AJ, 1984, BIOCHEM J, V218, P113, DOI 10.1042/bj2180113; BRILEY PA, 1977, BIOCHEM J, V161, P383, DOI 10.1042/bj1610383; Britton KL, 2000, STRUCTURE, V8, P349, DOI 10.1016/S0969-2126(00)00117-9; CHANG CC, 1968, PLANT PHYSIOL, V43, P1821, DOI 10.1104/pp.43.11.1821; Chaudhuri BN, 2003, STRUCTURE, V11, P753, DOI 10.1016/S0969-2126(03)00106-0; Chen CCH, 2006, BIOCHEMISTRY-US, V45, P11491, DOI 10.1021/bi061208l; DEGRAAFF L, 1992, CURR GENET, V22, P21, DOI 10.1007/BF00351737; Dutton MV, 1996, CAN J MICROBIOL, V42, P881, DOI 10.1139/m96-114; EMLY M, 1981, J AM CHEM SOC, V103, P628, DOI 10.1021/ja00393a022; ERLICK HA, 1992, PCR TECHNOLOGY PRINC; Gadd GM, 1999, ADV MICROB PHYSIOL, V41, P47, DOI 10.1016/S0065-2911(08)60165-4; GODOY G, 1990, PHYSIOL MOL PLANT P, V37, P179, DOI 10.1016/0885-5765(90)90010-U; Grimm C, 2003, J MOL BIOL, V328, P609, DOI 10.1016/S0022-2836(03)00358-9; Guimaraes RL, 2004, PLANT PHYSIOL, V136, P3703, DOI 10.1104/pp.104.049650; GUO Z, 1999, PLANT PHYSIOL BIOCH, V41, P47; HAMMEL KE, 1994, BIOCHEMISTRY-US, V33, P13349, DOI 10.1021/bi00249a022; HAN Y, 2006, THESIS U NEW MEXICO; HOMBERG U, 1995, CELL TISSUE RES, V279, P249, DOI 10.1007/s004410050280; HOUCK DR, 1987, ARCH BIOCHEM BIOPHYS, V259, P58, DOI 10.1016/0003-9861(87)90470-X; Huang K, 1999, STRUCT FOLD DES, V7, P539, DOI 10.1016/S0969-2126(99)80070-7; Kars I, 2005, MOL PLANT PATHOL, V6, P641, DOI [10.1111/j.1364-3703.2005.00312.x, 10.1111/J.1364-3703.2005.00312.X]; Kirkland BH, 2005, J MED ENTOMOL, V42, P346, DOI 10.1603/0022-2585(2005)042[0346:OAAAFA]2.0.CO;2; KUBICEK CP, 1988, APPL ENVIRON MICROB, V54, P633, DOI 10.1128/AEM.54.3.633-637.1988; LENZ H, 1976, EUR J BIOCHEM, V65, P225, DOI 10.1111/j.1432-1033.1976.tb10409.x; Liu SJ, 2005, BIOCHEMISTRY-US, V44, P2949, DOI 10.1021/bi0479712; Lu ZB, 2005, BIOCHEMISTRY-US, V44, P16365, DOI 10.1021/bi051776l; MAO HK, 1981, INORG CHEM, V20, P4240, DOI 10.1021/ic50226a042; MAXWELL DP, 1968, PHYTOPATHOLOGY, V58, P1635; MILLERD A, 1963, BIOCHEM J, V88, P281, DOI 10.1042/bj0880281; Munir E, 2001, P NATL ACAD SCI USA, V98, P11126, DOI 10.1073/pnas.191389598; Nakagawa Y., 1999, J Infect Chemother, V5, P97, DOI 10.1007/s101560050016; Pedersen H, 2000, MOL GEN GENET, V263, P281, DOI 10.1007/s004380051169; Pedersen H, 2000, METAB ENG, V2, P34, DOI 10.1006/mben.1999.0136; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; Ruijter GJG, 1999, MICROBIOL-SGM, V145, P2569, DOI 10.1099/00221287-145-9-2569; SAXTY BA, 1991, EUR J BIOCHEM, V202, P889, DOI 10.1111/j.1432-1033.1991.tb16448.x; Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964; SOMEREN MAK, 1991, CURR GENET, V20, P293, DOI 10.1007/BF00318518; Teplyakov A, 2005, BIOCHEMISTRY-US, V44, P16377, DOI 10.1021/bi051779y; VANDENHOMBERGH JPTW, 1995, CURR GENET, V28, P299, DOI 10.1007/BF00326427; Weir TL, 2006, PLANTA, V223, P785, DOI 10.1007/s00425-005-0192-x	43	78	89	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9581	9590		10.1074/jbc.M608961200	http://dx.doi.org/10.1074/jbc.M608961200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244616	Green Submitted, hybrid			2022-12-27	WOS:000245421700031
J	Herman, RE; Badders, D; Fuller, M; Makienko, EG; Houston, ME; Quay, SC; Johnson, PH				Herman, Richard E.; Badders, Douglas; Fuller, Mark; Makienko, Ekaterina G.; Houston, Michael E., Jr.; Quay, Steven C.; Johnson, Paul H.			The Trp cage motif as a scaffold for the display of a randomized peptide library on bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE DISPLAY; BINDING-PROTEINS; SEQUENCE; LIGANDS; STREPTAVIDIN; SUPPRESSION; MOLECULES; FINGERS; LEADS	Phage libraries displaying linear or disulfide-constrained pephdes often yield weak binders, upon screening against a target, and must be optimized to improve affinity. The disadvantages of libraries based on larger complex proteins, such as single chain antibodies, have stimulated interest in the development of smaller nonimmunoglobulin protein scaffolds. A promising candidate is the Trp cage motif, a 20-residue C-terminal sequence of exendin-4. Amino acid substitution within the Trp cage resulted in a 20-mer peptide recognized as an ultrafast cooperative folding miniprotein, with ideal characteristics for the discovery of small structured nonimmunoglobulin motifs having a stable tertiary structure. Although we were unable to display the Trp cage on M13 phage, successful display was achieved using the lytic T7 phage. Interestingly, mutations were observed at a frequency dependent on display valency. A Trp cage library designed with randomized amino acids at seven solvent-exposed positions was developed from 1.6 X 10(9) primary clones in T7Select10-3b. DNA sequencing of 109 library clones revealed 38% mutants and 16% truncations by TAG codons at randomized positions. Amino acid frequencies were largely within expected bounds and DIVAA analysis revealed that the library had an average diversity of 0.67. Utility of the library was demonstrated by identification of HPQ containing Trp cage miniproteins, which bound streptavidin, and AAADPYAQWLQSMGPHSGRPPPR, which bound to human bronchial epithelial cells. A high complexity library based on the Trp cage miniprotein has demonstrated potential for identifying novel cell and protein binding peptides that could be used for the delivery of therapeutic molecules or as target-specific therapeutic agents.	Nastech Pharmaceut Co Inc, Bothell, WA 98021 USA		Johnson, PH (corresponding author), Nastech Pharmaceut Co Inc, 3830 Monte Villa PKwy, Bothell, WA 98021 USA.	pjohnson@nastech.com		Quay, Steven Carl/0000-0002-0363-7651				ANDERSEN NH, 2001, PEPTIDES WAVE FUTURE, P406; BEAUCAGE SL, 1992, TETRAHEDRON, V48, P2223, DOI 10.1016/S0040-4020(01)88752-4; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Castagnoli L, 2001, COMB CHEM HIGH T SCR, V4, P121; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EDELMANN P, 1987, MOL GEN GENET, V207, P517, DOI 10.1007/BF00331625; EDGAR RS, 1963, METHODOLOGY BASIC GE, P19; Friesen WJ, 1998, NAT STRUCT BIOL, V5, P543, DOI 10.1038/794; GIEBEL LB, 1995, BIOCHEMISTRY-US, V34, P15430, DOI 10.1021/bi00047a006; GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501; KATZ BA, 1995, BIOCHEMISTRY-US, V34, P15421, DOI 10.1021/bi00047a005; Krotz AH, 1997, TETRAHEDRON LETT, V38, P3875, DOI 10.1016/S0040-4039(97)00798-3; Krumpe LRH, 2006, PROTEOMICS, V6, P4210, DOI 10.1002/pmic.200500606; LADNER RC, 1995, TRENDS BIOTECHNOL, V13, P426, DOI 10.1016/S0167-7799(00)88997-0; Ladner RC, 2001, CURR OPIN BIOTECH, V12, P406, DOI 10.1016/S0958-1669(00)00235-4; Lin JC, 2004, J AM CHEM SOC, V126, P13679, DOI 10.1021/ja047265o; Lowman HB, 1997, ANNU REV BIOPH BIOM, V26, P401, DOI 10.1146/annurev.biophys.26.1.401; MACRINA FL, 1978, PLASMID, V1, P417, DOI 10.1016/0147-619X(78)90056-2; Marvin DA, 1998, CURR OPIN STRUC BIOL, V8, P150, DOI 10.1016/S0959-440X(98)80032-8; MILLER JH, 1983, J MOL BIOL, V164, P59, DOI 10.1016/0022-2836(83)90087-6; Nakamura GR, 2001, BIOCHEMISTRY-US, V40, P9828, DOI 10.1021/bi0109360; Neidigh JW, 2001, BIOCHEMISTRY-US, V40, P13188, DOI 10.1021/bi010902s; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; *NEW ENGL BIOL INC, 2002, INSTR MAN PH D C7C P; Qiu LL, 2002, J AM CHEM SOC, V124, P12952, DOI 10.1021/ja0279141; RAPOZA MP, 1993, J BACTERIOL, V175, P1856, DOI 10.1128/JB.175.6.1856-1859.1993; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Steiner D, 2006, NAT BIOTECHNOL, V24, P823, DOI 10.1038/nbt1218; Uchiyama F, 2005, J BIOSCI BIOENG, V99, P448, DOI 10.1263/jbb.99.448	32	25	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9813	9824		10.1074/jbc.M610722200	http://dx.doi.org/10.1074/jbc.M610722200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17264074	hybrid			2022-12-27	WOS:000245421700056
J	Kim, SY; Levenson, JM; Korsmeyer, S; Sweatt, JD; Schumacher, A				Kim, Se Young; Levenson, Jonathan M.; Korsmeyer, Stanley; Sweatt, J. David; Schumacher, Armin			Developmental regulation of Eed complex composition governs a switch in global histone modification in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN EED; H3 LYSINE-27 METHYLATION; INACTIVE X-CHROMOSOME; EMBRYONIC STEM-CELLS; POLYCOMB-GROUP GENE; MLL-MUTANT MICE; METHYLTRANSFERASE ACTIVITY; MAMMALIAN TRITHORAX; RESPONSE ELEMENTS; BINDING PROTEIN	Originally discovered as epigenetic regulators of developmental gene expression, the Polycomb (PcG) and trithorax (trxG) group of proteins form distinct nuclear complexes governing post-translational modification of histone tails. This study identified a novel, developmentally regulated interface between Eed and Mll, pivotal constituents of PcG and trxG pathways, respectively, in mouse brain. Although the PcG proteins Eed and EzH2 (Enhancer of Zeste protein-2) engaged in a common complex during neurodevelopment, Eed associated with the trxG protein Mll upon brain maturation. Comprehensive analysis of multiple histone modifications revealed differential substrate specificity of the novel Eed-Mll complex in adult brain compared with the developmental Eed-EzH2 complex. Newborn brain from eed heterozygotes and eed;Mll double heterozygotes exhibited decreased trimethylation at lysine 27 of histone H3, as well as hyperacetylation of histone H4. In contrast, adult hippocampus from Mll heterozygotes was remarkable for decreased acetylation of histone H4, which restored to wild-type levels in eed;Mll double heterozygotes. A physiological role for the Eed-Mll complex in adult brain was evident from complementary defects in synaptic plasticity in eed and Mll mutant hippocampi. These results support the notion that developmental regulation of complex composition bestows the predominant Eed complex with the chromatin remodeling activity conducive for gene regulation during neurodevelopment and adult brain function. Thus, this study suggests dynamic regulation of chromatin complex composition as a molecular mechanism to coopt constituents of developmental pathways into the regulation of neuronal memory formation in adult brain.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Med,Dana Farber Canc Inst, Boston, MA 02115 USA	Baylor College of Medicine; Baylor College of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Schumacher, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	armins@bcm.tmc.edu		Sweatt, J. David/0000-0003-3567-485X				Alarcon JM, 2004, NEURON, V42, P947, DOI 10.1016/j.neuron.2004.05.021; Ayton P, 2001, GENESIS, V30, P201, DOI 10.1002/gene.1066; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Bloyer S, 2003, DEV BIOL, V261, P426, DOI 10.1016/S0012-1606(03)00314-2; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Chwang WB, 2006, LEARN MEMORY, V13, P322, DOI 10.1101/lm.152906; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Deschamps J, 1999, INT J DEV BIOL, V43, P635; FAUST C, 1995, DEVELOPMENT, V121, P273; Faust C, 1998, DEVELOPMENT, V125, P4495; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Grimaud C, 2006, CHROMOSOME RES, V14, P363, DOI 10.1007/s10577-006-1069-y; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Kalantry S, 2006, NAT CELL BIOL, V8, P195, DOI 10.1038/ncb1351; Kalantry S, 2006, PLOS GENET, V2, P656, DOI 10.1371/journal.pgen.0020066; Kim SY, 2006, DEVELOPMENT, V133, P4957, DOI 10.1242/dev.02677; Korzus E, 2004, NEURON, V42, P961, DOI 10.1016/j.neuron.2004.06.002; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mok H, 2004, DEVELOPMENT, V131, P4871, DOI 10.1242/dev.01342; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; Ringrose L, 2003, DEV CELL, V5, P759, DOI 10.1016/S1534-5807(03)00337-X; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Tillib S, 1999, MOL CELL BIOL, V19, P5189; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; Wang JB, 2002, MAMM GENOME, V13, P493, DOI 10.1007/s00335-002-2182-7; Wood MA, 2005, LEARN MEMORY, V12, P111, DOI 10.1101/lm.86605; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	60	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9962	9972		10.1074/jbc.M608722200	http://dx.doi.org/10.1074/jbc.M608722200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259173	hybrid			2022-12-27	WOS:000245421700071
J	Krig, SR; Jin, VX; Bieda, MC; O'Geen, H; Yaswen, P; Green, R; Farnham, PJ				Krig, Sheryl R.; Jin, Victor X.; Bieda, Mark C.; O'Geen, Henriette; Yaswen, Paul; Green, Roland; Farnham, Peggy J.			Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING SITES; CHROMOSOMAL REGION; BREAST-CANCER; CO-REPRESSOR; DNA-BINDING; TRANSCRIPTION; CTBP; SEQUENCES; GENOME; COREPRESSOR	It has been proposed that ZNF217, which is amplified at 20q13 in various tumors, plays a key role during neoplastic transformation. ZNF217 has been purified in complexes that contain repressor proteins such as CtBP2, suggesting that it acts as a transcriptional repressor. However, the function of ZNF217 has not been well characterized due to a lack of known target genes. Using a global chromatin immunoprecipitation (ChIP)-chip approach, we identified thousands of ZNF217 binding sites in three tumor cell lines (MCF7, SW480, and Ntera2). Further analysis of ZNF217 in Ntera2 cells showed that many promoters are bound by ZNF217 and CtBP2 and that a subset of these promoters are activated upon removal of ZNF217. Thus, our in vivo studies corroborate the in vitro biochemical analyses of ZNF217-containing complexes and support the hypothesis that ZNF217 functions as a transcriptional repressor. Gene ontology analysis showed that ZNF217 targets in Ntera2 cells are involved in organ development, suggesting that one function of ZNF217 may be to repress differentiation. Accordingly we show that differentiation of Ntera2 cells with retinoic acid led to down-regulation of ZNF217. Our identification of thousands of ZNF217 target genes will enable further studies of the consequences of aberrant expression of ZNF217 during neoplastic transformation.	Univ Calif Davis, Dept Pharmacol, Davis, CA 95616 USA; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; NimbleGen Syst Inc, Madison, WI 53711 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Davis; Roche Holding; Roche NimbleGen; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Farnham, PJ (corresponding author), Univ Calif Davis, Dept Pharmacol, 1 Shields Ave, Davis, CA 95616 USA.	pjfarnham@ucdavis.edu		Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA45250, R01 CA045240-21, R01 CA045240] Funding Source: Medline; NHGRI NIH HHS [R01 HG003129, HG003129, R01 HG003129-03] Funding Source: Medline; NIDDK NIH HHS [R01 DK067889-03, DK067889, R01 DK067889, R56 DK067889] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045240] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK067889, R01DK067889] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Bailey TL, 1997, J COMPUT BIOL, V4, P45, DOI 10.1089/cmb.1997.4.45; Bar-Shira A, 2002, CANCER RES, V62, P6803; Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; COWGER JJ, 2007, IN PRESS ONCOGENE; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Graves BJ, 1996, NATURE, V384, P322, DOI 10.1038/384322a0; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Harrow J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s4; Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582; Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352; IWABUCHI H, 1995, CANCER RES, V55, P6172; JIN VX, 2007, IN PRESS GENOME RES; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; LASSMANN S, 2007, IN PRESS J MOL MED; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Nonet GH, 2001, CANCER RES, V61, P1250; O'Geen H, 2006, BIOTECHNIQUES, V41, P577, DOI 10.2144/000112268; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Pavesi G, 2004, NUCLEIC ACIDS RES, V32, pW199, DOI 10.1093/nar/gkh465; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Scacheri PC, 2006, PLOS GENET, V2, P406, DOI 10.1371/journal.pgen.0020051; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Yang SH, 2005, CLIN CANCER RES, V11, P612; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhu H, 2007, CANCER LETT, V245, P303, DOI 10.1016/j.canlet.2006.01.020	45	66	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9703	9712		10.1074/jbc.M611752200	http://dx.doi.org/10.1074/jbc.M611752200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259635	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000245421700044
J	Ma, YM; Boucrot, E; Villen, J; Affar, E; Gygi, SP; Gottlinger, HG; Kirchhausen, T				Ma, Yu May; Boucrot, Emmanuel; Villen, Judit; Affar, El Bachir; Gygi, Steven P.; Goettlinger, Heinrich G.; Kirchhausen, Tomas			Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAIN; DEUBIQUITINATING ENZYMES; UBIQUITIN ISOPEPTIDASE; ESCRT-III; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; ENDOCYTIC PATHWAYS; DOWN-REGULATION; VPS PROTEIN; COMPLEX	To reach the lysosomes, down-regulated receptors such as the epidermal growth factor receptor must first be sorted into internal vesicles of late endosomes (multivesicular bodies), a ubiquitin-dependent event that requires the coordinated function of the endosome sorting complex required for transport (ESCRT) proteins. Here we report that CHMP3, an ESCRT-III complex component, and associated molecule of SH3 domain of STAM (AMSH), a deubiquitinating enzyme, interact with each other in cells. A dominant-negative version of CHMP3, which specifically prevents targeting of AMSH to endosomes, inhibits degradation but not internalization of EGFR, suggesting that endosomal AMSH is a functional component of the multivesicular body pathway.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	Kirchhausen@crystal.harvard.edu		Gottlinger, Heinrich/0000-0003-4124-5824; Villen, Judit/0000-0002-1005-1739	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029873, R01AI029873] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29873, R37 AI029873] Funding Source: Medline; NIGMS NIH HHS [GM036548] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agromayor M, 2006, J BIOL CHEM, V281, P23083, DOI 10.1074/jbc.M513803200; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Kaneko T, 2003, J BIOL CHEM, V278, P48162, DOI 10.1074/jbc.M306677200; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Massol RH, 2004, MOL BIOL CELL, V15, P3631, DOI 10.1091/mbc.E04-04-0283; McCullough J, 2006, CURR BIOL, V16, P160, DOI 10.1016/j.cub.2005.11.073; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mizuno E, 2004, J BIOCHEM, V135, P385, DOI 10.1093/jb/mvh046; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Nakamura M, 2006, GENES CELLS, V11, P593, DOI 10.1111/j.1365-2443.2006.00963.x; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pankratz Nathan, 2004, NeuroRx, V1, P235, DOI 10.1007/BF03206607; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Scott A, 2005, P NATL ACAD SCI USA, V102, P13813, DOI 10.1073/pnas.0502165102; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shiflett SL, 2004, J BIOL CHEM, V279, P10982, DOI 10.1074/jbc.M312669200; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Ward DMV, 2005, J BIOL CHEM, V280, P10548, DOI 10.1074/jbc.M413734200; Whitley P, 2003, J BIOL CHEM, V278, P38786, DOI 10.1074/jbc.M306864200; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747; Zamborlini A, 2006, P NATL ACAD SCI USA, V103, P19140, DOI 10.1073/pnas.0603788103	43	63	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9805	9812		10.1074/jbc.M611635200	http://dx.doi.org/10.1074/jbc.M611635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17261583	Green Accepted, hybrid			2022-12-27	WOS:000245421700055
J	Mix, KS; Attur, MG; Al-Mussawir, H; Abramson, SB; Brinckerhoff, CE; Murphy, EP				Mix, Kimberlee S.; Attur, Mukundan G.; Al-Mussawir, Hayf; Abramson, Steven B.; Brinckerhoff, Constance E.; Murphy, Evelyn P.			Transcriptional repression of matrix metalloproteinase gene expression by the orphan nuclear receptor NURR1 in cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE NUCLEOTIDE POLYMORPHISM; NF-KAPPA-B; RETINOID-X-RECEPTOR; ETS-BINDING-SITES; RHEUMATOID-ARTHRITIS; ARTICULAR CHONDROCYTES; DIFFERENTIAL REGULATION; COLLAGENASE 1; CELL-TYPE; PROMOTER	The NR4A orphan receptors (Nur77, NURR1, and NOR-1) are emerging as key regulators of cytokine and growth factor action in chronic inflammatory diseases. In this study, we address the role of these receptors in cartilage homeostasis during inflammatory joint disease. We document for the first time expression of the NR4A receptors in osteoarthritic cartilage. Relative to Nur77 and NOR- 1, NURR1. is expressed at the highest level and correlates with cyclooxygenase-2 levels in cartilage. Consistent with this observation, cyclooxygenase-2-derived prostaglandin E-2 (PGE(2)) rapidly and potently induces NURR1. expression in chondrocytes, suggesting that this receptor may regulate PGE2-mediated processes in cartilage. We demonstrate that PGE(2) represses interleukin-1 beta-induced matrix metalloproteinase (MMP)-1 and that transient overexpression of NURR1 is sufficient to antagonize expression of this gene. Furthermore, MMP-1 promoter activity is potently suppressed by NURR1, resulting in a significant reduction in endogenous NIMP-1 mRNA and secreted pro-MMP-1 protein. In addition, NURR1 selectively antagonizes cytokine-induced MMP-3 and -9 expression with minimal effects on MMP-2 and -13 and tissue inhibitor of matrix metalloproteinases-1 and -2. To explore the molecular mechanisms of NLJRR1 transrepression, we reveal that this receptor targets a critical region of the MMP-1 promoter (- 1772 to - 1546 bp) and that repression does not require consensus binding sites for NURR1. We confirm that NURR1. targets a 40-bp promoter sequence that is also positively regulated by ETS transcription factors. Finally, functional studies indicate that transcriptional antagonism exists between NURR1 and ETS1 on the NIMP-1 promoter. We propose a protective function for NURR1 in cartilage homeostasis by selectively repressing NIMP gene expression during inflammation.	Univ Coll Dublin, Vet Sci Ctr, Coll Life Sci, Dublin 4, Ireland; NYU, Hosp Joint Dis, Div Rheumatol, New York, NY 10003 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	University College Dublin; New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Dartmouth College; Norris Cotton Cancer Center	Mix, KS (corresponding author), Univ Coll Dublin, Vet Sci Ctr, Coll Life Sci, Dublin 4, Ireland.	kimberlee.mix@ucd.ie	Attur, Mukundan/O-1578-2019	Attur, Mukundan/0000-0001-7080-8118; Abramson, Steven/0000-0002-0668-6344; Murphy, Evelyn/0000-0002-6387-1992	NIAMS NIH HHS [AR-26599] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R37AR026599] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aarnisalo P, 2002, J BIOL CHEM, V277, P35118, DOI 10.1074/jbc.M201707200; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; Aoyama T, 2005, J BONE MINER RES, V20, P377, DOI 10.1359/JBMR.041122; Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Attur MG, 2001, ARTHRITIS RHEUM-US, V44, P578, DOI 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.3.CO;2-Z; Baillat D, 2006, ONCOGENE, V25, P5764, DOI 10.1038/sj.onc.1209583; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barish GD, 2005, MOL ENDOCRINOL, V19, P2466, DOI 10.1210/me.2004-0529; Beehler BC, 2003, J RHEUMATOL, V30, P355; Bonta PI, 2006, ARTERIOSCL THROM VAS, V26, P2288, DOI 10.1161/01.ATV.0000238346.84458.5d; Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chaturvedi P, 2006, ARTHRITIS RHEUM-US, V54, P3513, DOI 10.1002/art.22170; Codina A, 2004, J BIOL CHEM, V279, P53338, DOI 10.1074/jbc.M409096200; Davies Mark R, 2005, J Inflamm (Lond), V2, P15, DOI 10.1186/1476-9255-2-15; de Waard V, 2006, AM J PATHOL, V168, P2027, DOI 10.2353/ajpath.2006.050932; Diatchenko L, 2005, J LEUKOCYTE BIOL, V78, P1366, DOI 10.1189/jlb.0405211; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; Faour WH, 2005, J BIOL CHEM, V280, P9536, DOI 10.1074/jbc.M414067200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Galleguillos D, 2004, J BIOL CHEM, V279, P2005, DOI 10.1074/jbc.M308113200; Gebauer M, 2005, OSTEOARTHR CARTILAGE, V13, P697, DOI 10.1016/j.joca.2005.04.004; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; Goldring MB, 2004, CLIN ORTHOP RELAT R, pS37, DOI 10.1097/01.blo.0000144484.69656.e4; Gomez PF, 2005, J IMMUNOL, V175, P6924, DOI 10.4049/jimmunol.175.10.6924; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Harant H, 2004, NUCLEIC ACIDS RES, V32, P5280, DOI 10.1093/nar/gkh856; Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200; Hong CY, 2004, MOL CELL BIOL, V24, P2593, DOI 10.1128/MCB.24.7.2593-2604.2004; Jacques C, 1999, REV RHUM, V66, P701; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kong G, 2005, CANCER RES, V65, P3462, DOI 10.1158/0008-5472.CAN-03-2912; Koshy PJT, 2002, ARTHRITIS RHEUM, V46, P961, DOI 10.1002/art.10212; Kraan TCTMV, 2003, ARTHRITIS RHEUM-US, V48, P2132, DOI 10.1002/art.11096; Lai HC, 2005, GYNECOL ONCOL, V96, P314, DOI 10.1016/j.ygyno.2004.09.065; Lammi J, 2004, MOL ENDOCRINOL, V18, P1546, DOI 10.1210/me.2003-0247; Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maxwell Megan A, 2006, Nucl Recept Signal, V4, pe002; McCready J, 2005, INT J CANCER, V117, P781, DOI 10.1002/ijc.21207; McEvoy AN, 2002, J IMMUNOL, V168, P2979, DOI 10.4049/jimmunol.168.6.2979; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mix KS, 2004, MOL PHARMACOL, V65, P309, DOI 10.1124/mol.65.2.309; Murphy EP, 1996, GENE EXPRESSION, V5, P169; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; Nelson KK, 2006, J BIOL CHEM, V281, P14100, DOI 10.1074/jbc.M601820200; Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200; Park KC, 2005, MOL ENDOCRINOL, V19, P12, DOI 10.1210/me.2004-0107; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Petrow PK, 2000, ARTHRITIS RHEUM, V43, P1597, DOI 10.1002/1529-0131(200007)43:7<1597::AID-ANR25>3.0.CO;2-0; Pillinger MH, 2003, J IMMUNOL, V171, P6080, DOI 10.4049/jimmunol.171.11.6080; Pirih FQ, 2004, J BIOL CHEM, V279, P53167, DOI 10.1074/jbc.M405677200; Pirih FQ, 2005, BIOCHEM BIOPH RES CO, V332, P494, DOI 10.1016/j.bbrc.2005.04.132; Ralph JA, 2005, J IMMUNOL, V175, P555, DOI 10.4049/jimmunol.175.1.555; Raymond L, 2006, J CELL PHYSIOL, V207, P683, DOI 10.1002/jcp.20608; Richmond RS, 2000, ARTHRITIS RHEUM, V43, P2081, DOI 10.1002/1529-0131(200009)43:9<2081::AID-ANR20>3.0.CO;2-I; Riquet FB, 2000, MOL MED, V6, P705, DOI 10.1007/BF03402050; Rius J, 2006, ATHEROSCLEROSIS, V184, P276, DOI 10.1016/j.atherosclerosis.2005.04.008; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Rutter JL, 1998, CANCER RES, V58, P5321; Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x; Sacchetti P, 2002, J BIOL CHEM, V277, P35088, DOI 10.1074/jbc.M205816200; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Schroen DJ, 1997, BIOCHEM BIOPH RES CO, V237, P52, DOI 10.1006/bbrc.1997.7073; Su L, 2005, CANCER EPIDEM BIOMAR, V14, P567, DOI 10.1158/1055-9965.EPI-04-0482; Tetlow LC, 2001, OSTEOARTHR CARTILAGE, V9, P423, DOI 10.1053/joca.2000.0408; Tetradis S, 2001, ENDOCRINOLOGY, V142, P663, DOI 10.1210/en.142.2.663; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; Tower GB, 2003, EUR J BIOCHEM, V270, P4216, DOI 10.1046/j.1432-1033.2003.03821.x; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Wang XM, 2006, CLIN PHARMACOL THER, V79, P303, DOI 10.1016/j.clpt.2005.12.306; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wu YM, 2005, ENDOCRINOLOGY, V146, P237, DOI 10.1210/en.2004-0889; Wyatt CA, 2002, CANCER RES, V62, P7200; Xu GW, 2005, J CLIN INVEST, V115, P1060; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	84	55	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9492	9504		10.1074/jbc.M608327200	http://dx.doi.org/10.1074/jbc.M608327200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17283078	hybrid			2022-12-27	WOS:000245421700022
J	Parsons, SA; Millay, DP; Sargent, MA; Naya, FJ; McNally, EM; Sweeney, HL; Molkentin, JD				Parsons, Stephanie A.; Millay, Douglas P.; Sargent, Michelle A.; Naya, Francisco J.; McNally, Elizabeth M.; Sweeney, H. Lee; Molkentin, Jeffery D.			Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; FIBER-TYPE; GLYCOPROTEIN COMPLEX; HYPERTROPHIC RESPONSE; SIGNALING PATHWAYS; MYOSTATIN BLOCKADE; MYOCYTE APOPTOSIS; MDX MOUSE; IN-VIVO; NF-AT	Calcineurin (Cn) is a Ca2+/calmodulin-dependent serine/threonine phosphatase that regulates differentiation-specific gene expression in diverse tissues, including the control of fiber-type switching in skeletal muscle. Recent studies have implicated Cn signaling in diminishing skeletal muscle pathogenesis associated with muscle injury or disease-related muscle degeneration. For example, use of the Cn inhibitor cyclosporine A has been shown to delay muscle regeneration following toxin-induced injury and inhibit regeneration in the dystrophin-deficient mdx mouse model of Duchenne muscular dystrophy. In contrast, transgenic expression of an activated mutant of Cn in skeletal muscle was shown to increase utrophin expression and reduce overall disease pathology in mdx mice. Here we examine the effect of altered Cn activation in the context of the delta-sarcoglycan-null (scgd-/-) mouse model of limb-girdle muscular dystrophy. In contrast to results discussed in mdx mice, genetic deletion of a loxP-targeted calcineurin B1 (CnB1) gene using a skeletal muscle-specific cre allele in the scgd-/- background substantially reduced skeletal muscle degeneration and histopathology compared with the scgd-/- genotype alone. A similar regression in scgd-dependent disease manifestation was also observed in calcineurin A beta (CnA beta) gene-targeted mice in both skeletal muscle and heart. Conversely, increased Cn expression using a muscle-specific transgene increased cardiac fibrosis, decreased cardiac ventricular shortening, and increased muscle fiber loss in the quadriceps. Our results suggest that inhibition of Cn may benefit select types of muscular dystrophy.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Mol Genet, Cincinnati, OH 45267 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Boston University; University of Chicago; University of Pennsylvania	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Sweeney, H Lee/F-1862-2010; McNally, Elizabeth/W-4909-2019; Tuluc, Petronel/C-2527-2011	Molkentin, Jeffery/0000-0002-3558-6529; McNally, Elizabeth/0000-0002-1221-719X	Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [P50 HL077101-050004, P01 HL069779, R01 HL081104-04, R01 HL060562-11, P50 HL077101, P01 HL069779-06A10003, R01 HL062927, R01 HL062927-10A1, R01 HL060562, R01 HL081104, T32 HL007752] Funding Source: Medline; NIAMS NIH HHS [T32 AR053461] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062927, R01HL060562, P50HL077101, P01HL069779, R01HL081104, T32HL007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR053461] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Allen DG, 2005, J PHYSIOL-LONDON, V567, P723, DOI 10.1113/jphysiol.2005.091694; ANDERSON JE, 1987, ANAT REC, V219, P243, DOI 10.1002/ar.1092190305; Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bigard X, 2000, J BIOL CHEM, V275, P19653, DOI 10.1074/jbc.M000430200; Bothe GWM, 2000, GENESIS, V26, P165, DOI 10.1002/(SICI)1526-968X(200002)26:2<165::AID-GENE22>3.0.CO;2-F; Bueno OF, 2004, CIRC RES, V94, P91, DOI 10.1161/01.RES.0000107197.99679.77; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; BUTTINI M, 1995, HISTOCHEM J, V27, P291, DOI 10.1007/BF00398971; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Finsterer J, 2003, CARDIOLOGY, V99, P1, DOI 10.1159/000068446; Hack AA, 2000, J CELL SCI, V113, P2535; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Jiang HS, 1997, MOL IMMUNOL, V34, P663, DOI 10.1016/S0161-5890(97)00054-0; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Lang JM, 2004, EXP BIOL MED, V229, P503, DOI 10.1177/153537020422900608; Lapidos KA, 2004, CIRC RES, V94, P1023, DOI 10.1161/01.RES.0000126574.61061.25; Liu QH, 2006, MOL CELL BIOL, V26, P3785, DOI 10.1128/MCB.26.10.3785-3797.2006; Mano A, 2004, CIRCULATION, V110, P317, DOI 10.1161/01.CIR.0000135599.33787.CA; McCullagh KJA, 2004, P NATL ACAD SCI USA, V101, P10590, DOI 10.1073/pnas.0308035101; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; Miyazaki M, 2004, J PHYSIOL PHARMACOL, V55, P751; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Neilson JR, 2004, IMMUNITY, V20, P255, DOI 10.1016/S1074-7613(04)00052-4; Oh M, 2005, MOL CELL BIOL, V25, P6629, DOI 10.1128/MCB.25.15.6629-6638.2005; Parsons SA, 2004, J BIOL CHEM, V279, P26192, DOI 10.1074/jbc.M313800200; Parsons SA, 2003, MOL CELL BIOL, V23, P4331, DOI 10.1128/MCB.23.12.4331-4343.2003; Parsons SA, 2006, AM J PATHOL, V168, P1975, DOI 10.2353/ajpath.2006.051316; Patel K, 2005, NEUROMUSCULAR DISORD, V15, P117, DOI 10.1016/j.nmd.2004.10.018; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; St-Pierre SJG, 2004, FASEB J, V18, P1937, DOI 10.1096/fj.04-1859fje; Stupka N, 2004, ACTA NEUROPATHOL, V107, P299, DOI 10.1007/s00401-003-0807-x; TAKAISHI T, 1991, BIOCHEM BIOPH RES CO, V174, P393, DOI 10.1016/0006-291X(91)90533-D; Talmadge RJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-28; TANABE Y, 1986, ACTA NEUROPATHOL, V69, P91, DOI 10.1007/BF00687043; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963	57	29	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10068	10078		10.1074/jbc.M609368200	http://dx.doi.org/10.1074/jbc.M609368200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17289669	Green Accepted, hybrid			2022-12-27	WOS:000245421700081
J	Wang, ZX; Oh, EJ; Thurmond, DC				Wang, Zhanxiang; Oh, Eunjin; Thurmond, Debbie C.			Glucose-stimulated Cdc42 signaling is essential for the second phase of insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; LIGHT-CHAIN KINASE; DISSOCIATION INHIBITOR; CELL-MIGRATION; RHO-GTPASES; BETA-CELLS; PHOSPHORYLATION; ACTIVATION; MUNC18C; RAC	The small Rho family GTPases Cdc42 and Rac1 have each been shown to function in insulin exocytosis and are presumed to function in actin remodeling and insulin granule mobilization. However, whether either GTPase is required for the mobilization phase of insulin release (second phase) and are linked in a common signaling pathway has remained unknown. Here we demonstrate that small interfering RNA-mediated depletion of Cdc42 from isolated islets results in the selective loss of second-phase insulin release. Consistent with a role in this nutrient-dependent phase, Cdc42 activation was detected exclusively in response to D-glucose and was unresponsive to KCl or non-metabolizable glucose analogs in MIN6 beta-cells. Cdc42 activation occurred early in secretion (3 min), whereas Rac1 activation required similar to 15-20 min, suggesting Cdc42 as proximal and Rac1 as distal regulators of second-phase secretion. Importantly, Rac1 activation and function was linked in a common pathway downstream of Cdc42; Cdc42 depletion ablated glucose-induced Rac1 activation, and expression of constitutively active Rac1 in Cdc42-depleted cells functionally restored glucose-stimulated insulin secretion. Occurring at a time midway between Cdc42 and Racl activations was the phosphorylation of p21-activated-kinase 1 (Pak1), and this phosphorylation event required Cdc42. Moreover, small interfering RNA-mediated Pak1 depletion abolished Racl activation and glucose-stimulated insulin release, suggesting that Pak1 may mediate the link between Cdc42 and Racl in this pathway. Taken together, these data substantiate the existence of a novel signaling pathway in the islet beta-cell whereby Cdc42 functions as a key proximal transmitter of the glucose signal early in stimulus-secretion coupling to support the later stage of insulin release.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Thurmond, DC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,M54053, Indianapolis, IN 46202 USA.	dthurmon@iupui.edu			NIDDK NIH HHS [R01 DK067912, R01 DK067912-04, DK-067912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baird D, 2005, CURR BIOL, V15, P1, DOI 10.1016/j.cub.2004.12.040; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Diebold BA, 2004, J BIOL CHEM, V279, P28136, DOI 10.1074/jbc.M313891200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; IIDA Y, 1997, AM J PHYSIOL, V273, P782; Kowluru A, 2003, AM J PHYSIOL-ENDOC M, V285, pE669, DOI 10.1152/ajpendo.00196.2003; Kowluru A, 2005, DIABETES, V54, P3523, DOI 10.2337/diabetes.54.12.3523; Kowluru A, 1996, J CLIN INVEST, V98, P540, DOI 10.1172/JCI118822; Kowluru A, 1997, BIOCHEM PHARMACOL, V54, P1097, DOI 10.1016/S0006-2952(97)00314-6; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lawrence JTR, 2003, P NATL ACAD SCI USA, V100, P13320, DOI 10.1073/pnas.2232129100; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li JS, 2004, AM J PHYSIOL-ENDOC M, V286, pE818, DOI 10.1152/ajpendo.00307.2003; MACDONALD MJ, 1982, DIABETES, V31, P566, DOI 10.2337/diabetes.31.6.566; Nevins AK, 2005, J BIOL CHEM, V280, P1944, DOI 10.1074/jbc.M409528200; Nevins AK, 2003, AM J PHYSIOL-CELL PH, V285, pC698, DOI 10.1152/ajpcell.00093.2003; Nevins AK, 2006, J BIOL CHEM, V281, P18961, DOI 10.1074/jbc.M603604200; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; Niwa T, 1998, DIABETES, V47, P1699, DOI 10.2337/diabetes.47.11.1699; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oh E, 2006, J BIOL CHEM, V281, P17624, DOI 10.1074/jbc.M601581200; Preitner F, 2004, J CLIN INVEST, V113, P635, DOI 10.1172/JCI200420518; Puls A, 1999, J CELL SCI, V112, P2983; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Spurlin BA, 2006, MOL ENDOCRINOL, V20, P183, DOI 10.1210/me.2005-0157; Spurlin BA, 2003, DIABETES, V52, P1910, DOI 10.2337/diabetes.52.8.1910; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Trumper J, 2005, DIABETOLOGIA, V48, P1534, DOI 10.1007/s00125-005-1820-5; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Yu JS, 1998, BIOCHEM J, V334, P121, DOI 10.1042/bj3340121; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	44	113	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9536	9546		10.1074/jbc.M610553200	http://dx.doi.org/10.1074/jbc.M610553200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17289663	Green Accepted, hybrid			2022-12-27	WOS:000245421700026
J	Weng, N; Thomas, DDH; Groblewski, GE				Weng, Ning; Thomas, Diana D. H.; Groblewski, Guy E.			Pancreatic acinar cells express vesicle-associated membrane protein 2-and 8-specific populations of zymogen granules with distinct and overlapping roles in secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EXOCYTOSIS; EXOCRINE PANCREAS; PLASMA-MEMBRANE; FUSION; IDENTIFICATION; CALCIUM; SNARES; SYNTAXIN-2; CRHSP-28; SNAP-23	Previous studies have demonstrated roles for vesicle-associated membrane protein 2 (VAMP 2) and VAMP 8 in Ca2+-regulated pancreatic acinar cell secretion, however, their coordinated function in the secretory pathway has not been addressed. Here we provide evidence using immunofluorescence microscopy, cell fractionation, and SNARE protein interaction studies that acinar cells contain two distinct populations of zymogen granules (ZGs) expressing either VAMP 2 or VAMP 8. Further, VAMP 8-positive granules also contain the synaptosome-associated protein 29, whereas VAMP 2-expressing granules do not. Analysis of acinar secretion by Texas red-dextran labeling indicated that VAMP 2-positive ZGs mediate the majority of exocytotic events during constitutive secretion and also participate in Ca2+-regulated exocytosis, whereas VAMP 8-positive ZGs are more largely involved in Ca2+-stimulated secretion. Previously undefined functional roles for VAMP and syntaxin isoforms in acinar secretion were established by introducing truncated constructs of these proteins into permeabilized acini. VAMP 2 and VAMP 8 constructs each attenuated Ca2+-stimulated exocytosis by 50%, whereas the neuronal VAMP 1 had no effects. In comparison, the plasma membrane SNAREs syntaxin 2 and syntaxin 4 each inhibited basal exocytosis, but only syntaxin 4 significantly inhibited Ca2+-stimulated secretion. Syntaxin 3, which is expressed on ZGs, had no effects. Collectively, these data demonstrate that individual acinar cells express VAMP 2-and VAMP 8-specific populations of ZGs that orchestrate the constitutive and Ca2+-regulated secretory pathways.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Groblewski, GE (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.	groby@nutrisci.wisc.edu			NIDDK NIH HHS [DK062862, DK07088] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062862] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSON JW, 1989, AM J PHYSIOL, V256, pG817, DOI 10.1152/ajpgi.1989.256.5.G817; Antonin W, 2000, MOL BIOL CELL, V11, P3289, DOI 10.1091/mbc.11.10.3289; Castle AM, 2002, J CELL SCI, V115, P2963; Chen XQ, 2006, MOL CELL PROTEOMICS, V5, P306, DOI 10.1074/mcp.M500172-MCP200; Chen Y, 2005, AM J PHYSIOL-CELL PH, V289, pC1209, DOI 10.1152/ajpcell.00159.2005; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; Giovannucci DR, 1998, AM J PHYSIOL-CELL PH, V275, pC732, DOI 10.1152/ajpcell.1998.275.3.C732; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; Groblewski GE, 1996, J BIOL CHEM, V271, P31502, DOI 10.1074/jbc.271.49.31502; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Low SH, 2003, DEV CELL, V4, P753, DOI 10.1016/S1534-5807(03)00122-9; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Padfield PJ, 2000, FEBS LETT, V484, P129, DOI 10.1016/S0014-5793(00)02126-8; Pickett JA, 2005, J BIOL CHEM, V280, P1506, DOI 10.1074/jbc.M411967200; Polgar J, 2002, BLOOD, V100, P1081, DOI 10.1182/blood.V100.3.1081; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Su QN, 2001, P NATL ACAD SCI USA, V98, P14038, DOI 10.1073/pnas.251532398; Sutton R, 2003, PANCREATOLOGY, V3, P497, DOI 10.1159/000075581; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thomas DDH, 2004, AM J PHYSIOL-GASTR L, V287, pG253, DOI 10.1152/ajpgi.00033.2004; Thomas DDH, 2002, J BIOL CHEM, V277, P35496, DOI 10.1074/jbc.M110917200; Thomas DDH, 2001, J BIOL CHEM, V276, P28866, DOI 10.1074/jbc.M102214200; Turvey MR, 2004, PFLUG ARCH EUR J PHY, V448, P552, DOI 10.1007/s00424-004-1288-z; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002; Washbourne P, 2001, BIOCHEM J, V357, P625, DOI 10.1042/0264-6021:3570625; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 2003, METHODS, V30, P191, DOI 10.1016/S1046-2023(03)00025-2; Weng N, 2005, FASEB J, V19, pA742; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676; Yule DI, 1997, J BIOL CHEM, V272, P9093	41	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9635	9645		10.1074/jbc.M611108200	http://dx.doi.org/10.1074/jbc.M611108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272274	hybrid			2022-12-27	WOS:000245421700037
J	Yang, XXO; Panopoulos, AD; Nurieva, R; Chang, SH; Wang, DM; Watowich, SS; Dong, C				Yang, Xuexian O.; Panopoulos, Athanasia D.; Nurieva, Roza; Chang, Seon Hee; Wang, Demin; Watowich, Stephanie S.; Dong, Chen			STAT3 regulates cytokine-mediated generation of inflammatory helper T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW; MICE; DIFFERENTIATION; LINEAGE; RECEPTOR; DISTINCT; INTERLEUKIN-17; PROLIFERATION; NEUTROPHILS; EXPRESSION	Interleukin-17 (IL-17)-producing helper T (TH) cells, named as THIL-17, TH17, or inflammatory TH (THi), have been recently identified as a novel effector lineage. However, how cytokine signals mediate THi differentiation is unclear. We found that IL-6 functioned to up-regulate IL-23R and that IL-23 synergized with IL-6 in promoting THi generation. STAT3, activated by both IL-6 and IL-23, plays a critical role in THi development. A hyperactive form of STAT3 promoted THi development, whereas this differentiation process was greatly impaired in STAT3-deficient T cells. Moreover, STAT3 regulated the expression of retinoic acid receptor-related orphan receptor,gamma-T (ROR gamma t), a THi-specific transcriptional regulator; STAT3 deficiency impaired ROR gamma t expression and led to elevated expression of T-box expressed in T cells (T-bet) and Forkhead box P3 (Foxp3). Our data thus demonstrate a pathway whereby cytokines regulate THi differentiation through a selective STAT transcription factor that functions to regulate lineage-specific gene expression.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Blood Ctr Wisconsin, Blood Res Inst, Milwaukee, WI 53226 USA	University of Texas System; UTMD Anderson Cancer Center; Versiti Blood Center of Wisconsin	Dong, C (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	cdong@mdanderson.org	Chang, Seon Hee/AAQ-9521-2020; Wang, Demin/AAX-4449-2020; Yang, Xuexian/Y-2472-2019; dong, chen/B-3181-2009	Chang, Seon Hee/0000-0002-9389-508X; Wang, Demin/0000-0001-5549-3795; Yang, Xuexian/0000-0001-6816-7024; dong, chen/0000-0002-0084-9130; Watowich, Stephanie/0000-0003-1969-659X; Panopoulos, Athanasia/0000-0002-9610-2604				Akimzhanov AM, 2007, J BIOL CHEM, V282, P5969, DOI 10.1074/jbc.C600322200; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Cho ML, 2006, J IMMUNOL, V176, P5652, DOI 10.4049/jimmunol.176.9.5652; Chung YS, 2006, CELL RES, V16, P902, DOI 10.1038/sj.cr.7310106; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Dong C, 2000, ARTHRITIS RES, V2, P179, DOI 10.1186/ar85; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Glimcher LH, 2000, GENE DEV, V14, P1693; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kang HS, 2006, BIOCHEM J, V397, P89, DOI 10.1042/BJ20051781; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Laouar Y, 2003, IMMUNITY, V19, P903, DOI 10.1016/S1074-7613(03)00332-7; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Panopoulos AD, 2006, BLOOD, V108, P3682, DOI 10.1182/blood-2006-02-003012; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wen RR, 2003, J BIOL CHEM, V278, P43654, DOI 10.1074/jbc.M307318200	31	1084	1150	3	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9358	9363		10.1074/jbc.C600321200	http://dx.doi.org/10.1074/jbc.C600321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17277312	hybrid			2022-12-27	WOS:000245421700007
J	Yonekura-Sakakibara, K; Tohge, T; Niida, R; Saito, K				Yonekura-Sakakibara, Keiko; Tohge, Takayuki; Niida, Rie; Saito, Kazuki			Identification of a flavonol 7-O-rhamnosyltransferase gene determining flavonoid pattern in Arabidopsis by transcriptome coexpression analysis and reverse genetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHOCYANIN PIGMENTATION; MEDIATED TRANSFORMATION; SECONDARY METABOLISM; FUNCTIONAL GENOMICS; COLORFUL MODEL; PLANT; BIOSYNTHESIS; GLYCOSYLTRANSFERASES; THALIANA; CDNA	Glycosylation plays a major role in the remarkable chemical diversity of flavonoids in plants including Arabidopsis thaliana. The wide diversity encoded by the large family-1 glycosyltransferase ( UGT) gene family makes it difficult to determine the biochemical function of each gene solely from its primary sequence. Here we used transcriptome coexpression analysis combined with a reverse genetics approach to identify a gene that is prominent in determining the flavonoid composition of Arabidopsis. Using transcriptome coexpression analysis accessible on the ATTED-II public data base, the expression pattern of a UGT gene, UGT89C1, was found to be highly correlated with known flavonoid biosynthetic genes. No C-7 rhamnosylated flavonols were detected in either of two T-DNA ugt89c1 mutants. This specific metabolite deficiency in the mutants was complemented by stable transformation with the genomic fragment containing intact UGT89C1. Glutathione S-transferasefused recombinant UGT89C1 protein converted kaempferol 3-O-glucoside to kaempferol 3-O-glucoside-7-O-rhamnoside and recognized 3-O-glycosylated flavonols and UDP-rhamnose as substrates, but not flavonol aglycones, 3-O-glycosylated anthocyanins or other UDP-sugars. These results show that UGT89C1 is a flavonol 7-O-rhamnosyltransferase. The abundance of UGT89C1 transcripts in floral buds was consistent with the flavonoid accumulation of C-7 rhamnosylated flavonols in Arabidopsis organs. Our present study demonstrates that the integration of transcriptome coexpression analysis with a reverse genetic approach is a versatile tool for understanding a multigene family of a metabolic pathway in Arabidopsis.	RIKEN, Plant Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	RIKEN; Chiba University	Saito, K (corresponding author), RIKEN, Plant Sci Ctr, Tsurumi Ku, Suehiro Cho 1-7-22, Yokohama, Kanagawa 2300045, Japan.	ksaito@faculty.chiba-u.jp	Saito, Kazuki/D-2670-2009; Yonekura-Sakakibara, Keiko/J-8749-2014; Tohge, Takayuki/G-7924-2017	Saito, Kazuki/0000-0001-6310-5342; Yonekura-Sakakibara, Keiko/0000-0002-0409-1523; Tohge, Takayuki/0000-0001-5555-5650				BARBER GA, 1991, ARCH BIOCHEM BIOPHYS, V288, P239, DOI 10.1016/0003-9861(91)90190-T; Birnbaum K, 2003, SCIENCE, V302, P1956, DOI 10.1126/science.1090022; Bowles D, 2002, BIOCHEM SOC T, V30, P301, DOI 10.1042/BST0300301; Bowles D, 2006, ANNU REV PLANT BIOL, V57, P567, DOI 10.1146/annurev.arplant.57.032905.105429; BRUGLIERA F, 1994, PLANT J, V5, P81, DOI 10.1046/j.1365-313X.1994.5010081.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Craigon DJ, 2004, NUCLEIC ACIDS RES, V32, pD575, DOI 10.1093/nar/gkh133; D'Auria JC, 2005, CURR OPIN PLANT BIOL, V8, P308, DOI 10.1016/j.pbi.2005.03.012; Davies K. M., 2006, Flavonoids: chemistry, biochemistry and applications, P143; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Dixon RA, 2003, PHYTOCHEMISTRY, V62, P815, DOI 10.1016/S0031-9422(02)00712-4; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; Goossens A, 2003, P NATL ACAD SCI USA, V100, P8595, DOI 10.1073/pnas.1032967100; Graham TL, 1998, PLANT PHYSIOL BIOCH, V36, P135, DOI 10.1016/S0981-9428(98)80098-3; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Hirai MY, 2004, P NATL ACAD SCI USA, V101, P10205, DOI 10.1073/pnas.0403218101; HOFGEN R, 1988, NUCLEIC ACIDS RES, V16, P9877, DOI 10.1093/nar/16.20.9877; Jones P, 2003, J BIOL CHEM, V278, P43910, DOI 10.1074/jbc.M303523200; Koes R, 2005, TRENDS PLANT SCI, V10, P236, DOI 10.1016/j.tplants.2005.03.002; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; Kubo A, 2004, ARCH BIOCHEM BIOPHYS, V429, P198, DOI 10.1016/j.abb.2004.06.021; Mehrtens F, 2005, PLANT PHYSIOL, V138, P1083, DOI 10.1104/pp.104.058032; Morita Y, 2005, PLANT J, V42, P353, DOI 10.1111/j.1365-313X.2005.02383.x; Obayashi T, 2007, NUCLEIC ACIDS RES, V35, pD863, DOI 10.1093/nar/gkl783; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Paquette S, 2003, PHYTOCHEMISTRY, V62, P399, DOI 10.1016/S0031-9422(02)00558-7; Pelletier MK, 1996, PLANT PHYSIOL, V111, P339, DOI 10.1104/pp.111.1.339; Pelletier MK, 1997, PLANT PHYSIOL, V113, P1437, DOI 10.1104/pp.113.4.1437; QUATTROCCHIO F, 1993, PLANT CELL, V5, P1497, DOI 10.1105/tpc.5.11.1497; Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P224, DOI 10.1093/nar/gkg076; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Routaboul JM, 2006, PLANTA, V224, P96, DOI 10.1007/s00425-005-0197-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sawada S, 2005, J BIOL CHEM, V280, P899, DOI 10.1074/jbc.M410537200; Scalbert A, 2005, AM J CLIN NUTR, V81, p215S, DOI 10.1093/ajcn/81.1.215S; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; Shinbo Y, 2006, BIOTECH AGR FOREST, V57, P165; STAFFORD HA, 1991, PLANT PHYSIOL, V96, P680, DOI 10.1104/pp.96.3.680; Tohge T, 2005, PLANT J, V42, P218, DOI 10.1111/j.1365-313X.2005.02371.x; Tohge T, 2007, PURE APPL CHEM, V79, P811, DOI 10.1351/pac200779040811; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Veit M, 1999, J NAT PROD, V62, P1301, DOI 10.1021/np990080o; Williams C. A., 2006, Flavonoids: chemistry, biochemistry and applications, P749; Winkel-Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485; Yonekura-Sakakibara K, 2004, PLANT PHYSIOL, V134, P1654, DOI 10.1104/pp.103.037176	47	210	224	10	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14932	14941		10.1074/jbc.M611498200	http://dx.doi.org/10.1074/jbc.M611498200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17314094	hybrid			2022-12-27	WOS:000246589000031
J	Mussmann, R; Geese, M; Harder, F; Kegel, S; Andag, U; Lomow, A; Burk, U; Onichtchouk, D; Dohrmann, C; Austen, M				Mussmann, Rainer; Geese, Marcus; Harder, Friedrich; Kegel, Simone; Andag, Uwe; Lomow, Alexander; Burk, Ulrike; Onichtchouk, Daria; Dohrmann, Cord; Austen, Matthias			Inhibition of GSK3 promotes replication and survival of pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; EPIDERMAL-GROWTH-FACTOR; CYCLIN-DEPENDENT KINASE-4; TYPE-2 DIABETES-MELLITUS; ISLET REGENERATION; IN-VITRO; GLUCOSE; PROLIFERATION; MASS; ACTIVATION	Recent developments indicate that the regeneration of beta cell function and mass in patients with diabetes is possible. A regenerative approach may represent an alternative treatment option relative to current diabetes therapies that fail to provide optimal glycemic control. Here we report that the inactivation of GSK3 by small molecule inhibitors or RNA interference stimulates replication of INS-1E rat insulinoma cells. Specific and potent GSK3 inhibitors also alleviate the toxic effects of high concentrations of glucose and the saturated fatty acid palmitate on INS-1E cells. Furthermore, treatment of isolated rat islets with structurally diverse small molecule GSK3 inhibitors increases the rate beta cell replication by 2-3-fold relative to controls. We propose that GSK3 is a regulator of beta cell replication and survival. Moreover, our results suggest that specific inhibitors of GSK3 may have practical applications in beta cell regenerative therapies.	DeveloGen AG, D-37079 Gottingen, Germany		Mussmann, R (corresponding author), DeveloGen AG, Marie Curie Str 7, D-37079 Gottingen, Germany.	mussmann@develogen.com; austen@develogen.com	Onichtchouk, Daria/E-1741-2012	Onichtchouk, Daria/0000-0001-6497-1445				Arulmozhi DK, 2006, EUR J PHARM SCI, V28, P96, DOI 10.1016/j.ejps.2006.01.003; Atkinson MA, 2005, DIABETES, V54, P1253, DOI 10.2337/diabetes.54.5.1253; Baggio LL, 2006, ANNU REV MED, V57, P265, DOI 10.1146/annurev.med.57.110104.115624; Beattie GM, 2002, DIABETES, V51, P3435, DOI 10.2337/diabetes.51.12.3435; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Bernard-Kargar C, 2001, DIABETES, V50, pS30, DOI 10.2337/diabetes.50.2007.S30; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Boucher MJ, 2006, J BIOL CHEM, V281, P6395, DOI 10.1074/jbc.M511597200; Bouwens L, 2005, PHYSIOL REV, V85, P1255, DOI 10.1152/physrev.00025.2004; BRELJE TC, 1994, DIABETES, V43, P263, DOI 10.2337/diabetes.43.2.263; Brun T, 2004, J CELL BIOL, V167, P1123, DOI 10.1083/jcb.200405148; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Chen SY, 2006, P NATL ACAD SCI USA, V103, P8469, DOI 10.1073/pnas.0602921103; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cozar-Castellano I, 2004, DIABETES, V53, P149, DOI 10.2337/diabetes.53.1.149; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dokken BB, 2005, AM J PHYSIOL-ENDOC M, V288, pE1188, DOI 10.1152/ajpendo.00547.2004; Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108; El-Assaad W, 2003, ENDOCRINOLOGY, V144, P4154, DOI 10.1210/en.2003-0410; Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757; Gianani R, 2005, IMMUNOL REV, V204, P232, DOI 10.1111/j.0105-2896.2005.00248.x; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; Jetton TL, 2005, DIABETES, V54, P2294, DOI 10.2337/diabetes.54.8.2294; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kaidanovich-Beilin O, 2006, J PHARMACOL EXP THER, V316, P17, DOI 10.1124/jpet.105.090266; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kunick C, 2004, BIOORG MED CHEM LETT, V14, P413, DOI 10.1016/j.bmcl.2003.10.062; Kypta RM, 2005, EXPERT OPIN THER PAT, V15, P1315, DOI 10.1517/13543776.15.10.1315; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Meier JJ, 2005, DIABETOLOGIA, V48, P2221, DOI 10.1007/s00125-005-1949-2; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Mu J, 2006, DIABETES, V55, P1695, DOI 10.2337/db05-1602; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Murtaugh LC, 2005, DEVELOPMENT, V132, P4663, DOI 10.1242/dev.02063; Ogawa N, 2004, DIABETES, V53, P1700, DOI 10.2337/diabetes.53.7.1700; Otani K, 2004, AM J PHYSIOL-ENDOC M, V286, pE41, DOI 10.1152/ajpendo.00533.2001; Papadopoulou S, 2005, DIABETES, V54, P2844, DOI 10.2337/diabetes.54.10.2844; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Pospisilik JA, 2003, DIABETES, V52, P741, DOI 10.2337/diabetes.52.3.741; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Reimer MK, 2002, EUR J ENDOCRINOL, V146, P717, DOI 10.1530/eje.0.1460717; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Rooman I, 2004, DIABETOLOGIA, V47, P259, DOI 10.1007/s00125-003-1287-1; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Srinivasan S, 2005, DIABETES, V54, P968, DOI 10.2337/diabetes.54.4.968; Steffes MW, 2003, DIABETES CARE, V26, P832, DOI 10.2337/diacare.26.3.832; Suarez-Pinzon WL, 2005, J CLIN ENDOCR METAB, V90, P3401, DOI 10.1210/jc.2004-0761; Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339; Trucco M, 2005, J CLIN INVEST, V115, P5, DOI 10.1172/JCI200523935; Trumper A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740233; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Tyrberg B, 2001, DIABETES, V50, P301, DOI 10.2337/diabetes.50.2.301; Vasavada RC, 2006, INT J BIOCHEM CELL B, V38, P931, DOI 10.1016/j.biocel.2005.08.003; von Herrath M, 2004, PEDIATR DIABETES, V5, P23, DOI 10.1111/j.1399-543X.2004.00076.x; Wagman AS, 2004, CURR PHARM DESIGN, V10, P1105, DOI 10.2174/1381612043452668; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Wente W, 2006, DIABETES, V55, P2470, DOI 10.2337/db05-1435; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; Yoon KH, 2003, J CLIN ENDOCR METAB, V88, P2300, DOI 10.1210/jc.2002-020735	85	113	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12030	12037		10.1074/jbc.M609637200	http://dx.doi.org/10.1074/jbc.M609637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17242403	hybrid			2022-12-27	WOS:000245941900045
J	Seong, HA; Jung, H; Kim, KT; Ha, H				Seong, Hyun-A; Jung, Haiyoung; Kim, Kyong-Tai; Ha, Hyunjung			3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth factor-beta-induced signaling in a kinase-dependent manner through physical interaction with smad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATION INHIBITORY FACTOR; TGF-BETA; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIPROLIFERATIVE FUNCTION; MESENCHYMAL TRANSITION; PHOSPHORYLATION; ACTIVATION; SUPERFAMILY; RECEPTOR	We have reported previously that PDK1 physically interacts with STRAP, a transforming growth factor-beta ( TGF-beta) receptor-interacting protein, and enhances STRAP-induced inhibition of TGF-beta signaling. In this study we show that PDK1 coimmunoprecipitates with Smad proteins, including Smad2, Smad3, Smad4, and Smad7, and that this association is mediated by the pleckstrin homology domain of PDK1. The association between PDK1 and Smad proteins is increased by insulin treatment but decreased by TGF-beta treatment. Analysis of the interacting proteins shows that Smad proteins enhance PDK1 kinase activity by removing 14-3-3, a negative regulator of PDK1, from the PDK1-14-3-3 complex. Knockdown of endogenous Smad proteins, including Smad3 and Smad7, by transfection with small interfering RNA produced the opposite trend and decreased PDK1 activity, protein kinase B/Akt phosphorylation, and Bad phosphorylation. Moreover, coexpression of Smad proteins and wild-type PDK1 inhibits TGF-beta-induced transcription, as well as TGF-beta-mediated biological functions, such as apoptosis and cell growth arrest. Inhibition was dose-dependent on PDK1, but no inhibition was observed in the presence of an inactive kinase-dead PDK1 mutant. In addition, confocal microscopy showed that wild-type PDK1 prevents translocation of Smad3 and Smad4 from the cytoplasm to the nucleus, as well as the redistribution of Smad7 from the nucleus to the cytoplasm in response to TGF-beta. Taken together, our results suggest that PDK1 negatively regulates TGF-beta-mediated signaling in a PDK1 kinase-dependent manner via a direct physical interaction with Smad proteins and that Smad proteins can act as potential positive regulators of PDK1.	Chungbuk Natl Univ, Dept Biochem, Res Ctr Bioresource & Hlth, Biotechnol Res Inst,Sch Life Sci, Cheongju 361763, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Chungbuk National University; Pohang University of Science & Technology (POSTECH)	Ha, H (corresponding author), Chungbuk Natl Univ, Dept Biochem, Res Ctr Bioresource & Hlth, Biotechnol Res Inst,Sch Life Sci, Cheongju 361763, South Korea.	hyunha@chungbuk.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; DEL PL, 1997, SCIENCE, V278, P687; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; DOSSARBASSOV D, 2005, SCIENCE, V307, P1098; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Kim T, 1999, FEBS LETT, V460, P363, DOI 10.1016/S0014-5793(99)01375-7; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Liu F, 2005, CELL CYCLE, V4, P63, DOI 10.4161/cc.4.1.1366; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Pan D, 2005, J BIOL CHEM, V280, P15992, DOI 10.1074/jbc.M411234200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Seong HA, 2005, J BIOL CHEM, V280, P42897, DOI 10.1074/jbc.M507539200; Seong HA, 2003, J BIOL CHEM, V278, P9655, DOI 10.1074/jbc.M207478200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yamagata H, 2005, CANCER RES, V65, P157; Yao KS, 2005, CLIN CANCER RES, V11, P7264, DOI 10.1158/1078-0432.CCR-05-0135; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	48	32	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12272	12289		10.1074/jbc.M609279200	http://dx.doi.org/10.1074/jbc.M609279200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17327236	hybrid			2022-12-27	WOS:000245941900070
J	Takeda, K; Sasaki, AT; Ha, HJ; Seung, HA; Firtel, RA				Takeda, Kosuke; Sasaki, Atsuo T.; Ha, Hyunjung; Seung, Hyun-A; Firtel, Richard A.			Role of phosphatidylinositol 3-kinases in chemotaxis in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL POLARITY; LEADING-EDGE; NEUTROPHIL CHEMOTAXIS; SIGNALING PATHWAYS; ADENYLYL-CYCLASE; PI 3-KINASE; PROTEIN; ACTIVATION; MIGRATION; KINASE	Experiments in several cell types revealed that local accumulation of phosphatidylinositol 3,4,5-triphosphate mediates the ability of cells to migrate during gradient sensing. We took a systematic approach to characterize the functions of the six putative Class I phosphatidylinositol 3-kinases ( PI3K1-6) in Dictyostelium by creating a series of gene knockouts. These studies revealed that PI3K1-PI3K3 are the major PI3Ks for chemoattractant-mediated phosphatidylinositol 3,4,5-triphosphate production. We studied chemotaxis of the pi3k1/2/3 triple knock-out strain ( pi3k1/2/3 null cells) to cAMP under two distinct experimental conditions, an exponential gradient emitted from a micropipette and a shallow, linear gradient in a Dunn chamber, using four cAMP concentrations ranging over a factor of 10,000. Under all conditions tested pi3k1/2/3 null cells moved slower and had less polarity than wild-type cells. pi3k1/2/3 null cells moved toward a chemoattractant emitted by a micropipette, although persistence was lower than that of wildtype or pi3k1/2 null cells. In shallow linear gradients, pi3k1/2 null cells had greater directionality defects, especially at lower chemoattractant concentrations. Our studies suggest that although PI3K is not essential for directional movement under some chemoattractant conditions, it is a key component of the directional sensing pathway and plays a critical role in linear chemoattractant gradients, especially at low chemoattractant concentrations. The relative importance of PI3K in chemotaxis is also dependent on the developmental stage of the cells. Our data suggest that the output of other signaling pathways suffices to mediate directional sensing when cells perceive a strong signal, but PI3K signaling is crucial for detecting weaker signals.	Univ Calif San Diego, Sect Cell & Dev Biol, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Firtel, RA (corresponding author), Univ Calif San Diego, Sect Cell & Dev Biol, Div Biol Sci, Nat Sci Bldg,Rm 6316,9500 Gilman Dr, La Jolla, CA 92093 USA.	rafirtel@ucsd.edu		Sasaki, Atsuo/0000-0003-2963-4501				Aubry L, 1999, ANNU REV CELL DEV BI, V15, P469, DOI 10.1146/annurev.cellbio.15.1.469; Bagorda A, 2006, THROMB HAEMOSTASIS, V95, P12, DOI 10.1160/TH05-07-0483; Barber MA, 2006, B CANC, V93, P10044; Bourne HR, 2005, NAT CELL BIOL, V7, P777, DOI 10.1038/ncb0805-777; Charest PG, 2006, CURR OPIN GENET DEV, V16, P339, DOI 10.1016/j.gde.2006.06.016; Chen LF, 2003, MOL BIOL CELL, V14, P5028, DOI 10.1091/mbc.E03-05-0339; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Comer FI, 2006, MOL BIOL CELL, V17, P357, DOI 10.1091/mbc.E05-08-0781; Corner FI, 2005, CURR BIOL, V15, P134, DOI 10.1016/j.cub.2005.01.007; Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; Janetopoulos C, 2005, DEV CELL, V8, P467, DOI 10.1016/j.devcel.2005.02.010; Kimmel AR, 2003, SCIENCE, V300, P1525, DOI 10.1126/science.1085439; Kriebel PW, 2003, CELL, V112, P549, DOI 10.1016/S0092-8674(03)00081-3; Kunisaki Y, 2006, J CELL BIOL, V174, P647, DOI 10.1083/jcb.200602142; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Loovers HM, 2006, MOL BIOL CELL, V17, P1503, DOI 10.1091/mbc.E05-09-0825; Meili R, 2000, CURR BIOL, V10, P708, DOI 10.1016/S0960-9822(00)00536-4; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Nombela-Arrieta C, 2004, IMMUNITY, V21, P429, DOI 10.1016/j.immuni.2004.07.012; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Park KC, 2004, EMBO J, V23, P4177, DOI 10.1038/sj.emboj.7600368; Postma M, 2004, J CELL SCI, V117, P2925, DOI 10.1242/jcs.01143; Reif K, 2002, TRENDS CELL BIOL, V12, P368, DOI 10.1016/S0962-8924(02)02330-9; Sasaki AT, 2004, J CELL BIOL, V167, P505, DOI 10.1083/jcb.200406177; Sasaki AT, 2006, EUR J CELL BIOL, V85, P873, DOI 10.1016/j.ejcb.2006.04.007; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wessels D, 1998, CELL MOTIL CYTOSKEL, V41, P225, DOI 10.1002/(SICI)1097-0169(1998)41:3<225::AID-CM4>3.3.CO;2-9; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	42	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11874	11884		10.1074/jbc.M610984200	http://dx.doi.org/10.1074/jbc.M610984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17331950	hybrid			2022-12-27	WOS:000245941900030
J	Ishibashi, Y; Nakasone, T; Kiyohara, M; Horibata, Y; Sakaguchi, K; Hijikata, A; Ichinose, S; Omori, A; Yasui, Y; Imamura, A; Ishida, H; Kiso, M; Okino, N; Ito, M				Ishibashi, Yohei; Nakasone, Toru; Kiyohara, Masashi; Horibata, Yasuhiro; Sakaguchi, Keishi; Hijikata, Atsushi; Ichinose, Sachiyo; Omori, Akira; Yasui, Yasuyuki; Imamura, Akihiro; Ishida, Hideharu; Kiso, Makoto; Okino, Nozomu; Ito, Makoto			A novel endoglycoceramidase hydrolyzes oligogalactosylceramides to produce galactooligosaccharides and ceramides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECHINOCOCCUS-MULTILOCULARIS; TRICHODERMA-VIRIDE; MOLECULAR-CLONING; RHODOCOCCUS SP; GLYCOSPHINGOLIPIDS; SEQUENCE; PURIFICATION; STRAIN; METACESTODES; EXPRESSION	Enzymes capable of hydrolyzing the beta-glycosidic linkage between oligosaccharides and ceramides in various glyco-sphingolipids has been found in microorganisms and invertebrates and designated endoglycoceramidase ( EC 3.2.1.123) or ceramide glycanase. Here we report the molecular cloning, characterization, and homology modeling of a novel endoglycoceramidase that hydrolyzes oligogalactosylceramides to produce galactooligosaccharides and ceramides. The novel enzyme was purified from a culture supernatant of Rhodococcus equi, and the gene encoding 488 deduced amino acids was cloned using peptide sequences of the purified enzyme. Eight residues essential for the catalytic reaction in microbial and animal endoglycoceramidases were all conserved in the deduced amino acid sequence of the novel enzyme. Homology modeling of the enzyme using endocellulase E1 as a template revealed that the enzyme displays a (beta/alpha)(8) barrel structure in which Glu(234) at the end of beta-strand 4 and Glu(341) at the end of beta-strand 7 could function as an acid/base catalyst and a nucleophile, respectively. Site-directed mutagenesis of these glutamates resulted in a complete loss of the activity without a change in their CD spectra. The recombinant enzyme hydrolyzed the beta-galactosidic linkage between oligosaccharides and ceramides of 6-gala series glycosphingolipids that were completely resistant to hydrolysis by the enzymes reported so far. In contrast, the novel enzyme did not hydrolyze ganglio-, globo-, or lacto- series glycosphingolipids. The enzyme is therefore systematically named "oligogalactosyl-N-acylsphingosine 1,1'-beta-galactohydrolase" or tentatively designated " endogalactosylceramidase."	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Gifu Univ, Fac Appl Biol Sci, Gifu 5011193, Japan	Kyushu University; Mitsubishi Kagaku Institute of Life Sciences (MITILS); RIKEN; Gifu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-ac.jp	Ito, Makoto/Q-6164-2019; Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818; Hijikata, Atsushi/0000-0003-4297-8368				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aoki K, 2004, J BIOL CHEM, V279, P32028, DOI 10.1074/jbc.M312918200; ASHIDA H, 1992, EUR J BIOCHEM, V205, P729, DOI 10.1111/j.1432-1033.1992.tb16836.x; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; Chisada S, 2005, BIOCHEM BIOPH RES CO, V333, P367, DOI 10.1016/j.bbrc.2005.05.110; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DENNIS RD, 1992, EUR J BIOCHEM, V207, P1053, DOI 10.1111/j.1432-1033.1992.tb17142.x; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HIGASHI H, 1990, ANAL BIOCHEM, V186, P355, DOI 10.1016/0003-2697(90)90094-P; Horibata Y, 2004, J BIOL CHEM, V279, P33379, DOI 10.1074/jbc.M401460200; Horibata Y, 2000, J BIOL CHEM, V275, P31297, DOI 10.1074/jbc.M003575200; International Union of Biochemistry and Molecular Biology, 1992, ENZ NOM; ISEGAWA Y, 1992, MOL CELL PROBE, V6, P467, DOI 10.1016/0890-8508(92)90043-W; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KAWAKAMI Y, 1993, J BIOCHEM-TOKYO, V114, P677, DOI 10.1093/oxfordjournals.jbchem.a124236; Kotake T, 2004, BIOCHEM J, V377, P749, DOI 10.1042/bj20031145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI SC, 1986, BIOCHEM BIOPH RES CO, V141, P346, DOI 10.1016/S0006-291X(86)80375-8; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MATSUBARA T, 1981, J BIOCHEM-TOKYO, V89, P645, DOI 10.1093/oxfordjournals.jbchem.a133241; NISHIMURA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P141, DOI 10.1016/0005-2760(91)90001-X; Noda N, 1996, CHEM PHARM BULL, V44, P895, DOI 10.1248/cpb.44.895; Okemoto K, 2003, CARBOHYD RES, V338, P219, DOI 10.1016/S0008-6215(02)00405-6; Persat F, 1996, INFECT IMMUN, V64, P3682, DOI 10.1128/IAI.64.9.3682-3687.1996; PERSAT F, 1992, J BIOL CHEM, V267, P8764; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Sakaguchi K, 1999, BIOCHEM BIOPH RES CO, V260, P89, DOI 10.1006/bbrc.1999.0855; Sakaguchi K, 2000, J BIOCHEM-TOKYO, V128, P145, DOI 10.1093/oxfordjournals.jbchem.a022725; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sugita M, 1995, BBA-LIPID LIPID MET, V1259, P220, DOI 10.1016/0005-2760(95)00168-9; TAKI T, 1994, ANAL BIOCHEM, V223, P232, DOI 10.1006/abio.1994.1579; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	43	42	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11386	11396		10.1074/jbc.M608445200	http://dx.doi.org/10.1074/jbc.M608445200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17244618	hybrid			2022-12-27	WOS:000245941500061
J	Lea-Smith, DJ; Pyke, JS; Tull, D; McConville, MJ; Coppel, RL; Crellin, PK				Lea-Smith, David J.; Pyke, James S.; Tull, Dedreia; McConville, Malcolm J.; Coppel, Ross L.; Crellin, Paul K.			The reductase that catalyzes mycolic motif synthesis is required for efficient attachment of mycolic acids to arabinogalactan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; MYCOBACTERIUM-TUBERCULOSIS; CELL-WALL; CONDENSATION STEP; CLONING VECTORS; BIOSYNTHESIS; IDENTIFICATION; TREHALOSE; GENES; MACROPHAGES	Mycolic acids are essential components of the cell walls of bacteria belonging to the suborder Corynebacterineae, including the important human pathogens Mycobacterium tuberculosis and Mycobacterium leprae. Mycolic acid biosynthesis is complex and the target of several frontline antimycobacterial drugs. The condensation of two fatty acids to form a 2-alkyl-3-keto mycolate precursor and the subsequent reduction of this precursor represent two key and highly conserved steps in this pathway. Although the enzyme catalyzing the condensation step has recently been identified, little is known about the putative reductase. Using an extensive bioinformatic comparison of the genomes of M. tuberculosis and Corynebacterium glutamicum, we identified NCgl2385, the orthologue of Rv2509 in M. tuberculosis, as a potential reductase candidate. Deletion of the gene in C. glutamicum resulted in a slow growing strain that was deficient in arabinogalactan-linked mycolates and synthesized abnormal forms of the mycolate-containing glycolipids trehalose dicorynomycolate and trehalose mono-corynomycolate. Analysis of the native and acetylated trehalose glycolipids by MALDI-TOF mass spectrometry indicated that these novel glycolipids contained an unreduced beta-keto ester. This was confirmed by analysis of sodium borodeuteride-reduced mycolic acids by gas chromatography mass spectrometry. Reintroduction of the NCgl2385 gene into the mutant restored the transfer of mature mycolic acids to both the trehalose glycolipids and cell wall arabinogalactan. These data indicate that NCgl2385, which we have designated CmrA, is essential for the production of mature trehalose mycolates and subsequent covalent attachment of mycolic acids onto the cell wall, thus representing a focus for future structural and pathogenicity studies.	Monash Univ, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Dept Microbiol, Clayton, Vic 3800, Australia; Monash Univ, Dept Microbiol, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Inst Mol Sci & Biotechnol Bio21, Parkville, Vic 3010, Australia	Monash University; Monash University; University of Melbourne	Crellin, PK (corresponding author), Monash Univ, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Dept Microbiol, Clayton, Vic 3800, Australia.	paul.crellin@med.monash.edu.au	Coppel, Ross L/A-6626-2008; Lea-Smith, David/U-9151-2019	Coppel, Ross L/0000-0002-4476-9124; Lea-Smith, David/0000-0003-2463-406X; Crellin, Paul K/0000-0002-2017-4935; Tull, Dedreia/0000-0003-2546-6707				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; Billman-Jacobe H, 1999, MOL MICROBIOL, V33, P1244, DOI 10.1046/j.1365-2958.1999.01572.x; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; Chami M, 2002, FEMS IMMUNOL MED MIC, V32, P141, DOI 10.1111/j.1574-695X.2002.tb00546.x; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DATTA AK, 1993, BIOCHIM BIOPHYS ACTA, V1169, P135, DOI 10.1016/0005-2760(93)90198-I; De Sousa-D'Auria C, 2003, FEMS MICROBIOL LETT, V224, P35, DOI 10.1016/S0378-1097(03)00396-3; GAILLY C, 1982, EUR J BIOCHEM, V125, P83, DOI 10.1111/j.1432-1033.1982.tb06654.x; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; GASTAMBIDEODIER M, 1959, NATURE, V184, P1563, DOI 10.1038/1841563b0; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kovacevic S, 2006, J BIOL CHEM, V281, P9011, DOI 10.1074/jbc.M511709200; Lee RE, 1997, BBA-LIPID LIPID MET, V1346, P275, DOI 10.1016/S0005-2760(97)00051-9; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; McKean S, 2005, MICROBES INFECT, V7, P1352, DOI 10.1016/j.micinf.2005.05.002; Oswald IP, 1997, INFECT IMMUN, V65, P1364, DOI 10.1128/IAI.65.4.1364-1369.1997; Portevin D, 2005, J BIOL CHEM, V280, P8862, DOI 10.1074/jbc.M408578200; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; PUDLES J, 1953, BIOCHIM BIOPHYS ACTA, V11, P602, DOI 10.1016/0006-3002(53)90113-9; Puech V, 2002, MOL MICROBIOL, V44, P1109, DOI 10.1046/j.1365-2958.2002.02953.x; Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schroeder E. K., 2002, Current Pharmaceutical Biotechnology, V3, P197, DOI 10.2174/1389201023378328; Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005; Tatituri RVV, 2007, J BIOL CHEM, V282, P4561, DOI 10.1074/jbc.M608695200; Tropis M, 2005, J BIOL CHEM, V280, P26573, DOI 10.1074/jbc.M502104200; van der Rest ME, 1999, APPL MICROBIOL BIOT, V52, P541, DOI 10.1007/s002530051557; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	32	71	73	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11000	11008		10.1074/jbc.M608686200	http://dx.doi.org/10.1074/jbc.M608686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308303	hybrid			2022-12-27	WOS:000245941500020
J	Hattori, M; Miyake, H; Sugita, M				Hattori, Mitsuru; Miyake, Hiroshi; Sugita, Mamoru			A pentatricopeptide repeat protein is required for RNA processing of clpP pre-mRNA in moss chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEUS-ENCODED FACTOR; PHYSCOMITRELLA-PATENS; GENE-EXPRESSION; ARABIDOPSIS-THALIANA; RESTORES FERTILITY; HIGHER-PLANTS; LAND PLANT; PPR MOTIF; DNA; REVEALS	Pentatricopeptide repeat ( PPR) proteins are encoded by the nuclear genome as a large gene family in land plants. PPR proteins play essential roles in organelle-related functions, mostly in RNA-processing steps in plastids and mitochondria. In the moss Physcomitrella patens, there is also a large gene family, but the moss PPR proteins are likely to be divergent from those of higher plants. To investigate the function of plastid PPR proteins, we have generated and characterized a PPR protein gene disruptant of P. patens. The PPR531-11- disrupted mosses displayed abnormal phenotypic characteristics, such as a significantly smaller protonemal colony, different chloroplast morphology, and incomplete thylakoid membrane formation. In addition, the quantum yield of photosystem II was reduced in the disrupted mosses. To further investigate whether disruption of the PPR531-11 gene affects chloroplast gene expression, we performed Northern blot and reverse transcription polymerase chain reaction analyses. These analyses revealed that PPR531-11 has a role in intergenic RNA cleavage between clpP and 5'-rps12 and in the splicing of clpP pre-mRNA. Western blot analysis showed that disruption of PPR531-11 resulted in a reduced level of ClpP, photosystem II reaction center protein D1, and the stromal enzyme, ribulose-bisphosphate carboxylase/oxygenase. These reductions might result in the severely retarded growth of the protonemal colony. Taken together, we propose a model where PPR531-11 function affects the steady-state level of ClpP, which regulates the formation and maintenance of thylakoid membranes in chloroplasts. This is the first evidence of a PPR protein controlling the protein expression level of ClpP.	Nagoya Univ, Ctr Gene Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Sugita, M (corresponding author), Nagoya Univ, Ctr Gene Res, Chikusa Ku, Furo Cho 1, Nagoya, Aichi 4648602, Japan.	sugita@gene.nagoya-u.ac.jp						ARNON DI, 1949, SCIENCE, V110, P554, DOI 10.1126/science.110.2865.554; Bentolila S, 2002, P NATL ACAD SCI USA, V99, P10887, DOI 10.1073/pnas.102301599; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Cahoon AB, 2003, PLANT CELL PHYSIOL, V44, P93, DOI 10.1093/pcp/pcg003; Clarke AK, 2005, PHYSIOL PLANTARUM, V123, P406, DOI 10.1111/j.1399-3054.2005.00452.x; Cove D, 2005, ANNU REV GENET, V39, P339, DOI 10.1146/annurev.genet.39.073003.110214; Cushing DA, 2005, PLANTA, V221, P424, DOI 10.1007/s00425-004-1452-x; Ding YH, 2006, PLANT CELL, V18, P815, DOI 10.1105/tpc.105.039495; Duckett J.G., 1988, ADV BRYOL, V3, P33; Fisk DG, 1999, EMBO J, V18, P2621, DOI 10.1093/emboj/18.9.2621; GENTY E, 1989, BIOCHEM PHARMACOL, V38, P3885, DOI 10.1016/0006-2952(89)90600-X; Hasan R, 2005, PLANT PROD SCI, V8, P567, DOI 10.1626/pps.8.567; Hashimoto M, 2003, PLANT J, V36, P541, DOI 10.1046/j.1365-313X.2003.01900.x; Hattori M, 2004, GENE, V343, P305, DOI 10.1016/j.gene.2004.09.015; Herrmann R. G., 1992, Cell organelles., P275; Ichikawa K, 2004, PLANT PHYSIOL, V136, P4285, DOI 10.1104/pp.104.053033; Ikeda TM, 1999, MOL CELL BIOL, V19, P8113; Kabeya Y, 2005, PLANT PHYSIOL, V138, P369, DOI 10.1104/pp.105.059501; Kazama T, 2003, FEBS LETT, V544, P99, DOI 10.1016/S0014-5793(03)00480-0; Koizuka N, 2003, PLANT J, V34, P407, DOI 10.1046/j.1365-313X.2003.01735.x; Kotera E, 2005, NATURE, V433, P326, DOI 10.1038/nature03229; Kuroda H, 2003, NATURE, V425, P86, DOI 10.1038/nature01909; Kuroda H, 2002, PLANT PHYSIOL, V129, P1600, DOI 10.1104/pp.004986; Lurin C, 2004, PLANT CELL, V16, P2089, DOI 10.1105/tpc.104.022236; Majeran W, 2000, PLANT CELL, V12, P137; Meierhoff K, 2003, PLANT CELL, V15, P1480, DOI 10.1105/tpc.010397; Miyata Y, 2004, J PLANT PHYSIOL, V161, P113, DOI 10.1078/0176-1617-01220; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Nakamura T, 2005, PLANT BIOLOGY, V7, P258, DOI 10.1055/s-2005-865620; Nakamura T, 2003, EUR J BIOCHEM, V270, P4070, DOI 10.1046/j.1432-1033.2003.03796.x; Nakamura T, 2001, J BIOL CHEM, V276, P147, DOI 10.1074/jbc.M008817200; Nishiyama T, 2000, DNA RES, V7, P9, DOI 10.1093/dnares/7.1.9; Nishiyama T, 2003, P NATL ACAD SCI USA, V100, P8007, DOI 10.1073/pnas.0932694100; Okuda K, 2006, J BIOL CHEM, V281, P37661, DOI 10.1074/jbc.M608184200; Olsson T, 2003, J BIOL CHEM, V278, P44439, DOI 10.1074/jbc.M306265200; Ostersetzer O, 2005, PLANT CELL, V17, P241, DOI 10.1105/tpc.104.027516; Pfalz J, 2006, PLANT CELL, V18, P176, DOI 10.1105/tpc.105.036392; Reski R, 1998, BOT ACTA, V111, P1; Schaefer DG, 1997, PLANT J, V11, P1195, DOI 10.1046/j.1365-313X.1997.11061195.x; Schmitz-Linneweber C, 2005, PLANT CELL, V17, P2791, DOI 10.1105/tpc.105.034454; Shikanai T, 2006, CELL MOL LIFE SCI, V63, P698, DOI 10.1007/s00018-005-5449-9; Shikanai T, 2001, PLANT CELL PHYSIOL, V42, P264, DOI 10.1093/pcp/pce031; Sjogren LLE, 2006, PLANT CELL, V18, P2635, DOI 10.1105/tpc.106.044594; Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0; Sugita M, 1996, PLANT MOL BIOL, V32, P315, DOI 10.1007/BF00039388; Sugiura C, 2003, NUCLEIC ACIDS RES, V31, P5324, DOI 10.1093/nar/gkg726; Sugiura C, 2004, PLANT J, V40, P314, DOI 10.1111/j.1365-313X.2004.02202.x; TERASAWA K, 2007, IN PRESS MOL BIOL EV; Williams PM, 2003, PLANT J, V36, P675, DOI 10.1046/j.1365-313X.2003.01915.x; YAMAGUCHI K, 2005, PHOTOSYSTEM2 LIGHT D, P650; Yamazaki H, 2004, PLANT J, V38, P152, DOI 10.1111/j.1365-313X.2004.02035.x; Zheng B, 2006, PLANTA, V224, P1103, DOI 10.1007/s00425-006-0292-2	52	70	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10773	10782		10.1074/jbc.M608034200	http://dx.doi.org/10.1074/jbc.M608034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283080	hybrid			2022-12-27	WOS:000245941000071
J	Kleczka, B; Lamerz, AC; van Zandbergen, G; Wenzel, A; Gerardy-Schahn, R; Wiese, M; Routier, FH				Kleczka, Barbara; Lamerz, Anne-Christin; van Zandbergen, Ger; Wenzel, Alexander; Gerardy-Schahn, Rita; Wiese, Martin; Routier, Francoise H.			Targeted gene deletion of Leishmania major UDP-galactopyranose mutase leads to attenuated virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; PROTEIN-KINASE-C; GLYCOSYLATED PHOSPHATIDYLINOSITOLS; GLYCOINOSITOL PHOSPHOLIPIDS; MEXICANA; LIPOPHOSPHOGLYCAN; BIOSYNTHESIS; GALACTOFURANOSE; MACROPHAGES; IDENTIFICATION	Considering the high incidence of galactofuranose ( Galf) in pathogens and its absence from higher eukaryotes, the enzymes involved in the biosynthesis of this unusual monosaccharide appear as attractive drug targets. However, although the importance of Galf in bacterial survival or pathogenesis is established, its role in eukaryotic pathogens is still undefined. Recently, we reported the identification and characterization of the first eukaryotic UDP-galactopyranose mutases. This enzyme holds a central role in Galf metabolism by providing UDP-Gal(f) to all galactofuranosyltransferases. In this work, the therapeutical potential of Galf metabolism in Leishmania major was hence evaluated by targeted replacement of the GLF gene encoding UDP-galactopyranose mutase. In L. major, Galf is present in the membrane anchor of the lipophosphoglycan ( LPG) and in glycoinositolphospholipids. Accordingly, the generated glf(-) mutant is deficient in LPG backbone and expresses truncated glycoinositolphospholipids. These structural changes do not influence the in vitro growth of the parasite but lead to an attenuation of virulence comparable with that observed with a mutant exclusively deficient in LPG.	Hannover Med Sch, D-30625 Hannover, Germany; Inst Med Microbiol & Hyg, D-23538 Lubeck, Germany; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Hannover Medical School; Bernhard Nocht Institut fur Tropenmedizin	Routier, FH (corresponding author), Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Routier.Francoise@mh-hannover.de	van Zandbergen, Ger/M-1571-2013; Routier, Francoise/O-1611-2019	Routier, Francoise/0000-0002-7163-0590; Wiese, Martin/0000-0003-4493-0835				Bakker H, 2005, BIOL CHEM, V386, P657, DOI 10.1515/BC.2005.076; Beis K, 2005, J MOL BIOL, V348, P971, DOI 10.1016/j.jmb.2005.02.057; Beverley SM, 2005, EUKARYOT CELL, V4, P1147, DOI 10.1128/EC.4.6.1147-1154.2005; Carlson EE, 2006, CHEM BIOL, V13, P825, DOI 10.1016/j.chembiol.2006.06.007; CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473; Croft SL, 2006, INDIAN J MED RES, V123, P399; DEIBARRA AAL, 1982, PARASITOLOGY, V85, P523, DOI 10.1017/S0031182000056304; Fullerton SWB, 2003, BIOCHEMISTRY-US, V42, P2104, DOI 10.1021/bi027077f; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; Griffith CL, 2004, J BIOL CHEM, V279, P51669, DOI 10.1074/jbc.M408889200; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Harper AD, 2002, PLANT PHYSIOL, V130, P2188, DOI 10.1104/pp.009654; Hilley JD, 2000, MOL BIOL CELL, V11, P1183, DOI 10.1091/mbc.11.4.1183; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCNEELY TB, 1989, BIOCHEM J, V259, P601, DOI 10.1042/bj2590601; Mensa-Wilmot K, 1999, MOL BIOCHEM PARASIT, V99, P103, DOI 10.1016/S0166-6851(99)00003-1; Nassau PM, 1996, J BACTERIOL, V178, P1047, DOI 10.1128/jb.178.4.1047-1052.1996; Opperdoes FR, 2006, MOL BIOCHEM PARASIT, V147, P193, DOI 10.1016/j.molbiopara.2006.02.010; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Pedersen LL, 2003, CELL MOL LIFE SCI, V60, P259, DOI 10.1007/s000180300021; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; PROUDFOOT L, 1995, EUR J IMMUNOL, V25, P745, DOI 10.1002/eji.1830250318; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; Roper JR, 2005, J BIOL CHEM, V280, P19728, DOI 10.1074/jbc.M502370200; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; Sanders DAR, 2001, NAT STRUCT BIOL, V8, P858, DOI 10.1038/nsb1001-858; SCHNEIDER P, 1994, BIOCHEM J, V304, P603, DOI 10.1042/bj3040603; SCHNEIDER P, 1993, BIOCHEM J, V295, P555, DOI 10.1042/bj2950555; Soltero-Higgin M, 2004, J AM CHEM SOC, V126, P10532, DOI 10.1021/ja048017v; Soltero-Higgin M, 2004, NAT STRUCT MOL BIOL, V11, P539, DOI 10.1038/nsmb772; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Suzuki E, 2002, INFECT IMMUN, V70, P6592, DOI 10.1128/IAI.70.12.6592-6596.2002; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; van Zandbergen G, 2006, P NATL ACAD SCI USA, V103, P13837, DOI 10.1073/pnas.0600843103; WELLER CT, 1994, BIOPOLYMERS, V34, P1155, DOI 10.1002/bip.360340905; Weston A, 1998, TUBERCLE LUNG DIS, V78, P123, DOI 10.1016/S0962-8479(98)80005-1; WINTER G, 1994, J CELL SCI, V107, P2471; Zhang K, 2004, MOL BIOCHEM PARASIT, V136, P11, DOI 10.1016/j.molbiopara.2004.02.012; Zufferey R, 2003, J BIOL CHEM, V278, P44708, DOI 10.1074/jbc.M308063200	50	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10498	10505		10.1074/jbc.M700023200	http://dx.doi.org/10.1074/jbc.M700023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284446	Green Accepted, hybrid			2022-12-27	WOS:000245941000042
J	Kono, M; Belyantseva, IA; Skoura, A; Frolenkov, GI; Starost, MF; Dreier, JL; Lidington, D; Bolz, SS; Friedman, TB; Hla, T; Proia, RL				Kono, Mari; Belyantseva, Inna A.; Skoura, Athanasia; Frolenkov, Gregory I.; Starost, Matthew F.; Dreier, Jennifer L.; Lidington, Darcy; Bolz, Steffen-Sebastian; Friedman, Thomas B.; Hla, Timothy; Proia, Richard L.			Deafness and stria Vascularis defects in S1P(2) receptor-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; PROTEIN-COUPLED RECEPTOR; INNER-EAR; TIGHT JUNCTIONS; ENDOTHELIAL-CELLS; MOUSE; SPHINGOSINE-1-PHOSPHATE; DYSFUNCTION; MATURATION; HEARING	The S1P(2) receptor is a member of a family of G protein-coupled receptors that bind the extracellular sphingolipid metabolite sphingosine 1-phosphate with high affinity. The receptor is widely expressed and linked to multiple G protein signaling pathways, but its physiological function has remained elusive. Here we have demonstrated that S1P(2) receptor expression is essential for proper functioning of the auditory and vestibular systems. Auditory brainstem response analysis revealed that S1P(2) receptor-null mice were deaf by one month of age. These null mice exhibited multiple inner ear pathologies. However, some of the earliest cellular lesions in the cochlea were found within the stria vascularis, a barrier epithelium containing the primary vasculature of the inner ear. Between 2 and 4 weeks after birth, the basal and marginal epithelial cell barriers and the capillary bed within the stria vascularis of the S1P(2) receptor-null mice showed markedly disturbed structures. JTE013, an S1P(2) receptor-specific antagonist, blocked the S1P-induced vasoconstriction of the spiral modiolar artery, which supplies blood directly to the stria vascularis and protects its capillary bed from high perfusion pressure. Vascular disturbance within the stria vascularis is a potential mechanism that leads to deafness in the S1P(2) receptor-null mice.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIDCD, Mol Genet Lab, NIH, Rockville, MD 20850 USA; Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Cell Biol, Farmington, CT 06030 USA; NIH, Div Vet Resources, Bethesda, MD 20892 USA; Univ Toronto, Dept Physiol & Heart & Stroke, Richard Lewar Ctr Excellence, Toronto, ON M5S 1A8, Canada; NIDCD, Otolaryngol Branch, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Connecticut; National Institutes of Health (NIH) - USA; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012; Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065; Frolenkov, Gregory/0000-0002-9810-5024; Proia, Richard/0000-0003-0456-1270; Lidington, Darcy/0000-0001-7582-7924; Kono, Mari/0000-0003-2447-4350	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R37-HL-67330, P01-HL-70694] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070694, R37HL067330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000060] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; ANNIKO M, 1980, ARCH OTO-RHINO-LARYN, V229, P281, DOI 10.1007/BF02565531; Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200; Everett LA, 2001, HUM MOL GENET, V10, P153, DOI 10.1093/hmg/10.2.153; Gon Y, 2005, P NATL ACAD SCI USA, V102, P9270, DOI 10.1073/pnas.0501997102; Gow A, 2004, J NEUROSCI, V24, P7051, DOI 10.1523/JNEUROSCI.1640-04.2004; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hibino H, 1997, J NEUROSCI, V17, P4711; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Ikeda H, 2003, GASTROENTEROLOGY, V124, P459, DOI 10.1053/gast.2003.50049; Khan Z, 2004, NEUROSCIENCE, V127, P785, DOI 10.1016/j.neuroscience.2004.05.052; Kitajiri SI, 2004, J CELL SCI, V117, P5087, DOI 10.1242/jcs.01393; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lorenz JN, 2007, AM J PHYSIOL-REG I, V292, pR440, DOI 10.1152/ajpregu.00085.2006; MacLennan AJ, 2006, HEARING RES, V220, P38, DOI 10.1016/j.heares.2006.06.016; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Noguchi Y, 2006, GENETICS, V173, P2111, DOI 10.1534/genetics.106.057372; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Ruckenstein MJ, 1999, OTOLARYNG HEAD NECK, V121, P452, DOI 10.1016/S0194-5998(99)70236-6; SADANAGA M, 1995, HEARING RES, V89, P155, DOI 10.1016/0378-5955(95)00133-X; Scherer EQ, 2006, CARDIOVASC RES, V70, P79, DOI 10.1016/j.cardiores.2006.01.011; Scherer EQ, 2001, J MEMBRANE BIOL, V182, P183, DOI 10.1007/s00232-001-0041-1; SCHROTT A, 1990, HEARING RES, V46, P1, DOI 10.1016/0378-5955(90)90134-B; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; STEEL KP, 1987, HEARING RES, V27, P11, DOI 10.1016/0378-5955(87)90022-0; Wangemann P, 2006, J PHYSIOL-LONDON, V576, P11, DOI 10.1113/jphysiol.2006.112888; Wangemann P, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-30	30	143	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10690	10696		10.1074/jbc.M700370200	http://dx.doi.org/10.1074/jbc.M700370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284444	hybrid			2022-12-27	WOS:000245941000063
J	Silva, AM; Wang, D; Komar, AA; Castilho, BA; Williams, BRG				Silva, Aristobolo M.; Wang, Die; Komar, Anton A.; Castilho, Beatriz A.; Williams, Bryan R. G.			Salicylates trigger protein synthesis inhibition in a protein kinase R-like endoplasmic reticulum kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 2-ALPHA KINASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GLUCOSE-REGULATED PROTEINS; INDUCED GENE-EXPRESSION; TRANSLATION INITIATION; SODIUM-SALICYLATE; MAMMALIAN HOMOLOG; MESSENGER-RNA; KAPPA-B; CELLS	The non-steroidal anti-inflammatory drug aspirin and its metabolite, sodium salicylate, have profound effects on cellular protein synthesis and cell physiology. However, the underlying mechanism by which they cause these responses remains unclear. We show here that salicylates induce phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 (eIF2 similar to), resulting in the inhibition of mRNA translation in cells. Exposure of cells to acetyl salicylic acid resulted in strong activation of eIF2 alpha stress-activated protein kinase R-like endoplasmic reticulum kinase ( PERK). Analysis of fibroblasts with a targeted deletion of the perk gene revealed that PERK is indispensable for triggering the phosphorylation of eIF2 alpha as well as the inhibition of protein synthesis induced by salicylates. Although salicylate treatment did not trigger activation of inositol-requiring enzyme 1, there was an increased expression of the pro-apoptotic transcription factor CHOP-( gadd153), a downstream event to eIF2 alpha phosphorylation known to mediate endoplasmic reticulum stress-mediated responses. Thus, salicylates selectively trigger an endoplasmic reticulum stress-responsive signaling pathway initiated through activation of PERK to induce their cellular effects.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Monash Univ, Monash Inst Med Res, Melbourne, Vic 3168, Australia; Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; Escola Paulista Med, Dept Microbiol Imunol & Parasitol, BR-04023062 Sao Paulo, Brazil	Cleveland Clinic Foundation; Monash University; University System of Ohio; Cleveland State University; Universidade Federal de Sao Paulo (UNIFESP)	Williams, BRG (corresponding author), Monash Med Ctr, Mionash Inst Med Res, 246 Clayton Rd, Melbourne, Vic 3168, Australia.	bryan.williams@med.monash.edu.au	Williams, Bryan R. G./A-5021-2009; Silva, Aristobolo/CAF-4874-2022; Silva, Aristobolo AMS/F-7326-2016; Castilho, Beatriz A/C-2503-2012; Silva, Aristóbolo/AAA-2239-2021; Wang, Die/H-8860-2017	Williams, Bryan R. G./0000-0002-4969-1151; Castilho, Beatriz A/0000-0003-4509-5237; Silva, Aristóbolo/0000-0001-7473-7433; Wang, Die/0000-0001-7628-7309; Komar, Anton/0000-0003-4188-0633	NCI NIH HHS [U54CA116897] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann R, 2002, EUR J PHARMACOL, V447, P1, DOI 10.1016/S0014-2999(02)01828-9; Berlanga JJ, 1998, J BIOL CHEM, V273, P32340, DOI 10.1074/jbc.273.48.32340; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brune K, 1977, Agents Actions Suppl, V2, P163; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CRONSTEIN BN, 1994, INFLAMMATION, V18, P323, DOI 10.1007/BF01534273; Deng WG, 2001, FASEB J, V15, P2463, DOI 10.1096/fj.01-0259com; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hardman J.G., 1996, GOODMAN GILSMANS PHA, P617; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Kwon G, 1997, MOL PHARMACOL, V52, P398, DOI 10.1124/mol.52.3.398; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Meric F, 2002, MOL CANCER THER, V1, P971; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Pierce JW, 1996, J IMMUNOL, V156, P3961; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sood R, 2000, GENETICS, V154, P787; SPOHN M, 1980, BIOCHIM BIOPHYS ACTA, V608, P409, DOI 10.1016/0005-2787(80)90186-0; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Williamson RT, 1901, BRIT MED J, V1901, P760, DOI 10.1136/bmj.1.2100.760; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	48	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10164	10171		10.1074/jbc.M609996200	http://dx.doi.org/10.1074/jbc.M609996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284450	hybrid			2022-12-27	WOS:000245941000006
J	Sohn, DH; Lee, KY; Lee, C; Oh, J; Chung, H; Jeon, SH; Seong, RH				Sohn, Dong H.; Lee, Kyoo Y.; Lee, Changjin; Oh, Jaehak; Chung, Heekyoung; Jeon, Sung H.; Seong, Rho H.			SRG3 interacts directly with the major components of the SWI/SNF chromatin remodeling complex and protects them from proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-INDUCED APOPTOSIS; RECEPTOR-DEPENDENT TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; SWIRM DOMAIN; EXPRESSION; PROTEINS; HOMOLOG; BINDING; DNA; TRANSACTIVATION	The mammalian SWI/SNF complex is an evolutionarily conserved ATP-dependent chromatin remodeling complex that consists of nine or more components. SRG3, a murine homologue of yeast SWI3, Drosophila MOIRA, and human BAF155, is a core component of the murine SWI/SNF complex required for the regulation of transcriptional processes associated with development, cellular differentiation, and proliferation. Here we report that SRG3 interacts directly with other components of the mammalian SWI/SNF complex such as SNF5, BRG1, and BAF60a. The SWIRM domain and the SANT domain were required for SRG3-SNF5 and SRG3-BRG1 interactions, respectively. In addition, SRG3 stabilized SNF5, BRG1, and BAF60a by attenuating their proteasomal degradation, suggesting its general role in the stabilization of the SWI/SNF complex. Such a stabilization effect of SRG3 was not only observed in the in vitro cell system, but also in cells isolated from SRG3 transgenic mice or knock-out mice haploinsufficient for the Srg3 gene. Taken together, these results suggest the critical role of SRG3 in the post-transcriptional stabilization of the major components of the SWI/SNF complex.	Seoul Natl Univ, Res Ctr Funct Cellulom, Seoul 151742, South Korea; Seoul Natl Univ, Dept Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea; Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; Hallym Univ, Dept Life Sci, Chunchon 200702, South Korea; Hallym Univ, Inst Biosci & Biotechnol, Chunchon 200702, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Hallym University; Hallym University	Seong, RH (corresponding author), Seoul Natl Univ, Res Ctr Funct Cellulom, Bldg 105,San 56-1, Seoul 151742, South Korea.	rhseong@snu.ac.kr		Seong, Rho/0000-0001-5699-0718				Biegel JA, 1999, CANCER RES, V59, P74; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Choi YI, 2001, P NATL ACAD SCI USA, V98, P10267, DOI 10.1073/pnas.181076198; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; Da GP, 2006, P NATL ACAD SCI USA, V103, P2057, DOI 10.1073/pnas.0510949103; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Grune T, 2003, MOL CELL, V12, P449, DOI 10.1016/S1097-2765(03)00273-9; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Iyer L. M, 2002, GENOME BIOL, V3; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Ko M, 2004, J BIOL CHEM, V279, P21916, DOI 10.1074/jbc.M402145200; Ko M, 2004, J BIOL CHEM, V279, P21903, DOI 10.1074/jbc.M402144200; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mohrmann L, 2005, BBA-GENE STRUCT EXPR, V1681, P59, DOI 10.1016/j.bbaexp.2004.10.005; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Niimura M, 2005, J BIOL CHEM, V280, P12967, DOI 10.1074/jbc.M409829200; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Qian CM, 2005, NAT STRUCT MOL BIOL, V12, P1078, DOI 10.1038/nsmb1022; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Sawa H, 2000, MOL CELL, V6, P617, DOI 10.1016/S1097-2765(00)00060-5; Singh MV, 2004, MOL CELL BIOL, V24, P4929, DOI 10.1128/MCB.24.11.4929-4942.2004; Song MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200; Tochio N, 2006, STRUCTURE, V14, P457, DOI 10.1016/j.str.2005.12.004; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; TREICH I, 1995, MOL CELL BIOL, V15, P4240; Treich I, 1997, MOL CELL BIOL, V17, P1768, DOI 10.1128/MCB.17.4.1768; Treich I, 1998, NUCLEIC ACIDS RES, V26, P3739, DOI 10.1093/nar/26.16.3739; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117	50	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10614	10624		10.1074/jbc.M610563200	http://dx.doi.org/10.1074/jbc.M610563200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17255092	hybrid			2022-12-27	WOS:000245941000055
J	Treharne, KJ; Crawford, RM; Xu, Z; Chen, JH; Best, OG; Schulte, EA; Gruenert, DC; Wilson, SM; Sheppard, DN; Kunzelmann, K; Mehta, A				Treharne, Kate J.; Crawford, Russell M.; Xu, Zhe; Chen, Jeng-Haur; Best, O. Giles; Schulte, Eva A.; Gruenert, Dieter C.; Wilson, Stuart M.; Sheppard, David N.; Kunzelmann, Karl; Mehta, Anil			RETRACTED: Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the Delta F508 mutation (Retracted Article. See vol 283, pg 25103, 2008)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							NUCLEOSIDE DIPHOSPHATE KINASE; POLYAMINE METABOLISM; CHAPERONE CALNEXIN; MOLECULAR-BASIS; WILD-TYPE; CFTR; PHOSPHORYLATION; CELLS; CHANNEL; INHIBITION	Deletion of phenylalanine 508 ( Delta F508) from the first nucleotide-binding domain ( NBD1) of the cystic fibrosis transmembrane conductance regulator ( CFTR) is the most common mutation in cystic fibrosis. The F508 region lies within a surface-exposed loop that has not been assigned any interaction with associated proteins. Here we demonstrate that the pleiotropic protein kinase CK2 that controls protein trafficking, cell proliferation, and development binds wild-type CFTR near F508 and phosphorylates NBD1 at Ser-511 in vivo and that mutation of Ser-511 disrupts CFTR channel gating. Importantly, the interaction of CK2 with NBD1 is selectively abrogated by the Delta F508 mutation without disrupting four established CFTR-associated kinases and two phosphatases. Loss of CK2 association is functionally corroborated by the insensitivity of Delta F508-CFTR to CK2 inhibition, the absence of CK2 activity in Delta F508 CFTR-expressing cell membranes, and inhibition of CFTR channel activity by a peptide that mimics the F508 region of CFTR ( but not the equivalent Delta F508 peptide). Disruption of this CK2-CFTR association is the first described Delta F508-dependent protein-protein interaction that provides a new molecular paradigm in the most frequent form of cystic fibrosis.	Univ Dundee, Ninewells Hosp, Dept Maternal & Child Hlth, Dundee DD1 9SY, Scotland; Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA; Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany	University of Dundee; University of Bristol; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Regensburg	Mehta, A (corresponding author), Univ Dundee, Ninewells Hosp, Dept Maternal & Child Hlth, Dundee DD1 9SY, Scotland.	a.mehta@dundee.ac.uk	Sheppard, David N/AAV-4187-2021; Best, Oliver Giles/E-9060-2010; Best, Giles/F-3704-2019	Sheppard, David N/0000-0001-5533-9130; Best, Oliver Giles/0000-0003-2685-3880; Best, Giles/0000-0003-2685-3880; Kunzelmann, Karl/0000-0002-4583-7037	Wellcome Trust [069150/Z/02/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amaral MD, 2004, J MOL NEUROSCI, V23, P41, DOI 10.1385/JMN:23:1-2:041; Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLLETT A, 2002, AM J PHYSIOL, V28, pL261; Crawford RM, 2005, BIOCHEM J, V392, P201, DOI 10.1042/BJ20050269; Crawford RM, 2007, FASEB J, V21, P88, DOI 10.1096/fj.06-6804com; Crawford RM, 2006, MOL CELL BIOL, V26, P5921, DOI 10.1128/MCB.00315-06; Russell M, 2006, CELL SIGNAL, V18, P1595, DOI 10.1016/j.cellsig.2006.01.001; DAHAN D, 2001, PFLUEGERS ARCH S1, V443, P92; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Gruenert D C, 2004, J Cyst Fibros, V3 Suppl 2, P191, DOI 10.1016/j.jcf.2004.05.040; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Ishihara K, 2003, BIOCHEM J, V371, P917, DOI 10.1042/BJ20021331; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Korolchuk VI, 2002, TRAFFIC, V3, P428, DOI 10.1034/j.1600-0854.2002.30606.x; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Mehta A, 2005, PEDIATR PULM, V39, P292, DOI 10.1002/ppul.20147; Muimo R, 2000, J BIOL CHEM, V275, P36632, DOI 10.1074/jbc.M000829200; MURAO S, 1989, J BIOL CHEM, V264, P8356; OU WJ, 1992, J BIOL CHEM, V267, P23789; Penque D, 2000, LAB INVEST, V80, P857, DOI 10.1038/labinvest.3780090; PIND S, 1994, J BIOL CHEM, V269, P12784; RENNERT OM, 1976, TEX REP BIOL MED, V34, P187; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; RUSSELL DH, 1979, PEDIATR RES, V13, P1137, DOI 10.1203/00006450-197910000-00011; RUSSELL DH, 1983, CRC CR REV CL LAB SC, V18, P261; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Scott-ward TS, 2004, MOL MEMBR BIOL, V21, P27, DOI 10.1080/09687680310001597758; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tabary O, 2000, J IMMUNOL, V164, P3377, DOI 10.4049/jimmunol.164.6.3377; Thiagarajah JR, 2003, CURR OPIN PHARMACOL, V3, P594, DOI 10.1016/j.coph.2003.06.012; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; Tirouvanziam R, 2000, AM J RESP CELL MOL, V23, P121, DOI 10.1165/ajrcmb.23.2.4214; Tirouvanziam R, 2002, AM J PHYSIOL-LUNG C, V283, pL445, DOI 10.1152/ajplung.00419.2001; Townsend RR, 1996, PROTEIN SCI, V5, P1865, DOI 10.1002/pro.5560050912; Trehame KJ, 2001, PEDIATR PULM, V522, P240; Tugizov S, 2005, J VIROL, V79, P1099, DOI 10.1128/JVI.79.2.1099-1112.2005; Wang HM, 2001, MOL CELL BIOCHEM, V227, P167, DOI 10.1023/A:1013112908734; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Zhu Tang, 2002, Methods Mol Med, V70, P99	56	14	15	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10804	10813		10.1074/jbc.M610956200	http://dx.doi.org/10.1074/jbc.M610956200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289674	hybrid			2022-12-27	WOS:000245941000074
J	Fleischer, R; Heermann, R; Jung, K; Hunke, S				Fleischer, Rebecca; Heermann, Ralf; Jung, Kirsten; Hunke, Sabine			Purification, reconstitution, and characterization of the CpxRAP envelope stress system of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION SYSTEMS; BINDING CASSETTE TRANSPORTER; PERIPLASMIC PROTEASE; INHIBITORS; PATHWAY; GENE; EXPRESSION; CPXP; VANADATE; ENVZ	In Escherichia coli the Cpx sensor regulator system senses different kinds of envelope stress and responds by triggering the expression of periplasmic folding factors and proteases. It consists of the membrane-anchored sensor kinase CpxA, the response regulator CpxR, and the periplasmic protein CpxP. The Cpx pathway is induced in vivo by a variety of signals including pH variation, osmotic stress, and misfolded envelope proteins and is inhibited by overproduced CpxP. Because it is not clear how the Cpx pathway is able to recognize and correspond to so many different signals we overproduced, solubilized, purified, and incorporated the complete membrane-integral CpxA protein into proteoliposomes to analyze its biochemical properties in more detail. Autokinase and phosphotransfer activities of the reconstituted CpxA-His, protein were stimulated by KCI. NaCl also stimulated the activities but to a lesser extent. Other osmotic active solutes as glycine betaine, sucrose, and proline had no effect. The system was further characterized by testing for susceptibility to sensor kinase inhibitors. Among these, Closantel inhibited the activities of solubilized but not of the reconstituted CpxA-HiS(6) protein. We further analyzed the effect of CpxP on CpxA activities. Purified tagless CpxP protein reduced the phosphorylation status of CpxA to 50% but had no effect on CpxA phosphotransfer or phosphatase activities. As the in vitro system excludes the involvement of other factors our finding is the first biochemical evidence for direct protein-protein interaction between the sensor kinase CpxA and the periplasmic protein CpxP resulting in a down-regulation of the autokinase activity of CpxA.	Humboldt Univ, Inst Biol, Abt Physiol Mikroorganismen, D-10115 Berlin, Germany; Univ Munich, Dept Biol 1, Bereich Mikrobiol, D-80638 Munich, Germany	Humboldt University of Berlin; University of Munich	Hunke, S (corresponding author), Chausseestr 117, D-10115 Berlin, Germany.	sabine.hunke@rz.hu-berlin.de	Heermann, Ralf/E-1793-2013; Hunke, Sabine/B-7169-2011; Heermann, Ralf/CAF-8609-2022	Heermann, Ralf/0000-0003-0631-6156; 				Barrett JF, 1998, P NATL ACAD SCI USA, V95, P5317, DOI 10.1073/pnas.95.9.5317; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Buelow DR, 2005, J BACTERIOL, V187, P6622, DOI 10.1128/JB.187.19.6622-6630.2005; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; De Wulf P, 1999, J BACTERIOL, V181, P6772, DOI 10.1128/JB.181.21.6772-6778.1999; DONG JM, 1993, GENE, V136, P227; FORST S, 1987, J BIOL CHEM, V262, P16433; Foster JE, 2004, MICROBIOL-SGM, V150, P885, DOI 10.1099/mic.0.26824-0; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Hilliard JJ, 1995, ADV EXP MED BIOL, V390, P59; Hirakawa H, 2005, MOL MICROBIOL, V55, P1113, DOI 10.1111/j.1365-2958.2004.04449.x; Hlasta DJ, 1998, BIOORG MED CHEM LETT, V8, P1923, DOI 10.1016/S0960-894X(98)00326-6; Hunke S, 2003, MOL MICROBIOL, V50, P1579, DOI 10.1046/j.1365-2958.2003.03785.x; HUNKE S, 1995, BIOCHEM BIOPH RES CO, V216, P589, DOI 10.1006/bbrc.1995.2663; Isaac DD, 2005, P NATL ACAD SCI USA, V102, P17775, DOI 10.1073/pnas.0508936102; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; Jubelin G, 2005, J BACTERIOL, V187, P2038, DOI 10.1128/JB.187.6.2038-2049.2005; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MCEWEN J, 1980, P NATL ACAD SCI-BIOL, V77, P513, DOI 10.1073/pnas.77.1.513; Mileykovskaya E, 1997, J BACTERIOL, V179, P1029, DOI 10.1128/jb.179.4.1029-1034.1997; Nakayama SI, 1998, J BACTERIOL, V180, P3522, DOI 10.1128/JB.180.14.3522-3528.1998; Raivio TL, 1997, J BACTERIOL, V179, P7724, DOI 10.1128/jb.179.24.7724-7733.1997; Raivio TL, 1999, CURR OPIN MICROBIOL, V2, P159, DOI 10.1016/S1369-5274(99)80028-9; Raivio TL, 1999, J BACTERIOL, V181, P5263, DOI 10.1128/JB.181.17.5263-5272.1999; Raivio TL, 2001, ANNU REV MICROBIOL, V55, P591, DOI 10.1146/annurev.micro.55.1.591; Raivio TL, 2000, MOL MICROBIOL, V37, P1186, DOI 10.1046/j.1365-2958.2000.02074.x; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; SNYDER WB, 1995, J BACTERIOL, V177, P4216, DOI 10.1128/jb.177.15.4216-4223.1995; Stephenson K, 2000, J BIOL CHEM, V275, P38900, DOI 10.1074/jbc.M006633200; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Ulijasz AT, 1999, J BACTERIOL, V181, P627, DOI 10.1128/JB.181.2.627-631.1999; WEBER RF, 1988, J MOL BIOL, V203, P467, DOI 10.1016/0022-2836(88)90013-7; Yamamoto K, 2005, J BIOL CHEM, V280, P1448, DOI 10.1074/jbc.M410104200	40	78	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8583	8593		10.1074/jbc.M605785200	http://dx.doi.org/10.1074/jbc.M605785200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259177	hybrid			2022-12-27	WOS:000245780300004
J	Kumar, N; Robidoux, J; Daniel, KW; Guzman, G; Floering, LM; Collins, S				Kumar, Naresh; Robidoux, Jacques; Daniel, Kiefer W.; Guzman, Gabriel; Floering, Lisa M.; Collins, Sheila			Requirement of vimentin filament assembly for beta(3)-adrenergic receptor activation of ERK MAP kinase and lipolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CONVERSION; 3T3-L1 ADIPOCYTES; PROTEIN-KINASE; CYTOSKELETON; SRC; CLONING; CELLS; CDNA; GENE	Catecholamine stimulation of beta-adrenergic receptors (beta AR) in adipocytes activates the cAMP-dependent protein kinase to promote liberation of fatty acids as a fuel source. The adipocyte beta(3)AR also activates extracellular signal-regulated kinases (ERK)-1 and -2 through direct recruitment and activation of Src kinase. This pathway together with cAMP-dependent protein kinase contributes to maximal beta(3)AR-stimulated lipolysis. In a search for other molecules that might associate with beta(3)AR upon agonist stimulation, we identified vimentin using a proteomics approach. Immunoprecipitation of beta(3)AR from adipocytes in the absence or presence of the beta(3)AR agonist CL316,243, followed by Western blotting for vimentin confirmed this specific interaction. Since vimentin has also been identified on lipid droplets, the functional consequences of blocking the expression or structural integrity of vimentin intermediate filaments on beta(3)AR regulation of ERK activation and lipolysis was assessed. Following disruption of intermediate filaments with beta,beta'-iminodipropionitrile, as confirmed by confocal microscopy, beta(3)AR-stimulated ERK activation was blocked, and lipolysis was reduced by more than 40%. Independently, depletion of vimentin by small hairpin RNA (shRNA) completely inhibited beta(3)AR-mediated ERK activation and significantly reduced lipolysis. By contrast, disruption of actin-containing microfilaments by cytochalasin D or microtubules by nocodazole had no effect on either lipolysis or ERK activation. These results indicate that vimentin plays an essential role in the signal transduction pathway from beta(3)AR to the activation ERK and its contribution to lipolysis.	Hamner Inst Hlth Sci, Program Encocrine Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA	The Hamner Institutes for Health Sciences; Duke University	Collins, S (corresponding author), Chem Ind Inst Toxicol, Ctr Hlth Res, 6 Davis Dr,Box 12137, Res Triangle Pk, NC 27709 USA.	scollins@thehamner.org		Robidoux, JAcques/0000-0002-4809-4734	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053092, R01DK057698] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53092, R01-DK57698] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMANUMA K, 1986, VIRCHOWS ARCH A, V410, P231; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; CiesielskiTreska J, 1995, EUR J CELL BIOL, V68, P369; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; Ermakova S, 2005, J BIOL CHEM, V280, P16882, DOI 10.1074/jbc.M414185200; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Helfand BT, 2005, TRENDS CELL BIOL, V15, P568, DOI 10.1016/j.tcb.2005.09.009; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; Lieber JG, 1996, J CELL SCI, V109, P3047; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Martin NP, 2004, CELL SIGNAL, V16, P1397, DOI 10.1016/j.cellsig.2004.05.002; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; Parker Carol E., 2005, V301, P117; Perlson E, 2005, NEURON, V45, P715, DOI 10.1016/j.neuron.2005.01.023; Robidoux J, 2006, J BIOL CHEM, V281, P37794, DOI 10.1074/jbc.M605572200; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605	27	61	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9244	9250		10.1074/jbc.M605571200	http://dx.doi.org/10.1074/jbc.M605571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17251187	hybrid			2022-12-27	WOS:000245780300071
J	Xie, ZJ; Bikle, DD				Xie, Zhongjian; Bikle, Daniel D.			The recruitment of phosphatidylinositol 3-kinase to the E-cadherin-catenin complex at the plasma membrane is required for calcium-induced phospholipase C-gamma 1 activation and human keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMAS; TYROSINE KINASE SUBSTRATE; BETA-CATENIN; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR CALCIUM; ADHESION COMPLEX; EPIDERMAL-CELLS; C-GAMMA; ULTRASTRUCTURAL-LOCALIZATION; MURINE KERATINOCYTES	Calcium induces epidermal keratinocyte differentiation, but the mechanism is not completely understood. We have previously demonstrated that calcium-induced human keratinocyte differentiation requires an intracellular calcium rise caused by phosphatidylinositol 3-kinase (PI3K)-dependent activation of phospholipase C-gamma 1. In this study we sought to identify the upstream signaling pathway necessary for calcium activation of PI3K and its subsequent activation of phospholipase C-gamma 1. We found that calcium induces the recruitment of PI3K to the E-cadherin-catenin complex at the plasma membrane of human keratinocytes. Knocking-down E-cadherin, beta-catenin, or p120-catenin expression blocked calcium activation of PI3K and phospholipase C-gamma 1 and calcium-induced keratinocyte differentiation. However, knocking-down gamma-catenin expression had no effect. Calcium-induced PI3K recruitment to E-cadherin stabilized by p120-catenin at the plasma membrane requires beta-catenin but not gamma-catenin. These data indicate that the recruitment of PI3K to the E-cadherin/beta-catenin/p120-catenin complex via beta-catenin at the plasma membrane is required for calcium-induced phospholipase C-gamma 1 activation and, ultimately, keratinocyte differentiation.	Vet Affairs Med Ctr, Endocrine Unit, N Calif Inst Res & Educ, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA	Northern California Institute for Research & Education; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Xie, ZJ (corresponding author), Vet Affairs Med Ctr, Endocrine Unit, N Calif Inst Res & Educ, 4150 Clement St 111N, San Francisco, CA 94121 USA.	Zhongjian.Xie@ucsf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038386, P01AR039448] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR038386, P01AR39448] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andrews NA, 1997, BRIT J CANCER, V75, P1474, DOI 10.1038/bjc.1997.252; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bagutti C, 1998, J PATHOL, V186, P8, DOI 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Elias PM, 2002, J INVEST DERMATOL, V119, P1128, DOI 10.1046/j.1523-1747.2002.19512.x; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FURUKAWA F, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P802, DOI 10.1111/j.1346-8138.1994.tb03294.x; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, EXP CELL RES, V143, P127, DOI 10.1016/0014-4827(83)90115-5; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ishizaki Y, 2004, J DERMATOL SCI, V34, P99, DOI 10.1016/j.jdermsci.2003.12.001; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lawlor MA, 2001, J CELL SCI, V114, P2903; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MATTIJSSEN V, 1993, INT J CANCER, V55, P580, DOI 10.1002/ijc.2910550411; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Pang JH, 2005, J BIOL CHEM, V280, P3043, DOI 10.1074/jbc.M412148200; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; Posthaus H, 2002, J CELL SCI, V115, P4587, DOI 10.1242/jcs.00141; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; REISS M, 1991, J CELL PHYSIOL, V147, P281, DOI 10.1002/jcp.1041470213; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; TANG W, 1988, J INVEST DERMATOL, V90, P37, DOI 10.1111/1523-1747.ep12462536; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tinkle CL, 2004, P NATL ACAD SCI USA, V101, P552, DOI 10.1073/pnas.0307437100; Troyanovsky S, 2005, EUR J CELL BIOL, V84, P225, DOI 10.1016/j.ejcb.2004.12.009; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Wu H, 2000, ANTICANCER RES, V20, P1385; XIAO K, 2003, J CELL BIOL, V163, P437; Xie ZJ, 2005, MOL BIOL CELL, V16, P3236, DOI 10.1091/mbc.E05-02-0109; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Young P, 2003, EMBO J, V22, P5723, DOI 10.1093/emboj/cdg560; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	60	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8695	8703		10.1074/jbc.M609135200	http://dx.doi.org/10.1074/jbc.M609135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17242406	hybrid			2022-12-27	WOS:000245780300015
J	Sansen, S; Yano, JK; Reynald, RL; Schoch, GA; Griffin, KJ; Stout, CD; Johnson, EF				Sansen, Stefaan; Yano, Jason K.; Reynald, Rosamund L.; Schoch, Guillaume A.; Griffin, Keith J.; Stout, C. David; Johnson, Eric F.			Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME-P450 1A2; CRYSTAL-STRUCTURE; AMINO-ACID; RESOLUTION; BINDING; ENZYMES; SITE; CRYSTALLOGRAPHY; PURIFICATION; ACTIVATION	Microsomal cytochrome P450 family 1 enzymes play prominent roles in xenobiotic detoxication and procarcinogen activation. P450 1A2 is the principal cytochrome P450 family 1 enzyme expressed in human liver and participates extensively in drug oxidations. This enzyme is also of great importance in the bioactivation of mutagens, including the N-hydroxylation of arylamines. P450-catalyzed reactions involve a wide range of substrates, and this versatility is reflected in a structural diversity evident in the active sites of available P450 structures. Here, we present the structure of human P450 1A2 in complex with the inhibitor alpha-naphthoflavone, determined to a resolution of 1.95 angstrom. alpha-Naphthoflavone is bound in the active site above the distal surface of the heme prosthetic group. The structure reveals a compact, closed active site cavity that is highly adapted for the positioning and oxidation of relatively large, planar substrates. This unique topology is clearly distinct from known active site architectures of P450 family 2 and 3 enzymes and demonstrates how P450 family 1 enzymes have evolved to catalyze efficiently polycyclic aromatic hydrocarbon oxidation. This report provides the first structure of a microsomal P450 from family 1 and offers a template to study further structure-function relationships of alternative substrates and other cytochrome P450 family 1 members.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Johnson, EF (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM-255, La Jolla, CA 92037 USA.	johnson@scripps.edu		Yano, Jason/0000-0002-9774-2611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM031001] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agundez JAG, 2004, CURR DRUG METAB, V5, P211, DOI 10.2174/1389200043335621; BAUER E, 1995, CHEM RES TOXICOL, V8, P136, DOI 10.1021/tx00043a018; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho US, 2003, BBA-PROTEINS PROTEOM, V1648, P195, DOI 10.1016/S1570-9639(03)00148-1; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; de Visser SP, 2003, J AM CHEM SOC, V125, P7413, DOI 10.1021/ja034142f; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GOTOH O, 1992, J BIOL CHEM, V267, P83; Hodek P, 2002, CHEM-BIOL INTERACT, V139, P1, DOI 10.1016/S0009-2797(01)00285-X; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Lewis DFV, 1996, XENOBIOTICA, V26, P723, DOI 10.3109/00498259609046745; Liu JG, 2004, ARCH BIOCHEM BIOPHYS, V424, P33, DOI 10.1016/j.abb.2003.12.040; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozalp C, 2006, BIOCHEMISTRY-US, V45, P4629, DOI 10.1021/bi051372t; Parikh A, 1999, BIOCHEMISTRY-US, V38, P5283, DOI 10.1021/bi990142+; Poulos T. L., 2005, CYTOCHROME P450 STRU, P87; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; Rowland P, 2006, J BIOL CHEM, V281, P7614, DOI 10.1074/jbc.M511232200; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Shimada T, 1998, CHEM RES TOXICOL, V11, P1048, DOI 10.1021/tx980090+; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; Yano JK, 2005, NAT STRUCT MOL BIOL, V12, P822, DOI 10.1038/nsmb971; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2000, BIOCHEMISTRY-US, V39, P11319, DOI 10.1021/bi000869u	36	379	387	3	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14348	14355		10.1074/jbc.M611692200	http://dx.doi.org/10.1074/jbc.M611692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17311915	hybrid			2022-12-27	WOS:000246245800046
J	Nizzari, M; Venezia, V; Repetto, E; Caorsi, V; Magrassi, R; Gagliani, MC; Carlo, P; Florio, T; Schettini, G; Tacchetti, C; Russo, T; Diaspro, A; Russo, C				Nizzari, Mario; Venezia, Valentina; Repetto, Emanuela; Caorsi, Valentina; Magrassi, Raffaella; Gagliani, Maria Cristina; Carlo, Pia; Florio, Tullio; Schettini, Gennaro; Tacchetti, Carlo; Russo, Tommaso; Diaspro, Alberto; Russo, Claudio			Amyloid precursor protein and presenilin1 interact with the adaptor GRB2 and modulate ERK1,2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; GAMMA-SECRETASE CLEAVAGE; MAP KINASE PATHWAY; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; CELL-CYCLE; INTRAMEMBRANE PROTEOLYSIS; CHROMOSOME SEGREGATION; TERMINAL FRAGMENTS; BETA PRODUCTION	The amyloid precursor protein (APP) and the presenilins 1 and 2 are genetically linked to the development of familial Alzheimer disease. APP is a single-pass transmembrane protein and precursor of fibrillar and toxic amyloid-beta-peptides, which are considered responsible for Alzheimer disease neurodegeneration. Presenilins are multipass membrane proteins, involved in the enzymatic cleavage of APP and other signaling receptors and transducers. The role of APP and presenilins in Alzheimer disease development seems to be related to the formation of amyloid-beta-peptides; however, their physiological function, reciprocal interaction, and molecular mechanisms leading to neurodegeneration are unclear. APP and presenilins are also involved in multiple interactions with intracellular proteins, the significance of which is under investigation. Among the different APP-interacting proteins, we focused our interest on the GRB2 adaptor protein, which connects cell surface receptors to intracellular signaling pathways. In this study we provide evidence by co-immunoprecipitation experiments, confocal and electron microscopy, and by fluorescence resonance energy transfer experiments that both APP and presenilin1 interact with GRB2 in vesicular structures at the centrosome of the cell. The final target for these interactions is ERK1,2, which is activated in mitotic centrosomes in a PS1- and APP-dependent manner. These data suggest that both APP and presenilin1 can be part of a common signaling pathway that regulates ERK1,2 and the cell cycle.	Univ Genoa, Dipartimento Oncol Biol & Genet, I-16132 Genoa, Italy; Univ Genoa, LAMBS, Dipartmento Fis, I-16132 Genoa, Italy; Univ Genoa, MicroscoBio Res Ctr, I-16146 Genoa, Italy; Univ Genoa, Dipartimento Med Sperimentale, I-16132 Genoa, Italy; FIRC, Inst Mol Oncol, I-16132 Genoa, Italy; Univ Naples Federico II, CEINGE Biotecnol Avanzate, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Molise, Dipartimento Sci Salute, I-86100 Campobasso, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; IFOM - FIRC Institute of Molecular Oncology; CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Molise	Russo, C (corresponding author), Univ Genoa, Dipartimento Oncol Biol & Genet, Viale Benedetto 15 2, I-16132 Genoa, Italy.	Claudio.Russo@unimol.it	Russo, Claudio/AIA-1429-2022; FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012; Russo, Tommaso/K-1331-2016; Diaspro, Alberto/E-7833-2010	Florio, Tullio/0000-0002-2394-996X; Russo, Tommaso/0000-0003-4426-0106; Diaspro, Alberto/0000-0002-4916-5928; russo, claudio/0000-0002-2520-2958; REPETTO, EMANUELA/0000-0002-6270-3540; gagliani, maria cristina/0000-0002-2902-2719; MAGRASSI, RAFFAELLA/0000-0003-3187-7764; TACCHETTI, CARLO/0000-0003-4602-000X				Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Badano JL, 2005, NAT REV GENET, V6, P194, DOI 10.1038/nrg1557; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Berezovska O, 2003, J NEUROSCI, V23, P4560; Boeras DI, 2008, NEUROBIOL AGING, V29, P319, DOI 10.1016/j.neurobiolaging.2006.10.027; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Dranovsky A, 2001, NEUROBIOL AGING, V22, P517, DOI 10.1016/S0197-4580(00)00248-7; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fratta P, 2005, AM J PATHOL, V167, P517, DOI 10.1016/S0002-9440(10)62994-X; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; GOLDE TE, 2003, SCI STKE, pRE4; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Jeong SJ, 2000, FASEB J, V14, P2171, DOI 10.1096/fj.99-1068com; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kang DE, 2005, J BIOL CHEM, V280, P31537, DOI 10.1074/jbc.M500833200; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kim MY, 2005, BIOCHEM BIOPH RES CO, V332, P609, DOI 10.1016/j.bbrc.2005.05.001; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Matsuda S, 2005, J BIOL CHEM, V280, P28912, DOI 10.1074/jbc.C500217200; Matsumoto B, 2002, CELL BIOL APPL CONFO CELL BIOL APPL CONFO; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Millecamps S, 2005, BBA-MOL CELL RES, V1745, P84, DOI 10.1016/j.bbamcr.2004.12.008; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Parisiadou L, 2004, NEURODEGENER DIS, V1, P184, DOI 10.1159/000080984; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Periasamy A., 2005, MOL IMAGING FRET MIC; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Raemaekers T, 2005, BIOCHEM SOC T, V33, P559, DOI 10.1042/BST0330559; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Russo C, 2005, BRAIN RES REV, V48, P257, DOI 10.1016/j.brainresrev.2004.12.016; Russo C, 1997, FEBS LETT, V409, P411, DOI 10.1016/S0014-5793(97)00564-4; Russo C, 1998, P NATL ACAD SCI USA, V95, P15598, DOI 10.1073/pnas.95.26.15598; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Shaw RW, 2006, FASEB J, V20, pA898, DOI 10.1096/fj.05-4055fje; Shen TL, 2001, FEBS LETT, V499, P176, DOI 10.1016/S0014-5793(01)02545-5; Silva EFDE, 2003, NEUROCHEM RES, V28, P1553, DOI 10.1023/A:1025630627319; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Venezia V, 2004, J NEUROCHEM, V90, P1359, DOI 10.1111/j.1471-4159.2004.02618.x; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vingtdeux V, 2005, NEUROBIOL DIS, V20, P625, DOI 10.1016/j.nbd.2005.05.004; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Yang Y, 2006, J NEUROSCI, V26, P775, DOI 10.1523/JNEUROSCI.3707-05.2006; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; Yoon SY, 2002, J CELL BIOCHEM, V84, P150, DOI 10.1002/jcb.1275; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; Zhou DW, 2004, J BIOL CHEM, V279, P25374, DOI 10.1074/jbc.M400488200	81	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13833	13844		10.1074/jbc.M610146200	http://dx.doi.org/10.1074/jbc.M610146200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17314098	hybrid			2022-12-27	WOS:000246060300073
J	Lu, R; Wang, X; Chen, ZF; Sun, DF; Tian, XQ; Fang, JY				Lu, Rong; Wang, Xia; Chen, Zhao-Fei; Sun, Dan-Feng; Tian, Xiao-Qing; Fang, Jing-Yuan			Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CYCLE ARREST; EXPRESSION; METHYLTRANSFERASE; HYPOMETHYLATION; P21(CIP1); GENE; PCNA; HYPERMETHYLATION; PROLIFERATION	The extracellular signal-regulated kinase/mitogen-activated protein kinase ( ERK-MAPK) pathway is a critical intermediary for cell proliferation, differentiation, and survival. In the human colon cancer cell line SW1116, treatment with the DNA methyltransferase 1 ( DNMT1) inhibitor 5-aza-2'-deoxycytidine ( 5-aza-dC) or the ERK-MAPK inhibitors PD98059 or rottlerin, or transient transfection with the MAP/ERK kinase ( MEK)1/2 small interfering RNA down-regulates DNMT1 and proliferating cell nuclear antigen levels. In this report, we found that drug treatment or small interfering RNA transfection of SW1116 cells induced promoter demethylation of the p16(INK4A) and p21(WAF1) genes, which up-regulated their mRNA and protein expression levels. Flow cytometry revealed that rottlerin treatment induced cell cycle arrest at phase G(1) ( p < 0.05). Thus, the ERK-MAPK inhibitor treatment or siRNA-mediated knockdown of ERK-MAPK decreases DNA methylation via down-regulating DNMT1 expression and other unknown mediator( s) in SW1116 colon cancer cells.	Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Digest Dis, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University	Fang, JY (corresponding author), 145 Shandong Rd Middle, Shanghai 200001, Peoples R China.	jingyuanfang@yahoo.com						Bender CM, 1999, MOL CELL BIOL, V19, P6690; Biro T, 2004, SCAND J IMMUNOL, V60, P421, DOI 10.1111/j.0300-9475.2004.01485.x; Chae HJ, 2004, ACTA PHARMACOL SIN, V25, P1372; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Deng C, 1998, BIOL CHEM, V379, P1113, DOI 10.1515/bchm.1998.379.8-9.1113; Deng C, 2001, ARTHRITIS RHEUM, V44, P397, DOI 10.1002/1529-0131(200102)44:2<397::AID-ANR59>3.3.CO;2-E; Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081; Esteller M, 2000, CANCER RES, V60, P4366; Fang JY, 2006, CANCER LETT, V233, P124, DOI 10.1016/j.canlet.2005.03.005; Fang JY, 2001, J VIROL, V75, P9753, DOI 10.1128/JVI.75.20.9753-9761.2001; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Gao ZQ, 1999, INT J CANCER, V82, P346, DOI 10.1002/(SICI)1097-0215(19990730)82:3<346::AID-IJC7>3.0.CO;2-#; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jakubikova J, 2005, INT J ONCOL, V27, P1449; Jeon HK, 2005, CELL BIOL TOXICOL, V21, P115, DOI 10.1007/s10565-005-0148-8; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lin SY, 2002, MOL CARCINOGEN, V35, P21, DOI 10.1002/mc.10070; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Lunghi P, 2004, BLOOD, V104, P519, DOI 10.1182/blood-2003-08-2743; McMillan L, 2003, BRIT J CANCER, V88, P748, DOI 10.1038/sj.bjc.6600793; Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200; Ramirez T, 2003, MUTAT RES-FUND MOL M, V528, P61, DOI 10.1016/S0027-5107(03)00099-X; Rylova SN, 2002, CANCER RES, V62, P801; Scanlan MJ, 2002, CANCER RES, V62, P4041; SCHEINBART LS, 1991, J RHEUMATOL, V18, P530; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu SJ, 2005, LIFE SCI, V77, P938, DOI 10.1016/j.lfs.2005.02.005; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Zhang XM, 2005, CANCER CHEMOTH PHARM, V55, P251, DOI 10.1007/s00280-004-0863-5; Zhu HB, 2004, ONCOGENE, V23, P4984, DOI 10.1038/sj.onc.1207645	42	85	93	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12249	12259		10.1074/jbc.M608525200	http://dx.doi.org/10.1074/jbc.M608525200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17307743	hybrid			2022-12-27	WOS:000245941900068
J	Speck, C; Stillman, B				Speck, Christian; Stillman, Bruce			Cdc6 ATPase activity regulates ORC center dot Cdc6 stability and the selection of specific DNA sequences as origins of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALKER-A MOTIF; RECOGNITION COMPLEX; BUDDING YEAST; S-PHASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; ESCHERICHIA-COLI; IN-VITRO; CHROMOSOMAL ORIGIN; BINDING-SITES	DNA replication, as with all macromolecular synthesis steps, is controlled in part at the level of initiation. Although the origin recognition complex ( ORC) binds to origins of DNA replication, it does not solely determine their location. To initiate DNA replication ORC requires Cdc6 to target initiation to specific DNA sequences in chromosomes and with Cdt1 loads the ring-shaped mini-chromosome maintenance ( MCM) 2-7 DNA helicase component onto DNA. ORC and Cdc6 combine to form a ring-shaped complex that contains six AAA(+) subunits. ORC and Cdc6 ATPase mutants are defective in MCM loading, and ORC ATPase mutants have reduced activity in ORC.Cdc6.DNA complex formation. Here we analyzed the role of the Cdc6 ATPase on ORC.Cdc6 complex stability in the presence or absence of specific DNA sequences. Cdc6 ATPase is activated by ORC, regulates ORC.Cdc6 complex stability, and is suppressed by origin DNA. Mutations in the conserved origin A element, and to a lesser extent mutations in the B1 and B2 elements, induce Cdc6 ATPase activity and prevent stable ORC.Cdc6 formation. By analyzing ORC.Cdc6 complex stability on various DNAs, we demonstrated that specific DNA sequences control the rate of Cdc6 ATPase, which in turn controls the rate of Cdc6 dissociation from the ORC.Cdc6.DNA complex. We propose a mechanism explaining how Cdc6 ATPase activity promotes origin DNA sequence specificity; on DNA that lacks origin activity, Cdc6 ATPase promotes dissociation of Cdc6, whereas origin DNA down-regulates Cdc6 ATPase resulting in a stable ORC.Cdc6.DNA complex, which can then promote MCM loading. This model has relevance for origin specificity in higher eukaryotes.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	Stillman@cshl.edu	Speck, Christian/G-2882-2011	Speck, Christian/0000-0001-6646-1692; Stillman, Bruce/0000-0002-9453-4091	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045436] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045436, R01 GM045436-20, GM45436] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 2004, EMBO REP, V5, P686, DOI 10.1038/sj.embor.7400185; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; Clarey MG, 2006, NAT STRUCT MOL BIOL, V13, P684, DOI 10.1038/nsmb1121; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Dai JL, 2005, P NATL ACAD SCI USA, V102, P337, DOI 10.1073/pnas.0408811102; DeBeer MAP, 2003, GENE DEV, V17, P1817, DOI 10.1101/gad.1096703; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933; FALCONI MM, 1996, P NATL ACAD SCI USA, V93, P1566; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Green BM, 2006, MOL BIOL CELL, V17, P2401, DOI 10.1091/mbc.E05-11-1043; Heichinger C, 2006, EMBO J, V25, P5171, DOI 10.1038/sj.emboj.7601390; JACOB F, 1963, CR HEBD ACAD SCI, V256, P298; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Lemaitre JM, 2002, NATURE, V419, P718, DOI 10.1038/nature01046; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MacAlpine D, 2005, CHROMOSOME RES, V13, P309, DOI 10.1007/s10577-005-1508-1; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Mimura S, 2004, NATURE, V431, P1118, DOI 10.1038/nature03024; Mizushima T, 2000, GENE DEV, V14, P1631; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Patel PK, 2006, MOL BIOL CELL, V17, P308, DOI 10.1091/mbc.E05-07-0657; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Randell JCW, 2006, MOL CELL, V21, P29, DOI 10.1016/j.molcel.2005.11.023; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Roth A, 1998, MOL MICROBIOL, V28, P395, DOI 10.1046/j.1365-2958.1998.00813.x; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Schepers A, 2001, J MOL BIOL, V308, P597, DOI 10.1006/jmbi.2001.4637; Seki T, 2000, P NATL ACAD SCI USA, V97, P14115, DOI 10.1073/pnas.97.26.14115; Speck C, 2005, NAT STRUCT MOL BIOL, V12, P965, DOI 10.1038/nsmb1002; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Takahashi N, 2004, J BIOL CHEM, V279, P8469, DOI 10.1074/jbc.M305531200; Takahashi N, 2002, J BIOL CHEM, V277, P16033, DOI 10.1074/jbc.M108615200; Tanny RE, 2006, MOL BIOL CELL, V17, P2415, DOI 10.1091/mbc.E05-11-1037; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Wilmes GM, 2002, P NATL ACAD SCI USA, V99, P101, DOI 10.1073/pnas.012578499; Xu WH, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-276; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	57	69	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11705	11714		10.1074/jbc.M700399200	http://dx.doi.org/10.1074/jbc.M700399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314092	hybrid, Green Accepted			2022-12-27	WOS:000245941900012
J	Beguin, P; Ng, YJA; Krause, C; Mahalakshmi, RN; Ng, MY; Hunziker, W				Beguin, Pascal; Ng, Yu Jin Alvin; Krause, Carola; Mahalakshmi, Ramasubbu N.; Ng, Mei Yong; Hunziker, Walter			RGK small GTP-binding proteins interact with the nucleotide kinase domain of Ca2+-channel beta-subunits via an uncommon effector binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL ACTIVITY; GATED CA2+ CHANNELS; RAS FAMILY; CALMODULIN; COMPLEX; REM2; GEM; GTPASES; MEMBER; MODULATION	RGK proteins (Kir/Gem, Rad, Rem, and Rem2) form a small subfamily of the Ras superfamily. Despite a conserved GTP binding core domain, several differences suggest that structure, mechanism of action, and functional regulation differ from Ras. RGK proteins down-regulate voltage-gated calcium channel activity by binding in a GTP-dependent fashion to the Ca-v beta subunits. Mutational analysis combined with homology modeling reveal a novel effector binding mechanism distinct from that of other Ras GTPases. In this model the Switch 1 region acts as an allosteric activator that facilitates electrostatic interactions between Arg-196 in Kir/Gem and Asp-194, -270, and -272 in the nucleotide-kinase (NK) domain of Ca-v beta 3 and wedging Val-223 and His-225 of Kir/ Gem into a hydrophobic pocket in the NK domain. Kir/ Gem interacts with a surface on the NK domain that is distinct from the groove where the voltage-gated calcium channel Ca-v beta 1 subunit binds. A complex composed of the RGK protein and the Ca-v beta 3 and Cav1.2 subunits could be revealed in vivo using coimmunoprecipitation experiments. Intriguingly, docking of the RGK protein to the NK domain of the Ca-v beta subunit is reminiscent of the binding of GMP to guanylate kinase.	Inst Mol & Cell Biol, Epithelial Cell Biol Lab, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hunziker, W (corresponding author), Inst Mol & Cell Biol, Epithelial Cell Biol Lab, 61 Biopolis Dr, Singapore 138673, Singapore.	Hunziker@imcb.a-star.edu.sg	Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022	Hunziker, Walter/0000-0002-5265-4933; Ng, Alvin/0000-0002-1744-6063				Beguin P, 2006, J MOL BIOL, V355, P34, DOI 10.1016/j.jmb.2005.10.013; Beguin P, 2005, BIOCHEM J, V390, P67, DOI 10.1042/BJ20050414; Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Berrou L, 2002, BIOPHYS J, V83, P1429, DOI 10.1016/S0006-3495(02)73914-3; Berrou L, 2005, J BIOL CHEM, V280, P494, DOI 10.1074/jbc.M410859200; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Chen HM, 2005, J NEUROSCI, V25, P9762, DOI 10.1523/JNEUROSCI.3111-05.2005; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Finlin BS, 2006, J BIOL CHEM, V281, P23557, DOI 10.1074/jbc.M604867200; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163; Kelly K, 2005, TRENDS CELL BIOL, V15, P640, DOI 10.1016/j.tcb.2005.10.002; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Menetrey J, 1999, PROTEINS, V37, P465, DOI 10.1002/(SICI)1097-0134(19991115)37:3<465::AID-PROT13>3.0.CO;2-O; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Murata M, 2004, CIRC RES, V95, P398, DOI 10.1161/01.RES.0000138449.85324.c5; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; PIZON V, 1988, ONCOGENE, V3, P201; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Sasaki T, 2005, J BIOL CHEM, V280, P9308, DOI 10.1074/jbc.M413773200; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Yanuar A, 2006, GENES CELLS, V11, P961, DOI 10.1111/j.1365-2443.2006.00994.x	35	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11509	11520		10.1074/jbc.M606423200	http://dx.doi.org/10.1074/jbc.M606423200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303572	hybrid			2022-12-27	WOS:000245941500072
J	Ido, H; Nakamura, A; Kobayashi, R; Ito, S; Li, SL; Futaki, S; Sekiguchi, K				Ido, Hiroyuki; Nakamura, Aya; Kobayashi, Reiko; Ito, Shunsuke; Li, Shaoliang; Futaki, Sugiko; Sekiguchi, Kiyotoshi			The requirement of the glutamic acid residue at the third position from the carboxyl termini of the laminin gamma chains in integrin binding by laminins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-DYSTROGLYCAN-BINDING; CELL-ADHESION; GLOBULAR DOMAIN; EXTRACELLULAR-MATRIX; LG MODULES; LONG-ARM; IDENTIFICATION; RECOMBINANT; HEPARIN; LIGAND	Laminins are the major cell-adhesive proteins in the basement membrane, consisting of three subunits termed alpha, beta, and gamma. The putative binding site for integrins has been mapped to the G domain of the alpha chain, although trimerization with beta and gamma chains is necessary for the G domain to exert its integrin binding activity. The mechanism underlying the requirement of beta and gamma chains in integrin binding by laminins remains poorly understood. Here, we show that the C-terminal region of the gamma chain is involved in modulation of the integrin binding activity of laminins. We found that deletion of the C-terminal three but not two amino acids within the gamma 1 chain completely abrogated the integrin binding activity of laminin-511. Furthermore, substitution of Gln for Glu-1607, the amino acid residue at the third position from the C terminus of the gamma 1 chain, also abolished the integrin binding activity, underscoring the role of Glu-1607 in integrin binding by the laminin. We also found that the conserved Glu residue of the gamma 2 chain is necessary for integrin binding by laminin-332, suggesting that the same mechanism operates in the modulation of the integrin binding activity of laminins containing either gamma 1 or gamma 2 chains. However, the peptide segment modeled after the C-terminal region of gamma 1 chain was incapable of either binding to integrin or inhibiting integrin binding by laminin-511, making it unlikely that the Glu residue is directly recognized by integrin. These results, together, indicate a novel mechanism operating in ligand recognition by laminin binding integrins.	Osaka Univ, Inst Prot Res, Lab Extracellular Matrix Biochem, Suita, Osaka 5650871, Japan	Osaka University	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Lab Extracellular Matrix Biochem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sekiguch@protein.osaka-u.ac.jp						Airenne T, 1996, GENOMICS, V32, P54, DOI 10.1006/geno.1996.0076; Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; ANTONSSON P, 1995, J MOL BIOL, V250, P74, DOI 10.1006/jmbi.1995.0359; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hayashi Y, 2002, BIOCHEM BIOPH RES CO, V299, P498, DOI 10.1016/S0006-291X(02)02642-6; Hirosaki T, 2002, J BIOL CHEM, V277, P49287, DOI 10.1074/jbc.M111096200; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ido H, 2006, MATRIX BIOL, V25, P112, DOI 10.1016/j.matbio.2005.10.003; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; Katayama M, 2003, CANCER RES, V63, P222; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Kunneken K, 2004, J BIOL CHEM, V279, P5184, DOI 10.1074/jbc.M310424200; Li SH, 2003, DEV CELL, V4, P613, DOI 10.1016/S1534-5807(03)00128-X; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Nishimune H, 2004, NATURE, V432, P580, DOI 10.1038/nature03112; Nishiuchi R, 2006, MATRIX BIOL, V25, P189, DOI 10.1016/j.matbio.2005.12.001; Nishiuchi R, 2003, J BIOCHEM, V134, P497, DOI 10.1093/jb/mvg185; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Sasaki T, 2001, FEBS LETT, V509, P181, DOI 10.1016/S0014-5793(01)03167-2; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Yan HHN, 2006, J BIOL CHEM, V281, P17286, DOI 10.1074/jbc.M513218200; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500	51	78	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11144	11154		10.1074/jbc.M609402200	http://dx.doi.org/10.1074/jbc.M609402200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307733	Green Published, hybrid			2022-12-27	WOS:000245941500035
J	Ott, CM; Akhavan, A; Lingappa, VR				Ott, Carolyn M.; Akhavan, Armin; Lingappa, Vishwanath R.			Specific features of the prion protein transmembrane domain regulate nascent chain orientation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCES; MEMBRANE-PROTEIN; TOPOGENIC SEQUENCE; CHARGED RESIDUES; TRANSLOCATION; CODON-129; BIOGENESIS; TOPOLOGY	The sequence of a transmembrane ( TM) domain and the adjacent regions are important for recognition, orientation, and integration at the translocon during membrane protein biosynthesis. However, the sequences of individual TM domains vary considerably. Although some general effects of electrostatic and hydrophobic interactions have been observed, it is still not clear what features of diverse sequences influence TM domain orientation. Here we utilized the ability of the prion protein ( PrP) to be synthesized in multiple topological forms to assay the effects of substitutions and mutations on TM domain orientation. Several of the TM domains we tested appear to contain no inherent information regulating orientation. In contrast, we found that the middle region of the PrP TM domain significantly reduces the ability of the chain to invert its orientation in the translocon. We also observed that the C-terminal region of the PrP TM domain influences orientation, and we characterized the orientation differences between two forms of a physiologically relevant polymorphism in this region. Specifically, we found that the identity of a single amino acid, that at position 129, can significantly alter PrP TM domain orientation. Because position 129 is the location of the disease-associated Met/Val polymorphism, we discuss both how this small change may affect TMD orientation and the larger biological implications of these results.	Univ Calif San Francisco, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	vishwanath.lingappa@ucsf.edu		Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NIA NIH HHS [AG02132] Funding Source: Medline; NINDS NIH HHS [NS37365] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barclay GR, 1999, BRIT J HAEMATOL, V107, P804, DOI 10.1046/j.1365-2141.1999.01789.x; BELTZER JP, 1991, J BIOL CHEM, V266, P973; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; Collinge J, 1997, NATURE, V389, P526, DOI 10.1038/39116; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; Cooper JD, 2003, INT J EPIDEMIOL, V32, P784, DOI 10.1093/ije/dyg248; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Gambetti P, 2003, BRIT MED BULL, V66, P213, DOI 10.1093/bmb/66.1.213; Garrison JL, 2005, NATURE, V436, P285, DOI 10.1038/nature03821; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; Gu YP, 2006, MOL CELL BIOL, V26, P2697, DOI 10.1128/MCB.26.7.2697-2715.2006; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Higy M, 2005, BIOCHEMISTRY-US, V44, P2039, DOI 10.1021/bi047976z; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; Lewis PA, 2006, J GEN VIROL, V87, P2443, DOI 10.1099/vir.0.81630-0; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; Ott CM, 2004, BIOCHEMISTRY-US, V43, P11973, DOI 10.1021/bi049156s; Ott CM, 2002, J CELL SCI, V115, P2003; Panegyres PK, 2001, ARCH NEUROL-CHICAGO, V58, P1899, DOI 10.1001/archneur.58.11.1899; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; Sadlish H, 2005, NAT STRUCT MOL BIOL, V12, P870, DOI 10.1038/nsmb994; Santini S, 2003, PROTEINS, V51, P258, DOI 10.1002/prot.10348; Schatzl HM, 1997, LANCET, V349, P1603, DOI 10.1016/S0140-6736(05)61632-7; Shan SO, 2005, FEBS LETT, V579, P921, DOI 10.1016/j.febslet.2004.11.049; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zeidler M, 1997, LANCET, V350, P668, DOI 10.1016/S0140-6736(05)63366-1	42	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11163	11171		10.1074/jbc.M607660200	http://dx.doi.org/10.1074/jbc.M607660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17276986	hybrid			2022-12-27	WOS:000245941500037
J	Schromm, AB; Howe, J; Ulmer, AJ; Wiesmuller, KH; Seyberth, T; Jung, G; Rossle, M; Koch, MHJ; Gutsmann, T; Brandenburg, K				Schromm, Andra B.; Howe, Joerg; Ulmer, Artur J.; Wiesmueller, Karl-Heinz; Seyberth, Tobias; Jung, Guenther; Roessle, Manfred; Koch, Michel H. J.; Gutsmann, Thomas; Brandenburg, Klaus			Physicochemical and biological analysis of synthetic bacterial lipopeptides - Validity of the concept of endotoxic conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; LPS-BINDING PROTEIN; INDUCED ACTIVATION; ESCHERICHIA-COLI; CELL ACTIVATION; LIPOPOLYSACCHARIDE; RECOGNITION; LIPOPROTEIN; INNATE; CD14	The importance of the biological function and activity of lipoproteins from the outer or cytoplasmic membranes of Gram-positive and Gram-negative bacteria is being increasingly recognized. It is well established that they are like the endotoxins ( lipopolysaccharide ( LPS)), which are the main amphiphilic components of the outer membrane of Gram-negative bacteria, potent stimulants of the human innate immune system, and elicit a variety of proinflammatory immune responses. Investigations of synthetic lipopeptides corresponding to N-terminal partial structures of bacterial lipoproteins defined the chemical prerequisites for their biological activity and in particular the number and length of acyl chains and sequence of the peptide part. Here we present experimental data on the biophysical mechanisms underlying lipopeptide bioactivity. Investigation of selected synthetic diacylated and triacylated lipopeptides revealed that the geometry of these molecules ( i.e. the molecular conformations and supramolecular aggregate structures) and the preference for membrane intercalation provide an explanation for the biological activities of the different lipopeptides. This refers in particular to the agonistic or antagonistic activity ( i.e. their ability to induce cytokines in mononuclear cells or to block this activity, respectively). Biological activity of lipopeptides was hardly affected by the LPS-neutralizing antibiotic polymyxin B, and the biophysical interaction characteristics were found to be in sharp contrast to that of LPS with polymyxin B. The analytical data show that our concept of "endotoxic conformation," originally developed for LPS, can be applied also to the investigated lipopeptide and suggest that the molecular mechanisms of cell activation by amphiphilic molecules are governed by a general principle.	Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Dept Immunochem & Biochem Microbiol, D-23845 Borstel, Germany; Emmy Noether Grp Immunobiophys, D-23845 Borstel, Germany; Div Biophys, D-23845 Borstel, Germany; Div Immunol, D-23845 Borstel, Germany; EMC Microcollect GmbH, D-72070 Tubingen, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany	Forschungszentrum Borstel; EMC Microcollections GmbH; Eberhard Karls University of Tubingen; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Schromm, AB (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany.	aschromm@fz-borstel.de	Gutsmann, Thomas/E-6100-2011; Schromm, Andra/O-3936-2018	Rossle, Manfred/0000-0003-4196-0430				BESSLER WG, 1985, J IMMUNOL, V135, P1900; Blondin C, 1997, EUR J IMMUNOL, V27, P3303, DOI 10.1002/eji.1830271229; Blunck R, 2001, J IMMUNOL, V166, P1009, DOI 10.4049/jimmunol.166.2.1009; Boncheva M, 1996, LANGMUIR, V12, P5636, DOI 10.1021/la9605753; Brandenburg K, 2005, BIOPHYS J, V88, P1845, DOI 10.1529/biophysj.104.047944; Brandenburg K, 2004, BIOCHEMISTRY-US, V43, P4039, DOI 10.1021/bi0361158; Brandenburg K, 2002, THERMOCHIM ACTA, V382, P189, DOI 10.1016/S0040-6031(01)00731-6; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; Brandenburg K, 1998, CHEM PHYS LIPIDS, V91, P53, DOI 10.1016/S0009-3084(97)00093-5; Brandenburg K, 2004, CURR TOP MED CHEM, V4, P1127, DOI 10.2174/1568026043388213; BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; Buwitt-Beckmann U, 2006, J BIOL CHEM, V281, P9049, DOI 10.1074/jbc.M512525200; Buwitt-Beckmann U, 2005, FEBS J, V272, P6354, DOI 10.1111/j.1742-4658.2005.05029.x; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; El-Samalouti VT, 1999, FEMS IMMUNOL MED MIC, V23, P259, DOI 10.1111/j.1574-695X.1999.tb01247.x; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gioffre A, 2006, J VET MED B, V53, P34, DOI 10.1111/j.1439-0450.2006.00905.x; Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922-4927.1996; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; Gutsmann T, 2000, PHYS CHEM CHEM PHYS, V2, P4521, DOI 10.1039/b004188m; Hashimoto M, 2006, J IMMUNOL, V177, P3162, DOI 10.4049/jimmunol.177.5.3162; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Iontcheva I, 2004, INFECT IMMUN, V72, P2312, DOI 10.1128/IAI.72.4.2312-2320.2004; ISRAELACHVILI JN, 1991, INTERMOLECULAR SURFA, P366; Kataoka H, 2006, CELL MICROBIOL, V8, P1199, DOI 10.1111/j.1462-5822.2006.00702.x; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KIELIAN TL, 1995, IMMUNOPHARMACOLOGY, V29, P187, DOI 10.1016/0162-3109(95)00003-C; KOCH MHJ, 1988, MAKROMOL CHEM-M SYMP, V15, P79, DOI 10.1002/masy.19880150106; Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103; LUZZATI V, 1993, J MOL BIOL, V229, P540, DOI 10.1006/jmbi.1993.1053; MATHISON J, 1993, J CLIN INVEST, V92, P2053, DOI 10.1172/JCI116801; MELCHERS F, 1975, J EXP MED, V142, P473, DOI 10.1084/jem.142.2.473; METZGER J, 1991, INT J PEPT PROT RES, V37, P46; Metzger J W, 1995, J Pept Sci, V1, P184, DOI 10.1002/psc.310010305; METZGER JW, 1993, BIOCHIM BIOPHYS ACTA, V1149, P29, DOI 10.1016/0005-2736(93)90021-Q; Mueller M, 2005, J IMMUNOL, V174, P1091, DOI 10.4049/jimmunol.174.2.1091; Muller M, 2003, J ENDOTOXIN RES, V9, P181, DOI 10.1179/096805103125001595; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRASS W, 1987, BIOCHIM BIOPHYS ACTA, V900, P116, DOI 10.1016/0005-2736(87)90283-5; Reichel F, 2000, J ORG CHEM, V65, P3357, DOI 10.1021/jo991685s; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Sellati TJ, 2001, J IMMUNOL, V166, P4131, DOI 10.4049/jimmunol.166.6.4131; Seyberth T, 2006, J MED CHEM, V49, P1754, DOI 10.1021/jm050585d; Seydel U, 2003, EUR J IMMUNOL, V33, P1586, DOI 10.1002/eji.200323649; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Spohn R, 2004, VACCINE, V22, P2494, DOI 10.1016/j.vaccine.2003.11.074; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2002, CRIT REV IMMUNOL, V22, P251; Triantafilou M, 2002, J CELL SCI, V115, P2603; UHL B, 1991, J LEUKOCYTE BIOL, V50, P10, DOI 10.1002/jlb.50.1.10; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Viriyakosol S, 2005, INFECT IMMUN, V73, P1553, DOI 10.1128/IAI.73.3.1553-1560.2005; Wardenburg JB, 2006, P NATL ACAD SCI USA, V103, P13831, DOI 10.1073/pnas.0603072103; WIESMULLER KH, 1992, INT J PEPT PROT RES, V40, P255; WOLF B, 1989, IMMUNOBIOLOGY, V180, P93, DOI 10.1016/S0171-2985(89)80033-6; WOLF B, 1989, IMMUNOL LETT, V20, P121, DOI 10.1016/0165-2478(89)90096-5; Yadav M, 2006, BLOOD, V108, P3168, DOI 10.1182/blood-2006-05-024406; Yang XFF, 2003, P NATL ACAD SCI USA, V100, P11001, DOI 10.1073/pnas.1834315100	66	42	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11030	11037		10.1074/jbc.M700287200	http://dx.doi.org/10.1074/jbc.M700287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308304	Green Published, hybrid			2022-12-27	WOS:000245941500023
J	Grillo, C; D'Ambrosio, C; Consalvi, V; Chiaraluce, R; Scaloni, A; Maceroni, M; Eufemi, M; Altieri, F				Grillo, Caterina; D'Ambrosio, Chiara; Consalvi, Valerio; Chiaraluce, Roberta; Scaloni, Andrea; Maceroni, Manola; Eufemi, Margherita; Altieri, Fabio			DNA-binding activity of the ERp57 C-terminal domain is related to a redox-dependent conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; THIOREDOXIN REDUCTASE; NMR-SPECTROSCOPY; B' DOMAIN; SITE; CALRETICULIN; CALNEXIN; CELLS	ERp57, a member of the protein-disulfide isomerase family, although mainly localized in the endoplasmic reticulum is here shown to have a nuclear distribution. We previously showed the DNA-binding properties of ERp57, its association with the internal nuclear matrix, and identified the C-terminal region, containing the a' domain, as being directly involved in the DNA-binding activity. In this work, we demonstrate that its DNA-binding properties are strongly dependent on the redox state of the a' domain active site. Site-directed mutagenesis experiments on the first cysteine residue of the -CGHC-thioredoxinlike active site lead to a mutant domain (C406S) lacking DNA-binding activity. Biochemical studies on the recombinant domain revealed a conformational change associated with the redox-dependent formation of a homodimer, having two disulfide bridges between the cysteine residues of two a' domain active sites. The formation of intermolecular disulfide bridges rather than intramolecular oxidation of active site cysteines is important to generate species with DNA-binding properties. Thus, in the absence of any dedicated motif within the protein sequence, this structural rearrangement might be responsible for the DNA-binding properties of the C-terminal domain. Moreover, NADH-dependent thioredoxin reductase is active on intermolecular disulfides of the a' domain, allowing the control of dimeric protein content as well as its DNA-binding activity. A similar behavior was also observed for whole ERp57.	Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, CNR Inst Mol Biol & Pathol, I-00185 Rome, Italy; Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; ISPAAM, Natl Res Council, Proteom & Mass Spectrometry, I-80147 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR)	Altieri, F (corresponding author), Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, CNR Inst Mol Biol & Pathol, P Moro 5, I-00185 Rome, Italy.	fabio.altieri@uniroma1.it	Grillo, Caterina Maria/ABD-3404-2021; consalvi, valerio/F-1918-2011; Chiaraluce, Roberta/F-1920-2011; Altieri, Fabio/D-2790-2009; D'Ambrosio, Chiara/C-2753-2012	Altieri, Fabio/0000-0002-6546-2738; D'Ambrosio, Chiara/0000-0003-2810-9270; Scaloni, Andrea/0000-0001-9362-8515				ALTIERI F, 1993, BIOCHEM BIOPH RES CO, V194, P992, DOI 10.1006/bbrc.1993.1919; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Chichiarelli S, 2007, J CELL PHYSIOL, V210, P343, DOI 10.1002/jcp.20824; Coppari S, 2002, J CELL BIOCHEM, V85, P325, DOI 10.1002/jcb.10137; Dalle-Donne I, 2005, MASS SPECTROM REV, V24, P55, DOI 10.1002/mas.20006; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Eufemi M, 2004, BIOCHEM BIOPH RES CO, V323, P1306, DOI 10.1016/j.bbrc.2004.09.009; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Ferraro A, 1999, J CELL BIOCHEM, V72, P528, DOI 10.1002/(SICI)1097-4644(19990315)72:4<528::AID-JCB8>3.0.CO;2-V; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Gerner C, 1999, J CELL BIOCHEM, V74, P145, DOI 10.1002/(SICI)1097-4644(19990801)74:2<145::AID-JCB1>3.0.CO;2-#; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grillo C, 2002, BIOCHEM BIOPH RES CO, V295, P67, DOI 10.1016/S0006-291X(02)00634-4; Grillo C, 2006, FREE RADICAL BIO MED, V41, P1113, DOI 10.1016/j.freeradbiomed.2006.06.016; HANIU M, 1994, INT J PEPT PROT RES, V43, P81; Hennecke J, 1997, BIOCHEMISTRY-US, V36, P6391, DOI 10.1021/bi963017w; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON E, 1992, J BIOL CHEM, V267, P14412; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Krynetski EY, 2003, CANCER RES, V63, P100; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; Markus M, 1999, J BIOL CHEM, V274, P1040, DOI 10.1074/jbc.274.2.1040; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Mulkerrin Michael G., 1996, P5; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; OTHANI H, 1993, HISTOCHEMISTRY, V100, P423; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; ROZELL B, 1988, EUR J CELL BIOL, V46, P470; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sambrook J., 2001, MOL CLONING LAB MANU; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Silvennoinen L, 2004, J BIOL CHEM, V279, P13607, DOI 10.1074/jbc.M313054200; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Tian G, 2006, CELL, V124, P61, DOI 10.1016/j.cell.2005.10.044; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Urade R, 1997, J BIOCHEM-TOKYO, V122, P834; Vilardo PG, 2001, BIOCHEMISTRY-US, V40, P11985, DOI 10.1021/bi0104975; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Wyse B, 2002, AM J PHYSIOL-RENAL, V282, pF424, DOI 10.1152/ajprenal.0028.2001; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	56	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10299	10310		10.1074/jbc.M700966200	http://dx.doi.org/10.1074/jbc.M700966200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283067	hybrid			2022-12-27	WOS:000245941000020
J	Smrz, D; Draberova, L; Draber, P				Smrz, Daniel; Draberova, L'ubica; Draber, Petr			Non-apoptotic phosphatidylserine externalization induced by engagement of glycosylphosphatidylinositol-anchored proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; FC-EPSILON-RI; MEMBRANE PHOSPHOLIPID ASYMMETRY; RAT MAST-CELLS; PLASMA-MEMBRANE; SURFACE EXPOSURE; LIPID RAFTS; ANNEXIN-V; CARCINOEMBRYONIC ANTIGEN; BIOLOGICAL FUNCTIONS	The exposure of phosphatidylserine ( PS) on the cell surface is a general marker of apoptotic cells. Non-apoptotic PS externalization is induced by several activation stimuli, including engagement of immunoreceptors. Immune cells can also be activated by aggregation of glycosylphosphatidylinositol- anchored proteins ( GPI-APs). However, it is unknown whether cell triggering through these proteins, lacking transmembrane and cytoplasmic domains, also leads to PS externalization. Here we show that engagement of GPI-APs in rodent mast cells induces a rapid and reversible externalization of PS by a non-apoptotic mechanism. PS externalization triggered by GPI-AP-specific monoclonal antibodies was dependent on the activity of H+-ATP synthase and several other enzymes involved in mast cell signaling but was independent of cell degranulation, free cytoplasmic calcium up-regulation, and a decrease in lipid packing as determined by merocyanine 540 binding. Surprisingly, disruption of actin cytoskeleton by latrunculin B or plasma membrane integrity by methyl-beta-cyclodextrin had opposite effects on PS externalization triggered through GPI-AP or the high affinity IgE receptor. We further show that PS externalization mediated by GPI-APs was also observed in some other cells, and its extent varied with antibodies used. Interestingly, effects of different antibodies on PS externalization were additive, indicating that independent stimuli converge onto a signaling pathways leading to PS externalization. Our findings identify the cell surface PS exposure induced through GPI-AP as a distinct mechanism of cell signaling. Such a mechanism could contribute to "inside-out" signaling in response to pathogens and other external activators and/or to initiation of other functions associated with PS externalization.	Acad Sci Czech Republic, Inst Genet Mol, Dept Signal Transduct, CZ-14220 Prague 4, Czech Republic	Czech Academy of Sciences	Draber, P (corresponding author), Acad Sci Czech Republic, Inst Genet Mol, Dept Signal Transduct, Videnska 1083, CZ-14220 Prague 4, Czech Republic.	draberpe@biomed.cas.cz	Smrz, Daniel/D-4853-2014; Draberova, Lubica/G-3505-2014; Draber, Petr/E-1119-2018; Draber, Petr/G-3412-2014	Smrz, Daniel/0000-0003-0143-8744; Draberova, Lubica/0000-0002-2459-4435; Draber, Petr/0000-0002-3986-2025; Draber, Petr/0000-0002-3986-2025				BANIYASH M, 1987, J IMMUNOL, V138, P2999; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Brouckaert G, 2004, MOL BIOL CELL, V15, P1089, DOI 10.1091/mbc.E03-09-0668; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; DRABER P, 1980, J IMMUNOGENET, V7, P455; Draber P, 2002, MOL IMMUNOL, V38, P1247, DOI 10.1016/S0161-5890(02)00071-8; DRABEROVA L, 1991, EUR J IMMUNOL, V21, P1583, DOI 10.1002/eji.1830210703; Draberova L, 2004, EUR J IMMUNOL, V34, P2209, DOI 10.1002/eji.200322663; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; DRABEROVA L, 1989, EUR J IMMUNOL, V19, P1715, DOI 10.1002/eji.1830190928; Elliott JI, 2006, BLOOD, V108, P1611, DOI 10.1182/blood-2005-11-012328; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Fischer K, 2006, BLOOD, V108, P4094, DOI 10.1182/blood-2006-03-011742; Frigeri L, 1999, J IMMUNOL, V162, P2243; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Goth SR, 2001, INFECT IMMUN, V69, P1109, DOI 10.1128/IAI.69.2.1109-1119.2001; HAGGARTY A, 1986, CANCER RES, V46, P300; Halova I, 2002, INT IMMUNOL, V14, P213, DOI 10.1093/intimm/14.2.213; Heneberg P, 2006, EUR J IMMUNOL, V36, P2795, DOI 10.1002/eji.200636159; Hirt UA, 2003, CELL DEATH DIFFER, V10, P1156, DOI 10.1038/sj.cdd.4401286; Karmakar S, 2005, J BIOL CHEM, V280, P28623, DOI 10.1074/jbc.M414140200; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kunzelmann-Marche C, 2002, J BIOL CHEM, V277, P19876, DOI 10.1074/jbc.M200324200; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Malaviya R, 2001, IMMUNOL REV, V179, P16, DOI 10.1034/j.1600-065X.2001.790102.x; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; Maniatis T, 1982, MOL CLONING LAB MANU, P61; Martin S, 2000, INT ARCH ALLERGY IMM, V123, P249, DOI 10.1159/000024451; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MASON DW, 1980, BIOCHEM J, V187, P1; MOWER DA, 1994, J IMMUNOL, V152, P4832; Munoz S, 2003, J IMMUNOL, V170, P5590, DOI 10.4049/jimmunol.170.11.5590; ORTEGA E, 1988, EMBO J, V7, P4101, DOI 10.1002/j.1460-2075.1988.tb03304.x; Pomorski T, 2006, CELL MOL LIFE SCI, V63, P2908, DOI 10.1007/s00018-006-6167-7; Pomorski T, 2004, J CELL SCI, V117, P805, DOI 10.1242/jcs.01055; Raff M C, 1971, Transplant Rev, V6, P52; Rege TA, 2006, FASEB J, V20, P1045, DOI 10.1096/fj.05-5460rev; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Surviladze Z, 2001, EUR J IMMUNOL, V31, P1, DOI 10.1002/1521-4141(200101)31:1<1::AID-IMMU1>3.0.CO;2-W; THON IL, 1967, ACTA PHYSIOL SCAND, V71, P303, DOI 10.1111/j.1748-1716.1967.tb03737.x; Tolarova H, 2004, EUR J IMMUNOL, V34, P1627, DOI 10.1002/eji.200424991; van den Eijnde SM, 1998, APOPTOSIS, V3, P9, DOI 10.1023/A:1009650917818; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; Virji M, 2000, MOL MICROBIOL, V36, P784, DOI 10.1046/j.1365-2958.2000.01885.x; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; Volna P, 2004, J EXP MED, V200, P1001, DOI 10.1084/jem.20041213; WILLIAMSON P, 1983, BIOCHIM BIOPHYS ACTA, V732, P387, DOI 10.1016/0005-2736(83)90055-X; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574; Windmiller DA, 2003, J BIOL CHEM, V278, P11874, DOI 10.1074/jbc.M211787200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	70	59	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10487	10497		10.1074/jbc.M611090200	http://dx.doi.org/10.1074/jbc.M611090200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284440	hybrid			2022-12-27	WOS:000245941000041
J	Andersson, CX; Sopasakis, VR; Wallerstedt, E; Smith, U				Andersson, Christian X.; Sopasakis, Victoria Rotter; Wallerstedt, Emelie; Smith, Ulf			Insulin antagonizes interleukin-6 signaling and is anti-inflammatory in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; STAT3 SERINE PHOSPHORYLATION; ACTIVATED PROTEIN-KINASES; TYROSINE PHOSPHORYLATION; ADIPOSE-TISSUE; PPAR-GAMMA; FAT-CELLS; C-DELTA; RESISTANCE; INHIBITION	Adipose tissue secretes different adipokines, including interleukin-6 (IL-6), that have been implicated in the insulin resistance and inflammatory state characterizing obesity. We examined the putative cross-talk between insulin and IL-6 in adipose cells and found that insulin exerts an inhibitory effect on the IL-6 signaling pathway by altering the post-translational modifications of the signal transducer and activator of transcription 3 (STAT3). Insulin reduces the tyrosine phosphorylation and increases the serine phosphorylation of STAT3, thereby reducing its nuclear localization and transcriptional activity. Signaling through the MEK/MAPK pathway plays an important role as treatment with the MEK inhibitor PD98059 reduces the effects of insulin on IL-6 signaling. We also show that the protein tyrosine phosphatase SHP2 is activated upon insulin signaling and is required for the dephosphorylation of STAT3 and that insulin exerts a synergistic effect with IL-6 on suppressor of cytokine signaling 3 expression. As a consequence, the IL-6-induced expression of the inflammatory markers serum amyloid A 3 and haptoglobin are significantly decreased in celts incubated with both IL-6 and insulin. Thus, insulin exerts an important anti-inflammatory effect in adipose cells by impairing the IL-6 signal at several levels.	Univ Gothenburg, Lundberg Lab Diabet Res, Dept Mol & Clin Med, Sahlgrenska Acad, SE-41345 Gothenburg, Sweden	University of Gothenburg	Smith, U (corresponding author), Univ Gothenburg, Lundberg Lab Diabet Res, Dept Mol & Clin Med, Sahlgrenska Acad, SE-41345 Gothenburg, Sweden.	ulf.smith@medic.gu.se						Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Dandona P, 2001, J CLIN ENDOCR METAB, V86, P3257, DOI 10.1210/jc.86.7.3257; do Nascimento CO, 2004, BIOCHEM BIOPH RES CO, V313, P702, DOI 10.1016/j.bbrc.2003.12.008; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; Gunaje JJ, 2001, BIOCHEM BIOPH RES CO, V288, P252, DOI 10.1006/bbrc.2001.5759; Hammarstedt A, 2005, PROSTAG LEUKOTR ESS, V73, P65, DOI 10.1016/j.plefa.2005.04.008; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262; RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shi H, 2004, J BIOL CHEM, V279, P34733, DOI 10.1074/jbc.M403886200; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Smith U, 1999, ANN NY ACAD SCI, V892, P119, DOI 10.1111/j.1749-6632.1999.tb07790.x; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Wang CZ, 2006, MOL BIOL CELL, V17, P2839, DOI 10.1091/mbc.E05-11-1068; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	38	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9430	9435		10.1074/jbc.M609980200	http://dx.doi.org/10.1074/jbc.M609980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267401	hybrid			2022-12-27	WOS:000245421700015
J	Shi, YL; Dodson, GE; Mukhopadhyay, PS; Shanware, NP; Trinh, AT; Tibbetts, RS				Shi, Yuling; Dodson, Gerald E.; Mukhopadhyay, Partha S.; Shanware, Naval P.; Trinh, Anthony T.; Tibbetts, Randal S.			Identification of carboxyl-terminal MCM3 phosphorylation sites using polyreactive phosphospecific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATM-DEPENDENT PHOSPHORYLATION; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; HUMAN SMG-1; ACTIVATION; REPLICATION; COMPLEX; BINDING	The functionally related ATM (ataxia telangiectasia-mutated) and ATR (ATM-Rad3-related) protein kinases are critical regulators of DNA damage responses in mammalian cells. ATM and ATR share highly overlapping substrate specificities and show a strong preference for the phosphorylation of Ser or Thr residues followed by Gln. In this report we used a polyreactive phosphospecific antibody (alpha-pDSQ) that recognizes a subset of phosphorylated AspSer-Gln sequences to purify candidate ATM/ATR substrates. This led to the identification of phosphorylation sites in the carboxyl terminus of the minichromosome maintenance protein 3 (MCM3), a component of the hexameric MCM DNA helicase. We show that the alpha-DSQ antibody recognizes tandem DSQ phosphorylation sites (Ser-725 and Ser-732) in the carboxyl terminus of murine MCM3 (mMCM3) and that ATM phosphorylates both sites in vitro. ATM phosphorylated the carboxyl termini of mMCM3 and human MCM3 in vivo and the phosphorylated form of MCM3 retained association with the canonical MCM complex. Although DNA damage did not affect steady-state levels of chromatin-bound MCM3, the ATM-phosphorylated form of MCM3 was preferentially localized to the soluble, nucleoplasmic fraction. This finding suggests that the carboxyl terminus of chromatin-loaded MCM3 may be sequestered from ATM-dependent checkpoint signals. Finally, we show that ATM and ATR jointly contribute to UV light-induced MCM3 phosphorylation, but that ATM is the predominant UV-activated MCM3 kinase in vivo. The carboxyl-terminal ATM phosphorylation sites are conserved in vertebrate MCM3 orthologs suggesting that this motif may serve important regulatory functions in response to DNA damage. Our findings also suggest that DSQ motifs are common phosphoacceptor motifs for ATM family kinases.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Tibbetts, RS (corresponding author), 1300 Univ Ave, Madison, WI 53706 USA.	rstibbetts@wisc.edu		Tibbetts, Randal/0000-0003-2245-2297	NIGMS NIH HHS [GM067868-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067868] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2000, CANCER RES, V60, P5934; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; Dodson GE, 2006, J BIOL CHEM, V281, P1692, DOI 10.1074/jbc.M509577200; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin WC, 2001, GENE DEV, V15, P1833; Livingstone M, 2005, CANCER RES, V65, P7533, DOI 10.1158/0008-5472.CAN-04-3729; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sheu YJ, 2006, MOL CELL, V24, P101, DOI 10.1016/j.molcel.2006.07.033; Shi YL, 2005, J BIOL CHEM, V280, P40195, DOI 10.1074/jbc.C500400200; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Takahashi TS, 2005, TRENDS BIOCHEM SCI, V30, P437, DOI 10.1016/j.tibs.2005.06.007; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yoo HY, 2004, J BIOL CHEM, V279, P53353, DOI 10.1074/jbc.M408026200; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	59	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9236	9243		10.1074/jbc.M609256200	http://dx.doi.org/10.1074/jbc.M609256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244605	hybrid			2022-12-27	WOS:000245780300070
J	Thuswaldner, S; Lagerstedt, JO; Rojas-Stutz, M; Bouhidel, K; Der, C; Leborgne-Castel, N; Mishra, A; Marty, F; Schoefs, B; Adamska, I; Persson, BL; Spetea, C				Thuswaldner, Sophie; Lagerstedt, Jens O.; Rojas-Stuetz, Marc; Bouhidel, Karim; Der, Christophe; Leborgne-Castel, Nathalie; Mishra, Arti; Marty, Francis; Schoefs, Benoit; Adamska, Iwona; Persson, Bengt L.; Spetea, Cornelia			Identification, expression, and functional analyses of a thylakoid ATP/ADP carrier from Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE TRANSPORT-SYSTEM; PHOTOSYSTEM-II; PROTEIN; MITOCHONDRIAL; MEMBRANES; ATP; LOCALIZATION; PROVIDES; PATHWAY; BINDING	In plants the chloroplast thylakoid membrane is the site of light-dependent photosynthetic reactions coupled to ATP synthesis. The ability of the plant cell to build and alter this membrane system is essential for efficient photosynthesis. A nucleotide translocator homologous to the bovine mitochondrial ADP/ATP carrier (AAC) was previously found in spinach thylakoids. Here we have identified and characterized a thylakoid ATP/ADP carrier (TAAC) from Arabidopsis. (i) Sequence homology with the bovine AAC and the prediction of chloroplast transit peptides indicated a putative carrier encoded by the At5g01500 gene, as a TAAC. (ii) Transiently expressed TAAC-green fluorescent protein fusion construct was targeted to the chloroplast. Western blotting using a peptide-specific antibody together with immunogold electron microscopy revealed a major location of TAAC in the thylakoid membrane. Previous proteomic analyses identified this protein in chloroplast envelope preparations. (iii) Recombinant TAAC protein specifically imports ATP in exchange for ADP across the cytoplasmic membrane of Escherichia coli. Studies on isolated thylakoids from Arabidopsis confirmed these observations. (iv) The lack of TAAC in an Arabidopsis T-DNA insertion mutant caused a 30-40% reduction in the thylakoid ATP transport and metabolism. (v) TAAC is readily expressed in dark-grown Arabidopsis seedlings, and its level remains stable throughout the greening process. Its expression is highest in developing green tissues and in leaves undergoing senescence or abiotic stress. We propose that the TAAC protein supplies ATP for energy-dependent reactions during thylakoid biogenesis and turnover in plants.	Linkoping Univ, Div Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Dept Phys Chem & Biol, SE-58185 Linkoping, Sweden; Kalmar Univ, Dept Chem & Biomed Sci, SE-39182 Kalmar, Sweden; Univ Konstanz, Dept Physiol & Plant Biochem, D-78457 Constance, Germany; Univ Bourgogne, UMR Plante Microbe Environm 5184, CNRS, INRA 1088, F-21078 Dijon, France	Linkoping University; Linkoping University; Linnaeus University; University of Kalmar; University of Konstanz; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Bourgogne	Spetea, C (corresponding author), Linkoping Univ, Div Cell Biol, SE-58185 Linkoping, Sweden.	cornelia.spetea@ibk.liu.se	Schoefs, Benoit/AAE-4010-2019; Wiklund, Cornelia Spetea/S-3635-2019; Marty, Francis/L-2638-2013; Lagerstedt, Jens/AAF-9567-2021	Schoefs, Benoit/0000-0002-7804-8130; Mishra, Arti/0000-0002-5214-0676; Lagerstedt, Jens/0000-0002-4313-2666; Leborgne-Castel, Nathalie/0000-0001-8756-4463				ABBOTT MS, 1984, J BIOL CHEM, V259, P2271; Abdel-Ghany SE, 2005, PLANT CELL, V17, P1233, DOI 10.1105/tpc.104.030452; ANDERSON JM, 1982, TRENDS BIOCHEM SCI, V7, P288, DOI 10.1016/0968-0004(82)90014-7; BERTRAND M, 1988, Z NATURFORSCH C, V43, P443; Borisjuk L, 2004, PLANT BIOLOGY, V6, P375, DOI 10.1055/s-2004-817908; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Che FS, 2000, PLANT PHYSIOL, V124, P59, DOI 10.1104/pp.124.1.59; Ephritikhine G, 2004, PLANT PHYSIOL BIOCH, V42, P943, DOI 10.1016/j.plaphy.2004.11.004; Eshaghi S, 1999, FEBS LETT, V446, P23, DOI 10.1016/S0014-5793(99)00149-0; Ettinger WF, 1999, PLANT PHYSIOL, V119, P1379, DOI 10.1104/pp.119.4.1379; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Gao H, 2006, P NATL ACAD SCI USA, V103, P6759, DOI 10.1073/pnas.0507287103; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Haferkamp I, 2002, EUR J BIOCHEM, V269, P3172, DOI 10.1046/j.1432-1033.2002.02991.x; Heazlewood JL, 2004, PLANT CELL, V16, P241, DOI 10.1105/tpc.016055; Hinnah SC, 1998, EUR J BIOCHEM, V253, P606, DOI 10.1046/j.1432-1327.1998.2530606.x; Inoue K, 2005, J CELL BIOL, V171, P425, DOI 10.1083/jcb.200506171; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Klingenberg M, 2006, BBA-BIOENERGETICS, V1757, P1229, DOI 10.1016/j.bbabio.2006.04.010; Kunji ERS, 2004, FEBS LETT, V564, P239, DOI 10.1016/S0014-5793(04)00242-X; Lagerstedt JO, 2004, FEBS LETT, V578, P262, DOI 10.1016/j.febslet.2004.11.012; Laloi M, 1999, CELL MOL LIFE SCI, V56, P918, DOI 10.1007/s000180050484; Lundin B, 2007, BBA-BIOENERGETICS, V1767, P500, DOI 10.1016/j.bbabio.2006.10.009; MAGNUSSON RP, 1976, J BIOL CHEM, V251, P7417; McCarty RE, 2005, J BIOENERG BIOMEMBR, V37, P289, DOI 10.1007/s10863-005-8640-7; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; Millar AH, 2003, PLANT PHYSIOL, V131, P443, DOI 10.1104/pp.009985; Noren H, 2004, PHYSIOL PLANTARUM, V121, P343, DOI 10.1111/j.0031-9317.2004.00350.x; Nury H, 2006, ANNU REV BIOCHEM, V75, P713, DOI 10.1146/annurev.biochem.75.103004.142747; Palmieri L, 2006, PLANT PHYSIOL, V142, P855, DOI 10.1104/pp.106.086975; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Pottosin II, 1996, J MEMBRANE BIOL, V152, P223, DOI 10.1007/s002329900100; Rinalducci S, 2006, J PROTEOME RES, V5, P973, DOI 10.1021/pr050476n; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shingles R, 2004, PLANT PHYSIOL, V135, P145, DOI 10.1104/pp.103.037895; SMITH DJ, 1976, P NATL ACAD SCI USA, V73, P4314, DOI 10.1073/pnas.73.12.4314; Spetea C, 1999, P NATL ACAD SCI USA, V96, P6547, DOI 10.1073/pnas.96.11.6547; Spetea C, 2004, P NATL ACAD SCI USA, V101, P1409, DOI 10.1073/pnas.0308164100; Sun Q, 2004, PLANT PHYSIOL, V135, P723, DOI 10.1104/pp.104.040717; Tjaden J, 1998, J BIOL CHEM, V273, P9630, DOI 10.1074/jbc.273.16.9630; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; VAMBUTAS V, 1994, ARCH BIOCHEM BIOPHYS, V312, P401, DOI 10.1006/abbi.1994.1325; van Wijk KJ, 2004, PLANT PHYSIOL BIOCH, V42, P963, DOI 10.1016/j.plaphy.2004.10.015; van Wijk KJ, 2001, ADV PHOTOSYNTH, V11, P153; Vothknecht UC, 2001, BBA-MOL CELL RES, V1541, P91, DOI 10.1016/S0167-4889(01)00153-7; Wagner V, 2006, EUKARYOT CELL, V5, P457, DOI 10.1128/EC.5.3.457-468.2006; Weber APM, 2005, ANNU REV PLANT BIOL, V56, P133, DOI 10.1146/annurev.arplant.56.032604.144228; Winkler HH, 1999, TRENDS BIOCHEM SCI, V24, P64, DOI 10.1016/S0968-0004(98)01334-6; WINKLER HH, 1968, J BIOL CHEM, V243, P20; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	53	63	71	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8848	8859		10.1074/jbc.M609130200	http://dx.doi.org/10.1074/jbc.M609130200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17261580	hybrid, Green Published			2022-12-27	WOS:000245780300032
J	Yang, YY; Liu, Y; Dong, ZZ; Xu, JK; Peng, H; Liu, ZQ; Zhang, JT				Yang, Youyun; Liu, Yang; Dong, Zizheng; Xu, Junkang; Peng, Hui; Liu, Zhaoqian; Zhang, Jian-Ting			Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; P-GLYCOPROTEIN; LEUKOTRIENE C-4; ELECTRON-MICROSCOPY; PLASMA-MEMBRANE; EXPORT PUMP; MRP1 ABCC1; TRANSPORT; GLUTATHIONE; TOPOLOGY	Overexpression of some ATP-binding cassette (ABC) membrane transporters such as ABCB1/P-glycoprotein/MDR1 and ABCC1/MRP1 causes multidrug resistance in cancer chemotherapy. It has been thought that half-ABC transporters with one nucleotide-binding domain and one membrane-spanning domain (MSD) likely work as dimers, whereas full-length transporters with two nucleotide-binding domains and two or three MSDs function as monomers. In this study, we examined the oligomeric status of the human full-length ABC transporter ABCC1/MRP1 using several biochemical approaches. We found 1) that it is a homodimer, 2) that the dimerization domain is located in the amino-terminal MSD0L0 (where L0 is loop 0) region, and 3) that MSD0L0 has a dominant-negative function when coexpressed with wild-type ABCC1/MRP1. These findings suggest that ABCC1/MRP1 may exist and function as a dimer and that MSD0L0 likely plays some structural and regulatory functions. It is also tempting to propose that the MSD0L0-mediated dimerization may be targeted for therapeutic development to sensitize ABCC1/MRP1-mediated drug resistance in cancer chemotherapy.	Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Ctr Canc, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Canc Inst, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Ctr Canc, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015	Liu, Zhaoqian/0000-0003-0428-3928	NATIONAL CANCER INSTITUTE [R01CA094961, R01CA120221] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER; NCI NIH HHS [CA94961, CA120221] Funding Source: Medline; NHLBI NIH HHS [T32 HL07910] Funding Source: Medline; NIDDK NIH HHS [T32 DK07519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; Chen Q, 2002, BIOCHEMISTRY-US, V41, P9052, DOI 10.1021/bi025634s; Chen Q, 2006, J BIOL CHEM, V281, P31152, DOI 10.1074/jbc.M603529200; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GEORGES E, 1993, J BIOL CHEM, V268, P1792; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Han B., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P31, DOI 10.2174/1568011043482205; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hong M, 2005, J BIOL CHEM, V280, P32285, DOI 10.1074/jbc.M501447200; Ito K, 2003, BBA-BIOMEMBRANES, V1615, P103, DOI 10.1016/S0005-2736(03)00228-1; Jedlitschky G, 1996, CANCER RES, V56, P988; Jette L, 1997, BIOCHEMISTRY-US, V36, P13929, DOI 10.1021/bi970737+; Karwatsky J, 2003, BIOCHEMISTRY-US, V42, P3286, DOI 10.1021/bi0268807; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Leslie EM, 2003, BIOCHEMISTRY-US, V42, P5214, DOI 10.1021/bi027076n; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Mitic LL, 2003, PROTEIN SCI, V12, P218, DOI 10.1110/ps.0233903; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schillers H, 2004, CELL PHYSIOL BIOCHEM, V14, P1, DOI 10.1159/000076921; Soszynski M, 1998, ARCH BIOCHEM BIOPHYS, V354, P311, DOI 10.1006/abbi.1998.0687; Taylor JC, 2001, J BIOL CHEM, V276, P36075, DOI 10.1074/jbc.C100345200; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Westlake CJ, 2005, MOL BIOL CELL, V16, P2483, DOI 10.1091/mbc.E04-12-1113; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627; Zhang JT, 2000, BIOCHEM J, V348, P597, DOI 10.1042/0264-6021:3480597	47	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8821	8830		10.1074/jbc.M700152200	http://dx.doi.org/10.1074/jbc.M700152200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264072	hybrid			2022-12-27	WOS:000245780300029
J	Boura, E; Silhan, J; Herman, P; Vecer, J; Sulc, M; Teisinger, J; Obsilova, V; Obsil, T				Boura, Evzen; Silhan, Jan; Herman, Petr; Vecer, Jaroslav; Sulc, Miroslav; Teisinger, Jan; Obsilova, Veronika; Obsil, Tomas			Both the N-terminal loop and wing W2 of the forkhead domain of transcription factor FoxO4 are important for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DOUBLE-STRANDED DNA; HELIX PROTEIN; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; LIGAND-BINDING; CELL-CYCLE; FACTOR AFX; PHOSPHORYLATION	FoxO4 belongs to the "O" subset of forkhead transcription factors, which participate in various cellular processes. The forkhead DNA binding domain (DBD) consists of three-helix bundle resting on a small antiparallel beta-sheet from which two extended loops protrude and create two wing-like structures. The wing W2 of FoxO factors contains a 14-3-3 protein-binding motif that is phosphorylated by protein kinase B in response to insulin or growth factors. In this report, we investigated the role of the N-terminal loop (portion located upstream of first helix H I) and the C-terminal region (loop known as wing W2) of the forkhead domain of transcription factor FoxO4 in DNA binding. Although the deletion of either portion partly reduces the FoxO4-DBD binding to the DNA, the simultaneous deletion of both regions inhibits DNA binding significantly. Forser resonance energy transfer measurements and molecular dynamics simulations suggest that both studied N- and C-terminal regions of FoxO4-DBD directly interact with DNA. In the presence of the N-terminal loop the protein kinase B-induced phosphorylation of wing W2 by itself has negligible effect on DNA binding. On the other hand, in the absence of this loop the phosphorylation of wing W2 significantly inhibits the FoxO4-DBD binding to the DNA. The binding of the 14-3-3 protein efficiently reduces DNA-binding potential of phosphorylated FoxO4-DBD regardless of the presence of the N-terminal loop. Our results show that both N- and C-terminal regions of forkhead domain are important for stability of the FoxO4-DBD-DNA complex.	Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic; Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12843, Czech Republic; Charles Univ Prague, Inst Phys, Fac Math & Phys, CR-12116 Prague, Czech Republic; Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague, Czech Republic; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	Charles University Prague; Charles University Prague; Charles University Prague; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Obsil, T (corresponding author), Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic.	obsil@natur.cuni.cz	Sulc, Miroslav/K-1029-2014; Obsil, Tomas/B-7142-2012; Herman, Petr/A-2626-2008; Boura, Evzen/G-5275-2014; Teisinger, Jan/B-7122-2012; Boura, Evzen/I-2626-2012; Obsilova, Veronika/B-7116-2012	Sulc, Miroslav/0000-0002-2659-0489; Obsil, Tomas/0000-0003-4602-1272; Herman, Petr/0000-0001-6918-2576; Obsilova, Veronika/0000-0003-4887-0323; Boura, Evzen/0000-0002-9652-4065				Arden KC, 2004, MOL CELL, V14, P416, DOI 10.1016/S1097-2765(04)00213-8; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BIRMACHU W, 1989, BIOCHEMISTRY-US, V28, P3940, DOI 10.1021/bi00435a047; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jin CW, 1999, J MOL BIOL, V292, P641, DOI 10.1006/jmbi.1999.3106; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kaestner KH, 2000, GENE DEV, V14, P142; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kohler JJ, 2001, BIOCHEMISTRY-US, V40, P130, DOI 10.1021/bi001881p; Kovarova H, 2002, PROTEOMICS, V2, P85, DOI 10.1002/1615-9861(200201)2:1<85::AID-PROT85>3.3.CO;2-J; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; Norman DG, 2000, BIOCHEMISTRY-US, V39, P6317, DOI 10.1021/bi992944a; Obsil T, 2003, BIOCHEMISTRY-US, V42, P15264, DOI 10.1021/bi0352724; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Obsilova V, 2005, BIOCHEMISTRY-US, V44, P11608, DOI 10.1021/bi050618r; Obsilova V, 2004, J BIOL CHEM, V279, P4531, DOI 10.1074/jbc.M306939200; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Silhan J, 2004, J BIOL CHEM, V279, P49113, DOI 10.1074/jbc.M408671200; Sorin EJ, 2005, BIOPHYS J, V88, P2472, DOI 10.1529/biophysj.104.051938; SQUIER TC, 1987, J BIOL CHEM, V262, P4748; Van der Heide LP, 2005, BIOCHEM J, V391, P623, DOI 10.1042/BJ20050525; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; van Dongen MJP, 2000, J MOL BIOL, V296, P351, DOI 10.1006/jmbi.1999.3476; Weigelt J, 2001, BIOCHEMISTRY-US, V40, P5861, DOI 10.1021/bi001663w; Wolberger C, 2000, NAT STRUCT BIOL, V7, P261, DOI 10.1038/74004; Woods YL, 2002, BIOCHEM SOC T, V30, P391, DOI 10.1042/bst0300391; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	49	62	65	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8265	8275		10.1074/jbc.M605682200	http://dx.doi.org/10.1074/jbc.M605682200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17244620	hybrid			2022-12-27	WOS:000245081000059
J	Xue, ML; Campbell, D; Jackson, CJ				Xue, Meilang; Campbell, David; Jackson, Christopher J.			Protein C is an autocrine growth factor for human skin keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; EPIDERMAL DIFFERENTIATION; EXPRESSION; THROMBOMODULIN; ACTIVATION; INDUCTION; TRANSACTIVATION; PROLIFERATION; ANGIOGENESIS; INFLAMMATION	The protein C ( PC) pathway plays an important role in coagulation and inflammation. Many components of the PC pathway have been identified in epidermal keratinocytes, including endothelial protein C receptor ( EPCR), which is the specific receptor for PC/activatedPC (APC), but the core member of this pathway, PC, and its function in keratinocytes has not been defined. In this study, we reveal that PC is strongly expressed by human keratinocytes at both gene and protein levels. When endogenous PC was blocked by siRNA the proliferation of keratinocytes was significantly decreased. This inhibitory effect was restored by the addition of recombinant APC. PC siRNA treatment also increased cell apoptosis by 3-fold and inhibited cell migration by more than 20%. When keratinocytes were pretreated with RCR252, an EPCR-blocking antibody, or PD153035, an epidermal growth factor receptor (EGFR) inhibitor, cell proliferation was hindered by more than 30%. These inhibitors also completely abolished recombinant APC (10 mu g/ml)-stimulated proliferation. Blocking PC expression or inhibiting its binding to EPCR/EGFR decreased the phosphorylation of ERK1/2 but increased p38 activation. Furthermore, inhibition of ERK decreased cell proliferation by similar to 30% and completely abolished the stimulatory effect of APC on proliferation. Taken together, these results indicate that keratinocyte-derived PC promotes cell survival, growth, and migration in an autocrine manner via EPCR, EGFR, and activation of ERK1/2. Our results highlight a novel role for the PC pathway in normal skin physiology and wound healing.	Univ Sydney, Royal N Shore Hosp, Sutton Res Labs, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney	Xue, ML (corresponding author), Univ Sydney, Royal N Shore Hosp, Sutton Res Labs, Level 1,Block 4, St Leonards, NSW 2065, Australia.	mlxue@med.usyd.edu.au		Xue, Meilang/0000-0002-8563-7216; Jackson, Christopher/0000-0002-9234-9116				Artuc M, 2006, EXP DERMATOL, V15, P523, DOI 10.1111/j.1600-0625.2006.00444.x; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Dransfield DT, 2001, J INVEST DERMATOL, V117, P1588, DOI 10.1046/j.0022-202x.2001.01572.x; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Feistritzer C, 2006, J IMMUNOL, V176, P1019, DOI 10.4049/jimmunol.176.2.1019; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; Hague A, 2004, J PATHOL, V204, P175, DOI 10.1002/path.1630; Hudson LG, 1998, MICROSC RES TECHNIQ, V43, P444, DOI 10.1002/(SICI)1097-0029(19981201)43:5<444::AID-JEMT10>3.0.CO;2-C; Jackson CJ, 2005, WOUND REPAIR REGEN, V13, P284, DOI 10.1111/j.1067-1927.2005.00130311.x; JACKSON DE, 1995, J PATHOL, V175, P421, DOI 10.1002/path.1711750410; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Joyce DE, 2002, CRIT CARE MED, V30, pS288, DOI 10.1097/00003246-200205001-00019; Krajewska M, 1997, CANCER RES, V57, P1605; Krebs M, 1999, J INVEST DERMATOL, V113, P32, DOI 10.1046/j.1523-1747.1999.00644.x; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; MURAKAMI K, 1997, AM J PHYSIOL, V2, pL197; Nguyen M, 2000, J BIOL CHEM, V275, P9095, DOI 10.1074/jbc.275.13.9095; Piepkorn M, 2003, ARCH DERMATOL RES, V295, P93, DOI 10.1007/s00403-003-0391-x; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Pivarcsi A, 2003, INT IMMUNOL, V15, P721, DOI 10.1093/intimm/dxg068; Raife TJ, 1998, J INVEST MED, V46, P127; RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171; Ravanti L, 2000, INT J MOL MED, V6, P391; Rezaie AR, 2003, TRENDS CARDIOVAS MED, V13, P8, DOI 10.1016/S1050-1738(02)00191-3; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sabri A, 2002, CIRC RES, V91, P532, DOI 10.1161/01.RES.0000035242.96310.45; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; UCHIBA M, 1997, AM J HEMATOL, V2, P118; Villoutreix BO, 1999, PROTEIN ENG, V12, P833, DOI 10.1093/protein/12.10.833; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Xue ML, 2005, J INVEST DERMATOL, V125, P1279, DOI 10.1111/j.0022-202X.2005.23952.x; Xue ML, 2004, EXP CELL RES, V299, P119, DOI 10.1016/j.yexcr.2004.05.015; Yuksel M, 2002, THROMB HAEMOSTASIS, V88, P267; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	45	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13610	13616		10.1074/jbc.M610740200	http://dx.doi.org/10.1074/jbc.M610740200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17293597	hybrid			2022-12-27	WOS:000246060300050
J	Neeley, WL; Delaney, S; Alekseyev, YO; Jarosz, DF; Delaney, JC; Walker, GC; Essigmann, JM				Neeley, William L.; Delaney, Sarah; Alekseyev, Yuriy O.; Jarosz, Daniel F.; Delaney, James C.; Walker, Graham C.; Essigmann, John M.			DNA polymerase V allows bypass of toxic guanine oxidation products in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE-INDUCED REACTIONS; ESCHERICHIA-COLI; NITRIC-OXIDE; POL-II; TRANSLESION REPLICATION; POTENT SOURCES; DAMAGE; LESIONS; SPIROIMINODIHYDANTOIN; IV	Reactive oxygen and nitrogen radicals produced during metabolic processes, such as respiration and inflammation, combine with DNA to form many lesions primarily at guanine sites. Understanding the roles of the polymerases responsible for the processing of these products to mutations could illuminate molecular mechanisms that correlate oxidative stress with cancer. Using M13 viral genomes engineered to contain single DNA lesions and Escherichia coli strains with specific polymerase ( pol) knockouts, we show that pol V is required for efficient bypass of structurally diverse, highly mutagenic guanine oxidation products in vivo. We also find that pol IV participates in the bypass of two spiroiminodihydantoin lesions. Furthermore, we report that one lesion, 5-guanidino-4-nitroimidazole, is a substrate for multiple SOS polymerases, whereby pol II is necessary for error-free replication and pol V for error-prone replication past this lesion. The results spotlight a major role for pol V and minor roles for pol II and pol IV in the mechanism of guanine oxidation mutagenesis.	MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Essigmann, JM (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	jessig@mit.edu		/0000-0001-7243-8261; Alekseyev, Yuriy/0000-0001-6105-8861; Jarosz, Daniel/0000-0003-3497-5888	NATIONAL CANCER INSTITUTE [P01CA026731, R01CA080024, R01CA021615, R37CA080024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NCI NIH HHS [CA080024, R01 CA080024-09, R01 CA080024-08, CA26731, R01 CA080024, CA21615] Funding Source: Medline; NIEHS NIH HHS [P30ES02109] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al Mamun AAM, 2006, MUTAT RES-FUND MOL M, V593, P164, DOI 10.1016/j.mrfmmm.2005.07.016; Becherel OJ, 2001, P NATL ACAD SCI USA, V98, P8566, DOI 10.1073/pnas.141113398; Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; BONNER CA, 1988, J BIOL CHEM, V263, P18946; Bridges B, 2001, MUTAT RES-DNA REPAIR, V485, P61, DOI 10.1016/S0921-8777(00)00074-4; Burney S, 1999, CHEM RES TOXICOL, V12, P513, DOI 10.1021/tx980254m; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CADET J, 1994, J AM CHEM SOC, V116, P7403, DOI 10.1021/ja00095a052; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Delaney JC, 2005, NAT STRUCT MOL BIOL, V12, P855, DOI 10.1038/nsmb996; Delaney JC, 2004, P NATL ACAD SCI USA, V101, P14051, DOI 10.1073/pnas.0403489101; Duarte V, 1999, NUCLEIC ACIDS RES, V27, P496, DOI 10.1093/nar/27.2.496; Durandin A, 2006, CHEM RES TOXICOL, V19, P908, DOI 10.1021/tx060078e; ESCARCELLER M, 1994, J BACTERIOL, V176, P6221, DOI 10.1128/jb.176.20.6221-6228.1994; Finlay BB, 2006, CELL, V124, P767, DOI 10.1016/j.cell.2006.01.034; Gedik CM, 2005, FASEB J, V19, P82, DOI 10.1096/fj.04-1767fje; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gu F, 2002, BIOCHEMISTRY-US, V41, P7508, DOI 10.1021/bi020148q; Hailer MK, 2005, CHEM RES TOXICOL, V18, P1378, DOI 10.1021/tx0501379; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Henderson PT, 2005, CHEM RES TOXICOL, V18, P12, DOI 10.1021/tx049757k; Henderson PT, 2003, BIOCHEMISTRY-US, V42, P9257, DOI 10.1021/bi0347252; Henderson PT, 2002, BIOCHEMISTRY-US, V41, P914, DOI 10.1021/bi0156355; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Jarosz DF, 2006, NATURE, V439, P225, DOI 10.1038/nature04318; Jia L, 2005, BIOCHEMISTRY-US, V44, P13342, DOI 10.1021/bi050790v; Joffe A, 2003, CHEM RES TOXICOL, V16, P966, DOI 10.1021/tx025578w; Juedes MJ, 1996, MUTAT RES-FUND MOL M, V349, P51, DOI 10.1016/0027-5107(95)00152-2; Karwowski B, 2006, CHEM RES TOXICOL, V19, P1357, DOI 10.1021/tx060088f; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kornyushyna O, 2002, BIOCHEMISTRY-US, V41, P15304, DOI 10.1021/bi0264925; Kroeger KM, 2004, NUCLEIC ACIDS RES, V32, P5480, DOI 10.1093/nar/gkh873; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee CH, 2006, J MOL GRAPH MODEL, V25, P87, DOI 10.1016/j.jmgm.2005.10.009; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Luo WC, 2000, ORG LETT, V2, P613, DOI 10.1021/ol9913643; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; Maor-Shoshani A, 2003, P NATL ACAD SCI USA, V100, P14760, DOI 10.1073/pnas.2433503100; Maor-Shoshani A, 2003, DNA REPAIR, V2, P1227, DOI 10.1016/S1568-7864(03)00142-3; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; McNulty JM, 1998, CHEM RES TOXICOL, V11, P666, DOI 10.1021/tx970225w; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Neeley WL, 2006, CHEM RES TOXICOL, V19, P491, DOI 10.1021/tx0600043; Neeley WL, 2004, J BIOL CHEM, V279, P43568, DOI 10.1074/jbc.M407117200; Neeley WL, 2004, ORG LETT, V6, P245, DOI 10.1021/ol036188j; Niles JC, 2001, J AM CHEM SOC, V123, P12147, DOI 10.1021/ja004296k; Olinski R, 2002, FREE RADICAL BIO MED, V33, P192, DOI 10.1016/S0891-5849(02)00878-X; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Rangarajan S, 2002, MOL MICROBIOL, V43, P617, DOI 10.1046/j.1365-2958.2002.02747.x; Rangarajan S, 1999, P NATL ACAD SCI USA, V96, P9224, DOI 10.1073/pnas.96.16.9224; Raoul S, 1996, J AM CHEM SOC, V118, P1892, DOI 10.1021/ja952347l; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Sawa T, 2006, NITRIC OXIDE-BIOL CH, V14, P91, DOI 10.1016/j.niox.2005.06.005; Seo KY, 2006, DNA REPAIR, V5, P515, DOI 10.1016/j.dnarep.2005.12.009; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Steenken S, 2000, J AM CHEM SOC, V122, P2373, DOI 10.1021/ja993508e; Sugden KD, 2002, ENVIRON HEALTH PERSP, V110, P725, DOI 10.1289/ehp.02110s5725; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tretyakova NY, 1999, CHEM RES TOXICOL, V12, P459, DOI 10.1021/tx980235c; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wu XH, 2006, CANCER RES, V66, P748, DOI 10.1158/0008-5472.CAN-05-2884; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9	69	56	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12741	12748		10.1074/jbc.M700575200	http://dx.doi.org/10.1074/jbc.M700575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322566	hybrid			2022-12-27	WOS:000245942800044
J	De Felice, FG; Velasco, PT; Lambert, MP; Viola, K; Fernandez, SJ; Ferreira, ST; Klein, WL				De Felice, Fernanda G.; Velasco, Pauline T.; Lambert, Mary P.; Viola, Kirsten; Fernandez, Sara J.; Ferreira, Sergio T.; Klein, William L.			A beta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; CENTRAL-NERVOUS-SYSTEM; HYDROGEN-PEROXIDE; MITOCHONDRIA; MEMORY; A-BETA(1-42); AGGREGATION; TRAFFICKING; PLASTICITY; IMBALANCE	Oxidative stress is a major aspect of Alzheimer disease ( AD) pathology. We have investigated the relationship between oxidative stress and neuronal binding of A beta oligomers ( also known as ADDLs). ADDLs are known to accumulate in brain tissue of AD patients and are considered centrally related to pathogenesis. Using hippocampal neuronal cultures, we found that ADDLs stimulated excessive formation of reactive oxygen species ( ROS) through a mechanism requiring N-methyl-D-aspartate receptor ( NMDA-R) activation. ADDL binding to neurons was reduced and ROS formation was completely blocked by an antibody to the extracellular domain of the NR1 subunit of NMDA-Rs. In harmony with a steric inhibition of ADDL binding by NR1 antibodies, ADDLs that were bound to detergent-extracted synaptosomal membranes co-immunoprecipitated with NMDA-R subunits. The NR1 antibody did not affect ROS formation induced by NMDA, showing that NMDA-Rs themselves remained functional. Memantine, an open channel NMDA-R antagonist prescribed as a memory-preserving drug for AD patients, completely protected against ADDL-induced ROS formation, as did other NMDA-R antagonists. Memantine and the anti-NR1 antibody also attenuated a rapid ADDL-induced increase in intraneuronal calcium, which was essential for stimulated ROS formation. These results show that ADDLs bind to or in close proximity to NMDA-Rs, triggering neuronal damage through NMDA-R-dependent calcium flux. This response provides a pathologically specific mechanism for the therapeutic action of memantine, indicates a role for ROS dysregulation in ADDL-induced cognitive impairment, and supports the unifying hypothesis that ADDLs play a central role in AD pathogenesis.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim & Biofis Celular, BR-21944590 Rio De Janeiro, Brazil	Northwestern University; Universidade Federal do Rio de Janeiro	Ferreira, ST (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	ferreira@bioqmed.ufrj.br; wklein@northwestern.edu	Ferreira, Sergio/AAZ-1576-2020; De Felice, Fernanda G/M-1074-2017	Ferreira, Sergio/0000-0001-7160-9866; Dunne, Sara/0000-0002-0273-680X	NIA NIH HHS [R01-AG18877, R01-AG22547, R01-AG11385] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018877, R01AG011385, R01AG022547] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Aracava Y, 2005, J PHARMACOL EXP THER, V312, P1195, DOI 10.1124/jpet.104.077172; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Butterfield DA, 2005, BBA-PROTEINS PROTEOM, V1703, P149, DOI 10.1016/j.bbapap.2004.10.014; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Chang DTW, 2006, J NEUROSCI, V26, P7035, DOI 10.1523/JNEUROSCI.1012-06.2006; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; da-Silva WS, 2004, J BIOL CHEM, V279, P39846, DOI 10.1074/jbc.M403835200; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; DODD PR, 1981, BRAIN RES, V226, P107, DOI 10.1016/0006-8993(81)91086-6; Drake J, 2003, NEUROBIOL AGING, V24, P415, DOI 10.1016/S0197-4580(02)00225-7; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FISKUM G, 1985, ANN EMERG MED, V14, P810, DOI 10.1016/S0196-0644(85)80063-9; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Glaser CB, 2005, BBA-PROTEINS PROTEOM, V1703, P157, DOI 10.1016/j.bbapap.2004.10.008; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kawai H, 2002, J NEUROSCI, V22, P7903; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly BL, 2006, J BIOL CHEM, V281, P28079, DOI 10.1074/jbc.M605081200; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; Klein William L, 2006, Alzheimers Dement, V2, P43, DOI 10.1016/j.jalz.2005.11.003; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert MP, 2007, J NEUROCHEM, V100, P23, DOI 10.1111/j.1471-4159.2006.04157.x; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McShane R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003154.pub5; Moreira Paula I, 2005, Curr Alzheimer Res, V2, P403; Moreira PI, 2006, BIOL RES, V39, P7, DOI 10.4067/S0716-97602006000100002; Morris RGM, 2001, PHILOS T R SOC B, V356, P1453, DOI 10.1098/rstb.2001.0945; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; Nakazawa K, 2004, NAT REV NEUROSCI, V5, P361, DOI 10.1038/nrn1385; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Rizzuto R, 2003, J CELL BIOL, V163, P441, DOI 10.1083/jcb.200309111; Schmitt HP, 2005, MED HYPOTHESES, V65, P259, DOI 10.1016/j.mehy.2005.03.011; Schmitt HP, 2005, PSYCHOPHARMACOLOGY, V179, P151, DOI 10.1007/s00213-004-2110-5; Serrano F, 2004, AGEING RES REV, V3, P431, DOI 10.1016/j.arr.2004.05.002; Shulman RG, 2004, TRENDS NEUROSCI, V27, P489, DOI 10.1016/j.tins.2004.06.005; Skulachev VP, 2005, IUBMB LIFE, V57, P305, DOI 10.1080/15216540500092161; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; Stork CJ, 2006, J NEUROSCI, V26, P10430, DOI 10.1523/JNEUROSCI.1588-06.2006; Tabner BJ, 2005, BIOCHEM SOC T, V33, P548, DOI 10.1042/BST0330548; Thiels E, 2002, PHYSIOL BEHAV, V77, P601, DOI 10.1016/S0031-9384(02)00900-9; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wilcock GK, 2003, LANCET NEUROL, V2, P503, DOI 10.1016/S1474-4422(03)00486-1; Zhu XW, 2006, J ALZHEIMERS DIS, V9, P147; Zhu XW, 2005, MOL NEUROBIOL, V31, P205, DOI 10.1385/MN:31:1-3:205	63	686	698	0	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11590	11601		10.1074/jbc.M607483200	http://dx.doi.org/10.1074/jbc.M607483200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308309	hybrid			2022-12-27	WOS:000245941500080
J	Gal, J; Strom, AL; Kilty, R; Zhang, FJ; Zhu, HN				Gal, Jozsef; Strom, Anna-Lena; Kilty, Renee; Zhang, Fujian; Zhu, Haining			p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN P62; MOTOR-NEURON DEGENERATION; NF-KAPPA-B; PHOSPHOTYROSINE-INDEPENDENT LIGAND; MURINE PERITONEAL-MACROPHAGES; CU,ZN SUPEROXIDE-DISMUTASE; NERVE-GROWTH-FACTOR; ALS-LINKED SOD1; TRANSGENIC MICE; PROTEASOMAL INHIBITION	Amyotrophic lateral sclerosis ( ALS) is a progressive neurodegenerative disease characterized by motor neuron death. A hallmark of the disease is the appearance of protein aggregates in the affected motor neurons. We have found that p62, a protein implicated in protein aggregate formation, accumulated progressively in the G93A mouse spinal cord. The accumulation of p62 was in parallel to the increase of polyubiquitinated proteins and mutant SOD1 aggregates. Immunostaining studies showed that p62, ubiquitin, and mutant SOD1 co-localized in the protein aggregates in affected cells in G93A mouse spinal cord. The p62 protein selectively interacted with familial ALS mutants, but not WT SOD1. When p62 was co-expressed with SOD1 in NSC34 cells, it greatly enhanced the formation of aggregates of the ALS-linked SOD1 mutants, but not wild-type SOD1. Cell viability was measured in the presence and absence of overexpressed p62, and the results suggest that the large aggregates facilitated by p62 were not directly toxic to cells under the conditions in this study. Deletion of the ubiquitin-association ( UBA) domain of p62 significantly decreased the p62-facilitated aggregate formation, but did not completely inhibit it. Further protein interaction experiments also showed that the truncated p62 with the UBA domain deletion remained capable of interacting with mutant SOD1. The findings of this study show that p62 plays a critical role in forming protein aggregates in familial ALS, likely by linking misfolded mutant SOD1 molecules and other cellular proteins together.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Zhu, HN (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 741 S Limestone St, Lexington, KY 40536 USA.	haining@uky.edu	Zhu, Haining/A-6076-2008	Zhu, Haining/0000-0001-5498-6694; Gal, Jozsef/0000-0002-5865-6534	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049126] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS49126] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Fukada K, 2004, MOL CELL PROTEOMICS, V3, P1211, DOI 10.1074/mcp.M400094-MCP200; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Geetha T, 2005, EMBO J, V24, P3859, DOI 10.1038/sj.emboj.7600845; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; Hart PJ, 2006, CURR OPIN CHEM BIOL, V10, P131, DOI 10.1016/j.cbpa.2006.02.034; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; Ishii T, 1997, BIOCHEM BIOPH RES CO, V232, P33, DOI 10.1006/bbrc.1997.6221; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kabashi E, 2004, J NEUROCHEM, V89, P1325, DOI 10.1111/j.1471-4159.2004.02453.x; Kabuta T, 2006, J BIOL CHEM, V281, P30524, DOI 10.1074/jbc.M603337200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; Mizuno Y, 2006, J NEUROL SCI, V249, P13, DOI 10.1016/j.jns.2006.05.060; Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x; Nakano T, 2004, ACTA NEUROPATHOL, V107, P359, DOI 10.1007/s00401-004-0821-7; Nakaso K, 2004, BRAIN RES, V1012, P42, DOI 10.1016/j.brainres.2004.03.029; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Paine MG, 2005, FEBS LETT, V579, P5029, DOI 10.1016/j.febslet.2005.08.010; Parkinson N, 2006, NEUROLOGY, V67, P1074, DOI 10.1212/01.wnl.0000231510.89311.8b; Piao YS, 2003, BRAIN PATHOL, V13, P10; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Stieber A, 2000, J NEUROL SCI, V173, P53, DOI 10.1016/S0022-510X(99)00300-7; Stieber A, 2000, J NEUROL SCI, V177, P114, DOI 10.1016/S0022-510X(00)00351-8; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang ZY, 2005, MOL CELL NEUROSCI, V29, P222, DOI 10.1016/j.mcn.2005.02.011; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wooten MW, 2005, J BIOL CHEM, V280, P35625, DOI 10.1074/jbc.C500237200; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Zhang FJ, 2006, BBA-GEN SUBJECTS, V1760, P404, DOI 10.1016/j.bbagen.2005.11.024	50	139	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11068	11077		10.1074/jbc.M608787200	http://dx.doi.org/10.1074/jbc.M608787200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17296612	hybrid			2022-12-27	WOS:000245941500027
J	Lu, YJ; Zhang, F; Grimes, KD; Lee, RE; Rock, CO				Lu, Ying-Jie; Zhang, Fan; Grimes, Kimberly D.; Lee, Richard E.; Rock, Charles O.			Topology and active site of PlsY - The bacterial acylphosphate: Glycerol-3-phosphate acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPID-SYNTHESIS; TRANSMEMBRANE PROTEIN TOPOLOGY; SN-GLYCEROL 3-PHOSPHATE; ESCHERICHIA-COLI; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; FATTY-ACID; ATP-BINDING; TERMINAL DOMAIN; RECONSTITUTION; BIOSYNTHESIS	The most widely distributed biosynthetic pathway to initiate phosphatidic acid formation in bacterial membrane phospholipid biosynthesis involves the conversion of acyl-acyl carrier protein to acylphosphate by PlsX and the transfer of the acyl group from acylphosphate to glycerol 3-phosphate by an integral membrane protein, PlsY. The membrane topology of Streptococcus pneumoniae PlsY was determined using the substituted cysteine accessibility method. PlsY has five membrane-spanning segments with the amino terminus and two short loops located on the external face of the membrane. Each of the three larger cytoplasmic domains contains a highly conserved sequence motif. Site-directed mutagenesis revealed that each conserved domain was critical for PlsY catalysis. Motif 1 had an essential serine and arginine residue. Motif 2 had the characteristics of a phosphate-binding loop. Mutations of the conserved glycines in motif 2 to alanines resulted in a K-m defect for glycerol 3-phosphate binding leading to the conclusion that this motif corresponded to the glycerol 3-phosphate binding site. Motif 3 contained a conserved histidine and asparagine that were important for activity and a glutamate that was critical to the structural integrity of PlsY. PlsY was noncompetitively inhibited by palmitoyl-CoA. These data define the membrane architecture and the critical active site residues in the PlsY family of bacterial acyltransferases.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale, Memphis, TN 38105 USA.	charles.rock@stjude.org	Lee, Richard/J-4997-2013; Lee, Richard/AAX-3996-2021	Lee, Richard/0000-0002-2397-0443; Lee, Richard/0000-0002-2397-0443	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RM, 1975, J BIOL CHEM, V250, P7147; BELL RM, 1974, J BACTERIOL, V117, P1065, DOI 10.1128/JB.117.3.1065-1076.1974; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; Bogdanov M, 2005, METHODS, V36, P148, DOI 10.1016/j.ymeth.2004.11.002; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; GREEN PR, 1984, J BIOL CHEM, V259, P4688; GREEN PR, 1981, J BIOL CHEM, V256, P1151; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; Heath RJ, 1999, J BACTERIOL, V181, P1944, DOI 10.1128/JB.181.6.1944-1946.1999; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; LIGHTNER VA, 1983, J BIOL CHEM, V258, P856; LIGHTNER VA, 1980, J BIOL CHEM, V255, P9413; Lu YJ, 2006, MOL CELL, V23, P765, DOI 10.1016/j.molcel.2006.06.030; Lu YJ, 2006, MOL MICROBIOL, V59, P551, DOI 10.1111/j.1365-2958.2005.04951.x; Pellon-Maison M, 2006, ARCH BIOCHEM BIOPHYS, V450, P157, DOI 10.1016/j.abb.2006.03.009; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; ROCK CO, 1981, J BIOL CHEM, V256, P736; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHEIDELER MA, 1991, J BIOL CHEM, V266, P14321; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; Scholz B, 2003, NUCLEIC ACIDS RES, V31, P1426, DOI 10.1093/nar/gkg229; Schujman GE, 2003, DEV CELL, V4, P663, DOI 10.1016/S1534-5807(03)00123-0; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Zhang YM, 2006, J BIOL CHEM, V281, P107, DOI 10.1074/jbc.M508825200	34	29	33	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11339	11346		10.1074/jbc.M700374200	http://dx.doi.org/10.1074/jbc.M700374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308305	hybrid			2022-12-27	WOS:000245941500056
J	Rivera, SP; Wang, F; Saarikoski, ST; Taylor, RT; Chapman, B; Zhang, RX; Hankinson, O				Rivera, Steven P.; Wang, Feng; Saarikoski, Sirkku T.; Taylor, Robert T.; Chapman, Brett; Zhang, Ruixue; Hankinson, Oliver			A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; PROTEIN-DNA INTERACTIONS; LIGANDED AH RECEPTOR; ADULT TISSUES; BINDING; MOUSE; EXPRESSION; GENE; ENHANCER; IDENTIFICATION	Cytochrome P4502S1 (CYP2S1) is expressed at high levels in epithelial tissues and is inducible by 2,3,7,8-tetrachlorodibenzop-dioxin (dioxin) via the aryl hydrocarbon receptor (AHR). Transcriptional initiation of mouse Cyp2s1 was found to occur at three regions, similar to 198, 102, and 22 nucleotides from the translational initiation codon. Approximately 400 nucleotides upstream of its translational initiation codon, mouse Cyp2s1 contains three overlapping xenobiotic-responsive element (XRE) sequences, which make a major contribution toward dioxin inducibility. Each XRE sequence in this trimeric XRE can bind the AHR/aryl hydrocarbon receptor nuclear translocator (ARNT) dimer in a dioxin-dependent fashion in vitro and can mediate dioxin-dependent transcription. Cyp2s1 is also markedly inducible by hypoxia. Induction is dependent on hypoxiai-nducible factor-1 (HIF-1) and is mediated in large part by three overlapping hypoxia response elements (HREs) embedded within the trimeric XRE segment. Although each HRE within this segment can bind HIF-1 alpha/ ARNT in vitro, the most 3' HRE contributes the most toward hypoxia inducibility. AHR/ARNT and HIF-1 alpha/ARNT dimers bind to the region containing the trimeric XRE segment of the endogenous Cyp2s1 gene in vivo in a dioxin-dependent fashion and hypoxia-dependent fashion, respectively. These observations identify a novel regulatory cassette that mediates changes in Cyp2s1 expression.	Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Mol Toxicol Interdept Doctoral Program, Los Angeles, CA 90095 USA; Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, FI-00250 Helsinki, Finland	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Finnish Institute of Occupational Health	Hankinson, O (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, 10833 Le Conte Ave,POB 9517332, Los Angeles, CA 90095 USA.	ohank@mednet.ucla.edu			NCI NIH HHS [R01 CA028868] Funding Source: Medline; NIEHS NIH HHS [R01 ES015384] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015384] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arpiainen S, 2005, MOL PHARMACOL, V67, P1325, DOI 10.1124/mol.104.008078; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Choudhary D, 2005, ARCH BIOCHEM BIOPHYS, V436, P50, DOI 10.1016/j.abb.2005.02.001; Choudhary D, 2003, ARCH BIOCHEM BIOPHYS, V414, P91, DOI 10.1016/S0003-9861(03)00174-7; Covello KL, 2004, CURR TOP DEV BIOL, V62, P37; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; Karlgren Maria, 2005, Toxicol Appl Pharmacol, V207, P57, DOI 10.1016/j.taap.2004.12.022; Kinoshita K, 2004, NUCLEIC ACIDS RES, V32, P3169, DOI 10.1093/nar/gkh637; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; Lewis DFV, 2003, CURR MED CHEM, V10, P1955, DOI 10.2174/0929867033456855; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; PROBST MR, 1993, MOL PHARMACOL, V44, P511; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; Rylander T, 2001, BIOCHEM BIOPH RES CO, V281, P529, DOI 10.1006/bbrc.2001.4390; Saarikoski Sirkku T, 2005, Toxicol Appl Pharmacol, V207, P62, DOI 10.1016/j.taap.2004.12.027; Saarikoski ST, 2005, J HISTOCHEM CYTOCHEM, V53, P549, DOI 10.1369/jhc.4C6576.2005; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEN ES, 1992, J BIOL CHEM, V267, P6815; Smith G, 2003, LANCET, V361, P1336, DOI 10.1016/S0140-6736(03)13081-4; Stoilov I, 2001, TRENDS GENET, V17, P629, DOI 10.1016/S0168-9525(01)02444-1; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WENGER RH, 2005, SCI STKE 2005; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	35	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10881	10893		10.1074/jbc.M609617200	http://dx.doi.org/10.1074/jbc.M609617200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17277313	hybrid			2022-12-27	WOS:000245941500007
J	Baron, MJ; Filman, DJ; Prophete, GA; Hogle, JM; Madoff, LC				Baron, Miriam J.; Filman, David J.; Prophete, Gina A.; Hogle, James M.; Madoff, Lawrence C.			Identification of a glycosaminoglycan binding region of the alpha c protein that mediates entry of group B streptococci into host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; ANTIGEN GENE; INVASION; ADHERENCE; RECEPTOR; AGALACTIAE; EXPRESSION; CLEARANCE	Group B Streptococcus ( GBS) frequently colonizes the human gastrointestinal and gynecological tracts and less frequently causes deep tissue infections. The transition between colonization and infection depends upon the ability of the organism to cross epithelial barriers. The alpha C protein ( ACP) on the surface of GBS contributes to this process. A virulence factor in mouse models of infection, and prototype for a family of Gram-positive bacterial surface proteins, ACP facilitates GBS entry into human cervical epithelial cells and movement across cell layers. ACP binds to host cell surface glycosaminoglycan ( GAG). From crystallography, we have identified a cluster of basic residues ( BR2) that is a putative GAG binding area in Domain 2, near the junction of the N-terminal domain of ACP and the first of a series of tandem amino acid repeats. D2-R, a protein construct including this region, binds to cells similarly to full-length ACP. We now demonstrate that the predicted charged BR2 residues confer GAG binding; site-directed mutagenesis of these residues ( Arg(172), Arg(185), or Lys(196)) eliminates cell-binding activity of construct D2-R. In addition, we have constructed a GBS strain expressing a variant ACP with a charge-neutralizing substitution at residue 185. This strain enters host cells less effectively than does the wild-type strain and similarly to an ACP null mutant strain. The point mutant strain transcytoses similarly to the wild-type strain. These data indicate that GAG-binding activity underlies ACP-mediated cellular entry of GBS. GBS entry into host cells and transcytosis of host cells may occur by distinct mechanisms.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Baron, MJ (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	mbaron@partners.org	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504; filman, david/0000-0002-8714-1644	NIAID NIH HHS [AI059495, AI38424] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038424, K08AI059495, R56AI038424, R01AI038424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adderson EE, 2003, INFECT IMMUN, V71, P6857, DOI 10.1128/IAI.71.12.6857-6863.2003; Alberti S, 1998, MOL MICROBIOL, V28, P343, DOI 10.1046/j.1365-2958.1998.00800.x; Auperin TC, 2005, J BIOL CHEM, V280, P18245, DOI 10.1074/jbc.M412391200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baron MJ, 2004, J BIOL CHEM, V279, P24714, DOI 10.1074/jbc.M402164200; Bolduc GR, 2002, CELL MICROBIOL, V4, P751, DOI 10.1046/j.1462-5822.2002.00227.x; Brown CK, 2005, P NATL ACAD SCI USA, V102, P18391, DOI 10.1073/pnas.0504954102; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Carter WJ, 2005, J BIOL CHEM, V280, P2745, DOI 10.1074/jbc.M411606200; Cheng Q, 2002, INFECT IMMUN, V70, P6409, DOI 10.1128/IAI.70.11.6409-6415.2002; Cieslewicz MJ, 2001, J BIOL CHEM, V276, P139, DOI 10.1074/jbc.M005702200; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; Doran KS, 2002, J INFECT DIS, V185, P196, DOI 10.1086/338475; Dramsi S, 2006, MOL MICROBIOL, V60, P1401, DOI 10.1111/j.1365-2958.2006.05190.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fischer JR, 2006, INFECT IMMUN, V74, P435, DOI 10.1128/IAI.74.1.435-441.2006; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Gravekamp C, 1996, INFECT IMMUN, V64, P3576, DOI 10.1128/IAI.64.9.3576-3583.1996; Gutekunst H, 2004, INFECT IMMUN, V72, P3495, DOI 10.1128/IAI.72.6.3495-3504.2004; Henry-Stanley MJ, 2005, SHOCK, V24, P571, DOI 10.1097/01.shk.0000184286.95493.78; Kling DE, 1997, INFECT IMMUN, V65, P1462, DOI 10.1128/IAI.65.4.1462-1467.1997; LANCEFIELD RC, 1975, J EXP MED, V142, P165, DOI 10.1084/jem.142.1.165; Li J, 1997, P NATL ACAD SCI USA, V94, P13251, DOI 10.1073/pnas.94.24.13251; MADOFF LC, 1991, INFECT IMMUN, V59, P204, DOI 10.1128/IAI.59.1.204-210.1991; Madoff LC, 1996, P NATL ACAD SCI USA, V93, P4131, DOI 10.1073/pnas.93.9.4131; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paoletti LC, 1996, INFECT IMMUN, V64, P1220, DOI 10.1128/IAI.64.4.1220-1226.1996; Patrie KM, 1999, BIOCHEMISTRY-US, V38, P9264, DOI 10.1021/bi9903345; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pinheiro J. C., 2000, MIXED EFFECTS MODELS, P3, DOI DOI 10.1007/0-387-22747-4_1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Schubert A, 2004, INFECT IMMUN, V72, P6197, DOI 10.1128/IAI.72.11.6197-6205.2004; Soriani M, 2006, J INFECT DIS, V193, P241, DOI 10.1086/498982; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Tafazoli F, 2000, INFECT IMMUN, V68, P5335, DOI 10.1128/IAI.68.9.5335-5343.2000; TAMURA GS, 1994, INFECT IMMUN, V62, P2450, DOI 10.1128/IAI.62.6.2450-2458.1994; TETI G, 1987, INFECT IMMUN, V55, P3057, DOI 10.1128/IAI.55.12.3057-3064.1987; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Putten JPM, 1998, MOL MICROBIOL, V29, P369, DOI 10.1046/j.1365-2958.1998.00951.x	46	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10526	10536		10.1074/jbc.M608279200	http://dx.doi.org/10.1074/jbc.M608279200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17259175	Green Published, hybrid			2022-12-27	WOS:000245941000045
J	Dunys, J; Kawarai, T; Sevalle, J; Dolcini, V; George-Hyslop, PS; Da Costa, CA; Checler, F				Dunys, Julie; Kawarai, Toshitaka; Sevalle, Jean; Dolcini, Virginia; George-Hyslop, Peter St.; Da Costa, Cristine Alves; Checler, Frederic			p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the gamma-secretase complex but is independent of its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-SECRETASE; PRESENILIN-1 EXPRESSION; TRANSCRIPTION FACTORS; ASPARTYL PROTEASE; P53; NICASTRIN; ACTIVATION; CASPASE-3	The presenilin-dependent gamma-secretase activity, which is responsible for the generation of amyloid beta-peptide, is a high molecular weight complex composed of at least four components, namely, presenilin-1 ( or presenilin-2), nicastrin, Aph-1, and Pen-2. Previous data indicated that presenilins, which are thought to harbor the catalytic core of the complex, also control p53-dependent cell death. Whether the other components of the gamma-secretase complex could also modulate the cell death process in mammalian neurons remained to be established. Here, we examined the putative contribution of Aph-1 and Pen-2 in the control of apoptosis in TSM1 cells from a neuronal origin. We show by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and DNA fragmentation analyses that the overexpression of Aph-1a, Aph-1b, or Pen-2 drastically lowered staurosporine-induced cellular toxicity. In support of an apoptosis rather than necrosis process, Aph-1 and Pen- 2 also lower staurosporine- and etoposide-induced caspase- 3 expression and diminished caspase- 3 activity and poly( ADP-ribose) polymerase inactivation. The Aph-1 and Pen-2 anti-apoptotic phenotype was associated with a drastic reduction of p53 expression and activity and lowered p53 mRNA transcription. Furthermore, the Aph-1- and Pen-2-associated reduction of staurosporine- induced caspase- 3 activation was fully abolished by p53 deficiency. Conversely, Aph-1a, Aph-1b, and Pen-2 gene inactivation increases both caspase- 3 activity and p53 mRNA levels. Finally, we show that Aph-1 and Pen-2 did not trigger an anti-apoptotic response in cells devoid of presenilins or nicastrin, whereas the protective response was still observed in fibroblasts devoid of beta-amyloid precursor protein and amyloid precursor protein like-protein 2. Furthermore, Aph-1- and Pen-2-associated protection against staurosporine-induced caspase-3 activation was not affected by the gamma-secretase inhibitors N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S- phenylglycine t-butyl ester and difluoromethylketone. Altogether, our study indicates that Aph-1 and Pen-2 trigger an anti-apoptotic response by lowering p53-dependent control of caspase-3. Our work also demonstrates that this phenotype is strictly dependent on the molecular integrity of the gamma-secretase complex but remains independent of the gamma-secretase catalytic activity.	Fdn Rech Med, Inst Pharmacol Mol & Cellulaire, UMR 6097,Equipe Labellisee, CNRS,UNSA, F-06560 Valbonne, France; Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Toronto Western Hosp, Inst Res, Hlth Network, Toronto, ON M5S 3H2, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Da Costa, CA (corresponding author), Fdn Rech Med, Inst Pharmacol Mol & Cellulaire, UMR 6097,Equipe Labellisee, CNRS,UNSA, 660 Route Lucioles, F-06560 Valbonne, France.	acosta@ipmc.cnrs.fr; checler@ipmc.cnrs.fr	Kawarai, Toshitaka/C-2822-2013; Checler, Frederic/C-1241-2009; da Costa, Cristine Alves/G-8075-2011	Kawarai, Toshitaka/0000-0003-4547-8131; Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X				Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Beglopoulos V, 2004, J BIOL CHEM, V279, P46907, DOI 10.1074/jbc.M409544200; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Campbell WA, 2006, J NEUROCHEM, V96, P1423, DOI 10.1111/j.1471-4159.2006.03648.x; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Cregan SP, 1999, J NEUROSCI, V19, P7860; da Costa CA, 2006, J NEUROSCI, V26, P6377, DOI 10.1523/JNEUROSCI.0651-06.2006; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Decker Patrice, 2002, Current Pharmaceutical Biotechnology, V3, P275, DOI 10.2174/1389201023378265; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Dunys J, 2006, BIOCHEM J, V394, P501, DOI 10.1042/BJ20051197; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Engidawork E, 2001, NEUROSCI LETT, V303, P79, DOI 10.1016/S0304-3940(01)01618-4; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Garcia-Ospina GP, 2003, REV NEUROLOGIA, V36, P1004, DOI 10.33588/rn.3611.2002533; GINSBERG D, 1990, ONCOGENE, V5, P1285; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Heber S, 2000, J NEUROSCI, V20, P7951; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hong CS, 1999, J NEUROSCI, V19, P637; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kitamura Y, 1997, BIOCHEM BIOPH RES CO, V232, P418, DOI 10.1006/bbrc.1997.6301; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Lai MT, 2006, J NEUROCHEM, V96, P118, DOI 10.1111/j.1471-4159.2005.03528.x; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li JH, 2003, J BIOL CHEM, V278, P33445, DOI 10.1074/jbc.M301288200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marx J, 2001, SCIENCE, V293, P2192, DOI 10.1126/science.293.5538.2192; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Serneels L, 2005, P NATL ACAD SCI USA, V102, P1719, DOI 10.1073/pnas.0408901102; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xie ZC, 2004, J BIOL CHEM, V279, P34130, DOI 10.1074/jbc.M401094200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	66	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10516	10525		10.1074/jbc.M611572200	http://dx.doi.org/10.1074/jbc.M611572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17276981	hybrid			2022-12-27	WOS:000245941000044
J	Hedou, J; Cieniewski-Bernard, C; Leroy, Y; Michalski, JC; Mounier, Y; Bastide, B				Hedou, Julie; Cieniewski-Bernard, Caroline; Leroy, Yves; Michalski, Jean-Claude; Mounier, Yvonne; Bastide, Bruno			O-linked N-acetylglucosaminylation is involved in the Ca2+ activation properties of rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAINS; TIME-DEPENDENT CHANGES; RNA-POLYMERASE-II; SOLEUS MUSCLE; TROPONIN-C; HEAVY-CHAIN; CONTRACTILE PROPERTIES; CYTOPLASMIC PROTEINS; TERMINAL DOMAIN; NUCLEAR-PORE	O-Linked N-acetylglucosaminylation termed O-GlcNAc is a dynamic cytosolic and nuclear glycosylation that is dependent both on glucose flow through the hexosamine biosynthesis pathway and on phosphorylation because of the existence of a balance between phosphorylation and O-GlcNAc. This glycosylation is a ubiquitous post- translational modification, which probably plays an important role in many aspects of protein functions. We have previously reported that, in skeletal muscle, proteins of the glycolytic pathway, energetic metabolism, and contractile proteins were O-GlcNAc- modified and that O-GlcNAc variations could control the muscle protein homeostasis and be implicated in the regulation of muscular atrophy. In this paper, we report O-N-acetylglucosaminylation of a number of key contractile proteins ( i.e. myosin heavy and light chains and actin), which suggests that this glycosylation could be involved in skeletal muscle contraction. Moreover, our results showed that incubation of skeletal muscle skinned fibers in N-acetyl-D-glucosamine, in a concentration solution known to inhibit O-GlcNAc- dependent interactions, induced a decrease in calcium sensitivity and affinity of muscular fibers, whereas the cooperativity of the thin filament proteins was not modified. Thus, our results suggest that O-GlcNAc is involved in contractile protein interactions and could thereby modulate muscle contraction.	Univ Sci & Technol Lille, Lab Plast Neuromusculaire, Unite Neurosci & Physiol Adaptat, UPRES EA 4052, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, UMR Glycobiol Struct & Fonct 8576, CNRS, IFR 18, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Bastide, B (corresponding author), Univ Sci & Technol Lille, Lab Neurosci & Physiol Adaptat, EA 4052, UFR Biol, F-59655 Villeneuve Dascq, France.	bruno.bastide@univ-lille1.fr	Cieniewski-Bernard, Caroline/AAR-8967-2021; Cieniewski-Bernard, Caroline/AAK-7477-2021	Cieniewski-Bernard, Caroline/0000-0003-1449-0357; Bastide, bruno/0000-0002-7544-463X				Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Bastide B, 2002, PFLUG ARCH EUR J PHY, V444, P345, DOI 10.1007/s00424-002-0833-x; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; Bozzo C, 2003, AM J PHYSIOL-CELL PH, V285, pC575, DOI 10.1152/ajpcell.00441.2002; BRANDT PW, 1982, J GEN PHYSIOL, V79, P997, DOI 10.1085/jgp.79.6.997; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; Cieniewski-Bernard C, 2006, J APPL PHYSIOL, V100, P1499, DOI 10.1152/japplphysiol.00865.2005; Cieniewski-Bernard C, 2004, MOL CELL PROTEOMICS, V3, P577, DOI 10.1074/mcp.M400024-MCP200; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; DATTA B, 1989, J BIOL CHEM, V264, P20620; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hatsell S, 2003, J BIOL CHEM, V278, P37745, DOI 10.1074/jbc.M301346200; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kischel P, 2000, BRIT J PHARMACOL, V131, P1496, DOI 10.1038/sj.bjp.0703727; Kischel P, 2001, J APPL PHYSIOL, V90, P1095, DOI 10.1152/jappl.2001.90.3.1095; LUTHI T, 1991, J NEUROCHEM, V56, P1493; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOISESCU DG, 1979, BIOCHIM BIOPHYS ACTA, V546, P64, DOI 10.1016/0005-2728(79)90170-1; MOSS RL, 1986, J BIOL CHEM, V261, P6096; MOUNIER Y, 1989, PFLUG ARCH EUR J PHY, V415, P136, DOI 10.1007/BF00370583; MURAKAMI N, 1988, J BIOCHEM, V103, P209, DOI 10.1093/oxfordjournals.jbchem.a122249; ORENTLICHER M, 1977, AM J PHYSIOL, V233, pC127, DOI 10.1152/ajpcell.1977.233.5.C127; PERSECHINI A, 1985, J BIOL CHEM, V260, P7951; Pol-Rodriguez MM, 2001, J MUSCLE RES CELL M, V22, P513, DOI 10.1023/A:1015083616319; REISER PJ, 1988, AM J PHYSIOL, V254, pC605, DOI 10.1152/ajpcell.1988.254.5.C605; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Stevens L, 1999, AM J PHYSIOL-CELL PH, V277, pC1044, DOI 10.1152/ajpcell.1999.277.6.C1044; Stevens L, 2002, AM J PHYSIOL-CELL PH, V282, pC1025, DOI 10.1152/ajpcell.00252.2001; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; Szczesna D, 2002, J APPL PHYSIOL, V92, P1661, DOI 10.1152/japplphysiol.00858.2001; Szczesna D, 1996, J BIOL CHEM, V271, P5246; Terry M, 2006, CELL BIOCHEM BIOPHYS, V45, P265, DOI 10.1385/CBB:45:3:265; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Toursel T, 2000, EXP NEUROL, V162, P311, DOI 10.1006/exnr.1999.7349; Verbert A., 1995, METHODS GLYCOCONJUGA; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Whelan SA, 2003, CIRC RES, V93, P1047, DOI 10.1161/01.RES.0000103190.20260.37; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; XDING M, 1996, J BIOL CHEM, V271, P12555; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	58	50	50	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10360	10369		10.1074/jbc.M606787200	http://dx.doi.org/10.1074/jbc.M606787200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289664	Green Submitted, hybrid			2022-12-27	WOS:000245941000026
J	Kemp, M; Bae, B; Yu, JP; Ghosh, M; Leffak, M; Nair, SK				Kemp, Michael; Bae, Brian; Yu, John Paul; Ghosh, Maloy; Leffak, Michael; Nair, Satish K.			Structure and function of the c-myc DNA-unwinding element-binding protein DUE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AUTOMATED STRUCTURE SOLUTION; REPLICATION ORIGIN ACTIVITY; HELA-CELLS; D-TYR-TRNA(TYR) DEACYLASE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL LOCATION; DENSITY MODIFICATION; POLYMERASE-ALPHA	Local zones of easily unwound DNA are characteristic of prokaryotic and eukaryotic replication origins. The DNA-unwinding element of the human c-myc replication origin is essential for replicator activity and is a target of the DNA-unwinding element-binding protein DUE-B in vivo. We present here the 2.0 angstrom crystal structure of DUE-B and complementary biochemical characterization of its biological activity. The structure corresponds to a dimer of the N-terminal domain of the full-length protein and contains many of the structural elements of the nucleotide binding fold. A single magnesium ion resides in the putative active site cavity, which could serve to facilitate ATP hydrolytic activity of this protein. The structure also demonstrates a notable similarity to those of tRNA-editing enzymes. Consistent with this structural homology, the N-terminal core of DUE-B is shown to display both D-aminoacyl-tRNA deacylase activity and ATPase activity. We further demonstrate that the C-terminal portion of the enzyme is disordered and not essential for dimerization. However, this region is essential for DNA binding in vitro and becomes ordered in the presence of DNA.	Wright State Univ, Dept Biochem & Mol Biol, Boonshoft Sch Med, Dayton, OH 45435 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA	University System of Ohio; Wright State University Dayton; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Leffak, M (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, Boonshoft Sch Med, Dayton, OH 45435 USA.	michael.leffak@wright.edu; snair@uiuc.edu	Nair, Satish/AAY-2510-2021; Kemp, Michael G./AAT-1545-2021	Kemp, Michael G./0000-0001-8203-0745; Yu, John-Paul/0000-0003-1878-052X	NIGMS NIH HHS [GM53819] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053819] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; BERBERICH S, 1995, J MOL BIOL, V245, P92, DOI 10.1006/jmbi.1994.0010; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; Casper JM, 2005, J BIOL CHEM, V280, P13071, DOI 10.1074/jbc.M404754200; CASTROVIEJO M, 1982, BIOCHEM BIOPH RES CO, V107, P294, DOI 10.1016/0006-291X(82)91703-X; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Dwivedi S, 2005, NAT STRUCT MOL BIOL, V12, P556, DOI 10.1038/nsmb943; Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; Ghosh M, 2004, MOL CELL BIOL, V24, P10193, DOI 10.1128/MCB.24.23.10193-10207.2004; Ghosh M, 2006, MOL CELL BIOL, V26, P5270, DOI 10.1128/MCB.02137-05; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Huang RY, 1996, NUCLEIC ACIDS RES, V24, P816, DOI 10.1093/nar/24.5.816; HUANG RY, 1993, EMBO J, V12, P4521, DOI 10.1002/j.1460-2075.1993.tb06141.x; Hussain T, 2006, EMBO J, V25, P4152, DOI 10.1038/sj.emboj.7601278; Iakoucheva LM, 2001, PROTEIN SCI, V10, P560, DOI 10.1110/ps.29401; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Kemp MG, 2005, NUCLEIC ACIDS RES, V33, P325, DOI 10.1093/nar/gki177; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; LEFFAK M, 1989, MOL CELL BIOL, V9, P586, DOI 10.1128/MCB.9.2.586; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Lim K, 2003, J BIOL CHEM, V278, P13496, DOI 10.1074/jbc.M213150200; Liu GQ, 2003, MOL CELL BIOL, V23, P1832, DOI 10.1128/MCB.23.5.1832-1842.2003; Malott M, 1999, MOL CELL BIOL, V19, P5685; MCWHINNEY C, 1995, DNA CELL BIOL, V14, P565, DOI 10.1089/dna.1995.14.565; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; Mechali M, 2001, NAT REV GENET, V2, P640, DOI 10.1038/35084598; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NATALE DA, 1993, NUCLEIC ACIDS RES, V21, P555, DOI 10.1093/nar/21.3.555; Ng KKS, 2004, J BIOL CHEM, V279, P16638, DOI 10.1074/jbc.M400584200; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; RAPAPORT E, 1981, P NATL ACAD SCI-BIOL, V78, P838, DOI 10.1073/pnas.78.2.838; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Romero Pedro, 2004, Appl Bioinformatics, V3, P105, DOI 10.2165/00822942-200403020-00005; Schwob E, 2004, CURR OPIN MICROBIOL, V7, P680, DOI 10.1016/j.mib.2004.10.017; Shi L, 1998, FEMS MICROBIOL REV, V22, P229, DOI 10.1016/S0168-6445(98)00015-1; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Tao L, 2000, J CELL BIOCHEM, V78, P442, DOI 10.1002/1097-4644(20000901)78:3<442::AID-JCB9>3.0.CO;2-1; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Trivedi A, 1998, DNA CELL BIOL, V17, P885, DOI 10.1089/dna.1998.17.885; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; Waltz SE, 1996, NUCLEIC ACIDS RES, V24, P1887, DOI 10.1093/nar/24.10.1887; Wilmes GM, 2002, P NATL ACAD SCI USA, V99, P101, DOI 10.1073/pnas.012578499; Yang W, 2006, MOL CELL, V22, P5, DOI 10.1016/j.molcel.2006.03.013; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189	58	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10441	10448		10.1074/jbc.M609632200	http://dx.doi.org/10.1074/jbc.M609632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17264083	hybrid			2022-12-27	WOS:000245941000035
J	Lin, Y; Stevens, C; Hupp, T				Lin, Yao; Stevens, Craig; Hupp, Ted			Identification of a dominant negative functional domain on DAPK-1 that degrades DAPK-1 protein and stimulates TNFR-1-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; P53 POINT MUTATION; CATHEPSIN-B; TNF-ALPHA; KINASE; EXPRESSION; CHECKPOINT; MICE; TRANSCRIPTION; SUPPRESSOR	DAPK-1 is a stress-activated tumor suppressor protein that plays a role in both proapoptotic or antiapoptotic signal transduction pathways. To define mechanisms of DAPK-1 protein regulation, we have determined that DAPK-1 protein has a long half-life, and therefore its activity is primarily regulated at the protein level. Changes in DAPK-1 protein levels occur by a cathepsin B-dependent pathway, prompting us to evaluate whether cathepsin B plays positive or negative role in DAPK-1 function. The transfection of p55-TNFR-1 induced complex formation between DAPK-1 and cathepsin B. Depletion of cathepsin B protein using small interfering RNA stimulated TNFR-1 dependent apoptosis. The minimal binding region on DAPK-1 for cathepsin B was mapped to amino acids 836-947. The transfection of the DAPK-1-( 836-947) miniprotein acted in a dominant negative manner inducing endogenous DAPK-1 protein degradation in a TNFR-1-dependent manner. These data suggest that DAPK-1 forms a multiprotein survival complex with cathepsin B countering the rate of TNFR-1-dependent apoptosis and highlights the importance of developing DAPK-1 inhibitors as agents to sensitize cells to stress-induced apoptosis.	Univ Edinburgh, CRUK Signal Transduct Grp P53, Edinburgh EH4 2XR, Midlothian, Scotland	University of Edinburgh	Hupp, T (corresponding author), Univ Edinburgh, CRUK Signal Transduct Grp P53, S Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland.	ted.hupp@ed.ac.uk		, yao/0000-0002-0493-0155				Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050; Araki T, 2004, HIPPOCAMPUS, V14, P326, DOI 10.1002/hipo.10184; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bialik S, 2004, CELL DEATH DIFFER, V11, P631, DOI 10.1038/sj.cdd.4401386; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Bruins W, 2004, MOL CELL BIOL, V24, P8884, DOI 10.1128/mcb.24.20.8884-8894.2004; Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Ding WX, 2004, J CELL MOL MED, V8, P445, DOI 10.1111/j.1582-4934.2004.tb00469.x; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Finlan L, 2004, J BIOL CHEM, V279, P49395, DOI 10.1074/jbc.M405974200; Fleischer A, 2006, MOL IMMUNOL, V43, P1065, DOI 10.1016/j.molimm.2005.07.013; Gewies A, 2003, BRIT J CANCER, V89, P1574, DOI 10.1038/sj.bjc.6601297; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Henshall DC, 2004, ANN NEUROL, V55, P485, DOI 10.1002/ana.20001; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kadlcikova J, 2004, INT J EXP PATHOL, V85, P365, DOI 10.1111/j.0959-9673.2004.00405.x; Kastan MB, 2001, ACTA ONCOL, V40, P686; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Kuo JC, 2006, J CELL BIOL, V172, P619, DOI 10.1083/jcb.200505138; Landon Linda A, 2004, Curr Drug Discov Technol, V1, P113, DOI 10.2174/1570163043335108; LEVIN AJ, 2006, CELL DEATH DIFFER; Li JH, 2005, J IMMUNOL, V175, P1858, DOI 10.4049/jimmunol.175.3.1858; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; LOFFLER BM, 1989, ANAL BIOCHEM, V177, P100, DOI 10.1016/0003-2697(89)90021-3; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256; Nichols NM, 2002, BIOCHEMISTRY-US, V41, P170, DOI 10.1021/bi011736r; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Schneider-Stock R, 2006, J PATHOL, V209, P95, DOI 10.1002/path.1951; Shamloo M, 2005, J BIOL CHEM, V280, P42290, DOI 10.1074/jbc.M505804200; Shohat G, 2002, EUR CYTOKINE NETW, V13, P398; Stevens C, 2007, J BIOL CHEM, V282, P13791, DOI 10.1074/jbc.M605649200; Thoreen CC, 2005, CELL METAB, V1, P287, DOI 10.1016/j.cmet.2005.04.009; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Wethkamp N, 2006, EUR J CANCER, V42, P264, DOI 10.1016/j.ejca.2005.10.019; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	52	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16792	16802		10.1074/jbc.M611559200	http://dx.doi.org/10.1074/jbc.M611559200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17324927	hybrid			2022-12-27	WOS:000246946500011
J	Morss, AS; Edelman, ER				Morss, Alisa S.; Edelman, Elazer R.			Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; HEPARAN-SULFATE PROTEOGLYCAN; DIABETES-MELLITUS; NONENZYMATIC GLYCOSYLATION; CULTURED HUMAN; IV COLLAGEN; OVEREXPRESSION; INSULIN; LAMININ; INVITRO	The effects of glucose extremes on vascular physiology and endothelial cell function have been examined across a range of time scales. Not unexpectedly, chronic glucose exposure induces long term tissue effects. Yet short term exposure can also impose lasting consequences. The persistence of vascular pathology after euglycemic restoration further suggests a glucose exposure memory. Slow turnover reservoirs such as basement membrane are candidates for prolongation of acute events. We hypothesized that glucose-induced vascular dysfunction is related to altered vasoactive compound handling within the endothelial cell-basement membrane co-regulatory unit. Endothelial cell basement membrane-associated fibroblast growth factor-2 increased linearly with culture glucose within days of elevated glucose exposure. Surprisingly, basement membrane fibroblast growth factor-2 binding kinetics remained unchanged. The glucose- induced increase in basement membrane fibroblast growth factor-2 was instead related to enhanced endothelial cell fibroblast growth factor-2 release and permeability. Cellular fibroblast growth factor-2 release occurred concomitant with apoptosis but was not blocked by caspase inhibitors. These data suggest that release was associated with sub-lethal early apoptotic cell membrane damage, perhaps related to reactive oxygen species formation. High glucose basement membrane in turn enhanced endothelial cell proliferation in a fibroblast growth factor-2-dependent manner. We now show that glucose- induced alterations in endothelial cell function promote changes in basement membrane composition, and these changes further affect endothelial cell function. These data highlight the interrelationship of cell and basement membrane in pathological conditions such as hyperglycemia. These phenomena may explain long term effects on the endothelium of short term exposure to glucose extremes.	MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Morss, AS (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave,56-322, Cambridge, MA 02139 USA.	alisam@mit.edu	Clyne, Alisa/D-5471-2011	Clyne, Alisa/0000-0003-2462-2122; Edelman, Elazer/0000-0002-7832-7156	NHLBI NIH HHS [HL49309] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGSTAD HJ, 1994, DIABETOLOGIA, V37, P483, DOI 10.1007/s001250050136; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; BELL FP, 1974, EXP MOL PATHOL, V20, P57, DOI 10.1016/0014-4800(74)90043-4; Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437; Boullion RD, 2003, COMPARATIVE MED, V53, P42; CAGLIERO E, 1991, DIABETES, V40, P102, DOI 10.2337/diabetes.40.1.102; CARROZZA JP, 1993, ANN INTERN MED, V118, P344, DOI 10.7326/0003-4819-118-5-199303010-00004; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; COHEN MP, 1977, BIOCHIM BIOPHYS ACTA, V500, P395, DOI 10.1016/0304-4165(77)90030-7; Cowan KN, 2005, FASEB J, V19, P1848, DOI 10.1096/fj.05-3706fje; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; Gerrity RG, 2001, DIABETES, V50, P1654, DOI 10.2337/diabetes.50.7.1654; GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296; Gibbs RV, 2003, ADV EXP MED BIOL, V535, P125; GOSPODAROWICZ D, 1980, P NATL ACAD SCI-BIOL, V77, P4094, DOI 10.1073/pnas.77.7.4094; HAITOGLOU CS, 1992, J BIOL CHEM, V267, P12404; HANNEKEN A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1005, DOI 10.1001/archopht.1991.01080070117048; Hempel A, 1997, CIRC RES, V81, P363, DOI 10.1161/01.RES.81.3.363; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; LABATROBERT J, 1990, FEBS LETT, V268, P386, DOI 10.1016/0014-5793(90)81291-U; Mandal AK, 2000, KIDNEY INT, V57, P2492, DOI 10.1046/j.1523-1755.2000.00108.x; Martin A, 2003, MED RES REV, V23, P117, DOI 10.1002/med.10024; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Miao HQ, 1996, J BIOL CHEM, V271, P4879; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nissen NN, 1999, BIOCHEM J, V338, P637, DOI 10.1042/0264-6021:3380637; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Otero K, 2001, BIOCHEM J, V359, P567, DOI 10.1042/0264-6021:3590567; Roy S, 1996, INVEST OPHTH VIS SCI, V37, P258; Salameh A, 1997, J CARDIOVASC PHARM, V30, P182, DOI 10.1097/00005344-199708000-00006; SHIMOMURA H, 1987, DIABETES, V36, P374, DOI 10.2337/diabetes.36.3.374; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Tsilibary EC, 2003, J PATHOL, V200, P537, DOI 10.1002/path.1439; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Vogl-Willis CA, 2004, BBA-GEN SUBJECTS, V1672, P36, DOI 10.1016/j.bbagen.2004.02.005; WONG MKK, 1984, LAB INVEST, V51, P75	42	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14635	14644		10.1074/jbc.M608565200	http://dx.doi.org/10.1074/jbc.M608565200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17327226	hybrid			2022-12-27	WOS:000246245800077
J	Li, W; Adams, TE; Kjellberg, M; Stenflo, J; Huntington, JA				Li, Wei; Adams, Ty E.; Kjellberg, Margareta; Stenflo, Johan; Huntington, James A.			Structure of native protein C inhibitor provides insight into its multiple functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; HEPARIN-BINDING; CRYSTAL-STRUCTURE; HORMONE-BINDING; BASIC RESIDUES; ALPHA(1)-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGE; ACTIVE-SITE; SERPIN; ANTITHROMBIN	Protein C inhibitor (PCI) is a multifunctional serpin with wide ranging protease inhibitory functions, unique cofactor binding activities, and potential non-inhibitory functions akin to the hormone-transporting serpins. To gain insight into the molecular mechanisms utilized by PCI we developed a robust expression system in Escherichia coli and solved the crystal structure of PCI in its native state. The five monomers obtained from our two crystal forms provide an NMR-like ensemble revealing regions of inherent flexibility. The reactive center loop (RCL) of PCI is long and highly flexible with no evidence of hinge region incorporation into beta-sheet A, as seen for other heparin-binding serpins. We adapted an extrinsic fluorescence method for determining dissociation constants for heparin and find that the N-terminal tail of PCI and residues adjacent to helix H are not involved in heparin binding. The minimal heparin length capable of tight binding to PCI was determined to be chains of eight monosaccharide units. A large hydrophobic pocket occupied by hydrophobic crystal contacts was found in an analogous position to the hormone-binding site in thyroxine-binding globulin. In conclusion, the data presented here provide important insights into the mechanisms by which PCI exercises its multiple inhibitory and non-inhibitory functions.	Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust, Dept Haematol,Div Struct Med, Cambridge CB2 2XY, England; Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden	University of Cambridge; Wellcome Trust Sanger Institute; Lund University; Skane University Hospital	Huntington, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust, Dept Haematol,Div Struct Med, MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			Medical Research Council [G0601596, G117/444] Funding Source: Medline; MRC [G117/444, G0601596] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Dementiev A, 2003, J BIOL CHEM, V278, P37881, DOI 10.1074/jbc.M305195200; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; ECKE S, 1992, J BIOL CHEM, V267, P7048; Elisen MGLM, 1998, BLOOD, V91, P1542, DOI 10.1182/blood.V91.5.1542.1542_1542_1547; Elisen MGLM, 1996, THROMB HAEMOSTASIS, V75, P760; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Friedrich U, 2001, J BIOL CHEM, V276, P24122, DOI 10.1074/jbc.M011567200; Fujita M, 2002, THROMB RES, V105, P95, DOI 10.1016/S0049-3848(01)00398-X; Fulton KF, 2005, J BIOL CHEM, V280, P8435, DOI 10.1074/jbc.M410206200; GARG HG, 2005, CHEM BIOL HEPARIN HE, P367; Geiger M, 1996, IMMUNOPHARMACOLOGY, V32, P53, DOI 10.1016/0162-3109(96)00013-6; Geiger M, 1997, IMMUNOPHARMACOLOGY, V36, P279, DOI 10.1016/S0162-3109(97)00033-7; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Glasscock LN, 2003, BBA-PROTEINS PROTEOM, V1649, P106, DOI 10.1016/S1570-9639(03)00164-X; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; Horvath AJ, 2005, J BIOL CHEM, V280, P43168, DOI 10.1074/jbc.M505598200; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2003, STRUCTURE, V11, P205, DOI 10.1016/S0969-2126(02)00944-9; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 2006, TRENDS BIOCHEM SCI, V31, P427, DOI 10.1016/j.tibs.2006.06.005; Irving JA, 2002, BIOCHEMISTRY-US, V41, P4998, DOI 10.1021/bi0159985; Jerabek I, 2001, EUR J BIOCHEM, V268, P5989, DOI 10.1046/j.0014-2956.2001.02560.x; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2006, EMBO J, V25, P2029, DOI 10.1038/sj.emboj.7601089; Johnson DJD, 2006, J BIOL CHEM, V281, P35478, DOI 10.1074/jbc.M607204200; Komiyama T, 1996, PROTEIN SCI, V5, P874; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; Langdown J, 2006, FEBS LETT, V580, P4709, DOI 10.1016/j.febslet.2006.07.057; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Meagher JL, 2000, J BIOL CHEM, V275, P2698, DOI 10.1074/jbc.275.4.2698; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neese LL, 1998, ARCH BIOCHEM BIOPHYS, V355, P101, DOI 10.1006/abbi.1998.0716; Nishioka J, 1998, J BIOL CHEM, V273, P11281, DOI 10.1074/jbc.273.18.11281; O'Keeffe D, 2004, J BIOL CHEM, V279, P50267, DOI 10.1074/jbc.M408774200; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PRATT CW, 1992, J BIOL CHEM, V267, P8789; PRENDESGARCIA MJ, 2001, J THROMB HAEM    JUL; Rehault SM, 2005, BBA-PROTEINS PROTEOM, V1748, P57, DOI 10.1016/j.bbapap.2004.12.003; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shen L, 1999, THROMB HAEMOSTASIS, V82, P72, DOI 10.1055/s-0037-1614632; SHIRK RA, 1994, J BIOL CHEM, V269, P28690; Suda SA, 2000, ARCH BIOCHEM BIOPHYS, V384, P31, DOI 10.1006/abbi.2000.2110; SUZUKI K, 1983, J BIOL CHEM, V258, P163; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r; Zhou AW, 2006, P NATL ACAD SCI USA, V103, P13321, DOI 10.1073/pnas.0604080103	58	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13759	13768		10.1074/jbc.M701074200	http://dx.doi.org/10.1074/jbc.M701074200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337440	hybrid			2022-12-27	WOS:000246060300066
J	Shao, BM; Lu, MF; Katz, SC; Varley, AW; Hardwick, J; Rogers, TE; Ojogun, N; Rockey, DC; DeMatteo, RP; Munford, RS				Shao, Baomei; Lu, Mingfang; Katz, Steven C.; Varley, Alan W.; Hardwick, John; Rogers, Thomas E.; Ojogun, Noredia; Rockey, Donald C.; DeMatteo, Ronald P.; Munford, Robert S.			A host lipase detoxifies bacterial lipopolysaccharides in the liver and spleen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM LIPOPOLYSACCHARIDES; RAT KUPFFER CELLS; SINUSOIDAL ENDOTHELIAL-CELLS; GUT-DERIVED ENDOTOXINS; ACYLOXYACYL HYDROLASE; ESCHERICHIA-COLI; LEUKOCYTE ENZYME; GENE-EXPRESSION; LIPID-A; HUMAN-NEUTROPHILS	Much of the inflammatory response of the body to bloodborne Gram-negative bacteria occurs in the liver and spleen, the major organs that remove these bacteria and their lipopolysaccharide (LPS, endotoxin) from the bloodstream. We show here that LPS undergoes deacylation in the liver and spleen by acyloxyacyl hydrolase (AOAH), an endogenous lipase that selectively removes the secondary fatty acyl chains that are required for LPS recognition by its mammalian signaling receptor, MD-2-TLR4. We further show that Kupffer cells produce AOAH and are required for hepatic LPS deacylation in vivo. AOAH-deficient mice did not deacylate LPS and, whereas their inflammatory responses to low doses of LPS were similar to those of wild type mice for similar to 3 days after LPS challenge, they subsequently developed pronounced hepatosplenomegaly. Providing recombinant AOAH restored LPS deacylating ability to Aoah(-/-)mice and prevented LPS-induced hepatomegaly. AOAH-mediated deacylation is a previously unappreciated mechanism that prevents prolonged inflammatory reactions to Gram-negative bacteria and LPS in the liver and spleen.	Univ Texas, Southwestern Med Sch, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, Southwestern Med Sch, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, Southwestern Med Sch, Dept Pathol, Dallas, TX 75390 USA; Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, New York, NY 10021 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Memorial Sloan Kettering Cancer Center	Munford, RS (corresponding author), Univ Texas, Southwestern Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Robert.munford@utsouthwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI018188, R37AI018188, R01AI018188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068346] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI018188, AI18188] Funding Source: Medline; NIDDK NIH HHS [R01 DK068346, DK068346] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER PJ, 1992, INFECT IMMUN, V60, P2694, DOI 10.1128/IAI.60.7.2694-2701.1992; BAKER PJ, 1994, INFECT IMMUN, V62, P2257, DOI 10.1128/IAI.62.6.2257-2269.1994; BEESON PB, 1947, J EXP MED, V86, P39, DOI 10.1084/jem.86.1.39; BENACERRAF B, 1959, J EXP MED, V110, P27, DOI 10.1084/jem.110.1.27; Bentala H, 2002, SHOCK, V18, P561, DOI 10.1097/00024382-200212000-00013; Beumer C, 2003, J PHARMACOL EXP THER, V307, P737, DOI 10.1124/jpet.103.056606; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; CHENSUE SW, 1991, AM J PATHOL, V138, P395; Choi S, 2005, CURR OPIN GASTROEN, V21, P702, DOI 10.1097/01.mog.0000182863.96421.47; Cody MJ, 1997, J ENDOTOXIN RES, V4, P371, DOI 10.1177/096805199700400509; Coulthard MG, 1996, INFECT IMMUN, V64, P1510, DOI 10.1128/IAI.64.5.1510-1515.1996; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; Enomoto N, 2000, J GASTROEN HEPATOL, V15, pD20; FARRAR WE, 1966, ANN NY ACAD SCI, V133, P668, DOI 10.1111/j.1749-6632.1966.tb52397.x; Feulner JA, 2004, INFECT IMMUN, V72, P3171, DOI 10.1128/IAI.72.6.3171-3178.2004; FONG YM, 1990, J CLIN INVEST, V85, P1896, DOI 10.1172/JCI114651; FOX ES, 1989, GASTROENTEROLOGY, V96, P456, DOI 10.1016/0016-5085(89)91571-0; FOX ES, 1988, HEPATOLOGY, V8, P1550, DOI 10.1002/hep.1840080613; FREUDENBERG MA, 1985, EUR J BIOCHEM, V152, P353, DOI 10.1111/j.1432-1033.1985.tb09205.x; FUKUDA I, 1989, BRIT J EXP PATHOL, V70, P267; GE YM, 1994, J INFECT DIS, V169, P95, DOI 10.1093/infdis/169.1.95; GOLENBOCK DT, 1990, FASEB J, V4, pA2055; Gong JP, 2002, WORLD J GASTROENTERO, V8, P551, DOI 10.3748/wjg.v8.i3.551; Gregory SH, 1998, IMMUNOL TODAY, V19, P507, DOI 10.1016/S0167-5699(98)01319-X; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; HALL CL, 1983, P NATL ACAD SCI-BIOL, V80, P6671, DOI 10.1073/pnas.80.21.6671; Hurt M, 2003, INFECT IMMUN, V71, P6243, DOI 10.1128/IAI.71.11.6243-6255.2003; Katz SC, 2004, J IMMUNOL, V173, P230, DOI 10.4049/jimmunol.173.1.230; Katz SS, 1999, J BIOL CHEM, V274, P36579, DOI 10.1074/jbc.274.51.36579; Koyama I, 2002, CLIN BIOCHEM, V35, P455, DOI 10.1016/S0009-9120(02)00330-2; Liu SB, 2002, INFECT IMMUN, V70, P3433, DOI 10.1128/IAI.70.7.3433-3442.2002; Lu MF, 2005, NAT IMMUNOL, V6, P989, DOI 10.1038/ni1246; Lu MF, 2003, J EXP MED, V197, P1745, DOI 10.1084/jem.20030420; LUCHI M, 1993, J IMMUNOL, V151, P959; LUSTER MI, 1994, HEPATOLOGY, V19, P480; MATHISON JC, 1979, J IMMUNOL, V123, P2133; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Munford RS, 2006, PLOS PATHOG, V2, P467, DOI 10.1371/journal.ppat.0020067; Munford RS, 2005, J ENDOTOXIN RES, V11, P69, DOI 10.1179/096805105X35161; MUNFORD RS, 1978, GASTROENTEROLOGY, V75, P532; MUNFORD RS, 1992, METHOD ENZYMOL, V209, P485; MUNFORD RS, 1992, J BIOL CHEM, V267, P10116; MUNFORD RS, 1980, J BACTERIOL, V144, P630, DOI 10.1128/JB.144.2.630-640.1980; MUNFORD RS, 1989, J BIOL CHEM, V264, P15613; MUNFORD RS, 1982, J CLIN INVEST, V70, P877, DOI 10.1172/JCI110684; Nagy LE, 2003, EXP BIOL MED, V228, P882, DOI 10.1177/153537020322800803; NOLAN JP, 1989, HEPATOLOGY, V10, P887, DOI 10.1002/hep.1840100523; NOLAN JP, 1981, HEPATOLOGY, V1, P458, DOI 10.1002/hep.1840010516; O'Brien GC, 2005, J IMMUNOL, V174, P1020, DOI 10.4049/jimmunol.174.2.1020; Paik YH, 2003, HEPATOLOGY, V37, P1043, DOI 10.1053/jhep.2003.50182; Park SJ, 2006, J IMMUNOL, V176, P2538, DOI 10.4049/jimmunol.176.4.2538; Pillarisetty VG, 2004, J IMMUNOL, V172, P1009, DOI 10.4049/jimmunol.172.2.1009; Poltorak A, 2000, J ENDOTOXIN RES, V6, P51, DOI 10.1177/09680519000060010701; Su GL, 2002, AM J PHYSIOL-GASTR L, V283, pG256, DOI 10.1152/ajpgi.00550.2001; Tacke F, 2006, IMMUNOBIOLOGY, V211, P609, DOI 10.1016/j.imbio.2006.05.025; VANBOSSUYT H, 1989, VIRCHOWS ARCH B, V58, P89; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	59	71	76	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13726	13735		10.1074/jbc.M609462200	http://dx.doi.org/10.1074/jbc.M609462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17322564	hybrid			2022-12-27	WOS:000246060300062
J	Hines, JK; Fromm, HJ; Honzatko, RB				Hines, Justin K.; Fromm, Herbert J.; Honzatko, Richard B.			Structures of activated fructose-1,6-bisphosphatase from Escherichia coli - Coordinate regulation of bacterial metabolism and the conservation of the R-state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE-BISPHOSPHATASE; CRYSTAL-STRUCTURE; EXPRESSION; AMP; PURIFICATION; INHIBITION; MECHANISM; ENZYME; LIVER; GENE	The enteric bacterium Escherichia coli requires fructose-1,6-bisphosphatase ( FBPase) for growth on gluconeogenic carbon sources. Constitutive expression of FBPase and fructose-6-phosphate-1-kinase coupled with the absence of futile cycling implies an undetermined mechanism of coordinate regulation involving both enzymes. Tricarboxylic acids and phosphorylated three-carbon carboxylic acids, all intermediates of glycolysis and the tricarboxylic acid cycle, are shown here to activate E. coli FBPase. The two most potent activators, phosphoenolpyruvate and citrate, bind to the sulfate anion site, revealed previously in the first crystal structure of the E. coli enzyme. Tetramers ligated with either phosphoenolpyruvate or citrate, in contrast to the sulfate-bound structure, are in the canonical R-state of porcine FBPase but nevertheless retain sterically blocked AMP pockets. At physiologically relevant concentrations, phosphoenolpyruvate and citrate stabilize an active tetramer over a less active enzyme form of mass comparable with that of a dimer. The above implies the conservation of the R-state through evolution. FBPases of heterotrophic organisms of distantly related phylogenetic groups retain residues of the allosteric activator site and in those instances where data are available exhibit activation by phosphoenolpyruvate. Findings here unify disparate observations regarding bacterial FBPases, implicating a mechanism of feed-forward activation in bacterial central metabolism.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, 4206 Mol Biol Bldg, Ames, IA 50011 USA.	honzatko@iastate.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546, R01 NS010546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; CHAMBOST JP, 1980, J BIOL CHEM, V255, P2867; CHIN AM, 1989, J BACTERIOL, V171, P2424, DOI 10.1128/jb.171.5.2424-2434.1989; CHIN AM, 1987, J BACTERIOL, V169, P897, DOI 10.1128/jb.169.2.897-899.1987; Choe JY, 2003, J BIOL CHEM, V278, P51176, DOI 10.1074/jbc.M308396200; DALDAL F, 1983, J BACTERIOL, V153, P390, DOI 10.1128/JB.153.1.390-394.1983; Donahue JL, 2000, J BACTERIOL, V182, P5624, DOI 10.1128/JB.182.19.5624-5627.2000; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS P, 1992, MRC LAB MOL BIOL; FRAENKEL DG, 1966, ARCH BIOCHEM BIOPHYS, V114, P4, DOI 10.1016/0003-9861(66)90298-0; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Fujita Y, 1998, J BACTERIOL, V180, P4309, DOI 10.1128/JB.180.16.4309-4313.1998; FUJITA Y, 1979, J BIOL CHEM, V254, P5340; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hines JK, 2006, J BIOL CHEM, V281, P18386, DOI 10.1074/jbc.M602553200; Iancu CV, 2006, BIOCHEMISTRY-US, V45, P11703, DOI 10.1021/bi0607498; Iancu CV, 2005, J BIOL CHEM, V280, P19737, DOI 10.1074/jbc.M501011200; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; Kelley-Loughnane N, 2002, BBA-PROTEIN STRUCT M, V1594, P6, DOI 10.1016/S0167-4838(01)00261-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; Lu GQ, 1997, J BIOL CHEM, V272, P5076, DOI 10.1074/jbc.272.8.5076; MARCUS F, 1984, BIOCHEM BIOPH RES CO, V119, P1103, DOI 10.1016/0006-291X(84)90888-X; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Movahedzadeh F, 2004, MICROBIOL-SGM, V150, P3499, DOI 10.1099/mic.0.27204-0; Naderer T, 2006, P NATL ACAD SCI USA, V103, P5502, DOI 10.1073/pnas.0509196103; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson SW, 2002, J BIOL CHEM, V277, P15539, DOI 10.1074/jbc.M112304200; Nelson SW, 2001, FEBS LETT, V492, P254, DOI 10.1016/S0014-5793(01)02262-1; Nishimasu H, 2004, STRUCTURE, V12, P949, DOI 10.1016/j.str.2004.03.026; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; OPHEIM DJ, 1975, J BIOL CHEM, V250, P3024; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; RAMSEIER TM, 1995, MOL MICROBIOL, V16, P1157, DOI 10.1111/j.1365-2958.1995.tb02339.x; REEVES RE, 1973, BIOCHEM BIOPH RES CO, V50, P459, DOI 10.1016/0006-291X(73)90862-0; Rittmann D, 2003, ARCH MICROBIOL, V180, P285, DOI 10.1007/s00203-003-0588-6; Sato T, 2004, J BACTERIOL, V186, P5799, DOI 10.1128/JB.186.17.5799-5807.2004; SEDIVY JM, 1986, P NATL ACAD SCI USA, V83, P1656, DOI 10.1073/pnas.83.6.1656; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Stec B, 2000, NAT STRUCT BIOL, V7, P1046, DOI 10.1038/80968; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yanez AJ, 2003, J CELL PHYSIOL, V197, P189, DOI 10.1002/jcp.10337; YOSHIDA M, 1973, J BIOCHEM-TOKYO, V74, P1183, DOI 10.1093/oxfordjournals.jbchem.a130346; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	58	25	26	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11696	11704		10.1074/jbc.M611104200	http://dx.doi.org/10.1074/jbc.M611104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314096	hybrid			2022-12-27	WOS:000245941900011
J	Mukrasch, MD; von Bergen, M; Biernat, J; Fischer, D; Griesinger, C; Mandelkow, E; Zweckstetter, M				Mukrasch, Marco D.; von Bergen, Martin; Biernat, Jacek; Fischer, Daniela; Griesinger, Christian; Mandelkow, Eckhard; Zweckstetter, Markus			The "jaws" of the Tau-microtubule interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; RESIDUAL DIPOLAR COUPLINGS; ALZHEIMERS-DISEASE BRAIN; BETA-STRUCTURE; PROTEIN-TAU; RANDOM COIL; CHEMICAL-SHIFTS; ALPHA-SYNUCLEIN; IN-VITRO; LIMITED PROTEOLYSIS	Tau is the major microtubule-associated protein in neuronal axons. It aggregates into "neurofibrillary tangles" during the course of Alzheimer disease. Binding to microtubules and microtubule assembly requires the "repeat domain" in the C-terminal half of Tau, as well as the two regions flanking the repeats. Here we report the NMR characterization of a 198-residue Tau fragment composed of the four tandem repeats and the flanking domains and containing the full microtubule binding and assembly activity of Tau. NMR secondary chemical shifts and dipolar couplings detect the highest propensity for beta-structure within the four-repeat region, whereas the flanking domains are largely random coil, with an increased rigidity in the proline-rich region. Chemical shift perturbation experiments identify two motifs in the upstream flanking domain, (225)KVAVVRT(231) and (243)LQTA(246), and one downstream of the repeats, (KIETHKTFREN380)-K-370, which strongly contribute to the binding to the acidic outside of microtubules, as well as to the binding of other polyanions such as heparin. This is consistent with the "jaws" model of Tau-microtubule interactions and highlights the importance of the regions flanking the repeats for both microtubule binding and pathological Tau aggregation.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Max Planck Society; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Zweckstetter, M (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	mzwecks@gwdg.de	von Bergen, Martin/D-7960-2011	von Bergen, Martin/0000-0003-2732-2977; Zweckstetter, Markus/0000-0002-2536-6581				Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Barghorn S, 2004, BIOCHEMISTRY-US, V43, P1694, DOI 10.1021/bi0357006; Barre P, 2006, J MOL BIOL, V362, P312, DOI 10.1016/j.jmb.2006.07.018; Bernado P, 2005, J AM CHEM SOC, V127, P17968, DOI 10.1021/ja055538p; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bielska AA, 2006, BIOCHEMISTRY-US, V45, P5527, DOI 10.1021/bi052662c; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Bussell R, 2001, J BIOL CHEM, V276, P45996, DOI 10.1074/jbc.M106777200; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Craik D J, 1997, Methods Mol Biol, V60, P195; Delacourte Andre, 2000, Current Opinion in Neurology, V13, P371, DOI 10.1097/00019052-200008000-00002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeTure MA, 2002, J BIOL CHEM, V277, P34755, DOI 10.1074/jbc.M201201200; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Eliezer D, 2005, BIOCHEMISTRY-US, V44, P1026, DOI 10.1021/bi048953n; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fischer D, 2007, BIOCHEMISTRY-US, V46, P2574, DOI 10.1021/bi061318s; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Inouye H, 2006, BIOPHYS J, V90, P1774, DOI 10.1529/biophysj.105.070136; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones JA, 1996, J MAGN RESON SER B, V113, P25, DOI 10.1006/jmrb.1996.0151; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; Landrieu I, 2006, J AM CHEM SOC, V128, P3575, DOI 10.1021/ja054656+; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Louhivuori M, 2003, J AM CHEM SOC, V125, P15647, DOI 10.1021/ja035427v; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Mukrasch MD, 2005, J BIOL CHEM, V280, P24978, DOI 10.1074/jbc.M501565200; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; Pawar AP, 2005, J MOL BIOL, V350, P379, DOI 10.1016/j.jmb.2005.04.016; Perez M, 1996, J NEUROCHEM, V67, P1183; Preuss U, 1997, J CELL SCI, V110, P789; Quijano FAR, 2006, BIOCHEMISTRY-US, V45, P4638, DOI 10.1021/bi052226q; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; Sibille N, 2006, BIOCHEMISTRY-US, V45, P12560, DOI 10.1021/bi060964o; Smet C, 2004, BIOCHEMISTRY-US, V43, P2032, DOI 10.1021/bi035479x; Smet C, 2004, CHEMBIOCHEM, V5, P1639, DOI 10.1002/cbic.200400145; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tokimasa M, 2005, FEBS LETT, V579, P3481, DOI 10.1016/j.febslet.2005.05.020; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, MOL BIOL CELL, V11, p363A; von Bergen M, 2005, BBA-MOL BASIS DIS, V1739, P158, DOI 10.1016/j.bbadis.2004.09.010; von Bergen M, 2006, BIOCHEMISTRY-US, V45, P6446, DOI 10.1021/bi052530j; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1994, METHOD ENZYMOL, V239, P363	62	136	138	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12230	12239		10.1074/jbc.M607159200	http://dx.doi.org/10.1074/jbc.M607159200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17307736	Green Published, hybrid			2022-12-27	WOS:000245941900066
J	Sheppard, K; Akochy, PM; Salazar, JC; Soll, D				Sheppard, Kelly; Akochy, Pierre-Marie; Salazar, Juan C.; Soell, Dieter			The Helicobacter pylori amidotransferase GatCAB is equally efficient in glutamine-dependent transamidation of Asp-tRNA(Asn) and Glu-tRNA(Gln)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ASPARAGINYL-TRANSFER-RNA; LYS CATALYTIC TRIAD; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GENETIC-CODE; BIOSYNTHESIS; MECHANISM	The amide aminoacyl-tRNAs, Gln-tRNA(Gln) and Asn-tRNA(Asn), are formed in many bacteria by a pretranslational tRNA-dependent amidation of the mischarged tRNA species, GlutRNA(Gln) or Asp-tRNA(Asn). This conversion is catalyzed by a heterotrimeric amidotransferase GatCAB in the presence of ATP and an amide donor ( Gln or Asn). Helicobacter pylori has a single GatCAB enzyme required in vivo for both Gln-tRNA(Gln) and Asn-tRNA(Asn) synthesis. In vitro characterization reveals that the enzyme transamidates Asp-tRNA(Asn) and Glu-tRNA(Gln) with similar efficiency ( k(cat/)K(m) of 1368.4 s(-1)/mM and 3059.3 s(-1)/mM respectively). The essential glutaminase activity of the enzyme is a property of the A-subunit, which displays the characteristic amidase signature sequence. Mutations of the GatA catalytic triad residues ( Lys(52), Ser(128), Ser(152)) abolished glutaminase activity and consequently the amidotransferase activity with glutamine as the amide donor. However, the latter activity was rescued when the mutant enzymes were presented with ammonium chloride. The presence of Asp-tRNA(Asn) and ATP enhances the glutaminase activity about 22-fold. H. pylori GatCAB uses the amide donor glutamine 129-fold more efficiently than asparagine, suggesting that GatCAB is a glutamine-dependent amidotransferase much like the unrelated asparagine synthetase B. Genomic analysis suggests that most bacteria synthesize asparagine in a glutamine-dependent manner, either by a tRNA-dependent or in a tRNA-independent route. However, all known bacteria that contain asparagine synthetase A form Asn-tRNA(Asn) by direct acylation catalyzed by asparaginyl-tRNA synthetase. Therefore, bacterial amide aminoacyl-tRNA formation is intimately tied to amide amino acid metabolism.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.	dieter.soll@yale.edu	Garrido, Juan Carlos Salazar/H-2672-2017; Salazar, Juan/D-9368-2014	Garrido, Juan Carlos Salazar/0000-0002-2096-2050; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022854, R01GM022854] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22854] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akochy PM, 2004, J BACTERIOL, V186, P767, DOI 10.1128/JB.186.3.767-776.2004; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bailly M, 2006, NUCLEIC ACIDS RES, V34, P6083, DOI 10.1093/nar/gkl622; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Bullock TL, 2003, J MOL BIOL, V328, P395, DOI 10.1016/S0022-2836(03)00305-X; Cathopoulis TJT, 2007, ANAL BIOCHEM, V360, P151, DOI 10.1016/j.ab.2006.10.019; CEDAR H, 1969, J BIOL CHEM, V244, P4112; CEDAR H, 1969, J BIOL CHEM, V244, P4122; Chuawong P, 2006, BIOCHEMISTRY-US, V45, P8079, DOI 10.1021/bi060189c; Cummings L, 2002, FEMS MICROBIOL LETT, V216, P133, DOI 10.1016/S0378-1097(02)00955-2; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Feng L, 2005, J BIOL CHEM, V280, P8150, DOI 10.1074/jbc.M411098200; Fresquet V, 2004, BIOORG CHEM, V32, P63, DOI 10.1016/j.bioorg.2003.10.002; GATTI DL, 1991, J MOL BIOL, V218, P557, DOI 10.1016/0022-2836(91)90701-7; Harpel MR, 2002, BIOCHEMISTRY-US, V41, P6398, DOI 10.1021/bi012126u; Horiuchi KY, 2001, BIOCHEMISTRY-US, V40, P6450, DOI 10.1021/bi002599l; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404; JAHN D, 1990, J BIOL CHEM, V265, P8059; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; McKinney MK, 2003, J BIOL CHEM, V278, P37393, DOI 10.1074/jbc.M303922200; MILMAN HA, 1979, BIOCHEM J, V181, P51, DOI 10.1042/bj1810051; Min B, 2002, P NATL ACAD SCI USA, V99, P2678, DOI 10.1073/pnas.012027399; Nakamura A, 2006, SCIENCE, V312, P1954, DOI 10.1126/science.1127156; Nakatsu T, 1998, NAT STRUCT BIOL, V5, P15, DOI 10.1038/nsb0198-15; Narngoong S, 2007, FEBS LETT, V581, P309, DOI 10.1016/j.febslet.2006.12.033; Oshikane H, 2006, SCIENCE, V312, P1950, DOI 10.1126/science.1128470; Raczniak G, 2001, J BIOL CHEM, V276, P45862, DOI 10.1074/jbc.M109494200; Roy H, 2003, P NATL ACAD SCI USA, V100, P9837, DOI 10.1073/pnas.1632156100; Salazar JC, 2003, P NATL ACAD SCI USA, V100, P13863, DOI 10.1073/pnas.1936123100; Schmitt E, 2005, STRUCTURE, V13, P1421, DOI 10.1016/j.str.2005.06.016; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; Schulze JO, 2006, J MOL BIOL, V361, P888, DOI 10.1016/j.jmb.2006.06.054; Shin S, 2002, EMBO J, V21, P2509, DOI 10.1093/emboj/21.11.2509; Shin S, 2003, J BIOL CHEM, V278, P24937, DOI 10.1074/jbc.M302156200; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; TEMPEST DW, 1970, J GEN MICROBIOL, V64, P171, DOI 10.1099/00221287-64-2-171; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; WILCOX M, 1969, EUR J BIOCHEM, V11, P405, DOI 10.1111/j.1432-1033.1969.tb00788.x; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; WILCOX M, 1969, COLD SPRING HARB SYM, V34, P521, DOI 10.1101/SQB.1969.034.01.059; Wolf YI, 1999, GENOME RES, V9, P689; Wolfson AD, 1998, RNA, V4, P1019, DOI 10.1017/S1355838298980700	46	46	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11866	11873		10.1074/jbc.M700398200	http://dx.doi.org/10.1074/jbc.M700398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329242	hybrid			2022-12-27	WOS:000245941900029
J	Im, HJ; Muddasani, P; Natarajan, V; Schmid, TM; Block, JA; Davis, F; van Wijnen, AJ; Loeser, RF				Im, Hee-Jeong; Muddasani, Prasuna; Natarajan, Viswanathan; Schmid, Thomas M.; Block, Joel A.; Davis, Francesca; van Wijnen, Andre J.; Loeser, Richard F.			Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase C delta pathways in human adult articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; RECEPTOR TYROSINE KINASES; FACTOR-KAPPA-B; GENE-EXPRESSION; RHEUMATOID-ARTHRITIS; FACTOR-I; OSTEOARTHRITIC CARTILAGE; INTERLEUKIN-8 SECRETION; OSTEOGENIC PROTEIN-1; PROMOTER ACTIVITY	Excessive release of basic fibroblast growth factor ( bFGF) during loading and/or injury of the cartilage matrix may contribute to the onset or progression of osteoarthritis. This pathological role may be related to the ability of bFGF to decrease proteoglycan synthesis and to antagonize the activity of anabolic growth factors in cartilage such as insulin-like growth factor-1 and bone morphogenetic protein 7 ( BMP7 or OP-1). Matrix metalloproteinase-13 ( MMP-13), a catabolic cartilage-degrading enzyme, is dramatically up-regulated by inflammatory cytokines or by fibronectin fragments in articular chondrocytes. In this study, we investigated MMP-13 production by bFGF using human articular chondrocytes. Endogenous concentration of bFGF in synovial fluids collected from arthritis patients and asymptomatic subjects showed a good linear correlation with the endogenous levels of MMP-13. bFGF stimulation of MMP-13 was mediated at the transcriptional level and, at least in part, by stimulation of interleukin-1 production. Also, our findings suggest that bFGF stimulation of MMP-13 required the activation of multiple MAPKs ( ERK, p38, and JNK) by bFGF, and more importantly, bFGF activation of protein kinase C ( PKC) delta played a key role in the MMP-13 stimulation. Indeed, PKC delta is the only isoform associated with MMP-13 stimulation among the PKC isoforms tested. PKC delta controls the bFGF response by regulating multiple MAPK pathways. Our results suggest that PKC delta activation is a principal rate-limiting event in the bFGF-dependent stimulation of MMP-13 in human adult articular chondrocytes. We propose that deregulation of cross-talk between MAPK and PKC delta signaling may contribute to the etiology of osteoarthritis in human patients.	Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Wake Forest Univ, Dept Internal Med, Sect Mol Med, Winston Salem, NC 27157 USA	Rush University; Rush University; Rush University; University of Chicago; University of Massachusetts System; University of Massachusetts Worcester; Wake Forest University	Im, HJ (corresponding author), Rush Univ, Med Ctr, Dept Biochem, Cohn Res Bldg 516,1735 W Harrison, Chicago, IL 60612 USA.	Hee-Jeong_Sampen@rush.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946; Block, Joel/0000-0002-0330-7353	NIAMS NIH HHS [R01 AR053220-04, R01 AR049069, R37 AR049003, R01 AR049003, AR053220, AR49003, R01 AR053220] Funding Source: Medline; BLRD VA [I01 BX002647] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053220, R37AR049003, R01AR049069, R01AR049003] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002647] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); BLRD VA; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Veterans Affairs(US Department of Veterans Affairs)		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Bluteau G, 2002, BIORHEOLOGY, V39, P247; Boileau C, 2006, ANN RHEUM DIS, V65, P573, DOI 10.1136/ard.2005.041855; Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x; Carreras I, 2001, AM J PHYSIOL-LUNG C, V281, pL766, DOI 10.1152/ajplung.2001.281.4.L766; COLLINS DH, 1949, OSTEOARTHRITIS PATHO, P74; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; Daouti S, 2005, OSTEOARTHR CARTILAGE, V13, P508, DOI 10.1016/j.joca.2005.02.003; Davidson D, 2005, J BIOL CHEM, V280, P20509, DOI 10.1074/jbc.M410148200; Desai S, 2001, MATRIX BIOL, V20, P233, DOI 10.1016/S0945-053X(01)00140-8; Ellsworth JL, 2002, OSTEOARTHR CARTILAGE, V10, P308, DOI 10.1053/joca.2002.0514; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Iannone F, 2003, AGING CLIN EXP RES, V15, P364, DOI 10.1007/BF03327357; Im HJ, 2003, J BIOL CHEM, V278, P25386, DOI 10.1074/jbc.M302048200; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KEYSZER GM, 1995, J RHEUMATOL, V22, P275; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; Li TF, 2004, EXP CELL RES, V300, P159, DOI 10.1016/j.yexcr.2004.06.019; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Loeser RF, 2005, ARTHRITIS RHEUM-US, V52, P3910, DOI 10.1002/art.21472; Loeser RF, 2005, ARTHRITIS RHEUM, V52, P2376, DOI 10.1002/art.21199; Loeser RF, 2003, J BIOL CHEM, V278, P24577, DOI 10.1074/jbc.M304530200; Lohmander L Stefan, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS49; Manicourt DH, 2000, ARTHRITIS RHEUM, V43, P281, DOI 10.1002/1529-0131(200002)43:2<281::AID-ANR7>3.0.CO;2-7; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; MIDDLETON JFS, 1992, ANN RHEUM DIS, V51, P440, DOI 10.1136/ard.51.4.440; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Nedvetzki S, 2003, J CLIN INVEST, V111, P1211, DOI 10.1172/JCI200317100; Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564; NICOLE BW, 1999, BIOCHEM J, V342, P677; Orito Keisuke, 2003, J Orthop Sci, V8, P294, DOI 10.1007/s10776-003-0647-6; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pelletier JP, 2003, ARTHRITIS RHEUM-US, V48, P1582, DOI 10.1002/art.11014; Pendas AM, 2000, CLIN CHIM ACTA, V291, P137, DOI 10.1016/S0009-8981(99)00225-9; Pulai JI, 2005, J IMMUNOL, V174, P5781, DOI 10.4049/jimmunol.174.9.5781; QU ZH, 1995, LAB INVEST, V73, P339; Quintavalla J, 2005, J CELL PHYSIOL, V204, P560, DOI 10.1002/jcp.20345; Radons J, 2006, INT J MOL MED, V17, P661; Salminen HJ, 2002, ANN RHEUM DIS, V61, P591, DOI 10.1136/ard.61.7.591; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Sharaki Ola A, 2004, Egypt J Immunol, V11, P91; Shida J, 2001, J ORTHOPAED RES, V19, P259, DOI 10.1016/S0736-0266(00)90009-3; Smeets TJM, 2003, ANN RHEUM DIS, V62, P635, DOI 10.1136/ard.62.7.635; Starkman BG, 2005, BIOCHEM J, V389, P723, DOI 10.1042/BJ20041636; Tchetina EV, 2005, J RHEUMATOL, V32, P876; Valverde-Franco G, 2006, HUM MOL GENET, V15, P1783, DOI 10.1093/hmg/ddl100; van den Berg WB, 2001, CURR OPIN RHEUMATOL, V13, P452, DOI 10.1097/00002281-200109000-00019; Vincent T, 2002, P NATL ACAD SCI USA, V99, P8259, DOI 10.1073/pnas.122033199; Vincent TL, 2004, ARTHRITIS RHEUM, V50, P526, DOI 10.1002/art.20047; Wang XB, 2004, OSTEOARTHR CARTILAGE, V12, P963, DOI 10.1016/j.joca.2004.08.008; Yang GG, 2005, GENE, V363, P166, DOI 10.1016/j.gene.2005.08.006; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200	58	135	145	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11110	11121		10.1074/jbc.M609040200	http://dx.doi.org/10.1074/jbc.M609040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311929	Green Accepted, hybrid			2022-12-27	WOS:000245941500032
J	Kim, J; Temple, KA; Jones, SA; Meredith, KN; Basko, JL; Brady, MJ				Kim, Jaime; Temple, Karla A.; Jones, Sara A.; Meredith, Kimberly N.; Basko, Juliana L.; Brady, Matthew J.			Differential modulation of 3T3-L1 adipogenesis mediated by 11 beta-hydroxysteroid dehydrogenase-1 levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE STROMAL CELLS; CORTISOL METABOLISM; GLYCOGEN-SYNTHASE; VISCERAL OBESITY; TARGET-CELLS; TYPE-1; TISSUE; ADIPOCYTES; EXPRESSION; ISOFORM	The localized activation of circulating glucocorticoids in vivo by the enzyme 11 beta-hydroxysteroid dehydrogenase type 1 ( 11 beta-HSD1) plays a critical role in the development of the metabolic syndrome. However, the precise contribution of 11 beta-HSD1 in the initiation of adipogenesis by inactive glucocorticoids is not fully understood. 3T3-L1 fibroblasts can be terminally differentiated to mature adipocytes in a glucocorticoid-dependent manner. Both inactive rodent dehydrocorticosterone and human cortisone were able to substitute for the synthetic glucocorticoid dexamethasone in 3T3-L1 adipogenesis, suggesting a potential role for 11 beta-HSD1 in these effects. Differentiation of 3T3-L1 cells caused a strong increase in 11 beta-HSD1 protein levels, which occurred late in the differentiation protocol. Reduction of 11 beta-HSD1 activity in 3T3-L1 fibroblasts, achieved by pharmacological inhibition or adenovirally mediated delivery of short hairpin RNA constructs, specifically blocked the ability of inactive glucocorticoids to drive 3T3-L1 differentiation. However, even modest increases in exogenous 11 beta-HSD1 expression in 3T3-L1 fibroblasts, to levels comparable with endogenous 11 beta-HSD1 in differentiated 3T3-L1 adipocytes, were sufficient to block adipogenesis. Luciferase reporter assays indicated that overexpressed 11 beta-HSD1 was catalyzing the inactivating dehydrogenase reaction, because the ability of both active and inactive glucocorticoids to activate the glucocorticoid receptor were largely suppressed. These results suggest that the temporal regulation of 11 beta-HSD1 expression is tightly controlled in 3T3-L1 cells, so as to mediate the initiation of differentiation by inactive glucocorticoids and also to prevent the inhibitory activity of prematurely expressed 11 beta-HSD1 during adipogenesis.	Univ Chicago, Dept Med, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA; Univ Chicago, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Brady, MJ (corresponding author), MC1027,5841 S Maryland Ave, Chicago, IL 60637 USA.	mbrady@medicine.bsd.uchicago.edu			NHLBI NIH HHS [T32HL007909] Funding Source: Medline; NIDDK NIH HHS [P60DK020595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; Agarwal AK, 2003, ENDOCR RES, V29, P411, DOI 10.1081/ERC-120026947; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, P11; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; Bujalska IJ, 1999, ENDOCRINOLOGY, V140, P3188, DOI 10.1210/en.140.7.3188; Bujalska IJ, 2002, J CLIN ENDOCR METAB, V87, P1205, DOI 10.1210/jc.87.3.1205; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; Greenberg CC, 2006, MOL CELL BIOL, V26, P334, DOI 10.1128/MCB.26.1.334-342.2006; Greenberg CC, 2003, J BIOL CHEM, V278, P30835, DOI 10.1074/jbc.M303846200; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hautanen A, 1997, J INTERN MED, V241, P451; Hirasawa G, 1997, J CLIN ENDOCR METAB, V82, P3859, DOI 10.1210/jc.82.11.3859; Jamieson PM, 1999, J STEROID BIOCHEM, V68, P245, DOI 10.1016/S0960-0760(99)00037-0; Kershaw EE, 2005, DIABETES, V54, P1023, DOI 10.2337/diabetes.54.4.1023; KOTELEVTSEV Y, 1997, P NATL ACAD SCI USA, V94, P14929; LAKSHMI V, 1985, ENDOCRINOLOGY, V116, P552, DOI 10.1210/endo-116-2-552; Lavery GG, 2006, J BIOL CHEM, V281, P6546, DOI 10.1074/jbc.M512635200; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; Morton NM, 2001, J BIOL CHEM, V276, P41293, DOI 10.1074/jbc.M103676200; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; Paterson JM, 2004, P NATL ACAD SCI USA, V101, P7088, DOI 10.1073/pnas.0305524101; Paulmyer-Lacroix O, 2002, J CLIN ENDOCR METAB, V87, P2701, DOI 10.1210/jc.87.6.2701; Peeke PM, 1995, ANN NY ACAD SCI, V771, P665, DOI 10.1111/j.1749-6632.1995.tb44719.x; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; Rask E, 2002, J CLIN ENDOCR METAB, V87, P3330, DOI 10.1210/jc.87.7.3330; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; SCHADINGER SE, 2005, AM J PHYSIOL, V28, pR1195; SCHTEINGART DE, 2001, PRINCIPLES PRACTICE, P723; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Shimojo M, 1997, ENDOCRINOLOGY, V138, P1305, DOI 10.1210/en.138.3.1305; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; WHORWOOD CB, 1994, ENDOCRINOLOGY, V135, P2533, DOI 10.1210/en.135.6.2533; WHORWOOD CB, 1995, MOL CELL ENDOCRINOL, V110, pR7, DOI 10.1016/0303-7207(95)03546-J; Williams LJS, 2000, J BIOL CHEM, V275, P30232, DOI 10.1074/jbc.M001286200; Wu ZD, 1996, MOL CELL BIOL, V16, P4128	45	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11038	11046		10.1074/jbc.M606197200	http://dx.doi.org/10.1074/jbc.M606197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311922	hybrid			2022-12-27	WOS:000245941500024
J	Reddick, LE; Vaughn, MD; Wright, SJ; Campbell, IM; Bruce, BD				Reddick, L. Evan; Vaughn, Michael D.; Wright, Sarah J.; Campbell, Ian M.; Bruce, Barry D.			In vitro comparative kinetic analysis of the chloroplast toc GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT RECEPTOR; TRANSITION-STATE ANALOG; OUTER ENVELOPE; PREPROTEIN RECEPTOR; ANALYTICAL ULTRACENTRIFUGATION; PRECURSOR PROTEINS; NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GTP-HYDROLYSIS	A unique aspect of protein transport into plastids is the coordinate involvement of two GTPases in the translocon of the outer chloroplast membrane ( Toc). There are two subfamilies in Arabidopsis, the small GTPases ( Toc33 and Toc34) and the large acidic GTPases ( Toc90, Toc120, Toc132, and Toc159). In chloroplasts, Toc34 and Toc159 are implicated in precursor binding, yet mechanistic details are poorly understood. How the GTPase cycle is modulated by precursor binding is complex and in need of careful dissection. To this end, we have developed novel in vitro assays to quantitate nucleotide binding and hydrolysis of the Toc GTPases. Here we present the first systematic kinetic characterization of four Toc GTPases ( cytosolic domains of at Toc33, atToc34, psToc34, and the GTPase domain of at Toc159) to permit their direct comparison. We report the K-M, V-max, and E-a values for GTP hydrolysis and the K-d value for nucleotide binding for each protein. We demonstrate that GTP hydrolysis by psToc34 is stimulated by chloroplast transit peptides; however, this activity is not stimulated by homodimerization and is abolished by the R133A mutation. Furthermore, we show peptide stimulation of hydrolytic rates are not because of accelerated nucleotide exchange, indicating that transit peptides function as GTPase-activating proteins and not guanine nucleotide exchange factors in modulating the activity of psToc34. Finally, by using the psToc34 structure, we have developed molecular models for atToc33, atToc34, and at Toc159G. By combining these models with the measured enzymatic properties of the Toc GTPases, we provide new insights of how the chloroplast protein import cycle may be regulated.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Dept Bot, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Environm Biotechnol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville	Bruce, BD (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA.	bbruce@utk.edu	Wright, Sarah/J-6763-2012; Vaughn, Michael D/A-3908-2010	Wright, Sarah/0000-0002-1502-131X; Vaughn, Michael D/0000-0001-9357-094X; Campbell, Ian/0000-0002-3749-2884				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Aronsson H, 2006, FEBS LETT, V580, P649, DOI 10.1016/j.febslet.2005.12.055; Aronsson H, 2003, FEBS LETT, V544, P79, DOI 10.1016/S0014-5793(03)00478-2; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Becker T, 2004, EMBO J, V23, P520, DOI 10.1038/sj.emboj.7600089; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brown PH, 2006, BIOPHYS J, V90, P4651, DOI 10.1529/biophysj.106.081372; Bruce BD, 2000, TRENDS CELL BIOL, V10, P440, DOI 10.1016/S0962-8924(00)01833-X; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Chen KH, 2000, PLANT PHYSIOL, V122, P813, DOI 10.1104/pp.122.3.813; Dabney-Smith C, 1999, J BIOL CHEM, V274, P32351, DOI 10.1074/jbc.274.45.32351; Dam J, 2004, METHOD ENZYMOL, V384, P185; Dolezal P, 2006, SCIENCE, V313, P314, DOI 10.1126/science.1127895; Evdokimov AG, 2002, PROTEIN SCI, V11, P401, DOI 10.1110/ps.34102; Graham DL, 2002, CHEM BIOL, V9, P375, DOI 10.1016/S1074-5521(02)00112-6; Gutensohn M, 2000, PLANT J, V23, P771, DOI 10.1046/j.1365-313x.2000.00849.x; Harding MM, 2004, ACTA CRYSTALLOGR D, V60, P849, DOI 10.1107/S0907444904004081; Heinig M, 2004, NUCLEIC ACIDS RES, V32, pW500, DOI 10.1093/nar/gkh429; Hiltbrunner A, 2004, PLANT MOL BIOL, V54, P427, DOI 10.1023/B:PLAN.0000036374.92546.51; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; HUMPHRIES D, 2004, 56017 LAWR BERK NAT, P1; Ivey RA, 2000, PLANT PHYSIOL, V122, P1289, DOI 10.1104/pp.122.4.1289; Jelic M, 2003, BIOCHEMISTRY-US, V42, P5906, DOI 10.1021/bi034001q; Jelic M, 2002, BIOL CHEM, V383, P1875, DOI 10.1515/BC.2002.211; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; Kessler F, 2002, NAT STRUCT BIOL, V9, P81, DOI 10.1038/nsb0202-81; Kikuchi S, 2006, PLANT CELL PHYSIOL, V47, P363, DOI 10.1093/pcp/pcj002; Kosloff M, 2003, J MOL BIOL, V331, P1157, DOI 10.1016/S0022-2836(03)00847-7; Kubis S, 2004, PLANT CELL, V16, P2059, DOI 10.1105/tpc.104.023309; Kubis S, 2003, PLANT CELL, V15, P1859, DOI 10.1105/tpc.012955; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Litvak Y, 2003, TRENDS BIOCHEM SCI, V28, P628, DOI 10.1016/j.tibs.2003.10.001; Liu X, 2003, J BIOL CHEM, V278, P50061, DOI 10.1074/jbc.M309997200; Lu G, 2005, P NATL ACAD SCI USA, V102, P17969, DOI 10.1073/pnas.0506039102; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Moberg P, 2003, PLANT J, V36, P616, DOI 10.1046/j.1365-313X.2003.01904.x; Muto T, 2001, J MOL BIOL, V306, P137, DOI 10.1006/jmbi.2000.4397; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Pan XJ, 2006, NATURE, V442, P303, DOI 10.1038/nature04847; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; RAIMO G, 1995, J BIOL CHEM, V270, P21082, DOI 10.1074/jbc.270.36.21082; Reumann S, 1999, P NATL ACAD SCI USA, V96, P784, DOI 10.1073/pnas.96.2.784; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Roberts E, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-382; Rudhe C, 2002, PLANT J, V30, P213, DOI 10.1046/j.1365-313X.2002.01280.x; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; Schleiff E, 2002, BIOCHEMISTRY-US, V41, P1934, DOI 10.1021/bi011361+; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schweins T, 1997, J MOL BIOL, V266, P847, DOI 10.1006/jmbi.1996.0814; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Silva-Filho MC, 1996, PLANT MOL BIOL, V30, P769, DOI 10.1007/BF00019010; Smith MD, 2004, J CELL BIOL, V165, P323, DOI 10.1083/jcb.200311074; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; Sreerama N, 1999, PROTEIN SCI, V8, P370; Sun YJ, 2002, NAT STRUCT BIOL, V9, P95, DOI 10.1038/nsb744; Sveshnikova N, 2000, BIOL CHEM, V381, P687, DOI 10.1515/BC.2000.089; Sveshnikova N, 2000, P NATL ACAD SCI USA, V97, P4973, DOI 10.1073/pnas.080491597; Wallas TR, 2003, J BIOL CHEM, V278, P44289, DOI 10.1074/jbc.M307873200; Weibel P, 2003, J BIOL CHEM, V278, P37321, DOI 10.1074/jbc.M305946200; Wurtele M, 2001, NAT STRUCT BIOL, V8, P23	68	36	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11410	11426		10.1074/jbc.M609491200	http://dx.doi.org/10.1074/jbc.M609491200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17261588	hybrid			2022-12-27	WOS:000245941500063
J	Seth, A; Sheth, P; Elias, BC; Rao, R				Seth, Ankur; Sheth, Parimal; Elias, Bertha C.; Rao, Radhakrishna			Protein phosphatases 2A and 1 interact with occludin and negatively regulate the assembly of tight junctions in the CACO-2 cell monolayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; OXIDATIVE STRESS; EPITHELIAL-CELLS; POSSIBLE INVOLVEMENT; HYDROGEN-PEROXIDE; LOCALIZATION; PERMEABILITY; INHIBITION; DISRUPTION	Occludin is hyperphosphorylated on Ser and Thr residues in intact epithelial tight junction ( TJ); however, the role of this phosphorylation in the assembly of TJ is unclear. The influence of protein phosphatases PP2A and PP1 on the assembly of TJ and phosphorylation of occludin was evaluated in Caco-2 cells. Protein phosphatase inhibitors and reduced expression of PP2A-C alpha and PP1 alpha accelerated the calcium-induced increase in transepithelial electrical resistance and barrier to inulin permeability and also enhanced the junctional organization of occludin and ZO-1 during TJ assembly. Phosphorylation of occludin on Thr residues, but not on Ser residues, was dramatically reduced during the disassembly of TJ and was gradually increased during the reassembly. PP2A and PP1 co-immunoprecipitate with occludin, and this association was reduced during the assembly of TJ. Glutathione S-transferase ( GST) pull-down assay using recombinant GST-occludin demonstrated that cellular PP2A and PP1 bind to the C-terminal tail of occludin, and these interactions were also reduced during the assembly of TJ. Apairwise binding assay using GST- occludin and purified PP2A and PP1 demonstrates that PP2A and PP1 directly interacts with the C-terminal tail of occludin. In vitro incubation of phospho- occludin with PP2A or PP1 indicated that PP2A dephosphorylates occludin on phospho- Thr residues, whereas PP1 dephosphorylates it on phospho- Ser. This study shows that PP2A and PP1 directly interact with occludin and negatively regulate the assembly of TJ by modulating the phosphorylation status of occludin.	Univ Tennessee, Dept Physiol, Hlth Sci Ctr, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, R (corresponding author), Univ Tennessee, Dept Physiol, Hlth Sci Ctr, 894 Union Ave, Memphis, TN 38163 USA.	rkrao@physio1.utmem.edu	Seth, Ankur/AAE-1800-2020	Seth, Ankur/0000-0003-0140-4691	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012307] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA012307, R01-AA12307] Funding Source: Medline; NIDDK NIH HHS [R01 DK055532, R01-DK55532] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Andreeva AY, 2001, J BIOL CHEM, V276, P38480, DOI 10.1074/jbc.M104923200; Basuroy S, 2006, BIOCHEM J, V393, P69, DOI 10.1042/BJ20050959; Basuroy S, 2003, J BIOL CHEM, V278, P11916, DOI 10.1074/jbc.M211710200; Chen YH, 2002, MOL BIOL CELL, V13, P1227, DOI 10.1091/mbc.01-08-0423; Clarke H, 2000, J CELL SCI, V113, P3187; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Farshori P, 1999, J MEMBRANE BIOL, V170, P147, DOI 10.1007/s002329900544; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200; HOLLANDER D, 1994, GUT, V26, P1621; Kale G, 2003, BIOCHEM BIOPH RES CO, V302, P324, DOI 10.1016/S0006-291X(03)00167-0; Lee DBN, 2006, AM J PHYSIOL-RENAL, V290, pF20, DOI 10.1152/ajprenal.00052.2005; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matthay MA, 2002, CHEST, V122, p340S, DOI 10.1378/chest.122.6_suppl.340S; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rao RK, 1997, AM J PHYSIOL-GASTR L, V273, pG812, DOI 10.1152/ajpgi.1997.273.4.G812; Rao RK, 2000, AM J PHYSIOL-GASTR L, V279, pG332, DOI 10.1152/ajpgi.2000.279.2.G332; Ries J, 1997, AM J PHYSIOL-CELL PH, V272, pC794, DOI 10.1152/ajpcell.1997.272.3.C794; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Sheth P, 2003, J BIOL CHEM, V278, P49239, DOI 10.1074/jbc.M305654200; Simonovic I, 2000, CELL MICROBIOL, V2, P305, DOI 10.1046/j.1462-5822.2000.00055.x; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859	32	140	146	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11487	11498		10.1074/jbc.M610597200	http://dx.doi.org/10.1074/jbc.M610597200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17298946	hybrid			2022-12-27	WOS:000245941500070
J	Willmund, F; Muhlhaus, T; Wojciechowska, M; Schroda, M				Willmund, Felix; Muehlhaus, Timo; Wojciechowska, Maria; Schroda, Michael			The NH2-terminal domain of the chloroplast GrpE homolog CGE1 is required for dimerization and cochaperone function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; DNAK CHAPERONE SYSTEM; ESCHERICHIA-COLI; CHLAMYDOMONAS-REINHARDTII; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; HSP70 CHAPERONES; ATPASE DOMAIN; PROTEIN; SUBSTRATE	GrpE proteins function as nucleotide exchange factors for DnaK-type Hsp70s. We have previously identified a chloroplast homolog of GrpE in Chlamydomonas reinhardtii, termed CGE1. CGE1 exists as two isoforms, CGE1a and CGE1b, which are generated by temperature-dependent alternative splicing. CGE1b contains additional valine and glutamine residues in its extreme NH2-terminal region. Here we show that CGE1a is predominant at lower temperatures but that CGE1b becomes as abundant as CGE1a at elevated temperatures. Coimmunoprecipitation experiments revealed that CGE1b had a similar to 25% higher affinity for its chloroplast chaperone partner HSP70B than CGE1a. Modeling of the structure of CGE1b revealed that the extended alpha-helix formed by GrpE NH2 termini is 34 amino acids longer in CGE1 than in Escherichia coli GrpE and appears to contain a coiled coil motif. Progressive deletions of this coiled coil increasingly impaired the ability of CGE1 to form dimers, to interact with DnaK at elevated temperatures, and to complement temperature-sensitive growth of a Delta grpE E. coli strain. In contrast, deletion of the four-helix bundle required for dimerization of E. coli GrpE did not affect CGE1 dimer formation. Circular dichroism measurements revealed that CGE1, like GrpE, undergoes two thermal transitions, the first of which is in the physiologically relevant temperature range ( midpoint similar to 45 degrees C). Truncating the NH2-terminal coiled coil shifted the second transition to lower temperatures, whereas removal of the four- helix bundle abolished the first transition. Our data suggest that bacterial GrpE and chloroplast CGE1 share similar structural and biochemical properties, but some of these, like dimerization, are realized by different domains.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	University of Freiburg	Schroda, M (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	michael.schroda@biologie.uni-freiburg.de	Schroda, Michael/A-2651-2015	Schroda, Michael/0000-0001-6872-0483; Muhlhaus, Timo/0000-0003-3925-6778; Willmund, Felix/0000-0002-3988-4590				Borges JC, 2003, J BIOL CHEM, V278, P35337, DOI 10.1074/jbc.M305083200; Brehmer D, 2004, J BIOL CHEM, V279, P27957, DOI 10.1074/jbc.M403558200; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chesnokova LS, 2003, BIOCHEMISTRY-US, V42, P9028, DOI 10.1021/bi0346493; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; Deloche O, 1997, J BACTERIOL, V179, P6066, DOI 10.1128/jb.179.19.6066-6075.1997; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Drzymalla C, 1996, PLANT MOL BIOL, V31, P1185, DOI 10.1007/BF00040835; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; Grimshaw JPA, 2003, J BIOL CHEM, V278, P19048, DOI 10.1074/jbc.M300924200; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V305, P1173, DOI 10.1006/jmbi.2000.4373; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P26; Harrison C, 2003, CELL STRESS CHAPERON, V8, P218, DOI 10.1379/1466-1268(2003)008<0218:GANEFF>2.0.CO;2; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LEMAIRE C, 1989, J BIOL CHEM, V264, P10235; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIU C, 2007, IN PRESS PLANT J; Liu CM, 2005, MOL BIOL CELL, V16, P1165, DOI 10.1091/mbc.E04-08-0736; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Mehl AF, 2003, PROTEIN SCI, V12, P1205, DOI 10.1110/ps.0300803; Mehl AF, 2001, BIOCHEM BIOPH RES CO, V282, P562, DOI 10.1006/bbrc.2001.4567; Moro F, 2006, J MOL BIOL, V358, P1367, DOI 10.1016/j.jmb.2006.03.027; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schmidt M, 2006, PLANT CELL, V18, P1908, DOI 10.1105/tpc.106.041749; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schroda M, 2004, PHOTOSYNTH RES, V82, P221, DOI 10.1007/s11120-004-2216-y; Schroda M, 1999, PLANT CELL, V11, P1165, DOI 10.1105/tpc.11.6.1165; Schroda M, 2001, PLANT CELL, V13, P2823, DOI 10.1105/tpc.010202; Sichting M, 2005, EMBO J, V24, P1046, DOI 10.1038/sj.emboj.7600580; Siegenthaler RK, 2005, J BIOL CHEM, V280, P14395, DOI 10.1074/jbc.M413803200; Whitby FG, 2000, PROTEINS, V38, P49; Willmund F, 2005, PLANT PHYSIOL, V138, P2310, DOI 10.1104/pp.105.063578	42	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11317	11328		10.1074/jbc.M608854200	http://dx.doi.org/10.1074/jbc.M608854200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17289679	hybrid			2022-12-27	WOS:000245941500054
J	Haffner, C; Dettmer, U; Weiler, T; Haass, C				Haffner, Christof; Dettmer, Ulf; Weiler, Timotheus; Haass, Christian			The nicastrin-like protein nicalin regulates assembly and stability of the nicalin-nodal modulator (NOMO) membrane protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; GAMMA-SECRETASE CLEAVAGE; BETA-APP; VERTEBRATE DEVELOPMENT; APH-1; PEN-2; ACCUMULATION; TRAFFICKING; MATURATION; RECEPTOR	The assembly of the gamma-secretase complex, an Alzheimer disease-related protease required for beta-amyloid generation, is tightly regulated and predominantly limited by the stoichiometrical availability of its components. We have identified a novel endoplasmic reticulum-located protein complex that is regulated in a similar fashion. It contains the recently identified Nodal signaling antagonists Nicalin ( a distant homolog of the gamma-secretase component Nicastrin) and NOMO ( Nodal modulator). Using an RNA interference approach, we found that Nicalin and NOMO became unstable in the absence of the respective binding partner, suggesting that complex formation has a stabilizing effect. Overexpression of Nicalin resulted in an increase in NOMO, whereas endogenous Nicalin was reduced below the detection limit. Both effects were shown to occur at a post-transcriptional level. Thus, NOMO is most likely produced in excess amounts and either stabilized by Nicalin or rapidly degraded. In contrast, Nicalin levels are limited independently of NOMO. We, therefore, propose that Nicalin controls the assembly and stability of the Nicalin-NOMO complex.	Univ Munich, Dept Biochem, Lab Neurodegenerat Dis Res, D-80336 Munich, Germany; Univ Munich, Ctr Integrated Prot Sci, D-80336 Munich, Germany	University of Munich; University of Munich	Haffner, C (corresponding author), Univ Munich, Dept Biochem, Lab Neurodegenerat Dis Res, Schillerstr 44, D-80336 Munich, Germany.	chaffner@med.uni-muenchen.de	Haffner, Christof/AAG-6676-2020	Dettmer, Ulf/0000-0001-6676-0107				Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Haffner C, 2004, EMBO J, V23, P3041, DOI 10.1038/sj.emboj.7600307; Haffner C, 2004, NEURODEGENER DIS, V1, P192, DOI 10.1159/000080985; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c; Xia XG, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng098; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200	23	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10632	10638		10.1074/jbc.M611033200	http://dx.doi.org/10.1074/jbc.M611033200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17261586	hybrid			2022-12-27	WOS:000245941000057
J	Mascle, XH; Germain-Desprez, D; Huynh, P; Estephan, P; Aubry, M				Mascle, Xavier H.; Germain-Desprez, Delphine; Huynh, Phuong; Estephan, Patricia; Aubry, Muriel			Sumoylation of the transcriptional intermediary factor 1 beta (TIF1 beta), the co-repressor of the KRAB multifinger proteins, is required for its transcriptional activity and is modulated by the KRAB domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; UBIQUITIN-RELATED MODIFIER; SUMO E3 LIGASE; RESONANCE ENERGY-TRANSFER; NUCLEAR-MATRIX; HISTONE DEACETYLATION; DYNAMIC INTERPLAY; TRIPARTITE MOTIF; TIF1 FAMILY; COREPRESSOR	Small ubiquitin-related modifier (SUMO) has emerged as a key post-translational modulator of protein functions. Here we show that TIF1 ss, a developmental regulator proposed to act as a universal co-repressor for the large family of KRAB domain-containing zinc finger proteins, is a heavily SUMO-modified substrate. A combined analysis of deletion and punctual mutants identified TIF1 ss as a multilysine acceptor for SUMO which specifically targets six lysine residues (Lys(554), Lys(575), Lys(676), Lys(750), Lys(779), and Lys(804)) within the TIF1 ss C-terminal repressive region. Reporter gene assays indicate that TIF1 ss requires SUMO-modification for its repressive activity. Indeed, sumoylation-less mutants failed to recapitulate TIF1 ss-dependent repression. TIF1 ss homodimerization properties and interaction with the KRAB domain are preserved in the mutants with lysine to arginine substitutions as confirmed by in vivo bioluminescence resonance energy transfer (BRET). Using histone deacetylase ( HDAC) inhibitors, we also demonstrate that TIF1 ss sumoylation is a prerequisite for the recruitment of HDAC and that TIF1 ss SUMO-dependent repressive activity involves both HDAC-dependent and HDAC-independent components. Finally, we report that, in addition to relying on the integrity of its PHD finger and on its self-oligomerization, TIF1 ss sumoylation is positively regulated by its interaction with KRAB domain-containing proteins. Altogether, our results provide new mechanistic insights into TIF1 ss transcriptional repression and suggest that KRAB multifinger proteins not only recruit TIF1 ss co-repressor to target genes but also increase its repressive activity through enhancement of its sumoylation.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Aubry, M (corresponding author), Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada.	muriel.aubry@umontreal.ca						Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Azuma Y, 2002, DEV CELL, V2, P130, DOI 10.1016/S1534-5807(02)00124-7; Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Beckstead R, 2001, MOL CELL, V7, P753, DOI 10.1016/S1097-2765(01)00220-9; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Binda O, 2006, MOL CELL BIOL, V26, P1917, DOI 10.1128/MCB.26.5.1917-1931.2006; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Cammas F, 2000, DEVELOPMENT, V127, P2955; Cammas F, 2004, GENE DEV, V18, P2147, DOI 10.1101/gad.302904; Cammas F, 2002, J CELL SCI, V115, P3439; Cao TY, 1997, J CELL SCI, V110, P1563; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chupreta S, 2005, MOL CELL BIOL, V25, P4272, DOI 10.1128/MCB.25.10.4272-4282.2005; Cote F, 2001, DNA CELL BIOL, V20, P159, DOI 10.1089/104454901300069004; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fernandez-Lloris R, 2006, FEBS LETT, V580, P1215, DOI 10.1016/j.febslet.2006.01.031; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Germain-Desprez D, 2003, J BIOL CHEM, V278, P22367, DOI 10.1074/jbc.M302234200; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gong ZH, 2006, MOL CELL BIOL, V26, P4519, DOI 10.1128/MCB.00409-06; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; Hay RT, 2006, E SCHERING RES FDN W, V57, P173; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; HSU YH, 2006, J BIOL CHEM; Huang WC, 2004, EUR J BIOCHEM, V271, P4114, DOI 10.1111/j.1432-1033.2004.04349.x; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Khetchoumian K, 2004, J BIOL CHEM, V279, P48329, DOI 10.1074/jbc.M404779200; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kim YE, 2005, BIOCHEM BIOPH RES CO, V330, P746, DOI 10.1016/j.bbrc.2005.03.052; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; LE DB, 1996, EMBO J, V15, P6701; Lechner MS, 2005, BIOCHEM BIOPH RES CO, V331, P929, DOI 10.1016/j.bbrc.2005.04.016; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; LEE YK, 2006, J BIOL CHEM; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Long JY, 2004, BIOCHEM J, V379, P23, DOI 10.1042/BJ20031867; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; Lorenz P, 2001, BIOL CHEM, V382, P637, DOI 10.1515/BC.2001.075; Matunis MJ, 2005, NAT STRUCT MOL BIOL, V12, P565, DOI 10.1038/nsmb0705-565; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Motohashi H, 2006, MOL CELL BIOL, V26, P4652, DOI 10.1128/MCB.02193-05; Nakagawa K, 2005, GENES CELLS, V10, P835, DOI 10.1111/j.1365-2443.2005.00880.x; Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Pichler A, 2004, NAT STRUCT MOL BIOL, V11, P984, DOI 10.1038/nsmb834; Quimby BB, 2006, ONCOGENE, V25, P2999, DOI 10.1038/sj.onc.1209335; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rosendorff A, 2006, P NATL ACAD SCI USA, V103, P5308, DOI 10.1073/pnas.0601066103; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tiefenbach J, 2006, MOL BIOL CELL, V17, P1643, DOI 10.1091/mbc.E05-07-0610; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	90	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10190	10202		10.1074/jbc.M611429200	http://dx.doi.org/10.1074/jbc.M611429200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17298944	hybrid			2022-12-27	WOS:000245941000009
J	Hwang, SR; Garza, C; Mosier, C; Toneff, T; Wunderlich, E; Goldsmith, P; Hook, V				Hwang, Shin-Rong; Garza, Christina; Mosier, Charles; Toneff, Thomas; Wunderlich, Eric; Goldsmith, Paul; Hook, Vivian			Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE THIOL PROTEASE; INHIBITORY PEPTIDE CATESTATIN; ADRENAL CHROMAFFIN GRANULES; PROCESSING ENZYME; PC12 CELLS; CATECHOLAMINE RELEASE; ALZHEIMERS-DISEASE; AMINOPEPTIDASE-B; PROTEOLYTIC CLEAVAGE; ENDOGENOUS OPIOIDS	Proteases within secretory vesicles are required for conversion of neuropeptide precursors into active peptide neurotransmitters and hormones. This study demonstrates the novel cellular role of the cysteine protease cathepsin L for producing the (Met)enkephalin peptide neurotransmitter from proenkephalin (PE) in the regulated secretory pathway of neuroendocrine PC12 cells. These findings were achieved by coexpression of PE and cathepsin L cDNAs in PC12 cells with analyses of PE-derived peptide products. Expression of cathepsin L resulted in highly increased cellular levels of (Met)enkephalin, resulting from the conversion of PE to enkephalin-containing intermediates of 23, 18-19, 8-9, and 4.5 kDa that were similar to those present in vivo. Furthermore, expression of cathepsin L with PE resulted in increased amounts of nicotine-induced secretion of (Met)enkephalin. These results indicate increased levels of (Met)enkephalin within secretory vesicles of the regulated secretory pathway. Importantly, cathespin L expression was directed to secretory vesicles, demonstrated by colocalization of cathepsin L-DsRed fusion protein with enkephalin and chromogranin A neuropeptides that are present in secretory vesicles. In vivo studies also showed that cathepsin L in vivo was colocalized with enkephalin. The newly defined secretory vesicle function of cathepsin L for biosynthesis of active enkephalin opioid peptide contrasts with its function in lysosomes for protein degradation. These findings demonstrate cathepsin L as a distinct cysteine protease pathway for producing the enkephalin member of neuropeptides.	Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Sch Med, La Jolla, CA 92093 USA; Buck Inst, Novato, CA 94545 USA; Touro Univ, Coll Pharm, Vallejo, CA 94592 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Buck Institute for Research on Aging; Touro University California	Hook, V (corresponding author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Sch Med, 9500 Gilman Dr,MC 0744, La Jolla, CA 92093 USA.	vhook@ucsd.edu						AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; AWAGURI S, 1995, EUR J CELL BIOL, V67, P308; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; Balogh A, 1998, J CELL SCI, V111, P161; Barbero P, 1998, J BIOL CHEM, V273, P25339, DOI 10.1074/jbc.273.39.25339; BLOOM FE, 1983, PSYCHIAT CLIN N AM, V6, P365; Cadel S, 1997, P NATL ACAD SCI USA, V94, P2963, DOI 10.1073/pnas.94.7.2963; CADEL S, 1995, MOL CELL ENDOCRINOL, V110, P149, DOI 10.1016/0303-7207(95)03529-G; Cool DR, 1996, ENDOCRINOLOGY, V137, P5441, DOI 10.1210/en.137.12.5441; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; DAS B, 1992, J NEUROCHEM, V59, P2263; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; DOCHERTY K, 1984, J BIOL CHEM, V259, P6041; DOCHERTY K, 1983, P NATL ACAD SCI-BIOL, V80, P3245, DOI 10.1073/pnas.80.11.3245; Dohrman DP, 2003, ALCOHOL CLIN EXP RES, V27, P1846, DOI 10.1097/01.ALC.0000095923.41707.C8; FLEMINGER G, 1983, P NATL ACAD SCI-BIOL, V80, P6418, DOI 10.1073/pnas.80.20.6418; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; GAINER H, 1984, FEBS LETT, V175, P135, DOI 10.1016/0014-5793(84)80586-4; HILL RM, 1995, J NEUROCHEM, V65, P2318; Hook V, 2005, BIOL CHEM, V386, P931, DOI 10.1515/BC.2005.108; Hook V, 2004, BIOL CHEM, V385, P473, DOI 10.1515/BC.2004.055; HOOK VYH, 1982, NATURE, V295, P341, DOI 10.1038/295341a0; HOOK VYH, 1987, NEUROPEPTIDES, V9, P263, DOI 10.1016/0143-4179(87)90001-1; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; Hwang SR, 2007, J NEUROCHEM, V100, P1340, DOI 10.1111/j.1471-4159.2006.04325.x; Hwang SR, 2002, BIOCHEMISTRY-US, V41, P10397, DOI 10.1021/bi020088o; HWANG SR, 1994, P NATL ACAD SCI USA, V91, P9579, DOI 10.1073/pnas.91.20.9579; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Jiang QJ, 2001, J BIOL CHEM, V276, P25022, DOI 10.1074/jbc.M101545200; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Jutras I, 1999, FEBS LETT, V443, P48, DOI 10.1016/S0014-5793(98)01672-X; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; Kukor Z, 2002, J BIOL CHEM, V277, P21389, DOI 10.1074/jbc.M200878200; Li HY, 2005, NEURON, V48, P619, DOI 10.1016/j.neuron.2005.09.033; LODISH H, 2000, MOL CELL BIOL, P691; Mahapatra NR, 2006, J HYPERTENS, V24, P895, DOI 10.1097/01.hjh.0000222760.99852.e0; Mahata SK, 1999, J BIOL CHEM, V274, P2920, DOI 10.1074/jbc.274.5.2920; Miller R, 2003, NEUROPEPTIDES, V37, P140, DOI 10.1016/S0143-4179(03)00027-1; Neves FAR, 1996, HYPERTENSION, V27, P514, DOI 10.1161/01.HYP.27.3.514; SCHILLER MR, 1995, BIOCHEMISTRY-US, V34, P7988, DOI 10.1021/bi00025a004; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sharp BM, 2006, BRAIN BEHAV IMMUN, V20, P9, DOI 10.1016/j.bbi.2005.02.002; Sisodia SS, 1999, J CLIN INVEST, V104, P1169, DOI 10.1172/JCI8508; STEINER DF, 1984, J CELL BIOCHEM, V24, P121, DOI 10.1002/jcb.240240204; Taupenot L, 2005, J BIOL CHEM, V280, P3885, DOI 10.1074/jbc.M408197200; Taylor CV, 2000, J BIOL CHEM, V275, P22905, DOI 10.1074/jbc.M001232200; Taylor SC, 2000, J NEUROCHEM, V75, P1583, DOI 10.1046/j.1471-4159.2000.0751583.x; UCHIYAMA Y, 1999, J HISTOCHEM CYTOCHEM, V5, P633; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; Yasothornsrikul S, 1999, BIOCHEMISTRY-US, V38, P7421, DOI 10.1021/bi990239w; Yasothornsrikul S, 2003, P NATL ACAD SCI USA, V100, P9590, DOI 10.1073/pnas.1531542100; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	55	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9556	9563		10.1074/jbc.M605510200	http://dx.doi.org/10.1074/jbc.M605510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244622	hybrid			2022-12-27	WOS:000245421700028
J	Papadopoulos, M; Momburg, F				Papadopoulos, Martina; Momburg, Frank			Multiple residues in the transmembrane helix and connecting peptide of mouse tapasin stabilize the transporter associated with the antigen-processing TAP2 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ENDOPLASMIC-RETICULUM; LOADING COMPLEX; DIMERIZATION MOTIF; IMMUNE-RESPONSES; MEMBRANE-PROTEIN; MOLECULES; DEGRADATION; EXPRESSION; RETENTION	The type I endoplasmic reticulum (ER) glycoprotein tapasin (Tpn) is essential for loading of major histocompatibility complex class I (MHC-I) molecules with an optimal spectrum of antigenic peptides and for stable expression of the heterodimeric, polytopic TAP peptide transporter. In a detailed mutational analysis, the transmembrane domain (TMD) and ER-luminal connecting peptide (CP) of mouse Tpn were analyzed for their capacity to stabilize the TAP2 subunit. Replacement of the TMD of Tpn by TMDs from calnexin or the Tpn-related protein, respectively, completely abolished TAP2 stabilization after transfection of Tpn-deficient cells, whereas TMDs derived from distantly related Tpn molecules (chicken and fish) were functional. A detailed mutational analysis of the TMD and adjacent residues in the ER-luminal CP of mouse Tpn was performed to elucidate amino acids that control the stabilization of TAP2. Single amino acid substitutions, including a conserved Lys residue in the center of the putative TMD, did not affect TAP2 expression levels. Mutation of this Lys plus four additional residues, predicted to be neighbors in an assumed a-helical TMD arrangement, abrogated the TAP2-stabilizing capacity of Tpn. In the presence of a wild-type TMD, also the substitution of a highly conserved Glu residue in the CP of Tpn strongly affected TAP2 stabilization. Defective TAP2 stabilization resulted in impaired cell surface expression of MHC-1 molecules. This study thus defines a novel, spatially arranged motif in the TMD of Tpn essential for stable expression of the TAP2 protein and a novel protein interaction mode involving an ER-luminal Glu residue close to the membrane.	German Canc Res Ctr DKFZ, Dept Mol Immunol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Momburg, F (corresponding author), German Canc Res Ctr DKFZ, Dept Mol Immunol, D-69120 Heidelberg, Germany.	f.momburg@dkfz.de						Armandola EA, 1996, EUR J IMMUNOL, V26, P1748, DOI 10.1002/eji.1830260813; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Bolliger L, 1999, J IMMUNOL, V163, P3867; Boname JM, 2005, EUR J IMMUNOL, V35, P171, DOI 10.1002/eji.200425459; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; Garbi N, 2005, IMMUNOL REV, V207, P77, DOI 10.1111/j.0105-2896.2005.00303.x; Garbi N, 2003, EUR J IMMUNOL, V33, P264, DOI 10.1002/immu.200390029; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JONES B, 1981, EUR J IMMUNOL, V11, P584, DOI 10.1002/eji.1830110712; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; Koch J, 2006, CELL MOL LIFE SCI, V63, P653, DOI 10.1007/s00018-005-5462-z; Koch J, 2006, FEBS LETT, V580, P4091, DOI 10.1016/j.febslet.2006.06.053; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Leonhardt RM, 2005, J IMMUNOL, V175, P5104, DOI 10.4049/jimmunol.175.8.5104; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; Marassi FM, 2003, PROTEIN SCI, V12, P403, DOI 10.1110/ps.0211503; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; Momburg F, 2002, MOL IMMUNOL, V39, P217, DOI 10.1016/S0161-5890(02)00103-7; Momburg F, 1998, ADV IMMUNOL, V68, P191, DOI 10.1016/S0065-2776(08)60560-X; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paulsson K, 2003, BBA-MOL CELL RES, V1641, P1, DOI 10.1016/S0167-4889(03)00048-X; Paulsson KM, 2006, J IMMUNOL, V176, P7482, DOI 10.4049/jimmunol.176.12.7482; Paulsson KM, 2002, J BIOL CHEM, V277, P18266, DOI 10.1074/jbc.M201388200; Pentcheva T, 2002, J IMMUNOL, V168, P1538, DOI 10.4049/jimmunol.168.4.1538; Petersen JL, 2005, J IMMUNOL, V174, P962, DOI 10.4049/jimmunol.174.2.962; Rock KL, 2002, ADV IMMUNOL, V80, P1, DOI 10.1016/S0065-2776(02)80012-8; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sal-Man N, 2005, J BIOL CHEM, V280, P27449, DOI 10.1074/jbc.M503095200; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; Tan P, 2002, J IMMUNOL, V168, P1950, DOI 10.4049/jimmunol.168.4.1950; Ulmschneider MB, 2005, PROTEINS, V59, P252, DOI 10.1002/prot.20334; Williams A, 2002, TISSUE ANTIGENS, V59, P3, DOI 10.1034/j.1399-0039.2002.590103.x; Yu YYL, 1999, J IMMUNOL, V163, P4427	37	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9401	9410		10.1074/jbc.M610429200	http://dx.doi.org/10.1074/jbc.M610429200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17244610	hybrid			2022-12-27	WOS:000245421700012
J	Tullai, JW; Chen, J; Schaffer, ME; Kamenetsky, E; Kasif, S; Cooper, GM				Tullai, John W.; Chen, Jie; Schaffer, Michael E.; Kamenetsky, Eliza; Kasif, Simon; Cooper, Geoffrey M.			Glycogen synthase kinase-3 represses cyclic AMP response element-binding protein (CREB)-targeted immediate early genes in quiescent cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; SMALL-MOLECULE INHIBITORS; SIGNALING PATHWAY; CREB; PHOSPHORYLATION; CAMP; TRANSCRIPTION; ACTIVATION; SITES; IDENTIFICATION	Despite its central role in cell survival and proliferation, the transcriptional program controlled by GSK-3 is poorly understood. We have employed a systems level approach to characterize gene regulation downstream of PI 3-kinase/Akt/GSK-3 signaling in response to growth factor stimulation of quiescent cells. Of 31 immediate-early genes whose induction was dependent on PI 3-kinase signaling, 12 were induced directly by inhibition of GSK-3. Most of the GSK-3-regulated genes encoded transcription factors, growth factors, and signaling molecules. Binding sites for QREB were highly over-represented in the upstream regions of these genes, with 9 genes containing CREB sites that were conserved in mouse orthologs. Binding sites predicted in 6 genes were confirmed by CREB chromatin immunoprecipitation and forskolin induction of CBP binding. Moreover, CREB siRNA substantially blocked induction of 5 genes by forskolin and of 3 genes following inhibition of GSK-3. These results indicate that GSK-3 actively represses gene expression in quiescent cells, with inhibition of CREB playing a key role in this transcriptional response.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Boston Univ, Bioinformat Program, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Cooper, GM (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gmcooper@bu.edu			NCI NIH HHS [1R01-CA18689, R01 CA018689] Funding Source: Medline; NHGRI NIH HHS [1R33-HG002850, R33 HG002850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R33HG002850] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Hardenbol P, 1997, NUCLEIC ACIDS RES, V25, P3339, DOI 10.1093/nar/25.16.3339; Hardt SE, 2004, CIRC RES, V94, P926, DOI 10.1161/01.RES.0000124977.59827.80; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Sauer T, 2006, BIOINFORMATICS, V22, P430, DOI 10.1093/bioinformatics/bti819; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	35	65	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9482	9491		10.1074/jbc.M700067200	http://dx.doi.org/10.1074/jbc.M700067200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17277356	hybrid, Green Accepted			2022-12-27	WOS:000245421700021
J	Baehr, W; Karan, S; Maeda, T; Luo, DG; Li, S; Bronson, JD; Watt, CB; Yau, KW; Frederick, JM; Palczewski, K				Baehr, Wolfgang; Karan, Sukanya; Maeda, Tadao; Luo, Dong-Gen; Li, Sha; Bronson, J. Darin; Watt, Carl B.; Yau, King-Wai; Frederick, Jeanne M.; Palczewski, Krzysztof			The function of guanylate cyclase 1 and guanylate cyclase 2 in rod and cone photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PROTEINS; LEBER CONGENITAL AMAUROSIS; GUANYLATE-CYCLASE; CGMP-PHOSPHODIESTERASE; KNOCKOUT MICE; RETINAL DEGENERATION; IN-VIVO; ARRESTIN TRANSLOCATION; RHODOPSIN KINASE; DARK-ADAPTATION	Retinal guanylate cyclases 1 and 2 (GC1 and GC2) are responsible for synthesis of cyclic GMP in rods and cones, but their individual contributions to phototransduction are unknown. We report here that the deletion of both GC1 and GC2 rendered rod and cone photoreceptors nonfunctional and unstable. In the rod outer segments of GC double knock-out mice, guanylate cyclase-activating proteins 1 and 2, and cyclic GMP phosphodiesterase were undetectable, although rhodopsin and transducin alpha-subunit were mostly unaffected. Outer segment membranes of GC1(-/-) and GC double knock-out cones were destabilized and devoid of cone transducin (alpha- and gamma-subunits), cone phosphodiesterase, and G protein-coupled receptor kinase 1, whereas cone pigments were present at reduced levels. Real time reverse transcription-PCR analyses demonstrated normal RNA transcript levels for the downregulated proteins, indicating that down-regulation is posttranslational. We interpret these results to demonstrate an intrinsic requirement of GCs for stability and/or transport of a set of membrane-associated phototransduction proteins.	Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Anat & Neurobiol, Salt Lake City, UT 84132 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Case Western Reserve University; Johns Hopkins University	Baehr, W (corresponding author), Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 N Med Dr, Salt Lake City, UT 84132 USA.	wbaehr@hsc.utah.edu	Luo, Donggen/D-5990-2011		NEI NIH HHS [P30 EY014800, R01 EY008123, R01 EY009339-18, P30 EY11373, EY09339, R01 EY014596-05, R01 EY006837, R01 EY009339, P30 EY011373, F32 EY006837, P30 EY011373-119005, R01 EY006837-20A1, R01 EY014596-02, R01 EY014596-04, R01 EY006837-16A1, EY06837, R37 EY006837, R01 EY006837-17, R01 EY014596-01, R01 EY014596-03, R01 EY014596, R01 EY006837-18, EY08123, R01 EY006837-19] Funding Source: Medline; NIDCD NIH HHS [R01 DC006904-03, R01 DC006904-01, R01 DC006904-02, R01 DC006904] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY014800, R01EY009339, R37EY006837, F32EY006837, R01EY008123, R01EY006837, R01EY014596, P30EY011373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BESHARSE JC, 1979, INVEST OPHTH VIS SCI, V18, P1019; Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; Cao LX, 2000, VISUAL NEUROSCI, V17, P319, DOI 10.1017/S0952523800173018; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Coleman JE, 2005, INVEST OPHTH VIS SCI, V46, P12, DOI 10.1167/iovs.04-0691; Coleman JE, 2004, INVEST OPHTH VIS SCI, V45, P3397, DOI 10.1167/iovs.04-0392; Deretic D, 1998, EYE, V12, P526, DOI 10.1038/eye.1998.141; Deretic D, 2005, P NATL ACAD SCI USA, V102, P3301, DOI 10.1073/pnas.0500095102; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; Duda T, 2002, MOL CELL BIOCHEM, V230, P107, DOI 10.1023/A:1014290531357; Frederick JM, 2001, INVEST OPHTH VIS SCI, V42, P826; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Haeseleer F, 2004, NAT NEUROSCI, V7, P1079, DOI 10.1038/nn1320; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; Haire SE, 2006, INVEST OPHTH VIS SCI, V47, P3745, DOI 10.1167/iovs.06-0086; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; Hisatomi O, 1999, BIOCHEM BIOPH RES CO, V255, P216, DOI 10.1006/bbrc.1999.0165; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Howes KA, 2002, EMBO J, V21, P1545, DOI 10.1093/emboj/21.7.1545; Imanishi Y, 2004, J MOL EVOL, V59, P204, DOI 10.1007/s00239-004-2614-y; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; Koch KW, 2002, ADV EXP MED BIOL, V514, P349; Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849; Lem J, 2004, TRENDS MOL MED, V10, P150, DOI 10.1016/j.molmed.2004.02.009; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Luo DG, 2005, J GEN PHYSIOL, V126, P263, DOI 10.1085/jgp.200509342; Lyubarsky AL, 2000, J NEUROSCI, V20, P2209; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200; Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998; Milam AH, 2003, OPHTHALMOLOGY, V110, P549, DOI 10.1016/S0161-6420(02)01757-8; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; NOLL GN, 1994, NEUROPHARMACOLOGY, V33, P1407, DOI 10.1016/0028-3908(94)90042-6; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Pennesi ME, 2003, P NATL ACAD SCI USA, V100, P6783, DOI 10.1073/pnas.1130102100; Pepperberg DR, 1997, VISUAL NEUROSCI, V14, P73, DOI 10.1017/S0952523800008774; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; QIN N, 1994, J BIOL CHEM, V269, P3265; Rozet JM, 2001, INVEST OPHTH VIS SCI, V42, P1190; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Seebacher T, 1999, HEARING RES, V127, P95, DOI 10.1016/S0378-5955(98)00176-2; Semple-Rowland SL, 1998, P NATL ACAD SCI USA, V95, P1271, DOI 10.1073/pnas.95.3.1271; Sung CH, 2000, INT REV CYTOL, V195, P215; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tucker CL, 2004, MOL VIS, V10, P297; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Yang RB, 1999, J NEUROSCI, V19, P5889, DOI 10.1523/JNEUROSCI.19-14-05889.1999; Yang RB, 1996, GENOMICS, V31, P367, DOI 10.1006/geno.1996.0060; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124	55	130	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8837	8847		10.1074/jbc.M610369200	http://dx.doi.org/10.1074/jbc.M610369200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255100	Green Accepted, hybrid			2022-12-27	WOS:000245780300031
J	Liu, XP; Yan, QT; Baskerville, KL; Zweier, JL				Liu, Xiaoping; Yan, Qingtao; Baskerville, Kim L.; Zweier, Jay L.			Estimation of nitric oxide concentration in blood for different rates of generation - Evidence that intravascular nitric oxide levels are too low to exert physiological effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; HUMAN-ERYTHROCYTES; OXYGEN-UPTAKE; CARBON-MONOXIDE; DIFFUSION; CONSUMPTION; HEMOGLOBIN; KINETICS; O-2; NO	Endothelium-derived nitric oxide (NO) is a potent vasodilator in the cardiovascular system. Several lines of experimental evidence suggest that NO or NO equivalents may also be generated in the blood. However, blood contains a large amount of hemoglobin (Hb) in red blood cells (RBCs). The RBC-encapsulated Hb can react very quickly with NO, which is only limited by the rate of NO diffusion into the RBCs. It is unclear what the possible NO concentration levels in blood are and how the NO diffusion coefficient (D) and the permeability (P-m) of RBC membrane to NO affect the level of NO concentration. In this study, a steady-state concentration experimental method combined with a spherical diffusion model are presented for determining D and P-m and examining the effect of NO generation rate (V-o) and hematocrit (Hct) on NO concentration. It was determined that P-m is 4.5 +/- 1.5 cm/s and D is 3410 +/- 50 mu m(2)/s at 37 degrees C. Simulations based on experimental parameters show that, when the rate of NO formation is as high as 100 nM/s, the maximal NO concentration in blood is below 0.012 nM at P-m = 4.5 cm/s and Hct = 45%. Thus, it is unlikely that NO is directly exported or generated from the RBC as an intravascular signaling molecule, because its concentration would be too low to exert a physiological role. Furthermore, our results suggest that, if RBCs export NO bioactivity, this would be through NO-derived species that can release or form NO rather than NO itself.	Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Cardiovasc Med, Columbus, OH 43210 USA	Ohio State University; Ohio State University	Liu, XP (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst, 473 W 12th Ave, Columbus, OH 43210 USA.	Xiaoping.liu@osumc.edu	Liu, Xiaoping/A-4516-2008	Liu, Xiaoping/0000-0002-7516-382X	NHLBI NIH HHS [HL-38324, HL-63744, HL-65608] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608, R01HL063744, R01HL038324, R29HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTMAN PL, 1974, BIOL DATA BOOK, P1598; Azarov I, 2005, J BIOL CHEM, V280, P39024, DOI 10.1074/jbc.M509045200; Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; CARLSEN E, 1958, J GEN PHYSIOL, V42, P83, DOI 10.1085/jgp.42.1.83; COIN JT, 1979, J BIOL CHEM, V254, P1178; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Gladwin MT, 2005, NAT CHEM BIOL, V1, P245, DOI 10.1038/nchembio1005-245; Han TH, 2003, P NATL ACAD SCI USA, V100, P12504, DOI 10.1073/pnas.2133409100; Hartridge H, 1927, J PHYSIOL-LONDON, V52, P232, DOI 10.1113/jphysiol.1927.sp002354; HUXLEY VH, 1983, MICROVASC RES, V26, P89, DOI 10.1016/0026-2862(83)90058-4; HUXLEY VH, 1981, J PHYSIOL-LONDON, V316, P75, DOI 10.1113/jphysiol.1981.sp013773; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KREUZER F, 1960, J APPL PHYSIOL, V15, P1117, DOI 10.1152/jappl.1960.15.6.1117; KUTCHAI H, 1969, J GEN PHYSIOL, V53, P576, DOI 10.1085/jgp.53.5.576; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 2005, NITRIC OXIDE-BIOL CH, V13, P68, DOI 10.1016/j.niox.2005.04.011; Liu XP, 2002, J BIOL CHEM, V277, P26194, DOI 10.1074/jbc.M201939200; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; NICOLSON P, 1951, PROC R SOC SER B-BIO, V138, P241, DOI 10.1098/rspb.1951.0020; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Robinson JM, 2005, AM J RESP CELL MOL, V32, P257, DOI 10.1165/rcmb.F292; Roughton FJW, 1932, P R SOC LOND B-CONTA, V111, P1, DOI 10.1098/rspb.1932.0041; Russell JA, 2003, AM J PHYSIOL-HEART C, V285, pH251, DOI 10.1152/ajpheart.01086.2002; Subczynski WK, 1996, FREE RADICAL RES, V24, P343, DOI 10.3109/10715769609088032; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.98.1.355; Tsoukias NM, 2002, AM J PHYSIOL-HEART C, V282, pH2265, DOI 10.1152/ajpheart.01080.2001; VANDEGRIFF KD, 1984, BIOPHYS J, V45, P825, DOI 10.1016/S0006-3495(84)84226-5; VAUGHAN MW, 2003, AM J PHYSIOL, V274, pH1705; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; Vaughn MW, 2001, NITRIC OXIDE-BIOL CH, V5, P18, DOI 10.1006/niox.2000.0328; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; Zacharia IG, 2005, ANN BIOMED ENG, V33, P214, DOI 10.1007/s10439-005-8980-9	35	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8831	8836		10.1074/jbc.M611684200	http://dx.doi.org/10.1074/jbc.M611684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17267398	hybrid			2022-12-27	WOS:000245780300030
J	Magnet, S; Arbeloa, A; Mainardi, JL; Hugonnet, JE; Fourgeaud, M; Dubost, L; Marie, A; Delfosse, V; Mayer, C; Rice, LB; Arthur, M				Magnet, Sophie; Arbeloa, Ana; Mainardi, Jean-Luc; Hugonnet, Jean-Emmanuel; Fourgeaud, Martine; Dubost, Lionel; Marie, Arul; Delfosse, Vanessa; Mayer, Claudine; Rice, Louis B.; Arthur, Michel			Specificity of L,D-transpeptidases from gram-positive bacteria producing different peptidoglycan chemotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM RESISTANCE; R61 DD-PEPTIDASE; TRANSPEPTIDATION REACTIONS; VANCOMYCIN RESISTANCE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CROSS-BRIDGES; CELL-WALLS; BIOSYNTHESIS; EXPRESSION	We report here the first direct assessment of the specificity of a class of peptidoglycan cross-linking enzymes, the L,D-transpeptidases, for the highly diverse structure of peptidoglycan precursors of Gram-positive bacteria. The lone functionally characterized member of this new family of active site cysteine peptidases, Ldt(fm) from Enterococcus faecium, was previously shown to bypass the D,D-transpeptidase activity of the classical penicillin-binding proteins leading to high level cross-resistance to glycopeptide and beta-lactam antibiotics. Ldt(fm) homologues from Bacillus subtilis (Ldt(Bs)) and E. faecalis (Ldt(fs)) were found here to cross-link their cognate disaccharide-peptide subunits containing meso-diaminopimelic acid (mesoDAP(3)) and L-Lys(3)-L-Ala-L-Ala at the third position of the stem peptide, respectively, instead of L- Lys(3)D-iAsn in E. faecium. Ldt(fs) differed from Ldt(fm) and Ldt(Bs) by its capacity to hydrolyze the L-Lys(3)-D-Ala(4) bond of tetrapeptide (L,D-carboxypeptidase activity) and pentapeptide (L,D-endopeptidase activity) stems, in addition to the common cross-linking activity. The three enzymes were specific for their cognate acyl acceptors in the cross-linking reaction. In contrast to Ldt(fs), which was also specific for its cognate acyl donor, Ldt(fm) tolerated substitution of L-Lys(3)- D-iAsn by L-Lys(3)- L-Ala-L-Ala. Likewise, Ldt(Bs) tolerated substitution of mesoDAP(3) by L-Lys(3)-D-iAsn and L-Lys(3)-L-Ala-L- Ala in the acyl donor. Thus, diversification of the structure of peptidoglycan precursors associated with speciation has led to a parallel evolution of the substrate specificity of the L, D-transpeptidases affecting mainly the recognition of the acyl acceptor. Blocking the assembly of the side chain could therefore be used to combat antibiotic resistance involving L,D-transpeptidases.	Univ Paris 06, Ctr Rech Biomed Cordeliers, F-75006 Paris, France; Univ Paris 05, Ctr Rech Biomed Cordeliers, Fac Med Rene Descartes, F-75006 Paris, France; Hop Europeen Georges Pompidou, AP HP, F-75015 Paris, France; Museum Natl Hist Nat, Plateforme Spect Masse & Proteom, Dept Rech Dev & Divers Mol, F-75005 Paris, France; Louis Stokes Cleveland Vet Affairs Med Ctr, Med & Res Serv, Cleveland, OH 44106 USA	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Museum National d'Histoire Naturelle (MNHN); US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Arthur, M (corresponding author), Univ Paris 06, INSERM, U655 LRMA, Ctr Rech Biomed Cordeliers, 15 Rue Ecole Med, F-75270 Paris 06, France.	michel.arthur@bhdc.jussieu.fr	MAINARDI, Jean-Luc/E-2714-2014; HUGONNET, Jean-Emmanuel/H-3581-2014; HUGONNET, Jean-Emmanuel/ABC-7914-2021; Arthur, Michel/G-3680-2013	MAINARDI, Jean-Luc/0000-0002-4159-0129; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Arthur, Michel/0000-0003-1007-636X; MARIE, Arul/0000-0003-4104-140X; Delfosse, Vanessa/0000-0002-7436-7935	NIAID NIH HHS [R01 AI45626] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045626] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALOBEID S, 1992, FEMS MICROBIOL LETT, V91, P79, DOI 10.1111/j.1574-6968.1992.tb05187.x; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Anderson JW, 2003, BIOCHEM J, V373, P949, DOI 10.1042/BJ20030217; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; Arthur M, 1996, TRENDS MICROBIOL, V4, P401, DOI 10.1016/0966-842X(96)10063-9; Bellais S, 2006, J BIOL CHEM, V281, P11586, DOI 10.1074/jbc.M600114200; Benson TE, 2002, STRUCTURE, V10, P1107, DOI 10.1016/S0969-2126(02)00807-9; Bertsche U, 2005, J BIOL CHEM, V280, P38096, DOI 10.1074/jbc.M508646200; Biarrotte-Sorin S, 2006, J MOL BIOL, V359, P533, DOI 10.1016/j.jmb.2006.03.014; Bielnicki J, 2006, PROTEINS, V62, P144, DOI 10.1002/prot.20702; Born P, 2006, J BIOL CHEM, V281, P26985, DOI 10.1074/jbc.M604083200; Bouhss A, 2002, J BIOL CHEM, V277, P45935, DOI 10.1074/jbc.M207449200; Bouhss A, 2001, J BACTERIOL, V183, P5122, DOI 10.1128/JB.183.17.5122-5127.2001; Courtin P, 2006, J BACTERIOL, V188, P5293, DOI 10.1128/JB.00285-06; Cremniter J, 2006, J BIOL CHEM, V281, P32254, DOI 10.1074/jbc.M606920200; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GRANDCHAMPS J, 1995, BIOCHEM J, V307, P335, DOI 10.1042/bj3070335; Grohs P, 2000, J BACTERIOL, V182, P6228, DOI 10.1128/JB.182.21.6228-6232.2000; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; JACOB AE, 1974, J BACTERIOL, V117, P360, DOI 10.1128/JB.117.2.360-372.1974; JAMIN M, 1995, ESSAYS BIOCHEM, V29, P1; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; Korza HJ, 2005, J BIOL CHEM, V280, P40802, DOI 10.1074/jbc.M506328200; Kumar I, 2005, BIOCHEMISTRY-US, V44, P9961, DOI 10.1021/bi0505417; Kumar I, 2005, BIOCHEMISTRY-US, V44, P9971, DOI 10.1021/bi050542z; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2005, J BIOL CHEM, V280, P38146, DOI 10.1074/jbc.M507384200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; PLAPP R, 1970, J BIOL CHEM, V245, P3667; REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563; Rohrer S, 2003, ANTIMICROB AGENTS CH, V47, P837, DOI 10.1128/AAC.47.3.837-846.2003; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Severin A, 2004, J BIOL CHEM, V279, P3398, DOI 10.1074/jbc.M309593200; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R	38	61	63	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13151	13159		10.1074/jbc.M610911200	http://dx.doi.org/10.1074/jbc.M610911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17311917	Green Submitted, hybrid			2022-12-27	WOS:000246060300003
J	Avraham, E; Rott, R; Liani, E; Szargel, R; Engelender, S				Avraham, Eyal; Rott, Ruth; Liani, Esti; Szargel, Raymonde; Engelender, Simone			Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWY-BODY FORMATION; DISEASE GENE-PRODUCT; ALPHA-SYNUCLEIN; INCLUSION FORMATION; PROTEIN LIGASE; PROTEASOME IMPAIRMENT; PROTECTIVE FUNCTION; S-NITROSYLATION; CELL-DEATH; SYNPHILIN-1	Mutations in Parkin are responsible for a large percentage of autosomal recessive juvenile parkinsonism cases. Parkin displays ubiquitin-ligase activity and protects against cell death promoted by several insults. Therefore, regulation of Parkin activities is important for understanding the dopaminergic cell death observed in Parkinson disease. We now report that cyclin-dependent kinase 5 (Cdk5) phosphorylates Parkin both in vitro and in vivo. We found that highly specific Cdk5 inhibitors and a dominant negative Cdk5 construct inhibited Parkin phosphorylation, suggesting that a significant portion of Parkin is phosphorylated by Cdk5. Parkin interacts with Cdk5 as observed by co-immunoprecipitation experiments of transfected cells and rat brains. Phosphorylation by Cdk5 decreased the auto-ubiquitylation of Parkin both in vitro and in vivo. We identified Ser-131 located at the linker region of Parkin as the major Cdk5 phosphorylation site. The Cdk5 phosphorylation-deficient S131A Parkin mutant displayed a higher auto-ubiquitylation level and increased ubiquitylation activity toward its substrates synphilin-1 and p38. Additionally, the S131A Parkin mutant more significantly accumulated into inclusions in human dopaminergic cells when compared with the wild-type Parkin. Furthermore, S131A Parkin mutant increased the formation of synphilin1/alpha-synuclein inclusions, suggesting that the levels of Parkin phosphorylation and ubiquitylation may modulate the formation of inclusion bodies relevant to the disease. The data indicate that Cdk5 is a new regulator of the Parkin ubiquitin-ligase activity and modulates its ability to accumulate into and modify inclusions. Phosphorylation by Cdk5 may contribute to the accumulation of toxic Parkin substrates and decrease the ability of dopaminergic cells to cope with toxic insults in Parkinson disease.	Technion Israel Inst Technol, Bruce B Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Med Res Inst, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Engelender, S (corresponding author), Technion Israel Inst Technol, Bruce B Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel.	simone@tx.technion.ac.il		Engelender, Simone/0000-0001-7401-6855				Ardley HC, 2004, J NEUROCHEM, V90, P379, DOI 10.1111/j.1471-4159.2004.02485.x; Ardley HC, 2003, MOL BIOL CELL, V14, P4541, DOI 10.1091/mbc.E03-02-0078; Avraham E, 2005, J BIOL CHEM, V280, P42877, DOI 10.1074/jbc.M505608200; Bandopadhyay R, 2005, NEUROBIOL DIS, V20, P401, DOI 10.1016/j.nbd.2005.03.021; BRION JP, 1995, AM J PATHOL, V147, P1465; Cheung ZH, 2006, NEURON, V50, P13, DOI 10.1016/j.neuron.2006.02.024; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Cruz JC, 2004, TRENDS MOL MED, V10, P452, DOI 10.1016/j.molmed.2004.07.001; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Eyal A, 2006, P NATL ACAD SCI USA, V103, P5917, DOI 10.1073/pnas.0509707103; Eyal A, 2006, CELL CYCLE, V5, P2082, DOI 10.4161/cc.5.18.3209; Fischer A, 2005, NEURON, V48, P825, DOI 10.1016/j.neuron.2005.10.033; Forman MS, 2005, NEURON, V47, P479, DOI 10.1016/j.neuron.2005.07.021; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Huynh DP, 2003, HUM MOL GENET, V12, P2587, DOI 10.1093/hmg/ddg269; Hyun DH, 2005, J NEUROSCI RES, V82, P232, DOI 10.1002/jnr.20638; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Monaco EA, 2004, CURR ALZHEIMER RES, V1, P33, DOI 10.2174/1567205043480519; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Murakami T, 2004, ANN NEUROL, V55, P439, DOI 10.1002/ana.20064; Nakamura S, 1997, ACTA NEUROPATHOL, V94, P153, DOI 10.1007/s004010050687; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Sato S, 2006, EMBO J, V25, P211, DOI 10.1038/sj.emboj.7600774; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Sharma P, 1999, J BIOL CHEM, V274, P9600, DOI 10.1074/jbc.274.14.9600; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Smith PD, 2003, P NATL ACAD SCI USA, V100, P13650, DOI 10.1073/pnas.2232515100; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Sriram SR, 2005, HUM MOL GENET, V14, P2571, DOI 10.1093/hmg/ddi292; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Takahashi M, 2000, BRAIN RES, V862, P253, DOI 10.1016/S0006-8993(00)02086-2; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; von Coelln R, 2004, CELL TISSUE RES, V318, P175, DOI 10.1007/s00441-004-0924-4; Wang C, 2005, HUM MOL GENET, V14, P3885, DOI 10.1093/hmg/ddi413; Yamamoto A, 2005, J BIOL CHEM, V280, P3390, DOI 10.1074/jbc.M407724200; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	51	99	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12842	12850		10.1074/jbc.M608243200	http://dx.doi.org/10.1074/jbc.M608243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327227	hybrid			2022-12-27	WOS:000245942800056
J	Caldeira, MV; Melo, CV; Pereira, DB; Carvalho, R; Correia, SS; Backos, DS; Carvalho, AL; Esteban, JA; Duarte, CB				Caldeira, Margarida V.; Melo, Carlos V.; Pereira, Daniela B.; Carvalho, Ricardo; Correia, Susana S.; Backos, Donald S.; Carvalho, Ana Luisa; Esteban, Jose A.; Duarte, Carlos B.			Brain-derived neurotrophic factor regulates the expression and synaptic delivery of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CEREBELLAR GRANULE CELLS; AMPA RECEPTORS; SURFACE EXPRESSION; RAT HIPPOCAMPUS; TRKB RECEPTORS; LATE-PHASE; PHOSPHORYLATION SITES; NEOCORTICAL NEURONS; SIGNAL-TRANSDUCTION	Brain-derived neurotrophic factor ( BDNF) plays an important role in synaptic plasticity in the hippocampus, but the mechanisms involved are not fully understood. The neurotrophin couples synaptic activation to changes in gene expression underlying long term potentiation and short term plasticity. Here we show that BDNF acutely up-regulates GluR1, GluR2, and GluR3 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid ( AMPA) receptor subunits in 7-day tropomyosin-related kinase in vitro cultured hippocampal neurons. The increase in GluR1 and GluR2 protein levels in developing cultures was impaired by K252a, a Trk inhibitor, and by translation ( emetine and anisomycin) and transcription ( alpha-amanitine and actinomycin D) inhibitors. Accordingly, BDNF increased the mRNA levels for GluR1 and GluR2 subunits. Biotinylation studies showed that stimulation with BDNF for 30 min selectively increased the amount of GluR1 associated with the plasma membrane, and this effect was abrogated by emetine. Under the same conditions, BDNF induced GluR1 phosphorylation on Ser-831 through activation of protein kinase C and Ca2+-calmodulin-dependent protein kinase II. Chelation of endogenous extracellular BDNF with TrkB-IgG selectively decreased GluR1 protein levels in 14-day in vitro cultures of hippocampal neurons. Moreover, BDNF promoted synaptic delivery of homomeric GluR1 AMPA receptors in cultured organotypic slices, by a mechanism independent of NMDA receptor activation. Taken together, the results indicate that BDNF up-regulates the protein levels of AMPA receptor subunits in hippocampal neurons and induces the delivery of AMPA receptors to the synapse.	Univ Coimbra, Dept Zool, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	Universidade de Coimbra; University of Michigan System; University of Michigan	Duarte, CB (corresponding author), Univ Coimbra, Dept Zool, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal.	cbduarte@ci.uc.pt	Duarte, Carlos B/K-6358-2013; Esteban, Jose/L-4944-2014; Pereira, Daniela/AAZ-5285-2021; Backos, Donald/Q-4791-2018; Carvalho, Ana Luisa/K-6367-2013; Backos, Donald/N-5265-2019	Duarte, Carlos B/0000-0002-1474-0208; Esteban, Jose/0000-0002-3759-3300; Backos, Donald/0000-0001-6735-6210; Carvalho, Ana Luisa/0000-0001-8368-6666; Backos, Donald/0000-0001-6735-6210; Caldeira, Margarida/0000-0001-5107-1499; Vieira Melo, Carlos/0000-0001-5392-1258; B. Pereira, Daniela/0000-0003-4872-5505				Alder J, 2005, J NEUROSCI, V25, P3080, DOI 10.1523/JNEUROSCI.2970-04.2005; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Aoki C, 2000, J NEUROSCI RES, V59, P454, DOI 10.1002/(SICI)1097-4547(20000201)59:3<454::AID-JNR21>3.0.CO;2-H; Archibald K, 1998, NEUROPHARMACOLOGY, V37, P1345, DOI 10.1016/S0028-3908(98)00135-X; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Brene S, 2000, EUR J NEUROSCI, V12, P1525, DOI 10.1046/j.1460-9568.2000.00040.x; Chen GQ, 1999, J NEUROSCI, V19, P7983; Drake CT, 1999, J NEUROSCI, V19, P8009; Du JL, 2004, NATURE, V429, P878, DOI 10.1038/nature02618; Ernfors P, 2003, TRENDS NEUROSCI, V26, P171, DOI 10.1016/S0166-2236(03)00064-X; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Frerking M, 1998, J NEUROPHYSIOL, V80, P3383, DOI 10.1152/jn.1998.80.6.3383; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Gomes AR, 2004, J NEUROCHEM, V90, P673, DOI 10.1111/j.1471-4159.2004.02519.x; Gomes AR, 2003, NEUROCHEM RES, V28, P1459, DOI 10.1023/A:1025610122776; Gottschalk W, 1998, J NEUROSCI, V18, P6830; Groth RD, 2003, J NEUROSCI, V23, P8125; Hall RA, 1997, NEUROSCIENCE, V78, P361, DOI 10.1016/S0306-4522(96)00525-8; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Jourdi H, 2003, DEV BIOL, V263, P216, DOI 10.1016/j.ydbio.2003.07.008; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1998, NEUROPHARMACOLOGY, V37, P553, DOI 10.1016/S0028-3908(98)00035-5; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; Messaoudi E, 1998, J NEUROPHYSIOL, V79, P496, DOI 10.1152/jn.1998.79.1.496; Messaoudi E, 2002, J NEUROSCI, V22, P7453; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; Minichiello L, 2002, NEURON, V36, P121, DOI 10.1016/S0896-6273(02)00942-X; Nagano T, 2003, MOL CELL NEUROSCI, V24, P340, DOI 10.1016/S1044-7431(03)00172-6; Narisawa-Saito M, 1999, NEUROSCIENCE, V88, P1009, DOI 10.1016/S0306-4522(98)00496-5; Narisawa-Saito M, 1999, P NATL ACAD SCI USA, V96, P2461, DOI 10.1073/pnas.96.5.2461; Nguyen PV, 1996, J NEUROSCI, V16, P3189; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pereira DB, 2006, J NEUROSCI RES, V83, P832, DOI 10.1002/jnr.20784; Poncer JC, 2002, J NEUROSCI, V22, P4406, DOI 10.1523/JNEUROSCI.22-11-04406.2002; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Schratt GM, 2004, J NEUROSCI, V24, P7366, DOI 10.1523/JNEUROSCI.1739-04.2004; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; Strutz-Seebohm N, 2005, J PHYSIOL-LONDON, V565, P381, DOI 10.1113/jphysiol.2004.079582; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; Tanaka T, 1997, J NEUROSCI, V17, P2959; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Vicario-Abejon C, 2002, NAT REV NEUROSCI, V3, P965, DOI 10.1038/nrn988; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002; Zakharenko SS, 2003, NEURON, V39, P975, DOI 10.1016/S0896-6273(03)00543-9	62	182	185	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12619	12628		10.1074/jbc.M700607200	http://dx.doi.org/10.1074/jbc.M700607200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337442	hybrid			2022-12-27	WOS:000245942800031
J	Kohlhaas, SL; Craxton, A; Sun, XM; Pinkoski, MJ; Cohen, GM				Kohlhaas, Susan L.; Craxton, Andrew; Sun, Xiao-Ming; Pinkoski, Michael J.; Cohen, Gerald M.			Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT CASPASE CASCADES; INTERFERON-GAMMA RECEPTOR; SIGNALING COMPLEX; LIPID RAFTS; TYROSINE PHOSPHORYLATION; VESICLE FORMATION; DEATH RECEPTORS; DECOY RECEPTORS; CELL-DEATH; TRAIL	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is selectively toxic to tumor compared with normal cells. Other members of the TNF family of death ligands (TNF, CD95L) engage their respective receptors (TNF-R1 and CD95), resulting in internalization of receptor and ligand and recruitment of adaptor proteins to the caspase activation platform known as the death-inducing signaling complex (DISC). Recently, TNF-R1 and CD95 have been shown to induce apoptosis with an absolute requirement for internalization of their corresponding receptors in the formation of a DISC. We show that TRAIL and its receptors are rapidly endocytosed in a time- and concentration-dependent manner. Blockade of receptor internalization with hyperosmotic sucrose did not inhibit TRAIL-induced apoptosis but, rather, amplified the apoptotic signaling of TRAIL. Plate-bound and soluble TRAIL induced similar levels of apoptosis. Together these results suggest that neither ligand nor receptor internalization is required for TRAIL-induced apoptosis. Internalization of TRAIL is mediated primarily by clathrin-dependent endocytosis and also by clathrin-independent pathways. Inhibition of clathrin-dependent internalization by overexpression of dominant negative forms of dynamin or AP180 did not inhibit TRAIL-induced apoptosis. Consistent with the finding that neither internalization of TRAIL nor its receptors is required for transmission of its apoptotic signal, recruitment of FADD (Fas-associated death domain) and procaspase-8 to form the TRAIL-associated DISC occurred at 4 degrees C, independent of endocytosis. Our findings demonstrate that TRAIL and TRAIL receptor 1/2, unlike TNF-TNF-R1 or CD95L-CD95, do not require internalization for formation of the DISC, activation of caspase-8, or transmission of an apoptotic signal in BJAB type I cells.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Cohen, Gerald M/A-1687-2008		MRC [MC_U132688494, MC_U132615750] Funding Source: UKRI; Medical Research Council [MC_U132615750, MC_U132688494] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Austin CD, 2006, P NATL ACAD SCI USA, V103, P10283, DOI 10.1073/pnas.0604044103; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Criollo A, 2007, APOPTOSIS, V12, P3, DOI 10.1007/s10495-006-0328-x; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Eramo A, 2004, EUR J IMMUNOL, V34, P1930, DOI 10.1002/eji.200324786; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; McNiven MA, 2006, SCIENCE, V313, P1591, DOI 10.1126/science.1118133; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MOSSELMANS R, 1988, J IMMUNOL, V141, P3096; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schneider-Brachert W, 2006, J CLIN INVEST, V116, P2901, DOI 10.1172/JCI23771; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Thomas LR, 2004, J BIOL CHEM, V279, P52479, DOI 10.1074/jbc.M409578200; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WATANABE N, 1988, J BIOL CHEM, V263, P10262; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961	46	101	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12831	12841		10.1074/jbc.M700438200	http://dx.doi.org/10.1074/jbc.M700438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327223	hybrid			2022-12-27	WOS:000245942800055
J	Plumb, DA; Dhir, V; Mironov, A; Ferrara, L; Poulsom, R; Kadler, KE; Thornton, DJ; Briggs, MD; Boot-Handford, RP				Plumb, Darren A.; Dhir, Vivek; Mironov, Aleksandr; Ferrara, Laila; Poulsom, Richard; Kadler, Karl E.; Thornton, David J.; Briggs, Michael D.; Boot-Handford, Raymond P.			Collagen XXVII is developmentally regulated and forms thin fibrillar structures distinct from those of classical vertebrate fibrillar collagens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVOLUTION; MUTATIONS	We have generated an antiserum to the variable domain of mouse collagen XXVII, a recently discovered novel member of the fibrillar collagen family. Collagen XXVII protein was first detectable in the mouse at embryonic day 12.5 (E12.5). By E14.5, the protein localized to cartilage, developing dermis, cornea, the inner limiting membrane of the retina, and major arteries of the heart. However, at E18.5, collagen XXVII protein was no longer apparent in most tissues and appeared restricted mainly to cartilage where expression continued into adulthood. Type XXVII collagen immunolocalized to 10-nm-thick nonstriated fibrils that were distinct from fibrils formed by the classical fibrillar collagens. The transient nature of its expression and unusual fibrillar structure suggest that collagen XXVII plays a developmental role distinct from those of the classical fibrillar collagens.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Canc Res UK, London Res Inst, Histopathol Unit, London WC2A 3PX, England	University of Manchester; Cancer Research UK	Boot-Handford, RP (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.	ray.boot-handford@manchester.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Boot-Handford, Raymond/0000-0002-6167-8419; Thornton, David/0000-0001-7148-1970; Mironov, Aleksandr/0000-0002-1497-328X	Arthritis Research UK [17243, 15967] Funding Source: Medline; Wellcome Trust [084353] Funding Source: Medline	Arthritis Research UK(Versus Arthritis); Wellcome Trust(Wellcome TrustEuropean Commission)		Aouacheria A, 2004, J BIOL CHEM, V279, P47711, DOI 10.1074/jbc.M408950200; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Bailey WJ, 1997, MOL BIOL EVOL, V14, P843, DOI 10.1093/oxfordjournals.molbev.a025825; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Gopalakrishnan B, 2004, J BIOL CHEM, V279, P30904, DOI 10.1074/jbc.M402252200; Holmes DF, 2005, J MOL BIOL, V345, P773, DOI 10.1016/j.jmb.2004.10.078; Huxley-Jones J, 2007, MATRIX BIOL, V26, P2, DOI 10.1016/j.matbio.2006.09.008; Kadler KE, 1996, BIOCHEM J, V316, P1; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; Wada H, 2006, EVOL DEV, V8, P370, DOI 10.1111/j.1525-142X.2006.00109.x; Zhang XM, 2007, J BIOL CHEM, V282, P6792, DOI 10.1074/jbc.M607528200	18	50	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12791	12795		10.1074/jbc.C700021200	http://dx.doi.org/10.1074/jbc.C700021200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331945	Green Accepted, hybrid			2022-12-27	WOS:000245942800050
J	Thummer, R; Klimmek, O; Schmitz, RA				Thummer, Robert; Klimmek, Oliver; Schmitz, Ruth A.			Biochemical studies of Klebsiella pneumoniae NifL reduction using reconstituted partial anaerobic respiratory chains of Wolinella succinogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NIFL; TRANSCRIPTIONAL ACTIVATOR NIFA; DEPENDENT NITROGEN CONTROL; BINDING PROTEIN NIFA; TERMINAL GAF DOMAIN; GENE-EXPRESSION; ESCHERICHIA-COLI; MEMBRANE ASSOCIATION; ELECTRON-TRANSPORT; REGULATORY PROTEIN	In the diazotroph Klebsiella pneumoniae the flavoprotein NifL inhibits the activity of the nif-specific transcriptional activator NifA in response to molecular oxygen and combined nitrogen. Sequestration of reduced NifL to the cytoplasmic membrane under anaerobic and nitrogen-limited conditions impairs inhibition of cytoplasmic NifA by NifL. To analyze whether NifL is reduced by electrons directly derived from the reduced menaquinone pool, we studied NifL reduction using artificial membrane systems containing purified components of the anaerobic respiratory chain of Wolinella succinogenes. In this in vitro assay using proteoliposomes containing purified formate dehydrogenase and purified menaquinone ( MK6) or 8-methylmenaquinone ( MMK6) from W. succinogenes, reduction of purified NifL was achieved by formate oxidation. Furthermore, the respective reduction rates, which were determined using equal amounts of NifL, have been shown to be directly dependent on the concentration of both formate dehydrogenase and menaquinones incorporated into the proteoliposomes, demonstrating a direct electron transfer from menaquinone to NifL. When purified hydrogenase and MK6 from W. succinogenes were inserted into the proteoliposomes, NifL was reduced with nearly the same rate by hydrogen oxidation. In both cases reduced NifL was found to be highly associated to the proteoliposomes, which is in accordance with our previous findings in vivo. On the bases of these experiments, we propose that the redox state of the menaquinone pool is the redox signal for nif regulation in K. pneumoniae by directly transferring electrons onto NifL under anaerobic conditions.	Univ Kiel, Inst Allgemeine Mikrobiol, Bot Garden 19, D-24118 Kiel, Germany; Goethe Univ Frankfurt, Inst Mol Biowissensch, D-60438 Frankfurt, Germany	University of Kiel; Goethe University Frankfurt	Schmitz, RA (corresponding author), Univ Kiel, Inst Allgemeine Mikrobiol, Bot Garden 19, D-24118 Kiel, Germany.	rschmitz@ifam.uni-kiel.de		Schmitz-Streit, Ruth Anne/0000-0002-6788-0829				Arcondeguy T, 2000, J BIOL CHEM, V275, P38452, DOI 10.1074/jbc.M001935200; Arcondeguy T, 1999, FEMS MICROBIOL LETT, V180, P263, DOI 10.1016/S0378-1097(99)00497-8; Biel S, 2002, EUR J BIOCHEM, V269, P1974, DOI 10.1046/j.1432-1033.2002.02842.x; Bock A, 2002, EUR J BIOCHEM, V269, P3479, DOI 10.1046/j.1432-1033.2002.03029.x; BROWN ED, 1993, J BIOL CHEM, V268, P8972; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; DESPICER PO, 1991, J BACTERIOL, V173, P211, DOI 10.1128/jb.173.1.211-219.1991; Dietrich V, 2002, EUR J BIOCHEM, V269, P1086, DOI 10.1046/j.0014-2956.2001.02662.x; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; DROSS F, 1992, EUR J BIOCHEM, V206, P93, DOI 10.1111/j.1432-1033.1992.tb16905.x; Egener T, 2002, MICROBIOL-SGM, V148, P3203, DOI 10.1099/00221287-148-10-3203; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Grabbe R, 2003, EUR J BIOCHEM, V270, P1555, DOI 10.1046/j.1432-1033.2003.03520.x; Grabbe R, 2001, J BACTERIOL, V183, P1385, DOI 10.1128/JB.183.4.1385-1393.2001; Gross R, 2004, J BIOL CHEM, V279, P274, DOI 10.1074/jbc.M310610200; He LH, 1998, J BACTERIOL, V180, P6661, DOI 10.1128/JB.180.24.6661-6667.1998; HENDERSON N, 1989, MOL GEN GENET, V216, P484, DOI 10.1007/BF00334394; HILL S, 1981, NATURE, V290, P424, DOI 10.1038/290424a0; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Klopprogge K, 2002, ARCH MICROBIOL, V177, P223, DOI 10.1007/s00203-001-0379-x; KROGER A, 1994, PRACTICAL GUIDE MEMB; Lambert O, 1998, BIOPHYS J, V74, P918, DOI 10.1016/S0006-3495(98)74015-9; Lei S, 1999, J BACTERIOL, V181, P6535, DOI 10.1128/JB.181.20.6535-6539.1999; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; Little R, 2006, BIOCHEM SOC T, V34, P162, DOI 10.1042/BST0340162; Little R, 2003, J BIOL CHEM, V278, P28711, DOI 10.1074/jbc.M301992200; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Macheroux P, 1998, BIOCHEM J, V332, P413, DOI 10.1042/bj3320413; MALOY S, 1987, SALMONELLA TYPHIMURI, P1513; Malpica R, 2004, P NATL ACAD SCI USA, V101, P13318, DOI 10.1073/pnas.0403064101; Martinez-Argudo I, 2005, BIOCHEM SOC T, V33, P152, DOI 10.1042/BST0330152; Martinez-Argudo I, 2004, MOL MICROBIOL, V52, P1731, DOI 10.1111/j.1365-2958.2004.04089.x; Martinez-Argudo I, 2004, J BACTERIOL, V186, P601, DOI 10.1128/JB.186.3.601-610.2004; Matsson M, 2000, BIOCHEMISTRY-US, V39, P8617, DOI 10.1021/bi000271m; MERRICK M, 1982, MOL GEN GENET, V185, P75, DOI 10.1007/BF00333793; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; Money T, 2001, J BACTERIOL, V183, P1359, DOI 10.1128/JB.183.4.1359-1368.2001; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MuroPastor AM, 1997, J BACTERIOL, V179, P2788, DOI 10.1128/jb.179.8.2788-2791.1997; NARBERHAUS F, 1995, J BACTERIOL, V177, P5078, DOI 10.1128/jb.177.17.5078-5087.1995; OW DW, 1983, NATURE, V301, P307, DOI 10.1038/301307a0; Perry S, 2005, J MOL BIOL, V346, P935, DOI 10.1016/j.jmb.2004.12.033; Ray P, 2002, NUCLEIC ACIDS RES, V30, P3972, DOI 10.1093/nar/gkf528; Rees DC, 1999, J MOL BIOL, V293, P343, DOI 10.1006/jmbi.1999.3005; Reyes-Ramirez F, 2002, J BACTERIOL, V184, P6777, DOI 10.1128/JB.184.24.6777-6785.2002; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; Rudnick P, 2002, J BACTERIOL, V184, P812, DOI 10.1128/JB.184.3.812-820.2002; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmitz RA, 1997, FEMS MICROBIOL LETT, V157, P313, DOI 10.1111/j.1574-6968.1997.tb12791.x; Schmitz RA, 2002, J MOL MICROB BIOTECH, V4, P235; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; Stips J, 2004, EUR J BIOCHEM, V271, P3379, DOI 10.1111/j.1432-1033.2004.04272.x; Swem LR, 2006, J BIOL CHEM, V281, P6768, DOI 10.1074/jbc.M509687200; UNDEN G, 1988, ARCH MICROBIOL, V150, P499, DOI 10.1007/BF00422294; UNDEN G, 1982, BIOCHIM BIOPHYS ACTA, V682, P258, DOI 10.1016/0005-2728(82)90106-2; UNDEN G, 1986, METHOD ENZYMOL, V126, P387; WOOD JM, 1987, P NATL ACAD SCI USA, V84, P373, DOI 10.1073/pnas.84.2.373; Zhang WM, 2007, BIOCHEMISTRY-US, V46, P483, DOI 10.1021/bi061935g; Zhang WM, 2004, BIOCHEMISTRY-US, V43, P13165, DOI 10.1021/bi048596g	63	8	8	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12517	12526		10.1074/jbc.M609826200	http://dx.doi.org/10.1074/jbc.M609826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329251	hybrid			2022-12-27	WOS:000245942800020
J	Plata, C; Sussman, CR; Sindic, A; Liang, JO; Mount, DB; Josephs, ZM; Chang, MH; Romero, MF				Plata, Consuelo; Sussman, Caroline R.; Sindic, Aleksandra; Liang, Jennifer O.; Mount, David B.; Josephs, Zara M.; Chang, Min-Hwang; Romero, Michael F.			Zebrafish Slc5a12 encodes an electroneutral sodium monocarboxylate transporter (SMCTn) - A comparison with the electrogenic SMCT (SMCTe/Slc5a8)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; DEPOLARIZATION-INDUCED ALKALINIZATION; SUPPRESSOR GENE SLC5A8; CENTRAL-NERVOUS-SYSTEM; SPECTRUM LIPID DRUG; CHAIN FATTY-ACIDS; NICOTINIC-ACID; TUMOR-SUPPRESSOR; LACTATE TRANSPORT; GLUTAMATE TRANSPORTER	We have identified and characterized two different sodium-coupled monocarboxylate cotransporters ( SMCT) from zebrafish ( Danio rerio), electrogenic ( zSMCTe) and electroneutral ( zSMCTn). zSMCTn is the 12th member of the zebrafish Slc5 gene family ( zSlc5a12). Both zSMCT sequences have similar to 50% homology to human SLC5A8 ( hSMCT). Transport function and kinetics were measured in Xenopus oocytes injected with zSMCTcRNAs by measurement of intracellular Na+ concentration ([ Na+](i)) and membrane potential. Both zSMCTs oocytes increased [ Na+](i) with addition of monocarboxylates ( MC) such as lactate, pyruvate, nicotinate, and butyrate. By using two electrode voltage clamp experiments, we measured currents elicited from zSMCTe after MC addition. MC-elicited currents from zSMCTe were similar to hSMCT currents. In contrast, we found no significant MC-elicited current in either zSMCTn or control oocytes. Kinetic data show that zSMCTe has a higher affinity for lactate, nicotinate, and pyruvate ( K-m(L-lactate) = 0.17 +/- 0.02 mM, K-m(nicotinate) = 0.54 +/- 0.12 mM at -150 mV) than zSMCTn ( K-m(L-lactate) = 1.81 +/- 0.19 mM, K-m(nicotinate) = 23.68 +/- 4.88 mM). In situ hybridization showed that 1-, 3-, and 5-day-old zebrafish embryos abundantly express both zSMCTs in the brain, eyes, intestine, and kidney. Within the kidney, zSMCTn mRNA is expressed in pronephric tubules, whereas zSMCTe mRNA is more distal in pronephric ducts. zSMCTn is expressed in exocrine pancreas, but zSMCTe is not. Roles for Na+-coupled monocarboxylate cotransporters have not been described for the brain or eye. In summary, zSMCTe is the zebrafish SLC5A8 ortholog, and zSMCTn is a novel, electroneutral SMCT ( zSlc5a12). Slc5a12 in higher vertebrates is likely responsible for the electroneutral Na+/lactate cotransport reported in mammalian and amphibian kidneys.	Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biol, Cleveland, OH 44106 USA; Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Nefrol & Metab Mineral, Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City 14000, DF, Mexico; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Div Gen Internal Med, Sch Med, Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA	Mayo Clinic; Case Western Reserve University; Case Western Reserve University; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System	Romero, MF (corresponding author), Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, 200 1st St SW,Guggenheim 9-21D, Rochester, MN 55905 USA.	romero.michael@mayo.edu	Dugandzic, Aleksandra/AAL-7581-2020; Plata, Consuelo/M-4482-2015; Plata, Consuelo/M-6461-2019	Plata, Consuelo/0000-0001-9340-8950; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056218, R01DK057708, R21DK060845, R01DK059985] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-56218, DK-57708, DK-60845, DK-59985] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARACNIETO M, 1980, AM J PHYSIOL, V239, pF496, DOI 10.1152/ajprenal.1980.239.5.F496; BARBARAT B, 1988, J BIOL CHEM, V263, P12190; Becker HM, 2004, J BIOL CHEM, V279, P28057, DOI 10.1074/jbc.M402401200; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Carlson LA, 2005, J INTERN MED, V258, P94, DOI 10.1111/j.1365-2796.2005.01528.x; Carlson LA, 2004, INT J CLIN PRACT, V58, P706, DOI 10.1111/j.1368-5031.2004.00233.x; CHANG MH, 2004, J AM SOC NEPHROL, V15, P75; Coady MJ, 2004, J PHYSIOL-LONDON, V557, P719, DOI 10.1113/jphysiol.2004.063859; Costa RMB, 2003, GENE EXPR PATTERNS, V3, P509, DOI 10.1016/S1567-133X(03)00086-3; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Deitmer JW, 2002, J NEUROCHEM, V80, P721, DOI 10.1046/j.0022-3042.2002.00765.x; Dinour D, 2004, J BIOL CHEM, V279, P52238, DOI 10.1074/jbc.M406591200; Frayling TM, 2003, DIABETES, V52, P872, DOI 10.2337/diabetes.52.3.872; Furuta A, 2003, AM J PATHOL, V163, P779, DOI 10.1016/S0002-9440(10)63705-4; Ganapathy V, 2005, BIOCHEM SOC T, V33, P237, DOI 10.1042/BST0330237; GEIBISH G, 2003, MED PHYSL, P790; Gerhart DZ, 1999, NEUROSCIENCE, V92, P367, DOI 10.1016/S0306-4522(98)00699-X; Gopal E, 2005, BIOCHEM J, V388, P309, DOI 10.1042/BJ20041916; Gopal E, 2004, J BIOL CHEM, V279, P44522, DOI 10.1074/jbc.M405365200; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Hertz L, 2005, J NEUROSCI RES, V79, P11, DOI 10.1002/jnr.20294; Hong CB, 2005, CANCER RES, V65, P3617, DOI 10.1158/0008-5472.CAN-05-0048; JORGENSEN KE, 1986, BIOCHIM BIOPHYS ACTA, V860, P632, DOI 10.1016/0005-2736(86)90563-8; Juel C, 1999, J PHYSIOL-LONDON, V517, P633, DOI 10.1111/j.1469-7793.1999.0633s.x; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100; Lindgren CM, 2002, AM J HUM GENET, V70, P509, DOI 10.1086/338629; MANGANEL M, 1985, AM J PHYSIOL, V249, pF400, DOI 10.1152/ajprenal.1985.249.3.F400; MENGUAL R, 1990, J BIOL CHEM, V265, P292; MENGUAL R, 1989, J MEMBRANE BIOL, V108, P197, DOI 10.1007/BF01871734; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; Naoumova RP, 2003, ARTERIOSCL THROM VAS, V23, P2070, DOI 10.1161/01.ATV.0000095975.35247.9F; NORD E, 1982, AM J PHYSIOL, V243, pF456, DOI 10.1152/ajprenal.1982.243.5.F456; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pike Nicholas B, 2004, Curr Opin Investig Drugs, V5, P271; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; Porra V, 2005, J CLIN ENDOCR METAB, V90, P3028, DOI 10.1210/jc.2004-1394; Rodriguez AM, 2002, J CLIN ENDOCR METAB, V87, P3500, DOI 10.1210/jc.87.7.3500; Romero MF, 2000, J BIOL CHEM, V275, P24552, DOI 10.1074/jbc.M003476200; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; Shepherd J, 2005, CURR MED RES OPIN, V21, P665, DOI 10.1185/030079905X43677; Shoulders CC, 2004, HUM MOL GENET, V13, pR149, DOI 10.1093/hmg/ddh069; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF342, DOI 10.1152/ajprenal.1989.256.2.F342; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF354, DOI 10.1152/ajprenal.1989.256.2.F354; Soengas JL, 2002, COMP BIOCHEM PHYS B, V131, P271, DOI 10.1016/S1096-4959(02)00022-2; Srinivas SR, 2005, BIOCHEM J, V392, P655, DOI 10.1042/BJ20050927; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; Thirumurugan A, 2004, NEPHROL DIAL TRANSPL, V19, P1767, DOI 10.1093/ndt/gfh213; THISSE C, 1993, DEVELOPMENT, V119, P1203; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; Ueno M, 2004, TUMOR BIOL, V25, P134, DOI 10.1159/000079145; Wise A, 2003, J BIOL CHEM, V278, P9869, DOI 10.1074/jbc.M210695200; Wright EM, 2004, PHYSIOLOGY, V19, P370, DOI 10.1152/physiol.00026.2004; Wright EM, 2004, PFLUG ARCH EUR J PHY, V447, P510, DOI 10.1007/s00424-003-1063-6; Yoon HY, 1997, BIOCHEM BIOPH RES CO, V234, P90, DOI 10.1006/bbrc.1997.6588	62	16	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11996	12009		10.1074/jbc.M609313200	http://dx.doi.org/10.1074/jbc.M609313200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17255103	hybrid			2022-12-27	WOS:000245941900042
J	Saeki, M; Irie, Y; Ni, L; Itsuki, Y; Terao, Y; Kawabata, S; Kamisaki, Y				Saeki, Makio; Irie, Yasuyuki; Ni, Lin; Itsuki, Yuki; Terao, Yutaka; Kawabata, Shigetada; Kamisaki, Yoshinori			Calcineurin potentiates the activation of procaspase-3 by accelerating its proteolytic maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; PROGRAMMED CELL-DEATH; CYTOCHROME-C; CASPASE ACTIVATION; APOPTOSIS; COMPLEX; PROTEIN; DEPHOSPHORYLATION; APAF-1; CED-4	We have previously shown that procaspase-3 exists in a high molecular weight complex in neonatal rat brain. Here, we purify and identify the protein that interacts with procaspase-3 from rat neonatal cortex. We searched binding proteins to procaspase-3 from a cytosolic extract of neonatal rat brain using chromatogram, two-dimensional gel electrophoresis, and far Western immunoblot. Analysis by tandem mass spectrometry identified the protein as a regulatory subunit of calcineurin ( calcineurin B). Overexpression of calcineurin B in HEK293 cells potentiated processing of caspase-3 and apoptosis triggered by tumor necrosis factor-alpha and cycloheximide treatment. In a cell-free system, overexpression of calcineurin B in HEK293 cells markedly increased processing of caspase-3 by cytochrome c. Immunodepletion of calcineurin B from cytosolic extracts from Jurkat cells decreased processing of caspase-3 by cytochrome c. Knockdown of calcineurin B by RNA interference resulted in reduced apoptosis in HEK293 cells but not in caspase-3-deficient MCF-7 cells. These results suggest that calcineurin B potentiates the activation of procaspase-3 by accelerating its proteolytic maturation.	Osaka Univ, Dept Pharmacol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pharmacol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Dent, Dept Oral & Mol Microbiol, Suita, Osaka 5650871, Japan; Shanghai Univ E Inst, Div Nitr Oxide & Inflammatory Med, Shanghai 201203, Peoples R China	Osaka University; Osaka University; Osaka University	Saeki, M (corresponding author), Osaka Univ, Dept Pharmacol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	msaeki@dent.osaka-u.ac.jp		Terao, Yutaka/0000-0002-4450-5583				Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Feng B, 1999, BIOCHEMISTRY-US, V38, P12481, DOI 10.1021/bi990492w; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kurosu K, 2004, NEUROCHEM INT, V44, P199, DOI 10.1016/S0197-0186(03)00168-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Saeki M, 2002, J CELL BIOCHEM, V84, P708, DOI 10.1002/jcb.10086; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Springer JE, 2000, J NEUROSCI, V20, P7246; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Willis S, 2003, J CELL SCI, V116, P4053, DOI 10.1242/jcs.00754; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Yang SA, 2000, BIOCHEMISTRY-US, V39, P16147, DOI 10.1021/bi001321q; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	24	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11786	11794		10.1074/jbc.M609347200	http://dx.doi.org/10.1074/jbc.M609347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324936	hybrid			2022-12-27	WOS:000245941900021
J	Zhao, L; Kwon, MJ; Huang, SR; Lee, JY; Fukase, K; Inohara, N; Hwang, DH				Zhao, Ling; Kwon, Myung-Ja; Huang, Shurong; Lee, Joo Y.; Fukase, Koichi; Inohara, Naohiro; Hwang, Daniel H.			Differential modulation of nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; TOLL-LIKE RECEPTOR-4; KAPPA-B ACTIVATION; MURAMYL DIPEPTIDE RECOGNITION; HOST-MICROBIAL INTERACTIONS; INTERLEUKIN-8 EXPRESSION; BACTERIAL PEPTIDOGLYCAN; CROHNS-DISEASE; TNF-ALPHA; FAMILY	Nucleotide-binding oligomerization domain-containing proteins ( Nods) are intracellular pattern recognition receptors recognizing conserved moieties of bacterial peptidoglycan through their leucine-rich repeats domain. The agonists for Nods activate proinflammatory signaling pathways, including NF-kappa B pathways. The results from our previous studies showed that the activation of TLR4 and TLR2, leucine-rich repeat-containing pattern recognition receptors, were differentially modulated by saturated and n-3 polyunsaturated fatty acids in macrophages and dendritic cells. Here, we show the differential modulation of NF-kappa B activation and interleukin-8 ( IL-8) expression in colonic epithelial cells HCT116 by saturated and unsaturated fatty acids mediated through Nods proteins. Lauric acid ( C12:0) dose dependently activated NF-kappa B and induced IL-8 expression in HCT116 cells, which express both Nod1 and Nod2, but not detectable amounts of TLR2 and TLR4. These effects of lauric acid were inhibited by dominant negative forms of Nod1 or Nod2, but not by dominant negative forms of TLR2, TLR4, and TLR5. The effects of lauric acid were also attenuated by small RNA interference targeting Nod1 or Nod2. In contrast, polyunsaturated fatty acids, especially n-3 polyunsaturated fatty acids, inhibited the activation of NF-kappa B and IL-8 expression induced by lauric acid or known Nods ligands in HCT116. Furthermore, lauric acid induced, but docosahexaenoic acid inhibited lauric acid- or Nod2 ligand MDP-induced, Nod2 oligomerization in HEK293T cells transfected with Nod2. Together, these results provide new insights into the role of dietary fatty acids in modulating inflammation in colon epithelial cells. The results suggest that Nods may be involved in inducing sterile inflammation, one of the key etiological conditions in the development of many chronic inflammatory diseases.	USDA ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	United States Department of Agriculture (USDA); University of California System; University of California Davis; Gwangju Institute of Science & Technology (GIST); Osaka University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hwang, DH (corresponding author), USDA ARS, Western Human Nutr Res Ctr, 430 W Hlth Sci Dr,1 Shields Ave, Davis, CA 95616 USA.	dhwang@whnrc.usda.gov			NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064007, R01DK041868] Funding Source: NIH RePORTER; NCI NIH HHS [CA75613] Funding Source: Medline; NIDDK NIH HHS [DK064007, DK41868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Belluzzi A, 2000, AM J CLIN NUTR, V71, p339S, DOI 10.1093/ajcn/71.1.339s; Carneiro LAM, 2004, MICROBES INFECT, V6, P609, DOI 10.1016/j.micinf.2004.01.012; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; CHANG HR, 1992, METABOLISM, V41, P1, DOI 10.1016/0026-0495(92)90181-9; Fritsche KL, 1997, CLIN SCI, V92, P95, DOI 10.1042/cs0920095; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68; Haraguchi M, 2002, ONCOL REP, V9, P159; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hisamatsu T, 2003, J BIOL CHEM, V278, P32962, DOI 10.1074/jbc.M304355200; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; INOHARA N, 2004, ANN REV BIOCH; Inoue K, 2000, CANCER RES, V60, P2290; IZZO RS, 1993, SCAND J GASTROENTERO, V28, P296, DOI 10.3109/00365529309090244; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Kitadai Y, 1998, AM J PATHOL, V152, P93; Kuniyasu H, 2000, AM J PATHOL, V157, P1523, DOI 10.1016/S0002-9440(10)64790-6; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; Lee JY, 2004, J BIOL CHEM, V279, P16971, DOI 10.1074/jbc.M312990200; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; MAZZUCCHELLI L, 1994, AM J PATHOL, V144, P997; McLaughlan JM, 1997, J PATHOL, V181, P87; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Parilla NW, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-84; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; Taramelli D, 1998, T ROY SOC TROP MED H, V92, P57, DOI 10.1016/S0035-9203(98)90954-3; Uguccioni M, 1999, AM J PATHOL, V155, P331, DOI 10.1016/S0002-9440(10)65128-0; Villarete LH, 1996, AM J PATHOL, V149, P1685; Weatherill AR, 2005, J IMMUNOL, V174, P5390, DOI 10.4049/jimmunol.174.9.5390; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	55	90	96	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11618	11628		10.1074/jbc.M608644200	http://dx.doi.org/10.1074/jbc.M608644200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17303577	hybrid			2022-12-27	WOS:000245941900003
J	Liang, M; Tian, J; Liu, LJ; Pierre, S; Liu, J; Shapiro, J; Xie, ZJ				Liang, Man; Tian, Jiang; Liu, Lijun; Pierre, Sandrine; Liu, Jiang; Shapiro, Joseph; Xie, Zi-Jian			Identification of a pool of non-pumping Na/K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; CLATHRIN-DEPENDENT MECHANISM; SUBUNIT MESSENGER-RNAS; PROTEIN-KINASE-C; SODIUM-PUMP; CARDIAC-GLYCOSIDES; LLC-PK1 CELLS; ALPHA-SUBUNIT; OUABAIN; NA,K-ATPASE	Recent studies have ascribed many non-pumping functions to the Na/K-ATPase. Here, we present experimental evidence demonstrating that over half of the plasma membrane Na/K-ATPase in LLC-PK1 cells is performing cellular functions other than ion pumping. This "non-pumping" pool of Na/K-ATPase, like the pumping pump, binds ouabain. Depletion of either cholesterol or caveolin-1 moves some of the "non-pumping" Na/K-ATPase into the pumping pool. Graded knock-down of the alpha 1 subunit of the Na/K-ATPase eventually results in loss of this "non-pumping" pool while preserving the pumping pool. Our prior studies indicate that a loss of the non-pumping pool is associated with a loss of receptor function as evidenced by the failure of ouabain administration to induce the activation of Src and/or ERK. Therefore, our new findings suggest that a substantial amount of surface-expressed Na/K-ATPase, at least in some types of cells, may function as non-canonical ouabain-binding receptors.	Univ Toledo, Dept Physiol Pharmacol Metab & Cardiovasc Sci, Toledo, OH 43614 USA; Univ Toledo, Dept Med, Toledo, OH 43614 USA	University System of Ohio; University of Toledo; University System of Ohio; University of Toledo	Xie, ZJ (corresponding author), Univ Toledo, Dept Physiol Pharmacol Metab & Cardiovasc Sci, Hlth Sci Campus,Mail Stop 1008,3000 Arlington Ave, Toledo, OH 43614 USA.	zxie@meduohio.edu	Liu, Jiang/AAF-2742-2021		NHLBI NIH HHS [HL-67963, HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL067963] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aizman O, 2001, P NATL ACAD SCI USA, V98, P13420, DOI 10.1073/pnas.221315298; Aydemir-Koksoy A, 2001, J BIOL CHEM, V276, P46605, DOI 10.1074/jbc.M106178200; BAKER PF, 1972, J PHYSIOL-LONDON, V224, P441, DOI 10.1113/jphysiol.1972.sp009904; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BHUTADA A, 1990, AM J PHYSIOL, V258, pC1044, DOI 10.1152/ajpcell.1990.258.6.C1044; BHUTADA A, 1991, AM J PHYSIOL, V261, pC699, DOI 10.1152/ajpcell.1991.261.4.C699; BOARDMAN LJ, 1972, J PHYSIOL-LONDON, V225, P619, DOI 10.1113/jphysiol.1972.sp009960; Bossuyt J, 2005, CIRC RES, V97, P558, DOI 10.1161/01.RES.0000181172.27931.c3; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; ELMERNISSI G, 1984, AM J PHYSIOL, V247, pF158, DOI 10.1152/ajprenal.1984.247.1.F158; Ferrandi M, 1999, AM J PHYSIOL-HEART C, V277, pH1338, DOI 10.1152/ajpheart.1999.277.4.H1338; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; Gimenez I, 2005, AM J PHYSIOL-RENAL, V289, pF1341, DOI 10.1152/ajprenal.00214.2005; GONZALEZMARISCA.L, 1990, AM J PHYSIOL, V259, P978; GOTTARDI CJ, 1995, AM J PHYSIOL, V268, P285; GRIFFITHS NM, 1991, BRIT J PHARMACOL, V104, P419, DOI 10.1111/j.1476-5381.1991.tb12445.x; HABER RS, 1987, AM J PHYSIOL, V253, pF26, DOI 10.1152/ajprenal.1987.253.1.F26; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; Iglesias-Bartolome R, 2006, FEBS J, V273, P1744, DOI 10.1111/j.1742-4658.2006.05194.x; ITO S, 1992, J PHARMACOL EXP THER, V262, P109; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KIM D, 1984, J PHARMACOL EXP THER, V231, P326; KLAUSNER R, 1985, MATH MODELING RECEPT, P259; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; LAMB JF, 1971, J PHYSL, V213; Lavoie L, 1997, BIOCHEMISTRY-US, V36, P7726, DOI 10.1021/bi970109s; Lee K, 2001, BIOCHEM J, V353, P377, DOI 10.1042/0264-6021:3530377; Liang M, 2006, J BIOL CHEM, V281, P19709, DOI 10.1074/jbc.M512240200; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2002, KIDNEY INT, V62, P2118, DOI 10.1046/j.1523-1755.2002.00672.x; Liu J, 2004, KIDNEY INT, V66, P227, DOI 10.1111/j.1523-1755.2004.00723.x; Liu J, 2000, J BIOL CHEM, V275, P27838; Liu JA, 2005, KIDNEY INT, V67, P1844, DOI 10.1111/j.1523-1755.2005.00283.x; LIU L, 2006, AM J PHYSIOL, pC659; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; LUCIO FJ, 1991, EXP PHYSIOL, V76, P437, DOI 10.1113/expphysiol.1991.sp003510; Ma TY, 2000, MICROSC RES TECHNIQ, V51, P156, DOI 10.1002/1097-0029(20001015)51:2<156::AID-JEMT7>3.0.CO;2-J; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; POLLACK LR, 1981, AM J PHYSIOL, V241, pC173, DOI 10.1152/ajpcell.1981.241.5.C173; Rajasekaran SA, 2005, SEMIN NEPHROL, V25, P328, DOI 10.1016/j.semnephrol.2005.03.008; Schoner W, 2005, SEMIN NEPHROL, V25, P343, DOI 10.1016/j.semnephrol.2005.03.010; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Wang HJ, 2004, J BIOL CHEM, V279, P17250, DOI 10.1074/jbc.M313239200; YEAGLE PL, 1988, BIOCHEMISTRY-US, V27, P6449, DOI 10.1021/bi00417a037; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zhang XQ, 2006, J APPL PHYSIOL, V100, P212, DOI 10.1152/japplphysiol.00757.2005	51	193	206	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10585	10593		10.1074/jbc.M609181200	http://dx.doi.org/10.1074/jbc.M609181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17296611	hybrid			2022-12-27	WOS:000245941000052
J	Lim, Y; Park, H; Jeon, J; Han, I; Kim, J; Jho, EH; Oh, ES				Lim, Yangmi; Park, Haein; Jeon, Jihyun; Han, Innoc; Kim, Jinsook; Jho, Eek-Hoon; Oh, Eok-Soo			Focal adhesion kinase is negatively regulated by phosphorylation at tyrosine 407	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-CYCLE; SRC SH2; FAK; DOMAIN; MIGRATION; PATHWAY; SITE	Focal adhesion kinase ( FAK) mediates signal transduction in response to multiple extracellular inputs via tyrosine phosphorylation at specific residues. Although several tyrosine phosphorylation events have been linked to FAK activation and downstream signal transduction, the function of FAK phosphorylation at Tyr(407) was previously unknown. Here, we show for the first time that phosphorylation of FAK Tyr(407) increases during serum starvation, contact inhibition, and cell cycle arrest, all conditions under which activating FAK Tyr(397) phosphorylation decreases. Transfection of NIH3T3 cells with a phosphorylationmimicking FAK 407E mutant decreased autophosphorylation at Tyr(397) and inhibited bothFAKkinase activity in vitro and FAK- mediated functions such as cell adhesion, spreading, proliferation, and migration. The opposite effects were observed in cells transfected with nonphosphorylatable mutant FAK F-407. Taken together, these data suggest the novel concept that FAK Tyr(407) phosphorylation negatively regulates the enzymatic and biological activities of FAK.	Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Inha Univ, Coll Med, Dept Physiol & Biophys, Inchon 402751, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea	Ewha Womans University; Ewha Womans University; Inha University; University of Seoul	Oh, ES (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea.	OhES@ewha.ac.kr		Jho, Eek-hoon/0000-0003-2414-6234				Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Busse D, 2001, SEMIN ONCOL, V28, P47, DOI 10.1053/sonc.2001.28550; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hauck CR, 2001, CANCER RES, V61, P7079; Jacamo RO, 2005, BIOCHEM BIOPH RES CO, V334, P1299, DOI 10.1016/j.bbrc.2005.07.034; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Leu TH, 2002, ONCOGENE, V21, P6992, DOI 10.1038/sj.onc.1205904; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	27	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10398	10404		10.1074/jbc.M609302200	http://dx.doi.org/10.1074/jbc.M609302200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17303567	hybrid			2022-12-27	WOS:000245941000030
J	Tomimatsu, N; Tahimic, CGT; Otsuki, A; Burma, S; Fukuhara, A; Sato, K; Shiota, G; Oshimura, M; Chen, DJ; Kurimasa, A				Tomimatsu, Nozomi; Tahimic, Candice G. T.; Otsuki, Akihiro; Burma, Sandeep; Fukuhara, Akiko; Sato, Kenzo; Shiota, Goshi; Oshimura, Mitsuo; Chen, David J.; Kurimasa, Akihiro			Ku70/80 modulates ATM and ATR signaling pathways in response to DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DAMAGE-INDUCED PHOSPHORYLATION; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA; PHOSPHOINOSITIDE 3-KINASE; RADIOSENSITIZING AGENT; CATALYTIC SUBUNIT; REQUIRES ATM; KU PROTEIN; CHECKPOINT	Double strand break (DSB) recognition is the first step in the DSB damage response and involves activation of ataxia telangiectasiamutated( ATM) and phosphorylation of targets such as p53 to trigger cell cycle arrest, DNA repair, or apoptosis. It was reported that activation of ATM- and Rad3- related (ATR) kinase by DSBs also occurs in an ATM- dependent manner. On the other hand, Ku70/ 80 is known to participate at a later time point in the DSB response, recruiting DNA-PKcs to facilitate non-homologous end joining. Because Ku70/ 80 has a high affinity for broken DNA ends and is abundant in nuclei, we examined their possible involvement in other aspects of the DSB damage response, particularly in modulating the activity of ATM and other phosphatidylinositol ( PI) 3-related kinases during DSB recognition. We thus analyzed p53(Ser18) phosphorylation in irradiated Ku- deficient cells and observed persistent phosphorylation in these cells relative to wild type cells. ATM or ATR inhibition revealed that this phosphorylation is mainly mediated by ATM- dependent ATR activity at 2 h post-ionizing radiation in wild type cells, whereas in Ku-deficient cells, this occurs mainly through direct ATM activity, with a secondary contribution from ATR via a novel ATM- independent mechanism. Using ATM/Ku70 double-null cell lines, which we generated, we confirmed that ATM- independent ATR activity contributed to persistent phosphorylation of p53Ser18 in Ku- deficient cells at 12 h post- ionizing radiation. In summary, we discovered a novel role for Ku70/ 80 in modulating ATM-dependentATR activation during DSB damage response and demonstrated that these proteins confer a protective effect against ATM- independent ATR activation at later stages of the DSB damage response.	Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Tottori 6838503, Japan; Tottori Univ, Sch Life Sci, Tottori 6838503, Japan; Univ Texas, Southwestern Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA; Tottori Univ, Century COE Program 21, Tottori 6838503, Japan; Tottori Univ, Res Core Chromosome Engn Technol, Tottori 6838503, Japan	Tottori University; Tottori University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tottori University; Tottori University	Kurimasa, A (corresponding author), Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, 86 Nishimachi, Tottori 6838503, Japan.		Otsuki, Akihiro/C-1179-2009; Otsuki, Akihiro/AAW-8479-2020; Otsuki, Akihiro/AAI-5904-2021	Otsuki, Akihiro/0000-0001-9173-1148; Tahimic, Candice/0000-0001-5862-2652				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Drouet J, 2006, J BIOL CHEM, V281, P27784, DOI 10.1074/jbc.M603047200; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Liu QH, 2000, GENE DEV, V14, P1448; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Muller C, 2005, CELL CYCLE, V4, P438, DOI 10.4161/cc.4.3.1565; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ohsawa T, 2000, J Dermatol, V27, P244; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; POWIS G, 1994, CANCER RES, V54, P2419; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stavridi ES, 2005, NAT CELL BIOL, V7, P648, DOI 10.1038/ncb0705-648; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wang X, 2003, J BIOL CHEM, V278, P30869, DOI 10.1074/jbc.M301876200; Wang X, 2002, CANCER RES, V62, P6031; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou JQ, 2006, CANCER LETT, V243, P9, DOI 10.1016/j.canlet.2006.01.026; Zhou XY, 2002, ONCOGENE, V21, P6377, DOI 10.1038/sj.onc.1205782	49	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10138	10145		10.1074/jbc.M611880200	http://dx.doi.org/10.1074/jbc.M611880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17272272	Green Submitted, hybrid			2022-12-27	WOS:000245941000003
J	Sun, HY; Lin, SW; Ko, TP; Pan, JF; Liu, CL; Lin, CN; Wang, AHJ; Lin, CH				Sun, Han-Yu; Lin, Sheng-Wei; Ko, Tzu-Ping; Pan, Jia-Fu; Liu, Chia-Ling; Lin, Chun-Nan; Wang, Andrew H. -J.; Lin, Chun-Hung			Structure and mechanism of Helicobacter pylori fucosyltransferase - A basis for lipopolysaccharide variation and inhibitor design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; CRYSTAL-STRUCTURE; HUMAN ALPHA-1,3-FUCOSYL-TRANSFERASE; BIOSYNTHETIC-PATHWAY; PERSISTENT INFECTION; ULCER DISEASE; LEWIS-Y; EXPRESSION; GLUCOSYLTRANSFERASE; GLYCOSYLTRANSFERASES	Helicobacter pylori alpha 1,3-fucosyltransferase (FucT) is involved in catalysis to produce the Lewis x trisaccharide, the major component of the bacteria's lipopolysaccharides, which has been suggested to mimic the surface sugars in gastric epithelium to escape host immune surveillance. We report here three x-ray crystal structures of FucT, including the FucT-GDPfucose and FucT center dot GDP complexes. The protein structure is typical of the glycosyltransferase-B family despite little sequence homology. We identified a number of catalytically important residues, including Glu-95, which serves as the general base, and Glu-249, which stabilizes the developing oxonium ion during catalysis. The residues Arg-195, Tyr-246, Glu-249, and Lys-250 serve to interact with the donor substrate, GDP-fucose. Variations in the protein and ligand conformations, as well as a possible FucT dimer, were also observed. We propose a catalytic mechanism and a model of polysaccharide binding not only to explain the observed variations in H. pylori lipopolysaccharides, but also to facilitate the development of potent inhibitors.	Natl Taiwan Univ, Inst Biochem Sci, Taipei 10642, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan; Acad Sinica, Natl Core Facil HIgh Throughput Prog Crystallog, Taipei 11529, Taiwan	National Taiwan University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Academia Sinica - Taiwan	Wang, AHJ (corresponding author), Natl Taiwan Univ, Inst Biochem Sci, Taipei 10642, Taiwan.	ahjwang@gate.sinica.edu.tw; chunhung@gate.sinica.edu.tw	Lin, Sheng-Wei/G-8142-2015; Lin, Chun-Hung/AAM-9711-2021	Lin, Sheng-Wei/0000-0001-7777-2090; Lin, Chun-Hung/0000-0002-6795-8825				BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gibson RP, 2004, J BIOL CHEM, V279, P1950, DOI 10.1074/jbc.M307643200; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; Hallet B, 2001, CURR OPIN MICROBIOL, V4, P570, DOI 10.1016/S1369-5274(00)00253-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee LV, 2003, J AM CHEM SOC, V125, P9588, DOI 10.1021/ja0302836; Lin SW, 2006, BIOCHEMISTRY-US, V45, P8108, DOI 10.1021/bi0601297; Lozniewski A, 2003, INFECT IMMUN, V71, P2902, DOI 10.1128/IAI.71.5.2902-2906.2003; Ma B, 2006, J BIOL CHEM, V281, P6385, DOI 10.1074/jbc.M511320200; Ma B, 2003, J BIOL CHEM, V278, P21893, DOI 10.1074/jbc.M301704200; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; Mulichak AM, 2004, BIOCHEMISTRY-US, V43, P5170, DOI 10.1021/bi036130c; Mulichak AM, 2003, P NATL ACAD SCI USA, V100, P9238, DOI 10.1073/pnas.1233577100; Mulichak AM, 2001, STRUCTURE, V9, P547, DOI 10.1016/S0969-2126(01)00616-5; Murray BW, 1997, BIOCHEMISTRY-US, V36, P823, DOI 10.1021/bi962284z; Nakamura S, 1997, CANCER-AM CANCER SOC, V79, P3, DOI 10.1002/(SICI)1097-0142(19970101)79:1<3::AID-CNCR2>3.0.CO;2-P; Ni LS, 2006, BIOCHEMISTRY-US, V45, P2139, DOI 10.1021/bi0524013; Nilsson C, 2006, P NATL ACAD SCI USA, V103, P2863, DOI 10.1073/pnas.0511119103; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsonnet J, 1996, NEW ENGL J MED, V335, P278, DOI 10.1056/NEJM199607253350411; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Rasko DA, 2000, J BIOL CHEM, V275, P4988, DOI 10.1074/jbc.275.7.4988; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996	40	93	97	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9973	9982		10.1074/jbc.M610285200	http://dx.doi.org/10.1074/jbc.M610285200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17251184	hybrid, Green Published			2022-12-27	WOS:000245421700072
J	Ciftci-Yilmaz, S; Morsy, MR; Song, LH; Coutu, A; Krizek, BA; Lewis, MW; Warren, D; Cushman, J; Connolly, EL; Mittler, R				Ciftci-Yilmaz, Sultan; Morsy, Mustafa R.; Song, Luhua; Coutu, Alicia; Krizek, Beth A.; Lewis, Michael W.; Warren, Daniel; Cushman, John; Connolly, Erin L.; Mittler, Ron			The EAR-motif of the Cys2/His2-type zinc finger protein Zat7 plays a key role in the defense response of Arabidopsis to salinity stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ASCORBATE PEROXIDASE-1; ROLLING CIRCLE AMPLIFICATION; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; OXIDATIVE STRESS; REACTIVE OXYGEN; ABIOTIC STRESS; SALT TOLERANCE; PLANT DEFENSE; REPRESSORS	Cyst/His2-type zinc finger proteins, which contain the EAR transcriptional repressor domain, are thought to play a key role in regulating the defense response of plants to biotic and abiotic stress conditions. Although constitutive expression of several of these proteins was shown to enhance the tolerance of transgenic plants to abiotic stress, it is not clear whether the EAR-motif of these proteins is involved in this function. In addition, it is not clear whether suppression of plant growth, induced in transgenic plants by different Cyst/His2 EAR-containing proteins, is mediated by the EAR-domain. Here we report that transgenic Arabidopsis plants constitutively expressing the Cyst/His2 zinc finger protein Zat7 have suppressed growth and are more tolerant to salinity stress. A deletion or a mutation of the EAR-motif of Zat7 abolishes salinity tolerance without affecting growth suppression. These results demonstrate that the EAR-motif of Zat7 is directly involved in enhancing the tolerance of transgenic plants to salinity stress. In contrast, the EAR-motif appears not to be involved in suppressing the growth of transgenic plants. Further analysis of Zat7 using RNAi lines suggests that Zat7 functions in Arabidopsis to suppress a repressor of defense responses. A yeast two-hybrid analysis identified putative interactors of Zat7 and the EAR-domain, including WRKY70 and HASTY, a protein involved in miRNA transport. Our findings demonstrate that the EAR-domain of Cyst/His2-type zinc finger proteins plays a key role in the defense response of Arabidopsis to abiotic stresses.	Univ Nevada, Dept Biochem & Mol Biol, Reno, NV 89557 USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Mittler, R (corresponding author), Univ Nevada, Dept Biochem & Mol Biol, Mail Stop 200, Reno, NV 89557 USA.	ronm@unr.edu	Mittler, Ron/ABE-6496-2020; Connolly, Erin L/B-7648-2013; Morsy, Mustafa R/E-6245-2013; Ciftci-Yilmaz, Sultan/D-7971-2017	Morsy, Mustafa R/0000-0003-1803-4893; 	NCRR NIH HHS [RR-03-008] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Blumwald E, 2003, BIOTECHNOL GENET ENG, V20, P261, DOI 10.1080/02648725.2003.10648046; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Davletova S, 2005, PLANT PHYSIOL, V139, P847, DOI 10.1104/pp.105.068254; Ding XD, 2004, ANAL BIOCHEM, V331, P195, DOI 10.1016/j.ab.2004.03.052; Ding XD, 2003, BIOTECHNIQUES, V35, P774, DOI 10.2144/03354st08; Englbrecht CC, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-39; Eulgem T, 2005, TRENDS PLANT SCI, V10, P71, DOI 10.1016/j.tplants.2004.12.006; Horton P, 2006, SER ADV BIOINFORM, V3, P39, DOI 10.1142/9781860947292_0007; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Kazan K, 2006, TRENDS PLANT SCI, V11, P109, DOI 10.1016/j.tplants.2006.01.004; Kazuoka T, 2000, PLANT J, V24, P191, DOI 10.1046/j.1365-313x.2000.00864.x; LeClere S, 2001, PLANT MOL BIOL, V46, P695, DOI 10.1023/A:1011699722052; Lee H, 2002, EMBO J, V21, P2692, DOI 10.1093/emboj/21.11.2692; Li J, 2004, PLANT CELL, V16, P319, DOI 10.1105/tpc.016980; Li J, 2006, PLANT J, V46, P477, DOI 10.1111/j.1365-313X.2006.02712.x; Miller G, 2006, ANN BOT-LONDON, V98, P279, DOI 10.1093/aob/mcl107; Mittler R, 2001, PLANT J, V25, P407, DOI 10.1046/j.1365-313x.2001.00975.x; Mittler R, 2006, FEBS LETT, V580, P6537, DOI 10.1016/j.febslet.2006.11.002; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Ohta M, 2001, PLANT CELL, V13, P1959, DOI 10.1105/tpc.13.8.1959; Park MY, 2005, P NATL ACAD SCI USA, V102, P3691, DOI 10.1073/pnas.0405570102; Pnueli L, 2003, PLANT J, V34, P187, DOI 10.1046/j.1365-313X.2003.01715.x; Rizhsky L, 2004, J BIOL CHEM, V279, P11736, DOI 10.1074/jbc.M313350200; Sakamoto H, 2000, GENE, V248, P23, DOI 10.1016/S0378-1119(00)00133-5; Sakamoto H, 2004, PLANT PHYSIOL, V136, P2734, DOI 10.1104/pp.104.046599; Sunkar R, 2006, PLANT CELL, V18, P2051, DOI 10.1105/tpc.106.041673; Suzuki N, 2005, PLANT PHYSIOL, V139, P1313, DOI 10.1104/pp.105.070110; Thiel G, 2004, EUR J BIOCHEM, V271, P2855, DOI 10.1111/j.1432-1033.2004.04174.x; Vinocur B, 2005, CURR OPIN BIOTECH, V16, P123, DOI 10.1016/j.copbio.2005.02.001; Vogel JT, 2005, PLANT J, V41, P195, DOI 10.1111/j.1365-313X.2004.02288.x; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	35	191	216	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9260	9268		10.1074/jbc.M611093200	http://dx.doi.org/10.1074/jbc.M611093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259181	hybrid, Green Published			2022-12-27	WOS:000245780300073
J	Fujikawa, T; Shiraha, H; Ueda, N; Takaoka, N; Nakanishi, Y; Matsuo, N; Tanaka, S; Nishina, SI; Suzuki, M; Takaki, A; Sakaguchi, K; Shiratori, Y				Fujikawa, Tatsuya; Shiraha, Hidenori; Ueda, Naoki; Takaoka, Nobuyuki; Nakanishi, Yutaka; Matsuo, Noriyuki; Tanaka, Shigetomi; Nishina, Shin-ichi; Suzuki, Mayumi; Takaki, Akinobu; Sakaguchi, Kohsaku; Shiratori, Yasushi			Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR; INCREASED EXPRESSION; ALPHA-FETOPROTEIN; CLINICAL-SIGNIFICANCE; SIGNAL-TRANSDUCTION; TUMOR PROGRESSION; TYROSINE KINASE; VEGF RECEPTOR-1; VENOUS INVASION	Des-gamma-carboxyl prothrombin (DCP) is a well recognized tumor marker for hepatocellular carcinoma. Previously, we have demonstrated that DCP stimulates cell proliferation in hepatocellular carcinoma cell lines through Met-Janus kinase 1 signal transducer and activator of transcription 3 signaling pathway. In the present study, we demonstrated that DCP induces both cell proliferation and migration in human umbilical vein endothelial cells. DCP was found to bind with the kinase insert domain receptor (KDR), alternatively referred to as vascular endothelial growth factor receptor-2. Furthermore, DCP induced autophosphorylation of KDR and its downstream effector phospholipase C-gamma and mitogen-activated protein kinase (MAPK). To support these results, we showed that DCP-induced cell proliferation and cell migration were inhibited by KDR short interfering RNA, KDR kinase inhibitor, or MAPK inhibitor. In conclusion, these results indicate that DCP is a novel type of vascular endothelial growth factor that possesses potent mitogenic and migrative activities.	Okayama Univ, Grad Sch Med & Dent, Dept Med & Med Sci, Okayama 7008558, Japan	Okayama University	Shiraha, H (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Med & Med Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	hshiraha@md.okayama-u.ac.jp	Fujikawa, Tatsuya/P-1972-2018	Fujikawa, Tatsuya/0000-0003-3819-224X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Deli G, 2005, WORLD J GASTROENTERO, V11, P960, DOI 10.3748/wjg.v11.i7.960; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ding SL, 2003, BLOOD, V101, P4816, DOI 10.1182/blood-2002-06-1731; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gotoh M, 2003, JPN J CLIN ONCOL, V33, P522, DOI 10.1093/jjco/hyg096; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; INOUE S, 1994, AM J GASTROENTEROL, V89, P2222; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Ji-no K, 1998, CANCER-AM CANCER SOC, V82, P1260; Joukov V, 1996, EMBO J, V15, P290; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kim HK, 2003, EUR J CANCER, V39, P184, DOI 10.1016/S0959-8049(02)00596-8; Koike Y, 2001, CANCER, V91, P561, DOI 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Li B, 2002, HYPERTENSION, V39, P1095, DOI 10.1161/01.HYP.0000018588.56950.7A; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mise K, 1998, CLIN CANCER RES, V4, P1475; Mise M, 1996, HEPATOLOGY, V23, P455; Miura H, 1997, J HEPATOL, V27, P854, DOI 10.1016/S0168-8278(97)80323-6; Moon WS, 2003, MODERN PATHOL, V16, P552, DOI 10.1097/01.MP.0000071841.17900.69; Mulcahy Mary F, 2005, Curr Treat Options Oncol, V6, P423, DOI 10.1007/s11864-005-0045-7; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PARK JE, 1994, J BIOL CHEM, V269, P25646; Park YN, 2000, ARCH PATHOL LAB MED, V124, P1061; Poon RTP, 2001, AM J SURG, V182, P298, DOI 10.1016/S0002-9610(01)00708-5; Poon RTP, 2001, J CLIN ONCOL, V19, P1207, DOI 10.1200/JCO.2001.19.4.1207; Poon RTP, 2001, ANN SURG, V233, P227, DOI 10.1097/00000658-200102000-00012; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Roncalli M, 1999, HEPATOLOGY, V30, P1174, DOI 10.1002/hep.510300507; SAKON M, 1992, AM J SURG, V163, P251, DOI 10.1016/0002-9610(92)90111-4; Shimada M, 1996, CANCER, V78, P2094, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2094::AID-CNCR9>3.0.CO;2-O; SUEHIRO T, 1995, SURGERY, V117, P682, DOI 10.1016/S0039-6060(95)80013-1; Sugimachi K, 2002, SURGERY, V131, pS135, DOI 10.1067/msy.2002.119365; Suzuki K, 1996, CANCER RES, V56, P3004; Suzuki M, 2005, J BIOL CHEM, V280, P6409, DOI 10.1074/jbc.M406714200; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tamano M, 2002, HEPATOL RES, V22, P261, DOI 10.1016/S1386-6346(01)00150-4; TERADA T, 1995, HISTOPATHOLOGY, V27, P333, DOI 10.1111/j.1365-2559.1995.tb01523.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Torimura T, 1998, HUM PATHOL, V29, P986, DOI 10.1016/S0046-8177(98)90205-2; UEDA K, 1992, HUM PATHOL, V23, P619, DOI 10.1016/0046-8177(92)90316-U; Uehara S, 1999, CLIN CHIM ACTA, V289, P33, DOI 10.1016/S0009-8981(99)00152-7; Van Belle E, 1998, CIRCULATION, V97, P381; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Yamaguchi R, 2000, ONCOL REP, V7, P725; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zisch AH, 2001, J CONTROL RELEASE, V72, P101, DOI 10.1016/S0168-3659(01)00266-8	61	50	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8741	8748		10.1074/jbc.M609358200	http://dx.doi.org/10.1074/jbc.M609358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255102	hybrid			2022-12-27	WOS:000245780300020
J	Janciauskiene, SM; Nita, IM; Stevens, T				Janciauskiene, Sabina M.; Nita, Izabela M.; Stevens, Tim			alpha(1)-Antitrypsin, old dog, new tricks - alpha 1-Antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevatin cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-A; CYCLIC-AMP; CIGARETTE-SMOKE; TNF-ALPHA; INHIBITOR DEFICIENCY; ADENYLYL-CYCLASE; GENE-EXPRESSION; EMPHYSEMA; PHOSPHODIESTERASE-4	Regulation of serine protease activity is considered to be the sole mechanism for the function of alpha(1)-antitrypsin (AAT). However, recent reports of the anti-inflammatory effects of AAT are hard to reconcile with this classical mechanism. We discovered that two key activities of AAT in vitro, namely inhibition of endotoxin-stimulated tumor necrosis factor-a and enhancement of interleukin-10 in human monocytes, are mediated by an elevation of cAMP and activation of cAMP-dependent protein kinase A. As expected with this type of mechanism, the AAT mediated rise in cAMP and the impact on endotoxin-stimulated tumor necrosis factor-a and interleukin-10 was enhanced when the catabolism of cAMP was blocked by the phosphodiesterase inhibitor rolipram. These effects were still observed with modified forms of AAT lacking protease inhibitor activity.	Lund Univ, Wallenberg Lab, Dept Clin Sci, Malmo Univ Hosp, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Janciauskiene, SM (corresponding author), Lund Univ, Wallenberg Lab, Dept Clin Sci, Malmo Univ Hosp, SE-20502 Malmo, Sweden.	sabina.janciauskiene@med.lu.se						ARORA PK, 1978, NATURE, V274, P589, DOI 10.1038/274589a0; Banner KH, 2004, TRENDS PHARMACOL SCI, V25, P430, DOI 10.1016/j.tips.2004.06.008; Barnette M S, 2000, Curr Opin Pulm Med, V6, P164, DOI 10.1097/00063198-200003000-00014; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryce PJ, 1999, IMMUNOPHARMACOLOGY, V41, P139, DOI 10.1016/S0162-3109(98)00060-5; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CHUNG KF, 2005, SCI STKE, pPE47; Churg A, 2003, AM J RESP CRIT CARE, V168, P199, DOI 10.1164/rccm.200302-203OC; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; Dhami R, 2000, AM J RESP CELL MOL, V22, P244, DOI 10.1165/ajrcmb.22.2.3809; Gao YS, 2001, EUR J PHARMACOL, V418, P111, DOI 10.1016/S0014-2999(01)00929-3; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GRETEN TF, 1995, INT J IMMUNOPHARMACO, V17, P605, DOI 10.1016/0192-0561(95)00058-A; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Houslay MD, 1998, SEMIN CELL DEV BIOL, V9, P161, DOI 10.1006/scdb.1997.0221; HUTCHISON DCS, 1988, AM J MED, V84, P3; Janciauskiene S, 2004, BIOCHEM BIOPH RES CO, V321, P592, DOI 10.1016/j.bbrc.2004.06.123; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; KAMBAYASHI T, 1995, J IMMUNOL, V155, P4909; Knappstein S, 2004, INFECT IMMUN, V72, P4344, DOI 10.1128/IAI.72.8.4344-4350.2004; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; Lewis EC, 2005, P NATL ACAD SCI USA, V102, P12153, DOI 10.1073/pnas.0505579102; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; Mahadeva R, 1998, THORAX, V53, P501, DOI 10.1136/thx.53.6.501; MALEFYT RD, 1991, J EXP MED, V174, P1209; Martorana PA, 2005, AM J RESP CRIT CARE, V172, P848, DOI 10.1164/rccm.200411-1549OC; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NICOSIA S, 1989, FASEB J, V3, P1941, DOI 10.1096/fasebj.3.8.2542112; Nita I, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-12; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; Osawa Y, 2006, AM J PHYSIOL-CELL PH, V290, pC143, DOI 10.1152/ajpcell.00171.2005; Ouagued M, 2005, PULM PHARMACOL THER, V18, P49, DOI 10.1016/j.pupt.2004.09.031; Petrache L, 2006, AM J RESP CRIT CARE, V173, P1222, DOI 10.1164/rccm.200512-1842OC; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; Seldon Paul M., 1998, Cell Biochemistry and Biophysics, V29, P179, DOI 10.1007/BF02737835; SELDON PM, 1995, MOL PHARMACOL, V48, P747; Shames BD, 2001, J SURG RES, V99, P187, DOI 10.1006/jsre.2001.6178; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Stockley RA, 2000, CHEST, V117, p291S, DOI 10.1378/chest.117.5_suppl_1.291S; Stockley RA, 2000, THORAX, V55, P614, DOI 10.1136/thorax.55.7.614; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; TRAVIS J, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P313; TURINO GM, 1969, SCIENCE, V165, P709, DOI 10.1126/science.165.3894.709; Uchiba M, 2004, THROMB HAEMOSTASIS, V92, P1420, DOI 10.1160/TH04-03-0139; Yoshimura T, 1997, GEN PHARMACOL-VASC S, V29, P633, DOI 10.1016/S0306-3623(96)00580-0; Zhang YH, 1997, J CLIN INVEST, V99, P894, DOI 10.1172/JCI119254	56	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8573	8582		10.1074/jbc.M607976200	http://dx.doi.org/10.1074/jbc.M607976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17261591	Green Submitted, hybrid			2022-12-27	WOS:000245780300003
J	Zhang, SF; Zhou, YJ; Trusa, S; Meng, X; Lee, EYC; Lee, MYWT				Zhang, Sufang; Zhou, Yajing; Trusa, Sandra; Meng, Xiao; Lee, Ernest Y. C.; Lee, Marietta Y. W. T.			A novel DNA damage response - Rapid degradation of the p12 subunit of DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; REPLICATION DYNAMICS; CATALYTIC DOMAINS; PROTEIN; INITIATION; EPSILON; RECONSTITUTION; IDENTIFICATION; UBIQUITIN; ATR	Mammalian DNA polymerase (Pol) delta is essential for DNA replication. It consists of four subunits, p125, p50, p68, and p12. We report the discovery that the p12 subunit is rapidly degraded in cultured human cells by DNA damage or replication stress brought about by treatments with UV, methyl methanesulfonate, hydroxyurea, and aphidicolin. The degradation of p12 is due to an accelerated rate of proteolysis that is inhibited by the proteasome inhibitors, MG132 and lactacystin. UV treatment converts Pol delta in vivo to the three-subunit form lacking p12. This was demonstrated by its isolation using immunoaffinity chromatography. The three-subunit enzyme retains activity on poly(dA)/oligo(dT) templates but is impaired in its ability to extend singly primed M13 templates, clearly indicating that its in vivo functions are likely to be compromised. This transformation of Pol delta by modification of its quaternary structure is reversible in vitro by the addition of the p12 subunit and could represent a novel in vivo mechanism for the modulation of Pol delta function. UV and hydroxyurea-triggered p12 degradation is blocked in ATR(-/-) cells but not in ATM(-/-) cells, thereby demonstrating that p12 degradation is regulated by ATR, the apical kinase that regulates the damage response in S-phase. These findings reveal a novel addition to the cellular repertoire of DNA damage responses that also impacts our understanding of the role of Pol delta in both DNA replication and DNA repair.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	Marietta_Lee@NYMC.edu		Zhang, Sufang/0000-0003-3883-023X	NIGMS NIH HHS [GM31973] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Andreassen PR, 2006, CARCINOGENESIS, V27, P883, DOI 10.1093/carcin/bgi319; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; Busby EC, 2000, CANCER RES, V60, P2108; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Chastain PD, 2006, CELL CYCLE, V5, P2160, DOI 10.4161/cc.5.18.3236; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Dell'Era P, 2005, ONCOGENE, V24, P1117, DOI 10.1038/sj.onc.1208359; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Guterman A, 2004, CURR PROTEIN PEPT SC, V5, P201, DOI 10.2174/1389203043379756; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Jurvansuu J, 2005, J VIROL, V79, P569, DOI 10.1128/JVI.79.1.569-580.2005; Kaiser P, 2005, METHOD ENZYMOL, V399, P243, DOI 10.1016/S0076-6879(05)99016-2; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kitagawa R, 2005, COLD SH Q B, V70, P99, DOI 10.1101/sqb.2005.70.002; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Lee M Y, 1981, Prog Nucleic Acid Res Mol Biol, V26, P83; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Lehmann AR, 2006, EXP CELL RES, V312, P2673, DOI 10.1016/j.yexcr.2006.06.010; Li H, 2006, J BIOL CHEM, V281, P14748, DOI 10.1074/jbc.M600322200; Liu G, 2006, BIOCHEM BIOPH RES CO, V349, P360, DOI 10.1016/j.bbrc.2006.08.049; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Liu L, 2003, J BIOL CHEM, V278, P10041, DOI 10.1074/jbc.M208694200; Liu PJ, 2006, J BIOL CHEM, V281, P30631, DOI 10.1074/jbc.M602982200; Luciani MG, 2004, J CELL SCI, V117, P6019, DOI 10.1242/jcs.01400; Machida YJ, 2005, CELL, V123, P13, DOI 10.1016/j.cell.2005.09.019; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; PAINTER RB, 1985, MUTAT RES, V145, P63, DOI 10.1016/0167-8817(85)90041-0; Perucca P, 2006, J CELL SCI, V119, P1517, DOI 10.1242/jcs.02868; Petermann E, 2006, CELL CYCLE, V5, P2203, DOI 10.4161/cc.5.19.3256; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez-Bravo V, 2006, CANCER RES, V66, P8672, DOI 10.1158/0008-5472.CAN-05-4443; Rytkonen AK, 2006, FEBS J, V273, P2984, DOI 10.1111/j.1742-4658.2006.05310.x; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; Shikata Koh, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-21; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tsurimoto T, 2005, GENES CELLS, V10, P13, DOI 10.1111/j.1365-2443.2004.00812.x; Volk S, 2005, METHOD ENZYMOL, V399, P3, DOI 10.1016/S0076-6879(05)99001-0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Xie B, 2002, BIOCHEMISTRY-US, V41, P13133, DOI 10.1021/bi0262707; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	62	70	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15330	15340		10.1074/jbc.M610356200	http://dx.doi.org/10.1074/jbc.M610356200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17317665	hybrid			2022-12-27	WOS:000246589600008
J	Wu, SY; Chiang, CM				Wu, Shwu-Yuan; Chiang, Cheng-Ming			The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RNA-POLYMERASE-II; PAPILLOMAVIRUS E2 PROTEINS; MITOTIC CHROMOSOMES; VIRAL-DNA; P-TEFB; ACTIVATION; COMPLEX; RECOGNITION; RECRUITMENT; INTERACTS	Brd4 is a double bromodomain-containing protein that binds preferentially to acetylated chromatin. It belongs to the BET (bromodomains and extraterminal) family that includes mammalian Brd2, Brd3, Brd4, Brdt, Drosophila Fsh, yeast Bdf1, Bdf2, and corresponding homologues in other species. Brd4 is essential for cellular growth and has been implicated in cell cycle control, DNA replication, and gene rearrangement found in t( 15;19)-associated carcinomas. Recently, Brd4 has been found in several transcription complexes, including the general cofactor Mediator and the P-TEFb elongation factor, and is capable of stimulating HIV-1 transcription in a Tat-independent manner. In addition, Brd4 is used as a cellular adaptor by some animal and human papillomaviruses (HPV) for anchoring viral genomes to mitotic chromosomes. This tethering, mediated by Brd4 interaction with virus-encoded E2 protein, facilitates viral genome segregation during mitosis. Interestingly, Brd4 is also identified in a transcriptional silencing complex assembled by HPVE2 and turns out to be the long sought cellular corepressor that inhibits the expression of HPV-encoded E6 and E7 oncoproteins that antagonize p53 and pRB tumor suppressor activity, respectively. The dual role of Brd4 in gene activation and repression illustrates how a dynamic chromatin-binding adaptor is able to recruit distinct transcriptional regulators to modulate promoter activity through cell cycle progression.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Chiang, CM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	cmc23@cwru.edu			NCI NIH HHS [CA124760, CA103867] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA124760, R01CA103867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbate EA, 2006, MOL CELL, V24, P877, DOI 10.1016/j.molcel.2006.11.002; CHUA P, 1995, MOL CELL BIOL, V15, P3685; Dao LD, 2006, J VIROL, V80, P4792, DOI 10.1128/JVI.80.10.4792-4800.2006; Denis GV, 2000, CELL GROWTH DIFFER, V11, P417; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; Florence B, 2001, FRONT BIOSCI-LANDMRK, V6, pD1008, DOI 10.2741/Florence; French CA, 2003, CANCER RES, V63, P304; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; Hou SY, 2002, J BIOL CHEM, V277, P45619, DOI 10.1074/jbc.M206829200; Hou SY, 2000, MOL CELL BIOL, V20, P113, DOI 10.1128/MCB.20.1.113-125.2000; Houzelstein D, 2002, MOL CELL BIOL, V22, P3794, DOI 10.1128/MCB.22.11.3794-3802.2002; Ilves I, 2006, J VIROL, V80, P3660, DOI 10.1128/JVI.80.7.3660-3665.2006; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Kasahara M, 1999, IMMUNOGENETICS, V50, P134, DOI 10.1007/s002510050589; Kurg R, 2006, J VIROL, V80, P11218, DOI 10.1128/JVI.01127-06; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; Matangkasombut O, 2000, GENE DEV, V14, P951; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; McPhillips MG, 2006, J VIROL, V80, P9530, DOI 10.1128/JVI.01105-06; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Nakamura Y, 2007, J BIOL CHEM, V282, P4193, DOI 10.1074/jbc.M605971200; Nishiyama A, 2006, MOL BIOL CELL, V17, P814, DOI 10.1091/mbc.E05-08-0729; Oliveira JG, 2006, P NATL ACAD SCI USA, V103, P1047, DOI 10.1073/pnas.0507624103; Ottinger M, 2006, J VIROL, V80, P10772, DOI 10.1128/JVI.00804-06; Paillisson A, 2007, GENOMICS, V89, P215, DOI 10.1016/j.ygeno.2006.09.002; Parish JL, 2006, MOL CELL, V24, P867, DOI 10.1016/j.molcel.2006.11.005; Parish JL, 2006, J CELL SCI, V119, P4857, DOI 10.1242/jcs.03262; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Pivot-Pajot C, 2003, MOL CELL BIOL, V23, P5354, DOI 10.1128/MCB.23.15.5354-5365.2003; Potts PR, 2006, EMBO J, V25, P3377, DOI 10.1038/sj.emboj.7601218; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Schweiger MR, 2006, J VIROL, V80, P4276, DOI 10.1128/JVI.80.9.4276-4285.2006; Shang EY, 2004, GENE EXPR PATTERNS, V4, P513, DOI 10.1016/j.modgep.2004.03.002; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Van Tine BA, 2004, P NATL ACAD SCI USA, V101, P4030, DOI 10.1073/pnas.0306848101; Wu SY, 2006, GENE DEV, V20, P2383, DOI 10.1101/gad.1448206; Wu SY, 2003, MOL CELL BIOL, V23, P6229, DOI 10.1128/MCB.23.17.6229-6242.2003; Wu SY, 2001, J BIOL CHEM, V276, P34235, DOI 10.1074/jbc.M102463200; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7; You JX, 2006, J VIROL, V80, P8909, DOI 10.1128/JVI.00502-06; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	49	458	523	4	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13141	13145		10.1074/jbc.R700001200	http://dx.doi.org/10.1074/jbc.R700001200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17329240	hybrid			2022-12-27	WOS:000246060300001
J	Keppetipola, N; Jain, R; Shuman, S				Keppetipola, Niroshika; Jain, Ruchi; Shuman, Stewart			Novel triphosphate phosphohydrolase activity of Clostridium thermocellum TTM, a member of the triphosphate tunnel metalloenzyme superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING APPARATUS; MUTATIONAL ANALYSIS; THIAMINE TRIPHOSPHATASE; PLASMODIUM-FALCIPARUM; 2-METAL MECHANISM; ENZYME LEF4; YEAST; SITE; POLYMERASE; COMPONENT	Triphosphate tunnel metalloenzymes ( TTMs) are a newly recognized superfamily of phosphotransferases defined by a unique active site residing within an eight-stranded beta barrel. The prototypical members are the eukaryal metal-dependent RNA triphosphatases, which catalyze the initial step in mRNA capping. Little is known about the activities and substrate specificities of the scores of TTM homologs present in bacterial and archaeal proteomes, nearly all of which are annotated as adenylate cyclases. Here we have conducted a biochemical and structure-function analysis of a TTM protein ( CthTTM) from the bacterium Clostridium thermocellum. CthTTM is a metal-dependent tripolyphosphatase and nucleoside triphosphatase; it is not an adenylate cyclase. We have identified 11 conserved amino acids in the tunnel that are critical for tripolyphosphatase and ATPase activity. The most salient findings are that ( i) CthTTM is 150-fold more active in cleaving tripolyphosphate than ATP and ( ii) the substrate specificity of CthTTM can be transformed by a single mutation ( K8A) that abolishes tripolyphosphatase activity while strongly stimulating ATP hydrolysis. Our results underscore the plasticity of CthTTM substrate choice and suggest how novel specificities within the TTM superfamily might evolve through changes in the residues that line the tunnel walls.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskc.org			NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; Gallagher DT, 2006, J MOL BIOL, V362, P114, DOI 10.1016/j.jmb.2006.07.008; Gong CL, 2006, RNA, V12, P1468, DOI 10.1261/rna.119806; Gong CL, 2003, J BIOL CHEM, V278, P50843, DOI 10.1074/jbc.M309188200; Gong CL, 2003, VIROLOGY, V309, P125, DOI 10.1016/S0042-6822(03)00002-3; Gong CL, 2002, J BIOL CHEM, V277, P15317, DOI 10.1074/jbc.M200532200; Hausmann S, 2005, J BIOL CHEM, V280, P12077, DOI 10.1074/jbc.M412063200; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; Ho CK, 2001, J BIOL CHEM, V276, P46182, DOI 10.1074/jbc.M108706200; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iyer LM, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-33; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lakaye B, 2002, J BIOL CHEM, V277, P13771, DOI 10.1074/jbc.M111241200; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Martins A, 2003, NUCLEIC ACIDS RES, V31, P1455, DOI 10.1093/nar/gkg244; Martins A, 2001, J BIOL CHEM, V276, P45522, DOI 10.1074/jbc.M107615200; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Sismeiro O, 1998, J BACTERIOL, V180, P3339, DOI 10.1128/JB.180.13.3339-3344.1998; Takagi T, 2001, MOL BIOCHEM PARASIT, V114, P239, DOI 10.1016/S0166-6851(01)00254-7	24	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11941	11949		10.1074/jbc.M611328200	http://dx.doi.org/10.1074/jbc.M611328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17303560	hybrid			2022-12-27	WOS:000245941900037
J	Ramamoorthy, S; Samuvel, DJ; Buck, ER; Rudnick, G; Jayanthi, LD				Ramamoorthy, Sammanda; Samuvel, Devadoss J.; Buck, Eric R.; Rudnick, Gary; Jayanthi, Lankupalle D.			Phosphorylation of threonine residue 276 is required for acute regulation of serotonin transporter by cyclic GMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE; NEUROTRANSMITTER TRANSPORTERS; RAT-BRAIN; SURFACE EXPRESSION; ADENOSINE RECEPTOR; RELEASE; PATHWAY; ALPHA; STIMULATION	Cellular protein kinases, phosphatases, and other serotonin transporter ( SERT) interacting proteins participate in several signaling mechanisms regulating SERT activity. The molecular mechanisms of protein kinase G ( PKG)-mediated SERT regulation and the site of transporter phosphorylation were investigated. Treatment of rat midbrain synaptosomes with 8-bromo-cGMP increased SERT activity, and the increase was selectively blocked by PKG inhibitors. The V-max value for serotonin ( 5-HT) transport increased following cGMP treatment. However, surface biotinylation studies showed no change in SERT surface abundance following PKG activation. P-32 metabolic labeling experiments showed increased SERT phosphorylation in the presence of cGMP that was abolished by selectively inhibiting PKG. Phosphoamino acid analysis revealed that cGMP-stimulated native SERT phosphorylation occurred only on threonine residues. When added to CHO-1 cells expressing SERT, 8-bromo-cGMP stimulated 5-HT transport and SERT phosphorylation. Mutation of SERT threonine 276 to alanine completely abolished cGMP- mediated stimulation of 5-HT transport and SERT phosphorylation. Although the T276A mutation had no significant effect on 5-HT transport or SERT protein expression, mutation to aspartate ( T276D) increased the level of 5-HT uptake to that of cGMP-stimulated 5-HT uptake in wild-type SERT-expressing cells and was no longer sensitive to cGMP. These findings provide the first identification of a phosphorylation site in SERT and demonstrate that phosphorylation of Thr-276 is required for cGMP-mediated SERT regulation. They also constitute the first evidence that in the central nervous system PKG activation stimulates endogenous SERT activity by a trafficking-independent mechanism.	Med Univ S Carolina, Dept Neurosci, Div Neurosci Res, Charleston, SC 29425 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06519 USA	Medical University of South Carolina; Yale University	Ramamoorthy, S (corresponding author), Med Univ S Carolina, Dept Neurosci, Div Neurosci Res, 173 Ashley Ave,BSB 403, Charleston, SC 29425 USA.	rama@musc.edu			NIDA NIH HHS [DA8213] Funding Source: Medline; NIGMS NIH HHS [GM081054] Funding Source: Medline; NIMH NIH HHS [MH62612] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008213] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Barker Eric L., 1995, P321; Bauman AL, 2000, J NEUROSCI, V20, P7571; Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOULTON CL, 1994, EUR J NEUROSCI, V6, P1528, DOI 10.1111/j.1460-9568.1994.tb00543.x; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; FINK K, 1990, N-S ARCH PHARMACOL, V342, P513; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Jayanthi LD, 2006, J BIOL CHEM, V281, P23326, DOI 10.1074/jbc.M601156200; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; Kaehler ST, 1999, BRAIN RES, V835, P346, DOI 10.1016/S0006-8993(99)01599-1; Kilic F, 2003, MOL PHARMACOL, V64, P440, DOI 10.1124/mol.64.2.440; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Okada M, 1999, EUR J NEUROSCI, V11, P1, DOI 10.1046/j.1460-9568.1999.00415.x; Ozaki N, 2003, MOL PSYCHIATR, V8, P933, DOI 10.1038/sj.mp.4001365; Prasad HC, 2005, P NATL ACAD SCI USA, V102, P11545, DOI 10.1073/pnas.0501432102; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; RAMAMOORTHY S, 1989, BIOCHEM J, V258, P777, DOI 10.1042/bj2580777; RAMAMOORTHY S, 2002, ENUROTRANSMITTER TRA, P1; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Simpson KL, 2003, J COMP NEUROL, V466, P495, DOI 10.1002/cne.10912; Sinner C, 2001, N-S ARCH PHARMACOL, V364, P105, DOI 10.1007/s002100100428; SOUTHAM E, 1993, NEUROPHARMACOLOGY, V32, P1267, DOI 10.1016/0028-3908(93)90021-T; Threlfell S, 2004, J NEUROSCI, V24, P8704, DOI 10.1523/JNEUROSCI.2690-04.2004; Vaughan RA, 2004, J PHARMACOL EXP THER, V310, P1, DOI 10.1124/jpet.103.052423; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang YW, 2006, J BIOL CHEM, V281, P36213, DOI 10.1074/jbc.M605468200; Zhang YW, 2005, J BIOL CHEM, V280, P30807, DOI 10.1074/jbc.M504087200; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462; Zhu CB, 2004, EUR J PHARMACOL, V504, P1, DOI 10.1016/j.ejphar.2004.09.023	41	70	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11639	11647		10.1074/jbc.M611353200	http://dx.doi.org/10.1074/jbc.M611353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17310063	hybrid			2022-12-27	WOS:000245941900005
J	Li, Y; Hu, YF; Zhang, XX; Xu, HM; Lescop, E; Xia, B; Jin, CW				Li, You; Hu, Yunfei; Zhang, Xinxin; Xu, Huimin; Lescop, Ewen; Xia, Bin; Jin, Changwen			Conformational fluctuations coupled to the thiol-disulfide transfer between thioredoxin and arsenate reductase in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREUS PLASMID PI258; STAPHYLOCOCCUS-AUREUS; CATALYSIS; MECHANISM; DYNAMICS; PROGRAMS; PEPTIDE; CASCADE; TARGET; NMR	Arsenic compounds commonly exist in nature and are toxic to nearly all kinds of life forms, which directed the evolution of enzymes in many organisms for arsenic detoxification. In bacteria, the thioredoxin-coupled arsenate reductase catalyzes the reduction of arsenate to arsenite by intramolecular thiol-disulfide cascade. The oxidized arsenate reductase ArsC is subsequently regenerated by thioredoxin through an intermolecular thiol-disulfide exchange process. The solution structure of the Bacillus subtilis thioredoxin-arsenate reductase complex represents the transiently formed intermediate during the intermolecular thiol-disulfide exchange reaction. A comparison of the complex structure with that of thioredoxin and arsenate reductase proteins in redox states showed substantial conformational changes coupled to the reaction process, with arsenate reductase, especially, adopting an "intermediate" conformation in the complex. Our current studies provide novel insights into understanding the reaction mechanisms of the thioredoxin-arsenate reductase pathway.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	changwen@pku.edu.cn	zhang, xinxin/E-8629-2012; Lescop, Ewen/AAA-8700-2019	Lescop, Ewen/0000-0002-2623-9365				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bennett MS, 2001, P NATL ACAD SCI USA, V98, P13577, DOI 10.1073/pnas.241397198; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Guo XR, 2005, J BIOL CHEM, V280, P39601, DOI 10.1074/jbc.M508132200; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; JI GY, 1994, BIOCHEMISTRY-US, V33, P7294, DOI 10.1021/bi00189a034; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Messens J, 2004, J MOL BIOL, V339, P527, DOI 10.1016/j.jmb.2004.04.016; Messens J, 2004, ACTA CRYSTALLOGR D, V60, P1180, DOI 10.1107/S0907444904007334; Messens J, 2002, P NATL ACAD SCI USA, V99, P8506, DOI 10.1073/pnas.132142799; Messens J, 1999, BIOCHEMISTRY-US, V38, P16857, DOI 10.1021/bi9911841; Messens J, 2006, J MOL BIOL, V362, P1, DOI 10.1016/j.jmb.2006.07.002; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peterson FC, 2005, PROTEIN SCI, V14, P2195, DOI 10.1110/ps.051477905; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Wahl MC, 2005, J MOL BIOL, V345, P1119, DOI 10.1016/j.jmb.2004.11.004; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Zegers I, 2001, NAT STRUCT BIOL, V8, P843, DOI 10.1038/nsb1001-843	26	35	38	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11078	11083		10.1074/jbc.M700970200	http://dx.doi.org/10.1074/jbc.M700970200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303556	hybrid			2022-12-27	WOS:000245941500028
J	McIntosh, MT; Vaid, A; Hosgood, HD; Vijay, J; Bhattacharya, A; Sahani, MH; Baevova, P; Joiner, KA; Sharma, P				McIntosh, Michael T.; Vaid, Ankush; Hosgood, H. Dean; Vijay, Justin; Bhattacharya, Anindita; Sahani, Mayurbhai H.; Baevova, Pavlina; Joiner, Keith A.; Sharma, Pushkar			Traffic to the malaria parasite food vacuole - A novel pathway involving a phosphatidylinositol 3-phosphate-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; ALPHA-MANNOSIDASE; CRYSTAL-STRUCTURE; TARGETING SIGNAL; AMINOPEPTIDASE-I; FYVE; MEMBRANE; ENDOSOME; DOMAINS; YEAST	Phosphatidylinositol 3-phosphate (PI3P) is a key ligand for recruitment of endosomal regulatory proteins in higher eukaryotes. Subsets of these endosomal proteins possess a highly selective PI3P binding zinc finger motif belonging to the FYVE domain family. We have identified a single FYVE domain-containing protein in Plasmodium falciparum which we term FCP. Expression and mutagenesis studies demonstrate that key residues are involved in specific binding to PI3P. In contrast to FYVE proteins in other organisms, endogenous FCP localizes to a lysosomal compartment, the malaria parasite food vacuole ( FV), rather than to cytoplasmic endocytic organelles. Transfections of deletion mutants further indicate that FCP is essential for trophozoite and FV maturation and that it traffics to the FV via a novel constitutive cytoplasmic to vacuole targeting pathway. This newly discovered pathway excludes the secretory pathway and is directed by a C-terminal 44-amino acid peptide domain. We conclude that an FYVE protein that might be expected to participate in vesicle targeting in the parasite cytosol instead has a vital and functional role in the malaria parasite FV.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India	Yale University; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Sharma, P (corresponding author), Yale Univ, Sch Epidemiol & Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.	michael.mcintosh@yale.edu; pushkar@nii.res.in	Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akompong T, 2002, J BIOL CHEM, V277, P28923, DOI 10.1074/jbc.M201968200; ATKINSON CT, 1990, BLOOD CELLS, V16, P351; Bhaduri-McIntosh S, 1998, EXP PARASITOL, V88, P252, DOI 10.1006/expr.1998.4242; Birkeland HCG, 2004, CURR TOP MICROBIOL, V282, P89; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Danis M, 1998, Rev Prat, V48, P254; Deitsch KW, 2001, NUCLEIC ACIDS RES, V29, P850, DOI 10.1093/nar/29.3.850; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; ELABBADI N, 1994, MOL BIOCHEM PARASIT, V63, P179, DOI 10.1016/0166-6851(94)90054-X; Foth BJ, 2003, INT REV CYTOL, V224, P57, DOI 10.1016/S0074-7696(05)24003-2; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Gillooly DJ, 2003, HISTOCHEM CELL BIOL, V120, P445, DOI 10.1007/s00418-003-0591-7; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; HENDRICKS LC, 1992, P NATL ACAD SCI USA, V89, P7242, DOI 10.1073/pnas.89.15.7242; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Jensen RB, 2001, BIOCHEM J, V359, P165, DOI 10.1042/0264-6021:3590165; Klemba M, 2004, J CELL BIOL, V164, P47, DOI 10.1083/jcb200307147; Klemba M, 2004, J BIOL CHEM, V279, P43000, DOI 10.1074/jbc.M408123200; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; KUTNER S, 1985, J CELL PHYSIOL, V125, P521, DOI 10.1002/jcp.1041250323; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lopez-Estrano C, 2003, P NATL ACAD SCI USA, V100, P12402, DOI 10.1073/pnas.2133080100; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Nacer A, 2001, INT J PARASITOL, V31, P1371, DOI 10.1016/S0020-7519(01)00253-3; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Sato S, 2003, MOL BIOCHEM PARASIT, V130, P155, DOI 10.1016/S0166-6851(03)00166-X; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Skinner-Adams TS, 2003, TRENDS PARASITOL, V19, P17, DOI 10.1016/S1471-4922(02)00005-3; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; Woodman PG, 2000, TRAFFIC, V1, P695, DOI 10.1034/j.1600-0854.2000.010902.x; Wurmser AE, 2002, J CELL BIOL, V158, P761, DOI 10.1083/jcb.200112050; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418; Ziegler J, 2001, CURR MED CHEM, V8, P171, DOI 10.2174/0929867013373840	46	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11499	11508		10.1074/jbc.M610974200	http://dx.doi.org/10.1074/jbc.M610974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17289673	hybrid			2022-12-27	WOS:000245941500071
J	McKenna, SA; Lindhout, DA; Kim, I; Liu, CW; Gelev, VM; Wagner, G; Puglisi, JD				McKenna, Sean A.; Lindhout, Darrin A.; Kim, Insil; Liu, Corey W.; Gelev, Vladimir M.; Wagner, Gerhard; Puglisi, Joseph D.			Molecular framework for the activation of RNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INTERFERON ACTION; BINDING DOMAIN; PKR ACTIVATION; SUBSTRATE RECOGNITION; MEDIATED ACTIVATION; TAR RNA; MECHANISM; AUTOPHOSPHORYLATION; DSRNA	The RNA-dependent protein kinase ( PKR) plays an integral role in the antiviral response to cellular infection. PKR contains three distinct domains consisting of two conserved N-terminal double-stranded RNA ( dsRNA)- binding domains, a C-terminal Ser-Thr kinase domain, and a central 80-residue linker. Despite rich structural and biochemical data, a detailed mechanistic explanation of PKR activation remains unclear. Here we provide a framework for understanding dsRNA-dependent activation of PKR using nuclear magnetic resonance spectroscopy, dynamic light scattering, gel filtration, and autophosphorylation kinetics. In the latent state, PKR exists as an extended monomer, with an increase in self-affinity upon dsRNA association. Subsequent phosphorylation leads to efficient release of dsRNA followed by a greater increase in self-affinity. Activated PKR displays extensive conformational perturbations within the kinase domain. We propose an updated model for PKR activation in which the communication between RNA binding, central linker, and kinase domains is critical in the propagation of the activation signal and for PKR dimerization.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford Magnet Resonance Lab, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Stanford University; Stanford University; Harvard University; Harvard Medical School	Puglisi, JD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	Puglisi@stanford.edu		McKenna, Sean/0000-0002-9407-7257	NIAID NIH HHS [AI47365] Funding Source: Medline; NIGMS NIH HHS [GM078346] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047365, R01AI047365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078346] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dey M, 2005, CELL, V122, P901, DOI 10.1016/j.cell.2005.06.041; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157; Gelev V, 2006, J MOL BIOL, V364, P352, DOI 10.1016/j.jmb.2006.08.077; George CX, 1996, VIROLOGY, V221, P180, DOI 10.1006/viro.1996.0364; Jammi NV, 2001, NUCLEIC ACIDS RES, V29, P3020; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim I, 2006, J MOL BIOL, V358, P430, DOI 10.1016/j.jmb.2006.01.099; LASKY SR, 1982, J BIOL CHEM, V257, P1087; Lemaire PA, 2005, J MOL BIOL, V345, P81, DOI 10.1016/j.jmb.2004.10.031; Lemaire PA, 2006, BIOCHEMISTRY-US, V45, P9074, DOI 10.1021/bi060567d; Li SD, 2006, P NATL ACAD SCI USA, V103, P10005, DOI 10.1073/pnas.0602317103; Lukavsky PJ, 2004, RNA, V10, P889, DOI 10.1261/rna.5264804; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; McKenna SA, 2006, J MOL BIOL, V358, P1270, DOI 10.1016/j.jmb.2006.03.003; Nanduri S, 1998, J BIOMOL NMR, V12, P349, DOI 10.1023/A:1008259729432; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Peel AL, 2004, J NEUROPATH EXP NEUR, V63, P97, DOI 10.1093/jnen/63.2.97; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Su QZ, 2006, P NATL ACAD SCI USA, V103, P63, DOI 10.1073/pnas.0508207103; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995; Vattem KM, 2001, EUR J BIOCHEM, V268, P3674, DOI 10.1046/j.1432-1327.2001.02273.x; Wang ZX, 2002, BIOCHEM J, V368, P947, DOI 10.1042/BJ20020557; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291	33	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11474	11486		10.1074/jbc.M700301200	http://dx.doi.org/10.1074/jbc.M700301200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17284445	hybrid			2022-12-27	WOS:000245941500069
J	Pan, Y; Wang, BL				Pan, Yong; Wang, Baolin			A novel protein-processing domain in Gli2 and Gli3 differentially blocks complete protein degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCINE-RICH REGION; CUBITUS INTERRUPTUS; BETA-TRCP; TRANSCRIPTIONAL ACTIVATOR; REQUIRES PHOSPHORYLATION; PRECURSOR P105; HEDGEHOG; UBIQUITINATION; P50	The proteasome usually completely degrades its target proteins, but it can also degrade a handful of proteins in a limited and site-specific manner. The molecular mechanism for such limited degradation is unknown. The repressor forms of Gli2 and Gli3 transcription factors are generated from their full-length proteins through limited proteasome-mediated protein degradation. In this study, we have taken advantage of the fact that Gli3 is efficiently processed, whereas Gli2 is not, and identified a region of similar to 200 residues in their C termini that determine differential processing of the two proteins. This region, named processing determinant domain, functions as a signal for protein processing in the context of not only Gli2 and Gli3 protein sequences but also a heterologous hybrid protein, which would otherwise be completely degraded by the proteasome. Thus, the processing determinant domain constitutes a novel domain that functions independently. Our findings explain, at the molecular level, why Gli2 and Gli3 are differentially processed and, more importantly, may help understand a probably general mechanism by which the proteasome degrades some of its target proteins partially rather than completely.	Cornell Univ, Weill Med Coll, Dept Med Genet, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA	Cornell University; Cornell University	Wang, BL (corresponding author), Cornell Univ, Weill Med Coll, Dept Med Genet, 1300 York Ave,W404, New York, NY 10021 USA.	baw2001@med.cornell.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070820] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM70820] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Cohen S, 2004, MOL CELL BIOL, V24, P475, DOI 10.1128/MCB.24.1.475-486.2004; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; JIA J, 2002, NATURE, V416, P823; Jia JH, 2005, DEV CELL, V9, P819, DOI 10.1016/j.devcel.2005.10.006; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Moorthy AK, 2006, EMBO J, V25, P1945, DOI 10.1038/sj.emboj.7601081; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Piwko W, 2006, NAT STRUCT MOL BIOL, V13, P691, DOI 10.1038/nsmb1122; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Smelkinson MG, 2006, CURR BIOL, V16, P110, DOI 10.1016/j.cub.2005.12.012; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Tempe D, 2006, MOL CELL BIOL, V26, P4316, DOI 10.1128/MCB.02183-05; Tian L, 2005, NAT STRUCT MOL BIOL, V12, P1045, DOI 10.1038/nsmb1018; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wang CB, 2007, DEV DYNAM, V236, P769, DOI 10.1002/dvdy.21082; Wang QT, 1999, DEVELOPMENT, V126, P5097; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270	34	106	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10846	10852		10.1074/jbc.M608599200	http://dx.doi.org/10.1074/jbc.M608599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17283082	hybrid			2022-12-27	WOS:000245941500003
J	Rak, M; Tetaud, E; Godard, F; Sagot, I; Salin, B; Duvezin-Caubet, S; Slonimski, PP; Rytka, J; di Rago, JP				Rak, Malgorzata; Tetaud, Emmanuel; Godard, Francois; Sagot, Isabelle; Salin, Benedicte; Duvezin-Caubet, Stephane; Slonimski, Piotr P.; Rytka, Joanna; di Rago, Jean-Paul			Yeast cells lacking the mitochondrial gene encoding the ATP synthase subunit 6 exhibit a selective loss of complex IV and unusual mitochondrial morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR GENE; OXIDATIVE-PHOSPHORYLATION; ADP/ATP CARRIER; ENZYME COMPLEX; H+-ATPASE; F-1-ATPASE; CRISTAE; MEMBRANE; MUTANTS	Atp6p is an essential subunit of the ATP synthase proton translocating domain, which is encoded by the mitochondrial DNA (mtDNA) in yeast. We have replaced the coding sequence of Atp6p gene with the non-respiratory genetic marker ARG8m. Due to the presence of ARG8m, accumulation of rho(-)/rho(0) petites issued from large deletions in mtDNA could be restricted to 20 - 30% by growing the atp6 mutant in media lacking arginine. This moderate mtDNA instability created favorable conditions to investigate the consequences of a specific lack in Atp6p. Interestingly, in addition to the expected loss of ATP synthase activity, the cytochrome c oxidase respiratory enzyme steady-state level was found to be extremely low (< 5%) in the atp6 mutant. We show that the cytochrome c oxidase-poor accumulation was caused by a failure in the synthesis of one of its mtDNA-encoded subunits, Cox1p, indicating that, in yeast mitochondria, Cox1p synthesis is a key target for cytochrome c oxidase abundance regulation in relation to the ATP synthase activity. We provide direct evidence showing that in the absence of Atp6p the remaining subunits of the ATP synthase can still assemble. Mitochondrial cristae were detected in the atp6 mutant, showing that neither Atp6p nor the ATP synthase activity is critical for their formation. However, the atp6 mutant exhibited unusual mitochondrial structure and distribution anomalies, presumably caused by a strong delay in inner membrane fusion.	Univ Victor Segalen, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Univ Paris 06, Lab Propre Associe, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	UDICE-French Research Universities; Universite de Bordeaux; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; UDICE-French Research Universities; Sorbonne Universite	di Rago, JP (corresponding author), Univ Victor Segalen, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jp.dirago@ibgc.u-bordeaux2.fr		Duvezin-Caubet, Stephane/0000-0002-0243-2697				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackerman SH, 2005, PROG NUCLEIC ACID RE, V80, P95, DOI 10.1016/S0079-6603(05)80003-0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Amutha B, 2004, BIOCHEM J, V381, P19, DOI 10.1042/BJ20040566; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Brustovetsky N, 1996, P NATL ACAD SCI USA, V93, P664, DOI 10.1073/pnas.93.2.664; CHOO WM, 1985, BIOCHIM BIOPHYS ACTA, V806, P290, DOI 10.1016/0005-2728(85)90108-2; CLAISSE ML, 1980, MOL GEN GENET, V177, P375, DOI 10.1007/BF00271476; Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; Duvezin-Caubet S, 2003, P NATL ACAD SCI USA, V100, P13235, DOI 10.1073/pnas.2135169100; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Fillingame RH, 2000, NAT STRUCT BIOL, V7, P1002, DOI 10.1038/80902; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Frey TG, 2002, BBA-BIOENERGETICS, V1555, P196, DOI 10.1016/S0005-2728(02)00278-5; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; GUELIN E, 1993, J BIOL CHEM, V268, P161; Guerin B, 1979, Methods Enzymol, V55, P149; HEIMBERG H, 1990, GENE, V90, P69, DOI 10.1016/0378-1119(90)90440-3; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; JEANFRANCOIS MJB, 1986, BIOCHIM BIOPHYS ACTA, V852, P133, DOI 10.1016/0005-2728(86)90066-6; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; KOTYLAK Z, 1977, MITOCHONDRIA 1977, P161; LABOUESSE M, 1983, EMBO J, V2, P269, DOI 10.1002/j.1460-2075.1983.tb01416.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre-Legendre L, 2005, J BIOL CHEM, V280, P18386, DOI 10.1074/jbc.M410789200; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARZUKI S, 1989, BIOCHIM BIOPHYS ACTA, V975, P222, DOI 10.1016/S0005-2728(89)80252-X; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; NAKAGAWA K, 1991, J BIOL CHEM, V266, P1977; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nury H, 2006, ANNU REV BIOCHEM, V75, P713, DOI 10.1146/annurev.biochem.75.103004.142747; Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613; Ono S, 2004, J BIOL CHEM, V279, P33409, DOI 10.1074/jbc.M404993200; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Perez-Martinez X, 2003, EMBO J, V22, P5951, DOI 10.1093/emboj/cdg566; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SIMON M, 1984, MOL GEN GENET, V196, P266, DOI 10.1007/BF00328059; SOMLO M, 1985, EUR J BIOCHEM, V150, P89, DOI 10.1111/j.1432-1033.1985.tb08992.x; SOMLO M, 1968, EUR J BIOCHEM, V5, P276, DOI 10.1111/j.1432-1033.1968.tb00368.x; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; Steele DF, 1996, P NATL ACAD SCI USA, V93, P5253, DOI 10.1073/pnas.93.11.5253; Szczepanek T, 1996, EMBO J, V15, P3758, DOI 10.1002/j.1460-2075.1996.tb00746.x; Tzagoloff A, 2004, J BIOL CHEM, V279, P19775, DOI 10.1074/jbc.M401506200; TZAGOLOFF A, 1976, GENETIC FUNCTION MIT, P155; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; Venard R, 2003, BIOCHEMISTRY-US, V42, P7626, DOI 10.1021/bi034394t; Wittig I, 2005, PROTEOMICS, V5, P4338, DOI 10.1002/pmic.200500081; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963	69	92	92	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10853	10864		10.1074/jbc.M608692200	http://dx.doi.org/10.1074/jbc.M608692200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17261589	hybrid			2022-12-27	WOS:000245941500004
J	Noels, H; van Loo, G; Hagens, S; Broeckx, V; Beyaert, R; Marynen, P; Baens, M				Noels, Heidi; van Loo, Geert; Hagens, Sofie; Broeckx, Vicky; Beyaert, Rudi; Marynen, Peter; Baens, Mathijs			A novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappa B activation by API2 center dot MALT1 fusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOID-TISSUE LYMPHOMAS; T-CELL; CHROMOSOMAL TRANSLOCATION; UBIQUITIN LIGASE; BCL10; CARMA1; KINASE; INHIBITOR; T(1/14)(P22,Q32); BIOTINYLATION	The recurrent translocation t(11;18)(q21; q21) associated with mucosa-associated lymphoid tissue (MALT) lymphoma results in the expression of an API2 center dot MALT1 fusion protein that constitutively activates NF-kappa B. The first baculovirus IAP repeat (BIR) domain of API2 and the C terminus of MALT1, which contains its caspase-like domain, are present in all reported fusion variants and interact with TRAF2 and TRAF6, respectively, suggesting their contribution to NF-kappa B signaling by API2 center dot MALT1. Also, the involvement of BCL10 has been suggested via binding to BIR1 of API2 and via its interaction with the immunoglobulin domains of MALT1, present in half of the fusion variants. However, conflicting reports exist concerning their roles in API2 center dot MALT1-induced NF-kappa B signaling. In this report, streptavidin pulldowns of biotinylated API2 center dot MALT1 fusion variants showed that none of the fusion variants interacted with endogenous BCL10; its role in NF-kappa B signaling by API2 center dot MALT1 was further questioned by RNA interference experiments. In contrast, TRAF6 was essential for NF-kappa B activation by all fusion variants, and we identified a novel TRAF6 binding site in the second immunoglobulin domain of MALT1, which enhanced NF-kappa B activation when present in the fusion protein. Furthermore, inclusion of both immunoglobulin domains in API2 center dot MALT1 further enhanced NF-kappa B signaling via intramolecular TRAF6 activation. Finally, binding of TRAF2 to BIR1 contributed to NF-kappa B activation by API2 center dot MALT1, although additional mechanisms involving BIR1-mediated raft association are also important. Taken together, these data reveal distinct mechanisms of NF-kappa B activation by the different API2 center dot MALT1 fusion variants with an essential role for TRAF6.	Flanders Inst Biotechnol, VIB, Human Genome Lab, Dept Mol & Dev Genet, B-3000 Louvain, Belgium; KU Leuvan, Ctr Human Genet Mol Genet, Human Genome Lab, B-3000 Louvain, Belgium; Flanders Inst Biotechnol, VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB)	Baens, M (corresponding author), KU Leuvan, Ctr Human Genet Mol Genet, Human Genome Lab, Herestr 49, B-3000 Louvain, Belgium.	Mathijs.Baens@Med.KULeuven.be	, van Loo Geert/AAD-1220-2019; Beyaert, Rudi/B-2589-2009; van Loo, Geert/C-1505-2009; Noels, Heidi/AAQ-2622-2020	, van Loo Geert/0000-0002-8427-4775; Beyaert, Rudi/0000-0002-5704-582X				Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Bidere N, 2006, CURR BIOL, V16, P1666, DOI 10.1016/j.cub.2006.06.062; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Hara H, 2004, J EXP MED, V200, P1167, DOI 10.1084/jem.20032246; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Hosokawa Y, 2004, CANCER RES, V64, P3452, DOI 10.1158/0008-5472.CAN-03-3677; Hu SM, 2006, J CLIN INVEST, V116, P174, DOI 10.1172/JCI25641; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Rossman JS, 2006, MOL BIOL CELL, V17, P2166, DOI 10.1091/mbc.E05-10-0985; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Sanchez-Izquierdo D, 2003, BLOOD, V101, P4539, DOI 10.1182/blood-2002-10-3236; Stilo R, 2004, J BIOL CHEM, V279, P34323, DOI 10.1074/jbc.M402244200; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Varfolomeev E, 2006, J BIOL CHEM, V281, P29022, DOI 10.1074/jbc.M605116200; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wooff J, 2004, FEBS LETT, V566, P229, DOI 10.1016/j.febslet.2004.04.038; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	30	68	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10180	10189		10.1074/jbc.M611038200	http://dx.doi.org/10.1074/jbc.M611038200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287209	hybrid, Green Published			2022-12-27	WOS:000245941000008
J	El-Hallous, E; Sasaki, T; Hubmacher, D; Getie, M; Tiedemann, K; Brinckmann, J; Batge, B; Davis, EC; Reinhardt, DP				El-Hallous, Ehab; Sasaki, Takako; Hubmacher, Dirk; Getie, Melkamu; Tiedemann, Kerstin; Brinckmann, Juergen; Baetge, Boris; Davis, Elaine C.; Reinhardt, Dieter P.			Fibrillin-1 interactions with fibulins depend on the first hybrid domain and provide an adaptor function to tropoelastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; HONEYCOMB RETINAL DYSTROPHY; MARFAN-SYNDROME; CALCIUM-BINDING; CUTIS LAXA; ELASTIC FIBERS; IN-VIVO; GENE; MICROFIBRILS; EXPRESSION	Fibrillin-containing microfibrils in elastic and nonelastic extracellular matrices play important structural and functional roles in various tissues, including blood vessels, lung, skin, and bone. Microfibrils are supramolecular aggregates of several protein and nonprotein components. Recently, a large region in the N-terminal portion of fibrillin-1 was characterized as a multifunctional protein interaction site, including binding sites for fibulin-2 and -5 among others. Using a panel of recombinant fibrillin-1 swapped domain and deletion fragments, we demonstrate here that the conserved first hybrid domain in fibrillin-1 is essential for binding to fibulin-2, -4, and -5. Fibulin-3 and various isoforms of fibulin-1 did not interact with fibrillin-1. Although the first hybrid domain in fibrillin-1 is located in close vicinity to the self-assembly epitope, binding of fibulin-2, -4, and -5 did not interfere with self-assembly. However, these fibulins can associate with microfibrils at various levels of maturity. Formation of ternary complexes between fibrillin-1, fibulins, and tropoelastin demonstrated that fibulin-2 and -5 but much less fibulin-4, are able to act as molecular adaptors between fibrillin-1 and tropoelastin.	Fac Med, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Dent, Div Biomed Sci, Montreal, PQ H3A 2B2, Canada; Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Klinikum Neustadt, D-23730 Neustadt, Germany	McGill University; University of Lubeck; University of Lubeck; Max Planck Society	Reinhardt, DP (corresponding author), Fac Med, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada.	dieter.reinhardt@mcgill.ca	Hubmacher, Dirk/AAE-1875-2020; Reinhardt, Dieter P/A-3102-2008; Davis, Elaine/F-3449-2012; Tiedemann, one/A-9739-2016	Reinhardt, Dieter P/0000-0001-6535-9872; Hubmacher, Dirk/0000-0003-1569-9451; El-Hallous, Ehab/0000-0003-0189-3720				Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Brinckmann J, 2005, ARTHRITIS RES THER, V7, pR1221, DOI 10.1186/ar1813; Cain SA, 2005, J BIOL CHEM, V280, P30526, DOI 10.1074/jbc.M501390200; Carta L, 2006, J BIOL CHEM, V281, P8016, DOI 10.1074/jbc.M511599200; Chaudhry SS, 2001, HUM MOL GENET, V10, P835, DOI 10.1093/hmg/10.8.835; Chu Mon-Li, 2004, Birth Defects Res C Embryo Today, V72, P25, DOI 10.1002/bdrc.20003; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Freeman LJ, 2005, BIOCHEM J, V388, P1, DOI 10.1042/BJ20050368; Gallagher WM, 1999, ONCOGENE, V18, P3608, DOI 10.1038/sj.onc.1202937; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hucthagowder V, 2006, AM J HUM GENET, V78, P1075, DOI 10.1086/504304; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Katsanis N, 2000, HUM GENET, V106, P66, DOI 10.1007/s004390051011; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; KIELTY CM, 1994, MATRIX BIOL, V14, P191, DOI 10.1016/0945-053X(94)90008-6; Kielty CM, 2002, J CELL SCI, V115, P2817; Kowal RC, 1999, CIRC RES, V84, P1166, DOI 10.1161/01.RES.84.10.1166; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; Lin GQ, 2002, J BIOL CHEM, V277, P50795, DOI 10.1074/jbc.M210611200; Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113; Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940; Marson A, 2005, J BIOL CHEM, V280, P5013, DOI 10.1074/jbc.M409029200; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; McLaughlin PJ, 2006, MOL CELL BIOL, V26, P1700, DOI 10.1128/MCB.26.5.1700-1709.2006; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Raghunath M, 1999, J INVEST DERMATOL, V112, P97, DOI 10.1046/j.1523-1747.1999.00483.x; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Robinson PN, 2006, J MED GENET, V43, P769, DOI 10.1136/jmg.2005.039669; Rock MJ, 2004, J BIOL CHEM, V279, P23748, DOI 10.1074/jbc.M400212200; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833; Tiedemann K, 2005, J BIOL CHEM, V280, P11404, DOI 10.1074/jbc.M409882200; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHENG Q, 2006, IN PRESS J INVEST DE	65	89	95	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8935	8946		10.1074/jbc.M608204200	http://dx.doi.org/10.1074/jbc.M608204200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17255108	hybrid, Green Published			2022-12-27	WOS:000245780300040
J	Koizumi, S; Gong, PF; Suzuki, K; Murata, M				Koizumi, Shinji; Gong, Pengfei; Suzuki, Kaoru; Murata, Mie			Cadmium-responsive element of the human heme oxygenase-1 gene mediates heat shock factor 1-dependent transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MTF-1; METAL RESPONSE; HUMAN-CELLS; EXPRESSION; PROMOTER; IDENTIFICATION; REPRESSOR; INTERACTS; BINDING; BACH1	Transcription of a number of mammalian genes is activated by heavy metals, but mechanisms of signaling and transcriptional regulation are not well understood. From a comparison of heavy metal responses of several human genes, it was noted that the heme oxygenase-1 (HO-1) gene is quite similar in the spectrum of metal response and induction kinetics to the heat shock protein 70 (HSP70) gene, suggesting a common regulatory mechanism shared by these genes. The cadmium-responsive element (CdRE) known to be responsible for the metal regulation of ho-1 formed complexes with proteins from heavy metal-treated HeLa cells in an electrophoretic mobility shift assay (EMSA). These complexes were indistinguishable in mobility from those formed by the heat shock factor 1 (HSF1) and the heat shock element involved in hsp70 regulation, suggesting the involvement of HSF1 also in the CdRE complexes. Competitive EMSA and supershift analysis with an anti-HSF1 antibody revealed that HSF1 was in fact a component of the CdRE complexes. A fine analysis on the affinity of HSF1 to a series of mutant CdRE sequences showed that HSF1 recognizes a sequence motif TnCTAGA. Transient transfection analysis with overexpressed recombinant HSF1 demonstrated that CdRE has HSF1-dependent enhancer-like activity that requires direct binding of HSF1. In the absence of overexpressed HSF1, however, CdRE by itself was insufficient to mediate heavy metal-induced transcription, suggesting requirement of additional regulatory sequences. The finding that HSF1 is directly involved in the regulation of ho-1 with an anti-oxidative role revealed a new aspect of the biological defense mechanism.	Natl Inst Occupat Safety & Hlth, Mechanism Hlth Effect Res Grp, Tama Ku, Kawasaki, Kanagawa 2148585, Japan		Koizumi, S (corresponding author), Natl Inst Occupat Safety & Hlth, Mechanism Hlth Effect Res Grp, Tama Ku, 6-21-1,Ngao, Kawasaki, Kanagawa 2148585, Japan.	koizumi@h.jniosh.go.jp						Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EPNER DE, 1991, J CELL PHYSIOL, V148, P68, DOI 10.1002/jcp.1041480109; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; Kitamuro T, 2003, J BIOL CHEM, V278, P9125, DOI 10.1074/jbc.M209939200; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; LaRochelle O, 2001, J BIOL CHEM, V276, P41879, DOI 10.1074/jbc.M108313200; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; Murata M, 1999, J CELL PHYSIOL, V180, P105, DOI 10.1002/(SICI)1097-4652(199907)180:1<105::AID-JCP12>3.0.CO;2-5; PEI J, 1990, J BIOL CHEM, V265, P14061; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Saydam N, 2002, J BIOL CHEM, V277, P20438, DOI 10.1074/jbc.M110631200; Saydam N, 2003, J BIOL CHEM, V278, P31879, DOI 10.1074/jbc.M302138200; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Sikorski EM, 2006, J BIOL CHEM, V281, P24423, DOI 10.1074/jbc.M602287200; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; Uenishi R, 2006, BIOCHEM BIOPH RES CO, V341, P1072, DOI 10.1016/j.bbrc.2006.01.066; Uenishi R, 2005, J HEALTH SCI, V51, P242, DOI 10.1248/jhs.51.242; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Yamada H, 2002, IND HEALTH, V40, P159, DOI 10.2486/indhealth.40.159	23	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8715	8723		10.1074/jbc.M609427200	http://dx.doi.org/10.1074/jbc.M609427200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17244614	hybrid			2022-12-27	WOS:000245780300017
J	Sharma, M; Henderson, BR				Sharma, Manisha; Henderson, Beric R.			IQ-domain GTPase-activating protein 1 regulates beta-catenin at membrane ruffles and its role in macropinocytosis of N-cadherin and adenomatous polyposis coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; IQGAP1; APC; ENDOCYTOSIS; CDC42; RAC1; LOCALIZATION; ADHESION; FIBROBLASTS; EXPRESSION	beta-Catenin is an integral component of E-cadherin dependent cell-cell junctions. Here we show that beta-catenin co-localizes with IQ-domain GTPase-activating protein 1 (IQGAP1), adenomatous polyposis coli (APC), and N-cadherin at actin-positive membrane ruffles in NIH 3T3 fibroblasts. We used deletion mapping to identify the membrane ruffle-targeting region of beta-catenin, localizing it to amino acids 47-217, which overlap the IQGAP1 binding site. Knockdown by small interference RNA (siRNA) revealed IQGAP I-dependent membrane targeting of beta-catenin, APC, and N-cadherin. Transient overexpression of IQGAP1 or N-cadherin increased beta-catenin at membrane ruffles. IQGAP1/APC regulates cell migration, and using a wound healing assay we demonstrate that siRNA-mediated loss of beta-catenin also caused a modest reduction in the rate of cell migration. More significantly, we discovered that beta-catenin is internalized by Arf6-dependent macropinocytosis near sites of membrane ruffling. The beta-catenin macropinosomes co-stained for APC, N-cadherin, and to a lesser extent IQGAP1, and internalization of each binding partner was abrogated by siRNA-dependent knockdown of beta-catenin. In addition, beta-catenin macropinosomes co-localized with the lysosomal marker, lysosome associated membrane protein 1, consistent with their recycling by the late endosomal machinery. Our findings expand on current knowledge of beta-catenin function. We propose that in motile cells beta-catenin is recruited by IQGAP1 and N-cadherin to active membrane ruffles, wherein beta-catenin mediates the internalization and possible recycling of the membrane-associated proteins N-cadherin and APC.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Westmead Millennium Inst, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au		Sharma, Manisha/0000-0003-1892-9865				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Cardelli J, 2001, TRAFFIC, V2, P311, DOI 10.1034/j.1600-0854.2001.002005311.x; Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Le Stunff H, 2000, BIOCHEM J, V352, P491, DOI 10.1042/0264-6021:3520491; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Noritake J, 2004, MOL BIOL CELL, V15, P1065, DOI 10.1091/mbc.E03-08-0582; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Pece S, 2002, NAT CELL BIOL, V4, pE72, DOI 10.1038/ncb0402-e72; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Schafer DA, 2000, TRAFFIC, V1, P892; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; Sun P, 2003, J BIOL CHEM, V278, P4063, DOI 10.1074/jbc.M208699200; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	50	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8545	8556		10.1074/jbc.M610272200	http://dx.doi.org/10.1074/jbc.M610272200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17255093	hybrid			2022-12-27	WOS:000245081000086
